[{"orgOrder":0,"company":"Undisclosed","sponsor":"Nora Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Prucalopride Succinate","moa":"5-HT4","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Undisclosed \/ Nora Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Nora Pharma"},{"orgOrder":0,"company":"Innoviva Specialty Therapeutics","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Innoviva Specialty Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innoviva Specialty Therapeutics \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Innoviva Specialty Therapeutics \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"CNX Therapeutics","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CNX Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"CNX Therapeutics \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"CNX Therapeutics \/ Adalvo"},{"orgOrder":0,"company":"Undisclosed","sponsor":"MOMA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"MOMA-989","moa":"PARP1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Undisclosed \/ MOMA Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Undisclosed \/ MOMA Therapeutics"},{"orgOrder":0,"company":"Negev Labs","sponsor":"Hadassah Brain Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Negev Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Negev Labs \/ Hadassah Brain Labs","highestDevelopmentStatusID":"2","companyTruncated":"Negev Labs \/ Hadassah Brain Labs"},{"orgOrder":0,"company":"Neurobiogen","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurobiogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurobiogen \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neurobiogen \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"Atom Therapeutics","sponsor":"China Medical System Holdings","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Atom Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atom Therapeutics \/ China Medical System Holdings","highestDevelopmentStatusID":"9","companyTruncated":"Atom Therapeutics \/ China Medical System Holdings"},{"orgOrder":0,"company":"Cellistic","sponsor":"BrightPath Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"BP2202","moa":"BCMA","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellistic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellistic \/ BrightPath Bio","highestDevelopmentStatusID":"4","companyTruncated":"Cellistic \/ BrightPath Bio"},{"orgOrder":0,"company":"Tasca Therapeutics","sponsor":"Regeneron Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"CAS 77168-63-9","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tasca Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tasca Therapeutics \/ Regeneron Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Tasca Therapeutics \/ Regeneron Ventures"},{"orgOrder":0,"company":"Hervolution Therapeutics","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"IPT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hervolution Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Hervolution Therapeutics \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"Hervolution Therapeutics \/ Serum Institute of India"},{"orgOrder":0,"company":"Orthogon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orthogon Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Orthogon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Orthogon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Suvretta Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Veradermics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Veradermics \/ Suvretta Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Veradermics \/ Suvretta Capital Management"},{"orgOrder":0,"company":"TikkunLev Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TLT-101","moa":"BIN1","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"TikkunLev Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TikkunLev Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"TikkunLev Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TigaTx","sponsor":"Advanced Research Projects Agency for Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"TIGA-001","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"TigaTx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"TigaTx \/ Advanced Research Projects Agency for Health","highestDevelopmentStatusID":"4","companyTruncated":"TigaTx \/ Advanced Research Projects Agency for Health"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Nika Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Vinpocetine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Undisclosed \/ Nika Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Nika Pharmaceuticals"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Betaine","moa":"Methylation","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Undisclosed \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Undisclosed \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Adalvo"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"||Heme polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Population Health Research Institute \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Bayer AG"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2022","type":"Divestment","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Undisclosed \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Undisclosed \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Genomma Lab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ Genomma Lab","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Genomma Lab"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Undisclosed \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"The Ohio State University","sponsor":"Biological E","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Attenuated Recombinant Measles Virus","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Ohio State University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Ohio State University \/ Biological E","highestDevelopmentStatusID":"4","companyTruncated":"The Ohio State University \/ Biological E"},{"orgOrder":0,"company":"University of Wisconsin Madison","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CoroFlu Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Wisconsin Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Wisconsin Madison \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin Madison \/ Bharat Biotech"},{"orgOrder":0,"company":"Undisclosed","sponsor":"CorMedix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ CorMedix","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ CorMedix"},{"orgOrder":0,"company":"Undisclosed","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Undisclosed \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Undisclosed \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Shaare Zedek Scientific Ltd.\u00a0","sponsor":"Greater Cannabis Company","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shaare Zedek Scientific Ltd.\u00a0","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shaare Zedek Scientific Ltd.\u00a0 \/ Greater Cannabis Company","highestDevelopmentStatusID":"1","companyTruncated":"Shaare Zedek Scientific Ltd.\u00a0 \/ Greater Cannabis Company"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Undisclosed \/ Bionxt Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Undisclosed \/ Bionxt Solutions"},{"orgOrder":0,"company":"Undisclosed","sponsor":"AIkido Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Undisclosed \/ AIkido Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ AIkido Pharma"},{"orgOrder":0,"company":"Undisclosed","sponsor":"LifeArc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ LifeArc","highestDevelopmentStatusID":"4","companyTruncated":"Undisclosed \/ LifeArc"},{"orgOrder":0,"company":"Undisclosed","sponsor":"The Mark Foundation for Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Undisclosed \/ The Mark Foundation for Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"Undisclosed \/ The Mark Foundation for Cancer Research"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Vantage Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"VX-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Undisclosed \/ Vantage Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Undisclosed \/ Vantage Biosciences"},{"orgOrder":0,"company":"Cosmo Technologies","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Rifamycin","moa":"DdRP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosmo Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Cosmo Technologies \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Technologies \/ RedHill Biopharma"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Cosmos Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Undisclosed \/ Cosmos Health","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Cosmos Health"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Scilex Holding Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Undisclosed \/ Scilex Holding Company","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Scilex Holding Company"},{"orgOrder":0,"company":"Undisclosed","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Undisclosed \/ United Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ United Therapeutics"},{"orgOrder":0,"company":"Cornell Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cornell Medicine \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Cornell Medicine \/ Bayer AG"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"TRN-261","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ Tris Pharma Inc","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ Tris Pharma Inc"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Undisclosed \/ Bionxt Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ Bionxt Solutions"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Shorla Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PIP-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Undisclosed \/ Shorla Oncology","highestDevelopmentStatusID":"10","companyTruncated":"Undisclosed \/ Shorla Oncology"},{"orgOrder":0,"company":"Neurotheryx","sponsor":"Cyclica","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Neurotheryx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotheryx \/ Cyclica","highestDevelopmentStatusID":"1","companyTruncated":"Neurotheryx \/ Cyclica"},{"orgOrder":0,"company":"Undisclosed","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ BIOSYENT PHARMA INC","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ BIOSYENT PHARMA INC"},{"orgOrder":0,"company":"Upadia Holding","sponsor":"EsoCap","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Upadia Holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upadia Holding \/ EsoCap","highestDevelopmentStatusID":"4","companyTruncated":"Upadia Holding \/ EsoCap"},{"orgOrder":0,"company":"Universite de Sherbrooke Department of Medicine","sponsor":"Aker BioMarine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"||DGAT","graph1":"Neurology","graph2":"Preclinical","graph3":"Universite de Sherbrooke Department of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universite de Sherbrooke Department of Medicine \/ Aker BioMarine","highestDevelopmentStatusID":"4","companyTruncated":"Universite de Sherbrooke Department of Medicine \/ Aker BioMarine"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Controlled Substance","year":"2022","type":"Divestment","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Undisclosed \/ Altamira Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Undisclosed \/ Altamira Therapeutics"},{"orgOrder":0,"company":"Zylka Lab","sponsor":"University of North Carolina","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Zylka Lab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zylka Lab \/ University of North Carolina","highestDevelopmentStatusID":"4","companyTruncated":"Zylka Lab \/ University of North Carolina"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BA1105","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boan Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Boan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bioshin","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Bioshin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Bioshin \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bioshin \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"UAB Institut de Neuroci\u00e8ncies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"UAB Institut de Neuroci\u00e8ncies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UAB Institut de Neuroci\u00e8ncies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"UAB Institut de Neuroci\u00e8ncies \/ Inapplicable"},{"orgOrder":0,"company":"Biopeutics","sponsor":"Medical Center of Vienna","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alprostadil","moa":"EP1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Biopeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biopeutics \/ Medical Center of Vienna","highestDevelopmentStatusID":"10","companyTruncated":"Biopeutics \/ Medical Center of Vienna"},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||PAN-AMPK","graph1":"Endocrinology","graph2":"Phase I","graph3":"Amplifier Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amplifier Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amplifier Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reckitt Benckiser \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reckitt Benckiser \/ Inapplicable"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Advanced Accelerator Applications \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advanced Accelerator Applications \/ Inapplicable"},{"orgOrder":0,"company":"Rutgers Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rutgers Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rutgers Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Chemical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dubermatinib","moa":"||AXL receptor tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Chemical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Chemical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Chemical \/ Inapplicable"},{"orgOrder":0,"company":"Royal Melbourne Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Royal Melbourne Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Royal Melbourne Hospital \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Royal Melbourne Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University Irving Medical Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Columbia University Irving Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Columbia University Irving Medical Center \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Columbia University Irving Medical Center \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"||ROS1","graph1":"Oncology","graph2":"Preclinical","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evergreenhealth","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evergreenhealth","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Evergreenhealth \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evergreenhealth \/ Inapplicable"},{"orgOrder":0,"company":"Syntara Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib","moa":"||LOX","graph1":"Oncology","graph2":"Phase II","graph3":"Syntara Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syntara Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syntara Limited \/ Inapplicable"},{"orgOrder":0,"company":"Auro Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Auro Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Auro Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Auro Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sorriso Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SOR102","moa":"TNF alpha\/IL-23","graph1":"Immunology","graph2":"Phase I","graph3":"Sorriso Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorriso Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorriso Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PIF Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"PIF Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIF Partners \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PIF Partners \/ Inapplicable"},{"orgOrder":0,"company":"MetaVia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DA-1241","moa":"||GPR119","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"MetaVia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MetaVia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MetaVia \/ Inapplicable"},{"orgOrder":0,"company":"CureGene Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Benzenesulfonic Acid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"CureGene Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CureGene Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CureGene Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Immunering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunering","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunering \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunering \/ Inapplicable"},{"orgOrder":0,"company":"MMJ International Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MMJ-002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"MMJ International Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MMJ International Holding \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MMJ International Holding \/ Inapplicable"},{"orgOrder":0,"company":"Channel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Channel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Channel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Channel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pilatus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PLT012","moa":"CD36","graph1":"Oncology","graph2":"Preclinical","graph3":"Pilatus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pilatus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pilatus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Plan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RPT1G","moa":"NAMPT","graph1":"Oncology","graph2":"Phase I","graph3":"Remedy Plan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Remedy Plan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Remedy Plan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.11,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Segesterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0.42999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.42999999999999999,"dosageForm":"Vaginal Insert","sponsorNew":"Mayne Pharma \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Cosette Pharma"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kazia Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kazia Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Avecho","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2025","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avecho","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Avecho \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Avecho \/ Sandoz B2B"},{"orgOrder":0,"company":"Immuron","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuron \/ Monash University","highestDevelopmentStatusID":"3","companyTruncated":"Immuron \/ Monash University"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdvanCell \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AdvanCell \/ Eli Lilly"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Flu Lab","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Flu Lab","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Flu Lab"},{"orgOrder":0,"company":"AdvanCell","sponsor":"SV Health Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Series C Financing","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Intravenous","sponsorNew":"AdvanCell \/ SV Health Investors","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ SV Health Investors"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"MST Financial Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ MST Financial Services","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ MST Financial Services"},{"orgOrder":0,"company":"Immuron","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Opthea","sponsor":"Carlyle Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Financing","leadProduct":"Ranibizumab","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Carlyle Group","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Carlyle Group"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"AUSTRALIA","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Specialised Therapeutics \/ Ascendis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Ascendis Pharma"},{"orgOrder":0,"company":"CSL","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Pharmanovia"},{"orgOrder":0,"company":"Immutep","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ GSK"},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Neuren Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Neuren Pharmaceuticals \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neuren Pharmaceuticals \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Balance Medical","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Balance Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Balance Medical \/ MediWound","highestDevelopmentStatusID":"10","companyTruncated":"Balance Medical \/ MediWound"},{"orgOrder":0,"company":"Immuron","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Monash University"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Chroma Dermatology","sponsor":"DermBiont","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Ruboxistaurin","moa":"PKC-beta","graph1":"Dermatology","graph2":"Phase I","graph3":"Chroma Dermatology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chroma Dermatology \/ DermBiont","highestDevelopmentStatusID":"6","companyTruncated":"Chroma Dermatology \/ DermBiont"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Mannitol","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pharmaxis \/ Aptar Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pharmaxis \/ Aptar Pharma"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Cardinal Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"67-Cu MeCOSar-Tyr3-octreotate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Cardinal Health","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Cardinal Health"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Queensland","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Queensland \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"University of Queensland \/ CEPI"},{"orgOrder":0,"company":"University of Queensland","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Queensland \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"University of Queensland \/ CSL"},{"orgOrder":0,"company":"Defence Materials Technology Centre","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Chloroquine Phosphate","moa":"Heme polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Defence Materials Technology Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Defence Materials Technology Centre \/ Certara","highestDevelopmentStatusID":"11","companyTruncated":"Defence Materials Technology Centre \/ Certara"},{"orgOrder":0,"company":"HavaH Therapeutics","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone","moa":"||Androgen receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"HavaH Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"HavaH Therapeutics \/ Clarus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"HavaH Therapeutics \/ Clarus Therapeutics"},{"orgOrder":0,"company":"Imugene","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"CF33-CD19","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Imugene \/ Celularity","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Celularity"},{"orgOrder":0,"company":"oNKo-innate","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"oNKo-innate","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"oNKo-innate \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"oNKo-innate \/ Gilead Sciences"},{"orgOrder":0,"company":"Immutep","sponsor":"Maria Sk\u0142odowska-Curie National Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Maria Sk\u0142odowska-Curie National Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Maria Sk\u0142odowska-Curie National Research Institute"},{"orgOrder":0,"company":"CSL","sponsor":"University of Queensland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Squalene","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ University of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"CSL \/ University of Queensland"},{"orgOrder":0,"company":"CSL","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"The Peter Doherty Institute","sponsor":"Jack Ma Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Peter Doherty Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"The Peter Doherty Institute \/ Jack Ma Foundation","highestDevelopmentStatusID":"1","companyTruncated":"The Peter Doherty Institute \/ Jack Ma Foundation"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"QIMR Berghofer Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Curia","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Curia","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Curia"},{"orgOrder":0,"company":"Immuron","sponsor":"Medical Technology Enterprise Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Medical Technology Enterprise Consortium","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Medical Technology Enterprise Consortium"},{"orgOrder":0,"company":"Immutep","sponsor":"University Hospital Pilsen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"APC receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immutep \/ University Hospital Pilsen","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ University Hospital Pilsen"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imugene \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ MaxCyte"},{"orgOrder":0,"company":"Imugene","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"HER-Vaxx","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ Merck & Co"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Mayne Pharma \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ TherapeuticsMD"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ U.S. Department of Defense"},{"orgOrder":0,"company":"University of Queensland","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Queensland \/ ATAI Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"University of Queensland \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Signet","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Signet","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Signet"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"QIMR Berghofer Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Monrol","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"177-Lu DOTA Girentuximab","moa":"||CA IX","graph1":"Oncology","graph2":"Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Telix Pharmaceuticals \/ Monrol","highestDevelopmentStatusID":"8","companyTruncated":"Telix Pharmaceuticals \/ Monrol"},{"orgOrder":0,"company":"Cell Therapies","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Cell Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cell Therapies \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Cell Therapies \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantrixil","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Kazia Therapeutics \/ Oasmia Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Oasmia Pharmaceutical"},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Undisclosed"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pharmaxis \/ Aptar Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Pharmaxis \/ Aptar Pharma"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Bell Potter Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Bell Potter Securities","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Bell Potter Securities"},{"orgOrder":0,"company":"CMAX","sponsor":"Claritas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Nitric oxide donor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"CMAX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CMAX \/ Claritas Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"CMAX \/ Claritas Pharmaceuticals"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"CSIRO","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Recce Pharmaceuticals \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ CSIRO"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"PT Etana Biotechnologies Indonesia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ PT Etana Biotechnologies Indonesia","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ PT Etana Biotechnologies Indonesia"},{"orgOrder":0,"company":"Rhine Pharma","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Demerger","leadProduct":"188-Re PSMA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhine Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhine Pharma \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Rhine Pharma \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Novotech","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Novotech \/ Skye Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Novotech \/ Skye Bioscience"},{"orgOrder":0,"company":"Griffith University","sponsor":"Indian Immunologicals Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS \u2013 CoV-2 Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Griffith University \/ Indian Immunologicals Limited","highestDevelopmentStatusID":"1","companyTruncated":"Griffith University \/ Indian Immunologicals Limited"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Morningside","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Series B Financing","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AdvanCell \/ Morningside","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Morningside"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ BioSenic"},{"orgOrder":0,"company":"Mesoblast","sponsor":"BMT CTN","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ BMT CTN","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ BMT CTN"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Psylo","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Psylo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Psylo \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Psylo \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Cartherics","sponsor":"Shunxi Holding Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CTH-004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartherics \/ Shunxi Holding Group","highestDevelopmentStatusID":"5","companyTruncated":"Cartherics \/ Shunxi Holding Group"},{"orgOrder":0,"company":"Queensland University of Technology","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"VCAM 1","graph1":"Dermatology","graph2":"Discovery","graph3":"Queensland University of Technology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queensland University of Technology \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Queensland University of Technology \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Genesiscare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Genesiscare","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Genesiscare"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Tenmile","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carina Biotech \/ Tenmile","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Tenmile"},{"orgOrder":0,"company":"Vaxine","sponsor":"Medytox","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Covax-19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Medytox","highestDevelopmentStatusID":"4","companyTruncated":"Vaxine \/ Medytox"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Collaboration","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AdvanCell \/ Point Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Point Biopharma"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microba Life Sciences \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Microba Life Sciences \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute"},{"orgOrder":0,"company":"Griffith University","sponsor":"Luina Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Griffith University \/ Luina Bio","highestDevelopmentStatusID":"1","companyTruncated":"Griffith University \/ Luina Bio"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FivepHusion \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Syneos Health"},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Financing","leadProduct":"Ranibizumab","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Undisclosed"},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Aflibercept","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2024","type":"Funding","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"PolyActiva \/ Medical Research Future Fund","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Medical Research Future Fund"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Private Placement","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Lantheus Holding","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Lantheus Holding"},{"orgOrder":0,"company":"Immutep","sponsor":"Australian Ethical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Australian Ethical","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Australian Ethical"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute"},{"orgOrder":0,"company":"Hudson Institute of Medical Research","sponsor":"Noxopharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA Vaccine","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Hudson Institute of Medical Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hudson Institute of Medical Research \/ Noxopharm","highestDevelopmentStatusID":"2","companyTruncated":"Hudson Institute of Medical Research \/ Noxopharm"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Olaratumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Canaccord Genuity Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Canaccord Genuity Corp","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Canaccord Genuity Corp"},{"orgOrder":0,"company":"Immuron","sponsor":"NMRC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ NMRC","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ NMRC"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ U.S. Department of Defense"},{"orgOrder":0,"company":"CORTx","sponsor":"MRFF","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"CORTx","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"CORTx \/ MRFF","highestDevelopmentStatusID":"2","companyTruncated":"CORTx \/ MRFF"},{"orgOrder":0,"company":"Tessara Therapeutics","sponsor":"CRC-P","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Neuroplastogen","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Tessara Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tessara Therapeutics \/ CRC-P","highestDevelopmentStatusID":"2","companyTruncated":"Tessara Therapeutics \/ CRC-P"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Medical Research Future Fund","highestDevelopmentStatusID":"1","companyTruncated":"University of Melbourne \/ Medical Research Future Fund"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Cartherics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CTH-401","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartherics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cartherics \/ Undisclosed"},{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Platinum International Health Care Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"HaemaLogiX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HaemaLogiX \/ Platinum International Health Care Fund","highestDevelopmentStatusID":"8","companyTruncated":"HaemaLogiX \/ Platinum International Health Care Fund"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Australian Government Department of Industry, Science, Energy and Resources","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Recce Pharmaceuticals \/ Australian Government Department of Industry, Science, Energy and Resources","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Australian Government Department of Industry, Science, Energy and Resources"},{"orgOrder":0,"company":"Cyteph","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Cyteph","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Cyteph \/ CUREator","highestDevelopmentStatusID":"4","companyTruncated":"Cyteph \/ CUREator"},{"orgOrder":0,"company":"Ab Initio Pharma","sponsor":"ResolutionRx","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Ab Initio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ab Initio Pharma \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"Ab Initio Pharma \/ ResolutionRx"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ SHINE Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm Theranostics \/ SHINE Technologies"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incannex Healthcare \/ Monash University","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Monash University"},{"orgOrder":0,"company":"Uniquest","sponsor":"Alterity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"PBT2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Uniquest","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Uniquest \/ Alterity Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Uniquest \/ Alterity Therapeutics"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Malta Enerprises","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"||Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"MGC Pharmaceuticals \/ Malta Enerprises","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Malta Enerprises"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2020","type":"Financing","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Gelteq","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Gelteq","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gelteq \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"Gelteq \/ The Benchmark Company"},{"orgOrder":0,"company":"Gelteq","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Gelteq","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gelteq \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"Gelteq \/ The Benchmark Company"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prota Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Brandon Capital","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Brandon Capital"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"COPD Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ COPD Foundation","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ COPD Foundation"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Peter MacCallum Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Partnership","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Peter MacCallum Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Peter MacCallum Cancer Center"},{"orgOrder":0,"company":"Psylo","sponsor":"University of Sydney","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psylo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Psylo \/ University of Sydney","highestDevelopmentStatusID":"1","companyTruncated":"Psylo \/ University of Sydney"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"WuXi Advanced Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"CHM 1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Chimeric Therapeutics \/ WuXi Advanced Therapies","highestDevelopmentStatusID":"6","companyTruncated":"Chimeric Therapeutics \/ WuXi Advanced Therapies"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"University of Jaen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ University of Jaen","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ University of Jaen"},{"orgOrder":0,"company":"Immuron","sponsor":"Pharmaron","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Pharmaron","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Pharmaron"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Oberon Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"MGC Pharmaceuticals \/ Oberon Capital","highestDevelopmentStatusID":"15","companyTruncated":"MGC Pharmaceuticals \/ Oberon Capital"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Gregory George","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mesoblast \/ Gregory George","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Gregory George"},{"orgOrder":0,"company":"Cambium Bio","sponsor":"Aventacell Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"CAM-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cambium Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambium Bio \/ Aventacell Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Cambium Bio \/ Aventacell Biomedical"},{"orgOrder":0,"company":"BioCina","sponsor":"Australian Government Department of Industry","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"BioCina","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCina \/ Australian Government Department of Industry","highestDevelopmentStatusID":"2","companyTruncated":"BioCina \/ Australian Government Department of Industry"},{"orgOrder":0,"company":"University of Sydney","sponsor":"Medicinova","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II","graph3":"University of Sydney","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Sydney \/ Medicinova","highestDevelopmentStatusID":"8","companyTruncated":"University of Sydney \/ Medicinova"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"CSIRO","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"AMP945","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Amplia Therapeutics \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Amplia Therapeutics \/ CSIRO"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Avance Clinical \/ Atossa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avance Clinical \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Fiona Stanley Hospital","sponsor":"Recce Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fiona Stanley Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Fiona Stanley Hospital \/ Recce Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Fiona Stanley Hospital \/ Recce Pharmaceuticals"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eckert & Ziegler Strahlen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Eckert & Ziegler Strahlen","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Eckert & Ziegler Strahlen"},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"Macquarie University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medlab Clinical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medlab Clinical \/ Macquarie University","highestDevelopmentStatusID":"4","companyTruncated":"Medlab Clinical \/ Macquarie University"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Transcutaneous Injection","sponsorNew":"University of Adelaide \/ Enesi Pharma Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Adelaide \/ Enesi Pharma Limited"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"CSL","sponsor":"Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Hematology","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CSL \/ Translational Sciences","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ Translational Sciences"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FivepHusion \/ Allarity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Allarity Therapeutics"},{"orgOrder":0,"company":"BioCina","sponsor":"GPN Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Gamma-PN3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCina","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCina \/ GPN Vaccines","highestDevelopmentStatusID":"6","companyTruncated":"BioCina \/ GPN Vaccines"},{"orgOrder":0,"company":"Immutep","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Immutep \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Starpharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Starpharma \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma \/ Merck & Co"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"EDV","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"EnGeneIC \/ ImmunityBio"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Professor Colin Masters","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PBT2","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Professor Colin Masters","highestDevelopmentStatusID":"4","companyTruncated":"Alterity Therapeutics \/ Professor Colin Masters"},{"orgOrder":0,"company":"Starpharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Starpharma \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Starpharma \/ Merck & Co"},{"orgOrder":0,"company":"CSL","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Syringe","sponsorNew":"CSL \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ BARDA"},{"orgOrder":0,"company":"Glytherix","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"177-Lu DOTA Miltuximab","moa":"GPC1","graph1":"Oncology","graph2":"Phase I","graph3":"Glytherix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glytherix \/ SHINE Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Glytherix \/ SHINE Technologies"},{"orgOrder":0,"company":"QIMR Berghofer Medical Research Institute","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"EMB-01","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"QIMR Berghofer Medical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"QIMR Berghofer Medical Research Institute \/ EpimAb Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"QIMR Berghofer Medical Research Institute \/ EpimAb Biotherapeutics"},{"orgOrder":0,"company":"Baker Institute","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Baker Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Baker Institute \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Baker Institute \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Imugene","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Avelumab","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ Merck & Co"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"Monash University","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monash University \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Monash University \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Walter and Eliza Hall Institute of Medical Research","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Walter and Eliza Hall Institute of Medical Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Walter and Eliza Hall Institute of Medical Research \/ ONK Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Walter and Eliza Hall Institute of Medical Research \/ ONK Therapeutics"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Specialised Therapeutics \/ CanariaBio"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Nyrada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NYX-PCSK9i","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nyrada","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nyrada \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nyrada \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Bacthera","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"MAP 315","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Microba Life Sciences \/ Bacthera","highestDevelopmentStatusID":"6","companyTruncated":"Microba Life Sciences \/ Bacthera"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast \/ Cleveland Clinic"},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Neuren Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuren Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuren Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Neuren Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neuren Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuren Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXS-6302","moa":"Pan-LOX","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Pharmaxis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaxis \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetazolamide","moa":"||CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZLT-101","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zelira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"||Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Immunomodulator","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Grunenthal"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Immunomodulator","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"E-EDV-D682","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EnGeneIC \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanamem","moa":"11beta-HSD1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"CSL \/ Travere Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Travere Therapeutics"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetazolamide","moa":"||CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"NeuClone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"NeuClone","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuClone \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuClone \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||FAK","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||FAK","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMP945","moa":"||FAK","graph1":"Oncology","graph2":"Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amplia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Sydney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Sydney","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Sydney \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"University of Sydney \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"HaemaLogiX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaemaLogiX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HaemaLogiX \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"||DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ATL1102","moa":"CD49d","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Astodrimer Sodium","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Starpharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Starpharma \/ Inapplicable"},{"orgOrder":0,"company":"Biotron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cinnamoylguanidine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biotron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotron \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Biotron \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CHM 1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Chimeric Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chimeric Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CHM 2101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chimeric Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chimeric Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CF33-hNIS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Imugene \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ City of Hope"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carina Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Queensland","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Queensland \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"University of Queensland \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Apolipoprotein A-I, Human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYP-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYP-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CYP-001","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"De Motu Cordis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"De Motu Cordis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"De Motu Cordis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"De Motu Cordis \/ Inapplicable"},{"orgOrder":0,"company":"Dimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Propagermanium","moa":"CCR2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dimerix \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dimerix \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Merck Group"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Eoc Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Eoc Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Eoc Pharma"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Elixinol Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Elixinol Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Elixinol Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elixinol Wellness \/ Inapplicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eptifibatide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVT801","moa":"VEGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVT801","moa":"VEGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVT801","moa":"VEGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EVT801","moa":"VEGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Chlorzoxazone","moa":"KCNN4","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paxalisib","moa":"||PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"GPN Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Gamma-PN3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GPN Vaccines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GPN Vaccines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GPN Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Global Coalition for Adaptive Research"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IMU-131","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetazolamide","moa":"||CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"68-Ga Gozetotide","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMM-529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMM-529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Command","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ US Naval Medical Research Command","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ US Naval Medical Research Command"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Merck Group"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IMU-131","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Monash University","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Monash University \/ Incannex Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Monash University \/ Incannex Healthcare"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CYP-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Inapplicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Inapplicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"ENA Respiratory \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Inapplicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"ENA Respiratory \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Artemisinin","moa":"||Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"MGC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Island Pharmaceuticals","sponsor":"State University of New York","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ISLA-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Island Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Island Pharmaceuticals \/ State University of New York","highestDevelopmentStatusID":"8","companyTruncated":"Island Pharmaceuticals \/ State University of New York"},{"orgOrder":0,"company":"CSL","sponsor":"Cara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL \/ Cara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Cara Therapeutics"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Accelagen","sponsor":"Kiora Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KIO-301","moa":"Photoswitch","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Accelagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Accelagen \/ Kiora Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Accelagen \/ Kiora Pharmaceuticals"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Sleep","graph2":"Phase I","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"HaemaLogiX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HaemaLogiX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HaemaLogiX \/ Inapplicable"},{"orgOrder":0,"company":"Melbourne\u2019s Walter and Eliza Hall Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Melbourne\u2019s Walter and Eliza Hall Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Melbourne\u2019s Walter and Eliza Hall Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Melbourne\u2019s Walter and Eliza Hall Institute \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Curcumin","moa":"||PPA receptor-gamma","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"MGC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MGC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Garvan Institute of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Microba Life Sciences \/ Garvan Institute of Medical Research","highestDevelopmentStatusID":"2","companyTruncated":"Microba Life Sciences \/ Garvan Institute of Medical Research"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Revascor","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transendocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Medlab Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Medlab Clinical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medlab Clinical \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monepantel","moa":"DEG-3\/DES-2 type nAChR","graph1":"Neurology","graph2":"Phase I","graph3":"Neurizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Drospirenone","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"RECCE 435","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Drospirenone","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Drospirenone","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mayne Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mayne Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mayne Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Neurizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monepantel","moa":"DEG-3\/DES-2 type nAChR","graph1":"Neurology","graph2":"Phase I","graph3":"Neurizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant, Sustained Release","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PBT2","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"ATONCO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Telix Pharmaceuticals \/ ATONCO","highestDevelopmentStatusID":"6","companyTruncated":"Telix Pharmaceuticals \/ ATONCO"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Immunomodulator","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant, Sustained Release","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PharmAust","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monepantel","moa":"DEG-3\/DES-2 type nAChR","graph1":"Neurology","graph2":"Phase I","graph3":"PharmAust","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PharmAust \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAust \/ Inapplicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Blue Knight","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Blue Knight","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Blue Knight"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Veru","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Adelaide \/ Veru","highestDevelopmentStatusID":"8","companyTruncated":"University of Adelaide \/ Veru"},{"orgOrder":0,"company":"University of South Australia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","graph1":"Oncology","graph2":"Preclinical","graph3":"University of South Australia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of South Australia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of South Australia \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Propagermanium","moa":"CCR2","graph1":"Nephrology","graph2":"Phase II","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dimerix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dimerix \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ATL1102","moa":"CD49d","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prota Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incannex Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Aravax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PVX108","moa":"Basophil","graph1":"Immunology","graph2":"Phase I","graph3":"Aravax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Aravax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aravax \/ Inapplicable"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"||Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Pharmaxis \/ University of Rochester Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ University of Rochester Medical Center"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Pharmaxis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monash University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"QPX9003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Monash University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monash University \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monash University \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RAD204","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"R529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FT011","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Certa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Immunomodulator","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"||Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"Sar-Bombesin","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR Bombesin","moa":"||GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR-BBN","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Botanix Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Astodrimer Sodium","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Starpharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Starpharma \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Astodrimer Sodium","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Starpharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Starpharma \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"ChemoCentryx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ ChemoCentryx","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ ChemoCentryx"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Australasian Leukaemia And Lymphoma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Australasian Leukaemia And Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Australasian Leukaemia And Lymphoma Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Australasian Leukaemia And Lymphoma Group \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Murdoch Children\u2019s Research Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Murdoch Children\u2019s Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Murdoch Children\u2019s Research Institute \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Murdoch Children\u2019s Research Institute \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Idronoxil","moa":"||cGAS-STING signaling pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leramilimab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Novotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Panaphix","moa":"Cytokine","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Novotech \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starpharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ArtemiC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MGC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Queensland University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Queensland University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Queensland University \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Queensland University \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"BiomeBank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BiomeBank","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BiomeBank \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BiomeBank \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"University of Queensland","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Queensland \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"University of Queensland \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Griffith University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DpC","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Griffith University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Griffith University \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Griffith University \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Genentech","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ US Naval Medical Research Center","highestDevelopmentStatusID":"5","companyTruncated":"Immuron \/ US Naval Medical Research Center"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXS-6302","moa":"Pan-LOX","graph1":"Dermatology","graph2":"Phase I","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Pharmaxis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pharmaxis \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYP-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Parexel Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Pharmaxis \/ Parexel Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ Parexel Biotech"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starpharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ATL1102","moa":"CD49d","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT120","moa":"B Cell Ige production","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prota Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prota Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"64-Cu MeCOSar-Tyr3-octreotate","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Merck & Co"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"||cGAS-STING signaling pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"QBiotics Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tigilanol Tiglate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"QBiotics Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"QBiotics Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"QBiotics Group \/ Inapplicable"},{"orgOrder":0,"company":"Ampion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampion \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Artemisinin","moa":"||Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"MGC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IC14","moa":"CD14","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Implicit Bioscience \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Implicit Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"University of Queensland","sponsor":"CSL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V451","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Queensland \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"University of Queensland \/ CSL"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"64-Cu SAR-bisPSMA","moa":"PET","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"||VEGF-C\/D","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Immutep","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leramilimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"COVID-EDV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnGeneIC \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"||cGAS-STING signaling pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"||LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA Girentuximab","moa":"||CA IX","graph1":"Oncology","graph2":"Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA-RADmAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"64-Cu DOTA-TLX592","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cymerus Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cynata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"CSL \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Starpharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Astodrimer Sodium","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Starpharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Starpharma \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paxalisib","moa":"||PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanamem","moa":"11beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11beta-HSD1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanamem","moa":"11beta-HSD1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ PharmaMar"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zucero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pixatimod","moa":"Spike protein S1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Zucero Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zucero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Zucero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immuron \/ Inapplicable"},{"orgOrder":0,"company":"Opthea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"||PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Neratinib","moa":"||HER2\/4\/EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Specialised Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"11beta-HSD1","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Actinogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Actinogen \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paxalisib","moa":"||PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"INNA-051","moa":"TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal Dry Powder","sponsorNew":"ENA Respiratory \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ENA Respiratory \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CSL \/ Arcturus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Neurizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monepantel","moa":"DEG-3\/DES-2 type nAChR","graph1":"Neurology","graph2":"Phase I","graph3":"Neurizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"AUSTRALIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Podiatry","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Recce Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rexlemestrocel-L","moa":"Immunomodulator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"||PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"pharma&","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"pharma&","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pharma& \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"pharma& \/ Tolmar"},{"orgOrder":0,"company":"Affiris","sponsor":"Frontier Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Affitope AT04","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affiris \/ Frontier Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ Frontier Biotechnologies"},{"orgOrder":0,"company":"Affiris","sponsor":"AC Immune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ AC Immune","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ AC Immune"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Biomay","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomay \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Biomay \/ BioNTech"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Carragelose","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Marinomed Biotech \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"1","companyTruncated":"Marinomed Biotech \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Proxygen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Proxygen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Proxygen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Proxygen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Invios","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invios \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"QUANTRO Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"QUANTRO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QUANTRO Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"QUANTRO Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Seibersdorf Labor","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Seibersdorf Labor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seibersdorf Labor \/ Blue Earth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Seibersdorf Labor \/ Blue Earth Therapeutics"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AOP Orphan \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Invios","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invios \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"China National Biotech Group","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ China National Biotech Group","highestDevelopmentStatusID":"15","companyTruncated":"Croma-Pharma \/ China National Biotech Group"},{"orgOrder":0,"company":"VALANX Biotech","sponsor":"Fina Biosolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VALANX Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VALANX Biotech \/ Fina Biosolutions","highestDevelopmentStatusID":"4","companyTruncated":"VALANX Biotech \/ Fina Biosolutions"},{"orgOrder":0,"company":"Invios","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invios \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Themis Bioscience \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"YGION Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"YG-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"YGION Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YGION Biomedical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"YGION Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Tubepharma","sponsor":"Oncomatryx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"OMTX705","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Tubepharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tubepharma \/ Oncomatryx","highestDevelopmentStatusID":"6","companyTruncated":"Tubepharma \/ Oncomatryx"},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRIA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Proxygen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proxygen \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Proxygen \/ Merck & Co"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Marinomed Biotech \/ Luoxin Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Marinomed Biotech \/ Luoxin Pharmaceutical"},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Technology","graph2":"Discovery","graph3":"Proxygen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proxygen \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"Proxygen \/ Merck Group"},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"Viravaxx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Azithromycin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Vienna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Medical University of Vienna \/ Viravaxx","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Vienna \/ Viravaxx"},{"orgOrder":0,"company":"Affiris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AT04A","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ Inapplicable"},{"orgOrder":0,"company":"Apeptico","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Solnatide","moa":"Sodium channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeptico","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apeptico \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeptico \/ Inapplicable"},{"orgOrder":0,"company":"Invios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invios \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AOP Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"AOP Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Inapplicable"},{"orgOrder":0,"company":"AOP Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"AOP Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"||Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Carrageenan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Marinomed Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinomed Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"F4 Pharma","sponsor":"Assistance Publique Hopitaux de Paris","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"FX06","moa":"Pro-inflammatory fibrin E1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F4 Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F4 Pharma \/ Assistance Publique Hopitaux de Paris","highestDevelopmentStatusID":"8","companyTruncated":"F4 Pharma \/ Assistance Publique Hopitaux de Paris"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Croma-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Carrageenan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Marinomed Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinomed Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"OrphanDC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pint Pharma \/ OrphanDC","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ OrphanDC"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eribulin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Affiris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"mAB C6-17","moa":"mtHTT","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affiris \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Affiris \/ Inapplicable"},{"orgOrder":0,"company":"Affiris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ Inapplicable"},{"orgOrder":0,"company":"Invios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Invios \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Inapplicable"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Carrageenan","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Marinomed Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinomed Biotech \/ Inapplicable"},{"orgOrder":0,"company":"OncoOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ON203","moa":"MIF","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoOne","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoOne \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoOne \/ Inapplicable"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Panoptes Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PP-OO1","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panoptes Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panoptes Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Panoptes Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Croma-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AOP Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AOP Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AOP Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AOP Health \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506 binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Marinomed Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRIA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Invios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Invios \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Inapplicable"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506 binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Marinomed Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cebina","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cebina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cebina \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cebina \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Alunacedase Alpha","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pint Pharma \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ PharmaEssentia"},{"orgOrder":0,"company":"QUANTRO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"QUANTRO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QUANTRO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"QUANTRO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BANGLADESH","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Beximco Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Beximco Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beximco Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Beximco Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beximco Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beximco Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Globe Biotech Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"D614G variant LNP-encapsulated mRNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Globe Biotech Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Globe Biotech Limited \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Globe Biotech Limited \/ Inapplicable"},{"orgOrder":0,"company":"Etherna","sponsor":"Dropshot Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Etherna","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Etherna \/ Dropshot Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Etherna \/ Dropshot Therapeutics"},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"AGT-100216","moa":"HDAC6","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Augustine Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Augustine Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Augustine Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"BIOX-101","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Bioxodes","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioxodes \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Undisclosed"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"ESO-T01","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":1,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Intravenous Injection","sponsorNew":"EsoBiotec \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ AstraZeneca"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tibolone","moa":"Sulphatase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mithra Pharmaceuticals \/ BIOSYENT PHARMA INC","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ BIOSYENT PHARMA INC"},{"orgOrder":0,"company":"Galapagos","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Alfasigma"},{"orgOrder":0,"company":"Galapagos","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Alfasigma"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"AGMB-129","moa":"ALK-5","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Pfizer Inc"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"AGMB-129","moa":"ALK-5","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ EQT Life Sciences"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"AGMB-129","moa":"ALK-5","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Sanofi"},{"orgOrder":0,"company":"Syndesi Therapeutics","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"SDI-118","moa":"SV2A","graph1":"Neurology","graph2":"Phase I","graph3":"Syndesi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndesi Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Syndesi Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Handl therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Handl therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Handl therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"Handl therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Alprostadil","moa":"EP1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Advanz Pharma"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Bio-Pharma \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto Bio-Pharma \/ Humanigen"},{"orgOrder":0,"company":"Aji Bio Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Expanded Collaboration","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Aji Bio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aji Bio Pharma \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Aji Bio Pharma \/ Humanigen"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ajinomoto Bio-Pharma \/ Revance Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto Bio-Pharma \/ Revance Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Pregene","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Pregene"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Drugs for Neglected Disease Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"CpG-D35","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Bio-Pharma \/ Drugs for Neglected Disease Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Bio-Pharma \/ Drugs for Neglected Disease Initiative"},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Gestys Sant\u00e9 Biotech","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Gestys Sant\u00e9 Biotech"},{"orgOrder":0,"company":"Ncardia","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Cardiomyocytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Ncardia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ncardia \/ BlueRock Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Ncardia \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Implant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Implant Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Bone Therapeutics \/ Implant Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Etherna","sponsor":"VUB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Etherna","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Etherna \/ VUB","highestDevelopmentStatusID":"7","companyTruncated":"Etherna \/ VUB"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Spirig Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tibolone","moa":"Sulphatase","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mithra Pharmaceuticals \/ Spirig Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Spirig Healthcare"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Clonidine","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Ghent University","sponsor":"eTheRNA immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ghent University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ghent University \/ eTheRNA immunotherapies","highestDevelopmentStatusID":"1","companyTruncated":"Ghent University \/ eTheRNA immunotherapies"},{"orgOrder":0,"company":"Exothera","sponsor":"Cyanvac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"CVXGA1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exothera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Exothera \/ Cyanvac","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/ Cyanvac"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Clonidine","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Berenberg","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Berenberg"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Berenberg","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Berenberg"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"VHH72-FC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ Undisclosed"},{"orgOrder":0,"company":"BioSenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Phebra","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Phebra"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Zentiva"},{"orgOrder":0,"company":"Nipro Glass","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Recombinant Chadox1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nipro Glass","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nipro Glass \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Nipro Glass \/ AstraZeneca"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"NVD-X3","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Science Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Novadip Biosciences \/ Science Ventures"},{"orgOrder":0,"company":"Oxurion","sponsor":"Bank Degroof Petercam","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Bank Degroof Petercam","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Bank Degroof Petercam"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Breast International Group","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Amcenestrant","moa":"SER","graph1":"Oncology","graph2":"Phase II","graph3":"Breast International Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breast International Group \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Breast International Group \/ Sanofi"},{"orgOrder":0,"company":"reMYND","sponsor":"Korys Investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"reMYND \/ Korys Investments","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ Korys Investments"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"Lsp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"eTheRNA immunotherapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"eTheRNA immunotherapies \/ Lsp","highestDevelopmentStatusID":"1","companyTruncated":"eTheRNA immunotherapies \/ Lsp"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"AGMB-101","moa":"MET","graph1":"Immunology","graph2":"IND Enabling","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgomAb Therapeutics N.V \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"AgomAb Therapeutics N.V \/ Redmile Group"},{"orgOrder":0,"company":"Exothera","sponsor":"Remedium","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"RMD 1101","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Exothera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Exothera \/ Remedium","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/ Remedium"},{"orgOrder":0,"company":"Global Stem Cell Technology","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Arti-Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Global Stem Cell Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Stem Cell Technology \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"Global Stem Cell Technology \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bone Therapeutics \/ Medsenic","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Medsenic"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Pheno Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCB Pharma S.A \/ Pheno Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"UCB Pharma S.A \/ Pheno Therapeutics"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Confo Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Alprostadil","moa":"EP1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Advanz Pharma"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"BELGIUM","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ AbCellera"},{"orgOrder":0,"company":"Etherna","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Etherna","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Etherna \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"Etherna \/ Almirall"},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"Dynacure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Oligonucleotide","year":"2023","type":"Merger","leadProduct":"Danvatirsen","moa":"||STAT3 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Flamingo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Flamingo Therapeutics \/ Dynacure","highestDevelopmentStatusID":"8","companyTruncated":"Flamingo Therapeutics \/ Dynacure"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Private Placement","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"XVR012","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ European Investment Bank","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ European Investment Bank"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Endocrinology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Exothera","sponsor":"Rokote Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"FINCoVac 2.0","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exothera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Exothera \/ Rokote Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/ Rokote Laboratories"},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"VLAIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"Danvatirsen","moa":"||STAT3 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Flamingo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Flamingo Therapeutics \/ VLAIO","highestDevelopmentStatusID":"8","companyTruncated":"Flamingo Therapeutics \/ VLAIO"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Imotope","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"XVR021","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Walloon Region","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"HY-083","moa":"TRPV1","graph1":"Immunology","graph2":"Preclinical","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hyloris Pharmaceuticals \/ Walloon Region","highestDevelopmentStatusID":"4","companyTruncated":"Hyloris Pharmaceuticals \/ Walloon Region"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"AstriVax","sponsor":"VLAIO","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"AstriVax","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstriVax \/ VLAIO","highestDevelopmentStatusID":"3","companyTruncated":"AstriVax \/ VLAIO"},{"orgOrder":0,"company":"Etherna","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Etherna","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Etherna \/ European Commission","highestDevelopmentStatusID":"7","companyTruncated":"Etherna \/ European Commission"},{"orgOrder":0,"company":"AstriVax","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstriVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstriVax \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"4","companyTruncated":"AstriVax \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Private Placement","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"KBC Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ KBC Securities","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ KBC Securities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Kreos Capital","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Kreos Capital"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Plecoid","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyloris Pharmaceuticals \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hyloris Pharmaceuticals \/ Pleco Therapeutics"},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"AGT100216","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Augustine Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Augustine Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Augustine Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Financing","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ ABO Securities"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ ABO Securities"},{"orgOrder":0,"company":"Precirix","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabelled Compounds","year":"2022","type":"Series B Financing","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ INKEF Capital","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ INKEF Capital"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Driehaus Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Driehaus Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ Driehaus Capital Management"},{"orgOrder":0,"company":"ATB Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ATB Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATB Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"ATB Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"4","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mithra Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Mithra Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"reMYND","sponsor":"National Institute of Neurological Disorders","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ReS3-T","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"reMYND","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"reMYND \/ National Institute of Neurological Disorders","highestDevelopmentStatusID":"4","companyTruncated":"reMYND \/ National Institute of Neurological Disorders"},{"orgOrder":0,"company":"Ncardia","sponsor":"Kiniciti","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ncardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ncardia \/ Kiniciti","highestDevelopmentStatusID":"4","companyTruncated":"Ncardia \/ Kiniciti"},{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"DT-001","moa":"TNFR2","graph1":"Immunology","graph2":"IND Enabling","graph3":"Dualyx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dualyx \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"5","companyTruncated":"Dualyx \/ Fountain Healthcare Partners"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Sotalol Hydrochloride","moa":"hREG","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Termination","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Trio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ajinomoto Bio-Pharma \/ Trio Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Bio-Pharma \/ Trio Pharmaceuticals"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ CBC Group"},{"orgOrder":0,"company":"Ardena","sponsor":"Race Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bisantrene DiHCl","moa":"FTO protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Ardena","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ardena \/ Race Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Ardena \/ Race Oncology"},{"orgOrder":0,"company":"KU Leuven","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"BHV-2100","moa":"TRPM3","graph1":"Neurology","graph2":"Preclinical","graph3":"KU Leuven","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KU Leuven \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"KU Leuven \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Searchlight Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Searchlight Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Searchlight Pharma"},{"orgOrder":0,"company":"Oxurion","sponsor":"VIB","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ VIB","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ VIB"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Fuji Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Fuji Pharma"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Fuji Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Fuji Pharma"},{"orgOrder":0,"company":"Biocartis","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Biocartis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biocartis \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Biocartis \/ AstraZeneca"},{"orgOrder":0,"company":"Anima Medical Centre","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Huntingtin protein","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anima Medical Centre","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anima Medical Centre \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Anima Medical Centre \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Complix","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Complix","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complix \/ Jiangsu Nhwa Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Complix \/ Jiangsu Nhwa Pharmaceutical"},{"orgOrder":0,"company":"Complix","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Complix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complix \/ I-Mab Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Complix \/ I-Mab Biopharma"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Farmitalia","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Farmitalia","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Farmitalia"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Confo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Galapagos","sponsor":"NovAliX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Galapagos \/ NovAliX","highestDevelopmentStatusID":"2","companyTruncated":"Galapagos \/ NovAliX"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Searchlight Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Searchlight Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Searchlight Pharma"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Bioqube Ventures","sponsor":"Metrion Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"KV1.3 potassium ion channel","graph1":"Immunology","graph2":"Discovery","graph3":"Bioqube Ventures","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioqube Ventures \/ Metrion Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Bioqube Ventures \/ Metrion Biosciences"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Gynial","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Mithra Pharmaceuticals \/ Gynial","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Gynial"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"XVR011","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ExeVir Bio \/ VIB","highestDevelopmentStatusID":"5","companyTruncated":"ExeVir Bio \/ VIB"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"ExeVir Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"XVR011","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mithra Pharmaceuticals \/ ExeVir Bio","highestDevelopmentStatusID":"7","companyTruncated":"Mithra Pharmaceuticals \/ ExeVir Bio"},{"orgOrder":0,"company":"Ziphius Vaccines","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"ZIP-1642","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ziphius Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ziphius Vaccines \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Ziphius Vaccines \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Inapplicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5","graph1":"Immunology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"A.forall","sponsor":"Sagent Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"A.forall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A.forall \/ Sagent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"A.forall \/ Sagent Pharmaceuticals"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AGMB-447","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AgomAb Therapeutics N.V \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Inapplicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AGMB-447","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AgomAb Therapeutics N.V \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb Therapeutics N.V \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Vaneltix Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Pre-Filled Syringe","sponsorNew":"Hyloris Pharmaceuticals \/ Vaneltix Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Hyloris Pharmaceuticals \/ Vaneltix Pharma"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Anima Medical Centre","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anima Medical Centre","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anima Medical Centre \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Anima Medical Centre \/ Moderna Therapeutics"},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pipamperone","moa":"5-HT2A\/D4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANeuroTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Padsevonil","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BIOX-101","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Bioxodes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioxodes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Precirix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Inapplicable"},{"orgOrder":0,"company":"myNEO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CAMYO-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"myNEO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"myNEO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"myNEO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Biogen"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Confo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Confo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"BCI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mithra Pharmaceuticals \/ BCI Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Mithra Pharmaceuticals \/ BCI Pharma"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GLPG2737","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"BELGIUM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Serb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Serb \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serb \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Confo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CYAD-01","moa":"NKG2D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-02","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"University of Antwerp","sponsor":"Fidec Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"nOPV2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"University of Antwerp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Antwerp \/ Fidec Corporation","highestDevelopmentStatusID":"15","companyTruncated":"University of Antwerp \/ Fidec Corporation"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estetrol","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estetrol","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Amgen Inc"},{"orgOrder":0,"company":"EXO Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EXOB-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"EXO Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"EXO Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EXO Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Podophyllotoxin","moa":"TUBA4A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoietic Research Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GLPG5201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GLPG5301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valacyclovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imcyse","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IMCY-0098","moa":"CD4 T cell","graph1":"Endocrinology","graph2":"Phase II","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Imcyse \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imcyse \/ Inapplicable"},{"orgOrder":0,"company":"Imcyse","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IMCY-0141","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Imcyse \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imcyse \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estetrol","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mithra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intraperitoneal Solution","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"||Adrenergic receptor-alpha 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLPG1205","moa":"GPR84","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Purna Female Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Miconazole Nitrate","moa":"||Ergosterol synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Cream","sponsorNew":"Hyloris Pharmaceuticals \/ Purna Female Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Hyloris Pharmaceuticals \/ Purna Female Healthcare"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NVD-001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NVD-001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NVD-X3","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLPG3970","moa":"TOL2\/3","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Imcyse","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"IMCY-0098","moa":"CD4 T cell","graph1":"Endocrinology","graph2":"Phase II","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Imcyse \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imcyse \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PTX-252","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyloris Pharmaceuticals \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hyloris Pharmaceuticals \/ Pleco Therapeutics"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"reMYND","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"reMYND \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ Inapplicable"},{"orgOrder":0,"company":"reMYND","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"reMYND \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ Inapplicable"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RJB-0402","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Rejuvenate Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rejuvenate Biomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rejuvenate Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Galantamine Hydrobromide","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rejuvenate Biomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rejuvenate Biomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rejuvenate Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Hydrobromide","moa":"||Ach receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rejuvenate Biomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rejuvenate Biomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rejuvenate Biomed \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLPG1205","moa":"GPR84","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioSenic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/ Inapplicable"},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pipamperone","moa":"||5-HT2A\/D4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANeuroTech \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech \/ Johnson & Johnson"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Gilead Sciences"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoietic Research Corporation \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoietic Research Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"eTheRNA immunotherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"eTheRNA immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"eTheRNA immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Confo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-211","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Complix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MCL1","graph1":"Oncology","graph2":"Preclinical","graph3":"Complix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Complix \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VIB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"VIB \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"VIB \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Merck & Co"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Inapplicable"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Hyloris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hyloris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-101","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bepranemab","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"XVR012","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ Inapplicable"},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"XVR013","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeVir Bio \/ VIB","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio \/ VIB"},{"orgOrder":0,"company":"AstriVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"AVX70120","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstriVax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstriVax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AstriVax \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Ziphius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ZIP-1642","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ziphius Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ziphius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ziphius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Dermatology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AGMB-129","moa":"ALK-5","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Inapplicable"},{"orgOrder":0,"company":"Allegro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Hydrocelin","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Allegro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Allegro \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allegro \/ Inapplicable"},{"orgOrder":0,"company":"Allegro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Hydrocelin","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Allegro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allegro \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allegro \/ Inapplicable"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BIOX-101","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Bioxodes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioxodes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Inapplicable"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BIOX-101","moa":"FXIa\/XIIa","graph1":"Neurology","graph2":"Phase II","graph3":"Bioxodes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioxodes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Inapplicable"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EsoBiotec \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ Inapplicable"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EsoBiotec \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NVD-003","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Novadip Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"A.forall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tromethamine API","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"A.forall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A.forall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"A.forall \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minzasolmin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"UCB Pharma S.A \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Radiolabelled Compounds","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Bentonite","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"AM-401","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Univercells","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Univercells"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Heqet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BERMUDA","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Heqet Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Heqet Therapeutics"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BERMUDA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BERMUDA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BERMUDA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"AM-411","moa":"Nf-kB","graph1":"Immunology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BERMUDA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BERMUDA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BERMUDA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BERMUDA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BERMUDA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"BERMUDA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BERMUDA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"AM-401","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BERMUDA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"University of Michigan School","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BERMUDA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altamira Therapeutics \/ University of Michigan School","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ University of Michigan School"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corpometria Institute","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"||Steroid 5-alpha-reductase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corpometria Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corpometria Institute \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Corpometria Institute \/ Applied Biology"},{"orgOrder":0,"company":"University of Campinas","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Campinas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"University of Campinas \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"University of Campinas \/ Moleculin Biotech"},{"orgOrder":0,"company":"Albert Einstein Israelite Hospital","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Albert Einstein Israelite Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Albert Einstein Israelite Hospital \/ CytoDyn","highestDevelopmentStatusID":"8","companyTruncated":"Albert Einstein Israelite Hospital \/ CytoDyn"},{"orgOrder":0,"company":"Fiocruz","sponsor":"Nortec Quimica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Benznidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fiocruz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fiocruz \/ Nortec Quimica","highestDevelopmentStatusID":"8","companyTruncated":"Fiocruz \/ Nortec Quimica"},{"orgOrder":0,"company":"Farmacore Biotechnology","sponsor":"MCTIC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"PDS0204","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Farmacore Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Farmacore Biotechnology \/ MCTIC","highestDevelopmentStatusID":"4","companyTruncated":"Farmacore Biotechnology \/ MCTIC"},{"orgOrder":0,"company":"Biomm","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Phase III","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomm \/ Lupin Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Lupin Ltd"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"ACH000029","moa":"Adrenergic receptor-alpha 1","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"Nortec Quimica","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nortec Quimica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nortec Quimica \/ The Medicines Patent Pool","highestDevelopmentStatusID":"9","companyTruncated":"Nortec Quimica \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"L-Arginine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Megalabs \/ Inapplicable"},{"orgOrder":0,"company":"Anvisa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anvisa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Anvisa \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anvisa \/ Inapplicable"},{"orgOrder":0,"company":"HempMeds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"HempMeds","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"HempMeds \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HempMeds \/ Inapplicable"},{"orgOrder":0,"company":"Uniao Quimica Farmaceutica Nacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Uniao Quimica Farmaceutica Nacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Uniao Quimica Farmaceutica Nacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Uniao Quimica Farmaceutica Nacional \/ Inapplicable"},{"orgOrder":0,"company":"Fiocruz research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atazanavir","moa":"||Mpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fiocruz research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fiocruz research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fiocruz research \/ Inapplicable"},{"orgOrder":0,"company":"Biomm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biomm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Inapplicable"},{"orgOrder":0,"company":"HempMeds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"HempMeds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"HempMeds \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HempMeds \/ Inapplicable"},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Butantan Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Butantan Institute \/ Inapplicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"UT Health San Antonio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ UT Health San Antonio","highestDevelopmentStatusID":"7","companyTruncated":"PharmAla Biotech \/ UT Health San Antonio"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Swanielle Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Collaboration","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicus Pharma \/ Swanielle Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Swanielle Inc"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"Aspect Biosystems","sponsor":"Dimension","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Aspect Biosystems","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Aspect Biosystems \/ Dimension","highestDevelopmentStatusID":"3","companyTruncated":"Aspect Biosystems \/ Dimension"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"BioStem Technologies","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"||Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ BioStem Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ BioStem Technologies"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Best Buy Medical Canada","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Best Buy Medical Canada","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Best Buy Medical Canada"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Variational AI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"ATR","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Variational AI","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Variational AI"},{"orgOrder":0,"company":"Congruence","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Congruence","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Congruence \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Congruence \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Bloom Burton Securities Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Bloom Burton Securities Inc","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Bloom Burton Securities Inc"},{"orgOrder":0,"company":"Variational AI","sponsor":"Nimbus Synergies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Variational AI","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Variational AI \/ Nimbus Synergies","highestDevelopmentStatusID":"3","companyTruncated":"Variational AI \/ Nimbus Synergies"},{"orgOrder":0,"company":"Paradox Immunotherapeutics","sponsor":"SymBiosis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"LX-96","moa":"Diseased IgG light chain","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Paradox Immunotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Paradox Immunotherapeutics \/ SymBiosis","highestDevelopmentStatusID":"4","companyTruncated":"Paradox Immunotherapeutics \/ SymBiosis"},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"AMP01","moa":"PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Reverb Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Reverb Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Reverb Therapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"M4K Pharma","sponsor":"Conscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"ALK-2","graph1":"Oncology","graph2":"Preclinical","graph3":"M4K Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M4K Pharma \/ Conscience","highestDevelopmentStatusID":"4","companyTruncated":"M4K Pharma \/ Conscience"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Velan Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody","year":"2025","type":"Private Placement","leadProduct":"EB06","moa":"CXCL10","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Edesa Biotech \/ Velan Capital","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ Velan Capital"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film, Dispersible","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Variational AI","sponsor":"Merck Global Health Innovation Fund","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Variational AI","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Variational AI \/ Merck Global Health Innovation Fund","highestDevelopmentStatusID":"3","companyTruncated":"Variational AI \/ Merck Global Health Innovation Fund"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Epitopea","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Epitopea","highestDevelopmentStatusID":"3","companyTruncated":"Genevant Sciences \/ Epitopea"},{"orgOrder":0,"company":"AbCellera","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ AbbVie Inc"},{"orgOrder":0,"company":"Zymeworks","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Zymeworks","amount2":1.1000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.1000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks \/ GSK"},{"orgOrder":0,"company":"Immunovaccine Technologies","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Immunovaccine Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovaccine Technologies \/ Biovaxys","highestDevelopmentStatusID":"8","companyTruncated":"Immunovaccine Technologies \/ Biovaxys"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Firefly Neuroscience","sponsor":"Bright Minds Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Firefly Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Firefly Neuroscience \/ Bright Minds Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Firefly Neuroscience \/ Bright Minds Biosciences"},{"orgOrder":0,"company":"Sagard Healthcare","sponsor":"Mannkind","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sagard Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Sagard Healthcare \/ Mannkind","highestDevelopmentStatusID":"15","companyTruncated":"Sagard Healthcare \/ Mannkind"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Raymond James Ltd","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Raymond James Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Raymond James Ltd"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Raymond James Ltd","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Raymond James Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Raymond James Ltd"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Seleni Institute","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Reunion Neuroscience \/ Seleni Institute","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Seleni Institute"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"The Benchmark Company, LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Cognition \/ The Benchmark Company, LLC","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ The Benchmark Company, LLC"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Cognition \/ Titan Partners Group","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Titan Partners Group"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Canaccord Genuity Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Canaccord Genuity Corp","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Canaccord Genuity Corp"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dalton Pharma Services \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dalton Pharma Services \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaTher \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Revive Therapeutics"},{"orgOrder":0,"company":"Primary Peptides","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"PP-001","moa":"DHODH","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Primary Peptides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primary Peptides \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Primary Peptides \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Dalmore Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon NeuroScience \/ Dalmore Group","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Dalmore Group"},{"orgOrder":0,"company":"ExCellThera","sponsor":"IRICoR","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExCellThera \/ IRICoR","highestDevelopmentStatusID":"4","companyTruncated":"ExCellThera \/ IRICoR"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"DHA","moa":"DHA level","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lobe Sciences \/ Pentec Health","highestDevelopmentStatusID":"15","companyTruncated":"Lobe Sciences \/ Pentec Health"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Amplitude Ventures"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"QBECO-SSI","moa":"Site specific immuno","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Karolinska Institute"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Amplitude Ventures"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Crohn\u2019s and Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Crohn\u2019s and Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Giiant pharma \/ Crohn\u2019s and Colitis Foundation"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"QBECO-SSI","moa":"Site specific immuno","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Palisade Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GT-2108","moa":"PDE4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Palisade Bio","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pharma \/ Palisade Bio"},{"orgOrder":0,"company":"The Valens Company","sponsor":"PMI Mexico","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oil","sponsorNew":"The Valens Company \/ PMI Mexico","highestDevelopmentStatusID":"1","companyTruncated":"The Valens Company \/ PMI Mexico"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Case Western Reserve University","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Infusion","sponsorNew":"PharmaTher \/ Case Western Reserve University","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Case Western Reserve University"},{"orgOrder":0,"company":"Marvel Biosciences","sponsor":"iBraiN Institute","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Istradefylline","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Marvel Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marvel Biosciences \/ iBraiN Institute","highestDevelopmentStatusID":"4","companyTruncated":"Marvel Biosciences \/ iBraiN Institute"},{"orgOrder":0,"company":"Prometic Biotherapeutic","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Prometic Biotherapeutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder","sponsorNew":"Prometic Biotherapeutic \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Prometic Biotherapeutic \/ Kedrion"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"University of L\u2019Aquila","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ University of L\u2019Aquila","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ University of L\u2019Aquila"},{"orgOrder":0,"company":"McGill University","sponsor":"Clarus","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"McGill University \/ Clarus","highestDevelopmentStatusID":"1","companyTruncated":"McGill University \/ Clarus"},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"KYE Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KYE Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"KYE Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"BWX Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2023","type":"Agreement","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ BWX Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ BWX Technologies"},{"orgOrder":0,"company":"48Hour Discovery","sponsor":"Alberta Cancer Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"48Hour Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"48Hour Discovery \/ Alberta Cancer Foundation","highestDevelopmentStatusID":"3","companyTruncated":"48Hour Discovery \/ Alberta Cancer Foundation"},{"orgOrder":0,"company":"Covar Pharmaceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Covar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Covar Pharmaceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Covar Pharmaceuticals \/ FSD Pharma"},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"AazeinTX","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"NEO6860","moa":"TRPV1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"adMare BioInnovations \/ AazeinTX","highestDevelopmentStatusID":"4","companyTruncated":"adMare BioInnovations \/ AazeinTX"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Gilead Sciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Tachyon Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"TACH204","moa":"LEFTY1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Tachyon Technologies","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Tachyon Technologies"},{"orgOrder":0,"company":"AbCellera","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ IGM Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ IGM Biosciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AbCellera \/ Kodiak Sciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Kodiak Sciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Deaconess Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Deaconess Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Deaconess Research Institute"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Protein","year":"2021","type":"Divestment","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Liminal BioSciences \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Liminal BioSciences \/ Kedrion"},{"orgOrder":0,"company":"Maxima Pharmaceuticals","sponsor":"Medisca","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Pluronic Lecithin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maxima Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Maxima Pharmaceuticals \/ Medisca","highestDevelopmentStatusID":"15","companyTruncated":"Maxima Pharmaceuticals \/ Medisca"},{"orgOrder":0,"company":"Acuitas","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acuitas \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Bayer AG"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Aditxt","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Aditxt"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Aditxt","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Aditxt"},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"Nav1.5 Sodium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Correvio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Correvio Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Correvio Pharma \/ Advanz Pharma"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Defense Threat Reduction Agency"},{"orgOrder":0,"company":"Triple Hair","sponsor":"Akums Drugs & Pharmaceuticals Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Dermatology","graph2":"Phase II","graph3":"Triple Hair","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alladapt Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"ADP101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Altasciences Company Inc \/ Alladapt Immunotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Altasciences Company Inc \/ Alladapt Immunotherapeutics"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2020","type":"Series A Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ripple Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Ripple Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"CQDM","sponsor":"Quebec Breast Cancer Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Funding","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"CQDM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CQDM \/ Quebec Breast Cancer Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CQDM \/ Quebec Breast Cancer Foundation"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||RAR beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Long Zone Holdings Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Long Zone Holdings Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Long Zone Holdings Inc."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Lind Partners","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Lind Partners"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Lind Global Fund II, LP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Lind Global Fund II, LP","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Lind Global Fund II, LP"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ The Lind Partners","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ The Lind Partners"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Defense Threat Reduction Agency"},{"orgOrder":0,"company":"Covar Pharmaceuticals","sponsor":"Aptorum","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"SACT-COV19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Covar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Covar Pharmaceuticals \/ Aptorum","highestDevelopmentStatusID":"1","companyTruncated":"Covar Pharmaceuticals \/ Aptorum"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Aronnax","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Aronnax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aronnax \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aronnax \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Population Council","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Segesterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Duchesnay \/ Population Council","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Population Council"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Fujifilm Toyama Chemical","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Fujifilm Toyama Chemical"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Yale University"},{"orgOrder":0,"company":"Cyclica","sponsor":"Structural Genomics Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"DCAF1","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclica \/ Structural Genomics Consortium","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ Structural Genomics Consortium"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"Bausch Health","sponsor":"MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Chlordiazepoxide","moa":"||Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica"},{"orgOrder":0,"company":"Brains Bioceutical","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Brains Bioceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Brains Bioceutical \/ Icahn School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Brains Bioceutical \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bryden Stokes Limited","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Bryden Stokes Limited","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/ Bryden Stokes Limited"},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Invetx"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Bayer AG"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Carleton University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Carleton University","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Carleton University"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Negev Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Negev Capital","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Negev Capital"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Hospices Civils de Lyon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Hospices Civils de Lyon","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Hospices Civils de Lyon"},{"orgOrder":0,"company":"Biovectra Inc","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Biovectra Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biovectra Inc \/ PhaseBio Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biovectra Inc \/ PhaseBio Pharmaceuticals"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"EMD Financial","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ EMD Financial","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ EMD Financial"},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"BVX-0320","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ The Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ The Ohio State University"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bio-Gate AG","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Avicanna \/ Bio-Gate AG","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Bio-Gate AG"},{"orgOrder":0,"company":"Cyclica","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyclica \/ Cerevel Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ Cerevel Therapeutics"},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"Champignon","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dalriada Drug Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dalriada Drug Discovery \/ Champignon","highestDevelopmentStatusID":"4","companyTruncated":"Dalriada Drug Discovery \/ Champignon"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Deferiprone","moa":"Iron","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apotex Inc \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Chiesi Group"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Clearmind Medicine \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"1","companyTruncated":"Clearmind Medicine \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"Akshaya Bio","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Akshaya Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Akshaya Bio \/ Cytovance Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Akshaya Bio \/ Cytovance Biologics"},{"orgOrder":0,"company":"PharmaTher","sponsor":"TSRL","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ TSRL","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ TSRL"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Repare Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Psyence","sponsor":"Pure Extracts Technologies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Pure Extracts Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ Pure Extracts Technologies"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Minakem (formerly Delmar Chemicals)","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Minakem (formerly Delmar Chemicals)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Minakem (formerly Delmar Chemicals) \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minakem (formerly Delmar Chemicals) \/ Undisclosed"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"ROS","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Croma-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Croma-Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Crescita Therapeutics \/ Croma-Pharma"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"CBR","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cronos Group \/ Ginkgo Bioworks","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biotech \/ Core One Labs"},{"orgOrder":0,"company":"Cybin","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Deep Track Capital"},{"orgOrder":0,"company":"Cybin","sponsor":"Bloom Burton Securities Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Bloom Burton Securities Inc","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Bloom Burton Securities Inc"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cybin Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntelGenx \/ Cybin Corp","highestDevelopmentStatusID":"1","companyTruncated":"IntelGenx \/ Cybin Corp"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Neurology","graph2":"Discovery","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclica \/ Arctoris","highestDevelopmentStatusID":"2","companyTruncated":"Cyclica \/ Arctoris"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Health Canada","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dalton Pharma Services \/ Health Canada","highestDevelopmentStatusID":"15","companyTruncated":"Dalton Pharma Services \/ Health Canada"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"DanCann Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tetra BioPharma \/ DanCann Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ DanCann Pharma"},{"orgOrder":0,"company":"Deep Genomics","sponsor":"SoftBank Vision Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Oligonucleotide","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Deep Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Deep Genomics \/ SoftBank Vision Fund","highestDevelopmentStatusID":"3","companyTruncated":"Deep Genomics \/ SoftBank Vision Fund"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University Of Health Sciences Antigua","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Revive Therapeutics \/ University Of Health Sciences Antigua","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ University Of Health Sciences Antigua"},{"orgOrder":0,"company":"Rapid Dose Therapeutics","sponsor":"Natural Sciences and Engineering Research Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rapid Dose Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Rapid Dose Therapeutics \/ Natural Sciences and Engineering Research Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Rapid Dose Therapeutics \/ Natural Sciences and Engineering Research Council of Canada"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"University of Maryland School of Medicine\u2019s Institute of Human Virology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Enzyme","year":"2022","type":"Collaboration","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-film","sponsorNew":"Kane Biotech \/ University of Maryland School of Medicine\u2019s Institute of Human Virology","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ University of Maryland School of Medicine\u2019s Institute of Human Virology"},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"World Orphan Drug Alliance","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ World Orphan Drug Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ World Orphan Drug Alliance"},{"orgOrder":0,"company":"Partner International","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Partner International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Partner International \/ Emmaus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Partner International \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PALADIN LABS \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ Endo International"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Jefferies and Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Jefferies and Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Jefferies and Piper Sandler"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Jefferies"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Atropine","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Spray","sponsorNew":"Bausch & Lomb Incorporated \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Eyenovia"},{"orgOrder":0,"company":"Notch Therapeutics","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Notch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Notch Therapeutics \/ Allogene Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Notch Therapeutics \/ Allogene Therapeutics"},{"orgOrder":0,"company":"AbCellera","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbCellera \/ Government of Canada","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Government of Canada"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"OB-002","moa":"CCR5 pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Biotechnology \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"4","companyTruncated":"Orion Biotechnology \/ National Research Council Industrial Research Assistance Program"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"St. Baldrick\u2019s Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ St. Baldrick\u2019s Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ St. Baldrick\u2019s Foundation"},{"orgOrder":0,"company":"Virica Biotech","sponsor":"Innovation, Science and Economic Development Canada","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Re-engineered AAV-LPL","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Virica Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virica Biotech \/ Innovation, Science and Economic Development Canada","highestDevelopmentStatusID":"1","companyTruncated":"Virica Biotech \/ Innovation, Science and Economic Development Canada"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Us Department Of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasomune Therapeutics \/ Us Department Of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune Therapeutics \/ Us Department Of Defense"},{"orgOrder":0,"company":"IMV","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMV \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ NRC IRAP"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2022","type":"Financing","leadProduct":"111-In FPI-1547","moa":"||IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Oxford Finance","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Oxford Finance"},{"orgOrder":0,"company":"Gandeeva Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Gandeeva Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gandeeva Therapeutics \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Gandeeva Therapeutics \/ Lux Capital"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Tome Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Tome Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Genevant Sciences \/ Tome Biosciences"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Technology","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cronos Group \/ Geocann","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Geocann"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Expanded Collaboration","leadProduct":"Cisplatin","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"RBI-1000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Precision NanoSystems","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Precision NanoSystems \/ Replicate Bioscience"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Ingenu CRO","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum BioPharma \/ Ingenu CRO","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Ingenu CRO"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Public Offering","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Roth Capital Partners"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"IntelGenx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IntelGenx \/ ATAI Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"IntelGenx \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Acuitas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-LNP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Pfizer Inc"},{"orgOrder":0,"company":"Universit\u00e9 de Montr\u00e9al","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Universit\u00e9 de Montr\u00e9al","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Universit\u00e9 de Montr\u00e9al \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Universit\u00e9 de Montr\u00e9al \/ Ipsen"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zymeworks \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2021","type":"Divestment","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Kedrion","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Kedrion"},{"orgOrder":0,"company":"Lactiga","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactiga \/ Icahn School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Sequence Bio","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Sequence Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Sequence Bio \/ Leo Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sequence Bio \/ Leo Pharma"},{"orgOrder":0,"company":"Panag Pharma","sponsor":"True North Cannabis Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Panag Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Panag Pharma \/ True North Cannabis Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Panag Pharma \/ True North Cannabis Corp."},{"orgOrder":0,"company":"The Valens Company","sponsor":"Valens Company","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Agreement","leadProduct":"Capsaicin","moa":"||TRPV1","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"The Valens Company","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"The Valens Company \/ Valens Company","highestDevelopmentStatusID":"15","companyTruncated":"The Valens Company \/ Valens Company"},{"orgOrder":0,"company":"LQT Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"LQT Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LQT Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"LQT Therapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital Corp."},{"orgOrder":0,"company":"University of Montreal","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Montreal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Montreal \/ Medigene","highestDevelopmentStatusID":"1","companyTruncated":"University of Montreal \/ Medigene"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Funding","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"MediPharm Labs \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm Labs \/ National Institutes of Health"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Miravo Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Miravo Healthcare \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Miravo Healthcare \/ Orion Corporation"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Funding","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Immunology","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"NeuroPharma","sponsor":"Mydecine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NeuroPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroPharma \/ Mydecine","highestDevelopmentStatusID":"1","companyTruncated":"NeuroPharma \/ Mydecine"},{"orgOrder":0,"company":"Naltrexone Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Naltrexone Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Naltrexone Therapeutics \/ Love Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Naltrexone Therapeutics \/ Love Pharma"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Neurasic Therapeutic","sponsor":"McGill University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Acid-sensing ion channel","graph1":"Neurology","graph2":"Discovery","graph3":"Neurasic Therapeutic","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurasic Therapeutic \/ McGill University","highestDevelopmentStatusID":"2","companyTruncated":"Neurasic Therapeutic \/ McGill University"},{"orgOrder":0,"company":"McMaster University","sponsor":"Ceapro","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"PGX-YBG","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"McMaster University \/ Ceapro","highestDevelopmentStatusID":"4","companyTruncated":"McMaster University \/ Ceapro"},{"orgOrder":0,"company":"NanoVation Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"NanoVation Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoVation Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"NanoVation Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"OMERS Life Sciences","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Antibody","year":"2023","type":"Divestment","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"OMERS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OMERS Life Sciences \/ Xencor","highestDevelopmentStatusID":"15","companyTruncated":"OMERS Life Sciences \/ Xencor"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Bloom Psychedelic Therapy and Research Centre","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Optimi Health \/ Bloom Psychedelic Therapy and Research Centre","highestDevelopmentStatusID":"6","companyTruncated":"Optimi Health \/ Bloom Psychedelic Therapy and Research Centre"},{"orgOrder":0,"company":"48Hour Discovery","sponsor":"Oranomed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"48Hour Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"48Hour Discovery \/ Oranomed","highestDevelopmentStatusID":"3","companyTruncated":"48Hour Discovery \/ Oranomed"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"European Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ European Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ European Pharmaceutical"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Peptilogics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orion Biotechnology \/ Peptilogics","highestDevelopmentStatusID":"3","companyTruncated":"Orion Biotechnology \/ Peptilogics"},{"orgOrder":0,"company":"PharmaTher","sponsor":"MediSynergics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaTher \/ MediSynergics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ MediSynergics"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Alcami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Alcami","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Alcami"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Precision NanoSystems \/ Government of Canada"},{"orgOrder":0,"company":"CanProbe","sponsor":"POINT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"177-Lu Octreotate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"CanProbe","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CanProbe \/ POINT Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"CanProbe \/ POINT Biopharma"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ New Enterprise Associates","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ New Enterprise Associates"},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"FAV LS Fund I","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamond Therapeutics \/ FAV LS Fund I","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Therapeutics \/ FAV LS Fund I"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Forbion"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Fenway Sports Group"},{"orgOrder":0,"company":"Avicanna","sponsor":"Ei.Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avicanna \/ Ei.Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Ei.Ventures"},{"orgOrder":0,"company":"Psyence","sponsor":"Brandon Kerzner","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Brandon Kerzner","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ Brandon Kerzner"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"National Research Council of Canada Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"QBKPN SSI","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Camonsertib","moa":"Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Camonsertib","moa":"Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Zhejiang Ausun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Repirinast","moa":"Mast cell","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Zhejiang Ausun Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Zhejiang Ausun Pharmaceutical"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Camonsertib","moa":"Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Pharmadrug Production GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Cepharanthine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairiyo Therapeutics \/ Pharmadrug Production GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Sairiyo Therapeutics \/ Pharmadrug Production GmbH"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Sairiyo Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Sairiyo Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"International Centre for Genetic Engineering and Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"Sernova","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Human Donor Islet Cell","moa":"||Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Evotec"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Seyltx","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Seyltx","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Seyltx"},{"orgOrder":0,"company":"panCELLa","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human Embryonic Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"panCELLa","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"panCELLa \/ NRC IRAP","highestDevelopmentStatusID":"3","companyTruncated":"panCELLa \/ NRC IRAP"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Genevant Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Carleton University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Carleton University","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Carleton University"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Cannvalate"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntelGenx \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Tetra BioPharma"},{"orgOrder":0,"company":"Cybin","sponsor":"Adelia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Tryptamine Derivative","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Adelia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Adelia Therapeutics"},{"orgOrder":0,"company":"Endoceutics","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Prasterone","moa":"Corticosteroid-binding globulin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Endoceutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Endoceutics \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Endoceutics \/ Cosette Pharma"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2024","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha wave","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaTher \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Revive Therapeutics"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biotech \/ Core One Labs"},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lucid Psycheceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lucid Psycheceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lucid Psycheceuticals \/ FSD Pharma"},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lucid Psycheceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lucid Psycheceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lucid Psycheceuticals \/ FSD Pharma"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ GSK"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ GSK"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"University of Sydney","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ University of Sydney"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tilray","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Tilray","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Tilray"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"HEC88473","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Apollo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Biopharma \/ Apollo Therapeutics"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Nuvo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvo Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Nuvo Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Camonsertib","moa":"Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Repare Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Johns Hopkins University","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Johns Hopkins University"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Defence R&D Canada","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Defence R&D Canada","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Defence R&D Canada"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BriaCell Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Filament Health","sponsor":"Psyence","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Filament Health \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Filament Health \/ Psyence"},{"orgOrder":0,"company":"ASEP Medical","sponsor":"Bohai Biomedical Technology Development Co.","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"ASEP Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ASEP Medical \/ Bohai Biomedical Technology Development Co.","highestDevelopmentStatusID":"4","companyTruncated":"ASEP Medical \/ Bohai Biomedical Technology Development Co."},{"orgOrder":0,"company":"Microbix Biosystems","sponsor":"Sequel Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Urokinase","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Microbix Biosystems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Microbix Biosystems \/ Sequel Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Microbix Biosystems \/ Sequel Pharma"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"MMCAP Infuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Buprenorphine","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Purdue Pharma \/ MMCAP Infuse","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ MMCAP Infuse"},{"orgOrder":0,"company":"Canntab Therapeutics","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Canntab Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Canntab Therapeutics \/ MediPharm Labs","highestDevelopmentStatusID":"15","companyTruncated":"Canntab Therapeutics \/ MediPharm Labs"},{"orgOrder":0,"company":"PharmaTher","sponsor":"CC Biotechnology Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaTher \/ CC Biotechnology Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ CC Biotechnology Corporation"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ University of California","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ University of California"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Plushcare","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Steroid","year":"2020","type":"Partnership","leadProduct":"Ospemifene","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duchesnay \/ Plushcare","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Plushcare"},{"orgOrder":0,"company":"HEC Group","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"HEC Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HEC Group \/ Lannett Company, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"HEC Group \/ Lannett Company, Inc."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Piramal Pharma Solutions"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Salud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Salud Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Salud Pharma"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Patch","sponsorNew":"Revive Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Variational AI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ Variational AI","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Variational AI"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Sirnaomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Precision NanoSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Precision NanoSystems \/ Sirnaomics","highestDevelopmentStatusID":"8","companyTruncated":"Precision NanoSystems \/ Sirnaomics"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Attwill Medical Solutions","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Revive Therapeutics \/ Attwill Medical Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Attwill Medical Solutions"},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Royalmount Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Reverb Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reverb Therapeutics \/ Royalmount Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Reverb Therapeutics \/ Royalmount Laboratories"},{"orgOrder":0,"company":"KisoJi Biotechnology","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"KJ-103","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"KisoJi Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KisoJi Biotechnology \/ Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"KisoJi Biotechnology \/ Cancer Research"},{"orgOrder":0,"company":"N-Zyme Biomedical","sponsor":"LGM Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Fosamprenavir Sodium Alginate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"N-Zyme Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"N-Zyme Biomedical \/ LGM Pharma","highestDevelopmentStatusID":"4","companyTruncated":"N-Zyme Biomedical \/ LGM Pharma"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Editas Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Genevant Sciences \/ Editas Medicine"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Genevant Sciences \/ Novo Nordisk"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"MYND Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of British Columbia \/ MYND Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ MYND Life Sciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Biogen"},{"orgOrder":0,"company":"ME Therapeutics","sponsor":"NanoVation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ME Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ME Therapeutics \/ NanoVation Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"ME Therapeutics \/ NanoVation Therapeutics"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Hebrew University"},{"orgOrder":0,"company":"Avicanna","sponsor":"Applied Research Centre at Langara College","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Applied Research Centre at Langara College","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Applied Research Centre at Langara College"},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Raya Therapeutic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Raya Therapeutic \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Raya Therapeutic \/ Argenx"},{"orgOrder":0,"company":"OpenBench","sponsor":"ORIC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"OpenBench","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OpenBench \/ ORIC Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"OpenBench \/ ORIC Pharmaceuticals"},{"orgOrder":0,"company":"Fibrocor Therapeutics","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"FIB918","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Fibrocor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fibrocor Therapeutics \/ McQuade Center","highestDevelopmentStatusID":"5","companyTruncated":"Fibrocor Therapeutics \/ McQuade Center"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Pharma Inventor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ Pharma Inventor","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Pharma Inventor"},{"orgOrder":0,"company":"IRICoR","sponsor":"Universite de Montreal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"IRICoR","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRICoR \/ Universite de Montreal","highestDevelopmentStatusID":"3","companyTruncated":"IRICoR \/ Universite de Montreal"},{"orgOrder":0,"company":"Alectos Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AL01811","moa":"GBA2","graph1":"Neurology","graph2":"Preclinical","graph3":"Alectos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alectos Therapeutics \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Alectos Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"ImmunoBiochem","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ImmunoBiochem","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoBiochem \/ Immunogen","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoBiochem \/ Immunogen"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"AbCellera","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Everest Medicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Everest Medicines"},{"orgOrder":0,"company":"Phenomic AI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Phenomic AI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phenomic AI \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Phenomic AI \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ceapro","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceapro \/ Aeterna Zentaris","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Aeterna Zentaris"},{"orgOrder":0,"company":"Ceapro","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceapro \/ Aeterna Zentaris","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Aeterna Zentaris"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Crescita Therapeutics \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Securities LLC"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Optimi Health","sponsor":"SABI Mind","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ SABI Mind","highestDevelopmentStatusID":"1","companyTruncated":"Optimi Health \/ SABI Mind"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Alliance Global Partners"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Leede Jones Gable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Leede Jones Gable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Private Placement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Hampton Securities Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Hampton Securities Limited","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Hampton Securities Limited"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Jefferies"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Jefferies"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Zymeworks","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zymeworks \/ J.P. Morgan Securities","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Research Capital Corporation"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cantone Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Cantone Research","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Cantone Research"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"AbCellera","sponsor":"BMO Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ BMO Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"AbCellera \/ BMO Capital Markets"},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Reverb Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reverb Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Reverb Therapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Mydecine","sponsor":"Canaccord Genuity Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Canaccord Genuity Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Canaccord Genuity Corp."},{"orgOrder":0,"company":"35Pharma","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Series C Financing","leadProduct":"HS135","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"35Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"35Pharma \/ Frazier Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"35Pharma \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ TSX Venture Exchange","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Research Capital Corporation"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"||Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Research Capital Corporation"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"||Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Research Capital Corporation"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Lactiga","sponsor":"1517 Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactiga \/ 1517 Fund","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ 1517 Fund"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Integrated Nanotherapeutics","sponsor":"Breakthrough T1D","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Integrated Nanotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Integrated Nanotherapeutics \/ Breakthrough T1D","highestDevelopmentStatusID":"4","companyTruncated":"Integrated Nanotherapeutics \/ Breakthrough T1D"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Regenerative Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Agreement","leadProduct":"Chitosan-PRP","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Ortho Regenerative Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ortho Regenerative Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ortho Regenerative Technologies \/ Undisclosed"},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"XPhyto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"XPhyto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XPhyto \/ Undisclosed"},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"XPhyto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"XPhyto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XPhyto \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Borealis Biosciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Borealis Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Borealis Biosciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Borealis Biosciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"K1.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"National Research Council of Canada","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Pan-Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Research Council of Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Research Council of Canada \/ VBI Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"National Research Council of Canada \/ VBI Vaccines"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"University of Arizona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"SBFM-PL4","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ University of Arizona","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ University of Arizona"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Rapid Dose Therapeutics","sponsor":"McMaster University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rapid Dose Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Rapid Dose Therapeutics \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Rapid Dose Therapeutics \/ McMaster University"},{"orgOrder":0,"company":"Ability Biologics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ability Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ability Biologics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"3","companyTruncated":"Ability Biologics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radiant Biotherapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Biotherapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"enGene","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Hercules Capital"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Prevail Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Prevail Partners"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Qu\u00e9bec government","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Qu\u00e9bec government","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Qu\u00e9bec government"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocyte","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"SMITH & NEPHEW INC \/ Healiva","highestDevelopmentStatusID":"8","companyTruncated":"SMITH & NEPHEW INC \/ Healiva"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Egis Pharmaceuticals PLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crescita Therapeutics \/ Egis Pharmaceuticals PLC","highestDevelopmentStatusID":"15","companyTruncated":"Crescita Therapeutics \/ Egis Pharmaceuticals PLC"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Government Of Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Government Of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Scientific \/ Government Of Canada"},{"orgOrder":0,"company":"McGill University","sponsor":"Brain Canada","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Brain Canada","highestDevelopmentStatusID":"2","companyTruncated":"McGill University \/ Brain Canada"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Symvivo","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"bacTRL-Spike Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ National Research Council Industrial Research Assistance Program"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Enzyme","year":"2022","type":"Funding","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Genson Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Funding","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Genson Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Genson Capital"},{"orgOrder":0,"company":"Therini Bio","sponsor":"Dementia Discovery Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"THN391","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therini Bio \/ Dementia Discovery Fund","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bio \/ Dementia Discovery Fund"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Marc Edwards","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2022","type":"Private Placement","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Marc Edwards","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Marc Edwards"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"U.S. Air Force Academy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ U.S. Air Force Academy","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ U.S. Air Force Academy"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"USAFA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ USAFA","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ USAFA"},{"orgOrder":0,"company":"Hemostemix","sponsor":"McGill University Health Centre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"ACP-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hemostemix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hemostemix \/ McGill University Health Centre","highestDevelopmentStatusID":"8","companyTruncated":"Hemostemix \/ McGill University Health Centre"},{"orgOrder":0,"company":"Esperas Pharma","sponsor":"TVM Capital Life Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"ESP-001","moa":"||Check 1","graph1":"Oncology","graph2":"Phase II","graph3":"Esperas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Esperas Pharma \/ TVM Capital Life Science","highestDevelopmentStatusID":"8","companyTruncated":"Esperas Pharma \/ TVM Capital Life Science"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Enzyme","year":"2024","type":"Funding","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ NRC IRAP","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ NRC IRAP"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"DDR","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ NRC IRAP"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"NSERC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"INM-900","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InMed Pharmaceuticals \/ NSERC","highestDevelopmentStatusID":"4","companyTruncated":"InMed Pharmaceuticals \/ NSERC"},{"orgOrder":0,"company":"University of Saskatchewan","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Saskatchewan","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Saskatchewan \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"4","companyTruncated":"University of Saskatchewan \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"ASEP Medical","sponsor":"NMIN","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"CANADA","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"ASEP Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"ASEP Medical \/ NMIN","highestDevelopmentStatusID":"4","companyTruncated":"ASEP Medical \/ NMIN"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"AMRMC","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Galantamine Benzoate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Alpha Cognition \/ AMRMC","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ AMRMC"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"JN Nova Pharma","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"KG2019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JN Nova Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JN Nova Pharma \/ Government of Canada","highestDevelopmentStatusID":"4","companyTruncated":"JN Nova Pharma \/ Government of Canada"},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Brain Cancer Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of British Columbia \/ Brain Cancer Canada","highestDevelopmentStatusID":"1","companyTruncated":"The University of British Columbia \/ Brain Cancer Canada"},{"orgOrder":0,"company":"McMaster University","sponsor":"Brain Cancer Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Brain Cancer Canada","highestDevelopmentStatusID":"2","companyTruncated":"McMaster University \/ Brain Cancer Canada"},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Hong Kong Teson Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tirofiban","moa":"Integrin-alpha 2b\/beta 3","graph1":"Hematology","graph2":"Approved FDF","graph3":"Correvio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Correvio Pharma \/ Hong Kong Teson Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Correvio Pharma \/ Hong Kong Teson Pharma"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ripple Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Ripple Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"OpenBench","sponsor":"Tavros Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"OpenBench","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OpenBench \/ Tavros Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"OpenBench \/ Tavros Therapeutics"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Affinity Asset Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Affinity Asset Advisors","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Affinity Asset Advisors"},{"orgOrder":0,"company":"enGene","sponsor":"Forbion Growth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Forbion Growth","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Forbion Growth"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ RTW Investments"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Mr. Doug Janzen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2023","type":"Financing","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Mr. Doug Janzen","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Mr. Doug Janzen"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Research Capital Corporation"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Desjardins Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Desjardins Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Desjardins Capital Markets"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities Inc","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities Inc"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptose Biosciences \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"enGene","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Adage Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Adage Capital Partners"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"KT-2000","moa":"PARP","graph1":"Oncology","graph2":"Discovery","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"KT-2000","moa":"PARP","graph1":"Oncology","graph2":"Discovery","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Accelerating Clinical Trial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Qbeco","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Accelerating Clinical Trial","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Accelerating Clinical Trial"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Digital Offering, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Digital Offering, LLC","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Digital Offering, LLC"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Zymeworks","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"ZW171","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks \/ EcoR1 Capital"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Canadian Institute of Health Resources","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arch Biopartners \/ Canadian Institute of Health Resources","highestDevelopmentStatusID":"1","companyTruncated":"Arch Biopartners \/ Canadian Institute of Health Resources"},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"Bellus Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"adMare BioInnovations \/ Bellus Health","highestDevelopmentStatusID":"8","companyTruncated":"adMare BioInnovations \/ Bellus Health"},{"orgOrder":0,"company":"IGY Life Sciences","sponsor":"MMS Holdings","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"IgY-110","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IGY Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"IGY Life Sciences \/ MMS Holdings","highestDevelopmentStatusID":"4","companyTruncated":"IGY Life Sciences \/ MMS Holdings"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"NYCBS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ NYCBS","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ NYCBS"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"QBECO-SSI","moa":"Site specific immuno","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Foundation Medicine"},{"orgOrder":0,"company":"AbCellera","sponsor":"RQ Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"AbCellera \/ RQ Bio","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ RQ Bio"},{"orgOrder":0,"company":"NanoVation Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"NanoVation Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoVation Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"NanoVation Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"SemaThera Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Semaphorin-3A","graph1":"Ophthalmology","graph2":"Discovery","graph3":"SemaThera Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SemaThera Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"SemaThera Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"NIMIUM Therapeutics","sponsor":"Paraza Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"NIMIUM Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"NIMIUM Therapeutics \/ Paraza Pharma","highestDevelopmentStatusID":"4","companyTruncated":"NIMIUM Therapeutics \/ Paraza Pharma"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Cannvalate"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Nova Mentis Life Science","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Wellbeing Digital Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Nova Mentis Life Science","highestDevelopmentStatusID":"5","companyTruncated":"Wellbeing Digital Sciences \/ Nova Mentis Life Science"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Marathon Asset Management"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Great Point Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Great Point Partners","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Great Point Partners"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"enGene","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"enGene \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Deep Track Capital"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Fenway Sports Group"},{"orgOrder":0,"company":"Psyence","sponsor":"Cantheon Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Cantheon Capital","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Cantheon Capital"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Private Placement","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Undisclosed"},{"orgOrder":0,"company":"Alpha-9 Oncology","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alpha-9 Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpha-9 Oncology \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Alpha-9 Oncology \/ Lightspeed Venture Partners"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"BTIG, LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ BTIG, LLC","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ BTIG, LLC"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2024","type":"Financing","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Islasertib","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thryv Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Devonian Health Group \/ TSX Venture Exchange","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Starpax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"SN38","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Starpax Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Starpax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Starpax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Natural Sciences and Engineering Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"QBSAU","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Natural Sciences and Engineering Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Qu Biologics Inc \/ Natural Sciences and Engineering Council of Canada"},{"orgOrder":0,"company":"PharmaTher","sponsor":"The Queen's University of Belfast","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Infusion","sponsorNew":"PharmaTher \/ The Queen's University of Belfast","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ The Queen's University of Belfast"},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Invetx"},{"orgOrder":0,"company":"Avicanna","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Avicanna \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Avicanna \/ Tetra BioPharma"},{"orgOrder":0,"company":"Avicanna","sponsor":"University of Toronto","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AVCN319302","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avicanna \/ University of Toronto","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/ University of Toronto"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BriaCell Therapeutics \/ Harvard Medical School","highestDevelopmentStatusID":"2","companyTruncated":"BriaCell Therapeutics \/ Harvard Medical School"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Jewish General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Adva-27a","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Biopharma \/ Jewish General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Jewish General Hospital"},{"orgOrder":0,"company":"Psyence","sponsor":"Newcourt Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Newcourt Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Newcourt Acquisition Corp"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Supreme Council of the Arab-African Economy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Supreme Council of the Arab-African Economy","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Supreme Council of the Arab-African Economy"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"ProvideGx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Inc \/ ProvideGx","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ ProvideGx"},{"orgOrder":0,"company":"Core One Labs","sponsor":"Core One Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Core One Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Core One Labs \/ Core One Labs","highestDevelopmentStatusID":"1","companyTruncated":"Core One Labs \/ Core One Labs"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Agreement","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Bayer AG"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"University of Barcelona","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"Akome Biotech \/ University of Barcelona","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biotech \/ University of Barcelona"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Italian Medicines Agency","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Italian Medicines Agency"},{"orgOrder":0,"company":"Pacylex Pharmaceuticals","sponsor":"Canadian angel investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"PCLX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pacylex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacylex Pharmaceuticals \/ Canadian angel investors","highestDevelopmentStatusID":"5","companyTruncated":"Pacylex Pharmaceuticals \/ Canadian angel investors"},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Johns Hopkins University","highestDevelopmentStatusID":"2","companyTruncated":"Mydecine \/ Johns Hopkins University"},{"orgOrder":0,"company":"The University of Calgary","sponsor":"Therapix Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"THX-160","moa":"CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"The University of Calgary","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Calgary \/ Therapix Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"The University of Calgary \/ Therapix Biosciences"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Repare Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Biomedical \/ Cybin"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"QBKPN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ NRC IRAP","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ NRC IRAP"},{"orgOrder":0,"company":"MicroDoz Therapy Inc.","sponsor":"Love Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"MicroDoz Therapy Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"MicroDoz Therapy Inc. \/ Love Pharma","highestDevelopmentStatusID":"1","companyTruncated":"MicroDoz Therapy Inc. \/ Love Pharma"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Ocugen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Liminal BioSciences \/ Ocugen","highestDevelopmentStatusID":"15","companyTruncated":"Liminal BioSciences \/ Ocugen"},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Dalriada Drug Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Dalriada Drug Discovery \/ ATAI Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Dalriada Drug Discovery \/ ATAI Life Sciences"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||RAR beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2024","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Cyclica","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyclica \/ Recursion Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ Recursion Pharma"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Acuitas","sponsor":"Myeloid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Microorganism","year":"2022","type":"Agreement","leadProduct":"MT-301","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ Myeloid Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Acuitas \/ Myeloid Therapeutics"},{"orgOrder":0,"company":"Eyam Vaccines and Immunotherapeutics","sponsor":"Mitacs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eyam Vaccines and Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyam Vaccines and Immunotherapeutics \/ Mitacs","highestDevelopmentStatusID":"4","companyTruncated":"Eyam Vaccines and Immunotherapeutics \/ Mitacs"},{"orgOrder":0,"company":"Ceapro","sponsor":"McMaster University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"PGX-YBG","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ceapro \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ McMaster University"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"TRIUMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"n.c.a 225-Ac","moa":"Alpha radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ TRIUMF","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ TRIUMF"},{"orgOrder":0,"company":"Avicanna","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ University Health Network","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ University Health Network"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExCellThera \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"ExCellThera \/ Astellas Pharma"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Avicanna","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ MediPharm Labs","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ MediPharm Labs"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Suppository","sponsorNew":"BIOSYENT PHARMA INC \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BIOSYENT PHARMA INC \/ Undisclosed"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"225-Ac","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Discovery","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ Fusion Pharma","highestDevelopmentStatusID":"2","companyTruncated":"BWX Technologies \/ Fusion Pharma"},{"orgOrder":0,"company":"Congruence","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Congruence","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Congruence \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Congruence \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Pepscan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fusion Pharma \/ Pepscan Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Fusion Pharma \/ Pepscan Therapeutics"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Gritstone bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genevant Sciences \/ Gritstone bio","highestDevelopmentStatusID":"3","companyTruncated":"Genevant Sciences \/ Gritstone bio"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"IMP Clinical Supply Services","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ IMP Clinical Supply Services","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ IMP Clinical Supply Services"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Agreement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Agreement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Ceapro","sponsor":"Symrise","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Avenanthramides","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Ceapro \/ Symrise","highestDevelopmentStatusID":"15","companyTruncated":"Ceapro \/ Symrise"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptose Biosciences \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"KALEO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Hormone","year":"2022","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valeo Pharma \/ KALEO INC","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ KALEO INC"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"TFC-039","moa":"SGLT2","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Aureuspharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Aureuspharma","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Aureuspharma"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Solarvest Bioenergy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Solarvest Bioenergy","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma \/ Solarvest Bioenergy"},{"orgOrder":0,"company":"AbCellera","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Incyte Corporation"},{"orgOrder":0,"company":"AbCellera","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ABCL575","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Viking Global Investors","highestDevelopmentStatusID":"5","companyTruncated":"AbCellera \/ Viking Global Investors"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sernova","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sernova \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Sernova \/ AstraZeneca"},{"orgOrder":0,"company":"Future Fields","sponsor":"Jenthera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Future Fields","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Future Fields \/ Jenthera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Future Fields \/ Jenthera Therapeutics"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Vitruvias Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Vitruvias Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Vitruvias Therapeutics"},{"orgOrder":0,"company":"Phenomic AI","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Phenomic AI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phenomic AI \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Phenomic AI \/ Astellas Pharma"},{"orgOrder":0,"company":"Ceapro","sponsor":"Angiogenesis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Beta Glucan","moa":"Beta glucan receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceapro \/ Angiogenesis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Angiogenesis Foundation"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"University of Montreal Hospital Research Centre","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ University of Montreal Hospital Research Centre","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioPharma \/ University of Montreal Hospital Research Centre"},{"orgOrder":0,"company":"Inspirevax","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"BDX301","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inspirevax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Inspirevax \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Inspirevax \/ Oragenics"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Repair Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Repair Biotechnologies","highestDevelopmentStatusID":"5","companyTruncated":"Genevant Sciences \/ Repair Biotechnologies"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Akanda Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Akanda Corp","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Akanda Corp"},{"orgOrder":0,"company":"Mydecine","sponsor":"Combat Stress","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Combat Stress","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Combat Stress"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Ripple Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ripple Therapeutics \/ Glaukos","highestDevelopmentStatusID":"3","companyTruncated":"Ripple Therapeutics \/ Glaukos"},{"orgOrder":0,"company":"AbCellera","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Versant Ventures"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"MegaTAL mRNA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ 2Seventy Bio","highestDevelopmentStatusID":"1","companyTruncated":"Genevant Sciences \/ 2Seventy Bio"},{"orgOrder":0,"company":"AbCellera","sponsor":"Rallybio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AbCellera \/ Rallybio","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Rallybio"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Caris Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Caris Life Sciences"},{"orgOrder":0,"company":"CPDC Centre for Probe Development and Commercialization","sponsor":"CellBion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu PSMA-D GUL","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"CPDC Centre for Probe Development and Commercialization","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CPDC Centre for Probe Development and Commercialization \/ CellBion","highestDevelopmentStatusID":"8","companyTruncated":"CPDC Centre for Probe Development and Commercialization \/ CellBion"},{"orgOrder":0,"company":"Entourage Health","sponsor":"Irwin Naturals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Entourage Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Gel","sponsorNew":"Entourage Health \/ Irwin Naturals","highestDevelopmentStatusID":"15","companyTruncated":"Entourage Health \/ Irwin Naturals"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Caris Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Caris Life Sciences"},{"orgOrder":0,"company":"Psyence","sponsor":"Filament Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Filament Health","highestDevelopmentStatusID":"5","companyTruncated":"Psyence \/ Filament Health"},{"orgOrder":0,"company":"Acuitas","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ GC Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ GC Biopharma"},{"orgOrder":0,"company":"Symvivo","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Symvivo \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Juyou Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Juyou Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Crescita Therapeutics \/ Juyou Biotechnology"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Xing Pharmaceuticals"},{"orgOrder":0,"company":"Aspect Biosystems","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Aspect Biosystems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aspect Biosystems \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Aspect Biosystems \/ Novo Nordisk"},{"orgOrder":0,"company":"Optimi Health","sponsor":"M\u0101tai Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ M\u0101tai Medical Research Institute","highestDevelopmentStatusID":"5","companyTruncated":"Optimi Health \/ M\u0101tai Medical Research Institute"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Gesval S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Gesval S.A","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Gesval S.A"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"VaxAlta","sponsor":"Scandinavian Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Campylobacter Jejuni Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxAlta","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VaxAlta \/ Scandinavian Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"VaxAlta \/ Scandinavian Biopharma"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"RODAN & FIELDS LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ RODAN & FIELDS LLC","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ RODAN & FIELDS LLC"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Crescita Therapeutics \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Genevant Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Treventis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Treventis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treventis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Treventis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Therapure Biomanufacturing","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VBI-2901","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapure Biomanufacturing","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapure Biomanufacturing \/ VBI Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Therapure Biomanufacturing \/ VBI Vaccines"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Verity Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Bria-Pros","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ University of Wisconsin\u2013Madison","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ University of Wisconsin\u2013Madison"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Saptalis Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Appili Therapeutics \/ Saptalis Pharm","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Saptalis Pharm"},{"orgOrder":0,"company":"Andira Pharmaceuticals","sponsor":"University of British Columbia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Andira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andira Pharmaceuticals \/ University of British Columbia","highestDevelopmentStatusID":"4","companyTruncated":"Andira Pharmaceuticals \/ University of British Columbia"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Midomafetamine","moa":"5-HT\/Noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Revive Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ PharmaTher"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Discovery","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"BWX Technologies \/ Bayer AG"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Group Purchasing Organizations","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Group Purchasing Organizations","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Group Purchasing Organizations"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Exeltis"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zymeworks \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks \/ Merck & Co"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"RP-2119","moa":"Polymerase Theta","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Repare Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Primary Peptides","sponsor":"Qingdao Primedicine Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"PP-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Primary Peptides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primary Peptides \/ Qingdao Primedicine Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Primary Peptides \/ Qingdao Primedicine Pharmaceutical"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 mRNA-LNP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ CanSino Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Precision NanoSystems \/ CanSino Biologics"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Virna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Toronto \/ Virna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of Toronto \/ Virna Therapeutics"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"VIDO-InterVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Dalton Pharma Services \/ VIDO-InterVac","highestDevelopmentStatusID":"1","companyTruncated":"Dalton Pharma Services \/ VIDO-InterVac"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska Institute"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"VG201","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Virogin Biotech \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Virogin Biotech \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Oak Bay Biosciences","sponsor":"FrontFundr","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Complement pathway","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oak Bay Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oak Bay Biosciences \/ FrontFundr","highestDevelopmentStatusID":"4","companyTruncated":"Oak Bay Biosciences \/ FrontFundr"},{"orgOrder":0,"company":"Prometic LifeSciences Inc","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Prometic LifeSciences Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Prometic LifeSciences Inc \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Prometic LifeSciences Inc \/ Kedrion"},{"orgOrder":0,"company":"AbCellera","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ OrbiMed"},{"orgOrder":0,"company":"Exactis Innovation","sponsor":"Sermonix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Partnership","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Exactis Innovation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exactis Innovation \/ Sermonix Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Exactis Innovation \/ Sermonix Pharmaceuticals"},{"orgOrder":0,"company":"Vitaeris","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Clazakizumab","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Vitaeris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitaeris \/ CSL","highestDevelopmentStatusID":"10","companyTruncated":"Vitaeris \/ CSL"},{"orgOrder":0,"company":"Kinectrics","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ytterbium-176","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kinectrics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinectrics \/ Point Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Kinectrics \/ Point Biopharma"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Public Offering","leadProduct":"Ezogabine","moa":"KCNQ potassium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Jefferies"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NBI-921352","moa":"Nav1.6 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NBI-921352","moa":"Nav1.6 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zymeworks \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zymeworks \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Fulvestrant","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Pfizer Inc"},{"orgOrder":0,"company":"VIDO-InterVac","sponsor":"ZYUS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Plant Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIDO-InterVac","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIDO-InterVac \/ ZYUS Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"VIDO-InterVac \/ ZYUS Life Sciences"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ursodeoxycholic Acid","moa":"AKR1C2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akome Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NoNO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nerinetide","moa":"PSD-95","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NoNO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NoNO \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NoNO \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ceapro \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ceapro \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ceapro \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ceapro \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Immunology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amiselimod HCl","moa":"S1PR","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Pan-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Pan-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pan-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pan-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"MetaBlok","moa":"DPEP1","graph1":"Immunology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cilastatin","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cilastatin","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"University of Calgary","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ University of Calgary","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ University of Calgary"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"KYE Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KYE Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KYE Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MEDUNIK CANADA","sponsor":"Jacobus Pharmaceutical Company, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"MEDUNIK CANADA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MEDUNIK CANADA \/ Jacobus Pharmaceutical Company, Inc","highestDevelopmentStatusID":"15","companyTruncated":"MEDUNIK CANADA \/ Jacobus Pharmaceutical Company, Inc"},{"orgOrder":0,"company":"Filament Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Filament Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Filament Health \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FPI-2059","moa":"NTSR1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Ipsen"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"225-Ac FPI-2068","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"||5-HT\/Noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/Noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Microneedle Patch","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Delta Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Delta Health","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Delta Health"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Omega-3 Phospholipid","moa":"PPA receptor-gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mountain Valley MD \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain Valley MD \/ Inapplicable"},{"orgOrder":0,"company":"Inspire Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Inspire Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspire Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Inspire Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPAR-gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"PurGenesis Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Devonian Health Group \/ PurGenesis Technologies","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ PurGenesis Technologies"},{"orgOrder":0,"company":"Defence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AccuTOX","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Defence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Defence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Defence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Oncology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alzamend Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase III","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altasciences Company Inc \/ Alzamend Neuro","highestDevelopmentStatusID":"10","companyTruncated":"Altasciences Company Inc \/ Alzamend Neuro"},{"orgOrder":0,"company":"Alethia Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AB-16B5","moa":"||EMT","graph1":"Oncology","graph2":"Phase II","graph3":"Alethia Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alethia Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alethia Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Progranulin","moa":"Progranulin","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Progranulin","moa":"Progranulin","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Progranulin","moa":"Progranulin","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ALPHA-0702","moa":"||Granulin epithelin motifs","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AmacaThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AMT-143","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AmacaThera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmacaThera \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AmacaThera \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezagepras","moa":"GPR84","graph1":"Hematology","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Omega-3 Phospholipid","moa":"PPA receptor-gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Angany","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ANG-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Angany","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angany \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Angany \/ Inapplicable"},{"orgOrder":0,"company":"Angany","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ANG-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Angany","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angany \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Angany \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quaternary Ammonium Palmitoyl Glycol Chitosan","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altasciences Company Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Altasciences Company Inc \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Algernon NeuroScience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon NeuroScience \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apabetalone","moa":"||BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"||BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aciclovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Apotex Fermentation Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Fermentation Inc. \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Paromomycin","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APTO-253","moa":"Myc","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onternabez","moa":"CB2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Altasciences Company Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altasciences Company Inc \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Paromomycin","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharmascience Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmascience Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avenanthramide","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ceapro \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ceapro \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Awakn Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Awakn Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Awakn Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Awakn Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Vaccine Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bebtelovimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Vaccine Research Center","highestDevelopmentStatusID":"8","companyTruncated":"AbCellera \/ Vaccine Research Center"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fezagepras","moa":"GPR84","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apotex Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydrohonokiol-B","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurora Cannabis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Aurora Cannabis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurora Cannabis \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Knight Therapeutics \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ TherapeuticsMD"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Bio Elpida","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Bio Elpida"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bio-Gate AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"||CB1\/2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Avicanna \/ Bio-Gate AG","highestDevelopmentStatusID":"6","companyTruncated":"Avicanna \/ Bio-Gate AG"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMND07","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Dinitrophenyl Modified S-spike Protein of SARS-CoV-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Inapplicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Procare Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0918C","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Procare Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Procare Pharmaceutical"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lutein","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mescaline","moa":"5-HT2A receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Ferndale Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CTX-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Ferndale Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Crescita Therapeutics \/ Ferndale Laboratories"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"TH1904","moa":"Sortilin receptor 1","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Epacadostat","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inycte","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inycte","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inycte"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SV-BR-1-GM","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Bria-Pros+","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"||Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Suffield Research Centre","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Suffield Research Centre","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Suffield Research Centre"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"DRDC","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ DRDC","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ DRDC"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0320","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ The Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ The Ohio State University"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Merck Millipore","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0320","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Merck Millipore","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Merck Millipore"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50s ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50s ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50s ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apotex Fermentation Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Fermentation Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mountain Valley MD \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain Valley MD \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Ach receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Apotex Fermentation Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Fermentation Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Aphria","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"Tilray \/ Aphria","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Aphria"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Medicago","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CoVLP","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medicago \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GSK4362620A","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"CanaQuest Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"CanaQuest Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanaQuest Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CanaQuest Medical \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Clinilabs"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"Cytochrome P450 3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"JAMP PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"JAMP PHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JAMP PHARMA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JAMP PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"PGX-YBG","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ceapro \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ McMaster University"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ZT-01","moa":"SST2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zucara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Discovery","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Can-Fite BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Can-Fite BioPharma"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"DehydraTECH-Nicotine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pouch","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Baymedica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InMed Pharmaceuticals \/ Baymedica","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ Baymedica"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Thylakoid extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Devonian Health Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Devonian Health Group \/ Inapplicable"},{"orgOrder":0,"company":"Altius Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexlansoprazole","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Altius Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Altius Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altius Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APTO-253","moa":"Myc","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"EB06","moa":"CXCL10","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ExCellThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExCellThera \/ Inapplicable"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ExCellThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExCellThera \/ Inapplicable"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ExCellThera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ExCellThera \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"enGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EmpowerPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Inapplicable"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EmpowerPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Inapplicable"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Endosane Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"PreveCeutical Medical \/ Endosane Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Endosane Pharmaceuticals"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EPI-8207","moa":"ANITAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Altasciences Company Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Altasciences Company Inc \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Knight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Knight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Ortho Regenerative Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Chitosan-PRP","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Ortho Regenerative Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ortho Regenerative Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ortho Regenerative Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyridoxal Phosphate","moa":"Purinergic receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polydextrose Iron Complex","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BIOSYENT PHARMA INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BIOSYENT PHARMA INC \/ Inapplicable"},{"orgOrder":0,"company":"Field Trip Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FT-104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Field Trip Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip Health \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Brain and Cognition Discovery Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Braxia Scientific \/ Brain and Cognition Discovery Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Brain and Cognition Discovery Foundation"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoFlex","sponsor":"Chemistree","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Immunology","graph2":"Approved FDF","graph3":"ImmunoFlex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ImmunoFlex \/ Chemistree","highestDevelopmentStatusID":"15","companyTruncated":"ImmunoFlex \/ Chemistree"},{"orgOrder":0,"company":"Rapid Dose Therapeutics","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rapid Dose Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Rapid Dose Therapeutics \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Rapid Dose Therapeutics \/ McMaster University"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BVX-0320","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"||BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Entheon Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entheon Biomedical \/ Laboratorium Ofichem B.V","highestDevelopmentStatusID":"7","companyTruncated":"Entheon Biomedical \/ Laboratorium Ofichem B.V"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"225-Ac Vofatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FPI-2058","moa":"||NTSR1","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha wave","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA","moa":"Alpha wave","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Immunology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Lucid Psycheceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lucid Psycheceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lucid Psycheceuticals \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Find Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"FTX-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Find Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Find Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Find Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"WEX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"WEX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TerSera Canada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"TerSera Canada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"TerSera Canada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Canada \/ Inapplicable"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HLS Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Montreal Heart Institute \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","highestDevelopmentStatusID":"15","companyTruncated":"Montreal Heart Institute \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HLS Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Knight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repirinast","moa":"Mast cell","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"||NMDA 2B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Novotech"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Devonian Health Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"||RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"BayMedica","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ BayMedica","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ BayMedica"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inositol","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BIOSYENT PHARMA INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BIOSYENT PHARMA INC \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"PGX-YBG","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ceapro \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ McMaster University"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jay Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Jay Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Jay Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jay Pharma \/ Inapplicable"},{"orgOrder":0,"company":"JN Nova Pharma","sponsor":"NRC Human Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JN2019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JN Nova Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JN Nova Pharma \/ NRC Human Health","highestDevelopmentStatusID":"4","companyTruncated":"JN Nova Pharma \/ NRC Human Health"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"The University of Kansas","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"PharmaTher \/ The University of Kansas","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ The University of Kansas"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"LTS LOHMANN Therapie-Systeme AG","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"PharmaTher \/ LTS LOHMANN Therapie-Systeme AG","highestDevelopmentStatusID":"5","companyTruncated":"PharmaTher \/ LTS LOHMANN Therapie-Systeme AG"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Nucro-Technics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Nucro-Technics","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Nucro-Technics"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"kt-3283","moa":"PARP-HDAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"kt-4000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocin Analog","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lobe Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Saptalis Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Appili Therapeutics \/ Saptalis Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Saptalis Pharm"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GRT-R910","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genevant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genevant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Islasertib","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thryv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dofetilide","moa":"||SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thryv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"London Research & Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol Sulphate","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"London Research & Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"London Research & Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"London Research & Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Sunnybrook Research Institute"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pyridoxal Phosphate","moa":"Purinergic receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ McMaster University"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Optimi Health \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Medicago \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicago \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ National Institutes of Health"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Sunnybrook Research Institute"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Ingenew Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hesperidin","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valeo Pharma \/ Ingenew Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Valeo Pharma \/ Ingenew Pharma"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Medpace, Inc"},{"orgOrder":0,"company":"Evolve Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Evolve Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Evolve Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolve Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins Psychedelic Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Johns Hopkins Psychedelic Research Group","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Johns Hopkins Psychedelic Research Group"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Johns Hopkins University","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Johns Hopkins University"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"MYCO-003","moa":"Serotonin","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/Noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmascience Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"||CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"||CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nora Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nora Pharma \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apex Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban","moa":"||Integrin-alpha 2b\/beta 3","graph1":"Hematology","graph2":"Phase II","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Wellbeing Digital Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Wellbeing Digital Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zileuton","moa":"||5-LOX","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novateur Ventures \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novateur Ventures \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Repirinast","moa":"Mast cell","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Bayer AG"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Numinus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Numinus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numinus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Numinus \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"Angiogenesis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oat Beta Glucan","moa":"Collagen synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceapro \/ Angiogenesis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Angiogenesis Foundation"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Avicanna \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avicanna \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"||GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"MYND Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MYND Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"MYND Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MYND Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZT-01","moa":"SST2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zucara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apotex Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acidified Nitrite","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"TALLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TA-A001","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"TALLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"TALLC \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TALLC \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"Nrf2\/Keap1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sairiyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cepharanthine DiHCl","moa":"Nrf2\/Keap1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sairiyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sairiyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Waverley Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Waverley Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Waverley Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Waverley Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Groupe Persavita","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Groupe Persavita","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Persavita \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Persavita \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence Biomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Filament Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Filament Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Filament Health \/ Inapplicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAla Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmAla Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biotech \/ Core One Labs"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Duchesnay \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Inapplicable"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Healthcare's Memorial Health University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"||Methemoglobin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center"},{"orgOrder":0,"company":"Mannin Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mannin Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Mannin Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mannin Research \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PMN400","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||CD8+ T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"ProteinQure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ProteinQure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProteinQure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProteinQure \/ Inapplicable"},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"The University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of British Columbia \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"The University of British Columbia \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmAla Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"Everest Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Halucenex Life Sciences \/ Everest Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex Life Sciences \/ Everest Clinical Research"},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Halucenex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Optimi Health \/ Inapplicable"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence Biomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence Biomed \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbCellera \/ Inapplicable"},{"orgOrder":0,"company":"Pulmonem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pulmonem \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/ Inapplicable"},{"orgOrder":0,"company":"MUHC Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MUHC Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MUHC Foundation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MUHC Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"QBECO-SSI","moa":"Site specific immuno","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Health Canada","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"QBKPN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Health Canada","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Health Canada"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RepliCel","sponsor":"Innovacell Biotechnologie","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cultured, Autologous Hair Follicle Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"RepliCel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"RepliCel \/ Innovacell Biotechnologie","highestDevelopmentStatusID":"6","companyTruncated":"RepliCel \/ Innovacell Biotechnologie"},{"orgOrder":0,"company":"Avicanna","sponsor":"Harrington Wellness","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Avicanna \/ Harrington Wellness","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Harrington Wellness"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Canada Royal Enoch Phytomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Ginsenoside","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Canada Royal Enoch Phytomedicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Canada Royal Enoch Phytomedicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Canada Royal Enoch Phytomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Optimi Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Optimi Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Optimi Health \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"University of Waterloo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"University of Waterloo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"University of Waterloo \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"University of Waterloo \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Interferon alpha-2b","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Ach receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Reunion Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ University of Wisconsin","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ University of Wisconsin"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"||Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Inapplicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution\/Drops","sponsorNew":"Avicanna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Inapplicable"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Translational Research In Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Translational Research In Oncology \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Gensco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Gensco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Gensco Pharma"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"XPhyto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"XPhyto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"XPhyto \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"XPhyto \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RP-1664","moa":"PLK4","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RP-1664","moa":"PLK4","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"||Pol-theta ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Camonsertib","moa":"Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camonsertib","moa":"||Ataxia-Telangiectasia","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Canadian Cancer Trials Group","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Canadian Cancer Trials Group"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Raya Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raya Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raya Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"ROS","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"||Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||5-HT1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bausch Health \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Sernova","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"||Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Evotec"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"||Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Numinus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Numinus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numinus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Numinus \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Firefly Neuroscience","sponsor":"Arrivo BioVentures","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Firefly Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Firefly Neuroscience \/ Arrivo BioVentures","highestDevelopmentStatusID":"8","companyTruncated":"Firefly Neuroscience \/ Arrivo BioVentures"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apotex Fermentation Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Fermentation Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Entourage Health","sponsor":"NordicCan","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Entourage Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Entourage Health \/ NordicCan","highestDevelopmentStatusID":"15","companyTruncated":"Entourage Health \/ NordicCan"},{"orgOrder":0,"company":"AbCellera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Symvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"bacTRL-Spike","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"UC San Diego School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ UC San Diego School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife Pharma \/ UC San Diego School of Medicine"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Ambio","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Apotex Fermentation Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apotex Fermentation Inc. \/ Ambio","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Fermentation Inc. \/ Ambio"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Targeted Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onternabez","moa":"CB2 receptor","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetra BioPharma \/ Targeted Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Tetra BioPharma \/ Targeted Pharmaceuticals"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Radicle Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"InMed Pharmaceuticals \/ Radicle Science","highestDevelopmentStatusID":"15","companyTruncated":"InMed Pharmaceuticals \/ Radicle Science"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ PPD"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor 1","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor 1","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor 1","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Windtree Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor 1","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor 1","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATB-352","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"VIDO-InterVac","sponsor":"Vaccine Formulation Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVAC-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VIDO-InterVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VIDO-InterVac \/ Vaccine Formulation Institute","highestDevelopmentStatusID":"4","companyTruncated":"VIDO-InterVac \/ Vaccine Formulation Institute"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Devonian Health Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Crescita Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Donor Islet Cell","moa":"Insulin hormone","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Origin Therapeutics","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Origin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Origin Therapeutics \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Origin Therapeutics \/ Clairvoyant Therapeutics"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Clearside Biomedical"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PreveCeutical Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Omega-3 Phospholipid","moa":"PPA receptor-gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Apobiologix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apobiologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Apobiologix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apobiologix \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocin Analog","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lobe Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch Health \/ Clearside Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Clearside Biomedical"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ceapro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beta Glucan","moa":"Beta glucan receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ceapro \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZT-01","moa":"SST2","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zucara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zucara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirofiban","moa":"||Integrin-alpha 2b\/beta 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"||BET","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Omega-3 Phospholipid","moa":"PPA receptor-gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Mind Cure Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"8-Methoxycoronaridine HCl","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Mind Cure Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Cure Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Cure Health \/ Inapplicable"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Braxia Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braxia Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mountain Valley MD \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain Valley MD \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Altum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Altum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Altum Pharmaceuticals"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Avicanna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Inapplicable"},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Vectura Fertin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aurora Cannabis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurora Cannabis \/ Vectura Fertin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aurora Cannabis \/ Vectura Fertin Pharma"},{"orgOrder":0,"company":"Love Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Love Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Love Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Love Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mimetogen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavilermide","moa":"TrkA receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mimetogen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mimetogen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mimetogen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mydecine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mydecine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"||Vasodilator","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OB-002","moa":"CCR5 pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"0B-002","moa":"CCR5","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"IMV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Maveropepimut-S","moa":"||Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Novaliq"},{"orgOrder":0,"company":"Medicago","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Coronavirus Virus-Like Particle COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Pulmonem","sponsor":"Mcgill University Health Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pulmonem \/ Mcgill University Health Centre","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/ Mcgill University Health Centre"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Epacadostat","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Neurology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orion Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Cato Research","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Cato Research"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"XPhyto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XPhyto","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"XPhyto \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"XPhyto \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onternabez","moa":"||CB2 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Nova Mentis Life Science Corp","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Wellbeing Digital Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Nova Mentis Life Science Corp","highestDevelopmentStatusID":"6","companyTruncated":"Wellbeing Digital Sciences \/ Nova Mentis Life Science Corp"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"QBECO-SSI","moa":"Site specific immuno","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Fluorodeschloroketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Knight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Knight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camlipixant","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BELLUS Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Health \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pike Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Pike Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Injection","sponsorNew":"Pike Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pike Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"BET","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Resverlogix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Inapplicable"},{"orgOrder":0,"company":"enGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Inapplicable"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZT-01","moa":"SST2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zucara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masofaniten","moa":"||Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Essa Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Interferon alpha-2b","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"QBECO-SSI","moa":"Site specific immuno","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Paromomycin","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Symvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"bacTRL-Spike Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbCellera \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Psirenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Psirenity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Psirenity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Psirenity \/ Inapplicable"},{"orgOrder":0,"company":"Immunitor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepcortespenlisimut-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Immunitor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunitor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunitor \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"ALX Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ ALX Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ ALX Oncology"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Pontificia Universidad Catolica de Chile","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ Pontificia Universidad Catolica de Chile","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ Pontificia Universidad Catolica de Chile"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Canadian Cancer Society","sponsor":"Canadian Institutes Of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Neurology","graph2":"Phase III","graph3":"Canadian Cancer Society","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canadian Cancer Society \/ Canadian Institutes Of Health Research","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Cancer Society \/ Canadian Institutes Of Health Research"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Therini Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"THN391","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therini Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bio \/ Inapplicable"},{"orgOrder":0,"company":"Therini Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"THN391","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therini Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bio \/ Inapplicable"},{"orgOrder":0,"company":"Therini Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"THN391","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therini Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bio \/ Inapplicable"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thryv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Thryv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Devonian Health Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Inapplicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tilray \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rutherrin","moa":"TfR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mountain Valley MD \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain Valley MD \/ Inapplicable"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase I","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Helix BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Omega-3 Phospholipid","moa":"PPA receptor-gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Dialco Medical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell membrane synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Dialco Medical","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Dialco Medical"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Triptax","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Avicanna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ SciSparc"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Tie2","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasomune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vasomune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExCellThera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ExCellThera \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revive Therapeutics \/ University of Wisconsin","highestDevelopmentStatusID":"6","companyTruncated":"Revive Therapeutics \/ University of Wisconsin"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aloe Vera","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Acacia Catechu","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"Cybin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Cybin \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cybin \/ Inapplicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"HCN4","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dequalinium Chloride","moa":"Bacterial cell permeability","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Tablet","sponsorNew":"Duchesnay \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Inapplicable"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hesperidin","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valeo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valeo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amikacin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Valeo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valeo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HLS Therapeutics \/ Amarin","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therapeutics \/ Amarin"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"VERITY-BCG","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verity Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Verity Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verity Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Loxapine","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Altasciences Company Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altasciences Company Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Altasciences Company Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Halobetasol","moa":"||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xpira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Xpira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xpira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Xpira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"KV7 potassium ion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ezogabine","moa":"KCNQ potassium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bausch Health \/ Salix Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Salix Pharmaceuticals"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZT-01","moa":"SST2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zucara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Purdue Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW171","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW171","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW191","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW191","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Auristatin","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Med-Life Discoveries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ppi-1011","moa":"Plasmalogen","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Med-Life Discoveries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"Med-Life Discoveries \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Med-Life Discoveries \/ Inapplicable"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Medicus Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AchE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Etripamil","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Psyence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Psyence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Inapplicable"},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nora Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nora Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"AnGes","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vasculotide","moa":"Angiopoietin-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ AnGes","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune Therapeutics \/ AnGes"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Bionxt Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Solutions \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"DRDC","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Neurology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ DRDC","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ DRDC"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cilastatin","moa":"DPEP1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Variational AI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ATR","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Variational AI","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Variational AI"},{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Thyroid Cell","moa":"T3\/4","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"enGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"enGene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Submucosal Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tuspetinib","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"K1.1 mRNA","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"||Methemoglobin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Ondine Biomedical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"NEU-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Neurenati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Neurenati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurenati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Onco-Innovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onco-Innovations \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lexaria Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Phoenix Molecular Designs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Pan-RSK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phoenix Molecular Designs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phoenix Molecular Designs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phoenix Molecular Designs \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProMIS Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PARP1","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TLD-1433","moa":"Photosensitiser","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor 1","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Onco-Innovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Onco-Innovations \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ Inapplicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Devonian Health Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Devonian Health Group \/ Inapplicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Devonian Health Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Devonian Health Group \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Quallent Pharmaceuticals","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CAYMAN ISLANDS","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Quallent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quallent Pharmaceuticals \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"Quallent Pharmaceuticals \/ Alvotech"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Termination","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"RareStone Group \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Mankind Pharma"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Nanjing King-friend Biochemical Pharmaceutical","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nanjing King-friend Biochemical Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Zhuhai Beihai Biotech","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Licensing Agreement","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zhuhai Beihai Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zhuhai Beihai Biotech \/ Zydus Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Zhuhai Beihai Biotech \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Leo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Leo Pharma"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Accord BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Accord BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Accord BioPharma"},{"orgOrder":0,"company":"Vincentage Pharma","sponsor":"Corxel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Vincentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vincentage Pharma \/ Corxel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vincentage Pharma \/ Corxel Pharmaceuticals"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Centers for Disease Control and Prevention","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Nitroxoline","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Asieris Pharmaceuticals \/ Centers for Disease Control and Prevention","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1312","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Acquisition","leadProduct":"Carboplatin","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Biotheus","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.94999999999999996,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Agreement","leadProduct":"DB-1324","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ GSK"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"SIM0500","moa":"GPRC5D\/BCMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":1.0600000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.0600000000000001,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ AbbVie Inc"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hunan Mabgeek Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"MG-K10","moa":"IL-4R alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chime Biologics \/ Hunan Mabgeek Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Chime Biologics \/ Hunan Mabgeek Biotechnology"},{"orgOrder":0,"company":"Porton Pharma Solutions","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Porton Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Porton Pharma Solutions \/ Eureka Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Porton Pharma Solutions \/ Eureka Therapeutics"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"LAE102","moa":"ActRIIA","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Laekna Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Series C Financing","leadProduct":"AGA2118","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Angitia Biopharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Angitia Biopharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Yangzhou Guojin Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Peptide","year":"2025","type":"Series C Financing","leadProduct":"Solnatide","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Alebund Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.080000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"Alebund Pharmaceuticals \/ Yangzhou Guojin Investment Group","highestDevelopmentStatusID":"10","companyTruncated":"Alebund Pharmaceuticals \/ Yangzhou Guojin Investment Group"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Shanghai Allink Biotherapeutics","sponsor":"Lanchi Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Series A Financing","leadProduct":"ALK201","moa":"FGFR2b","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Allink Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Allink Biotherapeutics \/ Lanchi Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Allink Biotherapeutics \/ Lanchi Ventures"},{"orgOrder":0,"company":"Medicilon","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medicilon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicilon \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Medicilon \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"SynerK PharmaTech","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"SNK-2726","moa":"Angiotensin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huadong Medicine \/ SynerK PharmaTech","highestDevelopmentStatusID":"4","companyTruncated":"Huadong Medicine \/ SynerK PharmaTech"},{"orgOrder":0,"company":"WuXi XDC","sponsor":"Ligachem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"WuXi XDC","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi XDC \/ Ligachem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"WuXi XDC \/ Ligachem Biosciences"},{"orgOrder":0,"company":"Zai Lab","sponsor":"MediLink Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"ZL-6201","moa":"LRRC15","graph1":"Oncology","graph2":"Preclinical","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ MediLink Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Zai Lab \/ MediLink Therapeutics"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0.93000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.93000000000000005,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Candid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Polymed Biopharmaceuticals","sponsor":"Photys Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2025","type":"Licensing Agreement","leadProduct":"PHT-776","moa":"IRAK4","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Polymed Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Polymed Biopharmaceuticals \/ Photys Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Polymed Biopharmaceuticals \/ Photys Therapeutics"},{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"FZ002-037","moa":"SSTR4","graph1":"Neurology","graph2":"Phase I","graph3":"Guangzhou Fermion Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Guangzhou Fermion Technology \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Fermion Technology \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"VS-7375","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Verastem Oncology"},{"orgOrder":0,"company":"Suzhou Puhe Biopharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"BAY 3713372","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Suzhou Puhe Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Suzhou Puhe Biopharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Puhe Biopharma \/ Bayer AG"},{"orgOrder":0,"company":"CSPC Zhongqi Pharmaceutical Technology","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SYH2039","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Zhongqi Pharmaceutical Technology","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"CSPC Zhongqi Pharmaceutical Technology \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Zhongqi Pharmaceutical Technology \/ BeiGene"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Climb Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"CLYM116","moa":"APRIL","graph1":"Nephrology","graph2":"Preclinical","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Mabworks Biotech \/ Climb Bio","highestDevelopmentStatusID":"4","companyTruncated":"Beijing Mabworks Biotech \/ Climb Bio"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"IBI3009","moa":"DLL3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Innovent Biologics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"HRS-5346","moa":"Lipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":1.97,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.97,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Merck & Co"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Prolium Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"CM355","moa":"CD20\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0.52000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.52000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"InnoCare Pharma \/ Prolium Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Prolium Bioscience"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Verdiva Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":2.4700000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.4700000000000002,"dosageForm":"Oral Tablet","sponsorNew":"Sciwind Biosciences \/ Verdiva Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Verdiva Bio"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"SOT109","moa":"CDH17","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Sotio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Sotio"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1418","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Duality Biologics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"BC3195","moa":"||CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCity Biopharma \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Adcendo"},{"orgOrder":0,"company":"Drug Farm","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drug Farm \/ NIAID","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ NIAID"},{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"ArriVent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"MRG007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lepu Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lepu Biopharma \/ ArriVent","highestDevelopmentStatusID":"4","companyTruncated":"Lepu Biopharma \/ ArriVent"},{"orgOrder":0,"company":"Akeso","sponsor":"Sichuan Kelun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Cisplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Sichuan Kelun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Sichuan Kelun Pharmaceutical"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Timberlyne Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"CM313","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Connoya Biomedical Technology \/ Timberlyne Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Timberlyne Therapeutics"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"SteinCares","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ SteinCares","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ SteinCares"},{"orgOrder":0,"company":"Syneron Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Syneron Bio","amount2":3.48,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":3.48,"dosageForm":"Undisclosed","sponsorNew":"Syneron Bio \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Syneron Bio \/ AstraZeneca"},{"orgOrder":0,"company":"SanReno Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"SanReno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"SanReno Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"SanReno Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Pfizer Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"I-Mab Hangzhou Company","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2024","type":"Divestment","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"I-Mab Biopharma \/ I-Mab Hangzhou Company","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ I-Mab Hangzhou Company"},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Kexing Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Eribulin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xiling Lab \/ Kexing Biopharm","highestDevelopmentStatusID":"15","companyTruncated":"Xiling Lab \/ Kexing Biopharm"},{"orgOrder":0,"company":"Biosion","sponsor":"Aclaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Bosakitug","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biosion \/ Aclaris Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ Aclaris Therapeutics"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series E Financing","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TenNor Therapeutics \/ AMR Action Fund","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ AMR Action Fund"},{"orgOrder":0,"company":"Jixing Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Jixing Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jixing Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Jixing Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"Corxel Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corxel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corxel Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Corxel Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Jiangsu Nhwa Pharmaceutical","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Jiangsu Nhwa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Simcere Zaiming","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ Simcere Zaiming","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Simcere Zaiming"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Limertinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aosaikang Pharmaceutical \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Aosaikang Pharmaceutical \/ Innovent Biologics"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jacobio Pharma \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Pharma \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Myung In Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Myung In Pharm"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Exeltis"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Zambon Group SpA","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Zambon Group SpA"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nuvation Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnHeart Therapeutics \/ Nuvation Bio","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Nuvation Bio"},{"orgOrder":0,"company":"Cholesgen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Cholesgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cholesgen \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Cholesgen \/ AstraZeneca"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"LongRiver Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"RN0191","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rona Therapeutics \/ LongRiver Investments","highestDevelopmentStatusID":"6","companyTruncated":"Rona Therapeutics \/ LongRiver Investments"},{"orgOrder":0,"company":"Anbison","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Anbison","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbison \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Anbison \/ Ethypharm"},{"orgOrder":0,"company":"LianBio","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LianBio \/ NImmune Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ NImmune Biopharma"},{"orgOrder":0,"company":"OBiO Technology","sponsor":"Chinagene","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"ZVS101e","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"OBiO Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"OBiO Technology \/ Chinagene","highestDevelopmentStatusID":"7","companyTruncated":"OBiO Technology \/ Chinagene"},{"orgOrder":0,"company":"Tianjin Tiancheng Pharma. Co., Ltd.","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"BT524","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Tianjin Tiancheng Pharma. Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tianjin Tiancheng Pharma. Co., Ltd. \/ Grifols International","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tiancheng Pharma. Co., Ltd. \/ Grifols International"},{"orgOrder":0,"company":"Fudan University","sponsor":"RNACure Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Fudan University \/ RNACure Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Fudan University \/ RNACure Biopharma"},{"orgOrder":0,"company":"Tianjin University","sponsor":"Beroni Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Tianjin University \/ Beroni Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin University \/ Beroni Group"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ BioNTech"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Lemzoparlimab","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Institut Pasteur Shanghai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Alphamab Oncology \/ Institut Pasteur Shanghai","highestDevelopmentStatusID":"1","companyTruncated":"Alphamab Oncology \/ Institut Pasteur Shanghai"},{"orgOrder":0,"company":"CMAB Biopharma","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Afuresertib","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"CMAB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CMAB Biopharma \/ Laekna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CMAB Biopharma \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"5","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Towa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Docetaxel","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alphamab Oncology \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Sanofi"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Bevacizumab","moa":"||VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Sandoz B2B"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Yonghe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ablaze Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablaze Pharma \/ Yonghe Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ablaze Pharma \/ Yonghe Pharma"},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIO","graph1":"Oncology","graph2":"Preclinical","graph3":"Levena Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Levena Biopharma \/ Navrogen","highestDevelopmentStatusID":"4","companyTruncated":"Levena Biopharma \/ Navrogen"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National University Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Adg106","moa":"||CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ National University Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ National University Cancer Institute"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ EQRx","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ EQRx"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Solnatide","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Alebund Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alebund Pharmaceuticals \/ Quan Capital","highestDevelopmentStatusID":"10","companyTruncated":"Alebund Pharmaceuticals \/ Quan Capital"},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yangtze River Pharmaceutical Group \/ Alvotech","highestDevelopmentStatusID":"1","companyTruncated":"Yangtze River Pharmaceutical Group \/ Alvotech"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Tarlatamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"MediLink Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"TSB Therapeutics","sponsor":"China Resources Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TSB Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TSB Therapeutics \/ China Resources Pharmaceutical Group","highestDevelopmentStatusID":"15","companyTruncated":"TSB Therapeutics \/ China Resources Pharmaceutical Group"},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ WuXi Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Antengene \/ WuXi Biologics"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"uPARAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"BeiGene","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nitroxoline","moa":"||MetAP2","graph1":"Oncology","graph2":"Preclinical","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"BeiGene \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Loyal Valley Capital","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Loyal Valley Capital"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"BW-02","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"University of Hong Kong","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"ARVN601","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arctic Vision \/ University of Hong Kong","highestDevelopmentStatusID":"4","companyTruncated":"Arctic Vision \/ University of Hong Kong"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TenNor Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"TenNor Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Galmed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Aramchol","moa":"||THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Galmed Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Galmed Pharmaceuticals"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaBlock Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PharmaBlock Sciences \/ Ascentage Pharma","highestDevelopmentStatusID":"8","companyTruncated":"PharmaBlock Sciences \/ Ascentage Pharma"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AZD0780","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"CSPC Pharmaceutical Group \/ AstraZeneca"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Antengene","sponsor":"MSD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ATG-037","moa":"||CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ MSD","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ MSD"},{"orgOrder":0,"company":"VelaVigo","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Nectin4\/TROP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"VelaVigo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VelaVigo \/ Avenzo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"VelaVigo \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Termination","leadProduct":"AV-203","moa":"ErbB3","graph1":"Oncology","graph2":"Phase I","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Aveo Oncology","highestDevelopmentStatusID":"6","companyTruncated":"CANbridge Pharmaceuticals \/ Aveo Oncology"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ Axis Therapeutics"},{"orgOrder":0,"company":"HitGen","sponsor":"Guangzhou Baiyunshan Pharmaceutical Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"HG030","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Guangzhou Baiyunshan Pharmaceutical Holdings","highestDevelopmentStatusID":"4","companyTruncated":"HitGen \/ Guangzhou Baiyunshan Pharmaceutical Holdings"},{"orgOrder":0,"company":"Peking University","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Peking University \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Peking University \/ Bayer AG"},{"orgOrder":0,"company":"BeiGene","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Biocytogen","sponsor":"BioCopy AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ BioCopy AG","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ BioCopy AG"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Ona Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Ona Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Ona Therapeutics"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Guangzhou FineImmune Biotechnology Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Guangzhou FineImmune Biotechnology Co","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Guangzhou FineImmune Biotechnology Co"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Biogen"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Biogen"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"PM8002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PM8002","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Biosion","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biosion \/ Immunogen","highestDevelopmentStatusID":"2","companyTruncated":"Biosion \/ Immunogen"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"BrighGene Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"GQ1007","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ BrighGene Biomedical","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ BrighGene Biomedical"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Qilu Pharmaceutical \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharmaceutical \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"SCB-2019","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 S-Trimer Vaccine","moa":"S-Trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chime Biologics \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Chime Biologics \/ Humanigen"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qilu Pharmaceutical \/ ECI Pharmaceuticals LLC","highestDevelopmentStatusID":"15","companyTruncated":"Qilu Pharmaceutical \/ ECI Pharmaceuticals LLC"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"JS006","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Coherus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Wuxi Shuangliang Biotechnology","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"C-005","moa":"||VEGFR2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wuxi Shuangliang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuxi Shuangliang Biotechnology \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Wuxi Shuangliang Biotechnology \/ PharmAbcine"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ Aravive","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Aravive"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CTGF","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ Aravive","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Aravive"},{"orgOrder":0,"company":"Baili","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Osimertinib","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Baili","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Baili \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Baili \/ AstraZeneca"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Xuanzhu Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"KM257","moa":"HER2D4","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Renaissance Capital"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"CS1002","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CStone Pharmaceuticals \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Shanghai Guoxin Investment & Development","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Series C Financing","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Shanghai Guoxin Investment & Development","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Shanghai Guoxin Investment & Development"},{"orgOrder":0,"company":"Hunan Warrant Chiral Pharmaceutical","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hunan Warrant Chiral Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hunan Warrant Chiral Pharmaceutical \/ CytoDyn","highestDevelopmentStatusID":"10","companyTruncated":"Hunan Warrant Chiral Pharmaceutical \/ CytoDyn"},{"orgOrder":0,"company":"InventisBio","sponsor":"GL Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"D-0502","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ GL Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InventisBio \/ GL Ventures"},{"orgOrder":0,"company":"Jiangsu Wuzhong Pharmaceutical Group Corporation","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Endostatin","moa":"VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Wuzhong Pharmaceutical Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Wuzhong Pharmaceutical Group Corporation \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Wuzhong Pharmaceutical Group Corporation \/ Denovo Biopharma"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"MSD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"DR30303","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Doer Biologics \/ MSD","highestDevelopmentStatusID":"4","companyTruncated":"Zhejiang Doer Biologics \/ MSD"},{"orgOrder":0,"company":"HitGen","sponsor":"Uppthera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"E3 ligase","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ Uppthera","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Uppthera"},{"orgOrder":0,"company":"HitGen","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"EdiGene","sponsor":"3H Health Investment","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"Botulinum Toxin A","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EdiGene \/ 3H Health Investment","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ 3H Health Investment"},{"orgOrder":0,"company":"EdiGene","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EdiGene \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Greater Bay Area Homeland Development Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"ES002","moa":"CD39 ATPase","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpiscience \/ Greater Bay Area Homeland Development Fund","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscience \/ Greater Bay Area Homeland Development Fund"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Etana Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Etana Biotechnologies","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Etana Biotechnologies"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Chipscreen NewWay Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"YH008","moa":"CTL4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eucure Biopharma \/ Chipscreen NewWay Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Eucure Biopharma \/ Chipscreen NewWay Biosciences"},{"orgOrder":0,"company":"China Resources Pharmaceutical Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"China Resources Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"China Resources Pharmaceutical Group \/ Everest Medicines","highestDevelopmentStatusID":"8","companyTruncated":"China Resources Pharmaceutical Group \/ Everest Medicines"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"AMP945","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Exelixis"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Exelixis"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Suzhou Limited \/ Exelixis"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Focus-X Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Full-Life Technologies \/ Focus-X Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Focus-X Therapeutics"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"S-Trimer COVID Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Xicheng Jinrui Equity Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Xicheng Jinrui Equity Investment Fund","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Xicheng Jinrui Equity Investment Fund"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 S-Trimer Vaccine","moa":"S-Trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"InxMed","sponsor":"Ennovation Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Ennovation Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Ennovation Ventures"},{"orgOrder":0,"company":"RemeGen","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RemeGen \/ Lilly Asia Ventures","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Genmab"},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Hillhouse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Genolimzumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Genor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genor Biopharma \/ Hillhouse","highestDevelopmentStatusID":"8","companyTruncated":"Genor Biopharma \/ Hillhouse"},{"orgOrder":0,"company":"BravoVax","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BravoVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BravoVax \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"BravoVax \/ GeoVax Labs"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"China Life Private Equity Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Series C Financing","leadProduct":"GQ1001","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GeneQuantum Healthcare \/ China Life Private Equity Investment","highestDevelopmentStatusID":"6","companyTruncated":"GeneQuantum Healthcare \/ China Life Private Equity Investment"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Vivo Capital","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Vivo Capital"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Series C Financing","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ OrbiMed"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Jefferies"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 S-Trimer Vaccine","moa":"S-Trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Clover Biopharmaceuticals \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ GSK"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Accord healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Accord healthcare"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"TCM Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Endocrinology","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HighTide Therapeutics \/ TCM Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ TCM Healthcare"},{"orgOrder":0,"company":"HitGen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Merck & Co"},{"orgOrder":0,"company":"HitGen","sponsor":"UPPTHERA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"E3 ligase","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ UPPTHERA","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ UPPTHERA"},{"orgOrder":0,"company":"HitGen","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Evotec"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"HK inno.N","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"GLP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ HK inno.N","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ HK inno.N"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dorzagliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hua Medicine \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Bayer AG"},{"orgOrder":0,"company":"Suzhou GenHouse","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"HBI-2376","moa":"SHP2","graph1":"Oncology","graph2":"Preclinical","graph3":"Suzhou GenHouse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou GenHouse \/ HUYA Bioscience International","highestDevelopmentStatusID":"4","companyTruncated":"Suzhou GenHouse \/ HUYA Bioscience International"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Tucidinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/ Cabaletta Bio"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Binimetinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Abbvie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Abbvie Inc"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"China International Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ China International Capital","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ China International Capital"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"WeComput","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ WeComput","highestDevelopmentStatusID":"4","companyTruncated":"Innovent Biologics \/ WeComput"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Instil Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"IMM2510","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Instil Bio","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnco \/ Instil Bio"},{"orgOrder":0,"company":"InxMed","sponsor":"Hyfinity Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InxMed \/ Hyfinity Investments","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Hyfinity Investments"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"JS016","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Eli Lilly"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Inaticabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juventas Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"CICC Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"Inaticabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juventas Cell Therapy \/ CICC Capital","highestDevelopmentStatusID":"8","companyTruncated":"Juventas Cell Therapy \/ CICC Capital"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"CR-CP Life Science Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"Autoleucel Relmacabtagen","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Therapeutics \/ CR-CP Life Science Fund","highestDevelopmentStatusID":"8","companyTruncated":"JW Therapeutics \/ CR-CP Life Science Fund"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Uliledlimab","moa":"CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Gree Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kintor Pharmaceutical \/ Gree Group","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Gree Group"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2020","type":"Financing","leadProduct":"P014","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kira Pharmaceuticals \/ Quan Capital","highestDevelopmentStatusID":"3","companyTruncated":"Kira Pharmaceuticals \/ Quan Capital"},{"orgOrder":0,"company":"Respirent Pharmaceuticals","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Tiotropium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Respirent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Respirent Pharmaceuticals \/ Lannett Company, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"Respirent Pharmaceuticals \/ Lannett Company, Inc."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"IKS014","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WuXi Biologics \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ LegoChem Biosciences"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"FCN-338","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Fosun Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distribution Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Distribution Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Distribution Solutions"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"ICI Pakistan Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ ICI Pakistan Limited","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ ICI Pakistan Limited"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Zuellig Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Alvogen","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Alvogen"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cap Alter Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cap Alter Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cap Alter Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"DCH Auriga","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ DCH Auriga","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ DCH Auriga"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distriphil","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Distriphil","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Distriphil"},{"orgOrder":0,"company":"Medicilon","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Medicilon","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicilon \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Medicilon \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SKB571","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Merck & Co"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Luye Pharma \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"HitGen","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"HitGen \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Almirall"},{"orgOrder":0,"company":"WuXi XDC","sponsor":"Multitude Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"WuXi XDC","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi XDC \/ Multitude Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"WuXi XDC \/ Multitude Therapeutics"},{"orgOrder":0,"company":"ImmVira","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Agreement","leadProduct":"Cobimetinib","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JW Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"JW Therapeutics \/ Goldman Sachs"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Newg Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Newg Lab","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Newg Lab"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Shandong Boan Biological Technology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OcuMension Therapeutics \/ Shandong Boan Biological Technology","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Shandong Boan Biological Technology"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi AppTec \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"WuXi AppTec \/ Orbit Discovery"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Aumolertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ EQRx","highestDevelopmentStatusID":"15","companyTruncated":"Hansoh Pharma \/ EQRx"},{"orgOrder":0,"company":"Novogene","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Novogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novogene \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Novogene \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Institute of Microbiology of the Chinese Academy of Sciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Microbiology of the Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Institute of Microbiology of the Chinese Academy of Sciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Microbiology of the Chinese Academy of Sciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"225-Ac","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ablaze Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablaze Pharma \/ Vivo Capital","highestDevelopmentStatusID":"15","companyTruncated":"Ablaze Pharma \/ Vivo Capital"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Series D Financing","leadProduct":"Undisclosed","moa":"CIAO2B","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuance Pharma \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Nuance Pharma \/ RTW Investments"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"Matrix Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"AT19","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Yousino Biotechnology \/ Matrix Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chengdu Yousino Biotechnology \/ Matrix Partners"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"China Merchants Bank International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"EMB-01","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ China Merchants Bank International","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ China Merchants Bank International"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Shiyu Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"OQL011","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"OnQuality Pharma \/ Shiyu Capital","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Shiyu Capital"},{"orgOrder":0,"company":"Antengene","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Series C Financing","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Morningside Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Epigenic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Epigenic Therapeutics \/ Morningside Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Epigenic Therapeutics \/ Morningside Venture Capital"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Sequoia China","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Sequoia China","highestDevelopmentStatusID":"15","companyTruncated":"Visen Pharmaceuticals \/ Sequoia China"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"3H Health Investment","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"AP-302","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Alebund Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alebund Pharmaceuticals \/ 3H Health Investment","highestDevelopmentStatusID":"5","companyTruncated":"Alebund Pharmaceuticals \/ 3H Health Investment"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Dingxin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Senaparib","moa":"PARP","graph1":"Oncology","graph2":"Phase III","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Dingxin Capital","highestDevelopmentStatusID":"10","companyTruncated":"IMPACT Therapeutics, Inc \/ Dingxin Capital"},{"orgOrder":0,"company":"LianBio","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ RA Capital","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ RA Capital"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Series D Financing","leadProduct":"Adg106","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ General Atlantic","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Suzhou Limited \/ General Atlantic"},{"orgOrder":0,"company":"Brise Pharma","sponsor":"Shunxi Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"BR01T","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Brise Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brise Pharma \/ Shunxi Fund","highestDevelopmentStatusID":"6","companyTruncated":"Brise Pharma \/ Shunxi Fund"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Sequoia China","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Series A Financing","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Sequoia China","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Sequoia China"},{"orgOrder":0,"company":"Biocytogen","sponsor":"CMB International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Series D Financing","leadProduct":"Undisclosed","moa":"CD137","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ CMB International","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ CMB International"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Essex Biotechnology","sponsor":"Henlius","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Essex Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Essex Biotechnology \/ Henlius","highestDevelopmentStatusID":"10","companyTruncated":"Essex Biotechnology \/ Henlius"},{"orgOrder":0,"company":"STA Pharmaceutical","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"STA Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"STA Pharmaceutical \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"STA Pharmaceutical \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"SDIC Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"RAG-06","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ SDIC Venture Capital","highestDevelopmentStatusID":"5","companyTruncated":"Ractigen Therapeutics \/ SDIC Venture Capital"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Radiance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"YH012","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Radiance Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Radiance Biopharma"},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"AZD1222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Shenzhen Kangtai Biological Products \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Shenzhen Kangtai Biological Products \/ AstraZeneca"},{"orgOrder":0,"company":"Biocytogen","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ BeiGene"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Phokam Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ritonavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Phokam Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ascletis Pharma \/ Phokam Pharmaceutical"},{"orgOrder":0,"company":"Zion Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"ZN-A-1041","moa":"RTK","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Zion Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"LianBio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Sisunatovir","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LianBio \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ Pfizer Inc"},{"orgOrder":0,"company":"Ping An-Shionogi","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ping An-Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ping An-Shionogi \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Ping An-Shionogi \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Carlyle","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Dragon Sail Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Tusamitamab Ravtansine","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Sanofi"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Gavi","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Gavi"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Mabylon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"TDP-43","graph1":"Neurology","graph2":"Discovery Platform","graph3":"SciNeuro Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SciNeuro Pharmaceuticals \/ Mabylon","highestDevelopmentStatusID":"3","companyTruncated":"SciNeuro Pharmaceuticals \/ Mabylon"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"LYFE Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Ecnoglutide","moa":"GLP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ LYFE Capital","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ LYFE Capital"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"IDG Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Series C Financing","leadProduct":"Ecnoglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ IDG Capital","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ IDG Capital"},{"orgOrder":0,"company":"RemeGen","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Disitamab Vedotin","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Seagen"},{"orgOrder":0,"company":"3S Bio Inc","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"3S Bio Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"3S Bio Inc \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"3S Bio Inc \/ Selecta Biosciences"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenFleet Therapeutics \/ Sellas Life Sciences Group","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Sellas Life Sciences Group"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Series C Financing","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Loyal Valley Capital","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Loyal Valley Capital"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Sinopharm \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Pregene","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"PRG1801","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pregene \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Sino Biological","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sino Biological","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sino Biological \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"Sino Biological \/ GeoVax Labs"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Bio Farma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Bio Farma","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Bio Farma"},{"orgOrder":0,"company":"Sironax","sponsor":"Gaorong Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"SIR0365","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sironax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sironax \/ Gaorong Capital","highestDevelopmentStatusID":"7","companyTruncated":"Sironax \/ Gaorong Capital"},{"orgOrder":0,"company":"LianBio","sponsor":"ReViral","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sisunatovir","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ ReViral","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ ReViral"},{"orgOrder":0,"company":"Beijing Wonner Biotech","sponsor":"Shineco","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"SNG","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Beijing Wonner Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Wonner Biotech \/ Shineco","highestDevelopmentStatusID":"1","companyTruncated":"Beijing Wonner Biotech \/ Shineco"},{"orgOrder":0,"company":"Mabpharm","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"ACE-MAB","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mabpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabpharm \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mabpharm \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Sequoia Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Stemirna Therapeutics \/ Sequoia Capital","highestDevelopmentStatusID":"5","companyTruncated":"Stemirna Therapeutics \/ Sequoia Capital"},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Shouyao","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"SY-707","moa":"ALK\/FAK\/IGF1R multi-target kinase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"PharmaBlock Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaBlock Sciences \/ Shouyao","highestDevelopmentStatusID":"9","companyTruncated":"PharmaBlock Sciences \/ Shouyao"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AB2 Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Tadekinig Alpha","moa":"IL-18","graph1":"Immunology","graph2":"Phase III","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ AB2 Bio","highestDevelopmentStatusID":"10","companyTruncated":"WuXi Biologics \/ AB2 Bio"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Sirona Biochem Corp","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"WuXi AppTec \/ Sirona Biochem Corp","highestDevelopmentStatusID":"4","companyTruncated":"WuXi AppTec \/ Sirona Biochem Corp"},{"orgOrder":0,"company":"East China Normal University","sponsor":"ImmuneCyte Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"East China Normal University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"East China Normal University \/ ImmuneCyte Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"East China Normal University \/ ImmuneCyte Life Sciences"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nuvation Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnHeart Therapeutics \/ Nuvation Bio","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Nuvation Bio"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Genmab"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ AstraZeneca"},{"orgOrder":0,"company":"Jemincare","sponsor":"Rapt Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"JYB1904","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Rapt Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Rapt Therapeutics"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Leads Biolabs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"LBL-007","moa":"||LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chime Biologics \/ Leads Biolabs","highestDevelopmentStatusID":"7","companyTruncated":"Chime Biologics \/ Leads Biolabs"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Sinorda Biomedicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LM-299","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ Merck & Co"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HSK31858","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haisco Pharmaceutical \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Chiesi Group"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Mass General Brigham","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Mass General Brigham","highestDevelopmentStatusID":"2","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Mass General Brigham"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ AstraZeneca"},{"orgOrder":0,"company":"Foreseen Biotechnology","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"FS001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Foreseen Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foreseen Biotechnology \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Foreseen Biotechnology \/ Ipsen"},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Graviton","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"TDI01","moa":"ROCK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Beijing Tide Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Tide Pharmaceutical \/ Graviton","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Tide Pharmaceutical \/ Graviton"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Neurocrine Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Organon"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Government of Brazil","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Government of Brazil","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Government of Brazil"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sinopharm Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"GFH018","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Sinopharm Capital","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Sinopharm Capital"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Applied Biology","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Applied Biology"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"AMB302","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Aimed Bio","highestDevelopmentStatusID":"4","companyTruncated":"GeneQuantum Healthcare \/ Aimed Bio"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnHeart Therapeutics \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Foundation Medicine"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Exelixis"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"ES019","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpiscience \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Agilent Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transcenta Holding \/ Agilent Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Transcenta Holding \/ Agilent Technologies"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Biocytogen","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ ABL Bio"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BC3402","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ AstraZeneca"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Nucleai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Buparlisib","moa":"||Pan-PI3K","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlai Nortye \/ Nucleai","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Nucleai"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Claudin18.2 mRNA Vaccine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"CARsgen Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"FutureGen","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CLDN18.2","graph1":"Oncology","graph2":"Discovery Platform","graph3":"FutureGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FutureGen \/ Gracell Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"FutureGen \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"BeiGene","sponsor":"The Max Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ The Max Foundation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ The Max Foundation"},{"orgOrder":0,"company":"HitGen","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Cure Genetics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Cure Genetics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure Genetics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Cure Genetics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ Medigene","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Medigene"},{"orgOrder":0,"company":"BJ Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BJ-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BJ Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BJ Bioscience \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"BJ Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"RemeGen","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"RC88","moa":"||Mesothelin protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Innovent Biologics"},{"orgOrder":0,"company":"EdiGene","sponsor":"Neukio Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EdiGene \/ Neukio Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ Neukio Biotherapeutics"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein-protein interaction","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Huadong Medicine \/ Insilico Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Huadong Medicine \/ Insilico Medicine"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Linperlisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yingli Pharmaceutical \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Junshi Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EpimAb Biotherapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"EpimAb Biotherapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"AllianThera Biopharma","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"AllianThera Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AllianThera Biopharma \/ Insilico Medicine","highestDevelopmentStatusID":"1","companyTruncated":"AllianThera Biopharma \/ Insilico Medicine"},{"orgOrder":0,"company":"Burning Rock Dx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Phase III","graph3":"Burning Rock Dx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burning Rock Dx \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Burning Rock Dx \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Laekna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighTide Therapeutics \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ U.S. Food and Drug Administration"},{"orgOrder":0,"company":"Zai Lab","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ J. P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ J. P. Morgan"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Series C Financing","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"IASO Bio","sponsor":"CDH Baifu","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"RD126","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ CDH Baifu","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/ CDH Baifu"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"I-Mab Biopharma \/ Hillhouse Capital Group","highestDevelopmentStatusID":"1","companyTruncated":"I-Mab Biopharma \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Chengdu Baiyu Pharmaceutical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Chengdu Baiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chengdu Baiyu Pharmaceutical \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Chengdu Baiyu Pharmaceutical \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Synaffix","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Synaffix"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Longbio Pharma \/ Qiming Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Qiming Venture Partners"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"Rinatabart Sesutecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Ally Bridge Group","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Ally Bridge Group"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Series C Financing","leadProduct":"Apatinib","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaNova Medicines \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"LaNova Medicines \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"D3S-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"D3 Bio \/ Medicxi","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Medicxi"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Prosperity7 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Prosperity7 Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Prosperity7 Ventures"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Ghit Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Artemether","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Ghit Fund","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ Ghit Fund"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Kaitai Capital","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Kaitai Capital","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Kaitai Capital"},{"orgOrder":0,"company":"Delonix Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"Synthetic Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Delonix Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delonix Bioworks \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Delonix Bioworks \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"CMG-SDIC Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"NFS-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ CMG-SDIC Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neurophth Therapeutics \/ CMG-SDIC Capital"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Ming Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"Help Therapeutics \/ Ming Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"Help Therapeutics \/ Ming Bioventures"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"CICC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"GT101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GRIT Biotechnology \/ CICC","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ CICC"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Shandong Quangang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"125SER","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRIT Biotechnology \/ Shandong Quangang Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"GRIT Biotechnology \/ Shandong Quangang Pharmaceutical"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Sana Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Sana Biotechnology"},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Tsing Song Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"INV-1120","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionova Life Science \/ Tsing Song Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Life Science \/ Tsing Song Capital"},{"orgOrder":0,"company":"Suzhou Ribo","sponsor":"Capital Venture Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Oligonucleotide","year":"2020","type":"Series C Financing","leadProduct":"RB-RQ007","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Suzhou Ribo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Ribo \/ Capital Venture Capital Fund","highestDevelopmentStatusID":"4","companyTruncated":"Suzhou Ribo \/ Capital Venture Capital Fund"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Advantech Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Advantech Capital","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Advantech Capital"},{"orgOrder":0,"company":"ImmVira","sponsor":"China Merchants China Direct Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ China Merchants China Direct Investments","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ China Merchants China Direct Investments"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Sequoia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Fibroblast protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Full-Life Technologies \/ Sequoia","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Sequoia"},{"orgOrder":0,"company":"neoX Biotech","sponsor":"Sky9 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"neoX Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"neoX Biotech \/ Sky9 Capital","highestDevelopmentStatusID":"3","companyTruncated":"neoX Biotech \/ Sky9 Capital"},{"orgOrder":0,"company":"Alternative Bio","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alternative Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alternative Bio \/ F-Prime Capital","highestDevelopmentStatusID":"3","companyTruncated":"Alternative Bio \/ F-Prime Capital"},{"orgOrder":0,"company":"Beijing Advaccine Biotechnology","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beijing Advaccine Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Beijing Advaccine Biotechnology \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Beijing Advaccine Biotechnology \/ Inovio Pharmaceuticals"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"B7H3\/PTK7 topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Ideaya Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Avistone Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"c-Met receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avistone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Avistone Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"1","companyTruncated":"Avistone Pharmaceuticals \/ Vivo Capital"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Rohto Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Rohto Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Rohto Pharmaceutical"},{"orgOrder":0,"company":"Biosion","sponsor":"OBI Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"BSI0-4702","moa":"Trop2","graph1":"Oncology","graph2":"Preclinical","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosion \/ OBI Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Biosion \/ OBI Pharma"},{"orgOrder":0,"company":"ImmVira","sponsor":"Shanghai Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Shanghai Pharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ Shanghai Pharma"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ABK3376","moa":"||EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Aerogen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AP-002","moa":"RANKL","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuance Pharma \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Nuance Pharma \/ Aerogen"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"N1 Life","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"N1-109","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AccurEdit Therapeutics \/ N1 Life","highestDevelopmentStatusID":"4","companyTruncated":"AccurEdit Therapeutics \/ N1 Life"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Yangtze River-CMB International Industry Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Series C Financing","leadProduct":"Esonadogene Imvoparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Yangtze River-CMB International Industry Fund","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Yangtze River-CMB International Industry Fund"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"LVRNA009","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIM Vaccine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AIM Vaccine \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"SDIC CS Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"||Pan-PI3K","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"||Pan-PI3K","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"Ori-C101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OriCell Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"OriCell Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"LYFE Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediLink Therapeutics \/ LYFE Capital","highestDevelopmentStatusID":"4","companyTruncated":"MediLink Therapeutics \/ LYFE Capital"},{"orgOrder":0,"company":"Triastek","sponsor":"Matrix Partners China","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"T19","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Matrix Partners China","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Matrix Partners China"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSPC Pharmaceutical Group \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"CSPC Pharmaceutical Group \/ Pfizer Inc"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AC Immune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Anti-TDP-43 antibody","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ AC Immune","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ AC Immune"},{"orgOrder":0,"company":"DP Technology","sponsor":"Lepu Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DP Technology \/ Lepu Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Lepu Biopharma"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Sirnaomics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2021","type":"Partnership","leadProduct":"STP702","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Walvax Biotechnology \/ Sirnaomics","highestDevelopmentStatusID":"5","companyTruncated":"Walvax Biotechnology \/ Sirnaomics"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"TB Alliance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Pretomanid","moa":"Mycolic acid biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ TB Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ TB Alliance"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"LNK01002","moa":"Triple kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lynk Pharmaceuticals \/ Lilly Asia Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"3E Bioventures Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"A-319","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tianweiyuanhe Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tianweiyuanhe Biomedical \/ 3E Bioventures Capital","highestDevelopmentStatusID":"6","companyTruncated":"Tianweiyuanhe Biomedical \/ 3E Bioventures Capital"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"3W Fund Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2020","type":"Series E Financing","leadProduct":"Idursulfase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ 3W Fund Management","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ 3W Fund Management"},{"orgOrder":0,"company":"Zephyrm Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"ZH901","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Zephyrm Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zephyrm Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zephyrm Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Kanglin Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"KL003","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Kanglin Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kanglin Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kanglin Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hasten Biopharmaceutic \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ CBC Group"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GL Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Series C Financing","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ GL Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ GL Ventures"},{"orgOrder":0,"company":"Eccogene","sponsor":"New Alliance Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"ECC5004","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I","graph3":"Eccogene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eccogene \/ New Alliance Capital","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/ New Alliance Capital"},{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Epigenic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epigenic Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Epigenic Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2020","type":"Series D Financing","leadProduct":"Idursulfase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ General Atlantic"},{"orgOrder":0,"company":"NanoMab","sponsor":"University Hospital Aachen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"NM-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoMab \/ University Hospital Aachen","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab \/ University Hospital Aachen"},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CAStem","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinese Academy of Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chinese Academy of Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rona Therapeutics \/ Lilly Asia Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rona Therapeutics \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"Apricot Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediLink Therapeutics \/ Apricot Capital","highestDevelopmentStatusID":"4","companyTruncated":"MediLink Therapeutics \/ Apricot Capital"},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Denosumab","moa":"RANK","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BeiGene \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Amgen Inc"},{"orgOrder":0,"company":"NeuShen Therapeutics","sponsor":"LAPAM","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"NeuShen Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuShen Therapeutics \/ LAPAM","highestDevelopmentStatusID":"2","companyTruncated":"NeuShen Therapeutics \/ LAPAM"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Rxilient Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Rxilient Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Rxilient Biotech"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"UNICEF","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"SCB-2019","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ UNICEF","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ UNICEF"},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Amgen Inc"},{"orgOrder":0,"company":"Baidu Research","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Baidu Research","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baidu Research \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Baidu Research \/ Sanofi"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Institut of Butantan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Inactivated Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Institut of Butantan","highestDevelopmentStatusID":"4","companyTruncated":"Sinovac Biotech \/ Institut of Butantan"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Innovent Biologics"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ UMass Chan Medical School"},{"orgOrder":0,"company":"Drug Farm","sponsor":"BioVeda China Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Farm \/ BioVeda China Fund","highestDevelopmentStatusID":"5","companyTruncated":"Drug Farm \/ BioVeda China Fund"},{"orgOrder":0,"company":"Xiamen Biotime Biotechnology","sponsor":"Adlai Nortye","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"AN4005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Xiamen Biotime Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xiamen Biotime Biotechnology \/ Adlai Nortye","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Biotime Biotechnology \/ Adlai Nortye"},{"orgOrder":0,"company":"ImmVira","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2020","type":"Series B Financing","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ Shanghai Healthcare Capital"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Pharmapark"},{"orgOrder":0,"company":"Burning Rock Dx","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Brigimadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase II","graph3":"Burning Rock Dx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Burning Rock Dx \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Burning Rock Dx \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"HanBio Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"HanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HanBio Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"4","companyTruncated":"HanBio Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ University Medical Center Utrecht","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ University Medical Center Utrecht"},{"orgOrder":0,"company":"Xuanzhu Biopharma","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"KM-501","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Xuanzhu Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanzhu Biopharma \/ Innovent Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Xuanzhu Biopharma \/ Innovent Biologics"},{"orgOrder":0,"company":"GT Apeiron","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Apeiron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Apeiron \/ Exscientia","highestDevelopmentStatusID":"7","companyTruncated":"GT Apeiron \/ Exscientia"},{"orgOrder":0,"company":"Chimagen Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"CMG1A46","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Chimagen Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimagen Biosciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Chimagen Biosciences \/ GSK"},{"orgOrder":0,"company":"Meiji Pharmaceutical","sponsor":"Zhejiang Hengkang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Acquisition","leadProduct":"KD-370","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meiji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Pharmaceutical \/ Zhejiang Hengkang Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Pharmaceutical \/ Zhejiang Hengkang Pharmaceutical"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Domain Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"DT-7012","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chime Biologics \/ Domain Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chime Biologics \/ Domain Therapeutics"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alphamab Oncology \/ Arrivent","highestDevelopmentStatusID":"2","companyTruncated":"Alphamab Oncology \/ Arrivent"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Gilead Sciences"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Asklepios BioPharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Belief BioMed \/ Asklepios BioPharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Belief BioMed \/ Asklepios BioPharmaceutical"},{"orgOrder":0,"company":"Biotheus","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"HS-20117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ Hansoh Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/ Hansoh Pharma"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"SPU-16","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi AppTec \/ Silo Pharma","highestDevelopmentStatusID":"4","companyTruncated":"WuXi AppTec \/ Silo Pharma"},{"orgOrder":0,"company":"Shanghai Cell Therapy Group","sponsor":"Baize Plan Fund","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Shanghai Cell Therapy Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Cell Therapy Group \/ Baize Plan Fund","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Cell Therapy Group \/ Baize Plan Fund"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"JAB-3312","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jacobio Pharma \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ Abbvie Inc"},{"orgOrder":0,"company":"Tibet Rhodiola Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tibet Rhodiola Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tibet Rhodiola Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tibet Rhodiola Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Toregem BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"TRG035","moa":"USAG1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Toregem BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Toregem BioPharma"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Turning Point Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Turning Point Therapeutics, Inc","highestDevelopmentStatusID":"6","companyTruncated":"LaNova Medicines \/ Turning Point Therapeutics, Inc"},{"orgOrder":0,"company":"Sinopharm","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sinopharm \/ ChromaDex, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ ChromaDex, Inc"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyligand Bioscience \/ Context Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tyligand Bioscience \/ Context Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Unity Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ascentage Pharma \/ Unity Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Unity Biotechnology"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Expanded Collaboration","leadProduct":"Ociperlimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"DB-1312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"DB-1312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Biocytogen","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ ADC Therapeutics"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"BHV-8000","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Biomm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Biomm","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Biomm"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"LianBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"EdiGene","sponsor":"Haihe Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Botulinum Toxin A","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EdiGene \/ Haihe Laboratory","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ Haihe Laboratory"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Techdow USA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Fosaprepitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA","highestDevelopmentStatusID":"15","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zhejiang Doer Biologics \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Zhejiang Doer Biologics \/ BioNTech"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceuticals","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jiangsu Hengrui Pharmaceuticals \/ Elevar Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Pharmaceuticals \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Cure Genetics","sponsor":"Frametact","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cure Genetics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cure Genetics \/ Frametact","highestDevelopmentStatusID":"3","companyTruncated":"Cure Genetics \/ Frametact"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"InxMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GeneQuantum Healthcare \/ InxMed","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ InxMed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20093","moa":"Topoisomerase","graph1":"Oncology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ GSK"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20089","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ GSK"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"HS-10535","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Antengene","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Hansoh Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Hansoh Pharma"},{"orgOrder":0,"company":"Chengdu Kanghua Biological Products","sponsor":"HilleVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"HIL-216","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chengdu Kanghua Biological Products","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Kanghua Biological Products \/ HilleVax","highestDevelopmentStatusID":"4","companyTruncated":"Chengdu Kanghua Biological Products \/ HilleVax"},{"orgOrder":0,"company":"HitGen","sponsor":"ARase Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ ARase Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ ARase Therapeutics"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Arrivent"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Alector","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"SIRP alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ Alector","highestDevelopmentStatusID":"4","companyTruncated":"Innovent Biologics \/ Alector"},{"orgOrder":0,"company":"RemeGen","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"RC88","moa":"||Mesothelin protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Innovent Biologics"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"LianBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"LianBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"YL211","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"MediLink Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HRS-1167","moa":"PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Merck Group"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Pimicotinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abbisko Therapeutics \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||TNFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Myricx Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"N-Myristoyltransferase","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ Myricx Bio","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Myricx Bio"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"2","companyTruncated":"Duality Biologics \/ Adcendo"},{"orgOrder":0,"company":"OBiO Technology","sponsor":"Refreshgene Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"RRG-001","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"OBiO Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBiO Technology \/ Refreshgene Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"OBiO Technology \/ Refreshgene Therapeutics"},{"orgOrder":0,"company":"Shenzhen Hepalink Pharmaceutical","sponsor":"Orient EuroPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Hepalink Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ PharmaEssentia","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Pint Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Pint Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Pint Pharma"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"AB011","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Sunshine Guojian","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"ND021","moa":"4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Guojian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Guojian \/ Numab Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Guojian \/ Numab Therapeutics"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ BioNTech"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"IMIDomics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"IMB1001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ IMIDomics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ IMIDomics"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Institute of Materia Medica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica"},{"orgOrder":0,"company":"Biocytogen","sponsor":"CtM Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ CtM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ CtM Biotech"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"IMP9064","moa":"||ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Burning Rock Dx","highestDevelopmentStatusID":"5","companyTruncated":"IMPACT Therapeutics, Inc \/ Burning Rock Dx"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"IMP1734","moa":"PARP1","graph1":"Oncology","graph2":"Preclinical","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMPACT Therapeutics, Inc \/ Eikon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IMPACT Therapeutics, Inc \/ Eikon Therapeutics"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GeneQuantum Healthcare \/ Aimed Bio","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ Aimed Bio"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Merck Group"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GeneQuantum Healthcare \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ Nona Biosciences"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Suzhou Limited \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chongqing Zhifei Biological Products","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chongqing Zhifei Biological Products","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Chongqing Zhifei Biological Products \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Chongqing Zhifei Biological Products \/ Merck & Co"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Bentonite","moa":"||Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nuance Pharma \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Nuance Pharma \/ DKSH"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Expanded Collaboration","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Hong Kong \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"University of Hong Kong \/ CEPI"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"225-Ac FL-091","moa":"NTSR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Full-Life Technologies \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aadi Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"PTK7-CPT113","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Aadi Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Aadi Bioscience"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SHR-4849","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Ideaya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Keyuan Xinhai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Quadrivalent Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Keyuan Xinhai","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Keyuan Xinhai"},{"orgOrder":0,"company":"EdiGene","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EdiGene \/ University of Wisconsin\u2013Madison","highestDevelopmentStatusID":"2","companyTruncated":"EdiGene \/ University of Wisconsin\u2013Madison"},{"orgOrder":0,"company":"Shanghai Pharma Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Pharma Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Pharma Group \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Pharma Group \/ Everest Medicines"},{"orgOrder":0,"company":"Thousand Oaks Biologics","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Thousand Oaks Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thousand Oaks Biologics \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"Thousand Oaks Biologics \/ GeneQuantum Healthcare"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Ociperlimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"AmMax Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evopoint Biosciences \/ AmMax Bio","highestDevelopmentStatusID":"4","companyTruncated":"Evopoint Biosciences \/ AmMax Bio"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hope Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chime Biologics \/ Hope Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Chime Biologics \/ Hope Medicine"},{"orgOrder":0,"company":"Hainan Poly Pharm","sponsor":"Imunon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"DNA-Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hainan Poly Pharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Hainan Poly Pharm \/ Imunon","highestDevelopmentStatusID":"4","companyTruncated":"Hainan Poly Pharm \/ Imunon"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"VivaVision","sponsor":"Everads Therapy","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VivaVision \/ Everads Therapy","highestDevelopmentStatusID":"2","companyTruncated":"VivaVision \/ Everads Therapy"},{"orgOrder":0,"company":"Sinovent","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"XNW1011","moa":"Bruton\\'s tyrosine kinase","graph1":"Nephrology","graph2":"Preclinical","graph3":"Sinovent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sinovent \/ Everest Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Sinovent \/ Everest Medicines"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbisko Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Abbisko Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"FutureGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"FG-M701","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"FutureGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FutureGen \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"FutureGen \/ AbbVie Inc"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adagene Suzhou Limited \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Suzhou Limited \/ Sanofi"},{"orgOrder":0,"company":"Yousen Jianheng Biopharmaceutical","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"UA022","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Yousen Jianheng Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yousen Jianheng Biopharmaceutical \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Yousen Jianheng Biopharmaceutical \/ AstraZeneca"},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Enzyme","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"Asymchem Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asymchem Laboratories \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Asymchem Laboratories \/ First Wave BioPharma"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"LBL-007","moa":"||LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leads Biolabs \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ BeiGene"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ BeiGene"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Bliss Bio","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"BB-1701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bliss Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bliss Bio \/ Eisai","highestDevelopmentStatusID":"6","companyTruncated":"Bliss Bio \/ Eisai"},{"orgOrder":0,"company":"Precision Autoimmune Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"CID-103","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Precision Autoimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision Autoimmune Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Precision Autoimmune Therapeutics \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-001","moa":"Undisclosed","graph1":"Hematology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Disc medicine","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ Disc medicine"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSPC Pharmaceutical Group \/ Elevation Oncology","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Pharmaceutical Group \/ Elevation Oncology"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Jemincare","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JMKX002992","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Genentech"},{"orgOrder":0,"company":"Henlius","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"5 Fluorouracil","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Henlius \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Henlius \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Toripalimab","moa":"||IgG2","graph1":"Oncology","graph2":"Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eucure Biopharma \/ ISU ABXIS","highestDevelopmentStatusID":"8","companyTruncated":"Eucure Biopharma \/ ISU ABXIS"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Italfarmaco S.p.A"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TT-01025","moa":"VAP-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TransThera Biosciences \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"TransThera Biosciences \/ LG Chem"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MediLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediLink Therapeutics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"MediLink Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Nanjing King-friend Biochemical Pharmaceutical","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Nanjing King-friend Biochemical Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curon Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Merck & Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Merck & Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Myricx Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"N-Myristoyltransferase","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Myricx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Myricx Bio"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nippon Kayaku","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Nippon Kayaku","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Nippon Kayaku"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Pheon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Pheon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Pheon Therapeutics"},{"orgOrder":0,"company":"Singlomics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"DXP-593","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Singlomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Singlomics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Singlomics \/ BeiGene"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Syncromune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"YH002","moa":"OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Eucure Biopharma \/ Syncromune","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Syncromune"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"JAB-BX102","moa":"||CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jacobio Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Merck & Co"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"WuXi Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Vir Biotechnology"},{"orgOrder":0,"company":"Yimiao Shenzhou","sponsor":"EdiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yimiao Shenzhou","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yimiao Shenzhou \/ EdiGene","highestDevelopmentStatusID":"1","companyTruncated":"Yimiao Shenzhou \/ EdiGene"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"SARS-CoV-2 s-protein Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Biovaxys","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Biovaxys"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"InflaRx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WuXi Biologics \/ InflaRx","highestDevelopmentStatusID":"15","companyTruncated":"WuXi Biologics \/ InflaRx"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Xencor","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Xencor"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Nevakar","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Zhaoke Ophthalmology \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke Ophthalmology \/ Nevakar"},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"BeiGene","sponsor":"Immune-Onc Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"IO-108","moa":"||LILRB2","graph1":"Oncology","graph2":"Preclinical","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Immune-Onc Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"BeiGene \/ Immune-Onc Therapeutics"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Expanded Collaboration","leadProduct":"CD421","moa":"CD73","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Cidara Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Cidara Therapeutics"},{"orgOrder":0,"company":"HitGen","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HitGen \/ Morphic Therapeutic","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Morphic Therapeutic"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Bright Peak Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"LZM009","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics"},{"orgOrder":0,"company":"MabCare Therapeutics","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MTX-13","moa":"PTK7","graph1":"Oncology","graph2":"Preclinical","graph3":"MabCare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MabCare Therapeutics \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MabCare Therapeutics \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LaNova Medicines \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Medicines \/ AstraZeneca"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CD39","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ Arcus Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Arcus Biosciences"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EpimAb Biotherapeutics \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"EpimAb Biotherapeutics \/ Almirall"},{"orgOrder":0,"company":"Suzhou Alphamab Co","sponsor":"Ascletis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Suzhou Alphamab Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Suzhou Alphamab Co \/ Ascletis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Alphamab Co \/ Ascletis Pharma"},{"orgOrder":0,"company":"BeiGene","sponsor":"Hutchison China MediTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Surufatinib","moa":"||VEGFR","graph1":"Oncology","graph2":"Undisclosed","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Hutchison China MediTech","highestDevelopmentStatusID":"1","companyTruncated":"BeiGene \/ Hutchison China MediTech"},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"INV-1120","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionova Life Science \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Life Science \/ Merck & Co"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Huadong Medicine \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Huadong Medicine \/ Exscientia"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Vemurafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Kechow Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Kechow Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"A*STAR's Bioprocessing Technology Institute","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute"},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"WJ1075","moa":"XPO1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wigen Biomedicine Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wigen Biomedicine Technology \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Wigen Biomedicine Technology \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Drug Farm","sponsor":"YD Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Series C Financing","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Drug Farm \/ YD Capital","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ YD Capital"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OriCell Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Inaticabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juventas Cell Therapy \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Juventas Cell Therapy \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"WuXi Biologics \/ Almirall","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Almirall"},{"orgOrder":0,"company":"CF PharmTech","sponsor":"BioTrack Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Series F Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CF PharmTech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"CF PharmTech \/ BioTrack Capital","highestDevelopmentStatusID":"1","companyTruncated":"CF PharmTech \/ BioTrack Capital"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"ViGeneron","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"VG901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"WuXi Biologics \/ ViGeneron","highestDevelopmentStatusID":"5","companyTruncated":"WuXi Biologics \/ ViGeneron"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Tubulis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"TUB-010","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Tubulis","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Tubulis"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Antengene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"ATG-022","moa":"CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WuXi Biologics \/ Antengene","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ Antengene"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"TAA","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Biologics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ GSK"},{"orgOrder":0,"company":"Sironax","sponsor":"X-Chem","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Sironax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sironax \/ X-Chem","highestDevelopmentStatusID":"2","companyTruncated":"Sironax \/ X-Chem"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"CD40","graph1":"Oncology","graph2":"Discovery","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eucure Biopharma \/ ISU ABXIS","highestDevelopmentStatusID":"2","companyTruncated":"Eucure Biopharma \/ ISU ABXIS"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Linperlisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Oceanpine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"YSJA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Oceanpine","highestDevelopmentStatusID":"15","companyTruncated":"Yisheng Biopharma \/ Oceanpine"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"YOLT-101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YolTech Therapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD"},{"orgOrder":0,"company":"Zai Lab","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Public Offering","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ J. P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ J. P. Morgan"},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Zhifei Longcom Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Chinese Academy of Sciences \/ Zhifei Longcom Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Chinese Academy of Sciences \/ Zhifei Longcom Biopharmaceutical"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HF1K16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafolecimab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ongericimab","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafolecimab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafolecimab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tafolecimab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"HGF-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Creative Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tafolecimab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafolecimab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Kind Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AND017","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kind Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kind Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kind Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"APL-1401","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BGB-23339","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ectoine","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBP-307","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CBP-307","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Centre for Chinese Herbal Medicine Drug Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CDD-2103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Centre for Chinese Herbal Medicine Drug Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Chinese Herbal Medicine Drug Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Chinese Herbal Medicine Drug Development \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23p19 subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23p19 subunit","graph1":"Immunology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01003","moa":"JAK","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LNK01003","moa":"JAK","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CBP-307","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CBP-307","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reistone Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"T21","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"T21","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APL-1401","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RareStone Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"HBV capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shanghai Zhimeng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zhimeng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI110","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"7MW3711","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"7MW3711","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"7MW3711","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"8MW0511","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"9MW2921","moa":"Apoptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Disc medicine","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Disc medicine"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3811","moa":"IL-11 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3811","moa":"IL-11 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ablaze Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablaze Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ablaze Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Optune","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PIKA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"A166","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Levena Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Kelun Pharmaceutical \/ Levena Biopharma"},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"A166","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Levena Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Levena Biopharma \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Levena Biopharma \/ Sichuan Kelun-Biotech Biopharmaceutical"},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"A-337","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tianweiyuanhe Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianweiyuanhe Biomedical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tianweiyuanhe Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AB011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AB011","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Newg Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Newg Lab","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Newg Lab"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Safusidenib","moa":"mIDH1","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnHeart Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-329","moa":"AXL","graph1":"Oncology","graph2":"Phase I","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Helicobacter Pylori","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-168","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-168","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABP-745","moa":"Undisclosed","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pimicotinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abbisko Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pimicotinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abbisko Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pimicotinib","moa":"CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abbisko Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Diacerein","moa":"TYK2\/JAK1","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accro Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Accro Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yiling Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yiling Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Sabin Strain Based Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Ascendis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Ascendis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Visen Pharmaceuticals \/ Ascendis Pharma"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ADG116","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Merck & Co"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AMP945","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Merck & Co"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ADG138","moa":"HER2\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Quadrivalent Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AGA2118","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angitia Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Angitia Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sperogenix Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sperogenix Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ebdarokimab","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Anlotinib HCl","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Drebuxelimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK115","moa":"NGF","graph1":"Neurology","graph2":"Preclinical","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK130","moa":"TIGIT\/TGF-beta","graph1":"Oncology","graph2":"Preclinical","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK131","moa":"Adenosine receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danoprevir","moa":"||NS3\/4A protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"||Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hua Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Tangdu Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Tangdu Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tangdu Hospital \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tangdu Hospital \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighTide Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Palupiprant","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nortye \/ Inapplicable"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buparlisib","moa":"||Pan-PI3K","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlai Nortye \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Inapplicable"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Anaprazole Sodium","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sihuan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Zuberitamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS014004","moa":"Type 2 c-met tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AP303","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alebund Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alebund Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alebund Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kexing Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-1387","moa":"IAP","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-2449","moa":"FAK\/ALK\/ROS1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APL-1202","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ BeiGene"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APL-1202","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Incyte Corporation"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"China's military-backed research unit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCoV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"China's military-backed research unit","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China's military-backed research unit \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"China's military-backed research unit \/ Inapplicable"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Walvax Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Artemisinin","moa":"Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fosun Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Arctic Vision \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Eyenovia"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Arctic Vision \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vision \/ Eyenovia"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Adagene Suzhou Limited \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adagene Suzhou Limited \/ National Institutes of Health"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TAEST16001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ GenScript Biotech Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue Life Sciences \/ GenScript Biotech Corporation"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC11","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC11","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ASC11","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Hypodermic Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Public Health Clinical Center","sponsor":"Ascletis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai Public Health Clinical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Hypodermic Injection","sponsorNew":"Shanghai Public Health Clinical Center \/ Ascletis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Public Health Clinical Center \/ Ascletis Pharma"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASC30","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denifanstat","moa":"||Fatty acid synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC41","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC41","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC40","moa":"||THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC41","moa":"||THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASC47","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC60","moa":"Fatty acid synthase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APG-3526","moa":"MCL1","graph1":"Oncology","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC41","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"APL-2301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATG-017","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATG-017","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ AstraZeneca"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATG-017","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATG-018","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ATG-022","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ATG-022","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATG-037","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APL-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurisco Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dydrogesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aurisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurisco Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurisco Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zorifertinib","moa":"EGFR-TKI reversible","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Alpha Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alpha Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alpha Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AK127","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BAT2022","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BAT2022","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BAT1308","moa":"||OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"BAT6026","moa":"||Water","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BAT7104","moa":"PD-1\/L1","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8007","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8008","moa":"Trop2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8010","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Institute of Biological Products","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBIBP-CorV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Beijing Institute of Biological Products","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Institute of Biological Products \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Institute of Biological Products \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BBM-H803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Belief BioMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Belief BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BBM-H901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Belief BioMed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belief BioMed \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ AstraZeneca"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BC2027","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BC3195","moa":"CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BC3448","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"LiberoThera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BCG005","moa":"CCR8","graph1":"Oncology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ LiberoThera","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ LiberoThera"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Mirati Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Mirati Therapeutics"},{"orgOrder":0,"company":"BeiGene","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lifirafenib","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Bened Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum","moa":"Dopamine","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bened Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bened Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bened Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Hospital of Shandong University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Qilu Hospital of Shandong University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Hospital of Shandong University \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Qilu Hospital of Shandong University \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Etana","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Etana","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Etana"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BG1805","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Guangzhou Bio-gene Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Bio-gene Technology \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BG-68501","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Ensem Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BG-68501","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Ensem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Ensem Therapeutics"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BGB-15025","moa":"||HPK1","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BGB-16673","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chiglitazar Sodium","moa":"PPAR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Viwit Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Viwit Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Viwit Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viwit Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BC3402","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ AstraZeneca"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"RenNano","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Inapplicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biocytogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Inapplicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"CtM Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ CtM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ CtM Biotech"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"National Tsing Hua University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Tsing Hua University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Tsing Hua University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"National Tsing Hua University \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Duality Biologics \/ BioNTech"},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Boceprevir","moa":"HCV proteases\/NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese Academy of Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Chinese Academy of Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK129","moa":"PD-1\/LAG-3","graph1":"Oncology","graph2":"Preclinical","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Brise Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BR01T","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Brise Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brise Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Brise Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BR105","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adlai Nortye \/ Oncolytics Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nortye \/ Oncolytics Biotech"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Medison Pharma"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BRY812","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Biosion","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bosakitug","moa":"||TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biosion \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ Sanofi"},{"orgOrder":0,"company":"Biosion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bosakitug","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biosion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Asunercept","moa":"||CD95","graph1":"Oncology","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Asunercept","moa":"||CD95","graph1":"Oncology","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Asunercept","moa":"||CD95","graph1":"Oncology","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ WuXi Biologics"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"CARE Pharma Shanghai Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ CARE Pharma Shanghai Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ CARE Pharma Shanghai Ltd."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ WuXi Biologics"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ WuXi Biologics"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ WuXi Biologics"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shenyang Tonglian Medicines Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Carrimycin","moa":"mTOR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenyang Tonglian Medicines Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Shenyang Tonglian Medicines Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shenyang Tonglian Medicines Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LintonPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"LintonPharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"LintonPharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LintonPharm \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CB03","moa":"KCNQ2\/3","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Zhimeng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zhimeng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CB03","moa":"KCNQ2\/3","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zhimeng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zhimeng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CB06","moa":"TLR8","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zhimeng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zhimeng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CBP-174","moa":"H3 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Connoya Biomedical Technology","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Connoya Biomedical Technology"},{"orgOrder":0,"company":"CD (Suzhou) Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CD-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CD (Suzhou) Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CD (Suzhou) Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CD (Suzhou) Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Dawnrays Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK109","moa":"||PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Dawnrays Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Dawnrays Pharmaceutical"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CellOrigin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SY001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CellOrigin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellOrigin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CellOrigin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Photocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Photocure","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Photocure"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chiauranib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Chidamide","moa":"||HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tigermed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tigermed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"23-Valent Pneumococcal Polysaccharide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Genexine","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Genexine"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autoleucel Relmacabtagen","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Inactivated Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IBI939","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"GenEros BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clinflamozyde","moa":"STAT","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GenEros BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenEros BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GenEros BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pamiparib","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23p19 subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"||Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"S-Trimer","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 S-Trimer Vaccine","moa":"S-Trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"IDOR","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ IDOR","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ IDOR"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Clover Biopharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Biocytogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"YH001","moa":"||OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Eucure Biopharma \/ Biocytogen","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Biocytogen"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"HLX301","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ritonavir","moa":"HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137 antigen","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"WGc-043","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Weisijin Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"iCamuno","sponsor":"I Peace","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"iCamuno","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"iCamuno \/ I Peace","highestDevelopmentStatusID":"6","companyTruncated":"iCamuno \/ I Peace"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RenNano","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-Valent HPV Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Conbercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Kanghong Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Yipurun Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Yipurun Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yipurun Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yipurun Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"COVID-19 Bivalent Protein Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"WestVac Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"WestVac Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cali Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Cali Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Cali Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cali Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CS12192","moa":"JAK3\/JAK1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chiauranib","moa":"||VEGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CS231295","moa":"Protein kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CS32582","moa":"TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CT011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CT071","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT125A","moa":"CD5","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioheng Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTB001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioheng Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CTD401","moa":"CD7","graph1":"Oncology","graph2":"Preclinical","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioheng Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioheng Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"D3S-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"D3 Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ADG116","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Chidamide","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HUYA Bioscience International \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Suzhou Connect Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Suzhou Connect Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Suzhou Connect Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Connect Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Duality Biologics \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"C5252","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"ALPK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"Drug Farm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DF-006","moa":"ALPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Drug Farm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm \/ Inapplicable"},{"orgOrder":0,"company":"DP Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPT0218","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DP Technology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Inapplicable"},{"orgOrder":0,"company":"DP Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPT0416","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DP Technology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"DR10624","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"DR10624","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DR10624","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fulzerasib","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||ERBB 2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Golidocitinib","moa":"||JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Golidocitinib","moa":"JAK1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Golidocitinib","moa":"||JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Golidocitinib","moa":"||JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Burning Rock Dx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Burning Rock Dx","highestDevelopmentStatusID":"15","companyTruncated":"Dizal Pharmaceutical \/ Burning Rock Dx"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Eluminex Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-105","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eluminex Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eluminex Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eluminex Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Eccogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ECC4703","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Eccogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eccogene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eccogene \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Oncology","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"I-Mab Biopharma \/ Genexine","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Genexine"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"EMB-01","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ UMass Chan Medical School"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cetuximab Beta","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Nuance Pharma \/ Verona Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Verona Pharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Nuance Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eoc Pharma \/ Immutep","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Immutep"},{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EPI-003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Epigenic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epigenic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epigenic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ES005","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ES009","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Escugen Biotechnology","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ESG401","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Escugen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Escugen Biotechnology \/ Levena Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Escugen Biotechnology \/ Levena Biopharma"},{"orgOrder":0,"company":"EdiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EdiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CAR-BCMA T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Icatolimab","moa":"||BTLA","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bofutrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Frontier Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Frontier Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Felzartamab","moa":"||CD38","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APG-1387","moa":"||IAP","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Durlobactam","moa":"||Beta-lactamases A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 S-Trimer Vaccine","moa":"S-Trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palupiprant","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adlai Nortye \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Merck & Co"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onatasertib","moa":"TORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Xiling Lab \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"Genuine Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azvudine","moa":"Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genuine Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genuine Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genuine Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Pharmaceutical \/ BioNTech"},{"orgOrder":0,"company":"Fapon Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"FP002","moa":"CD47","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fapon Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fapon Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fapon Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FZ007-119","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Guangzhou Fermion Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangzhou Fermion Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Guangzhou Fermion Technology \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"GB08","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kexing Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"RenJi Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ RenJi Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ RenJi Hospital"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GC019F","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T lymphocyte","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Anti-Cd19 Ucar-T","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Suzhou GenAssist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GEN6050","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Suzhou GenAssist Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou GenAssist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Suzhou GenAssist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GFH018","moa":"||TGF-beta-1","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GLR2007","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GMA106","moa":"GIPR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gmax Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gmax Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gmax Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"GQ1001","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"GQ1005","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneQuantum Healthcare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gritgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GS1191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Gritgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gritgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gritgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT1708F","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT19715","moa":"c-Myc\/GSPT1","graph1":"Oncology","graph2":"Preclinical","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Green Valley Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Green Valley Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedCloud Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Inapplicable"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedCloud Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Serplulimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Henlius","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Henlius \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Henlius \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Serplulimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Genhouse Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HBI-2376","moa":"SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Genhouse Bio","highestDevelopmentStatusID":"5","companyTruncated":"HUYA Bioscience International \/ Genhouse Bio"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tucidinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Chidamide","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Zhongnan Hospital of Wuhan University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dipyridamole","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhongnan Hospital of Wuhan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhongnan Hospital of Wuhan University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhongnan Hospital of Wuhan University \/ Inapplicable"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HDM1002","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huadong Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Huadong Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Henlius","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Henlius \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Henlius \/ Inapplicable"},{"orgOrder":0,"company":"Henlius","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henlius \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Henlius \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"PML-RAR alpha protein","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"PML-RAR alpha protein","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"PML-RAR alpha protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"PML-RAR alpha protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tretinoin","moa":"PML-RAR alpha protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HF158K1","moa":"ErbB2","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HG004","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HG004","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HG004","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HG004","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HG004","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Huahui Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Libevitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Huahui Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huahui Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Huahui Health \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HiCM-188","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Help Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Help Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HiCM-188","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Help Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Help Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HighTide Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tucidinostat","moa":"HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"Mitogen-activated protein kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Kechow Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HLX07","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||EGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Organon"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HLX22","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Hope Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hope Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hope Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hinova \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hinova \/ Inapplicable"},{"orgOrder":0,"company":"Hinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Inapplicable"},{"orgOrder":0,"company":"Hinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Inapplicable"},{"orgOrder":0,"company":"Hepagene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HPG7233","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Hepagene Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hepagene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hepagene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Ascentage Pharma"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Shenzhen Second People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Shenzhen Second People's Hospital","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Shenzhen Second People's Hospital"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Innovent Biologics"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HS-20093","moa":"Topoisomerase","graph1":"Oncology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Endocrinology","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HighTide Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HighTide Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Crown Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HX009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HanX Biopharmaceuticals \/ Crown Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Crown Bioscience"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HX009","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HanX Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zinc Hyaluronate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"SunHo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"IAP0971","moa":"PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"SunHo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SunHo \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SunHo \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"IASO-782","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IASO-782","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"IBB0979","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunHo BioPharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioPharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI110","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23p19 subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23p19 subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23p19 subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23p19 subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23p19 subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IBI3002","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Sanegene Bio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SGB-3908","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Sanegene Bio","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Sanegene Bio"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efdamrofusp Alpha","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efdamrofusp Alpha","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efdamrofusp Alpha","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IBI311","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI324","moa":"VEGF-A\/Ang-2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IBI333","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Union Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Union Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Union Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IBI363","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI363","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI389","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ICP-189","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gunagratinib","moa":"Selective pan-FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Bcl-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Immunology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ICP-490","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"Pan-TRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"Pan-TRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zurletrectinib","moa":"Pan-TRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Connoya Biomedical Technology","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Connoya Biomedical Technology"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMC-001","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunofoco \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunofoco \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Creative Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical \/ Inapplicable"},{"orgOrder":0,"company":"Immunocan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Immunocan","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunocan \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Immunocan \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"IMPACT Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Senaparib","moa":"PARP","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ IMPACT Therapeutics, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ IMPACT Therapeutics, Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"QureBio Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"QureBio Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"QureBio Ltd. \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QureBio Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC11","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ADG153","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IBI319","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Cali Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Cali Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Cali Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cali Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shanghai Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Shanghai Institute \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Shanghai Institute \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NFS-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ansofaxine HCl","moa":"Serotonin\/norepinephrine\/dopamine triple reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MSB2311","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gunagratinib","moa":"Selective pan-FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"CMAB Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Innovent Biologics \/ CMAB Biopharma Inc","highestDevelopmentStatusID":"5","companyTruncated":"Innovent Biologics \/ CMAB Biopharma Inc"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NFS-02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LAE001","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CStone Pharmaceuticals \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JAB-2485","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JAB-30300","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glecirasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Jiuyuan Gene Engineering \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JMB2002","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JMKX003801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Johnpro Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Siroquine","moa":"||Dual autophagy","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"HebaBiz Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HebaBiz Biotech \/ Johnpro Biotech","highestDevelopmentStatusID":"9","companyTruncated":"HebaBiz Biotech \/ Johnpro Biotech"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tifcemalimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JS016","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"CMAB Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JS201","moa":"PD-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ CMAB Biopharma Inc","highestDevelopmentStatusID":"4","companyTruncated":"Shanghai Junshi Biosciences \/ CMAB Biopharma Inc"},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"JS InnoPharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPharm \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"JSKN003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuremidevir Hydrobromide","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuremidevir Hydrobromide","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuremidevir Hydrobromide","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"JWATM214","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Shenzhen Kangtai Biological Products \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen Kangtai Biological Products \/ Inapplicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Stapokibart","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Neumentum","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nuance Pharma \/ Neumentum","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Neumentum"},{"orgOrder":0,"company":"Chengdu Origen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KH631","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Chengdu Origen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Chengdu Origen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Origen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Applied Biology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Applied Biology","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Applied Biology"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Jiangsu Alphamab Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Jiangsu Alphamab Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Jiangsu Alphamab Biopharmaceuticals"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KP104","moa":"Complement pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KP104","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KP104","moa":"Complement pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Perelman School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KP104","moa":"Complement pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kira Pharmaceuticals \/ Perelman School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharmaceuticals \/ Perelman School of Medicine"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VS-7375","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zai Lab \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ IQVIA"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bened Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Plantarum","moa":"Dopamine","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bened Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bened Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bened Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LAE001","moa":"CYP17","graph1":"Oncology","graph2":"Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LBL-024","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etoposide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"LBL-033","moa":"MUC16\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LBL-034","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leads Biolabs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Suzhou OSAI Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vaginal L. Crispatus Live Bacteria","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Suzhou OSAI Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Suzhou OSAI Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou OSAI Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"||GLP-1\/GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"BioNova Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"BioNova Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"BioNova Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"BioNova Pharma \/ Sanofi"},{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clevudine","moa":"HBV DNA chain replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HebaBiz Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"HebaBiz Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"HebaBiz Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Lianhua Qingwen","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yiling Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yiling Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linperlisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Linperlisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Likang Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"LK101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Likang Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Likang Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Likang Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"TopAlliance Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Longbio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Longbio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP-003","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longbio Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Longbio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Lumenis","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Lumenis","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Lumenis"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"MindRank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"MindRank \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MindRank \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 R","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 R","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MHB018A","moa":"IGF-1\/IGF-2 R","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"MHB036C","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MHB039A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MHB088C","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Minghui Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Beijing Institute of Biological Product","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sinopharm \/ Beijing Institute of Biological Product","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ Beijing Institute of Biological Product"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InnoCare Pharma \/ MorphoSys","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ MorphoSys"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"C5252","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"MyoKardia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ MyoKardia","highestDevelopmentStatusID":"15","companyTruncated":"LianBio \/ MyoKardia"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"China Pharma Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"China Pharma Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"China Pharma Holdings \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"China Pharma Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Neuboron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"P-Borono-L-Phenylalanine","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neuboron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuboron \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuboron \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fosun Kite Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fosun Kite Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Kite Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10-A","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NFS-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"NK CellTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NK010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NK CellTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NK CellTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NK CellTech \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pamiparib","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chiglitazar Sodium","moa":"||PPAR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"AD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ebronucimab","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akeso \/ AD Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ AD Pharmaceuticals"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Conbercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Kanghong Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OQL011","moa":"VEGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NFS-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"rAAV2-ND4","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"rAAV2-ND4","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NFS-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuShen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NS-136","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"NeuShen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuShen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuShen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NWY001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ociperlimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enarodustat","moa":"Egl nine homolog 1","graph1":"Hematology","graph2":"Approved FDF","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OQL011","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Esonadogene Imvoparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OQL011","moa":"VEGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OQL025","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OQL036","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OQL051","moa":"CDK4","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MOR210","moa":"||C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ MorphoSys","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biopharma \/ MorphoSys"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Ascentage Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Ascentage Pharma"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OriCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OriCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OriCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OriCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Hefei Tianmai Biotechnology Development","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hefei Tianmai Biotechnology Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hefei Tianmai Biotechnology Development \/ Oramed Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hefei Tianmai Biotechnology Development \/ Oramed Pharmaceuticals"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated Quadrivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OQL011","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gumokimab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Sino Biopharmaceutical Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Penpulimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Sino Biopharmaceutical Limited","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Sino Biopharmaceutical Limited"},{"orgOrder":0,"company":"HJB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HJB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HJB \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HJB \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BGB-11417","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Uliledlimab","moa":"CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Ark Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ziresovir","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ark Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ark Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ark Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Incyte Corporation"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Inactivated Rabies Vaccine, PIKA-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PIKA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nanjing Jianyou Biochemical Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plerixafor","moa":"CXCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nanjing Jianyou Biochemical Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nanjing Jianyou Biochemical Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nanjing Jianyou Biochemical Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"GM-CSF","graph1":"Immunology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CStone Pharmaceuticals \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Blueprint Medicines"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GFH312","moa":"RIPK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ADG138","moa":"HER2\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Inapplicable"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OQL051","moa":"CDK4","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnQuality Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 S-Trimer Vaccine","moa":"S-Trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SK10","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhiyi Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zhiyi Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HLX07","moa":"EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Shingles Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CLDN18.2\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JMB2002","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Dragon Boat Pharmaceutical","sponsor":"Sanyou Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BC008","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dragon Boat Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PRO1107","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Inapplicable"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Inapplicable"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Prosit Sole Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"PSP001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Prosit Sole Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prosit Sole Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prosit Sole Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"Hanx Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pucotenlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lepu Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lepu Biopharma \/ Hanx Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Lepu Biopharma \/ Hanx Biopharmaceutical"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pucotenlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chime Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chime Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Qure Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qure Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qure Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qure Biotech \/ Inapplicable"},{"orgOrder":0,"company":"QureBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"QureBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"QureBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QureBio \/ Inapplicable"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Qihan Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Qihan Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Iparomlimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"RAG-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RAG-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"RAG-17","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RAG-17","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"RAG-17","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RAG-17","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RAG-18","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RAG-18","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RAG-21","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tot Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Tot Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tot Biopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tot Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"RC118","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RC88","moa":"Mesothelin protein","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Shingles Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Shingles Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Shingles Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recov","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Protein COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recov","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recov","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omoprubart","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ UMass Chan Medical School"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Henlius","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Henlius \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Henlius \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"CS5001","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafolecimab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"rAAV2-ND4","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Rinatabart Sesutecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProfoundBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Nuance Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"RiboX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RXRG001","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"RiboX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RiboX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RiboX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SA55","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SA55","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Safusidenib","moa":"mIDH1","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"||Lipid peroxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"NeuroDerm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"||Lipid peroxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ NeuroDerm","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ NeuroDerm"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SC0062","moa":"Endothelin A receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SC0062","moa":"Endothelin A receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SC0062","moa":"Endothelin A receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SC0062","moa":"Endothelin A receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SCB-1019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SCB-1019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SCB-1019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SCB-2019","moa":"SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ The International Vaccine Institute","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ The International Vaccine Institute"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reistone Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GPRC5D-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OriCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sinomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sinomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinomed \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sinomed \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovant Sciences","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sinovant Sciences \/ Nabriva Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sinovant Sciences \/ Nabriva Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SK10","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Zhiyi Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhiyi Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhiyi Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase III","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Skyline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SKG0106","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Skyline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Skyline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Skyline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Skyline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SKG0106","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Skyline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Skyline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Skyline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8009","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Summit Therapeutics"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SNP318","moa":"Lp-PLA2","graph1":"Neurology","graph2":"Phase I","graph3":"SciNeuro Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciNeuro Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciNeuro Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SNP318","moa":"Lp-PLA2","graph1":"Neurology","graph2":"Phase I","graph3":"SciNeuro Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciNeuro Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciNeuro Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Chidamide","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"IL-7 expression","graph1":"Oncology","graph2":"Preclinical","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PiCoVacc","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SW1115C3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SYS6016","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SYS6020","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Zhijiang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SYZJ001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shanghai Zhijiang Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Shanghai Zhijiang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shanghai Zhijiang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"T22","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"JS006","moa":"||CD112R","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiST Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"HiST Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"HiST Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiST Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-Beta 1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"TechnoDerma Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Inapplicable"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-Beta 1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"TechnoDerma Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Inapplicable"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"TechnoDerma Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Inapplicable"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"TechnoDerma Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Inapplicable"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"TechnoDerma Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"TNP-2092","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TenNor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TenNor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG ImmunoPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Inapplicable"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGI-6","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG ImmunoPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lisinopril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Yiling Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yiling Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BeiGene \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Amgen Inc"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"IBI326","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ IASO","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ IASO"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BA1202","moa":"CEA","graph1":"Oncology","graph2":"Preclinical","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"G42 Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sinopharm \/ G42 Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ G42 Healthcare"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zorifertinib","moa":"EGFR-TKI reversible","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Alpha Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alpha Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alpha Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Golidocitinib","moa":"JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JMB2002","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK127","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Laekna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Innovent Biologics \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"HLX71","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighTide Therapeutics \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ U.S. Food and Drug Administration"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Interferon Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC007g","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai SIMR Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SR419","moa":"Ion Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai SIMR Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Shanghai SIMR Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai SIMR Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onatasertib","moa":"||TORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denifanstat","moa":"||Fatty acid synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denifanstat","moa":"||Fatty acid synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danoprevir","moa":"||NS3\/4A protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"EMB-01","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Endocrinology","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HighTide Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CTA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioheng Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Henan Normal University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Azvudine","moa":"Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Henan Normal University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Henan Normal University \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Henan Normal University \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulcardine Sulfate","moa":"Fast sodium current","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HUYA Bioscience International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Inapplicable"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EMB-02","moa":"PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Institute of Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Beijing Institute of Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Beijing Institute of Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Institute of Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APG-1387","moa":"||IAP","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pamiparib","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RD118","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Academia Sinica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Academia Sinica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Academia Sinica \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Academia Sinica \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pamiparib","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APG-1387","moa":"||IAP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Ascendis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Ascendis Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Visen Pharmaceuticals \/ Ascendis Pharma"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"WuXi Advanced Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ WuXi Advanced Therapies","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ WuXi Advanced Therapies"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eltanexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fosun Kite Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fosun Kite Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Kite Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pamiparib","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ AnHeart Therapeutics"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IBI321","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"Zhaoke Ophthalmology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke Ophthalmology \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BGB-3245","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137 antigen","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Letaplimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"I-Mab Biopharma \/ Genexine","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Genexine"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC10","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"YH001","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocytogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biocytogen \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SCB-313","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PIKA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"||Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hua Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denifanstat","moa":"||Fatty acid synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Peking University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BD-368-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Peking University \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Tibet Rhodiola Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Stemirna Therapeutics \/ Tibet Rhodiola Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Stemirna Therapeutics \/ Tibet Rhodiola Pharmaceutical"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IBI319","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137 antigen","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CLDN18.2\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Senaparib","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Sagimet Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Sagimet Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Sagimet Biosciences"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IBI318","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Hepagene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HPG1860","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepagene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepagene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepagene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onatasertib","moa":"||TORC1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Adocia","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Dongbao Pharma \/ Adocia"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASC41","moa":"THR-beta","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Quadrivalent HPV Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KN046","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Hubei Soundny Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hubei Soundny Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hubei Soundny Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hubei Soundny Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Apogenix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Asunercept","moa":"||CD95","graph1":"Oncology","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Apogenix","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Apogenix"},{"orgOrder":0,"company":"Createrna Science and Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QR052107B","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Createrna Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Createrna Science and Technology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Createrna Science and Technology \/ Inapplicable"},{"orgOrder":0,"company":"Institute of Materia Medica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bilobalide","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Institute of Materia Medica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Materia Medica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Institute of Materia Medica \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Vigonvita Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuremidevir Hydrobromide","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Vigonvita Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Vigonvita Life Sciences"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Anaprazole Sodium","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sihuan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sihuan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Albuvirtide","moa":"||HIV-1 fusion","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frontier Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Frontier Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT120","moa":"CD19\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Merck & Co"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GC007g","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APL-1202","moa":"MetAP2","graph1":"Oncology","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"GM-CSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23","graph1":"Immunology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efdamrofusp Alpha","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JS016","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"JSI-1187","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"JS InnoPharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPharm \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Shanghai Jiao Tong University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TST003","moa":"BMP","graph1":"Oncology","graph2":"Preclinical","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Shanghai Jiao Tong University","highestDevelopmentStatusID":"4","companyTruncated":"Transcenta Holding \/ Shanghai Jiao Tong University"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Xiamen University","sponsor":"Yiling Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lianhua Qingwen","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Xiamen University","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xiamen University \/ Yiling Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Xiamen University \/ Yiling Pharmaceutical"},{"orgOrder":0,"company":"Henlius","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Henlius","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Henlius \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Henlius \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Vigonvita Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuremidevir Hydrobromide","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Vigonvita Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Vigonvita Life Sciences"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Edding Pharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Edding Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Kangtai Biological Products \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shenzhen Kangtai Biological Products \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC41","moa":"THR-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eccogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ECC0509","moa":"SSAO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Eccogene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eccogene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/ Inapplicable"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"LintonPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"LintonPharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"LintonPharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LintonPharm \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Endocrinology","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HighTide Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Adenovirus Vector Based SARS-COV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CanSino Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBIBP-CorV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinopharm \/ Inapplicable"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"Collagen synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tongji Hospital \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tongji Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sintilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recov","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATG-019","moa":"||PAK4","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fisogatinib","moa":"||FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TJ-C64B","moa":"4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CLDN18.2\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TJ-L14B","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"TNP-2092","moa":"RNA polymerase","graph1":"Neurology","graph2":"Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TenNor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TenNor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TenNor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Zhongze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ZZ6398","moa":"D2\/3","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Zhongze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhongze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhongze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"Tarsus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LianBio \/ Tarsus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Tarsus Pharmaceuticals"},{"orgOrder":0,"company":"LianBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LianBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hong Kong \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of Hong Kong \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"QED Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase II","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ QED Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ QED Therapeutics"},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TSN1611","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyligand Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyligand Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyligand Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Epizyme","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Epizyme"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Blosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Blosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Blosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Eli Lilly"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TST003","moa":"Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TST003","moa":"Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TST003","moa":"Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TST004","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TST004","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TST010","moa":"Treg","graph1":"Oncology","graph2":"Preclinical","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TT-00420","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TT-00420","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-00420","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TT-02332","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD73","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"T19","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Utidelone","moa":"Microtubule","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Utidelone","moa":"Microtubule","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Utidelone","moa":"Microtubule","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Utidelone","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Edding Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Edding Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Edding Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PIKA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APL-1202","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vicagrel","moa":"P2Y12R","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Mycovia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Mycovia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Hengrui Medicine \/ Mycovia Pharmaceuticals"},{"orgOrder":0,"company":"VivaVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VVN461","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VivaVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Inapplicable"},{"orgOrder":0,"company":"VivaVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VVN539","moa":"ROCK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"VivaVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Argenx"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Neurology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"RareStone Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"WGc-043","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Weisijin Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Tongji University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tongji University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tongji University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tongji University \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JS110","moa":"XPO1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"WuXi Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ritonavir","moa":"||SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"||GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sciwind Biosciences \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Novotech"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XW014","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocytogen \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Biocytogen \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"YH008","moa":"CTL4","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fosun Kite Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fosun Kite Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Kite Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fosun Kite Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fosun Kite Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Kite Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Renhui Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Beinaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Shanghai Renhui Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Renhui Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Renhui Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Renhui Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Beinaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Shanghai Renhui Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Renhui Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Renhui Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"YOLT-101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"YOLT-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"YOLT-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"YOLT-203","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"YS-HBV-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Yisheng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yisheng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gloria Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gloria Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MingMed Biotechnology","sponsor":"Claruvis Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"MingMed Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MingMed Biotechnology \/ Claruvis Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"MingMed Biotechnology \/ Claruvis Pharmaceutical"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ PharmaMar"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ PharmaMar"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zimberelimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gloria Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gloria Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Gloria Biosciences \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZL-1102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ZL-1310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ZL-1310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"HBV capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shanghai Zhimeng Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Zhimeng Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Zion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZN-A-1041","moa":"RTK","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zorifertinib","moa":"EGFR-TKI reversible","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alpha Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zenshine Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zenshine Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"9MW2821","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Wanbang Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fosun Wanbang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Fosun Wanbang Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Wanbang Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Teprotumumab N01","moa":"IGF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IBI363","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI354","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HLX22","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HLX22","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Merck & Co"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Elevar Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Elevar Therapeutics"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"TopAlliance Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fosun Pharmaceutical \/ Ardelyx","highestDevelopmentStatusID":"15","companyTruncated":"Fosun Pharmaceutical \/ Ardelyx"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RAG-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Arctic Vision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"15","companyTruncated":"Arctic Vision \/ Clearside Biomedical"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||EGFR2","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Innovent Biologics \/ Hutchmed","highestDevelopmentStatusID":"9","companyTruncated":"Innovent Biologics \/ Hutchmed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"BAT4406F","moa":"CD20","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Golidocitinib","moa":"||JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Limertinib","moa":"EGFR TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aosaikang Pharmaceutical \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aosaikang Pharmaceutical \/ Innovent Biologics"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Telitacicept","moa":"BLyS\/APRIL","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"||Lipid peroxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Towa Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharma \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AC-101","moa":"RIPK2","graph1":"Immunology","graph2":"Phase I","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Accro Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Accro Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"AMP945","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Adagene Suzhou Limited \/ Merck & Co"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"AGA111","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intervertebral","sponsorNew":"Angitia Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Angitia Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AusperBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"AHB-137","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AusperBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AusperBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AusperBio \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Gumokimab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AK138D1","moa":"HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS03","moa":"Tyrosine kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AccurEdit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AccurEdit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASC47","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Inapplicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BR111","moa":"ROR1","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Phase I","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CS2009","moa":"PD-1\/VEGF\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CS2009","moa":"PD-1\/VEGF\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CS5001","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Satricabtagene Autoleucel","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1R\/GCGR\/FGF21R","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Fapon Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"FP-008","moa":"PD-1\/IL-10M","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fapon Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fapon Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fapon Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase III","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Human Interferon Alpha","moa":"IFNAR-1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Kexing Biopharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kexing Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Suzhou GenAssist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"GEN6050X","moa":"E50","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Suzhou GenAssist Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Suzhou GenAssist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Suzhou GenAssist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HF50","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"HLX22","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Alligator Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Alligator Bioscience"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jiangsu Hengrui Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HX044","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HanX Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HanX Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IBI363","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"HUNAN JIUDIAN PHARMACEUTICAL CO LTD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"HUNAN JIUDIAN PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HUNAN JIUDIAN PHARMACEUTICAL CO LTD \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HUNAN JIUDIAN PHARMACEUTICAL CO LTD \/ Inapplicable"},{"orgOrder":0,"company":"China Resources Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Irbesartan","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"China Resources Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"China Resources Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"China Resources Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Stapokibart","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"KJ-C2219","moa":"CD19\/20","graph1":"Immunology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"KJ-C2219","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LAE120","moa":"USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hunan Mabgeek Biotechnology","sponsor":"Chime Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Hunan Mabgeek Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hunan Mabgeek Biotechnology \/ Chime Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Hunan Mabgeek Biotechnology \/ Chime Biologics"},{"orgOrder":0,"company":"MindRank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MRANK-106","moa":"WEE1\/YES1 kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MindRank \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MindRank \/ Inapplicable"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Senaparib","moa":"PARP","graph1":"Oncology","graph2":"Approved FDF","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IMPACT Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IMPACT Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RAG-17","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RN0361","moa":"APOC3 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RiboX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RXRG001","moa":"hAQP1 overexpression","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"RiboX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Intraductal Injection","sponsorNew":"RiboX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"RiboX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SC0062","moa":"Endothelin A receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"SCB-1019","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Sungen Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SGC001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Beijing Sungen Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Sungen Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Sungen Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"SineuGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SNUG01","moa":"TRIM72","graph1":"Neurology","graph2":"Phase I","graph3":"SineuGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"SineuGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SineuGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Triastek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"T20G","moa":"Non-vitamin K","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Triastek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/ Inapplicable"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"TechnoDerma Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"CLDN 18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"||CLDN 18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"VectorBuilder","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"UC101","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Chengdu Yousino Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Yousino Biotechnology \/ VectorBuilder","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Yousino Biotechnology \/ VectorBuilder"},{"orgOrder":0,"company":"VivaVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VVN461","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"VivaVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"YOLT-201","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Northwestern University","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"YOLT-203","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"YolTech Therapeutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Northwestern University"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"YOLT-204","moa":"Fetal hemoglobin expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Softigel Procaps","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"COLOMBIA","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Softigel Procaps","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Softigel Procaps \/ SciSparc","highestDevelopmentStatusID":"8","companyTruncated":"Softigel Procaps \/ SciSparc"},{"orgOrder":0,"company":"Alter Pharma group","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"COSTA RICA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alter Pharma group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alter Pharma group \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Alter Pharma group \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Finlay Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CUBA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"FINLAY-FR-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Finlay Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Finlay Institute \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Finlay Institute \/ Inapplicable"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Axon Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Axon Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CYPRUS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axon Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axon Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"AEGIS Ltd. Cyprus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CYPRUS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VAX-001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AEGIS Ltd. Cyprus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEGIS Ltd. Cyprus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AEGIS Ltd. Cyprus \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"SOT112","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Synaffix","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Synaffix"},{"orgOrder":0,"company":"AbCheck","sponsor":"Ampersand Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CZECH REPUBLIC","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCheck","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCheck \/ Ampersand Biomedicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCheck \/ Ampersand Biomedicines"},{"orgOrder":0,"company":"AbCheck","sponsor":"Czech Republic","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CZECH REPUBLIC","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCheck","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCheck \/ Czech Republic","highestDevelopmentStatusID":"3","companyTruncated":"AbCheck \/ Czech Republic"},{"orgOrder":0,"company":"Sotio","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"SOT106","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Sotio","sponsor":"PPF Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ PPF Group","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ PPF Group"},{"orgOrder":0,"company":"AbCheck","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CZECH REPUBLIC","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"AbCheck","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCheck \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"AbCheck \/ Undisclosed"},{"orgOrder":0,"company":"Sotio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Merck & Co"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BOXR1030","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"SSRI","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"SOT102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"SOT102","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SOT201","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cytune Pharma"},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cytune Pharma"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":1,"company":"Cayman Pharma s.r.o","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KMN-159","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Cayman Pharma s.r.o","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Dental Implant","sponsorNew":"Cayman Pharma s.r.o \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Pharma s.r.o \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SOT109","moa":"CDH17","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Er-Kim","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Er-Kim","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Er-Kim"},{"orgOrder":0,"company":"Muna Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Muna Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Muna Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Muna Therapeutics \/ GSK"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"EIS-12656","moa":"||ALC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisbach Bio \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ CPRIT"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"STAT6","graph1":"Immunology","graph2":"Preclinical","graph3":"Leo Pharma","amount2":1.7,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.7,"dosageForm":"Oral","sponsorNew":"Leo Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Leo Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Neumirna Therapeutics","sponsor":"Angelini Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Oligonucleotide","year":"2025","type":"Series A Financing","leadProduct":"NMT.001","moa":"miR-134","graph1":"Neurology","graph2":"Preclinical","graph3":"Neumirna Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Neumirna Therapeutics \/ Angelini Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Neumirna Therapeutics \/ Angelini Ventures"},{"orgOrder":0,"company":"Commit Biologics","sponsor":"Korys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"C1q","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Commit Biologics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Commit Biologics \/ Korys","highestDevelopmentStatusID":"3","companyTruncated":"Commit Biologics \/ Korys"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Public Offering","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Lake Street Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Public Offering","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Lake Street Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Adcendo","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"ADCE-T02","moa":"Tissue Factor","graph1":"Oncology","graph2":"Phase I","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adcendo \/ TCGX","highestDevelopmentStatusID":"6","companyTruncated":"Adcendo \/ TCGX"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"CT-388","moa":"||GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":5.2999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":5.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Gubra","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":2.23,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.23,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ AbbVie Inc"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ BARDA"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Gavi","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Gavi"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Financing","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Carnegie Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Carnegie Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Carnegie Investment Bank"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Adcendo","sponsor":"Pontifax Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Pontifax Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Adcendo \/ Pontifax Venture Capital"},{"orgOrder":0,"company":"Adcendo","sponsor":"Dawn Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Dawn Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Adcendo \/ Dawn Biopharma"},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symphogen \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen \/ Servier"},{"orgOrder":0,"company":"Var2 Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Var2 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Var2 Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Var2 Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bactolife","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bactolife","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bactolife \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bactolife \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"AdaptVac","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CLP Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AdaptVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdaptVac \/ Bavarian Nordic","highestDevelopmentStatusID":"4","companyTruncated":"AdaptVac \/ Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"MVA-BN Filo Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ GSK"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Commit Biologics","sponsor":"Bioqube Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Commit Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Commit Biologics \/ Bioqube Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Commit Biologics \/ Bioqube Ventures"},{"orgOrder":0,"company":"Orphazyme","sponsor":"CytRx Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ CytRx Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ CytRx Corporation"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"FT-3171","moa":"USP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Debiopharm"},{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"FB-101","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freya Biosciences \/ Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Freya Biosciences \/ Sofinnova Partners"},{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"FB-101","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freya Biosciences \/ Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Freya Biosciences \/ Sofinnova Partners"},{"orgOrder":0,"company":"Carelink","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carelink","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Carelink \/ Fujifilm holding","highestDevelopmentStatusID":"10","companyTruncated":"Carelink \/ Fujifilm holding"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ CARB-X","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ CARB-X"},{"orgOrder":0,"company":"Galecto","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Soleus Capital"},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Undisclosed"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"EVX-B2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ National Institutes of Health"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Almirall"},{"orgOrder":0,"company":"IO Biotech","sponsor":"HBM Healthcare Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ HBM Healthcare Investment","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ HBM Healthcare Investment"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Lantern Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Lantern Pharma"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"ISD017","moa":"STING","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISD Immunotech \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Biogen"},{"orgOrder":0,"company":"ALK","sponsor":"Grandpharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Epinephrine Bitartrate","moa":"Adrenergic receptor-alpha 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"ALK \/ Grandpharma","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Grandpharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Union Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leo Pharma \/ Union Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Union Therapeutics"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Idalopirdine","moa":"5-HT6 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Denovo Biopharma"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Hyphens Pharma"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Zydus Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Muna Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Progranulin pathway","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Muna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Muna Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"3","companyTruncated":"Muna Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Health Emergency Preparedness and Response Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Health Emergency Preparedness and Response Authority","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Health Emergency Preparedness and Response Authority"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"HERA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ HERA","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ HERA"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"MVA-BN-WEV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian Nordic \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascendis Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Ascendis Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Sass & Larsen Aps","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncology Venture \/ Sass & Larsen Aps","highestDevelopmentStatusID":"10","companyTruncated":"Oncology Venture \/ Sass & Larsen Aps"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Smerud Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncology Venture \/ Smerud Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncology Venture \/ Smerud Medical Research"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"VAP-1","graph1":"Dermatology","graph2":"Discovery","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leo Pharma \/ Kubota Vision Inc","highestDevelopmentStatusID":"2","companyTruncated":"Leo Pharma \/ Kubota Vision Inc"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Preclinical","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Orphazyme \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"Galecto","sponsor":"Providence Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Galecto \/ Providence Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Providence Cancer Institute"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Hemab Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemab Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Hemab Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Jeito Capital","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Jeito Capital"},{"orgOrder":0,"company":"MinervaX","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"GBS-NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"MinervaX \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/ Sanofi"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion Channel","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Saniona \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Saniona","sponsor":"Foundation for Prader-Willi Research","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Foundation for Prader-Willi Research","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Foundation for Prader-Willi Research"},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symphogen \/ Servier Canada","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen \/ Servier Canada"},{"orgOrder":0,"company":"Synklino","sponsor":"The Danish Growth Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"SYN002","moa":"US28","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Synklino","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synklino \/ The Danish Growth Fund","highestDevelopmentStatusID":"4","companyTruncated":"Synklino \/ The Danish Growth Fund"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Pharm Technologies \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tetra Pharm Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Orphazyme","sponsor":"KemPharm","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ KemPharm","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ KemPharm"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Endo Pharm"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ DKSH"},{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"The EU Horizon 2020 consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ExpreS2ion Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 consortium","highestDevelopmentStatusID":"1","companyTruncated":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 consortium"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Afrigen Biologics and Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"EVX-B2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Afrigen Biologics and Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Afrigen Biologics and Vaccines"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordisk \/ Evotec"},{"orgOrder":0,"company":"Glysious","sponsor":"Tetra Pharm Technologies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"TPT0201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Glysious","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glysious \/ Tetra Pharm Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Glysious \/ Tetra Pharm Technologies"},{"orgOrder":0,"company":"Gubra","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Gubra \/ Bayer AG"},{"orgOrder":0,"company":"Genmab","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genmab \/ Argenx","highestDevelopmentStatusID":"2","companyTruncated":"Genmab \/ Argenx"},{"orgOrder":0,"company":"Bacthera","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bacthera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bacthera \/ Seres Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Bacthera \/ Seres Therapeutics"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Gilead Sciences"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"2X Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oncology Venture \/ 2X Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Oncology Venture \/ 2X Oncology"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Divestment","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Leo Pharma \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"IO Biotech","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ EIB","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ EIB"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Canaan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"AP31969","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acesion Pharma \/ Canaan","highestDevelopmentStatusID":"5","companyTruncated":"Acesion Pharma \/ Canaan"},{"orgOrder":0,"company":"InProTher","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"IPT001","moa":"HERVs","graph1":"Oncology","graph2":"IND Enabling","graph3":"InProTher","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InProTher \/ European Innovation Council","highestDevelopmentStatusID":"5","companyTruncated":"InProTher \/ European Innovation Council"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Danish Ministry of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Danish Ministry of Health","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Danish Ministry of Health"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ BARDA"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Preclinical","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesper Bio \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Vesper Bio \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"HMB-001","moa":"Factor VIIa","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hemab Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SNIPR Biome \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SNIPR Biome \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ European Union","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ European Union"},{"orgOrder":0,"company":"ResoTher Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"RTP-026","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"ResoTher Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ResoTher Pharma \/ European Innovation Council","highestDevelopmentStatusID":"6","companyTruncated":"ResoTher Pharma \/ European Innovation Council"},{"orgOrder":0,"company":"Orbis Medicines","sponsor":"Novo Holding","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbis Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbis Medicines \/ Novo Holding","highestDevelopmentStatusID":"3","companyTruncated":"Orbis Medicines \/ Novo Holding"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Innovation Fund Denmark","highestDevelopmentStatusID":"1","companyTruncated":"Rigshospitalet \/ Innovation Fund Denmark"},{"orgOrder":0,"company":"MinervaX","sponsor":"REPAIR Impact Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"GBS-NN\/NN2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"MinervaX \/ REPAIR Impact Fund","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/ REPAIR Impact Fund"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Endovion","moa":"||ABCG2\/UGT1A1\/Drug efflux pump","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scandion Oncology \/ Innovation Fund Denmark","highestDevelopmentStatusID":"8","companyTruncated":"Scandion Oncology \/ Innovation Fund Denmark"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"P-300","moa":"CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novo Nordisk \/ Pathos","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Pathos"},{"orgOrder":0,"company":"Genmab","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Gubra","sponsor":"Skandinaviska Enskilda Banken","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Amylin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Skandinaviska Enskilda Banken","highestDevelopmentStatusID":"4","companyTruncated":"Gubra \/ Skandinaviska Enskilda Banken"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Private Placement","leadProduct":"Typhoid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bavarian Nordic \/ Danske Bank","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank A\/S","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Danske Bank A\/S","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank A\/S"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Lundbeckfonden BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Private Placement","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Lundbeckfonden BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Lundbeckfonden BioCapital"},{"orgOrder":0,"company":"Hoba Therapeutics","sponsor":"Indaco Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"Recombinant Human Meteorin","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoba Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoba Therapeutics \/ Indaco Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Hoba Therapeutics \/ Indaco Venture Partners"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Negma Group"},{"orgOrder":0,"company":"Adcendo","sponsor":"Novo Seeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"uPARAP","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adcendo \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Adcendo \/ Novo Seeds"},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genmab \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ Tavotek Biotherapeutics"},{"orgOrder":0,"company":"Genmab","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Camidanlumab Tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ ADC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ ADC Therapeutics"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Kvantify","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra Pharm Technologies \/ Kvantify","highestDevelopmentStatusID":"2","companyTruncated":"Tetra Pharm Technologies \/ Kvantify"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian Nordic \/ CEPI"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Series A Financing","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antag Therapeutic \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Antag Therapeutic \/ Versant Ventures"},{"orgOrder":0,"company":"Draupnir Bio","sponsor":"MP Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Draupnir Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Draupnir Bio \/ MP Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Draupnir Bio \/ MP Healthcare"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Organovo Holdings"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Financing","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"RevOpsis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevOpsis Therapeutics \/ National Eye Institute","highestDevelopmentStatusID":"5","companyTruncated":"RevOpsis Therapeutics \/ National Eye Institute"},{"orgOrder":0,"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"SAN711","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Galecto","sponsor":"Pharmakea Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"PAT-1251","moa":"LOXL2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galecto \/ Pharmakea Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Pharmakea Therapeutics"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Massachusetts Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Massachusetts Institute of Technology","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Massachusetts Institute of Technology"},{"orgOrder":0,"company":"MinervaX","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Aluminium","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"MinervaX \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/ EQT Life Sciences"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Ixabepilone","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2020","type":"Financing","leadProduct":"Ixabepilone","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2020","type":"Financing","leadProduct":"Ixabepilone","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Negma Group"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2021","type":"Financing","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Oberland Capital Management"},{"orgOrder":0,"company":"Meabco","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"BP-C2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meabco \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ National Institutes of Health"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NN-8828","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Almirall"},{"orgOrder":0,"company":"Fertin Pharma AS","sponsor":"Philip Morris International","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Fertin Pharma AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Fertin Pharma AS \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Fertin Pharma AS \/ Philip Morris International"},{"orgOrder":0,"company":"Fertin Pharma AS","sponsor":"Philip Morris International","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Fertin Pharma AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Fertin Pharma AS \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Fertin Pharma AS \/ Philip Morris International"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Expanded Collaboration","leadProduct":"EVX-B2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Merck & Co"},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"RevOpsis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevOpsis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"RevOpsis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Octarine Bio","sponsor":"Clerkenwell Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Octarine Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Octarine Bio \/ Clerkenwell Health","highestDevelopmentStatusID":"4","companyTruncated":"Octarine Bio \/ Clerkenwell Health"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Novo Nordisk \/ Novo Nordisk"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ European Union","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ European Union"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Neuro3 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Neuro3 Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"H. Lundbeck AS \/ Neuro3 Therapeutics"},{"orgOrder":0,"company":"Cessatech","sponsor":"Proveca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cessatech \/ Proveca","highestDevelopmentStatusID":"9","companyTruncated":"Cessatech \/ Proveca"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Teijin Pharma"},{"orgOrder":0,"company":"Vipergen","sponsor":"Theseus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"TYK","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vipergen \/ Theseus Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ Theseus Pharmaceuticals"},{"orgOrder":0,"company":"Saniona","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SAN711","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Lophora","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"LPH-5","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lophora","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lophora \/ Beckley Psytech","highestDevelopmentStatusID":"4","companyTruncated":"Lophora \/ Beckley Psytech"},{"orgOrder":0,"company":"Vipergen","sponsor":"PhoreMost","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vipergen \/ PhoreMost","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ PhoreMost"},{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Otonomy"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"IO102-IO103","moa":"||IDO","graph1":"Oncology","graph2":"Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"IO Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Expanded Collaboration","leadProduct":"BNT313","moa":"CD27","graph1":"Oncology","graph2":"Preclinical","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Vipergen","sponsor":"Casma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vipergen \/ Casma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ Casma Therapeutics"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Licensing Agreement","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"ExpreS2ion Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"EVX-V1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ ExpreS2ion Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ ExpreS2ion Biotechnologies"},{"orgOrder":0,"company":"Zerion Pharma","sponsor":"Hovione","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"DENMARK","productType":"Protein","year":"2022","type":"Expanded Collaboration","leadProduct":"Beta-lactoglobulin","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Zerion Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zerion Pharma \/ Hovione","highestDevelopmentStatusID":"4","companyTruncated":"Zerion Pharma \/ Hovione"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Institut Pasteur Korea","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Institut Pasteur Korea","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Institut Pasteur Korea"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"H. Lundbeck AS \/ Otsuka Holdings","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Otsuka Holdings"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Radboud University Medical Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Radboud University Medical Centre","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Radboud University Medical Centre"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADCE-D01","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Short Ragweed Pollen Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Ixabepilone","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Oncoheroes Biosciences Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Oncoheroes Biosciences Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Oncoheroes Biosciences Inc."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AP30663","moa":"SK ion channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acesion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acesion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AP31969","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Acesion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acesion Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acesion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antag Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Antag Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"ABCG2\/UGT1A1\/Drug efflux pump","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scandion Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scandion Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"BI 1820237","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Meabco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BP-C2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meabco \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-0045","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoki Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-0045","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoki Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Tetra Pharm Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tetra Pharm Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SAN711","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MVA-BN-WEV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN711","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EIS-12656","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisbach Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ Inapplicable"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EIS-12656","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisbach Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eisbach Bio \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-02","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EVX-V1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EVX-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-02","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EVX-02","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EVX-B1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EVX-B1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EVX-B2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EVX-B3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FB-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Freya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||Chloride channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB2064","moa":"LOXL2","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GB1211","moa":"||Galectin-3","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB2064","moa":"LOXL2","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"MinervaX","sponsor":"European and Developing Countries Clinical Trials Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GBS-NN\/NN2","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"MinervaX \/ European and Developing Countries Clinical Trials Partnership","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/ European and Developing Countries Clinical Trials Partnership"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ BioNTech"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enapotamab Vedotin","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"MinervaX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GBS-NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"MinervaX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HMB-001","moa":"Factor VIIa","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hemab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eptacog Alpha","moa":"Coagulation cascade","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TransCon IL-2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monlunabant","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IO Biotech \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"IO Biotech \/ Merck & Co"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRX4204","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRX4204","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"DENMARK","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Temtokibart","moa":"IL-22RA1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Argenx"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Temtokibart","moa":"IL-22RA1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amlenetug","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amlenetug","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"MC2-25","moa":"Carbamylation","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"MC2-25","moa":"Carbamylation","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"MC2-25 VLS","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"MC2-25 CKD","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MC2-32","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mim8","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pharmacosmos AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacosmos AS \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Modified Vaccinia Virus Ankara, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMD1343","moa":"CIC-1","graph1":"Neurology","graph2":"Phase I","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Immunology","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1R\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1R\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mim8","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mim8","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Neurology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oncology Venture","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncology Venture \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncology Venture \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"||HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GB2064","moa":"LOXL2","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||GLP-1R","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"Chloride channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Somapacitan","moa":"SST","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiquimod","moa":"TLR7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"||IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN711","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SAN711","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN903","moa":"KCa3.1","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"University of Arhus","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN903","moa":"KCa3.1","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ University of Arhus","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ University of Arhus"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ GSK"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Somapacitan","moa":"SST","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Somapacitan","moa":"SST","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dovitinib","moa":"||Pan-TKI","graph1":"Oncology","graph2":"Phase I","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Fleroxacin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Viroclinics Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Allarity Therapeutics \/ Viroclinics Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Allarity Therapeutics \/ Viroclinics Biosciences"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||ABCG2\/UGT1A1\/Drug efflux pump","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scandion Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scandion Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aarhus University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Senicapoc","moa":"KCNN4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aarhus University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aarhus University \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aarhus University \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TLR7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"PDE10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dovitinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SNIPR001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biome \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"IO102","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Haemnet","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HMB-001","moa":"Factor VIIa","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hemab Therapeutics \/ Haemnet","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Haemnet"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Radhoud University Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Radhoud University Medical","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Radhoud University Medical"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"||HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endovion","moa":"||Chloride channel","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Foliglurax","moa":"mGluR4","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Pantherna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evaxion Biotech \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Pantherna Therapeutics"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LEO 152020","moa":"H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN711","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SAN711","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"MinervaX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GBS-NN\/NN2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"MinervaX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ziltivekimab","moa":"IL-6 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IDO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Personalis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Personalis","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Personalis"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ GSK"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Initiator Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IPED2015","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Initiator Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Initiator Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Initiator Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AJ Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AJ Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"AJ Vaccines \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AJ Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olitigaltin","moa":"Galectin-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Seagen"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Pfizer Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Pfizer Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TPT0701","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra Pharm Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra Pharm Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Navepegritide","moa":"C-type natriuretic peptide","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TransCon IL-2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resiquimod","moa":"TLR7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Icodec","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"ISD017","moa":"STING","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISD Immunotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Inapplicable"},{"orgOrder":0,"company":"Curasight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"68-Ga NOTA-AE105","moa":"uPAR","graph1":"Oncology","graph2":"Preclinical","graph3":"Curasight","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curasight \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Curasight \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VES001","moa":"PGRN","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesper Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Xellia Pharmaceuticals ApS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xellia Pharmaceuticals ApS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xellia Pharmaceuticals ApS \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||Amylin\/calcitonin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Palopegteriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||Amylin\/calcitonin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Immunology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Union Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Stenoparib","moa":"||PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ADCE-T02","moa":"Tissue Factor","graph1":"Oncology","graph2":"Phase I","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"PXVX0317","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVX-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HMB-002","moa":"VMF\/Factor VII level","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hemab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amlenetug","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amlenetug","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1R\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mim8","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"ALK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"ALK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ALK \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Rinatabart Sesutecan","moa":"FR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bavarian Nordic \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minapharm Pharmaceuticals \/ Bioventure Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Minapharm Pharmaceuticals \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"EGYPT","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minapharm Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Minapharm Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Alliance Pharmaceutical Company","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"EGYPT","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tetracaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alliance Pharmaceutical Company","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alliance Pharmaceutical Company \/ Valeo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Alliance Pharmaceutical Company \/ Valeo Pharma"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"EGYPT","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Minapharm Pharmaceuticals \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Minapharm Pharmaceuticals \/ Biocon"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"EGYPT","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Evariste","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Evariste","highestDevelopmentStatusID":"1","companyTruncated":"Orion Corporation \/ Evariste"},{"orgOrder":0,"company":"Aplagon","sponsor":"FSG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FINLAND","productType":"Radiolabelled Compounds","year":"2025","type":"Financing","leadProduct":"89-Zr Megabecquerel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aplagon","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Aplagon \/ FSG","highestDevelopmentStatusID":"6","companyTruncated":"Aplagon \/ FSG"},{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"RPT04402","moa":"PP2A","graph1":"Oncology","graph2":"Preclinical","graph3":"Rappta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rappta Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Rappta Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Orion Corporation \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Marinus Pharmaceuticals"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Invenra","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Invenra","highestDevelopmentStatusID":"3","companyTruncated":"Orion Corporation \/ Invenra"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FINLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orion Corporation \/ Tenax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corporation \/ Tenax Therapeutics"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"DelSiTech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"DelSiTech \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Lifeline Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Lifeline Ventures"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Business Finland","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faron Pharmaceuticals \/ Business Finland","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Business Finland"},{"orgOrder":0,"company":"University of Helsinki","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"PeptiCRAd-1","moa":"CD8+ T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Helsinki","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"University of Helsinki \/ Valo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Helsinki \/ Valo Therapeutics"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Nanoform","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Large Molecule","year":"2020","type":"Agreement","leadProduct":"CDNF","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Herantis Pharma \/ Nanoform","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Nanoform"},{"orgOrder":0,"company":"Nanoform","sponsor":"Nacuity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FINLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nanoform \/ Nacuity Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Nacuity Pharmaceuticals"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Merck & Co"},{"orgOrder":0,"company":"University of Helsinki","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"PeptiCRAd","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"University of Helsinki","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Helsinki \/ Valo Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"University of Helsinki \/ Valo Therapeutics"},{"orgOrder":0,"company":"DelSiTech","sponsor":"DRW Venture Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Entecavir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"DelSiTech \/ DRW Venture Capital LLC","highestDevelopmentStatusID":"1","companyTruncated":"DelSiTech \/ DRW Venture Capital LLC"},{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"Novo Seeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"PTPA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Rappta Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rappta Therapeutics \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Rappta Therapeutics \/ Novo Seeds"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FINLAND","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"CD73","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nanoform","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"FINLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nanoform \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Nanoform \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Finland\u2019s Lifeline Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"Avelumab","moa":"||TNF-alpha\/IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Finland\u2019s Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Finland\u2019s Lifeline Ventures"},{"orgOrder":0,"company":"Veripalvelu","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Veripalvelu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veripalvelu \/ Orion Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Veripalvelu \/ Orion Corporation"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"CuraTeQ Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orion Corporation \/ CuraTeQ Biologics","highestDevelopmentStatusID":"3","companyTruncated":"Orion Corporation \/ CuraTeQ Biologics"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Opevesostat","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Merck & Co"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Biotheus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"Igrelimogene Litadenorepvec","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ Biotheus","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Biotheus"},{"orgOrder":0,"company":"Glykos","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glykos","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glykos \/ Orion Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Glykos \/ Orion Corporation"},{"orgOrder":0,"company":"Nanoform","sponsor":"PlusVitech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Oncology","graph2":"Phase II","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Nanoform \/ PlusVitech","highestDevelopmentStatusID":"8","companyTruncated":"Nanoform \/ PlusVitech"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FINLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Orion Corporation \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Marinus Pharmaceuticals"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FINLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Interferon-alpha\/beta receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FINLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DST-2105","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"DelSiTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"DelSiTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"DelSiTech \/ Inapplicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"ONConcept Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Nanoform \/ ONConcept Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ ONConcept Consortium"},{"orgOrder":0,"company":"Nanoform","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piroxicam","moa":"COX-1","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nanoform \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Fermion Oy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FZ008-145","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Fermion Oy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fermion Oy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fermion Oy \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piroxicam","moa":"COX-1","graph1":"Immunology","graph2":"Preclinical","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoform \/ Quotient Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nanoform \/ Quotient Sciences"},{"orgOrder":0,"company":"Nanoform","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FINLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piroxicam","moa":"COX-1","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nanoform \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ODM-111","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rokote Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Rokote Lab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Rokote Lab \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Rokote Lab \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fermion Oy","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fermion Oy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fermion Oy \/ G1 Therapeutics, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Fermion Oy \/ G1 Therapeutics, Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piroxicam","moa":"COX-1","graph1":"Neurology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Nanoform \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Igrelimogene Litadenorepvec","moa":"TNF-alpha\/IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Igrelimogene Litadenorepvec","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"CDNF","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Herantis Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Herantis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Bayer AG"},{"orgOrder":0,"company":"Valneva","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Agreement","leadProduct":"Inactivated Japanese Encephalitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Financing","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0.31,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0.31,"dosageForm":"Topical Patch","sponsorNew":"DBV Technologies \/ MPM BioImpact","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ MPM BioImpact"},{"orgOrder":0,"company":"Osivax","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Series B Financing","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Aqemia","sponsor":"Cathay Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Aqemia \/ Cathay Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ Cathay Innovation"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":2.5899999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.5899999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Iktos","sponsor":"Cube Biotech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Amylin receptor","graph1":"Technology","graph2":"Discovery Platform","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iktos \/ Cube Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Iktos \/ Cube Biotech"},{"orgOrder":0,"company":"EG 427","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"EG110A","moa":"Botulinum toxin fragment","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"EG 427","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intradetrusor Injection","sponsorNew":"EG 427 \/ Andera Partners","highestDevelopmentStatusID":"7","companyTruncated":"EG 427 \/ Andera Partners"},{"orgOrder":0,"company":"PulseSight Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"PST-611","moa":"Transferrin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"PulseSight Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PulseSight Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"PulseSight Therapeutics \/ Pureos Bioventures"},{"orgOrder":0,"company":"Cellectis","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ EIB","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ EIB"},{"orgOrder":0,"company":"Genfit","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.19,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Genfit \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ HealthCare Royalty"},{"orgOrder":0,"company":"Genfit","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.20000000000000001,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Genfit \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ HealthCare Royalty"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"CTx-TFEB","moa":"TFEB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2025","type":"Funding","leadProduct":"CER-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Bpifrance","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Bpifrance"},{"orgOrder":0,"company":"Allogenica","sponsor":"French Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"XL-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogenica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogenica \/ French Government","highestDevelopmentStatusID":"4","companyTruncated":"Allogenica \/ French Government"},{"orgOrder":0,"company":"Theranexus","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"TX01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Theranexus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theranexus \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Theranexus \/ Exelixis"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Divestment","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Ammtek","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ammtek","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ammtek \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ammtek \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Acquisition","leadProduct":"Levalbuterol Hydrochloride","moa":"Adrenergic beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Sanofi \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Lupin Ltd"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Orphelia Pharma","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Orphelia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orphelia Pharma \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Orphelia Pharma \/ Ethypharm"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Recordati"},{"orgOrder":0,"company":"Laboratoires CTRS","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cholic Acid","moa":"Bile acid synthesis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Laboratoires CTRS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires CTRS \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Laboratoires CTRS \/ Ethypharm"},{"orgOrder":0,"company":"Poxel","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ OrbiMed","highestDevelopmentStatusID":"15","companyTruncated":"Poxel \/ OrbiMed"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ European Investment Bank"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inventiva Pharma \/ New Enterprise Associates","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ New Enterprise Associates"},{"orgOrder":0,"company":"Valbiotis","sponsor":"TP ICAP Midcap","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Public Offering","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ TP ICAP Midcap","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ TP ICAP Midcap"},{"orgOrder":0,"company":"Sanofi","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Global Blood Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ Global Blood Therapeutics"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"Abivax","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Kreos Capital"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"Cellectis","sponsor":"Primera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Primera Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Primera Therapeutics"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Agence Nationale de la Recherche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"DT-7012","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Domain Therapeutics \/ Agence Nationale de la Recherche","highestDevelopmentStatusID":"4","companyTruncated":"Domain Therapeutics \/ Agence Nationale de la Recherche"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"5-Methyltetrazole","moa":"A2AR\/BR","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Domain Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"ABL Europe","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"ODI-2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Odimma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Odimma Therapeutics \/ ABL Europe","highestDevelopmentStatusID":"4","companyTruncated":"Odimma Therapeutics \/ ABL Europe"},{"orgOrder":0,"company":"Gamut Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"SPVN20","moa":"GIRK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gamut Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gamut Therapeutics \/ SparingVision","highestDevelopmentStatusID":"4","companyTruncated":"Gamut Therapeutics \/ SparingVision"},{"orgOrder":0,"company":"Sanofi","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Bismuth Subsalicylate","moa":"COX","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Arcadia Consumer Healthcare"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Mediolanum Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Inolimomab","moa":"IL-2-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ElsaLys Biotech \/ Mediolanum Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Mediolanum Farmaceutici"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"University of Birmingham","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acticor Biotech SAS \/ University of Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Biotech SAS \/ University of Birmingham"},{"orgOrder":0,"company":"SparingVision","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SparingVision \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SparingVision \/ Undisclosed"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Series A Financing","leadProduct":"PATAS","moa":"ALMS1","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"Advanced BioDesign","sponsor":"Xerys Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ABD-3001","moa":"ALDH1","graph1":"Oncology","graph2":"Preclinical","graph3":"Advanced BioDesign","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced BioDesign \/ Xerys Funds","highestDevelopmentStatusID":"4","companyTruncated":"Advanced BioDesign \/ Xerys Funds"},{"orgOrder":0,"company":"Sanofi","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Aztreonam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Advanz Pharma"},{"orgOrder":0,"company":"MAbSilico solutions","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Nivolumab","moa":"||CTLs","graph1":"Oncology","graph2":"Phase II","graph3":"MAbSilico solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MAbSilico solutions \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"8","companyTruncated":"MAbSilico solutions \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Sanofi","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sanofi \/ European Union","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ European Union"},{"orgOrder":0,"company":"Servier","sponsor":"Aitia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Servier \/ Aitia","highestDevelopmentStatusID":"2","companyTruncated":"Servier \/ Aitia"},{"orgOrder":0,"company":"Seppic","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Engineered SARS-CoV-2-RBD-Fc Fusion Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Seppic","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Seppic \/ Akston Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Seppic \/ Akston Biosciences"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Series C Financing","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Sofinnova Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Sofinnova Partners"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Sectoral Asset Management","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Sectoral Asset Management"},{"orgOrder":0,"company":"Affilogic","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"APL-1030","moa":"C3 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Affilogic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affilogic \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Affilogic \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Aqemia","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aqemia \/ Servier","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ Servier"},{"orgOrder":0,"company":"Aqemia","sponsor":"Wendel Growth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aqemia \/ Wendel Growth","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ Wendel Growth"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Araris Biotech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innate Pharma \/ Araris Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Araris Biotech"},{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Eirion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"HTL Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Liniment","sponsorNew":"HTL Biotechnology \/ Eirion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"HTL Biotechnology \/ Eirion Therapeutics"},{"orgOrder":0,"company":"Cellectis","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellectis \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Cellectis \/ AstraZeneca"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bisoprolol Fumarate","moa":"||ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athena Pharmaceutiques \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Pharmaceutiques \/ Undisclosed"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"BI 765063","moa":"||SIRP alpha","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"BioVaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ BioVaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ BioVaxys"},{"orgOrder":0,"company":"Biomunex Pharmaceutical","sponsor":"Onward Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"BMX-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomunex Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomunex Pharmaceutical \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biomunex Pharmaceutical \/ Onward Therapeutics"},{"orgOrder":0,"company":"Biomunex Pharmaceutical","sponsor":"Onward Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomunex Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomunex Pharmaceutical \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biomunex Pharmaceutical \/ Onward Therapeutics"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"BioVaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ BioVaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ BioVaxys"},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Bone Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Medsenic \/ Bone Therapeutics"},{"orgOrder":0,"company":"Genethon","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"GNT0004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Genethon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genethon \/ Sarepta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Genethon \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Cedirogant","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inventiva Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Cellectis","sponsor":"Servier Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Servier Canada","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Servier Canada"},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Cytovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellectis \/ Cytovia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectis \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cellectis","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"UCART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Jefferies LLC","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Jefferies LLC"},{"orgOrder":0,"company":"Cellectis","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Servier"},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"CYT-150","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Cytovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Cenexi","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cenexi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cenexi \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Cenexi \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Institut Pasteur \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ CEPI"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CTx-PDE6b","moa":"PDE6B gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coave Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"CTx-PDE6b","moa":"PDE6B gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Coave Therapeutics \/ Seroba Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Seroba Life Sciences"},{"orgOrder":0,"company":"Sanofi","sponsor":"U.S Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sanofi \/ U.S Department of Health and Human Services","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ U.S Department of Health and Human Services"},{"orgOrder":0,"company":"Kiadis","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Isatuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Kiadis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiadis \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Kiadis \/ Sanofi"},{"orgOrder":0,"company":"Roca Therapeutics","sponsor":"3B Future Health Fund II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"RCT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Roca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roca Therapeutics \/ 3B Future Health Fund II","highestDevelopmentStatusID":"5","companyTruncated":"Roca Therapeutics \/ 3B Future Health Fund II"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"FRANCE","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Zolpidem Tartrate","moa":"GABA-A receptor-alpha1\/beta1\/gamma2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Cosette Pharma"},{"orgOrder":0,"company":"Creapharm","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"Creapharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Creapharm \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Creapharm \/ First Wave BioPharma"},{"orgOrder":0,"company":"Biocodex","sponsor":"PANTHERx Rare Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Stiripentol","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biocodex \/ PANTHERx Rare Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ PANTHERx Rare Pharmacy"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Panacea Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Panacea Venture"},{"orgOrder":0,"company":"Eurobio Scientific","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"AGN-231868","moa":"Chemokine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eurobio Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eurobio Scientific \/ Allergan Aesthetics","highestDevelopmentStatusID":"8","companyTruncated":"Eurobio Scientific \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"EB005","moa":"Microbiome","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Eligo Bioscience \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ GSK"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Ensho Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EA Pharma \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"EA Pharma \/ Ensho Therapeutics"},{"orgOrder":0,"company":"Enterome","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"EB1010","moa":"IL-10","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enterome \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Enterome \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Esteve Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Steroid","year":"2024","type":"Divestment","leadProduct":"Metyrapone","moa":"CYP450","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"HRA Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"HRA Pharma \/ Esteve Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"HRA Pharma \/ Esteve Healthcare"},{"orgOrder":0,"company":"EUROAPI","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"EUROAPI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EUROAPI \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"EUROAPI \/ Sanofi"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"GamaMabs Pharma","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Murlentamab","moa":"AMHR2","graph1":"Oncology","graph2":"Preclinical","graph3":"GamaMabs Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GamaMabs Pharma \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"GamaMabs Pharma \/ Exelixis"},{"orgOrder":0,"company":"Enterome","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Vonafexor","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Enyo Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ OrbiMed","highestDevelopmentStatusID":"5","companyTruncated":"Enyo Pharma \/ OrbiMed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Dynacure","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Series C Financing","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Perceptive Advisors"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korean Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"PDC lung01","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Korean Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Korean Investment Partners"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"OSE2101","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Bpifrance"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Valneva","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ UK Government","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ UK Government"},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Ulipristal Acetate","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"HRA Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HRA Pharma \/ Perrigo Company plc","highestDevelopmentStatusID":"15","companyTruncated":"HRA Pharma \/ Perrigo Company plc"},{"orgOrder":0,"company":"Synsight","sponsor":"Iktos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synsight","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synsight \/ Iktos","highestDevelopmentStatusID":"3","companyTruncated":"Synsight \/ Iktos"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Cellectis","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Cellectis"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Lusvertikimab","moa":"IL-7 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Servier"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"||GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sanofi \/ Sciwind Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Sciwind Biosciences"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Roche Diagnostics GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Roche Diagnostics GmbH"},{"orgOrder":0,"company":"Cellectis","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellectis \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectis \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"IPH5201","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"IPH6401","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"225-Ac","moa":"||NTSR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Fusion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Fusion Pharma"},{"orgOrder":0,"company":"Biomunex Pharmaceutical","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"BMX-502","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomunex Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomunex Pharmaceutical \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Biomunex Pharmaceutical \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Phillips - Medisize","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Lanreotide Acetate","moa":"SSTR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Phillips - Medisize","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Phillips - Medisize"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cedirogant","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inventiva Pharma \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva Pharma \/ Abbvie Inc"},{"orgOrder":0,"company":"Iktos","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iktos \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"3","companyTruncated":"Iktos \/ Italfarmaco S.p.A"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ European Investment Bank"},{"orgOrder":0,"company":"Valneva","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Inactivated Japanese Encephalitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Valneva","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Inactivated Japanese Encephalitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ US Government","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ US Government"},{"orgOrder":0,"company":"Jalon Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"JRT39","moa":"AAC-11","graph1":"Oncology","graph2":"Preclinical","graph3":"Jalon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jalon Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Jalon Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Kiadis","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"K-NK002","moa":"CD16","graph1":"Oncology","graph2":"Phase II","graph3":"Kiadis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiadis \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kiadis \/ Sanofi"},{"orgOrder":0,"company":"Kiadis","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Isatuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Kiadis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiadis \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Kiadis \/ Sanofi"},{"orgOrder":0,"company":"Osivax","sponsor":"KM Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ KM Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ KM Biologics"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Sino Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Sino Biopharm","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Sino Biopharm"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ LianBio"},{"orgOrder":0,"company":"LinKinVax","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"CD40HVac","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LinKinVax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LinKinVax \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"LinKinVax \/ Gustave Roussy"},{"orgOrder":0,"company":"LinKinVax","sponsor":"Andre-Jacques Auberton-Herve","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Protein-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"LinKinVax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LinKinVax \/ Andre-Jacques Auberton-Herve","highestDevelopmentStatusID":"7","companyTruncated":"LinKinVax \/ Andre-Jacques Auberton-Herve"},{"orgOrder":0,"company":"Sanofi","sponsor":"Ltl Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fexofenadine Hydrochloride","moa":"||H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Ltl Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Ltl Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Sodium Cromoglicate","moa":"||Mast cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Lupin Ltd"},{"orgOrder":0,"company":"SATT Conectus","sponsor":"Lysogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"FXS01","moa":"DGKk","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SATT Conectus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"SATT Conectus \/ Lysogene","highestDevelopmentStatusID":"4","companyTruncated":"SATT Conectus \/ Lysogene"},{"orgOrder":0,"company":"Vectans Pharma","sponsor":"M8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Miconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vectans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vectans Pharma \/ M8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Vectans Pharma \/ M8 Pharmaceuticals"},{"orgOrder":0,"company":"Biophytis","sponsor":"BPI","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2021","type":"Funding","leadProduct":"Macuneos","moa":"PPAR alpha","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ BPI","highestDevelopmentStatusID":"4","companyTruncated":"Biophytis \/ BPI"},{"orgOrder":0,"company":"MedinCell","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MedinCell \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ AbbVie Inc"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Virbac","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Milbemycin Oxime","moa":"||Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Virbac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virbac \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Virbac \/ Merck & Co"},{"orgOrder":0,"company":"Virbac","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Milbemycin Oxime","moa":"||Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Virbac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virbac \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Virbac \/ Merck & Co"},{"orgOrder":0,"company":"Poxel","sponsor":"Metavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Metavant Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Poxel \/ Metavant Sciences"},{"orgOrder":0,"company":"BCI Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CSF-1R kinase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"BCI Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BCI Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"BCI Pharma \/ Mithra Pharmaceuticals"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pierre Fabre \/ Talem Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Pierre Fabre \/ Talem Therapeutics"},{"orgOrder":0,"company":"Mutabilis","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"EBL-1463","moa":"PBP2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mutabilis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mutabilis \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Mutabilis \/ CARB-X"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Public Offering","leadProduct":"Nicotine","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"French Government","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Funding","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ French Government","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ French Government"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"EMERCell","sponsor":"Cell-Easy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"NK-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"EMERCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMERCell \/ Cell-Easy","highestDevelopmentStatusID":"4","companyTruncated":"EMERCell \/ Cell-Easy"},{"orgOrder":0,"company":"McSAF","sponsor":"Novasep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Adcitmer","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"McSAF","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McSAF \/ Novasep","highestDevelopmentStatusID":"4","companyTruncated":"McSAF \/ Novasep"},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Neuraxpharm"},{"orgOrder":0,"company":"GUERBET","sponsor":"NUCLIDIUM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"NuriPro","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GUERBET \/ NUCLIDIUM","highestDevelopmentStatusID":"4","companyTruncated":"GUERBET \/ NUCLIDIUM"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"NY-ESO-1.siTCR","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Takara Bio \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Iktos","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iktos \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"EMERCell","sponsor":"Onward Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"NK-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"EMERCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMERCell \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"EMERCell \/ Onward Therapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Nantes Metropole","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Nantes Metropole","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Nantes Metropole"},{"orgOrder":0,"company":"Osivax","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"OVX836","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Bpifrance","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Bpifrance"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Partnership","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Anaxago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series A Financing","leadProduct":"PEP-010","moa":"Caspase9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Anaxago","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Anaxago"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Italian Angels for Growth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series A Financing","leadProduct":"PEP-010","moa":"Caspase9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Italian Angels for Growth","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Italian Angels for Growth"},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sanofi \/ Perrigo Company plc","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Perrigo Company plc"},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sanofi \/ Perrigo Company plc","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Perrigo Company plc"},{"orgOrder":0,"company":"Sanofi","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Controlled Substance","year":"2023","type":"Divestment","leadProduct":"Clobazam","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Pharmanovia"},{"orgOrder":0,"company":"Servier","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Servier \/ Precision BioSciences","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Precision BioSciences"},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Orano","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NP137","moa":"Netrin-1","graph1":"Oncology","graph2":"Phase II","graph3":"NETRIS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NETRIS Pharma \/ Orano","highestDevelopmentStatusID":"8","companyTruncated":"NETRIS Pharma \/ Orano"},{"orgOrder":0,"company":"SparingVision","sponsor":"4BIO Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ 4BIO Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ 4BIO Capital"},{"orgOrder":0,"company":"SparingVision","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Jeito Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Jeito Capital"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Goldman Sachs"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"PDC lung01","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Korea Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Korea Investment Partners"},{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Bismuth Potassium Citrate","moa":"||Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Juvise Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Juvise Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Juvise Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rallybio","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB-331","moa":"Matriptase-2","graph1":"Hematology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Rallybio"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Eusa Pharma \/ Recordati"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rona Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Rona Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Rona Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sanofi \/ Gavi","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Gavi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"B7-H3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"B7-H3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"TargEDys","sponsor":"Inoliva","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Hafnia alvei HA4597","moa":"Alpha-MSH","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"TargEDys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TargEDys \/ Inoliva","highestDevelopmentStatusID":"15","companyTruncated":"TargEDys \/ Inoliva"},{"orgOrder":0,"company":"Sensorion","sponsor":"Institut Pasteur","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"OTOF-GT","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Institut Pasteur","highestDevelopmentStatusID":"4","companyTruncated":"Sensorion \/ Institut Pasteur"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Financing","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Soleus Capital","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Soleus Capital"},{"orgOrder":0,"company":"Stimunity","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"STI-001","moa":"STING","graph1":"Oncology","graph2":"Preclinical","graph3":"Stimunity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Stimunity \/ Portage Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Stimunity \/ Portage Biotech"},{"orgOrder":0,"company":"Pherecydes Pharma","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pherecydes Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Pherecydes Pharma \/ Erytech Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pherecydes Pharma \/ Erytech Pharma"},{"orgOrder":0,"company":"Poxel","sponsor":"Sumitomo Dainippon Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Poxel \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Termination","leadProduct":"Canerpaturev","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Takara Bio \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ European Investment Bank"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"BrainVectis","sponsor":"Asklepios BioPharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"BV-CYP01","moa":"CYP46A1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"BrainVectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrainVectis \/ Asklepios BioPharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"BrainVectis \/ Asklepios BioPharmaceutical"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Adare Biome","sponsor":"Royal DSM","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Acquisition","leadProduct":"Lactobacillus LB","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adare Biome","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adare Biome \/ Royal DSM","highestDevelopmentStatusID":"15","companyTruncated":"Adare Biome \/ Royal DSM"},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Neuraxpharm"},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Undisclosed"},{"orgOrder":0,"company":"Seqens","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Seqens","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seqens \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Seqens \/ Biophytis"},{"orgOrder":0,"company":"Vetophage","sponsor":"Phaxiam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vetophage","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vetophage \/ Phaxiam Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Vetophage \/ Phaxiam Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Fidia Farmaceutici Spa","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Fidia Farmaceutici Spa"},{"orgOrder":0,"company":"Genfit","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Ipsen"},{"orgOrder":0,"company":"Lysogene","sponsor":"Weizmann Institute of Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Lysogene \/ Weizmann Institute of Science","highestDevelopmentStatusID":"1","companyTruncated":"Lysogene \/ Weizmann Institute of Science"},{"orgOrder":0,"company":"LinKinVax","sponsor":"GTP Bioways","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"COVID-19 Anti-CD40.COV2 Vaccine","moa":"CD40","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LinKinVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LinKinVax \/ GTP Bioways","highestDevelopmentStatusID":"4","companyTruncated":"LinKinVax \/ GTP Bioways"},{"orgOrder":0,"company":"Sanofi","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Private Placement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Onxeo","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Niraparib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Gustave Roussy"},{"orgOrder":0,"company":"Sanofi","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Meiji Seika Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"EUROAPI","sponsor":"Priothera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Mocravimod","moa":"S1PR","graph1":"Oncology","graph2":"Phase III","graph3":"EUROAPI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EUROAPI \/ Priothera","highestDevelopmentStatusID":"10","companyTruncated":"EUROAPI \/ Priothera"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"BI 754091","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"CellProthera","sponsor":"BioCardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CellProthera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellProthera \/ BioCardia","highestDevelopmentStatusID":"8","companyTruncated":"CellProthera \/ BioCardia"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Plerixafor","moa":"CXCR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"4P-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"4P-Pharma \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"4P-Pharma \/ Sanofi"},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Gustave Roussy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gustave Roussy \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Gustave Roussy \/ Daiichi Sankyo"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Invectys","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"IVS-3001","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invectys \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Institute of Neurodegenerative Diseases of Bordeaux","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CTx-TFEB","moa":"TFEB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ Institute of Neurodegenerative Diseases of Bordeaux","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ Institute of Neurodegenerative Diseases of Bordeaux"},{"orgOrder":0,"company":"Diabeloop","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2023","type":"Collaboration","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Diabeloop","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Diabeloop \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Diabeloop \/ Novo Nordisk"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"K-NK-ID101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Poxel","sponsor":"Sumitomo Dainippon Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Poxel \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Novadiscovery","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Novadiscovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Novadiscovery \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Novadiscovery \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Goldman Sachs"},{"orgOrder":0,"company":"Argobio","sponsor":"Oncode Bridge Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Argobio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Argobio \/ Oncode Bridge Fund","highestDevelopmentStatusID":"3","companyTruncated":"Argobio \/ Oncode Bridge Fund"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Samsara BioCapital"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Jefferies LLC"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Jefferies"},{"orgOrder":0,"company":"Ermium Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"CXCR4 receptor","graph1":"Immunology","graph2":"Discovery","graph3":"Ermium Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ermium Therapeutics \/ Kurma Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ermium Therapeutics \/ Kurma Partners"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ European Investment Bank"},{"orgOrder":0,"company":"Cellectis","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"UCART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Jefferies LLC","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Jefferies LLC"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ European Investment Bank"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ European Investment Bank"},{"orgOrder":0,"company":"Nicox SA","sponsor":"HBM Healthcare Investments","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Private Placement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ HBM Healthcare Investments","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ HBM Healthcare Investments"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Qatar Holding","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Qatar Holding","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Qatar Holding"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kreos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Kreos","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ Kreos"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Gho Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Divestment","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Gho Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Gho Capital"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Skyepharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Skyepharma","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Skyepharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Bpifrance"},{"orgOrder":0,"company":"Adcytherix","sponsor":"Pontifax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Adcytherix","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adcytherix \/ Pontifax","highestDevelopmentStatusID":"2","companyTruncated":"Adcytherix \/ Pontifax"},{"orgOrder":0,"company":"Biophytis","sponsor":"ATLAS PHARMS LLC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ ATLAS PHARMS LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ ATLAS PHARMS LLC"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Redmile Group"},{"orgOrder":0,"company":"Biophta","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Biophta \/ HTL Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Biophta \/ HTL Biotechnology"},{"orgOrder":0,"company":"Biophta","sponsor":"UI Investissement","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Biophta \/ UI Investissement","highestDevelopmentStatusID":"4","companyTruncated":"Biophta \/ UI Investissement"},{"orgOrder":0,"company":"Crossject","sponsor":"Heights Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Heights Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Heights Capital Management"},{"orgOrder":0,"company":"Pharnext","sponsor":"Neovacs","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Neovacs","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Neovacs"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4P-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4P-Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"4P-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"EB005","moa":"Microbiome","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Eligo Bioscience \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Hsbc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Hsbc","highestDevelopmentStatusID":"9","companyTruncated":"Nanobiotix \/ Hsbc"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"IFLI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"IPH6501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ IFLI","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ IFLI"},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"Capital Grand Est","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Financing","leadProduct":"ODI-2001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Odimma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Odimma Therapeutics \/ Capital Grand Est","highestDevelopmentStatusID":"4","companyTruncated":"Odimma Therapeutics \/ Capital Grand Est"},{"orgOrder":0,"company":"Valneva","sponsor":"Scottish Enterprise","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Scottish Enterprise","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Scottish Enterprise"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Bpifrance"},{"orgOrder":0,"company":"Antabio","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"ANT3310","moa":"||Serine beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Antabio \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Bpifrance"},{"orgOrder":0,"company":"Antabio","sponsor":"Carb-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Pseudomonas elastase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Antabio \/ Carb-X","highestDevelopmentStatusID":"1","companyTruncated":"Antabio \/ Carb-X"},{"orgOrder":0,"company":"VECT-HORUS","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2021","type":"Series D Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VECT-HORUS","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VECT-HORUS \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VECT-HORUS \/ Undisclosed"},{"orgOrder":0,"company":"PK MED","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"PKM-02","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"PK MED","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PK MED \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"PK MED \/ Bpifrance"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Financing","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OSE2101","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Bpifrance"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Funding","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Bpifrance"},{"orgOrder":0,"company":"EG 427","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"EG110A","moa":"Undisclosed","graph1":"Urology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EG 427 \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"INO-02","moa":"TREM-1","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Funding","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Bpifrance"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Pasteur Institute","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pasteur Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasteur Institute \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Pasteur Institute \/ Vingroup Innovation Foundation"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Funding","leadProduct":"PATAS","moa":"ALMS1","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"Osivax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"CTx-TFEB","moa":"TFEB","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"ICT01","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"Osivax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Osivax \/ National Institutes of Health"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"INO-02","moa":"TREM-1","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Valneva","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ CEPI","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ CEPI"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Angelor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ Angelor","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ Angelor"},{"orgOrder":0,"company":"MedinCell","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Hormone","year":"2022","type":"Funding","leadProduct":"Progesterone","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MedinCell \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Cryostem","sponsor":"Rheos Medicines","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cryostem","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cryostem \/ Rheos Medicines","highestDevelopmentStatusID":"5","companyTruncated":"Cryostem \/ Rheos Medicines"},{"orgOrder":0,"company":"MedinCell","sponsor":"Unitaid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Unitaid","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Unitaid"},{"orgOrder":0,"company":"Osivax","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ European Innovation Council","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ European Innovation Council"},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Valneva","sponsor":"Kingdom of Bahrain","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Kingdom of Bahrain","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Kingdom of Bahrain"},{"orgOrder":0,"company":"MedinCell","sponsor":"Unitaid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Unitaid","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Unitaid"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Relyens Innovation Sant\u00e9","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Relyens Innovation Sant\u00e9","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Relyens Innovation Sant\u00e9"},{"orgOrder":0,"company":"Smart Immune","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Smart Immune \/ European Innovation Council","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ European Innovation Council"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"BioWin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDC*line Pharma \/ BioWin","highestDevelopmentStatusID":"4","companyTruncated":"PDC*line Pharma \/ BioWin"},{"orgOrder":0,"company":"Crossject","sponsor":"Gemmes Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Gemmes Venture","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Gemmes Venture"},{"orgOrder":0,"company":"Onxeo","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Belinostat","moa":"HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Onxeo \/ Acrotech Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Onxeo \/ Acrotech Biopharma"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Large Molecule","year":"2023","type":"Merger","leadProduct":"PhagoDAIR","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Phaxiam Therapeutics \/ Erytech Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Therapeutics \/ Erytech Pharma"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Smart Immune \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"French National Institute of Health and Medical Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Magnesium Potentiated Oxytocin","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"French National Institute of Health and Medical Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"French National Institute of Health and Medical Research \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"5","companyTruncated":"French National Institute of Health and Medical Research \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"BB Pureos Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"ICT01","moa":"BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ BB Pureos Bioventures","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ BB Pureos Bioventures"},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"TREM-1","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ Crohn\u2019s & Colitis Foundation"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"French Blood Establishment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ French Blood Establishment","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ French Blood Establishment"},{"orgOrder":0,"company":"Seqens","sponsor":"Smart Immune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seqens","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seqens \/ Smart Immune","highestDevelopmentStatusID":"7","companyTruncated":"Seqens \/ Smart Immune"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"The Dion Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atamyo Therapeutics \/ The Dion Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ The Dion Foundation"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Diverchim S.A.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Agreement","leadProduct":"Nicotine","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Diverchim S.A.","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Diverchim S.A."},{"orgOrder":0,"company":"Lysarc","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Lysarc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lysarc \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"Lysarc \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncodesign","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Oncodesign \/ Servier"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EORTC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pierre Fabre \/ EORTC","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ EORTC"},{"orgOrder":0,"company":"Fillmed Laboratories","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fillmed Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fillmed Laboratories \/ Crescita Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Fillmed Laboratories \/ Crescita Therapeutics"},{"orgOrder":0,"company":"Takara Bio","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"BNT211","moa":"CLDN6","graph1":"Oncology","graph2":"Preclinical","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takara Bio \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Takara Bio \/ BioNTech"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Private Placement","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Kreos Capital"},{"orgOrder":0,"company":"DiogenX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"DiogenX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DiogenX \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"DiogenX \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Hadean Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Preclinical","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Step Pharma \/ Hadean Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Step Pharma \/ Hadean Ventures"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Earlybird","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Series C Financing","leadProduct":"ICT01","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Earlybird","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Earlybird"},{"orgOrder":0,"company":"HEPHAISTOS-Pharma","sponsor":"Xista Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Onco-Boost","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HEPHAISTOS-Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"HEPHAISTOS-Pharma \/ Xista Science Ventures","highestDevelopmentStatusID":"5","companyTruncated":"HEPHAISTOS-Pharma \/ Xista Science Ventures"},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Crossject","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Bpifrance","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Bpifrance"},{"orgOrder":0,"company":"Mnemo Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Mnemo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mnemo Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"3","companyTruncated":"Mnemo Therapeutics \/ Casdin Capital"},{"orgOrder":0,"company":"Alderaan Biotechnology","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD25","graph1":"Oncology","graph2":"Preclinical","graph3":"Alderaan Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alderaan Biotechnology \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alderaan Biotechnology \/ Medicxi"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"Inolimomab","moa":"IL-2-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ElsaLys Biotech \/ Bpifrance","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Bpifrance"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Ribonexus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"K01401","moa":"eIF4A","graph1":"Oncology","graph2":"Preclinical","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Ribonexus","highestDevelopmentStatusID":"4","companyTruncated":"Pierre Fabre \/ Ribonexus"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"ORI-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Translate Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ Translate Bio"},{"orgOrder":0,"company":"Poxel","sponsor":"Jmp Securities","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Poxel \/ Jmp Securities","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Jmp Securities"},{"orgOrder":0,"company":"Sanofi","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sanofi \/ European Union","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ European Union"},{"orgOrder":0,"company":"Sanofi","sponsor":"UK government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sanofi \/ UK government","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ UK government"},{"orgOrder":0,"company":"Seekyo","sponsor":"French Tech Seed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Funding","leadProduct":"SKY01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Seekyo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seekyo \/ French Tech Seed","highestDevelopmentStatusID":"4","companyTruncated":"Seekyo \/ French Tech Seed"},{"orgOrder":0,"company":"Ciloa","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Exosome-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ciloa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ciloa \/ Bpifrance","highestDevelopmentStatusID":"1","companyTruncated":"Ciloa \/ Bpifrance"},{"orgOrder":0,"company":"Institute of Cardiovascular and Metabolic Diseases","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Institute of Cardiovascular and Metabolic Diseases","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Cardiovascular and Metabolic Diseases \/ CSL","highestDevelopmentStatusID":"2","companyTruncated":"Institute of Cardiovascular and Metabolic Diseases \/ CSL"},{"orgOrder":0,"company":"Inserm","sponsor":"T.H.A.C.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"ALF-5755","moa":"ROS","graph1":"Endocrinology","graph2":"Phase I","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ T.H.A.C.","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ T.H.A.C."},{"orgOrder":0,"company":"Sanofi","sponsor":"Rancho Santa Fe Bio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ataciguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Rancho Santa Fe Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Rancho Santa Fe Bio"},{"orgOrder":0,"company":"Biose Industrie","sponsor":"Biomica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Agreement","leadProduct":"BMC121","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biose Industrie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biose Industrie \/ Biomica","highestDevelopmentStatusID":"4","companyTruncated":"Biose Industrie \/ Biomica"},{"orgOrder":0,"company":"AB Science","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ European Investment Bank","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ European Investment Bank"},{"orgOrder":0,"company":"AB Science","sponsor":"University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ University of Chicago","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ University of Chicago"},{"orgOrder":0,"company":"Pharnext","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Alpha Blue Ocean","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Lysogene","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Bpifrance"},{"orgOrder":0,"company":"Mutabilis","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"2G-Dabocins","moa":"Diazabicyclooctanes penicillin-binding proteins","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mutabilis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mutabilis \/ Organovo Holdings","highestDevelopmentStatusID":"2","companyTruncated":"Mutabilis \/ Organovo Holdings"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Tedopi","moa":"||Killer T-cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"1","companyTruncated":"OSE Immunotherapeutics SA \/ European Investment Bank"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"MedinCell","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ The Medicines Patent Pool","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Institut Curie","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"BMX-500","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Institut Curie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Curie \/ Biomunex Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Institut Curie \/ Biomunex Pharmaceutical"},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion \/ Redmile Group"},{"orgOrder":0,"company":"Genfit","sponsor":"Genoscience Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ Genoscience Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ Genoscience Pharma"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Corona Remedies","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Thiocolchicoside","moa":"GABA A receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Corona Remedies","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Corona Remedies"},{"orgOrder":0,"company":"Mablink Bioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Mablink Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mablink Bioscience \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mablink Bioscience \/ Eli Lilly"},{"orgOrder":0,"company":"Medisol","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Medisol","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medisol \/ Lupin Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Medisol \/ Lupin Ltd"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Cilcare","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"CIL001","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Cilcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cilcare \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Cilcare \/ Shionogi"},{"orgOrder":0,"company":"SparingVision","sponsor":"Tenpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"SPVN20","moa":"GIRK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Tenpoint Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SparingVision \/ Tenpoint Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-818","moa":"||Dysregulated protease","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Vir Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Vir Biotechnology"},{"orgOrder":0,"company":"Sanofi","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-818","moa":"||Dysregulated protease","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Vir Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Vir Biotechnology"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"TPM-1116","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"Bioprojet Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioprojet Pharma \/ Harmony Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Bioprojet Pharma \/ Harmony Biosciences"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Kreos Capital"},{"orgOrder":0,"company":"Genkyotex","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genkyotex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genkyotex \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"8","companyTruncated":"Genkyotex \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Transgene","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"Flucytosine","moa":"||FCU1 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Tianjin Tasly Group","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Ethypharm","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ethypharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ethypharm \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ethypharm \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Valneva","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Dynavax Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Dynavax Technologies"},{"orgOrder":0,"company":"Crossject","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ AFT Pharmaceuticals"},{"orgOrder":0,"company":"Horus Pharma","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2023","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Horus Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Horus Pharma \/ Alimera Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Horus Pharma \/ Alimera Sciences"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Amring Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pierre Fabre \/ Amring Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Amring Pharma"},{"orgOrder":0,"company":"Enterome","sponsor":"BIOASTER Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enterome \/ BIOASTER Institute","highestDevelopmentStatusID":"4","companyTruncated":"Enterome \/ BIOASTER Institute"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Hepalys Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Hepalys Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Hepalys Pharma"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ GSK"},{"orgOrder":0,"company":"Phost'in Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PhOx430","moa":"GnT-V","graph1":"Oncology","graph2":"Phase I","graph3":"Phost'in Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phost'in Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Phost'in Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Idazoxan","moa":"Adrenergic alpha-2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pierre Fabre \/ Terran Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Terran Biosciences"},{"orgOrder":0,"company":"TreeFrog Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"TreeFrog Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"TreeFrog Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"TreeFrog Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Iktos","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iktos \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Aqemia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Aqemia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aqemia \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Aqemia \/ Sanofi"},{"orgOrder":0,"company":"Iktos","sponsor":"Curreio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iktos \/ Curreio","highestDevelopmentStatusID":"3","companyTruncated":"Iktos \/ Curreio"},{"orgOrder":0,"company":"Depixus","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Depixus","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Depixus \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Depixus \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Osivax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"OVX836","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ National Institutes of Health"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Valneva","sponsor":"Instituto Butantan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Instituto Butantan","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Instituto Butantan"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NCX 1728","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nicox SA \/ Glaukos","highestDevelopmentStatusID":"4","companyTruncated":"Nicox SA \/ Glaukos"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Corlieve Therapeutics","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"AMT-260","moa":"Kainate receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Corlieve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corlieve Therapeutics \/ Uniqure","highestDevelopmentStatusID":"4","companyTruncated":"Corlieve Therapeutics \/ Uniqure"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Artemis Biotech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Partnership","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Artemis Biotech","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Artemis Biotech"},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellectis \/ Cytovia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectis \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"One Biosciences","sponsor":"AP-HP","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery","graph3":"One Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"One Biosciences \/ AP-HP","highestDevelopmentStatusID":"2","companyTruncated":"One Biosciences \/ AP-HP"},{"orgOrder":0,"company":"Skyepharma","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Skyepharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Skyepharma \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Skyepharma \/ Biophytis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ipsen \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Galderma"},{"orgOrder":0,"company":"Transgene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Transgene \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Transgene \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"NFL Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Agreement","leadProduct":"NFL-301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athena Pharmaceutiques \/ NFL Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Athena Pharmaceutiques \/ NFL Biosciences"},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Faran","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quantum Genomics \/ Faran","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Faran"},{"orgOrder":0,"company":"Sanofi","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Capeserod","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ First Wave BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ First Wave BioPharma"},{"orgOrder":0,"company":"Advicenne","sponsor":"FrostPharma AB","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ FrostPharma AB","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ FrostPharma AB"},{"orgOrder":0,"company":"Intsel Chimos","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Intsel Chimos","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intsel Chimos \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Intsel Chimos \/ Biophytis"},{"orgOrder":0,"company":"Dynacure","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Nippon Shinyaku","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quantum Genomics \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Oncodesign","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Oncodesign \/ Servier"},{"orgOrder":0,"company":"Valneva","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"3-Antigen HBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ VBI Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ VBI Vaccines"},{"orgOrder":0,"company":"Valneva","sponsor":"Batavia Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Batavia Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Valneva \/ Batavia Bioscience"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quantum Genomics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"CEA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Collaboration","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ CEA","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ CEA"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Ensho Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EA Pharma \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"EA Pharma \/ Ensho Therapeutics"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Pharmaleads","sponsor":"IACTA Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"IC 800","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pharmaleads","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Pharmaleads \/ IACTA Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Pharmaleads \/ IACTA Pharmaceuticals"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ABL","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CTx-GBA1","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coave Therapeutics \/ ABL","highestDevelopmentStatusID":"4","companyTruncated":"Coave Therapeutics \/ ABL"},{"orgOrder":0,"company":"Delpharm Group","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"Delpharm Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Delpharm Group \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Delpharm Group \/ First Wave BioPharma"},{"orgOrder":0,"company":"Valneva","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Inactivated Japanese Encephalitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ United States Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ United States Department of Defense"},{"orgOrder":0,"company":"Ipsen","sponsor":"University of Montreal","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipsen \/ University of Montreal","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ University of Montreal"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLA2001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ UK Government","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ UK Government"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Valneva","sponsor":"U.K. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"CpG 1018","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ U.K. Government","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ U.K. Government"},{"orgOrder":0,"company":"Transgene","sponsor":"Vaxxel","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"DuckCelt-T17","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Vaxxel","highestDevelopmentStatusID":"1","companyTruncated":"Transgene \/ Vaxxel"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"VTX-803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivet Therapeutics \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"French Government","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"VTX-806","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivet Therapeutics \/ French Government","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ French Government"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ European Commission"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Sanofi","sponsor":"Laboratoires Delbert","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Lithium Carbonate","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Laboratoires Delbert","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Laboratoires Delbert"},{"orgOrder":0,"company":"Sanofi","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Crossject","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ BARDA"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EB003","moa":"STEC bacteria","graph1":"Hematology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eligo Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sibofimloc","moa":"E.coli fimH protein","graph1":"Immunology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lusvertikimab","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lusvertikimab","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sibofimloc","moa":"E.coli fimH protein","graph1":"Immunology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Allergan Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CER-001","moa":"||APOA-I","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CER-001","moa":"||APOA-I","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"TYK","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"TYK","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Olipudase Alpha","moa":"SMPD1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PP1493","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phaxiam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"4Moving Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI 765063","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine HCl","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","graph1":"Hematology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"||miR-124","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"DNDi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acoziborole","moa":"Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ DNDi","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ DNDi"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Inapplicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Inapplicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"The University of Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acticor Biotech SAS \/ The University of Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Biotech SAS \/ The University of Birmingham"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Inapplicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Inapplicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Inapplicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Inapplicable"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Hydroxylapatite","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"EA Pharma \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"EA Pharma \/ Eisai"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MUC1","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||SER","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Alize\u0301 Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Alize\u0301 Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alize\u0301 Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alize\u0301 Pharma \/ Inapplicable"},{"orgOrder":0,"company":"LFB","sponsor":"HEMA Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eptacog Alpha","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB \/ HEMA Biologics","highestDevelopmentStatusID":"15","companyTruncated":"LFB \/ HEMA Biologics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Translate Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Translate Bio"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Phaxiam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phaxiam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IPH5201","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PP1493","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phaxiam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y, W) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Danone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Iron","moa":"||Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Danone","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"Danone \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Danone \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Neurology","graph2":"Preclinical","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Averoa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Averoa","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Averoa \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Averoa \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Hepatitis A Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alzprotect","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ezeprogind","moa":"Progranulin","graph1":"Neurology","graph2":"Phase II","graph3":"Alzprotect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Alzprotect \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzprotect \/ Inapplicable"},{"orgOrder":0,"company":"Alzprotect","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ezeprogind","moa":"Progranulin","graph1":"Neurology","graph2":"Phase II","graph3":"Alzprotect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alzprotect \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzprotect \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"PeptiDream","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"AZP-3813","moa":"GHR","graph1":"Endocrinology","graph2":"Phase I","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ PeptiDream","highestDevelopmentStatusID":"6","companyTruncated":"Amolyt Pharma \/ PeptiDream"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Xenothera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"XAV-19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xenothera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xenothera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenothera \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nordic Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Theranexus","sponsor":"Beyond Batten Disease Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Miglustat","moa":"Glucosylceramide synthase","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Theranexus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Theranexus \/ Beyond Batten Disease Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Theranexus \/ Beyond Batten Disease Foundation"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI 754091","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 770371","moa":"||SIRP alpha","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"European Organisation for Research and Treatment of Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"BioVaxys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0918A","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ BioVaxys","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ BioVaxys"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"LinKinVax","sponsor":"Gustave Roussy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CD40HVac","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LinKinVax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LinKinVax \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"LinKinVax \/ Gustave Roussy"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCARTCS1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CER-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CER-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CER-001","moa":"||APOA-I","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abionyx Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abionyx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eliglustat","moa":"Glucosylceramide synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"LFB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eptacog Beta","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LFB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LFB \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLRs","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CTx-PDE6b","moa":"PDE6B gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coave Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Merck & Co"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||SER","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"Ethypharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Morphine Sulfate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ethypharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethypharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ethypharm \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CTx-PDE6b","moa":"PDE6B gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Coave Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"CYTOO","sponsor":"Astellas Gene Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CYTOO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CYTOO \/ Astellas Gene Therapies","highestDevelopmentStatusID":"1","companyTruncated":"CYTOO \/ Astellas Gene Therapies"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Protein-Based COVID-19 Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Givosiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Diaccurate","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DIACC2010","moa":"KIF20A","graph1":"Oncology","graph2":"Preclinical","graph3":"Diaccurate","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diaccurate \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Diaccurate \/ Inapplicable"},{"orgOrder":0,"company":"Diaccurate","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DIACC3010","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diaccurate","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diaccurate \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diaccurate \/ Inapplicable"},{"orgOrder":0,"company":"Biocodex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biocodex \/ Inapplicable"},{"orgOrder":0,"company":"Biocodex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biocodex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DNL758","moa":"RIPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Denali Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Denali Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA damage response","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DT-9045","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-9081","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"SER","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pierre Fabre \/ Atara Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Atara Biotherapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"EG 427","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EG110A","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EG 427 \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Inapplicable"},{"orgOrder":0,"company":"EG 427","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EG110A","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EG 427 \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inolimomab","moa":"IL-2-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ElsaLys Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EO2040","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2401","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ Labcorp Drug Development","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EO4010","moa":"||Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"GoLiver Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"GoLiver Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GoLiver Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GoLiver Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Dynacure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexinidazole","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MRT5005","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ABX196","moa":"||Invariant natural killer T-cells","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"KD033","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quantum Genomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"NEC Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TG4050","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ NEC Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ NEC Corporation"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Nantes University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Nantes University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"OSE Immunotherapeutics SA \/ Nantes University Hospital"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Genfit","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Genfit"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"Genethon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GNT-003","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Genethon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genethon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genethon \/ Inapplicable"},{"orgOrder":0,"company":"Genethon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GNT0004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Genethon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genethon \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genethon \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GS030","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Protein-Based COVID-19 Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART20x22","moa":"CD20\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"K-NK002","moa":"CD16","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inolimomab","moa":"IL-2-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ElsaLys Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ElsaLys Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ElsaLys Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inserm","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inserm \/ World Health Organization","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ World Health Organization"},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IPH45","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IPH4502","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IPH5201","moa":"||CD39","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKCE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IPH6501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IPN60090","moa":"||Glutaminase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"PPAR-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"||PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"||PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Invectys","sponsor":"CTMA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IVS-3001","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invectys \/ CTMA","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ CTMA"},{"orgOrder":0,"company":"Invectys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invectys \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ Inapplicable"},{"orgOrder":0,"company":"Invectys","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invectys \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Invectys","sponsor":"CTMC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IVS-3001","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invectys \/ CTMC","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ CTMC"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Kinnov Therapeutics","sponsor":"ECSOR","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cyproheptadine Hydrochloride","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kinnov Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kinnov Therapeutics \/ ECSOR","highestDevelopmentStatusID":"8","companyTruncated":"Kinnov Therapeutics \/ ECSOR"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cross-linked Hyaluronic Acid","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"Nordic Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"||PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Theravectys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Lenti-HPV-07","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theravectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravectys \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theravectys \/ Inapplicable"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Athena Pharmaceutiques \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Athena Pharmaceutiques \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Taiho Oncology"},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Taiho Oncology"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ INRAE"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Gastrointestinal microbiome","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ INRAE"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Gastrointestinal microbiome","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","graph1":"Hematology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||PDGFRA","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||PDGFRA","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Mablink Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MBK-103","moa":"FR alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Mablink Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mablink Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mablink Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"NIHR","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ NIHR","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ NIHR"},{"orgOrder":0,"company":"Antabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ANT3310","moa":"||Serine beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antabio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antabio \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPAR-gamma","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"EA Pharma \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"EA Pharma \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nemera","sponsor":"Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Nemera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nemera \/ Ache Laboratorios Farmaceuticos SA","highestDevelopmentStatusID":"15","companyTruncated":"Nemera \/ Ache Laboratorios Farmaceuticos SA"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tobacco Leaf Extract","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Netrin-1","graph1":"Oncology","graph2":"Phase I","graph3":"NETRIS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NETRIS Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NETRIS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NP137","moa":"||Netrin-1","graph1":"Oncology","graph2":"Phase II","graph3":"NETRIS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NETRIS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NETRIS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Athena Pharmaceutiques","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Athena Pharmaceutiques \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Athena Pharmaceutiques \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OX401","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLEC-1","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lusvertikimab","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"OSE-279","moa":"PD-1R \/IL-7","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"OSE-279","moa":"PD-1R \/IL-7","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OVX033","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OVX033","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inactivated Quadrivalent Influenza Vaccine","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OVX836","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OVX836","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Bioprojet Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bioprojet Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioprojet Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"PDC lung01","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"PEP-010","moa":"Caspase9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"PEP-010","moa":"Caspase9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Scorpion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"STX-241","moa":"C797S","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Scorpion Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pierre Fabre \/ Scorpion Therapeutics"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Phaxiam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phaxiam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"||PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quantum Genomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Inapplicable"},{"orgOrder":0,"company":"SYSNAV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"SYSNAV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"SYSNAV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SYSNAV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"PK MED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"||Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"PK MED","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intra-articular Injection, Prolonged Release","sponsorNew":"PK MED \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PK MED \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Recombinant Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"LFB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eptacog Beta","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LFB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LFB \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"K-NK002","moa":"CD16","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"SER","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Translate Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MRT5500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Translate Bio"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"TOTUM\u2022854","moa":"NOS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valbiotis \/ University of Avignon","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ University of Avignon"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"||VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ICT01","moa":"||BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DaVolterra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DAV132","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"DaVolterra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"DaVolterra \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DaVolterra \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Step Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"PulseSight Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PST-809","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"PulseSight Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PulseSight Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"PulseSight Therapeutics \/ Pureos Bioventures"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Neurology","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Eusa Pharma \/ BeiGene"},{"orgOrder":0,"company":"Antabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ANT3310","moa":"||Serine beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MRT5005","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PDC lung01","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PDC*line Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Niraparib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Evexta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rupitasertib","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Evexta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evexta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evexta Bio \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tusamitamab Ravtansine","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Translate Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MRT5400","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Translate Bio"},{"orgOrder":0,"company":"Sanofi","sponsor":"Translate Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MRT5400","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Translate Bio"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inactivated Poliomyelitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tusamitamab Ravtansine","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Frexalimab","moa":"CD40L","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Frexalimab","moa":"CD40L","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Frexalimab","moa":"CD40L","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKCE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexatamig","moa":"NKCE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Riliprubart","moa":"C1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IPH6401","moa":"NKp46\/CD16 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Intsel Chimos","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Intsel Chimos","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Intsel Chimos"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Cochlear Limited","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Cochlear Limited","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Cochlear Limited"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Association for Research in Otolaryngology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Association for Research in Otolaryngology","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Association for Research in Otolaryngology"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"LimmaTech Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Shigella4V2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ LimmaTech Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ LimmaTech Biologics"},{"orgOrder":0,"company":"Valneva","sponsor":"LimmaTech Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Shigella4V2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ LimmaTech Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ LimmaTech Biologics"},{"orgOrder":0,"company":"Advicenne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Advicenne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advicenne \/ Inapplicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Smart Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Inapplicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Smart Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Inapplicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Smart Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Inapplicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Smart Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Inapplicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Smart Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"MedDay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Biotin","moa":"Krebs cycle activatior","graph1":"Neurology","graph2":"Phase III","graph3":"MedDay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MedDay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MedDay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL gene","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"STC-1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brenus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brenus Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Brenus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Step Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STP938","moa":"CTPS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Step Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Recombinant Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Laboratoires Thea \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratoires Thea \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MUC1","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"OSE2101","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OSE2101","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OSE2101","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DTaP-IPV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TG4050","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"IUCT-Oncopole","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ IUCT-Oncopole","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ IUCT-Oncopole"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TG6050","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TG6050","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BiCKI-IL-7","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Filgrastim","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quantum Genomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Merck Group"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Isatuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Nangibotide","moa":"TREM-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"LinKinVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CD40.HIVRI.Env","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"LinKinVax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LinKinVax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LinKinVax \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amolyt Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EB003","moa":"STEC bacteria","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eligo Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OX401","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Themis Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MV-SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Themis Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Institut Pasteur \/ Themis Bioscience"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GS030","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odiparcil","moa":"Glycosaminoglycans","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quantum Genomics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"SER","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ICT01","moa":"BTN3A\/gamma 9-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tipapkinogen sovacivec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Transgene \/ Merck Group"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA damage response","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Protein-Based COVID-19 Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Alzprotect","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ezeprogind","moa":"Progranulin","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzprotect","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alzprotect \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alzprotect \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Genkyotex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genkyotex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genkyotex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genkyotex \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MRT5500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"TG6002","moa":"FCU1 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"SER","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odiparcil","moa":"Glycosaminoglycans","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||SER","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"IDUA gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"RAR-gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Medsenic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medsenic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FXS01","moa":"DGKk","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y, W) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odiparcil","moa":"Glycosaminoglycans","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"TOTUM\u2022854","moa":"NOS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ University of Avignon","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ University of Avignon"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Lyon Sud Hospital Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Lyon Sud Hospital Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyon Sud Hospital Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyon Sud Hospital Center \/ Inapplicable"},{"orgOrder":0,"company":"Smart Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SMART101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Smart Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immune \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venglustat","moa":"Glycosphingolipid pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB8939","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Arcagy Gineco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Arcagy Gineco","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Arcagy Gineco"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sutimlimab","moa":"C1 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fexinidazole","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||FCU1 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCARTCS1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Dynacure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Inapplicable"},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Glenzocimab","moa":"GPVI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Biotech SAS \/ Inapplicable"},{"orgOrder":0,"company":"Invectys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INVAC-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invectys \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invectys \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene \/ BioInvent"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Niraparib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Genkyotex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Genkyotex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genkyotex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genkyotex \/ Inapplicable"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"SGS Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ SGS Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Biophytis \/ SGS Life Sciences"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Theranexus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Donepezil","moa":"||AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Theranexus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Theranexus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theranexus \/ Inapplicable"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Synthorx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"THOR-707","moa":"||Non-alpha IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImCheck Therapeutics \/ Synthorx","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Synthorx"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||AMY1\/CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Mission Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Mission Bio","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Mission Bio"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"TOTUM\u2022854","moa":"NOS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"INAF","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ INAF","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ INAF"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TG4050","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Brainever","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Homeoprotein Engrailed 1","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Brainever","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brainever \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Brainever \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amitriptyline","moa":"Serotonin transporter","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Dynacure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART20x22","moa":"CD20\/22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine TetraHCl","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Variant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VAR002","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Variant","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Variant \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Variant \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DTwP Hib","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Rabies Vaccine, Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Monovalent COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Monovalent Recombinant-protein COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Protein Monovalent COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Monovalent COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VLA1601","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VLA2001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Whole-virus Inactivated SARS-CoV-2 Vaccine, Adjuvanted","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CpG 1018","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA2001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VTX-801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivet Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VTX-801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VTX-803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VTX-806","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Vaccinia virus Copenhagen Strain","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Bioprojet Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bioprojet Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioprojet Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Crossject","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"\u0394TRACCAR\u0394B2MHLAE","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Servier","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Servier \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Hepalys Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Hepalys Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Hepalys Pharma"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Viaskin Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"DBV Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DBV Technologies \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"||Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Inapplicable"},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherapeutix \/ Inapplicable"},{"orgOrder":0,"company":"EG 427","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EG110A","moa":"Botulinum toxin fragment","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"EG 427","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"EG 427 \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EG 427 \/ Inapplicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterome \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"ExPEC9V","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Genethon","sponsor":"Hansa Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GNT-0003","moa":"UGT1A1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Genethon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genethon \/ Hansa Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Genethon \/ Hansa Biopharma"},{"orgOrder":0,"company":"EyeDNA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAV2\/5-hPDE6B","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeDNA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"EyeDNA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EyeDNA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IPH4502","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Chikungunya Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Valneva \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"MTND4 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"||Tumor cell lysis","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Inapplicable"},{"orgOrder":0,"company":"PulseSight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PST-611","moa":"Transferrin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"PulseSight Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PulseSight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PulseSight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deuterated Pioglitazone","moa":"ACSL4\/MPC","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"Sensorion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OTOF-GT","moa":"OTOF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Sensorion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensorion \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"OSE2101","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OSE2101","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Richard E. Uihlein","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Richard E. Uihlein","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Richard E. Uihlein"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GEORGIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belapectin","moa":"||Galectin-3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GEORGIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GEORGIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GEORGIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GEORGIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GEORGIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Catumaxomab","moa":"EpCAM\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Lindis Biotech \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Lindis Biotech \/ Pharmanovia"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2025","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Grunenthal \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Grunenthal \/ Apotex Inc"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Torrent Pharmaceuticals Limited"},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Klinge Pharma \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Klinge Pharma \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Klinge Pharma \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Klinge Pharma \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Lavipharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Paracetamol","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Lavipharm","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Lavipharm"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Viking Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2025","type":"Partnership","leadProduct":"VK2735","moa":"GLP-1R\/GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CordenPharma \/ Viking Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CordenPharma \/ Viking Therapeutics"},{"orgOrder":0,"company":"Glycotope","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Acquisition","leadProduct":"DS-3939","moa":"TA-MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycotope","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycotope \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Glycotope \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"177Lu-Satoreotide Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics"},{"orgOrder":0,"company":"Eleva","sponsor":"3PBIOVIAN","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Factor H","moa":"CFH","graph1":"Nephrology","graph2":"Preclinical","graph3":"Eleva","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eleva \/ 3PBIOVIAN","highestDevelopmentStatusID":"4","companyTruncated":"Eleva \/ 3PBIOVIAN"},{"orgOrder":0,"company":"Evotec","sponsor":"Korea Institute of Advanced Technology","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Antibody","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Korea Institute of Advanced Technology","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Korea Institute of Advanced Technology"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"InflaRx","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Guggenheim Securities"},{"orgOrder":0,"company":"InflaRx","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Guggenheim Securities"},{"orgOrder":0,"company":"Cellex Cell Professionals","sponsor":"Swarm Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellex Cell Professionals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellex Cell Professionals \/ Swarm Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Cellex Cell Professionals \/ Swarm Oncology"},{"orgOrder":0,"company":"GQ Bio Therapeutics","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"GQ-501","moa":"PRG4","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"GQ Bio Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.029999999999999999,"dosageForm":"Intra-articular Injection","sponsorNew":"GQ Bio Therapeutics \/ Pacira BioSciences","highestDevelopmentStatusID":"5","companyTruncated":"GQ Bio Therapeutics \/ Pacira BioSciences"},{"orgOrder":0,"company":"Medigene","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ EpimAb Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ EpimAb Biotherapeutics"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Agreement","leadProduct":"225-Ac Satoreotide Tetraxetan","moa":"SSTR2","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Ariceum Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Ariceum Therapeutics"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Catumaxomab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindis Biotech \/ Pharmanovia","highestDevelopmentStatusID":"10","companyTruncated":"Lindis Biotech \/ Pharmanovia"},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Candesartan Cilexetil","moa":"||AT1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Apontis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Apontis Pharma \/ Midas Pharma"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Incyte Corporation"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Acquisition","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Bisoprolol Fumarate","moa":"||ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Apontis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Apontis Pharma \/ Midas Pharma"},{"orgOrder":0,"company":"Evotec","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Pfizer Inc"},{"orgOrder":0,"company":"Axplora","sponsor":"Sensorion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"OTOF-GT","moa":"||Otoferlin protein producer","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axplora \/ Sensorion","highestDevelopmentStatusID":"4","companyTruncated":"Axplora \/ Sensorion"},{"orgOrder":0,"company":"PolyMedics Innovations","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"PolyMedics Innovations","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PolyMedics Innovations \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"PolyMedics Innovations \/ MediWound"},{"orgOrder":0,"company":"Merck Group","sponsor":"4D Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ 4D Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ 4D Pharma"},{"orgOrder":0,"company":"Merck Group","sponsor":"4D Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"||TLR5","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck Group \/ 4D Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Merck Group \/ 4D Pharma"},{"orgOrder":0,"company":"CureVac","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Oncology","graph2":"Discovery","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"CureVac \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"EVT8683","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Charit\u00e9 Universit\u00e4tsmedizin","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Adrenergic-beta 1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Charit\u00e9 Universit\u00e4tsmedizin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charit\u00e9 Universit\u00e4tsmedizin \/ Actimed Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Charit\u00e9 Universit\u00e4tsmedizin \/ Actimed Therapeutics"},{"orgOrder":0,"company":"ABX Advanced Biochemical Compounds","sponsor":"Endocyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"ABX Advanced Biochemical Compounds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ABX Advanced Biochemical Compounds \/ Endocyte","highestDevelopmentStatusID":"15","companyTruncated":"ABX Advanced Biochemical Compounds \/ Endocyte"},{"orgOrder":0,"company":"MolGenie","sponsor":"OntoChem","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MolGenie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"MolGenie \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"MolGenie \/ OntoChem"},{"orgOrder":0,"company":"MODAG","sponsor":"The Michael J. Fox Foundation For Parkinson'S Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Anle138b","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"MODAG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MODAG \/ The Michael J. Fox Foundation For Parkinson'S Research","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ The Michael J. Fox Foundation For Parkinson'S Research"},{"orgOrder":0,"company":"TME Pharma","sponsor":"ATLAS PHARMS LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Financing","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ ATLAS PHARMS LLC","highestDevelopmentStatusID":"8","companyTruncated":"TME Pharma \/ ATLAS PHARMS LLC"},{"orgOrder":0,"company":"Merck Group","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Exelixis"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Bayer AG","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"Heme polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ U.S. Government","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ U.S. Government"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Fosnetupitant Chloride","moa":"||NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Berlin Chemie \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Berlin Chemie \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"BioNTech","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"BNT165e","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ CEPI"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"BioNTech","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"BioNTech","sponsor":"U.S. government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ U.S. government","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ U.S. government"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"BioNTech","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ German Federal Ministry of Education and Research","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Quallent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Curetis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curetis \/ BioVersys AG","highestDevelopmentStatusID":"6","companyTruncated":"Curetis \/ BioVersys AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"BWXT Medical Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ BWXT Medical Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ BWXT Medical Ltd."},{"orgOrder":0,"company":"Glycotope","sponsor":"Byondis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"GlycoTarget","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glycotope \/ Byondis","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ Byondis"},{"orgOrder":0,"company":"Captain T Cell","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captain T Cell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captain T Cell \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Captain T Cell \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Cara Care","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Hyoscine Butyl Bromide","moa":"M3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cara Care","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cara Care \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Cara Care \/ Sanofi"},{"orgOrder":0,"company":"Cevec","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cevec \/ Carisma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Omeprazole","moa":"||K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Carlin Consumer Health","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Carlin Consumer Health"},{"orgOrder":0,"company":"CatalYm","sponsor":"Vesalius Biocapital III","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Visugromab","moa":"GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Vesalius Biocapital III","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Vesalius Biocapital III"},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centogene \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Centogene \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CordenPharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CordenPharma \/ Revolo Biotherapeutics"},{"orgOrder":0,"company":"CureVac","sponsor":"Tesla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Tesla","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Tesla"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bayer AG \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"CV0501","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Immatics","sponsor":"Arya Sciences Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immatics \/ Arya Sciences Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ Arya Sciences Acquisition Corp"},{"orgOrder":0,"company":"BioNTech","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ European Investment Bank","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ European Investment Bank"},{"orgOrder":0,"company":"Ethris","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"ETH45","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Cipla","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Cipla"},{"orgOrder":0,"company":"Ethris","sponsor":"DIOSynVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ethris \/ DIOSynVax","highestDevelopmentStatusID":"4","companyTruncated":"Ethris \/ DIOSynVax"},{"orgOrder":0,"company":"Evonik","sponsor":"Cassava Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase II","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evonik \/ Cassava Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Evonik \/ Cassava Sciences"},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"EVT801","moa":"VEGFR3","graph1":"Oncology","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evotec \/ Kazia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"EVT8683","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Merck Group","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pimasertib","moa":"||MEK1\/2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Koate DVI","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ WuXi Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ WuXi Biologics"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Treeway","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Treeway","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Treeway"},{"orgOrder":0,"company":"Schreiner MediPharm","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Schreiner MediPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Syringe","sponsorNew":"Schreiner MediPharm \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Schreiner MediPharm \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"FundaMental Pharma","sponsor":"BGV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"FundaMental Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FundaMental Pharma \/ BGV","highestDevelopmentStatusID":"4","companyTruncated":"FundaMental Pharma \/ BGV"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"ELSA Eckert Life Science Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Pentixafor","moa":"CXCR4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ ELSA Eckert Life Science Accelerator","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPharm \/ ELSA Eckert Life Science Accelerator"},{"orgOrder":0,"company":"CureVac","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ German Federal Ministry of Education and Research","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2020","type":"Agreement","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Point Biopharma"},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Klinge Pharma \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Klinge Pharma \/ Coherus Biosciences"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ G1 Therapeutics, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ G1 Therapeutics, Inc"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grunenthal \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Grunenthal \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Immatics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immatics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ GSK"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"University of Goettingen","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Goettingen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Goettingen \/ Iksuda Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of Goettingen \/ Iksuda Therapeutics"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"177-Lu DOTA","moa":"||GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Y-mAbs Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ Y-mAbs Therapeutics"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Endocyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2020","type":"Agreement","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotope Technologies Munich \/ Endocyte","highestDevelopmentStatusID":"15","companyTruncated":"Isotope Technologies Munich \/ Endocyte"},{"orgOrder":0,"company":"Evonik","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evonik \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Evonik \/ BioNTech"},{"orgOrder":0,"company":"Evonik","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Evonik \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Evonik \/ BARDA"},{"orgOrder":0,"company":"LTS","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"LTS \/ Livzon Pharmaceutical Group","highestDevelopmentStatusID":"4","companyTruncated":"LTS \/ Livzon Pharmaceutical Group"},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Medac","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medac \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"BioMed X","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"DNA damage response","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioMed X","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioMed X \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"BioMed X \/ Merck Group"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"8","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Merck Group","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck Group \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ Incyte Corporation","highestDevelopmentStatusID":"9","companyTruncated":"MorphoSys \/ Incyte Corporation"},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"MS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Klinge Pharma \/ MS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Klinge Pharma \/ MS Pharma"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Mustang Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirion Biotech \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Sirion Biotech \/ Mustang Bio"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bayer AG \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Grunenthal"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bayer AG \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Grunenthal"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Icahn School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Icahn School of Medicine"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Vifor Pharma"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Secarna Pharma \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Pharma \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Pasithea Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Pasithea Therapeutics"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Premier"},{"orgOrder":0,"company":"AiCuris","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AiCuris \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AiCuris \/ Royalty Pharma"},{"orgOrder":0,"company":"ProBioGen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Glymaxx","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProBioGen \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"ProBioGen \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"ProBioGen","sponsor":"ImmunOs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2023","type":"Partnership","leadProduct":"IOS-1002","moa":"||LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"Phase I","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ProBioGen \/ ImmunOs Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"ProBioGen \/ ImmunOs Therapeutics"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProBioGen \/ Heidelberg Pharma","highestDevelopmentStatusID":"4","companyTruncated":"ProBioGen \/ Heidelberg Pharma"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Asher Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProBioGen \/ Asher Bio","highestDevelopmentStatusID":"5","companyTruncated":"ProBioGen \/ Asher Bio"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2020","type":"Series C Financing","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Pontifax Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2021","type":"Series A Financing","leadProduct":"ETx-22","moa":"Nectin-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergence Therapeutics \/ Pontifax Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Emergence Therapeutics \/ Pontifax Venture Capital"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Bayer AG"},{"orgOrder":0,"company":"Qiagen","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qiagen \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Qiagen \/ Amgen Inc"},{"orgOrder":0,"company":"Qiagen","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT113","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Qiagen \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Qiagen \/ BioNTech"},{"orgOrder":0,"company":"Qiagen","sponsor":"OncXerna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qiagen \/ OncXerna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Qiagen \/ OncXerna Therapeutics"},{"orgOrder":0,"company":"Qiagen","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qiagen \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Recognify Life Sciences","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"RL-007","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Recognify Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recognify Life Sciences \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Recognify Life Sciences \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Medigene","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Rentschler Biopharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rentschler Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rentschler Biopharma \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Rentschler Biopharma \/ BioNTech"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"InfectoPharm Drugs and Consilium \/ Societal CDMO","highestDevelopmentStatusID":"15","companyTruncated":"InfectoPharm Drugs and Consilium \/ Societal CDMO"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MorphoSys \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Royalty Pharma"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirion Biotech \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Sirion Biotech \/ Sanofi"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Achilles Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Secarna Pharma \/ Achilles Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Secarna Pharma \/ Achilles Therapeutics"},{"orgOrder":0,"company":"Tacalyx","sponsor":"Thuja Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TCX-101","moa":"TACA","graph1":"Oncology","graph2":"Preclinical","graph3":"Tacalyx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tacalyx \/ Thuja Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tacalyx \/ Thuja Capital"},{"orgOrder":0,"company":"Zedira","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"TAK-227","moa":"TG2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zedira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zedira \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Zedira \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"177-Lu","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"4SC AG","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase II","graph3":"4SC AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"4SC AG \/ Immunic Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"4SC AG \/ Immunic Therapeutics"},{"orgOrder":0,"company":"Labor Dr. Merk & Kollegen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Labor Dr. Merk & Kollegen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Labor Dr. Merk & Kollegen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Labor Dr. Merk & Kollegen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MYR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MYR Pharmaceuticals \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"MYR Pharmaceuticals \/ Gilead Sciences"},{"orgOrder":0,"company":"Novasep","sponsor":"Sensorion","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"OTOF-GT","moa":"Otoferlin protein producer","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Novasep","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Novasep \/ Sensorion","highestDevelopmentStatusID":"4","companyTruncated":"Novasep \/ Sensorion"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Glycotope","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glycotope \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ Evotec"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"3B Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"3B Pharmaceuticals \/ ARTBIO","highestDevelopmentStatusID":"4","companyTruncated":"3B Pharmaceuticals \/ ARTBIO"},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glycotope \/ LegoChem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Max Planck","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Max Planck","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Max Planck \/ Scinai Immunotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck \/ Scinai Immunotherapeutics"},{"orgOrder":0,"company":"Tubulis","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tubulis \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Gilead Sciences"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"FAP-2286","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"3B Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3B Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"3B Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Grunenthal \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Shionogi"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Technical University of Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Isotope Technologies Munich \/ Technical University of Munich","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Technical University of Munich"},{"orgOrder":0,"company":"CureVac","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ CEPI"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CordenPharma \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CordenPharma \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Erdal","sponsor":"ActoPharma","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||SARS-CoV-2-viral spike protein","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Erdal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erdal \/ ActoPharma","highestDevelopmentStatusID":"1","companyTruncated":"Erdal \/ ActoPharma"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Emapticap pegol","moa":"CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Caeregen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"CTR-107","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Wacker Chemie AG \/ Caeregen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Wacker Chemie AG \/ Caeregen Therapeutics"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Merck Group","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2021","type":"Collaboration","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"||PSMA","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck Group \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Merck Group \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Secarna Pharma \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Pharma \/ Orbit Discovery"},{"orgOrder":0,"company":"Glycotope","sponsor":"Max Delbr\u00fcck Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ Max Delbr\u00fcck Center","highestDevelopmentStatusID":"4","companyTruncated":"Glycotope \/ Max Delbr\u00fcck Center"},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bayer AG"},{"orgOrder":0,"company":"Evotec","sponsor":"Inserm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Inserm","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Inserm"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"MinervaX ApS","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"GBS-NN\/NN2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wacker Chemie AG \/ MinervaX ApS","highestDevelopmentStatusID":"9","companyTruncated":"Wacker Chemie AG \/ MinervaX ApS"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"BAMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Isotope Technologies Munich \/ BAMF","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ BAMF"},{"orgOrder":0,"company":"Evotec","sponsor":"Centogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Expanded Collaboration","leadProduct":"Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Centogene","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Centogene"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"PerkinElmer","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sirion Biotech \/ PerkinElmer","highestDevelopmentStatusID":"4","companyTruncated":"Sirion Biotech \/ PerkinElmer"},{"orgOrder":0,"company":"Evotec","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ GSK"},{"orgOrder":0,"company":"Merck Group","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck Group \/ Genome & Company","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Genome & Company"},{"orgOrder":0,"company":"Affimed","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"AFM32","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Roivant Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Roivant Sciences"},{"orgOrder":0,"company":"Evotec","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Chinook Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Chinook Therapeutics"},{"orgOrder":0,"company":"DZNE","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"DZNE","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DZNE \/ Eisai","highestDevelopmentStatusID":"2","companyTruncated":"DZNE \/ Eisai"},{"orgOrder":0,"company":"Evotec","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Bayer AG \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Nuvisan GmbH","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Nuvisan GmbH","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"vgAAV.GL","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViGeneron \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron \/ Daiichi Sankyo"},{"orgOrder":0,"company":"BioNTech","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT111","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Medigene","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Intellia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"RevCAR-T 1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GEMoaB \/ Intellia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GEMoaB \/ Intellia Therapeutics"},{"orgOrder":0,"company":"Immatics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Shingles Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"VG801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron \/ Biogen"},{"orgOrder":0,"company":"Avextra","sponsor":"German Pain Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ German Pain Association","highestDevelopmentStatusID":"1","companyTruncated":"Avextra \/ German Pain Association"},{"orgOrder":0,"company":"CureVac","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"CV0501","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Raymond James & Associates"},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Raymond James & Associates"},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Raymond James & Associates"},{"orgOrder":0,"company":"Innovative Molecules","sponsor":"Life Sciences Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"IM-250","moa":"Helicase-primase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovative Molecules","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovative Molecules \/ Life Sciences Partners","highestDevelopmentStatusID":"4","companyTruncated":"Innovative Molecules \/ Life Sciences Partners"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"EYS606","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyevensys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyevensys \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Eyevensys \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"CureVac","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ European Investment Bank"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Licensing Agreement","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Evotec","sponsor":"Related Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Related Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Related Sciences"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2023","type":"Agreement","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Point Biopharma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Broad Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Broad Institute","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Broad Institute"},{"orgOrder":0,"company":"BioNTech","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Expanded Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ U.S. Government","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ U.S. Government"},{"orgOrder":0,"company":"Tubulis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tubulis \/ EQT Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ EQT Life Sciences"},{"orgOrder":0,"company":"TME Pharma","sponsor":"NYIP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Private Placement","leadProduct":"Emapticap pegol","moa":"CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ NYIP","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ NYIP"},{"orgOrder":0,"company":"SciRhom","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"SR-878","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"SciRhom","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciRhom \/ Andera Partners","highestDevelopmentStatusID":"5","companyTruncated":"SciRhom \/ Andera Partners"},{"orgOrder":0,"company":"Affimed","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Silicon Valley Bank","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"EYS809","moa":"VEGF","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Eyevensys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyevensys \/ Korea Investment Partners","highestDevelopmentStatusID":"4","companyTruncated":"Eyevensys \/ Korea Investment Partners"},{"orgOrder":0,"company":"CatalYm","sponsor":"Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Series C Financing","leadProduct":"Nivolumab","moa":"||GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Brandon Capital","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Brandon Capital"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Financing","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"TME Pharma \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Ethris","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"ETH47","moa":"SARS-CoV-2-viral spike protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Ethris \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Vesalius Biocapital IV","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"HRX-215","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"HepaRegeniX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HepaRegeniX \/ Vesalius Biocapital IV","highestDevelopmentStatusID":"6","companyTruncated":"HepaRegeniX \/ Vesalius Biocapital IV"},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Evotec","sponsor":"Open Philanthropy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Open Philanthropy","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Open Philanthropy"},{"orgOrder":0,"company":"TME Pharma","sponsor":"BMBF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"Emapticap pegol","moa":"CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TME Pharma \/ BMBF","highestDevelopmentStatusID":"8","companyTruncated":"TME Pharma \/ BMBF"},{"orgOrder":0,"company":"Tubulis","sponsor":"BioMedPartners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"TUB-010","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tubulis \/ BioMedPartners","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ BioMedPartners"},{"orgOrder":0,"company":"Smartbax","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Smartbax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Smartbax \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Smartbax \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"OncoBeta","sponsor":"NanoMab Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2020","type":"Agreement","leadProduct":"188-Re","moa":"Beta radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"OncoBeta","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoBeta \/ NanoMab Technology","highestDevelopmentStatusID":"1","companyTruncated":"OncoBeta \/ NanoMab Technology"},{"orgOrder":0,"company":"Centogene","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centogene \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Centogene \/ Pfizer Inc"},{"orgOrder":0,"company":"Qiagen","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Qiagen \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Inovio Pharmaceuticals"},{"orgOrder":0,"company":"Heidelberg University","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2024","type":"Licensing Agreement","leadProduct":"225-Ac PSMA","moa":"Alpha wave","graph1":"Oncology","graph2":"Phase II","graph3":"Heidelberg University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Heidelberg University \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Heidelberg University \/ Fusion Pharma"},{"orgOrder":0,"company":"CureVac","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ European Commission"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"VIP236","moa":"AlphaV beta 3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Leerink Partners"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"DISCO Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"DISCO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DISCO Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"3","companyTruncated":"DISCO Pharmaceuticals \/ Sofinnova Partners"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"VIP924","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincerx Pharma \/ Leerink Partners","highestDevelopmentStatusID":"4","companyTruncated":"Vincerx Pharma \/ Leerink Partners"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"CureVac","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ BofA Securities"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Undisclosed"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Athos Service","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"IMT-07","moa":"SIK3 kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iOmx Therapeutics \/ Athos Service","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Therapeutics \/ Athos Service"},{"orgOrder":0,"company":"BioNTech","sponsor":"New Zealand government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ New Zealand government","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ New Zealand government"},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BAY401016","moa":"Semaphorin-3A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Bayer AG"},{"orgOrder":0,"company":"BioNTech","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"BNT166","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ CEPI"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiefenbacher Group \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Tiefenbacher Group \/ OnDosis"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Swiss TPH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Partnership","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Swiss TPH","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Swiss TPH"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2024","type":"Partnership","leadProduct":"225-Ac PSMA-RADmAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"ProBioGen","sponsor":"DIOSynVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"DIOS-HFVac3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProBioGen \/ DIOSynVax","highestDevelopmentStatusID":"4","companyTruncated":"ProBioGen \/ DIOSynVax"},{"orgOrder":0,"company":"Proteros","sponsor":"Adrestia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Proteros","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteros \/ Adrestia Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Proteros \/ Adrestia Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Samsung Bioepis"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein degradation","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Sernova","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Evotec \/ Sernova","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ Sernova"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"Satoreotide Tetraxetan","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ariceum Therapeutics \/ Healthcaps India","highestDevelopmentStatusID":"7","companyTruncated":"Ariceum Therapeutics \/ Healthcaps India"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Deerfield Management"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed"},{"orgOrder":0,"company":"Seamless Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Seamless Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seamless Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seamless Therapeutics \/ Wellington Partners"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"AVC-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AvenCell Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Ethris","sponsor":"Laureus Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"ETH47","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Laureus Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ethris \/ Laureus Capital"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Indigenous Critical Infrastructure Fund Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada"},{"orgOrder":0,"company":"Booster Therapeutics","sponsor":"Apollo Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Booster Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Booster Therapeutics \/ Apollo Health Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Booster Therapeutics \/ Apollo Health Ventures"},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"MAPK4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"HepaRegeniX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HepaRegeniX \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"HepaRegeniX \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2024","type":"Financing","leadProduct":"177-Lu Edotreotide","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"Abalos","sponsor":"Seventure Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abalos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abalos \/ Seventure Partners","highestDevelopmentStatusID":"5","companyTruncated":"Abalos \/ Seventure Partners"},{"orgOrder":0,"company":"Tubulis","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tubulis \/ Andera Partners","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Andera Partners"},{"orgOrder":0,"company":"CatalYm","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Series D Financing","leadProduct":"Nivolumab","moa":"||GDF-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CatalYm \/ Canaan Partners","highestDevelopmentStatusID":"7","companyTruncated":"CatalYm \/ Canaan Partners"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"BankM AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Y90-PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ BankM AG","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ BankM AG"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Medigene","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ 2Seventy Bio","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ 2Seventy Bio"},{"orgOrder":0,"company":"Evotec","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Protein","year":"2022","type":"Expanded Collaboration","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Evotec \/ Alpine Immune Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Alpine Immune Sciences"},{"orgOrder":0,"company":"InflaRx","sponsor":"German Federal Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ German Federal Government","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ German Federal Government"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Broad Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Broad Institute","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Broad Institute"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inkef Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inkef Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inkef Capital"},{"orgOrder":0,"company":"OntoChem","sponsor":"Anixa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OntoChem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"OntoChem \/ Anixa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"OntoChem \/ Anixa Biosciences"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Hong Kong Winhealth Pharma Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"L-Ornithine L-aspartate","moa":"Ammonia detoxification","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merz Pharma \/ Hong Kong Winhealth Pharma Group","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Hong Kong Winhealth Pharma Group"},{"orgOrder":0,"company":"Evotec","sponsor":"Variant Bio","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Evotec \/ Variant Bio","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Variant Bio"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Merck Group","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Merck Group \/ Immutep","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Immutep"},{"orgOrder":0,"company":"ProBioGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProBioGen \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"ProBioGen \/ AbbVie Inc"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desogestrel","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Organon"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Debio 0228","moa":"CA IX","graph1":"Oncology","graph2":"Discovery","graph3":"3B Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3B Pharmaceuticals \/ Debiopharm","highestDevelopmentStatusID":"2","companyTruncated":"3B Pharmaceuticals \/ Debiopharm"},{"orgOrder":0,"company":"Relaxera Pharmazeutische","sponsor":"CBL- Chemical and Biopharmaceutical Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Relaxin-2 protein, human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Relaxera Pharmazeutische","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relaxera Pharmazeutische \/ CBL- Chemical and Biopharmaceutical Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Relaxera Pharmazeutische \/ CBL- Chemical and Biopharmaceutical Laboratories"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Aspirin","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"IMA401","moa":"MAGE-A4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Grcbds","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Enzyme","year":"2020","type":"Partnership","leadProduct":"L-Asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Grcbds","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grcbds \/ Erytech Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Grcbds \/ Erytech Pharma"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"TME Pharma \/ Merck & Co"},{"orgOrder":0,"company":"CureVac","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ Biogen"},{"orgOrder":0,"company":"Novaliq","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Harrow"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Alpha-9 Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Alpha-9 Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Alpha-9 Oncology"},{"orgOrder":0,"company":"Evotec","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Evotec \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Biocure Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"zapnometinib","moa":"MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atriva Therapeutics \/ Biocure Technology","highestDevelopmentStatusID":"8","companyTruncated":"Atriva Therapeutics \/ Biocure Technology"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"ETx-22","moa":"Nectin-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergence Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Emergence Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase 4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Lupin Ltd"},{"orgOrder":0,"company":"Glycotope","sponsor":"PentixaPharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"GT-001","moa":"Lewis Y","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ PentixaPharm","highestDevelopmentStatusID":"4","companyTruncated":"Glycotope \/ PentixaPharm"},{"orgOrder":0,"company":"Novasep","sponsor":"Celladon","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"AAV1\/SERCA2a","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novasep","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Novasep \/ Celladon","highestDevelopmentStatusID":"8","companyTruncated":"Novasep \/ Celladon"},{"orgOrder":0,"company":"Axplora","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Nivolumab","moa":"||Tissue Factor","graph1":"Oncology","graph2":"Phase I","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Axplora \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Axplora \/ Exelixis"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Pantherna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"PAN004","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wacker Chemie AG \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Wacker Chemie AG \/ Pantherna Therapeutics"},{"orgOrder":0,"company":"Tubulis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tubulis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Acasunlimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Genmab"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sirion Biotech \/ Cellectis","highestDevelopmentStatusID":"3","companyTruncated":"Sirion Biotech \/ Cellectis"},{"orgOrder":0,"company":"Exyte","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exyte","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Exyte \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"Exyte \/ Univercells"},{"orgOrder":0,"company":"T-knife","sponsor":"Fidelity Management & Research Company, LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"T-knife \/ Fidelity Management & Research Company, LLC","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Fidelity Management & Research Company, LLC"},{"orgOrder":0,"company":"T-knife","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"T-knife \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"T-knife \/ Versant Ventures"},{"orgOrder":0,"company":"Phenex Pharmaceuticals","sponsor":"OrsoBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"TLC-2716","moa":"Liver X receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Phenex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phenex Pharmaceuticals \/ OrsoBio","highestDevelopmentStatusID":"6","companyTruncated":"Phenex Pharmaceuticals \/ OrsoBio"},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Steroid","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Mundipharma \/ Vectura Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Vectura Ltd"},{"orgOrder":0,"company":"Proteros","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Proteros","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteros \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Proteros \/ AstraZeneca"},{"orgOrder":0,"company":"Cevec","sponsor":"Rokote Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"FINCoVac 2.1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cevec \/ Rokote Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Cevec \/ Rokote Laboratories"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Preclinical","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eckert & Ziegler Strahlen \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Eckert & Ziegler Strahlen \/ Point Biopharma"},{"orgOrder":0,"company":"Evotec","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Evotec","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Eli Lilly"},{"orgOrder":0,"company":"Evotec","sponsor":"OncoResponse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"OR2805","moa":"CD163","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ OncoResponse","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ OncoResponse"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Medigene","highestDevelopmentStatusID":"2","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Medigene"},{"orgOrder":0,"company":"Merck Group","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ITM-52","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Isotope Technologies Munich","highestDevelopmentStatusID":"4","companyTruncated":"Merck Group \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"CBE-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Cell BioEngines","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Cell BioEngines"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Biosolution","highestDevelopmentStatusID":"1","companyTruncated":"Mundipharma \/ Biosolution"},{"orgOrder":0,"company":"NEOsphere Biotechnologies","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"NEOsphere Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NEOsphere Biotechnologies \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"NEOsphere Biotechnologies \/ Kymera Therapeutics"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"225-Ac Satoreotide Trizoxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"4","companyTruncated":"Ariceum Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"LTS - Lohmann Therapie Systeme \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohmann Therapie Systeme \/ PharmaTher"},{"orgOrder":0,"company":"Qiagen","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Enzastaurin","moa":"||PKC-beta","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Qiagen \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Denovo Biopharma"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"RefleXion Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"RXM-4768","moa":"FAP","graph1":"Oncology","graph2":"Preclinical","graph3":"3B Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3B Pharmaceuticals \/ RefleXion Medical","highestDevelopmentStatusID":"4","companyTruncated":"3B Pharmaceuticals \/ RefleXion Medical"},{"orgOrder":0,"company":"Novaliq","sponsor":"Senju Pharmaceutical Co Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Senju Pharmaceutical Co Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Senju Pharmaceutical Co Ltd"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Syena","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SY-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Syena","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Syena"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Agreement","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Paul Scherrer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Terbium-161","moa":"Beta radiation\/auger electron","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Paul Scherrer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Technologies Munich \/ Paul Scherrer Institute"},{"orgOrder":0,"company":"Medac","sponsor":"UroGen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Preclinical","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Medac \/ UroGen Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Medac \/ UroGen Pharma"},{"orgOrder":0,"company":"InflaRx","sponsor":"Staidson Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"BDB-001","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Staidson Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Staidson Biopharma"},{"orgOrder":0,"company":"Ethris","sponsor":"Neurimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"NI007","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Neurimmune","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Neurimmune"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"IBM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boehringer Ingelheim GmbH \/ IBM","highestDevelopmentStatusID":"2","companyTruncated":"Boehringer Ingelheim GmbH \/ IBM"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Secarna Pharma \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Pharma \/ SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ariceum Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"Ariceum Therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Vibalogics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vibalogics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vibalogics \/ Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Vibalogics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"STADA Arzneimittel \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Recursion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Recursion Pharma"},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"PTXmRNAs","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pantherna Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Pantherna Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Scleroderma Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"VG801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViGeneron \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Affimed","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"AB-101","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"ANSTO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"No-carrier-added 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ ANSTO","highestDevelopmentStatusID":"15","companyTruncated":"Isotope Technologies Munich \/ ANSTO"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bioiberica","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Chondroitin Sulfate Sodium","moa":"||Neurotrophic factor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Bioiberica","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Bioiberica"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bayer AG \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ CureVac"},{"orgOrder":0,"company":"T-knife","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"T-knife \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"T-knife \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Cevec","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cevec \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Biogen"},{"orgOrder":0,"company":"University of Bonn","sponsor":"DiosCURE","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"DIOS-203","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Bonn","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Bonn \/ DiosCURE","highestDevelopmentStatusID":"4","companyTruncated":"University of Bonn \/ DiosCURE"},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Mablink Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Nectin-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emergence Therapeutics \/ Mablink Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Emergence Therapeutics \/ Mablink Bioscience"},{"orgOrder":0,"company":"Curexsys Gmbh","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Curexsys Gmbh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curexsys Gmbh \/ Evotec","highestDevelopmentStatusID":"1","companyTruncated":"Curexsys Gmbh \/ Evotec"},{"orgOrder":0,"company":"Evotec","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"IDG16177","moa":"GPR40","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CV7301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"Ethris","sponsor":"Heqet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"ETH51","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Ethris \/ Heqet Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Heqet Therapeutics"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2021","type":"Licensing Agreement","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"LTS - Lohmann Therapie Systeme \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohmann Therapie Systeme \/ Revive Therapeutics"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Lenalidomide","moa":"||CD47","graph1":"Oncology","graph2":"Preclinical","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"MorphoSys \/ Pfizer Inc"},{"orgOrder":0,"company":"Cevec","sponsor":"Rznomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cevec \/ Rznomics","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Rznomics"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Lenalidomide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ Xencor","highestDevelopmentStatusID":"1","companyTruncated":"MorphoSys \/ Xencor"},{"orgOrder":0,"company":"MorphoSys","sponsor":"HIBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ HIBio","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ HIBio"},{"orgOrder":0,"company":"Axplora","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axplora \/ Paratek Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Axplora \/ Paratek Pharmaceuticals"},{"orgOrder":0,"company":"CureVac","sponsor":"Wacker Chemie AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Wacker Chemie AG","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Wacker Chemie AG"},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Preclinical","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Isotope Technologies Munich","highestDevelopmentStatusID":"4","companyTruncated":"Helmholtz Zentrum M\u00fcnchen \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centogene \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Centogene \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"||CD38","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ I-Mab Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ I-Mab Biopharma"},{"orgOrder":0,"company":"Merck Group","sponsor":"NKMax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ NKMax","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ NKMax"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Lipigon","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Secarna Pharma \/ Lipigon","highestDevelopmentStatusID":"1","companyTruncated":"Secarna Pharma \/ Lipigon"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Secarna Pharma \/ Sun Yat-sen University","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Pharma \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Hauck Aufh\u00e4user Lampe Privatbank AG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Hauck Aufh\u00e4user Lampe Privatbank AG","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Hauck Aufh\u00e4user Lampe Privatbank AG"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"IDT Biologika GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IDT Biologika GmbH \/ Valneva","highestDevelopmentStatusID":"15","companyTruncated":"IDT Biologika GmbH \/ Valneva"},{"orgOrder":0,"company":"Evonik","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evonik \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Evonik \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"SIRS Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"FX06","moa":"Pro-inflammatory fibrin E1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIRS Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIRS Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"1","companyTruncated":"SIRS Therapeutics \/ Wellington Partners"},{"orgOrder":0,"company":"Axplora","sponsor":"Lysogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Axplora \/ Lysogene","highestDevelopmentStatusID":"6","companyTruncated":"Axplora \/ Lysogene"},{"orgOrder":0,"company":"Merck Group","sponsor":"The Department of Health, Abu Dhabi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Merck Group \/ The Department of Health, Abu Dhabi","highestDevelopmentStatusID":"1","companyTruncated":"Merck Group \/ The Department of Health, Abu Dhabi"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"YL202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"OMEICOS Therapeutics GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OMT-28","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"OMEICOS Therapeutics GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OMEICOS Therapeutics GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OMEICOS Therapeutics GmbH \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Omicron KP.2-adapted Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"MK-0616","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Alvotech"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Alvotech"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"123-I ATT001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Satoreotide Tetraxetan","moa":"||SST2","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"IDT Biologika GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MVA-SARS-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"German Center for Infection Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Center for Infection Research \/ IDT Biologika GmbH","highestDevelopmentStatusID":"6","companyTruncated":"German Center for Infection Research \/ IDT Biologika GmbH"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"BioMed X","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioMed X","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioMed X \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"BioMed X \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"||CYP17A1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"AudioCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AC102","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AudioCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"AudioCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AudioCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acousia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Cologne","sponsor":"Apogenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Cologne","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Cologne \/ Apogenix","highestDevelopmentStatusID":"9","companyTruncated":"University of Cologne \/ Apogenix"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IMA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAY2416964","moa":"Aryl hydrocarbon receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Gilead Sciences"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Affimed \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM28","moa":"||CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AFM28","moa":"CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM28","moa":"CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"AiCuris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AIC468","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiCuris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiCuris \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3K p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Enmetazobactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allecra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allecra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Algiax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AP-325","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Algiax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Algiax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algiax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Algiax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AP-325","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Algiax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Algiax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algiax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Arpraziquantel","moa":"CYP11B1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"zapnometinib","moa":"MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"zapnometinib","moa":"MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATT001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evonik","sponsor":"Allay Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Evonik \/ Allay Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Evonik \/ Allay Therapeutics"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVC-101","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AvenCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Staphylococcus Epidermidis Strain","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BAY 2927088","moa":"Tyrosine Kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BAY 2927088","moa":"Tyrosine Kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BAY 3018250","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BAY 3283142","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Antihemophilic Factor Recombinant PEGylated","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"Coronavirus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cures \/ Inapplicable"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"Coronavirus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cures \/ Inapplicable"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"Coronavirus spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Berlin Cures \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berzosertib","moa":"||ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berzosertib","moa":"ATR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Merck Group \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nelivaptan","moa":"V1b receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HMNC Brain Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nerandomilast","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nerandomilast","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zongertinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Gubra","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"BI 3034701","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Gubra","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Gubra"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 690517","moa":"||Aldosterone synthase","graph1":"Nephrology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BI 764524","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Enleofen Bio Pte","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BI 765423","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Boehringer Ingelheim GmbH \/ Enleofen Bio Pte","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Enleofen Bio Pte"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BI 770371","moa":"||SIRP alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BI 771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Formycon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT165","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BNT111","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"BNT111","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT113","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Autogene Cevumeran","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Genentech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Genentech"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"qIRV","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BNT211","moa":"CLDN6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"OncoC4","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Gotistobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ OncoC4","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ OncoC4"},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DB-1303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Duality Biologics"},{"orgOrder":0,"company":"BioNTech","sponsor":"DualityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"DB-1311","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ DualityBio","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ DualityBio"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Pharmaxis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BI 1467335","moa":"AOC3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Pharmaxis","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Pharmaxis"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Forma Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BI 1701963","moa":"pan-KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Forma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Forma Therapeutics"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Bayer AG \/ BlueRock Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"Avextra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avextra \/ Inapplicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Visugromab","moa":"GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Inapplicable"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Lindis Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lindis Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Center for Infection Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"German Center for Infection Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"German Center for Infection Research \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AFM24","moa":"EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iclepertin","moa":"Glycine transporter-1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Corat Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COR-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Corat Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Corat Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corat Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"||EZH1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GDF-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CatalYm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CatalYm \/ Inapplicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Inapplicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Visugromab","moa":"GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Bayer AG"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CV0501","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CV0501","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CV0501","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CV0701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"CV8102","moa":"TLR 7\/8\/RIG-1","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"CV8102","moa":"TLR 7\/8\/RIG-1","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"CV8102","moa":"TLR 7\/8\/RIG-1","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CVGBM","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"Cytochrome P450 3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM28","moa":"CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asundexian","moa":"Factor XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI 765063","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AFM24","moa":"EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Tyrosine Kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BNT325","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Duality Biologics"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"Adrenomedullin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Evonik","sponsor":"JeNaCell","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cellulose","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Evonik \/ JeNaCell","highestDevelopmentStatusID":"15","companyTruncated":"Evonik \/ JeNaCell"},{"orgOrder":0,"company":"Evonik","sponsor":"JeNaCell","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cellulose","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Dressing","sponsorNew":"Evonik \/ JeNaCell","highestDevelopmentStatusID":"15","companyTruncated":"Evonik \/ JeNaCell"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2-viral spike protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2-viral spike protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Merck & Co"},{"orgOrder":0,"company":"Evotec","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EVT894","moa":"Chikungunya viral protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Evotec \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ National Institutes of Health"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allecra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allecra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allecra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allecra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Enmetazobactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allecra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allecra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EYS611","moa":"Human transferrin","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Eyevensys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyevensys \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eyevensys \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Autologous Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"||PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IMA202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Biotest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Trimodulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotest \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FNP-223","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FNP-223","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ferrer Internacional \/ Inapplicable"},{"orgOrder":0,"company":"Formycon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Inapplicable"},{"orgOrder":0,"company":"FundaMental Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FP802","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"FundaMental Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FundaMental Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"FundaMental Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Formycon"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-PSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Syringe","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etifoxine Deuterated","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Otilimab","moa":"||GCSF","graph1":"Immunology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"H5N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"Adrenomedullin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Inapplicable"},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RHCDS-13b","moa":"Alpha-ketoamide protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Center for Infection Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Center for Infection Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"German Center for Infection Research \/ Inapplicable"},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MYR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MYR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MYR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HRX-215","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"HepaRegeniX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HepaRegeniX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HepaRegeniX \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMA401","moa":"MAGE-A4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMA401","moa":"MAGE-A4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IMA401","moa":"MAGE-A4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IMA402","moa":"T-cell engaging receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Larotrectinib","moa":"Neurotrophic TYK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"||C5a receptor","graph1":"Oncology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"IMA402","moa":"T-cell engaging receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3K p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Bintrafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Alteplase","moa":"Plasminogen","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"||SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Isotope Technologies Munich \/ Helmholtz Zentrum M\u00fcnchen","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ Helmholtz Zentrum M\u00fcnchen"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"University Hospital Muenster","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Isotope Technologies Munich \/ University Hospital Muenster","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ University Hospital Muenster"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CPC Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ CPC Clinical Research","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ CPC Clinical Research"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"American Association of Kidney Patients","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ American Association of Kidney Patients","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ American Association of Kidney Patients"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Ketabon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ketabon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ketabon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ketabon \/ Inapplicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"STADA Arzneimittel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KUR-101","moa":"MOR","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KUR-101","moa":"MOR","graph1":"Neurology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ EMD Serono","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ EMD Serono"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MDG1011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG1015","moa":"NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MDG2011","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDG2021","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Merck Group","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Bintrafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Merck Group \/ GSK"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MOR210","moa":"||C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ I-Mab Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys \/ I-Mab Biopharma"},{"orgOrder":0,"company":"H\u00e4mophilie-Zentrum Rhein Main","sponsor":"Octapharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Simoctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"H\u00e4mophilie-Zentrum Rhein Main","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"H\u00e4mophilie-Zentrum Rhein Main \/ Octapharma","highestDevelopmentStatusID":"15","companyTruncated":"H\u00e4mophilie-Zentrum Rhein Main \/ Octapharma"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"STADA Arzneimittel \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM28","moa":"||CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CXCL12","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iOmx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iOmx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"iOmx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MYR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MYR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MYR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"OncoC4","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gotistobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ OncoC4","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ OncoC4"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius SE & Co. KGaA \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Formycon"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roche Diagnostics GmbH \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Roche Diagnostics GmbH \/ AstraZeneca"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nerandomilast","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AFM24","moa":"EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Cologne University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"DZIF-10c","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Cologne University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Cologne University Hospital"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grunenthal \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3K p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plerixafor","moa":"CXCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CV2CoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grunenthal \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Omicron BA.4\/BA.5-adapted Bivalent Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"DiosCURE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DIOS-202","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DiosCURE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiosCURE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"DiosCURE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acasunlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Radium-223","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Tyrosine Kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"||DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Medac","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medac \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Eisai"},{"orgOrder":0,"company":"Qiagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qiagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Qiagen \/ Inapplicable"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Midas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Midas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AiCuris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Viral Helicase-primase enzyme complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AiCuris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Repairon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Engineered Heart Muscle","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Repairon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Repairon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Repairon \/ Inapplicable"},{"orgOrder":0,"company":"German Primate Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"Proteinase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Primate Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"German Primate Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"German Primate Center \/ Inapplicable"},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"zapnometinib","moa":"MEK receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iclepertin","moa":"Glycine transporter-1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eliapixant","moa":"P2X3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Evotec","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Evotec"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roche Diagnostics GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Roche Diagnostics GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RL-007","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MorphoSys \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Grunenthal \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT111","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"MyoPax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Satori-01","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"MyoPax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraurethral Injection","sponsorNew":"MyoPax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MyoPax \/ Inapplicable"},{"orgOrder":0,"company":"MyoPax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Satori-01","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"MyoPax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraurethral Injection","sponsorNew":"MyoPax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MyoPax \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"||ERBB4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"||M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||Tyrosine Kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Povidone-Iodine","moa":"Inflammatory mediator","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Midas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Midas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Formycon","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Formycon \/ Bioeq IP AG","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Bioeq IP AG"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BI 764198","moa":"TRPC6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP-25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Apogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"CD95","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/ Inapplicable"},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Bulevirtide","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MYR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MYR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MYR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Algiax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AP-325","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Algiax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Algiax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algiax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BNT211","moa":"CLDN6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Bausch Health"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mundipharma \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI 905711","moa":"TRAILR2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BI 765063","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IMA402","moa":"T-cell engaging receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CV0601","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT163","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Inapplicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"STADA Arzneimittel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PD1-41BB switch receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"IgNova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IgNova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IgNova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IgNova \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Calcilytix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calcilytix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calcilytix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calcilytix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MDG1021","moa":"Antigen HA-1","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grunenthal \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"||COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ferrer Internacional \/ CNIC","highestDevelopmentStatusID":"15","companyTruncated":"Ferrer Internacional \/ CNIC"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"PharmaZell","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"PharmaZell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PharmaZell \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"PharmaZell \/ Breckenridge Pharmaceutical"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Merck & Co"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"MODAG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Anle138b","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"MODAG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MODAG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"TolerogenixX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MIC-Lx","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"TolerogenixX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TolerogenixX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TolerogenixX \/ Inapplicable"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"Adrenomedullin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ University Medical Center"},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"CDR132L","moa":"miR-132","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BNT111","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"IQWiG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"IQWiG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IQWiG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IQWiG \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ifx-1","moa":"||C5a receptor","graph1":"Oncology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Finerenone","moa":"||Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Orion Corporation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Max Planck Institute for Infection Biology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Max Planck Institute for Infection Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Max Planck Institute for Infection Biology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck Institute for Infection Biology \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"IMA201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT165","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MVA-SARS-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IDT Biologika GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDT Biologika GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IDT Biologika GmbH \/ Inapplicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HMNC Brain Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Inapplicable"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roche Diagnostics GmbH \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Roche Diagnostics GmbH \/ Merck & Co"},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Roche Diagnostics GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Apogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"CD95","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nerandomilast","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"T-knife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TK-2504","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"T-knife \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"T-knife \/ Inapplicable"},{"orgOrder":0,"company":"T-knife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"T-knife \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Inapplicable"},{"orgOrder":0,"company":"T-knife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"T-knife \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Inapplicable"},{"orgOrder":0,"company":"Topas Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"TPM502","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Topas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topas Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Topas Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"Adrenomedullin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Adrenomed \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BNT211","moa":"CLDN6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Tubulis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tubulis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Inapplicable"},{"orgOrder":0,"company":"Tubulis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"TUB-040","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tubulis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IMA204","moa":"COL6A3","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BAY2599023","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Nifurtimox","moa":"Nitroreductases","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Acimtamig","moa":"CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindis Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lindis Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Mainz University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simeprevir","moa":"HCV proteases\/NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mainz University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mainz University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mainz University \/ Inapplicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"STADA Arzneimittel \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzneimittel \/ Inapplicable"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ProBioGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProBioGen \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Nordic Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Nordic Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Nordic Bioscience"},{"orgOrder":0,"company":"Vasopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ronopterin","moa":"iNOS","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Merck & Co"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"Novaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novaliq","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novaliq \/ Inapplicable"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VG901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ViGeneron \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Innovaderm Research","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Innovaderm Research","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Innovaderm Research"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enitociclib","moa":"||PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VIP236","moa":"AlphaV beta 3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VIP236","moa":"AlphaV beta 3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VIP236","moa":"AlphaV beta 3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Inapplicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Inapplicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Larotrectinib","moa":"Neurotrophic TYK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Larotrectinib","moa":"Neurotrophic TYK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP-25","graph1":"Neurology","graph2":"Approved FDF","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Xbrane Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"STADA Arzneimittel \/ Xbrane Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Xbrane Biopharma"},{"orgOrder":0,"company":"Biotest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biotest \/ Inapplicable"},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Pharmanovia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Catumaxomab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lindis Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Lindis Biotech \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Lindis Biotech \/ Pharmanovia"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Algiax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AP-325","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Algiax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Algiax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Algiax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R\/NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Romidepsin","moa":"HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivoryon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nab-Paclitaxel","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AB-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Gerresheimer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Gerresheimer AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Gerresheimer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gerresheimer AG \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"225-Ac Satoreotide Tetraxetan","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"225-Ac Satoreotide Tetraxetan","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avobis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Avobis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avobis Bio \/ Inapplicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nelivaptan","moa":"V1b receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HMNC Brain Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nerandomilast","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nerandomilast","moa":"PDE4B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zongertinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OXB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BI 3720931","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Boehringer Ingelheim GmbH \/ OXB","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ OXB"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iclepertin","moa":"Glycine transporter-1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iclepertin","moa":"GlyT1","graph1":"Neurology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"BNT327","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2-viral spike protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ifx-1","moa":"C5a receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu Edotreotide","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ESG401","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tubulis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TUB-030","moa":"5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tubulis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ Inapplicable"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VG801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ViGeneron \/ Inapplicable"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"VG901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ViGeneron \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"ATAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GREECE","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Pharmathen SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmathen SA \/ Neuraxpharm","highestDevelopmentStatusID":"1","companyTruncated":"Pharmathen SA \/ Neuraxpharm"},{"orgOrder":0,"company":"Famar","sponsor":"D-sight","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"DPP-IV","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Famar \/ D-sight","highestDevelopmentStatusID":"4","companyTruncated":"Famar \/ D-sight"},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GREECE","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GENESIS Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GENESIS Pharma \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GREECE","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GENESIS Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GENESIS Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Famar","sponsor":"Lavipharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GREECE","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Famar \/ Lavipharm","highestDevelopmentStatusID":"15","companyTruncated":"Famar \/ Lavipharm"},{"orgOrder":0,"company":"Brain Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GREECE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Brain Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Brain Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Brain Therapeutics \/ Neuraxpharm"},{"orgOrder":0,"company":"Famar","sponsor":"Active Biotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Famar \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Famar \/ Active Biotech"},{"orgOrder":0,"company":"Famar","sponsor":"Medicom Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"HPAPI","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Famar \/ Medicom Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Famar \/ Medicom Healthcare"},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Pharmathen SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmathen SA \/ Partners Group","highestDevelopmentStatusID":"1","companyTruncated":"Pharmathen SA \/ Partners Group"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abiraterone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GREECE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asofarma Central America and Caribbean","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GUATEMALA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asofarma Central America and Caribbean","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Asofarma Central America and Caribbean \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Asofarma Central America and Caribbean \/ Moderna Therapeutics"},{"orgOrder":0,"company":"The United Laboratories","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"HONG KONG","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"UBT251","moa":"GLP-1\/GIP\/Glucagon","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"The United Laboratories","amount2":2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2,"dosageForm":"Subcutaneous Injection","sponsorNew":"The United Laboratories \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"The United Laboratories \/ Novo Nordisk"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Value Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Series E Financing","leadProduct":"INS018_055","moa":"TNIK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.11,"dosageForm":"Oral Capsule","sponsorNew":"Insilico Medicine \/ Value Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Value Partners Group"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody-drug Conjugate","year":"2025","type":"Divestment","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Hutchmed \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0.56999999999999995,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.56999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Insilico Medicine \/ Stemline Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hong Kong Winhealth Pharma Group","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Hong Kong Winhealth Pharma Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hong Kong Winhealth Pharma Group \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Hong Kong Winhealth Pharma Group \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ National Healthcare Security Administration"},{"orgOrder":0,"company":"Axis Therapeutics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axis Therapeutics \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"Axis Therapeutics \/ PharmaEssentia"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"BHR Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"INS018_055","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ BHR Partners","highestDevelopmentStatusID":"6","companyTruncated":"Insilico Medicine \/ BHR Partners"},{"orgOrder":0,"company":"The University of Hong Kong","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"The University of Hong Kong \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"The University of Hong Kong \/ CEPI"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hutchison China MediTech \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Hutchmed","sponsor":"GL Mountrose Investment Two","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ GL Mountrose Investment Two","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ GL Mountrose Investment Two"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Surufatinib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ HengRui","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ HengRui"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"HONG KONG","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hutchmed \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Jacobson Pharma","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jacobson Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jacobson Pharma \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Jacobson Pharma \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Syracuse Biopharma","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Syracuse Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syracuse Biopharma \/ JW Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Syracuse Biopharma \/ JW Therapeutics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ National Healthcare Security Administration"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insilico Medicine \/ Stemline Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Baring Private Equity Asia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Baring Private Equity Asia","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Baring Private Equity Asia"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ EQRx","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ EQRx"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ISM3091","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Exelixis"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Regent Pacific","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Regent Pacific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cutaneous Spray","sponsorNew":"Regent Pacific \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Regent Pacific \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Hutchison China MediTech \/ Eli Lilly"},{"orgOrder":0,"company":"KYM Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"KYM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KYM Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"KYM Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"KYM Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"KYM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KYM Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"KYM Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Innorna","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Innorna","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innorna \/ BeiGene","highestDevelopmentStatusID":"2","companyTruncated":"Innorna \/ BeiGene"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Insilico Medicine \/ Sanofi"},{"orgOrder":0,"company":"Regencell Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RGCA-CV01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regencell Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Regencell Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regencell Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hong Kong Baptist University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hong Kong Baptist University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hong Kong Baptist University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hong Kong Baptist University \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amdizalisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Arbele","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"CDH17","graph1":"Oncology","graph2":"Phase I","graph3":"Arbele","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Arbele \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbele \/ Inapplicable"},{"orgOrder":0,"company":"Arbele","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"CDH17","graph1":"Oncology","graph2":"Phase I","graph3":"Arbele","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Arbele \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbele \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ISM001-055","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Innovent Biologics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ HengRui","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ HengRui"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HMPL-415S1","moa":"SHP2 allosteric","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HMPL-306","moa":"Isocitrate dehydrogenase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HMPL-306","moa":"Isocitrate dehydrogenase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HMPL-506","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amdizalisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HMPL-A83","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INS018_055","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ISM025","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ISM001-055","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ISM3312","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Meta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"META-001-PH","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Meta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Meta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MAT2A","graph1":"Oncology","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"SYK","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Epizyme","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Epizyme"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Zhaoke","sponsor":"Nevakar","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Zhaoke \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke \/ Nevakar"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"LakeShore Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Rabies Vaccine, PIKA Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LakeShore Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LakeShore Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LakeShore Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hong Kong Baptist University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hong Kong Baptist University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hong Kong Baptist University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hong Kong Baptist University \/ Inapplicable"},{"orgOrder":0,"company":"Regencell Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RGCA-CV01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regencell Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Regencell Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regencell Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Surufatinib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fanregratinib Tartrate","moa":"FGFR 1\/2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"||VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Hutchmed \/ Innovent Biologics"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ISM5411","moa":"PHD","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insilico Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Savolitinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"HUNGARY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gedeon Richter \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gedeon Richter \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Gedeon Richter \/ AbbVie Inc"},{"orgOrder":0,"company":"Turbine","sponsor":"Cancer Research Horizons","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"CRT\u20192199","moa":"CDC7","graph1":"Oncology","graph2":"Preclinical","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turbine \/ Cancer Research Horizons","highestDevelopmentStatusID":"4","companyTruncated":"Turbine \/ Cancer Research Horizons"},{"orgOrder":0,"company":"Turbine","sponsor":"Harmonic Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turbine \/ Harmonic Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ Harmonic Discovery"},{"orgOrder":0,"company":"Turbine","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turbine \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gedeon Richter \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Gedeon Richter \/ AbbVie Inc"},{"orgOrder":0,"company":"Turbine","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turbine \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Turbine","sponsor":"MSD Global Health Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turbine \/ MSD Global Health Innovation","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ MSD Global Health Innovation"},{"orgOrder":0,"company":"Turbine","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turbine \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ AstraZeneca"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"HUNGARY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Sumitomo","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"HUNGARY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Sumitomo","highestDevelopmentStatusID":"15","companyTruncated":"Gedeon Richter \/ Sumitomo"},{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"National Institute of Pharmacy and Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Egis Pharmaceuticals PLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition","highestDevelopmentStatusID":"15","companyTruncated":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition"},{"orgOrder":0,"company":"Arctic Therapeutics","sponsor":"EIC Fund","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ICELAND","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Grapiprant","moa":"Aldose reductase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Arctic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Arctic Therapeutics \/ EIC Fund","highestDevelopmentStatusID":"8","companyTruncated":"Arctic Therapeutics \/ EIC Fund"},{"orgOrder":0,"company":"Coripharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ICELAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Raltegravir Potassium","moa":"Integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Coripharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Coripharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Coripharma \/ Midas Pharma"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Alvotech","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Private Placement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ICELAND","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Alvotech \/ Fuji Pharma"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Flerie Invest","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Flerie Invest","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Flerie Invest"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"ATP Holdings","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ ATP Holdings","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ ATP Holdings"},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Vedolizumab","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Alvotech \/ Fuji Pharma"},{"orgOrder":0,"company":"3Z","sponsor":"biotx.ai","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ICELAND","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"3Z","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"3Z \/ biotx.ai","highestDevelopmentStatusID":"2","companyTruncated":"3Z \/ biotx.ai"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Alvotech","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ DKSH"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Alvotech","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ICELAND","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alvotech \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Alvotech \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Cipla","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Cipla"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ICELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EP395","moa":"Epithelial cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Kerecis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ICELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omega3 Viruxide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerecis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Kerecis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kerecis \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ICELAND","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"3Z","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ICELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amlodipine","moa":"L-Type VGCC","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"3Z","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3Z \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"3Z \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"Chikungunya Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Bavarian Nordic","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Bavarian Nordic"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"CVS Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ CVS Health","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ CVS Health"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bharat Serums & Vaccines ltd","amount2":1.6399999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1.6399999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Serums & Vaccines ltd \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Serums & Vaccines ltd \/ Mankind Pharma"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BDR Pharmaceuticals \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Mankind Pharma"},{"orgOrder":0,"company":"Auro Vaccines","sponsor":"Hilleman Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Large Molecule","year":"2025","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Auro Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Auro Vaccines \/ Hilleman Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Auro Vaccines \/ Hilleman Laboratories"},{"orgOrder":0,"company":"PopVax","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PopVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PopVax \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"PopVax \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Suven Pharmaceuticals","sponsor":"Right Brain Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"RB-190","moa":"Dopamine","graph1":"Neurology","graph2":"IND Enabling","graph3":"Suven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suven Pharmaceuticals \/ Right Brain Bio","highestDevelopmentStatusID":"5","companyTruncated":"Suven Pharmaceuticals \/ Right Brain Bio"},{"orgOrder":0,"company":"Peptris Technologies","sponsor":"Revio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"RT001","moa":"Lipid peroxidation","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Peptris Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptris Technologies \/ Revio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Peptris Technologies \/ Revio Therapeutics"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Synthon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Synthon Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Synthon Pharmaceuticals"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Celnova Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Celnova Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Celnova Pharma"},{"orgOrder":0,"company":"Mangalam Drugs & Organics Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Pyronaridine Tetraphosphate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mangalam Drugs & Organics Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"15","companyTruncated":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Metoprolol Succinate","moa":"Adrenergic-beta 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"Biocon Biologics \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocon Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ The Medicines Patent Pool","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"JB Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ JB Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ JB Pharma"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Government of Bangladesh","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Government of Bangladesh","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Government of Bangladesh"},{"orgOrder":0,"company":"Virchow Group","sponsor":"The Russian Direct Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Virchow Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Virchow Group \/ The Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Virchow Group \/ The Russian Direct Investment Fund"},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Akers Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Premas Biotech \/ Akers Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Premas Biotech \/ Akers Biosciences"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Lyrus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Lyrus Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Lyrus Life Sciences"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Neuraxpharm"},{"orgOrder":0,"company":"Cipla","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cipla \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Eli Lilly"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"MediCane Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ MediCane Health","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\'s Laboratories \/ MediCane Health"},{"orgOrder":0,"company":"Cipla","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Cipla \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Alvotech"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Novumcella","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Novumcella","highestDevelopmentStatusID":"15","companyTruncated":"Stempeutics \/ Novumcella"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Simtra BioPharma Solutions","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Simtra BioPharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Simtra BioPharma Solutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Simtra BioPharma Solutions \/ Novavax"},{"orgOrder":0,"company":"Indian Defence Research And Development Organisation","sponsor":"BDR Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"2-Deoxy-D-Glucose","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Defence Research And Development Organisation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Indian Defence Research And Development Organisation \/ BDR Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Indian Defence Research And Development Organisation \/ BDR Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Beximco Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Beximco Pharmaceuticals"},{"orgOrder":0,"company":"Biocon","sponsor":"Biomm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Biomm","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Biomm"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"BBV87","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Bharat Biotech \/ CEPI"},{"orgOrder":0,"company":"Biological E","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Biological E \/ CEPI","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ CEPI"},{"orgOrder":0,"company":"Cipla","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Wanbury Limited","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Folic Acid","moa":"||Dihydrofolate reductase","graph1":"Hematology","graph2":"Approved FDF","graph3":"Wanbury Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Wanbury Limited \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Wanbury Limited \/ Cipla"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Cipla"},{"orgOrder":0,"company":"Cipla","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Partnership","leadProduct":"Clobazam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cipla \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Sanofi"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Serum Institute of India \/ Codagenix","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Codagenix"},{"orgOrder":0,"company":"Veritaz Healthcare","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Azithromycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Veritaz Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veritaz Healthcare \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"Veritaz Healthcare \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"DTaP-IPV-HB-Hib","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Syringe","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Sanofi"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Gilead Sciences"},{"orgOrder":0,"company":"Edge Pharma","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Vancomycin HCl","moa":"Cell wall synthesis","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Edge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edge Pharma \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Edge Pharma \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences"},{"orgOrder":0,"company":"Entero Healthcare Solutions","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Entero Healthcare Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entero Healthcare Solutions \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Entero Healthcare Solutions \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Ethypharm"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Excellgene","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ Excellgene","highestDevelopmentStatusID":"4","companyTruncated":"Bharat Biotech \/ Excellgene"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"XL102","moa":"Cyclin-dependent kinase 7","graph1":"Oncology","graph2":"Preclinical","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Aurigene \/ Exelixis"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"Fermenta Biotech Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurigene Pharmaceutical Services \/ Fermenta Biotech Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aurigene Pharmaceutical Services \/ Fermenta Biotech Limited"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"The Department of Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ The Department of Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ The Department of Biotechnology"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Wockhardt \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Wockhardt \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Olopatadine Hydrochloride","moa":"||5-HT1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Menarini"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glenmark Pharmaceuticals \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ BeiGene"},{"orgOrder":0,"company":"Hester Biosciences","sponsor":"BIRAC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hester Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hester Biosciences \/ BIRAC","highestDevelopmentStatusID":"15","companyTruncated":"Hester Biosciences \/ BIRAC"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Olopatadine Hydrochloride","moa":"||5-HT1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Excelra","sponsor":"HotSpot Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Excelra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Excelra \/ HotSpot Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Excelra \/ HotSpot Therapeutics"},{"orgOrder":0,"company":"Jawaharlal Nehru Centre for Advanced Scientific Research","sponsor":"India Globalization Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"TGR-63","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Jawaharlal Nehru Centre for Advanced Scientific Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jawaharlal Nehru Centre for Advanced Scientific Research \/ India Globalization Capital","highestDevelopmentStatusID":"4","companyTruncated":"Jawaharlal Nehru Centre for Advanced Scientific Research \/ India Globalization Capital"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aragen Life Sciences \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ Clearmind Medicine"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"XL114","moa":"BTK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Aurigene \/ Exelixis"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Lee Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"2-Deoxy-D-Glucose","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ Lee Pharma","highestDevelopmentStatusID":"1","companyTruncated":"CSIR-Indian Institute of Chemical Technology \/ Lee Pharma"},{"orgOrder":0,"company":"Biological E","sponsor":"International Finance Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Biological E \/ International Finance Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ International Finance Corporation"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"Kainomyx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aurigene Pharmaceutical Services \/ Kainomyx","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene Pharmaceutical Services \/ Kainomyx"},{"orgOrder":0,"company":"Institute of Chemical Technology","sponsor":"Lasa Supergenerics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Institute of Chemical Technology \/ Lasa Supergenerics","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Chemical Technology \/ Lasa Supergenerics"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Lipidor AB","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Cadila Pharmaceuticals \/ Lipidor AB","highestDevelopmentStatusID":"8","companyTruncated":"Cadila Pharmaceuticals \/ Lipidor AB"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"ABBV-525","moa":"MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lupin Ltd \/ AbbVie Inc"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Evofem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Divestment","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Evofem Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Evofem Biosciences"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BI 1701963","moa":"||MEK receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupin Ltd \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Lupin Ltd \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Salus Pharmaceuticals","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Salus Pharmaceuticals \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Salus Pharmaceuticals \/ AFT Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"DNDi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ DNDi","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Reddy\\'s Laboratories \/ DNDi"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Natco Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"OLIC","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Drospirenone","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ OLIC","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ OLIC"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Lupin Ltd \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Nicox SA"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Diclofenac","moa":"COX-1\/2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vildagliptin","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Novavax"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Ocugen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Whole-Virion Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Ocugen","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Ocugen"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Sertaconzole Nitrate","moa":"Cell membrane synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Glenmark Pharmaceuticals \/ Eris Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Eris Lifesciences"},{"orgOrder":0,"company":"Cellogen Therapeutics","sponsor":"Natco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellogen Therapeutics \/ Natco Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Cellogen Therapeutics \/ Natco Pharma"},{"orgOrder":0,"company":"VedTechBio","sponsor":"RenaissThera","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"VedTechBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"VedTechBio \/ RenaissThera","highestDevelopmentStatusID":"3","companyTruncated":"VedTechBio \/ RenaissThera"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Supriya Lifescience \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Supriya Lifescience \/ Revive Therapeutics"},{"orgOrder":0,"company":"Biological E","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Daptomycin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biological E \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Sandoz B2B"},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Phenobarbital Sodium","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SPARC \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"SPARC \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cipla","sponsor":"Stempeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Allogeneic Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ Stempeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Stempeutics"},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"SCD-044","moa":"S1P1R","graph1":"Dermatology","graph2":"Phase II","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SPARC \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"SPARC \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Formoterol Fumarate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Mankind Pharma"},{"orgOrder":0,"company":"Channel BioSciences","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"BHV-7000","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Channel BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Channel BioSciences \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Channel BioSciences \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Nicotinamide","moa":"Fatty-acid amide hydrolase 1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Anglo-French Drugs and industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anglo-French Drugs and industries \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Anglo-French Drugs and industries \/ Lupin Ltd"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"ImmunoACT","sponsor":"Caring Cross","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Actalycabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunoACT","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoACT \/ Caring Cross","highestDevelopmentStatusID":"15","companyTruncated":"ImmunoACT \/ Caring Cross"},{"orgOrder":0,"company":"Biological E","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Biological E \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Medicure","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Reliance Life Sciences Private Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reliance Life Sciences Private Limited \/ Medicure","highestDevelopmentStatusID":"1","companyTruncated":"Reliance Life Sciences Private Limited \/ Medicure"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Marc Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"S007-867","moa":"Collagen induced aggregation","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ Marc Laboratories","highestDevelopmentStatusID":"5","companyTruncated":"CSIR-Indian Institute of Chemical Technology \/ Marc Laboratories"},{"orgOrder":0,"company":"Cipla","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Gilead Sciences"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Monopar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aragen Life Sciences \/ Monopar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ Monopar Therapeutics"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lupin Ltd \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ DKSH"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Tiotropium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Lupin Ltd \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Mark Cuban Cost Plus Drug Company"},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Curadev Pharma Private Limited","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curadev Pharma Private Limited \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Curadev Pharma Private Limited \/ Bayer AG"},{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Syngene International Limited","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syngene International Limited \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Syngene International Limited \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"CSIR-CDRI","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Discovery","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ CSIR-CDRI","highestDevelopmentStatusID":"2","companyTruncated":"Zydus Lifesciences \/ CSIR-CDRI"},{"orgOrder":0,"company":"Biological E","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Tetravalent Dengue Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biological E \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Brinton Pharmaceuticals","sponsor":"University of Central Lancashire","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Brinton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Brinton Pharmaceuticals \/ University of Central Lancashire","highestDevelopmentStatusID":"4","companyTruncated":"Brinton Pharmaceuticals \/ University of Central Lancashire"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Gavi","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Gavi"},{"orgOrder":0,"company":"Sami-Sabinsa Group","sponsor":"Postbiotics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"Lactobacillus Paracasei","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sami-Sabinsa Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sami-Sabinsa Group \/ Postbiotics","highestDevelopmentStatusID":"15","companyTruncated":"Sami-Sabinsa Group \/ Postbiotics"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2020","type":"Divestment","leadProduct":"Mometasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eli Lilly"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Steven & Alexandra Cohen Foundation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Steven & Alexandra Cohen Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Steven & Alexandra Cohen Foundation"},{"orgOrder":0,"company":"Indian Institute of Science","sponsor":"Ignite Life Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Indian Institute of Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Indian Institute of Science \/ Ignite Life Science Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Indian Institute of Science \/ Ignite Life Science Foundation"},{"orgOrder":0,"company":"Immuneel Therapeutics","sponsor":"taiba Healthcare Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Varnimcabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immuneel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immuneel Therapeutics \/ taiba Healthcare Group","highestDevelopmentStatusID":"8","companyTruncated":"Immuneel Therapeutics \/ taiba Healthcare Group"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ The Medicines Patent Pool","highestDevelopmentStatusID":"15","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Centaur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centaur Pharmaceuticals \/ Vaxart","highestDevelopmentStatusID":"6","companyTruncated":"Centaur Pharmaceuticals \/ Vaxart"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Strides Pharma Science \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd"},{"orgOrder":0,"company":"Central Drug Research Institute","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Central Drug Research Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Central Drug Research Institute \/ Cipla","highestDevelopmentStatusID":"4","companyTruncated":"Central Drug Research Institute \/ Cipla"},{"orgOrder":0,"company":"Bugworks","sponsor":"Cytecare Cancer Hospitals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bugworks \/ Cytecare Cancer Hospitals","highestDevelopmentStatusID":"2","companyTruncated":"Bugworks \/ Cytecare Cancer Hospitals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Biotechnology Industry Research Assistance Council","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Biotechnology Industry Research Assistance Council","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Biotechnology Industry Research Assistance Council"},{"orgOrder":0,"company":"Intas Pharmaceuticals","sponsor":"Naari","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Intas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intas Pharmaceuticals \/ Naari","highestDevelopmentStatusID":"15","companyTruncated":"Intas Pharmaceuticals \/ Naari"},{"orgOrder":0,"company":"Sanzyme","sponsor":"J.B.Chemicals & Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Microorganism","year":"2022","type":"Acquisition","leadProduct":"Lacticacid Bacillus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sanzyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanzyme \/ J.B.Chemicals & Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanzyme \/ J.B.Chemicals & Pharmaceuticals"},{"orgOrder":0,"company":"PopVax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PopVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PopVax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"PopVax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"NovoMedix","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"NMX1","moa":"mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"NovoMedix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NovoMedix \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"NovoMedix \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Cipla","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Cipla \/ SIGA Technologies"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506 binding protein 1A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mankind Pharma \/ Panacea Biotec Limited","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Panacea Biotec Limited"},{"orgOrder":0,"company":"Nestl\u00e9 India Limited","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Biotin","moa":"||Oligodendrocytes myelin synthesis","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Nestl\u00e9 India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nestl\u00e9 India Limited \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Nestl\u00e9 India Limited \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Seagull Biosolutions","sponsor":"The Union science and technology ministry of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Active Virosome Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Seagull Biosolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagull Biosolutions \/ The Union science and technology ministry of India","highestDevelopmentStatusID":"1","companyTruncated":"Seagull Biosolutions \/ The Union science and technology ministry of India"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"||IL-6-alpha receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Enzene Biosciences \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Enzene Biosciences \/ Theramex"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Natco Pharma \/ The Medicines Patent Pool","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Bugworks","sponsor":"University Of Tokyo Edge Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"GYROX-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bugworks \/ University Of Tokyo Edge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ University Of Tokyo Edge Capital"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"PENAO Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"PENAO","moa":"||AdNT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd"},{"orgOrder":0,"company":"Excelra","sponsor":"X-Chem","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Excelra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Excelra \/ X-Chem","highestDevelopmentStatusID":"2","companyTruncated":"Excelra \/ X-Chem"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"ErbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enzene Biosciences \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Enzene Biosciences \/ Lupin Ltd"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1.6399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Serums & Vaccines ltd \/ Mankind Pharma"},{"orgOrder":0,"company":"Aksigen Hospital Care","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Bromelain","moa":"||Prostaglandin","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aksigen Hospital Care","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aksigen Hospital Care \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aksigen Hospital Care \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Kalinga Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Crosslinked Hydrogel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supriya Lifescience \/ Kalinga Institute of Technology","highestDevelopmentStatusID":"4","companyTruncated":"Supriya Lifescience \/ Kalinga Institute of Technology"},{"orgOrder":0,"company":"Orchid Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Orchid Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchid Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Orchid Pharma \/ Cipla"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biocon Biologics \/ Eris Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Eris Lifesciences"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Unitaid","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Rifapentine","moa":"||DdRP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Unitaid","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Unitaid"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Bilthoven Biologicals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Polio Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution\/Drops","sponsorNew":"Bharat Biotech \/ Bilthoven Biologicals","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Bilthoven Biologicals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Hempstreet","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Curcumin","moa":"||PPA receptor-gamma","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Hempstreet \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hempstreet \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"The Translational Health Science and Technology Institute","sponsor":"Nanogen Pharmaceutical Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Nanocovax","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Translational Health Science and Technology Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Translational Health Science and Technology Institute \/ Nanogen Pharmaceutical Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"The Translational Health Science and Technology Institute \/ Nanogen Pharmaceutical Biotechnology"},{"orgOrder":0,"company":"Jagdale Industries","sponsor":"Bharat Serums & Vaccines ltd","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Isoxsuprine Hydrochloride","moa":"ADRB2","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Jagdale Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jagdale Industries \/ Bharat Serums & Vaccines ltd","highestDevelopmentStatusID":"15","companyTruncated":"Jagdale Industries \/ Bharat Serums & Vaccines ltd"},{"orgOrder":0,"company":"SPARC","sponsor":"Tripoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SPARC \/ Tripoint Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"SPARC \/ Tripoint Therapeutics"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Biolexis","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biolexis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biolexis \/ Akston Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Biolexis \/ Akston Biosciences"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Abatacept","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Coya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Coya Therapeutics"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eris Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eris Lifesciences"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Cediprof","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Cediprof"},{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Omexa Formulary","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ipca Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipca Laboratories \/ Omexa Formulary","highestDevelopmentStatusID":"1","companyTruncated":"Ipca Laboratories \/ Omexa Formulary"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"EGFR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Exeltis"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"FAR Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aragen Life Sciences \/ FAR Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ FAR Biotech"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Refana","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Panacea Biotec Limited \/ Refana","highestDevelopmentStatusID":"4","companyTruncated":"Panacea Biotec Limited \/ Refana"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Novavax"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Deactivated Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ Thomas Jefferson University","highestDevelopmentStatusID":"4","companyTruncated":"Bharat Biotech \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Aurigene Oncology","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aurigene Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene Oncology \/ Indian Council of Medical Research","highestDevelopmentStatusID":"4","companyTruncated":"Aurigene Oncology \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Biogenomics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2023","type":"Partnership","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"USV Private Limited \/ Biogenomics","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Biogenomics"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"Aurigene","sponsor":"Olema Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aurigene \/ Olema Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene \/ Olema Oncology"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Evive Biotech","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"G-CSF receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurobindo Pharma Limited \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo Pharma Limited \/ Evive Biotech"},{"orgOrder":0,"company":"Jubilant Generics","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jubilant Generics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jubilant Generics \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Jubilant Generics \/ Novavax"},{"orgOrder":0,"company":"Saptagir Laboratories","sponsor":"Jubilant Generics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Saptagir Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Saptagir Laboratories \/ Jubilant Generics","highestDevelopmentStatusID":"15","companyTruncated":"Saptagir Laboratories \/ Jubilant Generics"},{"orgOrder":0,"company":"Rivaara Labs","sponsor":"GC Cell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Immuncell-LC","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rivaara Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Rivaara Labs \/ GC Cell","highestDevelopmentStatusID":"15","companyTruncated":"Rivaara Labs \/ GC Cell"},{"orgOrder":0,"company":"Aurigene","sponsor":"EQRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aurigene \/ EQRx","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene \/ EQRx"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CHO-DG44","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aragen Life Sciences \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"Aragen Life Sciences \/ Serum Institute of India Private Limited"},{"orgOrder":0,"company":"Verve","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Verve","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Verve \/ Eli Lilly"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Jiangxi Jemincare Group Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Nafithromycin","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wockhardt \/ Jiangxi Jemincare Group Company","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ Jiangxi Jemincare Group Company"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Tildrakizumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Biocon \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Zentiva"},{"orgOrder":0,"company":"Biocon","sponsor":"Juno Pharmaceuticals Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Biocon \/ Juno Pharmaceuticals Pty Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Juno Pharmaceuticals Pty Ltd"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Vital Therapeutics & Formulations Pvt Ltd","sponsor":"Cambrian BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"VTA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vital Therapeutics & Formulations Pvt Ltd","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vital Therapeutics & Formulations Pvt Ltd \/ Cambrian BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"Vital Therapeutics & Formulations Pvt Ltd \/ Cambrian BioPharma"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Wockhardt","sponsor":"ICICI Prudential","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wockhardt \/ ICICI Prudential","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ ICICI Prudential"},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Famy Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Famy Life Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Famy Life Sciences \/ Viatris"},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Famy Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Famy Life Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Famy Life Sciences \/ Viatris"},{"orgOrder":0,"company":"Wockhardt","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Wockhardt \/ UK Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ UK Government"},{"orgOrder":0,"company":"Wockhardt","sponsor":"U.S Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Wockhardt \/ U.S Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ U.S Government"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Everolimus","moa":"||IGF-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aragen Life Sciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Aragen Life Sciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bumetanide","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Moebius Medical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MM-II","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Moebius Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Moebius Medical"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Moebius Medical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MM-II","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Moebius Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Moebius Medical"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Royalsense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"||H\/K ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Royalsense","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royalsense \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Royalsense \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quinidine sulphate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirabegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ropanicant","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Colestipol","moa":"Bile acid reabsorption","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Indian Council of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocon \/ Equillium","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Equillium"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Albumin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Deoxy-D-Glucose","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interferon Alpha-2B","moa":"INF-alpha receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adapalene","moa":"||RAR-beta","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vilanterol Trifenatate","moa":"||Adrenergic beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"Zydus Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olmesartan Medoxomil","moa":"||Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Mynvax","sponsor":"Indian Institute of Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mynvax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Mynvax \/ Indian Institute of Science","highestDevelopmentStatusID":"1","companyTruncated":"Mynvax \/ Indian Institute of Science"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interferon Alpha-2B","moa":"INF-alpha receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"SDN-037","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"All India Institutes of Medical Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"All India Institutes of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"All India Institutes of Medical Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"All India Institutes of Medical Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Axon Drugs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Drugs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Axon Drugs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Drugs \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Prochlorperazine Edisylate","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caplin Steriles \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Caplin Steriles \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Viatris"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"||CYP17A1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NLP21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaLead Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Marksans Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acetazolamide","moa":"Carbonic anhydrase","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aciclovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cadila Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Enzene Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Enzene Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adapalene","moa":"||RAR-beta","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pregabalin","moa":"||Alpha 2-beta subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Anglo-French Drugs and industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anglo-French Drugs and industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Anglo-French Drugs and industries \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Alchem International Private Ltd","sponsor":"AIIMS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Curcuminoid","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alchem International Private Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Alchem International Private Ltd \/ AIIMS","highestDevelopmentStatusID":"1","companyTruncated":"Alchem International Private Ltd \/ AIIMS"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Albendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"M2 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavaborole","moa":"Leucine-tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"||H1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Equillium","highestDevelopmentStatusID":"6","companyTruncated":"Biocon \/ Equillium"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"14-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bisoprolol Fumarate","moa":"||ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apex Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Andrographis Paniculata","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Apex Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Apex Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apex Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Themis Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inosine Pranobex","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Themis Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Themis Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Themis Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Zingivir-H","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pankajakasthuri Herbal Research Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atenolol","moa":"||Adrenergic-beta 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hetero Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hetero Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hetero Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Azithromycin","moa":"70s ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Bal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bal Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bal Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indian Council of Medical Research \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Indian Council of Medical Research \/ University of Oxford"},{"orgOrder":0,"company":"IDMC","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"IDMC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IDMC \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"IDMC \/ AstraZeneca"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ The International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Bharat Biotech \/ The International Vaccine Institute"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Biapenem","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Biological E \/ Dynavax Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Dynavax Technologies"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Film, Dispersible","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone Valerate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Enzene Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enzene Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Enzene Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"AIIMS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ AIIMS","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ AIIMS"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elobixibat Hydrate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bromfenac","moa":"Prostaglandin G\/H synthase 1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bumetanide","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bumetanide","moa":"NK ATPase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Difgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Difgen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Difgen \/ Inapplicable"},{"orgOrder":0,"company":"Difgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Film","sponsorNew":"Difgen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Difgen \/ Inapplicable"},{"orgOrder":0,"company":"Bugworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bugworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zenara Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zenara Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zenara Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Caplin Steriles \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Caplin Steriles \/ Inapplicable"},{"orgOrder":0,"company":"Caplin Point Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Argatroban","moa":"Thrombin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Caplin Point Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caplin Point Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Caplin Point Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milrinone","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Caplin Steriles \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Caplin Steriles \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SucrAlphate","moa":"Pepsin A5","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Carmustine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Indian Immunologicals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CDO-7N-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Immunologicals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Immunologicals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indian Immunologicals \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silodosin","moa":"||Adrenergic alpha-1A receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"4-Valent HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Washington University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAd36-SARS-CoV-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bharat Biotech \/ Washington University","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Washington University"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAdOx1 biEBOV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ University of Oxford","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ University of Oxford"},{"orgOrder":0,"company":"Cintex","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlorzoxazone","moa":"KCNN4","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Cintex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cintex \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cintex \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cinacalcet Hydrochloride","moa":"CaR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Indian Institute Of Chemical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cipla \/ Indian Institute Of Chemical Technology","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Indian Institute Of Chemical Technology"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sumatriptan","moa":"5-HT1B receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Cohance Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cohance Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cohance Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cohance Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Loratadine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marksans Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Akumentis Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Akumentis Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Akumentis Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akumentis Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Akumentis Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Akumentis Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Akumentis Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akumentis Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tetravalent HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Zingivir-H","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pankajakasthuri Herbal Research Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"ADRB","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eisai","highestDevelopmentStatusID":"4","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eisai"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR-alpha\/gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mankind Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inactivated Trivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venlafaxine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cangrelor","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MSN Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Bayer college of medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Biological E \/ Bayer college of medicine","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Bayer college of medicine"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Ocugen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Ocugen","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Ocugen"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Octavius Pharma Pvt. Ltd","sponsor":"Senta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Menthol","moa":"||Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Octavius Pharma Pvt. Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Octavius Pharma Pvt. Ltd \/ Senta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Octavius Pharma Pvt. Ltd \/ Senta Pharma"},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CRD3874-SI","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"Curadev Pharma Private Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curadev Pharma Private Limited \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Curadev Pharma Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"||Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ LAXAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"CSIR-Indian Institute of Chemical Technology \/ LAXAI Life Sciences"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"||Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Entod Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Entod Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Entod Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Darunavir","moa":"HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Darunavir","moa":"HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Entod Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Entod Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Entod Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||Adrenergic alpha-A1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"LifeCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"LifeCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LifeCell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LifeCell \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Desonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trazodone Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amphetamine","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dichlorphenamide","moa":"CA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Torrent Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"COX","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Digoxin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Docosanol","moa":"Viral fusion","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxepin Hydrochloride","moa":"H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"J.B.Chemicals & Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxepin Hydrochloride","moa":"H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxepin Hydrochloride","moa":"H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"ForDoz","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ ForDoz","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ ForDoz"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Capecitabine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Appili Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Appili Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Appili Therapeutics"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Succinylcholine Chloride","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aurigene Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ribrecabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aurigene Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aurigene Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Famotidine","moa":"||H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Hib DTP Poliovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azilsartan","moa":"||Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Efavirenz","moa":"||Reverse ttranscriptase\/RNaseH","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"||Mucopeptide synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eribulin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ertapenem Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Erythromycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Orchid Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Orchid Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchid Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchid Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Eyestem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelium Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyestem \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eyestem \/ Inapplicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Marksans Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zenara Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zenara Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zenara Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Brinton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brinton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Brinton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Brinton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dextroamphetamine Saccharate","moa":"||VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Febuxostat","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Febuxostat","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenofibrate","moa":"PPA receptor-alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fesoterodine","moa":"M2 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levomilnacipran","moa":"SNR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aqueous Extract of Cocculus Hirsutus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fludrocortisone Acetate","moa":"Mineralocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fluocytosine","moa":"Thymidylate synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Marksans Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gabapentin","moa":"CaV channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gabapentin","moa":"CaV channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganirelix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foscarnet Sodium","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Methylprednisolone Sodium Succinate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Guaifenesin","moa":"||NMDA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Loperamide Hydrochloride","moa":"||Mu opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"||ACE2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metoprolol Succinate","moa":"Adrenergic-beta 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Venlafaxine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ HDT Biotech"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506 binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remogliflozin Etabonate","moa":"||SGLT","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remogliflozin Etabonate","moa":"||SGLT","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||5-HT1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Adroit Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setria Glutathione","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adroit Biomed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"Adroit Biomed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adroit Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Syringe","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GRC 54276","moa":"HPK1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Guaifenesin","moa":"NMDA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Marksans Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Guaifenesin","moa":"NMDA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Triazolam","moa":"GABA A receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Indian Immunologicals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Havisure","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Immunologicals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Indian Immunologicals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indian Immunologicals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hetero Drugs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hetero Drugs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hetero Drugs \/ Inapplicable"},{"orgOrder":0,"company":"Hetero","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hetero","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hetero \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hetero \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"BBV131","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Quadrivalent HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Insulin","moa":"Protein tyrosine kinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydralazine Hydrochloride","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isosorbide Mononitrate","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Immuneel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Varnimcabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immuneel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immuneel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immuneel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Alpha-2B","moa":"INF-alpha receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Optimus Pharma","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Optimus Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Optimus Pharma \/ JSS Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Optimus Pharma \/ JSS Medical Research"},{"orgOrder":0,"company":"AIIMS","sponsor":"CSIR-Indian Institute of Chemical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"BGR-34","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AIIMS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AIIMS \/ CSIR-Indian Institute of Chemical Technology","highestDevelopmentStatusID":"15","companyTruncated":"AIIMS \/ CSIR-Indian Institute of Chemical Technology"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Celon Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CPL\u2019280","moa":"GPR40","graph1":"Endocrinology","graph2":"Phase I","graph3":"Celon Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Celon Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celon Labs \/ Inapplicable"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Adrenergic receptor-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"4-Valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Indian Institute of Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Indian Institute of Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Indian Institute of Science \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Indian Institute of Science \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Indomethacin","moa":"COX-1\/COX-2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"INJA Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glutathione","moa":"Glutathione peroxidase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"INJA Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INJA Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"INJA Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Intas Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Itraconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Intas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intas Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intas Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"HCN4","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Pharmova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Jubilant Pharmova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Pharmova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant Pharmova \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vodobatinib","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharma Advanced Research Company \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma Advanced Research Company \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vodobatinib","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharma Advanced Research Company \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma Advanced Research Company \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Biocon \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Viatris"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MSN Laboratories \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Breckenridge Pharmaceutical"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Sanzyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic Strain SNZ 1969","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sanzyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanzyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanzyme \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Natco Pharma \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"SunTrap","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lesoleil","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SunTrap","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunTrap \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SunTrap \/ Inapplicable"},{"orgOrder":0,"company":"SunTrap","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lesoleil","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SunTrap","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunTrap \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SunTrap \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR-alpha\/gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Biocon \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Zentiva"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Linagliptin","moa":"Dipeptidyl peptidase 4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lobeglitazone","moa":"PPAR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lobeglitazone","moa":"PPAR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Loperamide Hydrochloride","moa":"Mu opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Pressurised Metered Dose Inhaler","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevelamer Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kwality Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kwality Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha 2-beta subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha 2-beta subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha 2-beta subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha 2-beta subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Macitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Saffron Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Entod Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Entod Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Entod Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Maiden Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Promethazine","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Maiden Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Syrup","sponsorNew":"Maiden Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Maiden Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mankind Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mankind Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Maps Laboratories Private Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Maps Laboratories Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Indian Immunologicals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Measles-rubella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Indian Immunologicals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indian Immunologicals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indian Immunologicals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Micafungin","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Nafithromycin","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wockhardt \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wockhardt \/ Inapplicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MKP10241","moa":"GPR119","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Mankind Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mankind Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Moebius Medical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MM-II","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Moebius Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Moebius Medical"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MM-II","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MSN Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MSN Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Hetero","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Natco Pharma \/ Hetero","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Hetero"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Biofabri","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Bharat Biotech \/ Biofabri","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Biotech \/ Biofabri"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucine-tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aleor Dermaceuticals \/ Alembic Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Alembic Pharmaceuticals Limited"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Entod Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Entod Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entod Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Concord Biotech","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||IMPDH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Concord Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concord Biotech \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Concord Biotech \/ Lupin Ltd"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||IMPDH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirabegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Nelarabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Nelarabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoACT","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Actalycabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunoACT","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoACT \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunoACT \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nicardipine Hydrochloride","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Senores Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senores Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Senores Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nicardipine Hydrochloride","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Norethisterone","moa":"LH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amrta Karuna","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Vopec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Vopec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Vopec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NovaLead Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Novavax"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonidegib Phosphate","moa":"Homolog","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Curcuma Longa","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline","moa":"MMP-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Northwestern University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"||RNR","graph1":"Oncology","graph2":"Phase I","graph3":"Nanopharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanopharmaceutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Nanopharmaceutics \/ Northwestern University"},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Emcure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emcure Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emcure Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZY-19489","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxcarbazepine","moa":"Voltage sensitive sodium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MSN Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Panacea Biotec Limited \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Panacea Biotec Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"H\/K ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Alpha-2B","moa":"INF-alpha receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Akums Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"FDC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"FDC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FDC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"FDC \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plerixafor","moa":"CXCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plerixafor","moa":"CXCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Salk Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Alfred E Tiefenbacher GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Lupin Ltd \/ Alfred E Tiefenbacher GmbH","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Alfred E Tiefenbacher GmbH"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Enteric Coated","sponsorNew":"Mankind Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"MSN Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Bajaj Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bajaj Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bajaj Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bajaj Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Cadila Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic alpha-1A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic alpha-1A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Utreglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha 2-beta subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Triple Antigen Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Premas Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Premas Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Premas Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Premas Biotech \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Premas Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Entod Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entod Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Entod Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Entod Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entod Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Entod Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Darunavir","moa":"HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Prochlorperazine Maleate","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Adrenergic receptor-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Pyrimethamine","moa":"DHFR","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Zentiva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Zentiva"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ranolazine","moa":"SCN4A\/SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Protein-Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Reliance Life Sciences Private Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reliance Life Sciences Private Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Reliance Life Sciences Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Cassiopea","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Cassiopea","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Cassiopea"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akums Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Nicotinic receptor-alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rosuvastatin","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Bionxt Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Lifesciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Bionxt Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rufinamide","moa":"Sodium channel alpha subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rufinamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||5-HT1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||5-HT1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||5-HT1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lupin Ltd \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Sandoz B2B"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Exemed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exemed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR-alpha\/gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR-alpha\/gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR-alpha\/gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Hempstreet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Jatamansi","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hempstreet \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hempstreet \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 mAChR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CDX-005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serum Institute of India \/ Codagenix","highestDevelopmentStatusID":"4","companyTruncated":"Serum Institute of India \/ Codagenix"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ AstraZeneca"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevelamer Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Phenobarbital Sodium","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Phenobarbital Sodium","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"sigx1094","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Signet \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||5-hydroxytryptamine receptor 1A","graph1":"Urology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"M3 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"M3 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"||M3 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"MSN Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"SP Accure Labs Pvt. Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SP Accure Labs Pvt. Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"SP Accure Labs Pvt. Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SP Accure Labs Pvt. Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Stelis Biopharma","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Stelis Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Stelis Biopharma \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Stelis Biopharma \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Merck & Co"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxybutynin Hydrochloride","moa":"M2 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ethacrynic Acid","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Butalbital","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ursodeoxycholic Acid","moa":"AKR1C2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LAXAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LAXAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LAXAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hetero Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hetero Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hetero Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Sugammadex rocuronium chelating complex","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Masupirdine","moa":"||5-HT6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masupirdine","moa":"||5-HT6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Samelisant","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tavaborole","moa":"Leucine-tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tavaborole","moa":"Leucine-tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Drugs","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hetero Drugs \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Drugs \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Protein Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Reliance Life Sciences Private Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reliance Life Sciences Private Limited \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Reliance Life Sciences Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nystatin","moa":"||Ergosterol sequestering agent","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aleor Dermaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metolazone","moa":"Sodium-chloride cotransporter","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nystatin","moa":"||Ergosterol sequestering agent","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Lincoln Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cephalexin Hydrochloride","moa":"PBP3","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lincoln Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lincoln Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lincoln Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"PNB Vesper","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GPP-Baladol","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PNB Vesper","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PNB Vesper \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PNB Vesper \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Vivimed Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Vivimed Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vivimed Labs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivimed Labs \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Immunology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Gufic Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gufic Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gufic Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gufic Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Emcure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Emcure Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emcure Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PNB Vesper","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GPP-Baladol","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PNB Vesper","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PNB Vesper \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PNB Vesper \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Global Response Aid FZCO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Global Response Aid FZCO","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Global Response Aid FZCO"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR-alpha\/gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Gennova Biopharmaceuticals \/ HDT Biotech"},{"orgOrder":0,"company":"PNB Vesper","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GPP-Baladol","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PNB Vesper","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PNB Vesper \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PNB Vesper \/ Inapplicable"},{"orgOrder":0,"company":"Biological E","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biological E \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Indian Council of Medical Research \/ Bharat Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Indian Council of Medical Research \/ Bharat Biotech"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lee Pharma \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Aurigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AUR101","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurigene \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aurigene \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Gilead Sciences"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"COX","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fluphenazine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sapropterin Hydrochloride","moa":"PAH","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sapropterin Hydrochloride","moa":"PAH","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlordiazepoxide","moa":"||Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Tergene Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tergene Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tergene Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tergene Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"PNB Vesper","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GPP-Baladol","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PNB Vesper","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PNB Vesper \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PNB Vesper \/ Inapplicable"},{"orgOrder":0,"company":"National Institute of Immunology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Immunology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"National Institute of Immunology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Immunology \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating, Delayed Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hetero Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hetero Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ AstraZeneca"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Novavax"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Zingivir-H","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pankajakasthuri Herbal Research Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Desidustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"The Himalaya Drug Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Guduchi","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Himalaya Drug Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Himalaya Drug Company \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The Himalaya Drug Company \/ Inapplicable"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Indian Council of Medical Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indian Council of Medical Research \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"CSIR-Indian Institute of Chemical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LAXAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LAXAI Life Sciences \/ CSIR-Indian Institute of Chemical Technology","highestDevelopmentStatusID":"8","companyTruncated":"LAXAI Life Sciences \/ CSIR-Indian Institute of Chemical Technology"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Urinastatin","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Mycobacterium w","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Cadila Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Topiramate","moa":"GABA-alpha 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Midodrine","moa":"Adrenergic receptor-alpha 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Loratadine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"J.B.Chemicals & Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"10-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ AstraZeneca"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Thiamine Hydrochloride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Topiramate","moa":"GABA-alpha 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"||RNR","graph1":"Oncology","graph2":"Phase III","graph3":"Nanopharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nanopharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanopharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trospium Chloride","moa":"Undisclosed","graph1":"Urology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Labetalol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Caplin Steriles","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Caplin Steriles \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Caplin Steriles \/ Inapplicable"},{"orgOrder":0,"company":"Ispen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ispen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ispen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ispen \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolterodine Tartrate","moa":"M3 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Unichem Laboratories Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Loratadine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Butalbital","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Butalbital","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fluocytosine","moa":"Thymidylate synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gabapentin","moa":"CaV channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen Sodium","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha 2-beta subunit","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tetracycline Hydrochloride","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ursodeoxycholic Acid","moa":"AKR1C2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Nicotinic receptor-alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Strides Pharma Science \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Venus Remedies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Venus Remedies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Venus Remedies \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Vestige Marketing","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Biotin","moa":"Krebs cycle activatior","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Vestige Marketing","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vestige Marketing \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vestige Marketing \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vilanterol Trifenatate","moa":"||Adrenergic beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Glenmark Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vilanterol Trifenatate","moa":"||Adrenergic beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vilanterol Trifenatate","moa":"||Adrenergic beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Themis Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inosine Pranobex","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Themis Medicare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Themis Medicare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Themis Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vopec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vopec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vopec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Vaxart","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syngene International Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syngene International Limited \/ Vaxart","highestDevelopmentStatusID":"8","companyTruncated":"Syngene International Limited \/ Vaxart"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bharat Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diperoxochloric Acid","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Centaur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Centaur Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centaur Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zenara Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zenara Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zenara Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zenara Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zenara Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Zenara Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lee Pharma \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Covimabs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline","moa":"MMP-13","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nortriptyline","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Midodrine","moa":"Adrenergic receptor-alpha 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cisatracurium Besylate","moa":"Nicotinic acetylcholine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Alpha-2B","moa":"INF-alpha receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Typhoid Vi Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Quadrivalent Inactivated Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Methenamine Hippurate","moa":"Formaldehyde synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akums Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Nectar Lifecare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Nectar Lifecare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nectar Lifecare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nectar Lifecare \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Bilayer","sponsorNew":"Mascot Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Avas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Avas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Avas Pharmaceuticals"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPAR-gamma","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bosentan Hydrate","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, For Suspension","sponsorNew":"Lupin Ltd \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Natco Pharma"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dronedarone Hydrochloride","moa":"Na\/K\/Ca channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dronedarone Hydrochloride","moa":"Na\/K\/Ca channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"||Adrenergic-beta 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Senores Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Senores Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Senores Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nor Ursodeoxycholic Acid","moa":"Cholesterol","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shilpa Medicare \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shilpa Medicare \/ Inapplicable"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Bilayer","sponsorNew":"Exemed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exemed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Macleods Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Macleods Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Macleods Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Macleods Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Eluxadoline","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Darunavir","moa":"||HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"||COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"CuraTeQ Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"CuraTeQ Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CuraTeQ Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CuraTeQ Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage CSF1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eugia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eugia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Deoxy-D-Glucose","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mankind Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akums Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ipratropium Bromide","moa":"mAChRs M3","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lactulose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cadila Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cadila Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Mascot Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Inapplicable"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supriya Lifescience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supriya Lifescience \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Utreglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P-450","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Shampoo","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Hematology","graph2":"Preclinical","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwality Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kwality Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Nafithromycin","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Wockhardt \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wockhardt \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Vitamin K1","moa":"Vitamin K","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Vitamin K1","moa":"Vitamin K","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"sigx1094","moa":"FAK\/YAP","graph1":"Oncology","graph2":"Phase I","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Signet \/ Inapplicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"sigx1094","moa":"FAK","graph1":"Oncology","graph2":"Phase I","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Signet \/ Inapplicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SUVN-I6107","moa":"M1","graph1":"Neurology","graph2":"Phase I","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Suven Life Sciences Limited \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Suven Life Sciences Limited \/ Inapplicable"},{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"17-beta estradiol","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kwality Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kwality Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Typhoid Vi Conjugate Vaccine","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Glenmark Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDONESIA","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Powder for Injection","sponsorNew":"Dexa Medica \/ Debiopharm","highestDevelopmentStatusID":"15","companyTruncated":"Dexa Medica \/ Debiopharm"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"4-Valent HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bio Farma \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Bio Farma \/ Merck & Co"},{"orgOrder":0,"company":"Etana Biotechnologies","sponsor":"Yunfeng Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDONESIA","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Etana Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Etana Biotechnologies \/ Yunfeng Capital","highestDevelopmentStatusID":"15","companyTruncated":"Etana Biotechnologies \/ Yunfeng Capital"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bio Farma \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Sinovac Biotech"},{"orgOrder":0,"company":"Avicenna Pharmaceutical","sponsor":"Molecure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"USP-7","graph1":"Oncology","graph2":"Discovery","graph3":"Avicenna Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avicenna Pharmaceutical \/ Molecure","highestDevelopmentStatusID":"2","companyTruncated":"Avicenna Pharmaceutical \/ Molecure"},{"orgOrder":0,"company":"Varian Biopharmaceuticals","sponsor":"Healthtech Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRAN","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"VAR-101","moa":"PKC-iota","graph1":"Oncology","graph2":"Preclinical","graph3":"Varian Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Varian Biopharmaceuticals \/ Healthtech Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Varian Biopharmaceuticals \/ Healthtech Solutions"},{"orgOrder":0,"company":"CinnaGen Co","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Advax-SM","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CinnaGen Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CinnaGen Co \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen Co \/ Vaxine"},{"orgOrder":0,"company":"NanoAlvand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"NanoAlvand","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NanoAlvand \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NanoAlvand \/ Inapplicable"},{"orgOrder":0,"company":"NanoAlvand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"NanoAlvand","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NanoAlvand \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NanoAlvand \/ Inapplicable"},{"orgOrder":0,"company":"NanoAlvand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CBL-B","graph1":"Oncology","graph2":"Approved FDF","graph3":"NanoAlvand","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NanoAlvand \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NanoAlvand \/ Inapplicable"},{"orgOrder":0,"company":"NanoAlvand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Ifosfamide","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"NanoAlvand","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NanoAlvand \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NanoAlvand \/ Inapplicable"},{"orgOrder":0,"company":"NanoAlvand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"Cytochrome P450 3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"NanoAlvand","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NanoAlvand \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NanoAlvand \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Enzyme","year":"2025","type":"Merger","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Endo International \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Nemysis","sponsor":"Avia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Financing","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nemysis \/ Avia Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nemysis \/ Avia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2023","type":"Termination","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Adalvo"},{"orgOrder":0,"company":"Exicure","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"GPC-100","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exicure \/ GPCR Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ GPCR Therapeutics"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Oligonucleotide","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ Ipsen"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Altaris Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Adapalene","moa":"RAR-beta","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Altaris Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Altaris Capital Partners"},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aerogen \/ CanSino Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aerogen \/ CanSino Biologics"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Prothena","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Birtamimab","moa":"||Light chain aggregate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Jefferies"},{"orgOrder":0,"company":"Exicure","sponsor":"Bluejay","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Cavrotolimod","moa":"TLR9","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exicure \/ Bluejay","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ Bluejay"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"Cholinesterase","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Pharma Sciences, LLC.","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Exela Pharma Sciences, LLC."},{"orgOrder":0,"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Prasinezumab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Trigr","sponsor":"Compass Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"CTX-009","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trigr \/ Compass Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Compass Therapeutics"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Phase III","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Perrigo Company plc \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Trigr","sponsor":"Elpiscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Asciminib","moa":"Dll4-Notch1","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trigr \/ Elpiscience","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Elpiscience"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Chiesi Group"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"U.S. Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ U.S. Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ U.S. Food & Drug Administration"},{"orgOrder":0,"company":"GH Research","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Series B Financing","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ RA Capital","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ RA Capital"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Fosfomycin Sodium","moa":"UDP-N-acetylglucosamine 1-carboxyvinyl transferase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"ERS Genomics","sponsor":"Lepton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ERS Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ERS Genomics \/ Lepton Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ERS Genomics \/ Lepton Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"Priothera","sponsor":"Fountain Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Series A financing","leadProduct":"Mocravimod","moa":"S1PR","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Fountain Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Fountain Healthcare"},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Novo Nordisk"},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"NNC6019","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Novo Nordisk"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Silence Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Silence Therapeutics"},{"orgOrder":0,"company":"Exicure","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Oligonucleotide","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Exicure \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ AbbVie Inc"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Divestment","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Chiesi Group"},{"orgOrder":0,"company":"Inflazome","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Endo International","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Bivalirudin","moa":"Thrombin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ MAIA Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ MAIA Biotechnology"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Stand Up To Cancer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2021","type":"Collaboration","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Stand Up To Cancer","highestDevelopmentStatusID":"1","companyTruncated":"Jazz Pharmaceuticals \/ Stand Up To Cancer"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Sulopenem","moa":"Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SynOx Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Kurma Partners\u2019 Growth Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SH-105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Kurma Partners\u2019 Growth Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Oncology \/ Kurma Partners\u2019 Growth Opportunities Fund"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"ONKT102","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Acorn Bioventures"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Emactuzumab","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase I","graph3":"SynOx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynOx Therapeutics \/ Healthcaps India","highestDevelopmentStatusID":"6","companyTruncated":"SynOx Therapeutics \/ Healthcaps India"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ RTW Investments"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"SH-105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Seroba Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Oncology \/ Seroba Life Sciences"},{"orgOrder":0,"company":"ERS Genomics","sponsor":"IRBM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ERS Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ERS Genomics \/ IRBM","highestDevelopmentStatusID":"4","companyTruncated":"ERS Genomics \/ IRBM"},{"orgOrder":0,"company":"Nemysis","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"Endoprotease 40 Glutenase","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ European Union","highestDevelopmentStatusID":"6","companyTruncated":"Nemysis \/ European Union"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"Amarin","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ BARDA"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"NY-303","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Naya Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"ONK Therapeutics \/ Naya Biosciences"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Gilde Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SynOx Therapeutics \/ Gilde Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Therapeutics \/ Gilde Healthcare"},{"orgOrder":0,"company":"Oranda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Oranda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oranda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SynOx Therapeutics \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Evergreen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"EG-009A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icon Plc \/ Evergreen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/ Evergreen Therapeutics"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Sinovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Sinovant Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Sinovant Sciences"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"CVC Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners"},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"PRX019","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Prothena \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Nemysis","sponsor":"Bruno Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nemysis \/ Bruno Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Nemysis \/ Bruno Farmaceutici"},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ Ipsen"},{"orgOrder":0,"company":"Nogra Pharma","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NAC-GED-0507","moa":"PPAR-gamma","graph1":"Dermatology","graph2":"Phase III","graph3":"Nogra Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nogra Pharma \/ Torii Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Nogra Pharma \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"PRX005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Endo International","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2023","type":"Collaboration","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Endo International \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Premier"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Tedizolid","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nabriva Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Acacia Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyundai Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyundai Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hyundai Pharm"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Nuvothera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Licensing Agreement","leadProduct":"Omega-3","moa":"||PPAR-gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"DS Biopharma \/ Nuvothera","highestDevelopmentStatusID":"15","companyTruncated":"DS Biopharma \/ Nuvothera"},{"orgOrder":0,"company":"Amarin","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Seqirus"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Lefamulin Acetate","moa":"Peptidyl transferase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Erkim"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Medison Pharma"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tedizolid","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nabriva Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Amarin","sponsor":"Vianex S.A","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Vianex S.A","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Vianex S.A"},{"orgOrder":0,"company":"Nuritas","sponsor":"Advanced Computing In Europe","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nuritas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Nuritas \/ Advanced Computing In Europe","highestDevelopmentStatusID":"2","companyTruncated":"Nuritas \/ Advanced Computing In Europe"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ 3S Bio Inc","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ 3S Bio Inc"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Wep","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Wep","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Wep"},{"orgOrder":0,"company":"Newport Pharmaceuticals","sponsor":"WellSpring","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Newport Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Newport Pharmaceuticals \/ WellSpring","highestDevelopmentStatusID":"4","companyTruncated":"Newport Pharmaceuticals \/ WellSpring"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hyphens Pharma"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"JZP-258","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Cultured Keratinocytes Dermal Fibroblasts Murine Collagen","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Stratagraft Skin Tissue","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Gas for Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Corticotropin","moa":"MC2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2R","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2R","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALKS 2680","moa":"OX2R","graph1":"Sleep","graph2":"Phase I","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RCSI University of Medicine and Health Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1-antitrypsin","moa":"Alpha-1 antiproteinase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"RCSI University of Medicine and Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RCSI University of Medicine and Health Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RCSI University of Medicine and Health Sciences \/ Inapplicable"},{"orgOrder":0,"company":"RCSI University of Medicine and Health Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Alpha-1-antitrypsin","moa":"Alpha-1 antiproteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RCSI University of Medicine and Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RCSI University of Medicine and Health Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RCSI University of Medicine and Health Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Argatroban","moa":"Thrombin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Renexxion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Renexxion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Renexxion \/ Inapplicable"},{"orgOrder":0,"company":"Renexxion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Renexxion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Inapplicable"},{"orgOrder":0,"company":"Renexxion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Renexxion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Renexxion \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Birtamimab","moa":"||Light chain aggregate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bismuth Subcitrate Potassium","moa":"||Clp protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bivalirudin","moa":"Thrombin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"CB5064 Analog","moa":"Apelin receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aerogen \/ CanSino Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aerogen \/ CanSino Biologics"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CT7439","moa":"CDK12\/13","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CT7439","moa":"CDK12\/13","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"ILT7","graph1":"Dermatology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Edding Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Edding Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Edding Pharm"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emactuzumab","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SynOx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"IRELAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Defibrotide Sodium","moa":"Plasminogen","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Erwinia Asparaginase","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Thiotepa","moa":"DNA bond","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"Priothera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"HZN-457","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Horizon Therapeutics \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Horizon Therapeutics \/ Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"ILT7","graph1":"Nephrology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"ILT7","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"ILT7","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Gas for Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Gas for Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JZP150","moa":"FAAH2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suvecaltamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Bionical Emas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Asparaginase Erwinia Chrysanthemi","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Bionical Emas","highestDevelopmentStatusID":"9","companyTruncated":"Jazz Pharmaceuticals \/ Bionical Emas"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JZP815","moa":"Fibrosarcoma","graph1":"Oncology","graph2":"Preclinical","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JZP815","moa":"Fibrosarcoma","graph1":"Oncology","graph2":"Preclinical","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Priothera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Inapplicable"},{"orgOrder":0,"company":"Priothera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Inapplicable"},{"orgOrder":0,"company":"Priothera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lomitapide","moa":"MTP","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Priothera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mocravimod","moa":"||S1PR","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Inapplicable"},{"orgOrder":0,"company":"Priothera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mocravimod","moa":"S1PR","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosfomycin Sodium","moa":"UDP-N-acetylglucosamine 1-carboxyvinyl transferase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renexxion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renexxion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Renexxion \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Eversana","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Nelarabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Eversana"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"CyGenica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CyGenica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CyGenica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CyGenica \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ONKT102","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ONKT102","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Orbsen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orbsen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orbsen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Orbsen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orbsen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orbsen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Neostigmine Methylsulfate","moa":"||Cholinesterase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Pre-Filled Syringe","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perrigo Company plc \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Cystine reducer","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Cystine reducer","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PRX005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PRX123","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"MedStar Health Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ MedStar Health Research Institute","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ MedStar Health Research Institute"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Somalix","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Corticotropin","moa":"MC2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SH-105","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SH-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Shorla Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Perrigo Company plc \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Organon"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Arvinas","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Arvinas"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"||5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Ovoca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BP-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Ovoca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ovoca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovoca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nemysis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nemysis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nemysis \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ University of Michigan"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"||Uric acid oxidative enzyme","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Colvis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alkermes Plc \/ Colvis Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Alkermes Plc \/ Colvis Oncology"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Dazodalibep","moa":"CD40","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rifamycin","moa":"DdRP","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Iterum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tiopronin","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ BARDA"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"MBT5","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Daunorubicin","moa":"||DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Afimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Epeleuton","moa":"Reperfusion stress","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Afimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Afimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Samidorphan L-Malate","moa":"||Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Perrigo Company plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Edding Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Edding Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Edding Pharm"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amarin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amarin \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Daunorubicin","moa":"||DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subacromial Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocoll Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 50S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"70s ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Calcium","moa":"||Dopamine receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ PharmaMar"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jazz Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Zymeworks","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Zymeworks","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Zymeworks"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Endo Pharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Brepco Biopharma","sponsor":"Piramal Critical Care","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dopamine","moa":"Adrenergic receptor-beta-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Brepco Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brepco Biopharma \/ Piramal Critical Care","highestDevelopmentStatusID":"15","companyTruncated":"Brepco Biopharma \/ Piramal Critical Care"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"GH Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"GH Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline","moa":"MMP-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cosmo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cosmo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Hepion Pharmaceuticals"},{"orgOrder":0,"company":"BioLineRx","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Motixafortide","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Neuraxpharm"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Rabies Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Apotex Inc"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Zinc Acetate Dihydrate","moa":"Intestinal cell metallothionein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Pluri","sponsor":"Hemafund","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Avoplacel","moa":"PPi\/Adenosine","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Hemafund","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Hemafund"},{"orgOrder":0,"company":"SciSparc","sponsor":"N2Off","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Divestment","leadProduct":"Undisclosed","moa":"SLC25A transporter","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ N2Off","highestDevelopmentStatusID":"3","companyTruncated":"SciSparc \/ N2Off"},{"orgOrder":0,"company":"Remedy Cell","sponsor":"Qureight","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"RC-0315","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Remedy Cell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Cell \/ Qureight","highestDevelopmentStatusID":"4","companyTruncated":"Remedy Cell \/ Qureight"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"PL-14","moa":"IL-8 secretion","graph1":"Immunology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Polyrizon \/ Eurofins CDMO","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Eurofins CDMO"},{"orgOrder":0,"company":"BiomX","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2025","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"BiomX \/ Laidlaw & Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Laidlaw & Company"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Topical Gel","sponsorNew":"Lutris Pharma \/ Columbus Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Public Offering","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silexion Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Evonik","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silexion Therapeutics \/ Evonik","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Evonik"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Termination","leadProduct":"BND-22","moa":"||ILT2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"RedHill Biopharma \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Trigone Pharma","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2025","type":"Licensing Agreement","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Trigone Pharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Trigone Pharma \/ Relmada Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Trigone Pharma \/ Relmada Therapeutics"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Highbridge Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Acquisition","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Essential Pharma"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Orasis Pharmaceuticals \/ Arboretum Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Orasis Pharmaceuticals \/ Arboretum Ventures"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Henry M. Jackson Foundation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Jmp Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Jmp Securities","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Jmp Securities"},{"orgOrder":0,"company":"PolyPid","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Citizens JMP"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"BND-35","moa":"||LT3\/LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biond Biologics \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Biond Biologics \/ Merck Group"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Ayrmid","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Ayrmid","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Ayrmid"},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children's Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"CXCL12","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ St. Jude Children's Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ St. Jude Children's Research Hospital"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"||CXCL12","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"TEV-48574","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medison Pharma \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Medison Pharma \/ BeiGene"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Fondazione Telethon","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Fondazione Telethon","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite BioPharma \/ Fondazione Telethon"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minovia Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Minovia Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sol-Gel Technologies \/ Raymond James & Associates","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Raymond James & Associates"},{"orgOrder":0,"company":"MediWound","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"MediWound","sponsor":"Ghassan Aboud Group","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Partnership","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Ghassan Aboud Group","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Ghassan Aboud Group"},{"orgOrder":0,"company":"MediWound","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ U.S. Department of Defense"},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"Isotopia","sponsor":"Philochem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"177-Lu OncoFAP-23","moa":"FAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isotopia \/ Philochem","highestDevelopmentStatusID":"4","companyTruncated":"Isotopia \/ Philochem"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"State Of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ State Of Pennsylvania","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ State Of Pennsylvania"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Medison Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Medison Pharma"},{"orgOrder":0,"company":"PolyPid","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Advanz Pharma"},{"orgOrder":0,"company":"Luminera","sponsor":"Innovative Luminera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Luminera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luminera \/ Innovative Luminera","highestDevelopmentStatusID":"15","companyTruncated":"Luminera \/ Innovative Luminera"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Partnership","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Therapix Biosciences","sponsor":"Evero","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Therapix Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapix Biosciences \/ Evero","highestDevelopmentStatusID":"8","companyTruncated":"Therapix Biosciences \/ Evero"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Rilvegostomig","moa":"PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Beimei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Agreement","leadProduct":"Tretinoin","moa":"||RAR beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Beimei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Beimei Pharma"},{"orgOrder":0,"company":"BioLineRx","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"BiomX","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BiomX \/ OrbiMed Advisors","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ OrbiMed Advisors"},{"orgOrder":0,"company":"BiomX","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BiomX \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ OrbiMed"},{"orgOrder":0,"company":"BiomX","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BiomX \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Aegis Capital Corp"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Society","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Society","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Max Planck Society"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Proglumide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"BND-22","moa":"ILT2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"BNS Ophthalmics","sponsor":"BioNanoSim","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"BNS Ophthalmics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"BNS Ophthalmics \/ BioNanoSim","highestDevelopmentStatusID":"4","companyTruncated":"BNS Ophthalmics \/ BioNanoSim"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"ApoGraft Treated Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Cellect Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellect Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cellect Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Research Development Company \/ Clearmind Medicine"},{"orgOrder":0,"company":"Edith Wolfson Medical Center","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Edith Wolfson Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edith Wolfson Medical Center \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Edith Wolfson Medical Center \/ Orgenesis"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"CollPlant","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"rhCollagen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"CollPlant","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CollPlant \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"CollPlant \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"COM503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"COM503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Cutia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Cutia Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Foamix Pharmaceuticals \/ Cutia Therapeutics"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medison Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Myeloma Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2022","type":"Financing","leadProduct":"DSP107","moa":"CD47\/41BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Myeloma Investment Fund","highestDevelopmentStatusID":"4","companyTruncated":"Kahr Medical \/ Myeloma Investment Fund"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Funding","leadProduct":"Azacytidine","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Cancer Focus Fund","highestDevelopmentStatusID":"5","companyTruncated":"Kahr Medical \/ Cancer Focus Fund"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Ewopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Ewopharma","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Ewopharma"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Psagot Investment House","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Financing","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Psagot Investment House","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Psagot Investment House"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Marius Nacht","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"BGC101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BioGenCell \/ Marius Nacht","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell \/ Marius Nacht"},{"orgOrder":0,"company":"MigVax","sponsor":"OurCrowd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"MigVax-101","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MigVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"MigVax \/ OurCrowd","highestDevelopmentStatusID":"4","companyTruncated":"MigVax \/ OurCrowd"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"TRS01","moa":"Nf-kB","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarsier Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kamada \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Omnix Medical","sponsor":"EIC Accelerator Programme","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"OMN6","moa":"Gram-negative bacterial membrane","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Omnix Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omnix Medical \/ EIC Accelerator Programme","highestDevelopmentStatusID":"5","companyTruncated":"Omnix Medical \/ EIC Accelerator Programme"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Gaelan Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Gaelan Medical","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Gaelan Medical"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Piper Sandler"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Piper Sandler & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Piper Sandler & Co."},{"orgOrder":0,"company":"OncoHost","sponsor":"Hengenix Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"OncoHost","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoHost \/ Hengenix Biotech","highestDevelopmentStatusID":"10","companyTruncated":"OncoHost \/ Hengenix Biotech"},{"orgOrder":0,"company":"MigVax","sponsor":"OurCrowd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"MigVax \/ OurCrowd","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ OurCrowd"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"JAG101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Gene Therapy \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gene Therapy \/ Eli Lilly"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"PD-1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Teva Pharmaceutical Industries \/ Mabxience","highestDevelopmentStatusID":"1","companyTruncated":"Teva Pharmaceutical Industries \/ Mabxience"},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Agreement","leadProduct":"BX005","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Maruho"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HCR","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RedHill Biopharma \/ HCR","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ HCR"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Highbridge Capital Management"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Israeli Shekels","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Israeli Shekels","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Israeli Shekels"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Selenium Sulfide","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Azura Ophthalmics \/ OrbiMed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ OrbiMed"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Expanded Collaboration","leadProduct":"BMS-986207","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Trinity College Dublin","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"ONKT103","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Trinity College Dublin","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trinity College Dublin \/ ONK Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Trinity College Dublin \/ ONK Therapeutics"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Mapi Pharma \/ Viatris"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"PhaseV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ PhaseV","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ PhaseV"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Aurum Ventures"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Bluestem Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"CSF-1","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Orasis Pharmaceuticals \/ Bluestem Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pharmaceuticals \/ Bluestem Capital"},{"orgOrder":0,"company":"PolyPid","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Financing","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Kreos Capital"},{"orgOrder":0,"company":"BiomX","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Deerfield Management Company"},{"orgOrder":0,"company":"Biosight","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Series C Financing","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosight \/ Israel Biotech Fund","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Israel Biotech Fund"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Flerie Invest AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Atezolizumab","moa":"||SIRP alpha\/41BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Flerie Invest AB","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Flerie Invest AB"},{"orgOrder":0,"company":"SpliSense","sponsor":"Biotel Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"SPL84-23","moa":"CFTR","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SpliSense \/ Biotel Limited","highestDevelopmentStatusID":"5","companyTruncated":"SpliSense \/ Biotel Limited"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Atezolizumab","moa":"||SIRP alpha\/41BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ aMoon","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ aMoon"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ NIAID","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ NIAID"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Entera Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Entera Health","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Entera Health"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Financing","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Remepy","sponsor":"NFX","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Remepy","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Remepy \/ NFX","highestDevelopmentStatusID":"2","companyTruncated":"Remepy \/ NFX"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"RZL 012","moa":"Cell membrane synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Soroka Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Soroka Medical Center"},{"orgOrder":0,"company":"SciSparc","sponsor":"The Sheba Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ The Sheba Fund","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ The Sheba Fund"},{"orgOrder":0,"company":"SciSparc","sponsor":"Polyrizon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"N-Acylethanolamine","moa":"||CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Polyrizon","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Polyrizon"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SCI-160","moa":"CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"Isotopia","sponsor":"Seibersdorf Labor GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotopia \/ Seibersdorf Labor GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/ Seibersdorf Labor GmbH"},{"orgOrder":0,"company":"SipNose","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"ST266","moa":"SIRT1","graph1":"Ophthalmology","graph2":"Phase I","graph3":"SipNose","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"SipNose \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"SipNose \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"SuperTrans Medical","sponsor":"Mediforum Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SuperTrans Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"SuperTrans Medical \/ Mediforum Pharm","highestDevelopmentStatusID":"1","companyTruncated":"SuperTrans Medical \/ Mediforum Pharm"},{"orgOrder":0,"company":"FameWave","sponsor":"Kitov Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"FameWave","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"FameWave \/ Kitov Pharma","highestDevelopmentStatusID":"6","companyTruncated":"FameWave \/ Kitov Pharma"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Rilvegostomig","moa":"PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"MagnaPharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||RAR beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ MagnaPharm","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ MagnaPharm"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Rabies Immune Globulin (Human)","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Hebrew University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innocan Pharma \/ Hebrew University","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Hebrew University"},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Research Development Company \/ Clearmind Medicine"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"LUT017","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lutris Pharma \/ California Institute of Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Lutris Pharma \/ California Institute of Regenerative Medicine"},{"orgOrder":0,"company":"Biomica","sponsor":"Rambam Health Care Campus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Agreement","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Rambam Health Care Campus","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Rambam Health Care Campus"},{"orgOrder":0,"company":"Insightec","sponsor":"SonALAsense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Insightec \/ SonALAsense","highestDevelopmentStatusID":"4","companyTruncated":"Insightec \/ SonALAsense"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Royalty Pharma"},{"orgOrder":0,"company":"PolyPid","sponsor":"ImmunoGenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"IMGS-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyPid \/ ImmunoGenesis","highestDevelopmentStatusID":"4","companyTruncated":"PolyPid \/ ImmunoGenesis"},{"orgOrder":0,"company":"Everads Therapy","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Everads Therapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Everads Therapy \/ Kriya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Everads Therapy \/ Kriya Therapeutics"},{"orgOrder":0,"company":"Pharmaseed","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Pharmaseed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pharmaseed \/ Mira Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaseed \/ Mira Pharmaceuticals"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inteligex","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Inteligex","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Inteligex"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Launch Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Steroid","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Launch Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Launch Therapeutics"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Institute for Multidisciplinary Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"||TNF-alpha","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Pluri","sponsor":"Bar-Ilan University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pluri \/ Bar-Ilan University","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Bar-Ilan University"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Duke University School","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Duke University School","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Duke University School"},{"orgOrder":0,"company":"Pangea Biomed","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Rigosertib","moa":"||RAS pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pangea Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pangea Biomed \/ Onconova Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pangea Biomed \/ Onconova Therapeutics"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytoreason \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Cytoreason \/ Sanofi"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Menlo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Serlopitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foamix Pharmaceuticals \/ Menlo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Menlo Therapeutics"},{"orgOrder":0,"company":"Biosight","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biosight \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Biosight \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"Biosight","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biosight \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Biosight \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"Kamari Pharma","sponsor":"GIBF2","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"TRPV3","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kamari Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Kamari Pharma \/ GIBF2","highestDevelopmentStatusID":"4","companyTruncated":"Kamari Pharma \/ GIBF2"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Public Offering","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"PolyPid","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Citizens JMP"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Jefferies"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"ChemomAb","sponsor":"HBM Healthcare Investments","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ HBM Healthcare Investments","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ HBM Healthcare Investments"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"Durvalumab","moa":"||5T4","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institutes of Health"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"PainReform","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution, Extended Release","sponsorNew":"PainReform \/ Maxim Group","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Maxim Group"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Panaxia","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CB receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Panaxia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Panaxia \/ Neuraxpharm","highestDevelopmentStatusID":"1","companyTruncated":"Panaxia \/ Neuraxpharm"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Deep Insight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"BND-22","moa":"||ILT2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Deep Insight","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Deep Insight"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"M. Arkin Dermatology Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Benzoyl Peroxide","moa":"||Keratinocyte","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ BARDA"},{"orgOrder":0,"company":"Trobix Bio","sponsor":"Chartered Opus","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Series A Financing","leadProduct":"TBX101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Trobix Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trobix Bio \/ Chartered Opus","highestDevelopmentStatusID":"4","companyTruncated":"Trobix Bio \/ Chartered Opus"},{"orgOrder":0,"company":"Protai","sponsor":"Grove Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Protai","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Protai \/ Grove Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Protai \/ Grove Ventures"},{"orgOrder":0,"company":"Quris","sponsor":"Welltech Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Quris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quris \/ Welltech Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Quris \/ Welltech Ventures"},{"orgOrder":0,"company":"MediWound","sponsor":"EIC","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Funding","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ EIC","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ EIC"},{"orgOrder":0,"company":"SpliSense","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"SpliSense \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ EIC Accelerator"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"EIC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Funding","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ EIC","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ EIC"},{"orgOrder":0,"company":"Pluri","sponsor":"European Union\u2019s Horizon Europe","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ European Union\u2019s Horizon Europe","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ European Union\u2019s Horizon Europe"},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ National Institute on Aging"},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Selenium Sulfide","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Azura Ophthalmics \/ CUREator","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ CUREator"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"Recombinant Human Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Elgan Pharma \/ European Innovation Council","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ European Innovation Council"},{"orgOrder":0,"company":"Neuromagen Pharma","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"AGS-499","moa":"Telomerase reverse transcriptase","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuromagen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Neuromagen Pharma \/ Israel Innovation Authority","highestDevelopmentStatusID":"4","companyTruncated":"Neuromagen Pharma \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Kamada","sponsor":"Israeli Health Authorities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kamada \/ Israeli Health Authorities","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Israeli Health Authorities"},{"orgOrder":0,"company":"The Israeli Medical Center for Alzheimer's","sponsor":"SciSparc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"The Israeli Medical Center for Alzheimer's","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Israeli Medical Center for Alzheimer's \/ SciSparc","highestDevelopmentStatusID":"8","companyTruncated":"The Israeli Medical Center for Alzheimer's \/ SciSparc"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Notable Labs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Notable Labs","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therapeutics \/ Notable Labs"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Immunocore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Immunocore","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Immunocore"},{"orgOrder":0,"company":"Pluri","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ National Institutes of Health"},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Molnlycke Health Care","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Molnlycke Health Care"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"BioLineRx","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ BlackRock","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ BlackRock"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Steroid","year":"2024","type":"Financing","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Abingworth","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Abingworth"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2023","type":"Expanded Collaboration","leadProduct":"Givosiran Sodium","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytoreason \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Cytoreason \/ Pfizer Inc"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytoreason \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Cytoreason \/ Pfizer Inc"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Kukbo Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Kukbo Co","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Kukbo Co"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"||TNF-alpha","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Yale University"},{"orgOrder":0,"company":"Trobix Bio","sponsor":"Chartered Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Series A Financing","leadProduct":"TBX201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Trobix Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trobix Bio \/ Chartered Group","highestDevelopmentStatusID":"4","companyTruncated":"Trobix Bio \/ Chartered Group"},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Aurum Ventures"},{"orgOrder":0,"company":"Biomica","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Shanghai Healthcare Capital"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Sands Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Sands Capital","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Sands Capital"},{"orgOrder":0,"company":"Converge Bio","sponsor":"TLV Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Converge Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Converge Bio \/ TLV Partners","highestDevelopmentStatusID":"3","companyTruncated":"Converge Bio \/ TLV Partners"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Deerfield Management Company"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Morningside Venture","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Morningside Venture"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Israel Institute for Biological Research \/ Dyadic International, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Israel Institute for Biological Research \/ Dyadic International, Inc"},{"orgOrder":0,"company":"K S Kim International","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"ArtemiC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"K S Kim International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"K S Kim International \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"K S Kim International \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Biosight","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Series C Financing","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Israel Biotech Fund","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Israel Biotech Fund"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Hormone","year":"2021","type":"Agreement","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medison Pharma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Amryt Pharma"},{"orgOrder":0,"company":"Tel Aviv Medical Center","sponsor":"Vaxil Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Peptide Based Covid-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tel Aviv Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tel Aviv Medical Center \/ Vaxil Bio","highestDevelopmentStatusID":"4","companyTruncated":"Tel Aviv Medical Center \/ Vaxil Bio"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Bonus BioGroup","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Wize Pharma \/ Bonus BioGroup","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Bonus BioGroup"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytoreason \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Cytoreason \/ Merck & Co"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Menashe Bar-Eli","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NT219","moa":"||IRS1\/2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purple Biotech \/ Menashe Bar-Eli","highestDevelopmentStatusID":"1","companyTruncated":"Purple Biotech \/ Menashe Bar-Eli"},{"orgOrder":0,"company":"Vensica Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"ISRAEL","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"Incobotulinumtoxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Phase III","graph3":"Vensica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Vensica Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Pluri","sponsor":"Bar-Ilan University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Bar-Ilan University","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Bar-Ilan University"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Hepion Pharmaceuticals"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ European Investment Bank","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ European Investment Bank"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medison Pharma \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Albireo Pharma"},{"orgOrder":0,"company":"Neopharm","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Neopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neopharm \/ Amarin","highestDevelopmentStatusID":"15","companyTruncated":"Neopharm \/ Amarin"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"||PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Hebrew University","sponsor":"Beyond Air","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"7-nitroindazole","moa":"nNOS","graph1":"Neurology","graph2":"Preclinical","graph3":"Hebrew University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebrew University \/ Beyond Air","highestDevelopmentStatusID":"4","companyTruncated":"Hebrew University \/ Beyond Air"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Gloria Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Gloria Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Gloria Biosciences"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Ewopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Ewopharma","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Ewopharma"},{"orgOrder":0,"company":"BIRAD","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BIRAD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BIRAD \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BIRAD \/ Clearmind Medicine"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"||PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Medomie","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Medomie","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Medomie \/ Aytu BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Medomie \/ Aytu BioPharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Phil","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Phil","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Phil"},{"orgOrder":0,"company":"SciSparc","sponsor":"Polyrizon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"N-Acylethanolamine","moa":"||CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Polyrizon","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Polyrizon"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Searchlight Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||RAR beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Searchlight Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Searchlight Pharma"},{"orgOrder":0,"company":"Short Wave Pharma","sponsor":"The Sheba Center for Eating Disorders","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Short Wave Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Short Wave Pharma \/ The Sheba Center for Eating Disorders","highestDevelopmentStatusID":"7","companyTruncated":"Short Wave Pharma \/ The Sheba Center for Eating Disorders"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"DSP502","moa":"DSP-Fc","graph1":"Oncology","graph2":"Preclinical","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kahr Medical \/ Thomas Jefferson University","highestDevelopmentStatusID":"4","companyTruncated":"Kahr Medical \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BiomX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"BX003","moa":"Klebsiella pneumoniae","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BiomX \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Quris","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Quris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quris \/ Merck Group","highestDevelopmentStatusID":"4","companyTruncated":"Quris \/ Merck Group"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Biologics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Teduglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ OPKO Biologics","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Biologics"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"||TNF-alpha","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Everads Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Everads Therapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Everads Therapy \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Everads Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Optus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Pilocarpine Hydrochloride","moa":"M1 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orasis Pharmaceuticals \/ Optus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orasis Pharmaceuticals \/ Optus Pharmaceuticals"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Padagis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Aciclovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Padagis","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Padagis"},{"orgOrder":0,"company":"Cannasoul","sponsor":"Synaptogenix","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Cannasoul","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cannasoul \/ Synaptogenix","highestDevelopmentStatusID":"1","companyTruncated":"Cannasoul \/ Synaptogenix"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Kukbo Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Kukbo Co","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Kukbo Co"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Research Development Company \/ Clearmind Medicine"},{"orgOrder":0,"company":"BioLineRx","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Myung In Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Myung In Pharm"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RedHill Biopharma \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Apotex Inc"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Varicella Zoster Immune Globulin (Human)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Vivox","sponsor":"NurExone Biologic","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vivox","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vivox \/ NurExone Biologic","highestDevelopmentStatusID":"4","companyTruncated":"Vivox \/ NurExone Biologic"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCL12","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Foam","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Duvakitug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Immunology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MNV-BLD","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Minovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Minovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sol-Gel Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SGT-210","moa":"EGFR","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Sol-Gel Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sol-Gel Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Avoplacel","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Isotopia","sponsor":"CPDC Centre for Probe Development and Commercialization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotopia \/ CPDC Centre for Probe Development and Commercialization","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/ CPDC Centre for Probe Development and Commercialization"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Israel Institute for Biological Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Israel Institute for Biological Research \/ Inapplicable"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AstroRx","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kadimastem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"United States Army Medical Research Institute of Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ United States Army Medical Research Institute of Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ United States Army Medical Research Institute of Infectious Diseases"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AGI-134","moa":"Alpha-galactosidase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Lutris Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Immunology","graph2":"Phase I","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||Immunotolerance","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||Immunotolerance","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Aummune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AM003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aummune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aummune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aummune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Galderma"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Virginia Commonwealth University","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pharmaceuticals \/ Virginia Commonwealth University"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Biosight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Inapplicable"},{"orgOrder":0,"company":"Biosight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Inapplicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mapi Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Assia Chemical Industries Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assia Chemical Industries Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Assia Chemical Industries Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Azura Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Azura Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Azura Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Azura Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BAY1905254","moa":"ILDR2","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BGC101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BioGenCell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BX001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BND-22","moa":"||ILT2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BND-22","moa":"||ILT2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BND-35","moa":"||LT3\/LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biond Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biond Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Activated Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bonus BioGroup \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Inapplicable"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Activated Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bonus BioGroup \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"CA2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"FutuRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BSEN760","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"FutuRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FutuRx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"FutuRx \/ Inapplicable"},{"orgOrder":0,"company":"Biosight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Inapplicable"},{"orgOrder":0,"company":"Biosight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BX001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BX003","moa":"Klebsiella pneumoniae","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BX005","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Maruho"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CSF-1","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Orasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||Immunotolerance","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"A3AR","graph1":"Immunology","graph2":"Discovery","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Podiatry","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"||A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"||A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CF602","moa":"Adenosine A3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purple Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Purple Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Donepezil","moa":"||AChE","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"COM503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM902","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"||IRS1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TRS01","moa":"||Nf-kB","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Coravax","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kahr Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kahr Medical \/ Inapplicable"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Orasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Cytomegalovirus Immune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Cytomegalovirus Immune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hypromellose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"SPL23-ASO","moa":"CFTR RNA","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sisram Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sisram Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sisram Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sisram Medical \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Ayana Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Padagis \/ Ayana Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Ayana Pharma"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||SIRP alpha\/41BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ U.S. Food and Drug Administration"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Immunology","graph2":"Phase I","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Health"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Epitomee","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Epitomee","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Epitomee","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Epitomee \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epitomee \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ExoPTEN\u00a0","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ExoPTEN\u00a0","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ExoPTEN\u00a0","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ExoPTEN\u00a0","moa":"PTEN","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Univo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Univo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Can-Fite BioPharma \/ Univo Pharmaceuticals"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Sheba Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||Immunotolerance","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Sheba Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Sheba Medical Center"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Tumor vasculature disruption","graph1":"Oncology","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nasus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Mapi Pharma \/ Viatris"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mapi Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ PRA Health Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Mapi Pharma \/ PRA Health Sciences"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GDA-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hypromellose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IBC-Ab002","moa":"PD-L1","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrain Checkpoint \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Israel Institute for Biological Research \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Israel Institute for Biological Research \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MUC1-SP-L","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxil Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TRS02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hebrew University of Jerusalem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenofibrate","moa":"PPA receptor-alpha","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hebrew University of Jerusalem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebrew University of Jerusalem \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hebrew University of Jerusalem \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"MigVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MigVax-101","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MigVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"MigVax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MigVax \/ Inapplicable"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunity Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"BX005","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Gynica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"S-301","moa":"CB receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Gynica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"Gynica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gynica \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IPL344","moa":"AKT signaling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunity Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"JAG101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Inapplicable"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Nanovo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nanovo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nanovo \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nanovo \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Levation Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Levation Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Levation Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Wize Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NeuroDerm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"NeuroDerm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeuroDerm \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lutris Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lutris Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lutris Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lutris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"MediWound","sponsor":"Soroka Medical Cente","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MWPC005","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Soroka Medical Cente","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Soroka Medical Cente"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Bioeq IP AG","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Bioeq IP AG"},{"orgOrder":0,"company":"Rafa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Rafa","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rafa \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rafa \/ Inapplicable"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"||A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"LD PepGNP-SARSCoV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoPass Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"NanoPass Technologies \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"6","companyTruncated":"NanoPass Technologies \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Translational Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||5T4","graph1":"Oncology","graph2":"Phase II","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Translational Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"NeoTX Therapeutics \/ Translational Drug Development"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||5T4","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"NeuroDerm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"NeuroDerm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeuroDerm \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Univo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Univo Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Univo Pharmaceuticals"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"||SPHK2","graph1":"Oncology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nanovo","sponsor":"BGN Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Nanovo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nanovo \/ BGN Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Nanovo \/ BGN Technologies"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"||SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteraBio Ltd \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Health"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Crisaborole","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Ben-Gurion University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"P-Esbp Conjugated Doxorubicin","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxil Bio \/ Ben-Gurion University","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Ben-Gurion University"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"||IRS1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Biosight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GDA-301","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PLX Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"JAG101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BX003","moa":"Klebsiella pneumoniae","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"PainReform","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution, Extended Release","sponsorNew":"PainReform \/ Lotus Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Lotus Clinical Research"},{"orgOrder":0,"company":"PainReform","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution, Extended Release","sponsorNew":"PainReform \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PainReform \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"NeuraLight","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ NeuraLight","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ NeuraLight"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"PRX-115","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Bioeq IP AG","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Bioeq IP AG"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"||SPHK2","graph1":"Oncology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RHB-106","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"MSIDS Research Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MSIDS Research Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSIDS Research Foundation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MSIDS Research Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Inapplicable"},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharma Two B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two B \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Proglumide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Immunology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TRS01","moa":"Nf-kB","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upamostat","moa":"||Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Hannover Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Hannover Medical School","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Hannover Medical School"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Hannover Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Hannover Medical School","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Hannover Medical School"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SCI-160","moa":"CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Negev Autism Center Soroka University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Negev Autism Center Soroka University Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Negev Autism Center Soroka University Medical Center"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Yale University"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-13","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SIL-204","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurim Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor 1A","graph1":"Sleep","graph2":"Phase III","graph3":"Neurim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurim Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurim Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"||COX-2","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stero Biotechs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Stero Biotechs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stero Biotechs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stero Biotechs \/ Inapplicable"},{"orgOrder":0,"company":"Stero Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Stero Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Stero Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stero Biotech \/ Inapplicable"},{"orgOrder":0,"company":"LipoMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Promitil","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Inapplicable"},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Assia Chemical Industries Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Assia Chemical Industries Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Assia Chemical Industries Ltd \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Elgan Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||SIRP alpha\/41BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypromellose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypromellose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brinzolamide","moa":"CA2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tiopronin","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Hebrew University Of Jerusalem","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Amilo-5MER","moa":"Serum amyloid A","graph1":"Immunology","graph2":"Preclinical","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galmed Pharmaceuticals \/ Hebrew University Of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Galmed Pharmaceuticals \/ Hebrew University Of Jerusalem"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MOSPD2","graph1":"Oncology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Wize Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ApoGraft","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cellect Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellect Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellect Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MUC1-SP-L","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxil Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Max Planck Innovation"},{"orgOrder":0,"company":"Biosight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Proglumide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Immunology","graph2":"Phase I","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BX002","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Israel Institute for Biological Research \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Israel Institute for Biological Research \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"Trigone Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"||M1\/M2\/M3 receptor","graph1":"Urology","graph2":"Preclinical","graph3":"Trigone Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Trigone Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Trigone Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Israel Institute for Biological Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Israel Institute for Biological Research \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"||Immunotolerance","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"3-Methylmethcathinone","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Proglumide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Soroka University Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Soroka University Medical Center"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ofranergene obadenovec","moa":"||Angiogenic\/vascular","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"Immunotolerance","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kitov Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Kitov Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Avoplacel","moa":"Bone marrow cell","graph1":"Hematology","graph2":"Phase I","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"BX002","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Biosight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kadimastem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Human Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"IRS1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Yale University"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Proglumide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scinai Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"YNC Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NanoPass Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"NanoPass Technologies \/ YNC Medical","highestDevelopmentStatusID":"1","companyTruncated":"NanoPass Technologies \/ YNC Medical"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CorVax","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxil Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder, Extended Release","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Omidubicel","moa":"CD34","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"MHC-II gene","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Mapi Pharma \/ Viatris"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Rabies Immune Globulin (Human)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MIGAL Research Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"MIGAL Research Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"MIGAL Research Institute \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"MIGAL Research Institute \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lutris Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Soroka Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Soroka Medical Center"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||Immunotolerance","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Tel Aviv Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vaxil Bio \/ Tel Aviv Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Tel Aviv Medical Center"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70s ribosome","graph1":"Immunology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MesenCure","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bonus BioGroup \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Yale Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||Immunotolerance","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Enlivex Therapeutics \/ Yale Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Yale Cancer Center"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRS01","moa":"Nf-kB","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRS01","moa":"Nf-kB","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TRS01","moa":"Nf-kB","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRS01","moa":"Nf-kB","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TRS01","moa":"Nf-kB","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TRS01","moa":"Nf-kB","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Orasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Orasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Emiplacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||SIRP alpha\/41BBL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Oncology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Neurology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VXL-301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxil Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Oncology","graph2":"Phase I","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Apogee Biotechnology Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Apogee Biotechnology Corporation","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Apogee Biotechnology Corporation"},{"orgOrder":0,"company":"Padagis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Padagis \/ Inapplicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Padagis \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemomAb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Namodenoson","moa":"A3AR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||Potassium transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Can-Fite BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ MedinCell"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Doxycycline","moa":"MMP-13","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S Ribosomal Subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Duvakitug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"GABA A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Polyrizon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"COM503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"MitoCareX Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SLC25","graph1":"Oncology","graph2":"Preclinical","graph3":"MitoCareX Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MitoCareX Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MitoCareX Bio \/ Inapplicable"},{"orgOrder":0,"company":"Raphael Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CB2\/CB1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Raphael Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raphael Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Raphael Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Exosome","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurExone Biologic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone Biologic \/ Inapplicable"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogeneic Cell Therapy","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bonus BioGroup \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bonus BioGroup \/ Inapplicable"},{"orgOrder":0,"company":"Polyrizon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Polyrizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Polyrizon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyrizon \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Silexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Oil","sponsorNew":"SciSparc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Opaganib","moa":"||SPHK2","graph1":"Oncology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ University of California","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ University of California"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Medis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Medis","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Medis"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Streeterville","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2025","type":"Collaboration","leadProduct":"NP-300","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Napo Therapeutics \/ Streeterville","highestDevelopmentStatusID":"5","companyTruncated":"Napo Therapeutics \/ Streeterville"},{"orgOrder":0,"company":"Genenta Science","sponsor":"ENEA Tech and Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Genenta Science \/ ENEA Tech and Biomedical","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ ENEA Tech and Biomedical"},{"orgOrder":0,"company":"ReiThera","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"SJ-600","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ SillaJen, Inc","highestDevelopmentStatusID":"4","companyTruncated":"ReiThera \/ SillaJen, Inc"},{"orgOrder":0,"company":"Kolinpharma","sponsor":"Nemysis","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"ITALY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Kolinpharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kolinpharma \/ Nemysis","highestDevelopmentStatusID":"15","companyTruncated":"Kolinpharma \/ Nemysis"},{"orgOrder":0,"company":"IRBM","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"IRBM","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IRBM \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Merck & Co"},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"GENE202","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Genespire","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"5","companyTruncated":"Genespire \/ Sofinnova Partners"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Linear DNA Vaccine","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takis Biotech \/ Applied DNA Sciences Inc","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biotech \/ Applied DNA Sciences Inc"},{"orgOrder":0,"company":"Molteni Farmaceutici","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Molteni Farmaceutici","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Molteni Farmaceutici \/ Titan Pharmaceuticals Inc","highestDevelopmentStatusID":"4","companyTruncated":"Molteni Farmaceutici \/ Titan Pharmaceuticals Inc"},{"orgOrder":0,"company":"Noventia Pharma","sponsor":"Delbert Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Histamine Dihydrochloride","moa":"||Immune","graph1":"Oncology","graph2":"Approved FDF","graph3":"Noventia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Noventia Pharma \/ Delbert Lab","highestDevelopmentStatusID":"15","companyTruncated":"Noventia Pharma \/ Delbert Lab"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pressurised Metered Dose Inhaler","sponsorNew":"Chiesi Group \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Bayer AG"},{"orgOrder":0,"company":"Recordati","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recordati \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Tolmar"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAMA Therapeutics \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Flamma SpA","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Flamma SpA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flamma SpA \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Flamma SpA \/ Gilead Sciences"},{"orgOrder":0,"company":"IRBM","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IRBM","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IRBM \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Merck & Co"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Linear DNA Vaccine","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takis Biotech \/ Applied DNA Sciences Inc","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biotech \/ Applied DNA Sciences Inc"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"NMS-03305293","moa":"PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Merck & Co"},{"orgOrder":0,"company":"NTC","sponsor":"I-MED","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"NTC \/ I-MED","highestDevelopmentStatusID":"15","companyTruncated":"NTC \/ I-MED"},{"orgOrder":0,"company":"NTC","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Levofloxacin","moa":"||DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NTC \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"NTC \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Napo EU","sponsor":"Oasis Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo EU \/ Oasis Capital","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Oasis Capital"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sibylla Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sibylla Biotech \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Sibylla Biotech \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Palladio Zannini Industrie","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Zannini Industrie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Zannini Industrie \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Zannini Industrie \/ Samsara BioCapital"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Ent001","moa":"IGFBP3\/TMEM219","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enthera Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Pharmaceuticals \/ Sofinnova Partners"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Claris Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"KIT2014","moa":"cAMP","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kither Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kither Biotech \/ Claris Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Kither Biotech \/ Claris Ventures"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"PsychoGenics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAMA Therapeutics \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Therapeutics \/ PsychoGenics"},{"orgOrder":0,"company":"University of L'Aquila","sponsor":"SiSaf Ltd","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"SIS-101-ADO","moa":"CLCN7","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"University of L'Aquila","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of L'Aquila \/ SiSaf Ltd","highestDevelopmentStatusID":"5","companyTruncated":"University of L'Aquila \/ SiSaf Ltd"},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Onfekafusp Alpha","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Ospedale San Raffaele","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genenta Science \/ Ospedale San Raffaele","highestDevelopmentStatusID":"5","companyTruncated":"Genenta Science \/ Ospedale San Raffaele"},{"orgOrder":0,"company":"ReiThera","sponsor":"The Ragon Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"GRAd-HIV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ The Ragon Institute","highestDevelopmentStatusID":"4","companyTruncated":"ReiThera \/ The Ragon Institute"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Folding interfering","graph1":"Oncology","graph2":"Discovery","graph3":"Sibylla Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sibylla Biotech \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Sibylla Biotech \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"IRBM","sponsor":"Rainwater Charitable Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"IRBM","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRBM \/ Rainwater Charitable Foundation","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Rainwater Charitable Foundation"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Sapienza University of Rome","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAMA Therapeutics \/ Sapienza University of Rome","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Therapeutics \/ Sapienza University of Rome"},{"orgOrder":0,"company":"Stevanato Group","sponsor":"Bexson Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Undisclosed","graph3":"Stevanato Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stevanato Group \/ Bexson Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Stevanato Group \/ Bexson Biomedical"},{"orgOrder":0,"company":"Menarini","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Picosulfate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Menarini \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Lupin Ltd"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napo Therapeutics \/ SPRIM Global investments","highestDevelopmentStatusID":"6","companyTruncated":"Napo Therapeutics \/ SPRIM Global investments"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody","year":"2021","type":"Termination","leadProduct":"Cusatuzumab","moa":"||CD70","graph1":"Oncology","graph2":"Phase II","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Janssen-Cilag \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Janssen-Cilag \/ Argenx"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AAVantgarde Bio \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"AAVantgarde Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Claris Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Claris Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Claris Ventures"},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire \/ Sofinnova Partners"},{"orgOrder":0,"company":"Advent","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Vitamin A Palmitate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Advent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Advent \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Advent \/ National Institutes of Health"},{"orgOrder":0,"company":"Achilles Vaccines","sponsor":"The EU Malaria Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Malaria Vaccine","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Achilles Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achilles Vaccines \/ The EU Malaria Fund","highestDevelopmentStatusID":"1","companyTruncated":"Achilles Vaccines \/ The EU Malaria Fund"},{"orgOrder":0,"company":"Advent","sponsor":"The Jenner Institute, Oxford University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Advent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advent \/ The Jenner Institute, Oxford University","highestDevelopmentStatusID":"6","companyTruncated":"Advent \/ The Jenner Institute, Oxford University"},{"orgOrder":0,"company":"ReiThera","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Adenoviral Vector-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"ReiThera \/ Univercells"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Ent001","moa":"IGFBP3\/TMEM219","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enthera Pharmaceuticals \/ Roche Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Pharmaceuticals \/ Roche Venture Fund"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"V-Bio Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CDK4\/6","graph1":"Oncology","graph2":"Discovery","graph3":"Sibylla Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sibylla Biotech \/ V-Bio Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Sibylla Biotech \/ V-Bio Ventures"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sunstone Life Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Sunstone Life Science Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Sunstone Life Science Ventures"},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire \/ Sofinnova Partners"},{"orgOrder":0,"company":"ReiThera","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ChAd3-SUDV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"ReiThera \/ BARDA"},{"orgOrder":0,"company":"MolMed","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Zalmoxis","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"MolMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MolMed \/ AGC Biologics","highestDevelopmentStatusID":"10","companyTruncated":"MolMed \/ AGC Biologics"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"EryDel","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"EryDel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"EryDel \/ Quince Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"EryDel \/ Quince Therapeutics"},{"orgOrder":0,"company":"EryDel","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"EryDel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"EryDel \/ Quince Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"EryDel \/ Quince Therapeutics"},{"orgOrder":0,"company":"Genomic Biopharma","sponsor":"POIC e dintorni","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Genomic Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genomic Biopharma \/ POIC e dintorni","highestDevelopmentStatusID":"2","companyTruncated":"Genomic Biopharma \/ POIC e dintorni"},{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus DMCC","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"ITALY","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"Factor IIa","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratori Derivati Organici \/ Cerus DMCC","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori Derivati Organici \/ Cerus DMCC"},{"orgOrder":0,"company":"IGEA Clinical Biophysics","sponsor":"OncoSec Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"CORVax12","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IGEA Clinical Biophysics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGEA Clinical Biophysics \/ OncoSec Medical","highestDevelopmentStatusID":"6","companyTruncated":"IGEA Clinical Biophysics \/ OncoSec Medical"},{"orgOrder":0,"company":"IRBM","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IRBM","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRBM \/ Antios Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IRBM \/ Antios Therapeutics"},{"orgOrder":0,"company":"Recordati","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Recordati \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"Napo EU","sponsor":"Quadri Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Napo EU \/ Quadri Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Quadri Pharmaceuticals"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"PsychoGenics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAMA Therapeutics \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Therapeutics \/ PsychoGenics"},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Italian Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Sodium\/potassium\/chloride cotransporter","graph1":"Neurology","graph2":"Discovery","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Italian Institute of Technology","highestDevelopmentStatusID":"2","companyTruncated":"IAMA Therapeutics \/ Italian Institute of Technology"},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Philogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Bifikafusp Alpha","moa":"||Angiogenesis","graph1":"Oncology","graph2":"Undisclosed","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Philogen \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Philogen \/ Merck & Co"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"2","companyTruncated":"Nerviano Medical Sciences \/ Italfarmaco S.p.A"},{"orgOrder":0,"company":"SR-Tiget","sponsor":"Genespire","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Microrna-Regulated Lentiviral Vectors","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"SR-Tiget","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SR-Tiget \/ Genespire","highestDevelopmentStatusID":"1","companyTruncated":"SR-Tiget \/ Genespire"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Rottapharm Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-eVax","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takis Biotech \/ Rottapharm Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biotech \/ Rottapharm Biotech"},{"orgOrder":0,"company":"Napo EU","sponsor":"Atlas Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"NP-500","moa":"Lipase","graph1":"Endocrinology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Napo EU \/ Atlas Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Atlas Sciences"},{"orgOrder":0,"company":"MolMed","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Libmeldy","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"MolMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MolMed \/ Orchard Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"MolMed \/ Orchard Therapeutics"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Pari","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Liposomal Cyclosporine A","moa":"Calcineurin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Pari","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Pari"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"Genomic Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Dellera","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Genomic Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genomic Biopharma \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Genomic Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen-beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAVB-081","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AAVantgarde Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AAVantgarde Bio \/ Inapplicable"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAVB-081","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AAVantgarde Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AAVantgarde Bio \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Durbin","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Durbin","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Durbin"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Linear DNA Vaccine","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takis Biotech \/ Applied DNA Sciences Inc","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biotech \/ Applied DNA Sciences Inc"},{"orgOrder":0,"company":"IRBM","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AM E3-SG3249","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IRBM","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRBM \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IRBM \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Janssen-Cilag \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tanimilast","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Global Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Global Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ent001","moa":"IGFBP3\/TMEM219","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Enthera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enthera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enthera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pressurised Metered Dose Inhaler","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Global Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Global Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Episalvan","moa":"Keratinocyte","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Chiesi Global Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Global Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IAMA-6","moa":"NKCC1","graph1":"Neurology","graph2":"IND Enabling","graph3":"IAMA Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IAMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reparixin","moa":"IL-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfarmaco Group \/ Inapplicable"},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"The Italfarmaco Group \/ Syneos Health"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"KIT2014","moa":"cAMP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kither Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kither Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kither Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"KIT2014","moa":"cAMP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Kither Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kither Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kither Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Fibromun","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ University Hospital Z\u00fcrich","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Velmanase Alpha","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Angelini Pharma \/ Sunovion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Angelini Pharma \/ Sunovion Pharmaceuticals"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Topoisomerse IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chiesi Global Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Global Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Fidia Farmaceutici Spa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Fidia Farmaceutici Spa \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fidia Farmaceutici Spa \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Angelini Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Angelini Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"European Organisation for Research and Treatment of Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ European Organisation for Research and Treatment of Cancer","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ European Organisation for Research and Treatment of Cancer"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Lo.Li. Pharma International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lo.Li. Pharma International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lo.Li. Pharma International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lo.Li. Pharma International \/ Inapplicable"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Angelini Pharma \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Angelini Pharma \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Progesterone","moa":"PR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takis Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ladarixin","moa":"IL-8A receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Santa Lucia Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rotigotine","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Santa Lucia Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Santa Lucia Foundation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Santa Lucia Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Menarini \/ Ryvu Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Ryvu Therapeutics"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bifikafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napo EU \/ Jaguar Health","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Jaguar Health"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibromun","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Vitalunga","sponsor":"Hebrew University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Vitalunga","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitalunga \/ Hebrew University","highestDevelopmentStatusID":"2","companyTruncated":"Vitalunga \/ Hebrew University"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"ReiThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GRAd-COV2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReiThera \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reparixin","moa":"IL-8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfarmaco Group \/ Inapplicable"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"ReiThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ReiThera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReiThera \/ Inapplicable"},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Linear DNA Vaccine","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takis Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biotech \/ Inapplicable"},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfarmaco Group \/ Inapplicable"},{"orgOrder":0,"company":"Rigenerand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RR001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Rigenerand","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigenerand \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rigenerand \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pressurised Metered Dose Inhaler","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen-beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Temferon","moa":"IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genenta Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Napo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Napo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Neupharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Aerosol for Inhalation","sponsorNew":"Neupharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neupharma \/ Inapplicable"},{"orgOrder":0,"company":"Neupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Neupharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Aerosol for Inhalation","sponsorNew":"Neupharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neupharma \/ Inapplicable"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Zambon Group SpA \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAVB-081","moa":"MYO7A gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AAVantgarde Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AAVantgarde Bio \/ Inapplicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Napo EU \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Napo EU \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ DKSH"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Tai Tien Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Tai Tien Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Tai Tien Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Holling Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Holling Bio-Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Holling Bio-Pharma"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Bain Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":3.2999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":3.2999999999999998,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Mitsubishi Tanabe Pharma \/ Bain Capital","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Bain Capital"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Cenerimod","moa":"S1P1R","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Viatris"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Martin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Docarpamine","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mitsubishi Tanabe Pharma \/ Martin Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Martin Pharmaceuticals"},{"orgOrder":0,"company":"Shionogi","sponsor":"Jordan\u2019s Guardian Angels","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shionogi \/ Jordan\u2019s Guardian Angels","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Jordan\u2019s Guardian Angels"},{"orgOrder":0,"company":"Axcelead","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Axcelead","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcelead \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Axcelead \/ Astellas Pharma"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Modalis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JCR Pharmaceuticals \/ Modalis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"JCR Pharmaceuticals \/ Modalis Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Alkem Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Alkem Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Alkem Laboratories"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Lupin Ltd"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Teneligliptin Hydrobromide","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mitsubishi Tanabe Pharma \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Heptares \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Shionogi"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"DCI Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Series B Financing","leadProduct":"Tamibarotene","moa":"RAR-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ DCI Partners","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ DCI Partners"},{"orgOrder":0,"company":"Stella Pharma","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"P-Borono-L-Phenylalanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stella Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stella Pharma \/ TAE Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Stella Pharma \/ TAE Life Sciences"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Amgen Inc"},{"orgOrder":0,"company":"Shionogi","sponsor":"Stemrim","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Redasemtide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Stemrim","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/ Stemrim"},{"orgOrder":0,"company":"Hitachi Chemicals","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Lentiglobin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hitachi Chemicals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hitachi Chemicals \/ Bluebird Bio","highestDevelopmentStatusID":"7","companyTruncated":"Hitachi Chemicals \/ Bluebird Bio"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LUCA Science \/ Kyowa Kirin","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Science \/ Kyowa Kirin"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"HTL0018318","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Allergan Aesthetics","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Neurelis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aculys Pharma \/ Neurelis","highestDevelopmentStatusID":"15","companyTruncated":"Aculys Pharma \/ Neurelis"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Micafungin","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Kitasato Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Influenza HA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Kitasato Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Kitasato Pharmaceutical"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Alisertib","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Puma Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Puma Biotechnology"},{"orgOrder":0,"company":"Eisai","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Eisai \/ Allarity Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ Allarity Therapeutics"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Sosei Group Corporation \/ Formosa Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Group Corporation \/ Formosa Laboratories"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Appili Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Appili Therapeutics"},{"orgOrder":0,"company":"ActualEyes","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Rho-Associated Kinase-Human Corneal Endothelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ActualEyes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ActualEyes \/ Arctic Vision","highestDevelopmentStatusID":"4","companyTruncated":"ActualEyes \/ Arctic Vision"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chugai Pharmaceutical \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pharmaceutical \/ Argenx"},{"orgOrder":0,"company":"Ajinomoto Company, Inc.","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ajinomoto Company, Inc.","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ajinomoto Company, Inc. \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Ajinomoto Company, Inc. \/ Exelixis"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Autobahn Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"ABX-003","moa":"||FAAH","graph1":"Neurology","graph2":"Preclinical","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Autobahn Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Astellas Pharma \/ Autobahn Therapeutics"},{"orgOrder":0,"company":"Axcelead","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Axcelead","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcelead \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Axcelead \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Kyorin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kyorin Pharmaceutical \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Kyorin Pharmaceutical \/ Eisai"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"BioAge Labs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"BGE-117","moa":"HIF-PH","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taisho Pharmaceutical \/ BioAge Labs","highestDevelopmentStatusID":"6","companyTruncated":"Taisho Pharmaceutical \/ BioAge Labs"},{"orgOrder":0,"company":"TMS","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"TMS-007","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TMS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TMS \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"TMS \/ Biogen"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"QP50ESO5RA","moa":"CGRP receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Takeda Pharmaceutical \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Neuraxpharm"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nippon Shinyaku \/ Capricor Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nippon Shinyaku \/ Capricor Therapeutics"},{"orgOrder":0,"company":"Optieum Biotechnologies","sponsor":"GI CELL","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Optieum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optieum Biotechnologies \/ GI CELL","highestDevelopmentStatusID":"3","companyTruncated":"Optieum Biotechnologies \/ GI CELL"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AEVI-002","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Cerecor","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Kirin \/ Cerecor"},{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Henlius","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"LIV-2008","moa":"Trop2","graph1":"Oncology","graph2":"Preclinical","graph3":"Chiome Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiome Bioscience \/ Henlius","highestDevelopmentStatusID":"4","companyTruncated":"Chiome Bioscience \/ Henlius"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Termination","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taisho Pharmaceutical \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Taisho Pharmaceutical \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"CMIC Holdings","sponsor":"Fujifilm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CMIC Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CMIC Holdings \/ Fujifilm","highestDevelopmentStatusID":"10","companyTruncated":"CMIC Holdings \/ Fujifilm"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"4-Valent DTP-Poliovirus Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Daiichi Sankyo \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Sanofi"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Urate transporter 1","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fuji Yakuhin \/ Fortress Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Fuji Yakuhin \/ Fortress Biotech"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Ministry of Health, Labour and Welfare of Japan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Ministry of Health, Labour and Welfare of Japan","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Ministry of Health, Labour and Welfare of Japan"},{"orgOrder":0,"company":"Eisai","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Betahistine Dimesilate","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"National Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ National Cancer Center","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ National Cancer Center"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Meiji Seika Pharma \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Eisai"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nippon Shinyaku \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Nippon Shinyaku \/ Menarini"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Argatroban Monohydrate","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Ethypharm"},{"orgOrder":0,"company":"PeptiDream","sponsor":"RayzeBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ RayzeBio","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ RayzeBio"},{"orgOrder":0,"company":"GNI Group","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Hydronidone","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"GNI Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GNI Group \/ Catalyst Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"GNI Group \/ Catalyst Biosciences"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Steroid","year":"2021","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sosei Heptares \/ Formosa Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Heptares \/ Formosa Laboratories"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fujifilm holding \/ Sana Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm holding \/ Sana Biotechnology"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"VLP Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Fujifilm holding \/ VLP Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm holding \/ VLP Therapeutics"},{"orgOrder":0,"company":"Kao Corporation","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Cry5B protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kao Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kao Corporation \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Kao Corporation \/ GHIT Fund"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Daiichi Sankyo \/ GHIT Fund"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPR35","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ GSK"},{"orgOrder":0,"company":"Eisai","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"H3B-8800","moa":"Pre-messenger RNA splicing","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Roivant Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Roivant Sciences"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"HANDOK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sosei Group Corporation \/ HANDOK","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ HANDOK"},{"orgOrder":0,"company":"Heartseed","sponsor":"UTokyo Innovation Platform","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ UTokyo Innovation Platform","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ UTokyo Innovation Platform"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Frazier Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Norovirus Bivalent GI.1\/GII.4 VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Frazier Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Frazier Healthcare"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"HLS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Porcine recombinant Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ HLS Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ HLS Therapeutics"},{"orgOrder":0,"company":"Heartseed","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ Novo Nordisk","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Novo Nordisk"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"HTL0016878","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Mitsubishi Ufj Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"GtCCR4","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Mitsubishi Ufj Capital","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Mitsubishi Ufj Capital"},{"orgOrder":0,"company":"TOA EIYO","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Isosorbide Dinitrate","moa":"Myosin dephosphorylator","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"TOA EIYO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tape","sponsorNew":"TOA EIYO \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"TOA EIYO \/ Astellas Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"JAPAN","productType":"Protein","year":"2020","type":"Termination","leadProduct":"Human Fibrinogen","moa":"||Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Johnson & Johnson"},{"orgOrder":0,"company":"EditForce","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RNA","graph1":"Neurology","graph2":"Discovery","graph3":"EditForce","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EditForce \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"2","companyTruncated":"EditForce \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"National Center for Global Health and Medicine","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Eritoran","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Center for Global Health and Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Center for Global Health and Medicine \/ Eisai","highestDevelopmentStatusID":"4","companyTruncated":"National Center for Global Health and Medicine \/ Eisai"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"E6742","moa":"TLR7\/8","graph1":"Immunology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"KP-723","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaken Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Kaken Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Kyowa Kirin \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Grunenthal"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Amgen Inc"},{"orgOrder":0,"company":"Kortuc","sponsor":"AXA Japan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Hydrogen Peroxide","moa":"Free radical","graph1":"Oncology","graph2":"Phase II","graph3":"Kortuc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Kortuc \/ AXA Japan","highestDevelopmentStatusID":"8","companyTruncated":"Kortuc \/ AXA Japan"},{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Sumitomo","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Kyorin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kyorin Pharmaceutical \/ Sumitomo","highestDevelopmentStatusID":"15","companyTruncated":"Kyorin Pharmaceutical \/ Sumitomo"},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AK1780","moa":"P2X7 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Asahi Kasei Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asahi Kasei Pharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Asahi Kasei Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Chugai Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sit Laboratorio Farmaceutico","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Metoprolol Tartrate","moa":"Adrenergic-beta 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Sit Laboratorio Farmaceutico","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Sit Laboratorio Farmaceutico"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Axil Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LUCA Science \/ Axil Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Science \/ Axil Capital Partners"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Summit Pharmaceuticals Europe Srl","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl"},{"orgOrder":0,"company":"Kobe University","sponsor":"Lynk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RAS","graph1":"Oncology","graph2":"Discovery","graph3":"Kobe University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kobe University \/ Lynk Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Kobe University \/ Lynk Pharmaceuticals"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Modalis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JCR Pharmaceuticals \/ Modalis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"JCR Pharmaceuticals \/ Modalis Therapeutics"},{"orgOrder":0,"company":"OriCiro Genomics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"OriCiro Genomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OriCiro Genomics \/ Moderna Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"OriCiro Genomics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Eribulin","moa":"||FR alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Eisai","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Eperisone Hydrochloride","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ DKSH"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NEC Corporation \/ AGC Biologics","highestDevelopmentStatusID":"6","companyTruncated":"NEC Corporation \/ AGC Biologics"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Nichi-Iko Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Licensing Agreement","leadProduct":"Limaprost Alphadex","moa":"PGE2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Oak Hill Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"OHB-607","moa":"IGF-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Oak Hill Bio","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Oak Hill Bio"},{"orgOrder":0,"company":"SanBio","sponsor":"Ocumension","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SanBio \/ Ocumension","highestDevelopmentStatusID":"4","companyTruncated":"SanBio \/ Ocumension"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Prism Biolab","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Prism Biolab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prism Biolab \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Prism Biolab \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"KYORIN PHARMACEUTICAL CO LTD","sponsor":"Otonomy","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"OTO-6XX","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"KYORIN PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KYORIN PHARMACEUTICAL CO LTD \/ Otonomy","highestDevelopmentStatusID":"4","companyTruncated":"KYORIN PHARMACEUTICAL CO LTD \/ Otonomy"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Lotiglipron","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Heptares \/ Pfizer Inc"},{"orgOrder":0,"company":"Ciitizen","sponsor":"Praxis Precision Medicines","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Relutrigine","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase I","graph3":"Ciitizen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ciitizen \/ Praxis Precision Medicines","highestDevelopmentStatusID":"6","companyTruncated":"Ciitizen \/ Praxis Precision Medicines"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Fast Track Initiative","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LUCA Science \/ Fast Track Initiative","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ Fast Track Initiative"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ RedHill Biopharma"},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"RevolKa \/ Daiichi Sankyo"},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"RK007","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"1","companyTruncated":"RevolKa \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Micafungin","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Toshiba Corporation","sponsor":"Shinshu University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Toshiba Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Toshiba Corporation \/ Shinshu University","highestDevelopmentStatusID":"1","companyTruncated":"Toshiba Corporation \/ Shinshu University"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ AbbVie Inc"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"SHP2","graph1":"Oncology","graph2":"Discovery","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taiho Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Taiho Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Calithera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Sapanisertib","moa":"TORC1\/2","graph1":"Oncology","graph2":"Preclinical","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Calithera Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Takeda Pharmaceutical \/ Calithera Biosciences"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Teijin Pharma \/ TransThera Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Teijin Pharma \/ TransThera Biosciences"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teijin Pharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Teijin Pharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Aditum Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TMP-301","moa":"mGluR5","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Aditum Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Aditum Bio"},{"orgOrder":0,"company":"Contract Sales Organization","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Triethanolamine Salicylate","moa":"COX-2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Contract Sales Organization","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Contract Sales Organization \/ Tetra BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Contract Sales Organization \/ Tetra BioPharma"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Harvard University","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Harvard University","highestDevelopmentStatusID":"2","companyTruncated":"Kyowa Kirin \/ Harvard University"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ UMass Chan Medical School","highestDevelopmentStatusID":"2","companyTruncated":"Astellas Pharma \/ UMass Chan Medical School"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Sumitomo Dainippon Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Amlodipine","moa":"||L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Cosette Pharma"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Oncolys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Microorganism","year":"2021","type":"Termination","leadProduct":"Pembrolizumab","moa":"||Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Oncolys","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Oncolys"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Large Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Luxna Biotech \/ Aligos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Aligos Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Tottori University","sponsor":"GC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Tottori University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tottori University \/ GC Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Tottori University \/ GC Pharma"},{"orgOrder":0,"company":"Shionogi","sponsor":"Clinton Health Access Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shionogi \/ Clinton Health Access Initiative","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Clinton Health Access Initiative"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Mass General Brigham","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Mass General Brigham","highestDevelopmentStatusID":"2","companyTruncated":"Astellas Pharma \/ Mass General Brigham"},{"orgOrder":0,"company":"RevolKa","sponsor":"La Jolla Institute for Immunology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"RK009","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevolKa \/ La Jolla Institute for Immunology","highestDevelopmentStatusID":"2","companyTruncated":"RevolKa \/ La Jolla Institute for Immunology"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Osaka University","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Osaka University","highestDevelopmentStatusID":"4","companyTruncated":"Astellas Pharma \/ Osaka University"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Genentech"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Astellas Pharma"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"HTL0039732","moa":"EP4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Heptares \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Group Corporation \/ AbbVie Inc"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JCR Pharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Angelini Pharma"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"PharmEnable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ PharmEnable","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Heptares \/ PharmEnable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Washington University School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Eisai \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Carmine Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Takeda Pharmaceutical \/ Carmine Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pharmaceutical \/ Carmine Therapeutics"},{"orgOrder":0,"company":"Axcelead","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Axcelead","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcelead \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Axcelead \/ Eli Lilly"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Diclofenac Conjugated Sodium Hyaluronate","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seikagaku \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Eisai"},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"||Adenosine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Polysulfated Glycosaminoglycan","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ American Regent"},{"orgOrder":0,"company":"Alpha Fusion","sponsor":"Sumitomo Heavy Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Astatine-211","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alpha Fusion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpha Fusion \/ Sumitomo Heavy Industries","highestDevelopmentStatusID":"2","companyTruncated":"Alpha Fusion \/ Sumitomo Heavy Industries"},{"orgOrder":0,"company":"Eisai","sponsor":"Ghit Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"SJ733","moa":"PfATP4 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Ghit Fund","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Ghit Fund"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Catalys Pacific","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Catalys Pacific"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ University of Oxford"},{"orgOrder":0,"company":"Eisai","sponsor":"GHIT","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Fosravuconazole","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ GHIT","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ GHIT"},{"orgOrder":0,"company":"Ehime University","sponsor":"GHIT","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ehime University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ehime University \/ GHIT","highestDevelopmentStatusID":"1","companyTruncated":"Ehime University \/ GHIT"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pharmaceutical \/ GHIT Fund"},{"orgOrder":0,"company":"GHIT Fund","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Fosravuconazole","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GHIT Fund","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GHIT Fund \/ Eisai","highestDevelopmentStatusID":"8","companyTruncated":"GHIT Fund \/ Eisai"},{"orgOrder":0,"company":"Shionogi","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shionogi \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/ GHIT Fund"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Wellcome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"SH-879","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Wellcome","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Wellcome"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"SBI Investment Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Disulfide Rich Peptides","moa":"Ion Channel","graph1":"Neurology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veneno Technologies \/ SBI Investment Co","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Technologies \/ SBI Investment Co"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"OPC-167832","moa":"||DprE1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Shionogi","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/ The Global Health Innovative Technology"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Mitsubishi Tanabe Pharma \/ The Global Health Innovative Technology"},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Corallopyronin A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ The Global Health Innovative Technology"},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Eisai \/ The Global Health Innovative Technology"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Peptide","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"TfR1","graph1":"Neurology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Fujitsu","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"PeptiDream \/ Fujitsu","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Fujitsu"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Immunic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sankyo \/ Immunic Therapeutics"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Immunis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Nalfurafine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Immunis","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Immunis"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Elixirgen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Elixirgen Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Taisho Pharmaceutical \/ Elixirgen Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Teijin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Teijin Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"||Adenosine receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hypera Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Fursultiamine","moa":"Hepcidin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Celltrion","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Celltrion"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Urapidil Hydrochloride","moa":"AR Alpha1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Teijin Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Teijin Pharma"},{"orgOrder":0,"company":"RevolKa","sponsor":"DEEPCORE","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"RKD001","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevolKa \/ DEEPCORE","highestDevelopmentStatusID":"2","companyTruncated":"RevolKa \/ DEEPCORE"},{"orgOrder":0,"company":"Center for iPS Cell Research and Application","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Center for iPS Cell Research and Application","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Center for iPS Cell Research and Application \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Center for iPS Cell Research and Application \/ Astellas Pharma"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"PrecisionLife","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ PrecisionLife","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ PrecisionLife"},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Coalition For Adaptive Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Eritoran","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ The Global Coalition For Adaptive Research","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ The Global Coalition For Adaptive Research"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Pfizer Inc"},{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LUCA Science \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ University of Oxford"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Heptares \/ Eli Lilly"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Santen Pharmaceutical \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Harrow"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Santen Pharmaceutical \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Harrow"},{"orgOrder":0,"company":"IPGaia","sponsor":"Duke-NUS Medical School","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"IPGaia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IPGaia \/ Duke-NUS Medical School","highestDevelopmentStatusID":"2","companyTruncated":"IPGaia \/ Duke-NUS Medical School"},{"orgOrder":0,"company":"Eisai","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Loxapine Succinate","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eisai \/ CNX Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ CNX Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"The University Of Tokyo","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Daiichi Sankyo \/ The University Of Tokyo","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ The University Of Tokyo"},{"orgOrder":0,"company":"Gifu University","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Gifu University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gifu University \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Gifu University \/ Astellas Pharma"},{"orgOrder":0,"company":"Heartseed","sponsor":"Itochu Chemical Frontier","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ Itochu Chemical Frontier","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Itochu Chemical Frontier"},{"orgOrder":0,"company":"Shionogi","sponsor":"OrsoBio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ OrsoBio","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/ OrsoBio"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"KinoPharma","sponsor":"Aska Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"RKP00156","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"KinoPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KinoPharma \/ Aska Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"KinoPharma \/ Aska Pharmaceutical"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Tillotts Pharma AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Large Molecule","year":"2020","type":"Agreement","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Tillotts Pharma AG","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Tillotts Pharma AG"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Janssen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nippon Shinyaku \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Nippon Shinyaku \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Cellusion","sponsor":"Hangzhou Celregen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellusion \/ Hangzhou Celregen Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion \/ Hangzhou Celregen Therapeutics"},{"orgOrder":0,"company":"Eisai","sponsor":"DRI Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ DRI Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ DRI Healthcare"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DSP-0187","moa":"Orexin-2 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Scohia Pharma","sponsor":"Kuria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"KTX-101","moa":"Nrf2","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Scohia Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scohia Pharma \/ Kuria Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Scohia Pharma \/ Kuria Therapeutics"},{"orgOrder":0,"company":"MabGenesis","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"MabGenesis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MabGenesis \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"MabGenesis \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Peficitinib Hydrobromide","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Menarini"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Merck Group"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Eli Lilly"},{"orgOrder":0,"company":"Sony Corporation","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Sony Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sony Corporation \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sony Corporation \/ Astellas Pharma"},{"orgOrder":0,"company":"Shionogi","sponsor":"Charioteer","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ Charioteer","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Charioteer"},{"orgOrder":0,"company":"bitBiome","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"bitBiome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"bitBiome \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"bitBiome \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veneno Technologies \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Technologies \/ Astellas Pharma"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Sumitomo Dainippon Pharma Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veneno Technologies \/ Sumitomo Dainippon Pharma Co., Ltd","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Technologies \/ Sumitomo Dainippon Pharma Co., Ltd"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Visiox Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Omidenepag Isopropyl","moa":"EP2 R","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Visiox Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Visiox Pharmaceuticals"},{"orgOrder":0,"company":"xFOREST Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"xFOREST Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"xFOREST Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"xFOREST Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Nagoya University","sponsor":"Ymmunobio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"YB-800","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nagoya University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nagoya University \/ Ymmunobio","highestDevelopmentStatusID":"4","companyTruncated":"Nagoya University \/ Ymmunobio"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"HTL0039732","moa":"EP4 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Group Corporation \/ Cancer Research"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"GAIA BioMedicine","sponsor":"TreeFrog Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"GAIA-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GAIA BioMedicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GAIA BioMedicine \/ TreeFrog Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"GAIA BioMedicine \/ TreeFrog Therapeutics"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Genentech"},{"orgOrder":0,"company":"Prism Biolab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Prism Biolab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prism Biolab \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Prism Biolab \/ Eli Lilly"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Darinaparsin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Nippon Kayaku","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nippon Kayaku \/ Solasia Pharma KK","highestDevelopmentStatusID":"8","companyTruncated":"Nippon Kayaku \/ Solasia Pharma KK"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Luxna Biotech \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Luxna Biotech \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Chiome Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chiome Bioscience \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Chiome Bioscience \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Noile-Immune","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Nib-102","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Noile-Immune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Noile-Immune \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Noile-Immune \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JCR Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pharmaceutical \/ Novo Nordisk"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Kirin \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"CTX-177","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chordia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chordia Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Chordia Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Granisetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kyowa Kirin \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Wakamoto Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Hormone","year":"2021","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wakamoto Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Wakamoto Pharmaceutical \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Wakamoto Pharmaceutical \/ Harrow"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meiji Seika Pharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"KRAS","graph1":"Oncology","graph2":"Discovery","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taiho Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Taiho Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Burosumab","moa":"FGF23","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tak-733","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Recursion Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pharmaceutical \/ Recursion Pharma"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Schrodinger","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Otsuka Pharmaceutical \/ Schrodinger","highestDevelopmentStatusID":"2","companyTruncated":"Otsuka Pharmaceutical \/ Schrodinger"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Luvadaxistat","moa":"DAAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Naxitamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Y-mAbs Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Y-mAbs Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Corza","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"JAPAN","productType":"Protein","year":"2020","type":"Divestment","leadProduct":"Human Fibrinogen","moa":"||Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Corza","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Corza"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Verastem Oncology"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Pabinafusp Alpha","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Shionogi","sponsor":"Nagasaki University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shionogi \/ Nagasaki University","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/ Nagasaki University"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Government of Japan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Government of Japan","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Government of Japan"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Affinivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"24-Valent Streptococcus Pneumoniae Vaccine","moa":"B-cell antibody","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Astellas Pharma \/ Affinivax","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Affinivax"},{"orgOrder":0,"company":"PDRadiopharma","sponsor":"CURIUM US LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Radiolabelled Compounds","year":"2024","type":"Partnership","leadProduct":"177-Lu PSMA-I&T","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"PDRadiopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDRadiopharma \/ CURIUM US LLC","highestDevelopmentStatusID":"10","companyTruncated":"PDRadiopharma \/ CURIUM US LLC"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Cipla"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Mankind Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Zydus Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Eisai","sponsor":"Sato Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Fosravuconazole","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Sato Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Sato Pharma"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Urate transporter 1","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Eisai"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Affamed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"KDT-3594","moa":"Dopamine receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ Affamed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Affamed"},{"orgOrder":0,"company":"Ribomic","sponsor":"AJU Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Umedaptanib Pegol","moa":"FGFR 2\/3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ribomic \/ AJU Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ AJU Pharma"},{"orgOrder":0,"company":"Kyowa Pharmaceutical Industry","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Kyowa Pharmaceutical Industry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Two Cells","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"gMSC1","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Two Cells","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Two Cells \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Two Cells \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Urica Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Urate transporter 1","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fuji Yakuhin \/ Urica Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Fuji Yakuhin \/ Urica Therapeutics"},{"orgOrder":0,"company":"Yoshindo","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Yoshindo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Yoshindo \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Yoshindo \/ Biocon"},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Termination","leadProduct":"Farletuzumab Ecteribulin","moa":"FR alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Epsilon Molecular Engineering","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Epsilon Molecular Engineering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Epsilon Molecular Engineering \/ Mitsubishi UFJ Capital","highestDevelopmentStatusID":"2","companyTruncated":"Epsilon Molecular Engineering \/ Mitsubishi UFJ Capital"},{"orgOrder":0,"company":"Shionogi","sponsor":"BioAge Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Asapiprant","moa":"DP1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ BioAge Labs","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ BioAge Labs"},{"orgOrder":0,"company":"Dydo Pharma","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Dydo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dydo Pharma \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dydo Pharma \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Zeria Pharmaceutical \/ Vifor Pharma"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Prasugrel Hydrochloride","moa":"P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Prasugrel Hydrochloride","moa":"P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HTL0033744","moa":"EP4 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"Alpha 4 integrin","graph1":"Immunology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ EA Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin Cell adhesion molecule-1","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe","highestDevelopmentStatusID":"4","companyTruncated":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Dong-A Socio Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meiji Seika Pharma \/ Dong-A Socio Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Dong-A Socio Holdings"},{"orgOrder":0,"company":"Taiko Pharmaceutical","sponsor":"Kitasato University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlorine Dioxide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Taiko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Taiko Pharmaceutical \/ Kitasato University","highestDevelopmentStatusID":"1","companyTruncated":"Taiko Pharmaceutical \/ Kitasato University"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Nihon Medi-Physics","sponsor":"Cyclotron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"225-Ac PET","moa":"Alpha radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nihon Medi-Physics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nihon Medi-Physics \/ Cyclotron","highestDevelopmentStatusID":"1","companyTruncated":"Nihon Medi-Physics \/ Cyclotron"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Seagen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Seagen"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Brand Institute"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Genentech"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Perilesional Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AMY109","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"E2814","moa":"||MTBR-tau","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Washington University School of Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TAK-888","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Alebund Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EOS789","moa":"Phosphate transport protein","graph1":"Nephrology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Alebund Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Alebund Pharmaceuticals"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ AbbVie Inc"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"L-praziquantel","moa":"Calcium channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1 gene","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AT845","moa":"GAA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Folinic Acid","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AT845","moa":"GAA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AT845","moa":"GAA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AT845","moa":"GAA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deudextromethorphan Hydrobromide","moa":"||MAO","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aculys Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aculys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Taisho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibandronate Sodium","moa":"Hydroxylapatite","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chugai Pharmaceutical \/ Taisho Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Taisho Pharmaceutical"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jadeite Medicines","sponsor":"Albireo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Jadeite Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jadeite Medicines \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Jadeite Medicines \/ Albireo Pharma"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PeptiDream \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glycerine","moa":"||PPAR","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Galderma"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Serotonin uptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Serotonin uptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"CG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kissei Pharmaceutical \/ CG Oncology","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ CG Oncology"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chugai Pharmaceutical \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zonisamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CTX-712","moa":"CLK kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Chordia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chordia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chordia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Omicron XBB.1.5-adapted Monovalent mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Darvadstrocel","moa":"IFN-gamma","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Darinaparsin","moa":"Apoptosis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Solasia Pharma KK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Solasia Pharma KK \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"Solasia Pharma KK \/ Brand Institute"},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Darinaparsin","moa":"Apoptosis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Solasia Pharma KK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Solasia Pharma KK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Solasia Pharma KK \/ Inapplicable"},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Nippon Kayaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Darinaparsin","moa":"Apoptosis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Solasia Pharma KK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Solasia Pharma KK \/ Nippon Kayaku","highestDevelopmentStatusID":"15","companyTruncated":"Solasia Pharma KK \/ Nippon Kayaku"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Neutralizing IgG\/Opsonins","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"ubenimex","moa":"||CD13","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Delamanid","moa":"H37Rv","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Teserpaturev","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delta-Fly Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"ubenimex","moa":"||CD13","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"ubenimex","moa":"||CD13","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DFP-14927","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difamilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Medimetriks Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difamilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Medimetriks Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Medimetriks Pharmaceuticals"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DONQ52","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Urate transporter 1","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sanford Burnham Prebys","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"N-Acetyl-D-Leucine","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Sanford Burnham Prebys","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Sanford Burnham Prebys"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DS-3939","moa":"TA-MUC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sarah Cannon Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"O-(3,5-Dichlorophenyl)hydroxylamine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Sarah Cannon Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Sarah Cannon Research Institute"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"O-(3,5-Dichlorophenyl)hydroxylamine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pyrrolobenzodiazepine ADC","moa":"CLDN6","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DSP-0390","moa":"EBP","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzomenib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"E2086","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tasurgratinib Succinate","moa":"TYK","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"PRISM BioLab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"E7386","moa":"||CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ PRISM BioLab","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ PRISM BioLab"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eritoran","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"GNI Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydronidone","moa":"||TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"GNI Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GNI Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GNI Group \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Farletuzumab Ecteribulin","moa":"FR alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"||PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"National Institutes of Biomedical Innovation, Health and nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DSP-0546LP","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ National Institutes of Biomedical Innovation, Health and nutrition","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ National Institutes of Biomedical Innovation, Health and nutrition"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"DS-6157","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sarah Cannon Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DS-6000","moa":"CDH6 IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Sarah Cannon Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Sarah Cannon Research Institute"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||FGFR 2\/3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"DS-1055","moa":"Anti-glycoprotein A repetitions predominant","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"Proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Midwest Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR 2\/3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ribomic \/ Midwest Eye Institute","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Midwest Eye Institute"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Tsukuba Research Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Tsukuba Research Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Tsukuba Research Laboratories"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Bonac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BNC-1322","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bonac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bonac \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonac \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Healios K.K \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Healios K.K \/ Inapplicable"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Athersys"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hutchmed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"VEGFR 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Hutchmed"},{"orgOrder":0,"company":"Heartseed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Inapplicable"},{"orgOrder":0,"company":"Heartseed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HTL\u2019149","moa":"GPR52","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Cancer Research UK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sosei Heptares \/ Cancer Research UK","highestDevelopmentStatusID":"7","companyTruncated":"Sosei Heptares \/ Cancer Research UK"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"Neutralizing IgG\/Opsonins","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"Neutralizing IgG\/Opsonins","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"Neutralizing IgG\/Opsonins","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Neutralizing IgG\/Opsonins","graph1":"Neurology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Neutralizing IgG\/Opsonins","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Neutralizing IgG\/Opsonins","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ifinatamab Deruxtecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Prophylactic Recombinant Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Von Willebrand Factor","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tasurgratinib Succinate","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Rovatirelin","moa":"TRHR","graph1":"Neurology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JR-141","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Lepunafusp Alpha","moa":"Dermatan sulfate hydrolytic enzyme","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Otsuka Holdings \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Holdings \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ American Regent"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rufinamide","moa":"Sodium channel alpha subunit","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pabinafusp Alpha","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"IVERIC bio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ IVERIC bio","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ IVERIC bio"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JR-141","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pabinafusp Alpha","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Lepunafusp Alpha","moa":"Dermatan sulfate hydrolytic enzyme","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Lepunafusp Alpha","moa":"Dermatan sulfate hydrolytic enzyme","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Lepunafusp Alpha","moa":"Dermatan sulfate hydrolytic enzyme","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Medipal Holdings Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-446","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JCR Pharmaceuticals \/ Medipal Holdings Corporation","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Medipal Holdings Corporation"},{"orgOrder":0,"company":"RaQualia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"RaQualia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"RaQualia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RaQualia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Amgen Inc"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kyowa Kirin \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Ardelyx"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KW-6356","moa":"||A2AR","graph1":"Neurology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ BioArctic AB"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"C2N Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ C2N Diagnostics","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ C2N Diagnostics"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Genentech"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mosunetuzumab","moa":"CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kyowa Kirin \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ MEI Pharma"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"MedRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"MedRx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"MedRx \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MedRx \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Methylcobalamin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ Nippon Medac","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Nippon Medac"},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ Nippon Medac","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Nippon Medac"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Difamilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Athersys"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Athersys"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo \/ Pfizer Inc"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NBI-1117570","moa":"Muscarinic M1\/M4 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Heptares \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"NeuroDerm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ NeuroDerm","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ NeuroDerm"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Lenograstim","moa":"VEGF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Ach receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"STA551","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Aculys Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aculys Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aculys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SanBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"UBE Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omidenepag Isopropyl","moa":"EP2 R","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ UBE Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ UBE Corporation"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"Proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tirabrutinib Hydrochloride","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OPC-167832","moa":"||DprE1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Millmount Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"V2R","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Millmount Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Millmount Healthcare"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"5-HT1A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Galderma"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"CCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PeptiDream \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotiglipron","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Heptares \/ Pfizer Inc"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyowa Kirin \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ MEI Pharma"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"S-268019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||EGFR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||EGFR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"CCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"CCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASP0367","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DS-6000","moa":"CDH6 IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Neurology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Ovid Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Ovid Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Lactiplantibacillus Pentosus ONRICb0240","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9vHPV Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quizartinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR 2\/3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR 2\/3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR 2\/3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Raludotatug Deruxtecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"University of Tokyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Tokyo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Tokyo \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Tokyo \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eribulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Holdings \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Holdings \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"ZENOAQ","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"ZENOAQ","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZENOAQ \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"ZENOAQ \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"RAR-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Nephrology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kyowa Kirin \/ Reata Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Reata Pharmaceuticals"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"S-268019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"S-268019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Farletuzumab Ecteribulin","moa":"FR alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolvaptan Sodium Phosphate","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolvaptan Sodium Phosphate","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Otsuka Holdings \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Partner Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nobelpharma \/ Partner Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma \/ Partner Therapeutics"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kaken Pharmaceuticals \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health"},{"orgOrder":0,"company":"Sawai Pharmaceutical Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"M3 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Sawai Pharmaceutical Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sawai Pharmaceutical Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sawai Pharmaceutical Co \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Tafluprost","moa":"||FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sonire therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Sonire therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonire therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sonire therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosnetupitant Chloride","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mezagitamab","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apadamtase Alpha","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TAK-755","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TAK-861","moa":"OX2R","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TAK-994","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TAK-888","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pevonedistat","moa":"||NEDD8","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9vHPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9vHPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Talazoparib","moa":"PARP 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Tafluprost","moa":"||FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mirogabalin Besylate","moa":"CaV1\/2 channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deudextromethorphan Hydrobromide","moa":"||MAO","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Otsuka Holdings \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosnetupitant Chloride","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Novavax"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pevonedistat","moa":"||NEDD8","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Exelixis"},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Biogen"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Merck & Co"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carotuximab","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pevonedistat","moa":"||NEDD8","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Parathyroid Hormone","moa":"Calcium","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mogamulizumab","moa":"CCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"KM Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"KD-414","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KM Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"KM Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KM Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nichi-Iko Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nichi-Iko Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Soleo Health"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lemborexant","moa":"OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pabinafusp Alpha","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirabegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"The National Institutes of Biomedical Innovation, Health and Nutrition","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The National Institutes of Biomedical Innovation, Health and Nutrition","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"The National Institutes of Biomedical Innovation, Health and Nutrition \/ Shionogi","highestDevelopmentStatusID":"4","companyTruncated":"The National Institutes of Biomedical Innovation, Health and Nutrition \/ Shionogi"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Asahi Kasei Finechem","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Finechem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asahi Kasei Finechem \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Finechem \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dersimelagon","moa":"MC1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"||Integrin-alpha 4\/beta 7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JR-141","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Darinaparsin","moa":"Apoptosis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Solasia Pharma KK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Solasia Pharma KK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Solasia Pharma KK \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aichi Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Neoantigen","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Discovery","graph3":"Aichi Cancer Center","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aichi Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Aichi Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"SHIRE LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maribavir","moa":"BGLF4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ SHIRE LLC","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ SHIRE LLC"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"||GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ FibroGen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healios K.K \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Healios K.K \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"||DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Engineered Gingival Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ National Institutes of Health"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perampanel","moa":"AMPA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Seagen"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K.K \/ Athersys"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pevonedistat","moa":"||NEDD8","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"QP50ESO5RA","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sosei Group Corporation \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Group Corporation \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirabegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Tanabe Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DS-5670","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nippon Shinyaku \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nippon Shinyaku \/ Inapplicable"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEC Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NEC Corporation \/ Inapplicable"},{"orgOrder":0,"company":"SanBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1 gene","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Soleo Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health","highestDevelopmentStatusID":"15","companyTruncated":"Mitsubishi Chemical Holdings Corporation \/ Soleo Health"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Delamanid","moa":"||H37Rv","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Infusion","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9vHPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TMP-301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"||Proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TP-3654","moa":"PIM kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TP-3654","moa":"PIM kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Chugai Pharmaceutical \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ AstraZeneca"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Poxel","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitomo Pharma \/ Poxel","highestDevelopmentStatusID":"11","companyTruncated":"Sumitomo Pharma \/ Poxel"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cellusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellusion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"||PBP","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Sunovion Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Otsuka Pharmaceutical \/ Sunovion Pharmaceuticals"},{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upacicalcet Sodium","moa":"CaR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sanwa Kagaku Kenkyusho \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Mitsubishi Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glutathione","moa":"Glutathione peroxidase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Mitsubishi Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mitsubishi Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mitsubishi Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Akebia Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tirabrutinib Hydrochloride","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fezolinetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santen Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"M3 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sibeprenlimab","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sibeprenlimab","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Holdings \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sibeprenlimab","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Von Willebrand Factor","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Von Willebrand Factor","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Ohara Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Micafungin","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Teijin Pharma \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Teijin Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shionogi \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ National Institutes of Health"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Blood and Marrow Transplant Clinical Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Blood and Marrow Transplant Clinical Trials Network","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Blood and Marrow Transplant Clinical Trials Network"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kotobuki Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Kotobuki Pharmaceutical"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kotobuki Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Kotobuki Pharmaceutical"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alvocidib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Etelcalcetide","moa":"CaSR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Sugammadex rocuronium chelating complex","graph1":"Neurology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Radgocitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Loxoprofen Sodium","moa":"COX","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Tape","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sumatriptan","moa":"5-HT1B receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Dydo Pharma","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Dydo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dydo Pharma \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dydo Pharma \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Renalys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Condoliase","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Seikagaku \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quizartinib","moa":"||FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Shionogi"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"JAPAN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sosei Group Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Group Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Film-Forming Solution","sponsorNew":"Torii Pharmaceutical \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sumitomo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sumitomo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"BB-1701","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Redalsomatropin Alpha","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Medipal Holdings Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-446","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Medipal Holdings Corporation","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Medipal Holdings Corporation"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PD-29875","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PeptiDream \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Axantia Group","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JORDAN","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Axantia Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Axantia Group \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Axantia Group \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"NexThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"KOSOVO","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"NT-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"NexThera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NexThera \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NexThera \/ Inapplicable"},{"orgOrder":0,"company":"Olpha","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"LATVIA","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"Furazidin","moa":"Bacterial ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Olpha","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olpha \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Olpha \/ Adalvo"},{"orgOrder":0,"company":"Pharmidea","sponsor":"Lidds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LATVIA","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"NZ-TLR9","moa":"TLR9","graph1":"Oncology","graph2":"Preclinical","graph3":"Pharmidea","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Pharmidea \/ Lidds","highestDevelopmentStatusID":"4","companyTruncated":"Pharmidea \/ Lidds"},{"orgOrder":0,"company":"Silvanols","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"LATVIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olea Europea Extract","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Silvanols","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Silvanols \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Silvanols \/ Inapplicable"},{"orgOrder":0,"company":"Silvanols","sponsor":"University of Latvia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"LATVIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olea Europea","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Silvanols","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Silvanols \/ University of Latvia","highestDevelopmentStatusID":"15","companyTruncated":"Silvanols \/ University of Latvia"},{"orgOrder":0,"company":"Silvanols","sponsor":"University of Lorraine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"LATVIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crocus Sativus","moa":"||GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Silvanols","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Silvanols \/ University of Lorraine","highestDevelopmentStatusID":"15","companyTruncated":"Silvanols \/ University of Lorraine"},{"orgOrder":0,"company":"Grindeks AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"LATVIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyl-GBB","moa":"GBBH","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Grindeks AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grindeks AS \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grindeks AS \/ Inapplicable"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Micreos Human Health","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"LITHUANIA","productType":"Enzyme","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northway Biotechpharma \/ Micreos Human Health","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Micreos Human Health"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Mallia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"LITHUANIA","productType":"Protein","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"CD38","graph1":"Dermatology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northway Biotechpharma \/ Mallia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Mallia Therapeutics"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"iTolerance","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"LITHUANIA","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Northway Biotechpharma \/ iTolerance","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ iTolerance"},{"orgOrder":0,"company":"Caszyme","sponsor":"Integra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"LITHUANIA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Caszyme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caszyme \/ Integra Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Caszyme \/ Integra Therapeutics"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"LITHUANIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"IMP761","moa":"LAG3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northway Biotechpharma \/ Immutep","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Immutep"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Memo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"LITHUANIA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"MTX-COVAB","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northway Biotechpharma \/ Memo Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Northway Biotechpharma \/ Memo Therapeutics"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"LITHUANIA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Northway Biotechpharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Northway Biotechpharma \/ Revolo Biotherapeutics"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Covis Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Covis Pharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Inceptua Group","sponsor":"Oxurion","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"LUXEMBOURG","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Ocriplasmin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Inceptua Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inceptua Group \/ Oxurion","highestDevelopmentStatusID":"15","companyTruncated":"Inceptua Group \/ Oxurion"},{"orgOrder":0,"company":"Fareva","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"LUXEMBOURG","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fareva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fareva \/ CureVac","highestDevelopmentStatusID":"8","companyTruncated":"Fareva \/ CureVac"},{"orgOrder":0,"company":"Procaps Group","sponsor":"BDR Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Tyrosine kinase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Procaps Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Procaps Group \/ BDR Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Procaps Group \/ BDR Pharmaceuticals"},{"orgOrder":0,"company":"Inceptua Group","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Inceptua Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inceptua Group \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Inceptua Group \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Blood coagulation factor","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Covis Pharma \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Norgine"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aclidinium Bromide","moa":"||M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Covis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"LUXEMBOURG","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Covis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/ Inapplicable"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"LUXEMBOURG","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Covis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Blood coagulation factor","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Covis Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Covis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mitotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/ Inapplicable"},{"orgOrder":0,"company":"Mitotech","sponsor":"Essex Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Essex Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/ Essex Biotechnology"},{"orgOrder":0,"company":"TRON Group","sponsor":"Nanopharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"MALAYSIA","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"||RNR","graph1":"Oncology","graph2":"Phase III","graph3":"TRON Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TRON Group \/ Nanopharmaceutics","highestDevelopmentStatusID":"10","companyTruncated":"TRON Group \/ Nanopharmaceutics"},{"orgOrder":0,"company":"Tropical Infectious Diseases Research and Education Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MALAYSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Povidone-Iodine","moa":"Inflammatory mediator","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tropical Infectious Diseases Research and Education Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Tropical Infectious Diseases Research and Education Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tropical Infectious Diseases Research and Education Center \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacare Premium","sponsor":"Midas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"MALTA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage CSF1R","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacare Premium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharmacare Premium \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacare Premium \/ Midas Pharma"},{"orgOrder":0,"company":"Emifarma","sponsor":"Mangoceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emifarma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Emifarma \/ Mangoceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Emifarma \/ Mangoceuticals"},{"orgOrder":0,"company":"Vanquish Group","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Vanquish Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Vanquish Group \/ Aspargo Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Vanquish Group \/ Aspargo Laboratories"},{"orgOrder":0,"company":"Medix","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Medix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medix \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Medix \/ Biocon"},{"orgOrder":0,"company":"OpenEye","sponsor":"ASAP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"OpenEye","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OpenEye \/ ASAP","highestDevelopmentStatusID":"3","companyTruncated":"OpenEye \/ ASAP"},{"orgOrder":0,"company":"Pharma 5","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MOROCCO","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharma 5","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharma 5 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharma 5 \/ Inapplicable"},{"orgOrder":0,"company":"Aspen API","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Aspen API","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen API \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aspen API \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"RSRT","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"AX-2402","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ RSRT","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Therapeutics \/ RSRT"},{"orgOrder":0,"company":"Synaffix","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":1.3,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Synaffix \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Merus","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Merus \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ADU-1604","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Sairopa","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Citryll","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Johnson & Johnson"},{"orgOrder":0,"company":"Uniqure","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intrastriatal Infusion","sponsorNew":"Uniqure \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Leerink Partners"},{"orgOrder":0,"company":"Uniqure","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intrastriatal Infusion","sponsorNew":"Uniqure \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Leerink Partners"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Jefferies"},{"orgOrder":0,"company":"Khondrion","sponsor":"UMDF","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Khondrion \/ UMDF","highestDevelopmentStatusID":"10","companyTruncated":"Khondrion \/ UMDF"},{"orgOrder":0,"company":"Merus","sponsor":"Partner Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Partner Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merus \/ Partner Therapeutics"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Lifesciences Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation"},{"orgOrder":0,"company":"QliniQ","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"QliniQ","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QliniQ \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"QliniQ \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Cowen Healthcare Investments","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Cowen Healthcare Investments"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Barth Syndrome Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Barth Syndrome Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Scenic Biotech \/ Barth Syndrome Foundation"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Rett Syndrome Research Trust","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Rett Syndrome Research Trust","highestDevelopmentStatusID":"3","companyTruncated":"ProQR Therapeutics \/ Rett Syndrome Research Trust"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"SIFI","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polyhexanide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Avanzanite Bioscience \/ SIFI","highestDevelopmentStatusID":"10","companyTruncated":"Avanzanite Bioscience \/ SIFI"},{"orgOrder":0,"company":"Synaffix","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Amgen Inc"},{"orgOrder":0,"company":"Frame Cancer Therapeutics","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Frame Cancer Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frame Cancer Therapeutics \/ CureVac","highestDevelopmentStatusID":"3","companyTruncated":"Frame Cancer Therapeutics \/ CureVac"},{"orgOrder":0,"company":"Synaffix","sponsor":"BigHat Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ BigHat Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ BigHat Biosciences"},{"orgOrder":0,"company":"Intravacc","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Beijing Zhifei Lvzhu Biopharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Beijing Zhifei Lvzhu Biopharmaceutical"},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VSV\u2206G-SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Batavia Bioscience \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Batavia Bioscience \/ IAVI"},{"orgOrder":0,"company":"CellPoint","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellPoint","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CellPoint \/ Galapagos","highestDevelopmentStatusID":"7","companyTruncated":"CellPoint \/ Galapagos"},{"orgOrder":0,"company":"Intravacc","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Avacc 101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ CEPI"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centre for Human Drug Research \/ Aim ImmunoTech","highestDevelopmentStatusID":"4","companyTruncated":"Centre for Human Drug Research \/ Aim ImmunoTech"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"NICHD","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ NICHD","highestDevelopmentStatusID":"2","companyTruncated":"Scenic Biotech \/ NICHD"},{"orgOrder":0,"company":"Intravacc","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Polyglycine alanine","graph1":"Neurology","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intravacc \/ European Union","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ European Union"},{"orgOrder":0,"company":"Argenx","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Medison Pharma"},{"orgOrder":0,"company":"Synaffix","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Emergence Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Emergence Therapeutics"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarna Therapeutics \/ Eurostars","highestDevelopmentStatusID":"3","companyTruncated":"Amarna Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"ADU-1805","moa":"SIRP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Thirona Bio","sponsor":"Mannkind","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"FBM5712","moa":"ALK-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Thirona Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"Thirona Bio \/ Mannkind","highestDevelopmentStatusID":"4","companyTruncated":"Thirona Bio \/ Mannkind"},{"orgOrder":0,"company":"Synaffix","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Genmab","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Genmab"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Emotional Brain BV","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"||PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Emotional Brain BV","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Emotional Brain BV"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Morningside Venture","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Morningside Venture","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Morningside Venture"},{"orgOrder":0,"company":"TargED Biopharmaceuticals","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"Microlyse","moa":"ULVWF","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"TargED Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TargED Biopharmaceuticals \/ Andera Partners","highestDevelopmentStatusID":"4","companyTruncated":"TargED Biopharmaceuticals \/ Andera Partners"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"LUMICKS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glycostem Therapeutics \/ LUMICKS","highestDevelopmentStatusID":"4","companyTruncated":"Glycostem Therapeutics \/ LUMICKS"},{"orgOrder":0,"company":"Halix BV","sponsor":"NovalGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halix BV \/ NovalGen","highestDevelopmentStatusID":"6","companyTruncated":"Halix BV \/ NovalGen"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Horama SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"HORA-001","moa":"CRB1 gene","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Horama SA","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Horama SA"},{"orgOrder":0,"company":"Xinvento","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Xinvento","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xinvento \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xinvento \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Lead Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Lead Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lead Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Lead Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Genistein","moa":"PTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Royal DSM \/ Humanetics","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM \/ Humanetics"},{"orgOrder":0,"company":"Intravacc","sponsor":"CimCure","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ CimCure","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ CimCure"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"ISA103","moa":"||PRAME protein","graph1":"Oncology","graph2":"Preclinical","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISA Pharmaceuticals \/ Cancer Focus Fund","highestDevelopmentStatusID":"4","companyTruncated":"ISA Pharmaceuticals \/ Cancer Focus Fund"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Health~Holland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"ISA104","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISA Pharmaceuticals \/ Health~Holland","highestDevelopmentStatusID":"7","companyTruncated":"ISA Pharmaceuticals \/ Health~Holland"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"LAVA-051","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lava Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"5-gamma 9V-delta 2 T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lava Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Lava Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"PF-08046052","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Lava Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Jefferies"},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Jefferies"},{"orgOrder":0,"company":"Synaffix","sponsor":"Shanghai Miracogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Shanghai Miracogen","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Shanghai Miracogen"},{"orgOrder":0,"company":"Leyden Labs","sponsor":"Nanopharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Leyden Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Leyden Labs \/ Nanopharm","highestDevelopmentStatusID":"4","companyTruncated":"Leyden Labs \/ Nanopharm"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"||SLC12A1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Faes Farma","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Faes Farma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Financing","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Series B Financing","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Undisclosed","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"VarmX \/ Ysios Capital"},{"orgOrder":0,"company":"VectorY","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Forbion"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Icosabutate","moa":"CETP","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NorthSea Therapeutics \/ Venbio Partners","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Venbio Partners"},{"orgOrder":0,"company":"Sapreme","sponsor":"Aglaia Oncology Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Series A Financing","leadProduct":"SPT001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sapreme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapreme \/ Aglaia Oncology Funds","highestDevelopmentStatusID":"4","companyTruncated":"Sapreme \/ Aglaia Oncology Funds"},{"orgOrder":0,"company":"Delta Crystallon","sponsor":"Serenity Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Recombinant Human HspB5","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Delta Crystallon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta Crystallon \/ Serenity Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Delta Crystallon \/ Serenity Bioworks"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"15","companyTruncated":"Avanzanite Bioscience \/ Advicenne"},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Kyowa Kirin","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Kyowa Kirin"},{"orgOrder":0,"company":"Gadeta","sponsor":"Clade Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"GDT002","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gadeta \/ Clade Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ Clade Therapeutics"},{"orgOrder":0,"company":"Immunorizon","sponsor":"Purple Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"5T4 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunorizon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunorizon \/ Purple Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Immunorizon \/ Purple Biotech"},{"orgOrder":0,"company":"TerThera","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"RAD602","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TerThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TerThera \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"TerThera \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"Intravacc","sponsor":"Wageningen Bioveterinary Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Wageningen Bioveterinary Research","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Wageningen Bioveterinary Research"},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ CSL Behring"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Dutch Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Funding","leadProduct":"INT-1B3","moa":"Adenosine A2AR pathway","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Dutch Government","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Dutch Government"},{"orgOrder":0,"company":"Merus","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Foundation Medicine"},{"orgOrder":0,"company":"Rabian BV","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rabian BV","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabian BV \/ Dyadic International, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Rabian BV \/ Dyadic International, Inc"},{"orgOrder":0,"company":"VectorY","sponsor":"University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ University Medical Center"},{"orgOrder":0,"company":"Merus","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merus \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Merus \/ Gilead Sciences"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Lava Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Tessellate BIO","sponsor":"Omico","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Tessellate BIO","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tessellate BIO \/ Omico","highestDevelopmentStatusID":"2","companyTruncated":"Tessellate BIO \/ Omico"},{"orgOrder":0,"company":"GEDiCube","sponsor":"Renovaro Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GEDiCube","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GEDiCube \/ Renovaro Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"GEDiCube \/ Renovaro Biosciences"},{"orgOrder":0,"company":"myTomorrows","sponsor":"AiCuris","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Pritelivir","moa":"Viral Helicase-primase enzyme complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"myTomorrows","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"myTomorrows \/ AiCuris","highestDevelopmentStatusID":"8","companyTruncated":"myTomorrows \/ AiCuris"},{"orgOrder":0,"company":"SkylineDx","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I","graph3":"SkylineDx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SkylineDx \/ BioInvent","highestDevelopmentStatusID":"6","companyTruncated":"SkylineDx \/ BioInvent"},{"orgOrder":0,"company":"Intravacc","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Inactivated EV D68 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intravacc \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc \/ National Institutes of Health"},{"orgOrder":0,"company":"Uniqure","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ HealthCare Royalty"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2023","type":"Divestment","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2023","type":"Divestment","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Alveron Pharma","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"OKL-1111","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Alveron Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alveron Pharma \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Alveron Pharma \/ Broadview Ventures"},{"orgOrder":0,"company":"Hercules Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"HRS-7535","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase II","graph3":"Hercules Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hercules Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Hercules Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Seroba","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2024","type":"Series B Financing","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vico Therapeutics \/ Seroba","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Seroba"},{"orgOrder":0,"company":"Flindr Therapeutics","sponsor":"V-Bio Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Flindr Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flindr Therapeutics \/ V-Bio Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Flindr Therapeutics \/ V-Bio Ventures"},{"orgOrder":0,"company":"Azafaros","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Forbion","highestDevelopmentStatusID":"1","companyTruncated":"Azafaros \/ Forbion"},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Allosteric phosphatase","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Anavo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavo Therapeutics \/ MRL Ventures Fund","highestDevelopmentStatusID":"3","companyTruncated":"Anavo Therapeutics \/ MRL Ventures Fund"},{"orgOrder":0,"company":"Tessellate BIO","sponsor":"BioGeneration Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tessellate BIO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tessellate BIO \/ BioGeneration Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Tessellate BIO \/ BioGeneration Ventures"},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"TGW101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tagworks Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tagworks Pharmaceuticals \/ Ysios Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tagworks Pharmaceuticals \/ Ysios Capital"},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"TGW101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tagworks Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tagworks Pharmaceuticals \/ Ysios Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tagworks Pharmaceuticals \/ Ysios Capital"},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Allosteric phosphatase","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Anavo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavo Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Anavo Therapeutics \/ M Ventures"},{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Oost NL","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"PTX-061","moa":"Metal","graph1":"Oncology","graph2":"Preclinical","graph3":"Pleco Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pleco Therapeutics \/ Oost NL","highestDevelopmentStatusID":"4","companyTruncated":"Pleco Therapeutics \/ Oost NL"},{"orgOrder":0,"company":"PureIMS","sponsor":"Boost-UP Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PureIMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"PureIMS \/ Boost-UP Foundation","highestDevelopmentStatusID":"10","companyTruncated":"PureIMS \/ Boost-UP Foundation"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"C4 holding BV","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"AMA005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarna Therapeutics \/ C4 holding BV","highestDevelopmentStatusID":"5","companyTruncated":"Amarna Therapeutics \/ C4 holding BV"},{"orgOrder":0,"company":"Intravacc","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"NGoXIM","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ National Institutes of Health"},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ CSL Behring"},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"||Water","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"AX-0810","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Evercore ISI","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Evercore ISI"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Jefferies"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Batavia Bioscience \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Batavia Bioscience \/ Candel Therapeutics"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"NorthX Biologics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Nimvec AM510","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarna Therapeutics \/ NorthX Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Amarna Therapeutics \/ NorthX Biologics"},{"orgOrder":0,"company":"Citryll","sponsor":"ReumaNederland","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citryll \/ ReumaNederland","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ ReumaNederland"},{"orgOrder":0,"company":"Citryll","sponsor":"BOM Brabant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citryll \/ BOM Brabant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Citryll \/ BOM Brabant Ventures"},{"orgOrder":0,"company":"Intravacc","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Avacc 11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Intravacc \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ CARB-X"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Mydecine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leiden University Medical Center \/ Mydecine","highestDevelopmentStatusID":"4","companyTruncated":"Leiden University Medical Center \/ Mydecine"},{"orgOrder":0,"company":"VectorY","sponsor":"Wageningen University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Wageningen University","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Wageningen University"},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Kyowa Kirin","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Kyowa Kirin"},{"orgOrder":0,"company":"Viroclinics Biosciences","sponsor":"University of Queensland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Viroclinics Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Viroclinics Biosciences \/ University of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"Viroclinics Biosciences \/ University of Queensland"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Novo Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"5-gamma 9V-delta 2 T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lava Therapeutics \/ Novo Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Lava Therapeutics \/ Novo Ventures"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Funding","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"Intravacc","sponsor":"Dutch Leiden University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Nanovac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Intravacc \/ Dutch Leiden University Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Intravacc \/ Dutch Leiden University Medical Center"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Tracer","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tracer","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tracer \/ Akston Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Tracer \/ Akston Biosciences"},{"orgOrder":0,"company":"Biosana Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Biosana Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosana Pharma \/ Alvotech","highestDevelopmentStatusID":"6","companyTruncated":"Biosana Pharma \/ Alvotech"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lava Therapeutics \/ ProBioGen","highestDevelopmentStatusID":"4","companyTruncated":"Lava Therapeutics \/ ProBioGen"},{"orgOrder":0,"company":"Synaffix","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ ABL Bio"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProteoNic \/ GigaGen","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ GigaGen"},{"orgOrder":0,"company":"Halix BV","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Halix BV \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Halix BV \/ AstraZeneca"},{"orgOrder":0,"company":"ProteoNic","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProteoNic \/ Immunomedics","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ Immunomedics"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Synaffix","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Sotio","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Sotio"},{"orgOrder":0,"company":"TerThera","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"RAD 402","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TerThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TerThera \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"TerThera \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"SeraNovo","sponsor":"Carna Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","graph1":"Oncology","graph2":"Discovery","graph3":"SeraNovo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SeraNovo \/ Carna Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"SeraNovo \/ Carna Bioscience"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Menarini"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Biotech \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Halix BV","sponsor":"University\u2019s Jenner Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Halix BV \/ University\u2019s Jenner Institute","highestDevelopmentStatusID":"10","companyTruncated":"Halix BV \/ University\u2019s Jenner Institute"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lava Therapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"4","companyTruncated":"Lava Therapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Synaffix","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ ADC Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"XMT-1592","moa":"NaPi2b","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaffix \/ Mersana Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Synaffix \/ Mersana Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Argenx","sponsor":"OncoVerity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Cusatuzumab","moa":"||CD70","graph1":"Oncology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ OncoVerity","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ OncoVerity"},{"orgOrder":0,"company":"Treeway","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase III","graph3":"Treeway","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Treeway \/ Specialised Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Treeway \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Synaffix","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Elevation Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Elevation Oncology"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Potassium Citrate","moa":"||Calcium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Granule, Prolonged Release","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"15","companyTruncated":"Avanzanite Bioscience \/ Advicenne"},{"orgOrder":0,"company":"Cristal Therapeutics","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Cristal Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cristal Therapeutics \/ Intravacc","highestDevelopmentStatusID":"3","companyTruncated":"Cristal Therapeutics \/ Intravacc"},{"orgOrder":0,"company":"Synaffix","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Medac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Medac","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Medac"},{"orgOrder":0,"company":"Merus","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merus \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Merus \/ Eli Lilly"},{"orgOrder":0,"company":"Pharming","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Conestat Alpha","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharming \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Biotech \/ Genentech"},{"orgOrder":0,"company":"Synaffix","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Innovent Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Innovent Biologics"},{"orgOrder":0,"company":"VectorY","sponsor":"Annogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Annogen","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Annogen"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Yarrow Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Yarrow Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Therapeutics \/ Yarrow Biotechnology"},{"orgOrder":0,"company":"Synaffix","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Synaffix \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Synaffix \/ Innovent Biologics"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"ProQR Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Synaffix","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synaffix \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ CSL Behring"},{"orgOrder":0,"company":"VectorY","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ MRL Ventures Fund","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ MRL Ventures Fund"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vico Therapeutics \/ Life Science Partners","highestDevelopmentStatusID":"4","companyTruncated":"Vico Therapeutics \/ Life Science Partners"},{"orgOrder":0,"company":"VectorY","sponsor":"UMC Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ UMC Utrecht","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ UMC Utrecht"},{"orgOrder":0,"company":"Oncode-PACT","sponsor":"National Growth Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncode-PACT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncode-PACT \/ National Growth Fund","highestDevelopmentStatusID":"4","companyTruncated":"Oncode-PACT \/ National Growth Fund"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alkaline Phosphatase","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Alloksys Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alloksys Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alloksys Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Radboud University Medical Center"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Radboud University Medical Center"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"QR-421a","moa":"USH2A","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AAV5-hFIX","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Hercules Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HP163","moa":"Aryl hydrocarbon receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hercules Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hercules Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hercules Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ADU-1805","moa":"SIRP-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-162","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AMT-210","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT\u2011240","moa":"AOPE gene","graph1":"Neurology","graph2":"Preclinical","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-260","moa":"Kainate receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-260","moa":"Kainate receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-260","moa":"Kainate receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Medac","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Medac"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Empasiprubart","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"AIMM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AT1412","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AIMM Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIMM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AIMM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Avacc 10","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Liquid","sponsorNew":"Intravacc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intravacc \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Gonorrhea Vaccine Avacc 11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AX-0810","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Radboud University","sponsor":"Hellenic Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Radboud University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Radboud University \/ Hellenic Institute","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University \/ Hellenic Institute"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BYON3521","moa":"c-Met","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Syneos Health"},{"orgOrder":0,"company":"Synthon Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"(vic-) Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Synthon Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthon Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synthon Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Citryll","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citryll \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Inapplicable"},{"orgOrder":0,"company":"VarmX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Preclinical","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VarmX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VarmX \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"European Hematology Association","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Phase III","graph3":"European Hematology Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"European Hematology Association \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"European Hematology Association \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Lifesciences Acquisition Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation"},{"orgOrder":0,"company":"Intravacc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Sabin Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Intravacc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intravacc \/ Inapplicable"},{"orgOrder":0,"company":"Erasmus University Medical Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erasmus University Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasmus University Medical Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Erasmus University Medical Center \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Conestat Alpha","moa":"C1 esterase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Niraparib","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2AR pathway","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Conestat Alpha","moa":"C1 esterase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Gadeta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GDT002","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gadeta \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Gadeta \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NorthSea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Merus","sponsor":"Chiltern International Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Chiltern International Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Chiltern International Ltd"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2AR pathway","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ISA104","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ISA106","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Norgine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Kling Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KBA1412","moa":"||CD9","graph1":"Oncology","graph2":"Phase I","graph3":"Kling Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Kling Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kling Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ CSL Behring"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"LAVA-051","moa":"5-gamma 9V-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"5-gamma 9V-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"LAVA-051","moa":"5-gamma 9V-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"5-gamma 9V-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"5-gamma 9V-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"LAVA-1207","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"PureIMS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PureIMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"PureIMS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PureIMS \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"||PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Freya Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MCLA-129","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Incyte Corporation"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR\/LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Merck & Co"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"GPCR5","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micreos Human Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Micreos Human Health \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Amphera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MesoPher","moa":"||Mature dendritic cell","graph1":"Oncology","graph2":"Phase II","graph3":"Amphera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Amphera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amphera \/ Inapplicable"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Inapplicable"},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Modra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Lumana Invest","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Fresh Stem Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroplast \/ Lumana Invest","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Lumana Invest"},{"orgOrder":0,"company":"Neuroplast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neuro Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Neuroplast \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Norgine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Inapplicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NorthSea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Orziloben","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"NorthSea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"oNKord","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycostem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MesoPher","moa":"Mature dendritic cell","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Amphera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amphera \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Amphera \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Forbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PJS-539","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Inapplicable"},{"orgOrder":0,"company":"Pepscan","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pepscan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pepscan \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Pepscan \/ Mayo Clinic"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SEFA-6179","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthSea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NorthSea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"QR-421a","moa":"USH2A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Saillant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Saillant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saillant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Saillant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SC-2882","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scenic Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SEFA-1024","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthSea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NorthSea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SEFA-6179","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthSea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Staten Biotechnology","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SST-5058","moa":"APOC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Staten Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Staten Biotechnology \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Staten Biotechnology \/ Novo Nordisk"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Neurology","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Xenikos B.V \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B.V \/ Inapplicable"},{"orgOrder":0,"company":"Utrecht University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Utrecht University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Utrecht University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Utrecht University \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Sabin Strain Based Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intravacc \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Intravacc \/ Sinovac Biotech"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Institut Pasteur","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SF2a-TT15","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intravacc \/ Institut Pasteur","highestDevelopmentStatusID":"8","companyTruncated":"Intravacc \/ Institut Pasteur"},{"orgOrder":0,"company":"Amphera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MesoPher","moa":"Mature dendritic cell","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Amphera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amphera \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Amphera \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LAVA-051","moa":"5-gamma 9V-delta 2 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SYD1875","moa":"5T4","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"University Medical Center Utrecht","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Medical Center Utrecht","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University Medical Center Utrecht \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Utrecht \/ Inapplicable"},{"orgOrder":0,"company":"DCprime","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"DCprime","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"DCprime \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DCprime \/ Inapplicable"},{"orgOrder":0,"company":"Orca Therapeutics","sponsor":"CMX Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"ORCA-010","moa":"CD8 positive T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Orca Therapeutics \/ CMX Research","highestDevelopmentStatusID":"7","companyTruncated":"Orca Therapeutics \/ CMX Research"},{"orgOrder":0,"company":"DCprime","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"DCprime","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"DCprime \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DCprime \/ Inapplicable"},{"orgOrder":0,"company":"Amphera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MesoPher","moa":"||Mature dendritic cell","graph1":"Oncology","graph2":"Phase II","graph3":"Amphera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Amphera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amphera \/ Inapplicable"},{"orgOrder":0,"company":"Gadeta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GDT002","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gadeta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV-VecTabs","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"AMZ002","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Amzell B.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amzell B.V \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amzell B.V \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Avacc 10","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Liquid","sponsorNew":"Intravacc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intravacc \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2AR pathway","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Institut Pasteur","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SF2a-TT15","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intravacc \/ Institut Pasteur","highestDevelopmentStatusID":"8","companyTruncated":"Intravacc \/ Institut Pasteur"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Alkaline Phosphatase","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Sepofarsen","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"UPMC Hillman Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ UPMC Hillman Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharmaceuticals \/ UPMC Hillman Cancer Center"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RSVDG Vaccine","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intravacc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intravacc \/ Inapplicable"},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"COX","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Amzell B.V","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amzell B.V \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Amzell B.V \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Saillant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ST02","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Saillant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saillant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Saillant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VSY Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TR-C 19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VSY Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VSY Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VSY Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VTx-002","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||HER2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Norgine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Inapplicable"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"||CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NewAmsterdam Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterdam Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Neurology","graph2":"Approved FDF","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zenocutuzumab","moa":"HER2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrastriatal Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AMT-162","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LAVA-1266","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||GPCR5","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"GPCR5","graph1":"Oncology","graph2":"Phase III","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PTX-252","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pleco Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pleco Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pleco Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TargED Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGD001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"TargED Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TargED Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TargED Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NEW ZEALAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"AFT Pharmaceuticals \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"AFT Pharmaceuticals \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NEW ZEALAND","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Dermatology","graph2":"Phase II","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"AFT Pharmaceuticals \/ Timber Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AFT Pharmaceuticals \/ Timber Pharmaceuticals"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NEW ZEALAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AFT Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AFT Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NEW ZEALAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Douglas CDMO \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Douglas CDMO \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"SRW Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NEW ZEALAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fisetin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SRW Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SRW Laboratories \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SRW Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Inapplicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Inapplicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Inapplicable"},{"orgOrder":0,"company":"HJF Medical Research International","sponsor":"IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NIGERIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"HJF Medical Research International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HJF Medical Research International \/ IAVI","highestDevelopmentStatusID":"8","companyTruncated":"HJF Medical Research International \/ IAVI"},{"orgOrder":0,"company":"Cytovation","sponsor":"Norwegian Cancer Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"CY-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Norwegian Cancer Society","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Norwegian Cancer Society"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Zelluna Immunotherapy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2024","type":"Merger","leadProduct":"ZI-MA4-1","moa":"MAGEA4","graph1":"Oncology","graph2":"Preclinical","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultimovacs \/ Zelluna Immunotherapy","highestDevelopmentStatusID":"4","companyTruncated":"Ultimovacs \/ Zelluna Immunotherapy"},{"orgOrder":0,"company":"Asamedic","sponsor":"Bormioli Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Asamedic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asamedic \/ Bormioli Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Asamedic \/ Bormioli Pharma"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VB10.NEO","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"APIM Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Bupivacaine","moa":"PCNA\/APIM PPI","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nordic Nanovector \/ APIM Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ APIM Therapeutics"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ GOG Foundation"},{"orgOrder":0,"company":"University of Oslo","sponsor":"BioArctic AB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"APOE","graph1":"Neurology","graph2":"Discovery","graph3":"University of Oslo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Oslo \/ BioArctic AB","highestDevelopmentStatusID":"2","companyTruncated":"University of Oslo \/ BioArctic AB"},{"orgOrder":0,"company":"Calluna Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Idelalisib","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Calluna Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calluna Pharma \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Calluna Pharma \/ Forbion"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"PCI Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Termination","leadProduct":"Bempegaldesleukin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Apricoxib","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nykode Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Nykode Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VB10.NEO","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Genentech"},{"orgOrder":0,"company":"ARTBIO","sponsor":"FogPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ARTBIO \/ FogPharma","highestDevelopmentStatusID":"3","companyTruncated":"ARTBIO \/ FogPharma"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Cytovation","sponsor":"Recurrent Respiratory Papillomatosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CyPep-1","moa":"||Tumorolysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Recurrent Respiratory Papillomatosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Recurrent Respiratory Papillomatosis Foundation"},{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Lion TCR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zelluna Immunotherapy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelluna Immunotherapy \/ Lion TCR","highestDevelopmentStatusID":"1","companyTruncated":"Zelluna Immunotherapy \/ Lion TCR"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Meteva AS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Meteva AS","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Meteva AS"},{"orgOrder":0,"company":"ARTBIO","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"212-Pb NG001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ARTBIO \/ F-Prime Capital","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ F-Prime Capital"},{"orgOrder":0,"company":"Coalition for Epidemic Preparedness Innovations","sponsor":"U.K Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Coalition for Epidemic Preparedness Innovations","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Coalition for Epidemic Preparedness Innovations \/ U.K Government","highestDevelopmentStatusID":"1","companyTruncated":"Coalition for Epidemic Preparedness Innovations \/ U.K Government"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase I","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Lytix Biopharma \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Linc AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoinvent \/ Linc AB","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Linc AB"},{"orgOrder":0,"company":"EXACT Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"EXACT Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EXACT Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EXACT Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"CyPep-1","moa":"||Tumorolysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Sandwater"},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"CyPep-1","moa":"||Tumorolysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Sandwater"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2023","type":"Series A Financing","leadProduct":"212-Pb NG001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ARTBIO \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ Third Rock Ventures"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"MDimune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PCI Biotech \/ MDimune","highestDevelopmentStatusID":"4","companyTruncated":"PCI Biotech \/ MDimune"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Tempus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Tempus","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Tempus"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Apricoxib","moa":"||KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Pharma Nordic","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pharma Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pharma Nordic \/ Altamira Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pharma Nordic \/ Altamira Therapeutics"},{"orgOrder":0,"company":"Pharma Nordic","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Bentonite","moa":"Viruses and allergen entrapment","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pharma Nordic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pharma Nordic \/ Altamira Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pharma Nordic \/ Altamira Therapeutics"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Apricoxib","moa":"||KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ Agenus"},{"orgOrder":0,"company":"Cresence","sponsor":"Bioasis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NORWAY","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"CRES101","moa":"M2 polarization","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cresence","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cresence \/ Bioasis","highestDevelopmentStatusID":"5","companyTruncated":"Cresence \/ Bioasis"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"MSD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ MSD","highestDevelopmentStatusID":"4","companyTruncated":"Nykode Therapeutics \/ MSD"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biopharma \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Targovax","sponsor":"Innovation Norway","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Apricoxib","moa":"||KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Targovax \/ Innovation Norway","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Innovation Norway"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"Alpha37","moa":"CD37","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"AXL","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Calluna Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Idelalisib","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Calluna Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calluna Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calluna Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"AXL","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||Tumorolysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CyPep-1","moa":"Tumorolysis","graph1":"Oncology","graph2":"Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytovation \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||Tumorolysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Inapplicable"},{"orgOrder":0,"company":"Cytovation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CyPep-1","moa":"Tumorolysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Merck & Co"},{"orgOrder":0,"company":"Cytovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CyPep-1","moa":"||Tumorolysis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"AXL","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-NNV003","moa":"||CD37","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nanovector \/ AstraZeneca"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University Hospital Southampton","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"AXL","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ University Hospital Southampton","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ University Hospital Southampton"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"ICON Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ ICON Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ ICON Clinical Research"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"AXL","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radspherin","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Oslo University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Oslo University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Oslo University Hospital"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Targovax \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ AstraZeneca"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Theradex"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ University of Alabama","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ University of Alabama"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||hTERT","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD4","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nykode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VB10.16","moa":"APC receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nykode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VB10.2210","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nykode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Nykode Therapeutics \/ Genentech"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bemcentinib","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"OMAN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Remington Pharmaceuticals","sponsor":"TB Alliance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Pretomanid","moa":"Mycolic acid biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Remington Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Remington Pharmaceuticals \/ TB Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Remington Pharmaceuticals \/ TB Alliance"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"POLAND","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Therapeutics \/ Galapagos"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Polish National Center for Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Polish National Center for Research and Development","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharmaceuticals \/ Polish National Center for Research and Development"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"WPD Pharmaceuticals \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharmaceuticals \/ CNS Pharmaceuticals"},{"orgOrder":0,"company":"Molecure","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecure \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"Molecure \/ Galapagos"},{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"OncoArendi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoArendi Therapeutics \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"OncoArendi Therapeutics \/ Galapagos"},{"orgOrder":0,"company":"Polpharma","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Preclinical","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Polpharma \/ Ryvu Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Polpharma \/ Ryvu Therapeutics"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"nCage Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ nCage Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Ryvu Therapeutics \/ nCage Therapeutics"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"STING","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"Ryvu Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"STING","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"Ryvu Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Polpharma","sponsor":"Pikralida biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"PKL-021","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Polpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polpharma \/ Pikralida biopharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Polpharma \/ Pikralida biopharmaceutical"},{"orgOrder":0,"company":"Reakiro","sponsor":"A2W Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"POLAND","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Reakiro","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reakiro \/ A2W Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Reakiro \/ A2W Pharma"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"National Centre For Research And Development","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ National Centre For Research And Development","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ National Centre For Research And Development"},{"orgOrder":0,"company":"Ziololek","sponsor":"Polpharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Flaxseed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ziololek","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ziololek \/ Polpharma","highestDevelopmentStatusID":"15","companyTruncated":"Ziololek \/ Polpharma"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"POLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Captor Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Molecure","sponsor":"Ocean Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"OAT-3912","moa":"YKL-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecure \/ Ocean Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Molecure \/ Ocean Biomedical"},{"orgOrder":0,"company":"Selvita S.A","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"POLAND","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Selvita S.A","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Selvita S.A \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Selvita S.A \/ University of Oxford"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Dermin","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"WPD Pharmaceuticals \/ Dermin","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharmaceuticals \/ Dermin"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"MS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma Biologics \/ MS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Polpharma Biologics \/ MS Pharma"},{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"OncoArendi Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoArendi Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"OncoArendi Therapeutics \/ University of Michigan"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"WPD Pharmaceuticals \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharmaceuticals \/ CNS Pharmaceuticals"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mabion SA \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Novavax"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Polpharma Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Molecure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Inapplicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Molecure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Inapplicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Molecure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Inapplicable"},{"orgOrder":0,"company":"Molecure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Molecure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Molecure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/ Inapplicable"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Polpharma Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Polpharma Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CT-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CPL\u2019280","moa":"GPR40","graph1":"Endocrinology","graph2":"Phase I","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CPL500036","moa":"PDE10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CPL\u2019 116","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CPT-6281","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JJP Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JJP-1212","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"JJP Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JJP Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"JJP Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polpharma Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polpharma Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"PolTREG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PolTREG \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PolTREG \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolTREG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Inapplicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolTREG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Inapplicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolTREG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Inapplicable"},{"orgOrder":0,"company":"PolTREG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolTREG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RVU120","moa":"||CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CT-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Human Biome Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HBI-06","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Human Biome Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Human Biome Institute \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Human Biome Institute \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Moleculin Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Moleculin Biotech","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharmaceuticals \/ Moleculin Biotech"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polpharma Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Polpharma Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CPL500036","moa":"PDE10A","graph1":"Neurology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celon Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RVU120","moa":"||CDK8\/19","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bial","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Eslicarbazepine Acetate","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bial \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Bial \/ Eisai"},{"orgOrder":0,"company":"FairJourney Biologics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"PORTUGAL","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"FairJourney Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FairJourney Biologics \/ Argenx","highestDevelopmentStatusID":"3","companyTruncated":"FairJourney Biologics \/ Argenx"},{"orgOrder":0,"company":"Hovione","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"PORTUGAL","productType":"Other Large Molecule","year":"2020","type":"Partnership","leadProduct":"Modified Cyclodextrin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hovione \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Hovione \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Bial","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bial \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bial \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Hovione","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"PORTUGAL","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JX08","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hovione \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hovione \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Bial","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BIA 28-6156","moa":"Glucocerebrosidase","graph1":"Neurology","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bial \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Inapplicable"},{"orgOrder":0,"company":"Hovione","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"PORTUGAL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Hovione \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hovione \/ Inapplicable"},{"orgOrder":0,"company":"Bial","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"PORTUGAL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BIA 28-6156","moa":"Glucocerebrosidase","graph1":"Neurology","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bial \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Inapplicable"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"U.S. Army Medical Research Acquisition Activity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"PUERTO RICO","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"IC 800","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"IACTA Pharmaceuticals \/ U.S. Army Medical Research Acquisition Activity","highestDevelopmentStatusID":"4","companyTruncated":"IACTA Pharmaceuticals \/ U.S. Army Medical Research Acquisition Activity"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Ophthalmology Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"PUERTO RICO","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"IC 265","moa":"SYK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical"},{"orgOrder":0,"company":"Romanian National Institute of Infectious Diseases","sponsor":"CervoMed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ROMANIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Romanian National Institute of Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Romanian National Institute of Infectious Diseases \/ CervoMed","highestDevelopmentStatusID":"4","companyTruncated":"Romanian National Institute of Infectious Diseases \/ CervoMed"},{"orgOrder":0,"company":"InSysBio","sponsor":"Discoveric Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"NIDB-3101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"InSysBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSysBio \/ Discoveric Bio","highestDevelopmentStatusID":"4","companyTruncated":"InSysBio \/ Discoveric Bio"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Binnopharm Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Binnopharm Group \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Binnopharm Group \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"InSysBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"GEN1042","moa":"CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InSysBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSysBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"InSysBio \/ Genmab"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Mabwell","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Binnopharm Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Binnopharm Group \/ Mabwell","highestDevelopmentStatusID":"15","companyTruncated":"Binnopharm Group \/ Mabwell"},{"orgOrder":0,"company":"ChemRar","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ChemRar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ChemRar \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"ChemRar \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Pharmsynthez","sponsor":"HiFiBiO Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pharmsynthez","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmsynthez \/ HiFiBiO Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Pharmsynthez \/ HiFiBiO Therapeutics"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"Sechenov University Center for Clinical Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sechenov University Center for Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Solution","sponsorNew":"Sechenov University Center for Clinical Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sechenov University Center for Clinical Research \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Biocad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Biocad \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Biocad \/ Inapplicable"},{"orgOrder":0,"company":"Vector State Virology Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Vesicular Stomatitis Virus-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vector State Virology Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vector State Virology Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vector State Virology Institute \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac Lyo","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"Petrovax","sponsor":"ISU ABXIS","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Petrovax \/ ISU ABXIS","highestDevelopmentStatusID":"15","companyTruncated":"Petrovax \/ ISU ABXIS"},{"orgOrder":0,"company":"Generium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Generium \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Olokizumab","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"R-Pharm \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"R-Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Chumakov Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chumakov Centre","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Chumakov Centre \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chumakov Centre \/ Inapplicable"},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Siberian Vector institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Siberian Vector institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Siberian Vector institute \/ Inapplicable"},{"orgOrder":0,"company":"Russian Ministry of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Russian Ministry of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Russian Ministry of Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Russian Ministry of Health \/ Inapplicable"},{"orgOrder":0,"company":"ChemRar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ChemRar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ChemRar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChemRar \/ Inapplicable"},{"orgOrder":0,"company":"Petrovax","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Petrovax \/ CanSino Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Petrovax \/ CanSino Biologics"},{"orgOrder":0,"company":"Federal Biomedical Agency of Russia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Leitragin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Federal Biomedical Agency of Russia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federal Biomedical Agency of Russia \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Federal Biomedical Agency of Russia \/ Inapplicable"},{"orgOrder":0,"company":"Vector virology institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EpiVacCorona","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vector virology institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vector virology institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vector virology institute \/ Inapplicable"},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Siberian Vector institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Siberian Vector institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Siberian Vector institute \/ Inapplicable"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Russian Direct Investment Fund \/ AstraZeneca"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"Biocad","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BCD-100","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocad \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EpiVacCorona","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Siberian Vector institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Siberian Vector institute \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Siberian Vector institute \/ Inapplicable"},{"orgOrder":0,"company":"ChemRar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ChemRar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ChemRar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChemRar \/ Inapplicable"},{"orgOrder":0,"company":"Russian Defence Ministry","sponsor":"National Research Center for Epidemiology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Russian Defence Ministry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Russian Defence Ministry \/ National Research Center for Epidemiology","highestDevelopmentStatusID":"1","companyTruncated":"Russian Defence Ministry \/ National Research Center for Epidemiology"},{"orgOrder":0,"company":"R-Pharm","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"R-Pharm \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"R-Pharm \/ AstraZeneca"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Gamalei National Research Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gamalei National Research Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gamalei National Research Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gamalei National Research Center \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Russian Direct Investment Fund \/ AstraZeneca"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rAd26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Siberian Vector institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Siberian Vector institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Siberian Vector institute \/ Inapplicable"},{"orgOrder":0,"company":"Chumakov Federal Scientific Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chumakov Federal Scientific Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Chumakov Federal Scientific Center \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chumakov Federal Scientific Center \/ Inapplicable"},{"orgOrder":0,"company":"The Chumakov Federal Scientific Center","sponsor":"Vektor State Research Center of Virology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Whole-Virion Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Chumakov Federal Scientific Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Chumakov Federal Scientific Center \/ Vektor State Research Center of Virology","highestDevelopmentStatusID":"1","companyTruncated":"The Chumakov Federal Scientific Center \/ Vektor State Research Center of Virology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SAUDI ARABIA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Tabuk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tabuk Pharmaceuticals \/ Biocon","highestDevelopmentStatusID":"1","companyTruncated":"Tabuk Pharmaceuticals \/ Biocon"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SAUDI ARABIA","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tabuk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tabuk Pharmaceuticals \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Tabuk Pharmaceuticals \/ Biocon"},{"orgOrder":0,"company":"SciGen","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Zoledronic Acid","moa":"Bone resorption","graph1":"Oncology","graph2":"Approved FDF","graph3":"SciGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciGen \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"SciGen \/ DKSH"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"SunAct Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytoMed Therapeutics \/ SunAct Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ SunAct Cancer Institute"},{"orgOrder":0,"company":"MerLion Pharmaceuticals","sponsor":"Fonseca Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SINGAPORE","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Finafloxacin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"MerLion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"MerLion Pharmaceuticals \/ Fonseca Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"MerLion Pharmaceuticals \/ Fonseca Biosciences"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Sengkang General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SINGAPORE","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoMed Therapeutics \/ Sengkang General Hospital","highestDevelopmentStatusID":"2","companyTruncated":"CytoMed Therapeutics \/ Sengkang General Hospital"},{"orgOrder":0,"company":"Enleofen Bio Pte","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Enx108A","moa":"IL-11 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Enleofen Bio Pte","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enleofen Bio Pte \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"5","companyTruncated":"Enleofen Bio Pte \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"HistoIndex","sponsor":"Galecto","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"PAT-1251","moa":"LOXL2","graph1":"Oncology","graph2":"Phase II","graph3":"HistoIndex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HistoIndex \/ Galecto","highestDevelopmentStatusID":"8","companyTruncated":"HistoIndex \/ Galecto"},{"orgOrder":0,"company":"GERO.AI","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"GERO.AI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GERO.AI \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"GERO.AI \/ Pfizer Inc"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Thermo Fisher Scientific"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"AUM001","moa":"MNK receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AUM Biosciences \/ SPRIM Global investments","highestDevelopmentStatusID":"1","companyTruncated":"AUM Biosciences \/ SPRIM Global investments"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Mountain Crest Acquisition Corp. V","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Mountain Crest Acquisition Corp. V","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Mountain Crest Acquisition Corp. V"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Anzu Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoScape \/ Anzu Partners","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScape \/ Anzu Partners"},{"orgOrder":0,"company":"University of Singapore","sponsor":"Monopar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"MNPR-202","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Singapore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Singapore \/ Monopar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Singapore \/ Monopar Therapeutics"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Proteona","sponsor":"Flinders University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Proteona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteona \/ Flinders University","highestDevelopmentStatusID":"1","companyTruncated":"Proteona \/ Flinders University"},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"Sen-Jam Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Duke-NUS Medical School","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Duke-NUS Medical School \/ Sen-Jam Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Duke-NUS Medical School \/ Sen-Jam Pharmaceutical"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"Bendamustine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Polaris Partners"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Zenyaku Kogyo","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ASLAN Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ K2 HealthVentures"},{"orgOrder":0,"company":"GERO.AI","sponsor":"Bulba Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"GERO.AI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GERO.AI \/ Bulba Ventures","highestDevelopmentStatusID":"2","companyTruncated":"GERO.AI \/ Bulba Ventures"},{"orgOrder":0,"company":"Engine Biosciences","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"ENB-812","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Engine Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engine Biosciences \/ Polaris Partners","highestDevelopmentStatusID":"5","companyTruncated":"Engine Biosciences \/ Polaris Partners"},{"orgOrder":0,"company":"Albatroz Therapeutics","sponsor":"Outram Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Tumor surface protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Albatroz Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albatroz Therapeutics \/ Outram Bio","highestDevelopmentStatusID":"4","companyTruncated":"Albatroz Therapeutics \/ Outram Bio"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"Nuevocor","sponsor":"EVX Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuevocor \/ EVX Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ EVX Ventures"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Pure MHC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ImmunoScape \/ Pure MHC","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScape \/ Pure MHC"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytoMed Therapeutics \/ Benchmark Company","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Benchmark Company"},{"orgOrder":0,"company":"BioSyngen","sponsor":"A STAR","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSyngen \/ A STAR","highestDevelopmentStatusID":"2","companyTruncated":"BioSyngen \/ A STAR"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"||VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Pharmapark"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Johns Hopkins University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Johns Hopkins University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Johns Hopkins University School of Medicine"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoMed Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CytoMed Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Vaxine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Covax-19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Prestige BioPharma Pte Ltd \/ Vaxine","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Vaxine"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Experimental Drug Development Centre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoScape \/ Experimental Drug Development Centre","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScape \/ Experimental Drug Development Centre"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"TT11X","moa":"CD30","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Tessa Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TT11X","moa":"CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"iX Biopharma","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"iX Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Wafer","sponsorNew":"iX Biopharma \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"iX Biopharma \/ Seelos Therapeutics"},{"orgOrder":0,"company":"Juniper Biologics","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Juniper Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Juniper Biologics \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Juniper Biologics \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Zenyaku Kogyo","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo"},{"orgOrder":0,"company":"Moleac","sponsor":"PT Ferron Par Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SINGAPORE","productType":"Plant Extract\/Herbal","year":"2024","type":"Partnership","leadProduct":"MLC901","moa":"Cholinesterase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleac \/ PT Ferron Par Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moleac \/ PT Ferron Par Pharmaceuticals"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Asymchem Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AUM601","moa":"TrkA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Asymchem Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ Asymchem Laboratories"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Trastuzumab","moa":"||HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Peptide Based-pan Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoScape \/ Valo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"ImmunoScape \/ Valo Therapeutics"},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"A*STAR","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Cytochrome-C oxidase","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Duke-NUS Medical School","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke-NUS Medical School \/ A*STAR","highestDevelopmentStatusID":"2","companyTruncated":"Duke-NUS Medical School \/ A*STAR"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SINGAPORE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moleac","sponsor":"National University Hospital Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"MLC901","moa":"Cholinesterase","graph1":"Neurology","graph2":"Phase II","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Moleac \/ National University Hospital Singapore","highestDevelopmentStatusID":"8","companyTruncated":"Moleac \/ National University Hospital Singapore"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM001","moa":"||MNK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM302","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AUM302","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"HANDOK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM601","moa":"TrkA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ HANDOK","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ HANDOK"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM601","moa":"TrkA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRG01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRG01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRL03","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BST02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BST02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"CellResearch Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellResearch Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CellResearch Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytoMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tychan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TY014","moa":"Viral envelope protein epitope","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tychan \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tychan \/ Inapplicable"},{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EBC-129","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Experimental Drug Development Centre \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Experimental Drug Development Centre \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ulenistamab","moa":"PAUF protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||PAUF protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRx-237-801","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"IND Enabling","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LiberaTx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"LiberaTx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LiberaTx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"LiberaTx \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Farudodstat","moa":"DHODH","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nuevocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"LMNA gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuevocor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||PAUF protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||PAUF protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||PAUF protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ulenistamab","moa":"PAUF protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tychan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TY027","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ Inapplicable"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SCG101","moa":"HBsAg","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SCG Cell Therapy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SCG Cell Therapy \/ Inapplicable"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SCG142","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCG Cell Therapy \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SCG Cell Therapy \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HistoIndex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tropifexor","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HistoIndex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HistoIndex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HistoIndex \/ Inapplicable"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CD30 CAR-T","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Duke-Nus Medical School","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ETC-159","moa":"||Wnt signalling pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Duke-Nus Medical School","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duke-Nus Medical School \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Duke-Nus Medical School \/ Inapplicable"},{"orgOrder":0,"company":"Nuevocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuevocor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ Inapplicable"},{"orgOrder":0,"company":"Nanyang Technological University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"CSM5-K5","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Nanyang Technological University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanyang Technological University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nanyang Technological University \/ Inapplicable"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Bendamustine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Singapore-MIT Alliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TY014","moa":"Viral envelope protein epitope","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Singapore-MIT Alliance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Singapore-MIT Alliance \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Singapore-MIT Alliance \/ Inapplicable"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Bendamustine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ACM Biolabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pindolol","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ACM Biolabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ACM Biolabs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ACM Biolabs \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Tychan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TY027","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ Inapplicable"},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Duke-NUS Medical School","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Duke-NUS Medical School \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Duke-NUS Medical School \/ Inapplicable"},{"orgOrder":0,"company":"Lion TCR","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LioCyx-M004","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lion TCR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lion TCR \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lion TCR \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerecin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Ketone body","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerecin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerecin \/ Inapplicable"},{"orgOrder":0,"company":"Cerecin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tricaprylin","moa":"Ketone body","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerecin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerecin \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TauRx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Bendamustine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TT11X","moa":"CD30","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tessa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ulenistamab","moa":"PAUF protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige BioPharma Pte Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Xylonix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"010DS-Zn","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xylonix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xylonix \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Xylonix \/ Inapplicable"},{"orgOrder":0,"company":"Axcynsis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AT03-65","moa":"CLDN6","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axcynsis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcynsis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Axcynsis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Educell","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SLOVENIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Educell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Educell \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Educell \/ Orgenesis"},{"orgOrder":0,"company":"Medis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SLOVENIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Medis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medis \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Medis \/ Lupin Ltd"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH AFRICA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Conjugated Estrogens","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Pharmacare Holdings \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Avion Pharmaceuticals"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Biovac Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Biovac Institute \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"The Biovac Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH AFRICA","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Debiopharm","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Debiopharm"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Wellcome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Cholera Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Biovac Institute \/ Wellcome","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac Institute \/ Wellcome"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"10-Valent Pneumococcal Polysaccharide Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Serum Institute of India","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Serum Institute of India"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Pneumococcal Polysaccharide Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Gates Foundation"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH AFRICA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Sandoz B2B"},{"orgOrder":0,"company":"Christian Social Services Commission","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SOUTH AFRICA","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Rh-insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Christian Social Services Commission","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Christian Social Services Commission \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Christian Social Services Commission \/ Biocon"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Johnson & Johnson"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Cholera Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Biovac Institute \/ The International Vaccine Institute","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac Institute \/ The International Vaccine Institute"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Acino Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH AFRICA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Esomeprazole Magnesium","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aspen Pharmacare Holdings \/ Acino Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Acino Pharma"},{"orgOrder":0,"company":"H3D Foundation","sponsor":"LifeArc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"H3D Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H3D Foundation \/ LifeArc","highestDevelopmentStatusID":"2","companyTruncated":"H3D Foundation \/ LifeArc"},{"orgOrder":0,"company":"Actor Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SOUTH AFRICA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Glycine","moa":"||NMDA 1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Actor Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Actor Pharma \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Actor Pharma \/ Cipla"},{"orgOrder":0,"company":"Afrigen Biologics and Vaccines","sponsor":"Curapath","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA Based SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Afrigen Biologics and Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Afrigen Biologics and Vaccines \/ Curapath","highestDevelopmentStatusID":"4","companyTruncated":"Afrigen Biologics and Vaccines \/ Curapath"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SOUTH AFRICA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Pharmacare Holdings \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Viatris"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH AFRICA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Aspen Pharmacare Holdings \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Inapplicable"},{"orgOrder":0,"company":"TASK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TASK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"TASK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TASK \/ Inapplicable"},{"orgOrder":0,"company":"University of the Witwatersrand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ox1Cov-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of the Witwatersrand","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of the Witwatersrand \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of the Witwatersrand \/ Inapplicable"},{"orgOrder":0,"company":"Growlab Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH AFRICA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Growlab Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Growlab Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Growlab Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH AFRICA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Eli Lilly"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Exicure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Burixafor","moa":"||CXCL12\/CXCR4","graph1":"Oncology","graph2":"Phase II","graph3":"GPCR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GPCR Therapeutics \/ Exicure","highestDevelopmentStatusID":"8","companyTruncated":"GPCR Therapeutics \/ Exicure"},{"orgOrder":0,"company":"Alteogen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ AstraZeneca"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"DNDi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hyundai Bioscience \/ DNDi","highestDevelopmentStatusID":"5","companyTruncated":"Hyundai Bioscience \/ DNDi"},{"orgOrder":0,"company":"AbTis","sponsor":"AppClon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbTis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbTis \/ AppClon","highestDevelopmentStatusID":"3","companyTruncated":"AbTis \/ AppClon"},{"orgOrder":0,"company":"ReCerise Therapeutics","sponsor":"National Cancer Centre Singapore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"RCT1213","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ReCerise Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReCerise Therapeutics \/ National Cancer Centre Singapore","highestDevelopmentStatusID":"2","companyTruncated":"ReCerise Therapeutics \/ National Cancer Centre Singapore"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"PCV21 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"LigaChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ LigaChem Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ LigaChem Biosciences"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"ProEn Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Biopharmaceuticals \/ ProEn Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"SK Biopharmaceuticals \/ ProEn Therapeutics"},{"orgOrder":0,"company":"GI Innovation","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"GI-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GI Innovation \/ LaNova Medicines","highestDevelopmentStatusID":"4","companyTruncated":"GI Innovation \/ LaNova Medicines"},{"orgOrder":0,"company":"AbTis","sponsor":"Y-Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbTis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbTis \/ Y-Biologics","highestDevelopmentStatusID":"3","companyTruncated":"AbTis \/ Y-Biologics"},{"orgOrder":0,"company":"Brexogen","sponsor":"BMI Korea","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"BxC-I17e","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Brexogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brexogen \/ BMI Korea","highestDevelopmentStatusID":"6","companyTruncated":"Brexogen \/ BMI Korea"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"GENA-104","moa":"CNTN4","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genome & Company \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Ellipses Pharma"},{"orgOrder":0,"company":"DAAN Biotherapeutics","sponsor":"Ligachem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"DAAN Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DAAN Biotherapeutics \/ Ligachem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"DAAN Biotherapeutics \/ Ligachem Biosciences"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"OLX75016","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliX Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huons CO., LTD \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Huons CO., LTD \/ Lupin Ltd"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Financing","leadProduct":"IKS014","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LegoChem Biosciences \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"LegoChem Biosciences \/ Orion Corporation"},{"orgOrder":0,"company":"AriBio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Undisclosed"},{"orgOrder":0,"company":"Medytox","sponsor":"Bloomage Biotechnology Corp., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Medytox","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medytox \/ Bloomage Biotechnology Corp., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Medytox \/ Bloomage Biotechnology Corp., Ltd"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Seoul National University Hospital \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Inovio Pharmaceuticals"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"||CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Y-Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-Biologics \/ 3D Medicines Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Y-Biologics \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Emory University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"BBT-877","moa":"||Autotaxin","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Emory University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ Emory University School of Medicine"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"ABL301","moa":"IGF-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ Sanofi"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Polifarma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Darbepoetin Alpha","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Polifarma","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Polifarma"},{"orgOrder":0,"company":"GtreeBNT","sponsor":"HLB Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"GtreeBNT \/ HLB Group","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/ HLB Group"},{"orgOrder":0,"company":"IntoCell","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"IntoCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntoCell \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IntoCell \/ ADC Therapeutics"},{"orgOrder":0,"company":"Cyan Bio","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Partnership","leadProduct":"Elocalcitol","moa":"Vitamin D receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyan Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyan Bio \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cyan Bio \/ Adge Pharmaceuticals"},{"orgOrder":0,"company":"Alteogen","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ Sandoz B2B","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Sandoz B2B"},{"orgOrder":0,"company":"Binex","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"Binex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Binex \/ PharmAbcine","highestDevelopmentStatusID":"8","companyTruncated":"Binex \/ PharmAbcine"},{"orgOrder":0,"company":"Gicell","sponsor":"HK inno.N","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Gicell","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gicell \/ HK inno.N","highestDevelopmentStatusID":"2","companyTruncated":"Gicell \/ HK inno.N"},{"orgOrder":0,"company":"GC Cell","sponsor":"PT Bifarma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Immuncell-LC","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Cell \/ PT Bifarma","highestDevelopmentStatusID":"10","companyTruncated":"GC Cell \/ PT Bifarma"},{"orgOrder":0,"company":"Binex","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"Binex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Binex \/ PharmAbcine","highestDevelopmentStatusID":"8","companyTruncated":"Binex \/ PharmAbcine"},{"orgOrder":0,"company":"Inventage Lab","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Inventage Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inventage Lab \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Inventage Lab \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"GPCR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"GPCR Therapeutics \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GPCR Therapeutics \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GBP510","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"HANDOK","sponsor":"AUM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"CHC2014","moa":"Pan-TRK","graph1":"Oncology","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HANDOK \/ AUM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ AUM Biosciences"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"DynamiCure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OliX Pharmaceutical \/ DynamiCure","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharmaceutical \/ DynamiCure"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Checkpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Biologics \/ Checkpoint Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Biologics \/ Checkpoint Therapeutics"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"LCB71","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem Biosciences \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"||VEGF-C","graph1":"Oncology","graph2":"Preclinical","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"D&D Pharmatech \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"D&D Pharmatech \/ Yale University"},{"orgOrder":0,"company":"Alteogen","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alteogen \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"Alteogen \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genome & Company \/ Debiopharm","highestDevelopmentStatusID":"3","companyTruncated":"Genome & Company \/ Debiopharm"},{"orgOrder":0,"company":"Dream CIS","sponsor":"Curi Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Clostridium Botulinum Toxin Type A","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dream CIS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dream CIS \/ Curi Bio","highestDevelopmentStatusID":"15","companyTruncated":"Dream CIS \/ Curi Bio"},{"orgOrder":0,"company":"Kainos Medicine","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"KM10544","moa":"IRAK4","graph1":"Oncology","graph2":"Preclinical","graph3":"Kainos Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kainos Medicine \/ Emmaus Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Kainos Medicine \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Mosedipimod","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Enzychem Lifesciences Corporation \/ National Institutes of Health"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LegoChem Biosciences \/ Iksuda Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Iksuda Therapeutics"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novelty Nobility \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Novelty Nobility \/ GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"KabaFusion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ KabaFusion","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ KabaFusion"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"GX-19N","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hanmi Pharmaceutical \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ Genexine"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Glycotope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"GT-00X","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ Glycotope","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Glycotope"},{"orgOrder":0,"company":"Genuv","sponsor":"Nanocarry Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"GNUV201","moa":"PD-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genuv \/ Nanocarry Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Genuv \/ Nanocarry Therapeutics"},{"orgOrder":0,"company":"Humedix","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Humedix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humedix \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Humedix \/ Kineta"},{"orgOrder":0,"company":"Institut Pasteur Korea","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"GX-19N","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Institut Pasteur Korea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Institut Pasteur Korea \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"Institut Pasteur Korea \/ Genexine"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Kineta","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ Kineta"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Green Cross Lab Cell \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Green Cross Lab Cell \/ Kleo Pharmaceuticals"},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Tigulixostat","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LG Chem \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Innovent Biologics"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LegoChem Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"LCB73","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ Iksuda","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem Biosciences \/ Iksuda"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Mayo Clinic"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2021","type":"Series B Financing","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"NASA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ NASA","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem Lifesciences Corporation \/ NASA"},{"orgOrder":0,"company":"Ubix Therapeutics","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ubix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ubix Therapeutics \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Ubix Therapeutics \/ NeoImmuneTech"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"OLX301A","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Laboratoires Thea","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Laboratoires Thea"},{"orgOrder":0,"company":"Ligachem Biosciences","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LCB97","moa":"L1CAM","graph1":"Oncology","graph2":"Preclinical","graph3":"Ligachem Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligachem Biosciences \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ligachem Biosciences \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Merck & Co"},{"orgOrder":0,"company":"Voronoi","sponsor":"ORIC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Voronoi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voronoi \/ ORIC Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Voronoi \/ ORIC Pharmaceuticals"},{"orgOrder":0,"company":"ABL Bio","sponsor":"HiFiBiO Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ HiFiBiO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ABL Bio \/ HiFiBiO Therapeutics"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"MSD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ MSD","highestDevelopmentStatusID":"4","companyTruncated":"PharmAbcine \/ MSD"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"DS Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Peptide","year":"2021","type":"Series C Financing","leadProduct":"DD01","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"D&D Pharmatech \/ DS Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"D&D Pharmatech \/ DS Asset Management"},{"orgOrder":0,"company":"NKMax","sponsor":"Affimed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"AFM24","moa":"||EGFR\/CD16A","graph1":"Oncology","graph2":"Preclinical","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Affimed","highestDevelopmentStatusID":"4","companyTruncated":"NKMax \/ Affimed"},{"orgOrder":0,"company":"Rznomics","sponsor":"Charles River","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rznomics \/ Charles River","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Charles River"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"STCube","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"STT-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ STCube","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ STCube"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"ImmuneOncia Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"IMC-002","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ ImmuneOncia Therapeutics, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Biologics \/ ImmuneOncia Therapeutics, Inc"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kanaph Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"KNP-301","moa":"C3B receptor","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Biologics \/ Kanaph Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Biologics \/ Kanaph Therapeutics"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Panolos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"PB101","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Panolos","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Panolos"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ PharmAbcine"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Doherty Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Quadrivalent Cell Culture-based Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Doherty Institute","highestDevelopmentStatusID":"2","companyTruncated":"SK Bioscience \/ Doherty Institute"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"SK Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Expanded Collaboration","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"SK Bioscience \/ AstraZeneca"},{"orgOrder":0,"company":"Ewha Womans University","sponsor":"SOM Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ewha Womans University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ewha Womans University \/ SOM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Ewha Womans University \/ SOM Biotech"},{"orgOrder":0,"company":"Ensol BioSciences","sponsor":"Spine BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Ensol BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensol BioSciences \/ Spine BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Ensol BioSciences \/ Spine BioPharma"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Ublituximab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samsung Biologics \/ TG Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Biologics \/ TG Therapeutics"},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Autotelic Bio \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic Bio \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Autotelic Bio \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic Bio \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Johnson & Johnson"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"U.S. Army DEVCOM","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iNtRON Biotechnology \/ U.S. Army DEVCOM","highestDevelopmentStatusID":"3","companyTruncated":"iNtRON Biotechnology \/ U.S. Army DEVCOM"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"ZMA001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"ZYMEDI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZYMEDI \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"ZYMEDI \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Shaperon","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shaperon \/ Dong-A ST Co., Ltd.","highestDevelopmentStatusID":"3","companyTruncated":"Shaperon \/ Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"EuBiologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Euvichol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"GC Biopharma \/ EuBiologics","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ EuBiologics"},{"orgOrder":0,"company":"ANL Bio","sponsor":"Biovian","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"ANL-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"ANL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANL Bio \/ Biovian","highestDevelopmentStatusID":"4","companyTruncated":"ANL Bio \/ Biovian"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LegoChem Biosciences \/ Iksuda Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Iksuda Therapeutics"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Y-Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Y-Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Y-Biologics \/ Pierre Fabre"},{"orgOrder":0,"company":"ImmuneOncia Therapeutics, Inc","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"IMC-002","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOncia Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOncia Therapeutics, Inc \/ 3D Medicines Corporation","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOncia Therapeutics, Inc \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"Syntekabio","sponsor":"Enamine Ltd","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Syntekabio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syntekabio \/ Enamine Ltd","highestDevelopmentStatusID":"3","companyTruncated":"Syntekabio \/ Enamine Ltd"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"APRINOIA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ APRINOIA Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ APRINOIA Therapeutics"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"KB Investment","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Financing","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ KB Investment","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ KB Investment"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"KIRAMS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SK Biopharmaceuticals \/ KIRAMS","highestDevelopmentStatusID":"3","companyTruncated":"SK Biopharmaceuticals \/ KIRAMS"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ABL103","moa":"||B7-H4\/4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ Merck & Co"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Turn Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Hanall Biopharma \/ Turn Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"Hanall Biopharma \/ Turn Biotechnologies"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"University of Colorado School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ University of Colorado School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ University of Colorado School of Medicine"},{"orgOrder":0,"company":"IntoCell","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"IntoCell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntoCell \/ Cellectar","highestDevelopmentStatusID":"1","companyTruncated":"IntoCell \/ Cellectar"},{"orgOrder":0,"company":"GI Innovation","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"GI-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GI Innovation \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"GI Innovation \/ Merck & Co"},{"orgOrder":0,"company":"OSR Holdings","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"BAL0891","moa":"||Checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"OSR Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSR Holdings \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"OSR Holdings \/ SillaJen, Inc"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"BH3120","moa":"||PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"GenKOre","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"GenKOre","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"GenKOre \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"GenKOre \/ Undisclosed"},{"orgOrder":0,"company":"Mediforum","sponsor":"Vision Sensing Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"PM012","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Mediforum","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mediforum \/ Vision Sensing Acquisition Corp","highestDevelopmentStatusID":"9","companyTruncated":"Mediforum \/ Vision Sensing Acquisition Corp"},{"orgOrder":0,"company":"Oncocross","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncocross","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncocross \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Oncocross \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"International Vaccine Institute","sponsor":"Sumagen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Viral Vaccine Vector","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Vaccine Institute \/ Sumagen","highestDevelopmentStatusID":"4","companyTruncated":"International Vaccine Institute \/ Sumagen"},{"orgOrder":0,"company":"Binex","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GX-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Binex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Binex \/ Genexine","highestDevelopmentStatusID":"1","companyTruncated":"Binex \/ Genexine"},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"BRV Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Udenafil","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ BRV Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Pharma Co Ltd \/ BRV Capital Management"},{"orgOrder":0,"company":"Avelos Therapeutics","sponsor":"Stassets Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"AD1208","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avelos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avelos Therapeutics \/ Stassets Investment","highestDevelopmentStatusID":"5","companyTruncated":"Avelos Therapeutics \/ Stassets Investment"},{"orgOrder":0,"company":"PINOTBIO","sponsor":"Lotte Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","graph1":"Oncology","graph2":"Preclinical","graph3":"PINOTBIO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PINOTBIO \/ Lotte Biologics","highestDevelopmentStatusID":"4","companyTruncated":"PINOTBIO \/ Lotte Biologics"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Avacta Group","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong Pharmaceutical \/ Avacta Group"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Yuhan Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"JIN-A04","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"J Ints Bio \/ Yuhan Corporation","highestDevelopmentStatusID":"4","companyTruncated":"J Ints Bio \/ Yuhan Corporation"},{"orgOrder":0,"company":"GI Innovation","sponsor":"Agilent Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"GI-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GI Innovation \/ Agilent Technologies","highestDevelopmentStatusID":"7","companyTruncated":"GI Innovation \/ Agilent Technologies"},{"orgOrder":0,"company":"AffyXell","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"AffyXell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AffyXell \/ GenScript ProBio","highestDevelopmentStatusID":"1","companyTruncated":"AffyXell \/ GenScript ProBio"},{"orgOrder":0,"company":"Tiumbio","sponsor":"SK Chemicals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tiumbio \/ SK Chemicals","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ SK Chemicals"},{"orgOrder":0,"company":"Aston Sci","sponsor":"Timefolio Asset","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aston Sci","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Aston Sci \/ Timefolio Asset","highestDevelopmentStatusID":"8","companyTruncated":"Aston Sci \/ Timefolio Asset"},{"orgOrder":0,"company":"Genencell","sponsor":"Ordi Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2022","type":"Agreement","leadProduct":"ES16001","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Genencell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Genencell \/ Ordi Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Genencell \/ Ordi Pharma"},{"orgOrder":0,"company":"Toolgen","sponsor":"mCureX","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"TGT-101","moa":"VEGF","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Toolgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toolgen \/ mCureX","highestDevelopmentStatusID":"2","companyTruncated":"Toolgen \/ mCureX"},{"orgOrder":0,"company":"Novacell","sponsor":"Ad Korea","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Heptameric peptide FPR2","moa":"G protein-coupled receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novacell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novacell \/ Ad Korea","highestDevelopmentStatusID":"4","companyTruncated":"Novacell \/ Ad Korea"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ABL Bio \/ Themis Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ Themis Bioscience"},{"orgOrder":0,"company":"Gyeonggido Business and Science Accelerator","sponsor":"CINECA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen-beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Gyeonggido Business and Science Accelerator","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gyeonggido Business and Science Accelerator \/ CINECA","highestDevelopmentStatusID":"1","companyTruncated":"Gyeonggido Business and Science Accelerator \/ CINECA"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"AprilBio","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"EVO301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"AprilBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AprilBio \/ Evommune","highestDevelopmentStatusID":"6","companyTruncated":"AprilBio \/ Evommune"},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Hansoh Pharma","highestDevelopmentStatusID":"2","companyTruncated":"OliX Pharmaceutical \/ Hansoh Pharma"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Boryeong","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Boryeong","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Boryeong"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ Vir Biotechnology"},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Genexine","sponsor":"EPD Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genexine \/ EPD Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Genexine \/ EPD Biotherapeutics"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GC Biopharma \/ Novelty Nobility","highestDevelopmentStatusID":"1","companyTruncated":"GC Biopharma \/ Novelty Nobility"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Aclipse Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lobeglitazone","moa":"PPAR","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Aclipse Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Aclipse Therapeutics"},{"orgOrder":0,"company":"Cureverse","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"CV-01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cureverse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cureverse \/ Angelini Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Cureverse \/ Angelini Pharma"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Biotechnology \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"RNAGENE Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmAbcine \/ RNAGENE Inc.","highestDevelopmentStatusID":"2","companyTruncated":"PharmAbcine \/ RNAGENE Inc."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"NuclixBio Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmAbcine \/ NuclixBio Inc.","highestDevelopmentStatusID":"2","companyTruncated":"PharmAbcine \/ NuclixBio Inc."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"LISCure Biosciences \/ Celltrion","highestDevelopmentStatusID":"2","companyTruncated":"LISCure Biosciences \/ Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celltrion \/ Rani Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Celltrion \/ Rani Therapeutics"},{"orgOrder":0,"company":"Curacle","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"CU06","moa":"Endothelial dysfunction","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Curacle","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Curacle \/ Laboratoires Thea","highestDevelopmentStatusID":"6","companyTruncated":"Curacle \/ Laboratoires Thea"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Cooper Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Cooper Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Cooper Pharma"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Vitalli Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"DWP213388","moa":"ITK\/BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Vitalli Bio","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Vitalli Bio"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Duke University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunoforge \/ Duke University","highestDevelopmentStatusID":"2","companyTruncated":"Immunoforge \/ Duke University"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"BMD-001","moa":"miR-485-3p","graph1":"Neurology","graph2":"Preclinical","graph3":"Biorchestra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biorchestra \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biorchestra \/ Undisclosed"},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Healis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"CKDB-501","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CKD Bio Corporation \/ Healis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CKD Bio Corporation \/ Healis Therapeutics"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"iNtRON Biotechnology \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Enavogliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Efinopegdutide","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CKD-510","moa":"HDAC6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Petrovax","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Agalsidase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ISU ABXIS \/ Petrovax","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Petrovax"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Bivamelagon","moa":"MC4R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Samsung Biologics \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Biologics \/ AstraZeneca"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Checkpoint protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Wellmarker Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wellmarker Bio \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Wellmarker Bio \/ Merck & Co"},{"orgOrder":0,"company":"Biorchestra","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Neurology","graph2":"Discovery","graph3":"Biorchestra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorchestra \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Biorchestra \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"BostonGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"LCB84","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LegoChem Biosciences \/ BostonGene","highestDevelopmentStatusID":"7","companyTruncated":"LegoChem Biosciences \/ BostonGene"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"NeuroBo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DA-1241","moa":"GPR119","graph1":"Endocrinology","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dong-A ST Co., Ltd. \/ NeuroBo Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST Co., Ltd. \/ NeuroBo Pharmaceuticals"},{"orgOrder":0,"company":"NuclixBio","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"NuclixBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NuclixBio \/ GenScript ProBio","highestDevelopmentStatusID":"2","companyTruncated":"NuclixBio \/ GenScript ProBio"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"ALT-B4","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Undisclosed"},{"orgOrder":0,"company":"Alteogen","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"ALT-B4","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Aptose Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tuspetinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Aptose Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ Aptose Biosciences"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"LCB84","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LegoChem Biosciences \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"7","companyTruncated":"LegoChem Biosciences \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"LG Chem","sponsor":"UNICEF","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Sabin Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"LG Chem \/ UNICEF","highestDevelopmentStatusID":"15","companyTruncated":"LG Chem \/ UNICEF"},{"orgOrder":0,"company":"Neuramedy","sponsor":"Bioasis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Tomaralimab","moa":"TLR2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuramedy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Neuramedy \/ Bioasis","highestDevelopmentStatusID":"4","companyTruncated":"Neuramedy \/ Bioasis"},{"orgOrder":0,"company":"Peptron","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"PAb001-ADC","moa":"MUC1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Peptron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptron \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Peptron \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Belimumab","moa":"TNFSF13B","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Biologics \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Biologics \/ GSK"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kahr Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"DSP502","moa":"DSP-Fc","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Kahr Medical","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ Kahr Medical"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daewoong Pharmaceutical \/ Zydus Lifesciences","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Samsung Biologics \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Biologics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Genexine","sponsor":"PT Kalbe Farma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"GX-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ PT Kalbe Farma","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ PT Kalbe Farma"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"LCB20A","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LegoChem Biosciences \/ Sotio","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem Biosciences \/ Sotio"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Scripps Research","highestDevelopmentStatusID":"3","companyTruncated":"Bridge Biotherapeutics \/ Scripps Research"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samsung Biologics \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Pfizer Inc"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Neurogastrx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Neurogastrx","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Neurogastrx"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Y-Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Y-Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Y-Biologics \/ Pierre Fabre"},{"orgOrder":0,"company":"Voronoi","sponsor":"METiS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Pan-RAF","graph1":"Oncology","graph2":"Discovery","graph3":"Voronoi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voronoi \/ METiS Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Voronoi \/ METiS Therapeutics"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2024","type":"Partnership","leadProduct":"LCB73","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Hana Pharm","sponsor":"Bold Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hana Pharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hana Pharm \/ Bold Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hana Pharm \/ Bold Therapeutics"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"PMC-403","moa":"Tie2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"PharmAbcine \/ National Institutes of Health"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Oncodesign","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Oncodesign","highestDevelopmentStatusID":"4","companyTruncated":"Tiumbio \/ Oncodesign"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Dinona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"DNP-019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Dinona","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Dinona"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"BioEleven","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"BN-101A","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ BioEleven","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Biologics \/ BioEleven"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"PMC-402","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Biologics \/ PharmAbcine"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Shanghai Haini Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Shanghai Haini Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Shanghai Haini Pharmaceutical"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Tegoprazan","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HK inno.N \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"iNtRON Biotechnology \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Samsung Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Samsung Biologics"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genome & Company \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Genome & Company \/ Merck & Co"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"ValenzaBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"VB517","moa":"c-KIT","graph1":"Immunology","graph2":"IND Enabling","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novelty Nobility \/ ValenzaBio","highestDevelopmentStatusID":"5","companyTruncated":"Novelty Nobility \/ ValenzaBio"},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"HK inno.N","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ILIAS Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ILIAS Biologics \/ HK inno.N","highestDevelopmentStatusID":"2","companyTruncated":"ILIAS Biologics \/ HK inno.N"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Zastaprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Livzon Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Therapeutics \/ Livzon Pharmaceutical Group"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nelonemdaz","moa":"NMDA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GNT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rosuvastatin","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LC51-0255","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"LG Chem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"PRG S&Tech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Progerinin","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"PRG S&Tech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PRG S&Tech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PRG S&Tech \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Curocell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Anbalcabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Curocell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curocell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curocell \/ Inapplicable"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IDG16177","moa":"GPR40","graph1":"Endocrinology","graph2":"Phase I","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ildong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ildong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"GC Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AB-201","moa":"||CD16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Inapplicable"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ISU ABXIS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Inapplicable"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ISU ABXIS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Inapplicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"ADEL Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADEL-Y01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oscotec \/ ADEL Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ ADEL Inc."},{"orgOrder":0,"company":"Oscotec","sponsor":"ADEL Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADEL-Y01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oscotec \/ ADEL Inc","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ ADEL Inc"},{"orgOrder":0,"company":"Altos Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Altos Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Altos Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Altos Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Altos Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Altos Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altos Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Altos Biologics \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Aptabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APX-115","moa":"NADPH oxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aptabio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptabio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptabio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Adaptive Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Adaptive Research","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Adaptive Research"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ SK Chemicals","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ SK Chemicals"},{"orgOrder":0,"company":"GtreeBNT","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"GtreeBNT \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBT-207","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-301","moa":"KCa3.1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBT-877","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBT-877","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BH3120","moa":"||PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BMD-001","moa":"miR-485-3p","graph1":"Neurology","graph2":"Preclinical","graph3":"Biorchestra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biorchestra \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorchestra \/ Inapplicable"},{"orgOrder":0,"company":"Brexogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRE-AD01","moa":"IL-31","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Brexogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brexogen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Brexogen \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"CDL200","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"iNtRON Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CT-P63","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Angelini Pharma"},{"orgOrder":0,"company":"CTCBIO INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CTCBIO INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CTCBIO INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTCBIO INC \/ Inapplicable"},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Healis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Serotype A Botulinum Toxin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CKD Bio Corporation \/ Healis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CKD Bio Corporation \/ Healis Therapeutics"},{"orgOrder":0,"company":"Qurient","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telacebec","moa":"Cytochrome bc1 complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Qurient \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qurient \/ Inapplicable"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genome & Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Inapplicable"},{"orgOrder":0,"company":"Connext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CNT201","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Connext","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connext \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Connext \/ Inapplicable"},{"orgOrder":0,"company":"NKMax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CWP291","moa":"Wnt\/beta-catenin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JW Pharmaceutical Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"JW Pharmaceutical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"DD01","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"D&D Pharmatech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"D&D Pharmatech \/ Inapplicable"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"DD01","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"D&D Pharmatech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"D&D Pharmatech \/ Inapplicable"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"DD01","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"D&D Pharmatech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"D&D Pharmatech \/ Inapplicable"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dongkook Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dutasteride","moa":"||Cholestenone 5-alpha reductase","graph1":"Urology","graph2":"Phase III","graph3":"Dongkook Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dongkook Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dongkook Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"ICURE PHARM, INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"ICURE PHARM, INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"ICURE PHARM, INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ICURE PHARM, INC \/ Inapplicable"},{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DuoChol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"The International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The International Vaccine Institute \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"The International Vaccine Institute \/ Inapplicable"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Cholestenone 5-alpha reductase","graph1":"Dermatology","graph2":"Preclinical","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Yuyu Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Yuyu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DWP213388","moa":"ITK\/BTK","graph1":"Immunology","graph2":"IND Enabling","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"SGLT2","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR4","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Efepoetin Alpha","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genexine \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Genexine \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EU307","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eutilex Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eutilex Inc \/ GenScript ProBio","highestDevelopmentStatusID":"6","companyTruncated":"Eutilex Inc \/ GenScript ProBio"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Korea Institute of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"EuBiologics \/ Korea Institute of Science and Technology","highestDevelopmentStatusID":"7","companyTruncated":"EuBiologics \/ Korea Institute of Science and Technology"},{"orgOrder":0,"company":"NKMax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GX-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"G+FLAS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Immunogenic Recombinant Vaccine","moa":"S-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"G+FLAS Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G+FLAS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"G+FLAS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"SK Bioscience \/ Sanofi"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GBP560","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GC5107","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GC1109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"GC1126A","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Heparan N-Sulfatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Heparan N-Sulfatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Heparan N-Sulfatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Heparan N-Sulfatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"alpha-galactosidase A","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"GC Biopharma \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GC5107","moa":"Gamma Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tertomotide","moa":"Telomere lenth modification","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Inapplicable"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genome & Company \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Genome & Company \/ Merck & Co"},{"orgOrder":0,"company":"Genexine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GX-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Eftansomatropin Alpha","moa":"IGF-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genexine \/ I-Mab Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Genexine \/ I-Mab Biopharma"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genome & Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Inapplicable"},{"orgOrder":0,"company":"Dx&Vx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Dx&Vx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dx&Vx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dx&Vx \/ Inapplicable"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tertomotide","moa":"Telomere lenth modification","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GemVax & KAEL \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GemVax & KAEL \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GX-188E","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GX-188E","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GX-188E","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/ Merck & Co"},{"orgOrder":0,"company":"Genexine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GX-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tanfanercept","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Hanall Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tanfanercept","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HL192","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Hanall Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"NurrOn Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HL192","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hanall Biopharma \/ NurrOn Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Hanall Biopharma \/ NurrOn Pharmaceuticals"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hugel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Yifan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Yifan Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"LG Chem \/ Yifan Pharmaceutical"},{"orgOrder":0,"company":"Yunovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ID110521156","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Yunovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yunovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yunovia \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"ImmunAbs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IM-101","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"ImmunAbs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunAbs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunAbs \/ Inapplicable"},{"orgOrder":0,"company":"ImmunAbs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IM-101","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"ImmunAbs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunAbs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunAbs \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneOncia Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMC-001","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"ImmuneOncia Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralymphatic","sponsorNew":"ImmuneOncia Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmuneOncia Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneMed, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Virus Suppressing Factor","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuneMed, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneMed, Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneMed, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immunoforge","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Froniglutide","moa":"GLP-1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunoforge \/ PhaseBio Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Immunoforge \/ PhaseBio Pharmaceuticals"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Immunovant","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hanall Biopharma \/ Immunovant","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Biopharma \/ Immunovant"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Nona Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hanall Biopharma \/ Nona Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Nona Biosciences"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium transporting ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"HK inno.N \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"HK inno.N \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"DongWha Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"DW2008","moa":"TIGIT","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DongWha Pharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DongWha Pharm \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"DongWha Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Innovo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INV-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CG200745","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CrystalGenomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGenomics \/ Inapplicable"},{"orgOrder":0,"company":"Inventage Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Inventage Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inventage Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inventage Lab \/ Inapplicable"},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zastaprazan Citrate","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Onconic Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onconic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"J Ints Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Inapplicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"J Ints Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Inapplicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"J Ints Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Inapplicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"J Ints Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kine Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"KINE-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kine Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kine Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kine Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LB-LR1109","moa":"LILRB1","graph1":"Oncology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Aveo Oncology","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Aveo Oncology"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"LB-P8","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"LEM-mR203","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lemonex Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bio \/ Inapplicable"},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"LEM-mR203","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lemonex Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bio \/ Inapplicable"},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LEM-S401","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lemonex Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bio \/ Inapplicable"},{"orgOrder":0,"company":"Hugel","sponsor":"Sihuan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Sihuan Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Hugel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hugel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Inapplicable"},{"orgOrder":0,"company":"Hugel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Inapplicable"},{"orgOrder":0,"company":"Bukwang Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clevudine","moa":"Protein P","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bukwang Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bukwang Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bukwang Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LG203003","moa":"DGAT2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LG Chem \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MAb-AR20.5","moa":"MUC1","graph1":"Oncology","graph2":"Preclinical","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"Sahmyook University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Meclofenamic Acid","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Sahmyook University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sahmyook University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sahmyook University \/ Inapplicable"},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Udenafil","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Pharma Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MIT-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"MitoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MitoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MitoImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Udenafil","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Pharma Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nelonemdaz","moa":"NMDA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GNT Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Novocellbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NOVO-NK","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novocellbio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novocellbio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novocellbio \/ Inapplicable"},{"orgOrder":0,"company":"Shaperon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"NLRP3","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Shaperon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmAbcine \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcine \/ Merck & Co"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX104C","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Novotech"},{"orgOrder":0,"company":"OliPass","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Inapplicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Inapplicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Neurology","graph2":"Phase I","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliPass \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX10212","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX10212","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX104C","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OLX702A","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX72021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX72021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"OLX75016","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncocross","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OC514","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Oncocross","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncocross \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross \/ Inapplicable"},{"orgOrder":0,"company":"Oncocross","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OC514","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Oncocross","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncocross \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase II","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanariaBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CanariaBio \/ Inapplicable"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"P18-BE3CRC","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iNtRON Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Froniglutide","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunoforge \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunoforge \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"Aston Sci","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aston Sci","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Aston Sci \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aston Sci \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Pharmamar","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Pharmamar","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Pharmamar"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Cleveland Clinic","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Cleveland Clinic"},{"orgOrder":0,"company":"YD Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YD Life Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Yuyu Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-207","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mirodenafil","moa":"PDE5","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AriBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ GSK"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Sandoz B2B"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Sandoz B2B"},{"orgOrder":0,"company":"Qurient","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adrixetinib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qurient \/ Inapplicable"},{"orgOrder":0,"company":"Qurient","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adrixetinib","moa":"||Axl\/Mer\/CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Qurient \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Inapplicable"},{"orgOrder":0,"company":"Qurient","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Q901","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qurient \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tigulixostat","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LG Chem \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ildong Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Ildong Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","graph1":"Neurology","graph2":"Phase III","graph3":"Daehwa Pharmaceutical Co. Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Daehwa Pharmaceutical Co. Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Daehwa Pharmaceutical Co. Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Hematology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chong Kun Dang Pharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cevidoplenib","moa":"SYK","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oscotec \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Inapplicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cevidoplenib","moa":"SYK","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oscotec \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Inapplicable"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Varicella Virus, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SK Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Chemicals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Chemicals \/ Inapplicable"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine Recombinant, Adjuvanted","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Chemicals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Chemicals \/ Inapplicable"},{"orgOrder":0,"company":"Selecxine","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SLC-3010","moa":"IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Selecxine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecxine \/ GenScript ProBio","highestDevelopmentStatusID":"5","companyTruncated":"Selecxine \/ GenScript ProBio"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Inapplicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Inapplicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Inapplicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Inapplicable"},{"orgOrder":0,"company":"Genuv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"MEK1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genuv \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Inapplicable"},{"orgOrder":0,"company":"Genuv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"MEK1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genuv \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"ST Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STP0404","moa":"HIV-1 allosteric integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ST Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ST Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ST Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ National OncoVenture","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Biologics \/ National OncoVenture"},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"EU101","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eutilex Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eutilex Inc \/ Samsung Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Eutilex Inc \/ Samsung Biologics"},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Udenafil","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Pharma Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"CanariaBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CanariaBio \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio \/ GSK"},{"orgOrder":0,"company":"Syntekabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Syntekabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Syntekabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Syntekabio \/ Inapplicable"},{"orgOrder":0,"company":"S.Biomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TED-A9","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"S.Biomedics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.Biomedics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"S.Biomedics \/ Inapplicable"},{"orgOrder":0,"company":"NKMax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBT-176","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incheon National University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BODIPY","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Incheon National University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incheon National University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Incheon National University \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GC5107","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX75016","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"NKMax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camostat","moa":"Proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"GPCR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"GPCR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GPCR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Standigm","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Standigm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Standigm \/ SK Chemicals","highestDevelopmentStatusID":"4","companyTruncated":"Standigm \/ SK Chemicals"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chong Kun Dang Pharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"EuBiologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EuBiologics \/ Inapplicable"},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Udenafil","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Pharma Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CT-P63","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"Green Cross Well-being","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BST204","moa":"IL-6 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Green Cross Well-being","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Well-being \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Well-being \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Hugel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hugel \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Microneedle Patch","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lazertinib","moa":"EGFR mutant-selective","graph1":"Oncology","graph2":"Approved FDF","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Yuhan Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yuhan Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Udenafil","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Pharma Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cellivery","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"iCP-NI","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellivery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellivery \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellivery \/ Inapplicable"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Idursulfase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX10212","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OLX702A","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Pharm Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"JBPOS0101","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Bio-Pharm Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bio-Pharm Solutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Pharm Solutions \/ Inapplicable"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tertomotide","moa":"Telomere lenth modification","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Biogen"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genome & Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Hyper Immunoglobulin","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Green Cross Lab Cell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Lab Cell \/ Inapplicable"},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tertomotide","moa":"Telomere lenth modification","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & KAEL \/ Inapplicable"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Hyper Immunoglobulin","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PMC-309","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OLX301A","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ NeoImmuneTech"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR4","graph1":"Rheumatology","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MG1111","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Hyper Immunoglobulin","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Helixmith","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Donaperminogene Seltoplasmid","moa":"HGF","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Helixmith \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Helixmith \/ Inapplicable"},{"orgOrder":0,"company":"GeneOne Life Science, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLS-1027","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeneOne Life Science, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"GeneOne Life Science, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GeneOne Life Science, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mosedipimod","moa":"TLR signaling","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Alteogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ALT-P7","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alteogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/ Inapplicable"},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ILB-202","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ILIAS Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ILIAS Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ILIAS Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"HyLeukin-7","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genexine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmAbcine \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DWP710","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Syntekabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"STB-C017","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Preclinical","graph3":"Syntekabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntekabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Syntekabio \/ Inapplicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TGFR1\/VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tiumbio \/ Inapplicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tiumbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ Inapplicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Merigolix","moa":"GnRH receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiumbio \/ Hansoh Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ Hansoh Pharma"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"TU7710","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiumbio \/ Inapplicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"OLX10010","moa":"CTGF","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"WM-S1-030","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Wellmarker Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wellmarker Bio \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"Wellmarker Bio \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyundai Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Hyundai Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hyundai Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"SK Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Yuyu Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Yuyu Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZMA001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"ZYMEDI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZYMEDI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYMEDI \/ Inapplicable"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZMA001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"ZYMEDI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZYMEDI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYMEDI \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Oncology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hanall Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irbesartan","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"HANDOK \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"HANDOK \/ Sanofi"},{"orgOrder":0,"company":"CJ Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"CJRB-201","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"CJ Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CJ Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CJ Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"DD01","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"D&D Pharmatech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"D&D Pharmatech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"D&D Pharmatech \/ Inapplicable"},{"orgOrder":0,"company":"ENCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ENCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ENCell \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"GBP560","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SK Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"GC Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AB-205","moa":"||CD5","graph1":"Oncology","graph2":"Phase I","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Cell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GC Cell \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Hyundai ADM Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Hyundai ADM Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hyundai ADM Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hyundai ADM Bio \/ Inapplicable"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunoforge \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunoforge \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SN BioScience \/ Inapplicable"},{"orgOrder":0,"company":"Reyon Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Teicoplanin","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reyon Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reyon Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Reyon Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Vivozon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Opiranserin Hydrochloride","moa":"GlyT2\/5-HT2a","graph1":"Neurology","graph2":"Approved FDF","graph3":"Vivozon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vivozon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivozon \/ Inapplicable"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"ChAdOx1.HTI","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aelix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Viralgen","sponsor":"MIT","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Viralgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viralgen \/ MIT","highestDevelopmentStatusID":"4","companyTruncated":"Viralgen \/ MIT"},{"orgOrder":0,"company":"Viralgen","sponsor":"Axovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"AXV-101","moa":"BBS1","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Viralgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viralgen \/ Axovia","highestDevelopmentStatusID":"4","companyTruncated":"Viralgen \/ Axovia"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"CDTI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2025","type":"Financing","leadProduct":"OMTX705","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Oncomatryx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ CDTI","highestDevelopmentStatusID":"6","companyTruncated":"Oncomatryx \/ CDTI"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2022","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Mabxience","sponsor":"Biosidus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Biosidus","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Biosidus"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Adium Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Adium Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Adium Pharma"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Origo Biopharma","sponsor":"AgomAb Therapeutics N.V","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"ORG-129","moa":"TGF-beta","graph1":"Immunology","graph2":"Phase I","graph3":"Origo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Origo Biopharma \/ AgomAb Therapeutics N.V","highestDevelopmentStatusID":"6","companyTruncated":"Origo Biopharma \/ AgomAb Therapeutics N.V"},{"orgOrder":0,"company":"Telara Pharma","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cilastatin","moa":"DPEP1","graph1":"Nephrology","graph2":"Preclinical","graph3":"Telara Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telara Pharma \/ Arch Biopartners","highestDevelopmentStatusID":"4","companyTruncated":"Telara Pharma \/ Arch Biopartners"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kabuki Syndrome Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Kabuki Syndrome Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Kabuki Syndrome Foundation"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kennedy Krieger Institute","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Kennedy Krieger Institute","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Kennedy Krieger Institute"},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Buzzard Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Isunakinra","moa":"IL-1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"3P Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"3P Biopharmaceuticals \/ Buzzard Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"3P Biopharmaceuticals \/ Buzzard Pharmaceuticals"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"CTI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"5 Fluorouracil","moa":"||mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ability Pharma \/ CTI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ CTI Life Sciences"},{"orgOrder":0,"company":"Mabxience","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Bevacizumab","moa":"||VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Zentiva","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Zentiva"},{"orgOrder":0,"company":"Almirall","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Almirall \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Neuraxpharm"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Apsen","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Apsen","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Apsen"},{"orgOrder":0,"company":"Grifols International","sponsor":"Endpoint Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Endpoint Health","highestDevelopmentStatusID":"4","companyTruncated":"Grifols International \/ Endpoint Health"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Viralgen","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"AXO-AAV-GM1","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Viralgen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viralgen \/ Sio Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Viralgen \/ Sio Gene Therapies"},{"orgOrder":0,"company":"Rubio Laboratories","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Rubio Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Rubio Laboratories \/ Aspargo Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Rubio Laboratories \/ Aspargo Laboratories"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaMar \/ Pharmapark","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Pharmapark"},{"orgOrder":0,"company":"Blumentech S.L.","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Blumentech S.L.","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blumentech S.L. \/ Terran Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Blumentech S.L. \/ Terran Biosciences"},{"orgOrder":0,"company":"Bioiberica","sponsor":"ByHealth","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Undenatured Type II Collagen","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ ByHealth","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ ByHealth"},{"orgOrder":0,"company":"EntreChem","sponsor":"AI Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"AIT-102","moa":"SWI\/SNF protein","graph1":"Oncology","graph2":"Preclinical","graph3":"EntreChem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EntreChem \/ AI Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"EntreChem \/ AI Therapeutics"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Eczac\u0131ba\u015f\u0131 Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Eczac\u0131ba\u015f\u0131 Group","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Eczac\u0131ba\u015f\u0131 Group"},{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ BARDA"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Immedica Pharma","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Immedica Pharma"},{"orgOrder":0,"company":"Hospital Clinic of Barcelona","sponsor":"Immuneel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Autologous T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hospital Clinic of Barcelona","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hospital Clinic of Barcelona \/ Immuneel Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hospital Clinic of Barcelona \/ Immuneel Therapeutics"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Mabxience","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mabxience \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Microviable Therapeutics","sponsor":"Inmunomet Intolerancia y Disbiosis SL","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Large Molecule","year":"2022","type":"Financing","leadProduct":"MVT-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microviable Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microviable Therapeutics \/ Inmunomet Intolerancia y Disbiosis SL","highestDevelopmentStatusID":"4","companyTruncated":"Microviable Therapeutics \/ Inmunomet Intolerancia y Disbiosis SL"},{"orgOrder":0,"company":"Zendal","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zendal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zendal \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Zendal \/ IAVI"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Eurostars","highestDevelopmentStatusID":"1","companyTruncated":"Oryzon Genomics \/ Eurostars"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Spanish Ministry Of Science And Innovation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Spanish Ministry Of Science And Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Spanish Ministry Of Science And Innovation"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"PharmaMar","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ STADA Arzneimittel"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Key Oncologics","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Key Oncologics"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ EIC Accelerator","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ EIC Accelerator"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Leriglitazone","moa":"PPAR-gamma","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Sperogenix Therapeutics"},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"3P Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3P Biopharmaceuticals \/ SpyBiotech","highestDevelopmentStatusID":"1","companyTruncated":"3P Biopharmaceuticals \/ SpyBiotech"},{"orgOrder":0,"company":"Libera Bio","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Libera Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Libera Bio \/ Talem Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Libera Bio \/ Talem Therapeutics"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"VIVEbiotech","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"VIVEbiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VIVEbiotech \/ Xyphos Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"VIVEbiotech \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Monteloeder","sponsor":"Suanfarma","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Lemon Verbena Extract","moa":"GABA-A receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Monteloeder","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Monteloeder \/ Suanfarma","highestDevelopmentStatusID":"15","companyTruncated":"Monteloeder \/ Suanfarma"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuraxpharm \/ Panaxia","highestDevelopmentStatusID":"1","companyTruncated":"Neuraxpharm \/ Panaxia"},{"orgOrder":0,"company":"Almirall","sponsor":"University of Dundee","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Dermatology","graph2":"Discovery","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ University of Dundee","highestDevelopmentStatusID":"2","companyTruncated":"Almirall \/ University of Dundee"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDSIR \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"MEDSIR \/ Debiopharm"},{"orgOrder":0,"company":"Progreso y Salud Foundation","sponsor":"Amarna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"SVec","moa":"AChE","graph1":"Neurology","graph2":"Undisclosed","graph3":"Progreso y Salud Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progreso y Salud Foundation \/ Amarna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Progreso y Salud Foundation \/ Amarna Therapeutics"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Leriglitazone","moa":"PPAR-gamma","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Ona Therapeutics","sponsor":"Fund+","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ona Therapeutics \/ Fund+","highestDevelopmentStatusID":"4","companyTruncated":"Ona Therapeutics \/ Fund+"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ European Commission"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Nice & Green"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ European Commission"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ORY-4001","moa":"HDAC-6","graph1":"Neurology","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ ALS Association"},{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Grifols International \/ BARDA"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Permira","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Neuraxpharm \/ Permira","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Permira"},{"orgOrder":0,"company":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Celyvir","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas \/ Orgenesis","highestDevelopmentStatusID":"6","companyTruncated":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas \/ Orgenesis"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"ABCA4 gene","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpliceBio \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"SpliceBio \/ Ysios Capital"},{"orgOrder":0,"company":"Insud Pharma","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Hormone","year":"2024","type":"Funding","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Insud Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insud Pharma \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Insud Pharma \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Columbus Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Universitat Aut\u00f2noma de Barcelona","sponsor":"Anew Medical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Universitat Aut\u00f2noma de Barcelona","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Universitat Aut\u00f2noma de Barcelona \/ Anew Medical","highestDevelopmentStatusID":"4","companyTruncated":"Universitat Aut\u00f2noma de Barcelona \/ Anew Medical"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2022","type":"Financing","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oncomatryx \/ Undisclosed"},{"orgOrder":0,"company":"Biofabri","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"BCG Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Biofabri \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ Bharat Biotech"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOM Biotech \/ University of Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotech \/ University of Minnesota"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Megapharm","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Megapharm"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2022","type":"Expanded Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Exeltis \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Lupin Ltd"},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Toleranzia","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"TOL2","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"3P Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3P Biopharmaceuticals \/ Toleranzia","highestDevelopmentStatusID":"4","companyTruncated":"3P Biopharmaceuticals \/ Toleranzia"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Onko Kocsel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Onko Kocsel Pharmaceuticals"},{"orgOrder":0,"company":"Mabxience","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mabxience \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Abbott Laboratories"},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"SRB21","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunRock Biopharma \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Biopharma \/ Debiopharm"},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Ellipses Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"SRB22","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunRock Biopharma \/ Ellipses Pharma Limited","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Biopharma \/ Ellipses Pharma Limited"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ IAVI"},{"orgOrder":0,"company":"Mabxience","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Mabxience \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"SpliceBio \/ Spark Therapeutics, Inc","highestDevelopmentStatusID":"2","companyTruncated":"SpliceBio \/ Spark Therapeutics, Inc"},{"orgOrder":0,"company":"PharmaMar","sponsor":"TOYO Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ TOYO Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ TOYO Pharmaceutical"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Faes Farma \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Faes Farma \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ National Cancer Institute"},{"orgOrder":0,"company":"Grifols International","sponsor":"Savara","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Grifols International \/ Savara","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Savara"},{"orgOrder":0,"company":"Almirall","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"SRD5A2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Almirall \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HDAC6","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ CMT Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ CMT Research Foundation"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2021","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"VCN Biosciences \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Grifols International"},{"orgOrder":0,"company":"Viralgen","sponsor":"Elpida","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Melpida","moa":"AP4M1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Viralgen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Viralgen \/ Elpida","highestDevelopmentStatusID":"7","companyTruncated":"Viralgen \/ Elpida"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"BT524","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Ab-Biotics","sponsor":"Zambon Group SpA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"KABP022","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ab-Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ab-Biotics \/ Zambon Group SpA","highestDevelopmentStatusID":"1","companyTruncated":"Ab-Biotics \/ Zambon Group SpA"},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ACT-01","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"Accure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Accure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Perflutren","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALM223","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Harpagophytum Procumbens Extract","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Protein COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Laboratorios HIPRA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Laboratorios HIPRA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Laboratorios HIPRA \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Protein COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Laboratorios HIPRA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Laboratorios HIPRA \/ Veristat","highestDevelopmentStatusID":"15","companyTruncated":"Laboratorios HIPRA \/ Veristat"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"Neurotrophic factor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BO-112","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Midazolam Maleate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Neuraxpharm \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Pivotal","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Pivotal","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Pivotal"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Hyperimmune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GIGA-2050","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vesatolimod","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aelix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"IDP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IDP Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IDP Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"IDP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Eli Lilly"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Esteve Quimica","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Esteve Quimica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Esteve Quimica \/ Acorda Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Esteve Quimica \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laminar Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laminar Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inbiomotion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clodronic Acid Disodium Salt","moa":"Bone resorption factor","graph1":"Oncology","graph2":"Phase III","graph3":"Inbiomotion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inbiomotion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inbiomotion \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Protein Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Laboratorios HIPRA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios HIPRA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios HIPRA \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPAR-gamma","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sesderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sesderma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sesderma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sesderma \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncomatryx \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Vall d\u2019Hebr\u00f3n Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Vall d\u2019Hebr\u00f3n Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Vall d\u2019Hebr\u00f3n Hospital"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORY-4001","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oxolife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Tungstate","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Oxolife","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxolife \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxolife \/ Inapplicable"},{"orgOrder":0,"company":"Peptomyc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omomyc","moa":"Myc","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peptomyc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptomyc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Peptomyc \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Apices Soluciones"},{"orgOrder":0,"company":"Grifols International","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ National Institutes of Health"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PM534","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relutrigine","moa":"NaV sodium channel","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Praxis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BO-112","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Perflutren","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Praxis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Praxis Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Pulmobiotics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pulmobiotics Engineered Live Biotherapeutic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pulmobiotics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pulmobiotics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pulmobiotics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Archivel Farma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RUTI Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archivel Farma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Archivel Farma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Archivel Farma \/ Inapplicable"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SB-007","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpliceBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliceBio \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SOM3355","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SOM3355","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Synletis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SYL1801","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Synletis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Synletis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synletis \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Messenger RNA Based COVID Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Laboratorios HIPRA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios HIPRA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios HIPRA \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPAR-gamma","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IPR-179","moa":"MMP","graph1":"Neurology","graph2":"Discovery","graph3":"Accure Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Accure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Chondroitin Sulphate","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Sylentis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"SYL18001","moa":"Nrarp","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sylentis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sylentis \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPAR-gamma","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BO-112","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Abraxane","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"Guanine","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Lurbinectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leriglitazone","moa":"PPAR-gamma","graph1":"Neurology","graph2":"Phase II","graph3":"Minoryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Minoryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Minoryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laminar Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ IAVI"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SB-007","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SpliceBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliceBio \/ Inapplicable"},{"orgOrder":0,"company":"Veos Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"ThymoTropin","moa":"Myostatin","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Veos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veos Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Veos Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Relmada Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Relmada Therapeutics"},{"orgOrder":0,"company":"Iconovo","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Iconovo \/ Lonza Group","highestDevelopmentStatusID":"1","companyTruncated":"Iconovo \/ Lonza Group"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salipro Biotech \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Salipro Biotech \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Orexo","sponsor":"Abera Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Orexo \/ Abera Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"Orexo \/ Abera Bioscience"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ European Innovation Council","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ European Innovation Council"},{"orgOrder":0,"company":"Abliva","sponsor":"Pharming","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"KL1333","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Abliva","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Abliva \/ Pharming","highestDevelopmentStatusID":"8","companyTruncated":"Abliva \/ Pharming"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2025","type":"Acquisition","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xbrane Biopharma \/ Alvotech","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Alvotech"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"BAN1503","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":1.3500000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.3500000000000001,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"IRLAB","sponsor":"Formue Nord Fokus","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Formue Nord Fokus","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Formue Nord Fokus"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Veld Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Veld Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Veld Pharmaceuticals"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Vinnova","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Vinnova"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Cancer Research"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"Exidavnemab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ AbbVie Inc"},{"orgOrder":0,"company":"Abigo Medical AB","sponsor":"Essity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Dialkylcarbamoylchloride","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Abigo Medical AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abigo Medical AB \/ Essity","highestDevelopmentStatusID":"15","companyTruncated":"Abigo Medical AB \/ Essity"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Vinnova","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Oblique Therapeutics \/ Vinnova","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Therapeutics \/ Vinnova"},{"orgOrder":0,"company":"Anocca","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Anocca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anocca \/ European Investment Bank","highestDevelopmentStatusID":"4","companyTruncated":"Anocca \/ European Investment Bank"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Recipharm AB \/ Arcturus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Recipharm AB \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Beactica","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beactica \/ Dong-A ST Co., Ltd.","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/ Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Expanded Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"Tribune Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"CCN2","graph1":"Nephrology","graph2":"Preclinical","graph3":"Tribune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tribune Therapeutics \/ Healthcaps India","highestDevelopmentStatusID":"4","companyTruncated":"Tribune Therapeutics \/ Healthcaps India"},{"orgOrder":0,"company":"BioInvent","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"DS-1055","moa":"Anti-glycoprotein A repetitions predominant","graph1":"Oncology","graph2":"Phase I","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"BioInvent \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Lobsor Pharmaceuticals","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lobsor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lobsor Pharmaceuticals \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Lobsor Pharmaceuticals \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Jefferies LLC"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cantargia AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Immunology","graph2":"Preclinical","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"BioInvent \/ Cantargia AB","highestDevelopmentStatusID":"4","companyTruncated":"BioInvent \/ Cantargia AB"},{"orgOrder":0,"company":"Impilo Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Impilo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Impilo Therapeutics \/ Lisata Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Impilo Therapeutics \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Mendus","sponsor":"Minaris","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ Minaris","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Minaris"},{"orgOrder":0,"company":"Cellectricon","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cellectricon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectricon \/ Delix Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectricon \/ Delix Therapeutics"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Agnafit Bidco","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Efmoroctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Agnafit Bidco","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Agnafit Bidco"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Birinapant","moa":"||SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"Durvalumab","moa":"||5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center"},{"orgOrder":0,"company":"Iconovo","sponsor":"Immune System Regulation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Iconovo \/ Immune System Regulation","highestDevelopmentStatusID":"4","companyTruncated":"Iconovo \/ Immune System Regulation"},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"KKR","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Acquisition","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Immedica Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immedica Pharma \/ KKR","highestDevelopmentStatusID":"15","companyTruncated":"Immedica Pharma \/ KKR"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Everest Medicines"},{"orgOrder":0,"company":"Dilafor AB","sponsor":"Liverpool University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Tafoxiparin","moa":"Uterine contractility","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dilafor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dilafor AB \/ Liverpool University","highestDevelopmentStatusID":"4","companyTruncated":"Dilafor AB \/ Liverpool University"},{"orgOrder":0,"company":"Simris","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Simris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Simris \/ Lonza Group","highestDevelopmentStatusID":"2","companyTruncated":"Simris \/ Lonza Group"},{"orgOrder":0,"company":"Medivir","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Ubiquitin specific peptidase 7","graph1":"Oncology","graph2":"Preclinical","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medivir \/ Ubiquigent","highestDevelopmentStatusID":"4","companyTruncated":"Medivir \/ Ubiquigent"},{"orgOrder":0,"company":"Medivir","sponsor":"Hallberg Management AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Hallberg Management AB","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Hallberg Management AB"},{"orgOrder":0,"company":"Mendus","sponsor":"Flerie","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ Flerie","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Flerie"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Viatris"},{"orgOrder":0,"company":"OncoZenge","sponsor":"Baltic Sea Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"OncoZenge","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"OncoZenge \/ Baltic Sea Foundation","highestDevelopmentStatusID":"8","companyTruncated":"OncoZenge \/ Baltic Sea Foundation"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Oncternal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"ROR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karolinska Institutet \/ Oncternal Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Karolinska Institutet \/ Oncternal Therapeutics"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alligator Bioscience \/ Orion Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Alligator Bioscience \/ Orion Corporation"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ European Investment Bank","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ European Investment Bank"},{"orgOrder":0,"company":"Lidds","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Lidds \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Nice & Green"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Recipharm AB \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Recipharm AB \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"SAKK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ SAKK","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pharmaceutical \/ SAKK"},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"SB02024","moa":"Vps34","graph1":"Oncology","graph2":"Preclinical","graph3":"Sprint Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sprint Bioscience \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sprint Bioscience \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioInvent \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"BioInvent \/ Exelixis"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"BAN2802","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Eisai Inc","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Eisai Inc"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Medical AB \/ Protein Sciences Corporation"},{"orgOrder":0,"company":"Iconovo","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"RES030-085","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iconovo \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Iconovo \/ Undisclosed"},{"orgOrder":0,"company":"Iconovo","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Hormone","year":"2020","type":"Collaboration","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iconovo \/ Monash University","highestDevelopmentStatusID":"15","companyTruncated":"Iconovo \/ Monash University"},{"orgOrder":0,"company":"Medivir","sponsor":"Shijiazhuang Yuanmai Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Aciclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Medivir \/ Shijiazhuang Yuanmai Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Medivir \/ Shijiazhuang Yuanmai Biotechnology"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Professor Rikard Holmdahl","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"T20K","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Professor Rikard Holmdahl","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB \/ Professor Rikard Holmdahl"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"SciLifeLab","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"SARS CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SciLifeLab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"SciLifeLab \/ Medivir","highestDevelopmentStatusID":"2","companyTruncated":"SciLifeLab \/ Medivir"},{"orgOrder":0,"company":"Oncorena","sponsor":"Linc AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorena \/ Linc AB","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Linc AB"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Icosagen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salipro Biotech \/ Icosagen","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ Icosagen"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"XNK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Evencaleucel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Karolinska Development AB \/ XNK Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ XNK Therapeutics"},{"orgOrder":0,"company":"Ribocure Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Ribocure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Ribocure Pharmaceuticals \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Ribocure Pharmaceuticals \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ JDRF","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ JDRF"},{"orgOrder":0,"company":"Mendus","sponsor":"Australasian Leukaemia & Lymphoma Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Azacitidine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ Australasian Leukaemia & Lymphoma Group","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Australasian Leukaemia & Lymphoma Group"},{"orgOrder":0,"company":"Gabather","sponsor":"Centre for Neuropsychiatric Schizophrenia Research","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"GT-002","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salipro Biotech \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ Sanofi"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"DyNAbind","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salipro Biotech \/ DyNAbind","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ DyNAbind"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Zelluna Immunotherapy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karolinska Institutet \/ Zelluna Immunotherapy","highestDevelopmentStatusID":"4","companyTruncated":"Karolinska Institutet \/ Zelluna Immunotherapy"},{"orgOrder":0,"company":"Tikomed","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"LMW-Dextran Sulfate","moa":"TGF-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ IQVIA"},{"orgOrder":0,"company":"SmartCella","sponsor":"Fj\u00e4rde AP-fonden","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"PROC-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"SmartCella","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SmartCella \/ Fj\u00e4rde AP-fonden","highestDevelopmentStatusID":"4","companyTruncated":"SmartCella \/ Fj\u00e4rde AP-fonden"},{"orgOrder":0,"company":"Asgard Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"AT-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Asgard Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asgard Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Asgard Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Anocca","sponsor":"AMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Anocca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anocca \/ AMF","highestDevelopmentStatusID":"4","companyTruncated":"Anocca \/ AMF"},{"orgOrder":0,"company":"Asgard Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Asgard Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asgard Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Asgard Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Thioredoxin Systems","sponsor":"Mikael Lonn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Ebselen","moa":"||Glutathione peroxidase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Thioredoxin Systems","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thioredoxin Systems \/ Mikael Lonn","highestDevelopmentStatusID":"4","companyTruncated":"Thioredoxin Systems \/ Mikael Lonn"},{"orgOrder":0,"company":"Betagenon","sponsor":"Ivy Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"O304","moa":"PAN-AMPK","graph1":"Endocrinology","graph2":"Phase II","graph3":"Betagenon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Betagenon \/ Ivy Capital","highestDevelopmentStatusID":"8","companyTruncated":"Betagenon \/ Ivy Capital"},{"orgOrder":0,"company":"Amniotics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"PulmoStem","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Amniotics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amniotics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amniotics \/ Undisclosed"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Hadean Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"GS-248","moa":"mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gesynta Pharma \/ Hadean Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Pharma \/ Hadean Ventures"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Biotheus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alligator Bioscience \/ Biotheus","highestDevelopmentStatusID":"4","companyTruncated":"Alligator Bioscience \/ Biotheus"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Paladin Labs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Paladin Labs","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Paladin Labs"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Solasia Pharma KK","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Solasia Pharma KK"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ European Investment Bank","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ European Investment Bank"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"National Health Service (NHS)","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Efmoroctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ National Health Service (NHS)","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ National Health Service (NHS)"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Citigroup Global Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Citigroup Global Markets","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Citigroup Global Markets"},{"orgOrder":0,"company":"IRLAB","sponsor":"Fenja Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Fenja Capital","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Fenja Capital"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Recipharm AB \/ Bial","highestDevelopmentStatusID":"15","companyTruncated":"Recipharm AB \/ Bial"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affibody \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oblique Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Oblique Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"DiaUnion","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ DiaUnion","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ DiaUnion"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Oasmia Pharmaceutical \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"||IgG-mediated immune response","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Argenx","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Argenx"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Fourth Swedish National Pension Fund","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Linaprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cinclus Pharma \/ Fourth Swedish National Pension Fund","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Fourth Swedish National Pension Fund"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"5 Fluorouracil","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Alligator Bioscience \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ University of Pennsylvania"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Scandion Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Mitazalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Scandion Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Scandion Oncology"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sumitomo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salipro Biotech \/ Sumitomo","highestDevelopmentStatusID":"3","companyTruncated":"Salipro Biotech \/ Sumitomo"},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sensidose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"Sensidose \/ Navamedic"},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sensidose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"Sensidose \/ Navamedic"},{"orgOrder":0,"company":"Kemwell Biopharma Private Limited","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kemwell Biopharma Private Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Targovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"RAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oblique Therapeutics \/ Targovax","highestDevelopmentStatusID":"4","companyTruncated":"Oblique Therapeutics \/ Targovax"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alligator Bioscience \/ Orion Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Alligator Bioscience \/ Orion Corporation"},{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"BEA-17","moa":"LSD1-CoREST","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ Oscotec"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"VRK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sprint Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sprint Bioscience \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sprint Bioscience \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Vector Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Vector Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Vector Pharma"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Molnlycke Health Care AB \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"Molnlycke Health Care AB \/ MediWound"},{"orgOrder":0,"company":"Beactica","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"YAP\u2013TEAD","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beactica \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Abliva","sponsor":"Owl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"OWL-1410","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abliva \/ Owl Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Abliva \/ Owl Therapeutics"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Vector Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Vector Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Vector Pharma"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"BAN1503","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.3500000000000001,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"XNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XNK Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"XNK Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Cantrixil","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oasmia Pharmaceutical \/ Lonza Group","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pharmaceutical \/ Lonza Group"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xbrane Biopharma \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Biogen"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Elicera Therapeutics","sponsor":"Immunicum AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Ad5PTD","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elicera Therapeutics \/ Immunicum AB","highestDevelopmentStatusID":"4","companyTruncated":"Elicera Therapeutics \/ Immunicum AB"},{"orgOrder":0,"company":"AcuCort","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AcuCort","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"AcuCort \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"AcuCort \/ Kamada"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Oncode Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tasquinimod","moa":"S100A9","graph1":"Oncology","graph2":"Preclinical","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Active Biotech \/ Oncode Institute","highestDevelopmentStatusID":"4","companyTruncated":"Active Biotech \/ Oncode Institute"},{"orgOrder":0,"company":"Orexo","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Accord healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Orexo \/ Accord healthcare"},{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"LSD1 allosteric","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/ Oscotec"},{"orgOrder":0,"company":"Affibody","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affibody \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Affibody \/ Chiesi Group"},{"orgOrder":0,"company":"Aqilion","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Aqilion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aqilion \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Aqilion \/ Merck & Co"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Menarini"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Abliva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KL1333","moa":"NAD","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abliva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abliva \/ Inapplicable"},{"orgOrder":0,"company":"OxThera AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Oxalobacter Formigenes","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"OxThera AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OxThera AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OxThera AB \/ Inapplicable"},{"orgOrder":0,"company":"OxThera AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Oxalobacter Formigenes","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"OxThera AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OxThera AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OxThera AB \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC-0027875","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACD137","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACD440","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACD440","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACD440","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACD680","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VP01","moa":"Angiotensin II receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"VU University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ VU University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ VU University Medical Center"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Aptevo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Aptevo Therapeutics"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Icon Plc"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HLX22","moa":"||HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mitazalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hamlet Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Alpha1H","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hamlet Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"Hamlet Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hamlet Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftrenonacog Alpha","moa":"Coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACD137","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AnaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnaMar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Inapplicable"},{"orgOrder":0,"company":"AnaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AM1476","moa":"5-HT2B receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnaMar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABA-A receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Umecrine Cognition \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Anocca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ANOC-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anocca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anocca \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Anocca \/ Inapplicable"},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Annexin A5","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Annexin A5","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oasmia Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Atrogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATR-258","moa":"Insulin signaling","graph1":"Endocrinology","graph2":"Phase I","graph3":"Atrogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atrogi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atrogi \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATX-304","moa":"PAN-AMPK","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Amplifier Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifier Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Amplifier Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATX-304","moa":"PAN-AMPK","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Amplifier Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifier Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amplifier Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Beactica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEA-17","moa":"LSD1-CoREST","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beactica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BI-1607","moa":"||FcyRIIB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNFR2 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Biosergen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BSG005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Biosergen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosergen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosergen \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CAS 138564-60-0","moa":"Angiotensin II receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"NZ-TLR9","moa":"TLR9","graph1":"Oncology","graph2":"Preclinical","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"CombiGene","sponsor":"Cobra Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CG01","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"CombiGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CombiGene \/ Cobra Biologics","highestDevelopmentStatusID":"4","companyTruncated":"CombiGene \/ Cobra Biologics"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xbrane Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Xbrane Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AP1189","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynAct Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SynAct Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Birinapant","moa":"||SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isoflurane","moa":"Glycine receptor positive","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedana Medical \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"HDAC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cereno Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oasmia Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Dicot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LIB-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dicot","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dicot \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dicot \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Elicera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ELC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elicera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Emplicure","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Emplicure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emplicure \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Emplicure \/ Quotient Sciences"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitisinone","moa":"HPDD","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Evencaleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"XNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XNK Therapeutics \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"XNK Therapeutics \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Evencaleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"XNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"XNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganirelix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GS-248","moa":"mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gesynta Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Setanaxib","moa":"||NOX1","graph1":"Oncology","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"||NOX1","graph1":"Oncology","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Setanaxib","moa":"||NOX1","graph1":"Oncology","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABA-A receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karolinska Development AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Inapplicable"},{"orgOrder":0,"company":"Gabather","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-002","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gabather \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HNSA-5487","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HNSA-5487","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iconovo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iconovo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iconovo \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Imlifidase","moa":"||IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Medison Pharma"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Tikomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LMW-Dextran Sulfate","moa":"TGF-beta","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Activated Allogeneic Dendritic Cell","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"ILYA Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Emilimogene Sigulactibac","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILYA Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"ILYA Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILYA Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Impilo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Impilo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Impilo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Impilo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Hellenic Institute for the Study of Sepsis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Activated Allogeneic Dendritic Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"5-Azacytidine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Dizlin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dizlin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dizlin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dizlin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1015","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IRL1117","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Integrative Research Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Integrative Research Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Integrative Research Laboratories"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Kancera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KAND567","moa":"Fractalkine receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Kancera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kancera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kancera \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Abliva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KL1333","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Abliva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abliva \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Acetate","moa":"Carbonic anhydrase 1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MIV-711","moa":"Cathepsin-K","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Quotient Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Quotient Sciences"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Modus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevuparin","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Modus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Modus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Everest Medicines"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncorena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorena \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"OPD5","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncorena","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorena \/ Karolinska University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1 beta\/IL-6\/IL-8\/TNF-alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Promore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CS585","moa":"Prostacyclin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"Cereno Scientific \/ University of Michigan"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"S100A9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncorena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorena \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1 beta\/IL-6\/IL-8\/TNF-alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Promore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mitazalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ty1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Institutet \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Karolinska Institutet \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karolinska Development AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Inapplicable"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABA-A receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karolinska Development AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Eurocine Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-Based HSV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eurocine Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurocine Vaccines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eurocine Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isoflurane","moa":"Glycine receptor positive","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isoflurane","moa":"Glycine receptor positive","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isoflurane","moa":"Glycine receptor positive","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sigrid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Synthetic Amorphous Silicon Dioxide","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sigrid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"Sigrid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sigrid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"||Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1015","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABA-A receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karolinska Development AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Inapplicable"},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Ume\u00e5 University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ume\u00e5 University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ume\u00e5 University \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ume\u00e5 University \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"||S100A9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"S100A9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Orphan Reach"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AD1503","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"XNK03","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"XNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"XNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Neogap","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogap","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neogap \/ Karolinska University Hospital","highestDevelopmentStatusID":"5","companyTruncated":"Neogap \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BI 1029539","moa":"Microsomal prostaglandin E synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Gesynta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gesynta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gesynta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Activated Allogeneic Dendritic Cell","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1 beta\/IL-6\/IL-8\/TNF-alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Promore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Pergamum AB","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1 beta\/IL-6\/IL-8\/TNF-alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Promore Pharma \/ Pergamum AB","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Pergamum AB"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AP1189","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SynAct Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Tikomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LMW-Dextran Sulfate","moa":"MMP","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leucovorin","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Emeriti Bio","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CAS 138564-60-0","moa":"Angiotensin II receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vicore Pharma \/ Emeriti Bio","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pharma \/ Emeriti Bio"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ALZ-201","moa":"Amyloid-beta 42 aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ropocamptide","moa":"Keratinocyte","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Cutaneous Injection","sponsorNew":"Promore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Medivir","sponsor":"Rheos Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MALT1","graph1":"Oncology","graph2":"Preclinical","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medivir \/ Rheos Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Medivir \/ Rheos Medicines"},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arfolitixorin","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Medical \/ Inapplicable"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PD-BT2238","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegadricase","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001V","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Braeburn","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Braeburn","highestDevelopmentStatusID":"15","companyTruncated":"Camurus \/ Braeburn"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Transgene"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tafoxiparin","moa":"Uterine contractility","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Karolinska Development AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC-0027875","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1015","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"S100A9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Amniotics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PulmoStem","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Amniotics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amniotics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amniotics \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remetinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tafoxiparin","moa":"Uterine contractility","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Karolinska Development AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska Development AB \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ilixadencel","moa":"||CTLA-4","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SB02024","moa":"Vps34","graph1":"Oncology","graph2":"Preclinical","graph3":"Sprint Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sprint Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sprint Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mitazalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isoflurane","moa":"Glycine receptor positive","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"NZ-TLR9","moa":"TLR9","graph1":"Oncology","graph2":"Preclinical","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1015","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VP01","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC-0027838","moa":"TrkA receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MIV-711","moa":"Cathepsin-K","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Erdosteine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recipharm AB \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Recipharm AB \/ Inapplicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SN132D","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNFR2 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNFR2 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"||GABA receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isoflurane","moa":"Glycine receptor positive","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NOX1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"ISR","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Corona Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ISR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISR \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ISR \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AlzeCure Pharma AB \/ Inapplicable"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Xbrane Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xbrane Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Tikomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LMW-Dextran Sulfate","moa":"TGF-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troxacitabine","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rabeximod","moa":"TNF","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Tango Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"USP1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medivir \/ Tango Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Medivir \/ Tango Therapeutics"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu SN201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spago Nanomedical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nanomedical \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medivir \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Inapplicable"},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Golexanolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Umecrine Cognition \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Oblique Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VP01","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"T20K","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II receptor type 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Evencaleucel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"XNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XNK Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"XNK Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase I","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xspray Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pirepemat","moa":"5-HT7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"BioArctic AB \/ Eisai"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Emapalumab","moa":"INF-gamma","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IgG-mediated immune response","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"Aqilion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TAK1","graph1":"Immunology","graph2":"Discovery","graph3":"Aqilion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqilion \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Aqilion \/ Inapplicable"},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Exidavnemab","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"BioArctic AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioArctic AB \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"BI-1808","moa":"||TNFR2 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Inapplicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/33\/36","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cantargia AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Oncorena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Orellanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorena \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"Celonic","sponsor":"LINDIS Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Catumaxomab","moa":"EpCAM\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Celonic \/ LINDIS Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Celonic \/ LINDIS Biotech"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Avir Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Avir Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Avir Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Tadekinig Alpha","moa":"IL-18","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AB2 Bio","amount2":0.68999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.68999999999999995,"dosageForm":"Subcutaneous Injection","sponsorNew":"AB2 Bio \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Esteve Quimica","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Netupitant","moa":"||NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Esteve Quimica","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Esteve Quimica"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.23000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Cenerimod","moa":"S1P1R","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Suspension","sponsorNew":"Idorsia Pharmaceuticals \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Clinigen Group"},{"orgOrder":0,"company":"Oculis","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Neurology","graph2":"Phase II","graph3":"Oculis","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Oculis \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ BofA Securities"},{"orgOrder":0,"company":"Windward Bio","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series A Financing","leadProduct":"HBM-9378","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Windward Bio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Windward Bio \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Windward Bio \/ OrbiMed"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ EQT Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ EQT Life Sciences"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"LBT-SA7","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"LimmaTech Biologics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"LimmaTech Biologics \/ CARB-X","highestDevelopmentStatusID":"6","companyTruncated":"LimmaTech Biologics \/ CARB-X"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"BAL2420","moa":"LptA","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Pharmaceutica \/ CARB-X"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ EQT Life Sciences"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series C Financing","leadProduct":"NM26-2198","moa":"IL-4R alpha\/IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Cormorant Asset Management"},{"orgOrder":0,"company":"TargImmune Therapeutics","sponsor":"iOncologi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2025","type":"Acquisition","leadProduct":"TAR001","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"TargImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TargImmune Therapeutics \/ iOncologi","highestDevelopmentStatusID":"4","companyTruncated":"TargImmune Therapeutics \/ iOncologi"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":1.1399999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.1399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Araris Biotech \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0.78000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.78000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Araris Biotech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Debiopharm","sponsor":"GARDP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2025","type":"Agreement","leadProduct":"Debio 1453","moa":"FabI","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ GARDP","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ GARDP"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurimmune \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Neurimmune \/ Biogen"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Selatogrel","moa":"P2Y12R","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Selatogrel","moa":"P2Y12R","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Juvise Pharmaceuticals"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sandoz B2B \/ Aspen Pharmacare Holdings","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Aspen Pharmacare Holdings"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Almirall"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"GENESIS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ GENESIS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ GENESIS Pharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ASTE","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ASTE","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ASTE"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"USV Private Limited","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Vildagliptin","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ USV Private Limited","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ USV Private Limited"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Allarity Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Allarity Therapeutics"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"HTX-001","moa":"IncRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"HAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAYA Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"4","companyTruncated":"HAYA Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Sickle Cell Disease Association of America","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Sickle Cell Disease Association of America","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Sickle Cell Disease Association of America"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Aruvant Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Aruvant Sciences"},{"orgOrder":0,"company":"BaseLaunch","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Immunology","graph2":"Phase II","graph3":"BaseLaunch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BaseLaunch \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BaseLaunch \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Olamkicept","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ferring Pharmaceuticals \/ I-Mab Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ I-Mab Biopharma"},{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Versameb \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Undisclosed"},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"OT-58","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orphan Technologies \/ Travere Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Technologies \/ Travere Therapeutics"},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"OT-58","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orphan Technologies \/ Travere Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Technologies \/ Travere Therapeutics"},{"orgOrder":0,"company":"EspeRare","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"ER-004","moa":"EDA1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"EspeRare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"EspeRare \/ Pierre Fabre","highestDevelopmentStatusID":"8","companyTruncated":"EspeRare \/ Pierre Fabre"},{"orgOrder":0,"company":"Genfa Medica","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Genfa Medica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Genfa Medica \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"Genfa Medica \/ MediWound"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fexinidazole","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"World Health Organization \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"World Health Organization \/ Sanofi"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Abicipar Pegol","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Molecular Partners \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ AbbVie Inc"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"Acino Pharma","sponsor":"Allecra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Acino Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acino Pharma \/ Allecra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acino Pharma \/ Allecra Therapeutics"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amino Acids Mixture","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule, Controlled Release","sponsorNew":"APR Applied Pharma Research \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"APR Applied Pharma Research \/ Relief Therapeutics"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Amring Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Amring Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Amring Pharma"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Canadian Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Canadian Government","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Canadian Government"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Group \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Armistice Master Fund"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Licensing Agreement","leadProduct":"Elocalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffmann-La Roche \/ Adge Pharmaceuticals"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Helsinn Advanced Synthesis \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Oberland Capital Management"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Controlled Release","sponsorNew":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"Lausanne University Hospital","sponsor":"Prokarium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"Salmonella Typhi Ty21a","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lausanne University Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Lausanne University Hospital \/ Prokarium","highestDevelopmentStatusID":"4","companyTruncated":"Lausanne University Hospital \/ Prokarium"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Immedica Pharma"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Morningside Venture","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Morningside Venture"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Altimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Lonza Group \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Altimmune"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"AMP-100","moa":"Sodium channel","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"SINTETICA SA \/ Harrow","highestDevelopmentStatusID":"10","companyTruncated":"SINTETICA SA \/ Harrow"},{"orgOrder":0,"company":"COVAX Advance Market Commitment","sponsor":"Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"COVAX Advance Market Commitment","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"COVAX Advance Market Commitment \/ Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"COVAX Advance Market Commitment \/ Gates Foundation"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Oxiconazole Nitrate","moa":"Ergosterol biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Sandoz B2B \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Araris Biotech \/ Innosuisse","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ Innosuisse"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ypsomed \/ Viridian Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ypsomed \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ajinomoto Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Peak Therapeutics \/ Ajinomoto Bio-Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ajinomoto Bio-Pharma"},{"orgOrder":0,"company":"Liechti Lab","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Liechti Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Liechti Lab \/ Mind Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Liechti Lab \/ Mind Medicine"},{"orgOrder":0,"company":"Om Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"OM-85","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Om Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Om Pharma \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Om Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"SixPeaks Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SixPeaks Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SixPeaks Bio \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"SixPeaks Bio \/ AstraZeneca"},{"orgOrder":0,"company":"Polyphor","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Murepavadin","moa":"Imp protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Polyphor \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Polyphor \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Polyphor","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Thanatin-Derivative Antibiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyphor \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Polyphor \/ CARB-X"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"BAL0891","moa":"Checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ SillaJen, Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Celonic","sponsor":"Airway Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Zelpultide Alpha","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celonic \/ Airway Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Celonic \/ Airway Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Gavi","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gavi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gavi \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Gavi \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ AMR Action Fund","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ AMR Action Fund"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"BPT-143","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ RA Capital","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ RA Capital"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD25","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery"},{"orgOrder":0,"company":"EpiPharm","sponsor":"CalciMedica","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"CM5480","moa":"CARC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"EpiPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiPharm \/ CalciMedica","highestDevelopmentStatusID":"4","companyTruncated":"EpiPharm \/ CalciMedica"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Capricor Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Capricor Therapeutics"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ferring Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Lonza Group","sponsor":"CellPoint","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lonza Group \/ CellPoint","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ CellPoint"},{"orgOrder":0,"company":"Celonic","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Celonic \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Celonic \/ CureVac"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ADX10061","moa":"D1 receptor","graph1":"Neurology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addex Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"2","companyTruncated":"Addex Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Zilebesiran","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Civica Rx","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Partnership","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Ypsomed \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Ypsomed \/ Civica Rx"},{"orgOrder":0,"company":"InfoRLife SA","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Clindamycin Hydrochloride","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InfoRLife SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InfoRLife SA \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"InfoRLife SA \/ Navamedic"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Immunomedics","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Immunomedics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Group \/ Humanigen"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"Endogenous T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Triumvira Immunologics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BioNTech"},{"orgOrder":0,"company":"Optifye Therapeutics","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Optifye Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optifye Therapeutics \/ DelSiTech","highestDevelopmentStatusID":"4","companyTruncated":"Optifye Therapeutics \/ DelSiTech"},{"orgOrder":0,"company":"Celonic","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Celonic \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"Celonic \/ Intravacc"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CSL"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Curon Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tenalisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Curon Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Rhizen Pharmaceuticals \/ Curon Biopharmaceutical"},{"orgOrder":0,"company":"EpiPharm","sponsor":"CycloLab Cyclodextrin Research and Development Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"EpiPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EpiPharm \/ CycloLab Cyclodextrin Research and Development Laboratory","highestDevelopmentStatusID":"4","companyTruncated":"EpiPharm \/ CycloLab Cyclodextrin Research and Development Laboratory"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Whitelab Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Debiopharm \/ Whitelab Genomics","highestDevelopmentStatusID":"3","companyTruncated":"Debiopharm \/ Whitelab Genomics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Debio 1453","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ CARB-X"},{"orgOrder":0,"company":"Debiopharm","sponsor":"WhiteLab Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Debiopharm \/ WhiteLab Genomics","highestDevelopmentStatusID":"3","companyTruncated":"Debiopharm \/ WhiteLab Genomics"},{"orgOrder":0,"company":"Lausanne University Hospital","sponsor":"Prokarium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lausanne University Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lausanne University Hospital \/ Prokarium","highestDevelopmentStatusID":"4","companyTruncated":"Lausanne University Hospital \/ Prokarium"},{"orgOrder":0,"company":"Drugs for Neglected Diseases initiative","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"LXE408","moa":"Proteasome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Drugs for Neglected Diseases initiative","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Drugs for Neglected Diseases initiative \/ Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"Drugs for Neglected Diseases initiative \/ Wellcome Trust"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Cenegermin","moa":"TrkA receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"FarmaMondo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"FarmaMondo \/ Dompe Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"FarmaMondo \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"ObsEva","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Organon","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Organon"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Diurnal Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"EffRx Pharmaceuticals \/ Diurnal Group","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Diurnal Group"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"Adrenergic receptor-alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Essential Pharma"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics"},{"orgOrder":0,"company":"itheranostics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"FAPI-46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"itheranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"itheranostics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"itheranostics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BioNTech"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Sofinnova Partners","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Sofinnova Partners"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Kurma Partners","highestDevelopmentStatusID":"4","companyTruncated":"Synendos Therapeutics \/ Kurma Partners"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Arvelle Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ Angelini Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Pharmaceutica \/ CARB-X"},{"orgOrder":0,"company":"GeNeuro","sponsor":"Swiss Federal Office of Public Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"Temelimab","moa":"HERV-W","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GeNeuro \/ Swiss Federal Office of Public Health","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ Swiss Federal Office of Public Health"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"HTX-001","moa":"IncRNA","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"HAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAYA Therapeutics \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"HAYA Therapeutics \/ Broadview Ventures"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Helsinn Advanced Synthesis \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Kyowa Kirin"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Juniper Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Juniper Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Juniper Biologics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Nepafenac","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension\/Drops","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Harrow"},{"orgOrder":0,"company":"Medlight SA","sponsor":"Rakuten Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Acquisition","leadProduct":"Cetuximab Sarotalocan","moa":"ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Medlight SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medlight SA \/ Rakuten Medical","highestDevelopmentStatusID":"10","companyTruncated":"Medlight SA \/ Rakuten Medical"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Idebenone","moa":"Cytochrome P450 2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NI504","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurimmune \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Neurimmune \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"INDV-1000","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Ionctura","sponsor":"European Investment Council","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ European Investment Council","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ European Investment Council"},{"orgOrder":0,"company":"Ionctura","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ INKEF Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ INKEF Capital"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Astellas Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"177-Lu DPI-4452","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Isotope Technologies Munich","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Beyond Batten Disease Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Miglustat","moa":"||Glucosylceramide synthase","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Beyond Batten Disease Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Beyond Batten Disease Foundation"},{"orgOrder":0,"company":"Curatis","sponsor":"Great Health Companion Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curatis \/ Great Health Companion Group","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Great Health Companion Group"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Knight Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"FAZ053","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Laekna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Laekna Therapeutics"},{"orgOrder":0,"company":"KeyBioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"LY3541105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"KeyBioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KeyBioscience \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"KeyBioscience \/ Eli Lilly"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Xortx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lonza Group \/ Xortx Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Xortx Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Surrozen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Wnt signalling pathway","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Surrozen","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Surrozen"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Pionyr Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"PY265","moa":"MARCO receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Pionyr Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Pionyr Immunotherapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Group \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Group","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Group \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ AstraZeneca"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Immunitas Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Immunitas Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Immunitas Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"LamKap Bio Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"NILK-2301","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ LamKap Bio Group","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ LamKap Bio Group"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Naporafenib","moa":"Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Erasca","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Erasca"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Matterhorn Biosciences","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Matterhorn Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matterhorn Biosciences \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Matterhorn Biosciences \/ Versant Ventures"},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University Hospital Basel","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Basel \/ Mind Medicine"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Mitem Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Group \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Moderna Therapeutics"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"||IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Helix BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Helix BioPharma"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ J.P. Morgan"},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Hospital Basel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Basel \/ Mind Medicine"},{"orgOrder":0,"company":"NBE-Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"NBE-002","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"NBE-Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NBE-Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"NBE-Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Bioiberica","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Bioiberica"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Angelini Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Series C Financing","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ Angelini Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Angelini Ventures"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ACT-709478","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Novaremed","sponsor":"NeuroFront Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ NeuroFront Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ NeuroFront Therapeutics"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"Transthyretin amyloid","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ BVF Partners"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Laidlaw & Company","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Laidlaw & Company"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Nodus Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"PARG","graph1":"Oncology","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Nodus Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Pharmaceutica \/ Nodus Oncology"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"MSD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"MVA-209-FSP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ MSD"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"CALY-002","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Novocure","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/ Merck & Co"},{"orgOrder":0,"company":"ObsEva","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Theramex"},{"orgOrder":0,"company":"Octapharma","sponsor":"Norton Heart & Vascular Institute in Louisvill","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Norton Heart & Vascular Institute in Louisvill","highestDevelopmentStatusID":"1","companyTruncated":"Octapharma \/ Norton Heart & Vascular Institute in Louisvill"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Licaminlimab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"BBA\/\/Fjeldco","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Licaminlimab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ BBA\/\/Fjeldco","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ BBA\/\/Fjeldco"},{"orgOrder":0,"company":"Oculis","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Public Offering","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ BofA Securities"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"NM49","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Numab Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Owkin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"OKN4395","moa":"EP2\/4","graph1":"Oncology","graph2":"Preclinical","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Owkin","highestDevelopmentStatusID":"4","companyTruncated":"Idorsia Pharmaceuticals \/ Owkin"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Pharvaris","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ General Atlantic","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ General Atlantic"},{"orgOrder":0,"company":"PolyPeptide Group","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PolyPeptide Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PolyPeptide Group \/ Novavax","highestDevelopmentStatusID":"6","companyTruncated":"PolyPeptide Group \/ Novavax"},{"orgOrder":0,"company":"CDR Life","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Series A Financing","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Jeito Capital"},{"orgOrder":0,"company":"Engimmune Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Engimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Engimmune Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"2","companyTruncated":"Engimmune Therapeutics \/ Pureos Bioventures"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"4BIO Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Araris Biotech \/ 4BIO Capital","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ 4BIO Capital"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Helix BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ Helix BioPharma"},{"orgOrder":0,"company":"Oculis","sponsor":"BVCF Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Series C Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ BVCF Management","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ BVCF Management"},{"orgOrder":0,"company":"Anaveon","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Forbion"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"VectivBio","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Surveyor Capital"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"NM21-1480","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Numab Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Stalicla","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ SPRIM Global investments","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ SPRIM Global investments"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Agreement","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Lonza Group \/ Kodiak Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Group \/ Kodiak Sciences"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ BVF Partners"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GeNeuro","sponsor":"Northwestern University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Temelimab","moa":"HERV-W","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GeNeuro \/ Northwestern University","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ Northwestern University"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"4D-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ 4D Molecular Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ 4D Molecular Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Celleron","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Emactuzumab","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Celleron","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Celleron"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Civica Rx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Pantoprazole Sodium","moa":"H\/K ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sandoz B2B \/ Civica Rx","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Civica Rx"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Idorsia Pharmaceuticals \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"CSHL","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Lonodelestat","moa":"Human neutrophil elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santhera Pharmaceuticals \/ CSHL","highestDevelopmentStatusID":"1","companyTruncated":"Santhera Pharmaceuticals \/ CSHL"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Brinzolamide","moa":"||CA2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alcon Inc"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Vetter Pharma-Fertigung GmbH & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Vetter Pharma-Fertigung GmbH & Co","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Vetter Pharma-Fertigung GmbH & Co"},{"orgOrder":0,"company":"Quercis Pharma","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Isoquercitrin","moa":"sP-selectin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quercis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quercis Pharma \/ FDA","highestDevelopmentStatusID":"10","companyTruncated":"Quercis Pharma \/ FDA"},{"orgOrder":0,"company":"Stalicla","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Firefly Neuroscience","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Firefly Neuroscience"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Medicines Patent Pool \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Undisclosed"},{"orgOrder":0,"company":"GeNeuro","sponsor":"Bryan, Garnier & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"Temelimab","moa":"HERV-W","graph1":"Neurology","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeNeuro \/ Bryan, Garnier & Co","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ Bryan, Garnier & Co"},{"orgOrder":0,"company":"Debiopharm","sponsor":"SunRock Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SRB19","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ SunRock Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ SunRock Biopharma"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Swiss Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Swiss Government","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Swiss Government"},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"T3P-Y058-739","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"T3 Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"T3 Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"T3 Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Galderma","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"MIJ821","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"PFL-002","moa":"c-Met receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Pierre Fabre"},{"orgOrder":0,"company":"Arctos Medical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Arctos Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Arctos Medical \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Arctos Medical \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"NM26-2198","moa":"IL-4R alpha\/IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Yellow Jersey Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"NM26-2198","moa":"IL-4R alpha\/IL-31","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Yellow Jersey Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yellow Jersey Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Yellow Jersey Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Chugai Pharma Europe","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Netupitant","moa":"||NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Medicines Patent Pool \/ Strides Pharma Science","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Strides Pharma Science"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"BAL0891","moa":"Checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ SillaJen, Inc"},{"orgOrder":0,"company":"Curatis","sponsor":"ChaoDian","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curatis \/ ChaoDian","highestDevelopmentStatusID":"6","companyTruncated":"Curatis \/ ChaoDian"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ Anthos Therapeutics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Debiopharm \/ Knight Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Spexis","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"POL7306","moa":"LPS transport pathway","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spexis \/ CARB-X","highestDevelopmentStatusID":"2","companyTruncated":"Spexis \/ CARB-X"},{"orgOrder":0,"company":"Mysthera Therapeutics","sponsor":"Forty51 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Mysthera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mysthera Therapeutics \/ Forty51 Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mysthera Therapeutics \/ Forty51 Ventures"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"SHL Medical AG","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Adalimumab","moa":"||IL-17A\/F","graph1":"Immunology","graph2":"Phase II","graph3":"SHL Medical AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SHL Medical AG \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SHL Medical AG \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"Athebio","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Athebio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athebio \/ Point Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Athebio \/ Point Biopharma"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ND081","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"GRC 54276","moa":"||HPK1","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"AC Immune","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"ACI3024","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AC Immune \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"AC Immune \/ Eli Lilly"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"2","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Pierre Fabre"},{"orgOrder":0,"company":"Lonza Group","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lonza Group \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ ABL Bio"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"DARPin-RLTs","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Numab Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Numab Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Alpibectir","moa":"||Transcription factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Cristal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lonza Group \/ Cristal Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Group \/ Cristal Therapeutics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Debiopharm \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Edesa Biotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"NI-0101","moa":"TLR4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Light Chain Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Light Chain Bioscience \/ Edesa Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Light Chain Bioscience \/ Edesa Biotech"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chord Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"GliaPharm","sponsor":"Wyss Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"GliaPharm","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GliaPharm \/ Wyss Center","highestDevelopmentStatusID":"3","companyTruncated":"GliaPharm \/ Wyss Center"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"CAD-9303","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Cowen"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GIBF2","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GIBF2","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GIBF2"},{"orgOrder":0,"company":"Neovii","sponsor":"Tel Aviv University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neovii \/ Tel Aviv University","highestDevelopmentStatusID":"1","companyTruncated":"Neovii \/ Tel Aviv University"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lonza Group \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Group \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Ramucirumab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Eli Lilly"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Series A Financing","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvelle Therapeutics \/ NovaQuest Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"R-Bridge","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Financing","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ R-Bridge","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ R-Bridge"},{"orgOrder":0,"company":"Release Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Release Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Release Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Release Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"LBT-SA7","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LimmaTech Biologics \/ Adjuvant Capital","highestDevelopmentStatusID":"5","companyTruncated":"LimmaTech Biologics \/ Adjuvant Capital"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2020","type":"Series A Financing","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chord Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"1","companyTruncated":"Chord Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"Ionctura","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Syncona Limited","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Syncona Limited"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Financing","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spexis \/ SPRIM Global investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global investments"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Owl Rock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Owl Rock","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Owl Rock"},{"orgOrder":0,"company":"Virometix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"V-306","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virometix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virometix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Virometix \/ Undisclosed"},{"orgOrder":0,"company":"Neurosterix","sponsor":"Perceptive Xontogeny Venture Fund II","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neurosterix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurosterix \/ Perceptive Xontogeny Venture Fund II","highestDevelopmentStatusID":"4","companyTruncated":"Neurosterix \/ Perceptive Xontogeny Venture Fund II"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Series C Financing","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Series D Financing","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Deerfield Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Deerfield Partners","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Deerfield Partners"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Tolremo therapeutics","sponsor":"Pierre Fabre Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"TT125-802","moa":"CBP\/p300 bromodomain","graph1":"Oncology","graph2":"Preclinical","graph3":"Tolremo therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tolremo therapeutics \/ Pierre Fabre Invest","highestDevelopmentStatusID":"4","companyTruncated":"Tolremo therapeutics \/ Pierre Fabre Invest"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"SWK Funding LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relief Therapeutics \/ SWK Funding LLC","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ SWK Funding LLC"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"SWK Funding LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relief Therapeutics \/ SWK Funding LLC","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ SWK Funding LLC"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Naason Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Naason Science","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Naason Science"},{"orgOrder":0,"company":"Debiopharm","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Debio 1453","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm \/ CARB-X"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Funding","leadProduct":"OCi mAb","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunOs Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"ImmunOs Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Asceneuron","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ASN51","moa":"OGA","graph1":"Neurology","graph2":"Phase II","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asceneuron \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Asceneuron \/ EQT Life Sciences"},{"orgOrder":0,"company":"NBE-Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Series C Financing","leadProduct":"NBE-002","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"NBE-Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NBE-Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"NBE-Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Somagenetix","sponsor":"Vi Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"SGX-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Somagenetix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Somagenetix \/ Vi Partners","highestDevelopmentStatusID":"4","companyTruncated":"Somagenetix \/ Vi Partners"},{"orgOrder":0,"company":"Ionctura","sponsor":"Health Holland","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"IOA-359","moa":"TGF-beta","graph1":"Oncology","graph2":"Preclinical","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Health Holland","highestDevelopmentStatusID":"4","companyTruncated":"Ionctura \/ Health Holland"},{"orgOrder":0,"company":"Asceneuron","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"ASN51","moa":"OGA","graph1":"Neurology","graph2":"Preclinical","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asceneuron \/ The Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Asceneuron \/ The Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Financing","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"DiNAQOR AG","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"DiNA-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DiNAQOR AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiNAQOR AG \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"DiNAQOR AG \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Light Chain Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Light Chain Bioscience \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Light Chain Bioscience \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Private Placement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Financing","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Vandria","sponsor":"ND Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"VNA-318","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vandria \/ ND Capital","highestDevelopmentStatusID":"6","companyTruncated":"Vandria \/ ND Capital"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Samsung Venture Investment Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Araris Biotech \/ Samsung Venture Investment Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Araris Biotech \/ Samsung Venture Investment Corporation"},{"orgOrder":0,"company":"SEAL Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Laminin-alpha 2 protein","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SEAL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SEAL Therapeutics \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"SEAL Therapeutics \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Series C Financing","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Ysios Capital"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"S4V","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LimmaTech Biologics \/ Valneva","highestDevelopmentStatusID":"8","companyTruncated":"LimmaTech Biologics \/ Valneva"},{"orgOrder":0,"company":"MindShift Compounds","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MindShift Compounds","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"MindShift Compounds \/ Mind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"MindShift Compounds \/ Mind Medicine"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Governemnt of Mexico","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"World Health Organization \/ Governemnt of Mexico","highestDevelopmentStatusID":"1","companyTruncated":"World Health Organization \/ Governemnt of Mexico"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Oncolytics Biotech","highestDevelopmentStatusID":"1","companyTruncated":"F. Hoffmann-La Roche \/ Oncolytics Biotech"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"SOLTI Innovative Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ SOLTI Innovative Cancer Research","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ SOLTI Innovative Cancer Research"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Charcot Marie Tooth Association","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Charcot Marie Tooth Association","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Charcot Marie Tooth Association"},{"orgOrder":0,"company":"Oculis","sponsor":"European Biotech Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Merger","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ European Biotech Acquisition Corp","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ European Biotech Acquisition Corp"},{"orgOrder":0,"company":"Anjarium Biosciences","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Anjarium Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anjarium Biosciences \/ Abingworth","highestDevelopmentStatusID":"1","companyTruncated":"Anjarium Biosciences \/ Abingworth"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Financing","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Series C Financing","leadProduct":"BPT567","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharvaris \/ Viking Global Investors","highestDevelopmentStatusID":"6","companyTruncated":"Pharvaris \/ Viking Global Investors"},{"orgOrder":0,"company":"Novaremed","sponsor":"GEM Global Yield","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ GEM Global Yield","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ GEM Global Yield"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swisscanto","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"MTX-COVAB","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memo Therapeutics \/ Swisscanto","highestDevelopmentStatusID":"8","companyTruncated":"Memo Therapeutics \/ Swisscanto"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Forbion","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Forbion"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"LMTB Gonococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LimmaTech Biologics \/ Adjuvant Capital","highestDevelopmentStatusID":"4","companyTruncated":"LimmaTech Biologics \/ Adjuvant Capital"},{"orgOrder":0,"company":"Novocure","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2024","type":"Financing","leadProduct":"Gemcitabine","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Pharmakon Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Pharmakon Advisors"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swisscanto","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"MTX-005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Swisscanto","highestDevelopmentStatusID":"6","companyTruncated":"Memo Therapeutics \/ Swisscanto"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Series C Financing","leadProduct":"MVA-209-FSP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ Andera Partners","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ Andera Partners"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"FMRP","graph1":"Oncology","graph2":"Discovery","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Opna Bio \/ Longitude Capital","highestDevelopmentStatusID":"2","companyTruncated":"Opna Bio \/ Longitude Capital"},{"orgOrder":0,"company":"SixPeaks Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SixPeaks Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SixPeaks Bio \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"SixPeaks Bio \/ Versant Ventures"},{"orgOrder":0,"company":"GlycoEra","sponsor":"5AM Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GlycoEra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GlycoEra \/ 5AM Ventures","highestDevelopmentStatusID":"3","companyTruncated":"GlycoEra \/ 5AM Ventures"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"CF AMR Syndicate","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"BV500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioVersys AG \/ CF AMR Syndicate","highestDevelopmentStatusID":"2","companyTruncated":"BioVersys AG \/ CF AMR Syndicate"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Japanese Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"World Health Organization \/ Japanese Government","highestDevelopmentStatusID":"1","companyTruncated":"World Health Organization \/ Japanese Government"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swiss Federal Funding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"Covab 36","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Memo Therapeutics \/ Swiss Federal Funding","highestDevelopmentStatusID":"4","companyTruncated":"Memo Therapeutics \/ Swiss Federal Funding"},{"orgOrder":0,"company":"Mymetics","sponsor":"PCI Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"CD4","graph1":"Oncology","graph2":"Preclinical","graph3":"Mymetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mymetics \/ PCI Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Mymetics \/ PCI Biotech"},{"orgOrder":0,"company":"Octapharma","sponsor":"University of California San Diego School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Funding","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ University of California San Diego School of Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma \/ University of California San Diego School of Medicine"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Indivior"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ferring Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Twentyeight-Seven Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"CLK kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Twentyeight-Seven Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Pharmaceutica \/ Twentyeight-Seven Therapeutics"},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"Swiss Innovation Agency","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"GNU201","moa":"Gut microbiota","graph1":"Oncology","graph2":"Preclinical","graph3":"Gnubiotics Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gnubiotics Sciences \/ Swiss Innovation Agency","highestDevelopmentStatusID":"4","companyTruncated":"Gnubiotics Sciences \/ Swiss Innovation Agency"},{"orgOrder":0,"company":"ATHOS","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"ATHOS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATHOS \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"ATHOS \/ Formycon"},{"orgOrder":0,"company":"Athos","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Athos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Athos \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"Athos \/ Formycon"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spexis \/ SPRIM Global investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global investments"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"ADX71149","moa":"mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"4","companyTruncated":"Synendos Therapeutics \/ Ysios Capital"},{"orgOrder":0,"company":"Liechti Laboratory","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Liechti Laboratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liechti Laboratory \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Liechti Laboratory \/ Mind Medicine"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Antares Pharma","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Antares Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Antares Pharma"},{"orgOrder":0,"company":"University of Geneva","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"University of Geneva","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Geneva \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"University of Geneva \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"F. Hoffmann-La Roche \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ NeoImmuneTech"},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan Bioscience Technology","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Nolasiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Yuyuan Bioscience Technology","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Yuyuan Bioscience Technology"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nestle Health Sciences SA \/ Codexis","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Codexis"},{"orgOrder":0,"company":"Vandria","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"VNA-052","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vandria \/ Eurostars","highestDevelopmentStatusID":"5","companyTruncated":"Vandria \/ Eurostars"},{"orgOrder":0,"company":"Vandria","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"VNA-318","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vandria \/ Innosuisse","highestDevelopmentStatusID":"6","companyTruncated":"Vandria \/ Innosuisse"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Abiogen Pharma S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Alendronate Sodium","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A"},{"orgOrder":0,"company":"Spexis","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spexis \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"T3 Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"T3 Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"T3 Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Sosei Heptares","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Sosei Heptares"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Nimesulide","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Angelini Pharma"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"HAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"HAYA Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"HAYA Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"RocketVax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"RVX-sCPD9","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RocketVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RocketVax \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"RocketVax \/ National Institutes of Health"},{"orgOrder":0,"company":"Nestle","sponsor":"Stallergenes Greer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Divestment","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nestle","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Nestle \/ Stallergenes Greer","highestDevelopmentStatusID":"15","companyTruncated":"Nestle \/ Stallergenes Greer"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Lonza Group","sponsor":"McSAF","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lonza Group \/ McSAF","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Group \/ McSAF"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"WHO","sponsor":"Government of Belgium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WHO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"WHO \/ Government of Belgium","highestDevelopmentStatusID":"1","companyTruncated":"WHO \/ Government of Belgium"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IBSA Institut Biochimique \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"15","companyTruncated":"IBSA Institut Biochimique \/ Mark Cuban Cost Plus Drug Company"},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CDR Life \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Mainbridge Health Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Mainbridge Health Partners","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Mainbridge Health Partners"},{"orgOrder":0,"company":"Neovii","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Rabbit Anti-human T-lymphocyte Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neovii \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Neovii \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Teoxane SA","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Teoxane SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teoxane SA \/ Revance Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Teoxane SA \/ Revance Therapeutics"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"Transthyretin amyloid","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"ISB 880","moa":"IL-1RAP","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Sciences \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Ichnos Sciences \/ Almirall"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Combioxin","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"CAL02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Combioxin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Combioxin \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Combioxin \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Alendronate Sodium","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Radius Health","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Radius Health"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Ceftriaxone","moa":"Mucopeptide synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Ionctura","sponsor":"Clavius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"IOA-359","moa":"TGF-beta","graph1":"Oncology","graph2":"Preclinical","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Clavius Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ionctura \/ Clavius Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"IOV-3001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Zambon Switzerland \/ Newron Pharmaceuticals"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Aexon Labs","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"NLS Pharmaceutics \/ Aexon Labs","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Aexon Labs"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"NEC OncoImmunity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaximm AG \/ NEC OncoImmunity","highestDevelopmentStatusID":"4","companyTruncated":"Vaximm AG \/ NEC OncoImmunity"},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eracal Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eracal Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Eracal Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PsychoGenics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"RO7117997","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffmann-La Roche \/ PsychoGenics"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ferring Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Samsung Bioepis"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Swixx BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swixx BioPharma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Swixx BioPharma \/ Amryt Pharma"},{"orgOrder":0,"company":"AC Immune","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Valeo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Valeo Pharma"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Araris Biotech \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Araris Biotech \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"PharmaBiome","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"PharmaBiome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaBiome \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"PharmaBiome \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"leadXpro","sponsor":"Cumulus Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Discovery","graph3":"leadXpro","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"leadXpro \/ Cumulus Oncology","highestDevelopmentStatusID":"2","companyTruncated":"leadXpro \/ Cumulus Oncology"},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"CDR202","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"IL-4R alpha\/IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Vaxcyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Group \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Vaxcyte"},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eracal Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eracal Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Eracal Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ASN90","moa":"OGA","graph1":"Neurology","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Ferrer Internacional"},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Nolasiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Yuyuan Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Yuyuan Bioscience"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Medicines Patent Pool \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"The Medicines Patent Pool \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Nodus Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Divestment","leadProduct":"Undisclosed","moa":"PARG","graph1":"Oncology","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Nodus Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Pharmaceutica \/ Nodus Oncology"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Glioblastoma Foundation Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Lisavanbulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Glioblastoma Foundation Inc","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Glioblastoma Foundation Inc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Boston Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Efimosfermin Alpha","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Boston Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Boston Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Idebenone","moa":"Cytochrome P450 2C9","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Santhera Pharmaceuticals \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Chiesi Group"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Vildagliptin","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Cipla"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Disc medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Disc medicine","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffmann-La Roche \/ Disc medicine"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"FarmaMondo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"FarmaMondo \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"FarmaMondo \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Lonza Group","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"ATYR2810","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ aTyr Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ aTyr Pharma"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Medicines Patent Pool \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Patent Pool \/ Merck & Co"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Memo Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Memo Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Sperogenix Therapeutics"},{"orgOrder":0,"company":"Stalicla","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Mavoglurant","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ObsEva","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ XOMA","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ XOMA"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ BridgeBio Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Leucid Bio","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Leucid Bio"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"STAR-0310","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Sciences \/ Astria Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ichnos Sciences \/ Astria Therapeutics"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Numab Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Xbiome","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"AUP-16","moa":"FGF2","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Aurealis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aurealis Therapeutics \/ Xbiome","highestDevelopmentStatusID":"7","companyTruncated":"Aurealis Therapeutics \/ Xbiome"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Elthera","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Elthera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Elthera \/ LegoChem Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Elthera \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Acer Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Relief Therapeutics \/ Acer Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Acer Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"PsiVac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Agreement","leadProduct":"Ixovex-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lonza Group \/ PsiVac","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ PsiVac"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ACT-709478","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AAVCOVID","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Pierre Fabre"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Griffith University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Gonococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LimmaTech Biologics \/ Griffith University","highestDevelopmentStatusID":"4","companyTruncated":"LimmaTech Biologics \/ Griffith University"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Financing","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Highbridge Capital Management"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ SVB Securities"},{"orgOrder":0,"company":"Kuros Biosciences","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Acquisition","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Kuros Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Kuros Biosciences \/ XOMA","highestDevelopmentStatusID":"8","companyTruncated":"Kuros Biosciences \/ XOMA"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"4","companyTruncated":"The Medicines Patent Pool \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Versantis","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Genfit","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Genfit"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ 3SBio","highestDevelopmentStatusID":"5","companyTruncated":"Numab Therapeutics \/ 3SBio"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"DNDi","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"LXE408","moa":"Proteasome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DNDi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"DNDi \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"DNDi \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Xevinapant","moa":"||IAP","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Merck & Co"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ypsomed \/ Astria Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Ypsomed \/ Astria Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Cellerys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CLS12311","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Cellerys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellerys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Cellerys \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zanidatamab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Beta-7 integrin ligand","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Beta-7 integrin ligand","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Suspension\/Drops","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"EspeRare","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ER-004","moa":"EDA1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"EspeRare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"EspeRare \/ Pierre Fabre","highestDevelopmentStatusID":"8","companyTruncated":"EspeRare \/ Pierre Fabre"},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"OT-58","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orphan Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Technologies \/ Inapplicable"},{"orgOrder":0,"company":"EspeRare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ER-004","moa":"EDA1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"EspeRare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"EspeRare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EspeRare \/ Inapplicable"},{"orgOrder":0,"company":"EspeRare","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ER-004","moa":"EDA1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"EspeRare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"EspeRare \/ Pierre Fabre","highestDevelopmentStatusID":"8","companyTruncated":"EspeRare \/ Pierre Fabre"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvelle Therapeutics \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Perelman School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Perelman School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Perelman School of Medicine"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Menotropins","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Acer Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relief Therapeutics \/ Acer Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Relief Therapeutics \/ Acer Therapeutics"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ACI-7104.056","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Janssen Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Janssen Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Janssen Biotech"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cenerimod","moa":"S1P1R","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACT-539313","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"BerGenBio ASA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ BerGenBio ASA","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ BerGenBio ASA"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TAR DNA binding protein 43","graph1":"Neurology","graph2":"Preclinical","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX71149","moa":"||mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ GSK"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX71149","moa":"||mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ GSK"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX71149","moa":"||mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADX71149","moa":"||mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AEX-2","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AEX-41","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALE.C04","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glucocorticoid","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lixudebart","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALE.P02","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virometix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V-306","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virometix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virometix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Virometix \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Ipsen"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANV600","moa":"||PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANK-700","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ANV419","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ANV419","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Endocrinology","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Endocrinology","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3K-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARC-01","moa":"CD79","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Araris Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARC-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Araris Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASN120290","moa":"OGA","graph1":"Neurology","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asceneuron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Spexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL12","graph1":"Oncology","graph2":"Preclinical","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spexis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Balixafortide","moa":"CXCR4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naldemedine Tosylate","moa":"Mu-opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Sandoz B2B \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Shionogi"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Agilent Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Agilent Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Agilent Technologies"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BI 771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CDR Life \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"CDR Life \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linzagolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BPT-143","moa":"IL-2-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BPT567","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Peak Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bright Peak Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Branaplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Branaplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Ach receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CALY-002","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Calypso Biotech SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Biotech SA \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"||IL-1-beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CDR404","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CDR813","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cenerimod","moa":"S1P1R","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bioeq IP AG \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Bioeq IP AG \/ Coherus Biosciences"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"CARE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||TLR7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARE \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Artemether","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Banner Alzheimer\u2019s Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"C-PBTE-01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"C-PTBE-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Scientis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Glutathione synthase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Scientis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Scientis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scientis \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idebenone","moa":"Cytochrome P450 2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idebenone","moa":"Cytochrome P450 2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"FerGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Phase III","graph3":"FerGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"FerGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FerGene \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DPI-4452","moa":"||CAIX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||IAP","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"||SSTR","graph1":"Endocrinology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Propeller Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Propeller Health","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Propeller Health"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Astellas Pharma"},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tillotts Pharma AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tillotts Pharma AG \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TNO155","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PHE885","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genentech"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Tumor Treating Field","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ EirGenix","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ EirGenix"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"KD Pharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"KD Pharma Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"KD Pharma Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"KD Pharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"EsoCap","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EsoCap \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Inapplicable"},{"orgOrder":0,"company":"EsoCap","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EsoCap \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Inapplicable"},{"orgOrder":0,"company":"EsoCap","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EsoCap \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASN90","moa":"OGA","graph1":"Neurology","graph2":"Preclinical","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Asceneuron \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APR-OD031","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APR Applied Pharma Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"APR Applied Pharma Research \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Minigastrin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Camidanlumab Tesirine","moa":"||CD25","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BeiGene"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Loxo Oncology Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bioeq IP AG \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Bioeq IP AG \/ Formycon"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Blueprint Medicines"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"GeNeuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Temelimab","moa":"HERV-W","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GeNeuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ Inapplicable"},{"orgOrder":0,"company":"GeNeuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Temelimab","moa":"HERV-W","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GeNeuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Selective M4 receptor positive allosteric","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genentech"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imlunestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PN-1007","moa":"IgM","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyneuron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Semorinemab","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"Novaremed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Branaplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lisavanbulin","moa":"Tumour checkpoint controller","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Novaremed","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ National Institutes of Health"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MTX-COVAB","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"URO-902","moa":"Maxi-K protein expression","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"Spexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Balixafortide","moa":"CXCR4 receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spexis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spexis \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ISB 2001","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INE963","moa":"Pf parasite resistant","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Spexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Murepavadin","moa":"Imp protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spexis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spexis \/ Inapplicable"},{"orgOrder":0,"company":"Inositec AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INS-3001","moa":"Vascular calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inositec AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inositec AG \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inositec AG \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Maxi-K protein expression","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Maxi-K protein expression","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"||Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IOS-1002","moa":"LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunOs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunOs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"IOS-1002","moa":"LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunOs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunOs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ISB 1442","moa":"CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ichnos Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ISB 1442","moa":"CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ichnos Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ISB 2001","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CDR Life","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDR Life \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JDQ443","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADX71149","moa":"||mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ADX71149","moa":"mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaplacide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Kanyos Bio","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Kanyos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Kanyos Bio"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CARA Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Develco Pharma","sponsor":"HMNC Brain Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Develco Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Develco Pharma \/ HMNC Brain Health","highestDevelopmentStatusID":"8","companyTruncated":"Develco Pharma \/ HMNC Brain Health"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||p38\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||p38\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||p38\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"p38\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Curatis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||p38\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curatis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Translational Research In Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Translational Research In Oncology"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Inapplicable"},{"orgOrder":0,"company":"Laevoroc Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ulodesine","moa":"PNPase","graph1":"Oncology","graph2":"Preclinical","graph3":"Laevoroc Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laevoroc Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laevoroc Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sorafenib","moa":"Tyrosine protein kinase receptor RET","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azathioprine","moa":"||IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Coacillium","moa":"E selectin expression","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Legacy Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Coacillium","moa":"E selectin expression","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Legacy Healthcare \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Solution\/Drops","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SINTETICA SA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SINTETICA SA \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linzagolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"||ANGPTL3","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Laevoroc Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulodesine","moa":"PNPase","graph1":"Oncology","graph2":"Preclinical","graph3":"Laevoroc Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laevoroc Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laevoroc Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lucerastat","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SSTR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SSTR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SSTR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LXE408","moa":"Proteasome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Wellcome Trust"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LXE408","moa":"Proteasome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Siponimod fumarate","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||TIM-3","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Menotropins","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Merotocin","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antion Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"miCAR19","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Antion Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antion Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antion Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Antion Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"miCAR7","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Antion Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antion Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antion Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Miltefosine","moa":"Cytochrome-C oxidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"World Health Organization \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"World Health Organization \/ Inapplicable"},{"orgOrder":0,"company":"Amazentis","sponsor":"Scripps Research","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Urolithin A","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Amazentis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amazentis \/ Scripps Research","highestDevelopmentStatusID":"4","companyTruncated":"Amazentis \/ Scripps Research"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DARPin","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Molecular Partners \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Immunology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MP0310","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Partners \/ Amgen Inc"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MP0533","moa":"CD33\/CD123\/CD70","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Partners \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MP0712","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Oranomed","highestDevelopmentStatusID":"4","companyTruncated":"Molecular Partners \/ Oranomed"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Potravitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MTX-005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Memo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"MTX-COVAB","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memo Therapeutics \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"Memo Therapeutics \/ Serum Institute of India"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Naratuximab Emtansine","moa":"||CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Polpharma","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Polpharma"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pracinostat","moa":"||pan-HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alpelisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Amazentis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Urolithin A","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Amazentis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amazentis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amazentis \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Follitropin Delta","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APR-TD011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R alpha\/IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R alpha\/IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NM32-2668","moa":"ROR1\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Basimglurant","moa":"mGluR5","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemlapodect","moa":"PDE10A","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gemlapodect","moa":"PDE10A","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gemlapodect","moa":"PDE10A","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemlapodect","moa":"PDE10A","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NOE-115","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noema Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"ObsEva \/ Yuyuan Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Yuyuan Bioscience"},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan Bioscience Technology","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"ObsEva \/ Yuyuan Bioscience Technology","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Yuyuan Bioscience Technology"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ Inapplicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Inapplicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Inapplicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Inapplicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"ProBioGen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MVA-209-FSP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ ProBioGen","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG \/ ProBioGen"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"NOUS-PEV","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nouscom AG \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"||IL-1-beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DKY709","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SSTR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"FerGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Phase III","graph3":"FerGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"FerGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FerGene \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Simoctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Neurology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"OCTA12","moa":"||Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Pooled Plasma","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opna Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orphenadrine","moa":"H1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OT-A201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onward Therapeutics \/ Biomunex Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Onward Therapeutics \/ Biomunex Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NI006","moa":"Transthyretin amyloid","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"||IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"||IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alpelisib","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule, Controlled Release","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"||Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"||IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alisporivir","moa":"Cyclophilin","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"F. Hoffmann-La Roche \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ National Institutes of Health"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linzagolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Controlled Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BeiGene"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Idebenone","moa":"Cytochrome P450 2C9","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Rebiotix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Rebiotix","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Rebiotix"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Live Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Suspension","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PN-1007","moa":"IgM","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polyneuron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Follitropin Delta","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Advita","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Advita","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Advita"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Frontier Science Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||ErbB2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Frontier Science Foundation","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Frontier Science Foundation"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BAL0891","moa":"Checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linzagolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Glofitamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trontinemab","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tadekinig Alpha","moa":"IL-18","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AB2 Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AB2 Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RP12146","moa":"PARP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rhizen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sapropterin Hydrochloride","moa":"PAH","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sapropterin Hydrochloride","moa":"PAH","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"APR-TD011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RO7617991","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Astellas Pharma"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RG6217","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RP7214","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhizen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"S4V","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LimmaTech Biologics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"LimmaTech Biologics \/ GSK"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||TIM-3","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Semorinemab","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Condoliase","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenalisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OAV-101","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Stalicla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"mGluR5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stalicla \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CARA Therapeutics"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Siponimod fumarate","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BeiGene"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Swissx Labs AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Naja Venom","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Swissx Labs AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Swissx Labs AG \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Swissx Labs AG \/ Inapplicable"},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SYT-510","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Synendos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synendos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Synendos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"TargImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"TAR001","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"TargImmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TargImmune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TargImmune \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenalisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenalisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhizen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhizen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Iscalimab","moa":"||CD40","graph1":"Nephrology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ AbbVie Inc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvelle Therapeutics \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Rebiotix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Rebiotix","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Rebiotix"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||IAP","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurimmune \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurimmune \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"||Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin, Human","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"mGluR5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Molecular Partners","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Molecular Partners"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HM06","moa":"RET kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||IAP","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotuletinib","moa":"CSF-1R","graph1":"Neurology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Erenumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Amgen Inc"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cambritaxestat","moa":"Autotaxin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idebenone","moa":"Cytochrome P450 2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sorafenib","moa":"Tyrosine protein kinase receptor RET","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ANK-700","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ADX71149","moa":"mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ADX71149","moa":"mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ADX71149","moa":"mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Addex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Sterling Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Sterling Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Sterling Pharma Solutions"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Simoctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"5-HT1A\/D2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genmab"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novaremed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimtuzalcap","moa":"Calcium-sensitive potassium ion channel PAM","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NovoTTF-100L","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Murepavadin","moa":"Imp protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab-monomethyl Auristatin E","moa":"CD79b","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Araris Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD79b","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Araris Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"GCX","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gnubiotics Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gnubiotics Sciences \/ University of Zurich","highestDevelopmentStatusID":"5","companyTruncated":"Gnubiotics Sciences \/ University of Zurich"},{"orgOrder":0,"company":"Spexis","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spexis \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ University of Michigan"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Novaremed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SSTR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin, Human","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Araris Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Biotech \/ Inapplicable"},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Immunology","graph2":"Preclinical","graph3":"MetrioPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MetrioPharm \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MetrioPharm \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Normal Human Immunoglobulin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lucerastat","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Balixafortide","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IBSA Institut Biochimique \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IBSA Institut Biochimique \/ Inapplicable"},{"orgOrder":0,"company":"Swiss PharmaCan","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Artemisinin","moa":"||Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Swiss PharmaCan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Swiss PharmaCan \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Swiss PharmaCan \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BeiGene"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Derazantinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Geneva Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Geneva Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geneva Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Geneva Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Approved FDF","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ AC Immune"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Drugs For Neglected Diseases Initiative","sponsor":"Inserm-ANRS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Drugs For Neglected Diseases Initiative","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drugs For Neglected Diseases Initiative \/ Inserm-ANRS","highestDevelopmentStatusID":"10","companyTruncated":"Drugs For Neglected Diseases Initiative \/ Inserm-ANRS"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeNeuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Temelimab","moa":"HERV-W","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeNeuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Telazorlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||IAP","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NOUS-209","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nouscom AG \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Canakinumab","moa":"IL-1-beta receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Muvon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Muvon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Muvon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Muvon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ensovibep","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Molecular Partners","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Molecular Partners"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Pelacarsen","moa":"Apolipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ EirGenix","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ EirGenix"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Inclisiran","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ United Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ United Therapeutics"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Endogenous T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ferring Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ Polpharma Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Polpharma Biologics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basilea Pharmaceutica \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Innovent Biologics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ANK-700","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inositec AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INS-3001","moa":"Vascular calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inositec AG","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inositec AG \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inositec AG \/ Inapplicable"},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"S.K Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Arvelle Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvelle Therapeutics \/ S.K Biopharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Arvelle Therapeutics \/ S.K Biopharmaceutical"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idebenone","moa":"Cytochrome P450 2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novocure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Temozolomide","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"URO-902","moa":"Maxi-K protein expression","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VAD044","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vaderis Therapeutics \/ Medicxi","highestDevelopmentStatusID":"6","companyTruncated":"Vaderis Therapeutics \/ Medicxi"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VAD044","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vaderis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaderis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VAD044","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vaderis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaderis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vepafestinib","moa":"RET kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vepafestinib","moa":"RET kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hematology","graph2":"Preclinical","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Versameb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Inapplicable"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Touchlight"},{"orgOrder":0,"company":"Vandria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VNA-318","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vandria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vandria \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vandria \/ Inapplicable"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selexipag","moa":"||Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"World Health Organization \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"World Health Organization \/ Inapplicable"},{"orgOrder":0,"company":"WHO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"WHO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"WHO \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"WHO \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Shenzhen China Resources Gosun Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Shenzhen China Resources Gosun Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Shenzhen China Resources Gosun Pharmaceuticals"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Genentech"},{"orgOrder":0,"company":"Ymmunobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"YB-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ymmunobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ymmunobio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ymmunobio \/ Inapplicable"},{"orgOrder":0,"company":"ObsEva","sponsor":"Theramex","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Theramex"},{"orgOrder":0,"company":"ObsEva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ObsEva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ObsEva \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sandoz B2B \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Samsung Bioepis"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iptacopan HCl","moa":"Factor B","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ACI-24.060","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Aexon Labs","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AEX-2","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"NLS Pharmaceutics \/ Aexon Labs","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Aexon Labs"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AEX-41","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"GlucoCorticoid","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Torqur","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"pan-PI3K\/mTOR","graph1":"Dermatology","graph2":"Phase II","graph3":"Torqur","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Torqur \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Torqur \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"MEDSIR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ MEDSIR","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ MEDSIR"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KAN-101","moa":"IL-2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Inapplicable"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"LBT-SA7","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LimmaTech Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LimmaTech Biologics \/ Inapplicable"},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"LBT-SA7","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"LimmaTech Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LimmaTech Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LimmaTech Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Oculis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Neurology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oculis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Inapplicable"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OPN-2853","moa":"||BRD4-selective protein","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Opna Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Opna Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ AstraZeneca"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharmaceutics \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenalisib","moa":"||PI3K-delta\/gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2025","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Formosa Pharmaceuticals \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Cipla"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoNex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Undisclosed"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"DotBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"DB007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bora Pharmaceuticals \/ DotBio","highestDevelopmentStatusID":"4","companyTruncated":"Bora Pharmaceuticals \/ DotBio"},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TLC BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TLC BioSciences \/ Strides Pharma Science","highestDevelopmentStatusID":"15","companyTruncated":"TLC BioSciences \/ Strides Pharma Science"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formosa Pharmaceuticals \/ Apotex Inc","highestDevelopmentStatusID":"10","companyTruncated":"Formosa Pharmaceuticals \/ Apotex Inc"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"AcedrA BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"TaiMed Biologics \/ AcedrA BioPharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"TaiMed Biologics \/ AcedrA BioPharmaceuticals"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"||VM","graph1":"Oncology","graph2":"Phase II","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bora Pharmaceuticals \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"Bora Pharmaceuticals \/ TaiRx"},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Microorganism","year":"2021","type":"Private Placement","leadProduct":"Decoy20","moa":"||TLR4","graph1":"Oncology","graph2":"Preclinical","graph3":"Intech Biopharm Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intech Biopharm Ltd \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Intech Biopharm Ltd \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"EI-1071","moa":"CSF-1R","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron Immunotherapeutics \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"Health2Sync","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Merdury Pharmaceutical \/ Health2Sync","highestDevelopmentStatusID":"4","companyTruncated":"Merdury Pharmaceutical \/ Health2Sync"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Jiaozuo Joincare Biotechnological Co Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TaiGen Biotechnology \/ Jiaozuo Joincare Biotechnological Co Ltd","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Jiaozuo Joincare Biotechnological Co Ltd"},{"orgOrder":0,"company":"Pharmosa Biopharm","sponsor":"Liquidia Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmosa Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Pharmosa Biopharm \/ Liquidia Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Pharmosa Biopharm \/ Liquidia Corporation"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Medigen Vaccine Biologics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Medigen Vaccine Biologics \/ National Institutes of Health"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"FB825","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oneness Biotech \/ Leo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Leo Pharma"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"HMBD-002","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Mycenax Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mycenax Biotech \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Mycenax Biotech \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Pangu Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"EI-1071","moa":"CSF-1R","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Pangu Capital","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron Immunotherapeutics \/ Pangu Capital"},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Mycenax Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mycenax Biotech \/ Gedeon Richter","highestDevelopmentStatusID":"6","companyTruncated":"Mycenax Biotech \/ Gedeon Richter"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Hong Kong Winhealth Pharma Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Diacerein","moa":"CASP1\/IL-1 beta","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"TWi Biotechnology \/ Hong Kong Winhealth Pharma Group","highestDevelopmentStatusID":"8","companyTruncated":"TWi Biotechnology \/ Hong Kong Winhealth Pharma Group"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Pharmosa Biopharm","sponsor":"Liquidia Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmosa Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Pharmosa Biopharm \/ Liquidia Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Pharmosa Biopharm \/ Liquidia Corporation"},{"orgOrder":0,"company":"Define Biotech","sponsor":"ABVC BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Beta Glucan","moa":"Beta glucan receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Define Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Define Biotech \/ ABVC BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"Define Biotech \/ ABVC BioPharma"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"BIOKEY","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"TAIWAN","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merdury Pharmaceutical \/ BIOKEY","highestDevelopmentStatusID":"3","companyTruncated":"Merdury Pharmaceutical \/ BIOKEY"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ABT-301","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbogen Therapeutics \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Anbogen Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"CDIB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"ABT-101","moa":"RTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anbogen Therapeutics \/ CDIB","highestDevelopmentStatusID":"7","companyTruncated":"Anbogen Therapeutics \/ CDIB"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"KGI Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"ABT-301","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbogen Therapeutics \/ KGI Venture Capital","highestDevelopmentStatusID":"6","companyTruncated":"Anbogen Therapeutics \/ KGI Venture Capital"},{"orgOrder":0,"company":"Acepodia","sponsor":"Ridgeback Capital Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"ACE1702","moa":"HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Ridgeback Capital Investments","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Ridgeback Capital Investments"},{"orgOrder":0,"company":"Acepodia","sponsor":"Digital Mobile Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"ACE1831","moa":"CD20","graph1":"Oncology","graph2":"Preclinical","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Digital Mobile Venture","highestDevelopmentStatusID":"4","companyTruncated":"Acepodia \/ Digital Mobile Venture"},{"orgOrder":0,"company":"Acepodia","sponsor":"Digital Mobile Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2023","type":"Series D Financing","leadProduct":"ACE1831","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Digital Mobile Venture","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Digital Mobile Venture"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Medigen Vaccine Biologics \/ Dynavax Technologies"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Partnership","leadProduct":"Menaquinone-7","moa":"||SXR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SunWay Biotech \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"SunWay Biotech \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"Ainos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Merdury Pharmaceutical \/ Ainos","highestDevelopmentStatusID":"8","companyTruncated":"Merdury Pharmaceutical \/ Ainos"},{"orgOrder":0,"company":"AnnJi Pharmaceutical","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"AnnJi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"AnnJi Pharmaceutical \/ Avenue Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"AnnJi Pharmaceutical \/ Avenue Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Cristalia Produtos Quimicos Farma. Ltda","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Cristalia Produtos Quimicos Farma. Ltda"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Y.S.P. Industries M Sdn Bhd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TaiGen Biotechnology \/ Y.S.P. Industries M Sdn Bhd","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Y.S.P. Industries M Sdn Bhd"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Medvisis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Medvisis","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Medvisis"},{"orgOrder":0,"company":"Development Center for Biotechnology","sponsor":"HoneyBear Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Development Center for Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Development Center for Biotechnology \/ HoneyBear Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Development Center for Biotechnology \/ HoneyBear Biosciences"},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"CT-G20","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bora Pharmaceuticals \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Bora Pharmaceuticals \/ Celltrion"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"DAVI Farmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ DAVI Farmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ DAVI Farmaceutica"},{"orgOrder":0,"company":"Regimmune","sponsor":"San Fu Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"RGI-2001","moa":"T reg Cells","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regimmune \/ San Fu Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ San Fu Biotech"},{"orgOrder":0,"company":"Adimmune","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Quadrivalent Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adimmune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adimmune \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Adimmune \/ Clover Biopharmaceuticals"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Burixafor","moa":"CXCL12\/CXCR4","graph1":"Immunology","graph2":"Phase II","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ GPCR Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"TaiGen Biotechnology \/ GPCR Therapeutics"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Luminarie","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Nemonoxacin","moa":"Topoisomerase II","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TaiGen Biotechnology \/ Luminarie","highestDevelopmentStatusID":"15","companyTruncated":"TaiGen Biotechnology \/ Luminarie"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Agreement","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Taiwan Liposome Company \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Liposome Company \/ Endo International"},{"orgOrder":0,"company":"AnnJi Pharmaceutical","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"AnnJi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"AnnJi Pharmaceutical \/ Avenue Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"AnnJi Pharmaceutical \/ Avenue Therapeutics"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Adimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Eden Biologics \/ Adimmune","highestDevelopmentStatusID":"1","companyTruncated":"Eden Biologics \/ Adimmune"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAHO Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"OBI-888","moa":"Globo H","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"National Health Research Institutes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABT-101","moa":"RTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anbogen Therapeutics \/ National Health Research Institutes","highestDevelopmentStatusID":"7","companyTruncated":"Anbogen Therapeutics \/ National Health Research Institutes"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TWi Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ACE1831","moa":"CD20","graph1":"Immunology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ACE2016","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ACE2016","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"ACRO Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Collagen Ophthalmic Matrix","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ACRO Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ACRO Biomedical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ACRO Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Adimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Adimmune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adimmune \/ Inapplicable"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allgenesis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"AG-80308","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Allgenesis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allgenesis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"AKT\/EGFR\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Golden Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"AKT\/EGFR\/MAPK","graph1":"Oncology","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Golden Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"AKT\/EGFR\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Golden Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DBPR115","moa":"Cancer cell membrane protein-phosphatidyl serine","graph1":"Oncology","graph2":"Phase I","graph3":"National Health Research Institutes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Health Research Institutes \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Health Research Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eden Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Inapplicable"},{"orgOrder":0,"company":"EirGenix","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"EirGenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EirGenix \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"EirGenix \/ Sandoz B2B"},{"orgOrder":0,"company":"EirGenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"EGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"EirGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EirGenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EirGenix \/ Inapplicable"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Medigen Vaccine Biologics \/ Dynavax Technologies"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"AKT\/EGFR\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Golden Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ISPM21","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Taiwan Liposome Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Inapplicable"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TWi Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"||AKT\/EGFR\/MAPK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Golden Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Golden Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"OBI-833","moa":"Globo H","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eden Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Lin BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Granaticin B","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lin BioScience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lin BioScience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lin BioScience \/ Inapplicable"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nalbuphine Sebacate","moa":"Kappa\/Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lumosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lumosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LT-3001","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lumosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Undisclosed","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NaviFUS \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NaviFUS \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"NaviFUS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Undisclosed","graph3":"NaviFUS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NaviFUS \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NaviFUS \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OBI-3424","moa":"||AKR1C3","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Biosion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Biosion","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Biosion"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OBI-992","moa":"Trop2","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"OBI-999","moa":"Globo H glycolipid antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Peter MacCallum Cancer Centre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Peter MacCallum Cancer Centre","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Peter MacCallum Cancer Centre"},{"orgOrder":0,"company":"Genovate","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cilostazol","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Genovate","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genovate \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genovate \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OBI-3424","moa":"||AKR1C3","graph1":"Oncology","graph2":"Phase III","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Charsire Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Multiglycan Complex","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Charsire Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Charsire Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Charsire Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"TLC BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"TLC BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TLC BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Regimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RGI-2001","moa":"T reg Cells","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Inapplicable"},{"orgOrder":0,"company":"Regimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RGI-2001","moa":"T reg Cells","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"OBI-999","moa":"Globo H glycolipid antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Center for Advanced Research and Education","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Center for Advanced Research and Education","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Center for Advanced Research and Education"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SNS812","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oneness Biotech \/ Microbio","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Microbio"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoNex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Inapplicable"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TaiGen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TaiGen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Joincare Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TaiGen Biotechnology \/ Joincare Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Joincare Pharmaceutical"},{"orgOrder":0,"company":"Alar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"UB-621","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CpG 1018","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Medigen Vaccine Biologics \/ Dynavax Technologies"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Liposome Company \/ Inapplicable"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"AKT\/EGFR\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Golden Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"EirGenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"EirGenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EirGenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EirGenix \/ Inapplicable"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medigen Vaccine Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medigen Vaccine Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eden Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Center Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CS02","moa":"||HbA1c","graph1":"Endocrinology","graph2":"Phase II","graph3":"Center Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Center Laboratories \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Center Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Formosa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Formosa Pharmaceuticals \/ AimMax Therapeutics"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"UB-421","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Taiwan Liposome Company \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Liposome Company \/ Inapplicable"},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TMB-365","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"TaiMed Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TaiMed Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TaiMed Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Merry Life Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Curcumin Analog","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Merry Life Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merry Life Biomedical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Merry Life Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"UB-221","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Chidamide","moa":"||CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Chidamide","moa":"||CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Shanghai Public Health Clinical Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"UB-621","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United BioPharma \/ Shanghai Public Health Clinical Centre","highestDevelopmentStatusID":"6","companyTruncated":"United BioPharma \/ Shanghai Public Health Clinical Centre"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"UB-421","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"||CK2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Xgene Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pregabalin","moa":"||Alpha 2-beta subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Xgene Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xgene Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xgene Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Orally Dissolving Thin Film","sponsorNew":"TAHO Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Orally Dissolving Thin Film","sponsorNew":"TAHO Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Microbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MS-20","moa":"||Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Microbio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Microbio \/ Inapplicable"},{"orgOrder":0,"company":"GlycoNex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"GlycoNex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoNex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoNex \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharma (Thailand)","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"THAILAND","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Hypromellose","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Teva Pharma (Thailand)","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharma (Thailand) \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharma (Thailand) \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Baiya Phytopharm","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"25 Baiya SARS-CoV-2 Vax 2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baiya Phytopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baiya Phytopharm \/ 3M Company","highestDevelopmentStatusID":"6","companyTruncated":"Baiya Phytopharm \/ 3M Company"},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Covitrap","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chulalongkorn University","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Chulalongkorn University \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chulalongkorn University \/ Inapplicable"},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChulaCov19 mRNA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Chulalongkorn University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chulalongkorn University \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chulalongkorn University \/ Inapplicable"},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChulaCov19 mRNA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Chulalongkorn University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chulalongkorn University \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chulalongkorn University \/ Inapplicable"},{"orgOrder":0,"company":"Erkim","sponsor":"MEDICE Health Family","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Erkim \/ MEDICE Health Family","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ MEDICE Health Family"},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131 Group","sponsor":"CURIUM US LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Radiolabelled Compounds","year":"2025","type":"Acquisition","leadProduct":"Lutetium (177Lu) Zadavotide Guraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Eczac\u0131ba\u015f\u0131 Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eczac\u0131ba\u015f\u0131 Group \/ CURIUM US LLC","highestDevelopmentStatusID":"10","companyTruncated":"Eczac\u0131ba\u015f\u0131 Group \/ CURIUM US LLC"},{"orgOrder":0,"company":"Erkim","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Erkim \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Erkim \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Erkim","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Erkim \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Erkim \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","sponsor":"FutureChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"177-Ludotadipep","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem","highestDevelopmentStatusID":"6","companyTruncated":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem"},{"orgOrder":0,"company":"Polifarma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"TURKEY","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Polifarma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polifarma \/ Alvotech","highestDevelopmentStatusID":"10","companyTruncated":"Polifarma \/ Alvotech"},{"orgOrder":0,"company":"Erkim","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"TURKEY","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erkim \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Humanis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"TURKEY","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Saffron Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humanis \/ Inapplicable"},{"orgOrder":0,"company":"Drogsan Pharmaceuticals","sponsor":"Rockwell Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Drogsan Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Drogsan Pharmaceuticals \/ Rockwell Medical","highestDevelopmentStatusID":"15","companyTruncated":"Drogsan Pharmaceuticals \/ Rockwell Medical"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.A.E","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"GH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vector Pharma \/ Ascendis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ Ascendis Pharma"},{"orgOrder":0,"company":"Genpharm","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.A.E","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Genpharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Genpharm \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Genpharm \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Cellvera","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.A.E","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cellvera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cellvera \/ Aditxt","highestDevelopmentStatusID":"15","companyTruncated":"Cellvera \/ Aditxt"},{"orgOrder":0,"company":"AiPharma","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.A.E","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AiPharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AiPharma \/ Appili Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"AiPharma \/ Appili Therapeutics"},{"orgOrder":0,"company":"TheiaLife","sponsor":"LifeSci Consulting","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.A.E","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"7-Methylxanthine","moa":"Adenosine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TheiaLife","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TheiaLife \/ LifeSci Consulting","highestDevelopmentStatusID":"8","companyTruncated":"TheiaLife \/ LifeSci Consulting"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.A.E","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"||Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ R-Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Vector Pharma \/ R-Pharm"},{"orgOrder":0,"company":"Burjeel Holdings","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.A.E","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Burjeel Holdings","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Burjeel Holdings \/ BridgeBio Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Burjeel Holdings \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Pemafibrate","moa":"PPA receptor-alpha","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kowa Pharmaceuticals America \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Kowa Pharmaceuticals America \/ DKSH"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.92000000000000004,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0.92000000000000004,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Tribe Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Series B Financing","leadProduct":"Hydroxyl Dendrimer","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"Ashvattha Therapeutics \/ Tribe Capital","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Tribe Capital"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"SWK Funding","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2025","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"ANI Pharmaceuticals Inc \/ SWK Funding","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ SWK Funding"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Smith & Sauer","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Smith & Sauer","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Smith & Sauer"},{"orgOrder":0,"company":"Merck & Co","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ DKSH"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.23999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ U.S. Department of Defense"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Public Offering","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase III","graph3":"PDS Biotechnology","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"PDS Biotechnology \/ Alliance Global Partners"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Mylan Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Partnership","leadProduct":"Lorazepam","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Mylan Group","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Mylan Group"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Double Point Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Double Point Ventures"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Personalis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Personalis","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intramuscular Injection","sponsorNew":"Personalis \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Personalis \/ Merck & Co"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Summit Biosciences","sponsor":"Scienture","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Summit Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Summit Biosciences \/ Scienture","highestDevelopmentStatusID":"15","companyTruncated":"Summit Biosciences \/ Scienture"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Duke University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Duke University School of Medicine"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intra-articular Injection","sponsorNew":"RenovoRx \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Titan Partners Group"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Public Offering","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intra-articular Injection","sponsorNew":"RenovoRx \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Titan Partners Group"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunityBio \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ BeiGene"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"Linnaeus Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Monopar Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Citizens JMP"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Citizens JMP"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Lyndra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Thermo Fisher Scientific \/ Lyndra Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Lyndra Therapeutics"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":3.0800000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":3.0800000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Anthos Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ ALK","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ University of Oxford","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ University of Oxford"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Series C Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ RA Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ RA Capital Management"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Nantahala Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Nantahala Capital","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Nantahala Capital"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Atropine","moa":"||mAChRs","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0.13,"dosageForm":"Intramuscular Injection","sponsorNew":"Kindeva Drug Delivery \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Etelcalcetide","moa":"CaSR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0.16,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0.16,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"Nanocopoeia","sponsor":"Handa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nanocopoeia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nanocopoeia \/ Handa Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nanocopoeia \/ Handa Pharmaceuticals"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ TD Cowen"},{"orgOrder":0,"company":"89bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.28999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"89bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.28999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"89bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.28999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Jupiter Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Soft gel Capsule","sponsorNew":"Catalent Pharma Solutions \/ Jupiter Neurosciences","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Jupiter Neurosciences"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Acquisition","leadProduct":"Gemcitabine","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Soft gel Capsule","sponsorNew":"Jupiter Neurosciences \/ Dominari Securities","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Dominari Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Soft gel Capsule","sponsorNew":"Jupiter Neurosciences \/ Dominari Securities","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Dominari Securities"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0.14999999999999999,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Adage Capital Partners LP","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Adage Capital Partners LP"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"MK-1167","moa":"nAChR alpha7","graph1":"Neurology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.48999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Neuphoria Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Series E Financing","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Artery Infusion","sponsorNew":"Delcath Systems \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Lupin Ltd"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Oberland Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Oberland Capital","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Oberland Capital"},{"orgOrder":0,"company":"GATC Health","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"GATC Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GATC Health \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GATC Health \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Savara","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2025","type":"Financing","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Savara \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Hercules Capital"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Taiba Healthcare"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Harrow","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Harrow \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Funding","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nuvation Bio","amount2":0.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Oral Capsule","sponsorNew":"Nuvation Bio \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Nuvation Bio \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Denatonium Acetate","moa":"TAS2R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Aardvark Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Aardvark Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Aardvark Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ CARA Therapeutics"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Jefferies"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Johnson & Johnson"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Arimoclomol","moa":"||HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0.14999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Windtree Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Red Queen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"RQ-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Red Queen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Red Queen Therapeutics"},{"orgOrder":0,"company":"Benuvia","sponsor":"Avernus Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Benuvia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Benuvia \/ Avernus Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Benuvia \/ Avernus Pharma"},{"orgOrder":0,"company":"Romeg Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Licensing Agreement","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Romeg Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Romeg Therapeutics \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Romeg Therapeutics \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Toray Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||CAPRIN1","graph1":"Oncology","graph2":"Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Toray Industries","highestDevelopmentStatusID":"8","companyTruncated":"Bolt Biotherapeutics \/ Toray Industries"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.28999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.28999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.28999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Innovent Biologics"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"GBG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"GLSI-100","moa":"||Granulocyte-macrophage","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ GBG","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ GBG"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Unicancer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"GLSI-100","moa":"||Granulocyte-macrophage","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Unicancer","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Unicancer"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"GIM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ GIM","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ GIM"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Checkpoint Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Renova Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Renova Health","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Renova Health"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Chimerix","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.93999999999999995,"dosageForm":"Oral Capsule","sponsorNew":"Chimerix \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Myung In Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Myung In Pharm"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"EA Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.12,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ EA Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ EA Pharma"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Oxford Finance","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Oxford Finance"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Hefei Tianhui Biotech","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Hefei Tianhui Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Hefei Tianhui Biotech"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.13,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Theramex"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"Olezarsen Sodium","moa":"APOC3","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Avexitide","moa":"GLP-1 ant","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Avexitide","moa":"GLP-1 ant","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.059999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Pulmokine","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Seralutinib","moa":"PDGFR\/ CSF1R\/ c-KIT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pulmokine","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Pulmokine \/ XOMA","highestDevelopmentStatusID":"10","companyTruncated":"Pulmokine \/ XOMA"},{"orgOrder":0,"company":"Optinose","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Optinose","amount2":0.33000000000000002,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Paratek Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Paratek Pharmaceuticals"},{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Cycle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Banner Life Sciences \/ Cycle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Banner Life Sciences \/ Cycle Pharmaceuticals"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ WestPark Capital","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ WestPark Capital"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ WestPark Capital","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ WestPark Capital"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0.26000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0.26000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Norgine"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"USSM","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ USSM","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ USSM"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Zina Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Soft gel Capsule","sponsorNew":"Jupiter Neurosciences \/ Zina Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Zina Biopharmaceuticals"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Mayo Clinic \/ Solid Biosciences"},{"orgOrder":0,"company":"Validcare","sponsor":"Algernon NeuroScience","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Partnership","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Validcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Validcare \/ Algernon NeuroScience","highestDevelopmentStatusID":"6","companyTruncated":"Validcare \/ Algernon NeuroScience"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"NHS England","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ NHS England","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ NHS England"},{"orgOrder":0,"company":"Tessera Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tessera Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Intravenous","sponsorNew":"Tessera Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Tessera Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"IMMvention Therapeutix","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"IMM\u2013004","moa":"BACH1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IMMvention Therapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"IMMvention Therapeutix \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"IMMvention Therapeutix \/ Novo Nordisk"},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Orna Therapeutics","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.69999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Orna Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Orna Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.24,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Immunovant","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Private Placement","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.45000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Undisclosed"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"TP-317","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Helmsley Charitable Trust"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"OR-812","moa":"RAR-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ NIDDK"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Aegis Capital Corp","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Aegis Capital Corp"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Aegis Capital Corp","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Aegis Capital Corp"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.01,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Maxim Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Maxim Group LLC"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"IL-23","graph1":"Dermatology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"Nimble Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Boost Neuroscience","sponsor":"Gate Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Boost Neuroscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boost Neuroscience \/ Gate Neurosciences","highestDevelopmentStatusID":"3","companyTruncated":"Boost Neuroscience \/ Gate Neurosciences"},{"orgOrder":0,"company":"1cBio","sponsor":"Alesta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"ALE1","moa":"PPi","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"1cBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"1cBio \/ Alesta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"1cBio \/ Alesta Therapeutics"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Steritas","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Steritas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steritas \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Steritas \/ Argenx"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||CD8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Alcon inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"Neltependocel","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Alcon inc","highestDevelopmentStatusID":"8","companyTruncated":"Aurion Biotech \/ Alcon inc"},{"orgOrder":0,"company":"Callio Therapeutics","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Callio Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Callio Therapeutics \/ Hummingbird Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"Callio Therapeutics \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"CD38-GEAR-NK","moa":"||CD38","graph1":"Oncology","graph2":"Preclinical","graph3":"VyGen-Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VyGen-Bio \/ Coeptis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"VyGen-Bio \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Sarborg","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Sarborg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sarborg \/ Conduit Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Sarborg \/ Conduit Pharma"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Conduit Pharma \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Abtis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript ProBio \/ Abtis","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ Abtis"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":1.6000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.6000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Henlius","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Bi-Sialidase","moa":"||NEU2","graph1":"Nephrology","graph2":"Preclinical","graph3":"Palleon Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Henlius","highestDevelopmentStatusID":"4","companyTruncated":"Palleon Pharmaceuticals \/ Henlius"},{"orgOrder":0,"company":"Humacyte","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0.050000000000000003,"dosageForm":"Intraarterial Implant","sponsorNew":"Humacyte \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ TD Cowen"},{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"KALA Bio \/ SR One","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/ SR One"},{"orgOrder":0,"company":"Leveragen","sponsor":"Moonlight Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Leveragen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leveragen \/ Moonlight Bio","highestDevelopmentStatusID":"3","companyTruncated":"Leveragen \/ Moonlight Bio"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"LPOXY Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Sidiprev","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"Xeno Biosciences \/ LPOXY Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ LPOXY Therapeutics"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"AMPK","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Veranova","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Veranova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Veranova \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Veranova \/ Nutriband"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"OPGx-LCA5","moa":"LCA5 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.02,"dosageForm":"Subretinal Injection","sponsorNew":"Opus Genetics \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Divestment","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Intraputaminal Infusion","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Termination","leadProduct":"Giroctocogene fitelparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sangamo Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Sangamo Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"DR-0201","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Dren Bio","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Intravenous","sponsorNew":"Dren Bio \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Sanofi"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Brentuximab Vedotin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Undisclosed","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Summit Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Summit Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":1.3,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Microsoft","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tevogen Bio \/ Microsoft","highestDevelopmentStatusID":"3","companyTruncated":"Tevogen Bio \/ Microsoft"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":1.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"STX-478","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":2.5,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":2.5,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Elutia","sponsor":"Vizient","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Agreement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Vizient","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Vizient"},{"orgOrder":0,"company":"Fzata","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Agreement","leadProduct":"FZ002","moa":"toxA\/toxB","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Fzata","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fzata \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Fzata \/ National Institutes of Health"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"CNAO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAE Life Sciences \/ CNAO","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life Sciences \/ CNAO"},{"orgOrder":0,"company":"Alexander Shulgin Research Institute","sponsor":"Negev Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Alexander Shulgin Research Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexander Shulgin Research Institute \/ Negev Labs","highestDevelopmentStatusID":"2","companyTruncated":"Alexander Shulgin Research Institute \/ Negev Labs"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Verana Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Verana Health","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Verana Health"},{"orgOrder":0,"company":"City Therapeutics","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"City Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.48999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"City Therapeutics \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"4","companyTruncated":"City Therapeutics \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"University of Pittsburgh","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Apimostinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gate Neurosciences \/ University of Pittsburgh","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ University of Pittsburgh"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Amazon Web Services","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ Amazon Web Services","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ Amazon Web Services"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Insilico Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Harbour BioMed \/ Insilico Medicine"},{"orgOrder":0,"company":"Vascarta","sponsor":"CUNY","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Collaboration","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vascarta \/ CUNY","highestDevelopmentStatusID":"4","companyTruncated":"Vascarta \/ CUNY"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Hologen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"AAV-GAD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"MeiraGTx","amount2":0.42999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Infusion","sponsorNew":"MeiraGTx \/ Hologen","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Hologen"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Cadrenal Therapeutics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"OnTargetx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ OnTargetx","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ OnTargetx"},{"orgOrder":0,"company":"Biogen","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Royalty Pharma"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"PeriNess","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Collaboration","leadProduct":"XBIO-015","moa":"NET","graph1":"Oncology","graph2":"Preclinical","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ PeriNess","highestDevelopmentStatusID":"4","companyTruncated":"Xenetic Biosciences \/ PeriNess"},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"Mytos","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"ANPD001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Neuroscience \/ Mytos","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ Mytos"},{"orgOrder":0,"company":"AI Proteins","sponsor":"University of Missouri-Columbia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AI Proteins","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AI Proteins \/ University of Missouri-Columbia","highestDevelopmentStatusID":"4","companyTruncated":"AI Proteins \/ University of Missouri-Columbia"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Mirror Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"AlloStim","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mirror Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mirror Biologics \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Mirror Biologics \/ Merck Group"},{"orgOrder":0,"company":"KORU Medical Systems","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"KORU Medical Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"KORU Medical Systems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"KORU Medical Systems \/ Undisclosed"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloy Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"YAP Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NorthStar Medical Radioisotopes \/ YAP Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ YAP Therapeutics"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Enzomenib","moa":"Menin and mixed-lineage leukemia interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foundation Medicine \/ Sumitomo Pharma America","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Sumitomo Pharma America"},{"orgOrder":0,"company":"Acellera Therapeutics","sponsor":"Psivant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Acellera Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acellera Therapeutics \/ Psivant Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Acellera Therapeutics \/ Psivant Therapeutics"},{"orgOrder":0,"company":"Alumis","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.17999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"GondolaBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ GondolaBio","highestDevelopmentStatusID":"3","companyTruncated":"n-Lorem Foundation \/ GondolaBio"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"BridGene Biosciences","amount2":0.81999999999999995,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.81999999999999995,"dosageForm":"Undisclosed","sponsorNew":"BridGene Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"BridGene Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"IDE397","moa":"||MAT2A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"MSKCC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ MSKCC","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ MSKCC"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Partner Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ BARDA"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"BioAge Labs","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.55000000000000004,"dosageForm":"Undisclosed","sponsorNew":"BioAge Labs \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"BioAge Labs \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Greenstone Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Creative Medical Technology \/ Greenstone Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Creative Medical Technology \/ Greenstone Biosciences"},{"orgOrder":0,"company":"Nosis Bio","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Nosis Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nosis Bio \/ Daiichi Sankyo","highestDevelopmentStatusID":"3","companyTruncated":"Nosis Bio \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0.55000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.55000000000000004,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Light Horse Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Light Horse Therapeutics","amount2":1.03,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Undisclosed","sponsorNew":"Light Horse Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Light Horse Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Photys Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Photys Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Photys Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Photys Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Neomorph","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Neomorph","amount2":1.6399999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.6399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Neomorph \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ AbbVie Inc"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"RIBOPRO","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ RIBOPRO","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ RIBOPRO"},{"orgOrder":0,"company":"Magnet Biomedicine","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Magnet Biomedicine","amount2":1.29,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.29,"dosageForm":"Undisclosed","sponsorNew":"Magnet Biomedicine \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Magnet Biomedicine \/ Eli Lilly"},{"orgOrder":0,"company":"Gensaic","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Gensaic","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gensaic \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Gensaic \/ Novo Nordisk"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xilio Therapeutics","amount2":2.1499999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":2.1499999999999999,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Xilio Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Transcripta Bio","sponsor":"SOLVE FSHD","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Discovery Platform","graph3":"Transcripta Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcripta Bio \/ SOLVE FSHD","highestDevelopmentStatusID":"3","companyTruncated":"Transcripta Bio \/ SOLVE FSHD"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Genesis Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BlueSphere Bio \/ Celularity","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ Celularity"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"ATTMOS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ ATTMOS","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Biosciences \/ ATTMOS"},{"orgOrder":0,"company":"Kenox Pharmaceuticals","sponsor":"Lactiga","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Kenox Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Kenox Pharmaceuticals \/ Lactiga","highestDevelopmentStatusID":"4","companyTruncated":"Kenox Pharmaceuticals \/ Lactiga"},{"orgOrder":0,"company":"Facet Life Sciences","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Facet Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Facet Life Sciences \/ Cybin","highestDevelopmentStatusID":"10","companyTruncated":"Facet Life Sciences \/ Cybin"},{"orgOrder":0,"company":"Kymanox","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Kymanox","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Kymanox \/ Silo Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kymanox \/ Silo Pharma"},{"orgOrder":0,"company":"OPKO Health","sponsor":"EnteraBio Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OPKO Health \/ EnteraBio Ltd","highestDevelopmentStatusID":"4","companyTruncated":"OPKO Health \/ EnteraBio Ltd"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Decoy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Decoy Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Salarius Pharmaceuticals \/ Decoy Therapeutics"},{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Helix Acquisition Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Oncology Therapeutics \/ Helix Acquisition Corp. II","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Helix Acquisition Corp. II"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kalaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Merger","leadProduct":"TH103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AlloVir \/ Kalaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"AlloVir \/ Kalaris Therapeutics"},{"orgOrder":0,"company":"AB Studio","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"AB Studio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Studio \/ Candid Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"AB Studio \/ Candid Therapeutics"},{"orgOrder":0,"company":"Primrose Bio","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Primrose Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primrose Bio \/ Serum Institute of India","highestDevelopmentStatusID":"3","companyTruncated":"Primrose Bio \/ Serum Institute of India"},{"orgOrder":0,"company":"Humanetics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Department of Defense"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"MT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Myosin Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"4","companyTruncated":"Myosin Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Epidural Injection","sponsorNew":"Scilex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Epidural Injection","sponsorNew":"Scilex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Celadon Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Celadon Partners","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Celadon Partners"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Brookline Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Brookline Capital Markets"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Brookline Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Brookline Capital Markets"},{"orgOrder":0,"company":"Valo Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Valo Health","amount2":4.79,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":4.79,"dosageForm":"Undisclosed","sponsorNew":"Valo Health \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Valo Health \/ Novo Nordisk"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Lynx1","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TSC-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Lynx1","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Lynx1"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Series B Financing","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Intramuscular Injection","sponsorNew":"Curevo Vaccine \/ Medicxi","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Medicxi"},{"orgOrder":0,"company":"Immunis","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunis \/ Remiges Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Remiges Ventures"},{"orgOrder":0,"company":"Qnovia","sponsor":"Blue Ledge Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"QN-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"Qnovia \/ Blue Ledge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Blue Ledge Capital"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"5 Horizons Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Naproxen","moa":"||COX-1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sen-Jam Pharmaceutical \/ 5 Horizons Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sen-Jam Pharmaceutical \/ 5 Horizons Capital"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Starwood Trust","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Telomir-1","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Starwood Trust","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Starwood Trust"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series D Financing","leadProduct":"EIK1001","moa":"||TLR7\/8","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Eikon Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Eikon Therapeutics \/ Lux Capital","highestDevelopmentStatusID":"9","companyTruncated":"Eikon Therapeutics \/ Lux Capital"},{"orgOrder":0,"company":"Elutia","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Financing","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series C Financing","leadProduct":"ENV-294","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"Enveda Bioscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Enveda Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Enveda Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Miist Therapeutics","sponsor":"Refactor Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"MST-01","moa":"nAChR","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Miist Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Miist Therapeutics \/ Refactor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Miist Therapeutics \/ Refactor Capital"},{"orgOrder":0,"company":"Character Biosciences","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Series B Financing","leadProduct":"CTX203","moa":"ABCA1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Character Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Character Biosciences \/ aMoon","highestDevelopmentStatusID":"5","companyTruncated":"Character Biosciences \/ aMoon"},{"orgOrder":0,"company":"iVeena","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"IVMED-85","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"iVeena \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"iVeena \/ Undisclosed"},{"orgOrder":0,"company":"Epicrispr Biotechnologies","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epicrispr Biotechnologies","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.070000000000000007,"dosageForm":"Intravenous","sponsorNew":"Epicrispr Biotechnologies \/ Ally Bridge Group","highestDevelopmentStatusID":"5","companyTruncated":"Epicrispr Biotechnologies \/ Ally Bridge Group"},{"orgOrder":0,"company":"Newleos Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"NTX-1955","moa":"GABAA-\u03b31","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Newleos Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.089999999999999997,"dosageForm":"Oral Capsule","sponsorNew":"Newleos Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"6","companyTruncated":"Newleos Therapeutics \/ Goldman Sachs"},{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"ATL-201","moa":"KCNT1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Atalanta Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Atalanta Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Atalanta Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"LTG-001","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Blue Owl Capital","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Blue Owl Capital"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Nasal Dry Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Belhaven Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Timberlyne Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Series A Financing","leadProduct":"CM313","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"Timberlyne Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Timberlyne Therapeutics \/ Abingworth","highestDevelopmentStatusID":"8","companyTruncated":"Timberlyne Therapeutics \/ Abingworth"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Yorkville","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"CYPS317","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"FibroBiologics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Yorkville","highestDevelopmentStatusID":"4","companyTruncated":"FibroBiologics \/ Yorkville"},{"orgOrder":0,"company":"VisiRose","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VisiRose","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VisiRose \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VisiRose \/ Undisclosed"},{"orgOrder":0,"company":"Light Horse Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Light Horse Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Light Horse Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Light Horse Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Tenvie Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"IND Enabling","graph3":"Tenvie Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Tenvie Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Tenvie Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Tune Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"Tune-401","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tune Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Tune Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"6","companyTruncated":"Tune Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Ampersand Biomedicines","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Ampersand Biomedicines","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Ampersand Biomedicines \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Ampersand Biomedicines \/ Flagship Pioneering"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Williamsburg Venture Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"ORGCAR19","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orgenesis \/ Williamsburg Venture Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Orgenesis \/ Williamsburg Venture Holdings"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Garuda Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Garuda Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Garuda Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"4","companyTruncated":"Garuda Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"STC-004","moa":"NaV1.8","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"SiteOne Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"Encoberminogene Rezmadenovec","moa":"GRP78 upregulation pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"XyloCor Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"CMTX-301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarametyx Biosciences \/ CARB-X","highestDevelopmentStatusID":"2","companyTruncated":"Clarametyx Biosciences \/ CARB-X"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"KAMRA Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Funding","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarametyx Biosciences \/ KAMRA Fund","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ KAMRA Fund"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Funding","leadProduct":"EGL-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Egle Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Egle Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"Egle Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"Ois\u00edn Biotechnologies","sponsor":"Methuselah Foundation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ois\u00edn Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ois\u00edn Biotechnologies \/ Methuselah Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Ois\u00edn Biotechnologies \/ Methuselah Foundation"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Dar\u00e9 Bioscience \/ NIAID","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ NIAID"},{"orgOrder":0,"company":"Myrobalan Therapeutics","sponsor":"National Multiple Sclerosis Society","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"MRO-002","moa":"GPR17","graph1":"Neurology","graph2":"Preclinical","graph3":"Myrobalan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Myrobalan Therapeutics \/ National Multiple Sclerosis Society","highestDevelopmentStatusID":"4","companyTruncated":"Myrobalan Therapeutics \/ National Multiple Sclerosis Society"},{"orgOrder":0,"company":"Omeros","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Eikonizo Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"EKZ-102","moa":"HDAC6","graph1":"Neurology","graph2":"IND Enabling","graph3":"Eikonizo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eikonizo Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Eikonizo Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Medical CBRN Defense Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Medical CBRN Defense Consortium","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Medical CBRN Defense Consortium"},{"orgOrder":0,"company":"Tolerance Bio","sponsor":"Pacific 8 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Tolerance Bio","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Tolerance Bio \/ Pacific 8 Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tolerance Bio \/ Pacific 8 Ventures"},{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"AKV9","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"AKAVA Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"TIXiMED","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"TIX100","moa":"TXNIP","graph1":"Endocrinology","graph2":"Phase I","graph3":"TIXiMED","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TIXiMED \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"6","companyTruncated":"TIXiMED \/ Helmsley Charitable Trust"},{"orgOrder":0,"company":"Vast Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"ALX1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vast Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vast Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Vast Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Kardigan","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Kardigan","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Perceptive Advisors","highestDevelopmentStatusID":"3","companyTruncated":"Kardigan \/ Perceptive Advisors"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Amphotericin B","moa":"||Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"ENTLEP001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entos Pharmaceuticals \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Entos Pharmaceuticals \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"KRHP LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"TVGN 489","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ KRHP LLC","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ KRHP LLC"},{"orgOrder":0,"company":"Micron Biomedical","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"MRV-MNP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Micron Biomedical","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Micron Biomedical \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Micron Biomedical \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Cancer Prevention & Research Institute of Texas"},{"orgOrder":0,"company":"Callio Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Callio Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Callio Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Callio Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"IPMC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scilex Pharmaceuticals \/ IPMC","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ IPMC"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Allosteric Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"GCPII","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Allosteric Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Johns Hopkins University \/ Allosteric Bioscience"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Carina Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"BNC101","moa":"LGR5","graph1":"Oncology","graph2":"Phase I","graph3":"Neuphoria Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuphoria Therapeutics \/ Carina Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Neuphoria Therapeutics \/ Carina Biotech"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Private Placement","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.19,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tectonic Therapeutic \/ Adage Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Adage Capital Partners"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||INF-gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"AIGH Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Private Placement","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Plus Therapeutics \/ AIGH Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ AIGH Capital Management"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Jefferies"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Jefferies"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Tetrodotoxin","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Maxim Group","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Maxim Group"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Candel Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Citigroup","highestDevelopmentStatusID":"10","companyTruncated":"Candel Therapeutics \/ Citigroup"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"SION\u2011719","moa":"NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Oral Tablet","sponsorNew":"Sionna Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"SION\u2011719","moa":"NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.22,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Oral Tablet","sponsorNew":"Sionna Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"D. Boral Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Private Placement","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intraventricular Infusion","sponsorNew":"Plus Therapeutics \/ D. Boral Capital","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ D. Boral Capital"},{"orgOrder":0,"company":"Abpro","sponsor":"YA II PN, LTD","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"ABP-201","moa":"ANG2\/VEGF","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ YA II PN, LTD","highestDevelopmentStatusID":"5","companyTruncated":"Abpro \/ YA II PN, LTD"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ The Column Group","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Private Placement","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Subdermal Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ Leerink Partners"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Alliance Global Partners"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Oppenheimer & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Oppenheimer & Co","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Oppenheimer & Co"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Oppenheimer & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Oppenheimer & Co","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Oppenheimer & Co"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Private Placement","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.17000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.17000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Elutia","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"Elutia \/ Lake Street Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Spartan Capital Securities","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Spartan Capital Securities","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Triton Funds","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Triton Funds","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Triton Funds"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Naya Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Naya Biosciences \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Naya Biosciences \/ Maxim Group LLC"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"DMT310","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"DMT310","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"DMT310","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Genelux","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Public Offering","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Genelux \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Titan Partners Group"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"MAR002","moa":"GHR","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marea Therapeutics \/ ProBioGen","highestDevelopmentStatusID":"5","companyTruncated":"Marea Therapeutics \/ ProBioGen"},{"orgOrder":0,"company":"Corsair Pharma","sponsor":"InstantGMP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Treprostinil Prodrug","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsair Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corsair Pharma \/ InstantGMP","highestDevelopmentStatusID":"6","companyTruncated":"Corsair Pharma \/ InstantGMP"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ConcertAI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"DPTX3186","moa":"CTNNB","graph1":"Oncology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ ConcertAI","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ ConcertAI"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Genetic Immunity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"Plasmid DNA-based HIV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"VectorBuilder \/ Genetic Immunity","highestDevelopmentStatusID":"8","companyTruncated":"VectorBuilder \/ Genetic Immunity"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"RGX-121","moa":"IDS gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0.81000000000000005,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.81000000000000005,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Nippon Shinyaku","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Kodiak Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Kodiak Sciences"},{"orgOrder":0,"company":"CareDx","sponsor":"TC BioPharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"OmnImmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ TC BioPharm","highestDevelopmentStatusID":"8","companyTruncated":"CareDx \/ TC BioPharm"},{"orgOrder":0,"company":"Resilience","sponsor":"Parvus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"PVT401","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Resilience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resilience \/ Parvus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Resilience \/ Parvus Therapeutics"},{"orgOrder":0,"company":"Pluristyx","sponsor":"Humacyte","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"BioVascular Pancreas","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Pluristyx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluristyx \/ Humacyte","highestDevelopmentStatusID":"4","companyTruncated":"Pluristyx \/ Humacyte"},{"orgOrder":0,"company":"Ainos","sponsor":"Taiwan Tanabe Seiyaku","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Partnership","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Taiwan Tanabe Seiyaku","highestDevelopmentStatusID":"15","companyTruncated":"Ainos \/ Taiwan Tanabe Seiyaku"},{"orgOrder":0,"company":"TheraVac","sponsor":"Perceiv AI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"TV-301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"TheraVac","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TheraVac \/ Perceiv AI","highestDevelopmentStatusID":"5","companyTruncated":"TheraVac \/ Perceiv AI"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ Undisclosed"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"JuvVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Financing","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Serina Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Serina Therapeutics \/ JuvVentures","highestDevelopmentStatusID":"5","companyTruncated":"Serina Therapeutics \/ JuvVentures"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Be Biopharma \/ Nextech","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Nextech"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Financing","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"Normunity","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series B Financing","leadProduct":"NRM-823","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Normunity","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Normunity \/ Enavate Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Normunity \/ Enavate Sciences"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"Rapamycin","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Umoja Biopharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Double Point Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Umoja Biopharma \/ Double Point Ventures"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"NVG-2089","moa":"Fc\u03b3R","graph1":"Neurology","graph2":"Phase II","graph3":"Nuvig Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Nuvig Therapeutics \/ Sanofi Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Nuvig Therapeutics \/ Sanofi Ventures"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Blue Owl Healthcare Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Blue Owl Healthcare Opportunities","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Blue Owl Healthcare Opportunities"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series C Financing","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.20999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"TN-401","moa":"PKP2 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"BioAtla","sponsor":"Tungsten Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Private Placement","leadProduct":"Mecbotamab Vedotin","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAtla \/ Tungsten Advisors","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Tungsten Advisors"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Surrozen","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Private Placement","leadProduct":"SZN-8141","moa":"FZD4\/VEGF","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Surrozen","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Undisclosed"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ DCVC Bio","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ DCVC Bio"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Rocketvax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"RVX-13","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Rocketvax","highestDevelopmentStatusID":"4","companyTruncated":"Emergent BioSolutions \/ Rocketvax"},{"orgOrder":0,"company":"Bambusa Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Series A Financing","leadProduct":"BBT001","moa":"IL-4R alpha\/IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Bambusa Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Bambusa Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Bambusa Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"TMP-301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"Oral Capsule","sponsorNew":"Tempero Bio \/ 8VC","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ 8VC"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"A2 Biotherapeutics \/ The Column Group","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ The Column Group"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"ABO-101","moa":"GOX","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies, Inc","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"Arbor Biotechnologies, Inc \/ ARCH Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies, Inc \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"ATL-201","moa":"KCNT1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Atalanta Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Atalanta Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Atalanta Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Hinge Bio","sponsor":"Ridgeback Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Series A Financing","leadProduct":"HB2198","moa":"CD19\/20","graph1":"Immunology","graph2":"Preclinical","graph3":"Hinge Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Hinge Bio \/ Ridgeback Capital","highestDevelopmentStatusID":"4","companyTruncated":"Hinge Bio \/ Ridgeback Capital"},{"orgOrder":0,"company":"Perceive Pharma","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"PBI-671","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Perceive Pharma","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Perceive Pharma \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Perceive Pharma \/ Johnson & Johnson"},{"orgOrder":0,"company":"Junevity","sponsor":"Goldcrest Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Junevity","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Junevity \/ Goldcrest Capital","highestDevelopmentStatusID":"4","companyTruncated":"Junevity \/ Goldcrest Capital"},{"orgOrder":0,"company":"Terray Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Terray Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terray Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Terray Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Cemiplimab","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Universal Cells","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Universal Cells","highestDevelopmentStatusID":"3","companyTruncated":"Ginkgo Bioworks \/ Universal Cells"},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Capsida","amount2":0.62,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.62,"dosageForm":"Intravenous","sponsorNew":"Capsida \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ AbbVie Inc"},{"orgOrder":0,"company":"Whitecap Biosciences","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"WB007","moa":"Adrenergic receptor alpha-1","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Whitecap Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Whitecap Biosciences \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"7","companyTruncated":"Whitecap Biosciences \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"Idecabtagene Vicleucel","moa":"CD-38","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0.28999999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0.28999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"2Seventy Bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"BRII-179","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Brii Biosciences"},{"orgOrder":0,"company":"Nova Pharmaceuticals","sponsor":"Galera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Targinine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nova Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nova Pharmaceuticals \/ Galera Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Nova Pharmaceuticals \/ Galera Therapeutics"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Immedica Pharma"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Acquisition","leadProduct":"177-Lu EVG-321","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Lantheus Holding","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen Theragnostics \/ Lantheus Holding"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"FXR314","moa":"FXR","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Eli Lilly"},{"orgOrder":0,"company":"Stanford University","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"VT-109","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Undisclosed","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Vera Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Stanford University \/ Vera Therapeutics"},{"orgOrder":0,"company":"Nudge Therapeutics","sponsor":"Veralox Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"cGAS","graph1":"Immunology","graph2":"Preclinical","graph3":"Nudge Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nudge Therapeutics \/ Veralox Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nudge Therapeutics \/ Veralox Therapeutics"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ABI-6250","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloy Therapeutics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Povetacicept","moa":"B cell cytokine","graph1":"Nephrology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vertex Pharmaceuticals \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Zai Lab"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"SGN-BB228","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Palvella Therapeutics \/ Pieris Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Palvella Therapeutics \/ Pieris Pharmaceuticals"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Ikena Oncology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Merger","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Ikena Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Ikena Oncology"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnershipjavscript:void(0)","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genesis Therapeutics \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Foundery Immune Studio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"PY314","moa":"TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ikena Oncology \/ Foundery Immune Studio","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Foundery Immune Studio"},{"orgOrder":0,"company":"Oqory","sponsor":"Vincerx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Termination","leadProduct":"ESG401","moa":"TROP2","graph1":"Oncology","graph2":"Phase III","graph3":"Oqory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oqory \/ Vincerx Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Oqory \/ Vincerx Pharma"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Verve Therapeutics","amount2":0.46999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0.46999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Verve Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"IDRx","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":1.1499999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1499999999999999,"dosageForm":"Oral Tablet","sponsorNew":"IDRx \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ GSK"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"TrialNet","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ TrialNet","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ TrialNet"},{"orgOrder":0,"company":"TRIO Pharmaceuticals","sponsor":"FBVF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"CD33 TRAILBody","moa":"CD33","graph1":"Oncology","graph2":"Preclinical","graph3":"TRIO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRIO Pharmaceuticals \/ FBVF","highestDevelopmentStatusID":"4","companyTruncated":"TRIO Pharmaceuticals \/ FBVF"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Genenta Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Pembrolizumab","moa":"||IL-alpha 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Genenta Science","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Genenta Science"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Alanis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ Alanis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Alanis Therapeutics"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Eckert & Ziegler Strahlen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Eckert & Ziegler Strahlen","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Eckert & Ziegler Strahlen"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Revance Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Therapeutics \/ Revance Therapeutics"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"GRC 65327","moa":"cbl-b","graph1":"Oncology","graph2":"Preclinical","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ichnos Glenmark Innovation \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Ichnos Glenmark Innovation \/ National Cancer Institute"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Kyorin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Kyorin Pharmaceutical"},{"orgOrder":0,"company":"InflammX Therapeutics","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Tonabersat","moa":"GJs","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"InflammX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InflammX Therapeutics \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"9","companyTruncated":"InflammX Therapeutics \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Kineta","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Agreement","leadProduct":"KCP506","moa":"nAchR","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kineta \/ Pacira BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Pacira BioSciences"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Cowellnex","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Cowellnex","highestDevelopmentStatusID":"2","companyTruncated":"Siolta Therapeutics \/ Cowellnex"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"UAB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ UAB","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ UAB"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"WY Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HCW Biologics \/ WY Biotech","highestDevelopmentStatusID":"4","companyTruncated":"HCW Biologics \/ WY Biotech"},{"orgOrder":0,"company":"MalarVx","sponsor":"HDT Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"MalarVx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MalarVx \/ HDT Biotech","highestDevelopmentStatusID":"3","companyTruncated":"MalarVx \/ HDT Biotech"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"ARO-DUX4","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":11.380000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":11.380000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Sarepta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Ailux Biologics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ailux Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ailux Biologics \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"Ailux Biologics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"AB-4000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArsenalBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"ArsenalBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AstralBio","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"IBIO-600","moa":"MSTN","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"AstralBio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Subcutaneous","sponsorNew":"AstralBio \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"AstralBio \/ iBio"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"MTX-463","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Mediar Therapeutics","amount2":0.79000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.79000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Mediar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"LX9851","moa":"ACSL5","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexicon pharmaceuticals","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lexicon pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"Sapablursen","moa":"TMPRSS6","graph1":"Oncology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.93999999999999995,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Megalith Pharmaceuticals","sponsor":"Radiance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"RB-164","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"Megalith Pharmaceuticals","amount2":1.1699999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Undisclosed","sponsorNew":"Megalith Pharmaceuticals \/ Radiance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Megalith Pharmaceuticals \/ Radiance Biopharma"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Restoration Biologics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CB\/COX-2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Restoration Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Restoration Biologics"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"BDTX-4933","moa":"RAS\/RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0.78000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.78000000000000003,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Servier"},{"orgOrder":0,"company":"MaxCyte","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MaxCyte \/ TG Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ TG Therapeutics"},{"orgOrder":0,"company":"HBM Alpha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"HAT001","moa":"CRH","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"HBM Alpha Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"HBM Alpha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"HBM Alpha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Tivic Health Systems","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"Entolimod","moa":"TLR5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Statera Biopharma \/ Tivic Health Systems","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ Tivic Health Systems"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AnaptysBio \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Windward Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"HBM-9378","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Harbour BioMed","amount2":0.96999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.96999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Windward Bio","highestDevelopmentStatusID":"6","companyTruncated":"Harbour BioMed \/ Windward Bio"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Alumis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acelyrin \/ Alumis","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Alumis"},{"orgOrder":0,"company":"Oqory","sponsor":"Vincerx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Merger","leadProduct":"ESG401","moa":"TROP2","graph1":"Oncology","graph2":"Phase III","graph3":"Oqory","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oqory \/ Vincerx Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Oqory \/ Vincerx Pharma"},{"orgOrder":0,"company":"Abpro","sponsor":"Atlantic Coastal Acquisition Corp II","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"ABP-201","moa":"ANG2\/VEGF","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Atlantic Coastal Acquisition Corp II","highestDevelopmentStatusID":"5","companyTruncated":"Abpro \/ Atlantic Coastal Acquisition Corp II"},{"orgOrder":0,"company":"Kineta","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Merger","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ TuHURA Biosciences"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"THIO-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ BeiGene"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Amivantamab","moa":"||EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"ORIC Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atavistik Bio \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Atavistik Bio \/ Pfizer Inc"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hummingbird Bioscience \/ Immunome","highestDevelopmentStatusID":"2","companyTruncated":"Hummingbird Bioscience \/ Immunome"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GV20 Therapeutics \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"3","companyTruncated":"GV20 Therapeutics \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Cellipont Bioservices","sponsor":"Secretome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cellipont Bioservices","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellipont Bioservices \/ Secretome Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cellipont Bioservices \/ Secretome Therapeutics"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"IDEA Pharma Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Partnership","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ IDEA Pharma Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Candel Therapeutics \/ IDEA Pharma Ltd"},{"orgOrder":0,"company":"IconOVir Bio","sponsor":"UroGen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Acquisition","leadProduct":"ICVB-1042","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IconOVir Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IconOVir Bio \/ UroGen Pharma","highestDevelopmentStatusID":"6","companyTruncated":"IconOVir Bio \/ UroGen Pharma"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"VCAR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Ypsilon Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"T cell receptor","graph1":"Oncology","graph2":"Discovery","graph3":"Ypsilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ypsilon Therapeutics \/ CPRIT","highestDevelopmentStatusID":"2","companyTruncated":"Ypsilon Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Evolus","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Leerink Partners"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Barclays","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Barclays"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Immunocore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"Brenetafusp","moa":"||PRAME","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Immunocore","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Immunocore"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"AGEPHA Pharma US","sponsor":"Caristo Diagnostics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Collaboration","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AGEPHA Pharma US","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AGEPHA Pharma US \/ Caristo Diagnostics","highestDevelopmentStatusID":"15","companyTruncated":"AGEPHA Pharma US \/ Caristo Diagnostics"},{"orgOrder":0,"company":"HOPE Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Merger","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HOPE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HOPE Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"HOPE Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Lee\u2019s Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Lee\u2019s Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Lee\u2019s Pharmaceutical"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Chang Gung University","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Chang Gung University","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Chang Gung University"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Ferrer Internacional","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Ferrer Internacional"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumos Pharma \/ Double Point Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Double Point Ventures"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Centhaquine","moa":"Adrenergic receptor-alpha 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Tenax Therapeutics \/ Orion Corporation"},{"orgOrder":0,"company":"INmune Bio","sponsor":"OmniScience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Partnership","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ OmniScience","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ OmniScience"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"VK2809","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"VK2809","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"VK2809","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Immunome"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Great Point Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Great Point Partners","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Great Point Partners"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Cosette Pharma"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Fampridine","moa":"Voltage-gated Potassium Channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"Acorda Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Itraconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Cipla","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Cipla"},{"orgOrder":0,"company":"CareMed","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"CareMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareMed \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"CareMed \/ Eisai"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Financing","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Abingworth","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Abingworth"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Medicinova","sponsor":"WideTrial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ WideTrial","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ WideTrial"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Divestment","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Sandoz B2B"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Divestment","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Sandoz B2B"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Emory University","sponsor":"MAPS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"3,4-Methylenedioxymethamphetamine HCl","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Emory University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emory University \/ MAPS","highestDevelopmentStatusID":"8","companyTruncated":"Emory University \/ MAPS"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tomivosertib","moa":"||MAPK 1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tomivosertib","moa":"||MAPK 1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Optime Care","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Optime Care","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Optime Care"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Paulson Investment Company","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Paulson Investment Company"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Gameday Men\u2019s Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Gameday Men\u2019s Health","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Gameday Men\u2019s Health"},{"orgOrder":0,"company":"Enable Injections","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Enable Injections","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Enable Injections \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Enable Injections \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Lipocine","sponsor":"Pharmalink, S.L.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Pharmalink, S.L.","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Pharmalink, S.L."},{"orgOrder":0,"company":"Lipocine","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Lipocine","sponsor":"SPC Pharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ SPC Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ SPC Pharm"},{"orgOrder":0,"company":"Lipocine","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Opus Genetics \/ Ocuphire Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Opus Genetics \/ Ocuphire Pharma"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Roth Capital Partners"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Roth Capital Partners"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Alliance Global Partners"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Premier"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sarissa Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series E Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sarissa Capital","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sarissa Capital"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"AV0328","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alopexx Oncology \/ Bharat Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Alopexx Oncology \/ Bharat Biotech"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Biotech Consortia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"AV0328","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alopexx Oncology \/ Biotech Consortia","highestDevelopmentStatusID":"7","companyTruncated":"Alopexx Oncology \/ Biotech Consortia"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"CONNECT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rigel Pharmaceuticals \/ CONNECT","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Pharmaceuticals \/ CONNECT"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Abiraterone Decanoate","moa":"||CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Neurelis","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ OrbiMed","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ OrbiMed"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Series B Financing","leadProduct":"ENX-102","moa":"GABA A Alpha 2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Engrail Therapeutics \/ F-Prime Capital","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ F-Prime Capital"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Zuellig Pharma"},{"orgOrder":0,"company":"Rho","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Rho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Rho \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"10","companyTruncated":"Rho \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Alliance Global Partners"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"ALK-ABELLO INC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ ALK-ABELLO INC","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ ALK-ABELLO INC"},{"orgOrder":0,"company":"TheracosBio","sponsor":"BAMCO Africa","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ BAMCO Africa","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ BAMCO Africa"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Independent Pharmacy Cooperative","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ Independent Pharmacy Cooperative","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Independent Pharmacy Cooperative"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ J.P. Morgan"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ BVF Partners LP","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ BVF Partners LP"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series A Financing","leadProduct":"Cusatuzumab","moa":"||CD70","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Argenx"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"TOUR006","moa":"IL-6 signalling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tourmaline Bio \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Jefferies"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"TOUR006","moa":"IL-6 signalling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tourmaline Bio \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Jefferies"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ U.S. Department of Defense"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ WallachBeth Capital","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ WallachBeth Capital"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rafael Holdings","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rafael Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rafael Holdings \/ Cyclo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Rafael Holdings \/ Cyclo Therapeutics"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Australian Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Linezolid","moa":"||Adenosine triphosphatase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Australian Government","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Australian Government"},{"orgOrder":0,"company":"Sycamore BioPharma","sponsor":"Branded Legacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sycamore BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Sycamore BioPharma \/ Branded Legacy","highestDevelopmentStatusID":"15","companyTruncated":"Sycamore BioPharma \/ Branded Legacy"},{"orgOrder":0,"company":"MacroGenics","sponsor":"TerSera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Margetuximab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ TerSera Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ TerSera Therapeutics"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Abbvie Inc"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Pathos","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Pathos"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Propel Bio Partners LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Propel Bio Partners LLC","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Propel Bio Partners LLC"},{"orgOrder":0,"company":"The Ritedose Corporation","sponsor":"Verona Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"The Ritedose Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"The Ritedose Corporation \/ Verona Pharma","highestDevelopmentStatusID":"15","companyTruncated":"The Ritedose Corporation \/ Verona Pharma"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Lupin Pharma Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aytu BioPharma \/ Lupin Pharma Canada","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Lupin Pharma Canada"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"WEX Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Tetrodotoxin","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dogwood Therapeutics \/ WEX Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ WEX Pharmaceuticals"},{"orgOrder":0,"company":"Talphera","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Talphera \/ XOMA","highestDevelopmentStatusID":"15","companyTruncated":"Talphera \/ XOMA"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"U.S. Renal Care","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akebia Therapeutics \/ U.S. Renal Care","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ U.S. Renal Care"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Bosakitug","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aclaris Therapeutics \/ Vivo Capital","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Vivo Capital"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Lonza Group","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Lonza Group"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Bezuclastinib","moa":"||KIT","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Nobelpharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Naxitamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Nobelpharma","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Nobelpharma"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ SWK Holdings Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"CrossLink Life Sciences","sponsor":"Heron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"CrossLink Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"CrossLink Life Sciences \/ Heron Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CrossLink Life Sciences \/ Heron Therapeutics"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Leiden University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Leiden University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Leiden University Medical Center"},{"orgOrder":0,"company":"Benuvia","sponsor":"Medra Brasil Medicamentos","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Benuvia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benuvia \/ Medra Brasil Medicamentos","highestDevelopmentStatusID":"15","companyTruncated":"Benuvia \/ Medra Brasil Medicamentos"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"VA CSRD","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benuvia Therapeutics \/ VA CSRD","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Therapeutics \/ VA CSRD"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Votoplam","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Bayer AG"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"NewCo","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Mk-3655","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ NewCo","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ NewCo"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"GEICAM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ GEICAM","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ GEICAM"},{"orgOrder":0,"company":"Sipp Industries","sponsor":"SinuSave","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sipp Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Sipp Industries \/ SinuSave","highestDevelopmentStatusID":"15","companyTruncated":"Sipp Industries \/ SinuSave"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Partnership","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Acquisition","leadProduct":"177-Lu PNT2002","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Divestment","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Tenacia Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Emcure Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Emcure Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Emcure Pharmaceuticals"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Eva Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Eva Pharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Ferozsons Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Ferozsons Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Ferozsons Laboratories"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Viatris"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Hetero Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Hetero Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Hetero Biopharma"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Prevail Partners","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Prevail Partners"},{"orgOrder":0,"company":"Geron","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Royalty Pharma"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Public Offering","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Geron","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ TD Cowen"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Norgine"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Bayer AG"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Bayer AG"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Blue Owl Capital","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Blue Owl Capital"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor ant","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olema Oncology \/ Adage Capital Partners LP","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Adage Capital Partners LP"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Inspirna","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"RGX-202","moa":"||SLC6a8\/CKB pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inspirna \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Inspirna \/ Merck Group"},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"LadRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"9","companyTruncated":"LadRx \/ XOMA"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Newron Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Zambon Group SpA"},{"orgOrder":0,"company":"Areteia Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Dexpramipexole","moa":"Eosinophil maturation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Areteia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Areteia Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"10","companyTruncated":"Areteia Therapeutics \/ Viking Global Investors"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Helena","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Series A Financing","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Helena","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Helena"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ J.P. Morgan"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Neuraxpharm"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Renalys Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Renalys Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Renalys Pharma"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Viatris"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Numan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Numan","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Numan"},{"orgOrder":0,"company":"Tolmar","sponsor":"UpScriptHealth","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tolmar \/ UpScriptHealth","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ UpScriptHealth"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Samsara BioCapital"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Charles River Laboratories, Inc \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Astellas Pharma"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Elevian","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"rGDF11","moa":"Nerve tissue growth","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elevian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevian \/ Prime Movers Lab","highestDevelopmentStatusID":"4","companyTruncated":"Elevian \/ Prime Movers Lab"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Craig-Hallum Capital Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Private Placement","leadProduct":"Rinvecalinase Alpha","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Craig-Hallum Capital Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Private Placement","leadProduct":"Rinvecalinase Alpha","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC"},{"orgOrder":0,"company":"Hopstem Biotechnology","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"hNPC01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Hopstem Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hopstem Biotechnology \/ Lilly Asia Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Hopstem Biotechnology \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Qatar Investment Authority","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Qatar Investment Authority","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Qatar Investment Authority"},{"orgOrder":0,"company":"Athersys","sponsor":"Healios K.K","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Healios K.K","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/ Healios K.K"},{"orgOrder":0,"company":"Censa Pharmaceuticals","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Endocrinology","graph2":"Phase II","graph3":"Censa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Censa Pharmaceuticals \/ PTC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Censa Pharmaceuticals \/ PTC Therapeutics"},{"orgOrder":0,"company":"MRM Health","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MRM Health \/ International Flavors and Fragrances","highestDevelopmentStatusID":"1","companyTruncated":"MRM Health \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Insitro","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Insitro","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insitro \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Insitro \/ Eli Lilly"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"AMPK","graph1":"Endocrinology","graph2":"Discovery","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Nimbus Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Michigan Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fractyl Health \/ Michigan Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Fractyl Health \/ Michigan Medicine"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regenxbio \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Regenxbio \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regor Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Regor Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Medicaid","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Medicaid","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Medicaid"},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Group \/ Editas Medicine"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Gen Pharmaceuticals and Health Products","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Gen Pharmaceuticals and Health Products","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Gen Pharmaceuticals and Health Products"},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/ White Lion Capital"},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Hercules Capital"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Asembia","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Asembia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Asembia \/ Emmaus Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Asembia \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Collaboration","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"MGTA-145","moa":"||CXCR2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Bluebird Bio"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ GSK"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korro Bio \/ Genevant Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Korro Bio \/ Genevant Sciences"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency Therapeutics \/ Korro Bio"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency Therapeutics \/ Korro Bio"},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/ White Lion Capital"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korro Bio \/ Eventide Asset Management","highestDevelopmentStatusID":"2","companyTruncated":"Korro Bio \/ Eventide Asset Management"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"National Heart, Lung, And Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, And Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, And Blood Institute"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Private Placement","leadProduct":"KRRO-110","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Group \/ Editas Medicine"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ DRI Healthcare Trust","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Magenta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"MGTA-117","moa":"CD117","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Magenta Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Beam Therapeutics \/ Magenta Therapeutics"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Newco","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Newco","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Newco"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Charles River Laboratories, Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Charles River Laboratories, Inc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Kamau Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Kamau Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Kamau Therapeutics"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.24,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Aldevron","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aldevron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aldevron \/ Aruvant Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Aldevron \/ Aruvant Sciences"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"PBGENE-HbE","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Immunogen","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Editas Medicine \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Guide Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Guide Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guide Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Guide Therapeutics \/ Beam Therapeutics"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Deep Track Capital","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Deep Track Capital"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etrasimod","moa":"S1PR","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Brazikumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Assembly Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Termination","leadProduct":"Brazikumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Divestment","leadProduct":"Brazikumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ AstraZeneca"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Astellas Pharma"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Merger","leadProduct":"CYTO-200","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Cleveland Clinic","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland Clinic"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"InDex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Immunology","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"Parexel Biotech \/ InDex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Biotech \/ InDex Pharmaceuticals"},{"orgOrder":0,"company":"D. E. Shaw Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DES-7114","moa":"KV1.3 potassium ion channel","graph1":"Immunology","graph2":"Phase I","graph3":"D. E. Shaw Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"D. E. Shaw Research \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"D. E. Shaw Research \/ Eli Lilly"},{"orgOrder":0,"company":"Reprocell","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"HT-003","moa":"TLR2","graph1":"Immunology","graph2":"Preclinical","graph3":"Reprocell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reprocell \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Reprocell \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Progenity","sponsor":"Crohn\u2019s & Colitis Foundation IBD Ventures Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Crohn\u2019s & Colitis Foundation IBD Ventures Fund","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Crohn\u2019s & Colitis Foundation IBD Ventures Fund"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ LianBio","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ LianBio"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"CYTO-201","moa":"Mu opioid receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Cleveland Clinic","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland Clinic"},{"orgOrder":0,"company":"NIMML Institute","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"NIMML Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NIMML Institute \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"NIMML Institute \/ NImmune Biopharma"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Nurix Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Niclosamide","moa":"Wnt signaling","graph1":"Immunology","graph2":"IND Enabling","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"PPD \/ First Wave BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"PPD \/ First Wave BioPharma"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ SVB Leerink"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"FIN-524","moa":"Microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Eli Lilly"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Tulisokibart","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Vivtex","sponsor":"AI Proteins","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Vivtex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vivtex \/ AI Proteins","highestDevelopmentStatusID":"3","companyTruncated":"Vivtex \/ AI Proteins"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"KU Leuven","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ KU Leuven","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ KU Leuven"},{"orgOrder":0,"company":"Synthekine","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synthekine \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Synthekine \/ Sanofi"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Strand Life Sciences"},{"orgOrder":0,"company":"Vitality","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Cannabosides","moa":"CB1 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Vitality","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitality \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vitality \/ Undisclosed"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Biotechnology Value Fund","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Biotechnology Value Fund"},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Jade Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jade Biosciences \/ Fairmount","highestDevelopmentStatusID":"2","companyTruncated":"Jade Biosciences \/ Fairmount"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"AMT-101","moa":"IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ BofA Securities"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roivant Sciences \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"DeepCure","sponsor":"IAG Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Brd4","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"DeepCure","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DeepCure \/ IAG Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"DeepCure \/ IAG Capital Partners"},{"orgOrder":0,"company":"Highmark","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Highmark","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highmark \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Highmark \/ UCB Pharma S.A"},{"orgOrder":0,"company":"AltruBio","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ BVF Partners LP","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ BVF Partners LP"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Foralumab","moa":"CD3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Parexel Biotech \/ Tiziana Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Parexel Biotech \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"STAT-201","moa":"Opioid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Statera Biopharma \/ EF Hutton","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ EF Hutton"},{"orgOrder":0,"company":"Cerecor","sponsor":"Horizon Technology Finance Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"AEVI-002","moa":"LIGHT","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Horizon Technology Finance Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Horizon Technology Finance Corporation"},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Telavant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Telavant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Niclosamide","moa":"DNA","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Vedolizumab","moa":"Integrin-alpha 4\/beta 7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Massachusetts General Hospital \/ Royalty Pharma"},{"orgOrder":0,"company":"Atomwise","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Pellino protein","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atomwise \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Applied BioMath","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celsius Therapeutics \/ Applied BioMath","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ Applied BioMath"},{"orgOrder":0,"company":"GenBio","sponsor":"Strainsforpains","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"GenBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenBio \/ Strainsforpains","highestDevelopmentStatusID":"5","companyTruncated":"GenBio \/ Strainsforpains"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Icotrokinra","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Protagonist Therapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Superior Biologics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Superior Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Superior Biologics \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Superior Biologics \/ Coherus Biosciences"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Brigham and Women\u2019s Hospital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Collaboration","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Immunology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Brigham and Women\u2019s Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Brigham and Women\u2019s Hospital"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"TScan Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Etrasimod","moa":"S1PR","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"VTX002","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"VTX002","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies LLC","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies LLC"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Merger","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"HintMD","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"HintMD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HintMD \/ Revance Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"HintMD \/ Revance Therapeutics"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Nephraegis Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"NPH-022","moa":"Epoxyeicosatrienoic acid","graph1":"Nephrology","graph2":"Preclinical","graph3":"Nephraegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nephraegis Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Nephraegis Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"AM-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Agreement","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KBI Biopharma \/ AM-Pharma","highestDevelopmentStatusID":"10","companyTruncated":"KBI Biopharma \/ AM-Pharma"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Stannic Protoporfin","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"Rex Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Nephrology","graph2":"Phase II","graph3":"Rediscovery Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rediscovery Life Sciences \/ Rex Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Rediscovery Life Sciences \/ Rex Health Ventures"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CalciMedica \/ Deerfield Management","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Deerfield Management"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Juniper Point","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Stannic Protoporfin","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Juniper Point","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Juniper Point"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Vera Therapeutics"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xortx Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Bio-Techne","sponsor":"Luminary Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"LMY-920","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio-Techne","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Techne \/ Luminary Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Techne \/ Luminary Therapeutics"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Pharmacyclics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Ibrutinib","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Pharmacyclics"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ RBC Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ RBC Capital Markets"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Xentria","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"XTMAB-16","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xentria \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"ER-004","moa":"EDA1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"AGC Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"AGC Biologics \/ Pierre Fabre"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"ACTX-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Alcyone Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcyone Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"4","companyTruncated":"Alcyone Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Gaboxadol","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Angelini Pharma"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"FOXG1 Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ FOXG1 Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ FOXG1 Research Foundation"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"University of North Carolina \/ AskBio"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"University of North Carolina \/ AskBio"},{"orgOrder":0,"company":"Foundation for Angelman Syndrome Therapeutics","sponsor":"Lixte Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"LB-100","moa":"PP2A","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Foundation for Angelman Syndrome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Foundation for Angelman Syndrome Therapeutics \/ Lixte Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Foundation for Angelman Syndrome Therapeutics \/ Lixte Biotechnology"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"TSHA-118","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gene Therapies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Dicerna Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"DyDo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ DyDo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ DyDo Pharma"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Pfizer Inc"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2022","type":"Acquisition","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Herophilus","sponsor":"Rett Syndrome Research Trust","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"HRP-12975","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Herophilus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Herophilus \/ Rett Syndrome Research Trust","highestDevelopmentStatusID":"4","companyTruncated":"Herophilus \/ Rett Syndrome Research Trust"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"ATR-12","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ ThinkEquity"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultragenyx Pharmaceutical \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Ultragenyx Pharmaceutical \/ n-Lorem Foundation"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Arctic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Arctic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Nacuity Pharmaceuticals \/ Arctic Therapeutics"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Usher III Initiative","sponsor":"Foundation Fighting Blindness","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"BF844","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Usher III Initiative","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Usher III Initiative \/ Foundation Fighting Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Usher III Initiative \/ Foundation Fighting Blindness"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"University of Connecticut","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Gaboxadol","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ University of Connecticut","highestDevelopmentStatusID":"1","companyTruncated":"Ovid Therapeutics \/ University of Connecticut"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PANTHERx Rare Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Pharmanovia","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ARM210","moa":"RYR2","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ARMGO Pharma \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Forbion"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Endo Ventures Limited","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Endo Ventures Limited","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Endo Ventures Limited"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"PellePharm","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"PellePharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PellePharm \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inozyme Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alexion Pharmaceuticals \/ Inozyme Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Alexion Pharmaceuticals \/ Inozyme Pharma"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Lantu Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"LTGT06","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"VectorBuilder \/ Lantu Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"VectorBuilder \/ Lantu Biopharma"},{"orgOrder":0,"company":"Aegle Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"AGLE-102","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Aegle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aegle Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Aegle Therapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Axovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"AXV-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Rhythm Pharmaceuticals \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Resilience","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"BBP-812","moa":"ASPA gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Resilience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Resilience \/ BridgeBio Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Resilience \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Axovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"AXV-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Neurogene","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Neoleukin Therapeutics \/ Neurogene","highestDevelopmentStatusID":"7","companyTruncated":"Neoleukin Therapeutics \/ Neurogene"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Neurogene","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Neoleukin Therapeutics \/ Neurogene","highestDevelopmentStatusID":"7","companyTruncated":"Neoleukin Therapeutics \/ Neurogene"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Public Offering","leadProduct":"Strain of Staphylococcus Epidermidis","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ ThinkEquity"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Public Offering","leadProduct":"ATR-12","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ ThinkEquity"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"ATR-12","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ ThinkEquity"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ BofA Securities"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Perceptive Advisors LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Perceptive Advisors LLC","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Perceptive Advisors LLC"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"10","companyTruncated":"Castle Creek Biosciences \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ RA Capital Management"},{"orgOrder":0,"company":"The Texas A&M University System","sponsor":"Engrail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Elesclomol","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"The Texas A&M University System","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"The Texas A&M University System \/ Engrail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Texas A&M University System \/ Engrail Therapeutics"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"AAV-ATP7A","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cyprium Therapeutics \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Cyprium Therapeutics \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ BVF Partners L.P","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ BVF Partners L.P"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"U.S. Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ U.S. Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Castle Creek Biosciences \/ U.S. Food & Drug Administration"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ GordonMD Global Investments","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Neurogene","sponsor":"Great Point Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Neurogene \/ Great Point Partners","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene \/ Great Point Partners"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Jefferies"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Jefferies"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ BofA Securities"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Peter Hecht","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Zagociguat","moa":"sGC","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclerion Therapeutics \/ Peter Hecht","highestDevelopmentStatusID":"4","companyTruncated":"Cyclerion Therapeutics \/ Peter Hecht"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Stifel","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Stifel"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Avoro Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Avoro Capital Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Avoro Capital Advisors"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Suvretta Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"HST5040","moa":"CoA","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"HemoShear Therapeutics \/ Suvretta Capital","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear Therapeutics \/ Suvretta Capital"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Agreement","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Cholic Acid","moa":"Bile acid synthesis","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Travere Therapeutics \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Pozelimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Astellas Pharma"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Orpharm","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Orpharm","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Orpharm"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Neopharm"},{"orgOrder":0,"company":"Pinetree Therapeutics","sponsor":"STIC Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Pinetree Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pinetree Therapeutics \/ STIC Investments","highestDevelopmentStatusID":"3","companyTruncated":"Pinetree Therapeutics \/ STIC Investments"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Isotopia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Isotopia","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Isotopia"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Novartis Innovative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Divestment","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Novartis Innovative Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Novartis Innovative Therapies"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Galinpepimut-S","moa":"WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"4D-125","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Arbor Biotechnologies, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Molecular Therapeutics \/ Arbor Biotechnologies, Inc","highestDevelopmentStatusID":"4","companyTruncated":"4D Molecular Therapeutics \/ Arbor Biotechnologies, Inc"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"7HP935","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ CPRIT"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"9 Meters Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Vurolenatide","moa":"GLP-1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Duke Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Duke Clinical Research Institute \/ 9 Meters Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Duke Clinical Research Institute \/ 9 Meters Biopharma"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Cancer Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ENB003","moa":"||ETB receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Cancer Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Coherus Biosciences \/ Cancer Research Institute"},{"orgOrder":0,"company":"APIRx","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tetrahydrocannabivarin","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"APIRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APIRx \/ Incannex Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"APIRx \/ Incannex Healthcare"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Gavi","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Gavi"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Iconic Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"XB002","moa":"Tissue Factor","graph1":"Oncology","graph2":"Preclinical","graph3":"Iconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iconic Therapeutics \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Iconic Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"Honeywell","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Partnership","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Honeywell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"Honeywell \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Honeywell \/ AstraZeneca"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Hercules Capital"},{"orgOrder":0,"company":"University of Massachusetts Medical School","sponsor":"Foundation to Fight H-ABC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"University of Massachusetts Medical School","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts Medical School \/ Foundation to Fight H-ABC","highestDevelopmentStatusID":"2","companyTruncated":"University of Massachusetts Medical School \/ Foundation to Fight H-ABC"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ BARDA"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"177-Lu EBTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Targeting Technologies \/ Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Targeting Technologies \/ Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Pharmakon Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Pharmakon Advisors"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Tumor cell killer","graph1":"Oncology","graph2":"Preclinical","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"A2 Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"A2 Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Access to Advanced Health Institute","sponsor":"Defense Innovation Unit","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Access to Advanced Health Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray, Metered","sponsorNew":"Access to Advanced Health Institute \/ Defense Innovation Unit","highestDevelopmentStatusID":"4","companyTruncated":"Access to Advanced Health Institute \/ Defense Innovation Unit"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Denatonium Acetate","moa":"TAS2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"NJ Biopharmaceuticals","sponsor":"Aarvik","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"NJ Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NJ Biopharmaceuticals \/ Aarvik","highestDevelopmentStatusID":"4","companyTruncated":"NJ Biopharmaceuticals \/ Aarvik"},{"orgOrder":0,"company":"AavantiBio","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AavantiBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AavantiBio \/ Sarepta Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"AavantiBio \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Angiocrine Bioscience","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"AB-205","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Angiocrine Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Angiocrine Bioscience \/ CIRM","highestDevelopmentStatusID":"10","companyTruncated":"Angiocrine Bioscience \/ CIRM"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Series C Financing","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Acidified Nitrite","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"University of Cincinnati \/ Arch Biopartners","highestDevelopmentStatusID":"4","companyTruncated":"University of Cincinnati \/ Arch Biopartners"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Abata Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ABBV-CLS-579","moa":"PTPN2","graph1":"Oncology","graph2":"Phase I","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calico Life Sciences \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Calico Life Sciences \/ Abbvie Inc"},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ AbbVie Inc"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"MORF-720","moa":"Alpha-V beta 6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Morphic Therapeutic \/ AbbVie Inc"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Parvus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"PVT-401","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Parvus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parvus Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Parvus Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Cugene","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"CUG252","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cugene \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Cugene \/ AbbVie Inc"},{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Aliada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"Nimble Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Regenxbio \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Regenxbio \/ Morgan Stanley"},{"orgOrder":0,"company":"Rectify Pharma","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Positive functional","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rectify Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rectify Pharma \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"Rectify Pharma \/ Atlas Venture"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Redmile Group"},{"orgOrder":0,"company":"ABEC","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ABEC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ABEC \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"ABEC \/ Serum Institute of India"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amneal Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Orion Corporation"},{"orgOrder":0,"company":"Advanced Bioscience laboratories","sponsor":"DAIDS","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"HIV-1 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Advanced Bioscience laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Bioscience laboratories \/ DAIDS","highestDevelopmentStatusID":"4","companyTruncated":"Advanced Bioscience laboratories \/ DAIDS"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"ABVC BioPharma \/ OncoX BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ OncoX BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"ABVC BioPharma \/ OncoX BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ OncoX BioPharma"},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Abveris","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Berkeley Lights","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Berkeley Lights \/ Abveris","highestDevelopmentStatusID":"2","companyTruncated":"Berkeley Lights \/ Abveris"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Vanderbilt University \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"AiPing Pharmaceutical Inc","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"AiPing Pharmaceutical Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AiPing Pharmaceutical Inc \/ ECI Pharmaceuticals LLC","highestDevelopmentStatusID":"15","companyTruncated":"AiPing Pharmaceutical Inc \/ ECI Pharmaceuticals LLC"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Piracetam","moa":"Ach receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Moksha8 Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Ascle Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Porton Advanced Solutions \/ Ascle Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ Ascle Therapeutics"},{"orgOrder":0,"company":"Proton Bio","sponsor":"Guizhou Sinorda Biomedicine Co. Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"SND002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Proton Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Proton Bio \/ Guizhou Sinorda Biomedicine Co. Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Proton Bio \/ Guizhou Sinorda Biomedicine Co. Ltd"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"U.S. Army Medical Research And Development Command","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ U.S. Army Medical Research And Development Command","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ U.S. Army Medical Research And Development Command"},{"orgOrder":0,"company":"Acelyrin","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ AyurMaya"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Acentrus Specialty","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Acentrus Specialty","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Acentrus Specialty"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Aytu BioPharma \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Enzyvant","sponsor":"Aceragen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Recombinant Human Acid Ceramidase","moa":"Acid ceramidase","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Enzyvant","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzyvant \/ Aceragen","highestDevelopmentStatusID":"5","companyTruncated":"Enzyvant \/ Aceragen"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"CytomX Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BigHat Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Mitobridge","sponsor":"OrsoBio","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Acquisition","leadProduct":"TLC-065","moa":"ACMSD","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Mitobridge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitobridge \/ OrsoBio","highestDevelopmentStatusID":"4","companyTruncated":"Mitobridge \/ OrsoBio"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"MK-7110","moa":"CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Achillion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Danicopan","moa":"Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Achillion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Achillion \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Achillion \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"ImmProNano","sponsor":"Emergex Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"Set-Point Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmProNano","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmProNano \/ Emergex Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"ImmProNano \/ Emergex Vaccines"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Maplirpacept","moa":"SIRP alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Disarm Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"Preclinical","graph3":"Disarm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Disarm Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Disarm Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Novan","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Novan"},{"orgOrder":0,"company":"DeuteRx","sponsor":"Salarius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"Preclinical","graph3":"DeuteRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DeuteRx \/ Salarius Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"DeuteRx \/ Salarius Pharmaceuticals"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"NeuBase Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"NT0200","moa":"DMPK","graph1":"Neurology","graph2":"Preclinical","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vera Therapeutics \/ NeuBase Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Vera Therapeutics \/ NeuBase Therapeutics"},{"orgOrder":0,"company":"Anelixis Therapeutics","sponsor":"Novus Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Anelixis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anelixis Therapeutics \/ Novus Therapeutics, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anelixis Therapeutics \/ Novus Therapeutics, Inc"},{"orgOrder":0,"company":"Kiq","sponsor":"Unum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Bezuclastinib","moa":"||D816V","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Kiq","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kiq \/ Unum Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Kiq \/ Unum Therapeutics"},{"orgOrder":0,"company":"Quellis Biosciences Inc","sponsor":"Catabasis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Quellis Biosciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quellis Biosciences Inc \/ Catabasis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Quellis Biosciences Inc \/ Catabasis Pharmaceuticals"},{"orgOrder":0,"company":"Clade Therapeutics","sponsor":"Century Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Clade Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clade Therapeutics \/ Century Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Clade Therapeutics \/ Century Therapeutics"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Hemera Biosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"HMR59","moa":"CD59","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hemera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Hemera Biosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hemera Biosciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfenex \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Sera Labs","sponsor":"Cure Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sera Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sera Labs \/ Cure Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sera Labs \/ Cure Pharmaceutical"},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Vedere Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Gilead Sciences"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"VelosBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Zilovertamab","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/ Merck & Co"},{"orgOrder":0,"company":"NLC Pharma","sponsor":"Todos Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NLC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NLC Pharma \/ Todos Medical","highestDevelopmentStatusID":"8","companyTruncated":"NLC Pharma \/ Todos Medical"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||GBA1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neogene \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Neogene \/ AstraZeneca"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Angiotensin II","moa":"Angiotensin II receptor type 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ Innoviva","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Innoviva"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Acrivon Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Public Offering","leadProduct":"Prexasertib","moa":"||CHK1","graph1":"Oncology","graph2":"Phase II","graph3":"Acrivon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acrivon Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"8","companyTruncated":"Acrivon Therapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Public Offering","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Public Offering","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ H.C. Wainwright","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ H.C. Wainwright"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Immedica Pharma"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Aveo Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Actinium pharmaceuticals \/ Aveo Oncology"},{"orgOrder":0,"company":"Rasna Therapeutics","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Dactinomycin","moa":"DNA adduct","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rasna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rasna Therapeutics \/ Tiziana Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rasna Therapeutics \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Rugen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"McQuade Center for Strategic Research and Development \/ Rugen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Rugen Therapeutics"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ BofA Securities"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Alexander Capital L.P.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Alexander Capital L.P.","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Alexander Capital L.P."},{"orgOrder":0,"company":"Apnimed","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Alpha Wave Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Johnson & Johnson"},{"orgOrder":0,"company":"Liminatus Pharma","sponsor":"Iris Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Ad5.F35-hGCC-PADRE","moa":"GCC","graph1":"Oncology","graph2":"Phase II","graph3":"Liminatus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Liminatus Pharma \/ Iris Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Liminatus Pharma \/ Iris Acquisition Corp"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Termination","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Afamitresgene Autoleucel","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Adaptimmune Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Overland ADCT BioPharma","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Overland ADCT BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Overland ADCT BioPharma \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Overland ADCT BioPharma \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"DynPort Vaccine Company","sponsor":"Altimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DynPort Vaccine Company","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"DynPort Vaccine Company \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"DynPort Vaccine Company \/ Altimmune"},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"CYBIN","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Ketamine Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Adelia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adelia Therapeutics \/ CYBIN","highestDevelopmentStatusID":"3","companyTruncated":"Adelia Therapeutics \/ CYBIN"},{"orgOrder":0,"company":"Invivyd","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Biocon","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Biocon"},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Melior Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adhera Therapeutics \/ Melior Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Melior Pharmaceuticals"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Morgan Stanley"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADMA Biologics \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Morgan Stanley"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Agreement","leadProduct":"Antihemophilic factor recombinant","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Prime Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Prime Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Immedica Pharma"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Public Offering","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ J. P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ J. P. Morgan"},{"orgOrder":0,"company":"National Institute of Neurological Disorders","sponsor":"MetVital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Enol-oxaloacetate","moa":"Glutamate","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute of Neurological Disorders","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Neurological Disorders \/ MetVital","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Neurological Disorders \/ MetVital"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Hangzhou Chance Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Hangzhou Chance Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Hangzhou Chance Pharmaceuticals"},{"orgOrder":0,"company":"Aerium Therapeutics","sponsor":"Lausanne University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"SARS-CoV-2 virus","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aerium Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Aerium Therapeutics \/ Lausanne University Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Aerium Therapeutics \/ Lausanne University Hospital"},{"orgOrder":0,"company":"Deerfield Management","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Termination","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Deerfield Management","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Deerfield Management \/ Windtree Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Deerfield Management \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Mtec","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Razuprotafib","moa":"VE-PTP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Mtec","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Mtec"},{"orgOrder":0,"company":"Aethon Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Aethon Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aethon Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"2","companyTruncated":"Aethon Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ AffaMed Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ AffaMed Therapeutics"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affinia Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"ElevateBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affini-T Therapeutics \/ ElevateBio","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ ElevateBio"},{"orgOrder":0,"company":"Affinivax","sponsor":"Rock Springs Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series C Financing","leadProduct":"AFX3772","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Rock Springs Capital","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Rock Springs Capital"},{"orgOrder":0,"company":"Affinivax","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"Staphylococcus Aureus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affinivax \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Affinivax \/ CARB-X"},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Healis Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Healis Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ BARDA"},{"orgOrder":0,"company":"X-Chem","sponsor":"Orexia Limited","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"X-Chem \/ Orexia Limited","highestDevelopmentStatusID":"2","companyTruncated":"X-Chem \/ Orexia Limited"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Abbott Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Molecular Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Ensovibep","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AGC Biologics \/ Molecular Partners","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biologics \/ Molecular Partners"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Faron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Faron Pharmaceuticals"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Trefoil Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"AGC Biologics \/ Trefoil Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Trefoil Therapeutics"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AGC Biologics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"AGC Biologics \/ Pfizer Inc"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M Vaccine, Adjuvanted","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AGC Biologics \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Novavax"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AGC Biologics \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biologics \/ Novavax"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Agenus","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Balstilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Lygenesis","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"AGEX-VASC1","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Lygenesis","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Lygenesis"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Axsome Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Evommune","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Evommune"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aptar Pharma \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"Aptar Pharma \/ Indivior"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Fsio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Lumacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Fsio","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Fsio"},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ National Research Council of Canada"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"University of Houston","sponsor":"AuraVax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Houston","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Houston \/ AuraVax Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Houston \/ AuraVax Therapeutics"},{"orgOrder":0,"company":"OncoQuest","sponsor":"Dual Industrial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Divestment","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoQuest \/ Dual Industrial","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest \/ Dual Industrial"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Advanz Pharma"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"CoVaccine HT","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG Specialty Pharmaceuticals \/ Soligenix","highestDevelopmentStatusID":"1","companyTruncated":"BTG Specialty Pharmaceuticals \/ Soligenix"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Afamitresgene Autoleucel","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Adaptimmune Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"ForDoz","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ForDoz \/ Lupin Ltd","highestDevelopmentStatusID":"1","companyTruncated":"ForDoz \/ Lupin Ltd"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ European Commission"},{"orgOrder":0,"company":"Ro","sponsor":"Greenstone LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ro","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ro \/ Greenstone LLC","highestDevelopmentStatusID":"15","companyTruncated":"Ro \/ Greenstone LLC"},{"orgOrder":0,"company":"Vitiprints","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Vitiprints","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitiprints \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Vitiprints \/ Tetra BioPharma"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Massachusetts Eye and Ear and Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"OPGx-003","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opus Genetics \/ Massachusetts Eye and Ear and Harvard Medical School","highestDevelopmentStatusID":"4","companyTruncated":"Opus Genetics \/ Massachusetts Eye and Ear and Harvard Medical School"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Xellia Pharmaceuticals ApS","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Xellia Pharmaceuticals ApS","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Xellia Pharmaceuticals ApS"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Apollomics Inc","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Therapeutics \/ Apollomics Inc"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"University College Cork","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quoin Pharmaceuticals \/ University College Cork","highestDevelopmentStatusID":"4","companyTruncated":"Quoin Pharmaceuticals \/ University College Cork"},{"orgOrder":0,"company":"Agtc","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Agtc","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alkido Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkido Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alkido Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Clear Street LLC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Private Placement","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Clear Street LLC","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Clear Street LLC"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Acorn Bioventures"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ BARDA"},{"orgOrder":0,"company":"Xencor","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"XmAb7195","moa":"IgE","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Aimmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Aimmune Therapeutics"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Acquisition","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Aimmune Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Aitia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Charles River Laboratories, Inc \/ Aitia","highestDevelopmentStatusID":"2","companyTruncated":"Charles River Laboratories, Inc \/ Aitia"},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Eli Lilly"},{"orgOrder":0,"company":"Akouos","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Akouos \/ BofA Securities","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ BofA Securities"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Akron Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Akron Biotech \/ Synairgen"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Stelis Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Termination","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Stelis Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Stelis Biopharma"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aktis Oncology \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ Eli Lilly"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aktis Oncology \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ EcoR1 Capital"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Ault Global Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Ault Global Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Ault Global Holdings"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Digital Power Lending","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Digital Power Lending","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Digital Power Lending"},{"orgOrder":0,"company":"Alastin Skincare","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Herbal Extract","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alastin Skincare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Alastin Skincare \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Alastin Skincare \/ Galderma"},{"orgOrder":0,"company":"Alastin Skincare","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Herbal Extract","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alastin Skincare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Alastin Skincare \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Alastin Skincare \/ Galderma"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Ad-RTS-hIL-12","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Therapeutics \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Ipsen"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Neopharm"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Kindeva Drug Delivery \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ Sandoz B2B"},{"orgOrder":0,"company":"Alcami","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alcami","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alcami \/ Trevena","highestDevelopmentStatusID":"15","companyTruncated":"Alcami \/ Trevena"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Alcon Inc"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Alcon Inc"},{"orgOrder":0,"company":"Alcresta Therapeutics","sponsor":"Linden Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALC-079","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Alcresta Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcresta Therapeutics \/ Linden Capital Partners","highestDevelopmentStatusID":"1","companyTruncated":"Alcresta Therapeutics \/ Linden Capital Partners"},{"orgOrder":0,"company":"Aldevron","sponsor":"AavantiBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Aldevron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aldevron \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Aldevron \/ AavantiBio"},{"orgOrder":0,"company":"Aldevron","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aldevron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aldevron \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Aldevron \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Cascade Chemistry","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cascade Chemistry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cascade Chemistry \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Cascade Chemistry \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Dartmouth College","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","graph1":"Oncology","graph2":"Preclinical","graph3":"Dartmouth College","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dartmouth College \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dartmouth College \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Armistice Capital","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Armistice Capital","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Armistice Capital"},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Grifols International","highestDevelopmentStatusID":"2","companyTruncated":"Alkahest \/ Grifols International"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Alkem Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Alkem Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Alkem Laboratories"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Arboretum Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Arboretum Ventures"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Public Offering","leadProduct":"Reloxaliase","moa":"Oxalate","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allermi","sponsor":"Lucas Venture Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Financing","leadProduct":"Triamcinolone","moa":"Ach receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Lucas Venture Group","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Lucas Venture Group"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Sarepta Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Codiak BioSciences \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Allied Corp","sponsor":"Havn Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Allied Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allied Corp \/ Havn Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Allied Corp \/ Havn Life Sciences"},{"orgOrder":0,"company":"Arrivent","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Hillhouse Capital Group","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"AlloVir","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"ALVR106","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ AlloVir","highestDevelopmentStatusID":"4","companyTruncated":"Baylor College of Medicine \/ AlloVir"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Kite Pharma","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Kite Pharma"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series D Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alloy Therapeutics \/ 8VC","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ 8VC"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ZKN-013","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eloxx Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Eloxx Pharmaceuticals \/ Almirall"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Almirall"},{"orgOrder":0,"company":"23andMe","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"IL-36","graph1":"Dermatology","graph2":"Preclinical","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"23andMe \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"23andMe \/ Almirall"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Divestment","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alpha-9 Theranostics","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alpha-9 Theranostics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha-9 Theranostics \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Alpha-9 Theranostics \/ Nextech Invest"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Private Placement","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Frazier Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Altimmune","sponsor":"Jefferies and Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Jefferies and Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Jefferies and Piper Sandler"},{"orgOrder":0,"company":"Vigene Bioscience","sponsor":"Altimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vigene Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Vigene Bioscience \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"Vigene Bioscience \/ Altimmune"},{"orgOrder":0,"company":"University of Alabama","sponsor":"Altimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Alabama","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"University of Alabama \/ Altimmune","highestDevelopmentStatusID":"6","companyTruncated":"University of Alabama \/ Altimmune"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Lightswitch Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Lightswitch Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Lightswitch Capital"},{"orgOrder":0,"company":"AltruBio","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ aMoon","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ aMoon"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alume Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Alume Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Alumis","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Foresite Capital"},{"orgOrder":0,"company":"ScalmiBio","sponsor":"ALX Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ScalmiBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ScalmiBio \/ ALX Oncology","highestDevelopmentStatusID":"1","companyTruncated":"ScalmiBio \/ ALX Oncology"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"ALX Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ ALX Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ ALX Oncology"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Piper Sandler"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Piper Sandler"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Piper Sandler"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Alys Pharmaceuticals \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alys Pharmaceuticals \/ Medicxi"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Biorasi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"ALZN002","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzamend Neuro \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Biorasi"},{"orgOrder":0,"company":"Amathus Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Chaperone","graph1":"Neurology","graph2":"Discovery","graph3":"Amathus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amathus Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Amathus Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved FDF","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"AmbioPharm \/ Upsher-Smith Laboratories"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Wellcome","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Wellcome","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Wellcome"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Medicines Development for Global Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"AMG 634","moa":"PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Medicines Development for Global Health","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Medicines Development for Global Health"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"ARYA Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ ARYA Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ ARYA Sciences"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Saol therapeutics \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Saol therapeutics \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Filgrastim","moa":"GCSF","graph1":"Oncology","graph2":"Phase III","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Specialty Pharmaceuticals \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"XOMA","sponsor":"Amolyt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"AZP-40XX","moa":"PTH1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Amolyt Pharma","highestDevelopmentStatusID":"4","companyTruncated":"XOMA \/ Amolyt Pharma"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Won & Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Supernova 1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Won & Partners","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Won & Partners"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Xiamen Amoytop Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ALG-000184","moa":"||Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Xiamen Amoytop Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Xiamen Amoytop Biotech"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Private Placement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Amphilix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eurofins Discovery \/ Amphilix","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins Discovery \/ Amphilix"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Omega Funds","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Omega Funds"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"GLP-1 ant","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"GLP-1 ant","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"AmbioPharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"AMTX-100","moa":"Nf-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amytrx Therapeutics \/ AmbioPharm","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ AmbioPharm"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Viloxazine Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Indivior","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Indivior \/ BARDA"},{"orgOrder":0,"company":"Anagenex","sponsor":"Catalio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Anagenex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anagenex \/ Catalio","highestDevelopmentStatusID":"2","companyTruncated":"Anagenex \/ Catalio"},{"orgOrder":0,"company":"Anakuria","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"AT-20494","moa":"mTORC1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anakuria","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Anakuria \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Anakuria \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"The Michael J. Fox Foundation For Parkinson'S Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ The Michael J. Fox Foundation For Parkinson'S Research","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ The Michael J. Fox Foundation For Parkinson'S Research"},{"orgOrder":0,"company":"Anew Medical","sponsor":"Redwoods Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Anew Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anew Medical \/ Redwoods Acquisition Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Anew Medical \/ Redwoods Acquisition Corp."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals"},{"orgOrder":0,"company":"AnGes","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AG0302-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Fluconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Anima Biotech","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Anima Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anima Biotech \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Anima Biotech \/ AbbVie Inc"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ OntoChem"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Broad Institute of MIT","sponsor":"Anji Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"ANJ810","moa":"MCL1","graph1":"Oncology","graph2":"Preclinical","graph3":"Broad Institute of MIT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Broad Institute of MIT \/ Anji Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Broad Institute of MIT \/ Anji Pharmaceutical"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Canaccord Genuity"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Infant Bacterial Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical College of Wisconsin \/ Infant Bacterial Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Medical College of Wisconsin \/ Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"Immunome","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ U.S. Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Amplitude Healthcare Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Merger","leadProduct":"Briquilimab","moa":"||CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Amplitude Healthcare Acquisition Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Amplitude Healthcare Acquisition Corporation"},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"2-Fucosyllactose-Synthetic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Public Offering","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Cowen"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Decheng Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series C Financing","leadProduct":"Sotigalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Decheng Capital","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Decheng Capital"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Canaccord Genuity","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics Inc \/ Canaccord Genuity"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Maxpro Capital Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Maxpro Capital Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Maxpro Capital Acquisition Corp."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VBI-2900","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBI Vaccines \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccines \/ CEPI"},{"orgOrder":0,"company":"Applied BioMath","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"CLN-049","moa":"FLT3","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Applied BioMath \/ Cullinan Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied BioMath \/ Cullinan Therapeutics"},{"orgOrder":0,"company":"Applied BioMath","sponsor":"OncoMyx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied BioMath \/ OncoMyx Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied BioMath \/ OncoMyx Therapeutics"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Entrectinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"APRINOIA Therapeutics","sponsor":"ROSS Acquisition Corp II","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"APNmAb005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"APRINOIA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II","highestDevelopmentStatusID":"6","companyTruncated":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Adaptive Phage Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Deerfield Management"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Divestment","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptevo Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Aptinyx","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ SVB Leerink"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Araris Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ARS Pharmaceuticals \/ Araris Biotech","highestDevelopmentStatusID":"4","companyTruncated":"ARS Pharmaceuticals \/ Araris Biotech"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Allos Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seaside Therapeutics \/ Allos Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Allos Pharma"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"2","companyTruncated":"Arbor Biotechnologies, Inc \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ CSL"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Israeli Ministry of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Israeli Ministry of Health","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Israeli Ministry of Health"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aardvark Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Ardigen","sponsor":"CVC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ardigen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardigen \/ CVC","highestDevelopmentStatusID":"3","companyTruncated":"Ardigen \/ CVC"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Argenx"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"RIST4721","moa":"CXCR2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva Strategic Opportunities LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Agreement","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities LLC","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities LLC"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva Strategic Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Agreement","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"AP-SA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Armata Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Armatus Bio","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solid Biosciences \/ Armatus Bio","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Armatus Bio"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"Armatus Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Andelyn Biosciences \/ Armatus Bio","highestDevelopmentStatusID":"4","companyTruncated":"Andelyn Biosciences \/ Armatus Bio"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"ArQule","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"ArQule","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ArQule \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"ArQule \/ Merck & Co"},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Arrakis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrakis Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Arrakis Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ Rubic Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ Rubic Consortium"},{"orgOrder":0,"company":"Aarvik Therapeutics","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aarvik Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aarvik Therapeutics \/ Arrivent","highestDevelopmentStatusID":"3","companyTruncated":"Aarvik Therapeutics \/ Arrivent"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Orlando Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Orlando Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Orlando Health Ventures"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Horizon Pharma Plc","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"ARO-XDH","moa":"Xanthine dehydrogenase","graph1":"Rheumatology","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Horizon Pharma Plc","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead Pharmaceuticals \/ Horizon Pharma Plc"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Merger","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Silverback Therapeutics \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Silverback Therapeutics \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Merger","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Silverback Therapeutics \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Silverback Therapeutics \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ArsenalBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"ArsenalBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ArTara Therapeutics","sponsor":"Proteon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Penicillin G Potassium","moa":"Bacterial penicillin-binding protein","graph1":"Oncology","graph2":"Phase III","graph3":"ArTara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ArTara Therapeutics \/ Proteon Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ArTara Therapeutics \/ Proteon Therapeutics"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Trinity College Dublin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ART26.12","moa":"FABP5","graph1":"Oncology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Trinity College Dublin","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Trinity College Dublin"},{"orgOrder":0,"company":"Asili Research Alliance","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Artemisinin","moa":"Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asili Research Alliance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asili Research Alliance \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Asili Research Alliance \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Venrock Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"AB-101","moa":"||ADCC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Venrock Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Venrock Healthcare Capital"},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"ARZC-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Artizan Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artizan Bioscience \/ Hatteras Venture","highestDevelopmentStatusID":"4","companyTruncated":"Artizan Bioscience \/ Hatteras Venture"},{"orgOrder":0,"company":"Arvinas","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Private Placement","leadProduct":"Vepdegestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arvinas \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ BofA Securities"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Zhejiang Medicine Co Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"ARX305","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ambrx Inc \/ Zhejiang Medicine Co Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Ambrx Inc \/ Zhejiang Medicine Co Ltd"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Financing","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ambrx Inc \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"6","companyTruncated":"Ambrx Inc \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Capsigen","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Capsigen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Capsigen \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Capsigen \/ Biogen"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Tenzing"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Portage Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Portage Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Portage Biotech"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Therapeutics \/ Shionogi"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"AllianceRx Walgreens","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Leadiant Biosciences \/ AllianceRx Walgreens","highestDevelopmentStatusID":"15","companyTruncated":"Leadiant Biosciences \/ AllianceRx Walgreens"},{"orgOrder":0,"company":"Revision Skincare","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Revision Skincare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Revision Skincare \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Revision Skincare \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"VIR-2482","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ BARDA"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"The Autism Impact Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ The Autism Impact Fund","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ The Autism Impact Fund"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Termination","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Empyrean Neuroscience","sponsor":"Veteran biotech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Psilocybin Derivative","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Empyrean Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Empyrean Neuroscience \/ Veteran biotech","highestDevelopmentStatusID":"5","companyTruncated":"Empyrean Neuroscience \/ Veteran biotech"},{"orgOrder":0,"company":"Inventprise","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"IVT-25","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inventprise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inventprise \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inventprise \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Orbital Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Orbital Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Beam Therapeutics \/ Orbital Therapeutics"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"DelSiTech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ DelSiTech","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio \/ DelSiTech"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Collaboration","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantheus Holding \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Lantheus Holding \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Diverse Biotech","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Diverse Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diverse Biotech \/ Enveric Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Diverse Biotech \/ Enveric Biosciences"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Maastricht University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Maastricht University","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Maastricht University"},{"orgOrder":0,"company":"ProThera Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ProThera Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProThera Biologics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"ProThera Biologics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor-alpha 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intraocular Solution","sponsorNew":"Omeros \/ Rayner Surgical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner Surgical Group Limited"},{"orgOrder":0,"company":"GenEdit","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"GenEdit","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenEdit \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GenEdit \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Acuitas","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ Acuitas","highestDevelopmentStatusID":"2","companyTruncated":"Arbor Biotechnologies, Inc \/ Acuitas"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Kanvas Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Federation Bio \/ Kanvas Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Federation Bio \/ Kanvas Biosciences"},{"orgOrder":0,"company":"Biogen","sponsor":"Envisagenics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biogen \/ Envisagenics","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ Envisagenics"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Ragon Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"exoVACC","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Codiak BioSciences \/ Ragon Institute","highestDevelopmentStatusID":"4","companyTruncated":"Codiak BioSciences \/ Ragon Institute"},{"orgOrder":0,"company":"Curia","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Curia \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Curia \/ Replicate Bioscience"},{"orgOrder":0,"company":"OneThree Biotech","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OneThree Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OneThree Biotech \/ Jubilant Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"OneThree Biotech \/ Jubilant Therapeutics"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"MiroliverELAP","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"5","companyTruncated":"United Therapeutics \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"NaNotics LLC","sponsor":"Mass General Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"TNF-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"NaNotics LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NaNotics LLC \/ Mass General Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"NaNotics LLC \/ Mass General Cancer Center"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"NaNotics LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mayo Clinic \/ NaNotics LLC","highestDevelopmentStatusID":"4","companyTruncated":"Mayo Clinic \/ NaNotics LLC"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Secarna Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Denali Therapeutics \/ Secarna Pharma"},{"orgOrder":0,"company":"Atreca","sponsor":"Zymeworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"ATRC-301","moa":"Ephrin type A receptor 2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Zymeworks","highestDevelopmentStatusID":"5","companyTruncated":"Atreca \/ Zymeworks"},{"orgOrder":0,"company":"Dante Labs","sponsor":"The Renato Dulbecco Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dante Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Dante Labs \/ The Renato Dulbecco Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Dante Labs \/ The Renato Dulbecco Foundation"},{"orgOrder":0,"company":"Atomwise","sponsor":"FutuRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atomwise \/ FutuRx","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/ FutuRx"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Australian Federal Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Australian Federal Government","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Australian Federal Government"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Tersera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"TPH","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Tersera","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Tersera"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Antion Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allogene Therapeutics \/ Antion Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Allogene Therapeutics \/ Antion Biosciences"},{"orgOrder":0,"company":"GigaGen","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GigaGen \/ Department of Defense","highestDevelopmentStatusID":"3","companyTruncated":"GigaGen \/ Department of Defense"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"SPVN50","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ SparingVision","highestDevelopmentStatusID":"2","companyTruncated":"Intellia Therapeutics \/ SparingVision"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Thermo Fisher Scientific \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Personalis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarepta Therapeutics \/ Personalis","highestDevelopmentStatusID":"1","companyTruncated":"Sarepta Therapeutics \/ Personalis"},{"orgOrder":0,"company":"Harvard Stem Cell Institute","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Harvard Stem Cell Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Stem Cell Institute \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Harvard Stem Cell Institute \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VBI-2900","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBI Vaccines \/ Government of Canada","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccines \/ Government of Canada"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Centyrins","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aro Biotherapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Aro Biotherapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"AzurRx BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ AzurRx BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ AzurRx BioPharma"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Forte Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"TLR5","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Forte Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Forte Biosciences \/ Forte Biosciences"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"||JAK1\/JAK2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cellenkos \/ Incyte Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos \/ Incyte Corporation"},{"orgOrder":0,"company":"PostEra","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PostEra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"PostEra \/ National Institutes of Health","highestDevelopmentStatusID":"3","companyTruncated":"PostEra \/ National Institutes of Health"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Expanded Collaboration","leadProduct":"ASC618","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Charles River Laboratories, Inc \/ ASC Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Charles River Laboratories, Inc \/ ASC Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ascidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascidian Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Ascidian Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReviR Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"ReviR Therapeutics \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"AskBio","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AskBio \/ ReCode Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"AskBio \/ ReCode Therapeutics"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"AAV2\/8LSPhGAA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Farmalider SA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Farmalider SA","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Farmalider SA"},{"orgOrder":0,"company":"Door Pharmaceuticals","sponsor":"Assembly Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Live Microbial Biotherapeutic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Door Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Door Pharmaceuticals \/ Assembly Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Door Pharmaceuticals \/ Assembly Biosciences"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Approved FDF","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assertio Therapeutics \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Assertio Therapeutics \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ionetix","sponsor":"Precision Molecular","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"PMI21","moa":"PSMA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ionetix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionetix \/ Precision Molecular","highestDevelopmentStatusID":"5","companyTruncated":"Ionetix \/ Precision Molecular"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TB Alliance \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"TB Alliance \/ Astellas Pharma"},{"orgOrder":0,"company":"Tolmar","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tolmar \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Astellas Pharma"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Adeno-associated Virus Vector","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"4D Molecular Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"KT430","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Kate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kate Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kate Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"IVX-A12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ AstraZeneca"},{"orgOrder":0,"company":"TeneoTwo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"TNB-486","moa":"CD3\/19","graph1":"Oncology","graph2":"Phase I","graph3":"TeneoTwo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TeneoTwo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"TeneoTwo \/ AstraZeneca"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regeneron Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Regeneron Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"ION455","moa":"PNPLA3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Scorpion Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Suvratoxumab","moa":"Staphylococcus aureus alpha toxin binding","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aridis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Partnership","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Societal CDMO \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Orange Grove Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Orange Grove Bio","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Orange Grove Bio"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Advanz Pharma"},{"orgOrder":0,"company":"eGenesis","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"eGenesis \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics \/ ATAI Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Atalanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Atalanta Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Atalanta Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Plex Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atavistik Bio \/ Plex Research","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ Plex Research"},{"orgOrder":0,"company":"Athenex","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ SVB Securities","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ SVB Securities"},{"orgOrder":0,"company":"Athersys","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"MultiStem","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athersys \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/ BofA Securities"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Lahey Hospital & Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ATH-63","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athos Therapeutics \/ Lahey Hospital & Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Athos Therapeutics \/ Lahey Hospital & Medical Center"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ATI-2173","moa":"||Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Assembly Biosciences \/ Antios Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Assembly Biosciences \/ Antios Therapeutics"},{"orgOrder":0,"company":"T-Cure Bioscience","sponsor":"Atlas Antibodies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"820TCR","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"T-Cure Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"T-Cure Bioscience \/ Atlas Antibodies","highestDevelopmentStatusID":"4","companyTruncated":"T-Cure Bioscience \/ Atlas Antibodies"},{"orgOrder":0,"company":"Atomic AI","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomic AI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atomic AI \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Atomic AI \/ Playground Global"},{"orgOrder":0,"company":"Atomwise","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"IL-6 signalling pathway","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Atomwise \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Undisclosed"},{"orgOrder":0,"company":"Aulos","sponsor":"ATPGroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aulos \/ ATPGroup","highestDevelopmentStatusID":"4","companyTruncated":"Aulos \/ ATPGroup"},{"orgOrder":0,"company":"Attralus","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Public Offering","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ SVB Securities"},{"orgOrder":0,"company":"AUM LifeTech","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM LifeTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AUM LifeTech \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"AUM LifeTech \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"AUR300","moa":"M2 macrophages dysregulation","graph1":"Immunology","graph2":"IND Enabling","graph3":"Riptide Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Riptide Bioscience \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Riptide Bioscience \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"3-Aminopyrrolidine dihydrochloride","moa":"VISTA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"9","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Austin Biosciences","sponsor":"Financial Strategies Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"ABC-0996","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Austin Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austin Biosciences \/ Financial Strategies Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Austin Biosciences \/ Financial Strategies Acquisition Corp."},{"orgOrder":0,"company":"EpiVax","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Avacc 101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"EpiVax \/ Intravacc","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ Intravacc"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"University Of Natural Resources","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"S-Layer COVID Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Avalon GloboCare \/ University Of Natural Resources","highestDevelopmentStatusID":"1","companyTruncated":"Avalon GloboCare \/ University Of Natural Resources"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Perceptive Xontogeny Venture Funds","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"Pirfenidone","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avalyn Pharma \/ Perceptive Xontogeny Venture Funds","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pharma \/ Perceptive Xontogeny Venture Funds"},{"orgOrder":0,"company":"RetinalGeniX Technologies","sponsor":"Avania","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"RTG-2023","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"RetinalGeniX Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RetinalGeniX Technologies \/ Avania","highestDevelopmentStatusID":"4","companyTruncated":"RetinalGeniX Technologies \/ Avania"},{"orgOrder":0,"company":"AVANIR PHARMS","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Deudextromethorphan Hydrobromide","moa":"||MAO","graph1":"Neurology","graph2":"Phase III","graph3":"AVANIR PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc."},{"orgOrder":0,"company":"AavantiBio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"AVB-202","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AavantiBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AavantiBio \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AavantiBio \/ Solid Biosciences"},{"orgOrder":0,"company":"AavantiBio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"AVB-202","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AavantiBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AavantiBio \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AavantiBio \/ Solid Biosciences"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Hercules Capital"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ LG Chem","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ LG Chem"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tivozanib","moa":"||VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Avexegen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avexegen Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Avexegen Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Avicanna","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Cannabinoid","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Knopp Biosciences LLC \/ Avicanna","highestDevelopmentStatusID":"15","companyTruncated":"Knopp Biosciences LLC \/ Avicanna"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Private Placement","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Adage Capital Partners LP","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Adage Capital Partners LP"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Avrobio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Morgan Stanley"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"ES Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"AVTX-007","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ ES Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ ES Therapeutics"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Undisclosed"},{"orgOrder":0,"company":"Axcella Health","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ J.P. Morgan"},{"orgOrder":0,"company":"Sapphire Biotech","sponsor":"AXIM Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sapphire Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sapphire Biotech \/ AXIM Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"Sapphire Biotech \/ AXIM Biotechnologies"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neos Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neos Therapeutics \/ Aytu BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Neos Therapeutics \/ Aytu BioPharma"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC-beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denovo Biopharma \/ Aytu BioScience","highestDevelopmentStatusID":"4","companyTruncated":"Denovo Biopharma \/ Aytu BioScience"},{"orgOrder":0,"company":"Rumpus Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC-beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rumpus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumpus Therapeutics \/ Aytu BioScience","highestDevelopmentStatusID":"4","companyTruncated":"Rumpus Therapeutics \/ Aytu BioScience"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"AZD5904","moa":"MPO","graph1":"Endocrinology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition Corp."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"vTv Therapeutics \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Prokarium \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"BAER-101","moa":"GABA-A-alpha 2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avenue Therapeutics \/ Avenue Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avenue Therapeutics \/ Avenue Therapeutics"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Baker Bros","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2021","type":"Termination","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Baker Bros","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Baker Bros"},{"orgOrder":0,"company":"United Health Group","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"United Health Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United Health Group \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"United Health Group \/ Eli Lilly"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Circuit Clinical","sponsor":"Intrommune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"IND Enabling","graph3":"Circuit Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Circuit Clinical \/ Intrommune Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Circuit Clinical \/ Intrommune Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Longview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basking Biosciences \/ Longview Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Longview Ventures"},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"RA 27\/3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"The Wistar Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Wistar Institute \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"The Wistar Institute \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Vizient","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Vizient","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Vizient"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ JMP Securities LLC","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ JMP Securities LLC"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Bausch Health"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baxter Healthcare Corporation \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dewpoint Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ BridgeBio Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Be Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Be Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Be Biopharma"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Zelquistinel","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gate Neurosciences \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Beacon Biosignals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ U.S. Government","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ U.S. Government"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Vebicorvir","moa":"Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ BeiGene"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Strand Therapeutics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Strand Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"BITT","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"BITR2101","moa":"||TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ BeiGene"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Belharra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Belharra Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Belharra Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Belharra Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Belharra Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Belharra Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Belite Bio","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ SVB Securities"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Benchmark Company"},{"orgOrder":0,"company":"Belite Bio","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ The Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ The Benchmark Company"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Baylor BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Baylor BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Baylor BioSciences"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Alfasigma"},{"orgOrder":0,"company":"XBiotech","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Divestment","leadProduct":"Bermekimab","moa":"IL-1-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ GSK"},{"orgOrder":0,"company":"VirTrial","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VirTrial","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"VirTrial \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VirTrial \/ BetterLife Pharma"},{"orgOrder":0,"company":"Florence Healthcare","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Florence Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"Florence Healthcare \/ BetterLife Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Florence Healthcare \/ BetterLife Pharma"},{"orgOrder":0,"company":"Viatris","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viatris \/ Beximco Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Beximco Pharmaceuticals"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Beyond Air","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Beyond Air","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Beyond Air"},{"orgOrder":0,"company":"Beyond Celiac","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Beyond Celiac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Beyond Celiac \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Celiac \/ Provention Bio"},{"orgOrder":0,"company":"Lysosomal Therapeutics","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"BIA 28-6156","moa":"Glucocerebrosidase","graph1":"Neurology","graph2":"Phase I","graph3":"Lysosomal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lysosomal Therapeutics \/ Bial","highestDevelopmentStatusID":"6","companyTruncated":"Lysosomal Therapeutics \/ Bial"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Ficerafusp Alpha","moa":"EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Biocon","highestDevelopmentStatusID":"7","companyTruncated":"Bicara Therapeutics \/ Biocon"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Funding","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"BIIB115","moa":"SMN protein synthesis","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Ionis Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"NuGenerex","sponsor":"Bintai Kinden","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Ii-Key-SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NuGenerex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuGenerex \/ Bintai Kinden","highestDevelopmentStatusID":"1","companyTruncated":"NuGenerex \/ Bintai Kinden"},{"orgOrder":0,"company":"Bioasis","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bioasis \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Midatech Pharma"},{"orgOrder":0,"company":"BioAtla","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Mecbotamab Vedotin","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ J.P. Morgan"},{"orgOrder":0,"company":"BioAtla","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Public Offering","leadProduct":"Mecbotamab Vedotin","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Acuta Capital Partners"},{"orgOrder":0,"company":"BioCardia","sponsor":"StemCardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"SCM-102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ StemCardia","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ StemCardia"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Naltrexone","moa":"||Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"CRX100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"ST-501","moa":"Tau protein production","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sangamo Therapeutics \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Genentech","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Lenalidomide","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Biogen"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Ginkgo Bioworks \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ Vir Biotechnology"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Genpharm"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Medison Pharma"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kleo Pharmaceuticals \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Kleo Pharmaceuticals \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"National Ataxia Foundation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"National Ataxia Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Ataxia Foundation \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"National Ataxia Foundation \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Sixth Street"},{"orgOrder":0,"company":"BIOKEY","sponsor":"Rgene Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"RGC-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIOKEY \/ Rgene Corporation","highestDevelopmentStatusID":"4","companyTruncated":"BIOKEY \/ Rgene Corporation"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Biological E","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BECOV2D","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Biological E","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Technologies \/ Biological E"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ J.P. Morgan"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Government Of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Government Of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Government Of Canada"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"BNT116","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ BioNTech"},{"orgOrder":0,"company":"BioSpecifics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"BioSpecifics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSpecifics \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"BioSpecifics \/ Endo Pharm"},{"orgOrder":0,"company":"Soligenix","sponsor":"NJEDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ NJEDA","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ NJEDA"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Biotheus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"TATX-20","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Biotheus","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Biotheus"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"BXT-25","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioxytran \/ Undisclosed"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Bixink Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Bixink Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Bixink Therapeutics"},{"orgOrder":0,"company":"BAKX Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BKX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BAKX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BAKX Therapeutics \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"BAKX Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Metalloenzyme","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Blacksmith Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blacksmith Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Blacksmith Medicines \/ Eli Lilly"},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"FG-2101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Blacksmith Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Blacksmith Medicines \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Blacksmith Medicines \/ National Institutes of Health"},{"orgOrder":0,"company":"Bloom Science","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Funding","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloom Science \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Bloom Science \/ ALS Association"},{"orgOrder":0,"company":"BlossomHill Therapeutics","sponsor":"Colt Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"BlossomHill Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BlossomHill Therapeutics \/ Colt Ventures","highestDevelopmentStatusID":"2","companyTruncated":"BlossomHill Therapeutics \/ Colt Ventures"},{"orgOrder":0,"company":"WraSer Pharmaceuticals","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Levoamlodipine","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"WraSer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"WraSer Pharmaceuticals \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"WraSer Pharmaceuticals \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"AbVacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Monkeypox Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ AbVacc","highestDevelopmentStatusID":"2","companyTruncated":"Blue Water Vaccines \/ AbVacc"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Streptococcus Pneumoniae Vaccine","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ Blue Water Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"St. Jude Children \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"St. Jude Children\u2019s Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"BWV-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Blue Water Vaccines \/ St. Jude Children\u2019s Research Hospital","highestDevelopmentStatusID":"5","companyTruncated":"Blue Water Vaccines \/ St. Jude Children\u2019s Research Hospital"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Divestment","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Sixth Street","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Sixth Street"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"ORM-6151","moa":"CD33\/GSPT1","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Ribon Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"DCR-LIV2","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dicerna Pharmaceuticals \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Dicerna Pharmaceuticals \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"3T Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"3T Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"3T Biosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"3T Biosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Fonadelpar","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Edenbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Edenbridge Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Edenbridge Pharmaceuticals"},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"Netcapital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Naltrexone Analog","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Pharmalabs \/ Netcapital","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ Netcapital"},{"orgOrder":0,"company":"Serenity LLC","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Serenity LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Serenity LLC \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serenity LLC \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Boudicca Dx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Boudicca Dx","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Boudicca Dx"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"BBI-355","moa":"CHK1","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Leaps by Bayer"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Knott Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series D Financing","leadProduct":"Azithromycin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Knott Partners","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Knott Partners"},{"orgOrder":0,"company":"Seattle Children\u2019s","sponsor":"BrainChild Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SC-CAR4BRAIN","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Seattle Children\u2019s","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seattle Children\u2019s \/ BrainChild Bio","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Children\u2019s \/ BrainChild Bio"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Abbhi Investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Autologous MSC-NTF Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Abbhi Investments","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Abbhi Investments"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Aggrega Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Succinylcholine Chloride","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Aggrega Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Aggrega Pharma"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ BriaCell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaPro Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaPro Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaPro Therapeutics \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"Bridge Medicines","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Medicines \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Medicines \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"BridgeBio Pharma \/ Columbia University"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"QED Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ QED Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ QED Therapeutics"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Qpex Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"QPX9003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Qpex Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Qpex Biopharma"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Acquisition","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"The Rockefeller University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"C-135-LS","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"The Rockefeller University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Rockefeller University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"The Rockefeller University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Xencor","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"C-135-LS","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Xencor \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Regenexx","sponsor":"Biorestorative Therapies","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Regenexx \/ Biorestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Regenexx \/ Biorestorative Therapies"},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope \/ BryoLogyx Inc"},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"Preclinical","graph3":"BryoLogyx Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"BryoLogyx Inc \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Serb","highestDevelopmentStatusID":"15","companyTruncated":"BTG Specialty Pharmaceuticals \/ Serb"},{"orgOrder":0,"company":"Burke Therapeutics","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Amlodipine Besylate","moa":"||Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Burke Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burke Therapeutics \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Burke Therapeutics \/ Coeptis Pharmaceuticals"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Cordis","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Cordis","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Cordis"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Acquisition","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Cvergenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ Cvergenx","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ Cvergenx"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Editas Medicine \/ Immatics","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Immatics"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Minotaur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"HSB-1940","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Minotaur Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hillstream BioPharma \/ Minotaur Therapeutics"},{"orgOrder":0,"company":"MGFB","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MGFB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGFB \/ Mayo Clinic","highestDevelopmentStatusID":"4","companyTruncated":"MGFB \/ Mayo Clinic"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Ingenia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Ingenia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Ingenia Therapeutics"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Mannin Research","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"MAN-01","moa":"IOP","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Q BioMed \/ Mannin Research","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Mannin Research"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Perceptive Advisors and Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Transcription factor","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Perceptive Advisors and Cobro Ventures","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Perceptive Advisors and Cobro Ventures"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Cowen and Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Cowen and Company","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Cowen and Company"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ TD Cowen"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Cajal Neuroscience","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Cajal Neuroscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cajal Neuroscience \/ The Column Group","highestDevelopmentStatusID":"2","companyTruncated":"Cajal Neuroscience \/ The Column Group"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Camargo Pharmaceutical","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Camargo Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Camargo Pharmaceutical \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Camargo Pharmaceutical \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord BioPharma \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Eversana"},{"orgOrder":0,"company":"OPKO Health","sponsor":"CAMP4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"OPK88001","moa":"SCN1A gene","graph1":"Neurology","graph2":"Preclinical","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OPKO Health \/ CAMP4 Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"OPKO Health \/ CAMP4 Therapeutics"},{"orgOrder":0,"company":"Immunogen","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Discovery","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunogen \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Immunogen \/ Eli Lilly"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Public Offering","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Candel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Canadian Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Canadian Government","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Canadian Government"},{"orgOrder":0,"company":"Scriptr","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Scriptr","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scriptr \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Scriptr \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aleta Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aleta Biotherapeutics \/ Cancer Research","highestDevelopmentStatusID":"5","companyTruncated":"Aleta Biotherapeutics \/ Cancer Research"},{"orgOrder":0,"company":"CancerVAX","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CancerVAX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CancerVAX \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"CancerVAX \/ Undisclosed"},{"orgOrder":0,"company":"Five Leaf Labs","sponsor":"Cannaworx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Phytocannabinoid","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Five Leaf Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Five Leaf Labs \/ Cannaworx","highestDevelopmentStatusID":"15","companyTruncated":"Five Leaf Labs \/ Cannaworx"},{"orgOrder":0,"company":"Cannex Scientific","sponsor":"Brigham And Women'S Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cannex Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cannex Scientific \/ Brigham And Women'S Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Cannex Scientific \/ Brigham And Women'S Hospital"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Harvard University","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantex Pharmaceuticals \/ Harvard University","highestDevelopmentStatusID":"6","companyTruncated":"Cantex Pharmaceuticals \/ Harvard University"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Imunon","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Lincoln Park Capital","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Capsida \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Capsida \/ AbbVie Inc"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Capstan Therapeutics \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ Novartis Venture Fund"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"BioCardia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Private Placement","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Undisclosed"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Poc Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Onvansertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiff Oncology \/ Poc Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff Oncology \/ Poc Capital"},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Vicineum","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Cardinal Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardinal Health \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Cardinal Health \/ Sesen Bio"},{"orgOrder":0,"company":"Care Access Research","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"AZD7442","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Care Access Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Care Access Research \/ AstraZeneca"},{"orgOrder":0,"company":"ProMab Biotechnologies","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProMab Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProMab Biotechnologies \/ Caribou Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"ProMab Biotechnologies \/ Caribou Biosciences"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Merger","leadProduct":"Beta-tricalcium Phosphate","moa":"||Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp."},{"orgOrder":0,"company":"CaroGen","sponsor":"Yale University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CaroGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CaroGen \/ Yale University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"CaroGen \/ Yale University School of Medicine"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CART-ddBCMA","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Cascade Chemistry","sponsor":"Renibus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Stannus Protoporphyrin","moa":"Nrf2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cascade Chemistry","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cascade Chemistry \/ Renibus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cascade Chemistry \/ Renibus Therapeutics"},{"orgOrder":0,"company":"Casma Therapeutics","sponsor":"Amgen Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Casma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Casma Therapeutics \/ Amgen Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Casma Therapeutics \/ Amgen Ventures"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Catamaran Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CAT-248","moa":"CD70","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MaxCyte \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Catamaran Bio"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Edasalonexent","moa":"Nf-kB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ AstraZeneca"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AavantiBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ AavantiBio"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Trizell","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Trizell","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Trizell"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Humanigen"},{"orgOrder":0,"company":"Catalyst Clinical Research","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalyst Clinical Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Catalyst Clinical Research \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Clinical Research \/ Moleculin Biotech"},{"orgOrder":0,"company":"Cato Research","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Cato Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cato Research \/ JanOne","highestDevelopmentStatusID":"5","companyTruncated":"Cato Research \/ JanOne"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Antengene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CB-708","moa":"CD73","graph1":"Oncology","graph2":"Preclinical","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Antengene","highestDevelopmentStatusID":"4","companyTruncated":"Calithera Biosciences \/ Antengene"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Biogen","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Genentech"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Bull Horn Holdings Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"CD38-GEAR-NK","moa":"||CD38","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coeptis Therapeutics \/ Bull Horn Holdings Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ Bull Horn Holdings Corp."},{"orgOrder":0,"company":"Icahn School of Medicine","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Icahn School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine \/ Cell BioEngines","highestDevelopmentStatusID":"3","companyTruncated":"Icahn School of Medicine \/ Cell BioEngines"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"The University of Pittsburgh School of Medicine \/ Astellas Pharma"},{"orgOrder":0,"company":"Cellarity","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Cellarity","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellarity \/ BlackRock","highestDevelopmentStatusID":"2","companyTruncated":"Cellarity \/ BlackRock"},{"orgOrder":0,"company":"Prostate Cancer Clinical Trial Consortium","sponsor":"CellCentric","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Inobrodib","moa":"p300\/CBP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prostate Cancer Clinical Trial Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prostate Cancer Clinical Trial Consortium \/ CellCentric","highestDevelopmentStatusID":"7","companyTruncated":"Prostate Cancer Clinical Trial Consortium \/ CellCentric"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"CDX-3379","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Cantor"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Rockefeller University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Fostemsavir","moa":"||CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Rockefeller University","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Rockefeller University"},{"orgOrder":0,"company":"Cellevolve","sponsor":"Acclaimed Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellevolve","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellevolve \/ Acclaimed Investors","highestDevelopmentStatusID":"1","companyTruncated":"Cellevolve \/ Acclaimed Investors"},{"orgOrder":0,"company":"CellReady","sponsor":"Marker Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"CellReady","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CellReady \/ Marker Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CellReady \/ Marker Therapeutics"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Aegis Capital Corp","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Aegis Capital Corp"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celsius Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Celularity","sponsor":"YA II PN","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ YA II PN","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ YA II PN"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Creative Medical Technology","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Creative Medical Technology","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Creative Medical Technology"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ General Atlantic"},{"orgOrder":0,"company":"US Naval Medical Research Center","sponsor":"Henry Jackson Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Centi-B9","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"US Naval Medical Research Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"US Naval Medical Research Center \/ Henry Jackson Foundation","highestDevelopmentStatusID":"4","companyTruncated":"US Naval Medical Research Center \/ Henry Jackson Foundation"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Century Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"CNTY-104","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Century Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Century Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Novavax","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ CEPI","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ CEPI"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ CEPI"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"SAM COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Gritstone bio \/ CEPI"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"VBI-2905","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"VBI Vaccines \/ CEPI"},{"orgOrder":0,"company":"Ceptur Therapeutics","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Ceptur Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceptur Therapeutics \/ venBio Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ceptur Therapeutics \/ venBio Partners"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Rislenemdaz","moa":"GluN2B","graph1":"Neurology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aevi Genomic Medicine \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Cerecor"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley & Co","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Morgan Stanley & Co"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Certara","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Certara \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Certara \/ Galderma"},{"orgOrder":0,"company":"Certara","sponsor":"Arvinas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Certara \/ Arvinas","highestDevelopmentStatusID":"1","companyTruncated":"Certara \/ Arvinas"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Funding","leadProduct":"Pathogen Reduced Lyophilized Cryoprecipitate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ U.S. Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Cerus Corporation \/ U.S. Department of Defense"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Public Offering","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Maxim Group","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect Corporation \/ Maxim Group"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Cebina","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Charles River Laboratories, Inc \/ Cebina","highestDevelopmentStatusID":"2","companyTruncated":"Charles River Laboratories, Inc \/ Cebina"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Checkmate Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"IND Enabling","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Series C Financing","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Longitude Capital","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Longitude Capital"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"Chemomab","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Merger","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ Chemomab","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ Chemomab"},{"orgOrder":0,"company":"Chiasma","sponsor":"Jefferies Llc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Jefferies Llc","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Jefferies Llc"},{"orgOrder":0,"company":"City of Hope","sponsor":"Chimeric","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Chimeric","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Chimeric"},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Chimerix","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chimerix \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ SVB Leerink"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Chinook Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Aduro Biotech","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Aduro Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Aduro Biotech"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"University of Texas Health San Antonio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"Chlamydia Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blue Water Vaccines \/ University of Texas Health San Antonio","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ University of Texas Health San Antonio"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Designs for Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Designs for Health","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Designs for Health"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"CC8464","moa":"NaV1.7 sodium channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chromocell Corporation \/ Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chromocell Corporation \/ Alliance Global Partners"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"CC8464","moa":"NaV1.7 sodium channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chromocell Corporation \/ Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chromocell Corporation \/ Alliance Global Partners"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Chrysalis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chrysalis BioTherapeutics \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Chrysalis BioTherapeutics \/ BARDA"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Collaboration","leadProduct":"Recombinant Human Hyaluronidase PH20 Enzyme","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halozyme Therapeutics \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Halozyme Therapeutics \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Cidara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Aegis Capital"},{"orgOrder":0,"company":"Allomek","sponsor":"Camac Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"CIP-137401","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allomek \/ Camac Partners","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ Camac Partners"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"Blood coagulation factor","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Norgine"},{"orgOrder":0,"company":"Esperovax","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Esperovax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Esperovax \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Esperovax \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Circularis Biotechnologies","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Circularis Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Circularis Biotechnologies \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Circularis Biotechnologies \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Civica Rx","sponsor":"GeneSys Biologics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Civica Rx \/ GeneSys Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Civica Rx \/ GeneSys Biologics"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"ImaginAb","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Collaboration","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ Clarity Pharmaceuticals"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Private Placement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Private Placement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Vivo Capital","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Vivo Capital"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Tottenham Acquisition"},{"orgOrder":0,"company":"ClinConnect","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ClinConnect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ClinConnect \/ Conduit Pharma","highestDevelopmentStatusID":"8","companyTruncated":"ClinConnect \/ Conduit Pharma"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"RP-L401","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rocket Pharmaceuticals \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Tottenham Acquisition"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Huons CO., LTD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Huons CO., LTD","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Huons CO., LTD"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Sonnet BioTherapeutics Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Sonnet BioTherapeutics Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Sonnet BioTherapeutics \/ Sonnet BioTherapeutics Holdings"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Technologies \/ Clover Biopharmaceuticals"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ J. P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ J. P. Morgan"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"Ischemix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"CMX-2043","moa":"AKT phosphorylation","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ischemix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ischemix \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Ischemix \/ US Department of Defense"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"CND106","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Candid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Candid Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Candid Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Kansas State University Research Foundation","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kansas State University Research Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kansas State University Research Foundation \/ Cocrystal Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Kansas State University Research Foundation \/ Cocrystal Pharma"},{"orgOrder":0,"company":"Kansas State University","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kansas State University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kansas State University \/ Cocrystal Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kansas State University \/ Cocrystal Pharma"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cocrystal Pharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Deverra Therapeutics","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"DVX201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Deverra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deverra Therapeutics \/ Coeptis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Deverra Therapeutics \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"||KIT","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"||KIT","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Jefferies"},{"orgOrder":0,"company":"CohBar","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"CB4211","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ Roth Capital Partners"},{"orgOrder":0,"company":"CoImmune","sponsor":"FIDIM Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"CMN-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CoImmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CoImmune \/ FIDIM Group","highestDevelopmentStatusID":"8","companyTruncated":"CoImmune \/ FIDIM Group"},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Montreal Heart Institute (Mhi) Research Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Partnership","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NYU Grossman School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Grossman School of Medicine \/ Montreal Heart Institute (Mhi) Research Center","highestDevelopmentStatusID":"10","companyTruncated":"NYU Grossman School of Medicine \/ Montreal Heart Institute (Mhi) Research Center"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Linnaeus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Linnaeus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Linnaeus Therapeutics"},{"orgOrder":0,"company":"CareDx","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CareDx \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"iBio","sponsor":"CC-Pharming","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Plant Derived Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iBio \/ CC-Pharming","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ CC-Pharming"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Foundation Medicine \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ NeoImmuneTech"},{"orgOrder":0,"company":"Vaccine and Immunotherapy Center","sponsor":"Voltron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Self-Assembling Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaccine and Immunotherapy Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccine and Immunotherapy Center \/ Voltron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vaccine and Immunotherapy Center \/ Voltron Therapeutics"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Wistar Institute \/ Jubilant Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar Institute \/ Jubilant Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Oncorus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"ONCR-177","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Oncorus","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Oncorus"},{"orgOrder":0,"company":"Autigen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Autigen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autigen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Autigen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xeris Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Xeris Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Beam Therapeutics \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Beam Therapeutics \/ Apellis Pharmaceuticals"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Collaboration","leadProduct":"Vepdegestrant","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Nona Biosciences \/ Mount Sinai Health System","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Mount Sinai Health System"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"Xencor","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xencor \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"TRB-051","moa":"Treg","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Eli Lilly"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fate Therapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Appia Bio","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Appia Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appia Bio \/ Kite Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Appia Bio \/ Kite Pharma"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Sentia Medical Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Sentia Medical Science \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"TRB-051","moa":"Treg","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Eli Lilly"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Poseida Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Poseida Therapeutics, Inc","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Poseida Therapeutics, Inc"},{"orgOrder":0,"company":"Partnership for Accelerating Cancer Therapies","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Partnership for Accelerating Cancer Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Partnership for Accelerating Cancer Therapies \/ Candel Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Partnership for Accelerating Cancer Therapies \/ Candel Therapeutics"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stoke Therapeutics \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Stoke Therapeutics \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Duke-NUS Medical School","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Partnership","leadProduct":"Starr RNA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcturus Therapeutics \/ Duke-NUS Medical School","highestDevelopmentStatusID":"2","companyTruncated":"Arcturus Therapeutics \/ Duke-NUS Medical School"},{"orgOrder":0,"company":"Harvard University","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Harvard University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Harvard University \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Harvard University \/ Astellas Pharma"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Refuge Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RB-340","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Refuge Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Refuge Biotechnologies"},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"TMEM175","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Caraway Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tentarix Biotherapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Milagro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Cure Pharmaceutical \/ Milagro Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharmaceutical \/ Milagro Pharmaceuticals"},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Serum Institute of India"},{"orgOrder":0,"company":"Greene Street Pharmaceuticals","sponsor":"VerdePharmHealth","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Greene Street Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Greene Street Pharmaceuticals \/ VerdePharmHealth","highestDevelopmentStatusID":"4","companyTruncated":"Greene Street Pharmaceuticals \/ VerdePharmHealth"},{"orgOrder":0,"company":"Chimerix","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chimerix \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ BARDA"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Chiasma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Amryt Pharma"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1 gene","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Audentes Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Zikani Therapeutics","sponsor":"Eloxx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zikani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zikani Therapeutics \/ Eloxx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Zikani Therapeutics \/ Eloxx Pharmaceuticals"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Biosight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Merger","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Biosight","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Biosight"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Aduro Biotech","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Aduro Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Aduro Biotech"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"X-Chem","sponsor":"BioDuro","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"X-Chem \/ BioDuro","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ BioDuro"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series C Financing","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Access Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Access Biotechnology"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SNAP CAR T-cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Coeptis Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"The University of Pittsburgh School of Medicine \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Virion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"VRON-0200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocean Biomedical \/ Virion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ocean Biomedical \/ Virion Therapeutics"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Nelitolimod","moa":"TLR9","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ TriSalus Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Vicineum","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"CB 2782-PEG","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Catalyst Biosciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Dexcom","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Dexcom","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dexcom \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Dexcom \/ Eli Lilly"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ Ascentage Pharma"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Canadian Institutes of Health Research (CIHR)","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Fusogenix DNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entos Pharmaceuticals \/ Canadian Institutes of Health Research (CIHR)","highestDevelopmentStatusID":"4","companyTruncated":"Entos Pharmaceuticals \/ Canadian Institutes of Health Research (CIHR)"},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ SVB Leerink"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taysha Gene Therapies \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Taysha Gene Therapies \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"University of Wisconsin","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of Wisconsin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Wisconsin \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Wisconsin \/ Revive Therapeutics"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Keystone Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Keystone Capital Partners"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Intellipharmaceutics Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Desvenlafaxine Succinate","moa":"SNRI","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Taro Pharmaceutical Industries \/ Intellipharmaceutics Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Intellipharmaceutics Corporation"},{"orgOrder":0,"company":"QurAlis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QurAlis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Eli Lilly"},{"orgOrder":0,"company":"PepGen","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Public Offering","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ BofA Securities"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ BTIG"},{"orgOrder":0,"company":"Humanigen","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Hercules Capital"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Cowen"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Cowen"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Coronavirus Immunotherapy Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"HiFiBiO Therapeutics \/ Coronavirus Immunotherapy Consortium","highestDevelopmentStatusID":"4","companyTruncated":"HiFiBiO Therapeutics \/ Coronavirus Immunotherapy Consortium"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Novo Hold\u00adings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Novo Hold\u00adings","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ Novo Hold\u00adings"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Miragen Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"5","companyTruncated":"Miragen Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Aisling Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Seribantumab","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Aisling Capital","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Aisling Capital"},{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nutcracker Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Metopimazine Mesylate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Vivo Capital"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Morgan Stanley"},{"orgOrder":0,"company":"Ensoma","sponsor":"5AM Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ensoma \/ 5AM Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ensoma \/ 5AM Ventures"},{"orgOrder":0,"company":"Scopus Biopharma","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"CO-sTiRNA","moa":"||STAT3 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scopus Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scopus Biopharma \/ The Benchmark Company","highestDevelopmentStatusID":"5","companyTruncated":"Scopus Biopharma \/ The Benchmark Company"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Connectyx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Connectyx","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ Connectyx"},{"orgOrder":0,"company":"Mid-Atlantic BioTherapeutics","sponsor":"Connectyx Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"IMT504","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mid-Atlantic BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mid-Atlantic BioTherapeutics \/ Connectyx Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Mid-Atlantic BioTherapeutics \/ Connectyx Technologies"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"MorphoSys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Constellation Pharmaceuticals \/ MorphoSys","highestDevelopmentStatusID":"10","companyTruncated":"Constellation Pharmaceuticals \/ MorphoSys"},{"orgOrder":0,"company":"Link Immunotherapeutics","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"CT-95","moa":"MSLN\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Link Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Link Immunotherapeutics \/ Context Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Link Immunotherapeutics \/ Context Therapeutics"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"National Institute of Allergy and Infectious Diseases.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ National Institute of Allergy and Infectious Diseases.","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ National Institute of Allergy and Infectious Diseases."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Public Offering","leadProduct":"Exebacase","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ SVB Leerink"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Mizuho Securities USA LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Public Offering","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ContraFect Corporation \/ Mizuho Securities USA LLC","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Mizuho Securities USA LLC"},{"orgOrder":0,"company":"Berkshire Biomedical","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Methadone","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Berkshire Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Berkshire Biomedical \/ National Institute of Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Berkshire Biomedical \/ National Institute of Drug Abuse"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Nephrology","graph2":"Phase IV","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ RBC Capital Markets"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Chardan","highestDevelopmentStatusID":"5","companyTruncated":"Coya Therapeutics \/ Chardan"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Chardan","highestDevelopmentStatusID":"5","companyTruncated":"Coya Therapeutics \/ Chardan"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Indiana University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Endocrinology","graph2":"Phase II","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ Indiana University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Panbela Therapeutics \/ Indiana University School of Medicine"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Adage Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Adage Capital Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metagenomi \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Metagenomi \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Senator Richard Lugar Research Institute","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Senator Richard Lugar Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Senator Richard Lugar Research Institute \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Senator Richard Lugar Research Institute \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Janus Henderson Investors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series A Financing","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curevo Vaccine \/ Janus Henderson Investors","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Janus Henderson Investors"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Alberta Innovation Employment Grant","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Alberta Innovation Employment Grant","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Alberta Innovation Employment Grant"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Divestment","leadProduct":"Burosumab","moa":"FGF23","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Kyowa Kirin"},{"orgOrder":0,"company":"CSL Behring","sponsor":"HCmed Innovations","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Human Plasma-Derived Polyvalent Immunoglobulin G","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"CSL Behring \/ HCmed Innovations","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ HCmed Innovations"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Seqirus","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharmaceuticals \/ Seqirus"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Curtana Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"CT-179","moa":"OLIG2","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Curtana Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Curtana Pharmaceuticals"},{"orgOrder":0,"company":"Curia","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curia \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Curia \/ AstraZeneca"},{"orgOrder":0,"company":"Curia","sponsor":"Cassiopea","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Curia \/ Cassiopea","highestDevelopmentStatusID":"15","companyTruncated":"Curia \/ Cassiopea"},{"orgOrder":0,"company":"Curia","sponsor":"Tryp Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curia \/ Tryp Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Curia \/ Tryp Therapeutics"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Curie Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthStar Medical Radioisotopes \/ Curie Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ Curie Therapeutics"},{"orgOrder":0,"company":"Curis","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coeptis Therapeutics \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Cybin","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Cybin"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Cybrexa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"National Institutes of Health \/ Cybrexa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ Cybrexa Therapeutics"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Rafael Holdings","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Rafael Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Rafael Holdings"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Rafael Holdings","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Rafael Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Rafael Holdings"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Series B Financing","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ DeepWork Capital"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ CytoDyn"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ RTW Investments"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ J.P. Morgan"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"CytoLynx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CYT-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ CytoLynx","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ CytoLynx"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"CYT-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"CytoImmune Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Macromoltek","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Macromoltek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Macromoltek \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Macromoltek \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Immunitybio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytRx Corporation \/ Immunitybio","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ Immunitybio"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"University of Illinois","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ University of Illinois","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ University of Illinois"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DA-1241","moa":"GPR119","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Dong-A ST Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"Daavlin","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Hypericin","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Daavlin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Daavlin \/ Soligenix","highestDevelopmentStatusID":"10","companyTruncated":"Daavlin \/ Soligenix"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurogastrx \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Neurogastrx \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"WEP Clinical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ WEP Clinical","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ WEP Clinical"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Avomeen","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Partnership","leadProduct":"Ferrous Gluconate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Avomeen","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Avomeen"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Day One Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series D Financing","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"HemoShear Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Florida","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"University of Florida \/ Decibel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Florida \/ Decibel Therapeutics"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Barclays","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Therapeutics \/ Barclays"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"DBTX","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ DBTX","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Therapeutics \/ DBTX"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Degron Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Degron Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Degron Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Degron Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Roth Capital Partners"},{"orgOrder":0,"company":"Capsida","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Capsida \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Global Coalition for Adaptive Research"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"SAR443820","moa":"RIPK1","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"DepYmed","sponsor":"Monash Biomedicine Discovery Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"PTP1B","graph1":"Oncology","graph2":"Preclinical","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Monash Biomedicine Discovery Institute","highestDevelopmentStatusID":"4","companyTruncated":"DepYmed \/ Monash Biomedicine Discovery Institute"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Design Therapeutics \/ Renaissance Capital","highestDevelopmentStatusID":"2","companyTruncated":"Design Therapeutics \/ Renaissance Capital"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Destum Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Revelation Biosciences \/ Destum Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Destum Partners"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Blueprint Medicines"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ University of Oxford"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dewpoint Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Michigan State University","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Orbus Therapeutics \/ Michigan State University","highestDevelopmentStatusID":"1","companyTruncated":"Orbus Therapeutics \/ Michigan State University"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"US WorldMeds \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Norgine"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"Pdx1\/Mafa gene","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"DT2216","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Diaprost","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"h5A10","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Diaprost","highestDevelopmentStatusID":"4","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Diaprost"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Gemini Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Gemini Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Gemini Therapeutics"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-003","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ Mabwell","highestDevelopmentStatusID":"5","companyTruncated":"Disc medicine \/ Mabwell"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Oxford Finance"},{"orgOrder":0,"company":"AustinPx","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"AustinPx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AustinPx \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"AustinPx \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"7HP349","moa":"||Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Continuus Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Continuus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Continuus Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Continuus Pharmaceuticals \/ Department of Defense"},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Stanford Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Boswellia Serata","moa":"||COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioAdaptives","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAdaptives \/ Stanford Medical Center","highestDevelopmentStatusID":"15","companyTruncated":"BioAdaptives \/ Stanford Medical Center"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Calcitonin gene-related peptide receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Weill Cornell Medicine \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"DR-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dren Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dren Bio \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dren Bio \/ Taiho Ventures"},{"orgOrder":0,"company":"iTolerance","sponsor":"Diabetes Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Diabetes Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Diabetes Research Institute"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shape Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Shape Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Protein-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Dyadic International, Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Pediatrix Therapeutics"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"||TLR9","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Valneva","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Valneva"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 S-Trimer Vaccine","moa":"||S-Trimer","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Dynavax Technologies \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Technologies \/ Clover Biopharmaceuticals"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Dyno Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dyno Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Dyno Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Pennsylvania \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"University of Pennsylvania \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"European Biomedical Research Institute of Salerno","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ European Biomedical Research Institute of Salerno","highestDevelopmentStatusID":"6","companyTruncated":"9 Meters Biopharma \/ European Biomedical Research Institute of Salerno"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Rakovina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"EO2000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Edison Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edison Oncology \/ Rakovina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Edison Oncology \/ Rakovina Therapeutics"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Termination","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Horizon Technology Finance Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Agreement","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Horizon Technology Finance Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Horizon Technology Finance Corporation"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Argenx"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"LSP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Egle Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Egle Therapeutics \/ LSP","highestDevelopmentStatusID":"4","companyTruncated":"Egle Therapeutics \/ LSP"},{"orgOrder":0,"company":"Eigen Therapeutics","sponsor":"Josh Kopelman","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eigen Therapeutics \/ Josh Kopelman","highestDevelopmentStatusID":"3","companyTruncated":"Eigen Therapeutics \/ Josh Kopelman"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Kalypso Wellness Centers","sponsor":"Eleusis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"ELE-Psilo+","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Kalypso Wellness Centers","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kalypso Wellness Centers \/ Eleusis","highestDevelopmentStatusID":"6","companyTruncated":"Kalypso Wellness Centers \/ Eleusis"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beam Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Beam Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Genelux","sponsor":"ELIAS Animal Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"V-VET1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ ELIAS Animal Health","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ ELIAS Animal Health"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"GKCC, LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Private Placement","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ GKCC, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ GKCC, LLC"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"AMP-CD19","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elicio Therapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Intermediate Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ETX-810","moa":"PPA receptor-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Intermediate Capital Group","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Intermediate Capital Group"},{"orgOrder":0,"company":"Elion Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Amphotericin B Analog","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Elion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elion Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Elion Therapeutics \/ Deerfield Management"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Hitachi Global Life Solutions","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"EXG-34217","moa":"ZSCAN4 gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Hitachi Global Life Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Elixirgen Therapeutics \/ Hitachi Global Life Solutions"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Fairmount","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Fairmount"},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"AnGes","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"EMD-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Emendo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emendo Biotherapeutics \/ AnGes","highestDevelopmentStatusID":"4","companyTruncated":"Emendo Biotherapeutics \/ AnGes"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"CDMRP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Alhydrogel","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ CDMRP","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ CDMRP"},{"orgOrder":0,"company":"Novavax","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Novavax \/ Emergent BioSolutions","highestDevelopmentStatusID":"6","companyTruncated":"Novavax \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M Vaccine, Adjuvanted","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Novavax"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Emergent BioSolutions \/ AstraZeneca"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Humanigen"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ AyurMaya"},{"orgOrder":0,"company":"Enlaza Therapeutics","sponsor":"Avalon GloboCare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlaza Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enlaza Therapeutics \/ Avalon GloboCare","highestDevelopmentStatusID":"4","companyTruncated":"Enlaza Therapeutics \/ Avalon GloboCare"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Commodore Capital"},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Danuo Science Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"EN1001","moa":"TNFR1","graph1":"Immunology","graph2":"Preclinical","graph3":"Enosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enosi Therapeutics \/ Danuo Science Group","highestDevelopmentStatusID":"4","companyTruncated":"Enosi Therapeutics \/ Danuo Science Group"},{"orgOrder":0,"company":"Enterin","sponsor":"Parkinson\u2019s Virtual Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Squalamine phosphate","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enterin \/ Parkinson\u2019s Virtual Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ Parkinson\u2019s Virtual Biotech"},{"orgOrder":0,"company":"Entactbio","sponsor":"4BIO Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Entactbio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Entactbio \/ 4BIO Capital","highestDevelopmentStatusID":"2","companyTruncated":"Entactbio \/ 4BIO Capital"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Private Placement","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Enterin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Squalamine phosphate","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer CentreOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer CentreOne \/ Enterin","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer CentreOne \/ Enterin"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Covigenix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entos Pharmaceuticals \/ NRC IRAP","highestDevelopmentStatusID":"6","companyTruncated":"Entos Pharmaceuticals \/ NRC IRAP"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Public Offering","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"ENTR-701","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entrada Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Janus Henderson Investors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Janus Henderson Investors","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Janus Henderson Investors"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Runway Growth Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Runway Growth Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Runway Growth Capital LLC"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Kinnevik","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Enveda Bioscience \/ Kinnevik","highestDevelopmentStatusID":"2","companyTruncated":"Enveda Bioscience \/ Kinnevik"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Enveda Bioscience \/ Lux Capital"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"MagicMed","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"MagicMed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MagicMed \/ Enveric Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"MagicMed \/ Enveric Biosciences"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"MiMedx \/ Gunze Medical Limited","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Gunze Medical Limited"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Epirium","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Piramal Pharma Solutions \/ Epirium","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Pharma Solutions \/ Epirium"},{"orgOrder":0,"company":"University of Georgia","sponsor":"EpiVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Georgia \/ EpiVax","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ EpiVax"},{"orgOrder":0,"company":"EpiVax","sponsor":"Generex Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Li-Key Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Generex Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Generex Biotechnology"},{"orgOrder":0,"company":"EpiVax","sponsor":"Leidos","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Malaria Vaccine","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Leidos","highestDevelopmentStatusID":"2","companyTruncated":"EpiVax \/ Leidos"},{"orgOrder":0,"company":"EpiVax","sponsor":"EpiVax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"EPV-CoV-19","moa":"SARS-CoV-2 viral spike N-terminal","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ EpiVax Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ EpiVax Therapeutics"},{"orgOrder":0,"company":"Epizyme","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Jefferies"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Erasca","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ J.P. Morgan"},{"orgOrder":0,"company":"Erasca","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ BofA Securities"},{"orgOrder":0,"company":"Systems Oncology LLC","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"ErSO","moa":"Unfolded protein response","graph1":"Oncology","graph2":"Preclinical","graph3":"Systems Oncology LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Systems Oncology LLC \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Systems Oncology LLC \/ Bayer AG"},{"orgOrder":0,"company":"Escape Bio","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"ESB1609","moa":"S1P5R","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Escape Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escape Bio \/ Wellington Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Escape Bio \/ Wellington Management Company"},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"3M Health Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"3M Health Care \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"3M Health Care \/ MediWound"},{"orgOrder":0,"company":"Alumis","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Foresite Capital"},{"orgOrder":0,"company":"Serometrix","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Serometrix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serometrix \/ Esperion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Serometrix \/ Esperion Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Galantamine Hydrobromide","moa":"Ach receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Prolonged Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Essential Pharma"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"TradeUP Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ TradeUP Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Estrella Biopharma \/ TradeUP Acquisition Corp."},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"TradeUP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ TradeUP","highestDevelopmentStatusID":"4","companyTruncated":"Estrella Biopharma \/ TradeUP"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Midcap Financial Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Midcap Financial Trust","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Midcap Financial Trust"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"GV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series D Financing","leadProduct":"ETX101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Encoded Therapeutics \/ GV","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Therapeutics \/ GV"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"ETX-810","moa":"PPA receptor-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Discovery","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Beacon Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beacon Discovery \/ Eurofins CDMO","highestDevelopmentStatusID":"2","companyTruncated":"Beacon Discovery \/ Eurofins CDMO"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Flagship Pioneering"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"BMO Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Private Placement","leadProduct":"EDP2939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ BMO Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ BMO Capital Markets"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Providence Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Everest Medicines"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Petrichor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Financing","leadProduct":"177-Lu EVG-321","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Petrichor","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen Theragnostics \/ Petrichor"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"AffaMed Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Everinsight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Everinsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Everinsight Therapeutics"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"1","companyTruncated":"Evofem Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Piper Sandler"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Piper Sandler"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Keystone Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Keystone Capital Partners"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Acquisition","leadProduct":"Norelgestromin","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Gedeon Richter","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Gedeon Richter"},{"orgOrder":0,"company":"FibroGen","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ NovaQuest Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"Evrys Bio","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"SIRT-2 protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evrys Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evrys Bio \/ US Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Evrys Bio \/ US Department of Defense"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"LNC-Based mRNA Vaccine","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ BioNTech"},{"orgOrder":0,"company":"Exelead","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exelead","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exelead \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Exelead \/ Merck & Co"},{"orgOrder":0,"company":"Exelead","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Exelead","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Exelead \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Exelead \/ Pfizer Inc"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Exelixis"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Good Works II Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Good Works II Acquisition Corp.","highestDevelopmentStatusID":"10","companyTruncated":"Direct Biologics \/ Good Works II Acquisition Corp."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Beauty Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organicell Regenerative Medicine \/ Beauty Health","highestDevelopmentStatusID":"1","companyTruncated":"Organicell Regenerative Medicine \/ Beauty Health"},{"orgOrder":0,"company":"Invenra","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Invenra \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"Invenra \/ Exelixis"},{"orgOrder":0,"company":"Biocentriq","sponsor":"Tevogen Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Biocentriq","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocentriq \/ Tevogen Bio","highestDevelopmentStatusID":"5","companyTruncated":"Biocentriq \/ Tevogen Bio"},{"orgOrder":0,"company":"EXUMA Biotechnology","sponsor":"MSD Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"EXUMA Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EXUMA Biotechnology \/ MSD Partners","highestDevelopmentStatusID":"1","companyTruncated":"EXUMA Biotechnology \/ MSD Partners"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"EyeGene","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"EG-COVID mRNA COVID-19 Vaccine","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriLink BioTechnologies \/ EyeGene","highestDevelopmentStatusID":"5","companyTruncated":"TriLink BioTechnologies \/ EyeGene"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Guggenheim Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Guggenheim Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Equinox Science","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Equinox Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Equinox Science \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Equinox Science \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"Stony Brook University","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","graph1":"Oncology","graph2":"Discovery","graph3":"Stony Brook University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stony Brook University \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"2","companyTruncated":"Stony Brook University \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Fathom Pharma","sponsor":"Consegna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"FP01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Fathom Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fathom Pharma \/ Consegna Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fathom Pharma \/ Consegna Pharma"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Carmot Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Carmot Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series A Financing","leadProduct":"Human Gut Microbiome","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federation Bio \/ Horizons Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Federation Bio \/ Horizons Ventures"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Felix Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Felix Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Felix Biotechnology"},{"orgOrder":0,"company":"Fulgent Pharma","sponsor":"Fulgent Genetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Fulgent Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fulgent Pharma \/ Fulgent Genetics","highestDevelopmentStatusID":"6","companyTruncated":"Fulgent Pharma \/ Fulgent Genetics"},{"orgOrder":0,"company":"EpicentRx","sponsor":"FightMND","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"RRx-001","moa":"CD47","graph1":"Neurology","graph2":"Preclinical","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EpicentRx \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"EpicentRx \/ FightMND"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strand Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Strand Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Epigenome","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"QVT","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"KT-A112","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kriya Therapeutics \/ QVT","highestDevelopmentStatusID":"1","companyTruncated":"Kriya Therapeutics \/ QVT"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series C Financing","leadProduct":"Evorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Vivo Capital","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Vivo Capital"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"S011806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase I","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"DICE Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Agenus","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ Cormorant Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Series A Financing","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"PagsGroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ratio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ratio Therapeutics \/ PagsGroup","highestDevelopmentStatusID":"4","companyTruncated":"Ratio Therapeutics \/ PagsGroup"},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Actym Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actym Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Actym Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"TSHA-101","moa":"HEXA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"LX1004","moa":"TPP1","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lexeo Therapeutics \/ Longitude Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Longitude Capital"},{"orgOrder":0,"company":"Slate Bio","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Financing","leadProduct":"IL233","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Slate Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Slate Bio \/ Epidarex Capital","highestDevelopmentStatusID":"4","companyTruncated":"Slate Bio \/ Epidarex Capital"},{"orgOrder":0,"company":"Prokarium","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"Vesibax","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prokarium \/ Korea Investment Partners","highestDevelopmentStatusID":"4","companyTruncated":"Prokarium \/ Korea Investment Partners"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Alta Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"TYK","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Alta Partners","highestDevelopmentStatusID":"1","companyTruncated":"Tyra Biosciences \/ Alta Partners"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"PBM Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"TGTX-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ PBM Capital","highestDevelopmentStatusID":"5","companyTruncated":"Taysha Gene Therapies \/ PBM Capital"},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ipilimumab","moa":"||BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Zenith Epigenetics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"BI 1701963","moa":"||pan-KRAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Mirati Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase II","graph3":"National Comprehensive Cancer Network","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"8","companyTruncated":"National Comprehensive Cancer Network \/ Taiho Oncology"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Selgantolimod","moa":"||TLR8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vir Biotechnology \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Gilead Sciences"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Hypoimmunogenic Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"AgeX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ContraFect Corporation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ContraFect Corporation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||FGFR2B","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Five Prime Therapeutics \/ Seagen","highestDevelopmentStatusID":"1","companyTruncated":"Five Prime Therapeutics \/ Seagen"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Bemarituzumab","moa":"FGFR2B","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||FGFR2B","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Theragent","sponsor":"CellVax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"FK-PC101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Theragent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Theragent \/ CellVax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Theragent \/ CellVax Therapeutics"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Leap Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"FL-301","moa":"CLDN 18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Leap Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Leap Therapeutics \/ Leap Therapeutics"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Flare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Flaskworks","sponsor":"Northwest Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Flaskworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Flaskworks \/ Northwest Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Flaskworks \/ Northwest Biotherapeutics"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"FHD-286","moa":"Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"FogPharma","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Beta catenin","graph1":"Oncology","graph2":"Preclinical","graph3":"FogPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"FogPharma \/ venBio Partners","highestDevelopmentStatusID":"4","companyTruncated":"FogPharma \/ venBio Partners"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Tolmar"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"KEAP1-Nrf2","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vividion Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Vividion Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Koligo Therapeutics","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Autologous Pancreatic Islets Cell","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Koligo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Koligo Therapeutics \/ Orgenesis","highestDevelopmentStatusID":"15","companyTruncated":"Koligo Therapeutics \/ Orgenesis"},{"orgOrder":0,"company":"PicnicHealth","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"PicnicHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PicnicHealth \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"PicnicHealth \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"MyMD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Akers Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Akers Biosciences \/ MyMD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Akers Biosciences \/ MyMD Pharmaceuticals"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Cancer Research UK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Cancer Research UK"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"HB-400","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Termination","leadProduct":"SAGE-324","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"9","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"IDBiologics","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IDBiologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IDBiologics \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"2","companyTruncated":"IDBiologics \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"NCK AS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ NCK AS","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ NCK AS"},{"orgOrder":0,"company":"OmniAb","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Demerger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"OmniAb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OmniAb \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"OmniAb \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ LipoMedix"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Life Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Forge Biologics \/ Life Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Forge Biologics \/ Life Biosciences"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Myrtelle","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Myr-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Forge Biologics \/ Myrtelle","highestDevelopmentStatusID":"5","companyTruncated":"Forge Biologics \/ Myrtelle"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"RTx-015","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Ray Therapeutics \/ Forge Biologics"},{"orgOrder":0,"company":"Fortrea","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Acetazolamide","moa":"||CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Fortrea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fortrea \/ Incannex Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"Fortrea \/ Incannex Healthcare"},{"orgOrder":0,"company":"ForwardVue","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Caroboxyamidotriazole","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ForwardVue","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ForwardVue \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ForwardVue \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thermo Fisher Scientific \/ Spur Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Thermo Fisher Scientific \/ Spur Therapeutics"},{"orgOrder":0,"company":"SGS Life Sciences","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"SGS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SGS Life Sciences \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"SGS Life Sciences \/ Biophytis"},{"orgOrder":0,"company":"MD Infusions","sponsor":"Front Door Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"MD Infusions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Infusions \/ Front Door Health","highestDevelopmentStatusID":"1","companyTruncated":"MD Infusions \/ Front Door Health"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"FS Development Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ FS Development Corp. II","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ FS Development Corp. II"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Fidelity Management and Research Company LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHINE Technologies \/ Fidelity Management and Research Company LLC","highestDevelopmentStatusID":"1","companyTruncated":"SHINE Technologies \/ Fidelity Management and Research Company LLC"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Fulcrum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ Fulcrum Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"CAMP4 Therapeutics \/ Fulcrum Therapeutics"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"DLA Piper","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ DLA Piper","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ DLA Piper"},{"orgOrder":0,"company":"EQRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Undisclosed"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Non-Beta-Lactam Antibiotic","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ NIAID","highestDevelopmentStatusID":"2","companyTruncated":"VenatoRx Pharmaceuticals \/ NIAID"},{"orgOrder":0,"company":"TAXIS Pharmaceuticals","sponsor":"Boston University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"TXA709","moa":"Efflux pump","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TAXIS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"TAXIS Pharmaceuticals \/ Boston University","highestDevelopmentStatusID":"6","companyTruncated":"TAXIS Pharmaceuticals \/ Boston University"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Intercept Treated Red Blood Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corporation \/ BARDA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Commonwealth of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Commonwealth of Pennsylvania","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Commonwealth of Pennsylvania"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"AR-701","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Aridis Pharmaceuticals \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Microbion","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CARB-X"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"ETX0462","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entasis Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Entasis Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Osanetant","moa":"NK-3R","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of North Carolina \/ Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"University of North Carolina \/ Department of Defense"},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone Analog","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Phoenix Pharmalabs \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chrysalis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chrysalis BioTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Chrysalis BioTherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ BlackRock","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ BlackRock"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Arkin Bio Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bluejay Therapeutics \/ Arkin Bio Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Bluejay Therapeutics \/ Arkin Bio Ventures"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"Medical Research Council (U.K)","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"M102","moa":"Nrf2","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ Medical Research Council (U.K)","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Therapeutics \/ Medical Research Council (U.K)"},{"orgOrder":0,"company":"Locanabio","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"C9orf2 -ALS","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Locanabio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locanabio \/ Vida Ventures LLC","highestDevelopmentStatusID":"2","companyTruncated":"Locanabio \/ Vida Ventures LLC"},{"orgOrder":0,"company":"resTORbio","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Dactolisib","moa":"TORC1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"resTORbio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"resTORbio \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"resTORbio \/ National Institute on Aging"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Viking Global Investors","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Viking Global Investors"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Ray-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"GentiBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"GentiBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GentiBio \/ Matrix Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"GentiBio \/ Matrix Capital Management"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aerovate Therapeutics \/ RA Capital","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ RA Capital"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanetics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ National Institutes of Health"},{"orgOrder":0,"company":"Vaxess","sponsor":"National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaxess","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Patch","sponsorNew":"Vaxess \/ National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vaxess \/ National Science Foundation"},{"orgOrder":0,"company":"Aravive","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Private Placement","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ BVF Partners"},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Coda Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Coda Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series B Financing","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"Trastuzumab Imbotolimod","moa":"TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hale Family Center for Pancreatic Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Dynavax Technologies \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Technologies \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Gliknik","sponsor":"First In Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series C Financing","leadProduct":"Biropepimut-S","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Gliknik","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gliknik \/ First In Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gliknik \/ First In Ventures"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Agencja Bada\u0144 Medycznych","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Agencja Bada\u0144 Medycznych","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Agencja Bada\u0144 Medycznych"},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ National Institute on Aging"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"U.S. Department Of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ U.S. Department Of Defense","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ U.S. Department Of Defense"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Endocrinology","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ General Atlantic","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ General Atlantic"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Craig-Hallum Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Craig-Hallum Capital Group","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Craig-Hallum Capital Group"},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"CincyTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"L-ICON3","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikonoklastes Therapeutics \/ CincyTech","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklastes Therapeutics \/ CincyTech"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medtronic Plc \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Medtronic Plc \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"LBP-EC01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intraurethral Infusion","sponsorNew":"Locus Biosciences \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Locus Biosciences \/ BARDA"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Azelaprag","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAge Labs \/ Sofinnova Investments","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Sofinnova Investments"},{"orgOrder":0,"company":"PhorMed","sponsor":"WeFunder","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"12-O-Tetradecanoylphorbol-13-acetate","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"PhorMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhorMed \/ WeFunder","highestDevelopmentStatusID":"6","companyTruncated":"PhorMed \/ WeFunder"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Prevention and Research Instituteof Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Cancer Prevention and Research Instituteof Texas","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Cancer Prevention and Research Instituteof Texas"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cystic Fibrosis Foundation \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cystic Fibrosis Foundation \/ Royalty Pharma"},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Noetic Psychedelic Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Series A Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bexson Biomedical \/ Noetic Psychedelic Fund","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Biomedical \/ Noetic Psychedelic Fund"},{"orgOrder":0,"company":"Delos Psyche Research Group","sponsor":"New Wave Holdings Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Funding","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Delos Psyche Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delos Psyche Research Group \/ New Wave Holdings Corp","highestDevelopmentStatusID":"1","companyTruncated":"Delos Psyche Research Group \/ New Wave Holdings Corp"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SiteOne Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ National Cancer Institute"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Funding","leadProduct":"PhageBank","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"NOP","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Tris Pharma Inc \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Immunology","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ JPEO-CBRND"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Omniose","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Bioconjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Omniose","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omniose \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Omniose \/ National Institutes of Health"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Dyno Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyno Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"3","companyTruncated":"Dyno Therapeutics \/ Andreessen Horowitz"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Private Placement","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ Omega Funds"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"MPM Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"VK-2019","moa":"EBNA1","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullinan Therapeutics \/ MPM Capital","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ MPM Capital"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Ascletis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Ascletis Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Ascletis Pharma"},{"orgOrder":0,"company":"Quest Products","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Quest Products","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quest Products \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quest Products \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"U.S. Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ U.S. Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ U.S. Food & Drug Administration"},{"orgOrder":0,"company":"Summit Biosciences","sponsor":"Polar Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Private Placement","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Summit Biosciences \/ Polar Capital","highestDevelopmentStatusID":"10","companyTruncated":"Summit Biosciences \/ Polar Capital"},{"orgOrder":0,"company":"Renovion","sponsor":"White Rock Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Series A Financing","leadProduct":"Ascorbic Acid","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renovion \/ White Rock Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Renovion \/ White Rock Capital Management"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series C Financing","leadProduct":"4D-310","moa":"GLA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Viking Global Investors"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"NV-HHV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NanoViricides \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"NanoViricides \/ Maxim Group LLC"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Quark Venture LP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series D Financing","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Quark Venture LP","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedica \/ Quark Venture LP"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"IP Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ IP Group","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ IP Group"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Boxer Capital","highestDevelopmentStatusID":"3","companyTruncated":"Scorpion Therapeutics \/ Boxer Capital"},{"orgOrder":0,"company":"Imvax","sponsor":"Hp Wild Holding Ag","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series C Financing","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ Hp Wild Holding Ag","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Hp Wild Holding Ag"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Gastro-Intestinal Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"ELI-007","moa":"BRAF","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elicio Therapeutics \/ Gastro-Intestinal Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ Gastro-Intestinal Research Foundation"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Auron Therapeutics \/ DCVC Bio"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Elpis Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Series A Financing","leadProduct":"EPIM-001","moa":"IL-2-beta receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpis Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpis Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Elpis Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SalioGen Therapeutics","sponsor":"PBM Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"SalioGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SalioGen Therapeutics \/ PBM Capital","highestDevelopmentStatusID":"4","companyTruncated":"SalioGen Therapeutics \/ PBM Capital"},{"orgOrder":0,"company":"MILLENNIUM PHARMS","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"MILLENNIUM PHARMS","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MILLENNIUM PHARMS \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"MILLENNIUM PHARMS \/ GHIT Fund"},{"orgOrder":0,"company":"Novavax","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Vickers Vantage Corp","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2022","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Pre-Filled Syringe","sponsorNew":"Scilex Pharmaceuticals \/ Vickers Vantage Corp","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Vickers Vantage Corp"},{"orgOrder":0,"company":"Imunon","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Silicon Valley Bank","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Symbiosis Ii, Llc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Series D Financing","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Symbiosis Ii, Llc","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Symbiosis Ii, Llc"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jasper Therapeutics \/ Abingworth","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Abingworth"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Minister Of Economy And Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Minister Of Economy And Research","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Minister Of Economy And Research"},{"orgOrder":0,"company":"Brown University","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ONC212","moa":"GPR132","graph1":"Oncology","graph2":"IND Enabling","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Brown University \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Brown University \/ Undisclosed"},{"orgOrder":0,"company":"Neurelis","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Series D Financing","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Cormorant Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Cormorant Asset Management"},{"orgOrder":0,"company":"BioAtla","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series D Financing","leadProduct":"Mecbotamab Vedotin","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Soleus Capital"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"ATH-063","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oragenics","sponsor":"A.G.P.\/Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Oragenics \/ A.G.P.\/Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ A.G.P.\/Alliance Global Partners"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Novo Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Novo Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Novo Ventures"},{"orgOrder":0,"company":"Soligenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"CiVax","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ National Institutes of Health"},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Guangzhou-Israel Biotechnology Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"NTX-1088","moa":"||CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nectin Therapeutics \/ Guangzhou-Israel Biotechnology Fund","highestDevelopmentStatusID":"6","companyTruncated":"Nectin Therapeutics \/ Guangzhou-Israel Biotechnology Fund"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Axiom Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Cure Pharmaceutical \/ Axiom Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharmaceutical \/ Axiom Capital Management"},{"orgOrder":0,"company":"NextPoint","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"NPX267","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Catalio Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Catalio Capital Management"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ SVB Securities","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ SVB Securities"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hims & Hers Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Hims & Hers Health","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Hims & Hers Health"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"National Institute for Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"KRM-II-81","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ National Institute for Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ National Institute for Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BridGene Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridGene Biosciences \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"BridGene Biosciences \/ Galapagos"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Nivolumab","moa":"||MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Galapagos","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Galapagos"},{"orgOrder":0,"company":"Bridge Medicines","sponsor":"Galecto","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"BRM-1420","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Medicines \/ Galecto","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Medicines \/ Galecto"},{"orgOrder":0,"company":"Bill & Melinda Gates Medical Research Institute","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"M72\/AS01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Medical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bill & Melinda Gates Medical Research Institute \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Melinda Gates Medical Research Institute \/ GSK"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Royalty Pharma"},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Alethea Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"GDD3898","moa":"SCD1","graph1":"Dermatology","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Lipidio Pharmaceuticals \/ Alethea Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Pharmaceuticals \/ Alethea Capital"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Celcuity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Gedatolisib","moa":"PI3K\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pfizer Inc \/ Celcuity","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Celcuity"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Gedeon Richter","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Gedeon Richter"},{"orgOrder":0,"company":"Genelux","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Private Placement","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Benchmark Company"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"RGT-419B","moa":"CDK4","graph1":"Oncology","graph2":"Phase I","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Regor Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Vixarelimab","moa":"Oncostatin M beta receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiniksa Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Kiniksa Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"VGXI","sponsor":"Geneos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VGXI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VGXI \/ Geneos Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"VGXI \/ Geneos Therapeutics"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Amgen Inc"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"GeneVentiv Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"GENV HEM","moa":"Factor Va","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"University of North Carolina \/ GeneVentiv Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"University of North Carolina \/ GeneVentiv Therapeutics"},{"orgOrder":0,"company":"Genocea","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Private Placement","leadProduct":"GEN-011","moa":"CD4+ T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Brookline Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Brookline Capital Markets"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Genomma Lab","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Oramed Pharmaceuticals \/ Genomma Lab","highestDevelopmentStatusID":"4","companyTruncated":"Oramed Pharmaceuticals \/ Genomma Lab"},{"orgOrder":0,"company":"Gensaic","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Gensaic","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gensaic \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Gensaic \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ GenScience Pharmaceuticals"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Synimmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Flysyn","moa":"FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenScript ProBio \/ Synimmune","highestDevelopmentStatusID":"7","companyTruncated":"GenScript ProBio \/ Synimmune"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"Beroni Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"GenScript Biotech Corporation \/ Beroni Group","highestDevelopmentStatusID":"4","companyTruncated":"GenScript Biotech Corporation \/ Beroni Group"},{"orgOrder":0,"company":"GentiBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Treg","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"GentiBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GentiBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"GentiBio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"EmVenio Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"GEO-CM04S1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GeoVax Labs \/ EmVenio Research","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ EmVenio Research"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"George Clinical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ George Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ George Clinical"},{"orgOrder":0,"company":"Geron","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Geron","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Public Offering","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Stifel","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Stifel"},{"orgOrder":0,"company":"Purdue University","sponsor":"Gibson Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Azaindenoisoquinolines","moa":"c-Myc","graph1":"Oncology","graph2":"Preclinical","graph3":"Purdue University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purdue University \/ Gibson Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Purdue University \/ Gibson Oncology"},{"orgOrder":0,"company":"Purdue University","sponsor":"Gibson Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Azaindenoisoquinolines","moa":"c-Myc","graph1":"Oncology","graph2":"Preclinical","graph3":"Purdue University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purdue University \/ Gibson Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Purdue University \/ Gibson Oncology"},{"orgOrder":0,"company":"GigaGen","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"GIGA-2050","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Grifols International"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"HIV-1 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Gritstone bio \/ Gilead Sciences"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"TTX-080","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Expanded Collaboration","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Forty Seven","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Magrolimab","moa":"CD47","graph1":"Oncology","graph2":"Phase II","graph3":"Forty Seven","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forty Seven \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Forty Seven \/ Gilead Sciences"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Gilead Sciences"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"XTX301","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xilio Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Xilio Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"||TREM-1","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pionyr Immunotherapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genesis Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Rockefeller University","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Elipovimab","moa":"GP41","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Rockefeller University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rockefeller University \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Rockefeller University \/ Gilead Sciences"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Sucrose Acetate Isobutyrate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Durect Corporation \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Durect Corporation \/ Gilead Sciences"},{"orgOrder":0,"company":"Agenus","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"AGEN2373","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Agenus \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Gilead Sciences"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Seladelpar Lysine","moa":"||PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Gilead Sciences"},{"orgOrder":0,"company":"Celanese","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Celanese","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Celanese \/ Glaukos","highestDevelopmentStatusID":"10","companyTruncated":"Celanese \/ Glaukos"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Global Wholehealth Partners Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Global Wholehealth Partners Corp","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Global Wholehealth Partners Corp"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Licensing Agreement","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"RxOMEG Therapeutics \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RxOMEG Therapeutics \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"GlycoMantra","sponsor":"University of Maryland","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"GM300","moa":"Galectin-3","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoMantra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoMantra \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"GlycoMantra \/ University of Maryland"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"GM-1020","moa":"NMDAR","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilgamesh Pharmaceuticals \/ Prime Movers Lab","highestDevelopmentStatusID":"4","companyTruncated":"Gilgamesh Pharmaceuticals \/ Prime Movers Lab"},{"orgOrder":0,"company":"Genascence","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Genascence \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Pacira BioSciences"},{"orgOrder":0,"company":"GO Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"GO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GO Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"GO Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Golden Mountain Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Golden Mountain Partners","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Golden Mountain Partners"},{"orgOrder":0,"company":"GondolaBio","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Demerger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GondolaBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GondolaBio \/ BridgeBio Pharma","highestDevelopmentStatusID":"4","companyTruncated":"GondolaBio \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Seralutinib","moa":"PDGFR\/ CSF1R\/ c-KIT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Gossamer Bio \/ Chiesi Group","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ Chiesi Group"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"GB001","moa":"Prostaglandin D2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ BofA Securities"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Seralutinib","moa":"PDGFR\/ CSF1R\/ c-KIT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ EcoR1 Capital"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Seralutinib","moa":"PDGFR\/ CSF1R\/ c-KIT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ New Enterprise Associates","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ New Enterprise Associates"},{"orgOrder":0,"company":"Novavax","sponsor":"Government of United Kingdom","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Government of United Kingdom","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Government of United Kingdom"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Acasti Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Acasti Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Acasti Pharma"},{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Soft Bones","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Tissue Non-Specific Alkaline Phosphatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Sanford Burnham Prebys Medical Discovery Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Burnham Prebys Medical Discovery Institute \/ Soft Bones","highestDevelopmentStatusID":"4","companyTruncated":"Sanford Burnham Prebys Medical Discovery Institute \/ Soft Bones"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GreenLight Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"GreenLight Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"GreenLight Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"GRI Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Vallon Pharmaceuticals \/ GRI Bio","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ GRI Bio"},{"orgOrder":0,"company":"Selagine","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"SLG-100","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Selagine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Selagine \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"Selagine \/ Grifols International"},{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aradigm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aradigm \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Aradigm \/ Grifols International"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Private Placement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Redmile Group"},{"orgOrder":0,"company":"Geron","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Goldman Sachs","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Goldman Sachs"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Hercules Capital"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"GS-1811","moa":"||TITR cell","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Latozinemab","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Tempus","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ GSK"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ GSK"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"GSK3903371","moa":"IL-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Boston Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Cytovance Biologics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Cytovance Biologics"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Hackensack Meridian CDI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Hackensack Meridian CDI \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Hackensack Meridian CDI \/ Merck & Co"},{"orgOrder":0,"company":"Hadassah","sponsor":"MyBiotics Pharma Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hadassah","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hadassah \/ MyBiotics Pharma Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Hadassah \/ MyBiotics Pharma Ltd"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Haloperidol Decanoate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Essential Pharma"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antares Pharma \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"NurrOn Pharmaceuticals","sponsor":"Hanall Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"ATH-399A","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NurrOn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurrOn Pharmaceuticals \/ Hanall Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"NurrOn Pharmaceuticals \/ Hanall Biopharma"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ CSPC Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ CSPC Pharmaceutical Group"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tufts Medical Center \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Tufts Medical Center \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Mycrodose Therapeutics","sponsor":"HAVN Life","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mycrodose Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mycrodose Therapeutics \/ HAVN Life","highestDevelopmentStatusID":"1","companyTruncated":"Mycrodose Therapeutics \/ HAVN Life"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Hadassah Medical Organization","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"HBI0101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Hadassah Medical Organization","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Hadassah Medical Organization"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Vir Biotechnology"},{"orgOrder":0,"company":"hC Bioscience","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"hC Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"hC Bioscience \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"hC Bioscience \/ ARCH Venture Partners"},{"orgOrder":0,"company":"hC Bioscience","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"hC Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"hC Bioscience \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"hC Bioscience \/ Taiho Ventures"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"hVIVO","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aim ImmunoTech \/ hVIVO","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ hVIVO"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Ardelyx","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"HemoShear Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"CpG 1018","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Bavarian Nordic","highestDevelopmentStatusID":"15","companyTruncated":"Dynavax Technologies \/ Bavarian Nordic"},{"orgOrder":0,"company":"Hexagon Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hexagon Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hexagon Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Hexagon Bio \/ The Column Group"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Mirae Asset Financial Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series D Financing","leadProduct":"HFB200301","moa":"TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group"},{"orgOrder":0,"company":"NemaLife","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Psychoplastogen","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NemaLife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NemaLife \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"NemaLife \/ University of California"},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HilleVax \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ J.P. Morgan"},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HilleVax \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ J.P. Morgan"},{"orgOrder":0,"company":"Applied Biomedical Science Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied Biomedical Science Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Applied Biomedical Science Institute \/ Hillstream BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Applied Biomedical Science Institute \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Amerimmune","sponsor":"Histogen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Emricasan","moa":"Caspase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Amerimmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amerimmune \/ Histogen","highestDevelopmentStatusID":"5","companyTruncated":"Amerimmune \/ Histogen"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"HMI-102","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"HB-700","moa":"KRAS G12D","graph1":"Oncology","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hookipa Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"CD8+ T-cell","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Viela Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viela Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Viela Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Curzion Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"HZN-825","moa":"LyLPAR1","graph1":"Dermatology","graph2":"Phase II","graph3":"Curzion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curzion Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Curzion Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Horizon Pharma Plc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Teprotumumab","moa":"||IGF-1 receptor","graph1":"Immunology","graph2":"Phase IV","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Horizon Pharma Plc","highestDevelopmentStatusID":"11","companyTruncated":"Halozyme Therapeutics \/ Horizon Pharma Plc"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Viela Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viela Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Viela Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Horizon Pharma Plc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AGC Biologics \/ Horizon Pharma Plc","highestDevelopmentStatusID":"15","companyTruncated":"AGC Biologics \/ Horizon Pharma Plc"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Self-Assembling Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Virginia Commonwealth University \/ Hoth Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Virginia Commonwealth University \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"George Washington University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ George Washington University","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ George Washington University"},{"orgOrder":0,"company":"Chelexa Biosciences","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Chelexa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Chelexa Biosciences \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chelexa Biosciences \/ Hoth Therapeutics"},{"orgOrder":0,"company":"George Washington University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Approved FDF","graph3":"George Washington University","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"George Washington University \/ Hoth Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"George Washington University \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"HT-TBI","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Altasciences Company Inc","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Humacyte","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ TD Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ TD Cowen"},{"orgOrder":0,"company":"Humacyte","sponsor":"Constellation Alpha Holdings","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Constellation Alpha Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Constellation Alpha Holdings"},{"orgOrder":0,"company":"Humanigen","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ J.P. Morgan"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"SK Holdings, Heritas Capital, SEEDS Enterprise","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hummingbird Bioscience \/ SK Holdings, Heritas Capital, SEEDS Enterprise","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ SK Holdings, Heritas Capital, SEEDS Enterprise"},{"orgOrder":0,"company":"Soligenix","sponsor":"U.S. Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ U.S. Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ U.S. Food & Drug Administration"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Umoja Biopharma \/ IASO Bio","highestDevelopmentStatusID":"2","companyTruncated":"Umoja Biopharma \/ IASO Bio"},{"orgOrder":0,"company":"IAVI","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"rVSV\u2206G-LASV-GPC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Merck & Co"},{"orgOrder":0,"company":"IAVI","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"rVSV\u2206G-LASV-GPC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ CEPI"},{"orgOrder":0,"company":"Texas A&M University System laboratories","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"IBIO-200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Texas A&M University System laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas A&M University System laboratories \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Texas A&M University System laboratories \/ iBio"},{"orgOrder":0,"company":"iBio","sponsor":"ATB Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Atbody-st-2","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iBio \/ ATB Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"iBio \/ ATB Therapeutics"},{"orgOrder":0,"company":"iBio","sponsor":"AzarGen Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iBio \/ AzarGen Biotechnologies","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ AzarGen Biotechnologies"},{"orgOrder":0,"company":"Safi Biosolutions","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Safi Biosolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Safi Biosolutions \/ iBio","highestDevelopmentStatusID":"1","companyTruncated":"Safi Biosolutions \/ iBio"},{"orgOrder":0,"company":"IBM Watson Health","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"IBIO-200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IBM Watson Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBM Watson Health \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"IBM Watson Health \/ iBio"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"University of Miami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ University of Miami"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Iconovo","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Agreement","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Amneal Pharmaceuticals \/ Iconovo","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Iconovo"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Ideaya Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Niraparib","moa":"||Polymerase theta helicase","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"OX1R\/OX2R","graph1":"Sleep","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"IDRx","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"IDRX-42","moa":"TYK","graph1":"Gastroenterology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDRx \/ Andreessen Horowitz","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Andreessen Horowitz"},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anagram Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anagram Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anagram Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Inflectis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Sephin1","moa":"PPP1R15A\/PP1c phosphatase complex","graph1":"Genetic Disease","graph2":"Phase I","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Chicago \/ Inflectis Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"University of Chicago \/ Inflectis Bioscience"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Omega Funds","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Omega Funds"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Jefferies","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Oncology \/ Jefferies"},{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Nepafenac","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Suspension\/Drops","sponsorNew":"Harrow \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Emmes Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Emmes Group","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Emmes Group"},{"orgOrder":0,"company":"Illumina","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Illumina","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Illumina \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Illumina \/ AstraZeneca"},{"orgOrder":0,"company":"ImaginAb","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImaginAb \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Farallon Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase III","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imago BioSciences \/ Farallon Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Imago BioSciences \/ Farallon Capital Management"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Medison Pharma"},{"orgOrder":0,"company":"Immunogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"Magrolimab","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Gilead Sciences"},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immetas Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Therapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"IL-2 Mutein","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyrus Biotechnology \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biotechnology \/ Selecta Biosciences"},{"orgOrder":0,"company":"Immunai","sponsor":"Viola Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunai","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunai \/ Viola Group","highestDevelopmentStatusID":"1","companyTruncated":"Immunai \/ Viola Group"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"IMM-1-104","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuneering Corporation \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Jefferies"},{"orgOrder":0,"company":"ImmuNext Inc","sponsor":"Curis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Onvatilimab","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuNext Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuNext Inc \/ Curis","highestDevelopmentStatusID":"6","companyTruncated":"ImmuNext Inc \/ Curis"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Altium Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Altium Capital","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Altium Capital"},{"orgOrder":0,"company":"Immunis","sponsor":"Springbok","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunis \/ Springbok","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Springbok"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"ImmunityBio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ZPC-21","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis Pharmaceuticals \/ Immunome"},{"orgOrder":0,"company":"Immunomedics","sponsor":"DLA Piper","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ DLA Piper","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ DLA Piper"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Cowen"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Cowen"},{"orgOrder":0,"company":"T-Cure Bioscience","sponsor":"Immunotech Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"HERV-E TCR Transduced CD8+\/CD34+ Enriched T Cell","moa":"HERV-E","graph1":"Oncology","graph2":"Phase I","graph3":"T-Cure Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T-Cure Bioscience \/ Immunotech Biopharm","highestDevelopmentStatusID":"6","companyTruncated":"T-Cure Bioscience \/ Immunotech Biopharm"},{"orgOrder":0,"company":"Immunovant","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Roivant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Roivant Sciences"},{"orgOrder":0,"company":"Biothera Pharmaceuticals","sponsor":"HiberCell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Odetiglucan","moa":"||Dectin receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Biothera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biothera Pharmaceuticals \/ HiberCell","highestDevelopmentStatusID":"8","companyTruncated":"Biothera Pharmaceuticals \/ HiberCell"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"IMSA101","moa":"||STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmuneSensor Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneSensor Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"ImStem Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ ImStem Biotechnology","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Therapeutics \/ ImStem Biotechnology"},{"orgOrder":0,"company":"ImStem Biotechnology","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImStem Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImStem Biotechnology \/ AgeX Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"ImStem Biotechnology \/ AgeX Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Imugene"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Imugene"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Mayne Pharma","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Mayne Pharma"},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Oncology Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"KTH-222","moa":"MAPK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalos Therapeutics \/ Oncology Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Therapeutics \/ Oncology Pharmaceuticals"},{"orgOrder":0,"company":"NCCN Oncology Research Program","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I","graph3":"NCCN Oncology Research Program","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NCCN Oncology Research Program \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"NCCN Oncology Research Program \/ Taiho Oncology"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"U.S. Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ U.S. Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ U.S. Food & Drug Administration"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Tuberculosis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ILiAD Biotechnologies \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ILiAD Biotechnologies \/ National Institutes of Health"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"CinPax","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ CinPax","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ CinPax"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Isleworth Healthcare Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovia Therapeutics \/ Isleworth Healthcare Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Isleworth Healthcare Acquisition Corp."},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ImmPACT Bio \/ venBio Partners","highestDevelopmentStatusID":"6","companyTruncated":"ImmPACT Bio \/ venBio Partners"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series B Financing","leadProduct":"Vevoctadekin","moa":"IL-18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Simcha Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Financing","leadProduct":"225-Ac Conjugated PSMA","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Ratio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ratio Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Ratio Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repertoire Immune Medicines \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire Immune Medicines \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Proteros","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Arbutus Biopharma \/ Proteros","highestDevelopmentStatusID":"2","companyTruncated":"Arbutus Biopharma \/ Proteros"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"VTX3232","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"LX2021","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexeo Therapeutics \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Lexeo Therapeutics \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Lipocine","sponsor":"Antares Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Antares Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Antares Pharma"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Enalare Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Evozyne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Evozyne","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Evozyne \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Evozyne \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Evozyne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Evozyne","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evozyne \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Evozyne \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Versamune-TARP","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDS Biotechnology \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ National Cancer Institute"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"CMAX","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ CMAX","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ CMAX"},{"orgOrder":0,"company":"Curia","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curia \/ BryoLogyx Inc","highestDevelopmentStatusID":"5","companyTruncated":"Curia \/ BryoLogyx Inc"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReviR Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"ReviR Therapeutics \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"GenScript","sponsor":"REMD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenScript \/ REMD","highestDevelopmentStatusID":"3","companyTruncated":"GenScript \/ REMD"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"y T-cell suppressor","graph1":"Oncology","graph2":"Preclinical","graph3":"Egle Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Egle Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Egle Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Indivior","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ BARDA"},{"orgOrder":0,"company":"Agenus","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Balstilimab","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Preclinical","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Agenus \/ VBI Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Agenus \/ VBI Vaccines"},{"orgOrder":0,"company":"FHI Clinical","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Foralumab","moa":"CD3","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"FHI Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"FHI Clinical \/ Tiziana Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"FHI Clinical \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"Applied BioMath","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied BioMath \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied BioMath \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"NVIDIA Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regor Therapeutics \/ NVIDIA Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Regor Therapeutics \/ NVIDIA Corporation"},{"orgOrder":0,"company":"FHI Clinical","sponsor":"Leidos Biomedical Research, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"FHI Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"FHI Clinical \/ Leidos Biomedical Research, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"FHI Clinical \/ Leidos Biomedical Research, Inc."},{"orgOrder":0,"company":"Melior Discovery","sponsor":"SFA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"SFA005","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melior Discovery \/ SFA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Melior Discovery \/ SFA Therapeutics"},{"orgOrder":0,"company":"Xencor","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"GS-9722","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Gilead Sciences"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"L-DOS47","moa":"VEGFR 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Helix BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Helix BioPharma"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"U.S. Army Contracting Command","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Ology Bioservices \/ U.S. Army Contracting Command","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ U.S. Army Contracting Command"},{"orgOrder":0,"company":"KYAN Therapeutics","sponsor":"Georgetown University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"KYAN-001","moa":"HDAC","graph1":"Oncology","graph2":"Preclinical","graph3":"KYAN Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KYAN Therapeutics \/ Georgetown University","highestDevelopmentStatusID":"4","companyTruncated":"KYAN Therapeutics \/ Georgetown University"},{"orgOrder":0,"company":"Inhalon Biopharma","sponsor":"USAMRDC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inhalon Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inhalon Biopharma \/ USAMRDC","highestDevelopmentStatusID":"6","companyTruncated":"Inhalon Biopharma \/ USAMRDC"},{"orgOrder":0,"company":"IN8bio","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"IN8bio","sponsor":"B. Riley Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"INB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Infusion","sponsorNew":"IN8bio \/ B. Riley Securities","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ B. Riley Securities"},{"orgOrder":0,"company":"IN8bio","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"INB-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Infusion","sponsorNew":"IN8bio \/ Barclays","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Barclays"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Catalent Pharma Solutions \/ Acorda Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"INCB99280","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimble Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Nimble Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Multiple Myeloma Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indapta Therapeutics \/ Multiple Myeloma Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ Multiple Myeloma Research Foundation"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company, LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company, LLC"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Infinimmune","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinimmune \/ Playground Global","highestDevelopmentStatusID":"2","companyTruncated":"Infinimmune \/ Playground Global"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inipharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Inipharm","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inipharm \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Inipharm \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"NAMRU-3","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"STI-2020","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ NAMRU-3","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ NAMRU-3"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"OrbiMed Asia Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ OrbiMed Asia Partners","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ OrbiMed Asia Partners"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Dragon Overseas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Dragon Overseas","highestDevelopmentStatusID":"4","companyTruncated":"Oncotelic Therapeutics \/ Dragon Overseas"},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"DARPA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"STI-2020","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SmartPharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SmartPharm Therapeutics \/ DARPA","highestDevelopmentStatusID":"7","companyTruncated":"SmartPharm Therapeutics \/ DARPA"},{"orgOrder":0,"company":"Arvinas","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Bavdegalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Foundation Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Foundation Medicine"},{"orgOrder":0,"company":"University of Georgia","sponsor":"CEL-SCI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Georgia \/ CEL-SCI","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ CEL-SCI"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CD371","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Caribou Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Caribou Biosciences"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Servier"},{"orgOrder":0,"company":"Baymedica","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Baymedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Baymedica \/ InMed Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Baymedica \/ InMed Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"InnoCare Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ InnoCare Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ InnoCare Pharma"},{"orgOrder":0,"company":"Viatris","sponsor":"Clinton Health Access Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Clinton Health Access Initiative","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Clinton Health Access Initiative"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"Rdd Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovate Biopharmaceuticals \/ Rdd Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate Biopharmaceuticals \/ Rdd Pharma"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Richter-Helm BioLogics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ K2 HealthVentures","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ K2 HealthVentures"},{"orgOrder":0,"company":"InSitu Biologics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"INSB400","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"InSitu Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSitu Biologics \/ Mayo Clinic","highestDevelopmentStatusID":"4","companyTruncated":"InSitu Biologics \/ Mayo Clinic"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Insitro","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Eli Lilly \/ Insitro","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Insitro"},{"orgOrder":0,"company":"Insitro","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Insitro","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insitro \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Insitro \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Insmed","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"ITIL-168","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio \/ Renaissance Capital"},{"orgOrder":0,"company":"Bigfoot Biomedical","sponsor":"Insulet Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Bigfoot Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bigfoot Biomedical \/ Insulet Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bigfoot Biomedical \/ Insulet Corporation"},{"orgOrder":0,"company":"Quantitative Medicine","sponsor":"Predictive Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Quantitative Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantitative Medicine \/ Predictive Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Quantitative Medicine \/ Predictive Oncology"},{"orgOrder":0,"company":"TetraGenetics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"TetraGenetics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TetraGenetics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"TetraGenetics \/ AbCellera"},{"orgOrder":0,"company":"IntroSpect Digital Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"IntroSpect Digital Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IntroSpect Digital Therapeutics \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"IntroSpect Digital Therapeutics \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"KYV-201","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Kyverna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Kyverna Therapeutics"},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"ATPGroup","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intergalactic Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Intergalactic Therapeutics \/ ATPGroup","highestDevelopmentStatusID":"2","companyTruncated":"Intergalactic Therapeutics \/ ATPGroup"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intersect ENT \/ Medtronic Plc","highestDevelopmentStatusID":"15","companyTruncated":"Intersect ENT \/ Medtronic Plc"},{"orgOrder":0,"company":"Therapyx","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"NGoXIM","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapyx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Therapyx \/ Intravacc","highestDevelopmentStatusID":"4","companyTruncated":"Therapyx \/ Intravacc"},{"orgOrder":0,"company":"EpiVax","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"OMV-peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Intravacc"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inimmune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Intrommune Therapeutics \/ Inimmune","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inimmune"},{"orgOrder":0,"company":"InveniAI","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"InveniAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InveniAI \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"InveniAI \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"XBiotech","sponsor":"The French National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"Trifluridine","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XBiotech \/ The French National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"XBiotech \/ The French National Cancer Institute"},{"orgOrder":0,"company":"Interline Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Interline Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interline Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"4","companyTruncated":"Interline Therapeutics \/ Foresite Capital"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"AZD8233","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aro Biotherapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Aro Biotherapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"IOV-3001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avid Bioservices \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avid Bioservices \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Lifileucel","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Lifileucel","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merrimack Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merrimack Pharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Merrimack Pharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Ipsen"},{"orgOrder":0,"company":"IQVIA","sponsor":"ASLAN Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13-alpha 1","graph1":"Dermatology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ ASLAN Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ ASLAN Pharmaceuticals"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"Biocorrx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"IRISYS, LLC \/ Biocorrx","highestDevelopmentStatusID":"4","companyTruncated":"IRISYS, LLC \/ Biocorrx"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Drinabant","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"IRISYS, LLC \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"IRISYS, LLC \/ National Institutes of Health"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"ISB 2001","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Glenmark Innovation \/ Certara","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Glenmark Innovation \/ Certara"},{"orgOrder":0,"company":"Institute for Systems Biology","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute for Systems Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Institute for Systems Biology \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Institute for Systems Biology \/ Merck & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Isoprene Pharmaceuticals"},{"orgOrder":0,"company":"IsoTherapeutics Group","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IsoTherapeutics Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IsoTherapeutics Group \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"2","companyTruncated":"IsoTherapeutics Group \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"ISOThrive","sponsor":"Virginia Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Funding","leadProduct":"Maltosyl-Isomaltooligosaccharide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"ISOThrive","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISOThrive \/ Virginia Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"ISOThrive \/ Virginia Catalyst"},{"orgOrder":0,"company":"Humanigen","sponsor":"KPM Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ KPM Tech","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ KPM Tech"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Aifa","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Aifa","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Aifa"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"RBI-5000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunomic Therapeutics \/ Replicate Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"Immunomic Therapeutics \/ Replicate Bioscience"},{"orgOrder":0,"company":"CoImmune","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1020","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"CoImmune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CoImmune \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CoImmune \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Ichor Medical Systems","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1001","moa":"pp65","graph1":"Oncology","graph2":"Preclinical","graph3":"Ichor Medical Systems","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ichor Medical Systems \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ichor Medical Systems \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Equillium","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Morgan Stanley"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Morgan Stanley"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Oasis Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Oasis Capital","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Oasis Capital"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"Soin Therapeutics","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Soin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soin Therapeutics \/ JanOne","highestDevelopmentStatusID":"4","companyTruncated":"Soin Therapeutics \/ JanOne"},{"orgOrder":0,"company":"CoreRx","sponsor":"JanOne","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CoreRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CoreRx \/ JanOne","highestDevelopmentStatusID":"8","companyTruncated":"CoreRx \/ JanOne"},{"orgOrder":0,"company":"Janpix","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"STAT3 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Janpix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janpix \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Janpix \/ Medicxi"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Hepatitis B Vaccine","moa":"TLR9","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bavarian Nordic","highestDevelopmentStatusID":"4","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Bavarian Nordic"},{"orgOrder":0,"company":"Arkuda Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"ARKD-104","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Arkuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arkuda Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Arkuda Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Jantibody Inc","sponsor":"H-CYTE","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Jantibody","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Jantibody Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jantibody Inc \/ H-CYTE","highestDevelopmentStatusID":"4","companyTruncated":"Jantibody Inc \/ H-CYTE"},{"orgOrder":0,"company":"Jantibody","sponsor":"H-CYTE","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Jantibody","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Jantibody","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jantibody \/ H-CYTE","highestDevelopmentStatusID":"4","companyTruncated":"Jantibody \/ H-CYTE"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ RBC Capital Markets","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ RBC Capital Markets"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Sagard Healthcare"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Tesaro, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AnaptysBio \/ Tesaro, Inc","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Tesaro, Inc"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"KN026","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Alphamab Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Alphamab Oncology"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Jnana Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Government of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Government of Canada"},{"orgOrder":0,"company":"TRexBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRexBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"TRexBio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Johnson & Johnson"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Eli Lilly \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Maruho"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Journey Medical Corporation \/ Fortress Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Fortress Biotech"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Avrobio","highestDevelopmentStatusID":"4","companyTruncated":"Jasper Therapeutics \/ Avrobio"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Jubilant Cadista Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jubilant Cadista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jubilant Cadista Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Jubilant Cadista Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jupiter Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jupiter Neurosciences \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Jupiter Neurosciences \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Neurology","graph2":"IND Enabling","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Juvena Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"5","companyTruncated":"Juvena Therapeutics \/ Mubadala Capital"},{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Smallpox And Monkeypox Vaccine, Live, Nonreplicating","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Grand River Aseptic Manufacturing","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grand River Aseptic Manufacturing \/ Bavarian Nordic","highestDevelopmentStatusID":"15","companyTruncated":"Grand River Aseptic Manufacturing \/ Bavarian Nordic"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"K2bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Partnership","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ K2bio","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ K2bio"},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Civica Rx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kaiser Permanente Washington Health Research \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Kaiser Permanente Washington Health Research \/ Civica Rx"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"KALA Bio \/ SR One","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/ SR One"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Oxford Finance"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Pan Canadian Pharmaceutical Alliance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KALEO INC \/ Pan Canadian Pharmaceutical Alliance","highestDevelopmentStatusID":"15","companyTruncated":"KALEO INC \/ Pan Canadian Pharmaceutical Alliance"},{"orgOrder":0,"company":"Kalthera","sponsor":"ImmPACT Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kalthera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalthera \/ ImmPACT Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kalthera \/ ImmPACT Bio"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Tempus","sponsor":"Kartos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Navtemadlin","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ Kartos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tempus \/ Kartos Therapeutics"},{"orgOrder":0,"company":"Prometrika","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Selinexor","moa":"XPO1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Prometrika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prometrika \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Prometrika \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"KayoThera","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"KayoThera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KayoThera \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"2","companyTruncated":"KayoThera \/ Accelerator Life Science Partners"},{"orgOrder":0,"company":"Pacific Pediatric Neuro-Oncology Consortium","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Dordaviprone","moa":"||DRD2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pacific Pediatric Neuro-Oncology Consortium","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Kedrion","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kedrion \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Kedrion \/ Columbia University"},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"ElevateBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kelonia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kelonia Therapeutics \/ ElevateBio","highestDevelopmentStatusID":"3","companyTruncated":"Kelonia Therapeutics \/ ElevateBio"},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"KemPharm \/ Corium","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Corium"},{"orgOrder":0,"company":"Delic Corp","sponsor":"Ketamine Wellness Centers","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Delic Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delic Corp \/ Ketamine Wellness Centers","highestDevelopmentStatusID":"1","companyTruncated":"Delic Corp \/ Ketamine Wellness Centers"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Jefferies LLC","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Jefferies LLC"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Cowen"},{"orgOrder":0,"company":"Kinnjiu Biopharma","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnjiu Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnjiu Biopharma \/ Kinnate Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Kinnjiu Biopharma \/ Kinnate Biopharma"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kindeva Drug Delivery \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Kindeva Drug Delivery \/ Nutriband"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"15","companyTruncated":"Kiniksa Pharmaceuticals \/ Goldman Sachs"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiniksa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Pharmaceuticals \/ Goldman Sachs"},{"orgOrder":0,"company":"Kinnear Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"CSA-131","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kinnear Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kinnear Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Kinnear Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"CART-ddBCMA","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Kite Pharma"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"KV7.2\/7.3 potassium channel","graph1":"Neurology","graph2":"Discovery","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Knopp Biosciences LLC \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Knopp Biosciences LLC \/ National Institutes of Health"},{"orgOrder":0,"company":"Kojin Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Ferroptosis","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kojin Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kojin Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"Kojin Therapeutics \/ Polaris Partners"},{"orgOrder":0,"company":"Koneksa","sponsor":"old Sano","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Koneksa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Koneksa \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"Koneksa \/ old Sano"},{"orgOrder":0,"company":"Kovina Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Kovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kovina Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Kovina Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"KemPharm","sponsor":"Hypersomnia Foundation","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Hypersomnia Foundation","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Hypersomnia Foundation"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Vixarelimab","moa":"Oncostatin M beta receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Kriya Therapeutics \/ Kriya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Kriya Therapeutics \/ Kriya Therapeutics"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Kumquat Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kumquat Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Kumquat Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Immunostimulant","graph1":"Oncology","graph2":"Discovery","graph3":"Kumquat Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kumquat Biosciences \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Kumquat Biosciences \/ Eli Lilly"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Ziftomenib","moa":"MLL-KMT2A\/MLL","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ EcoR1 Capital","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ EcoR1 Capital"},{"orgOrder":0,"company":"Kures","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"KUR-101","moa":"MOR","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Kures","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kures \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kures \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Kineta","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Private Placement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Yumanity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Yumanity Therapeutics"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"||H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK.Tech","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK.Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"SJP-100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK-Tech","highestDevelopmentStatusID":"4","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK-Tech"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kytopen","sponsor":"Mirus Bio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Kytopen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kytopen \/ Mirus Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kytopen \/ Mirus Bio"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Angiotensin II","moa":"Angiotensin II receptor type 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ Innoviva","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Innoviva"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"PAION UK LTD","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Angiotensin II","moa":"Angiotensin II receptor type 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ PAION UK LTD","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ PAION UK LTD"},{"orgOrder":0,"company":"LakePharma","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LakePharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LakePharma \/ Akston Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"LakePharma \/ Akston Biosciences"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Respirent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lannett Company, Inc. \/ Respirent Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Respirent Pharmaceuticals"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"LP-300","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"TTC Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lantern Pharma \/ TTC Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ TTC Oncology"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Focus Fund GP","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focus Fund GP","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Launch Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Upacicalcet Sodium","moa":"CaR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pathalys Pharma \/ Launch Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pathalys Pharma \/ Launch Therapeutics"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University of Illinois","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ University of Illinois","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ University of Illinois"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"5 Fluorouracil","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Piper Sandler & Co"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Leidos","sponsor":"Targovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Leidos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leidos \/ Targovax","highestDevelopmentStatusID":"1","companyTruncated":"Leidos \/ Targovax"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LENZ Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Humanigen","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ National Institutes of Health"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Leo Pharma"},{"orgOrder":0,"company":"Leading Edge Pharms","sponsor":"Evio Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Leading Edge Pharms","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Leading Edge Pharms \/ Evio Labs","highestDevelopmentStatusID":"15","companyTruncated":"Leading Edge Pharms \/ Evio Labs"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Macleods Pharmaceuticals Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Macleods Pharmaceuticals Limited","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Macleods Pharmaceuticals Limited"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"LX2022","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexeo Therapeutics \/ Lexeo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lexeo Therapeutics \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Cornell University","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornell University \/ Lexeo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cornell University \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"AC BioScience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"LX2931","moa":"S1P lyase","graph1":"Immunology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ AC BioScience","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ AC BioScience"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"MaxCyte","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LR19023","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ LG Chem"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"University of Maryland","sponsor":"AIkido Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"University of Maryland","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland \/ AIkido Pharma","highestDevelopmentStatusID":"2","companyTruncated":"University of Maryland \/ AIkido Pharma"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"ONKT101","moa":"CCR7","graph1":"Oncology","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ ONK Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"National Institutes of Health \/ ONK Therapeutics"},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfenex \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"CR Double-Crane Pharmaceuticals Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Ligand Pharmaceuticals \/ CR Double-Crane Pharmaceuticals Co., Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Ligand Pharmaceuticals \/ CR Double-Crane Pharmaceuticals Co., Ltd"},{"orgOrder":0,"company":"OmniAb","sponsor":"Avista Public Acquisition Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"OmniAb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OmniAb \/ Avista Public Acquisition Corp. II","highestDevelopmentStatusID":"3","companyTruncated":"OmniAb \/ Avista Public Acquisition Corp. II"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Eli Lilly"},{"orgOrder":0,"company":"Care Access Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Care Access Research \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Care Access Research \/ Eli Lilly"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Cinrebafusp Alpha","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"R552","moa":"RIPK1","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rigel Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Eli Lilly"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"Neurgain Technologies","sponsor":"Lineagen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Neurgain Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Neurgain Technologies \/ Lineagen","highestDevelopmentStatusID":"7","companyTruncated":"Neurgain Technologies \/ Lineagen"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ LipoMedix"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Liquidia Corporation \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Liquidia Corporation \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Satiogen","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Satiogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Satiogen \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Satiogen \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locus Biosciences \/ Hercules Capital","highestDevelopmentStatusID":"3","companyTruncated":"Locus Biosciences \/ Hercules Capital"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LogicBio Therapeutics \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"LogicBio Therapeutics \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longbow Immunotherapy","sponsor":"Versiti Blood Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Longbow Immunotherapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longbow Immunotherapy \/ Versiti Blood Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Longbow Immunotherapy \/ Versiti Blood Research Institute"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Longeveron","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Private Placement","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ EF Hutton","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ EF Hutton"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Longeveron","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Laromestrocel","moa":"VEGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Renaissance Capital"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Anc80L65","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affinia Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"4","companyTruncated":"Affinia Therapeutics \/ Lonza Group"},{"orgOrder":0,"company":"Biosplice","sponsor":"Samil Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Samil Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Samil Pharmaceutical"},{"orgOrder":0,"company":"Biosplice","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Lusaris Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Series A Financing","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lusaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Lusaris Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Lusaris Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Collaboration","leadProduct":"177-Lu PNT2002","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Lupin Ltd"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Pretomanid","moa":"||Mycolic acid biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"TB Alliance \/ Lupin Ltd"},{"orgOrder":0,"company":"Lyvgen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"LVGN7409","moa":"||CD40","graph1":"Oncology","graph2":"Preclinical","graph3":"Lyvgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyvgen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Lyvgen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LX1001","moa":"APOEII\/III","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Cerveau Technologies \/ Lexeo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmPACT Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Lyell Immunopharma"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmPACT Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Lygenesis","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"LYG-LIV0001","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lygenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lygenesis \/ AgeX Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lygenesis \/ AgeX Therapeutics"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"TenX Keane Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Oncology \/ TenX Keane Acquisition","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ TenX Keane Acquisition"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Aig Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Aig Investments","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Aig Investments"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"M.S. Howells & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ M.S. Howells & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ M.S. Howells & Co."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Brookline Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Brookline Capital","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Brookline Capital"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ LianBio"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Series C Financing","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"M1231","moa":"MUC1-EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck Group"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"SERB Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"Glucarpidase","moa":"Hydrolytic enzyme","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Magenta Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Magenta Partners","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Magenta Partners"},{"orgOrder":0,"company":"MagicMed","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MagicMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"MagicMed \/ Enveric Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"MagicMed \/ Enveric Biosciences"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Massachusetts General Hospital \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Mana Therapeutics","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"MANA-312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mana Therapeutics \/ Cobro Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Mana Therapeutics \/ Cobro Ventures"},{"orgOrder":0,"company":"Mannkind","sponsor":"Pulmatrix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ Pulmatrix","highestDevelopmentStatusID":"6","companyTruncated":"Mannkind \/ Pulmatrix"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Manus Bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Artemisinin","moa":"Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Manus Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manus Bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Manus Bio \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Mapp Biopharmaceutical","sponsor":"Avid Bioservices","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mapp Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mapp Biopharmaceutical \/ Avid Bioservices","highestDevelopmentStatusID":"5","companyTruncated":"Mapp Biopharmaceutical \/ Avid Bioservices"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Marathon Asset Management"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Invikafusp Alpha","moa":"TCR-V beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marengo Therapeutics \/ Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ SVB Securities","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ SVB Securities"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"nuBioAge","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"nuBioAge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"nuBioAge \/ Marius Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"nuBioAge \/ Marius Pharmaceuticals"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Maruho"},{"orgOrder":0,"company":"Meridian IT","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Meridian IT","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Meridian IT \/ Mateon Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Meridian IT \/ Mateon Therapeutics"},{"orgOrder":0,"company":"IBM Watson Health","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IBM Watson Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IBM Watson Health \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IBM Watson Health \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Public Offering","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ BTIG"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"National Resilience","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ National Resilience","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ National Resilience"},{"orgOrder":0,"company":"UC San Diego","sponsor":"MatriSys Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"MSB-3163","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"UC San Diego \/ MatriSys Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"UC San Diego \/ MatriSys Bioscience"},{"orgOrder":0,"company":"Metropolitan AntiViral Drug Accelerator","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Metropolitan AntiViral Drug Accelerator","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Metropolitan AntiViral Drug Accelerator \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Metropolitan AntiViral Drug Accelerator \/ National Institutes of Health"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maverick Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Maverick Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"McKesson","sponsor":"Centers for Disease Control","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"McKesson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"McKesson \/ Centers for Disease Control","highestDevelopmentStatusID":"1","companyTruncated":"McKesson \/ Centers for Disease Control"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Medable","sponsor":"Every Cure","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Medable","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medable \/ Every Cure","highestDevelopmentStatusID":"1","companyTruncated":"Medable \/ Every Cure"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Medidata","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Partnership","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Medidata"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Medison Pharma"},{"orgOrder":0,"company":"Medolife","sponsor":"Ministry of Environment of The Dominican Republic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Scorpion venom","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Medolife","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medolife \/ Ministry of Environment of The Dominican Republic","highestDevelopmentStatusID":"1","companyTruncated":"Medolife \/ Ministry of Environment of The Dominican Republic"},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Intersect ENT","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Implant","sponsorNew":"Intersect ENT \/ Medtronic Plc","highestDevelopmentStatusID":"15","companyTruncated":"Intersect ENT \/ Medtronic Plc"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Megapharm","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Megapharm"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Zandelisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Adhera Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pharmaceuticals \/ Adhera Therapeutics"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Harrow","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Harrow"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Menarini"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aligos Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Aligos Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Carbon Health","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carbon Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Carbon Health \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Carbon Health \/ Merck & Co"},{"orgOrder":0,"company":"Aulos","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Merck Group"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jenner Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Jenner Institute","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Jenner Institute"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Dewpoint Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"M6495","moa":"ADAMTS5","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Newco","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Demerger","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Merck & Co \/ Newco","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Newco"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"resTORbio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Merger","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ resTORbio","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ resTORbio"},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"Chemomab","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Merger","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ Chemomab","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano Therapeutics, Inc \/ Chemomab"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Equillium","sponsor":"Metacrine","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"MET642","moa":"FX receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Equillium \/ Metacrine","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Metacrine"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Hercules Credit Facility","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Hercules Credit Facility","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Hercules Credit Facility"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"MigVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"MigVax-101","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ MigVax","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ MigVax"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"miR-21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Minaris","sponsor":"MaxiVAX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"MVX-ONCO-2","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Minaris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minaris \/ MaxiVAX","highestDevelopmentStatusID":"8","companyTruncated":"Minaris \/ MaxiVAX"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Liechti Lab"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MindBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ MindBio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ MindBio Therapeutics"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Centre for Addiction and Mental Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Centre for Addiction and Mental Health","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Centre for Addiction and Mental Health"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Minerva Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"huMNC2-CAR44","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Seltorexant","moa":"OX2R","graph1":"Sleep","graph2":"Phase II","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minerva Neurosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Minerva Neurosciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"23andMe","sponsor":"Mirador Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Mirador Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"23andMe \/ Mirador Therapeutics"},{"orgOrder":0,"company":"Viridian Sciences","sponsor":"Miragen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Viridian Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viridian Sciences \/ Miragen Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Viridian Sciences \/ Miragen Therapeutics"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Eversana","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Maralixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eversana \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eversana \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Medicinova","sponsor":"Juntendo University","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Juntendo University","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Juntendo University"},{"orgOrder":0,"company":"Medicinova","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ University Health Network","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ University Health Network"},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ BARDA"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Moderna Therapeutics \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Ministry of Public Health of Qatar","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Ministry of Public Health of Qatar","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Ministry of Public Health of Qatar"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"CytomX Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"MDX-2201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OPKO Health \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"OPKO Health \/ Merck & Co"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"OPKO Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"ModeX Therapeutics \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ OPKO Health"},{"orgOrder":0,"company":"Alivexis","sponsor":"Green Coinvest Investment Limited","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"MOD-A","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Alivexis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alivexis \/ Green Coinvest Investment Limited","highestDevelopmentStatusID":"3","companyTruncated":"Alivexis \/ Green Coinvest Investment Limited"},{"orgOrder":0,"company":"Alivexis","sponsor":"SBI Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"kinase","graph1":"Oncology","graph2":"Discovery","graph3":"Alivexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alivexis \/ SBI Investments","highestDevelopmentStatusID":"2","companyTruncated":"Alivexis \/ SBI Investments"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"PBI-200","moa":"TRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pyramid Bio \/ Caris Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bio \/ Caris Life Sciences"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"MT-3724","moa":"CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Molecular Templates \/ BofA Securities"},{"orgOrder":0,"company":"University of Texas Medical Branch","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Texas Medical Branch","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"University of Texas Medical Branch \/ Moleculin Biotech","highestDevelopmentStatusID":"1","companyTruncated":"University of Texas Medical Branch \/ Moleculin Biotech"},{"orgOrder":0,"company":"Savara","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Silicon Valley Bank","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Merck & Co","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ U.S. Government","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ U.S. Government"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ SK Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ SK Holdings"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Hyperimmune Globulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ U.S. Department of Defense"},{"orgOrder":0,"company":"MRM Health","sponsor":"IFF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"M008","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ IFF","highestDevelopmentStatusID":"4","companyTruncated":"MRM Health \/ IFF"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ European Commission"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"The McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ The McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ The McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"BITT","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"BITD401412","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Private Placement","leadProduct":"MT-1002","moa":"SIRP alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Navidea Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Private Placement","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Stifel","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Stifel"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ BVF Partners","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ BVF Partners"},{"orgOrder":0,"company":"Curia","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Curia \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Curia \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Leiden University Medical Centre","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Leiden University Medical Centre","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Leiden University Medical Centre"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MycoMedica Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ MycoMedica Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ MycoMedica Life Sciences"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"MT-101","moa":"CD5-ATAK cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Myeloid Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myeloid Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"4","companyTruncated":"Myeloid Therapeutics \/ Newpath Partners"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Viatris","highestDevelopmentStatusID":"1","companyTruncated":"Revance Therapeutics \/ Viatris"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Bascom Palmer Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Bascom Palmer Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Bascom Palmer Eye Institute"},{"orgOrder":0,"company":"American College of Cardiology","sponsor":"MyoKardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"American College of Cardiology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American College of Cardiology \/ MyoKardia","highestDevelopmentStatusID":"10","companyTruncated":"American College of Cardiology \/ MyoKardia"},{"orgOrder":0,"company":"Myosana Therapeutics","sponsor":"CureDuchenne Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Dystrophin gene","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Myosana Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosana Therapeutics \/ CureDuchenne Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Myosana Therapeutics \/ CureDuchenne Ventures"},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"Mint12 Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"MT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Myosin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosin Therapeutics \/ Mint12 Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Myosin Therapeutics \/ Mint12 Pharma"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitomo Dainippon Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Accord healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Accord healthcare"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo EU","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo EU","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo EU"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mythic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Mythic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Mythic Therapeutics"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Bacillus Calmette Guerin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Piper Sandler & Co.","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Piper Sandler & Co."},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Nano Precision Medical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Merger","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Vivani Medical \/ Nano Precision Medical","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Nano Precision Medical"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO gene","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ National Eye Institute","highestDevelopmentStatusID":"5","companyTruncated":"Nanoscope Therapeutics \/ National Eye Institute"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"Mesothelin protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Navrogen"},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INVO Bioscience \/ Naya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"INVO Bioscience \/ Naya Biosciences"},{"orgOrder":0,"company":"Adtech Pharma","sponsor":"Ault Global Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Nabilone","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Adtech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Adtech Pharma \/ Ault Global Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Adtech Pharma \/ Ault Global Holdings"},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"NC410","moa":"LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Drinabant","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indivior \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Axitinib","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Nektar Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Neogene","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neogene \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Neogene \/ EcoR1 Capital"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Neopharm"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"NDI-5033","moa":"AMPK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"NephroDI Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Peanut (Arachis Hypogaea) Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Aimmune Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Acquisition","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Healthcare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Agreement","leadProduct":"Antihemophilic Factor Recombinant, PEGylated","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Healthcare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"Nektar Therapeutics \/ Healthcare Royalty"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Private Placement","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Syros Pharmaceuticals \/ Flagship Pioneering","highestDevelopmentStatusID":"10","companyTruncated":"Syros Pharmaceuticals \/ Flagship Pioneering"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Private Placement","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Piper Sandler & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Piper Sandler & Co."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Cowen"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Canaccord Genuity Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Financing","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Canaccord Genuity Corp","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Canaccord Genuity Corp"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Guggenheim Securities, Llc","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Public Offering","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Nephrology","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"DiaMedica Therapeutics \/ Guggenheim Securities, Llc","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Guggenheim Securities, Llc"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BlackRock Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ BlackRock Fund","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ BlackRock Fund"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series C Financing","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bluejay Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Bluejay Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"LX-101","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lirum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lirum Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Lirum Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Funding","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ New Jersey Economic Development Authority"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ TCGX","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Cellectar","sponsor":"Rosalind Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Private Placement","leadProduct":"131-I Iopofosine","moa":"DNA damage","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Rosalind Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Rosalind Advisors"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ORIC Pharmaceuticals \/ Viking Global Investors","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharmaceuticals \/ Viking Global Investors"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Private Placement","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Pyxis Oncology \/ Deep Track Capital"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"LBP-EC01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intraurethral Infusion","sponsorNew":"Locus Biosciences \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Locus Biosciences \/ BARDA"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Neurelis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"BA-1049","moa":"ROCK2","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Neurelis","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone BioSciences \/ Neurelis"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Gemphire Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Gemphire Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Gemphire Therapeutics"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Neurochase","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spark Therapeutics, Inc \/ Neurochase","highestDevelopmentStatusID":"2","companyTruncated":"Spark Therapeutics, Inc \/ Neurochase"},{"orgOrder":0,"company":"Advanced Neural Dynamics","sponsor":"Neuropathix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Advanced Neural Dynamics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Neural Dynamics \/ Neuropathix","highestDevelopmentStatusID":"1","companyTruncated":"Advanced Neural Dynamics \/ Neuropathix"},{"orgOrder":0,"company":"Myrobalan Therapeutics","sponsor":"Co-win Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Myrobalan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Myrobalan Therapeutics \/ Co-win Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Myrobalan Therapeutics \/ Co-win Ventures"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Denk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Denk Pharma","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Denk Pharma"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Brain Trust Accelerator Fund II","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Brain Trust Accelerator Fund II","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Brain Trust Accelerator Fund II"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Cleveland Clinic","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Cleveland Clinic"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Neurotrope"},{"orgOrder":0,"company":"Lacerta Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Lacerta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lacerta Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"Lacerta Therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Allinaire Therapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"EMAP-II","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Allinaire Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allinaire Therapeutics \/ Chiesi Group","highestDevelopmentStatusID":"4","companyTruncated":"Allinaire Therapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"mRNA Vaccine","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"Moderna Therapeutics \/ CEPI"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Immutep"},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Funding","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Chemotherapy Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced Chemotherapy Technologies \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Chemotherapy Technologies \/ National Institutes of Health"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Obicetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ NewAmsterdam Pharma"},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Fexofenadine Hydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adelia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adelia Therapeutics \/ Cybin","highestDevelopmentStatusID":"15","companyTruncated":"Adelia Therapeutics \/ Cybin"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Funding","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Vaxxas","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"RSV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Vaxxas","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ Vaxxas"},{"orgOrder":0,"company":"Scynexis","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"SCY-247","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Scynexis \/ National Institutes of Health"},{"orgOrder":0,"company":"Nika Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"ITV-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nika Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nika Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nika Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimble Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"NDI-101150","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Google Ventures"},{"orgOrder":0,"company":"Biotherapeutics","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotherapeutics \/ NImmune Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Biotherapeutics \/ NImmune Biopharma"},{"orgOrder":0,"company":"Genentech","sponsor":"Ningbo NewBay Medical Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"GDC-0570","moa":"Pan-PIM","graph1":"Oncology","graph2":"Preclinical","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Ningbo NewBay Medical Technology","highestDevelopmentStatusID":"4","companyTruncated":"Genentech \/ Ningbo NewBay Medical Technology"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"ATSN-101","moa":"LCA1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Nirogy therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SLCTs","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nirogy therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nirogy therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nirogy therapeutics \/ Sante Ventures"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Stanford School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Stanford School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Stanford School of Medicine"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nkarta Therapeutics \/ Adage Capital Partners LP","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Adage Capital Partners LP"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Parkinson\u2019s Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Parkinson\u2019s Foundation","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Parkinson\u2019s Foundation"},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"Nls Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Adare Pharma Solutions \/ Nls Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Adare Pharma Solutions \/ Nls Pharmaceutics"},{"orgOrder":0,"company":"Noachis Terra","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"Terra CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Noachis Terra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noachis Terra \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Noachis Terra \/ Oragenics"},{"orgOrder":0,"company":"Acerus Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Acerus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acerus Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Alkyon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Alkyon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Alkyon Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Candid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Candid Therapeutics"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Horizons Ventures","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Horizons Ventures"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Advanced Biofuels","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Norbaeocystin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PsyBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PsyBio Therapeutics \/ Advanced Biofuels","highestDevelopmentStatusID":"6","companyTruncated":"PsyBio Therapeutics \/ Advanced Biofuels"},{"orgOrder":0,"company":"NorthShore University","sponsor":"Johns Hopkins","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NorthShore University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"NorthShore University \/ Johns Hopkins","highestDevelopmentStatusID":"8","companyTruncated":"NorthShore University \/ Johns Hopkins"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NorthStar Medical Radioisotopes \/ Cellectar","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ Cellectar"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Convergent Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Expanded Collaboration","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NorthStar Medical Radioisotopes \/ Convergent Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NorthStar Medical Radioisotopes \/ Convergent Therapeutics"},{"orgOrder":0,"company":"CuradhMTR","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"CuradhMTR","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CuradhMTR \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"1","companyTruncated":"CuradhMTR \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"NNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwestern University \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Northwestern University \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Builders VC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ Builders VC","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ Builders VC"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"NovaBay Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Eyenovia"},{"orgOrder":0,"company":"Novan","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Novan","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Novan","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Novan","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Novan","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Alnylam Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Kedalion Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kedalion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kedalion Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Kedalion Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Arvinas","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Luxdegalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"PLN-1474","moa":"Integrin-alpha 5\/beta 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Pliant Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"IFM Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IFM Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novavax","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Government of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Government of Canada"},{"orgOrder":0,"company":"Novavax","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Novavax \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Novavax \/ CEPI"},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Novavax","sponsor":"Government of Australia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Government of Australia","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Government of Australia"},{"orgOrder":0,"company":"Novellus","sponsor":"NoveCite","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Induced Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ NoveCite","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/ NoveCite"},{"orgOrder":0,"company":"Celmatix","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celmatix \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Evotec"},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Tempus","sponsor":"Novellus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Plixorafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Tempus \/ Novellus"},{"orgOrder":0,"company":"Novitium Pharma LLC","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Aciclovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novitium Pharma LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Novitium Pharma LLC \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Novitium Pharma LLC \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Terragenx","sponsor":"Novo Integrated Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Iodine","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Terragenx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Terragenx \/ Novo Integrated Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Terragenx \/ Novo Integrated Sciences"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Flagship Pioneering \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Novo Nordisk"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"NRG5051","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Streeterville Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Streeterville Capital","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Streeterville Capital"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Partnership","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ National Institutes of Health"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Beijing ZhonghuaInvestment Fund Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Generex Biotechnology \/ Beijing ZhonghuaInvestment Fund Management","highestDevelopmentStatusID":"1","companyTruncated":"Generex Biotechnology \/ Beijing ZhonghuaInvestment Fund Management"},{"orgOrder":0,"company":"NuGenerex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Blarcamesine","moa":"||CD4 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"NuGenerex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuGenerex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuGenerex \/ Undisclosed"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Nurix Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"NUV-520","moa":"ROS1 selective kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Deerfield Management","highestDevelopmentStatusID":"5","companyTruncated":"Nuvalent \/ Deerfield Management"},{"orgOrder":0,"company":"Novavax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ J.P. Morgan"},{"orgOrder":0,"company":"Novavax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ J.P. Morgan"},{"orgOrder":0,"company":"Novavax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ J.P. Morgan"},{"orgOrder":0,"company":"Novavax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Sixth element capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Sixth element capital","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Sixth element capital"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nuvig Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuvig Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Nuvig Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Funding","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Invivyd","sponsor":"Population Health Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"NVD200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invivyd \/ Population Health Partners","highestDevelopmentStatusID":"5","companyTruncated":"Invivyd \/ Population Health Partners"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Neoletix","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Recombinant Human Coagulation Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript ProBio \/ Neoletix","highestDevelopmentStatusID":"4","companyTruncated":"GenScript ProBio \/ Neoletix"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"ENGOT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ ENGOT","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ ENGOT"},{"orgOrder":0,"company":"NYC Health + Hospitals\/Metropolitan","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"AT-H201","moa":"SARS-CoV-2 N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NYC Health + Hospitals\/Metropolitan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NYC Health + Hospitals\/Metropolitan \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"NYC Health + Hospitals\/Metropolitan \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Aptinyx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"NYX-783","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Aptinyx \/ National Institutes of Health"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"American Society of Ophthalmic Administrator","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ American Society of Ophthalmic Administrator","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ American Society of Ophthalmic Administrator"},{"orgOrder":0,"company":"Oakwood Laboratories","sponsor":"Flow Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"FlowVax COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oakwood Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oakwood Laboratories \/ Flow Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Oakwood Laboratories \/ Flow Pharma"},{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Acetylcysteine","moa":"||Glutathione synthase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Auditus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Auditus \/ Oblato","highestDevelopmentStatusID":"8","companyTruncated":"Auditus \/ Oblato"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Advanz Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Advanz Pharma"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Oculis","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Licaminlimab","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"AGC Biologics \/ Oculis","highestDevelopmentStatusID":"8","companyTruncated":"AGC Biologics \/ Oculis"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Ocugen","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BBV154","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ocugen \/ Washington University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Washington University School of Medicine"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Tesetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Paradigm BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor ant","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olema Oncology \/ Paradigm BioCapital","highestDevelopmentStatusID":"6","companyTruncated":"Olema Oncology \/ Paradigm BioCapital"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Olema Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Olema Oncology","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Olema Oncology"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Vivo Capital","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Vivo Capital"},{"orgOrder":0,"company":"Olimmune","sponsor":"Scopus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"OLIM-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Olimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olimmune \/ Scopus Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Olimmune \/ Scopus Biopharma"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Oligomerix","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"OLX-07010","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ National Institute on Aging"},{"orgOrder":0,"company":"Pharmaron","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"OLX703A","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pharmaron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmaron \/ OliX Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaron \/ OliX Pharmaceutical"},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"2-Fucosyllactose-Synthetic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp."},{"orgOrder":0,"company":"Agtc","sponsor":"Syncona","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Syncona","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Syncona"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Oberland Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Oberland Capital Management"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"The Menarini Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ The Menarini Group","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ The Menarini Group"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Chimerix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oncoceutics Inc \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Chimerix"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Onco360","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Onco360","highestDevelopmentStatusID":"15","companyTruncated":"Day One Biopharmaceuticals \/ Onco360"},{"orgOrder":0,"company":"Onco360","sponsor":"Geron","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Partnership","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Onco360 \/ Geron","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Geron"},{"orgOrder":0,"company":"Merck & Co","sponsor":"HM Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MK-7110","moa":"CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ HM Capital","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ HM Capital"},{"orgOrder":0,"company":"Pathogen and Microbiome Institute","sponsor":"Oncology Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Stenoparib","moa":"PARP1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pathogen and Microbiome Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathogen and Microbiome Institute \/ Oncology Venture","highestDevelopmentStatusID":"4","companyTruncated":"Pathogen and Microbiome Institute \/ Oncology Venture"},{"orgOrder":0,"company":"University of Florida","sponsor":"OncoMyx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"OM301","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florida \/ OncoMyx Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"University of Florida \/ OncoMyx Therapeutics"},{"orgOrder":0,"company":"Providence Cancer Institute","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Providence Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Cancer Institute \/ OncoSec Immunotherapies","highestDevelopmentStatusID":"6","companyTruncated":"Providence Cancer Institute \/ OncoSec Immunotherapies"},{"orgOrder":0,"company":"OncoSec Medical","sponsor":"The Australian Research and Development Tax Incentive","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Medical \/ The Australian Research and Development Tax Incentive","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Medical \/ The Australian Research and Development Tax Incentive"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Shanghai Haohai Biological Technology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"Botulinum Toxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Liniment","sponsorNew":"Eirion Therapeutics \/ Shanghai Haohai Biological Technology","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Shanghai Haohai Biological Technology"},{"orgOrder":0,"company":"Equillium","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"RBN-2397","moa":"PARP7","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Agreement","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Odyssey Health"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"AmerisourceBergen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ AmerisourceBergen","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ AmerisourceBergen"},{"orgOrder":0,"company":"Ophirex","sponsor":"AXA IM Prime Impact Master Fund","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Varespladib Methyl","moa":"Phospholipase A2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ophirex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ophirex \/ AXA IM Prime Impact Master Fund","highestDevelopmentStatusID":"8","companyTruncated":"Ophirex \/ AXA IM Prime Impact Master Fund"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Termination","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Vifor Pharma"},{"orgOrder":0,"company":"OPKO Health","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ HealthCare Royalty"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"OPL-002","moa":"S1P1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Ventyx Biosciences \/ Venbio Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Venbio Partners"},{"orgOrder":0,"company":"Indivior","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"10","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Piper Sandler"},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Piper Sandler"},{"orgOrder":0,"company":"Option Care Health","sponsor":"NS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Option Care Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Option Care Health \/ NS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Option Care Health \/ NS Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Opus Genetics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IVERIC bio \/ Opus Genetics","highestDevelopmentStatusID":"4","companyTruncated":"IVERIC bio \/ Opus Genetics"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"CMS","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ CMS","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ CMS"},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ National Research Council of Canada"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Fortovia Therapeutics","sponsor":"Galt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Miconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fortovia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fortovia Therapeutics \/ Galt Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Fortovia Therapeutics \/ Galt Pharmaceuticals"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Centessa Pharmaceuticals \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Regenerative Care Network","sponsor":"Organicell Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Partnership","leadProduct":"Zofin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Regenerative Care Network","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenerative Care Network \/ Organicell Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Regenerative Care Network \/ Organicell Regenerative Medicine"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Organon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Demerger","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Merck & Co \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Organon"},{"orgOrder":0,"company":"Organon","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Financing","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Organon \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Merck & Co"},{"orgOrder":0,"company":"Tamir Biotechnology","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"Ranpirnase","moa":"tRNA hydrolytic enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Tamir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tamir Biotechnology \/ Orgenesis","highestDevelopmentStatusID":"7","companyTruncated":"Tamir Biotechnology \/ Orgenesis"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Leidos","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Collaboration","leadProduct":"Ranpirnase","moa":"tRNA hydrolytic enzyme","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orgenesis \/ Leidos","highestDevelopmentStatusID":"4","companyTruncated":"Orgenesis \/ Leidos"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Elranatamab","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ORIC Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orionis Biosciences \/ Cormorant Asset Management","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Biosciences \/ Cormorant Asset Management"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CytRx Corporation \/ Orphazyme","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ Orphazyme"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Triheptanoin","moa":"Triglyceride","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orsini Specialty Pharmacy \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals"},{"orgOrder":0,"company":"Ostentus Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ostentus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ostentus Therapeutics \/ City of Hope","highestDevelopmentStatusID":"4","companyTruncated":"Ostentus Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Autotelic Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Autotelic Bio","highestDevelopmentStatusID":"4","companyTruncated":"Mateon Therapeutics \/ Autotelic Bio"},{"orgOrder":0,"company":"Otonomy","sponsor":"ALK","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Otonomy \/ ALK","highestDevelopmentStatusID":"15","companyTruncated":"Otonomy \/ ALK"},{"orgOrder":0,"company":"OtiTopic","sponsor":"Philip Morris International","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"OtiTopic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"OtiTopic \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"OtiTopic \/ Philip Morris International"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"BioLexis Pte. Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ BioLexis Pte. Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ BioLexis Pte. Ltd"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Syntone Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Syntone Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Syntone Ventures"},{"orgOrder":0,"company":"VelosBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Zilovertamab","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Matrix Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/ Matrix Capital Management"},{"orgOrder":0,"company":"Bioasis","sponsor":"Oxyrane","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bioasis \/ Oxyrane","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Oxyrane"},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Vida Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"CD8","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PACT Pharma \/ Vida Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharma \/ Vida Ventures"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Allergy Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Collaboration","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Allergy Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Allergy Partners"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Seneca Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Seneca Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Seneca Biopharma"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Sanwa Kagaku Kenkyusho","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Sanwa Kagaku Kenkyusho","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Sanwa Kagaku Kenkyusho"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Panbela Therapeutics \/ US WorldMeds"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"One-Two Therapeutics Assets Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ One-Two Therapeutics Assets Limited","highestDevelopmentStatusID":"15","companyTruncated":"Panbela Therapeutics \/ One-Two Therapeutics Assets Limited"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Takara Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Takara Bio","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Takara Bio"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"ITF Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PANTHERx Rare Pharmacy \/ ITF Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ ITF Therapeutics"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PANTHERx Rare Pharmacy \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Blueprint Medicines"},{"orgOrder":0,"company":"PAO Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"PAO Group \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group \/ Undisclosed"},{"orgOrder":0,"company":"ProCare Health","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ProCare Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"ProCare Health \/ Biovaxys","highestDevelopmentStatusID":"15","companyTruncated":"ProCare Health \/ Biovaxys"},{"orgOrder":0,"company":"PAQ Therapeutics","sponsor":"Sherpa Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Ubiquitin-proteosome pathway","graph1":"Genetic Disease","graph2":"Discovery","graph3":"PAQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAQ Therapeutics \/ Sherpa Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"PAQ Therapeutics \/ Sherpa Healthcare"},{"orgOrder":0,"company":"Parallel Bio","sponsor":"Refactor Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Parallel Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Parallel Bio \/ Refactor Capital","highestDevelopmentStatusID":"2","companyTruncated":"Parallel Bio \/ Refactor Capital"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"FS Development Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ FS Development Corp. II","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ FS Development Corp. II"},{"orgOrder":0,"company":"Park Therapeutics","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cebranopadol","moa":"NOP","graph1":"Neurology","graph2":"Phase II","graph3":"Park Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Park Therapeutics \/ Tris Pharma Inc","highestDevelopmentStatusID":"8","companyTruncated":"Park Therapeutics \/ Tris Pharma Inc"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Incendia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"PRTH-101","moa":"DDR1","graph1":"Oncology","graph2":"Preclinical","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Incendia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"ImaginAb \/ Incendia Therapeutics"},{"orgOrder":0,"company":"W. L. Gore & Associates","sponsor":"ViaCyte Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Encapsulated Pancreatic Islet Precursor Cell","moa":"Insulin secretion","graph1":"Endocrinology","graph2":"Preclinical","graph3":"W. L. Gore & Associates","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"W. L. Gore & Associates \/ ViaCyte Inc","highestDevelopmentStatusID":"4","companyTruncated":"W. L. Gore & Associates \/ ViaCyte Inc"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Athyrium Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Athyrium Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Athyrium Capital Management"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"EdiGene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Pharmaceuticals \/ EdiGene","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Pharmaceuticals \/ EdiGene"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"PhysIQ","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ PhysIQ","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ PhysIQ"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Foundation Medicine"},{"orgOrder":0,"company":"Immunogen","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"BioMed Valley Discoveries","sponsor":"Strata Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Ulixertinib","moa":"MAPK ERK1","graph1":"Oncology","graph2":"Phase II","graph3":"BioMed Valley Discoveries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMed Valley Discoveries \/ Strata Oncology","highestDevelopmentStatusID":"8","companyTruncated":"BioMed Valley Discoveries \/ Strata Oncology"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Octapharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Virally Inactivated Human AB Serum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akron Biotech \/ Octapharma","highestDevelopmentStatusID":"1","companyTruncated":"Akron Biotech \/ Octapharma"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ANA Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Abpro","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"ABP 102","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Celltrion","highestDevelopmentStatusID":"4","companyTruncated":"Abpro \/ Celltrion"},{"orgOrder":0,"company":"Pharmaceutics International","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Genistein","moa":"PTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharmaceutics International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmaceutics International \/ Humanetics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmaceutics International \/ Humanetics"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ IntelGenx"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Parexel Biotech \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Parexel Biotech \/ n-Lorem Foundation"},{"orgOrder":0,"company":"Codagenix","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Codagenix \/ Univercells","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Univercells"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"PAS-004","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ WuXi AppTec"},{"orgOrder":0,"company":"Pascal Biosciences","sponsor":"Sorse Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"PAS-393","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pascal Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pascal Biosciences \/ Sorse Technology","highestDevelopmentStatusID":"6","companyTruncated":"Pascal Biosciences \/ Sorse Technology"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Alpha-5 integrin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"PAT 103","moa":"Alpha V\/beta I integrin","graph1":"Neurology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Alpha-5 integrin","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea Therapeutics \/ Alpha-5 integrin"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Passage Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Pennsylvania \/ Passage Bio","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Passage Bio"},{"orgOrder":0,"company":"Passage Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ J.P. Morgan"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"DaVita Venture Group","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Upacicalcet Sodium","moa":"CaR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pathalys Pharma \/ DaVita Venture Group","highestDevelopmentStatusID":"15","companyTruncated":"Pathalys Pharma \/ DaVita Venture Group"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"NUV-422","moa":"CDK2\/4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nuvation Bio \/ Panacea Biotec Limited","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Panacea Biotec Limited"},{"orgOrder":0,"company":"Propeller Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Propeller Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Propeller Health \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Propeller Health \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ U.S. Government"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ U.S. Government"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Lind Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Lind Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Lind Global Partners"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Undisclosed","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpringWorks Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"1","companyTruncated":"SpringWorks Therapeutics \/ Precision BioSciences"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Elion Oncology","sponsor":"Processa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Elion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elion Oncology \/ Processa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Elion Oncology \/ Processa Pharmaceuticals"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"||Alpha radiation ionising","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Ionetix","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Ionetix"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Cantor Fitzgerald & Co"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"The Ministry of Science, Technology and Innovation of Brazil","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"PDS0203","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PDS Biotechnology \/ The Ministry of Science, Technology and Innovation of Brazil","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ The Ministry of Science, Technology and Innovation of Brazil"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"PDS0101","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ PDS Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ PDS Biotechnology"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare Capital Management"},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"PepGen \/ RA Capital Management"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"PIP-2","moa":"NOX2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Peroxitech Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peroxitech Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Peroxitech Therapeutics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Financing","leadProduct":"PIP-2","moa":"NOX2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Peroxitech Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peroxitech Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Peroxitech Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Neurotrope","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Neurotrope"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Quotient Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Pfenex","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CRM197","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfenex \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Pfenex \/ Serum Institute of India Private Limited"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Amlodipine","moa":"||L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Viatris"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Government of Isreal","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Government of Isreal","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Government of Isreal"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Royalty Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Arixa Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"ARX-1796","moa":"Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arixa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arixa Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Arixa Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Maplirpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pherin Pharmaceuticals \/ VistaGen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pharmaceuticals \/ VistaGen Therapeutics"},{"orgOrder":0,"company":"Pharma15","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pharma15","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharma15 \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"Pharma15 \/ Radiopharm Theranostics"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Athenex","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Abnova","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaJet \/ Abnova","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet \/ Abnova"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"GX-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"PharmaJet \/ Genexine"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Agreement","leadProduct":"212-Pb NG001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PharmaLogic \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"PharmaLogic \/ ARTBIO"},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Pharm-Olam \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam \/ U.S. Department of Defense"},{"orgOrder":0,"company":"PharmaJet","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaJet \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet \/ National Institutes of Health"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Seagen","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Cinrebafusp Alpha","moa":"||CD137","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagen \/ Pieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Pieris Pharmaceuticals"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Advanced Technology International","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Advanced Technology International","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Advanced Technology International"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"T3D-959","moa":"PPA receptor-delta\/gamma","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Flagship Pioneering \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Franklin Templeton","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"PIPE-505","moa":"Gamma secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Franklin Templeton","highestDevelopmentStatusID":"7","companyTruncated":"Contineum Therapeutics \/ Franklin Templeton"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Piramal Pharma Solutions \/ Theratechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Pharma Solutions \/ Theratechnologies"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Citi","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Citi","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Citi"},{"orgOrder":0,"company":"Pluristyx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"K-NK-ID101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Pluristyx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluristyx \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Pluristyx \/ Sanofi"},{"orgOrder":0,"company":"NanoTx Therapeutics","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Rhenium-186","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanoTx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoTx Therapeutics \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NanoTx Therapeutics \/ Plus Therapeutics"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holdings"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Dr. Daniel Carter","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"NSP-10 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Predictive Oncology \/ Dr. Daniel Carter","highestDevelopmentStatusID":"6","companyTruncated":"Predictive Oncology \/ Dr. Daniel Carter"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Public Offering","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Public Offering","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Piper Sandler"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Belgian Nuclear Research Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Licensing Agreement","leadProduct":"177-Lu","moa":"||Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Belgian Nuclear Research Center","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Belgian Nuclear Research Center"},{"orgOrder":0,"company":"Seagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Funding","leadProduct":"Polatuzumab Vedotin","moa":"CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagen \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Poseida Therapeutics, Inc \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Poseida Therapeutics, Inc \/ Xyphos Biosciences"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"scFv","graph1":"Oncology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc \/ Amgen Inc"},{"orgOrder":0,"company":"PostEra","sponsor":"Breyer Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PostEra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"PostEra \/ Breyer Capital","highestDevelopmentStatusID":"3","companyTruncated":"PostEra \/ Breyer Capital"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"PP-001","moa":"DHODH","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kiora Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Kiora Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"PPD","sponsor":"US Army","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPD \/ US Army","highestDevelopmentStatusID":"1","companyTruncated":"PPD \/ US Army"},{"orgOrder":0,"company":"Duchenne research","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"DMD gene","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Duchenne research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duchenne research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Duchenne research \/ Undisclosed"},{"orgOrder":0,"company":"Praetego","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"PTG-630","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Praetego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praetego \/ National Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"Praetego \/ National Eye Institute"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Praliciguat","moa":"sGC","graph1":"Nephrology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Microbion","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ US Navy"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"PRAX-114","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"PRAX-114","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ Eventide Asset Management","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ Eventide Asset Management"},{"orgOrder":0,"company":"Precigen","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Zopapogene Imadenovec","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Stifel","highestDevelopmentStatusID":"10","companyTruncated":"Precigen \/ Stifel"},{"orgOrder":0,"company":"Precigen","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Public Offering","leadProduct":"AG019","moa":"IL-10","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Precigen \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ JMP Securities"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Hana Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Hana Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Hana Pharm"},{"orgOrder":0,"company":"BlueWillow Biologics","sponsor":"Medigen Vaccine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"S-2P-NE-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BlueWillow Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueWillow Biologics \/ Medigen Vaccine Biologics","highestDevelopmentStatusID":"4","companyTruncated":"BlueWillow Biologics \/ Medigen Vaccine Biologics"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Denileukin Diftitox","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"University Medical Center Goettingen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ University Medical Center Goettingen","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ University Medical Center Goettingen"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IRISYS, LLC \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IRISYS, LLC \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amylyx Pharmaceuticals \/ Sunnybrook Research Institute"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Neuraly","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Neuraly","highestDevelopmentStatusID":"4","companyTruncated":"University of Pennsylvania \/ Neuraly"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Dostarlimab","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ GSK"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantCapital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"hAd5 S+N","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmunityBio \/ NantCapital","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ NantCapital"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"PRT2527","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Docetaxel","moa":"||SMARCA2","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Premier","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Partnership","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"IBUTILIDE FUMARATE","moa":"hREG","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Premier"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Population Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Population Health","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Population Health"},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"GTB-3550 TriKE","moa":"CD16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance Biologics \/ GT Biopharma"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Discovery","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"858 Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"858 Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"APOE4","graph1":"Oncology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lycia Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Morningside Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Morningside Venture","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Morningside Venture"},{"orgOrder":0,"company":"EQRx","sponsor":"CM Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ CM Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CM Life Sciences"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"affiliates of Magnetar Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Series D Financing","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ affiliates of Magnetar Capital","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ affiliates of Magnetar Capital"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Rotating Boulder Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Series D Financing","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Rotating Boulder Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Rotating Boulder Fund"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Structure Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Taniborbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VenatoRx Pharmaceuticals \/ AMR Action Fund","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ AMR Action Fund"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterome Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"5","companyTruncated":"Alterome Therapeutics \/ Goldman Sachs"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sana Biotechnology \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Sana Biotechnology \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Octantbio","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Octantbio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Octantbio \/ Catalio Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Octantbio \/ Catalio Capital Management"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"PhageBank","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Jmp Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Jmp Securities","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Jmp Securities"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"YA II PN","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ YA II PN","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ YA II PN"},{"orgOrder":0,"company":"Endpoint Health","sponsor":"Mayfield","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Endpoint Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endpoint Health \/ Mayfield","highestDevelopmentStatusID":"4","companyTruncated":"Endpoint Health \/ Mayfield"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"KeifeRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"KeifeRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KeifeRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KeifeRx \/ Undisclosed"},{"orgOrder":0,"company":"Normunity","sponsor":"Canaan Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Normunity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Normunity \/ Canaan Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Normunity \/ Canaan Ventures"},{"orgOrder":0,"company":"Delpor","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Tizanidine HCl","moa":"Adrenergic receptor-alpha 2","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Delpor \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Delpor \/ National Institutes of Health"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Deerfield Management"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Triwise Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"IO-108","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Triwise Capital","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Triwise Capital"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Boxcar PMJ","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"KRAS","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Boxcar PMJ","highestDevelopmentStatusID":"1","companyTruncated":"Immuneering Corporation \/ Boxcar PMJ"},{"orgOrder":0,"company":"Neuron23","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuron23 \/ Westlake Village BioPartners","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vanqua Bio \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"Vanqua Bio \/ Omega Funds"},{"orgOrder":0,"company":"BioTheryX","sponsor":"MSD Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioTheryX \/ MSD Partners","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ MSD Partners"},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Research Bridge Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asalyxa Bio \/ Research Bridge Partners","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bio \/ Research Bridge Partners"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Lake Bleu Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AffaMed Therapeutics \/ Lake Bleu Capital","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Lake Bleu Capital"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Janchor Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Janchor Partners","highestDevelopmentStatusID":"1","companyTruncated":"Everest Medicines \/ Janchor Partners"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DTx Pharma \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma \/ RA Capital Management"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Northpond Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Kyverna Therapeutics \/ Northpond Ventures"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Therapeutics \/ Vida Ventures"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LifeMine Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Avilar Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avilar Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Avilar Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Protego Biopharma","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Unfolded protein response","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Protego Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protego Biopharma \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Protego Biopharma \/ Lightspeed Venture Partners"},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ RA Capital Management"},{"orgOrder":0,"company":"Rallybio","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"RLYB-211","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rallybio \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Omega Funds"},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Terremoto Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terremoto Biosciences \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"Terremoto Biosciences \/ OrbiMed"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hummingbird Bioscience \/ Organovo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Organovo Holdings"},{"orgOrder":0,"company":"PIC Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"eIF4F-CAP complex","graph1":"Oncology","graph2":"Discovery","graph3":"PIC Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PIC Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"2","companyTruncated":"PIC Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"5","companyTruncated":"Verve Therapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Fexuprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neurogastrx \/ Vivo Capital"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"NEA","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"EP547","moa":"MRGPRX4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ NEA","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ NEA"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"UCB Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Neurona Therapeutics \/ UCB Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Neurona Therapeutics \/ UCB Ventures"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"A197","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aramis Biosciences \/ Safar Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Safar Partners"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"The Column Group and Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Cyclin A","graph1":"Oncology","graph2":"Discovery","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Circle Pharma \/ The Column Group and Nextech","highestDevelopmentStatusID":"2","companyTruncated":"Circle Pharma \/ The Column Group and Nextech"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Series B Financing","leadProduct":"METTL3","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accent Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"1","companyTruncated":"Accent Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Aer Therapeutics","sponsor":"Canaan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Fexlamose","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Aer Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Aer Therapeutics \/ Canaan","highestDevelopmentStatusID":"4","companyTruncated":"Aer Therapeutics \/ Canaan"},{"orgOrder":0,"company":"Glycomine","sponsor":"ImmuneID","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycomine \/ ImmuneID","highestDevelopmentStatusID":"4","companyTruncated":"Glycomine \/ ImmuneID"},{"orgOrder":0,"company":"ImmuneID","sponsor":"Alta Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"ImmuneID","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmuneID \/ Alta Partners","highestDevelopmentStatusID":"3","companyTruncated":"ImmuneID \/ Alta Partners"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series D Financing","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Petrichor Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Exosite binding agent","graph1":"Oncology","graph2":"Discovery","graph3":"Exo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exo Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"2","companyTruncated":"Exo Therapeutics \/ Newpath Partners"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Rock Springs Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series C Financing","leadProduct":"XTX202","moa":"Tumor selective IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Rock Springs Capital","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Rock Springs Capital"},{"orgOrder":0,"company":"Electra Therapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"ELA026","moa":"SIRP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Electra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Electra Therapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"Electra Therapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Alumis","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ AyurMaya","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ AyurMaya"},{"orgOrder":0,"company":"TRexBio","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Series A Financing","leadProduct":"TRB-051","moa":"Treg","graph1":"Immunology","graph2":"Discovery Platform","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"TRexBio \/ Polaris Partners"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"ReCode Therapeutics \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Leaps by Bayer"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Borealis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Borealis Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Borealis Ventures"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Takeda Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"XTX201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Takeda Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Xilio Therapeutics \/ Takeda Ventures"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Columbus VenturePartners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Columbus VenturePartners","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Columbus VenturePartners"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Matrix Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Matrix Capital Management"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"MTS Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Private Placement","leadProduct":"BPX-601","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ MTS Securities","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ MTS Securities"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Foundation Fighting Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Foundation Fighting Blindness","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Foundation Fighting Blindness"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyclix Bio \/ Boxer Capital","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Boxer Capital"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Arena Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Cybrexa Therapeutics \/ HighCape Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ HighCape Capital"},{"orgOrder":0,"company":"Intrance Medical System","sponsor":"Erik Selin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Intrance Medical System","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Intrance Medical System \/ Erik Selin","highestDevelopmentStatusID":"5","companyTruncated":"Intrance Medical System \/ Erik Selin"},{"orgOrder":0,"company":"Hexagon Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hexagon Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hexagon Bio \/ Nextech Invest","highestDevelopmentStatusID":"3","companyTruncated":"Hexagon Bio \/ Nextech Invest"},{"orgOrder":0,"company":"Seraxis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"SR-01","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Seraxis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seraxis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Seraxis \/ Eli Lilly"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ JSR Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ JSR Life Sciences"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Cormorant Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Biomea Fusion \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"TEAD","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedilla Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"KT-413","moa":"IRAKIMiD","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Biotechnology Value Fund","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Biotechnology Value Fund"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Cytokine signaling pathway","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajax Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"3","companyTruncated":"Ajax Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Appia Bio","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"CAR-iNKT","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Appia Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appia Bio \/ 8VC","highestDevelopmentStatusID":"2","companyTruncated":"Appia Bio \/ 8VC"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Abingworth LLP","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series C Financing","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Abingworth LLP","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Abingworth LLP"},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series B Financing","leadProduct":"RSV Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Serum Institute of India"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"REC-994","moa":"Superoxide Radical","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Viva BioInnovator"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Viva BioInnovator"},{"orgOrder":0,"company":"Antiva Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series D Financing","leadProduct":"ABI-2280","moa":"HPV replication","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Antiva Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antiva Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"5","companyTruncated":"Antiva Biosciences \/ Adjuvant Capital"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Private Placement","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Frazier Life Sciences Public Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Private Placement","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gritstone bio \/ Frazier Life Sciences Public Fund","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone bio \/ Frazier Life Sciences Public Fund"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Marathon Asset Management"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ BofA Securities"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"TEAD","graph1":"Oncology","graph2":"Preclinical","graph3":"BridGene Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridGene Biosciences \/ Lapam Capital","highestDevelopmentStatusID":"4","companyTruncated":"BridGene Biosciences \/ Lapam Capital"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"CpG 1018","moa":"||TLR9","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Cowen","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Cowen"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Acuta Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Dynamics Special Purpose Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Dynamics Special Purpose Corp","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Dynamics Special Purpose Corp"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"J. Wood Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ J. Wood Capital Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ J. Wood Capital Advisors"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Adjuvant Capital"},{"orgOrder":0,"company":"Inceptor Bio","sponsor":"Kineticos Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Inceptor Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inceptor Bio \/ Kineticos Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Inceptor Bio \/ Kineticos Ventures"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visus Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Pirfenidone","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avalyn Pharma \/ Norwest Venture Partners","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pharma \/ Norwest Venture Partners"},{"orgOrder":0,"company":"Affinivax","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"MAPS Pneumococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affinivax \/ Viking Global Investors","highestDevelopmentStatusID":"8","companyTruncated":"Affinivax \/ Viking Global Investors"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Eventide Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Eventide Asset Management"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B financing","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventus Therapeutics \/ BVF Partners L.P","highestDevelopmentStatusID":"2","companyTruncated":"Ventus Therapeutics \/ BVF Partners L.P"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Ping An Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Ping An Capital","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics Inc \/ Ping An Capital"},{"orgOrder":0,"company":"FogPharma","sponsor":"ARCH Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"FOG-001","moa":"Beta catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FogPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FogPharma \/ ARCH Venture","highestDevelopmentStatusID":"7","companyTruncated":"FogPharma \/ ARCH Venture"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"FS Development Corp","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ FS Development Corp","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ FS Development Corp"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"FoxWayne Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ FoxWayne Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ FoxWayne Enterprises"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kezar Life Sciences \/ Oxford Finance LLC","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Oxford Finance LLC"},{"orgOrder":0,"company":"Kineta","sponsor":"Cheongbo Industrial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Cheongbo Industrial","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Cheongbo Industrial"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Mass General Brigham Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Mass General Brigham Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Mass General Brigham Ventures"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"TSC-100","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ BlackRock"},{"orgOrder":0,"company":"Cellenkos","sponsor":"BVCF Management Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"CK0802","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ BVCF Management Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ BVCF Management Ltd"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jnana Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Jnana Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cedilla Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Therapeutics \/ Casdin Capital"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Kriya Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Kriya Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Artis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Series B Financing","leadProduct":"LBP-EC01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intraurethral Infusion","sponsorNew":"Locus Biosciences \/ Artis Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Locus Biosciences \/ Artis Ventures"},{"orgOrder":0,"company":"Clade Therapeutics","sponsor":"Syncona Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Clade Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clade Therapeutics \/ Syncona Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"Clade Therapeutics \/ Syncona Ltd."},{"orgOrder":0,"company":"Rezolute","sponsor":"Cam Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Cam Capital","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Cam Capital"},{"orgOrder":0,"company":"Synthekine","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series A Financing","leadProduct":"STK-012","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Canaan Partners","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Canaan Partners"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Pavilion Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series B Financing","leadProduct":"mRNA COVID Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RVAC Medicines \/ Pavilion Capital","highestDevelopmentStatusID":"4","companyTruncated":"RVAC Medicines \/ Pavilion Capital"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Adaptive Phage Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Deerfield Management"},{"orgOrder":0,"company":"GX Acquisition","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"CYNK-101","moa":"||CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"GX Acquisition","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GX Acquisition \/ Celularity","highestDevelopmentStatusID":"5","companyTruncated":"GX Acquisition \/ Celularity"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"S011806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase I","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"DICE Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Synthekine","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ The Column Group"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Wellington Management","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Wellington Management"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosciences \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Lumira Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"OM1","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoMyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"OncoMyx Therapeutics \/ Lumira Ventures","highestDevelopmentStatusID":"4","companyTruncated":"OncoMyx Therapeutics \/ Lumira Ventures"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"EP547","moa":"MRGPRX4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"StrideBio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"STRX-310","moa":"AChE","graph1":"Neurology","graph2":"Discovery","graph3":"StrideBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StrideBio \/ Northpond Ventures","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio \/ Northpond Ventures"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Marathon Asset Management"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"FBX-101","moa":"GALC gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ 5AM Ventures","highestDevelopmentStatusID":"5","companyTruncated":"CAMP4 Therapeutics \/ 5AM Ventures"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Hlb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"ITI-1000","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunomic Therapeutics \/ Hlb","highestDevelopmentStatusID":"8","companyTruncated":"Immunomic Therapeutics \/ Hlb"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series C Financing","leadProduct":"ADP101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Gurnet Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"AO-176","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Arch Oncology \/ Eventide Asset Management","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Eventide Asset Management"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Affinia Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Affinia Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2021","type":"Financing","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Matrix Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Matrix Capital Management"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series D Financing","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Baupost Group","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Baupost Group"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Neurogene","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"CLN5","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ EcoR1 Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene \/ EcoR1 Capital"},{"orgOrder":0,"company":"Mirador Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mirador Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirador Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Mirador Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"SoftBank Vision Fund 2","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ SoftBank Vision Fund 2","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ SoftBank Vision Fund 2"},{"orgOrder":0,"company":"Ten63 Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"c-Myc","graph1":"Oncology","graph2":"Discovery","graph3":"Ten63 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ten63 Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ten63 Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Be Biopharma \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Be Biopharma \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ United States Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Plus Therapeutics \/ United States Department of Defense"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"CPTX2309","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capstan Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"AMP CpG","moa":"||KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Umira Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"CNP-106","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Umira Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Umira Ventures"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Financing","leadProduct":"Ferrous Gluconate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ XOMA","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ XOMA"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ OrbiMed"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"AIGH Capital Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Financing","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ AIGH Capital Management LLC","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ AIGH Capital Management LLC"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Oberland Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Oberland Capital","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Oberland Capital"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Undisclosed"},{"orgOrder":0,"company":"NextRNA","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Non-coding RNA","graph1":"Oncology","graph2":"Discovery Platform","graph3":"NextRNA","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NextRNA \/ Cobro Ventures","highestDevelopmentStatusID":"3","companyTruncated":"NextRNA \/ Cobro Ventures"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"OCE-205","moa":"V1R","graph1":"Nephrology","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ocelot Bio \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio \/ RA Capital Management"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Genelux","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Guggenheim Securities"},{"orgOrder":0,"company":"Genelux","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Guggenheim Securities"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Zoic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Zoic Capital","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Zoic Capital"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Akouos","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akouos \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"SAR439483","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Methyl Amide Prodrug","moa":"THR-beta","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Autobahn Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Exo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exo Therapeutics \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Exo Therapeutics \/ Nextech Invest"},{"orgOrder":0,"company":"Casma Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"TRPML1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Casma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Casma Therapeutics \/ The Column Group","highestDevelopmentStatusID":"4","companyTruncated":"Casma Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ BVF Partners L.P","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ BVF Partners L.P"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"4","companyTruncated":"NiKang Therapeutics \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catamaran Bio \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Sofinnova Partners"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IL-1B","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventus Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Ventus Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Vita Therapeutics","sponsor":"Cambrian BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"VTA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vita Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vita Therapeutics \/ Cambrian BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"Vita Therapeutics \/ Cambrian BioPharma"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Bortezomib","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Morgan Stanley"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Gersizangitide","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Lygenesis","sponsor":"Juvenescence","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"LYG-LIV0001","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lygenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lygenesis \/ Juvenescence","highestDevelopmentStatusID":"8","companyTruncated":"Lygenesis \/ Juvenescence"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"GGV Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensem Therapeutics \/ GGV Capital","highestDevelopmentStatusID":"2","companyTruncated":"Ensem Therapeutics \/ GGV Capital"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Horizon Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Horizon Technology","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Horizon Technology"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Rick Klausner","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LifeMine Therapeutics \/ Rick Klausner","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ Rick Klausner"},{"orgOrder":0,"company":"Synnovation Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"SNV1521","moa":"PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"Synnovation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Synnovation Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Synnovation Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Children\u2019S Research Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Children\u2019S Research Holdings","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Children\u2019S Research Holdings"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"BBI-355","moa":"CHK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Alliance Global Partners"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Alliance Global Partners"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Alliance Global Partners"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Cantor Fitzgerald & Co"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Tumor cell killer","graph1":"Oncology","graph2":"Preclinical","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"A2 Biotherapeutics \/ The Column Group","highestDevelopmentStatusID":"4","companyTruncated":"A2 Biotherapeutics \/ The Column Group"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Undisclosed"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Jeffrey C. Thacker","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Jeffrey C. Thacker","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Jeffrey C. Thacker"},{"orgOrder":0,"company":"Novellus","sponsor":"Pontifax Medison Debt Financing","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Plixorafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novellus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novellus \/ Pontifax Medison Debt Financing","highestDevelopmentStatusID":"7","companyTruncated":"Novellus \/ Pontifax Medison Debt Financing"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"CFI-400945","moa":"||PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Treadwell Therapeutics \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Alliance Global Partners"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Surveyor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Surveyor Capital"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Delphia Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Delphia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delphia Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Delphia Therapeutics \/ Google Ventures"},{"orgOrder":0,"company":"Aegis Life","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aegis Life","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aegis Life \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aegis Life \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Huadong Medicine Investment Holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"OP-101","moa":"Glutathione synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Huadong Medicine Investment Holding","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Huadong Medicine Investment Holding"},{"orgOrder":0,"company":"Aeovian Pharmaceuticals","sponsor":"Hevolution","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"AV078","moa":"mTORC1","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Aeovian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeovian Pharmaceuticals \/ Hevolution","highestDevelopmentStatusID":"6","companyTruncated":"Aeovian Pharmaceuticals \/ Hevolution"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"LSP","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visus Therapeutics \/ LSP","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ LSP"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"AV-GBM-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"SION-638","moa":"NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Enavate Sciences"},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Prokarium \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Advanced Medicine Partners","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Advanced Medicine Partners","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Medicine Partners \/ Deerfield Management","highestDevelopmentStatusID":"4","companyTruncated":"Advanced Medicine Partners \/ Deerfield Management"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Oceanpine Capital"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Rad51-IN-2","moa":"Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyteir Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"D1 Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ D1 Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ D1 Capital Partners"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Acrivon Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Series B Financing","leadProduct":"Prexasertib","moa":"||CHK1","graph1":"Oncology","graph2":"Phase II","graph3":"Acrivon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acrivon Therapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"8","companyTruncated":"Acrivon Therapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcell Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xcell Biosciences \/ Casdin Capital","highestDevelopmentStatusID":"3","companyTruncated":"Xcell Biosciences \/ Casdin Capital"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Inspirna","sponsor":"Sands Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Sands Capital","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Sands Capital"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Nesvategrast","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ Ally Bridge Group","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Ally Bridge Group"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Financing","leadProduct":"ADP101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Enavate Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Enavate Sciences"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"BVF Partners L.P.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ BVF Partners L.P.","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ BVF Partners L.P."},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"RSBT-001","moa":"Cannabinoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Recipharm AB","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Recipharm AB"},{"orgOrder":0,"company":"ProFound Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"ProFound Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProFound Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"ProFound Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"University of California, Irvine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Neural Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ University of California, Irvine","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Therapeutics \/ University of California, Irvine"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"ProKidney","sponsor":"Social Capital Suvretta Holdings Corp. III","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Social Capital Suvretta Holdings Corp. III","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Social Capital Suvretta Holdings Corp. III"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"PR600","moa":"TNF","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma Gmbh","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma Gmbh"},{"orgOrder":0,"company":"Huntington Study Group","sponsor":"Prilenia therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Huntington Study Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Huntington Study Group \/ Prilenia therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Huntington Study Group \/ Prilenia therapeutics"},{"orgOrder":0,"company":"ReViral","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Sisunatovir","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ReViral \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Maplirpacept","moa":"SIRP alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Eli Lilly"},{"orgOrder":0,"company":"Histogen","sponsor":"Conatus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Conatus Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Conatus Pharmaceuticals"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"NTN Buzztime","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Cyclophosphamide","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ NTN Buzztime","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn ImmunoTherapeutics \/ NTN Buzztime"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracystic Injection","sponsorNew":"Protara Therapeutics \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Protomer Technologies","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Glucose Responsive Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Protomer Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protomer Technologies \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Protomer Technologies \/ Eli Lilly"},{"orgOrder":0,"company":"University of Miami","sponsor":"Provectus Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Rose Bengal Sodium","moa":"||IL-17","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"University of Miami \/ Provectus Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Provectus Biopharmaceuticals"},{"orgOrder":0,"company":"Dendreon Pharmaceuticals, Inc","sponsor":"Grant Hill","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Sipuleucel-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dendreon Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dendreon Pharmaceuticals, Inc \/ Grant Hill","highestDevelopmentStatusID":"15","companyTruncated":"Dendreon Pharmaceuticals, Inc \/ Grant Hill"},{"orgOrder":0,"company":"Sanofi","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ SVB Leerink"},{"orgOrder":0,"company":"Sanofi","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ SVB Leerink"},{"orgOrder":0,"company":"Sanofi","sponsor":"Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"PRV-3279","moa":"CD32B","graph1":"Immunology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Huadong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Huadong Pharmaceutical"},{"orgOrder":0,"company":"Celiac Disease Foundation","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celiac Disease Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celiac Disease Foundation \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Celiac Disease Foundation \/ Provention Bio"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Cetrorelix Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Calyptus Pharmaceuticals \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Providence Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Next Generation Manufacturing Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Providence Therapeutics \/ Next Generation Manufacturing Canada","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Next Generation Manufacturing Canada"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Bioresearch \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Bioresearch \/ National Institutes of Health"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"iNGEN\u016b","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Psycheceutical \/ iNGEN\u016b","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ iNGEN\u016b"},{"orgOrder":0,"company":"PsyLabs","sponsor":"Psyence Biomed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PsyLabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PsyLabs \/ Psyence Biomed","highestDevelopmentStatusID":"6","companyTruncated":"PsyLabs \/ Psyence Biomed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"PT199","moa":"||CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Catalyst Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Catalyst Health Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Catalyst Health Ventures"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Meridian Medical Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Public Health Vaccines","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"rVSV\u2206G-MARV (Angola) GP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Public Health Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Public Health Vaccines \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Public Health Vaccines \/ BARDA"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Itraconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"PRC Clinical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ PRC Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ PRC Clinical"},{"orgOrder":0,"company":"BioArdis","sponsor":"Shenogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"BIO-1262","moa":"FGFR4","graph1":"Oncology","graph2":"Phase III","graph3":"BioArdis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioArdis \/ Shenogen","highestDevelopmentStatusID":"10","companyTruncated":"BioArdis \/ Shenogen"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Cytokinetics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Cytokinetics","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Cytokinetics"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celgene Corporation \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Celgene Corporation \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allergan Aesthetics \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Heat Biologics"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"The University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Public Offering","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ The University of Chicago","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ The University of Chicago"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Arix Bioscience Plc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Series B Financing","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Arix Bioscience Plc","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Arix Bioscience Plc"},{"orgOrder":0,"company":"Igl Pharma","sponsor":"Q2Earth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Samarium Sm-153","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Igl Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Igl Pharma \/ Q2Earth","highestDevelopmentStatusID":"1","companyTruncated":"Igl Pharma \/ Q2Earth"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Journey Medical Corporation \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Maruho"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Wipes","sponsorNew":"Eli Lilly \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Hande Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Hande Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Hande Sciences"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Xeruborbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ BARDA"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Merger","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Oncology","graph2":"Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ritter Pharmaceuticals \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"University of Louisville","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Louisville \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Louisville \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"Quest Products","sponsor":"Quest Products, Llc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Docusate Potassium","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Quest Products","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quest Products \/ Quest Products, Llc","highestDevelopmentStatusID":"15","companyTruncated":"Quest Products \/ Quest Products, Llc"},{"orgOrder":0,"company":"QurAlis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"QRL-204","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Eli Lilly"},{"orgOrder":0,"company":"QurAlis","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QurAlis \/ Polaris Partners","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Polaris Partners"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Radionetics Oncology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radionetics Oncology \/ Frazier Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Radionetics Oncology \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Benuvia Therapeutics \/ Radius Health","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Therapeutics \/ Radius Health"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Sara\u2019s Cure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Guggenheim Securities"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Boxer Capital","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Boxer Capital"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Momentum Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Series D Financing","leadProduct":"Cetuximab Sarotalocan Sodium","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rakuten Medical \/ Momentum Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Rakuten Medical \/ Momentum Capital Markets"},{"orgOrder":0,"company":"Biolink LifeSciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Ramatroban","moa":"Thromboxane A2\/TP receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biolink LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolink LifeSciences \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"Biolink LifeSciences \/ BARDA"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Celltrion"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2020","type":"Series E Financing","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Oncology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Bentley University","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bentley University","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bentley University \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Bentley University \/ National Institutes of Health"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ U.S. Department Of Health And Human Services"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ U.S. Department Of Health And Human Services"},{"orgOrder":0,"company":"RApport","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"RApport","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RApport \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"RApport \/ Third Rock Ventures"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Ray-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therapeutics \/ Forge Biologics"},{"orgOrder":0,"company":"RayzeBio","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Series A Financing","leadProduct":"225-Ac Dotatate","moa":"||Alpha radiation ionising","graph1":"Oncology","graph2":"Undisclosed","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ venBio Partners","highestDevelopmentStatusID":"1","companyTruncated":"RayzeBio \/ venBio Partners"},{"orgOrder":0,"company":"Frontier Scientific","sponsor":"Renibus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Stannus Protoporphyrin","moa":"Nrf2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Frontier Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Frontier Scientific \/ Renibus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Frontier Scientific \/ Renibus Therapeutics"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"The Virginia Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ The Virginia Catalyst","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ The Virginia Catalyst"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bold Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Transpire Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"TRB-1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Transpire Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Transpire Bio \/ Recipharm AB","highestDevelopmentStatusID":"4","companyTruncated":"Transpire Bio \/ Recipharm AB"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"The Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol (PMDI)","sponsorNew":"ReCode Therapeutics \/ The Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ The Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"MPM Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReCode Therapeutics \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ MPM Capital"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Kinnevik AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Kinnevik AB","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Kinnevik AB"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Recursion Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Recurv Pharma","sponsor":"TVM Capital Life Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"RP-001","moa":"Microtubule","graph1":"Oncology","graph2":"Preclinical","graph3":"Recurv Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Recurv Pharma \/ TVM Capital Life Science","highestDevelopmentStatusID":"4","companyTruncated":"Recurv Pharma \/ TVM Capital Life Science"},{"orgOrder":0,"company":"Regenacy Pharmaceuticals","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Ricolinostat","moa":"HDAC6","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Regenacy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenacy Pharmaceuticals \/ Cobro Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Regenacy Pharmaceuticals \/ Cobro Ventures"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"2Seventy Bio \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Acquisition","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Private Placement","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Roth Capital Partners"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Healthcare Royalty Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Healthcare Royalty Management","highestDevelopmentStatusID":"15","companyTruncated":"Regenxbio \/ Healthcare Royalty Management"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Onasemnogene Abeparvovec","moa":"||SMN1 gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Regenxbio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Regenxbio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Lademirsen","moa":"miR-21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"RLY-1971","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Nextech"},{"orgOrder":0,"company":"University of California","sponsor":"Releviate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"RLVT-9-01","moa":"MMP-9","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Releviate Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Releviate Therapeutics"},{"orgOrder":0,"company":"Advita","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Advita","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Advita \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Advita \/ Relief Therapeutics"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Arbormentis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Arbormentis","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Arbormentis"},{"orgOrder":0,"company":"RenBio","sponsor":"Ruentex Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"RB-100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RenBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RenBio \/ Ruentex Group","highestDevelopmentStatusID":"4","companyTruncated":"RenBio \/ Ruentex Group"},{"orgOrder":0,"company":"Replay Bio","sponsor":"KKR","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ KKR","highestDevelopmentStatusID":"1","companyTruncated":"Replay Bio \/ KKR"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Replay Bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Replay Bio \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Reprocell","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"HT-003","moa":"TLR2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Reprocell","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Reprocell"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Res Nova Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Demerger","leadProduct":"ValloVax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Res Nova Bio","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Res Nova Bio"},{"orgOrder":0,"company":"Resbiotic","sponsor":"Timberline Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Resbiotic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Resbiotic \/ Timberline Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Resbiotic \/ Timberline Holdings"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WP1244","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNS Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"Manhattan BioSolutions","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manhattan BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manhattan BioSolutions \/ Nascent Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Manhattan BioSolutions \/ Nascent Biotech"},{"orgOrder":0,"company":"Flightpath Biosciences","sponsor":"Northeastern University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"FP-100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Flightpath Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flightpath Biosciences \/ Northeastern University","highestDevelopmentStatusID":"5","companyTruncated":"Flightpath Biosciences \/ Northeastern University"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"TCR-V beta","graph1":"Oncology","graph2":"Discovery","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Marengo Therapeutics \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Marengo Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Artizan Biosciences","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Intestinal microbial","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artizan Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artizan Biosciences \/ University Medical Center Utrecht","highestDevelopmentStatusID":"3","companyTruncated":"Artizan Biosciences \/ University Medical Center Utrecht"},{"orgOrder":0,"company":"Path BioAnalytics","sponsor":"Recce Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"R327","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Path BioAnalytics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Path BioAnalytics \/ Recce Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Path BioAnalytics \/ Recce Pharmaceuticals"},{"orgOrder":0,"company":"Phase Genomics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Phase Genomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phase Genomics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Phase Genomics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Reset Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Reset Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Reset Pharmaceuticals"},{"orgOrder":0,"company":"Resilia Pharmaceuticals","sponsor":"Pelle Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Resilia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Resilia Pharmaceuticals \/ Pelle Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Resilia Pharmaceuticals \/ Pelle Ventures"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"National Resilience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"OPGx-001","moa":"LCA5 gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Opus Genetics \/ National Resilience","highestDevelopmentStatusID":"5","companyTruncated":"Opus Genetics \/ National Resilience"},{"orgOrder":0,"company":"Resilience","sponsor":"AavantiBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Resilience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resilience \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Resilience \/ AavantiBio"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Ampakine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Department of Defense"},{"orgOrder":0,"company":"UWM Research Foundation","sponsor":"RespireRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"KRM-II-81","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"UWM Research Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UWM Research Foundation \/ RespireRx Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"UWM Research Foundation \/ RespireRx Pharmaceuticals"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Enzyvant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"Allogeneic Processed Thymus Tissue","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altavant Sciences \/ Enzyvant Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Altavant Sciences \/ Enzyvant Therapeutics"},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"QVC Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Vitamin A","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Pressure BioSciences \/ QVC Skincare","highestDevelopmentStatusID":"1","companyTruncated":"Pressure BioSciences \/ QVC Skincare"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"HemoShear Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"HemoShear Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"HemoShear Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"DSG","sponsor":"Reven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DSG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DSG \/ Reven Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DSG \/ Reven Pharmaceuticals"},{"orgOrder":0,"company":"Baymedica","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabichromene","moa":"TRPA1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baymedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baymedica \/ InMed Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Baymedica \/ InMed Pharmaceuticals"},{"orgOrder":0,"company":"ReViral","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Sisunatovir","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ReViral \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Pfizer Inc"},{"orgOrder":0,"company":"Revitalist Lifestyle and Wellness","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revitalist Lifestyle and Wellness","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"Revitalist Lifestyle and Wellness \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revitalist Lifestyle and Wellness \/ PharmaTher"},{"orgOrder":0,"company":"Revitope","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Revitope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revitope \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Revitope \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Titan Partners Group"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Vociprotafib","moa":"SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Asimov","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Asimov","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asimov \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Asimov \/ RevOpsis Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Optime Care","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Optime Care","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Optime Care"},{"orgOrder":0,"company":"Rezo Therapeutics","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Rezo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rezo Therapeutics \/ SR One","highestDevelopmentStatusID":"2","companyTruncated":"Rezo Therapeutics \/ SR One"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ SLR Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ SLR Capital Partners"},{"orgOrder":0,"company":"XOMA","sponsor":"Rezolute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Rezolute","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Rezolute"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenta Therapeutics \/ H. Lundbeck AS","highestDevelopmentStatusID":"3","companyTruncated":"Rgenta Therapeutics \/ H. Lundbeck AS"},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Ribometrix","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Ribometrix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribometrix \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Ribometrix \/ Genentech"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"RBN-2397","moa":"||PARP7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Ridgeback","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Innovation Ventures at Emory \/ Ridgeback","highestDevelopmentStatusID":"4","companyTruncated":"Drug Innovation Ventures at Emory \/ Ridgeback"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Rising Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Minnesota \/ Rising Pharmaceuticals Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Minnesota \/ Rising Pharmaceuticals Inc"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Arena Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"RIST4721","moa":"CXCR2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Societal CDMO \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"Societal CDMO \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"PFM Health Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series D Financing","leadProduct":"RIVAL-01","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Turnstone Biologics \/ PFM Health Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Turnstone Biologics \/ PFM Health Sciences"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Endocrinology","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rivus Pharmaceuticals \/ Longitude Capital","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Longitude Capital"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Granite Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Granite Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ Granite Point Capital"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"MOMA Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MOMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MOMA Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"MOMA Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Tominersen","moa":"Huntingtin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"CT-388","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||LILRB2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Remix Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Rodeo Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"15-PGDH","graph1":"Immunology","graph2":"Preclinical","graph3":"Rodeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rodeo Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Rodeo Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Montes Archimedes Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Roivant Sciences \/ Montes Archimedes Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Roivant Sciences \/ Montes Archimedes Acquisition Corporation"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Roivant Sciences \/ SK Holdings","highestDevelopmentStatusID":"3","companyTruncated":"Roivant Sciences \/ SK Holdings"},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"RPT-2950","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rome Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Rome Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Rome Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rome Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Rome Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"TCG GreenChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ TCG GreenChem","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ TCG GreenChem"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"RSVI-301","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RosVivo Therapeutics \/ Nexturn Bio","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Nexturn Bio"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"RSVI-301","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RosVivo Therapeutics \/ Nexturn Bio","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Nexturn Bio"},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"RSVI-301","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RosVivo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Government of Switzerland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Government of Switzerland","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Government of Switzerland"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agios Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Seltorexant","moa":"OX2R","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Royalty Pharma"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Royalty Pharma"},{"orgOrder":0,"company":"Replimune","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Replimune","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ J.P. Morgan"},{"orgOrder":0,"company":"Replimune","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Replimune \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"EpicentRx","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"RRx-001","moa":"CD47","graph1":"Neurology","graph2":"Preclinical","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EpicentRx \/ The Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"EpicentRx \/ The Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"RSBT-001","moa":"Cannabinoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ RTW Investments"},{"orgOrder":0,"company":"RubrYc Therapeutics","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"RTX-003","moa":"CD25","graph1":"Oncology","graph2":"Preclinical","graph3":"RubrYc Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RubrYc Therapeutics \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"RubrYc Therapeutics \/ iBio"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Rumpus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC-beta","graph1":"Oncology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denovo Biopharma \/ Rumpus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Rumpus Therapeutics"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Partnership","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)","moa":"Asparagine synthetase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Series D Financing","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ Viking Global Investors","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Viking Global Investors"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"SAB-195","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SAB Biotherapeutics \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biotherapeutics \/ Department of Defense"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ BARDA"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Big Cypress Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Merger","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Big Cypress Acquisition Corp","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Big Cypress Acquisition Corp"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Private Placement","leadProduct":"SAB-195","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SAB Biotherapeutics \/ Brookline Capital Markets","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biotherapeutics \/ Brookline Capital Markets"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"JanOne","sponsor":"SPYR Technologies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ SPYR Technologies","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ SPYR Technologies"},{"orgOrder":0,"company":"Salzman Group","sponsor":"Kalytera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Salzman Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salzman Group \/ Kalytera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Salzman Group \/ Kalytera Therapeutics"},{"orgOrder":0,"company":"Sanaria","sponsor":"EU Malaria Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"PfSPZ Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanaria \/ EU Malaria Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ EU Malaria Fund"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Slayback Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sangamo Therapeutics \/ Barclays","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Barclays"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sangamo Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Sanofi"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"212-Pb Dotamtate","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oranomed \/ Sanofi"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"AAV-AQP1","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/ Sanofi"},{"orgOrder":0,"company":"CannaGlobal Wellness","sponsor":"Sansero Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CannaGlobal Wellness","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"CannaGlobal Wellness \/ Sansero Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"CannaGlobal Wellness \/ Sansero Life Sciences"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Netarsudil","moa":"ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Netarsudil","moa":"ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"SaponiQx","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SaponiQx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SaponiQx \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"SaponiQx \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Novo Integrated Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Torsemide","moa":"NKCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sarfez Pharmaceuticals \/ Novo Integrated Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Sarfez Pharmaceuticals \/ Novo Integrated Sciences"},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Clear Creek Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Clear Creek Bio \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Clear Creek Bio \/ Pfizer Inc"},{"orgOrder":0,"company":"4E Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"4ET1103","moa":"MNK receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"4E Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4E Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"4E Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"SBT-77-7101","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Ally Bridge Group","highestDevelopmentStatusID":"5","companyTruncated":"Sonoma Biotherapeutics \/ Ally Bridge Group"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan Securities","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Synlogic","sponsor":"Science 37 Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Partnership","leadProduct":"Labafenogene Marselecobac","moa":"Phe level reducer","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Science 37 Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Science 37 Holdings"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Vickers Vantage Corp I","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Devart Middle East","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Devart Middle East","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Devart Middle East"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Scipher Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scipher Medicine \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Scipher Medicine \/ Galapagos"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Seaport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seaport Therapeutics \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Seaport Therapeutics \/ General Atlantic"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"VolitionRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ VolitionRx","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ VolitionRx"},{"orgOrder":0,"company":"Second Genome","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Second Genome \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Second Genome \/ Gilead Sciences"},{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"CD38-GEAR-NK","moa":"CD38","graph1":"Oncology","graph2":"Preclinical","graph3":"VyGen-Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VyGen-Bio \/ Coeptis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"VyGen-Bio \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Seed Health","sponsor":"The Craftory","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Series A Financing","leadProduct":"SEED Synbiotic","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seed Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seed Health \/ The Craftory","highestDevelopmentStatusID":"8","companyTruncated":"Seed Health \/ The Craftory"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Lind Global Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seelos Therapeutics \/ Lind Global Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Lind Global Asset Management"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"AT845","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Biosciences \/ Astellas Pharma"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Abingworth","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Abingworth"},{"orgOrder":0,"company":"Semnur Pharmaceuticals","sponsor":"Denali Capital Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Semnur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp","highestDevelopmentStatusID":"10","companyTruncated":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp"},{"orgOrder":0,"company":"Senda Biosciences","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Senda Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senda Biosciences \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Senda Biosciences \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"SEngine Precision Medicine","sponsor":"Oncodesign","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","graph1":"Oncology","graph2":"Discovery","graph3":"SEngine Precision Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SEngine Precision Medicine \/ Oncodesign","highestDevelopmentStatusID":"2","companyTruncated":"SEngine Precision Medicine \/ Oncodesign"},{"orgOrder":0,"company":"SEngine Precision Medicine","sponsor":"Washington Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"SEngine Precision Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SEngine Precision Medicine \/ Washington Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SEngine Precision Medicine \/ Washington Research Foundation"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Ketotifen Fumarate","moa":"||H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK.Tech","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK.Tech"},{"orgOrder":0,"company":"Sensorium Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"SENS-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sensorium Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensorium Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sensorium Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sensei Biotherapeutics \/ Apeiron Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sensei Biotherapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"RoosterBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senti Biosciences \/ RoosterBio","highestDevelopmentStatusID":"1","companyTruncated":"Senti Biosciences \/ RoosterBio"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Invivyd","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Polaris Partners","highestDevelopmentStatusID":"4","companyTruncated":"Invivyd \/ Polaris Partners"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adcentrx Therapeutics \/ CBC Group","highestDevelopmentStatusID":"2","companyTruncated":"Adcentrx Therapeutics \/ CBC Group"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Vida Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Vida Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Vida Ventures"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Lumira Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Lumira Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Therapeutics \/ Lumira Ventures"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Sernova","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Recombinant Pluripotent Stem Cell-Derived Pancreatic Islet Beta Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Sernova","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Therapeutics \/ Sernova"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"GreenLight Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GreenLight Biosciences \/ Serum Institute of India","highestDevelopmentStatusID":"3","companyTruncated":"GreenLight Biosciences \/ Serum Institute of India"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Private Placement","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Perceptive Advisors"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Decheng Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shape Therapeutics \/ Decheng Capital","highestDevelopmentStatusID":"2","companyTruncated":"Shape Therapeutics \/ Decheng Capital"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shattuck Labs \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Shattuck Labs \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Shifa Biomedical","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"P-21","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Shifa Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shifa Biomedical \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Shifa Biomedical \/ Xontogeny, LLC"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SHINE Technologies \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SHINE Technologies \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Shinobi Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"NJA-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Shinobi Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shinobi Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Shinobi Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Shionogi"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Vociprotafib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Revolution Medicines \/ Sanofi"},{"orgOrder":0,"company":"Skysong Innovations","sponsor":"Sapphire Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"SBI-183","moa":"QSOX1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Skysong Innovations","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skysong Innovations \/ Sapphire Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Skysong Innovations \/ Sapphire Biotech"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University \/ SIGA Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Vanderbilt University \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Immunology","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Meridian Medical Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ SIGA Technologies"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"SIG-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Commonwealth of Australia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"V451","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Commonwealth of Australia","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Commonwealth of Australia"},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Matrix-M Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"Novavax \/ Serum Institute of India"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SPC-14","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Ovoca Bio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"BP-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Forte Biosciences \/ Ovoca Bio","highestDevelopmentStatusID":"10","companyTruncated":"Forte Biosciences \/ Ovoca Bio"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"SBT6050","moa":"TLR8","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"SBT6050","moa":"TLR8","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series B Financing","leadProduct":"SBT6050","moa":"TLR8","graph1":"Oncology","graph2":"Undisclosed","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Silverback Therapeutics \/ Venture Partners"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series A Financing","leadProduct":"Vevoctadekin","moa":"IL-18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Simcha Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ WuXi AppTec"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"SION-638","moa":"||NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Rotating Boulder Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Series E Financing","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Rotating Boulder Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Rotating Boulder Fund"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Sirtex Medical","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Sirtex Medical"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp. IV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp. IV","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp. IV"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ CIRM","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ CIRM"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"||Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Ipilimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Mayo Clinic \/ Sorrento Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Argenx"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Immune Globulin (Human)","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Grifols International","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Grifols International"},{"orgOrder":0,"company":"Soleo Health","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ GC Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ GC Biopharma"},{"orgOrder":0,"company":"Soligenix","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Alliance Global Partners"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||INF-gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Chardan"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"SON-081","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ New Life Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ New Life Therapeutics"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Chardan Healthcare"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Brill International S.L","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Pharmaceuticals \/ Brill International S.L","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Brill International S.L"},{"orgOrder":0,"company":"SonoThera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"SonoThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SonoThera \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"SonoThera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"AZD1222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Mount Sinai Health System","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Mount Sinai Health System"},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SmartPharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SmartPharm Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SmartPharm Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Mount Sinai Health System","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AZD1222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mount Sinai Health System","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mount Sinai Health System \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mount Sinai Health System \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Sotio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"BOXR1030","moa":"T lymphocyte","graph1":"Oncology","graph2":"Preclinical","graph3":"Unum Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unum Therapeutics \/ Sotio","highestDevelopmentStatusID":"4","companyTruncated":"Unum Therapeutics \/ Sotio"},{"orgOrder":0,"company":"Southern Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Modified Horsepox Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southern Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Southern Research \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Southern Research \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Edaravone","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Eflapegrastim","moa":"||GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"SPR206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Spero Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"SPR206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Spero Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Financing","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ UK Government","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ UK Government"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alcyone Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Alcyone Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Spotlight Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Spotlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spotlight Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Spotlight Therapeutics \/ Google Ventures"},{"orgOrder":0,"company":"Spotlight Therapeutics","sponsor":"GordonMD Global","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Spotlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spotlight Therapeutics \/ GordonMD Global","highestDevelopmentStatusID":"4","companyTruncated":"Spotlight Therapeutics \/ GordonMD Global"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Ab Magnitude Ventures Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Discovery","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SpringWorks Therapeutics \/ Ab Magnitude Ventures Group","highestDevelopmentStatusID":"2","companyTruncated":"SpringWorks Therapeutics \/ Ab Magnitude Ventures Group"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Spiral Therapeutics","sponsor":"Savoir Capital","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"SPT-2101","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Spiral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Spiral Therapeutics \/ Savoir Capital","highestDevelopmentStatusID":"6","companyTruncated":"Spiral Therapeutics \/ Savoir Capital"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Catalent Pharma Solutions \/ Sarepta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"AJU Pharm","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Vezocolmitide","moa":"Helical collagen","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Stuart Therapeutics \/ AJU Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Stuart Therapeutics \/ AJU Pharm"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Sapience Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Sapience Therapeutics"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Kings College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Invikafusp Alpha","moa":"TCR-V beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marengo Therapeutics \/ Kings College London","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Kings College London"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Immune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Naltrexone Hydrochloride","moa":"Kappa\/Mu\/Delta Opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Statera Biopharma \/ Immune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Statera Biopharma \/ Immune Therapeutics"},{"orgOrder":0,"company":"Stellanova Therapeutics","sponsor":"Sporos Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Stellanova Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Stellanova Therapeutics \/ Sporos Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"Stellanova Therapeutics \/ Sporos Bioventures"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Genoa Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Human Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemson Therapeutics \/ Genoa Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Genoa Ventures"},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Fluasterone","moa":"NFkB","graph1":"Endocrinology","graph2":"Phase II","graph3":"SteroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SteroTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"SteroTherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strand Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Strand Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Strand Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Strand Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Facial Pain Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ligand gated ion channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coda Biotherapeutics \/ Facial Pain Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Coda Biotherapeutics \/ Facial Pain Research Foundation"},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ennaid Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ennaid Therapeutics \/ Strides Pharma Science","highestDevelopmentStatusID":"1","companyTruncated":"Ennaid Therapeutics \/ Strides Pharma Science"},{"orgOrder":0,"company":"Strm.Bio","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Strm.Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strm.Bio \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Strm.Bio \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ isoSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ isoSolutions"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"IGM Biosciences \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"IGM Biosciences \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kaiser Permanente Washington Health Research \/ Amarin","highestDevelopmentStatusID":"11","companyTruncated":"Kaiser Permanente Washington Health Research \/ Amarin"},{"orgOrder":0,"company":"Flugen","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"Influenza Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Flugen \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ US Department of Defense"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Stand Up Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"STUP-001","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectorBuilder \/ Stand Up Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"VectorBuilder \/ Stand Up Therapeutics"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"SU2C Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ SU2C Catalyst","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ SU2C Catalyst"},{"orgOrder":0,"company":"Aavnergene","sponsor":"Neurophth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Aavnergene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Aavnergene \/ Neurophth Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Aavnergene \/ Neurophth Therapeutics"},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Optum Frontier Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Partnership","leadProduct":"Sacrosidase","moa":"Sucrase enzyme","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Optum Frontier Therapies","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Optum Frontier Therapies"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"Carbonic anhydrase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"Carbonic anhydrase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"SNS-510","moa":"PDK-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunesis Pharmaceuticals \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Pharmaceuticals \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"University of Georgia","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"SBFM-PL4","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ Sunshine Biopharma"},{"orgOrder":0,"company":"Surrozen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"SZN-413","moa":"Wnt signaling","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Surrozen","sponsor":"Consonance-HFW","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Merger","leadProduct":"SZN-1326","moa":"Lrp6","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Consonance-HFW","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Consonance-HFW"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"MK-1484","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sutro Biopharma \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Baillie Gifford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Baillie Gifford","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Baillie Gifford"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sutro Biopharma \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ BofA Securities"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Cowen"},{"orgOrder":0,"company":"SutroVax","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Series D Financing","leadProduct":"SVX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SutroVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SutroVax \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"SutroVax \/ RA Capital Management"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Swixx BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Swixx BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Swixx BioPharma"},{"orgOrder":0,"company":"Sydnexis","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sydnexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sydnexis \/ Visionary Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Sydnexis \/ Visionary Ventures"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"LGS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Clobazam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Assertio Therapeutics \/ LGS Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Assertio Therapeutics \/ LGS Foundation"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Theriva Biologics"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nepicastat","moa":"DBH","graph1":"Neurology","graph2":"Preclinical","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acorda Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Acorda Therapeutics \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Parexel Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Biotech \/ Synairgen"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"Synedgen","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synedgen \/ National Eye Institute","highestDevelopmentStatusID":"2","companyTruncated":"Synedgen \/ National Eye Institute"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fibrosis Foundation \/ Synspira Therapeutics"},{"orgOrder":0,"company":"Synthekine","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"STK-012","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Deerfield Management"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Synthetic Lethality","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Synthetic Lethality","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Synthetic Lethality"},{"orgOrder":0,"company":"Orsenix","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Orsenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orsenix \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Orsenix \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syros Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Syros Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Syros Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Surrozen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ RA Capital Management"},{"orgOrder":0,"company":"Surrozen","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ National Institutes of Health"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"National Institute of Diabetes and Digestive Kidney Disease","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease","highestDevelopmentStatusID":"4","companyTruncated":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Nuntius Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nuntius Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuntius Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Nuntius Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"AB154","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Termination","leadProduct":"Pembrolizumab","moa":"||FIt3 ligand gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Turnstone Biologics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Turnstone Biologics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Termination","leadProduct":"WVE-003","moa":"SNP3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Neurology","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Private Placement","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Syros Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"10","companyTruncated":"Syros Pharmaceuticals \/ Oxford Finance"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Tasmanian Alkaloids Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Tasmanian Alkaloids Pty Ltd"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"SciClone","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"PI3K","graph1":"Oncology","graph2":"Preclinical","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarveda Therapeutics \/ SciClone","highestDevelopmentStatusID":"4","companyTruncated":"Tarveda Therapeutics \/ SciClone"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"UC San Diego","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"UC San Diego \/ BetterLife Pharma","highestDevelopmentStatusID":"4","companyTruncated":"UC San Diego \/ BetterLife Pharma"},{"orgOrder":0,"company":"Espero BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Espero BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Espero BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Espero BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ U.S. Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ U.S. Department of Defense"},{"orgOrder":0,"company":"OmniAb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"OmniAb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OmniAb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"OmniAb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"OmniAb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"OmniAb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OmniAb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"OmniAb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Tegmine Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alloy Therapeutics \/ Tegmine Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Tegmine Therapeutics"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tegoprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BRAINTREE LABS \/ Sebela Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE LABS \/ Sebela Pharmaceuticals"},{"orgOrder":0,"company":"Tellus Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"TT-20","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tellus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tellus Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Tellus Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Tellus Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"TT-20","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Tellus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tellus Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Tellus Therapeutics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Seneca Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Seneca Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Seneca Therapeutics"},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Tenax Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mateon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Mateon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"TERN-501","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"TERN-501","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Terran Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Terran Biosciences"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"old Sano","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Terran Biosciences \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"Terran Biosciences \/ old Sano"},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Terremoto Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terremoto Biosciences \/ EcoR1 Capital","highestDevelopmentStatusID":"3","companyTruncated":"Terremoto Biosciences \/ EcoR1 Capital"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"HMP Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ HMP Partners","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ HMP Partners"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"TF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovia Therapeutics \/ TF Capital","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ TF Capital"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"TFF Pharmaceuticals \/ Cleveland Clinic","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Cleveland Clinic"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Augmenta Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Augmenta Bioworks","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Augmenta Bioworks"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IRISYS, LLC \/ TFF Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"IRISYS, LLC \/ TFF Pharmaceuticals"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ TG Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ TG Therapeutics"},{"orgOrder":0,"company":"Columbia University","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Fortress Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Fortress Biotech"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"THB001","moa":"KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Third Harmonic Bio \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Morgan Stanley"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Dcvc Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Oxalate","graph1":"Nephrology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novome Biotechnologies \/ Dcvc Bio","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ Dcvc Bio"},{"orgOrder":0,"company":"Agenus","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"MK-4830","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Merck & Co"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sutro Biopharma \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Sutro Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Defense Advanced Research Projects Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Inovio Pharmaceuticals \/ Defense Advanced Research Projects Agency","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Defense Advanced Research Projects Agency"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"HT-003","moa":"TLR2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Weill Cornell Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova \/ Sanofi"},{"orgOrder":0,"company":"Amyris","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"hAd5 S+N","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Amyris","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amyris \/ ImmunityBio","highestDevelopmentStatusID":"7","companyTruncated":"Amyris \/ ImmunityBio"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Eagle Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Soligenix","sponsor":"Pontifax Medison Debt Financing","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Pontifax Medison Debt Financing","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Pontifax Medison Debt Financing"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"Dogma Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dogma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dogma Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Dogma Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Kala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kala Pharmaceuticals \/ Kala Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Kala Pharmaceuticals \/ Kala Pharmaceuticals"},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Greenteaspoon","sponsor":"PanTheryx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Goodgut","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Greenteaspoon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Greenteaspoon \/ PanTheryx","highestDevelopmentStatusID":"15","companyTruncated":"Greenteaspoon \/ PanTheryx"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Covis Pharma"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Andexanet Alpha","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Tenzing"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Coherus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Coherus Biosciences"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Coherus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Coherus Biosciences"},{"orgOrder":0,"company":"Reachbio Research Labs","sponsor":"Discovery Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Discovery","graph3":"Reachbio Research Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reachbio Research Labs \/ Discovery Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Reachbio Research Labs \/ Discovery Life Sciences"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Johnson & Johnson"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LogicBio Therapeutics \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"LogicBio Therapeutics \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Trianni","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Trianni","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trianni \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Trianni \/ AbCellera"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Dichlorphenamide","moa":"CA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Xeris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Strongbridge Biopharma \/ Xeris Pharmaceuticals"},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"K102","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kashiv Specialty Pharmaceuticals \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Harmony Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ Harmony Biosciences"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Ipsen"},{"orgOrder":0,"company":"Principia Biopharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Principia Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Principia Biopharma \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Principia Biopharma \/ Sanofi"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Andexanet Alpha","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Focus-X Therapeutics","sponsor":"Full-Life Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"NTSR1","moa":"Neurotensin","graph1":"Oncology","graph2":"Preclinical","graph3":"Focus-X Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Focus-X Therapeutics \/ Full-Life Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Focus-X Therapeutics \/ Full-Life Technologies"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aiolos Bio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ GSK"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Eli Lilly"},{"orgOrder":0,"company":"PH Precision Med","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"PH Precision Med","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PH Precision Med \/ Tenax Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PH Precision Med \/ Tenax Therapeutics"},{"orgOrder":0,"company":"zPREDICTA","sponsor":"Predictive Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"zPREDICTA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"zPREDICTA \/ Predictive Oncology","highestDevelopmentStatusID":"4","companyTruncated":"zPREDICTA \/ Predictive Oncology"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocyte","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"B. Braun Medical \/ Healiva","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Healiva"},{"orgOrder":0,"company":"Alchemee","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alchemee","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Alchemee \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alchemee \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Alpha-5 integrin","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Alpha V integrin","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha-5 integrin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpha-5 integrin \/ Pasithea Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Alpha-5 integrin \/ Pasithea Therapeutics"},{"orgOrder":0,"company":"Exacis Biotherapeutics","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Exacis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exacis Biotherapeutics \/ Eterna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Exacis Biotherapeutics \/ Eterna Therapeutics"},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Aileron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Lung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Lung Therapeutics \/ Aileron Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lung Therapeutics \/ Aileron Therapeutics"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Vocimagene Amiretrorepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Denovo Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Forte Biosciences \/ Denovo Biopharma"},{"orgOrder":0,"company":"Hilma","sponsor":"Biocodex","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Hilma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder In Sachet","sponsorNew":"Hilma \/ Biocodex","highestDevelopmentStatusID":"15","companyTruncated":"Hilma \/ Biocodex"},{"orgOrder":0,"company":"Teligent, Inc","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Atropine","moa":"mAChRs","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Teligent, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Teligent, Inc \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Teligent, Inc \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Affinivax","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"AFX3772","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ GSK"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aiolos Bio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ GSK"},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"SNAPvax CV","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avidea Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Avidea Technologies \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Avidea Technologies \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Sunovion Pharmaceuticals \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Lupin Ltd"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Ziltivekimab","moa":"IL-6 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corvidia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvidia Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Corvidia Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"KT809","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kate Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Kate Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"MAU868","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Vera Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Mirokidney","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Mirokidney","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Quince Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Quince Therapeutics"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Quince Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Quince Therapeutics"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Arranta Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Arranta Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arranta Bio \/ Recipharm AB","highestDevelopmentStatusID":"1","companyTruncated":"Arranta Bio \/ Recipharm AB"},{"orgOrder":0,"company":"Comet Therapeutics","sponsor":"VectivBio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"VB-1197","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Comet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Comet Therapeutics \/ VectivBio","highestDevelopmentStatusID":"4","companyTruncated":"Comet Therapeutics \/ VectivBio"},{"orgOrder":0,"company":"TeneoTwo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"TNB-486","moa":"CD3\/19","graph1":"Oncology","graph2":"Phase I","graph3":"TeneoTwo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TeneoTwo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"TeneoTwo \/ AstraZeneca"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"VC-02","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"ViaCyte Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"ViaCyte Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"ViaCyte Inc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Renovacor","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"REN-001","moa":"BAG3 Gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renovacor \/ Rocket Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Rocket Pharmaceuticals"},{"orgOrder":0,"company":"Redpin Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Redpin Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redpin Therapeutics \/ Kriya Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Redpin Therapeutics \/ Kriya Therapeutics"},{"orgOrder":0,"company":"PrimeFour Therapeutics","sponsor":"Transposon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PrimeFour Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PrimeFour Therapeutics \/ Transposon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PrimeFour Therapeutics \/ Transposon Therapeutics"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Engrail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Engrail Therapeutics \/ Engrail Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Engrail Therapeutics \/ Engrail Therapeutics"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Acquisition","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Veru","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Blue Water Vaccines"},{"orgOrder":0,"company":"PvP Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"TAK-062","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PvP Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PvP Biologics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"PvP Biologics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen"},{"orgOrder":0,"company":"Abexxa Biologics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"NKG2A:HLA-E complex","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Abexxa Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abexxa Biologics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Abexxa Biologics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Amgen"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Acquisition","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Alcon Inc"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"SNBL","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ SNBL","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ SNBL"},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"PD-1\/IL-2 receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bonum Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"xCella","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"OmniAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"xCella","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"xCella \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"xCella \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Taurus Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"OmniAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Taurus Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taurus Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Taurus Biosciences \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Sapien Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Salinomycin","moa":"||Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Sapien Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Sapien Biosciences"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"StrideBio","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"StrideBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StrideBio \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"Cowen Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aktis Oncology \/ Cowen Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ Cowen Healthcare"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Consonance Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"MT-3724","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Consonance Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Molecular Templates \/ Consonance Capital Management"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Galidesivir","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ AstraZeneca"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Arctic Vision","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Arctic Vision"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Onkure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Onkure","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Onkure"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"University of Iowa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ University of Iowa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ University of Iowa Pharmaceuticals"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Sever Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Implant","sponsorNew":"Silo Pharma \/ Sever Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Sever Pharma Solutions"},{"orgOrder":0,"company":"Sydnexis","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sydnexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Sydnexis \/ Santen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sydnexis \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"NDI-5001","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NephroDI Therapeutics \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI Therapeutics \/ McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"Levolta Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Zoledronic Acid Derivative","moa":"Bone resorption factor","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Levolta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Cenra Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Moderna Therapeutics \/ Cenra Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Cenra Healthcare"},{"orgOrder":0,"company":"Fujifilm Cellular Dynamics","sponsor":"Century Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Fujifilm Cellular Dynamics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fujifilm Cellular Dynamics \/ Century Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Fujifilm Cellular Dynamics \/ Century Therapeutics"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"KSQ-4279","moa":"USP-1","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KSQ Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"Somalab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Pressure BioSciences \/ Somalab","highestDevelopmentStatusID":"15","companyTruncated":"Pressure BioSciences \/ Somalab"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Washington","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Washington"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Farouk, Maamoun Tamer & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Farouk, Maamoun Tamer & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Farouk, Maamoun Tamer & Co."},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"Cr\u00e8me de Canna","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Pressure BioSciences \/ Cr\u00e8me de Canna","highestDevelopmentStatusID":"15","companyTruncated":"Pressure BioSciences \/ Cr\u00e8me de Canna"},{"orgOrder":0,"company":"Cellipont Bioservices","sponsor":"Mongoose Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"MGB-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellipont Bioservices","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellipont Bioservices \/ Mongoose Bio","highestDevelopmentStatusID":"4","companyTruncated":"Cellipont Bioservices \/ Mongoose Bio"},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"Anocca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Emendo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emendo Biotherapeutics \/ Anocca","highestDevelopmentStatusID":"5","companyTruncated":"Emendo Biotherapeutics \/ Anocca"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"GigaGen","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"LogiX Biosciences","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"LogiX Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LogiX Biosciences \/ Mayo Clinic","highestDevelopmentStatusID":"2","companyTruncated":"LogiX Biosciences \/ Mayo Clinic"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Department of Health - Abu Dhabi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Department of Health - Abu Dhabi","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Department of Health - Abu Dhabi"},{"orgOrder":0,"company":"University of Georgia Research Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AN15368","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"University of Georgia Research Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia Research Foundation \/ AN2 Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"University of Georgia Research Foundation \/ AN2 Therapeutics"},{"orgOrder":0,"company":"Nusano","sponsor":"Starget Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"DOTA-PTR-58","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ Starget Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Nusano \/ Starget Pharma"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Charles River Laboratories, Inc \/ H. Lundbeck AS","highestDevelopmentStatusID":"3","companyTruncated":"Charles River Laboratories, Inc \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Ingenu","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"Ingenu","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ingenu \/ FSD Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Ingenu \/ FSD Pharma"},{"orgOrder":0,"company":"Novavax","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Sanofi"},{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Sanofi"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Melinta Therapeutics \/ VenatoRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ VenatoRx Pharmaceuticals"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Day One Biopharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Day One Biopharmaceuticals \/ Ipsen"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Synaptogenix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Synaptogenix","highestDevelopmentStatusID":"4","companyTruncated":"Cleveland Clinic \/ Synaptogenix"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Beverly Hills Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Beverly Hills Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Beverly Hills Cancer Center"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Implant","sponsorNew":"Silo Pharma \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Zylo Therapeutics"},{"orgOrder":0,"company":"TFC Therapeutics","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"TFC Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TFC Therapeutics \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"TFC Therapeutics \/ Columbia University"},{"orgOrder":0,"company":"AtomVie Global Radiopharma","sponsor":"Radiopharm Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"177-Lu BetaBart","moa":"CD276","graph1":"Oncology","graph2":"Preclinical","graph3":"AtomVie Global Radiopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AtomVie Global Radiopharma \/ Radiopharm Ventures","highestDevelopmentStatusID":"4","companyTruncated":"AtomVie Global Radiopharma \/ Radiopharm Ventures"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Licensing Agreement","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Maruho"},{"orgOrder":0,"company":"Humanetics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Genistein","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Department of Defense"},{"orgOrder":0,"company":"Oblenio Bio","sponsor":"Aditum Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LBL-051","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Oblenio Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oblenio Bio \/ Aditum Bio","highestDevelopmentStatusID":"4","companyTruncated":"Oblenio Bio \/ Aditum Bio"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Elektrofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elektrofi \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Elektrofi \/ Eli Lilly"},{"orgOrder":0,"company":"Applied Biomedical Science Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"HER2\/3","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied Biomedical Science Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Applied Biomedical Science Institute \/ Hillstream BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Applied Biomedical Science Institute \/ Hillstream BioPharma"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"National Institute of Environmental Health Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol, Powder","sponsorNew":"TFF Pharmaceuticals \/ National Institute of Environmental Health Sciences","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ National Institute of Environmental Health Sciences"},{"orgOrder":0,"company":"Base4 Biotechnology","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Base4 Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Base4 Biotechnology \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Base4 Biotechnology \/ Servier"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic One Health","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dyadic International, Inc \/ Rubic One Health","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic International, Inc \/ Rubic One Health"},{"orgOrder":0,"company":"Imunon","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"DNA-Based Lassa Virus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imunon \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ National Institutes of Health"},{"orgOrder":0,"company":"Kineta","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"ASEAN","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ ASEAN","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ ASEAN"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"vitaCare Prescription Services","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ vitaCare Prescription Services","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ vitaCare Prescription Services"},{"orgOrder":0,"company":"Novavax","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Fujifilm Diosynth Biotechnologies","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Fujifilm Diosynth Biotechnologies"},{"orgOrder":0,"company":"BioAdaptives","sponsor":"LY Research Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lutein","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"BioAdaptives","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAdaptives \/ LY Research Corporation","highestDevelopmentStatusID":"4","companyTruncated":"BioAdaptives \/ LY Research Corporation"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Hebrew University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"180 Life Sciences \/ Hebrew University","highestDevelopmentStatusID":"4","companyTruncated":"180 Life Sciences \/ Hebrew University"},{"orgOrder":0,"company":"CancerVAX","sponsor":"Flashpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CancerVAX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CancerVAX \/ Flashpoint Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"CancerVAX \/ Flashpoint Therapeutics"},{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Approved FDF","graph3":"SK Pharmteco","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"SK Pharmteco \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SK Pharmteco \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Implant","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"KORU Medical Systems","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"KORU Medical Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KORU Medical Systems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"KORU Medical Systems \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Regeneron Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Bepirovirsen","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ GSK"},{"orgOrder":0,"company":"Institute for Protein Design","sponsor":"Vilya","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Macrocyclic Peptide","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Institute for Protein Design","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute for Protein Design \/ Vilya","highestDevelopmentStatusID":"3","companyTruncated":"Institute for Protein Design \/ Vilya"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"VOR33","moa":"CD33","graph1":"Oncology","graph2":"Preclinical","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arbor Biotechnologies, Inc \/ Vor Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Arbor Biotechnologies, Inc \/ Vor Biopharma"},{"orgOrder":0,"company":"Lay Sciences","sponsor":"Statera Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lay Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lay Sciences \/ Statera Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Lay Sciences \/ Statera Biopharma"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Emergent BioSolutions","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biotherapeutics \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Depuy Synthes Sales","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Depuy Synthes Sales","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Depuy Synthes Sales"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Boston Children's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Boston Children's Hospital"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Sorrento Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Biodextris","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BDX100","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biodextris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Biodextris \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Biodextris \/ Oragenics"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Lonza Group","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Lonza Group"},{"orgOrder":0,"company":"Megalith Pharmaceuticals","sponsor":"Corbus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Megalith Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Megalith Pharmaceuticals \/ Corbus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Megalith Pharmaceuticals \/ Corbus Pharmaceuticals"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Spanish government","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Spanish government","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Spanish government"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ European Commission"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"The European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ The European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ The European Commission"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"BITT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"BITR2101","moa":"TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ BITT","highestDevelopmentStatusID":"5","companyTruncated":"KBI Biopharma \/ BITT"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MDM2 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Michigan \/ Ascentage Pharma","highestDevelopmentStatusID":"5","companyTruncated":"University of Michigan \/ Ascentage Pharma"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Elevar Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Medicox Co.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Medicox Co.","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Medicox Co."},{"orgOrder":0,"company":"Aexon Labs","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AEX-2","moa":"Undisclosed","graph1":"Sleep","graph2":"Preclinical","graph3":"Aexon Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aexon Labs \/ NLS Pharmaceutics","highestDevelopmentStatusID":"4","companyTruncated":"Aexon Labs \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Oravax Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"MyMD Pharmaceuticals \/ Oravax Medical","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Oravax Medical"},{"orgOrder":0,"company":"City of Hope","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Allogeneic Neural Stem Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"BioCardia","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ BlueRock Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"ENTR-701","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entrada Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aptar Pharma \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"Aptar Pharma \/ Indivior"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"TriLink BioTechnologies \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"TriLink BioTechnologies \/ Department of Defense"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpine Immune Sciences \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"ATA3271","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atara Biotherapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Atara Biotherapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grand River Aseptic Manufacturing","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Grand River Aseptic Manufacturing \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Grand River Aseptic Manufacturing \/ Johnson & Johnson"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Li-Key-SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generex Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Generex Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Pluristyx","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"ESI Human Embryonic Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Pluristyx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluristyx \/ AgeX Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pluristyx \/ AgeX Therapeutics"},{"orgOrder":0,"company":"Nurx","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Nurx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Nurx \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Nurx \/ TherapeuticsMD"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta radiation","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Chengdu Syncor Pharmaceutical"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase I","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Panbela Therapeutics \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Guangdong Academy of Medical Sciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Guangdong Academy of Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Everest Medicines \/ Guangdong Academy of Medical Sciences"},{"orgOrder":0,"company":"Mapp Biopharmaceutical","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"MBP134","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mapp Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mapp Biopharmaceutical \/ KBI Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Mapp Biopharmaceutical \/ KBI Biopharma"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Contineum Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Cenegermin","moa":"TrkA receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tanner Pharma \/ Dompe Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Tanner Pharma \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aktis Oncology \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Serina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Serina Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Serina Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Bach Biosciences","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Licensing Agreement","leadProduct":"PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bach Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bach Biosciences \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Bach Biosciences \/ Point Biopharma"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"DNA","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Schrodinger \/ Zai Lab","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Zai Lab"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alloy Therapeutics \/ Scripps Research","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Scripps Research"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"CombiGene","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CG01","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spark Therapeutics, Inc \/ CombiGene","highestDevelopmentStatusID":"4","companyTruncated":"Spark Therapeutics, Inc \/ CombiGene"},{"orgOrder":0,"company":"Sidero Bioscience","sponsor":"SRS Life Sciences Pte ltd","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"FTH1","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Sidero Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidero Bioscience \/ SRS Life Sciences Pte ltd","highestDevelopmentStatusID":"1","companyTruncated":"Sidero Bioscience \/ SRS Life Sciences Pte ltd"},{"orgOrder":0,"company":"MAKScientific","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"MAKScientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAKScientific \/ Tetra BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"MAKScientific \/ Tetra BioPharma"},{"orgOrder":0,"company":"Vyluma","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Laboratoires Thea","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Laboratoires Thea"},{"orgOrder":0,"company":"IsoTherapeutics Group","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IsoTherapeutics Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IsoTherapeutics Group \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"IsoTherapeutics Group \/ Plus Therapeutics"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Longboard Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Societal CDMO \/ Longboard Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Longboard Pharmaceuticals"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Giroctocogene fitelparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sangamo Therapeutics \/ Biogen"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"NexImmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"||T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KBI Biopharma \/ NexImmune","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ NexImmune"},{"orgOrder":0,"company":"Lowell Therapeutics","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lowell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lowell Therapeutics \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Lowell Therapeutics \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Magdalena Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Magdalena Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Jaguar Health \/ Magdalena Biosciences"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ GC Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ GC Biopharma"},{"orgOrder":0,"company":"Biocept Inc","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocept Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Biocept Inc \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Biocept Inc \/ Plus Therapeutics"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vantage Outsourcing","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vantage Outsourcing","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Vantage Outsourcing"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vision Center Network Of America","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vision Center Network Of America","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Vision Center Network Of America"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Biologics Inc \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Lonza Biologics Inc \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Awakn Life Sciences Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT\/Noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Catalent Pharma Solutions \/ Novan","highestDevelopmentStatusID":"5","companyTruncated":"Catalent Pharma Solutions \/ Novan"},{"orgOrder":0,"company":"Kallyope","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Sosei Group Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Erasca","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erasca \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Pierre Fabre"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"Ionetix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"177-Lu PSMA-I&T","moa":"||PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Convergent Therapeutics \/ Ionetix","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ Ionetix"},{"orgOrder":0,"company":"Lewis Katz School of Medicine","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Piclidenoson","moa":"A3AR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lewis Katz School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lewis Katz School of Medicine \/ Can-Fite BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Lewis Katz School of Medicine \/ Can-Fite BioPharma"},{"orgOrder":0,"company":"Athenex","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Merck & Co"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Allderma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Allderma","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Allderma"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"131-I Iopofosine","moa":"DNA damage","graph1":"Oncology","graph2":"Phase II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Evergreen Theragnostics \/ Cellectar","highestDevelopmentStatusID":"8","companyTruncated":"Evergreen Theragnostics \/ Cellectar"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Genpharm"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Nice & Green S.A","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Nice & Green S.A","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Nice & Green S.A"},{"orgOrder":0,"company":"PsychoGenics","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"KAR-501","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"PsychoGenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PsychoGenics \/ Karuna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PsychoGenics \/ Karuna Therapeutics"},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Blau Farmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Epoetin Alpha","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"JSR Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"JSR Life Sciences \/ Blau Farmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"JSR Life Sciences \/ Blau Farmaceutica"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"CAT-5571","moa":"Autophagy","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catabasis Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Catabasis Pharmaceuticals \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Memgen","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"MEM-288","moa":"CD40","graph1":"Oncology","graph2":"Preclinical","graph3":"Memgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memgen \/ Moffitt Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Memgen \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Gavi","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Gavi"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"ABO-202","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abeona Therapeutics \/ Taysha Gene Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Abeona Therapeutics \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"ABO-202","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abeona Therapeutics \/ Taysha Gene Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Abeona Therapeutics \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CYTO NK-203","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"G42 Investments","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ G42 Investments","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ G42 Investments"},{"orgOrder":0,"company":"Abound Bio","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abound Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abound Bio \/ Galapagos","highestDevelopmentStatusID":"7","companyTruncated":"Abound Bio \/ Galapagos"},{"orgOrder":0,"company":"Merck & Co","sponsor":"RefleXion Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ RefleXion Medical","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ RefleXion Medical"},{"orgOrder":0,"company":"Allen Institute","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Allen Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Allen Institute \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Allen Institute \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Pierre Fabre"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Expanded Collaboration","leadProduct":"NGM621","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"NGM Biopharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"miR-21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TRC253","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Johnson & Johnson Innovative Medicine \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ TRACON Pharmaceuticals"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Minnesota \/ Carisma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"University of Minnesota \/ Carisma Therapeutics"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of North Carolina \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Licensing Agreement","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"EMD Serono","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prime Therapeutics \/ EMD Serono","highestDevelopmentStatusID":"15","companyTruncated":"Prime Therapeutics \/ EMD Serono"},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Afaxys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Afaxys Pharma \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"Afaxys Pharma \/ TherapeuticsMD"},{"orgOrder":0,"company":"SarcoMed","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Alidornase Alpha","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"SarcoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SarcoMed \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SarcoMed \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"Atomwise","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atomwise \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/ Sanofi"},{"orgOrder":0,"company":"Quantitative Biosciences Institute","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Quantitative Biosciences Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Quantitative Biosciences Institute \/ National Institutes of Health","highestDevelopmentStatusID":"3","companyTruncated":"Quantitative Biosciences Institute \/ National Institutes of Health"},{"orgOrder":0,"company":"University of Montana","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Opioid Vaccines","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"University of Montana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Montana \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"University of Montana \/ National Institutes of Health"},{"orgOrder":0,"company":"Kovina Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kovina Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Kovina Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"PLG0301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptilogics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Peptilogics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Privo Technologies","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Privo Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Privo Technologies \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Privo Technologies \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Kovina Therapeutics","sponsor":"National Institute of Dental and Craniofacial Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV E6","graph1":"Oncology","graph2":"Preclinical","graph3":"Kovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kovina Therapeutics \/ National Institute of Dental and Craniofacial Research","highestDevelopmentStatusID":"4","companyTruncated":"Kovina Therapeutics \/ National Institute of Dental and Craniofacial Research"},{"orgOrder":0,"company":"MiMedx","sponsor":"U.S. Army Medical Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Dehydrated Human Amnion Chorion Membrane","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ U.S. Army Medical Research and Development","highestDevelopmentStatusID":"1","companyTruncated":"MiMedx \/ U.S. Army Medical Research and Development"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"AB126","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Neurology","graph2":"Preclinical","graph3":"DTx Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DTx Pharma \/ Alzheimer's Association","highestDevelopmentStatusID":"4","companyTruncated":"DTx Pharma \/ Alzheimer's Association"},{"orgOrder":0,"company":"Princeton University","sponsor":"Barer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SHMT","graph1":"Oncology","graph2":"Discovery","graph3":"Princeton University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Princeton University \/ Barer Institute","highestDevelopmentStatusID":"2","companyTruncated":"Princeton University \/ Barer Institute"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"Forge Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Blacksmith Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blacksmith Medicines \/ Forge Therapeutics, Inc","highestDevelopmentStatusID":"3","companyTruncated":"Blacksmith Medicines \/ Forge Therapeutics, Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.K Governement","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ U.K Governement","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ U.K Governement"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Eventide Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Eventide Asset Management"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hercules Capital"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Agreement","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"PT00114","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Protagenic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagenic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Protagenic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Celesta Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prellis Biologics \/ Celesta Capital","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Celesta Capital"},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Series A Financing","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Chemotherapy Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced Chemotherapy Technologies \/ Khosla Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Chemotherapy Technologies \/ Khosla Ventures"},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"Khosla Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Series A Financing","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Chemotherapy Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced Chemotherapy Technologies \/ Khosla Venture","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Chemotherapy Technologies \/ Khosla Venture"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Avoro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Avoro Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Scribe Therapeutics \/ Avoro Ventures"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"ADP101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Holoclara","sponsor":"BOLD Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Holoclara","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holoclara \/ BOLD Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Holoclara \/ BOLD Capital Partners"},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Rome Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rome Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Rome Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Petra Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Merger","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Revelation Biosciences \/ Petra Acquisition","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Petra Acquisition"},{"orgOrder":0,"company":"AcuraStem","sponsor":"U.S Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Funding","leadProduct":"AS-202","moa":"PIKfyve kinase","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"AcuraStem \/ U.S Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem \/ U.S Department of Defense"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"CEL383","moa":"TREM-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celsius Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Celsius Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Sybleu","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Erlotinib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sybleu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sybleu \/ Oncology Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Sybleu \/ Oncology Pharma"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Chula Vaccine Research Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"ChulaCov19 mRNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"TriLink BioTechnologies \/ Chula Vaccine Research Center","highestDevelopmentStatusID":"6","companyTruncated":"TriLink BioTechnologies \/ Chula Vaccine Research Center"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"EBT-101","moa":"CRISPR-Cas9 gene","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Excision BioTherapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Excision BioTherapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicines","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ California Institute for Regenerative Medicines"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytomX Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"CytomX Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Atum Bio","sponsor":"Phylex BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VLP Based Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Atum Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atum Bio \/ Phylex BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Atum Bio \/ Phylex BioSciences"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Upacicalcet Sodium","moa":"CaR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pathalys Pharma \/ Abingworth","highestDevelopmentStatusID":"15","companyTruncated":"Pathalys Pharma \/ Abingworth"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Dyno Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dyno Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Dyno Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Mezigdomide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"MGD024","moa":"CD3\/123","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Gilead Sciences"},{"orgOrder":0,"company":"Cytiva","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Cytiva","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytiva \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Cytiva \/ n-Lorem Foundation"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Razuprotafib","moa":"VE-PTP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Surface Oncology"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ibuprofen","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Biosplice","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Rusalatide Acetate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Chrysalis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chrysalis BioTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Chrysalis BioTherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"NCATS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virpax Pharmaceuticals \/ NCATS","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ NCATS"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Beta Bionics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Beta Bionics","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Beta Bionics"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Tolerogenic Nanoparticle","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cour Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Cour Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"FSHD Society","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ FSHD Society","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ FSHD Society"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Preclinical","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Panbela Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Arovella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"SPX-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SparX Biopharmaceutical \/ Arovella Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SparX Biopharmaceutical \/ Arovella Therapeutics"},{"orgOrder":0,"company":"X-Chem","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"X-Chem \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Evotec"},{"orgOrder":0,"company":"Walgreens","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Walgreens","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Walgreens \/ Prothena","highestDevelopmentStatusID":"6","companyTruncated":"Walgreens \/ Prothena"},{"orgOrder":0,"company":"Neochromosome","sponsor":"University of Edinburgh","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Neochromosome","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neochromosome \/ University of Edinburgh","highestDevelopmentStatusID":"3","companyTruncated":"Neochromosome \/ University of Edinburgh"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HPK1","graph1":"Oncology","graph2":"Discovery","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullinan Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Cullinan Therapeutics \/ Icahn School of Medicine"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Jude Children \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"St. Jude Children \/ n-Lorem Foundation"},{"orgOrder":0,"company":"X-Chem","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"TNX-4200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X-Chem \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"X-Chem \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evive Biotech \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Evive Biotech \/ Nona Biosciences"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Seagen","highestDevelopmentStatusID":"4","companyTruncated":"Nurix Therapeutics \/ Seagen"},{"orgOrder":0,"company":"Atum Bio","sponsor":"Anagram Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"ANG003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Atum Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atum Bio \/ Anagram Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Atum Bio \/ Anagram Therapeutics"},{"orgOrder":0,"company":"GBI","sponsor":"Allterum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"4A10","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GBI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBI \/ Allterum Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GBI \/ Allterum Therapeutics"},{"orgOrder":0,"company":"Genetika","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"Genetika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Genetika \/ NeuroSense Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genetika \/ NeuroSense Therapeutics"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Imiquimod","moa":"||CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UroGen Pharma \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"UroGen Pharma \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"Matica Biotechnology","sponsor":"Treovir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"G207","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Matica Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matica Biotechnology \/ Treovir","highestDevelopmentStatusID":"8","companyTruncated":"Matica Biotechnology \/ Treovir"},{"orgOrder":0,"company":"GRI Bio","sponsor":"NIHR Respiratory TRC","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ NIHR Respiratory TRC","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ NIHR Respiratory TRC"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Agreement","leadProduct":"Decoy20","moa":"||TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Qnovia","sponsor":"University of Virginia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"QN-05","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qnovia \/ University of Virginia","highestDevelopmentStatusID":"4","companyTruncated":"Qnovia \/ University of Virginia"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Oxford Nanopore Technologies","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Oxford Nanopore Technologies","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Oxford Nanopore Technologies"},{"orgOrder":0,"company":"Sea Pharmaceuticals","sponsor":"TCG Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"SPM-0404","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sea Pharmaceuticals \/ TCG Lifesciences","highestDevelopmentStatusID":"5","companyTruncated":"Sea Pharmaceuticals \/ TCG Lifesciences"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Medical University of Innsbruck","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Collaboration","leadProduct":"177-Lu EVG-321","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Medical University of Innsbruck","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen Theragnostics \/ Medical University of Innsbruck"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Belrestotug","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"University of Colorado School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"RSBT-001","moa":"Cannabinoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ University of Colorado School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ University of Colorado School of Medicine"},{"orgOrder":0,"company":"Beacon Biosignals","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Beacon Biosignals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Beacon Biosignals \/ Skye Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Beacon Biosignals \/ Skye Bioscience"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Preclinical","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Summit Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Summit Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"ATPase","graph1":"Oncology","graph2":"Preclinical","graph3":"BridGene Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridGene Biosciences \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"BridGene Biosciences \/ Galapagos"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Hematology","graph2":"Phase II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Cadrenal Therapeutics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"PreCheck Health Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kairos Pharma \/ PreCheck Health Services","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ PreCheck Health Services"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Bilthoven Biologicals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Bilthoven Biologicals","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Bilthoven Biologicals"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"RSBT-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RS BioTherapeutics \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"DengueTcP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DEKA Research & Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"DEKA Research & Development \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"6","companyTruncated":"DEKA Research & Development \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"BioMap","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"BioMap","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioMap \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"BioMap \/ Sanofi"},{"orgOrder":0,"company":"Sanegene Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"SGB-3908","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Sanegene Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanegene Bio \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Sanegene Bio \/ Innovent Biologics"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"VRG50635","moa":"PIKFYVE","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Ferrer Internacional"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Df1001","moa":"||Mesothelin protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eurofins Discovery \/ Dompe Farmaceutici","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins Discovery \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"SAKK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Collaboration","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ SAKK","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ SAKK"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Effector Therapeutics \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"WARF Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"177-Lu ART-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SHINE Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHINE Technologies \/ WARF Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SHINE Technologies \/ WARF Therapeutics"},{"orgOrder":0,"company":"BostonGene","sponsor":"The Weinstock Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Duvelisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"BostonGene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BostonGene \/ The Weinstock Laboratory","highestDevelopmentStatusID":"8","companyTruncated":"BostonGene \/ The Weinstock Laboratory"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion Channel","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Metrion Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metrion Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"3","companyTruncated":"Metrion Biosciences \/ Sosei Heptares"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic International, Inc \/ Undisclosed"},{"orgOrder":0,"company":"UMass Medical School","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"UMass Medical School","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"UMass Medical School \/ Johns Hopkins University","highestDevelopmentStatusID":"8","companyTruncated":"UMass Medical School \/ Johns Hopkins University"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Stem Pharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Verge Genomics \/ Stem Pharm","highestDevelopmentStatusID":"2","companyTruncated":"Verge Genomics \/ Stem Pharm"},{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Wyss Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EnPlusOne Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnPlusOne Biosciences \/ Wyss Institute","highestDevelopmentStatusID":"3","companyTruncated":"EnPlusOne Biosciences \/ Wyss Institute"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Cyclin","graph1":"Oncology","graph2":"Preclinical","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Circle Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Circle Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"HypoSpray Pharma","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"HypoSpray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HypoSpray Pharma \/ Nascent Biotech","highestDevelopmentStatusID":"6","companyTruncated":"HypoSpray Pharma \/ Nascent Biotech"},{"orgOrder":0,"company":"MOMA Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MOMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MOMA Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"MOMA Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Evommune","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evommune \/ Maruho","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/ Maruho"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Obexelimab","moa":"CD19\/Fc\u03b3RIIb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Ziftomenib","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"FibroBiologics","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CYWC628","moa":"Undisclosed","graph1":"Podiatry","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ FibroBiologics","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ FibroBiologics"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"CX-801","moa":"||IFN-alpha-2b","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"CytomX Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Gladstone Institutes","sponsor":"InvisiShield","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"IS101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gladstone Institutes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Gladstone Institutes \/ InvisiShield","highestDevelopmentStatusID":"4","companyTruncated":"Gladstone Institutes \/ InvisiShield"},{"orgOrder":0,"company":"Celanese","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Celanese","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Celanese \/ Secarna Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Celanese \/ Secarna Pharma"},{"orgOrder":0,"company":"SpineThera","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"SpineThera \/ Mayo Clinic","highestDevelopmentStatusID":"1","companyTruncated":"SpineThera \/ Mayo Clinic"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Emory University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"TFF Pharmaceuticals \/ Emory University","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Emory University"},{"orgOrder":0,"company":"Inimmune","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inimmune \/ Boston Children's Hospital","highestDevelopmentStatusID":"2","companyTruncated":"Inimmune \/ Boston Children's Hospital"},{"orgOrder":0,"company":"BPGbio","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BPGbio \/ University of Oxford","highestDevelopmentStatusID":"3","companyTruncated":"BPGbio \/ University of Oxford"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skyhawk Therapeutics \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Skyhawk Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Collaboration","leadProduct":"Darolutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Thermo Fisher Scientific \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Bayer AG"},{"orgOrder":0,"company":"Vincere Biosciences","sponsor":"Hanall Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Vincere Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vincere Biosciences \/ Hanall Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Vincere Biosciences \/ Hanall Biopharma"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"HMNC Brain Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ HMNC Brain Health","highestDevelopmentStatusID":"6","companyTruncated":"Spruce Biosciences \/ HMNC Brain Health"},{"orgOrder":0,"company":"Jura Bio","sponsor":"Replay Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Jura Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jura Bio \/ Replay Bio","highestDevelopmentStatusID":"3","companyTruncated":"Jura Bio \/ Replay Bio"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alloy Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Breye Therapeutics","sponsor":"Golgi Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Breye Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Breye Therapeutics \/ Golgi Neurosciences","highestDevelopmentStatusID":"4","companyTruncated":"Breye Therapeutics \/ Golgi Neurosciences"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Merck Group","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seed Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Seed Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BigHat Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Surrozen","sponsor":"TCGFB","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Surrozen \/ TCGFB","highestDevelopmentStatusID":"2","companyTruncated":"Surrozen \/ TCGFB"},{"orgOrder":0,"company":"Acrobat Genomics","sponsor":"Stanford Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"Acrobat Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acrobat Genomics \/ Stanford Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Acrobat Genomics \/ Stanford Medicine"},{"orgOrder":0,"company":"TRIANA Biomedicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TRIANA Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRIANA Biomedicines \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"TRIANA Biomedicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Flare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orionis Biosciences \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Biosciences \/ Genentech"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"MZ Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Tetrahydrocannabinol Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ MZ Group","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ MZ Group"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Metsera","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"MET-097","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Metsera","highestDevelopmentStatusID":"6","companyTruncated":"Amneal Pharmaceuticals \/ Metsera"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Casdatifan","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arcus Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"ANK-101","moa":"||Cytokine","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenzo Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Avenzo Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||IL-18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Simcha Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Northwestern University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Tomivosertib","moa":"MAPK 1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Effector Therapeutics \/ Northwestern University"},{"orgOrder":0,"company":"Exelixis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Exelixis \/ Merck & Co"},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Azercabtagene Zapreleucel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoImmuneTech \/ Imugene","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ Imugene"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"INO-3112","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coherus Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Coherus Biosciences"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Leukemia & Lymphoma Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Ziftomenib","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Leukemia & Lymphoma Society","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Leukemia & Lymphoma Society"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Seagen"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Mayo Clinic"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Cancer Science Institute of Singapore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"225-Ac","moa":"||uPAR","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Cancer Science Institute of Singapore","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Cancer Science Institute of Singapore"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ReAlta Life Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"IND Enabling","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"ALX Oncology \/ Sanofi"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Adagrasib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EvolveImmune Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"3","companyTruncated":"EvolveImmune Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"UbiVac","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BMS-986178","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"UbiVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UbiVac \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"UbiVac \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Personalis","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Personalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Personalis \/ Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Personalis \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"CTMC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"KSQ-001EX","moa":"SOCS1 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KSQ Therapeutics \/ CTMC","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ CTMC"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"ElevateBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcell Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xcell Biosciences \/ ElevateBio","highestDevelopmentStatusID":"3","companyTruncated":"Xcell Biosciences \/ ElevateBio"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Lipella Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Urology","graph2":"Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Cook MyoSite \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cook MyoSite \/ Lipella Pharmaceuticals"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"UPMC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaLogic \/ UPMC","highestDevelopmentStatusID":"2","companyTruncated":"PharmaLogic \/ UPMC"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avidity Biosciences \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Avidity Biosciences \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"IDE161","moa":"||PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Sonata Therapeutics","sponsor":"Champalimaud Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"SNT-3012","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sonata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonata Therapeutics \/ Champalimaud Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Sonata Therapeutics \/ Champalimaud Foundation"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ABBV-303","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dragonfly Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"FibroGen","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Cemiplimab","moa":"||Galectin-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Anew Medical","sponsor":"Japan\u2019s Okinawa Research Center","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Anew Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anew Medical \/ Japan\u2019s Okinawa Research Center","highestDevelopmentStatusID":"4","companyTruncated":"Anew Medical \/ Japan\u2019s Okinawa Research Center"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Editas Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Rutgers Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Doxorubicin Hydrochloride","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"Haystack Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haystack Oncology \/ Rutgers Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Haystack Oncology \/ Rutgers Cancer Institute"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ University of Florida"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"AmplifyBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Xcell Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xcell Biosciences \/ AmplifyBio","highestDevelopmentStatusID":"4","companyTruncated":"Xcell Biosciences \/ AmplifyBio"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"PaxMedica","sponsor":"PoloMar Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Collaboration","leadProduct":"Emodin","moa":"P2X7 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PaxMedica \/ PoloMar Health","highestDevelopmentStatusID":"4","companyTruncated":"PaxMedica \/ PoloMar Health"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Biogen","highestDevelopmentStatusID":"2","companyTruncated":"C4 Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Rational Vaccines","sponsor":"Shenzhen Mellow Hope Pharm Industrial","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"RVx-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Rational Vaccines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rational Vaccines \/ Shenzhen Mellow Hope Pharm Industrial","highestDevelopmentStatusID":"5","companyTruncated":"Rational Vaccines \/ Shenzhen Mellow Hope Pharm Industrial"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Celmatix","sponsor":"Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celmatix \/ Ache Laboratorios Farmaceuticos SA","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Ache Laboratorios Farmaceuticos SA"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Primula Group","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"WAL0921","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Walden Biosciences \/ Primula Group","highestDevelopmentStatusID":"8","companyTruncated":"Walden Biosciences \/ Primula Group"},{"orgOrder":0,"company":"Tempus","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ JW Pharmaceutical Corporation"},{"orgOrder":0,"company":"Neomorph","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Neomorph","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neomorph \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ Biogen"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Boostimmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Boostimmune","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Boostimmune"},{"orgOrder":0,"company":"OmniaBio","sponsor":"Somite Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"SMT-M01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"OmniaBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OmniaBio \/ Somite Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"OmniaBio \/ Somite Therapeutics"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"RenovoRx \/ Imugene","highestDevelopmentStatusID":"3","companyTruncated":"RenovoRx \/ Imugene"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Chance Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Chance Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Chance Pharmaceuticals"},{"orgOrder":0,"company":"Genentech","sponsor":"NVIDIA","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genentech \/ NVIDIA","highestDevelopmentStatusID":"3","companyTruncated":"Genentech \/ NVIDIA"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Replimune","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Collaboration","leadProduct":"INCB99280","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Incyte Corporation"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Exosome-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capricor Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Capricor Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Houston Methodist Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Houston Methodist Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Houston Methodist Research Institute"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Repare Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Foundation Medicine \/ Repare Therapeutics"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"VS-7375","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CLD-400","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Calidi Biotherapeutics \/ SIGA Technologies"},{"orgOrder":0,"company":"Cartography Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cartography Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cartography Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Cartography Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Lonza Group","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Lonza Group"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"ANK-101","moa":"||Cytokine","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ankyra Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"D-Wave Quantum","sponsor":"Japan Tobacco","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"D-Wave Quantum","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"D-Wave Quantum \/ Japan Tobacco","highestDevelopmentStatusID":"3","companyTruncated":"D-Wave Quantum \/ Japan Tobacco"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"University College London","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Ampakine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ University College London","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ University College London"},{"orgOrder":0,"company":"Cellarity","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Cellarity","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellarity \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Cellarity \/ Novo Nordisk"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Vaccine and Immunotherapy Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Prophylactic Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Vaccine and Immunotherapy Center","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic International, Inc \/ Vaccine and Immunotherapy Center"},{"orgOrder":0,"company":"Normunity","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Normunity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Normunity \/ Alloy Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Normunity \/ Alloy Therapeutics"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BridGene Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridGene Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"BridGene Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"HB-700","moa":"KRAS G12D","graph1":"Oncology","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupus Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Lupus Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Rznomics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"SK Pharmteco","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SK Pharmteco \/ Rznomics","highestDevelopmentStatusID":"2","companyTruncated":"SK Pharmteco \/ Rznomics"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Korro Bio \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Korro Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Vyant Bio","sponsor":"OrganoTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Vyant Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vyant Bio \/ OrganoTherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Vyant Bio \/ OrganoTherapeutics"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lumen Bioscience \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bioscience \/ Novo Nordisk"},{"orgOrder":0,"company":"Abilita Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Abilita Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abilita Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Abilita Therapeutics \/ Orion Corporation"},{"orgOrder":0,"company":"AbSci","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbSci \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ AstraZeneca"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"CAMP4 Therapeutics \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Function Oncology","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"VLS-1488","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Function Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Function Oncology \/ Volastra Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Function Oncology \/ Volastra Therapeutics"},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immetas Therapeutics \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Therapeutics \/ GC Biopharma"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intellia Therapeutics \/ ReCode Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Intellia Therapeutics \/ ReCode Therapeutics"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BigHat Biosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Biosciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Neochromosome","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Neochromosome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neochromosome \/ Sumitovant Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Neochromosome \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Nexilico","sponsor":"Siolta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Nexilico","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexilico \/ Siolta Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nexilico \/ Siolta Therapeutics"},{"orgOrder":0,"company":"Biosplice","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Biosplice \/ Novo Nordisk"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"eOD-GT8 60mer","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ IAVI","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Therapeutics \/ IAVI"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Catalent Pharma Solutions \/ GSK"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"BMS-986288","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Fortis Therapeutics","sponsor":"FibroGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"FOR46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fortis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortis Therapeutics \/ FibroGen","highestDevelopmentStatusID":"7","companyTruncated":"Fortis Therapeutics \/ FibroGen"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Myotonic Dystrophy Clinical Research Network","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2020","type":"Collaboration","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Myotonic Dystrophy Clinical Research Network","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Myotonic Dystrophy Clinical Research Network"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"Preclinical","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johns Hopkins University \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Johns Hopkins University \/ Lantern Pharma"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Preclinical","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Georgetown University \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Georgetown University \/ Lantern Pharma"},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Expanded Collaboration","leadProduct":"TG4050","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"BostonGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BostonGene \/ Transgene","highestDevelopmentStatusID":"6","companyTruncated":"BostonGene \/ Transgene"},{"orgOrder":0,"company":"Elektrofi","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elektrofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Elektrofi \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"4","companyTruncated":"Elektrofi \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Oranomed","sponsor":"Molecular Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"MP0712","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Molecular Partners","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Molecular Partners"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Oregon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"XCE853","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lantern Pharma \/ Oregon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Oregon Therapeutics"},{"orgOrder":0,"company":"Metaba","sponsor":"MAX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Oxysterol","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Metaba","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metaba \/ MAX BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Metaba \/ MAX BioPharma"},{"orgOrder":0,"company":"Oranomed","sponsor":"Crescendo Biologics Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oranomed \/ Crescendo Biologics Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Oranomed \/ Crescendo Biologics Ltd"},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"LifeArc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Potassium ion channel","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Metrion Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metrion Biosciences \/ LifeArc","highestDevelopmentStatusID":"3","companyTruncated":"Metrion Biosciences \/ LifeArc"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Flare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caris Life Sciences \/ Flare Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Caris Life Sciences \/ Flare Therapeutics"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxinity \/ University of Florida"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Elanco","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"KIND-030","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kindred Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kindred Biosciences \/ Elanco","highestDevelopmentStatusID":"10","companyTruncated":"Kindred Biosciences \/ Elanco"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Schrodinger","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CBL-B","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Schrodinger","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Schrodinger"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"ATA2271","moa":"||Mesothelin protein","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrapleural Injection","sponsorNew":"Atara Biotherapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Drug Innovation Ventures at Emory","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ALT-2023","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altesa Biosciences \/ Drug Innovation Ventures at Emory","highestDevelopmentStatusID":"5","companyTruncated":"Altesa Biosciences \/ Drug Innovation Ventures at Emory"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"BRM","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Loxo Oncology Inc","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Therapeutics \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AB-MK-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Artiva Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron Pharmaceuticals \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"NexImmune","sponsor":"The Laura and Isaac Perlmutter Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NexImmune \/ The Laura and Isaac Perlmutter Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune \/ The Laura and Isaac Perlmutter Cancer Center"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Integra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ Integra Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ Integra Therapeutics"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Verastem Oncology \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Gatehouse Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"GHB-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Gatehouse Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gatehouse Bio \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Gatehouse Bio \/ AstraZeneca"},{"orgOrder":0,"company":"Natera","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Natera \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kineta \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Merck & Co"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"ALN-APP","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Cerveau Technologies \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"BPGbio","sponsor":"Debra of America","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Partnership","leadProduct":"Ubidecarenone","moa":"LDL-cholesterol oxidation","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BPGbio \/ Debra of America","highestDevelopmentStatusID":"6","companyTruncated":"BPGbio \/ Debra of America"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Preclinical","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Johns Hopkins University","highestDevelopmentStatusID":"4","companyTruncated":"Panbela Therapeutics \/ Johns Hopkins University"},{"orgOrder":0,"company":"Johns Hopkins University School of Medicine","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ivospemin","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Undisclosed","graph3":"Johns Hopkins University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johns Hopkins University School of Medicine \/ Panbela Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University School of Medicine \/ Panbela Therapeutics"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytomX Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"CytomX Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytomX Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"CytomX Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Grunenthal","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Grunenthal"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Neomorph","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Neomorph","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neomorph \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ Novo Nordisk"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Umoja Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Umoja Biopharma"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omega Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Omega Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prellis Biologics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Sanofi"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prellis Biologics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SSTR2","graph1":"Oncology","graph2":"Preclinical","graph3":"Ratio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ratio Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Ratio Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Selecta Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Skyhawk Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Skyhawk Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Tempus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ BioNTech"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"iADCs","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sutro Biopharma \/ Astellas Pharma"},{"orgOrder":0,"company":"M2Gen","sponsor":"Zephyr AI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"M2Gen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"M2Gen \/ Zephyr AI","highestDevelopmentStatusID":"2","companyTruncated":"M2Gen \/ Zephyr AI"},{"orgOrder":0,"company":"Vivera Pharmaceuticals","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"VVRA\u2013TM 008","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Vivera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Vivera Pharmaceuticals \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Vivera Pharmaceuticals \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Expert Systems","sponsor":"Polku Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Expert Systems \/ Polku Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Expert Systems \/ Polku Therapeutics"},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Louisville","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"INB-400","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ University of Louisville","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ University of Louisville"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Royalty Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"Bristol Myers Squibb \/ Evotec"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"||H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Predicine","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Predicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Predicine \/ Apollomics Inc","highestDevelopmentStatusID":"8","companyTruncated":"Predicine \/ Apollomics Inc"},{"orgOrder":0,"company":"Cove","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cove","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cove \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cove \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Tempus","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AeroRx Therapeutics","sponsor":"HCmed Innovations","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"AeroRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AeroRx Therapeutics \/ HCmed Innovations","highestDevelopmentStatusID":"1","companyTruncated":"AeroRx Therapeutics \/ HCmed Innovations"},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CyclinE1\/CDK2","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cedilla Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Halia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Biolexis Therapeutics \/ Halia Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Biolexis Therapeutics \/ Halia Therapeutics"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"2","companyTruncated":"Dyadic International, Inc \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Navega Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"NT-Z001","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Navega Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Charles River Laboratories, Inc \/ Navega Therapeutics"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"NX-0479","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AbSci","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbSci \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"MegaTAL mRNA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"2Seventy Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Canary Speech","sponsor":"Halia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"HT-4253","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Canary Speech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canary Speech \/ Halia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Canary Speech \/ Halia Therapeutics"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Cancer Research Horizons","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Glutaminase","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ Cancer Research Horizons","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ Cancer Research Horizons"},{"orgOrder":0,"company":"GNS healthcare","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"GNS healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GNS healthcare \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"GNS healthcare \/ Servier"},{"orgOrder":0,"company":"Sable Therapeutics","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SBL-001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Sable Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sable Therapeutics \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Sable Therapeutics \/ Columbia University"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"GV101","moa":"ROCK2","graph1":"Neurology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Graviton Bioscience \/ Ovid Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Ovid Therapeutics"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Graphite Bio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LENZ Therapeutics \/ Graphite Bio","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Graphite Bio"},{"orgOrder":0,"company":"Alaya.bio","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Alaya.bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alaya.bio \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alaya.bio \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Stanford Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Zotatifin","moa":"||eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Effector Therapeutics \/ Stanford Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Stanford Medicine"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Providence Therapeutics \/ University Health Network","highestDevelopmentStatusID":"2","companyTruncated":"Providence Therapeutics \/ University Health Network"},{"orgOrder":0,"company":"Arzeda","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Arzeda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arzeda \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Arzeda \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Outpace Bio","sponsor":"Century Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Outpace Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Outpace Bio \/ Century Therapeutic","highestDevelopmentStatusID":"3","companyTruncated":"Outpace Bio \/ Century Therapeutic"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"InSilicoTrials","sponsor":"Achilles Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"InSilicoTrials","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSilicoTrials \/ Achilles Vaccines","highestDevelopmentStatusID":"2","companyTruncated":"InSilicoTrials \/ Achilles Vaccines"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Sinovac Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Sinovac Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Sinovac Biotech"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Metagenomi \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Generation Bio \/ Moderna Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Generation Bio \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Rondo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Rondo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rondo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Rondo Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Aitia","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Aitia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aitia \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"Aitia \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adaptive Biotechnologies \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Biotechnologies \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genesis Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Vivtex","sponsor":"Orbis Medicines","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"nCycles","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Vivtex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivtex \/ Orbis Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Vivtex \/ Orbis Medicines"},{"orgOrder":0,"company":"eGenesis","sponsor":"University of Miami","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"HuCo Islet Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eGenesis \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/ University of Miami"},{"orgOrder":0,"company":"Disc medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lyvgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"LVGN6051","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Lyvgen","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Lyvgen"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cellular Biomedicine Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"C-TIL051","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Cellular Biomedicine Group","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Cellular Biomedicine Group"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Alpine Immune Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Alpine Immune Sciences"},{"orgOrder":0,"company":"SomaLogic","sponsor":"Ixaka","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SomaLogic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SomaLogic \/ Ixaka","highestDevelopmentStatusID":"4","companyTruncated":"SomaLogic \/ Ixaka"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Surface Oncology"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BI 1701963","moa":"pan-KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ IASO Bio","highestDevelopmentStatusID":"3","companyTruncated":"Umoja Biopharma \/ IASO Bio"},{"orgOrder":0,"company":"SyntheX","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SyntheX","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SyntheX \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"SyntheX \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"OliPass","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"mRNA","graph1":"Technology","graph2":"Preclinical","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ OliPass","highestDevelopmentStatusID":"4","companyTruncated":"Vanda Pharmaceuticals \/ OliPass"},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Serotype A Botulinum Toxin","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Healis Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Healis Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ Lantern Pharma","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ Lantern Pharma"},{"orgOrder":0,"company":"VantAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VantAI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Lung Cancer Initiative","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ankyra Therapeutics \/ Lung Cancer Initiative","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra Therapeutics \/ Lung Cancer Initiative"},{"orgOrder":0,"company":"Lacerta Therapeutics","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Lacerta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lacerta Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Lacerta Therapeutics \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Georgetown University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"SP-2-225","moa":"HDAC6","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Georgetown University","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Georgetown University"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Highlight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"BO-112","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Merck & Co \/ Highlight Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Highlight Therapeutics"},{"orgOrder":0,"company":"Lindy Biosciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Lindy Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lineage Cell Therapeutics \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Cell Therapeutics \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Biologics Inc \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Precisio Biotix Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precisio Biotix Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precisio Biotix Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"1","companyTruncated":"Precisio Biotix Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"University of Illinois","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Illinois","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Illinois \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Illinois \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Pearl Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Pearl Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pearl Bio \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Pearl Bio \/ Merck & Co"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Phlox Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solid Biosciences \/ Phlox Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Solid Biosciences \/ Phlox Therapeutics"},{"orgOrder":0,"company":"DeepCure","sponsor":"LIRMM","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"DC-9476","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"DeepCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DeepCure \/ LIRMM","highestDevelopmentStatusID":"4","companyTruncated":"DeepCure \/ LIRMM"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Duke Clinical Research Institute \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clinical Research Institute \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Federation Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Federation Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Federation Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"GuardRX","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"INO-4201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ GuardRX","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ GuardRX"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Evommune","highestDevelopmentStatusID":"3","companyTruncated":"AccutarBio \/ Evommune"},{"orgOrder":0,"company":"Autonomous Therapeutics","sponsor":"MiNK Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"MiNK-215","moa":"FAP-expressing CAF","graph1":"Oncology","graph2":"Preclinical","graph3":"Autonomous Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autonomous Therapeutics \/ MiNK Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Autonomous Therapeutics \/ MiNK Therapeutics"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Belharra Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Belharra Therapeutics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Belharra Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolojic Design \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic Design \/ Merck Group"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Oncology","graph2":"Discovery","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"BioTheryX \/ Incyte Corporation"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Cure AP-4","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Cure AP-4","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Cure AP-4"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"EvolveImmune Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Genetic Leap","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Genetic Leap","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genetic Leap \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genetic Leap \/ Eli Lilly"},{"orgOrder":0,"company":"NeoGenomics","sponsor":"Massive Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"NeoGenomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeoGenomics \/ Massive Bio","highestDevelopmentStatusID":"2","companyTruncated":"NeoGenomics \/ Massive Bio"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ PharmaEssentia","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ PharmaEssentia"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phanes Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Phanes Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"PostEra","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"PostEra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PostEra \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"PostEra \/ Amgen Inc"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Nocion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"PUR1800","moa":"p38\/MAPK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Nocion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Nocion Therapeutics"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Shoreline Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shoreline Biosciences \/ Kite Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Shoreline Biosciences \/ Kite Pharma"},{"orgOrder":0,"company":"Simulations Plus","sponsor":"SACF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Simulations Plus","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Simulations Plus \/ SACF","highestDevelopmentStatusID":"2","companyTruncated":"Simulations Plus \/ SACF"},{"orgOrder":0,"company":"Valo Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valo Health \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Valo Health \/ Novo Nordisk"},{"orgOrder":0,"company":"Vyriad","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vyriad \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Vyriad \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"XtalPi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XtalPi \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ Eli Lilly"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Halozyme Therapeutics \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Tempus","sponsor":"Avacta Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"AVA6103","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempus \/ Avacta Group","highestDevelopmentStatusID":"5","companyTruncated":"Tempus \/ Avacta Group"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LifeMine Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ GSK"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"LIV-1","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"2","companyTruncated":"BlueSphere Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Lassen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Lassen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cedars-Sinai \/ Lassen Therapeutics"},{"orgOrder":0,"company":"KBio","sponsor":"Leaf Expression Systems","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"KBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"KBio \/ Leaf Expression Systems","highestDevelopmentStatusID":"4","companyTruncated":"KBio \/ Leaf Expression Systems"},{"orgOrder":0,"company":"Erasca","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Gene Encoded Antibody Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SmartPharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SmartPharm Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"SmartPharm Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"2","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytomX Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"CytomX Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Seagen","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Seagen \/ Sanofi"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Astressin B","moa":"CRF1\/2","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sentia Medical Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sentia Medical Science \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Sosei Group Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Sosei Group Corporation"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ORIC-944","moa":"Polycomb repressive complex 2","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Microsoft","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveda Bioscience \/ Microsoft","highestDevelopmentStatusID":"3","companyTruncated":"Enveda Bioscience \/ Microsoft"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ NiKang Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ NiKang Therapeutics"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Alvogen","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Alvogen"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ SAB Biotherapeutics"},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Affinivax \/ CEPI","highestDevelopmentStatusID":"2","companyTruncated":"Affinivax \/ CEPI"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MOLCURE Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ MOLCURE Inc","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ MOLCURE Inc"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antares Pharma \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Mammoth Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mammoth Biosciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Mammoth Biosciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Bacillus Calmette Guerin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ NantKwest"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"MEI Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Infinity Pharmaceuticals \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ MEI Pharma"},{"orgOrder":0,"company":"Oscine","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oscine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oscine \/ Sana Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Oscine \/ Sana Biotechnology"},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Custopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Custopharm \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Custopharm \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Custopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Custopharm \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Custopharm \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Aceragen","sponsor":"Idera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sodium Fusidate","moa":"||Bacterial protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aceragen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aceragen \/ Idera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/ Idera Pharmaceuticals"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"AZD5904","moa":"MPO","graph1":"Endocrinology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Crescent Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"CR-001","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoMimetics \/ Crescent Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"GlycoMimetics \/ Crescent Biopharma"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"GRI Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Vallon Pharmaceuticals \/ GRI Bio","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ GRI Bio"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"BiomX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Merger","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Adaptive Phage Therapeutics \/ BiomX","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ BiomX"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"BiomX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Merger","leadProduct":"BX004","moa":"P. aeruginosa biofilm Destabilizer","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Adaptive Phage Therapeutics \/ BiomX","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ BiomX"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K Alpha H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Q32 Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Merger","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Homology Medicines \/ Q32 Bio","highestDevelopmentStatusID":"8","companyTruncated":"Homology Medicines \/ Q32 Bio"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"CT-0508","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sesen Bio \/ Carisma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sesen Bio \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Q32 Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Merger","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Homology Medicines \/ Q32 Bio","highestDevelopmentStatusID":"8","companyTruncated":"Homology Medicines \/ Q32 Bio"},{"orgOrder":0,"company":"Morphimmune","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Morphimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphimmune \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Morphimmune \/ Immunome"},{"orgOrder":0,"company":"Morphimmune","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Morphimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphimmune \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Morphimmune \/ Immunome"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Applied Molecular Transport \/ Cyclo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Applied Molecular Transport \/ Cyclo Therapeutics"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Applied Molecular Transport \/ Cyclo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Applied Molecular Transport \/ Cyclo Therapeutics"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Dianthus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Merger","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Magenta Therapeutics \/ Dianthus Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Dianthus Therapeutics"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Angion Biomedica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Angion Biomedica","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Angion Biomedica"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Imara"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Imara"},{"orgOrder":0,"company":"Enable Injections","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Enable Injections","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enable Injections \/ Serina Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Enable Injections \/ Serina Therapeutics"},{"orgOrder":0,"company":"Silexion Therapeutics","sponsor":"Silexion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Merger","leadProduct":"SIL-204","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Silexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silexion Therapeutics \/ Silexion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Silexion Therapeutics \/ Silexion Therapeutics"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerovate Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Aerovate Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"CohBar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"TuHURA Biosciences \/ CohBar","highestDevelopmentStatusID":"6","companyTruncated":"TuHURA Biosciences \/ CohBar"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K Alpha H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Merger","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AgeX Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Serina Therapeutics"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tectonic Therapeutic \/ Avrobio","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Avrobio"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Talaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Merger","leadProduct":"TOUR006","moa":"IL-6 signalling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tourmaline Bio \/ Talaris Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Talaris Therapeutics"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Tourmaline Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Merger","leadProduct":"TOUR006","moa":"IL-6 signalling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Talaris Therapeutics \/ Tourmaline Bio","highestDevelopmentStatusID":"8","companyTruncated":"Talaris Therapeutics \/ Tourmaline Bio"},{"orgOrder":0,"company":"Graybug Vision Inc","sponsor":"CalciMedica","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Graybug Vision Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Graybug Vision Inc \/ CalciMedica","highestDevelopmentStatusID":"8","companyTruncated":"Graybug Vision Inc \/ CalciMedica"},{"orgOrder":0,"company":"CalciMedica","sponsor":"CalciMedica","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CalciMedica \/ CalciMedica","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ CalciMedica"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Fulvestrant","moa":"||PI3K Alpha H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K Alpha H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Cullgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"CG001419","moa":"TRK","graph1":"Oncology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pulmatrix \/ Cullgen","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Cullgen"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Angion Biomedica \/ Elicio Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Angion Biomedica \/ Elicio Therapeutics"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Merger","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Merger","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Semper Paratus Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Merger","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Semper Paratus Acquisition Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Semper Paratus Acquisition Corporation"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kalaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"TH103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ Kalaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"AlloVir \/ Kalaris Therapeutics"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Onconetix","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Onconetix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconetix \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Onconetix \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"BioPharmX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ BioPharmX","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ BioPharmX"},{"orgOrder":0,"company":"Peak Bio","sponsor":"Akari Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Peak Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peak Bio \/ Akari Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Peak Bio \/ Akari Therapeutics"},{"orgOrder":0,"company":"Peak Bio","sponsor":"Akari Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Peak Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peak Bio \/ Akari Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Peak Bio \/ Akari Therapeutics"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Merger","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AgeX Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Serina Therapeutics"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Proteostasis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Proteostasis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Proteostasis Therapeutics"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Beijing Continent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Hydronidone","moa":"TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gyre Therapeutics \/ Beijing Continent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gyre Therapeutics \/ Beijing Continent Pharmaceuticals"},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteostasis Therapeutics \/ Yumanity Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Proteostasis Therapeutics \/ Yumanity Therapeutics"},{"orgOrder":0,"company":"Entero Therapeutics","sponsor":"Journey Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"Nano-Immunoconjugate","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Entero Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entero Therapeutics \/ Journey Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Entero Therapeutics \/ Journey Therapeutics"},{"orgOrder":0,"company":"CervoMed","sponsor":"CervoMed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ CervoMed","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ CervoMed"},{"orgOrder":0,"company":"CervoMed","sponsor":"EIP Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ EIP Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ EIP Pharma"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Afamitresgene Autoleucel","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ TCR2 Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Adaptimmune Therapeutics \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"INVO Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Naya Biosciences \/ INVO Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Naya Biosciences \/ INVO Bioscience"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Enalapril Maleate","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Arbor Pharmaceuticals \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Arbor Pharmaceuticals \/ Azurity Pharma"},{"orgOrder":0,"company":"Avra","sponsor":"Springs Rejuvenation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Avra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avra \/ Springs Rejuvenation","highestDevelopmentStatusID":"1","companyTruncated":"Avra \/ Springs Rejuvenation"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Graphite Bio \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ LENZ Therapeutics"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Rabies Immune Globulin (Human)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kedrion \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"Kedrion \/ Kamada"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Biomm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Biomm","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Biomm"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"CAS","sponsor":"Molecule.one","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"CAS","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CAS \/ Molecule.one","highestDevelopmentStatusID":"2","companyTruncated":"CAS \/ Molecule.one"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"ViiV Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Halozyme Therapeutics \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ ViiV Healthcare"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Generation Bio \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Generation Bio \/ Vir Biotechnology"},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"||Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosciences \/ Selecta Biosciences"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lannett Company, Inc. \/ Cediprof","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Cediprof"},{"orgOrder":0,"company":"TetraLogic","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Remetinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"TetraLogic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TetraLogic \/ Medivir","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic \/ Medivir"},{"orgOrder":0,"company":"Adjuvance Technologies","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Terra CoV-2","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adjuvance Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adjuvance Technologies \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Adjuvance Technologies \/ Oragenics"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Minaris Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Minaris Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Minaris Regenerative Medicine"},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Enzolytics","sponsor":"BioClonetics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Merger","leadProduct":"ITV-1","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enzolytics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzolytics \/ BioClonetics","highestDevelopmentStatusID":"1","companyTruncated":"Enzolytics \/ BioClonetics"},{"orgOrder":0,"company":"Enzolytics","sponsor":"BioClonetics Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Merger","leadProduct":"ITV-1","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enzolytics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzolytics \/ BioClonetics Immunotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Enzolytics \/ BioClonetics Immunotherapeutics"},{"orgOrder":0,"company":"Insitro","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Insitro","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insitro \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Insitro \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Curia","sponsor":"BioSig Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Curia \/ BioSig Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Curia \/ BioSig Technologies"},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Ablexis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Berkeley Lights","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Berkeley Lights \/ Ablexis","highestDevelopmentStatusID":"4","companyTruncated":"Berkeley Lights \/ Ablexis"},{"orgOrder":0,"company":"Quotient Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Quotient Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Quotient Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Avectas Limited","sponsor":"Vycellix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"VY-M","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avectas Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avectas Limited \/ Vycellix","highestDevelopmentStatusID":"1","companyTruncated":"Avectas Limited \/ Vycellix"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Shape Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Shape Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Adaptive Biotechnologies \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"Adaptive Biotechnologies \/ Amgen Inc"},{"orgOrder":0,"company":"GenEdit","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GenEdit","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenEdit \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"GenEdit \/ Genentech"},{"orgOrder":0,"company":"Exelixis","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Arcus Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Arcus Biosciences"},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"OXS-3550","moa":"CD16","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cytovance Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Cytovance Biologics \/ GT Biopharma"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Talem Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Talem Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionis Pharmaceuticals \/ Chinook Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ionis Pharmaceuticals \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Neogene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Neogene","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Neogene"},{"orgOrder":0,"company":"Atreca","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Atreca \/ BeiGene","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ BeiGene"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Takara Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Plasmid Dna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Takara Bio","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biologics \/ Takara Bio"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Alnylam Pharmaceuticals \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Alnylam Pharmaceuticals \/ Vir Biotechnology"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Terray Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odyssey Therapeutics \/ Terray Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Odyssey Therapeutics \/ Terray Therapeutics"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SGN Nanopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Eyenovia \/ SGN Nanopharma","highestDevelopmentStatusID":"1","companyTruncated":"Eyenovia \/ SGN Nanopharma"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Pierre Fabre"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ WestPark Capital","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ WestPark Capital"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ TD Cowen"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Palbociclib","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Lisata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pasithea Therapeutics \/ EF Hutton","highestDevelopmentStatusID":"1","companyTruncated":"Pasithea Therapeutics \/ EF Hutton"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Athenex","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Financing","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Citigroup"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Financing","leadProduct":"SBT-272","moa":"TDP-43","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Morningside Venture","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Morningside Venture"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"5am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ 5am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ 5am Ventures"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cannabidiol","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tetrahydrocannabinol Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Kingswood Investments"},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"AE-Keto-Sulf07","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"LadRx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"5","companyTruncated":"LadRx \/ XOMA"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"ARTIS Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"DLX-1","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ ARTIS Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ ARTIS Ventures"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Termination","leadProduct":"RX-5902","moa":"Phosphorylated-p68","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Rexahn Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Rexahn Pharmaceuticals Inc"},{"orgOrder":0,"company":"Novavax","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Sanofi","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Sanofi"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Public Offering","leadProduct":"ALG-010133","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Evolution Research Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Evolution Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Evolution Research Group"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Dechra Pharmaceuticals Manufacturing","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"5-HT2C receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Kindred Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing","highestDevelopmentStatusID":"15","companyTruncated":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"ViralClear Pharmaceuticals","sponsor":"NeuroClear","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Merimepodib","moa":"IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ViralClear Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ViralClear Pharmaceuticals \/ NeuroClear","highestDevelopmentStatusID":"1","companyTruncated":"ViralClear Pharmaceuticals \/ NeuroClear"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Roth Capital Partners"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ J.P. Morgan"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Titan Partners Group LLC","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Bridgewest Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Curcumin","moa":"||STAT3\/NF-kB\/poly-tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immix Biopharma \/ Bridgewest Group","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Bridgewest Group"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Aflibercept","moa":"||VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"CervoMed","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ RA Capital Management"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Avoro Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Avoro Capital","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Avoro Capital"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"IMU-935","moa":"ROR-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Citizens JMP","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ Citizens JMP"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Viscogliosi Bros.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Viscogliosi Bros.","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Viscogliosi Bros."},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Brooklyn ImmunoTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Brooklyn ImmunoTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Access Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Access Biotechnology"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"VectorBuilder","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorBuilder \/ Legend Capital","highestDevelopmentStatusID":"1","companyTruncated":"VectorBuilder \/ Legend Capital"},{"orgOrder":0,"company":"BioCardia","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Alliance Global Partners"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Aditxt","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aditxt \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Bevacizumab","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ BofA Securities"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BX1000","moa":"nAchR","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Undisclosed"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Chardan Capital Markets"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"Tharimmune","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Tharimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Tharimmune \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Tharimmune \/ Thinkequity"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Chardan Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Chardan Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Chardan Healthcare"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ The Benchmark Company","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ The Benchmark Company"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"B. Dyson Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ B. Dyson Capital Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ B. Dyson Capital Advisors"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcturus Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"1","companyTruncated":"Arcturus Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cartesian Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Thinkequity"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Enzastaurin","moa":"PKC-beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aytu BioPharma \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPharma \/ Canaccord Genuity"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ WestPark Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ WestPark Capital"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"JanOne","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Alliance Global Partners"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ WestPark Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ WestPark Capital"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Structure Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"BioVie","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Public Offering","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ ThinkEquity"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Defactinib","moa":"||Focal adhesion kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ RA Capital","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ RA Capital"},{"orgOrder":0,"company":"Aravive","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Aravive","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Thinkequity"},{"orgOrder":0,"company":"Oragenics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Thinkequity"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Private Placement","leadProduct":"BWV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Private Placement","leadProduct":"BWV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Private Placement","leadProduct":"BWV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ BVF Partners LP","highestDevelopmentStatusID":"15","companyTruncated":"Tenax Therapeutics \/ BVF Partners LP"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoPrecise \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoPrecise \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Armistice Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Armistice Capital","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ Armistice Capital"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ JMP Securities"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Alexander Capital L.P.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Alexander Capital L.P.","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Alexander Capital L.P."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"ROR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Anixa Biosciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BX1000","moa":"nAchR","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Cocrystal Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Roth Capital Partners"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ SVB Securities"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Fairmount Funds Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"SPY001","moa":"Alpha 4 beta 7","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeglea BioTherapeutics \/ Fairmount Funds Management","highestDevelopmentStatusID":"4","companyTruncated":"Aeglea BioTherapeutics \/ Fairmount Funds Management"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Nephrology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cadrenal Therapeutics \/ Boustead Securities","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Boustead Securities"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Global Health Investment Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Revelation Biosciences \/ Global Health Investment Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Global Health Investment Advisors"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Revelation Biosciences \/ National Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ National Securities Corporation"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ National Securities Corporation"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Ivospemin","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Phase II","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Panbela Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeterna Zentaris \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Aeterna Zentaris \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Wilmington Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Grifola Frondosa Maitake Mushroom Extract","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABVC BioPharma \/ Wilmington Capital Securities","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ Wilmington Capital Securities"},{"orgOrder":0,"company":"Equillium","sponsor":"Decheng Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Decheng Capital","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Decheng Capital"},{"orgOrder":0,"company":"PaxMedica","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"AlloVir","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ J.P. Morgan"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Jefferies"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Public Offering","leadProduct":"Pelareorep","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Leede Jones Gable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Leede Jones Gable"},{"orgOrder":0,"company":"Tome Biosciences","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Tome Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tome Biosciences \/ Andreessen Horowitz","highestDevelopmentStatusID":"2","companyTruncated":"Tome Biosciences \/ Andreessen Horowitz"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Citigroup","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Citigroup"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Boustead Securities","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Alliance Global Partners","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Alliance Global Partners"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Soligenix","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Alliance Global Partners"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Private Placement","leadProduct":"EDP2939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Flagship Pioneering"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Guangrun Health Industry","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"AR882","moa":"URAT1","graph1":"Rheumatology","graph2":"Phase II","graph3":"Arthrosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"Arthrosi Therapeutics \/ Guangrun Health Industry","highestDevelopmentStatusID":"8","companyTruncated":"Arthrosi Therapeutics \/ Guangrun Health Industry"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Thinkequity"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Thinkequity"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Alliance Global Partners"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Sternaegis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Sternaegis Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Sternaegis Ventures"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Morgan Stanley"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"||HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Undisclosed"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Financing","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ White Lion Capital","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ White Lion Capital"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"NRx Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"PRT3789","moa":"SMARCA2","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Tenax Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Financing","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ JMP Securities"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ JMP Securities"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Vurolenatide","moa":"GLP-1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Vurolenatide","moa":"GLP-1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ JMP Securities"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Titan Partners Group"},{"orgOrder":0,"company":"Genelux","sponsor":"Woodward Diversified Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ Woodward Diversified Capital","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Woodward Diversified Capital"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Thinkequity"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"Replimune","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase III","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ Redmile Group","highestDevelopmentStatusID":"10","companyTruncated":"Replimune \/ Redmile Group"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evoq Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Private Placement","leadProduct":"Atezolizumab","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Soleus Capital","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Soleus Capital"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Jefferies"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Jefferies"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Maxim Group","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Maxim Group"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"European Health Authorities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ European Health Authorities","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ European Health Authorities"},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series D Financing","leadProduct":"Encapsulated Pancreatic Islet Precursor Cell","moa":"Insulin secretion","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"ViaCyte Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"ViaCyte Inc \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"ViaCyte Inc \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Q-State Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Q-State Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q-State Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Q-State Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ BofA Securities"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"P-BCMA-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poseida Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Divestment","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Theravance Biopharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Theravance Biopharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series C Financing","leadProduct":"Obexelimab","moa":"CD19\/Fc\u03b3RIIb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ SR One","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ SR One"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Novit LP","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Novit LP","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Novit LP"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Kyttaro","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"LY3561774","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Kyttaro","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Kyttaro"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"AB-101","moa":"||ADCC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ 5AM Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ 5AM Ventures"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"FT576","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Lynx1 Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Sodium Valproate","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Lynx1 Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ Lynx1 Capital Management"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Capstan Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entrada Therapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"CorMedix","sponsor":"Suntrust Robinson Humphrey","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Suntrust Robinson Humphrey","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Suntrust Robinson Humphrey"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Bone Biologics","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"NELL1","moa":"IL-6 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Biologics \/ WallachBeth Capital","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biologics \/ WallachBeth Capital"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Nan Fung Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"ENX-101","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engrail Therapeutics \/ Nan Fung Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Therapeutics \/ Nan Fung Life Sciences"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series A Financing","leadProduct":"TAC-001","moa":"TLR9\/CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Tallac Therapeutics \/ venBio Partners","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ venBio Partners"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Longwood Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Be Biopharma \/ Longwood Fund","highestDevelopmentStatusID":"1","companyTruncated":"Be Biopharma \/ Longwood Fund"},{"orgOrder":0,"company":"INmune Bio","sponsor":"LifeSci Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ LifeSci Capital","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ LifeSci Capital"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jefferies LLC"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Healthwell Acquisition Corp. I","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Healthwell Acquisition Corp. I","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Healthwell Acquisition Corp. I"},{"orgOrder":0,"company":"VitriVax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VitriVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VitriVax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"VitriVax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Selah Therapeutics","sponsor":"Juvenescence","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Selah Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Selah Therapeutics \/ Juvenescence","highestDevelopmentStatusID":"1","companyTruncated":"Selah Therapeutics \/ Juvenescence"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Dawson James Securities","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Dawson James Securities"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Biological E","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Baylor College of Medicine \/ Biological E","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Biological E"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Anson Funds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Anson Funds","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Anson Funds"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Titan Partners Group LLC","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"KRAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"4","companyTruncated":"Quanta Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Verve Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Drive Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forge Biologics \/ Drive Capital","highestDevelopmentStatusID":"1","companyTruncated":"Forge Biologics \/ Drive Capital"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tango Therapeutics \/ Casdin Capital"},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"Alta Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kelonia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kelonia Therapeutics \/ Alta Partners","highestDevelopmentStatusID":"1","companyTruncated":"Kelonia Therapeutics \/ Alta Partners"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series D Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Inhalon Biopharma","sponsor":"USAMRDC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"Regdanvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inhalon Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inhalon Biopharma \/ USAMRDC","highestDevelopmentStatusID":"6","companyTruncated":"Inhalon Biopharma \/ USAMRDC"},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"TRPML1","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Caraway Therapeutics \/ The Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Therapeutics \/ The Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Public Offering","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Stifel","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Stifel"},{"orgOrder":0,"company":"Fzata","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Series A Financing","leadProduct":"FZ002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Fzata","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fzata \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fzata \/ Undisclosed"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ MBX Capital"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ J.P. Morgan"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"G-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"RNAimmune","sponsor":"Terra Magnum Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"RV-1730","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RNAimmune \/ Terra Magnum Capital Partners","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune \/ Terra Magnum Capital Partners"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Nan Fung Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"ENX-101","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engrail Therapeutics \/ Nan Fung Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Therapeutics \/ Nan Fung Life Sciences"},{"orgOrder":0,"company":"Humacyte","sponsor":"EF Hutton LLC","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ EF Hutton LLC","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ EF Hutton LLC"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD8 Treg cell","graph1":"Immunology","graph2":"Discovery","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Mozart Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"AL003","moa":"CD33","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ AbbVie Inc"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Rev1 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"DTRI-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basking Biosciences \/ Rev1 Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Basking Biosciences \/ Rev1 Ventures"},{"orgOrder":0,"company":"Twelve Bio","sponsor":"Ensoma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twelve Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twelve Bio \/ Ensoma","highestDevelopmentStatusID":"3","companyTruncated":"Twelve Bio \/ Ensoma"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Series A Financing","leadProduct":"ENS-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Concerto Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concerto Biosciences \/ Safar Partners","highestDevelopmentStatusID":"2","companyTruncated":"Concerto Biosciences \/ Safar Partners"},{"orgOrder":0,"company":"Elastrin Therapeutics","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Financing","leadProduct":"ELT-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elastrin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elastrin Therapeutics \/ Kizoo Technology Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elastrin Therapeutics \/ Kizoo Technology Capital"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Adenomed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Adenomed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Adenomed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Kingswood Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Kingswood Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Kingswood Capital Markets"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"RAF","graph1":"Oncology","graph2":"Preclinical","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Kinnate Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Slate Path Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ Slate Path Capital","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi Therapeutics \/ Slate Path Capital"},{"orgOrder":0,"company":"Valitor","sponsor":"Morningside","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"VLTR-557","moa":"VEGF","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Valitor","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valitor \/ Morningside","highestDevelopmentStatusID":"5","companyTruncated":"Valitor \/ Morningside"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Lysosomal targeting chimera","graph1":"Immunology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lycia Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Isoray","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Merger","leadProduct":"VMT01","moa":"MC1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viewpoint Molecular Targeting","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viewpoint Molecular Targeting \/ Isoray","highestDevelopmentStatusID":"7","companyTruncated":"Viewpoint Molecular Targeting \/ Isoray"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sensei Biotherapeutics \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Citigroup"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Cowen"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Institutional Review Board","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Institutional Review Board","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Institutional Review Board"},{"orgOrder":0,"company":"Libra Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Libra Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Libra Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Libra Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Avalon GloboCare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janux Therapeutics \/ Avalon GloboCare","highestDevelopmentStatusID":"4","companyTruncated":"Janux Therapeutics \/ Avalon GloboCare"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"PRT543","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Credit Suisse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"CTX-471","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Credit Suisse","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Credit Suisse"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"CTX-471","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Rezatapopt","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Goldman Sachs","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma \/ Goldman Sachs"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Entinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pharmaceuticals \/ Citigroup"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Noble Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series A Financing","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OS Therapies \/ Noble Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Noble Capital Markets"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"AIkido Pharma","sponsor":"Cedars-Sinai Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"T-cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"AIkido Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AIkido Pharma \/ Cedars-Sinai Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pharma \/ Cedars-Sinai Medical Center"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Prestige Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Sodium Carboxymethylcellulose","moa":"Human corneal endothelial cells","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Akorn Pharmaceuticals \/ Prestige Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Prestige Consumer Healthcare"},{"orgOrder":0,"company":"BioAtla","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"BA3362","moa":"Nectin-4","graph1":"Oncology","graph2":"Preclinical","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Context Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"BioAtla \/ Context Therapeutics"},{"orgOrder":0,"company":"Synedgen","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"MIIST305","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synedgen \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Synedgen \/ BARDA"},{"orgOrder":0,"company":"Indivior","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ BARDA"},{"orgOrder":0,"company":"Croda","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Croda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Croda \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Croda \/ Pfizer Inc"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter And Eliza Hall Institute Of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Cancer Prevention & Research Institute of Texas"},{"orgOrder":0,"company":"OncoResponse","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"OR502","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoResponse \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ CPRIT"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"MyPharma2Go Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Partnership","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ MyPharma2Go Corporation","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ MyPharma2Go Corporation"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"NV-HHV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NanoViricides \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NanoViricides \/ Undisclosed"},{"orgOrder":0,"company":"Katana Pharmaceuticals","sponsor":"March of Dimes","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Katana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Katana Pharmaceuticals \/ March of Dimes","highestDevelopmentStatusID":"1","companyTruncated":"Katana Pharmaceuticals \/ March of Dimes"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"RARE-X","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ RARE-X","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ RARE-X"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"National Institutes of Health \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Vir Biotechnology"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actinium pharmaceuticals \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Actinium pharmaceuticals \/ Astellas Pharma"},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Beijing Shenogen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"DI-LEU16-IL2","moa":"CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Alopexx Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alopexx Oncology \/ Beijing Shenogen Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Alopexx Oncology \/ Beijing Shenogen Pharma"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ BARDA"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Acquisition","leadProduct":"Eryaspase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"9","companyTruncated":"Erytech Pharma \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Calpain 3","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ginkgo Bioworks \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ginkgo Bioworks \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ligand Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Factor Bioscience","sponsor":"Brooklyn ImmunoTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Factor Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Factor Bioscience \/ Brooklyn ImmunoTherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Factor Bioscience \/ Brooklyn ImmunoTherapeutics"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"BNZ-1","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Almirall","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Almirall"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Caamtech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ Caamtech","highestDevelopmentStatusID":"1","companyTruncated":"National Institute on Drug Abuse \/ Caamtech"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"U.S. government","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ U.S. government","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ U.S. government"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Government of Singapore","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Government of Singapore","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Government of Singapore"},{"orgOrder":0,"company":"DoubleRainbow Biosciences","sponsor":"Kelai Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"DoubleRainbow Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"DoubleRainbow Biosciences \/ Kelai Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"DoubleRainbow Biosciences \/ Kelai Pharmaceuticals"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TFF Pharmaceuticals \/ Aptar Pharma","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Aptar Pharma"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Taiba Healthcare"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Divestment","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals"},{"orgOrder":0,"company":"Vicinitas Therapeutics","sponsor":"16z","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"WEE1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vicinitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicinitas Therapeutics \/ 16z","highestDevelopmentStatusID":"3","companyTruncated":"Vicinitas Therapeutics \/ 16z"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"||KRAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elicio Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ European Commission"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Agenus","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Balstilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Young Pharmaceuticals","sponsor":"Lactobio A\/S","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Partnership","leadProduct":"LB356R","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Young Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Young Pharmaceuticals \/ Lactobio A\/S","highestDevelopmentStatusID":"15","companyTruncated":"Young Pharmaceuticals \/ Lactobio A\/S"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Carnegie Mellon University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Treg-Derived Exosome","moa":"Treg","graph1":"Neurology","graph2":"Undisclosed","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Carnegie Mellon University","highestDevelopmentStatusID":"1","companyTruncated":"Coya Therapeutics \/ Carnegie Mellon University"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University of Louisville","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"RAS-F","moa":"RAS protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ University of Louisville","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen Therapeutics \/ University of Louisville"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Scribe Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KSQ Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"VIR-2482","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Epizyme","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Pharmakon Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Pharmakon Advisors"},{"orgOrder":0,"company":"X-Chem","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"X-Chem \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Kymera Therapeutics"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ BARDA"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Longitude Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Longitude Capital"},{"orgOrder":0,"company":"Celularity","sponsor":"Lung Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Lung Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Lung Biotechnology"},{"orgOrder":0,"company":"AavantiBio","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AavantiBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AavantiBio \/ University of Florida","highestDevelopmentStatusID":"1","companyTruncated":"AavantiBio \/ University of Florida"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ National Cancer Institute"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Immutep"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Poseida Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Thorne HealthTech","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Thorne HealthTech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thorne HealthTech \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Thorne HealthTech \/ AstraZeneca"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marker Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"Autogene Cevumeran","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ BioNTech"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"Autogene Cevumeran","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ BioNTech"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ U.S. Food and Drug Administration"},{"orgOrder":0,"company":"Kenai Therapeutics","sponsor":"Alaska Permanent Fund Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"RNDP-001","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Kenai Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kenai Therapeutics \/ Alaska Permanent Fund Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Kenai Therapeutics \/ Alaska Permanent Fund Corporation"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyne Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Therapeutics \/ Vida Ventures"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"TRIV-509","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Triveni Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triveni Bio \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"4","companyTruncated":"Triveni Bio \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"Santa Ana Bio","sponsor":"GV","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"SAB01","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Santa Ana Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santa Ana Bio \/ GV","highestDevelopmentStatusID":"5","companyTruncated":"Santa Ana Bio \/ GV"},{"orgOrder":0,"company":"Latus Bio","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Latus Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latus Bio \/ 8VC","highestDevelopmentStatusID":"4","companyTruncated":"Latus Bio \/ 8VC"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Sound Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"NDI-5001","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NephroDI Therapeutics \/ Sound Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI Therapeutics \/ Sound Bioventures"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series D Financing","leadProduct":"CID-078","moa":"Cyclin A\/B RxL","graph1":"Oncology","graph2":"Phase I","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circle Pharma \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Circle Pharma \/ The Column Group"},{"orgOrder":0,"company":"Imvax","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Undisclosed"},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"Solrikitug","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Uniquity Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniquity Bio \/ Blackstone Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Uniquity Bio \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"TCG","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Series A Financing","leadProduct":"Aldafermin","moa":"Bile acid synthesis","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ TCG","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ TCG"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"ABMRF","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"ANS-858","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ ABMRF","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ ABMRF"},{"orgOrder":0,"company":"Pathos","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"P-500","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Pathos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathos \/ New Enterprise Associates","highestDevelopmentStatusID":"6","companyTruncated":"Pathos \/ New Enterprise Associates"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marea Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Marea Therapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Restem Group Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Restem Group Inc","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Restem Group Inc"},{"orgOrder":0,"company":"Alzheon","sponsor":"Alerce Medical Technology Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series E Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Alerce Medical Technology Partners","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Alerce Medical Technology Partners"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"HB-500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Progentos Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Progentos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Progentos Therapeutics \/ Forbion","highestDevelopmentStatusID":"5","companyTruncated":"Progentos Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Kailera Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series A Financing","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Kailera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kailera Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"10","companyTruncated":"Kailera Therapeutics \/ Atlas Venture"},{"orgOrder":0,"company":"Firefly Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Firefly Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Firefly Bio \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Firefly Bio \/ Versant Ventures"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"PharmaCyte Biotech","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ PharmaCyte Biotech","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ PharmaCyte Biotech"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"SymBiosis and Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Series C Financing","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"CIN-109","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PhotonPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Autologous Cellular-Based Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PhotonPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PhotonPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PhotonPharma \/ Undisclosed"},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Undisclosed"},{"orgOrder":0,"company":"Pelage Pharmaceuticals","sponsor":"Main Street Advisors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"PP405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Pelage Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Pelage Pharmaceuticals \/ Main Street Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Pelage Pharmaceuticals \/ Main Street Advisors"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CinRx Pharma \/ CinRx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"ETX-19477","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"858 Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"6","companyTruncated":"858 Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"AN2 Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Arch Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Arch Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Arch Venture Partners"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Oaktree Capital","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Oaktree Capital"},{"orgOrder":0,"company":"Cerevance","sponsor":"Agent Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Agent Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Agent Capital"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Sixth Street"},{"orgOrder":0,"company":"Replimune","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Financing","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Hercules Capital","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Hercules Capital"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"PBM Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"XT-150","moa":"IL-10","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Xalud Therapeutics \/ PBM Capital","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Therapeutics \/ PBM Capital"},{"orgOrder":0,"company":"Diagonal Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Diagonal Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diagonal Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"4","companyTruncated":"Diagonal Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Frontier Medicine \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Frontier Medicine \/ Deep Track Capital"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Frontier Medicine \/ Deerfield Management","highestDevelopmentStatusID":"7","companyTruncated":"Frontier Medicine \/ Deerfield Management"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"GMS Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ GMS Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ GMS Ventures"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Athyrium Capital"},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"RVL Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"RVL Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"RVL Pharmaceuticals \/ Athyrium Capital"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"5","companyTruncated":"CAMP4 Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ancilia Bioscience \/ Safar Partners","highestDevelopmentStatusID":"3","companyTruncated":"Ancilia Bioscience \/ Safar Partners"},{"orgOrder":0,"company":"Vaxxas","sponsor":"OneVentures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"HexaPro","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Vaxxas \/ OneVentures","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ OneVentures"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Alzheimer\u2019s Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Alzheimer\u2019s Drug Discovery Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Alzheimer\u2019s Drug Discovery Foundation"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Encellin","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"ENC-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Encellin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Encellin \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Encellin \/ Khosla Ventures"},{"orgOrder":0,"company":"Airna","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Airna","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Airna \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Airna \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"IAM-H1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iambic Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"5","companyTruncated":"Iambic Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Novo Holdings A\/S","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"RTx-015","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ Novo Holdings A\/S","highestDevelopmentStatusID":"5","companyTruncated":"Ray Therapeutics \/ Novo Holdings A\/S"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Series A Financing","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Convergent Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Vida Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Third Arc Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Third Arc Bio \/ Vida Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Third Arc Bio \/ Vida Ventures"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Tobramycin Sulfate","moa":"||Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"IN8bio","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Kivu Bioscience","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"KIVU-107","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kivu Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kivu Bioscience \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"Kivu Bioscience \/ Organovo Holdings"},{"orgOrder":0,"company":"Attralus","sponsor":"venBio Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ venBio Partners","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ venBio Partners"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"GHS Investments","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ GHS Investments","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ GHS Investments"},{"orgOrder":0,"company":"Evommune","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IRAK4\/TrkA","graph1":"Dermatology","graph2":"Discovery","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Evommune \/ Andera Partners","highestDevelopmentStatusID":"2","companyTruncated":"Evommune \/ Andera Partners"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Neuvivo","sponsor":"PrimeStreet Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ PrimeStreet Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ PrimeStreet Capital"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sutro Biopharma \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Initial Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Initial Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Initial Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"3","companyTruncated":"Initial Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Leaps by Bayer","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Leaps by Bayer"},{"orgOrder":0,"company":"Georgiamune","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"GIM-122","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ General Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"Georgiamune \/ General Catalyst"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Christopher Schelling","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Christopher Schelling","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Christopher Schelling"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Phage Therapeutics \/ Deerfield Management"},{"orgOrder":0,"company":"CureLab","sponsor":"Dr. John Ballantyne","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"p62\/SQSTM1 gene","graph1":"Oncology","graph2":"Preclinical","graph3":"CureLab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CureLab \/ Dr. John Ballantyne","highestDevelopmentStatusID":"4","companyTruncated":"CureLab \/ Dr. John Ballantyne"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Cowen and Company LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Cowen and Company LLC","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Cowen and Company LLC"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"||mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Cullgen","sponsor":"AZ-CICC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"E3 ubiquitin ligase","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ AZ-CICC","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ AZ-CICC"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series C Financing","leadProduct":"GB-0669","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Generate Biomedicines \/ Amgen Inc"},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Undisclosed"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Serabelisb","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Faeth Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Faeth Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"FibroGen","sponsor":"Morgan Stanley Tactical Value","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Pamrevlumab","moa":"CTGF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Morgan Stanley Tactical Value","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Morgan Stanley Tactical Value"},{"orgOrder":0,"company":"Evozyne","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Evozyne","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evozyne \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"2","companyTruncated":"Evozyne \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"NextPoint","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PD-1\/L1","graph1":"Oncology","graph2":"Undisclosed","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NextPoint \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"NextPoint \/ Leaps by Bayer"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Series C Financing","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ RA Capital","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ RA Capital"},{"orgOrder":0,"company":"BioIntervene","sponsor":"MPM Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"BIO-205","moa":"A3AR","graph1":"Neurology","graph2":"Preclinical","graph3":"BioIntervene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioIntervene \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"BioIntervene \/ MPM Capital"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Avalon GloboCare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Trop2","graph1":"Oncology","graph2":"Preclinical","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Janux Therapeutics \/ Avalon GloboCare","highestDevelopmentStatusID":"4","companyTruncated":"Janux Therapeutics \/ Avalon GloboCare"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Storm Lake Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Storm Lake Capital","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Storm Lake Capital"},{"orgOrder":0,"company":"Alltrna","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Alltrna","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alltrna \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Alltrna \/ Flagship Pioneering"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"Pillar VC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"THY-100","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thymmune Therapeutics \/ Pillar VC","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ Pillar VC"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Private Placement","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tentarix Biotherapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Aldena Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aldena Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aldena Therapeutics \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Aldena Therapeutics \/ Medicxi"},{"orgOrder":0,"company":"Rampart Bioscience","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Rampart Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rampart Bioscience \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"Rampart Bioscience \/ OrbiMed"},{"orgOrder":0,"company":"Hyku Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Hyku Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hyku Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Hyku Biosciences \/ RA Capital Management"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"ABD-147","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"TandemAI","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"TandemAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TandemAI \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"TandemAI \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Fairmount Funds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Fairmount Funds","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Fairmount Funds"},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nido Biosciences \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ 5Am Ventures"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Sessa Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Sessa Capital","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Sessa Capital"},{"orgOrder":0,"company":"Modifi Bio","sponsor":"Connecticut Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Modifi Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Modifi Bio \/ Connecticut Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Modifi Bio \/ Connecticut Innovation"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Farallon Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Farallon Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Farallon Capital Management"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"TPG Life Sciences Innovations","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series B Financing","leadProduct":"Monomethyl Auristatin E","moa":"EphA5 MMAE","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBrace Therapeutics \/ TPG Life Sciences Innovations","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ TPG Life Sciences Innovations"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"AXA IM Alts","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ AXA IM Alts","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ AXA IM Alts"},{"orgOrder":0,"company":"Humacyte","sponsor":"Oberland Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Oberland Capital","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Oberland Capital"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbital Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbital Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Orbital Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Avenue Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beyond Air \/ Avenue Capital Group","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air \/ Avenue Capital Group"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Beiersdorf AG","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"RLS-1496","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Beiersdorf AG","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Beiersdorf AG"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN 6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Trace Neuroscience","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Trace Neuroscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trace Neuroscience \/ Third Rock Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Trace Neuroscience \/ Third Rock Ventures"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Jackson Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Calidi Biotherapeutics \/ Jackson Investment Group","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Jackson Investment Group"},{"orgOrder":0,"company":"Nested Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"NEST-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nested Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nested Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Nested Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Vivo Capital"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Fountain Healthcare Partners"},{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Polaris Innovation Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Pin1","graph1":"Oncology","graph2":"Discovery","graph3":"Larkspur Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Larkspur Biosciences \/ Polaris Innovation Fund","highestDevelopmentStatusID":"2","companyTruncated":"Larkspur Biosciences \/ Polaris Innovation Fund"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Radionetics Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radionetics Oncology \/ GordonMD Global Investments","highestDevelopmentStatusID":"2","companyTruncated":"Radionetics Oncology \/ GordonMD Global Investments"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Nant Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Nant Capital","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Nant Capital"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Lee'S Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Windtree Therapeutics \/ Lee'S Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Lee'S Pharmaceutical"},{"orgOrder":0,"company":"FogPharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series E Financing","leadProduct":"FOG-001","moa":"Beta catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FogPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"FogPharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"FogPharma \/ RA Capital Management"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rivus Pharmaceuticals \/ RA Capital","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ RA Capital"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"AstraZeneca-CICC Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"C-CAR039","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ AstraZeneca-CICC Fund","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ AstraZeneca-CICC Fund"},{"orgOrder":0,"company":"Rapafusyn Pharmaceuticals","sponsor":"3E Bioventures Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"ENT1","graph1":"Oncology","graph2":"Discovery","graph3":"Rapafusyn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapafusyn Pharmaceuticals \/ 3E Bioventures Capital","highestDevelopmentStatusID":"2","companyTruncated":"Rapafusyn Pharmaceuticals \/ 3E Bioventures Capital"},{"orgOrder":0,"company":"Corium","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Hercules Capital"},{"orgOrder":0,"company":"ElevateBio","sponsor":"The Invus Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ElevateBio \/ The Invus Group","highestDevelopmentStatusID":"2","companyTruncated":"ElevateBio \/ The Invus Group"},{"orgOrder":0,"company":"Radar Therapeutics","sponsor":"NfX Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Radar Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radar Therapeutics \/ NfX Bio","highestDevelopmentStatusID":"2","companyTruncated":"Radar Therapeutics \/ NfX Bio"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"TQS-168","moa":"PGC-1a","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Remiges Ventures"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Invivyd","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ RA Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ RA Capital Management"},{"orgOrder":0,"company":"Moonwalk Biosciences","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Moonwalk Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moonwalk Biosciences \/ Alpha Wave Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Moonwalk Biosciences \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ The Column Group"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Red Tree Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Red Tree Venture Capital","highestDevelopmentStatusID":"7","companyTruncated":"Bicara Therapeutics \/ Red Tree Venture Capital"},{"orgOrder":0,"company":"Magnet Biomedicine","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Magnet Biomedicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Magnet Biomedicine \/ Newpath Partners","highestDevelopmentStatusID":"3","companyTruncated":"Magnet Biomedicine \/ Newpath Partners"},{"orgOrder":0,"company":"Nexo Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nexo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nexo Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nexo Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Neuroplastogen","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Delix Therapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Series D Financing","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CG Oncology \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OrsoBio \/ Longitude Capital","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Longitude Capital"},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"TRIV-509","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Triveni Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triveni Bio \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"Triveni Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Zetagen Therapeutics","sponsor":"New York Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"ZetaMAST","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zetagen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Zetagen Therapeutics \/ New York Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Zetagen Therapeutics \/ New York Ventures"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Caffeine","moa":"||SARM1","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Oaktree Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Oaktree Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Oaktree Capital Management"},{"orgOrder":0,"company":"Ardelyx","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ SLR Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ SLR Capital Partners"},{"orgOrder":0,"company":"March Biosciences","sponsor":"Mission BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"MB-105","moa":"PSCA","graph1":"Oncology","graph2":"Phase II","graph3":"March Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"March Biosciences \/ Mission BioCapital","highestDevelopmentStatusID":"8","companyTruncated":"March Biosciences \/ Mission BioCapital"},{"orgOrder":0,"company":"Hemispherian","sponsor":"EIC fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"GLIX1","moa":"TET2","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemispherian \/ EIC fund","highestDevelopmentStatusID":"4","companyTruncated":"Hemispherian \/ EIC fund"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lightspeed Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series D Financing","leadProduct":"TRGFT-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Lightspeed Venture","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/ Lightspeed Venture"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Cullgen","sponsor":"3E Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"CG001419","moa":"TRK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ 3E Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ 3E Bioventures"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Maxim Merchant Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"GDD3898","moa":"SCD1","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Invus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Invus","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Invus"},{"orgOrder":0,"company":"Enlaza Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlaza Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enlaza Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Enlaza Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Nevakar","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Nevakar \/ Oxford Finance LLC","highestDevelopmentStatusID":"10","companyTruncated":"Nevakar \/ Oxford Finance LLC"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"INCE Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"ARTS-011","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allorion Therapeutics \/ INCE Capital","highestDevelopmentStatusID":"5","companyTruncated":"Allorion Therapeutics \/ INCE Capital"},{"orgOrder":0,"company":"Cerevance","sponsor":"Gates Frontier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Gates Frontier","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Gates Frontier"},{"orgOrder":0,"company":"Edity Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Edity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edity Therapeutics \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Edity Therapeutics \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Carisma Therapeutics \/ Sesen Bio","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Sesen Bio"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"VyGen-Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VyGen-Bio \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"VyGen-Bio \/ Coeptis Pharmaceuticals"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BBP-954","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Thunderbolt","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"IND Enabling","graph3":"Thunderbolt","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Thunderbolt \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Thunderbolt \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Akamis Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"NG-641","moa":"||AP\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Bristol Myers Squibb \/ Akamis Bio","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ Akamis Bio"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"ProvideGx","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Labetalol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pfizer Inc \/ ProvideGx","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ ProvideGx"},{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"UCLA \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ National Institutes of Health"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flagship Pioneering \/ GSK","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ GSK"},{"orgOrder":0,"company":"Resilience","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Resilience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Resilience \/ Mayo Clinic","highestDevelopmentStatusID":"4","companyTruncated":"Resilience \/ Mayo Clinic"},{"orgOrder":0,"company":"Burke Neurological Institute","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Funding","leadProduct":"Benfotiamine","moa":"Transketolase","graph1":"Neurology","graph2":"Phase II","graph3":"Burke Neurological Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Burke Neurological Institute \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Burke Neurological Institute \/ National Institutes of Health"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Preclinical","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fox Chase Cancer Center \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Fox Chase Cancer Center \/ Lantern Pharma"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"ABBV-47D11","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Formation Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"ASN008","moa":"NaV sodium channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Formation Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Formation Bio \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Formation Bio \/ Sanofi"},{"orgOrder":0,"company":"Phare Bio","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Phare Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phare Bio \/ ARPA-H","highestDevelopmentStatusID":"3","companyTruncated":"Phare Bio \/ ARPA-H"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Mov18 IgE","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovate Biopharmaceuticals \/ UK Government","highestDevelopmentStatusID":"6","companyTruncated":"Innovate Biopharmaceuticals \/ UK Government"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"PRTX007","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Primmune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vensica Medical","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2024","type":"Funding","leadProduct":"Incobotulinumtoxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Phase I","graph3":"Vensica Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Medical \/ Israel Biotech Fund","highestDevelopmentStatusID":"6","companyTruncated":"Vensica Medical \/ Israel Biotech Fund"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Wellcome Trust"},{"orgOrder":0,"company":"Immorna","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"JCXH-108","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immorna \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Immorna \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"CMV-modified Vaccinia Ankara Vaccine","moa":"pp65 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fortress Biotech \/ NIAID","highestDevelopmentStatusID":"8","companyTruncated":"Fortress Biotech \/ NIAID"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Endomimetics","sponsor":"Innovate Alabama","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Endomimetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endomimetics \/ Innovate Alabama","highestDevelopmentStatusID":"4","companyTruncated":"Endomimetics \/ Innovate Alabama"},{"orgOrder":0,"company":"CastleVax","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"CVAX-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CastleVax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CastleVax \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"CastleVax \/ BARDA"},{"orgOrder":0,"company":"Lucy Therapeutics","sponsor":"Engine Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"LucyTx-1209","moa":"F1F0-ATPase","graph1":"Neurology","graph2":"Preclinical","graph3":"Lucy Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lucy Therapeutics \/ Engine Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Lucy Therapeutics \/ Engine Ventures"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NIDCR","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ NIDCR","highestDevelopmentStatusID":"2","companyTruncated":"Sinopia Biosciences \/ NIDCR"},{"orgOrder":0,"company":"Conformation-X Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Conformation-X Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conformation-X Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Conformation-X Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Ibogaine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Gilgamesh Pharmaceuticals \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Selonabant","moa":"CB1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anebulo Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"LTG-001","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Hemispherian","sponsor":"Research Council of Norway","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"GLIX5","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemispherian \/ Research Council of Norway","highestDevelopmentStatusID":"4","companyTruncated":"Hemispherian \/ Research Council of Norway"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Vaxart","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ BARDA"},{"orgOrder":0,"company":"Trethera","sponsor":"Small Business Innovation Research","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Small Business Innovation Research","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ Small Business Innovation Research"},{"orgOrder":0,"company":"Code Bio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Code Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Code Bio \/ Northpond Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Code Bio \/ Northpond Ventures"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqualung Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"AMTX-100","moa":"Nf-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amytrx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"BioVie","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioVie \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"BioVie \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Histogen","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"HST-003","moa":"Hyaline cartilage","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"NDX-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Perceptive Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Perceptive Advisors"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"IP Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"CMD-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Kuur Therapeutics \/ IP Group","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ IP Group"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Trevena","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ CBC Group"},{"orgOrder":0,"company":"Innervace","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"TE-NSP","moa":"Dopamine receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Innervace","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Innervace \/ Deerfield Management","highestDevelopmentStatusID":"4","companyTruncated":"Innervace \/ Deerfield Management"},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"AnGes","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"OMNI Nuclease","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Emendo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emendo Biotherapeutics \/ AnGes","highestDevelopmentStatusID":"1","companyTruncated":"Emendo Biotherapeutics \/ AnGes"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Alzheimer's Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Alzheimer's Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Astrocyte Pharmaceuticals \/ Alzheimer's Drug Discovery Foundation"},{"orgOrder":0,"company":"The Mark Foundation for Cancer Research","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"The Mark Foundation for Cancer Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Mark Foundation for Cancer Research \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"The Mark Foundation for Cancer Research \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"U.S Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Adaptive Phage Therapeutics \/ U.S Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ U.S Department of Defense"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Spinogenix","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SPG302","moa":"Lost synapses","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Spinogenix \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Falk Medical Research Trust","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Falk Medical Research Trust","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Falk Medical Research Trust"},{"orgOrder":0,"company":"PureTech Health","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Ossium Health","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"OSSM-007","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossium Health \/ California Institute of Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ossium Health \/ California Institute of Regenerative Medicine"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Alberta Cancer Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Entos Pharmaceuticals \/ Alberta Cancer Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Entos Pharmaceuticals \/ Alberta Cancer Foundation"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Novasenta","sponsor":"UPMC Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series A Financing","leadProduct":"NST0023","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Novasenta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novasenta \/ UPMC Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"Novasenta \/ UPMC Enterprises"},{"orgOrder":0,"company":"Upstream","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series A Financing","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Upstream \/ OrbiMed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Talus Bioscience","sponsor":"Two Bear Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Talus Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talus Bioscience \/ Two Bear Capital","highestDevelopmentStatusID":"4","companyTruncated":"Talus Bioscience \/ Two Bear Capital"},{"orgOrder":0,"company":"Vaccine and Immunotherapy Center","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Prophylactic Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Vaccine and Immunotherapy Center","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccine and Immunotherapy Center \/ U.S. Department of Defense","highestDevelopmentStatusID":"3","companyTruncated":"Vaccine and Immunotherapy Center \/ U.S. Department of Defense"},{"orgOrder":0,"company":"PsychoGenics","sponsor":"SBIR Grant","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"PsychoGenics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"PsychoGenics \/ SBIR Grant","highestDevelopmentStatusID":"2","companyTruncated":"PsychoGenics \/ SBIR Grant"},{"orgOrder":0,"company":"Genosera","sponsor":"Solve GNE","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"GA-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Genosera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genosera \/ Solve GNE","highestDevelopmentStatusID":"4","companyTruncated":"Genosera \/ Solve GNE"},{"orgOrder":0,"company":"Helocyte","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"CMV-modified Vaccinia Ankara Vaccine","moa":"pp65 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Helocyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Helocyte \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"Helocyte \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Neurodon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurodon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurodon \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"Neurodon \/ National Institute on Aging"},{"orgOrder":0,"company":"Immunome","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ U.S. Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Vaxart","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ BARDA"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institute of Child Health and Human Development","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dar\u00e9 Bioscience \/ National Institute of Child Health and Human Development","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Bioscience \/ National Institute of Child Health and Human Development"},{"orgOrder":0,"company":"Omniose","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"GBS Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Omniose","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omniose \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Omniose \/ National Institutes of Health"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"DeGregorio Family Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ DeGregorio Family Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israel Deaconess Medical Center \/ DeGregorio Family Foundation"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"STC-004","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SiteOne Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Bioluminescence Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Resiquimod","moa":"TLR7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SURGE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"SURGE Therapeutics \/ Bioluminescence Ventures","highestDevelopmentStatusID":"7","companyTruncated":"SURGE Therapeutics \/ Bioluminescence Ventures"},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Oncoprex","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneBridge","sponsor":"Insight Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ImmuneBridge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneBridge \/ Insight Partners","highestDevelopmentStatusID":"4","companyTruncated":"ImmuneBridge \/ Insight Partners"},{"orgOrder":0,"company":"OverT Bio","sponsor":"Artis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"OverT Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OverT Bio \/ Artis Ventures","highestDevelopmentStatusID":"3","companyTruncated":"OverT Bio \/ Artis Ventures"},{"orgOrder":0,"company":"IAVI","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"rVSV\u0394G-MARV-GP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ BARDA"},{"orgOrder":0,"company":"Children\u2019S Hospital Los Angeles","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Lorazepam","moa":"||GABA A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Children\u2019S Hospital Los Angeles","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children\u2019S Hospital Los Angeles \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Children\u2019S Hospital Los Angeles \/ National Institutes of Health"},{"orgOrder":0,"company":"Nationwide Children\u2019s Hospital","sponsor":"Solve FSHD","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Nationwide Children\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nationwide Children\u2019s Hospital \/ Solve FSHD","highestDevelopmentStatusID":"4","companyTruncated":"Nationwide Children\u2019s Hospital \/ Solve FSHD"},{"orgOrder":0,"company":"Journey Colab","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Mescaline","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Journey Colab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Colab \/ MBX Capital","highestDevelopmentStatusID":"4","companyTruncated":"Journey Colab \/ MBX Capital"},{"orgOrder":0,"company":"Amber Bio","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Amber Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amber Bio \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Amber Bio \/ Playground Global"},{"orgOrder":0,"company":"Flashpoint Therapeutics","sponsor":"Beta Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Flashpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Flashpoint Therapeutics \/ Beta Lab","highestDevelopmentStatusID":"4","companyTruncated":"Flashpoint Therapeutics \/ Beta Lab"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Symbiosis II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Symbiosis II","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Symbiosis II"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dar\u00e9 Bioscience \/ ARPA-H","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ ARPA-H"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"4BIO Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Ray-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ 4BIO Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therapeutics \/ 4BIO Capital"},{"orgOrder":0,"company":"Rejuvenation Technologies","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"RTI-LNG1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Rejuvenation Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rejuvenation Technologies \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Rejuvenation Technologies \/ Khosla Ventures"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Funding","leadProduct":"LMN-201","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lumen Bioscience \/ U.S. Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ U.S. Department of Defense"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"MJFF","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SB-0110","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ MJFF","highestDevelopmentStatusID":"4","companyTruncated":"Sinopia Biosciences \/ MJFF"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NINDS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SB-0110","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ NINDS","highestDevelopmentStatusID":"4","companyTruncated":"Sinopia Biosciences \/ NINDS"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"FPV","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strand Therapeutics \/ FPV","highestDevelopmentStatusID":"4","companyTruncated":"Strand Therapeutics \/ FPV"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rubedo Life Sciences \/ Khosla Ventures"},{"orgOrder":0,"company":"Humanetics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Multiple Sclerosis Society","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Funding","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Multiple Sclerosis Society","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ National Multiple Sclerosis Society"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"NICHD","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Funding","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ NICHD","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ NICHD"},{"orgOrder":0,"company":"Codagenix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"CodaVax-DENV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codagenix \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Codagenix \/ US Department of Defense"},{"orgOrder":0,"company":"Caeregen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"CTR-107","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Caeregen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Caeregen Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Caeregen Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"VIR-7229","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vir Biotechnology \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Vir Biotechnology \/ BARDA"},{"orgOrder":0,"company":"Kanvas Biosciences","sponsor":"DCVC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"KAN-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Kanvas Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kanvas Biosciences \/ DCVC","highestDevelopmentStatusID":"4","companyTruncated":"Kanvas Biosciences \/ DCVC"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"ORI Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffyImmune Therapeutics \/ ORI Capital","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune Therapeutics \/ ORI Capital"},{"orgOrder":0,"company":"VitriVax","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Thermostable Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"VitriVax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VitriVax \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"2","companyTruncated":"VitriVax \/ Defense Threat Reduction Agency"},{"orgOrder":0,"company":"Celeris Therapeutics","sponsor":"Pace Ventures Enigma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Protein","graph1":"Neurology","graph2":"Discovery","graph3":"Celeris Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Celeris Therapeutics \/ Pace Ventures Enigma","highestDevelopmentStatusID":"2","companyTruncated":"Celeris Therapeutics \/ Pace Ventures Enigma"},{"orgOrder":0,"company":"Sarcomatrix","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"S-969","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sarcomatrix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcomatrix \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Sarcomatrix \/ National Institutes of Health"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Pragma Bio","sponsor":"Viking Global","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Pragma Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pragma Bio \/ Viking Global","highestDevelopmentStatusID":"2","companyTruncated":"Pragma Bio \/ Viking Global"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"CTT2274","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Targeted Technology \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Access to Advanced Health Institute","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Chikungunya Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Access to Advanced Health Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Access to Advanced Health Institute \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Access to Advanced Health Institute \/ National Institutes of Health"},{"orgOrder":0,"company":"Oragenics","sponsor":"CQDM","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oragenics \/ CQDM","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ CQDM"},{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"SBIR","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cayman Chemical Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cayman Chemical Company Inc \/ SBIR","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Chemical Company Inc \/ SBIR"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"Omeros","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"University of Tennessee Health Science Center","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"University of Tennessee Health Science Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Tennessee Health Science Center \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University of Tennessee Health Science Center \/ U.S. Department of Defense"},{"orgOrder":0,"company":"ResVita Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RVB-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"ResVita Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"ResVita Bio \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"ResVita Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Aegis Life","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aegis Life","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aegis Life \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aegis Life \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"SBT-272","moa":"TDP-43","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Cancer Prevention & Research Institute of Texas"},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Myeloma Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"NTX-1088","moa":"CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nectin Therapeutics \/ Myeloma Investment Fund","highestDevelopmentStatusID":"6","companyTruncated":"Nectin Therapeutics \/ Myeloma Investment Fund"},{"orgOrder":0,"company":"PharmaJet","sponsor":"DTRA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Venezuelan Equine Encephalitis Virus DNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ DTRA","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet \/ DTRA"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Chroma Medicine","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Chroma Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chroma Medicine \/ Google Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Chroma Medicine \/ Google Ventures"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Superluminal Medicines \/ RA Capital","highestDevelopmentStatusID":"2","companyTruncated":"Superluminal Medicines \/ RA Capital"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thymmune Therapeutics \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Tachyon Therapeutics","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"Phase I","graph3":"Tachyon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tachyon Therapeutics \/ Cirm","highestDevelopmentStatusID":"6","companyTruncated":"Tachyon Therapeutics \/ Cirm"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RTx-021","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ray Therapeutics \/ CIRM","highestDevelopmentStatusID":"2","companyTruncated":"Ray Therapeutics \/ CIRM"},{"orgOrder":0,"company":"Myrobalan Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Myrobalan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Myrobalan Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Myrobalan Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Ceftibuten-ledaborbactam Etzadroxil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"VenatoRx Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"VenatoRx Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"ALS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NRG Therapeutics \/ ALS Foundation","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ ALS Foundation"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Cancer Focus Fund","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Cancer Focus Fund"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Alzheimers Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"CST-3056","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"CuraSen Therapeutics \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"Myosana Therapeutics","sponsor":"John Ballantyne","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Myosana Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosana Therapeutics \/ John Ballantyne","highestDevelopmentStatusID":"2","companyTruncated":"Myosana Therapeutics \/ John Ballantyne"},{"orgOrder":0,"company":"GigaGen","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"GigaGen \/ BARDA"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"RLS-1496","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Khosla Ventures"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Elevian","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"rGDF11","moa":"Nerve tissue growth","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elevian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevian \/ Prime Movers Lab","highestDevelopmentStatusID":"4","companyTruncated":"Elevian \/ Prime Movers Lab"},{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"DecentraNet","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Ropocamptide","moa":"Hepatitis B virus membrane","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Maxwell Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maxwell Biosciences \/ DecentraNet","highestDevelopmentStatusID":"4","companyTruncated":"Maxwell Biosciences \/ DecentraNet"},{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Secretome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ArrePath","sponsor":"Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"ArrePath","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArrePath \/ Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"ArrePath \/ Venture Fund"},{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ancilia Bioscience \/ ARPA-H","highestDevelopmentStatusID":"4","companyTruncated":"Ancilia Bioscience \/ ARPA-H"},{"orgOrder":0,"company":"Valora Therapeutics","sponsor":"Avalon BioVentures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Valora Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Valora Therapeutics \/ Avalon BioVentures","highestDevelopmentStatusID":"3","companyTruncated":"Valora Therapeutics \/ Avalon BioVentures"},{"orgOrder":0,"company":"Vitanova Biomedical","sponsor":"National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"VNBp-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vitanova Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitanova Biomedical \/ National Science Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Vitanova Biomedical \/ National Science Foundation"},{"orgOrder":0,"company":"Surf Bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Surf Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Surf Bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Surf Bio \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Moat Biotechnology","sponsor":"Cortado Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moat Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Moat Biotechnology \/ Cortado Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Moat Biotechnology \/ Cortado Ventures"},{"orgOrder":0,"company":"CorMedix","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Taurolidine","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ New Jersey Economic Development Authority"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Carb-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Carb-X","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogics \/ Carb-X"},{"orgOrder":0,"company":"Phoenix Nest","sponsor":"Cure Sanfilippo Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"AAV-TT","moa":"HGSNAT gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Phoenix Nest","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Nest \/ Cure Sanfilippo Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Nest \/ Cure Sanfilippo Foundation"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Sodium Valproate","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"VitriVax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Hexavalent Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"VitriVax","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VitriVax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"VitriVax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Terray Therapeutics","sponsor":"Bedford Ridge Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Terray Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terray Therapeutics \/ Bedford Ridge Capital","highestDevelopmentStatusID":"3","companyTruncated":"Terray Therapeutics \/ Bedford Ridge Capital"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ ReGenTree"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Nitric Oxide","moa":"||sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cyanvac","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"CVXGA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyanvac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyanvac \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Cyanvac \/ BARDA"},{"orgOrder":0,"company":"Humanetics","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"Humanetics \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"BMS-984923","moa":"mGluR5","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Funding","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ CIRM"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Sovilnesib","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Volastra Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"6","companyTruncated":"Volastra Therapeutics \/ Polaris Partners"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Funding","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Quench Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Quench Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quench Bio \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Quench Bio \/ RA Capital Management"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ BARDA"},{"orgOrder":0,"company":"Esperovax","sponsor":"Blue Knight","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"COVID-19 RNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Esperovax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Esperovax \/ Blue Knight","highestDevelopmentStatusID":"4","companyTruncated":"Esperovax \/ Blue Knight"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cessation Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Cessation Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"CureDuchenne Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyne Therapeutics \/ CureDuchenne Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dyne Therapeutics \/ CureDuchenne Ventures"},{"orgOrder":0,"company":"Verndari","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"VaxiPatch","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verndari","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verndari \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Verndari \/ BARDA"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"AX-5006","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axial Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Axial Therapeutics \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ O-Bank Co., Ltd."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Series C Financing","leadProduct":"CT-868","moa":"GLP- 1","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Carmot Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"mRNA-1018","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ BARDA"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"The Conrad Prebys Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"n-Lorem Foundation \/ The Conrad Prebys Foundation","highestDevelopmentStatusID":"2","companyTruncated":"n-Lorem Foundation \/ The Conrad Prebys Foundation"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NRG Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapport Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"6","companyTruncated":"Rapport Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Passkey Therapeutics","sponsor":"Breakout Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Passkey Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Passkey Therapeutics \/ Breakout Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Passkey Therapeutics \/ Breakout Ventures"},{"orgOrder":0,"company":"GID BIO","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"GID BIO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GID BIO \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"1","companyTruncated":"GID BIO \/ Richard King Mellon Foundation"},{"orgOrder":0,"company":"NysnoBio","sponsor":"MJFF","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"NB001","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"NysnoBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NysnoBio \/ MJFF","highestDevelopmentStatusID":"5","companyTruncated":"NysnoBio \/ MJFF"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"RBO-0618","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Abu Dhabi Growth Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ Abu Dhabi Growth Fund","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Abu Dhabi Growth Fund"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenax Therapeutics \/ BVF Partners LP","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ BVF Partners LP"},{"orgOrder":0,"company":"iTolerance","sponsor":"BIRD Foundation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ BIRD Foundation","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ BIRD Foundation"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"DARE-PTB1","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"Dar\u00e9 Bioscience \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Bioscience \/ National Institutes of Health"},{"orgOrder":0,"company":"Biosplice","sponsor":"Roskamp Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"SM07883","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ Roskamp Institute","highestDevelopmentStatusID":"4","companyTruncated":"Biosplice \/ Roskamp Institute"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"AV-1959D","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"Aphios","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Bryoid","moa":"Protein kinase C","graph1":"Neurology","graph2":"Preclinical","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aphios \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"Aphios \/ National Institute on Aging"},{"orgOrder":0,"company":"Icosavax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"IVX-411","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icosavax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"ANPD001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Neuroscience \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ OrbiMed"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"U.S. Defense Department","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"||Ach receptor","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CMC Pharmaceuticals \/ U.S. Defense Department","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ U.S. Defense Department"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Titan Pharmaceuticals Inc \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"MDX2202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"GenEdit","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"GenEdit","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenEdit \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"GenEdit \/ Eli Lilly"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Funding","leadProduct":"Iduronate Sulfatase","moa":"Enzyme Replacement","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Immusoft Corporation \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Siren Biotechnology","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Siren Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siren Biotechnology \/ CIRM","highestDevelopmentStatusID":"4","companyTruncated":"Siren Biotechnology \/ CIRM"},{"orgOrder":0,"company":"Spinogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SPG302","moa":"Lost synapses","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"Remedium Bio","sponsor":"National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RMD1202","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Remedium Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Remedium Bio \/ National Science Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Remedium Bio \/ National Science Foundation"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"NIDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Langone Health \/ NIDA","highestDevelopmentStatusID":"5","companyTruncated":"NYU Langone Health \/ NIDA"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Canada Pension Plan Investment Board","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"SIG-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Canada Pension Plan Investment Board","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Canada Pension Plan Investment Board"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"SPR206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Spero Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ANS-858","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Wellcome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Typhoid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Wellcome","highestDevelopmentStatusID":"5","companyTruncated":"Vaxxas \/ Wellcome"},{"orgOrder":0,"company":"IAVI","sponsor":"German government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"IAVI \/ German government","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ German government"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institutes of Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"Duvax","moa":"Amyloid-beta plaque","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute for Molecular Medicine \/ National Institutes of Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institutes of Aging"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"mPTP","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NRG Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series D Financing","leadProduct":"CT-388","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Carmot Therapeutics \/ The Column Group","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IRAK1\/4","graph1":"Oncology","graph2":"Preclinical","graph3":"Kurome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kurome Therapeutics \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Kurome Therapeutics \/ Medicxi"},{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Financing","leadProduct":"Insulin","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abvance Therapeutics \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"4","companyTruncated":"Abvance Therapeutics \/ Helmsley Charitable Trust"},{"orgOrder":0,"company":"BITT","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"BITT-101","moa":"CD40","graph1":"Immunology","graph2":"Preclinical","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ National Institutes of Health"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"NPT1220-312","moa":"TLR2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuropore Therapies \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Neuropore Therapies \/ ALS Association"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Richard King Mellon Foundation"},{"orgOrder":0,"company":"BioVie","sponsor":"OHRO","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioVie \/ OHRO","highestDevelopmentStatusID":"6","companyTruncated":"BioVie \/ OHRO"},{"orgOrder":0,"company":"Ensoma","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensoma \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Ensoma \/ Kite Pharma"},{"orgOrder":0,"company":"Traverse Biotech","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Traverse Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Traverse Biotech \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Traverse Biotech \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Modulo Bio","sponsor":"Initialized Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Modulo Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Modulo Bio \/ Initialized Capital","highestDevelopmentStatusID":"2","companyTruncated":"Modulo Bio \/ Initialized Capital"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Alintegimod","moa":"Integrin alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ CPRIT"},{"orgOrder":0,"company":"ValenzaBio","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"CD19-targeting mAb","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ValenzaBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ValenzaBio \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"ValenzaBio \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"SoftBank Vision","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"AB-1015","moa":"CTLA-4x\/OX40","graph1":"Oncology","graph2":"Phase I","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ArsenalBio \/ SoftBank Vision","highestDevelopmentStatusID":"6","companyTruncated":"ArsenalBio \/ SoftBank Vision"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"OMERS Capital Market","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ OMERS Capital Market","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ OMERS Capital Market"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Advantech Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Advantech Capital","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Advantech Capital"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Valence Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Valence Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Valence Life Sciences"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Jefferies LLC"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Series A Financing","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"BW Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Undisclosed","graph3":"BW Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BW Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BW Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Nimbus Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"GI Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"ELI-007","moa":"BRAF","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elicio Therapeutics \/ GI Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ GI Research Foundation"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Cloudbreak Pharma","sponsor":"V-Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"CBT-001","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Cloudbreak Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Cloudbreak Pharma \/ V-Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cloudbreak Pharma \/ V-Capital"},{"orgOrder":0,"company":"EpiBiologics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EpiBiologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EpiBiologics \/ Mubadala Capital","highestDevelopmentStatusID":"3","companyTruncated":"EpiBiologics \/ Mubadala Capital"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Camford Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SURGE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"SURGE Therapeutics \/ Camford Capital","highestDevelopmentStatusID":"4","companyTruncated":"SURGE Therapeutics \/ Camford Capital"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ascidian Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascidian Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"5","companyTruncated":"Ascidian Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Aulos","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Apple Tree Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Apple Tree Partners"},{"orgOrder":0,"company":"HOPO Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"HOPO 14-1","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"HOPO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HOPO Therapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"HOPO Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genesis Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Andreessen Horowitz"},{"orgOrder":0,"company":"iECURE","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iECURE \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"iECURE \/ Versant Ventures"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReviR Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Yuma Regional Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Yuma Regional Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Yuma Regional Medical Center"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"5","companyTruncated":"Mateon Therapeutics \/ Oceanpine Capital"},{"orgOrder":0,"company":"Shasqi","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ Arcus Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Arcus Biosciences"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Series A Financing","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Remiges Ventures"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Valley Forge Investment Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation"},{"orgOrder":0,"company":"Adjuvance Technologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"TQL1055","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adjuvance Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adjuvance Technologies \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Adjuvance Technologies \/ National Institutes of Health"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Plex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plex Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Plex Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Mebias Discovery","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"MEB-1170","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mebias Discovery","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mebias Discovery \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Mebias Discovery \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Switch Therapeutics","sponsor":"Insight Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Switch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Switch Therapeutics \/ Insight Partners","highestDevelopmentStatusID":"4","companyTruncated":"Switch Therapeutics \/ Insight Partners"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"InVivium Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ InVivium Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ InVivium Capital"},{"orgOrder":0,"company":"Gradalis","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Gemogenovatucel-T","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gradalis \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ CPRIT"},{"orgOrder":0,"company":"Codagenix","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Codagenix \/ Adjuvant Capital","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Adjuvant Capital"},{"orgOrder":0,"company":"AlloVir","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"ALVR109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ BlackRock"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Lumen Bioscience \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bioscience \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"DMPK","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avidity Biosciences \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Avidity Biosciences \/ RTW Investments"},{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Kerry Murphy","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"KCC2","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Axonis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axonis Therapeutics \/ Kerry Murphy","highestDevelopmentStatusID":"2","companyTruncated":"Axonis Therapeutics \/ Kerry Murphy"},{"orgOrder":0,"company":"Hopewell Therapeutics","sponsor":"Mass Ave Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hopewell Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hopewell Therapeutics \/ Mass Ave Capital","highestDevelopmentStatusID":"3","companyTruncated":"Hopewell Therapeutics \/ Mass Ave Capital"},{"orgOrder":0,"company":"Imvaq Therapeutics","sponsor":"Hanne Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"MQ710","moa":"Immunostimulant","graph1":"Oncology","graph2":"Preclinical","graph3":"Imvaq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imvaq Therapeutics \/ Hanne Capital","highestDevelopmentStatusID":"4","companyTruncated":"Imvaq Therapeutics \/ Hanne Capital"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Zukunftsfonds Heilbronn","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Funding","leadProduct":"CPV-101","moa":"C3 receptor","graph1":"Nephrology","graph2":"Preclinical","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevar Therapeutics \/ Zukunftsfonds Heilbronn","highestDevelopmentStatusID":"4","companyTruncated":"Elevar Therapeutics \/ Zukunftsfonds Heilbronn"},{"orgOrder":0,"company":"Aptinyx","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ K2 HealthVentures","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ K2 HealthVentures"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Hudson Bay Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series C Financing","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Hudson Bay Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Hudson Bay Capital"},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ALV-304","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alivio Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Alivio Therapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Cell BioEngine","sponsor":"SOSV","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"CBE-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cell BioEngine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cell BioEngine \/ SOSV","highestDevelopmentStatusID":"4","companyTruncated":"Cell BioEngine \/ SOSV"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Remix Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ Foresite Capital"},{"orgOrder":0,"company":"Revel Pharmaceuticals","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Revel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revel Pharmaceuticals \/ Kizoo Technology Capital","highestDevelopmentStatusID":"2","companyTruncated":"Revel Pharmaceuticals \/ Kizoo Technology Capital"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"K36 Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"KTX-1001","moa":"Methyltransferase","graph1":"Oncology","graph2":"Phase I","graph3":"K36 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"K36 Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"K36 Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Preclinical","graph3":"Superluminal Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Superluminal Medicines \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Superluminal Medicines \/ RA Capital Management"},{"orgOrder":0,"company":"Biogen","sponsor":"Massachusetts Eye and Ear","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Massachusetts Eye and Ear","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Massachusetts Eye and Ear"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Texas Children\u2019s Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpicentRx \/ Texas Children\u2019s Hospital","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Texas Children\u2019s Hospital"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kuur Therapeutics \/ Athenex","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Athenex"},{"orgOrder":0,"company":"American Porphyria Foundation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"American Porphyria Foundation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Porphyria Foundation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"American Porphyria Foundation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Scynexis","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ FDA","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ FDA"},{"orgOrder":0,"company":"Invitae","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Invitae","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Invitae \/ BridgeBio Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Invitae \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Janux Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Janux Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Personalis","sponsor":"Olink Proteomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Personalis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Personalis \/ Olink Proteomics","highestDevelopmentStatusID":"15","companyTruncated":"Personalis \/ Olink Proteomics"},{"orgOrder":0,"company":"Mycotopia Therapies","sponsor":"Ei.Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mycotopia Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mycotopia Therapies \/ Ei.Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mycotopia Therapies \/ Ei.Ventures"},{"orgOrder":0,"company":"NexImmune","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NexImmune \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"2","companyTruncated":"NexImmune \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"University of Georgia","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"SBFM-PL4","moa":"PLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Georgia \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ Sunshine Biopharma"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"ZZ Biotech","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"3K3A-APC","moa":"Tissue plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ZZ Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZZ Biotech \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"8","companyTruncated":"ZZ Biotech \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Autologous MSC-NTF Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"RPESC-RPE-4W","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Luxa Biotechnology \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Atomwise","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atomwise \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"CMTX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarametyx Biosciences \/ CARB-X","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ CARB-X"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Mitacs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Mitacs","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Mitacs"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Agreement","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Beta-Amyloid Vaccine","moa":"Beta amyloid","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Institute for Molecular Medicine \/ National Institute on Aging"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Proniras","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Tezampanel","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Proniras","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proniras \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"1","companyTruncated":"Proniras \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"USAMRDC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ USAMRDC","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bioscience \/ USAMRDC"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute On Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Funding","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute On Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute On Drug Abuse"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Teriparatide","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProLynx \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ National Institutes of Health"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"U.S. National Institute of Neurological Disease and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ U.S. National Institute of Neurological Disease and Stroke","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ U.S. National Institute of Neurological Disease and Stroke"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"Pdx1\/Mafa gene","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ National Institutes of Health"},{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"IVMED-85","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"iVeena \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ National Eye Institute"},{"orgOrder":0,"company":"The University of New Mexico","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"The University of New Mexico","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"The University of New Mexico \/ Purdue Pharma","highestDevelopmentStatusID":"15","companyTruncated":"The University of New Mexico \/ Purdue Pharma"},{"orgOrder":0,"company":"Camino Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Camino Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Camino Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Camino Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"EpiVario","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"EpiVario","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVario \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"EpiVario \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Islatravir","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"NIDCR","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Collagen","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Cayman Chemical Company Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Dental Implant","sponsorNew":"Cayman Chemical Company Inc \/ NIDCR","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Chemical Company Inc \/ NIDCR"},{"orgOrder":0,"company":"EydisBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"EYD-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EydisBio \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"EydisBio \/ National Institutes of Health"},{"orgOrder":0,"company":"Cellectar","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Funding","leadProduct":"131-I Iopofosine","moa":"DNA damage","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"NPT1220-478","moa":"TLR2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neuropore Therapies \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Neuropore Therapies \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"DARE-LBT","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Trethera","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Cancer Institute"},{"orgOrder":0,"company":"University of Maryland","sponsor":"NICO Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Pioglitazone","moa":"PPAR-gamma","graph1":"Neurology","graph2":"Phase II","graph3":"University of Maryland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Maryland \/ NICO Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland \/ NICO Corporation"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"INmune Bio","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Immunology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ ALS Association","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ ALS Association"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Neurology","graph2":"IND Enabling","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Juvena Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Juvena Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Oregon Health & Science University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"CCR5","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Oregon Health & Science University","highestDevelopmentStatusID":"4","companyTruncated":"CytoDyn \/ Oregon Health & Science University"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Funding","leadProduct":"Saposin C","moa":"S1PR","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bexion Pharmaceuticals \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bexion Pharmaceuticals \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"9-Valent HPV Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Cornell Medicine \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Weill Cornell Medicine \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Novan","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"WH602","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Novan \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ National Institutes of Health"},{"orgOrder":0,"company":"Amplo Biotechnology","sponsor":"NIH-NIAMS","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"AMP-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Amplo Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplo Biotechnology \/ NIH-NIAMS","highestDevelopmentStatusID":"4","companyTruncated":"Amplo Biotechnology \/ NIH-NIAMS"},{"orgOrder":0,"company":"INmune Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aprea Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"ET140203","moa":"Alpha fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ CIRM"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Modifi Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"MGMT","graph1":"Oncology","graph2":"Preclinical","graph3":"Modifi Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Modifi Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Modifi Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"EydisBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EydisBio \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"EydisBio \/ National Institutes of Health"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"DLX-007","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Delix Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Delix Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Shasqi","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ National Cancer Institute"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Synergys Biotherapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"SYN-001","moa":"Vasculogenic","graph1":"Oncology","graph2":"Preclinical","graph3":"Synergys Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synergys Biotherapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Synergys Biotherapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"OverT Bio","sponsor":"ScaleReady","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"OverT Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OverT Bio \/ ScaleReady","highestDevelopmentStatusID":"3","companyTruncated":"OverT Bio \/ ScaleReady"},{"orgOrder":0,"company":"Kannalife","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"KLS-13019","moa":"mNCX-1","graph1":"Neurology","graph2":"Preclinical","graph3":"Kannalife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kannalife \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Kannalife \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"The ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"ASHA-624","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asha Therapeutics \/ The ALS Association","highestDevelopmentStatusID":"5","companyTruncated":"Asha Therapeutics \/ The ALS Association"},{"orgOrder":0,"company":"Sapphire Biotech","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"SPX-1009","moa":"QSOX1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sapphire Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sapphire Biotech \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Sapphire Biotech \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"cAd3-EBO-S","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sabin Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sabin Vaccine Institute \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Sabin Vaccine Institute \/ BARDA"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"1910 Genetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"1910 Genetics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"1910 Genetics \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"1910 Genetics \/ National Institutes of Health"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Target ALS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ Target ALS Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Target ALS Foundation"},{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"FightMND","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"M102","moa":"Nrf2","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Therapeutics \/ FightMND"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Private Placement","leadProduct":"SL-172154","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shattuck Labs \/ Evercore ISI","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Evercore ISI"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase III","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pyxis Oncology \/ Brookline Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Pyxis Oncology \/ Brookline Capital Markets"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Serpinpc","moa":"APC receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Goldman Sachs"},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Alkido Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkido Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alkido Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Dynport","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"ILR201104","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolo Biotherapeutics \/ Dynport","highestDevelopmentStatusID":"4","companyTruncated":"Revolo Biotherapeutics \/ Dynport"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"STING","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mersana Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Funding","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Oxford Finance"},{"orgOrder":0,"company":"UC Berkeley","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"UC Berkeley","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UC Berkeley \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"UC Berkeley \/ Genentech"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"MAGE-A4","graph1":"Oncology","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"2Seventy Bio \/ JW Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy Bio \/ JW Therapeutics"},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Illumina","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Navtemadlin","moa":"MDM2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kartos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kartos Therapeutics \/ Illumina","highestDevelopmentStatusID":"9","companyTruncated":"Kartos Therapeutics \/ Illumina"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Funding","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AbbVie Inc \/ Scripps Research","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ Scripps Research"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"RD Fund","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"OPGx-001","moa":"LCA5 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Opus Genetics \/ RD Fund","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ RD Fund"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ TD Cowen"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ TD Cowen"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Citigroup","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Citigroup"},{"orgOrder":0,"company":"Merck & Co","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Termination","leadProduct":"Bintrafusp Alpha","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ GSK"},{"orgOrder":0,"company":"DemeRx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Ibogaine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"DemeRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DemeRx \/ ATAI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"DemeRx \/ ATAI Life Sciences"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LENZ Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"JDRF T1D","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repertoire Immune Medicines \/ JDRF T1D","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire Immune Medicines \/ JDRF T1D"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Starton Therapeutics \/ Love Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Starton Therapeutics \/ Love Pharma"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"||LIV-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Series A Financing","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloom Science \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Bloom Science \/ Leaps by Bayer"},{"orgOrder":0,"company":"GluBio Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GluBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GluBio Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"GluBio Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Altay Therapeutics","sponsor":"SOLVE FSHD","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Altay Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altay Therapeutics \/ SOLVE FSHD","highestDevelopmentStatusID":"2","companyTruncated":"Altay Therapeutics \/ SOLVE FSHD"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Solve FSHD","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epic Bio \/ Solve FSHD","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Solve FSHD"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"Cardurion Pharmaceutical \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Cardurion Pharmaceutical \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"OncoResponse","sponsor":"RiverVest Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"OR502","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoResponse \/ RiverVest Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ RiverVest Venture Partners"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ HAVN Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Biotherapeutics \/ HAVN Life Sciences"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ HAVN Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Biotherapeutics \/ HAVN Life Sciences"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ Cowen"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"VT-01","moa":"TEAD palmitoylation","graph1":"Oncology","graph2":"Preclinical","graph3":"Vivace Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivace Therapeutics \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"4","companyTruncated":"Vivace Therapeutics \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Teplizumab","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune \/ JDRF"},{"orgOrder":0,"company":"University Hospital Institute","sponsor":"Pharnext","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University Hospital Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University Hospital Institute \/ Pharnext","highestDevelopmentStatusID":"4","companyTruncated":"University Hospital Institute \/ Pharnext"},{"orgOrder":0,"company":"Immgenuity","sponsor":"Biostax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"IMTVO14","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immgenuity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immgenuity \/ Biostax","highestDevelopmentStatusID":"4","companyTruncated":"Immgenuity \/ Biostax"},{"orgOrder":0,"company":"Promethera Biosciences","sponsor":"Aceso Life Science Holding","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"HepaStem","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Promethera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Promethera Biosciences \/ Aceso Life Science Holding","highestDevelopmentStatusID":"8","companyTruncated":"Promethera Biosciences \/ Aceso Life Science Holding"},{"orgOrder":0,"company":"LeaderMed Group","sponsor":"Combiphar","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"LM-008","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"LeaderMed Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LeaderMed Group \/ Combiphar","highestDevelopmentStatusID":"10","companyTruncated":"LeaderMed Group \/ Combiphar"},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zylo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Injection","sponsorNew":"Zylo Therapeutics \/ Silo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Zylo Therapeutics \/ Silo Pharma"},{"orgOrder":0,"company":"Apnimed","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Shionogi","highestDevelopmentStatusID":"2","companyTruncated":"Apnimed \/ Shionogi"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Collaboration","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ivy Brain Tumor Center \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ivy Brain Tumor Center \/ GSK"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"OLX-07010","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Undisclosed"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IL-2G receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tentarix Biotherapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Public Offering","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"IMM Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Series B Financing","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orum Therapeutics \/ IMM Investment","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ IMM Investment"},{"orgOrder":0,"company":"UNeMed","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"COYA 301","moa":"||Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"UNeMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UNeMed \/ Coya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"UNeMed \/ Coya Therapeutics"},{"orgOrder":0,"company":"University of Arizona","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Arizona \/ Sunshine Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Arizona \/ Sunshine Biopharma"},{"orgOrder":0,"company":"KemPharm","sponsor":"Commave Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Commave Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Commave Therapeutics"},{"orgOrder":0,"company":"Escugen","sponsor":"InxMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Escugen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escugen \/ InxMed","highestDevelopmentStatusID":"3","companyTruncated":"Escugen \/ InxMed"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Taiba Healthcare"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matrix Biomed \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Matrix Biomed \/ Adamis Pharmaceuticals"},{"orgOrder":0,"company":"Vaxxas","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"SARS-CoV-2 Vaccine Recombinant","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxxas \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alloy Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Welton Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"SN38","moa":"||Topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Lubrizol Life Science Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lubrizol Life Science Health \/ Welton Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lubrizol Life Science Health \/ Welton Pharma"},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MMP-13","graph1":"Oncology","graph2":"Undisclosed","graph3":"SteroTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SteroTherapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"SteroTherapeutics \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Oncology","graph2":"Undisclosed","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Moleculin Biotech \/ WPD Pharmaceuticals"},{"orgOrder":0,"company":"City of Hope","sponsor":"Scopus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"STAT3 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"City of Hope \/ Scopus Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Scopus Biopharma"},{"orgOrder":0,"company":"Puerto Rico Science Technology and Research Trust","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Puerto Rico Science Technology and Research Trust","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"188RNL-BAM","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Plus Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Athena Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tris Pharma Inc \/ Athena Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Tris Pharma Inc \/ Athena Bioscience"},{"orgOrder":0,"company":"NanoSmart Pharmaceuticals","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Dactinomycin","moa":"DNA adduct","graph1":"Oncology","graph2":"Preclinical","graph3":"NanoSmart Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoSmart Pharmaceuticals \/ Oncology Pharma","highestDevelopmentStatusID":"4","companyTruncated":"NanoSmart Pharmaceuticals \/ Oncology Pharma"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Neumentum","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Nuance Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum \/ Nuance Pharma"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"MK-5890","moa":"||CD27","graph1":"Oncology","graph2":"Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Chinook Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CG Oncology \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"EyeCRO","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Cannabinol","moa":"CB1\/2 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"EyeCRO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"EyeCRO \/ InMed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"EyeCRO \/ InMed Pharmaceuticals"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Financing","leadProduct":"Aglatimagene Besadenovec","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Silicon Valley Bank","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8+","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Microneedle Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"Zosano Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"PAO Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"PAO Group \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group \/ Undisclosed"},{"orgOrder":0,"company":"Genocea","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"GEN-003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Shionogi","highestDevelopmentStatusID":"1","companyTruncated":"Genocea \/ Shionogi"},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vizient \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Vizient \/ Pfizer Inc"},{"orgOrder":0,"company":"Attwill Medical Solutions","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Attwill Medical Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Attwill Medical Solutions \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Attwill Medical Solutions \/ Revive Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Advaxis Immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Tocagen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"TLR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Tocagen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Tocagen"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Merger","leadProduct":"Galacto-Oligosaccharide","moa":"Lactase enzyme","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ritter Pharmaceuticals \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Caladrius Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Merger","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Caladrius Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Caladrius Biosciences"},{"orgOrder":0,"company":"TeraImmune","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ Baudax Bio","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Baudax Bio"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Diclofenac Potassium","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assertio Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Assertio Therapeutics \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Zafgen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Zafgen","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Zafgen"},{"orgOrder":0,"company":"Notable Labs","sponsor":"VBL Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ VBL Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ VBL Therapeutics"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Notable stockholders Builders VC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ Notable stockholders Builders VC","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ Notable stockholders Builders VC"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Gabapentin","moa":"CaV channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assertio Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Assertio Therapeutics \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Tempest Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"TPST-1495","moa":"PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Tempest Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Millendo Therapeutics \/ Tempest Therapeutics"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Advaxis Immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Olatec Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Olatec Therapeutics \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Palvella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"Ligand Pharmaceuticals \/ Palvella Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ligand Pharmaceuticals \/ Palvella Therapeutics"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"ADI-002","moa":"Glypican 3 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Adicet Bio \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ GSK"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"Cara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Cara Therapeutics"},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ GSK"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Collaboration","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"M1231","moa":"MUC1-EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck Group"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Harrow","sponsor":"iOR Partners","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Harrow \/ iOR Partners","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ iOR Partners"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Gavi","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Gavi"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series D Financing","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Temasek Life Sciences Laboratory","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Temasek Life Sciences Laboratory"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Public Offering","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Morgan Stanley"},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"National Yang-Ming University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"VYR-206","moa":"CB1 receptor","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vyripharm Biopharmaceuticals \/ National Yang-Ming University","highestDevelopmentStatusID":"3","companyTruncated":"Vyripharm Biopharmaceuticals \/ National Yang-Ming University"},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CB Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"CB Therapeutics \/ Cleveland Clinic","highestDevelopmentStatusID":"1","companyTruncated":"CB Therapeutics \/ Cleveland Clinic"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"ATI-2173","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Antios Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Antios Therapeutics"},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The National Comprehensive Cancer Network \/ Puma Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"The National Comprehensive Cancer Network \/ Puma Biotechnology"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Abemaciclib","moa":"CDK6","graph1":"Oncology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ National Comprehensive Cancer Network"},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Decitabine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"1","companyTruncated":"The National Comprehensive Cancer Network \/ Taiho Oncology"},{"orgOrder":0,"company":"Invirsa","sponsor":"Cincytech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Nadolol","moa":"p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Invirsa \/ Cincytech","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Cincytech"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ 5Am Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ 5Am Ventures"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Fidelity Management & Research","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Fidelity Management & Research","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Fidelity Management & Research"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Altium Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ Altium Capital","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Altium Capital"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ Enavate Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Enavate Sciences"},{"orgOrder":0,"company":"EpiBiologics","sponsor":"Digitalis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EpiBiologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EpiBiologics \/ Digitalis Ventures","highestDevelopmentStatusID":"3","companyTruncated":"EpiBiologics \/ Digitalis Ventures"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Alger","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Alger","highestDevelopmentStatusID":"4","companyTruncated":"Forte Biosciences \/ Alger"},{"orgOrder":0,"company":"Tachyon Therapeutics","sponsor":"Veblen Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"Phase I","graph3":"Tachyon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tachyon Therapeutics \/ Veblen Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tachyon Therapeutics \/ Veblen Ventures"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"ML-007C-MA","moa":"Muscarinic M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MapLight Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"BVF Partners L.P.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Private Placement","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ BVF Partners L.P.","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ BVF Partners L.P."},{"orgOrder":0,"company":"Ryne Biotechnology","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RNDP-001","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ryne Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ryne Biotechnology \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ryne Biotechnology \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"KayoThera","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"KayoThera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KayoThera \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"2","companyTruncated":"KayoThera \/ Accelerator Life Science Partners"},{"orgOrder":0,"company":"KayoThera","sponsor":"NIH NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"KayoThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KayoThera \/ NIH NIDDK","highestDevelopmentStatusID":"1","companyTruncated":"KayoThera \/ NIH NIDDK"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN 6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ J.P. Morgan"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ TD Cowen"},{"orgOrder":0,"company":"Arrivent","sponsor":"Sofinnova","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Sofinnova","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Sofinnova"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Belrestotug","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Financing","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ The Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ The Lind Partners"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series C Financing","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Deep Track Capital","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Deep Track Capital"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"LTZ-301","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Star Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series C Financing","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Star Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"6","companyTruncated":"Star Therapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kriya Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"4","companyTruncated":"Kriya Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"CastleVax","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"NDV-HXP-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CastleVax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"CastleVax \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"7","companyTruncated":"CastleVax \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Codagenix","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Codagenix \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"GRT-R910","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"8","companyTruncated":"Gritstone bio \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"SA53","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lamassu Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Perceive Biotherapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Perceive Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Perceive Biotherapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Perceive Biotherapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adamis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adamis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Rostaporfin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Kintara Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Buck Institute for Research on Aging","sponsor":"Hevolution Foundation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Buck Institute for Research on Aging","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Buck Institute for Research on Aging \/ Hevolution Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Buck Institute for Research on Aging \/ Hevolution Foundation"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"Alumis","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Morgan Stanley"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Boustead Securities, LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kairos Pharma \/ Boustead Securities, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Boustead Securities, LLC"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Boustead Securities, LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kairos Pharma \/ Boustead Securities, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Boustead Securities, LLC"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"||KIT","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Public Offering","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Public Offering","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"CancerVAX","sponsor":"StartEngine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CancerVAX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CancerVAX \/ StartEngine","highestDevelopmentStatusID":"4","companyTruncated":"CancerVAX \/ StartEngine"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company LLC","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoPrecise \/ The Benchmark Company LLC","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company LLC"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Guggenheim Securities"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"LifeSci Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ LifeSci Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ LifeSci Capital LLC"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Cantor","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Cantor"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lassen Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Lassen Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ SVB Leerink"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ SVB Leerink"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ SVB Leerink"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ SVB Leerink"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Maxim Group LLC"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"PRT2527","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Eight Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Eight Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Eight Capital"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Aflibercept","moa":"||VEGF","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"MyoKardia","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ BofA Securities"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"CD19\/Fc\u03b3RIIb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"CD19\/Fc\u03b3RIIb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ TD Cowen"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ TD Cowen"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ TD Cowen"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PRAX-628","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PRAX-628","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series C Financing","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"ATTO-1310","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Attovia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"5","companyTruncated":"Attovia Therapeutics \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Chengwei Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shape Therapeutics \/ Chengwei Capital","highestDevelopmentStatusID":"2","companyTruncated":"Shape Therapeutics \/ Chengwei Capital"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Lysosomal-Targeted Chimeras","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Lycia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lycia Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Lycia Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Medicovestor","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicovestor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicovestor \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Medicovestor \/ Undisclosed"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Series A Financing","leadProduct":"Gersizangitide","moa":"VEGFR 2","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Enavate Sciences"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"GKCC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"MiNK-215","moa":"FAP-expressing CAF","graph1":"Oncology","graph2":"Preclinical","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiNK Therapeutics \/ GKCC","highestDevelopmentStatusID":"4","companyTruncated":"MiNK Therapeutics \/ GKCC"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Financing","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"IM-1021","moa":"ROR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"IM-1021","moa":"ROR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Brookline Capital Market","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"ADXS31-164","moa":"ERBB 2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Brookline Capital Market","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Brookline Capital Market"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"LongeVC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ LongeVC","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ LongeVC"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"Deep Apple Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Deep Apple Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deep Apple Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"2","companyTruncated":"Deep Apple Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Nephrology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cadrenal Therapeutics \/ Boustead Securities","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Boustead Securities"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Zevra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ DCVC Bio"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"2Seventy Bio \/ Goldman Sachs","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Goldman Sachs"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Jefferies"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Jefferies"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Jones","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elicio Therapeutics \/ Jones","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Jones"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Piper Sandler & Co"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Piper Sandler & Co"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Piper Sandler & Co"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"Cusatuzumab","moa":"||CD70","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Argenx"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Avalo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Avalo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Avalo Therapeutics"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"ACTM-838","moa":"IL-15plex\/eSTING","graph1":"Oncology","graph2":"Phase I","graph3":"Actym Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actym Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Actym Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Roth Capital Partners"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Roth Capital Partners"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CTX112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"||MLL-KMT2A\/MLL","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"||MLL-KMT2A\/MLL","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Savara","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Savara \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Jefferies"},{"orgOrder":0,"company":"Cypris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Cypris Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cypris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Cypris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ RA Capital Management"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eliem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ RA Capital Management"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Alliance Global Partners"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Public Offering","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cadrenal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Cadrenal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Guggenheim Securities, LLC"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Guggenheim Securities, LLC"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Douglas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Financing","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Douglas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Douglas Pharmaceuticals"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Structure Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Ascenta Capital"},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aiolos Bio \/ Atlas Venture","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Orlance","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orlance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Orlance \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Orlance \/ National Institutes of Health"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"MLL-KMT2A\/MLL","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Forward Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Forward Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forward Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Forward Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"BioLoomics","sponsor":"Innovation Endeavors","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"BioLoomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioLoomics \/ Innovation Endeavors","highestDevelopmentStatusID":"2","companyTruncated":"BioLoomics \/ Innovation Endeavors"},{"orgOrder":0,"company":"Claris Bio","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Oremepermin Alpha","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Claris Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Claris Bio \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Claris Bio \/ Organovo Holdings"},{"orgOrder":0,"company":"IgGenix","sponsor":"Alexandria Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IgGenix \/ Alexandria Venture","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ Alexandria Venture"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Alpha Wave Global","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Alpha Wave Global","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Alpha Wave Global"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Nafamostat","moa":"SARS-CoV-2-viral spike protein","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Vasa Therapeutics","sponsor":"NuFund Venture Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"VS-041","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Vasa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasa Therapeutics \/ NuFund Venture Group","highestDevelopmentStatusID":"6","companyTruncated":"Vasa Therapeutics \/ NuFund Venture Group"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Sanders Morris Harris","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olatec Therapeutics \/ Sanders Morris Harris","highestDevelopmentStatusID":"9","companyTruncated":"Olatec Therapeutics \/ Sanders Morris Harris"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Fairmount","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Fairmount"},{"orgOrder":0,"company":"Sail Biomedicines","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sail Biomedicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sail Biomedicines \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Sail Biomedicines \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase III","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Aura Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"CT-388","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Carmot Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Private Placement","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasca \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ J.P. Morgan"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Morgan Stanley"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"DermBiont","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"DermBiont \/ Double Point Ventures","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Double Point Ventures"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Jones","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Jones","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Jones"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Jones","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Jones","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Jones"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Agreement","leadProduct":"AP\u2010PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"Imagine Pharma","sponsor":"IP Investors LLC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"IMG-1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Imagine Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imagine Pharma \/ IP Investors LLC","highestDevelopmentStatusID":"6","companyTruncated":"Imagine Pharma \/ IP Investors LLC"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Crossbow Therapeutics","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"TCR","graph1":"Oncology","graph2":"Discovery","graph3":"Crossbow Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crossbow Therapeutics \/ MPM BioImpact","highestDevelopmentStatusID":"2","companyTruncated":"Crossbow Therapeutics \/ MPM BioImpact"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Bessemer Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series B Financing","leadProduct":"S-1117","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Bessemer Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Therapeutic \/ Bessemer Venture Partners"},{"orgOrder":0,"company":"Heranova Lifesciences","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Heranova Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heranova Lifesciences \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Heranova Lifesciences \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"TRX103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ The Column Group"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"GRT-R910","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Gritstone bio \/ BARDA"},{"orgOrder":0,"company":"IAVI","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"IAVI \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Universal Influenza Virus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"IMM20320","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Corner Therapeutics","sponsor":"Ziff Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Corner Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corner Therapeutics \/ Ziff Capital Partners","highestDevelopmentStatusID":"4","companyTruncated":"Corner Therapeutics \/ Ziff Capital Partners"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CinRx Pharma \/ CinRx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma"},{"orgOrder":0,"company":"Magdalena Biosciences","sponsor":"One Small Planet","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Magdalena Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Magdalena Biosciences \/ One Small Planet","highestDevelopmentStatusID":"1","companyTruncated":"Magdalena Biosciences \/ One Small Planet"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"PRTX007","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Primmune Therapeutics \/ Defense Threat Reduction Agency"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bitterroot Bio \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Bitterroot Bio \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Pionyr Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Pionyr Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Pionyr Immunotherapeutics"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"IC 100-08","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"University of Central florida","sponsor":"Ludwig Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Central florida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Central florida \/ Ludwig Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"University of Central florida \/ Ludwig Enterprises"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"CC8464","moa":"NaV1.7 sodium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chromocell Corporation \/ Maxim Group","highestDevelopmentStatusID":"6","companyTruncated":"Chromocell Corporation \/ Maxim Group"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Sparian Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SBS-518","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sparian Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sparian Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Sparian Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Jefferies"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ridgeback Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LENZ Therapeutics \/ Ridgeback Capital","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Ridgeback Capital"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Asset Management"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"GLSI-100","moa":"||Granulocyte-macrophage","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Jefferies"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw"},{"orgOrder":0,"company":"Septerna","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"SEP-786","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Septerna \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Septerna \/ J.P. Morgan"},{"orgOrder":0,"company":"Septerna","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"SEP-786","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Septerna \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Septerna \/ J.P. Morgan"},{"orgOrder":0,"company":"Septerna","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"SEP-786","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Septerna \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Septerna \/ J.P. Morgan"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Nextech","highestDevelopmentStatusID":"4","companyTruncated":"Context Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Leerink Partners"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"AB-101","moa":"||ADCC","graph1":"Oncology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Jefferies"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"ANB032","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ TD Cowen"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Celadon Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Celadon Partners","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Celadon Partners"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities, Inc","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities, Inc"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Serpinpc","moa":"APC receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"TIDAL-01","moa":"||TIL","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"GLP-1-Based Pancreatic Gene Therapy","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ BofA Securities","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ BofA Securities"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CRG-022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARGO Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ WallachBeth Capital","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ WallachBeth Capital"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Nextech"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"||PD-1\/CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"||PD-1\/CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"||PD-1\/CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"KB109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Structure Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Structure Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Syros Pharmaceuticals \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Syros Pharmaceuticals \/ TD Cowen"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Morgan Stanley & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Morgan Stanley & Co","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Morgan Stanley & Co"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Povetacicept","moa":"B cell cytokine","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Povetacicept","moa":"B cell cytokine","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"University of North Carolina \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University of North Carolina \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Solve GNE","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"GA-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Solve GNE","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solve GNE \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Solve GNE \/ Undisclosed"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG, LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"COYA 201","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ BTIG, LLC"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Flare Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ BTIG"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ BTIG"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan Securities","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Prime Medicine \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Empress Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Empress Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Empress Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Empress Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Ivonescimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Ivonescimab","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MimiVax","sponsor":"Brain Tumor Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Montanide","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MimiVax \/ Brain Tumor Investment Fund","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Brain Tumor Investment Fund"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Funding","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"IMIDomics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"IMB1001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMIDomics \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Nectero Medical","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Pentagalloyl Glucose","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Nectero Medical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"Nectero Medical \/ Norwest Venture Partners","highestDevelopmentStatusID":"9","companyTruncated":"Nectero Medical \/ Norwest Venture Partners"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ The Column Group"},{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kimia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kimia Therapeutics \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Kimia Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ J.P. Morgan"},{"orgOrder":0,"company":"Eyenovia","sponsor":"William Blair","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ William Blair","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ William Blair"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Shanghai Healthcare Capital"},{"orgOrder":0,"company":"Insmed","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"3B Future Health Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ 3B Future Health Fund","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ 3B Future Health Fund"},{"orgOrder":0,"company":"Camino Pharma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"SBP-9330","moa":"mGluR2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Camino Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Camino Pharma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Camino Pharma \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Darovasertib","moa":"PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Leerink Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Verve Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Clasp Therapeutics","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Clasp Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clasp Therapeutics \/ Catalio Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Clasp Therapeutics \/ Catalio Capital Management"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ATX-968","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accent Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Accent Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ J.P. Morgan"},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ J.P. Morgan"},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ J.P. Morgan"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Natural Sciences and Engineering Council","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"DB-007-4","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Natural Sciences and Engineering Council","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Natural Sciences and Engineering Council"},{"orgOrder":0,"company":"Leash Biosciences","sponsor":"Springtide Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Leash Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leash Biosciences \/ Springtide Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Leash Biosciences \/ Springtide Ventures"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eliem Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ SVB Leerink"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ OrbiMed Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Rifampicin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ HighCape Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ HighCape Capital"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Cartesian Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Cartesian Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Cartesian Therapeutics"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Premier","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Premier \/ Baudax Bio","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Baudax Bio"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ GSK"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University of Louisville","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qualigen Therapeutics \/ University of Louisville","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen Therapeutics \/ University of Louisville"},{"orgOrder":0,"company":"Exalys Therapeutics","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"EP4 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Exalys Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exalys Therapeutics \/ Catalys Pacific","highestDevelopmentStatusID":"1","companyTruncated":"Exalys Therapeutics \/ Catalys Pacific"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Societal CDMO \/ Undisclosed"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"CBL-B","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Pivotal bioVenture Partners"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ MBX Capital"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Clarke Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"MLX0800","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Clarke Capital","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Clarke Capital"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Tenaya Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Measles Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxxas \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"SNSP003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Anagram Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anagram Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anagram Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Humanetics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"The Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ The Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ The Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Premji Invest"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Roth Capital Partners"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"VIR-1388","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Vir Biotechnology \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Vir Biotechnology \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vir Biotechnology \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"ISA Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Cemiplimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ ISA Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ ISA Pharmaceuticals"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Staidson Biopharma","sponsor":"Pivotal","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"BDB-001","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Staidson Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Staidson Biopharma \/ Pivotal","highestDevelopmentStatusID":"8","companyTruncated":"Staidson Biopharma \/ Pivotal"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"PLN-1474","moa":"Integrin-alpha 5\/beta 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Pliant Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Eyconis","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Eyconis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Eyconis \/ Ascendis Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Eyconis \/ Ascendis Pharma"},{"orgOrder":0,"company":"Angiocrine Bioscience","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"AB-205","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Angiocrine Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Angiocrine Bioscience \/ Cobro Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Angiocrine Bioscience \/ Cobro Ventures"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Research Center","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fred Hutchinson Cancer Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Fred Hutchinson Cancer Research Center \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Fred Hutchinson Cancer Research Center \/ National Institutes of Health"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Arrevus","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"ARV-1502","moa":"DnaK protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrevus \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ National Institutes of Health"},{"orgOrder":0,"company":"Palette Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Palette Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palette Life Sciences \/ Silicon Valley Bank","highestDevelopmentStatusID":"15","companyTruncated":"Palette Life Sciences \/ Silicon Valley Bank"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Polymyxin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ CARB-X","highestDevelopmentStatusID":"5","companyTruncated":"MicuRx Pharmaceuticals \/ CARB-X"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ NovaQuest Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Financing","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Hercules Capital"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adimab","sponsor":"Ablexis","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Adimab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adimab \/ Ablexis","highestDevelopmentStatusID":"3","companyTruncated":"Adimab \/ Ablexis"},{"orgOrder":0,"company":"GB Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"GB Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GB Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ National Research Council of Canada"},{"orgOrder":0,"company":"Felix Biotechnology","sponsor":"The National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Felix Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Felix Biotechnology \/ The National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Felix Biotechnology \/ The National Science Foundation"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Yisheng Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Tavo-201","moa":"||CD4+ T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavotek Biotherapeutics \/ Yisheng Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Biotherapeutics \/ Yisheng Biopharma"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"InveniAI","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Immunology","graph2":"Discovery Platform","graph3":"InveniAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InveniAI \/ Sosei Heptares","highestDevelopmentStatusID":"3","companyTruncated":"InveniAI \/ Sosei Heptares"},{"orgOrder":0,"company":"Alternative Research Associates","sponsor":"Organicell Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Partnership","leadProduct":"Zofin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Alternative Research Associates","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alternative Research Associates \/ Organicell Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Alternative Research Associates \/ Organicell Regenerative Medicine"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"BRAIN Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TransCode Therapeutics \/ BRAIN Biotech","highestDevelopmentStatusID":"2","companyTruncated":"TransCode Therapeutics \/ BRAIN Biotech"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Eyenovia","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ National Securities Corporation"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ J. P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J. P. Morgan"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ J. P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J. P. Morgan"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Ohio State University","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AgeX-BAT1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ Ohio State University"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Recursion Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Singapore Economic Development Board","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Singapore Economic Development Board","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Singapore Economic Development Board"},{"orgOrder":0,"company":"Trutino Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"ODC-IL2","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Trutino Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trutino Biosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Trutino Biosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"CareDx","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CareDx \/ Vir Biotechnology"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Children\u2019S Oncology Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Children\u2019S Oncology Group","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Children\u2019S Oncology Group"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Exacis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"ExaNK","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eterna Therapeutics \/ Exacis Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Exacis Biotherapeutics"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Pentoxifylline","moa":"TNF-alpha","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Silk Road Therapies \/ Soligenix","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road Therapies \/ Soligenix"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"mSA2 affinity-enhanced biotin","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Coeptis Therapeutics \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"ARO-JNJ1","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"Eclipse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nucleus RadioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nucleus RadioPharma \/ Eclipse","highestDevelopmentStatusID":"1","companyTruncated":"Nucleus RadioPharma \/ Eclipse"},{"orgOrder":0,"company":"VantAI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VantAI \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Birinapant","moa":"SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TetraLogic Pharmaceuticals \/ Medivir","highestDevelopmentStatusID":"6","companyTruncated":"TetraLogic Pharmaceuticals \/ Medivir"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Ottawa Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Ottawa Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Ottawa Hospital"},{"orgOrder":0,"company":"Mapp Biopharmaceutical","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"MBP134","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mapp Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mapp Biopharmaceutical \/ Aridis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Mapp Biopharmaceutical \/ Aridis Pharmaceuticals"},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"OPC-167832","moa":"||DprE1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bill & Melinda Gates Foundation \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Melinda Gates Foundation \/ GSK"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Kennedy's Disease Association","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReviR Therapeutics \/ Kennedy's Disease Association","highestDevelopmentStatusID":"2","companyTruncated":"ReviR Therapeutics \/ Kennedy's Disease Association"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson"},{"orgOrder":0,"company":"Xencor","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Vibecotamab","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"NextCure","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ LegoChem Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Columbia University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Columbia University \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Columbia University \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"EDIRNA","sponsor":"Sirnaomics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"EDIRNA","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"EDIRNA \/ Sirnaomics","highestDevelopmentStatusID":"3","companyTruncated":"EDIRNA \/ Sirnaomics"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thermo Fisher Scientific \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Humanigen"},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Undisclosed"},{"orgOrder":0,"company":"Eversana","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eversana \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/ Humanigen"},{"orgOrder":0,"company":"CytoDyn","sponsor":"amfAR","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ amfAR","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ amfAR"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Greater NY Chamber of Commerce","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tadalafil","moa":"||PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Greater NY Chamber of Commerce","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Greater NY Chamber of Commerce"},{"orgOrder":0,"company":"Flashpoint Therapeutics","sponsor":"KAIMRC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"FLASH-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Flashpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flashpoint Therapeutics \/ KAIMRC","highestDevelopmentStatusID":"7","companyTruncated":"Flashpoint Therapeutics \/ KAIMRC"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PANTHERx Rare Pharmacy \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Gilead Sciences"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acrotech Biopharma \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acrotech Biopharma \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Galen Patient Recruitment","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Galen Patient Recruitment","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Galen Patient Recruitment"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"CHAI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ CHAI","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ CHAI"},{"orgOrder":0,"company":"Anova Enterprises","sponsor":"Dizal Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Sunvozertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Anova Enterprises","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anova Enterprises \/ Dizal Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Anova Enterprises \/ Dizal Pharmaceutical"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Bennu Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Porton Advanced Solutions \/ Bennu Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ Bennu Biotherapeutics"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Caris Life Sciences \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Merck Group"},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Neutron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Alpha radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aviko Radiopharmaceuticals \/ Neutron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Neutron Therapeutics"},{"orgOrder":0,"company":"BullFrog","sponsor":"Sage Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"BF-222","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BullFrog","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BullFrog \/ Sage Group","highestDevelopmentStatusID":"6","companyTruncated":"BullFrog \/ Sage Group"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Resyca BV Partner","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Resyca BV Partner","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Resyca BV Partner"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"ABI-4334","moa":"cccDNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Cellectar","sponsor":"Meaningful Insights-BioTech Analytics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Partnership","leadProduct":"131-I Iopofosine","moa":"DNA damage","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Meaningful Insights-BioTech Analytics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Meaningful Insights-BioTech Analytics"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Delafloxacin","moa":"Topoisomerse IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Melinta Therapeutics \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Avista Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Avista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Avista Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Avista Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Optime Care","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Optime Care","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Optime Care \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Optime Care \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Pendulum Therapeutics","sponsor":"Fonterra Co-operative Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Partnership","leadProduct":"Akkermansia Muciniphila","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Pendulum Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pendulum Therapeutics \/ Fonterra Co-operative Group","highestDevelopmentStatusID":"15","companyTruncated":"Pendulum Therapeutics \/ Fonterra Co-operative Group"},{"orgOrder":0,"company":"Topix Skin Health","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"ProteXidine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Topix Skin Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topix Skin Health \/ University of Minnesota","highestDevelopmentStatusID":"1","companyTruncated":"Topix Skin Health \/ University of Minnesota"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"ProGen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Partnership","leadProduct":"RT-114","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rani Therapeutics \/ ProGen","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ ProGen"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Rezatapopt","moa":"||p53","graph1":"Oncology","graph2":"Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PMV Pharma \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"PMV Pharma \/ Foundation Medicine"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Children\u2019s Hospital Capital institute of Pediatrics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Children\u2019s Hospital Capital institute of Pediatrics","highestDevelopmentStatusID":"6","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Children\u2019s Hospital Capital institute of Pediatrics"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Queen\u2019s University Belfast","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aviceda Therapeutics \/ Queen\u2019s University Belfast","highestDevelopmentStatusID":"2","companyTruncated":"Aviceda Therapeutics \/ Queen\u2019s University Belfast"},{"orgOrder":0,"company":"Metabolon\u202f","sponsor":"BioFINDER","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Metabolon\u202f","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metabolon\u202f \/ BioFINDER","highestDevelopmentStatusID":"2","companyTruncated":"Metabolon\u202f \/ BioFINDER"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Novo Nordisk"},{"orgOrder":0,"company":"Oragenics","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Avance Clinical"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Naval Medical Research Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Naval Medical Research Center","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Naval Medical Research Center"},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune \/ JDRF"},{"orgOrder":0,"company":"AmplifyBio","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AmplifyBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AmplifyBio \/ Xcell Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AmplifyBio \/ Xcell Biosciences"},{"orgOrder":0,"company":"Agenus","sponsor":"Tanner Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Tanner Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Tanner Pharma"},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"Laxxon Medical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adare Pharma Solutions \/ Laxxon Medical","highestDevelopmentStatusID":"2","companyTruncated":"Adare Pharma Solutions \/ Laxxon Medical"},{"orgOrder":0,"company":"Illumina","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Illumina","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Illumina \/ Deerfield Management","highestDevelopmentStatusID":"3","companyTruncated":"Illumina \/ Deerfield Management"},{"orgOrder":0,"company":"Syndesis Health","sponsor":"InSyBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Syndesis Health","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndesis Health \/ InSyBio","highestDevelopmentStatusID":"3","companyTruncated":"Syndesis Health \/ InSyBio"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"Hubble Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"HUB-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andelyn Biosciences \/ Hubble Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Andelyn Biosciences \/ Hubble Therapeutics"},{"orgOrder":0,"company":"SpectronRx","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Partnership","leadProduct":"212-Pb NG001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SpectronRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"SpectronRx \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"SpectronRx \/ ARTBIO"},{"orgOrder":0,"company":"Redwire Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"ELP-004","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Redwire Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redwire Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Redwire Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"HDT-521","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HDT Biotech \/ BARDA","highestDevelopmentStatusID":"5","companyTruncated":"HDT Biotech \/ BARDA"},{"orgOrder":0,"company":"Expert Systems","sponsor":"Eilean Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Expert Systems \/ Eilean Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Expert Systems \/ Eilean Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Siren Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Siren Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Siren Biotechnology"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"Grace Science","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Andelyn Biosciences \/ Grace Science","highestDevelopmentStatusID":"7","companyTruncated":"Andelyn Biosciences \/ Grace Science"},{"orgOrder":0,"company":"Shinobi Therapeutics","sponsor":"Anocca AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Shinobi Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shinobi Therapeutics \/ Anocca AB","highestDevelopmentStatusID":"2","companyTruncated":"Shinobi Therapeutics \/ Anocca AB"},{"orgOrder":0,"company":"Asymchem","sponsor":"LaNova","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Asymchem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asymchem \/ LaNova","highestDevelopmentStatusID":"1","companyTruncated":"Asymchem \/ LaNova"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dewpoint Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Dewpoint Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"AbSci","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"AbSci \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ Almirall"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Optimeos Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Optimeos Life Sciences"},{"orgOrder":0,"company":"Spanios","sponsor":"Unravel Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Spanios","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spanios \/ Unravel Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Spanios \/ Unravel Biosciences"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Chromocell Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Diclofenac","moa":"COX-1\/2","graph1":"Neurology","graph2":"Phase I","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Benuvia Therapeutics \/ Chromocell Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Benuvia Therapeutics \/ Chromocell Corporation"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"VIR-2482","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Expanded Collaboration","leadProduct":"TSHA-112","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Taysha Gene Therapies","highestDevelopmentStatusID":"2","companyTruncated":"UT Southwestern Medical Center \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"xCures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ xCures","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ xCures"},{"orgOrder":0,"company":"Transcell Oncologics","sponsor":"L2P Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Transcell Oncologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcell Oncologics \/ L2P Research","highestDevelopmentStatusID":"4","companyTruncated":"Transcell Oncologics \/ L2P Research"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ AmbioPharm"},{"orgOrder":0,"company":"Berg Health","sponsor":"AdventHealth","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Collaboration","leadProduct":"Ubidecarenone","moa":"LDL-cholesterol oxidation","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Berg Health \/ AdventHealth","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ AdventHealth"},{"orgOrder":0,"company":"Matica Biotechnology","sponsor":"Mongoose Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"MGB-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Matica Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matica Biotechnology \/ Mongoose Bio","highestDevelopmentStatusID":"4","companyTruncated":"Matica Biotechnology \/ Mongoose Bio"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Duchenne Uk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Edasalonexent","moa":"Nf-kB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Duchenne Uk","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Duchenne Uk"},{"orgOrder":0,"company":"Genovis","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Immunoglobulin G Protease","moa":"Neutralizing antibody","graph1":"Immunology","graph2":"Preclinical","graph3":"Genovis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genovis \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Genovis \/ Selecta Biosciences"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orca Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Orca Bio \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Citrine Medicine"},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Just \u2013 Evotec Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Just \u2013 Evotec Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"1","companyTruncated":"Just \u2013 Evotec Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Multiply Labs","sponsor":"Retro Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Multiply Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multiply Labs \/ Retro Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Multiply Labs \/ Retro Biosciences"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Sinopharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Sinopharm","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Sinopharm"},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Topiramate","moa":"Caveolin-1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikonoklastes Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklastes Therapeutics \/ Forge Biologics"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Forge Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Forge Biologics"},{"orgOrder":0,"company":"Alleo","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Alleo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alleo \/ Ubiquigent","highestDevelopmentStatusID":"2","companyTruncated":"Alleo \/ Ubiquigent"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Arcturus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Life Edit Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Life Edit Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Life Edit Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Life Edit Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Hongene Biotech","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Hongene Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hongene Biotech \/ n-Lorem Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Hongene Biotech \/ n-Lorem Foundation"},{"orgOrder":0,"company":"OmniaBio","sponsor":"Catamaran Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"OmniaBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OmniaBio \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"OmniaBio \/ Catamaran Bio"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"BRL Medicine","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"BRL-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Porton Advanced Solutions \/ BRL Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Porton Advanced Solutions \/ BRL Medicine"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Indegene Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Indegene Inc","highestDevelopmentStatusID":"15","companyTruncated":"Titan Pharmaceuticals Inc \/ Indegene Inc"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Rallybio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"RLYB-114","moa":"Complement C5","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"EyePoint Pharmaceuticals \/ Rallybio"},{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Filaggrin","graph1":"Dermatology","graph2":"Preclinical","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Azitra \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Azitra \/ Leaps by Bayer"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Brigimadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase II","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foundation Medicine \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Foundation Medicine \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"E3 ubiquitin ligase CBL-B","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ Caris Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Caris Life Sciences"},{"orgOrder":0,"company":"MyoKardia","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ LianBio"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Integral Molecular \/ Optimeos","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Optimeos"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"AFNT-111","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Affini-T Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Metagenomi \/ Affini-T Therapeutics"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Recursion Pharma \/ Bayer AG"},{"orgOrder":0,"company":"FibroGenesis","sponsor":"R4D Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"PneumoBlast","moa":"Tissue Factor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGenesis \/ R4D Biotech","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenesis \/ R4D Biotech"},{"orgOrder":0,"company":"Mandos Health","sponsor":"INPDR","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Adrabetadex","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Mandos Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Mandos Health \/ INPDR","highestDevelopmentStatusID":"9","companyTruncated":"Mandos Health \/ INPDR"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"||DHA level","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Hofseth BioCare"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Advanced Bioscience laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"MVA-Based SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GeoVax Labs \/ Advanced Bioscience laboratories","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ Advanced Bioscience laboratories"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ JW Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fisher Scientific \/ JW Therapeutics"},{"orgOrder":0,"company":"Cryoport Systems Inc","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cryoport Systems Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cryoport Systems Inc \/ Syneos Health","highestDevelopmentStatusID":"3","companyTruncated":"Cryoport Systems Inc \/ Syneos Health"},{"orgOrder":0,"company":"Argonaut Manufacturing Services","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Argonaut Manufacturing Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Argonaut Manufacturing Services \/ n-Lorem Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Argonaut Manufacturing Services \/ n-Lorem Foundation"},{"orgOrder":0,"company":"Open Book Extracts","sponsor":"Biopharmaceutical Research Company","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Open Book Extracts","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Open Book Extracts \/ Biopharmaceutical Research Company","highestDevelopmentStatusID":"1","companyTruncated":"Open Book Extracts \/ Biopharmaceutical Research Company"},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ElevateBio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReviR Therapeutics \/ CMT Research Foundation","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Therapeutics \/ CMT Research Foundation"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Sagesse Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Partnership","leadProduct":"Cotsiranib","moa":"||TGF-beta 1\/COX-2","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Sagesse Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Sagesse Bio"},{"orgOrder":0,"company":"Spanios","sponsor":"Rare Cancer Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Spanios","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanios \/ Rare Cancer Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Spanios \/ Rare Cancer Research Foundation"},{"orgOrder":0,"company":"VGXI","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Partnership","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"VGXI","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VGXI \/ Sutro Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"VGXI \/ Sutro Biopharma"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Broad Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"PARG","graph1":"Oncology","graph2":"Discovery","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Broad Institute","highestDevelopmentStatusID":"2","companyTruncated":"Ideaya Biosciences \/ Broad Institute"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"GEO-CM01","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ GeoVax Labs","highestDevelopmentStatusID":"4","companyTruncated":"National Institutes of Health \/ GeoVax Labs"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Isoquercitrin","moa":"sP-selectin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Quercis Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Beth Israel Deaconess Medical Center \/ Quercis Pharma"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Nrf2","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vividion Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Vividion Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ GSK"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Ministry of Health and Welfare, Taiwan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Ministry of Health and Welfare, Taiwan","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Ministry of Health and Welfare, Taiwan"},{"orgOrder":0,"company":"Copernicus Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Copernicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Copernicus Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Copernicus Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Columbia University","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Columbia University \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Columbia University \/ Ayala Pharmaceuticals"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"THOR-707","moa":"||Non-alpha IL-2","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Sanofi"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melior Pharmaceuticals \/ Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pharmaceuticals \/ Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Gemcitabine HCl","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alkermes Plc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Alkermes Plc","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Alkermes Plc"},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Gemcitabine","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"U.S. Defense Department","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CMC Pharmaceuticals \/ U.S. Defense Department","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharmaceuticals \/ U.S. Defense Department"},{"orgOrder":0,"company":"Merck & Co","sponsor":"QBiotics Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Tigilanol Tiglate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ QBiotics Group","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ QBiotics Group"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Olinvacimab","moa":"||VEGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ PharmAbcine","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ PharmAbcine"},{"orgOrder":0,"company":"Vapogenix","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Sevoflurane","moa":"GABA-A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Vapogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vapogenix \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Vapogenix \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ National Institutes of Health"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Nivolumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Piramal Pharma Solutions"},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"STI-2020dna","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SmartPharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SmartPharm Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SmartPharm Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Cincinnati Children's Hospital Medical Center","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Cincinnati Children's Hospital Medical Center","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cincinnati Children's Hospital Medical Center \/ Blue Water Vaccines","highestDevelopmentStatusID":"3","companyTruncated":"Cincinnati Children's Hospital Medical Center \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Tetherex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Single-Cycle Adenovirus Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Mayo Clinic \/ Tetherex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Tetherex Pharmaceuticals"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Kronos Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Entospletinib","moa":"||SYK","graph1":"Oncology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Kronos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Kronos Bio"},{"orgOrder":0,"company":"iQure Pharma","sponsor":"Keiretsu Mid-Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"iQ-007","moa":"EAAT2","graph1":"Neurology","graph2":"Preclinical","graph3":"iQure Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"iQure Pharma \/ Keiretsu Mid-Atlantic","highestDevelopmentStatusID":"4","companyTruncated":"iQure Pharma \/ Keiretsu Mid-Atlantic"},{"orgOrder":0,"company":"Seraph Research Institute","sponsor":"Enochian BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"ENOB-HB-01","moa":"HBV polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seraph Research Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seraph Research Institute \/ Enochian BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Seraph Research Institute \/ Enochian BioSciences"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Syntone Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Syntone Ventures LLC","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Syntone Ventures LLC"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Ipsen"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Astellas Pharma"},{"orgOrder":0,"company":"Charcot Marie Tooth Association","sponsor":"Pharnext","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Baclofen","moa":"||PMP22 gene overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Charcot Marie Tooth Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Charcot Marie Tooth Association \/ Pharnext","highestDevelopmentStatusID":"10","companyTruncated":"Charcot Marie Tooth Association \/ Pharnext"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Fairmount","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Day One Biopharmaceuticals \/ Fairmount","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Fairmount"},{"orgOrder":0,"company":"HI-Bio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ ARCH Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ ARCH Venture Partners"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"EM-113","moa":"NMDAR","graph1":"Neurology","graph2":"Phase II","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuMentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EuMentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Nextech","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"BCTG Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ BCTG Acquisition Corp","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ BCTG Acquisition Corp"},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Founding Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Brimonidine Tartrate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visiox Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visiox Pharma \/ Founding Partners","highestDevelopmentStatusID":"10","companyTruncated":"Visiox Pharma \/ Founding Partners"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"AJ1-11095","moa":"JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ajax Therapeutics \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"6","companyTruncated":"Ajax Therapeutics \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Gurnet Point Capital","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"JuvVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"POZ-apomorphine","moa":"D4\/D2\/D3\/D5\/Alpha1D\/Alpha2B\/Alpha2C receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Serina Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Serina Therapeutics \/ JuvVentures","highestDevelopmentStatusID":"5","companyTruncated":"Serina Therapeutics \/ JuvVentures"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Avoro Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series D Financing","leadProduct":"Undisclosed","moa":"p53 protein","graph1":"Oncology","graph2":"Discovery","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Avoro Capital","highestDevelopmentStatusID":"2","companyTruncated":"PMV Pharma \/ Avoro Capital"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series C Financing","leadProduct":"OBX-115","moa":"IL-15 production","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Obsidian Therapeutics \/ Wellington Management","highestDevelopmentStatusID":"7","companyTruncated":"Obsidian Therapeutics \/ Wellington Management"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"LTZ-301","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series C Financing","leadProduct":"AB-2100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArsenalBio \/ ARCH Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"AXN-027","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Axonis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axonis Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"Axonis Therapeutics \/ Cormorant Asset Management"},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"CRG-022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARGO Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"Outpace Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"OPB-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Outpace Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Outpace Bio \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Outpace Bio \/ RA Capital Management"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"5","companyTruncated":"Quanta Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Preclinical","graph3":"GRO Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRO Biosciences \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"GRO Biosciences \/ Atlas Venture"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Obvious Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"MycoMedica Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MycoMedica Life Sciences \/ Obvious Ventures","highestDevelopmentStatusID":"1","companyTruncated":"MycoMedica Life Sciences \/ Obvious Ventures"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Hematology","graph2":"Phase II","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cadrenal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Cadrenal Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"IAM1363","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iambic Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"6","companyTruncated":"Iambic Therapeutics \/ Mubadala Capital"},{"orgOrder":0,"company":"Judo Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"Judo Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Judo Bio \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"Judo Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Tolerance Bio","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Tolerance Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tolerance Bio \/ Columbus Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Tolerance Bio \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"HLD-0915","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halda Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Halda Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"TwoStep Therapeutics","sponsor":"NFX Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TwoStep Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TwoStep Therapeutics \/ NFX Bio","highestDevelopmentStatusID":"3","companyTruncated":"TwoStep Therapeutics \/ NFX Bio"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Canaan Partners","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Canaan Partners"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Arkin Bio Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Taplucanium","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Nocion Therapeutics \/ Arkin Bio Capital","highestDevelopmentStatusID":"6","companyTruncated":"Nocion Therapeutics \/ Arkin Bio Capital"},{"orgOrder":0,"company":"Retension Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"RTN-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Retension Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Retension Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Retension Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardurion Pharmaceutical \/ Ascenta Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cardurion Pharmaceutical \/ Ascenta Capital"},{"orgOrder":0,"company":"ReViral","sponsor":"Cr-Cp Life Science Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Sisunatovir","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ReViral \/ Cr-Cp Life Science Fund","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Cr-Cp Life Science Fund"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"SL-172154","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Redmile Group","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Redmile Group"},{"orgOrder":0,"company":"Amplicore","sponsor":"Photon Fund","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"AM3101","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Amplicore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amplicore \/ Photon Fund","highestDevelopmentStatusID":"4","companyTruncated":"Amplicore \/ Photon Fund"},{"orgOrder":0,"company":"Plexium","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"IKZF2 transcription factor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plexium \/ BVF Partners","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ BVF Partners"},{"orgOrder":0,"company":"QurAlis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ EQT Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ EQT Life Sciences"},{"orgOrder":0,"company":"Teclison","sponsor":"W.T.T. Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"TEC-001","moa":"Hypoxia","graph1":"Oncology","graph2":"Phase II","graph3":"Teclison","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teclison \/ W.T.T. Investment","highestDevelopmentStatusID":"8","companyTruncated":"Teclison \/ W.T.T. Investment"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Jnana Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Alexandria Venture Investments","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Ring Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ring Therapeutics \/ Alexandria Venture Investments","highestDevelopmentStatusID":"4","companyTruncated":"Ring Therapeutics \/ Alexandria Venture Investments"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Tybourne Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Tybourne Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Tybourne Capital Management"},{"orgOrder":0,"company":"Travecta Therapeutics","sponsor":"TKS1","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"TVT-004","moa":"CB receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Travecta Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travecta Therapeutics \/ TKS1","highestDevelopmentStatusID":"1","companyTruncated":"Travecta Therapeutics \/ TKS1"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Cambrian Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"SNS-301","moa":"Aspartyl-beta hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Cambrian Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sensei Biotherapeutics \/ Cambrian Biopharma"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ SR One Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"ADARx Pharmaceuticals \/ SR One Capital Management"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ATI-2173","moa":"||Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Ambys Medicines","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"AMI-918","moa":"Hepatocyte Cell","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ambys Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ambys Medicines \/ Third Rock Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ambys Medicines \/ Third Rock Ventures"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Labcorp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Presage Biosciences \/ Labcorp","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Labcorp"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ATI-2173","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Abingworth","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Abingworth"},{"orgOrder":0,"company":"Creyon Bio","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Creyon Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Creyon Bio \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Creyon Bio \/ DCVC Bio"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Portland Investment Counsel Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"212-Pb Dotamtate","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RadioMedix \/ Portland Investment Counsel Inc.","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Portland Investment Counsel Inc."},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Avalon BioVentures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"ART5803","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arialys Therapeutics \/ Avalon BioVentures","highestDevelopmentStatusID":"4","companyTruncated":"Arialys Therapeutics \/ Avalon BioVentures"},{"orgOrder":0,"company":"Disc medicine","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ OrbiMed","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ OrbiMed"},{"orgOrder":0,"company":"Onchilles Pharma","sponsor":"University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"ELANE pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Onchilles Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onchilles Pharma \/ University of Chicago","highestDevelopmentStatusID":"4","companyTruncated":"Onchilles Pharma \/ University of Chicago"},{"orgOrder":0,"company":"Senda Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Senda Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senda Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"4","companyTruncated":"Senda Biosciences \/ Flagship Pioneering"},{"orgOrder":0,"company":"Aevisbio","sponsor":"KB investment","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"3,6\u2019-dithiopomalidomide","moa":"TNF-alpha","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aevisbio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevisbio \/ KB investment","highestDevelopmentStatusID":"5","companyTruncated":"Aevisbio \/ KB investment"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Presight Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Series B Financing","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Presight Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogics \/ Presight Capital"},{"orgOrder":0,"company":"Cellarity","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Cellarity","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellarity \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Cellarity \/ Flagship Pioneering"},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"SLV213","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Selva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Selva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janux Therapeutics \/ BVF Partners L.P","highestDevelopmentStatusID":"4","companyTruncated":"Janux Therapeutics \/ BVF Partners L.P"},{"orgOrder":0,"company":"Icosavax","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"Stabilized Prefusion F Antigen","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/ RA Capital Management"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Cowen and Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Cowen and Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Cowen and Piper Sandler"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Westar Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Westar Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Westar Capital Limited"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"FP-025","moa":"MMP-12","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Frazier Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HilleVax \/ Frazier Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Frazier Healthcare"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"RNAimmune","sponsor":"Sirnaomics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series A Financing","leadProduct":"RIM730","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RNAimmune \/ Sirnaomics","highestDevelopmentStatusID":"4","companyTruncated":"RNAimmune \/ Sirnaomics"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Willett Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"STX-478","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Willett Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Willett Advisors"},{"orgOrder":0,"company":"TearSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series B Financing","leadProduct":"Lacritin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"TearSolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TearSolutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TearSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"National Institutes of Mental Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rumi Scientific \/ National Institutes of Mental Health","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scientific \/ National Institutes of Mental Health"},{"orgOrder":0,"company":"Acrivon Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Private Placement","leadProduct":"Prexasertib","moa":"||CHK1","graph1":"Oncology","graph2":"Phase II","graph3":"Acrivon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acrivon Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Acrivon Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Enavate Sciences"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Public Offering","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ J. P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ J. P. Morgan"},{"orgOrder":0,"company":"Genelux","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Private Placement","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Benchmark Company"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Abiologics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Abiologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abiologics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Abiologics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"225-Ac","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ J.P. Morgan"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sinopia Biosciences \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Sinopia Biosciences \/ National Institute of General Medical Sciences"},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Metaphore Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metaphore Biotechnologies \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Metaphore Biotechnologies \/ Flagship Pioneering"},{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Canaan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Actio Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actio Biosciences \/ Canaan","highestDevelopmentStatusID":"4","companyTruncated":"Actio Biosciences \/ Canaan"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Iron Sucrose","moa":"||Phosphate","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Bioluminescence Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"RCT1100","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Bioluminescence Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ReCode Therapeutics \/ Bioluminescence Ventures"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Oppenheimer & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"CUE-401","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Oppenheimer & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Oppenheimer & Co"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Oppenheimer & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"CUE-401","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Oppenheimer & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Oppenheimer & Co"},{"orgOrder":0,"company":"ElevateBio","sponsor":"AyurMaya Capital Management Fund","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series D Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ElevateBio \/ AyurMaya Capital Management Fund","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ AyurMaya Capital Management Fund"},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"AKY-1189","moa":"Nectin-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aktis Oncology \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Oncology \/ RA Capital Management"},{"orgOrder":0,"company":"Cerevance","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Google Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Google Ventures"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CAMP4 Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RAP-219","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RAP-219","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"5-Fluorocytosine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Denovo Biopharma \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Denovo Biopharma \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"Plixorafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fore Biotherapeutics \/ SR One","highestDevelopmentStatusID":"7","companyTruncated":"Fore Biotherapeutics \/ SR One"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cytarabine","moa":"||CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicines","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ California Institute for Regenerative Medicines"},{"orgOrder":0,"company":"Vilya","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Vilya","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vilya \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Vilya \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Gate Bioscience","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Gate Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Gate Bioscience \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Gate Bioscience \/ Versant Ventures"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Silicon Valley Bank","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Silicon Valley Bank"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ BofA Securities"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Adaptimmune Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verrica Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Synedgen","sponsor":"JWMRP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"MIIST305","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synedgen \/ JWMRP","highestDevelopmentStatusID":"4","companyTruncated":"Synedgen \/ JWMRP"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"TOUR006","moa":"IL-6 signalling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tourmaline Bio \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Sante Ventures"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ National Institutes of Health"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Phillip Frost","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Phillip Frost","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Phillip Frost"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"OrsoBio \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Ascenta Capital"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ReCode Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Pfizer Inc"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Attovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Attovia Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Attovia Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Colt Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterome Therapeutics \/ Colt Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Alterome Therapeutics \/ Colt Ventures"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Commodore Capital"},{"orgOrder":0,"company":"ATCC (American Type Culture Collection)","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Babesia Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ATCC (American Type Culture Collection)","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATCC (American Type Culture Collection) \/ NIAID","highestDevelopmentStatusID":"2","companyTruncated":"ATCC (American Type Culture Collection) \/ NIAID"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Tencent","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Series B Financing","leadProduct":"NB1000S","moa":"||Oxalate","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novome Biotechnologies \/ Tencent","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Tencent"},{"orgOrder":0,"company":"Ois\u00edn Biotechnologies","sponsor":"AbbVie Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ois\u00edn Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ois\u00edn Biotechnologies \/ AbbVie Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ois\u00edn Biotechnologies \/ AbbVie Ventures"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series A Financing","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnCusp Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"MTX-101","moa":"KIR dependent CD8 treg","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Mozart Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Avoro Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Avoro Capital Advisors","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Avoro Capital Advisors"},{"orgOrder":0,"company":"Leal Therapeutics","sponsor":"Chugai Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"LTX-002","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Leal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leal Therapeutics \/ Chugai Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Leal Therapeutics \/ Chugai Venture Fund"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Arda Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Arda Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arda Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"2","companyTruncated":"Arda Therapeutics \/ Andreessen Horowitz"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tectonic Therapeutic \/ TAS Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ TAS Partners"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ OrbiMed"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affinia Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Therapeutics \/ Atlas Venture"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"TRexBio","sponsor":"Delos Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"TRB-061","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Delos Capital","highestDevelopmentStatusID":"5","companyTruncated":"TRexBio \/ Delos Capital"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"XVIR-110","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Exavir Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Exavir Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Exavir Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Newpath Partners"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"Amniotic Tissue Allograft","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"New Leaf","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"HPN217","moa":"CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ New Leaf","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ New Leaf"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Foundation Fighting Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"OPGx-RHO","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opus Genetics \/ Foundation Fighting Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Opus Genetics \/ Foundation Fighting Blindness"},{"orgOrder":0,"company":"ArrePath","sponsor":"PACE","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"AP-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ArrePath","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArrePath \/ PACE","highestDevelopmentStatusID":"4","companyTruncated":"ArrePath \/ PACE"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Financing","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dyadic International, Inc \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ReCode Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"4M Therapeutics","sponsor":"SynGAP Research Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"4MT2001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4M Therapeutics \/ SynGAP Research Fund","highestDevelopmentStatusID":"4","companyTruncated":"4M Therapeutics \/ SynGAP Research Fund"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Soleus Capital","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Soleus Capital"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Sparian Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"SBS-226","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sparian Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sparian Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Sparian Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ BofA Securities"},{"orgOrder":0,"company":"CohBar","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Private Placement","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"CohBar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ Undisclosed"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"RevBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"TN-ADBS","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"RevBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RevBio \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"RevBio \/ National Institutes of Health"},{"orgOrder":0,"company":"Metsera","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series B Financing","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metsera \/ Wellington Management","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Wellington Management"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Omega Funds"},{"orgOrder":0,"company":"Solu Therapeutics","sponsor":"Longwood","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Solu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Solu Therapeutics \/ Longwood","highestDevelopmentStatusID":"3","companyTruncated":"Solu Therapeutics \/ Longwood"},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Duquesne Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ratio Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ratio Therapeutics \/ Duquesne Capital","highestDevelopmentStatusID":"3","companyTruncated":"Ratio Therapeutics \/ Duquesne Capital"},{"orgOrder":0,"company":"University of California","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"CNDR-51997","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ National Institute on Aging"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Casdatifan","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arcus Biosciences \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Hercules Capital"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Series E Financing","leadProduct":"CT-388","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Carmot Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Proniras","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Tezampanel","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Proniras","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proniras \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"7","companyTruncated":"Proniras \/ Accelerator Life Science Partners"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"IDG Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allorion Therapeutics \/ IDG Capital","highestDevelopmentStatusID":"4","companyTruncated":"Allorion Therapeutics \/ IDG Capital"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series C Financing","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"OKI-219","moa":"PI3K Alpha H1047R","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eterna Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Nabla Bio","sponsor":"Radical Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nabla Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nabla Bio \/ Radical Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nabla Bio \/ Radical Ventures"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LENZ Therapeutics \/ Sectoral Asset Management","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Sectoral Asset Management"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odyssey Therapeutics \/ General Catalyst","highestDevelopmentStatusID":"2","companyTruncated":"Odyssey Therapeutics \/ General Catalyst"},{"orgOrder":0,"company":"Orlance","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"MACH-1-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orlance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orlance \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Orlance \/ National Institutes of Health"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Hm Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Tobramycin","moa":"||Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Hm Capital","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Hm Capital"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Ohio Innovation Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series A Financing","leadProduct":"CMTX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarametyx Biosciences \/ Ohio Innovation Fund","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ Ohio Innovation Fund"},{"orgOrder":0,"company":"Alumis","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Morgan Stanley"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Turn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Turn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ BofA Securities"},{"orgOrder":0,"company":"89bio","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.28999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Lake Street Capital"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ TD Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ TD Cowen"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Jefferies"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Raymond James & Associates"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Raymond James & Associates"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Raymond James & Associates"},{"orgOrder":0,"company":"Replimune","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Public Offering","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Leerink Partners"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Septerna","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Septerna \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Septerna \/ RA Capital Management"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ TD Cowen"},{"orgOrder":0,"company":"Metsera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Metsera \/ ARCH Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Metsera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Humacyte","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Funding","leadProduct":"Ferrous Gluconate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Aflibercept","moa":"||VEGF","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Invivyd","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Google Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Google Ventures"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Upacicalcet Sodium","moa":"CaR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pathalys Pharma \/ TCGX","highestDevelopmentStatusID":"15","companyTruncated":"Pathalys Pharma \/ TCGX"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"MARATHON PHARMS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ MARATHON PHARMS","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ MARATHON PHARMS"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Triton Funds","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Triton Funds","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Triton Funds"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Reneo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Reneo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Reneo Pharmaceuticals"},{"orgOrder":0,"company":"Apnimed","sponsor":"Morningside Venture","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Morningside Venture","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Morningside Venture"},{"orgOrder":0,"company":"Nexcella","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexcella \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ CIRM"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Canaan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Qlaris Bio \/ Canaan","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Canaan"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GRO Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GRO Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"GRO Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Asteroid Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"Tobramycin Sulfate","moa":"||Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Asteroid Partners","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Asteroid Partners"},{"orgOrder":0,"company":"Chase Therapeutics","sponsor":"Chinalink Asia Holdings","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pramipexole DiHCl","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Chase Therapeutics \/ Chinalink Asia Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Chase Therapeutics \/ Chinalink Asia Holdings"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Undisclosed"},{"orgOrder":0,"company":"4E Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"4ET1103","moa":"MNK receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"4E Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4E Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"4E Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Series B Financing","leadProduct":"Carboplatin","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ MPM BioImpact","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ MPM BioImpact"},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Kate Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kate Therapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"2","companyTruncated":"Kate Therapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Mariana Oncology","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Series B Financing","leadProduct":"MC-339","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Mariana Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mariana Oncology \/ Deep Track Capital","highestDevelopmentStatusID":"4","companyTruncated":"Mariana Oncology \/ Deep Track Capital"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Odyssey Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odyssey Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"4","companyTruncated":"Odyssey Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Corsair Pharma","sponsor":"Junson Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Treprostinil Prodrug","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsair Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corsair Pharma \/ Junson Capital","highestDevelopmentStatusID":"6","companyTruncated":"Corsair Pharma \/ Junson Capital"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"FB-102","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Forte Biosciences \/ OrbiMed"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Hatteras Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||CD5-ATAK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Myeloid Therapeutics \/ Hatteras Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Therapeutics \/ Hatteras Investment Partners"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marker Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Foresite Capital"},{"orgOrder":0,"company":"Arcellx","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"CART-ddBCMA","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcellx \/ Samsara BioCapital","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Samsara BioCapital"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Valley Forge Investment Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation"},{"orgOrder":0,"company":"Hemispherian","sponsor":"Meneldor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"GLIX1","moa":"TET2","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemispherian \/ Meneldor","highestDevelopmentStatusID":"4","companyTruncated":"Hemispherian \/ Meneldor"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"ATEM Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"Cyclophosphamide","moa":"||Endogenous T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triumvira Immunologics \/ ATEM Capital","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ ATEM Capital"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ CIRM"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Maxim Group LLC"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Hercules Capital"},{"orgOrder":0,"company":"IDRx","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDRx \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ RA Capital Management"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ FDA","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ FDA"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tectonic Therapeutic \/ TAS Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ TAS Partners"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ K2 HealthVentures"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Rejoy Corporation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JW-500","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Topical","sponsorNew":"Safety Shot \/ Rejoy Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Safety Shot \/ Rejoy Corporation"},{"orgOrder":0,"company":"Wugen","sponsor":"Alpha Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wugen \/ Alpha Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Wugen \/ Alpha Biopharma"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"Pcori","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Duke Clinical Research Institute \/ Pcori","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clinical Research Institute \/ Pcori"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Bristol Myers Squibb \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Intensity Therapeutics"},{"orgOrder":0,"company":"AlivaMab","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AlivaMab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlivaMab \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"3","companyTruncated":"AlivaMab \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"PharmaJet","sponsor":"USAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Fractional Inactivated Poliovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaJet \/ USAID","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet \/ USAID"},{"orgOrder":0,"company":"Ceek Womens Health","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ceek Womens Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Ceek Womens Health \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Ceek Womens Health \/ Lupin Ltd"},{"orgOrder":0,"company":"U.S. Regional Biocontainment Laboratory","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"U.S. Regional Biocontainment Laboratory","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"U.S. Regional Biocontainment Laboratory \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"U.S. Regional Biocontainment Laboratory \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ European Union","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ European Union"},{"orgOrder":0,"company":"IQVIA","sponsor":"ProtoKinetix","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"PKX-001","moa":"S-opsin","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ ProtoKinetix","highestDevelopmentStatusID":"4","companyTruncated":"IQVIA \/ ProtoKinetix"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ebola Zaire Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lumos Pharma \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Lumos Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"The Progeria Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Akorn Pharmaceuticals \/ Laboratoires Thea","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Laboratoires Thea"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Maryland Board of Public Works","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Maryland Board of Public Works","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Maryland Board of Public Works"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Shenzhen Smoore Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Shenzhen Smoore Technology","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Shenzhen Smoore Technology"},{"orgOrder":0,"company":"Novavax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Crossject","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Crossject"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Southern Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"TNX-1800","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Southern Research","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Southern Research"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"French Health Authorities For The Cystic Fibrosis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ French Health Authorities For The Cystic Fibrosis","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ French Health Authorities For The Cystic Fibrosis"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aerpio Pharmaceuticals \/ Gossamer Bio","highestDevelopmentStatusID":"6","companyTruncated":"Aerpio Pharmaceuticals \/ Gossamer Bio"},{"orgOrder":0,"company":"UMass Dartmouth","sponsor":"Caamtech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"UMass Dartmouth","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMass Dartmouth \/ Caamtech","highestDevelopmentStatusID":"2","companyTruncated":"UMass Dartmouth \/ Caamtech"},{"orgOrder":0,"company":"Xencor","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Erasmus University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Collaboration","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Erasmus University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Erasmus University Medical Center"},{"orgOrder":0,"company":"Celularity","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celularity \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Celularity \/ Kleo Pharmaceuticals"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolojic Design \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic Design \/ Eli Lilly"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Expanded Collaboration","leadProduct":"TNX-1800","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Columbia University","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Columbia University"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Alberta","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Sangivamycin Hydrochloride","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Alberta","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Alberta"},{"orgOrder":0,"company":"George Mason University NCBID","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Onternabez","moa":"CB2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"George Mason University NCBID","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"George Mason University NCBID \/ Tetra BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"George Mason University NCBID \/ Tetra BioPharma"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ AstraZeneca"},{"orgOrder":0,"company":"Renovacor","sponsor":"University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"DSG2 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renovacor \/ University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"The Greehey Children's Cancer Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ The Greehey Children's Cancer Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ The Greehey Children's Cancer Research Institute"},{"orgOrder":0,"company":"Lygenesis","sponsor":"Imagine Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lygenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lygenesis \/ Imagine Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lygenesis \/ Imagine Pharma"},{"orgOrder":0,"company":"Equillium","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Equillium \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Equillium \/ University of Oxford"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Vanderbilt University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Vanderbilt University","highestDevelopmentStatusID":"4","companyTruncated":"Neumora therapeutics \/ Vanderbilt University"},{"orgOrder":0,"company":"Southern Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"TNX-1800","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Southern Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Southern Research \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Southern Research \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"HT-006","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cincinnati \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Cincinnati \/ Hoth Therapeutics"},{"orgOrder":0,"company":"NexImmune","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"AIM ACT","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NexImmune \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune \/ Columbia University"},{"orgOrder":0,"company":"University of Maryland","sponsor":"Mydecine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University of Maryland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland \/ Mydecine","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland \/ Mydecine"},{"orgOrder":0,"company":"Reservoir Neuroscience","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Reservoir Neuroscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reservoir Neuroscience \/ Kizoo Technology Capital","highestDevelopmentStatusID":"3","companyTruncated":"Reservoir Neuroscience \/ Kizoo Technology Capital"},{"orgOrder":0,"company":"Simulations Plus","sponsor":"Food and Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Simulations Plus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Simulations Plus \/ Food and Drug Administration","highestDevelopmentStatusID":"4","companyTruncated":"Simulations Plus \/ Food and Drug Administration"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"WestRiver Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"LMN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lumen Bioscience \/ WestRiver Management","highestDevelopmentStatusID":"8","companyTruncated":"Lumen Bioscience \/ WestRiver Management"},{"orgOrder":0,"company":"Neuron23","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuron23 \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/ Redmile Group"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human Ipsc-Derived Cardiac Tissues","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoSurface Biomedical \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurface Biomedical \/ National Institutes of Health"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"RABI-767","moa":"Lipase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lamassu Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense for Advanced Development","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Ology Bioservices \/ Department of Defense for Advanced Development","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense for Advanced Development"},{"orgOrder":0,"company":"SpineThera","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"SpineThera \/ Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Department of Defense"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Athyrium Capital"},{"orgOrder":0,"company":"Pan Cancer T","sponsor":"InnovationQuarter","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"PCT-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pan Cancer T","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pan Cancer T \/ InnovationQuarter","highestDevelopmentStatusID":"4","companyTruncated":"Pan Cancer T \/ InnovationQuarter"},{"orgOrder":0,"company":"Allermi","sponsor":"Nelstone Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Financing","leadProduct":"Triamcinolone","moa":"Ach receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Nelstone Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Nelstone Ventures"},{"orgOrder":0,"company":"Lassogen","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"LAS-103","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lassogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassogen \/ Playground Global","highestDevelopmentStatusID":"4","companyTruncated":"Lassogen \/ Playground Global"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seed Therapeutics \/ Eisai","highestDevelopmentStatusID":"2","companyTruncated":"Seed Therapeutics \/ Eisai"},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosciences \/ Selecta Biosciences"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"SLS-004","moa":"SNCA gene","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Invetx","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Neurology","graph2":"Discovery","graph3":"Invetx","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Invetx \/ Casdin Capital","highestDevelopmentStatusID":"2","companyTruncated":"Invetx \/ Casdin Capital"},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"INF-alpha","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bonum Therapeutics \/ Roche Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Therapeutics \/ Roche Venture Fund"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ DCVC Bio"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"MPM Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"VivoCAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ MPM Capital"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Mediar Therapeutics \/ Novartis Venture Fund"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seismic Therapeutic \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seismic Therapeutic \/ Lightspeed Venture Partners"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"VLX-1005","moa":"12-LOX","graph1":"Hematology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Veralox Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"T-cell","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sonoma Biotherapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Qnovia","sponsor":"Blue Ledge Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Series A Financing","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Blue Ledge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Blue Ledge Capital"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"mPTP","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NRG Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"Faze Medicines","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Faze Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Faze Medicines \/ Third Rock Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Faze Medicines \/ Third Rock Ventures"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Transcription factor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flare Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Flare Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"VOR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Tumor targeted protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ranok Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ranok Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Vertex Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"IMG-20","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Vertex Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Vertex Ventures"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"S.R. One","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PKC-theta","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ S.R. One","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Therapeutics \/ S.R. One"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"SoftBank Vision","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"UB-TT170","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ SoftBank Vision","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ SoftBank Vision"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Series B Financing","leadProduct":"Sialidase-fc","moa":"Sialoglycan","graph1":"Oncology","graph2":"Preclinical","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palleon Pharmaceuticals \/ Matrix Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Palleon Pharmaceuticals \/ Matrix Capital Management"},{"orgOrder":0,"company":"Garuda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Garuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Garuda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Garuda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bodor Laboratories","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Bodor Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Bodor Laboratories \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Bodor Laboratories \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Isotope Technologies Munich","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Isotope Technologies Munich"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BWV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ University of Oxford"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Morgan Stanley & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Morgan Stanley & Co","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Morgan Stanley & Co"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Checkpoint","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenScript ProBio \/ AskGene Pharma Inc","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ AskGene Pharma Inc"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Spinal Muscular Atrophy Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Spinal Muscular Atrophy Foundation","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Spinal Muscular Atrophy Foundation"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Eunice Kennedy Shriver National Institute Of Child Health","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Brown Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health","highestDevelopmentStatusID":"1","companyTruncated":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health"},{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"Carmot Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Demerger","leadProduct":"CT-388","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kimia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kimia Therapeutics \/ Carmot Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kimia Therapeutics \/ Carmot Therapeutics"},{"orgOrder":0,"company":"MetasTx","sponsor":"J-Star Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"MTX-101","moa":"PAK1","graph1":"Oncology","graph2":"Preclinical","graph3":"MetasTx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MetasTx \/ J-Star Research","highestDevelopmentStatusID":"4","companyTruncated":"MetasTx \/ J-Star Research"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"State of North Dakota","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ImmunoPrecise \/ State of North Dakota","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ State of North Dakota"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Heat Biologics"},{"orgOrder":0,"company":"Tempus","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ AstraZeneca"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Initium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenScript ProBio \/ Initium Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ Initium Therapeutics"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Daridorexant","moa":"OX1\/2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Myeloid cell\/phagocytosis","graph1":"Oncology","graph2":"Discovery","graph3":"Dren Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dren Bio \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Dren Bio \/ Pfizer Inc"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Suzhou Royaltech Med Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Porton Advanced Solutions \/ Suzhou Royaltech Med Co., Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ Suzhou Royaltech Med Co., Ltd."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Financing","leadProduct":"Cipaglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"ElevateBio","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Cyclophosphamide","moa":"||Mesothelin protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ElevateBio \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"ElevateBio \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"IQVIA \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ GSK"},{"orgOrder":0,"company":"Humanetics","sponsor":"Regenerative Medicine Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Genistein","moa":"PTK","graph1":"Oncology","graph2":"Preclinical","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Humanetics \/ Regenerative Medicine Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"Humanetics \/ Regenerative Medicine Minnesota"},{"orgOrder":0,"company":"Jeeva Clinical Trials","sponsor":"Redwood Scientific Technologies Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Cytisine","moa":"nAchR Alpha 5","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Jeeva Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"Jeeva Clinical Trials \/ Redwood Scientific Technologies Inc","highestDevelopmentStatusID":"11","companyTruncated":"Jeeva Clinical Trials \/ Redwood Scientific Technologies Inc"},{"orgOrder":0,"company":"IsoPlexis","sponsor":"MediMergent","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"IsoPlexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IsoPlexis \/ MediMergent","highestDevelopmentStatusID":"15","companyTruncated":"IsoPlexis \/ MediMergent"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Sansero Life Sciences","sponsor":"University Of Toronto","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sansero Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sansero Life Sciences \/ University Of Toronto","highestDevelopmentStatusID":"4","companyTruncated":"Sansero Life Sciences \/ University Of Toronto"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Ideaya Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Ideaya Biosciences"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Global Coalition for Adaptive Research \/ Kazia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Islatravir","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Sensei Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron Pharmaceuticals \/ Sensei Biotherapeutics"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"||CD163","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoResponse \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"OncoResponse \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"USAMRDC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Funding","leadProduct":"LMN-301","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lumen Bioscience \/ USAMRDC","highestDevelopmentStatusID":"5","companyTruncated":"Lumen Bioscience \/ USAMRDC"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Walter Reed Army Institute","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Noveome Biotherapeutics \/ Walter Reed Army Institute","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Walter Reed Army Institute"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Caring Cross","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enochian BioSciences \/ Caring Cross","highestDevelopmentStatusID":"7","companyTruncated":"Enochian BioSciences \/ Caring Cross"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Termination","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Technology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ BioNTech"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Lysogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Sarepta Therapeutics \/ Lysogene","highestDevelopmentStatusID":"9","companyTruncated":"Sarepta Therapeutics \/ Lysogene"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ CSL Behring"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"NM-102","moa":"Intestinal microbiome","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"9 Meters Biopharma \/ Gustave Roussy","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Gustave Roussy"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eureka Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Eureka Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CFTR","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Moderna Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Moderna Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Servier"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Merger","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"Indivior","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"10","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CTT1403","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Targeted Technology \/ National Institutes of Health"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TILT Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Merck & Co \/ TILT Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ TILT Biotherapeutics"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Piramal Pharma Solutions \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Piramal Pharma Solutions \/ Plus Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novocure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Tumor growth","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Merck & Co \/ Novocure","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Novocure"},{"orgOrder":0,"company":"Komodo Health","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase II","graph3":"Komodo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Komodo Health \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Komodo Health \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Nusano","sponsor":"PharmaLogic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nusano \/ PharmaLogic","highestDevelopmentStatusID":"1","companyTruncated":"Nusano \/ PharmaLogic"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"YuanBio Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Tavo111","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tavotek Biotherapeutics \/ YuanBio Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tavotek Biotherapeutics \/ YuanBio Venture Capital"},{"orgOrder":0,"company":"Apertura Gene Therapy","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Apertura Gene Therapy","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apertura Gene Therapy \/ Deerfield Management Company","highestDevelopmentStatusID":"2","companyTruncated":"Apertura Gene Therapy \/ Deerfield Management Company"},{"orgOrder":0,"company":"Rutgers University","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Collaboration","leadProduct":"Gut-Microbiome","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Rutgers University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers University \/ International Flavors and Fragrances","highestDevelopmentStatusID":"2","companyTruncated":"Rutgers University \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2020","type":"Funding","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ReveraGen BioPharma \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen BioPharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Celularity","sponsor":"GX Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ GX Acquisition Corp","highestDevelopmentStatusID":"6","companyTruncated":"Celularity \/ GX Acquisition Corp"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"U.S. government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ U.S. government","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ U.S. government"},{"orgOrder":0,"company":"Bioasis","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Transcend Peptide","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioasis \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"Bioasis \/ Chiesi Group"},{"orgOrder":0,"company":"Codexis","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Codexis \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Codexis \/ Pfizer Inc"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"BPX-601","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Abigail Wexner Research Institute","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"K-NK-ID101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Abigail Wexner Research Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abigail Wexner Research Institute \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Abigail Wexner Research Institute \/ Sanofi"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ATI-1701","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Chimeron Bio","sponsor":"Mason University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Self-Amplifying Rna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chimeron Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimeron Bio \/ Mason University","highestDevelopmentStatusID":"4","companyTruncated":"Chimeron Bio \/ Mason University"},{"orgOrder":0,"company":"Eighteen Fifty-Nine","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Eighteen Fifty-Nine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eighteen Fifty-Nine \/ Northpond Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Eighteen Fifty-Nine \/ Northpond Ventures"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Versatope Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Versatope Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Versatope Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Versatope Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"PureTech Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"IL-22","moa":"||IL-22","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alivio Therapeutics \/ PureTech Health","highestDevelopmentStatusID":"4","companyTruncated":"Alivio Therapeutics \/ PureTech Health"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AmMax Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"AMG 820","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ AmMax Bio","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ AmMax Bio"},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"TLY012","moa":"DR5","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Theraly Fibrosis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theraly Fibrosis \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Theraly Fibrosis \/ National Institutes of Health"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Acquisition","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Theramex"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Theramex"},{"orgOrder":0,"company":"Breathe Biologics","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Demerger","leadProduct":"Umbilical Cord Derived Monocyte","moa":"Cytokine production","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Breathe Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Breathe Biologics \/ Therapeutic Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Breathe Biologics \/ Therapeutic Solutions"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Rubric Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Financing","leadProduct":"Segesterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"TherapeuticsMD \/ Rubric Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Rubric Capital Management"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Public Offering","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Public Offering","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Theratechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Theratechnologies"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"GLPG5101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fisher Scientific \/ Galapagos"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Thermo Fisher Scientific \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Sylvester Comprehensive Cancer Center","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"STAT3 protein","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sylvester Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sylvester Comprehensive Cancer Center \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Sylvester Comprehensive Cancer Center \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Hercules Capital"},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"cAd3-Marburg","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sabin Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sabin Vaccine Institute \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Sabin Vaccine Institute \/ BARDA"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Interleukin 2","moa":"T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Erase PTSD","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Funding","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Erase PTSD","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Erase PTSD"},{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Copper Sulphate Pentahydrate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"iVeena \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ National Eye Institute"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"THE-630","moa":"pan-variant KIT","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theseus Pharmaceuticals \/ Foresite Capital","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Foresite Capital"},{"orgOrder":0,"company":"Third Pole Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Third Pole Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Third Pole Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Third Pole Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Descartes-30","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Menaquinone-7","moa":"SXR","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"NattoPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"NattoPharma \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"NattoPharma \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"Onspira Therapeutics","sponsor":"Altavant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"OSP-101","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Onspira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Onspira Therapeutics \/ Altavant Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Onspira Therapeutics \/ Altavant Sciences"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alexion Pharmaceuticals \/ Arcturus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ Pacira BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Flexion Therapeutics \/ Pacira BioSciences"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"PeriphaGen","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Acquisition","leadProduct":"rQNestin34.5","moa":"ICP34.5 gene","graph1":"Oncology","graph2":"Phase I","graph3":"PeriphaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeriphaGen \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"PeriphaGen \/ Candel Therapeutics"},{"orgOrder":0,"company":"CerSci Therapeutics","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"ACP-044","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"CerSci Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CerSci Therapeutics \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"CerSci Therapeutics \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Neon Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"NEO-STC-01","moa":"RAS neoantigen","graph1":"Oncology","graph2":"Preclinical","graph3":"Neon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neon Therapeutics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Neon Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ SLR Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ SLR Capital Partners"},{"orgOrder":0,"company":"AgilVax","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SLC7A11\/xCT","graph1":"Oncology","graph2":"Preclinical","graph3":"AgilVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AgilVax \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AgilVax \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"The Texas A&M University System","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"MPI8","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sorrento Therapeutics \/ The Texas A&M University System","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ The Texas A&M University System"},{"orgOrder":0,"company":"Sanofi","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"scFv","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Jadeite Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jadeite Medicines"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Thermo Fisher Scientific \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Merck & Co"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"AdaptVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 Capsid-Virus-like Particle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ AdaptVac","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biologics \/ AdaptVac"},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"VR588","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kinaset Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kinaset Therapeutics \/ Vectura Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Kinaset Therapeutics \/ Vectura Ltd"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Quratis Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Quratis Co., Ltd"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Erasca","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Erasca"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Riluzole","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chrysalis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chrysalis BioTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Chrysalis BioTherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Plakous Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Protego-PD","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Plakous Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plakous Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plakous Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"AnaBios","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"ANB-504","moa":"Dual sodium channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"AnaBios","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaBios \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"AnaBios \/ National Institutes of Health"},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Population Council","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Partnership","leadProduct":"Segesterone Acetate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Lubrizol Life Science Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lubrizol Life Science Health \/ Population Council","highestDevelopmentStatusID":"1","companyTruncated":"Lubrizol Life Science Health \/ Population Council"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Private placement","leadProduct":"Entospletinib","moa":"||SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kronos Bio \/ Jefferies LLC","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Jefferies LLC"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"CF-370","moa":"Pseudomonas aeruginosa cell wall","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ContraFect Corporation \/ CARB-X","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect Corporation \/ CARB-X"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Verastem Oncology"},{"orgOrder":0,"company":"Harvard University","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Harvard University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard University \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"Harvard University \/ AbbVie Inc"},{"orgOrder":0,"company":"Emery Pharma","sponsor":"Halodine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Povidone-Iodine","moa":"Inflammatory mediator","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emery Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Emery Pharma \/ Halodine","highestDevelopmentStatusID":"1","companyTruncated":"Emery Pharma \/ Halodine"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"METTL3","graph1":"Oncology","graph2":"Preclinical","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accent Therapeutics \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Accent Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avid Bioservices \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Avid Bioservices \/ Humanigen"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Transcenta Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Nivolumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Transcenta Holding","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Transcenta Holding"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akron Biotech \/ Vor Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Akron Biotech \/ Vor Biopharma"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ DanausGT Biotechnology"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ IQVIA"},{"orgOrder":0,"company":"Serotiny","sponsor":"Tessera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Serotiny","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serotiny \/ Tessera Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Serotiny \/ Tessera Therapeutics"},{"orgOrder":0,"company":"EpiVax","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Nucleic acid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"EpiVax \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Biotheus","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bitterroot Bio \/ Biotheus","highestDevelopmentStatusID":"2","companyTruncated":"Bitterroot Bio \/ Biotheus"},{"orgOrder":0,"company":"University of Massachusetts Medical School","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Massachusetts Medical School","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts Medical School \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Massachusetts Medical School \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"The Danish Cancer Society Research Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ The Danish Cancer Society Research Center","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ The Danish Cancer Society Research Center"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Elicio Therapeutics"},{"orgOrder":0,"company":"Adgero Biopharmaceuticals","sponsor":"Minakem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Adgero Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adgero Biopharmaceuticals \/ Minakem","highestDevelopmentStatusID":"8","companyTruncated":"Adgero Biopharmaceuticals \/ Minakem"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Geron","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Hercules Capital"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Therapeutics \/ Shionogi"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catamaran Bio \/ University of Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ University of Minnesota"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"PDS0103","moa":"MUC1","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ PDS Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ PDS Biotechnology"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Oxford Finance","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Oxford Finance"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Wu Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Korro Bio \/ Wu Capital","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio \/ Wu Capital"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Redmile Group","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Redmile Group"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Runway Growth Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Relmapirazin","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Runway Growth Capital","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Runway Growth Capital"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Simcah Management","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellphire Therapeutics \/ Simcah Management","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Simcah Management"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Park West Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Park West Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Park West Asset Management"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Undisclosed"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"CAM Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"PRTX007","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ CAM Capital","highestDevelopmentStatusID":"6","companyTruncated":"Primmune Therapeutics \/ CAM Capital"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"TAC01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triumvira Immunologics \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Bayer AG"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"THB001","moa":"KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Third Harmonic Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-383B","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Series C Financing","leadProduct":"Zelpultide Alpha","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Iduronicrin Genleukocel-T","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"AskBio","sponsor":"Scottish Enterprise","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"AAV2\/8LSPhGAA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Scottish Enterprise","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Scottish Enterprise"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"L2P Research","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"L2P Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular","sponsorNew":"L2P Research \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"L2P Research \/ National Institutes of Health"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cognition Therapeutics \/ The Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Cognition Therapeutics \/ The Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Celularity","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ CIRM"},{"orgOrder":0,"company":"Isoprene Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"MNK1\/2 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Isoprene Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Isoprene Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Isoprene Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"The Canadian Neuromuscular Disease Registry","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ The Canadian Neuromuscular Disease Registry","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ The Canadian Neuromuscular Disease Registry"},{"orgOrder":0,"company":"GelMEDIX","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GelMEDIX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"GelMEDIX \/ HTL Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"GelMEDIX \/ HTL Biotechnology"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Alloplex Biotherapeutics","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Suplexa","moa":"Immunostimulant","graph1":"Oncology","graph2":"Preclinical","graph3":"Alloplex Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloplex Biotherapeutics \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Alloplex Biotherapeutics \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"SalioGen Therapeutics","sponsor":"GordonMD Global","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SalioGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SalioGen Therapeutics \/ GordonMD Global","highestDevelopmentStatusID":"4","companyTruncated":"SalioGen Therapeutics \/ GordonMD Global"},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Mannkind","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ United Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ United Therapeutics"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"eIF4E","graph1":"Oncology","graph2":"Discovery","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Effector Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"RareStone","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ RareStone","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ RareStone"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Brain Tumor Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ National Brain Tumor Society","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ National Brain Tumor Society"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Conatus Pharmaceuticals","sponsor":"Histogen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Conatus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Conatus Pharmaceuticals \/ Histogen","highestDevelopmentStatusID":"6","companyTruncated":"Conatus Pharmaceuticals \/ Histogen"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Rexahn Pharmaceuticals Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Rexahn Pharmaceuticals Inc"},{"orgOrder":0,"company":"Codexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Codexis \/ GSK"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"Cardiothoracic Surgical Trials Network","sponsor":"Mesoblast","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiothoracic Surgical Trials Network","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiothoracic Surgical Trials Network \/ Mesoblast","highestDevelopmentStatusID":"9","companyTruncated":"Cardiothoracic Surgical Trials Network \/ Mesoblast"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Obsidian Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Obsidian Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion Channel","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ligand Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Microbion","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Microbion \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Microbion \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Intralytix","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Intralytix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intralytix \/ NIAID","highestDevelopmentStatusID":"7","companyTruncated":"Intralytix \/ NIAID"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"TSHA-120","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Silicon Valley Bank","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Oaktree Capital","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Oaktree Capital"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Emerald Health Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Emerald Health Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Emerald Health Therapeutics"},{"orgOrder":0,"company":"GAIA Vaccine Foundation","sponsor":"EpiVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"EPV-CoV-19","moa":"SARS-CoV-2 viral spike N-terminal","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GAIA Vaccine Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GAIA Vaccine Foundation \/ EpiVax","highestDevelopmentStatusID":"4","companyTruncated":"GAIA Vaccine Foundation \/ EpiVax"},{"orgOrder":0,"company":"Sabal Therapeutics","sponsor":"Athena Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sabal Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Sabal Therapeutics \/ Athena Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Sabal Therapeutics \/ Athena Bioscience"},{"orgOrder":0,"company":"Sarah Cannon","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sarah Cannon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarah Cannon \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sarah Cannon \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"EpiVax","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Fusogenix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ Entos Pharmaceuticals"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Beacon Biosignals"},{"orgOrder":0,"company":"Vivasc Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CTP-Amio","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Vivasc Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivasc Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Vivasc Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Locust Walk","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Locust Walk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Locust Walk \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Locust Walk \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"i2o Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"i2o Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"i2o Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"i2o Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bolt Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"3","companyTruncated":"Bolt Biotherapeutics \/ Genmab"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Flu Lab","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GreenLight Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"GreenLight Biosciences \/ Flu Lab","highestDevelopmentStatusID":"1","companyTruncated":"GreenLight Biosciences \/ Flu Lab"},{"orgOrder":0,"company":"Stargazer Pharmaceuticals","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"STG-001","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Stargazer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stargazer Pharmaceuticals \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Stargazer Pharmaceuticals \/ Organovo Holdings"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Agent Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunitas Therapeutics \/ Agent Capital","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Agent Capital"},{"orgOrder":0,"company":"Arkuda Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Progranulin","graph1":"Neurology","graph2":"Preclinical","graph3":"Arkuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna magna","sponsorNew":"Arkuda Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"4","companyTruncated":"Arkuda Therapeutics \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"HT-ALZ","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Washington University School of Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"Agile Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Afaxys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Afaxys Pharma \/ Agile Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Afaxys Pharma \/ Agile Therapeutics"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Oxford Finance"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"RadioMedix \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"RadioMedix \/ Plus Therapeutics"},{"orgOrder":0,"company":"Banner Alzheimer's Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Banner Alzheimer's Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Banner Alzheimer's Institute \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Banner Alzheimer's Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Divestment","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Olivia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"CTX-471","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Olivia Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Olivia Ventures"},{"orgOrder":0,"company":"CDG Care","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CDG Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDG Care \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"CDG Care \/ Cerecor"},{"orgOrder":0,"company":"AmideBio","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmideBio \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"AmideBio \/ NIDDK"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Washington University School of Medicine \/ Bharat Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Bharat Biotech"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"Harrow","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Harrow \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Apotex Inc"},{"orgOrder":0,"company":"BioClonetics Immunotherapeutics","sponsor":"Enzolytics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Merger","leadProduct":"ITV-1","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioClonetics Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioClonetics Immunotherapeutics \/ Enzolytics","highestDevelopmentStatusID":"4","companyTruncated":"BioClonetics Immunotherapeutics \/ Enzolytics"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Biogen"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Merger","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor ant","graph1":"Oncology","graph2":"Phase III","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olema Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Olema Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Unravel Biosciences","sponsor":"Jackson Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Unravel Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Unravel Biosciences \/ Jackson Laboratory","highestDevelopmentStatusID":"1","companyTruncated":"Unravel Biosciences \/ Jackson Laboratory"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"VY-FXN01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"GV101","moa":"ROCK2","graph1":"Immunology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Graviton Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Sanofi"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"3-Antigen HBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ K2 HealthVentures","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ K2 HealthVentures"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Mariana Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"MC-339","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Mariana Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mariana Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Mariana Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Avalo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Avalo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Avalo Therapeutics"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Aditxt","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Aditxt"},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Acquisition","leadProduct":"IVX-A12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ AstraZeneca"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Acquisition","leadProduct":"225-Ac PSMA","moa":"Alpha wave","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RadioMedix \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Fusion Pharma"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Abiraterone Decanoate","moa":"||CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Pathos","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Pathos"},{"orgOrder":0,"company":"Seagen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Brentuximab Vedotin","moa":"CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Pfizer Inc"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyros Pharmaceuticals \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pyros Pharmaceuticals \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"MTK-458","moa":"PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitokinin \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin \/ AbbVie Inc"},{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Aliada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Advancium Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Sulanemadlin","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aileron Therapeutics \/ Advancium Health","highestDevelopmentStatusID":"4","companyTruncated":"Aileron Therapeutics \/ Advancium Health"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Aeglea BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"SPY001","moa":"Alpha 4 beta 7","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Aeglea BioTherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Aeglea BioTherapeutics"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Alfasigma"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Alfasigma"},{"orgOrder":0,"company":"Avrio Health","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sennosides","moa":"Aquaporin-3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avrio Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Avrio Health \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Avrio Health \/ Arcadia Consumer Healthcare"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Slayback Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Gravitas Therapeutics","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"BAL2062","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gravitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gravitas Therapeutics \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"6","companyTruncated":"Gravitas Therapeutics \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Macrogol","moa":"PPAR-gamma","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Johnson & Johnson \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Biogen"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Nerio Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"PTPN1\/2","graph1":"Oncology","graph2":"Preclinical","graph3":"Nerio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerio Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Nerio Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals"},{"orgOrder":0,"company":"ALMATICA PHARMA INC","sponsor":"TWi Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Lisinopril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ALMATICA PHARMA INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"BRII-179","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Brii Biosciences"},{"orgOrder":0,"company":"Wellbeam Consumer Health","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Arnica Montana","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Wellbeam Consumer Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Wellbeam Consumer Health \/ Carlin Consumer Health","highestDevelopmentStatusID":"15","companyTruncated":"Wellbeam Consumer Health \/ Carlin Consumer Health"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cleave Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Private Placement","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Catabasis Pharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"Codexis","sponsor":"Crosswalk Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Crosswalk Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Codexis \/ Crosswalk Therapeutics"},{"orgOrder":0,"company":"Dana Solutions","sponsor":"Curi Bio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Human Ipsc-Derived Cardiomyocytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Dana Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana Solutions \/ Curi Bio","highestDevelopmentStatusID":"2","companyTruncated":"Dana Solutions \/ Curi Bio"},{"orgOrder":0,"company":"MenoLabs","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Bifidobacterium Animalis","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"MenoLabs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MenoLabs \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"MenoLabs \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cleave Therapeutics \/ Eikon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cleave Therapeutics \/ Eikon Therapeutics"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Radionetics Oncology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radionetics Oncology \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Radionetics Oncology \/ Eli Lilly"},{"orgOrder":0,"company":"Metacrine","sponsor":"Equillium","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"MET642","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Equillium","highestDevelopmentStatusID":"8","companyTruncated":"Metacrine \/ Equillium"},{"orgOrder":0,"company":"Renaissance Pharma","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Hu14.18K322A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Renaissance Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renaissance Pharma \/ Essential Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renaissance Pharma \/ Essential Pharma"},{"orgOrder":0,"company":"Oakrum Pharma, LLC","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Nitisinone","moa":"HPDD","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Oakrum Pharma, LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oakrum Pharma, LLC \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Oakrum Pharma, LLC \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Tulex Pharmaceutical","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Tulex Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tulex Pharmaceutical \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Tulex Pharmaceutical \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Merger","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Global Cord Blood Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"CK0802","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ Global Cord Blood Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Global Cord Blood Corporation"},{"orgOrder":0,"company":"XinThera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"XIN5104","moa":"PARP1","graph1":"Oncology","graph2":"IND Enabling","graph3":"XinThera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XinThera \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"XinThera \/ Gilead Sciences"},{"orgOrder":0,"company":"Modulus Therapeutics","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Modulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Modulus Therapeutics \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Modulus Therapeutics \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Valinor Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Valinor Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Valinor Pharma \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"Valinor Pharma \/ Grunenthal"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Harmony Biosciences"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Harmony Biosciences"},{"orgOrder":0,"company":"Intarcia","sponsor":"i2o Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"i2o-105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Intarcia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intarcia \/ i2o Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Intarcia \/ i2o Therapeutics"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Ikena Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"||TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pionyr Immunotherapeutics \/ Ikena Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Ikena Oncology"},{"orgOrder":0,"company":"Atreca","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"APN-497444","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Immunome","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ Immunome"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Immunome"},{"orgOrder":0,"company":"Proteologix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"PX128","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Proteologix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteologix \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Proteologix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Proteologix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"PX128","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Proteologix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteologix \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Proteologix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Leo Pharma"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Novan","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Novan","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Acquisition","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin type II receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Sigilon Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin type II receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Sigilon Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Lucy Scientific Discovery"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Lucy Scientific Discovery"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"MediPacific","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ MediPacific","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ MediPacific"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"MediPacific","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ MediPacific","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ MediPacific"},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Caraway Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Caraway Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Caraway Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Abceutics Inc","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Abceutics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abceutics Inc \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Abceutics Inc \/ Merck & Co"},{"orgOrder":0,"company":"Modifi Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"MOD-246","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Modifi Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modifi Bio \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Modifi Bio \/ Merck & Co"},{"orgOrder":0,"company":"T\u03c5HURA Biopharma","sponsor":"Morphogenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"T\u03c5HURA Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"T\u03c5HURA Biopharma \/ Morphogenesis","highestDevelopmentStatusID":"2","companyTruncated":"T\u03c5HURA Biopharma \/ Morphogenesis"},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INVO Bioscience \/ Naya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"INVO Bioscience \/ Naya Biosciences"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"DTx-1252","moa":"PMP22","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"DTx Pharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KBP Biosciences \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Novo Nordisk"},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Organon"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Jnana Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"PaxMedica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rediscovery Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rediscovery Life Sciences \/ PaxMedica","highestDevelopmentStatusID":"10","companyTruncated":"Rediscovery Life Sciences \/ PaxMedica"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Pharmacosmos AS","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Pharmacosmos AS"},{"orgOrder":0,"company":"Bonafide Health","sponsor":"Pharmavite","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Bonafide Pollen","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Bonafide Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bonafide Health \/ Pharmavite","highestDevelopmentStatusID":"15","companyTruncated":"Bonafide Health \/ Pharmavite"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Pyxis Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Sotigalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Pyxis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Pyxis Oncology"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Pyxis Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Sotigalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Pyxis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Pyxis Oncology"},{"orgOrder":0,"company":"RareGen","sponsor":"Liquidia Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"RareGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"RareGen \/ Liquidia Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RareGen \/ Liquidia Corporation"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"CT-388","moa":"GLP-1","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"ImmuNext Inc","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Frexalimab","moa":"CD40L","graph1":"Neurology","graph2":"Phase III","graph3":"ImmuNext Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmuNext Inc \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"ImmuNext Inc \/ Royalty Pharma"},{"orgOrder":0,"company":"Seagen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Brentuximab Vedotin","moa":"CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Pfizer Inc"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SFJ Pharmaceuticals \/ Serb","highestDevelopmentStatusID":"10","companyTruncated":"SFJ Pharmaceuticals \/ Serb"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Xeruborbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Shionogi"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Skye Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Skye Bioscience"},{"orgOrder":0,"company":"Cereius","sponsor":"Solve Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cereius","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cereius \/ Solve Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cereius \/ Solve Therapeutics"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Samarium-153 DOTMP","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Samarium-153 DOTMP","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"4SR Biosciences","sponsor":"hC Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"4SR Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4SR Biosciences \/ hC Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"4SR Biosciences \/ hC Bioscience"},{"orgOrder":0,"company":"Tenet Medicines","sponsor":"Eliem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Tenet Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tenet Medicines \/ Eliem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tenet Medicines \/ Eliem Therapeutics"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Mosaic ImmunoEngineering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Acquisition","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Mosaic ImmunoEngineering","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Mosaic ImmunoEngineering"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Tilde Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Acquisition","leadProduct":"Pyrimethamine","moa":"DHFR","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vyera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vyera Pharmaceuticals \/ Tilde Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Vyera Pharmaceuticals \/ Tilde Sciences"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Mirokidney","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Povetacicept","moa":"B cell cytokine","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alpine Immune Sciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pherin Pharmaceuticals \/ VistaGen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pharmaceuticals \/ VistaGen Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Zevra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Zevra Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Zevra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Zevra Therapeutics"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"Neumora therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Poolbeg Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Pentoxifylline","moa":"TNF-alpha","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Silk Road Therapies \/ Poolbeg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road Therapies \/ Poolbeg Pharma"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Yale University"},{"orgOrder":0,"company":"EQRx","sponsor":"Abdul Latif Jameel Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Abdul Latif Jameel Health","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Abdul Latif Jameel Health"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Tapentadol","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Avior Bio","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Avior Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Avior Bio \/ Hillstream BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Avior Bio \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Cincinnati","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ University of Cincinnati","highestDevelopmentStatusID":"2","companyTruncated":"Lisata Therapeutics \/ University of Cincinnati"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Afrigen Biologics and Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Afrigen Biologics and Vaccines","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Afrigen Biologics and Vaccines"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Oragenics"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Phoenix Biotech Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Pyrimethamine","moa":"DHFR","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vyera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vyera Pharmaceuticals \/ Phoenix Biotech Acquisition Corp","highestDevelopmentStatusID":"15","companyTruncated":"Vyera Pharmaceuticals \/ Phoenix Biotech Acquisition Corp"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinnate Biopharma \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Pierre Fabre"},{"orgOrder":0,"company":"Code Bio","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Code Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Code Bio \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Code Bio \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Agreement","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"ImmunityBio \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Serum Institute of India"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Daiichi Sankyo"},{"orgOrder":0,"company":"CorMedix","sponsor":"ARC Dialysis, LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ ARC Dialysis, LLC","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ ARC Dialysis, LLC"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"PUR1800","moa":"p38\/MAPK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Theramex"},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Theramex"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zura Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Tibulizumab","moa":"IL-17\/BAFF","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Zura Bio"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Acquisition","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Insud Pharma"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ XOMA","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ XOMA"},{"orgOrder":0,"company":"Sanegene Bio","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Sanegene Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanegene Bio \/ Orbit Discovery","highestDevelopmentStatusID":"2","companyTruncated":"Sanegene Bio \/ Orbit Discovery"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"DF9001","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Prizloncabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"7","companyTruncated":"Cellular Biomedicine Group \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Labcorp","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Labcorp \/ Xcell Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Labcorp \/ Xcell Biosciences"},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Haystack Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Haystack Oncology \/ Lisata Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Haystack Oncology \/ Lisata Therapeutics"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Dragonfly Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Dragonfly Therapeutics"},{"orgOrder":0,"company":"Aitia","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aitia","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aitia \/ Orion Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Aitia \/ Orion Corporation"},{"orgOrder":0,"company":"Tempus","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ Pfizer Inc"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Schrodinger \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Schrodinger \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Shasqi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Doxorubicin","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Shasqi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Doxorubicin","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Divestment","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ Alimera Sciences","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Alimera Sciences"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Amphastar Pharmaceuticals"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Hong Kong King-Friend Industrial Co. Ltd","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Divestment","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"OMERS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Glecaprevir","moa":"||HCV NS5A\/HCV NS3\/4A protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enanta Pharmaceuticals \/ OMERS Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Enanta Pharmaceuticals \/ OMERS Life Sciences"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Divestment","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Divestment","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AGC Biologics \/ Rocket Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AGC Biologics \/ Rocket Pharmaceuticals"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Viking Global Investors"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Deimos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Deimos Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"G1 Therapeutics, Inc \/ Deimos Biosciences"},{"orgOrder":0,"company":"Passage Bio","sponsor":"GEMMA Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ GEMMA Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ GEMMA Biotherapeutics"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolojic Design \/ Nektar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"P-500","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prelude Therapeutics \/ Pathos","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Pathos"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Topical Film-Forming Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"ViiV Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"XVIR-110","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exavir Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exavir Therapeutics \/ ViiV Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Exavir Therapeutics \/ ViiV Healthcare"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Zambon Group SpA"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"JTX-4014","moa":"||ICOS","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Concentra Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Concentra Biosciences"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tectonic Therapeutic \/ Avrobio","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Avrobio"},{"orgOrder":0,"company":"Centurion BioPharma Corporation","sponsor":"CytRx Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Merger","leadProduct":"Aldoxorubicin HCl","moa":"Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase III","graph3":"Centurion BioPharma Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centurion BioPharma Corporation \/ CytRx Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Centurion BioPharma Corporation \/ CytRx Corporation"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"DPI-125","moa":"Kappa\/Mu\/Delta Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"DPI-125","moa":"Kappa\/Mu\/Delta Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Merger","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Insud Pharma"},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Ocuvex Therpeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Omidenepag Isopropyl","moa":"EP2 R","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Visiox Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visiox Pharma \/ Ocuvex Therpeutics","highestDevelopmentStatusID":"15","companyTruncated":"Visiox Pharma \/ Ocuvex Therpeutics"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"Carbonic anhydrase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Merger","leadProduct":"NGM707","moa":"||ILT2\/4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NGM Biopharmaceuticals \/ The Column Group","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ The Column Group"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ Onconova Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Onconova Therapeutics"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Kintara Therapeutics \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Albert Einstein College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orange Grove Bio \/ Albert Einstein College of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Orange Grove Bio \/ Albert Einstein College of Medicine"},{"orgOrder":0,"company":"Lieber Institute for Brain Development","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"COMT","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lieber Institute for Brain Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lieber Institute for Brain Development \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Lieber Institute for Brain Development \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andelyn Biosciences \/ UMass Chan Medical School","highestDevelopmentStatusID":"3","companyTruncated":"Andelyn Biosciences \/ UMass Chan Medical School"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Interius BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"INT2104","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Advanced Therapies \/ Interius BioTherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Advanced Therapies \/ Interius BioTherapeutics"},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":"15","companyTruncated":"KVK.Tech \/ Medix"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Bennu Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Porton Advanced Solutions \/ Bennu Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ Bennu Biotherapeutics"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"BRL Medicine Inc","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"BRL-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Porton Advanced Solutions \/ BRL Medicine Inc","highestDevelopmentStatusID":"6","companyTruncated":"Porton Advanced Solutions \/ BRL Medicine Inc"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaPro Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaPro Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaPro Therapeutics \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Blue Water Vaccines \/ Cincinnati Children\u2019s Hospital Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ Cincinnati Children\u2019s Hospital Medical Center"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Termination","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Providence Therapeutics \/ Everest Medicines"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyoKardia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Alcon Inc"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"DAAN Bio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GenScript ProBio \/ DAAN Bio Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ DAAN Bio Therapeutics"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"InnoBation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"IBC 101","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript Biotech Corporation \/ InnoBation","highestDevelopmentStatusID":"1","companyTruncated":"GenScript Biotech Corporation \/ InnoBation"},{"orgOrder":0,"company":"Isoprene Pharmaceuticals","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Retinamide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Isoprene Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isoprene Pharmaceuticals \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Isoprene Pharmaceuticals \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Medical University of South Carolina","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kriya Therapeutics \/ Medical University of South Carolina","highestDevelopmentStatusID":"4","companyTruncated":"Kriya Therapeutics \/ Medical University of South Carolina"},{"orgOrder":0,"company":"OncoSec","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec \/ Sirtex Medical","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec \/ Sirtex Medical"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Baylor College of Medicine","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio Pharma \/ Baylor College of Medicine"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Kite Pharma","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Therapeutics \/ Kite Pharma"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"LY3819253","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Amgen Inc"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Komodo Health","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Komodo Health","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Komodo Health"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Tsinghua University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Amubarvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Tsinghua University","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Tsinghua University"},{"orgOrder":0,"company":"Refuge Biotechnologies","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Refuge Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Refuge Biotechnologies \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Refuge Biotechnologies \/ Kite Pharma"},{"orgOrder":0,"company":"InveniAI","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"InveniAI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InveniAI \/ Kyowa Kirin","highestDevelopmentStatusID":"2","companyTruncated":"InveniAI \/ Kyowa Kirin"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"NMDP BioTherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ NMDP BioTherapies","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ NMDP BioTherapies"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Instituto Butantan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"BWV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ Instituto Butantan","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ Instituto Butantan"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Caris Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ Caris Life Sciences"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Nanoscope Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"vMCO-010","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Charles River Laboratories, Inc \/ Nanoscope Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Charles River Laboratories, Inc \/ Nanoscope Therapeutics"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Times Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Hepatitis B Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Times Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"Dynavax Technologies \/ Times Pharmacy"},{"orgOrder":0,"company":"Tolmar","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tolmar \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Sanofi"},{"orgOrder":0,"company":"Tiba Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Tiba Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiba Biotech \/ BARDA","highestDevelopmentStatusID":"3","companyTruncated":"Tiba Biotech \/ BARDA"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Tidal","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tidal","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tidal \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Tidal \/ Sanofi"},{"orgOrder":0,"company":"JT Pharmaceuticals","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"JT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JT Pharmaceuticals \/ Titan Pharmaceuticals Inc","highestDevelopmentStatusID":"1","companyTruncated":"JT Pharmaceuticals \/ Titan Pharmaceuticals Inc"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"TLC-1235","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OrsoBio \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"OrsoBio \/ Yale University"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"HDX Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"BNCT","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAE Life Sciences \/ HDX Corporation","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life Sciences \/ HDX Corporation"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"TmXX-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kite Pharma \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kite Pharma \/ Kite Pharma"},{"orgOrder":0,"company":"Tmunity","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"TmXX-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tmunity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tmunity \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Tmunity \/ Kite Pharma"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"TN-301","moa":"HDAC6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Tenet Medicines","sponsor":"Eliem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"Budoprutug","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Tenet Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tenet Medicines \/ Eliem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tenet Medicines \/ Eliem Therapeutics"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Collaboration","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Kenya Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Kenya Medical Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Kenya Medical Research Institute"},{"orgOrder":0,"company":"NLC Pharma","sponsor":"Todos Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NLC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NLC Pharma \/ Todos Medical","highestDevelopmentStatusID":"8","companyTruncated":"NLC Pharma \/ Todos Medical"},{"orgOrder":0,"company":"Stanford Medical","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Stanford Medical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stanford Medical \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Stanford Medical \/ Sanofi"},{"orgOrder":0,"company":"Todos Medical","sponsor":"T-Cell Protect","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ T-Cell Protect","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ T-Cell Protect"},{"orgOrder":0,"company":"Healion Bio","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"TNX-3900","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Healion Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healion Bio \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Healion Bio \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Stanford University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Acquisition","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Stanford University \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"TNX-1810","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"5","companyTruncated":"University of Alberta \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"TNX-4200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ U.S. Department of Defense"},{"orgOrder":0,"company":"New American Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Metoprolol Succinate","moa":"Adrenergic-beta 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"New American Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"New American Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"New American Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"KaliVir Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Tecovirimat","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ KaliVir Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SIGA Technologies \/ KaliVir Immunotherapeutics"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ University of Oxford"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"OncoBeta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"188-Re","moa":"Beta radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Avion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Paste","sponsorNew":"Avion Pharmaceuticals \/ OncoBeta","highestDevelopmentStatusID":"15","companyTruncated":"Avion Pharmaceuticals \/ OncoBeta"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Millicent Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Divestment","leadProduct":"Prasterone","moa":"Corticosteroid-binding globulin","graph1":"Neurology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Vaginal","sponsorNew":"AMAG Pharmaceuticals \/ Millicent Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Millicent Pharma"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Locust Walk","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Tomivosertib","moa":"||MAPK 1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Locust Walk","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Locust Walk"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Iliad Research And Trading","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Iliad Research And Trading","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Iliad Research And Trading"},{"orgOrder":0,"company":"Blue Water Acquisition Corporation","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Merger","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Blue Water Acquisition Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blue Water Acquisition Corporation \/ Clarus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Blue Water Acquisition Corporation \/ Clarus Therapeutics"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"NeuroBo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ANA Therapeutics \/ NeuroBo Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ NeuroBo Pharmaceuticals"},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TG4050","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"BostonGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BostonGene \/ Transgene","highestDevelopmentStatusID":"6","companyTruncated":"BostonGene \/ Transgene"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Trethera","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Eye Institute"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"TrialSpark","sponsor":"resTORbio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Dactolisib","moa":"TORC1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TrialSpark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TrialSpark \/ resTORbio","highestDevelopmentStatusID":"10","companyTruncated":"TrialSpark \/ resTORbio"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Australian Pharmaceutical Benefits Scheme","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Australian Pharmaceutical Benefits Scheme","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Australian Pharmaceutical Benefits Scheme"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Ontorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Helocyte","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"CMV-modified Vaccinia Ankara Vaccine","moa":"pp65 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Helocyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Helocyte \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Helocyte \/ National Institutes of Health"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Perigon Pharmacy 360","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Perigon Pharmacy 360","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Perigon Pharmacy 360"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"MedTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Merger","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ MedTech","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ MedTech"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Astex Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Astex Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"atai Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CB Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"CB Therapeutics \/ atai Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"CB Therapeutics \/ atai Life Sciences"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Fludarabine","moa":"||HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ K2 HealthVentures"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"TSHA-120","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Myst Therapeutics","sponsor":"Turnstone Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Myst Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Myst Therapeutics \/ Turnstone Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Myst Therapeutics \/ Turnstone Biologics"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Seismic Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Seismic Bio","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Seismic Bio"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kriya Therapeutics \/ Twist Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"Kriya Therapeutics \/ Twist Bioscience"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ J.P. Morgan Securities LLC"},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Mammoth Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mammoth Biosciences \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Mammoth Biosciences \/ Bayer AG"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ligand Pharmaceuticals \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Carlsbad","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Carlsbad","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Carlsbad"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Viatris"},{"orgOrder":0,"company":"Sanofi","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Hercules Capital"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 DNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ U.S. Department of Defense"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Government","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ U.S. Government"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ U.S. Government","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ U.S. Government"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ BofA Securities"},{"orgOrder":0,"company":"Cornell University","sponsor":"Bridge Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||UBR5","graph1":"Oncology","graph2":"Preclinical","graph3":"Cornell University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cornell University \/ Bridge Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Cornell University \/ Bridge Medicines"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Minzasolmin","moa":"Alpha synuclein misfolding","graph1":"Neurology","graph2":"Phase II","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neuropore Therapies \/ UCB Pharma S.A","highestDevelopmentStatusID":"8","companyTruncated":"Neuropore Therapies \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ultragenyx Pharmaceutical \/ Daiichi Sankyo","highestDevelopmentStatusID":"3","companyTruncated":"Ultragenyx Pharmaceutical \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"suPAR","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Walden Biosciences \/ University of Michigan","highestDevelopmentStatusID":"1","companyTruncated":"Walden Biosciences \/ University of Michigan"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Locnartecan","moa":"HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"National Institute for Health and Care Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Funding","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"180 Life Sciences \/ National Institute for Health and Care Research","highestDevelopmentStatusID":"4","companyTruncated":"180 Life Sciences \/ National Institute for Health and Care Research"},{"orgOrder":0,"company":"Codexis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Codexis \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Codexis \/ Merck & Co"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"LB2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Collaboration","leadProduct":"SPR206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"6","companyTruncated":"Spero Therapeutics \/ Everest Medicines"},{"orgOrder":0,"company":"Aeolian Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"Multivalent Pneumococcal conjugate vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aeolian Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeolian Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aeolian Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Gavocabtagene Autoleucel","moa":"||MSLN","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ TCR2 Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"IAVI","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"IAVI \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"IAVI \/ Merck Group"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"University of Georgia","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"PDS0202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Georgia \/ PDS Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ PDS Biotechnology"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Ascentage Pharma"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Terra CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avid Bioservices \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Avid Bioservices \/ Oragenics"},{"orgOrder":0,"company":"Virology laboratory, U.S","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virology laboratory, U.S","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Virology laboratory, U.S \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Virology laboratory, U.S \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eton Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Agreement","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Convergent Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Nucleus RadioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthStar Medical Radioisotopes \/ Nucleus RadioPharma","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ Nucleus RadioPharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"HLS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ HLS Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ HLS Therapeutics"},{"orgOrder":0,"company":"Mosaic Biosciences","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Mosaic Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mosaic Biosciences \/ Ocular Therapeutix","highestDevelopmentStatusID":"2","companyTruncated":"Mosaic Biosciences \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Tolmar","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tolmar \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Verapamil Hydrochloride","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Societal CDMO \/ Lannett Company, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"Societal CDMO \/ Lannett Company, Inc."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Undisclosed"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Lee'S Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Lucinactant","moa":"SERCA2a","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Windtree Therapeutics \/ Lee'S Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Lee'S Pharmaceutical"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gilgamesh Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Gilgamesh Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"AmyriAD","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ AmyriAD","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ AmyriAD"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"Enkephalin","moa":"MAO transporter","graph1":"Neurology","graph2":"Preclinical","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Societal CDMO \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Societal CDMO \/ National Institutes of Health"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Yonsei University Health System","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orange Grove Bio \/ Yonsei University Health System","highestDevelopmentStatusID":"2","companyTruncated":"Orange Grove Bio \/ Yonsei University Health System"},{"orgOrder":0,"company":"Somerset Pharmaceuticals Inc","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Sulfamethoxazole","moa":"||Dihydropteroate synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Somerset Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Somerset Pharmaceuticals Inc \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Somerset Pharmaceuticals Inc \/ Premier"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Merck & Co"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Merck & Co"},{"orgOrder":0,"company":"Novavax","sponsor":"Israeli Ministry of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Israeli Ministry of Health","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Israeli Ministry of Health"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Acquisition","leadProduct":"Typhoid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emergent BioSolutions \/ Bavarian Nordic","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Bavarian Nordic"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"U.S. Army Medical Research And Development Command","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ U.S. Army Medical Research And Development Command","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ U.S. Army Medical Research And Development Command"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Sciences Ireland Unlimited","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CIN-109","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"||1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVSV Based Covid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ IAVI"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Expanded Collaboration","leadProduct":"MK-4464","moa":"||Natural killer cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Padagis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Padagis","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Padagis"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"ACEA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ ACEA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ ACEA Therapeutics"},{"orgOrder":0,"company":"Indivior","sponsor":"Alar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Alar Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Alar Pharmaceuticals"},{"orgOrder":0,"company":"ARScience Bio","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"ARScience Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARScience Bio \/ Coya Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ARScience Bio \/ Coya Therapeutics"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Fujifilm Diosynth Biotechnologies","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biotherapeutics \/ Fujifilm Diosynth Biotechnologies"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Chaperone-mediated protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ranok Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Ranok Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ Sagard Healthcare"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"GRI Bio \/ Aardvark Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"GRI Bio \/ Aardvark Therapeutics"},{"orgOrder":0,"company":"Surmodics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Abbott Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Abbott Laboratories"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"HPN217","moa":"CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scripps Research \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Scripps Research \/ AbbVie Inc"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Xinnovation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Xinnovation Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Xinnovation Therapeutics"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Licensing Agreement","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"National Center for Advancing Translational Sciences","sponsor":"Acer Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Emetine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Center for Advancing Translational Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Center for Advancing Translational Sciences \/ Acer Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"National Center for Advancing Translational Sciences \/ Acer Therapeutics"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Aditxt","sponsor":"Cellvera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aditxt \/ Cellvera","highestDevelopmentStatusID":"15","companyTruncated":"Aditxt \/ Cellvera"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Ray Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"AAV.7m8","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Ray Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Adverum Biotechnologies \/ Ray Therapeutics"},{"orgOrder":0,"company":"Aevitas Therapeutics","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"4D-175","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Aevitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevitas Therapeutics \/ 4D Molecular Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aevitas Therapeutics \/ 4D Molecular Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ AffaMed Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ AffaMed Therapeutics"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"MDG1015","moa":"||NY-ESO-1\/LAGE-1a","graph1":"Oncology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Medigene","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Medigene"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"The Jikei University","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AGC Biologics \/ The Jikei University","highestDevelopmentStatusID":"2","companyTruncated":"AGC Biologics \/ The Jikei University"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AGC Biologics \/ Provention Bio","highestDevelopmentStatusID":"15","companyTruncated":"AGC Biologics \/ Provention Bio"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Alnylam Pharmaceuticals \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Shionogi"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pfizer Inc \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pfizer Inc \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pfizer Inc \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pfizer Inc \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Immune Sciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Alvotech","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Alvotech"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Amgen Inc"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"Ampio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"OA-201","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendia Pharmaceuticals \/ Ampio Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ascendia Pharmaceuticals \/ Ampio Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Ascentage Pharma"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"P-MUC1C-ALLO1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"Invenra","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Invenra \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Invenra \/ Astellas Pharma"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allorion Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Allorion Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Omniose","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Omniose","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omniose \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Omniose \/ AstraZeneca"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Avance Clinical"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allorion Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Allorion Therapeutics \/ Avenzo Therapeutics"},{"orgOrder":0,"company":"Celcuity","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Bayer AG"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Beam Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Beam Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ETX-197","moa":"CDK2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensem Therapeutics \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"PRT2527","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Biddle Sawyer Corporation","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"TC-220","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biddle Sawyer Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biddle Sawyer Corporation \/ TAE Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Biddle Sawyer Corporation \/ TAE Life Sciences"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Avoralstat","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Clearside Biomedical \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adhera Therapeutics \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Fujifilm Cellular Dynamics","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"OpCT-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Fujifilm Cellular Dynamics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujifilm Cellular Dynamics \/ BlueRock Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm Cellular Dynamics \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"Artisan Bio","sponsor":"BrightPath Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artisan Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artisan Bio \/ BrightPath Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Artisan Bio \/ BrightPath Biotherapeutics"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"||TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"University of Texas Health Science Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"BWV-401","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blue Water Vaccines \/ University of Texas Health Science Center","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ University of Texas Health Science Center"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Gates MRI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CLB073","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Research \/ Gates MRI","highestDevelopmentStatusID":"4","companyTruncated":"Scripps Research \/ Gates MRI"},{"orgOrder":0,"company":"Civica Rx","sponsor":"CalRx Biosimilar Insulin Initiative","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Partnership","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Civica Rx \/ CalRx Biosimilar Insulin Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Civica Rx \/ CalRx Biosimilar Insulin Initiative"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Mind Medicine"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Harm Reduction Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"JOS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ JOS Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ JOS Pharmaceuticals"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ GSK"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Abatacept","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Capsida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CRISPR Therapeutics \/ Capsida","highestDevelopmentStatusID":"3","companyTruncated":"CRISPR Therapeutics \/ Capsida"},{"orgOrder":0,"company":"Crown Bioscience","sponsor":"ERS Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Crown Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crown Bioscience \/ ERS Genomics","highestDevelopmentStatusID":"3","companyTruncated":"Crown Bioscience \/ ERS Genomics"},{"orgOrder":0,"company":"Harbor Discoveries","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Harbor Discoveries","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Harbor Discoveries \/ Deerfield Management","highestDevelopmentStatusID":"2","companyTruncated":"Harbor Discoveries \/ Deerfield Management"},{"orgOrder":0,"company":"CSI Pharmacy","sponsor":"Bio Products Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSI Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSI Pharmacy \/ Bio Products Laboratory","highestDevelopmentStatusID":"15","companyTruncated":"CSI Pharmacy \/ Bio Products Laboratory"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Cullinan Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Cullinan Therapeutics"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"USAMMDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Defender Pharmaceuticals \/ USAMMDA","highestDevelopmentStatusID":"5","companyTruncated":"Defender Pharmaceuticals \/ USAMMDA"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Radius Health","sponsor":"DRI Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Radius Health \/ DRI Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ DRI Healthcare"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"CpG 1018","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Dynavax Technologies \/ US Department of Defense"},{"orgOrder":0,"company":"Radius Health","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radius Health \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Radius Health \/ Ellipses Pharma"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Emergent BioSolutions \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Emergent BioSolutions \/ Johnson & Johnson"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Endeavor Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HMBD-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hummingbird Bioscience \/ Endeavor Biomedicines","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Endeavor Biomedicines"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Hypoimmune Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eterna Therapeutics \/ Lineage Cell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eterna Therapeutics \/ Lineage Cell Therapeutics"},{"orgOrder":0,"company":"Novitium Pharma LLC","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Carglumic Acid","moa":"CPS1","graph1":"Hematology","graph2":"Approved FDF","graph3":"Novitium Pharma LLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novitium Pharma LLC \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novitium Pharma LLC \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Immunomedics","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Immunomedics"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Everest Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Everest Medicines"},{"orgOrder":0,"company":"Eversana","sponsor":"Xspray Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Dasatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase III","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eversana \/ Xspray Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/ Xspray Pharma"},{"orgOrder":0,"company":"EVQLV","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"EVQLV","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"EVQLV \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"EVQLV \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"United Therapeutics \/ Ferrer Internacional","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Ferrer Internacional"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"ForSeeCon Eye Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1701","moa":"Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ ForSeeCon Eye Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ ForSeeCon Eye Corporation"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Botanix Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Botanix Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Botanix Pharma"},{"orgOrder":0,"company":"Niowave","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Collaboration","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Niowave","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Niowave \/ Fusion Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Niowave \/ Fusion Pharma"},{"orgOrder":0,"company":"Atreca","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"ATRC-501","moa":"||CSP","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Atreca \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Seal Rock Therapeutics \/ Genfit","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock Therapeutics \/ Genfit"},{"orgOrder":0,"company":"Celloram","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CLM-022","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Celloram","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celloram \/ Genfit","highestDevelopmentStatusID":"4","companyTruncated":"Celloram \/ Genfit"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Genpharm"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"Pdx1\/Mafa gene","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Genprex"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"RVAC Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"RVM-V001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GenScript ProBio \/ RVAC Medicines","highestDevelopmentStatusID":"6","companyTruncated":"GenScript ProBio \/ RVAC Medicines"},{"orgOrder":0,"company":"GigaGen","sponsor":"ProteoNic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"GIGA-2050","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ ProteoNic","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ ProteoNic"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evoq Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"DF7001","moa":"5T4 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Dragonfly Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"ST-113","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stuart Therapeutics \/ Glaukos","highestDevelopmentStatusID":"5","companyTruncated":"Stuart Therapeutics \/ Glaukos"},{"orgOrder":0,"company":"Glaukos","sponsor":"Attillaps Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"AChE","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaukos \/ Attillaps Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Glaukos \/ Attillaps Holdings"},{"orgOrder":0,"company":"Nusano","sponsor":"Glytherix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"177-Lu","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ Glytherix","highestDevelopmentStatusID":"4","companyTruncated":"Nusano \/ Glytherix"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"GSK4532990","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Collaboration","leadProduct":"XMT-2056","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mersana Therapeutics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Therapeutics \/ GSK"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"GV20-0251","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GV20 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"GV20 Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Israeli Phage Therapy Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center"},{"orgOrder":0,"company":"City of Hope","sponsor":"Helocyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"Triplex","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ Helocyte","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Helocyte"},{"orgOrder":0,"company":"ImaginAb","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"ImaginAb \/ TriSalus Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"ImaginAb \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"ImaginAb","sponsor":"DynamiCure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"DCBY02","moa":"CD93","graph1":"Oncology","graph2":"Phase I","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImaginAb \/ DynamiCure","highestDevelopmentStatusID":"6","companyTruncated":"ImaginAb \/ DynamiCure"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Immedica Pharma"},{"orgOrder":0,"company":"Immunogen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Imunon","sponsor":"The Wistar Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imunon \/ The Wistar Institute","highestDevelopmentStatusID":"2","companyTruncated":"Imunon \/ The Wistar Institute"},{"orgOrder":0,"company":"Inceptor Bio","sponsor":"Avectas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Inceptor Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inceptor Bio \/ Avectas","highestDevelopmentStatusID":"4","companyTruncated":"Inceptor Bio \/ Avectas"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"Indegene","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indegene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indegene \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Indegene \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Inhibitor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Itraconazole","moa":"CYP51A1","graph1":"Oncology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Johns Hopkins University \/ Inhibitor Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Inhibitor Therapeutics"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"MeiraGTx \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"MeiraGTx \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"WTX-613","moa":"INF-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Werewolf Therapeutics \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"Georgetown University","sponsor":"KeifeRx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"KFRX03","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Georgetown University \/ KeifeRx","highestDevelopmentStatusID":"5","companyTruncated":"Georgetown University \/ KeifeRx"},{"orgOrder":0,"company":"Kincell Bio","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kincell Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kincell Bio \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Kincell Bio \/ Imugene"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Bol Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"BOL-DP-o-04","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kindeva Drug Delivery \/ Bol Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Kindeva Drug Delivery \/ Bol Pharma"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Kintara Therapeutics \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epic Bio \/ Kite Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Epic Bio \/ Kite Pharma"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kriya Therapeutics \/ Kriya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Kriya Therapeutics \/ Kriya Therapeutics"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"KSQ-4279","moa":"USP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KSQ Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"KSQ Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"RIVOPHARM SA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lannett Company, Inc. \/ RIVOPHARM SA","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ RIVOPHARM SA"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Perspective Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"212-Pb VMT-alpha-NET","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantheus Holding \/ Perspective Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Lantheus Holding \/ Perspective Therapeutics"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"LB2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Leveragen","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Leveragen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leveragen \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Leveragen \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"COR588","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lighthouse Pharmaceuticals \/ Quince Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Quince Therapeutics"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Lion TCR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MaxCyte \/ Lion TCR","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ Lion TCR"},{"orgOrder":0,"company":"Charles River Laboratories International","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Charles River Laboratories International","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Charles River Laboratories International \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Charles River Laboratories International \/ Flagship Pioneering"},{"orgOrder":0,"company":"Nevakar","sponsor":"Long Grove Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Norepinephrine Bitartrate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nevakar \/ Long Grove Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Long Grove Pharmaceuticals"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Lonza Inc & Lonza America Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Lonza Inc & Lonza America Inc","highestDevelopmentStatusID":"4","companyTruncated":"Context Therapeutics \/ Lonza Inc & Lonza America Inc"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Ianalumab","moa":"BAFF","graph1":"Nephrology","graph2":"Phase III","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lupus Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Lupus Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Medice Arzneimittel P\u00fctter GmbH&Co.KG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"Durvalumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Melt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Melt Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"MK-7762","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"United Nations Children\u2019s Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ United Nations Children\u2019s Fund","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ United Nations Children\u2019s Fund"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Orna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Orna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"MK-7110","moa":"CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ U.S. Government","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ U.S. Government"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Atropine","moa":"||mAChRs","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Meridian Medical Technologies \/ ASPR","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ ASPR"},{"orgOrder":0,"company":"Miralogx","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Miralogx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Miralogx \/ Mira Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Miralogx \/ Mira Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Abacus Medicine","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Abacus Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Abacus Medicine"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Caris Life Sciences \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"University of California San Diego","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"MIE-101","moa":"TLR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mosaic ImmunoEngineering \/ University of California San Diego","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ University of California San Diego"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"MyoKardia","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fulcrum Therapeutics \/ MyoKardia","highestDevelopmentStatusID":"2","companyTruncated":"Fulcrum Therapeutics \/ MyoKardia"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ MThera Pharma"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CohBar","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"CB5064 Analog","moa":"Apelin receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CohBar \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ National Institutes of Health"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Demerger","leadProduct":"INBRX-105","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Agreement","leadProduct":"64-Cu SAR-bisPSMA","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Northwell Health","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Northwell Health","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Northwell Health"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"NovaBay Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Amniotic Tissue Allograft","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ NovaBay Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ NovaBay Pharmaceuticals"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Pelacarsen","moa":"Apolipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novavax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Matrix-M","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Novavax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Novavax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Ventus Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Collaboration","leadProduct":"212-Pb NG001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nucleus RadioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nucleus RadioPharma \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"Nucleus RadioPharma \/ ARTBIO"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"OncoBay Clinical","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoBay Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoBay Clinical \/ Hillstream BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"OncoBay Clinical \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"OnCusp Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"Preclinical","graph3":"Multitude Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multitude Therapeutics \/ OnCusp Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Multitude Therapeutics \/ OnCusp Therapeutics"},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Organon \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Eli Lilly"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Amicus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Amicus Therapeutics"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ligand Pharmaceuticals \/ Pandion Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ligand Pharmaceuticals \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Humanigen","sponsor":"PCI Pharma Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Lenzilumab","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ PCI Pharma Services","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ PCI Pharma Services"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HBM9033","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Nona Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ U.S. Government"},{"orgOrder":0,"company":"Riparian Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Riparian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Riparian Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Riparian Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Riparian Pharmaceuticals","sponsor":"Viva Biotech","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Riparian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Riparian Pharmaceuticals \/ Viva Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Riparian Pharmaceuticals \/ Viva Biotech"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Expanded Collaboration","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Piramal Pharma Solutions \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Piramal Pharma Solutions \/ Plus Therapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PMV Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Rezatapopt","moa":"||p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ PMV Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ PMV Pharma"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Precigen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Precigen","highestDevelopmentStatusID":"6","companyTruncated":"Alaunos Therapeutics \/ Precigen"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"SMARCA","graph1":"Oncology","graph2":"Discovery","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"Prelude Therapeutics \/ AbCellera"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sangamo Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Prevail Therapeutics"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Prime Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Prime Medicine","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Prime Medicine"},{"orgOrder":0,"company":"ProgenaCare Global","sponsor":"Kane Biotech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"ProgenaCare Global","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"ProgenaCare Global \/ Kane Biotech","highestDevelopmentStatusID":"15","companyTruncated":"ProgenaCare Global \/ Kane Biotech"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Purisys LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Purisys LLC","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Purisys LLC"},{"orgOrder":0,"company":"University of Virginia School of Medicine","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"University of Virginia School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Virginia School of Medicine \/ Adial Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Virginia School of Medicine \/ Adial Pharmaceuticals"},{"orgOrder":0,"company":"City of Hope","sponsor":"Race Oncology Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bisantrene","moa":"FTO protein","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Race Oncology Limited","highestDevelopmentStatusID":"9","companyTruncated":"City of Hope \/ Race Oncology Limited"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"St. Jude Children \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children \/ Renaissance Pharma"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Reprocell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Dimesna","moa":"||ALK","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Reprocell","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Reprocell"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"ResolutionRx","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ ResolutionRx"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenta Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Rgenta Therapeutics \/ GSK"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Agreement","leadProduct":"Pertuzumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"Enzolytics","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enzolytics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Enzolytics \/ Samsung Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Enzolytics \/ Samsung Biologics"},{"orgOrder":0,"company":"Adalvo","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Sandoz B2B"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"JNJ-78901563","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Sanofi"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"JNJ-78901563","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Sanofi"},{"orgOrder":0,"company":"jCyte","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Columbia University"},{"orgOrder":0,"company":"Novavax","sponsor":"SK Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Expanded Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ SK Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ SK Bioscience"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Societal CDMO \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Societal CDMO \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"iNexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Xequel Bio \/ Societal CDMO","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Societal CDMO"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Syena","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SY-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Syena","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Syena"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syneos Health \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Syneos Health \/ Crossject","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Crossject"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"||CHK1","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Taiho Oncology"},{"orgOrder":0,"company":"TeraImmune","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ National Institutes of Health"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"BD9","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolojic Design \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Neuraxpharm"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Nephron Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Histogen","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Emricasan","moa":"Caspase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Histogen \/ Johns Hopkins University","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/ Johns Hopkins University"},{"orgOrder":0,"company":"University of Massachusetts","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"University of Massachusetts","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts \/ ASC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Massachusetts \/ ASC Therapeutics"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Corporation \/ Mississippi State University"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Corporation \/ Mississippi State University"},{"orgOrder":0,"company":"Xilis","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Xilis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xilis \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Xilis \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Tisento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Tisento Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Tisento Therapeutics"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"KEMRI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ KEMRI","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ KEMRI"},{"orgOrder":0,"company":"Premier","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Trevena","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Trevena"},{"orgOrder":0,"company":"Trutag Technologies","sponsor":"Spinnaker Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Partnership","leadProduct":"Silicon Oxide Loaded Ranibizumab","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Trutag Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Trutag Technologies \/ Spinnaker Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Trutag Technologies \/ Spinnaker Biosciences"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"TScan Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"TScan Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Bayer AG"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"uBriGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ uBriGene","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ uBriGene"},{"orgOrder":0,"company":"Apic Bio","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"APB-102","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Apic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apic Bio \/ Uniqure","highestDevelopmentStatusID":"5","companyTruncated":"Apic Bio \/ Uniqure"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Vaxcyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sutro Biopharma \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ Vaxcyte"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Brolucizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Pyxis Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Pyxis Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Vox Nova","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Vox Nova","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Vox Nova"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Walking Fish Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MaxCyte \/ Walking Fish Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ Walking Fish Therapeutics"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WuXi Advanced Therapies \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Advanced Therapies \/ Cabaletta Bio"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"PeriNess","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"XBIO-015","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ PeriNess","highestDevelopmentStatusID":"5","companyTruncated":"Xenetic Biosciences \/ PeriNess"},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"XtalPi","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XtalPi \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ GSK"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Immatics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"IMA402","moa":"T-cell engaging receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KBI Biopharma \/ Immatics","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Immatics"},{"orgOrder":0,"company":"BioAtla","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Evalstotug","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ BeiGene"},{"orgOrder":0,"company":"Iconic Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"XB002","moa":"Tissue Factor","graph1":"Oncology","graph2":"Phase I","graph3":"Iconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iconic Therapeutics \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Iconic Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Factor IX gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Miami University Broaden","sponsor":"PsyBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Miami University Broaden","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Miami University Broaden \/ PsyBio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Miami University Broaden \/ PsyBio Therapeutics"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ BARDA"},{"orgOrder":0,"company":"Yale University","sponsor":"Aptorum","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Aptorum","highestDevelopmentStatusID":"4","companyTruncated":"Yale University \/ Aptorum"},{"orgOrder":0,"company":"Exvastat","sponsor":"Innovative Medicines Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Imatinib Mesylate","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exvastat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exvastat \/ Innovative Medicines Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Exvastat \/ Innovative Medicines Initiative"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxxas \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Vaxxas \/ Merck & Co"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"PR600","moa":"TNF","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"OncoC4","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Docetaxel","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"OncoC4 \/ BioNTech"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"5 Prime Sciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"5 Prime Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"5 Prime Sciences \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"5 Prime Sciences \/ Eli Lilly"},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scripps Research \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Scripps Research \/ AbbVie Inc"},{"orgOrder":0,"company":"AbSci","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbSci \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"AbSci \/ Merck & Co"},{"orgOrder":0,"company":"Aethon Therapeutics","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aethon Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aethon Therapeutics \/ Revolution Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Aethon Therapeutics \/ Revolution Medicines"},{"orgOrder":0,"company":"AI Proteins","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"AI Proteins","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AI Proteins \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"AI Proteins \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ampersand Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Ampersand Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ampersand Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Ampersand Biosciences \/ Flagship Pioneering"},{"orgOrder":0,"company":"Anagenex","sponsor":"Nimbus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Anagenex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anagenex \/ Nimbus Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Anagenex \/ Nimbus Therapeutics"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astex Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Astex Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blue Water Vaccines \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Blue Water Vaccines \/ IQVIA"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"BRII-179","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Brii Biosciences"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Celest Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"SENTI-301A","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Celest Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Celest Therapeutics"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncternal Therapeutics \/ Celularity","highestDevelopmentStatusID":"4","companyTruncated":"Oncternal Therapeutics \/ Celularity"},{"orgOrder":0,"company":"Celularity","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celularity \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Celularity \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Cure Stat Rx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Collaboration","leadProduct":"Mifepristone","moa":"||Glucocorticoid\/progesterone receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Therapeutic Solutions \/ Cure Stat Rx","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Cure Stat Rx"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Curigin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"CA102","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Curigin","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Curigin"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Abemaciclib","moa":"||CHK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Genetic Cures for Kids","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Genetic Cures for Kids","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Genetic Cures for Kids"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"GDC-6036","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Genocea","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genocea \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"3","companyTruncated":"Genocea \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tentarix Biotherapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"EpiVax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"GreenLight Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GreenLight Biosciences \/ EpiVax","highestDevelopmentStatusID":"2","companyTruncated":"GreenLight Biosciences \/ EpiVax"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"||HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"InSilicoTrials","sponsor":"Axoltis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"NX210c","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"InSilicoTrials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InSilicoTrials \/ Axoltis Pharma","highestDevelopmentStatusID":"6","companyTruncated":"InSilicoTrials \/ Axoltis Pharma"},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Invasight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eurofins Discovery \/ Invasight","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins Discovery \/ Invasight"},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Scipher Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scipher Medicine \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Scipher Medicine \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Merck & Co"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Bielefeld University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Microtubule","graph1":"Oncology","graph2":"Discovery","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lantern Pharma \/ Bielefeld University","highestDevelopmentStatusID":"2","companyTruncated":"Lantern Pharma \/ Bielefeld University"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Lycia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Lycia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Lycia Therapeutics"},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Mammoth Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mammoth Biosciences \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Mammoth Biosciences \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MEDIC Life Sciences","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"MEDIC Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEDIC Life Sciences \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"MEDIC Life Sciences \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Menten AI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Menten AI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menten AI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Menten AI \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MiMedx","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MiMedx \/ MediWound","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ MediWound"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Donepepzil","moa":"||nAchR","graph1":"Neurology","graph2":"Phase I","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neuphoria Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Neuphoria Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Montai Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Montai Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Montai Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Montai Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor ant","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Olema Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Life Edit Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Life Edit Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Life Edit Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Life Edit Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Metaphore Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metaphore Biotechnologies \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Metaphore Biotechnologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Ideaya Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cimeio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CD117-shielded Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Cimeio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Cimeio Therapeutics"},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ AbbVie Inc"},{"orgOrder":0,"company":"X-Chem","sponsor":"Relay Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"X-Chem \/ Relay Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Relay Therapeutics"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Kronos Bio \/ Genentech"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Related Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Charles River Laboratories, Inc \/ Related Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Charles River Laboratories, Inc \/ Related Sciences"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Recludix Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Recludix Pharma \/ Sanofi"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shape Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Shape Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Vaxxas","sponsor":"SK Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Typhoid Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ SK Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ SK Bioscience"},{"orgOrder":0,"company":"TheracosBio","sponsor":"SmithRx","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ SmithRx","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ SmithRx"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CD8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SQZ Biotechnologies \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"SystImmune","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Eli Lilly"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"1","companyTruncated":"Adial Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"Tevard Biosciences","sponsor":"Zogenix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Tevard Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tevard Biosciences \/ Zogenix","highestDevelopmentStatusID":"3","companyTruncated":"Tevard Biosciences \/ Zogenix"},{"orgOrder":0,"company":"Creyon Bio","sponsor":"Cajal Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Creyon Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creyon Bio \/ Cajal Neuroscience","highestDevelopmentStatusID":"3","companyTruncated":"Creyon Bio \/ Cajal Neuroscience"},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"PathAI, inc","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"GSK4532990","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"PathAI, inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PathAI, inc \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"PathAI, inc \/ GSK"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MediSix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ MediSix","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ MediSix"},{"orgOrder":0,"company":"Ozette Technologies","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ozette Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ozette Technologies \/ Umoja Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Ozette Technologies \/ Umoja Biopharma"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"VS-7375","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Verastem Oncology \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Pritzker Neuropsychiatric Disorders Research Consortium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verge Genomics \/ Pritzker Neuropsychiatric Disorders Research Consortium","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Pritzker Neuropsychiatric Disorders Research Consortium"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Dualsystems Biotech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"aTyr Pharma \/ Dualsystems Biotech","highestDevelopmentStatusID":"2","companyTruncated":"aTyr Pharma \/ Dualsystems Biotech"},{"orgOrder":0,"company":"XtalPi","sponsor":"EDDC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"XtalPi \/ EDDC","highestDevelopmentStatusID":"2","companyTruncated":"XtalPi \/ EDDC"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeterna Zentaris \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Aeterna Zentaris \/ Novo Nordisk"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Celularity","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento Therapeutics \/ Celularity"},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Just \u2013 Evotec Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Just \u2013 Evotec Biologics \/ Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Just \u2013 Evotec Biologics \/ Department of Defense"},{"orgOrder":0,"company":"Chimeron Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chimeron Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimeron Bio \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Chimeron Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Th\u00e9a Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Akorn Pharmaceuticals \/ Th\u00e9a Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Th\u00e9a Pharma"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"AUG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ AUG Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ AUG Therapeutics"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Divestment","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals"},{"orgOrder":0,"company":"Avrobio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"CTNS-RD-04","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"DOD","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"EuMentis Therapeutics \/ DOD","highestDevelopmentStatusID":"2","companyTruncated":"EuMentis Therapeutics \/ DOD"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Aguettant","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Aguettant","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Aguettant"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"ATNAHS PHARMA UK LIMITED","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ ATNAHS PHARMA UK LIMITED","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ ATNAHS PHARMA UK LIMITED"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ BeiGene","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ BeiGene"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Expanded Collaboration","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Expanded Collaboration","leadProduct":"ACLX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Skyhawk Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Skyhawk Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Tango Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"Alpha-Lactalbumin-Based Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anixa Biosciences \/ Cleveland Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Cleveland Clinic"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Kansas State University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"TNX-2300","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Kansas State University","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Kansas State University"},{"orgOrder":0,"company":"Ingenus Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"Cytochrome P450 3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ingenus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ingenus Pharmaceuticals \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Ingenus Pharmaceuticals \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ GSK"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Nanomerics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Nanomerics","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Nanomerics"},{"orgOrder":0,"company":"Rutgers University","sponsor":"Sauvie Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"NK-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Rutgers University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rutgers University \/ Sauvie Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Rutgers University \/ Sauvie Inc."},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"RSBT-001","moa":"Cannabinoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Pediatrix Therapeutics"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sangamo Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Cortice Biosciences","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Abeotaxane","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cortice Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cortice Biosciences \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cortice Biosciences \/ CNS Pharmaceuticals"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"ST-501","moa":"Tau protein production","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sangamo Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Genentech"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenics \/ Incyte Corporation"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ MThera Pharma"},{"orgOrder":0,"company":"Trevena","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Jiangsu Nhwa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Jiangsu Nhwa Pharmaceutical"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"ARO-DUX4","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Sarepta Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Quemliclustat","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"MSN Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ MSN Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ MSN Laboratories"},{"orgOrder":0,"company":"iVeena","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Copper Sulphate Pentahydrate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"iVeena \/ Glaukos","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ Glaukos"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Eureka Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Eureka Therapeutics"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"STRO-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Sutro Biopharma \/ Ipsen"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Columbia University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"TNX-3600","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Columbia University \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Neuron23","sponsor":"Qiagen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuron23 \/ Qiagen","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/ Qiagen"},{"orgOrder":0,"company":"EmpathBio","sponsor":"Bionomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BNC210","moa":"||nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"EmpathBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EmpathBio \/ Bionomics","highestDevelopmentStatusID":"4","companyTruncated":"EmpathBio \/ Bionomics"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"180 Life Sciences \/ Celltrion","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Celltrion"},{"orgOrder":0,"company":"Infectious Disease Research Institute","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"IBIO-200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Infectious Disease Research Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infectious Disease Research Institute \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Infectious Disease Research Institute \/ iBio"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Caribou Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Caribou Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"E3 ligase","graph1":"Oncology","graph2":"Preclinical","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontier Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Frontier Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"The University Of Colorado Anschutz Medical Campus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Efgartigimod","moa":"Fc receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"CDI-873","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Abbvie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Abbvie Inc"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Amasa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lineage Cell Therapeutics \/ Amasa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Cell Therapeutics \/ Amasa Therapeutics"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Aligos Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Aligos Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OWP Pharmaceuticals \/ Eversana","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Eversana"},{"orgOrder":0,"company":"Specialty Process Labs","sponsor":"Letco Medical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Thyroid","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Specialty Process Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Specialty Process Labs \/ Letco Medical","highestDevelopmentStatusID":"15","companyTruncated":"Specialty Process Labs \/ Letco Medical"},{"orgOrder":0,"company":"Partillion Bioscience","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Partillion Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Partillion Bioscience \/ Alloy Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Partillion Bioscience \/ Alloy Therapeutics"},{"orgOrder":0,"company":"Braeburn","sponsor":"Altruix","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Altruix","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Altruix"},{"orgOrder":0,"company":"Arup Laboratories","sponsor":"Medicover","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Arup Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arup Laboratories \/ Medicover","highestDevelopmentStatusID":"15","companyTruncated":"Arup Laboratories \/ Medicover"},{"orgOrder":0,"company":"Humanigen","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Leo Cancer Care","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aviko Radiopharmaceuticals \/ Leo Cancer Care","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Leo Cancer Care"},{"orgOrder":0,"company":"Eversana","sponsor":"Yaral Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Diclofenac Epolamine","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Eversana \/ Yaral Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eversana \/ Yaral Pharma"},{"orgOrder":0,"company":"Pioneering Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Pioneering Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pioneering Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Pioneering Medicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontier Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Frontier Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"GeneFab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ GeneFab","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ GeneFab"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Grid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Infinimmune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Infinimmune \/ Grid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Infinimmune \/ Grid Therapeutics"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Caris Life Sciences \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Incyte Corporation"},{"orgOrder":0,"company":"Ingenu","sponsor":"Psyence","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ingenu","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ingenu \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Ingenu \/ Psyence"},{"orgOrder":0,"company":"COTA","sponsor":"Clinical Research Data Sharing Alliance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"COTA","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"COTA \/ Clinical Research Data Sharing Alliance","highestDevelopmentStatusID":"2","companyTruncated":"COTA \/ Clinical Research Data Sharing Alliance"},{"orgOrder":0,"company":"OnKai","sponsor":"Galmed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OnKai","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OnKai \/ Galmed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"OnKai \/ Galmed Pharmaceuticals"},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Cellares","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"NeoTCR-P1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PACT Pharma \/ Cellares","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharma \/ Cellares"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Partnership","leadProduct":"Zilebesiran","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"The Sage Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tecarfarin","moa":"||Vitamin K","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cadrenal Therapeutics \/ The Sage Group","highestDevelopmentStatusID":"9","companyTruncated":"Cadrenal Therapeutics \/ The Sage Group"},{"orgOrder":0,"company":"Novavax","sponsor":"SK Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ SK Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ SK Bioscience"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"E3 ligase","graph1":"Oncology","graph2":"Preclinical","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontier Medicine \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Frontier Medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"DLX-7","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide Clinical Trials \/ Cybin"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"X-Chem","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"iBRD9","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumi Scientific \/ X-Chem","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scientific \/ X-Chem"},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CAP4196","moa":"Alpha A crystallin","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Plex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Plex Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plex Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ European Commission"},{"orgOrder":0,"company":"La Jolla Institute","sponsor":"Cytocom","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"TLR","graph1":"Oncology","graph2":"Discovery Platform","graph3":"La Jolla Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"La Jolla Institute \/ Cytocom","highestDevelopmentStatusID":"3","companyTruncated":"La Jolla Institute \/ Cytocom"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Rosalind Franklin University of Medicine and Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Rosalind Franklin University of Medicine and Science","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Rosalind Franklin University of Medicine and Science"},{"orgOrder":0,"company":"Kansas State University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TNX-2300","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kansas State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kansas State University \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Kansas State University \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Talem Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Talem Therapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Sentia Medical Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Sentia Medical Science \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Omeros","sponsor":"DRI Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor-alpha 1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraocular Solution","sponsorNew":"Omeros \/ DRI Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ DRI Healthcare"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"PharmAla Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ PharmAla Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Mindset Pharma \/ PharmAla Biotech"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"The National Cancer Center Japan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Cetuximab Sarotalocan","moa":"ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakuten Medical \/ The National Cancer Center Japan","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ The National Cancer Center Japan"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Apeiron Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"DIMERx","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-201","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ DIMERx","highestDevelopmentStatusID":"2","companyTruncated":"Massachusetts General Hospital \/ DIMERx"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Olezarsen","moa":"APOC-III","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Theratechnologies","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Theratechnologies"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ New Life Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ New Life Therapeutics"},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kelonia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kelonia Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Kelonia Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"MEI Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Infinity Pharmaceuticals \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ MEI Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Merck Group","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Merck Group"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Sirexatamab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leap Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"University of California","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of California \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Apexian Pharmaceuticals","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Apexian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Apexian Pharmaceuticals \/ Ocuphire Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Apexian Pharmaceuticals \/ Ocuphire Pharma"},{"orgOrder":0,"company":"Synthorx Inc","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"THOR-707","moa":"Non-alpha IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Synthorx Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthorx Inc \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Synthorx Inc \/ Sanofi"},{"orgOrder":0,"company":"Cornell University","sponsor":"reVision Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"REV-0100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Cornell University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cornell University \/ reVision Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cornell University \/ reVision Therapeutics"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Lupagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Lupagen","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Lupagen"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Dyno Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyno Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Dyno Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Abintus Bio","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Abintus Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abintus Bio \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Abintus Bio \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"NovaRock Biotherapeutics","sponsor":"Flame Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"NBL-015","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"NovaRock Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaRock Biotherapeutics \/ Flame Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"NovaRock Biotherapeutics \/ Flame Biosciences"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA splicing","graph1":"Oncology","graph2":"Discovery","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Skyhawk Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Skyhawk Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Sinclair Research","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"AnQlar","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sinclair Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sinclair Research \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sinclair Research \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Carisma Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Vesalius Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vesalius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vesalius Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Vesalius Therapeutics \/ GSK"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Volastra Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Volastra Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Fosciclopirox","moa":"||Cell membrane synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"7","companyTruncated":"Notable Labs \/ CicloMed LLC"},{"orgOrder":0,"company":"Celcuity","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Celcuity \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Celcuity \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Collaboration","leadProduct":"177-Lu Rosopatamab Tetraxetan","moa":"||PSMA","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"3T Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"3T Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"3T Biosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"3T Biosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Celsius Therapeutics \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Therapeutics \/ Servier"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Strata Oncology \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Strata Oncology \/ Gilead Sciences"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Artisan Industries Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Artisan Industries Inc","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Artisan Industries Inc"},{"orgOrder":0,"company":"Adalvo","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ Zentiva"},{"orgOrder":0,"company":"Hunterian Medicine","sponsor":"Inscripta","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"MAD7 Nuclease","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Hunterian Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hunterian Medicine \/ Inscripta","highestDevelopmentStatusID":"1","companyTruncated":"Hunterian Medicine \/ Inscripta"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Granisetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Septerna","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Septerna \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Septerna \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"AbSci","sponsor":"Alpha Cancer Technologies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant Human Alpha-Fetoprotein","moa":"Alpha fetoprotein receptor","graph1":"Immunology","graph2":"Phase I","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbSci \/ Alpha Cancer Technologies","highestDevelopmentStatusID":"6","companyTruncated":"AbSci \/ Alpha Cancer Technologies"},{"orgOrder":0,"company":"Aquinnah Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Aquinnah Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aquinnah Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Aquinnah Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Horizon Pharma Plc","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HemoShear Therapeutics \/ Horizon Pharma Plc","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear Therapeutics \/ Horizon Pharma Plc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jacobio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"JAB-3068","moa":"SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Jacobio","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Jacobio"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Nkarta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Nkarta","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Nkarta"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KSQ Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Adimab","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Adimab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adimab \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Adimab \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Allergy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP-based Peanut Allergy Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AGC Biologics \/ Allergy Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Allergy Therapeutics"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Saiba AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Virus-like Particle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Saiba AG","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biologics \/ Saiba AG"},{"orgOrder":0,"company":"Agtc","sponsor":"TeamedOn","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"rAAV2tYF-CB-hRS1","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ TeamedOn","highestDevelopmentStatusID":"1","companyTruncated":"Agtc \/ TeamedOn"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aligos Therapeutics \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"2","companyTruncated":"Aligos Therapeutics \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Alivexis","sponsor":"Melodia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MDI-0151","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Alivexis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alivexis \/ Melodia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Alivexis \/ Melodia Therapeutics"},{"orgOrder":0,"company":"Vaxart","sponsor":"Altesa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Vapendavir","moa":"Capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Altesa Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Altesa Biosciences"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Agreement","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Amneal Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Acerus Pharmaceuticals"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"AnaptysBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CBS004","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ AnaptysBio","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ AnaptysBio"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"AnGes","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ AnGes","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ AnGes"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Apollo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Apollo Therapeutics"},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"EO1001","moa":"pan-ErbB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edison Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edison Oncology \/ Apollomics Inc","highestDevelopmentStatusID":"7","companyTruncated":"Edison Oncology \/ Apollomics Inc"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Apollomics Inc","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Apollomics Inc"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Israeli Ministry of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Israeli Ministry of Health","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Israeli Ministry of Health"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Arrakis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrakis Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Arrakis Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"GNS healthcare","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Arvinas \/ GNS healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Arvinas \/ GNS healthcare"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Propella Therapeutics \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Propella Therapeutics \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Cullgen","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cullgen \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ Astellas Pharma"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"VET2-L2","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KaliVir Immunotherapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"KaliVir Immunotherapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Pinetree Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Pinetree Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pinetree Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Pinetree Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biotherapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ruzasvir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Athenex","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Mutated p53","graph1":"Oncology","graph2":"Undisclosed","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athenex \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Athenex \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Partnership","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Beacon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"AAV204","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abeona Therapeutics \/ Beacon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Abeona Therapeutics \/ Beacon Therapeutics"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Bial","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Bial","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Bial"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Bintai Kinden","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Ii-Key-SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generex Biotechnology \/ Bintai Kinden","highestDevelopmentStatusID":"4","companyTruncated":"Generex Biotechnology \/ Bintai Kinden"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"CB 2782-PEG","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Catalyst Biosciences \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Biogen"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Taldefgrobep Alpha","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BioNova Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sutro Biopharma \/ BioNova Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ BioNova Pharmaceuticals"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Surrozen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"SZN-413","moa":"Wnt signaling","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Boston Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"PRS-342","moa":"4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pieris Pharmaceuticals \/ Boston Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pieris Pharmaceuticals \/ Boston Pharmaceuticals"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Adamas Pharmaceuticals"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Capsida","sponsor":"Kate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capsida \/ Kate Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ Kate Therapeutics"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Beijing Tianshi Tongda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"CID-103","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CASI Pharmaceuticals \/ Beijing Tianshi Tongda Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharmaceuticals \/ Beijing Tianshi Tongda Pharmaceuticals"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Merimepodib","moa":"IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Ennaid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"ENU200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Ennaid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Ennaid Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Voclosporin","moa":"||Calcineurin","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Catalent Pharma Solutions \/ Decibel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Decibel Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Spicona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"VLP Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Spicona","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Spicona"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"XB010","moa":"5T4","graph1":"Oncology","graph2":"Discovery","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Catalent Pharma Solutions \/ Exelixis"},{"orgOrder":0,"company":"jCyte","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Center for Breakthrough Medicines"},{"orgOrder":0,"company":"BioCardia","sponsor":"CellProthera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ CellProthera","highestDevelopmentStatusID":"8","companyTruncated":"BioCardia \/ CellProthera"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gritstone bio \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone bio \/ CEPI"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"CPG ODN 1018","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ CEPI","highestDevelopmentStatusID":"15","companyTruncated":"Dynavax Technologies \/ CEPI"},{"orgOrder":0,"company":"GigaMune","sponsor":"Champions Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GigaMune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GigaMune \/ Champions Oncology","highestDevelopmentStatusID":"3","companyTruncated":"GigaMune \/ Champions Oncology"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Xi'an Guokang Ruijin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Agreement","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CASI Pharmaceuticals \/ Xi'an Guokang Ruijin Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CASI Pharmaceuticals \/ Xi'an Guokang Ruijin Pharmaceutical"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Chroma Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sangamo Therapeutics \/ Chroma Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Sangamo Therapeutics \/ Chroma Medicine"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Cidara Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Cervical mucus","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Organon \/ Cirqle Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Organon \/ Cirqle Biomedical"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cleave Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Licensing Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Clionix","highestDevelopmentStatusID":"15","companyTruncated":"Q BioMed \/ Clionix"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Comera Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Comera Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"CUE-401","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Cue Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Cue Biopharma"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Curamys","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Curamys","highestDevelopmentStatusID":"1","companyTruncated":"MaxCyte \/ Curamys"},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ University of Florida"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Cybin","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Cybin"},{"orgOrder":0,"company":"American Regent","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"American Regent \/ CytoDyn"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"Zealand Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"DEKA Research & Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"DEKA Research & Development \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"DEKA Research & Development \/ Zealand Pharma"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Demelle","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Farnesyl-Di-Methyl-Chromanol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Demelle","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Cancer Center \/ Demelle"},{"orgOrder":0,"company":"Bioclinica","sponsor":"Direct Biologics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"DB-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bioclinica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioclinica \/ Direct Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Bioclinica \/ Direct Biologics"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CpG 1018","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Valneva","highestDevelopmentStatusID":"7","companyTruncated":"Dynavax Technologies \/ Valneva"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Egle Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Egle Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Egle Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Seven and Eight Biopharmaceuticals","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"BDB018","moa":"||TLR7\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Seven and Eight Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seven and Eight Biopharmaceuticals \/ Eikon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Seven and Eight Biopharmaceuticals \/ Eikon Therapeutics"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entos Pharmaceuticals \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Entos Pharmaceuticals \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Eoc Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Eoc Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Eoc Pharma"},{"orgOrder":0,"company":"AnGes","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Beperminogene Perplasmid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"AnGes \/ Erkim"},{"orgOrder":0,"company":"Factor Bioscience","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Factor Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Factor Bioscience \/ Eterna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Factor Bioscience \/ Eterna Therapeutics"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"225-Ac FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Undisclosed","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Evergreen Theragnostics","highestDevelopmentStatusID":"1","companyTruncated":"Clovis Oncology \/ Evergreen Theragnostics"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Eversana"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Hk Tainuo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ Hk Tainuo","highestDevelopmentStatusID":"15","companyTruncated":"Flexion Therapeutics \/ Hk Tainuo"},{"orgOrder":0,"company":"Fluence","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Fluence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fluence \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Fluence \/ Cybin"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"GentiBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forge Biologics \/ GentiBio","highestDevelopmentStatusID":"4","companyTruncated":"Forge Biologics \/ GentiBio"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GAL-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galimedix Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"George Mason University","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Set-Point Vaccines","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"George Mason University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"George Mason University \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"George Mason University \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NX-0479","moa":"IRAK4","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Gilead Sciences"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"SRF813","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ GSK"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hansoh Pharma"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"TRN-000632","moa":"BCR-ABL","graph1":"Oncology","graph2":"Preclinical","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terns Pharmaceuticals \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Terns Pharmaceuticals \/ Hansoh Pharma"},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voltron Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"HFB200301","moa":"||TNFR2","graph1":"Oncology","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"HFB200603","moa":"||BLTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"Cetuximab Sarotalocan","moa":"ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rakuten Medical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Rhoshan Pharmaceuticals","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Rhoshan Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rhoshan Pharmaceuticals \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Rhoshan Pharmaceuticals \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Planet Biotechnology","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"ACE2-Fc","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Planet Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Planet Biotechnology \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Planet Biotechnology \/ iBio"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"iECURE","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"PBGENE-PCSK9","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ iECURE","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ iECURE"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"89Zr-crefmirlimab","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Leucid Bio","highestDevelopmentStatusID":"4","companyTruncated":"ImaginAb \/ Leucid Bio"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Imbrium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"IMB-150","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Imbrium Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PureTech Health \/ Imbrium Therapeutics"},{"orgOrder":0,"company":"Immunome","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunome \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ AbbVie Inc"},{"orgOrder":0,"company":"Villaris Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Auremolimab","moa":"CD122","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Villaris Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Villaris Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Villaris Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"Amagma Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Amagma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amagma Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Amagma Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Cartexell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CLND18.2","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Integral Molecular \/ Cartexell","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Cartexell"},{"orgOrder":0,"company":"Intima Bioscience","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"||CISH","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intima Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intima Bioscience \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Intima Bioscience \/ MaxCyte"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coeptis Therapeutics \/ IQVIA","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ IQVIA"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Simcha Therapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"4","companyTruncated":"Simcha Therapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Bioasis","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioasis \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mersana Therapeutics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Therapeutics \/ GSK"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Solute carrier","graph1":"Immunology","graph2":"Discovery","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Jnana Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"KALEO INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KALEO INC \/ Optinose","highestDevelopmentStatusID":"15","companyTruncated":"KALEO INC \/ Optinose"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Licensing Agreement","leadProduct":"VET-ROG1","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"KaliVir Immunotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"KaliVir Immunotherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Ganciclovir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Saol therapeutics \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"Saol therapeutics \/ Kamada"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Goldfinch Bio, Inc \/ Karuna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Goldfinch Bio, Inc \/ Karuna Therapeutics"},{"orgOrder":0,"company":"KBio","sponsor":"ZabBio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"KBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"KBio \/ ZabBio","highestDevelopmentStatusID":"4","companyTruncated":"KBio \/ ZabBio"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kindred Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Kindred Biosciences \/ Vaxart","highestDevelopmentStatusID":"4","companyTruncated":"Kindred Biosciences \/ Vaxart"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Global Coalition for Adaptive Research"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"Landmark Bio","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Landmark Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Landmark Bio \/ Galapagos","highestDevelopmentStatusID":"1","companyTruncated":"Landmark Bio \/ Galapagos"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Lerodalcibep","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LIB Therapeutics \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"||HGF IgG1","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Aveo Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Aveo Oncology"},{"orgOrder":0,"company":"List Biological Laboratories","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"AP-003","moa":"Interferon alpha\/beta receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"List Biological Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"List Biological Laboratories \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"List Biological Laboratories \/ BetterLife Pharma"},{"orgOrder":0,"company":"Lonza Capsugel","sponsor":"Touchlight","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Capsugel","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Capsugel \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Capsugel \/ Touchlight"},{"orgOrder":0,"company":"Corium","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"mRNA-1172","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Yumanity Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"MTK-458","moa":"PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitokinin \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin \/ AbbVie Inc"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Moderna Therapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Institute for Life Changing Medicines","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"mRNA-3351","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Institute for Life Changing Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Institute for Life Changing Medicines"},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Eikonizo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"HDAC6","graph1":"Neurology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"McQuade Center for Strategic Research and Development \/ Eikonizo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Eikonizo Therapeutics"},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Sentinel Oncology","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"SOL784","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McQuade Center for Strategic Research and Development \/ Sentinel Oncology","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Sentinel Oncology"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Molecular Templates \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Molecular Templates \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"SLATE-KRAS","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Gritstone bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuBase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"NeuBase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nevakar","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Nevakar \/ Laboratoires Thea","highestDevelopmentStatusID":"10","companyTruncated":"Nevakar \/ Laboratoires Thea"},{"orgOrder":0,"company":"NorthShore University HealthSystem","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"NorthShore University HealthSystem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthStar Medical Radioisotopes \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ Bayer AG"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"||Alpha radiation ionising","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NorthStar Medical Radioisotopes \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ Point Biopharma"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Curadh","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthStar Medical Radioisotopes \/ Curadh","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ Curadh"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novavax","sponsor":"Operation Warp Speed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"NVX\u2011CoV2373","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Operation Warp Speed","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ Operation Warp Speed"},{"orgOrder":0,"company":"Emisphere Technologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Emisphere Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emisphere Technologies \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Emisphere Technologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Emisphere Technologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Emisphere Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emisphere Technologies \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Emisphere Technologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"DCR-NOVO1","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dicerna Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Dicerna Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novome Biotechnologies \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"PT627","moa":"PD-1","graph1":"Immunology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ Pandion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Vivet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"VTX-801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Vivet Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Vivet Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pfizer Inc \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Gilead Sciences"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"Viewpoint Molecular Targeting","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"VMT01","moa":"MC1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaLogic \/ Viewpoint Molecular Targeting","highestDevelopmentStatusID":"4","companyTruncated":"PharmaLogic \/ Viewpoint Molecular Targeting"},{"orgOrder":0,"company":"University of Kansas","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Kansas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kansas \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"University of Kansas \/ PharmaTher"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Novellus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Plixorafenib","moa":"BRAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Plexxikon \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon \/ Novellus"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Niclosamide","moa":"SARS-CoV-2 viral spike protein 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"PPD \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ First Wave BioPharma"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"PR600","moa":"TNF","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus Biosciences \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"PureForm","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"PureForm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"PureForm \/ Enveric Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"PureForm \/ Enveric Biosciences"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"GQ1010","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pyramid Bio \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Pyramid Bio \/ GeneQuantum Healthcare"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Partnership","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arbutus Biopharma \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA processing","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Remix Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ GSK"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Maryland","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Maryland"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"CD22","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Sana Biotechnology \/ National Institutes of Health"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Voyager Therapeutics, Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Schrodinger \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Schrodinger \/ Eli Lilly"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Sciclone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"RRx-001","moa":"CD47","graph1":"Oncology","graph2":"Phase III","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EpicentRx \/ Sciclone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EpicentRx \/ Sciclone Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Eli Lilly \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"Seagen","sponsor":"Lava Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"LAVA-1223","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagen \/ Lava Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Lava Therapeutics"},{"orgOrder":0,"company":"Alvaxa Biosciences","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alvaxa Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alvaxa Biosciences \/ Sensei Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Alvaxa Biosciences \/ Sensei Biotherapeutics"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Shoreline Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"EDIT-202","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Editas Medicine \/ Shoreline Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Shoreline Biosciences"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sionna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Galicaftor","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Sionna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Sionna Therapeutics"},{"orgOrder":0,"company":"Solve Therapeutics","sponsor":"Nerviano Medical Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Solve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Solve Therapeutics \/ Nerviano Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Solve Therapeutics \/ Nerviano Medical Sciences"},{"orgOrder":0,"company":"Agtc","sponsor":"SparingVision","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ SparingVision","highestDevelopmentStatusID":"5","companyTruncated":"Agtc \/ SparingVision"},{"orgOrder":0,"company":"NeuExcell therapeutics","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"NeuExcell therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuExcell therapeutics \/ Spark Therapeutics, Inc","highestDevelopmentStatusID":"5","companyTruncated":"NeuExcell therapeutics \/ Spark Therapeutics, Inc"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ GSK"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"PF-04457845","moa":"FAAH","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Starton Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strata Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strata Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Strata Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Urovant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Urology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Urovant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Urovant Sciences"},{"orgOrder":0,"company":"Verseau","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"VSIG4","graph1":"Oncology","graph2":"Preclinical","graph3":"Verseau","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verseau \/ 3S Bio Inc","highestDevelopmentStatusID":"4","companyTruncated":"Verseau \/ 3S Bio Inc"},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"NV-5138","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Navitor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Navitor Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Navitor Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Swixx BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Swixx BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Swixx BioPharma"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"SYN-020","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ Theriva Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Massachusetts General Hospital \/ Theriva Biologics"},{"orgOrder":0,"company":"Insmed","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"Amikacin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Taiba Healthcare"},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"LTI-01","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Lung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lung Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lung Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AcuraStem","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"AS-202","moa":"PIKfyve kinase","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"AcuraStem \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"OmniAb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"B7-H3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Talem Therapeutics \/ OmniAb","highestDevelopmentStatusID":"3","companyTruncated":"Talem Therapeutics \/ OmniAb"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Elevar Therapeutics \/ Tanner Pharma"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Tianjin Tasly Group","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Todos Medical","sponsor":"NLC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ NLC Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ NLC Pharma"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Tenacia Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"P-FVIII-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Poseida Therapeutics, Inc \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Plexium","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"E3 ligase mediated proteasomal","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plexium \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ Amgen Inc"},{"orgOrder":0,"company":"Covant Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"ADAR1","graph1":"Oncology","graph2":"Discovery","graph3":"Covant Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Covant Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Covant Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Atreca","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atreca \/ Xencor","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ Xencor"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Generian Pharmaceuticals","sponsor":"Mitobridge","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Generian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Generian Pharmaceuticals \/ Mitobridge","highestDevelopmentStatusID":"3","companyTruncated":"Generian Pharmaceuticals \/ Mitobridge"},{"orgOrder":0,"company":"Generian Pharmaceuticals","sponsor":"Mitobridge","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Generian Pharmaceuticals \/ Mitobridge","highestDevelopmentStatusID":"3","companyTruncated":"Generian Pharmaceuticals \/ Mitobridge"},{"orgOrder":0,"company":"Personalis","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Personalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Personalis \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Personalis \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Lysosomal targeting chimera","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Lycia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lycia Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Lycia Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ST-2427","moa":"NaV1.7 sodium channel","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SiteOne Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Sensory Cloud","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"PUR 003","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Pulmatrix \/ Sensory Cloud","highestDevelopmentStatusID":"1","companyTruncated":"Pulmatrix \/ Sensory Cloud"},{"orgOrder":0,"company":"Immunogen","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Pharmakon Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Pharmakon Advisors"},{"orgOrder":0,"company":"SRI International","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SRI International \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"SRI International \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Candel Therapeutics \/ University of Pennsylvania","highestDevelopmentStatusID":"3","companyTruncated":"Candel Therapeutics \/ University of Pennsylvania"},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Ocular Therapeutix","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"MUSC Foundation for Research Development","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"TP-2021","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development"},{"orgOrder":0,"company":"Oyagen","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Sangivamycin Hydrochloride","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oyagen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oyagen \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"5","companyTruncated":"Oyagen \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Totus Medicines \/ Eli Lilly"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Invetx","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Invetx"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Abcam plc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Abcam plc","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Abcam plc"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Deubiquitylase enzyme","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Ubiquigent","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Ubiquigent"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"UX111","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Unnatural Products","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Macrocyclic Peptide","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Unnatural Products","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unnatural Products \/ BridgeBio Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Unnatural Products \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Ramucirumab","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Innovent Biologics"},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"ValiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"KTH-222","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Kalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalos Therapeutics \/ ValiRx","highestDevelopmentStatusID":"4","companyTruncated":"Kalos Therapeutics \/ ValiRx"},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Pre-Filled Syringe","sponsorNew":"Vaneltix Pharma \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix Pharma \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MaxCyte \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"MaxCyte \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Terevalefim","moa":"HGF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Wistar Institute of Anatomy and Biology","sponsor":"Active Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tasquinimod","moa":"||S100A9","graph1":"Oncology","graph2":"Phase I","graph3":"Wistar Institute of Anatomy and Biology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wistar Institute of Anatomy and Biology \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Wistar Institute of Anatomy and Biology \/ Active Biotech"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Delafloxacin","moa":"Topoisomerse IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Melinta Therapeutics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BLU-945","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Zai Lab","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Zai Lab"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Zhaoke Ophthalmology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visus Therapeutics \/ Zhaoke Ophthalmology","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Zhaoke Ophthalmology"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Zymeworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Zymeworks","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Zymeworks"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Provention Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Provention Bio","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Provention Bio"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biopas Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Biopas Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Biopas Laboratories"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Leader Medical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"OPK88003","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Leader Medical","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Leader Medical"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria Monocytogene","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Hercules Capital"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Tetris Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Tetris Pharma"},{"orgOrder":0,"company":"Dualogics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Dualogics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dualogics \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Dualogics \/ AbCellera"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Unicycive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aadi Bioscience \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Bioscience \/ Mirati Therapeutics"},{"orgOrder":0,"company":"miRecule","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"MC-DX4","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"miRecule","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"miRecule \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"miRecule \/ Sanofi"},{"orgOrder":0,"company":"VeriSIM Life","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"VeriSIM Life","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VeriSIM Life \/ Mayo Clinic","highestDevelopmentStatusID":"3","companyTruncated":"VeriSIM Life \/ Mayo Clinic"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"VolitionRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xenetic Biosciences \/ VolitionRx","highestDevelopmentStatusID":"4","companyTruncated":"Xenetic Biosciences \/ VolitionRx"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"University of the Witwatersrand","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ University of the Witwatersrand","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ University of the Witwatersrand"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"ONO-8250","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Nona Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Capsida \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Capsida \/ AbbVie Inc"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"AvantGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adcentrx Therapeutics \/ AvantGen","highestDevelopmentStatusID":"2","companyTruncated":"Adcentrx Therapeutics \/ AvantGen"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArsenalBio \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"ArsenalBio \/ Genentech"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Center for Breakthrough Medicines","sponsor":"Virion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Center for Breakthrough Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Center for Breakthrough Medicines \/ Virion Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Center for Breakthrough Medicines \/ Virion Therapeutics"},{"orgOrder":0,"company":"Guardant Health","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Phase II","graph3":"Guardant Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Guardant Health \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Guardant Health \/ AnHeart Therapeutics"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"NKT-1992","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NiKang Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"NiKang Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"InveniAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"InveniAI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"InveniAI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"InveniAI \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ MAIA Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron Pharmaceuticals \/ MAIA Biotechnology"},{"orgOrder":0,"company":"METiS Therapeutics","sponsor":"Evopoint Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SOS1","graph1":"Oncology","graph2":"Discovery","graph3":"METiS Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"METiS Therapeutics \/ Evopoint Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"METiS Therapeutics \/ Evopoint Biosciences"},{"orgOrder":0,"company":"Oncorus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Oncorus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Oncorus \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Plexium","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plexium \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ AbbVie Inc"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ DanausGT Biotechnology"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Viva Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Schrodinger \/ Viva Biotech","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Viva Biotech"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Scribe Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Singota Solutions","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Singota Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Singota Solutions \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Singota Solutions \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Cerebral Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Cerebral Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Cerebral Therapeutics"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"PRAX-020","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Praxis Precision Medicines \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"Praxis Precision Medicines \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Verve Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"Lipoprotein","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Verve Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"ImprimisRx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Collaboration","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ ImprimisRx","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ ImprimisRx"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Hercules Capital"},{"orgOrder":0,"company":"Veristat","sponsor":"PreveCeutical Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Veristat \/ PreveCeutical Medical","highestDevelopmentStatusID":"4","companyTruncated":"Veristat \/ PreveCeutical Medical"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Emergent BioSolutions"},{"orgOrder":0,"company":"BIOKEY","sponsor":"NeuCen BioMed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"CEN501","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Strip","sponsorNew":"BIOKEY \/ NeuCen BioMed","highestDevelopmentStatusID":"8","companyTruncated":"BIOKEY \/ NeuCen BioMed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"USAMRIID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Recombinant Vesicular Stomatitis Virus Sars Cov-2 Glycoprotein","moa":"SARS-CoV-2 S glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"TFF Pharmaceuticals \/ USAMRIID","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ USAMRIID"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"TIDAL-01","moa":"||TIL","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Intratus","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"INT-11P001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Intratus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Intratus \/ Glaukos","highestDevelopmentStatusID":"8","companyTruncated":"Intratus \/ Glaukos"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Biodesix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Cetuximab","moa":"||HGF IgG1","graph1":"Oncology","graph2":"Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aveo Oncology \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"Aveo Oncology \/ Biodesix"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Precirix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Partnership","leadProduct":"131-I Conjugated Anti-HER2 sdAb 2Rs15d","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Evergreen Theragnostics \/ Precirix","highestDevelopmentStatusID":"7","companyTruncated":"Evergreen Theragnostics \/ Precirix"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Clobazam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Assertio Therapeutics"},{"orgOrder":0,"company":"PDL BioPharma","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PDL BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDL BioPharma \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"PDL BioPharma \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Entolimod","moa":"TLR5","graph1":"Oncology","graph2":"Preclinical","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Statera Biopharma \/ Coeptis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Statera Biopharma \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Acquisition","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"OP-101","moa":"Glutathione synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"Empirico","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Technology","graph2":"Discovery Platform","graph3":"Empirico","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Empirico \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Empirico \/ AbCellera"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Providence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Providence Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Providence Therapeutics"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Adhera Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pharmaceuticals \/ Adhera Therapeutics"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Qurient","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Telacebec","moa":"Cytochrome bc1 complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Qurient","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Qurient"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Ethicann Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Ethicann Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Ethicann Pharmaceuticals"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Drogsan Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rockwell Medical \/ Drogsan Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Drogsan Pharmaceuticals"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"FamyGen Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ FamyGen Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ FamyGen Life Sciences"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Kallyope","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kallyope \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/ Novo Nordisk"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria Monocytogene","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Pepper Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Pepper Bio","highestDevelopmentStatusID":"6","companyTruncated":"G1 Therapeutics, Inc \/ Pepper Bio"},{"orgOrder":0,"company":"ClearPoint Neuro","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ClearPoint Neuro","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ClearPoint Neuro \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"ClearPoint Neuro \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Vincera Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincera Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincera Pharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vincera Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Akos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"EV102","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Akos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Akos Biosciences"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Langone Health \/ Carisma Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"GC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ GC Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ GC Pharma"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Leyden Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"CR9114","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Leyden Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Leyden Laboratories"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Medison Pharma"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Sovilnesib","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Volastra Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Volastra Therapeutics"},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Gentbio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"T-cell","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seattle Children\u2019s Research Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seattle Children\u2019s Research Institute \/ Gentbio","highestDevelopmentStatusID":"3","companyTruncated":"Seattle Children\u2019s Research Institute \/ Gentbio"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Evorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Oxford Finance","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Oxford Finance"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"BioPharmX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ BioPharmX","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ BioPharmX"},{"orgOrder":0,"company":"Athersys","sponsor":"Healios K.K.","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Healios K.K.","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/ Healios K.K."},{"orgOrder":0,"company":"Xencor","sponsor":"Zenas BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Obexelimab","moa":"CD19\/Fc\u03b3RIIb","graph1":"Immunology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Zenas BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Zenas BioPharma"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Caris Life Sciences \/ Xencor","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Xencor"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Precision BioSciences \/ Servier"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Comera Life Sciences \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Comera Life Sciences \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"Gt Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovance Biologics \/ Gt Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance Biologics \/ Gt Biopharma"},{"orgOrder":0,"company":"Nanite","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Nanite","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nanite \/ CMT Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nanite \/ CMT Research Foundation"},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Similis Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"JSR Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"JSR Life Sciences \/ Similis Bio","highestDevelopmentStatusID":"4","companyTruncated":"JSR Life Sciences \/ Similis Bio"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Entos Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Entos Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Esteve Huayi Pharmaceutical"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"United Kingdom Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ United Kingdom Government","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ United Kingdom Government"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Terumo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Terumo","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Terumo"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Diclofenac","moa":"COX-1","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Charles River Laboratories, Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Oncoheroes Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ Oncoheroes Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Oncoheroes Biosciences"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Elektrofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elektrofi \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Elektrofi \/ Argenx"},{"orgOrder":0,"company":"Tanabe Research Laboratories","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tanabe Research Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tanabe Research Laboratories \/ Adagene Suzhou Limited","highestDevelopmentStatusID":"1","companyTruncated":"Tanabe Research Laboratories \/ Adagene Suzhou Limited"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MaxCyte \/ Apeiron Biologics","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Apeiron Biologics"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Distributed Bio","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Distributed Bio","highestDevelopmentStatusID":"4","companyTruncated":"Mediar Therapeutics \/ Distributed Bio"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"TRPharm","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"FP-045","moa":"ALDH2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foresee Pharmaceuticals \/ TRPharm","highestDevelopmentStatusID":"7","companyTruncated":"Foresee Pharmaceuticals \/ TRPharm"},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Inhibrx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Alpha radiation","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthStar Medical Radioisotopes \/ Inhibrx","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar Medical Radioisotopes \/ Inhibrx"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"AB154","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Hamden Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Naltrexone Hydrochloride","moa":"Kappa\/Mu\/Delta Opioid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halberd Corporation \/ Hamden Group","highestDevelopmentStatusID":"1","companyTruncated":"Halberd Corporation \/ Hamden Group"},{"orgOrder":0,"company":"IMIDomics","sponsor":"University of Barcelona","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"IMB-1003","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMIDomics \/ University of Barcelona","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ University of Barcelona"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Karveer Meditech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"NV-CoV-2","moa":"SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Karveer Meditech","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Karveer Meditech"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Linical","sponsor":"Alpha Cognition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Linical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Linical \/ Alpha Cognition","highestDevelopmentStatusID":"6","companyTruncated":"Linical \/ Alpha Cognition"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Rimiducid","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"PMC-309","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ PharmAbcine","highestDevelopmentStatusID":"4","companyTruncated":"Thermo Fisher Scientific \/ PharmAbcine"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Cetuximab Sarotalocan","moa":"ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakuten Medical \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ Merck & Co"},{"orgOrder":0,"company":"Forge Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Forge Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forge Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Forge Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"4D-710","moa":"CFTR gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"4D Molecular Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"IMIDomics","sponsor":"TNAX Biopharma Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"IMB1001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMIDomics \/ TNAX Biopharma Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ TNAX Biopharma Corporation"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WuXi Advanced Therapies \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Advanced Therapies \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"XtalPi","sponsor":"Incendia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XtalPi \/ Incendia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ Incendia Therapeutics"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vyera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Vyera Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Vyera Pharmaceuticals \/ Seelos Therapeutics"},{"orgOrder":0,"company":"US Oncology Network","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Seribantumab","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"US Oncology Network","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"US Oncology Network \/ Elevation Oncology","highestDevelopmentStatusID":"8","companyTruncated":"US Oncology Network \/ Elevation Oncology"},{"orgOrder":0,"company":"A2A Pharmaceuticals","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"A2A Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"A2A Pharmaceuticals \/ LAXAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"A2A Pharmaceuticals \/ LAXAI Life Sciences"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Arch Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"AO-176","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Arch Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Arch Oncology"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Vaxart","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emergent BioSolutions \/ Vaxart","highestDevelopmentStatusID":"4","companyTruncated":"Emergent BioSolutions \/ Vaxart"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"HMBD-002","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbird Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Rallybio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"haNK","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"NTX-1088","moa":"||CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nectin Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nectin Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytomX Therapeutics \/ Astellas","highestDevelopmentStatusID":"4","companyTruncated":"CytomX Therapeutics \/ Astellas"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Aposense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Aposense","highestDevelopmentStatusID":"1","companyTruncated":"Processa Pharmaceuticals \/ Aposense"},{"orgOrder":0,"company":"Crestone","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"MmpL3","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crestone \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Crestone","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"CRS0540","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crestone \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/ National Institutes of Health"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Imperial College London","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Self-Amplifying Rna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriLink BioTechnologies \/ Imperial College London","highestDevelopmentStatusID":"8","companyTruncated":"TriLink BioTechnologies \/ Imperial College London"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Crestone","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CRS3123","moa":"Methionyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crestone \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/ National Institutes of Health"},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Adcendo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"ADCE-T02","moa":"Tissue Factor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Multitude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multitude Therapeutics \/ Adcendo","highestDevelopmentStatusID":"5","companyTruncated":"Multitude Therapeutics \/ Adcendo"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hetero","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Hetero","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Hetero"},{"orgOrder":0,"company":"University of Louisville","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RAS-F","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Louisville \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Louisville \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Propella Therapeutics"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Southwest Research Institute","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southwest Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Southwest Research Institute \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Southwest Research Institute \/ Henry M. Jackson Foundation"},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Union Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Union Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Union Therapeutics"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Csl Behring","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Csl Behring","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Csl Behring"},{"orgOrder":0,"company":"Soligenix","sponsor":"University of Hawai'i at Manoa","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Filovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ University of Hawai\\'i at Manoa","highestDevelopmentStatusID":"1","companyTruncated":"Soligenix \/ University of Hawai\\'i at Manoa"},{"orgOrder":0,"company":"Miami Miller School of Medicine","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"gp-96 Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Miami Miller School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miami Miller School of Medicine \/ Heat Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Miami Miller School of Medicine \/ Heat Biologics"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"University of Ottawa","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ University of Ottawa","highestDevelopmentStatusID":"4","companyTruncated":"Bold Therapeutics \/ University of Ottawa"},{"orgOrder":0,"company":"Genprex","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"Pdx1\/Mafa gene","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Panacea Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"NUV-422","moa":"CDK2\/4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nuvation Bio \/ Panacea Acquisition","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Panacea Acquisition"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Second Sight Medical Products","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Merger","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Vivani Medical \/ Second Sight Medical Products","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Second Sight Medical Products"},{"orgOrder":0,"company":"OncoC4","sponsor":"AcroImmune","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"AI-071","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoC4 \/ AcroImmune","highestDevelopmentStatusID":"6","companyTruncated":"OncoC4 \/ AcroImmune"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Yumanity Therapeutics \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Yumanity Therapeutics \/ Kineta"},{"orgOrder":0,"company":"Synlogic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Synlogic \/ AbbVie Inc"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Divestment","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Samsung Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Samsung Biologics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"HBM7022","moa":"CLDN18.2\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ University of Rochester Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ University of Rochester Medical Center"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ The International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ The International Vaccine Institute"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Senhwa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Senhwa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Senhwa Biosciences"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ US WorldMeds"},{"orgOrder":0,"company":"Federal Emergency Management Agency","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Lofexidine","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Federal Emergency Management Agency","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Federal Emergency Management Agency \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Federal Emergency Management Agency \/ US WorldMeds"},{"orgOrder":0,"company":"Oncorus","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Financing","leadProduct":"ONCR-021","moa":"ICAM-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorus \/ K2 HealthVentures","highestDevelopmentStatusID":"4","companyTruncated":"Oncorus \/ K2 HealthVentures"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Microsoft","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"TVGN 920","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tevogen Bio \/ Microsoft","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bio \/ Microsoft"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Novo Nordisk"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ BridgeBio Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ BridgeBio Pharma"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"University of Georgia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TFF Pharmaceuticals \/ University of Georgia","highestDevelopmentStatusID":"1","companyTruncated":"TFF Pharmaceuticals \/ University of Georgia"},{"orgOrder":0,"company":"UT Southwestern","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"TGTX-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"UT Southwestern","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern \/ Taysha Gene Therapies","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwestern \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"UTMB","sponsor":"HDT Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"saRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"UTMB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UTMB \/ HDT Bio","highestDevelopmentStatusID":"4","companyTruncated":"UTMB \/ HDT Bio"},{"orgOrder":0,"company":"XOMA","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"XOMA \/ Blue Owl Capital","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Blue Owl Capital"},{"orgOrder":0,"company":"IAVI","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVSV\u0394G-SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IAVI \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ BARDA"},{"orgOrder":0,"company":"3M Company","sponsor":"IDRI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"3M-052","moa":"||TLR7","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"3M Company \/ IDRI","highestDevelopmentStatusID":"4","companyTruncated":"3M Company \/ IDRI"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Private Placement","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Columbia University \/ Oryzon Genomics","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Oryzon Genomics"},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"ValiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Termination","leadProduct":"KTH-222","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Kalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalos Therapeutics \/ ValiRx","highestDevelopmentStatusID":"4","companyTruncated":"Kalos Therapeutics \/ ValiRx"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Veltmeyer MD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"ValloVax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Veltmeyer MD","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Veltmeyer MD"},{"orgOrder":0,"company":"Varian Biopharmaceutical","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"VAR-101","moa":"PKC-iota","graph1":"Oncology","graph2":"Preclinical","graph3":"Varian Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Varian Biopharmaceutical \/ Windtree Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Varian Biopharmaceutical \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"KCNC1 Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Metrion Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metrion Biosciences \/ KCNC1 Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Metrion Biosciences \/ KCNC1 Foundation"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Vaxart","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"VXA-G1.1-NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Vaxart","sponsor":"hVIVO","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ hVIVO","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ hVIVO"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Vaxcyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sutro Biopharma \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ Vaxcyte"},{"orgOrder":0,"company":"USAMRIID","sponsor":"Vaxil Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CorVax","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"USAMRIID","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"USAMRIID \/ Vaxil Bio","highestDevelopmentStatusID":"4","companyTruncated":"USAMRIID \/ Vaxil Bio"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"Hepatitis B Vaccine","moa":"TLR9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"10","companyTruncated":"VBI Vaccines \/ Raymond James & Associates"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBI Vaccines \/ Government of Canada","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccines \/ Government of Canada"},{"orgOrder":0,"company":"Elanco","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Diclazuril","moa":"||Merozoite","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elanco","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elanco \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Elanco \/ Merck & Co"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Financing","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Octagon Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Vedere Bio \/ Octagon Capital","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio \/ Octagon Capital"},{"orgOrder":0,"company":"Ainos","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Lind Partners"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Gardp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Collaboration","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Gardp","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Gardp"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"MJFF","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"VENT-02","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventus Therapeutics \/ MJFF","highestDevelopmentStatusID":"7","companyTruncated":"Ventus Therapeutics \/ MJFF"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Redmile Group","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Redmile Group"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Amgen Inc"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ RBC Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ RBC Capital Markets"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Secura Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Secura Bio","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Secura Bio"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Secura Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Approved FDF","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Secura Bio","highestDevelopmentStatusID":"15","companyTruncated":"Verastem Oncology \/ Secura Bio"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"Versiti","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Phase III","graph3":"Versiti","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versiti \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Versiti \/ National Institutes of Health"},{"orgOrder":0,"company":"Mannkind","sponsor":"Vertice Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mannkind \/ Vertice Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Vertice Pharma"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Raymond James & Associates","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Raymond James & Associates","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Verve Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Vesigen Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vesigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vesigen Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Vesigen Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Vici Health Sciences","sponsor":"Psycheceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Vici Health Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vici Health Sciences \/ Psycheceutical","highestDevelopmentStatusID":"4","companyTruncated":"Vici Health Sciences \/ Psycheceutical"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Merger","leadProduct":"Oportuzumab Monatox","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Carisma Therapeutics \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Carisma Therapeutics \/ Sesen Bio"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Vigene Bioscience","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vigene Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigene Bioscience \/ ASC Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vigene Bioscience \/ ASC Therapeutics"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vigil Neuroscience \/ Atlas Venture","highestDevelopmentStatusID":"5","companyTruncated":"Vigil Neuroscience \/ Atlas Venture"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Vingroup","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Vingroup","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Vingroup"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Xencor","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Xencor \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Xencor \/ Vir Biotechnology"},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Vir Biotechnology"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Laidlaw & Company","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Laidlaw & Company"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Jefferies LLC"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Maxim Group","highestDevelopmentStatusID":"6","companyTruncated":"Virios Therapeutics \/ Maxim Group"},{"orgOrder":0,"company":"ViroVax","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Alhydroxiquim-II","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViroVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ViroVax \/ Bharat Biotech","highestDevelopmentStatusID":"8","companyTruncated":"ViroVax \/ Bharat Biotech"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Diclofenac","moa":"COX-1","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Maxim Group"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Maxim Group"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"BVF Partners L.P.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ BVF Partners L.P.","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ BVF Partners L.P."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Alessa Therapeutics","sponsor":"Celanese","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alessa Therapeutics \/ Celanese","highestDevelopmentStatusID":"1","companyTruncated":"Alessa Therapeutics \/ Celanese"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Vittoria Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Vittoria Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Vittoria Biotherapeutics"},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"YAP-TEAD transcription activity","graph1":"Oncology","graph2":"Preclinical","graph3":"Vivace Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vivace Therapeutics \/ Boxer Capital","highestDevelopmentStatusID":"4","companyTruncated":"Vivace Therapeutics \/ Boxer Capital"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivacelle Bio \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle Bio \/ US Navy"},{"orgOrder":0,"company":"Vivacitas Oncology","sponsor":"DSS Biomedical International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Silatecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Vivacitas Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vivacitas Oncology \/ DSS Biomedical International","highestDevelopmentStatusID":"8","companyTruncated":"Vivacitas Oncology \/ DSS Biomedical International"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Logos Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"KEAP1-Nrf2","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vividion Therapeutics \/ Logos Capital","highestDevelopmentStatusID":"4","companyTruncated":"Vividion Therapeutics \/ Logos Capital"},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vizient \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Vizient \/ Pfizer Inc"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Evercore Group L.L.C.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Evercore Group L.L.C.","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Evercore Group L.L.C."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Private Placement","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"VOR33","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Renaissance Capital"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Divestment","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Termination","leadProduct":"Undisclosed","moa":"MAPK tau protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Truist Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Truist Securities","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Truist Securities"},{"orgOrder":0,"company":"Lenire Biosciences","sponsor":"University College London","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"VSN16R","moa":"KCa channel","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lenire Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lenire Biosciences \/ University College London","highestDevelopmentStatusID":"4","companyTruncated":"Lenire Biosciences \/ University College London"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Viela Bio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Viela Bio","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Viela Bio"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Deutivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"WAL0921","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Walden Biosciences \/ University of Michigan","highestDevelopmentStatusID":"8","companyTruncated":"Walden Biosciences \/ University of Michigan"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"suPAR","graph1":"Nephrology","graph2":"Discovery","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walden Biosciences \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Walden Biosciences \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Walking Fish","sponsor":"Emerson Collective","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"WFT-1","moa":"Immunostimulant","graph1":"Oncology","graph2":"Preclinical","graph3":"Walking Fish","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walking Fish \/ Emerson Collective","highestDevelopmentStatusID":"4","companyTruncated":"Walking Fish \/ Emerson Collective"},{"orgOrder":0,"company":"Westport Bio","sponsor":"Greenwich LifeSciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GLSI-100","moa":"Granulocyte-macrophage","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Westport Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Westport Bio \/ Greenwich LifeSciences","highestDevelopmentStatusID":"4","companyTruncated":"Westport Bio \/ Greenwich LifeSciences"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"A*STAR","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Ring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Ring Therapeutics \/ A*STAR","highestDevelopmentStatusID":"2","companyTruncated":"Ring Therapeutics \/ A*STAR"},{"orgOrder":0,"company":"Windgap Medical","sponsor":"Taiwania Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Series B Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Windgap Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Windgap Medical \/ Taiwania Capital","highestDevelopmentStatusID":"1","companyTruncated":"Windgap Medical \/ Taiwania Capital"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Sinapultide","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"4","companyTruncated":"Windtree Therapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neogene \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Neogene \/ AstraZeneca"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adverum Biotechnologies \/ Lexeo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Adverum Biotechnologies \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Alprazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Engage Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Engage Therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PANTHERx Rare Pharmacy \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Blueprint Medicines"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affini-T Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ Vida Ventures"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Nebraska Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ University of Nebraska Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ University of Nebraska Medical Center"},{"orgOrder":0,"company":"Nevakar","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Gabapentin","moa":"||CaV channel","graph1":"Neurology","graph2":"Phase II","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nevakar \/ Endo International","highestDevelopmentStatusID":"8","companyTruncated":"Nevakar \/ Endo International"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Twist Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Twist Bioscience"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Acquisition","leadProduct":"Typhoid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emergent BioSolutions \/ Bavarian Nordic","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Bavarian Nordic"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Viatris"},{"orgOrder":0,"company":"Kineta","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"KCP506","moa":"nAchR","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Genentech"},{"orgOrder":0,"company":"Nanite","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nanite","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Nanite \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Nanite \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altesa Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Altesa Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"KVD001","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"KalVista Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"ecDNA","graph1":"Oncology","graph2":"Discovery","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Boundless Bio \/ Nextech Invest"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"IBSA Institut Biochimique","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Diclofenac Epolamine","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Pfizer Inc \/ IBSA Institut Biochimique","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ IBSA Institut Biochimique"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"SQZ Biotechnologies \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"SQZ Biotechnologies \/ National Institutes of Health"},{"orgOrder":0,"company":"LadRx","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Termination","leadProduct":"Aldoxorubicin HCl","moa":"Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase III","graph3":"LadRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LadRx \/ ImmunityBio","highestDevelopmentStatusID":"10","companyTruncated":"LadRx \/ ImmunityBio"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Pocono Coated Product","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Pocono Coated Product","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pocono Coated Product \/ Nutriband","highestDevelopmentStatusID":"1","companyTruncated":"Pocono Coated Product \/ Nutriband"},{"orgOrder":0,"company":"Fairhaven Pharmaceuticals","sponsor":"Liminal BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"OXE receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Fairhaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fairhaven Pharmaceuticals \/ Liminal BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Fairhaven Pharmaceuticals \/ Liminal BioSciences"},{"orgOrder":0,"company":"Hibiskus BioPharma","sponsor":"Lodo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"TIR-199","moa":"Syrbactin proteasome","graph1":"Oncology","graph2":"Preclinical","graph3":"Hibiskus BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hibiskus BioPharma \/ Lodo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hibiskus BioPharma \/ Lodo Therapeutics"},{"orgOrder":0,"company":"Promedior","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"PRM-151","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Promedior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promedior \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Promedior \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"TPH","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fate Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"SymBio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Eagle Pharmaceuticals \/ SymBio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ SymBio Pharmaceuticals"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Covis Pharma"},{"orgOrder":0,"company":"ARC Therapeutics","sponsor":"Eshelman Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"CDK2","graph1":"Oncology","graph2":"Preclinical","graph3":"ARC Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ARC Therapeutics \/ Eshelman Ventures","highestDevelopmentStatusID":"4","companyTruncated":"ARC Therapeutics \/ Eshelman Ventures"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Atlas Venture"},{"orgOrder":0,"company":"TumorGen","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TumorGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TumorGen \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"3","companyTruncated":"TumorGen \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"VLP Therapeutics","sponsor":"Nobelpharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series A Financing","leadProduct":"VLPM01","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"VLP Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"VLP Therapeutics \/ Nobelpharma","highestDevelopmentStatusID":"6","companyTruncated":"VLP Therapeutics \/ Nobelpharma"},{"orgOrder":0,"company":"Yale Cancer Center","sponsor":"Alliance for Cancer Gene Therapy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"MAEGI","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yale Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale Cancer Center \/ Alliance for Cancer Gene Therapy","highestDevelopmentStatusID":"1","companyTruncated":"Yale Cancer Center \/ Alliance for Cancer Gene Therapy"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"GTB-3550 TriKE","moa":"CD16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Roth Capital Partners"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"PF-05251749","moa":"CK1","graph1":"Neurology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Biogen"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"XBiotech","sponsor":"BioBridge Global","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"XBiotech \/ BioBridge Global","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ BioBridge Global"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ WPD Pharmaceuticals"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Wugen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MaxCyte \/ Wugen","highestDevelopmentStatusID":"7","companyTruncated":"MaxCyte \/ Wugen"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ New Enterprise Associates","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ New Enterprise Associates"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"X4 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PANTHERx Rare Pharmacy \/ X4 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ X4 Pharmaceuticals"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Piper Sandler"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Organon"},{"orgOrder":0,"company":"Xencor","sponsor":"MorphoSys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ MorphoSys","highestDevelopmentStatusID":"15","companyTruncated":"Xencor \/ MorphoSys"},{"orgOrder":0,"company":"Xencor","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Plamotamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ TTY BIOPHARM CO LTD","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ TTY BIOPHARM CO LTD"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Arctic Vision","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Arctic Vision"},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"XOMA","sponsor":"Viracta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"XOMA \/ Viracta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"XOMA \/ Viracta Therapeutics"},{"orgOrder":0,"company":"XOMA","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Cetrelimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ XOMA","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ XOMA"},{"orgOrder":0,"company":"XOMA","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Chiesi Group"},{"orgOrder":0,"company":"XOMA","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Mezagitamab","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Foundation Medicine \/ Karyopharm Therapeutics"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio \/ Department of Defense"},{"orgOrder":0,"company":"XtalPi","sponsor":"CK Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XtalPi \/ CK Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ CK Life Sciences"},{"orgOrder":0,"company":"XWPharma","sponsor":"Panacea Venture","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"XW10172","moa":"GABA-B receptor","graph1":"Sleep","graph2":"Phase I","graph3":"XWPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XWPharma \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"XWPharma \/ Panacea Venture"},{"orgOrder":0,"company":"Ordaos Bio","sponsor":"Yatiri Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ordaos Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ordaos Bio \/ Yatiri Bio","highestDevelopmentStatusID":"2","companyTruncated":"Ordaos Bio \/ Yatiri Bio"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Merck & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company"},{"orgOrder":0,"company":"Western New England University","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Zafirlukast","moa":"Thiol isomerase","graph1":"Hematology","graph2":"Phase II","graph3":"Western New England University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western New England University \/ Quercis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Western New England University \/ Quercis Pharma"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MacroGenics \/ Zai Lab","highestDevelopmentStatusID":"4","companyTruncated":"MacroGenics \/ Zai Lab"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Zai Lab"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"Obexelimab","moa":"CD19\/Fc\u03b3RIIb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Enavate Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Enavate Sciences"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Divestment","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AnaptysBio \/ DRI Healthcare Trust","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Parkinson\u2019s Foundation","sponsor":"Zelira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CB receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Parkinson\u2019s Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Parkinson\u2019s Foundation \/ Zelira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Parkinson\u2019s Foundation \/ Zelira Therapeutics"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Alvogen","sponsor":"AZTIQ PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Lisinopril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alvogen \/ AZTIQ PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"Alvogen \/ AZTIQ PHARMA"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"ZMI Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"DMK Pharmaceuticals \/ ZMI Pharma","highestDevelopmentStatusID":"15","companyTruncated":"DMK Pharmaceuticals \/ ZMI Pharma"},{"orgOrder":0,"company":"Aldevron","sponsor":"Alaunos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aldevron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldevron \/ Alaunos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Aldevron \/ Alaunos Therapeutics"},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"ZM008","moa":"LLT1 antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zumutor Biologics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Biologics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Eversana","sponsor":"Zosano Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Eversana \/ Zosano Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/ Zosano Pharma"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"CH Trading Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ CH Trading Group","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ CH Trading Group"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Zuellig Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Zuellig Pharma"},{"orgOrder":0,"company":"XOMA","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"XOMA \/ Zydus Lifesciences","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Zydus Lifesciences"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Mannkind","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mannkind \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Lincoln Park Capital","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Undisclosed"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"ANX009","moa":"C1q","graph1":"Nephrology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EVM16","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"||PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PL Developments","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Omeprazole","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PL Developments","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PL Developments \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PL Developments \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"TYK2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priovant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Priovant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accord BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ AstraZeneca"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Burke Neurological Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Burke Neurological Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burke Neurological Institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Burke Neurological Institute \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"||HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ainos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Favezelimab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"||PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR Alpha 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tafamidis Meglumine","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Colestipol","moa":"Bile acid reabsorption","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BXT-25","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"HGF-1","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"HGF-1","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Hutrukin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Hutrukin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"HGF-1","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"EnPlusOne Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"EnPlusOne Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EnPlusOne Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"MK-0616","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"MK-0616","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tafamidis","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"NeuroTrauma Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NTS-105 Prodrug","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"NeuroTrauma Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeuroTrauma Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTrauma Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"||Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aisa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"Medera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Medera \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Medera \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP135G","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"HGF-1","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indication BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"||HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Indication BioScience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indication BioScience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Indication BioScience \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXX-401","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tafamidis Meglumine","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CAR90972","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TNF-alpha","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AFYX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AFYX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Enzyme Replacement","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"University of Tennessee Graduate School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-peptide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ University of Tennessee Graduate School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/ University of Tennessee Graduate School of Medicine"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BEAM-101","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BEAM-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BEAM-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olinciguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Bluebird Bio","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Bluebird Bio"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTQ923","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"E-selectin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"KRRO-110","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lipid Nanoparticles","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Bluebird Bio"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NTLA-3001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-3001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VX-814","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DCR-A1AT","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ GSK"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theris Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Theris Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Patch","sponsorNew":"Theris Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theris Medical \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTQ923","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+ gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VX-634","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Hematology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Hematology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cadrenal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Hematology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ National Institute of General Medical Sciences"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pennsylvania University","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Pennsylvania University","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Pennsylvania University"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Morning side VENTURE","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ADS024","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Morning side VENTURE","highestDevelopmentStatusID":"8","companyTruncated":"Adiso Therapeutics \/ Morning side VENTURE"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leiolizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Everest Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"APPL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"ABI-M201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH-063","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Immunology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"BITT","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BITT-CD4D11","moa":"CD40","graph1":"Immunology","graph2":"Preclinical","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"NImmune Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NImmune Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NImmune Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"NImmune Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ NImmune Biopharma"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CEL383","moa":"TREM-1","graph1":"Immunology","graph2":"Preclinical","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celsius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Celsius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CERC-002","moa":"LIGHT","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Arena Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Everest Medicines"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"Wnt signaling","graph1":"Immunology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Immunology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Eisai"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Immunology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB295","moa":"Microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PNV-6005","moa":"ADORA2A","graph1":"Immunology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KB295","moa":"Microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KB295","moa":"Microbiome","graph1":"Immunology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MH002","moa":"Microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Inapplicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MH002","moa":"Microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Enterprises \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ludwig Enterprises \/ Inapplicable"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AstraGin","moa":"Bacterial gut","graph1":"Immunology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NuLiv Science \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Science \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-13","moa":"NLRX1","graph1":"Immunology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Thetis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TP-317","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Thetis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thetis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Thetis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ AbbVie Inc"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Vitamin D","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"BioAdaptives","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAdaptives \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioAdaptives \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PN-943","moa":"Alpha 4-beta 7 integrin","graph1":"Immunology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Celerion"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA052","moa":"CD30","graph1":"Immunology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RVT-3101","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"SER-301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"STAT-201","moa":"Opioid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Statera Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Statera Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Suono Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SUO-2002","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Suono Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Suono Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Suono Bio \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methimazole","moa":"Thyroid peroxidase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Immunology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CLS-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comera Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"||IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"PDE4","graph1":"Immunology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AEVI-002","moa":"LIGHT","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Immunology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"||IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PT101","moa":"CD25","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"VE202","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Vedanta Biosciences"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VTX002","moa":"S1P1R","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ PPD"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Syneos Health"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Syneos Health"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Oxybate","moa":"GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase I","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Calcium Gluconate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Potassium Phosphate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Potassium Phosphate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"REVTx-300","moa":"TLR4","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RVL-HV02","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Disodium Hydrogen Phosphate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Talphera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2-viral spike protein","graph1":"Nephrology","graph2":"Phase III","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talphera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talphera \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"c-Met receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"c-Met receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"c-Met receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Stannic Protoporfin","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kantum Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB-1801","moa":"P2Y14 receptor","graph1":"Nephrology","graph2":"Preclinical","graph3":"Kantum Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kantum Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kantum Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dana-Farber Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"VelosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zilovertamab","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Karolinska Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Karolinska Institute","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Karolinska Institute"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TG-1701","moa":"||BTK","graph1":"Oncology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Loxo-305","moa":"||BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptive Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fox Chase Cancer Center \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Fox Chase Cancer Center \/ Gilead Sciences"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KTE-X19","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cirmtuzumab","moa":"||ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 004","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Namilumab","moa":"GCSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kinevant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Kinevant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Namilumab","moa":"GCSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Kinevant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Kinevant Sciences"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xentria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xentria \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegtarviliase","moa":"Homocysteine","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegtarviliase","moa":"Homocysteine","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegtarviliase","moa":"Homocysteine","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aegle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AGLE-102","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Aegle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aegle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aegle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Azitra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"ATR-12","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Azitra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ Inapplicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"ATR-12","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Azitra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PTR-01","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ORF-229","moa":"GO","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BBP-812","moa":"ASPA gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BCX17725","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betaine","moa":"Methylation","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BPGbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Benzoquinone Ubidecarenone","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BPGbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Codexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"CDX-6512","moa":"Enzyme Replacement","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Codexis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Codexis \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CHK-336","moa":"LDH-A","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CHK-336","moa":"LDH-A","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegtarviliase","moa":"Homocysteine","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Therapeutics \/ Fortress Biotech"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Betaine","moa":"Methylation","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DPM-1003","moa":"PTP1B","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"},{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPM-1003","moa":"PTP1B","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Escape Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ESB1609","moa":"S1P5R","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Escape Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escape Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escape Bio \/ Inapplicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EXG-34217","moa":"ZSCAN4 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elixirgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EXG-001","moa":"||ZSCAN4 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elixirgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Dydo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Dydo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Dydo Pharma"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Dydo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Dydo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Dydo Pharma"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Castle Creek Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BBP-812","moa":"ASPA gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"GeneTx Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ GeneTx Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ GeneTx Biotherapeutics"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vyant Bio","sponsor":"The Loulou Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Vyant Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vyant Bio \/ The Loulou Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Vyant Bio \/ The Loulou Foundation"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HST5040","moa":"CoA","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"HemoShear Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"ATR-12","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Azitra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ Inapplicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegtibatinase","moa":"CBS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ImmTOR","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biom Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BIO017","moa":"TRPV1","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Biom Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biom Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biom Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Cyprium Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Cyprium Therapeutics"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION582","moa":"UB3EA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ION582","moa":"UB3EA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ION582","moa":"UB3EA","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LifeMax Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LM-030","moa":"KLK7\/ELA2","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"LifeMax Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"LifeMax Laboratories \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"LifeMax Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ImmTOR","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AskBio \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AskBio \/ Selecta Biosciences"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-3704","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"mRNA-3705","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"mRNA-3705","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MYR-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MYR-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGENE-PH1","moa":"HO-1","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NGN-401","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Arctic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Arctic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Nacuity Pharmaceuticals \/ Arctic Therapeutics"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Cyprium Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Cyprium Therapeutics"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGENE-PH1","moa":"HO-1","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"PellePharm","sponsor":"Phyton Biotech LLC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"PellePharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PellePharm \/ Phyton Biotech LLC","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm \/ Phyton Biotech LLC"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PLX-300","moa":"PPA receptor-alpha","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PellePharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"PellePharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PellePharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBKR03","moa":"Galactosylceramidase","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CHK-336","moa":"LDH-A","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"15-LOX","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"PTR-01","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SKINVISIBLE PHARMACEUTICALS INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"SKINVISIBLE PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"SKINVISIBLE PHARMACEUTICALS INC \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"SKINVISIBLE PHARMACEUTICALS INC \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Myrtelle \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Inapplicable"},{"orgOrder":0,"company":"Seaver Autism Center for Research and Treatment","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Seaver Autism Center for Research and Treatment","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seaver Autism Center for Research and Treatment \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaver Autism Center for Research and Treatment \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sarizotan","moa":"5-HT1A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vyant Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Vyant Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vyant Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vyant Bio \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rescindo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RSC-57","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Rescindo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rescindo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rescindo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ResVita Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"RVB-001","moa":"Proteolysis","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"ResVita Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"ResVita Bio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ResVita Bio \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SEL-302","moa":"AAV gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Selecta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SEL-302","moa":"AAV gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Selecta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sarizotan","moa":"5-HT1A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"SYNB1353","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Replay Bio \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Phoenix Tissue Repair","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"PTR-01","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Phoenix Tissue Repair","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Phoenix Tissue Repair"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Asklepios BioPharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SEL-399","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Asklepios BioPharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Selecta Biosciences \/ Asklepios BioPharmaceutical"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLN7 gene","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Prademagene Zamikeracel","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegtibatinase","moa":"CBS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegtibatinase","moa":"CBS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegtibatinase","moa":"CBS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pegtibatinase","moa":"CBS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegtibatinase","moa":"CBS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DPM-1003","moa":"PTP1B","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Asklepios BioPharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ImmTOR","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Asklepios BioPharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Biosciences \/ Asklepios BioPharmaceutical"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TSHA-102","moa":"MECP2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Unravel Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RVL001","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Unravel Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unravel Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Unravel Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ZKN-013","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ZKN-013","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cultured Epidermal Autograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avita Medical \/ Inapplicable"},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cerium Oxide","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioCurity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"RenovaCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tissue-Specific Pluripotent Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RenovaCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"RenovaCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RenovaCare \/ Inapplicable"},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"NMT-cP12","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NeoMatrix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeoMatrix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoMatrix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Xeno-Skin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"XenoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XenoTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"XenoTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Sofie Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"68-Ga FAPI-46","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sofie Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofie Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sofie Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"10xbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polidocanol","moa":"Endothelial cell","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"10xbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Lyophilized Powder for Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Lyophilized Powder for Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ontorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Omburtamab-DTPA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PF-06482077","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Oranomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"212-Pb DOTAM-GRPR1","moa":"GRPr","graph1":"Oncology","graph2":"Phase I","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oranomed \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GLS-5300","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Constellation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Constellation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ACTG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"10-1074-LS-J","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ACTG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ACTG \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ACTG \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"OTO-413","moa":"BDNF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Uzatresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-125","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"4D-310","moa":"GLA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"4D-310","moa":"GLA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4M Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"4MT2001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4M Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"4M Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"Mucin 16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"University of Kentucky","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta plaque","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Kentucky","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Kentucky \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Kentucky \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"68-Ga EVG321","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evergreen Theragnostics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha 4\/beta 1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha 4\/beta 1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alintegimod","moa":"||Integrin alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Texas Heart Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ Texas Heart Institute","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Texas Heart Institute"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"||Integrin alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Merck & Co"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elraglusib","moa":"GSK-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Developmental Therapeutics Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Developmental Therapeutics Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Developmental Therapeutics Consortium"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"scAAV2-P1ND4v2","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imago BioSciences \/ Washington University School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Imago BioSciences \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Everest Medicines \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Merck & Co"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COH04S1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GeoVax Labs \/ City of Hope","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ City of Hope"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"KCP506","moa":"nAchR","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atropine","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Innovation1 Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin Prodrug","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Innovation1 Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovation1 Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation1 Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VRDN-002","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta plaque","graph1":"Neurology","graph2":"IND Enabling","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BIOQUAL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BIOQUAL \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BIOQUAL \/ Inapplicable"},{"orgOrder":0,"company":"DemeRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibogaine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"DemeRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DemeRx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"DemeRx \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-3139","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Mannkind","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Mannkind","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Mannkind"},{"orgOrder":0,"company":"CancerVAX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CancerVAX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CancerVAX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CancerVAX \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"ACTG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ChAdOx1.HIVconsv62","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ACTG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ACTG \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ACTG \/ Inapplicable"},{"orgOrder":0,"company":"GeneCentric Therapeutics","sponsor":"Atrium Health Levine Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"GeneCentric Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"GeneCentric Therapeutics \/ Atrium Health Levine Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"GeneCentric Therapeutics \/ Atrium Health Levine Cancer Institute"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAVI","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1644","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM707","moa":"||ILT2\/4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pulmotect","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Oligodeoxynucleotide","moa":"||TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Pulmotect \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect \/ Inapplicable"},{"orgOrder":0,"company":"Nucleai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Naratuximab Emtansine","moa":"||CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nucleai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nucleai \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nucleai \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Eli Lilly"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"14-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AMB-05X","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"AmMax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio \/ Inapplicable"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AMB-05X","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"AmMax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio \/ Inapplicable"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AMB-05X","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"AmMax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bexson Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alliancerx Walgreens Prime","sponsor":"Duquesne University School of Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Alliancerx Walgreens Prime","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alliancerx Walgreens Prime \/ Duquesne University School of Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"Alliancerx Walgreens Prime \/ Duquesne University School of Pharmacy"},{"orgOrder":0,"company":"Oligon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Oligon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligon \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Oligon \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"STI-2099","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kimera Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Kimera Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kimera Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kimera Labs \/ Inapplicable"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NT-0231.F","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OP-101","moa":"Glutathione synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib Analog","moa":"VEGF","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"University of Colorado Denver","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alteplase","moa":"Plasminogen","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Colorado Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Colorado Denver \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado Denver \/ Inapplicable"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belnacasan","moa":"Caspase-1","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Alberta \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Florida","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Florida \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Florida \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ERBB 2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"A07D","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"A197","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aramis Biosciences \/ Dompe Farmaceutici","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A2 Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A2 Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"A2B530","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"A2 Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"A2B694","moa":"MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A2 Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAV-GAD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MeiraGTx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAVHSC16","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"AKSO Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"AKSO Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AKSO Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AKSO Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aronora","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Xisomab 3G3","moa":"Coagulation factor XI reciprocal","graph1":"Nephrology","graph2":"Phase II","graph3":"Aronora","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aronora \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aronora \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1003","moa":"FKRP gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1003","moa":"FKRP gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"ADCC","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"ADCC","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AB-101","moa":"PD-L1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AB-101","moa":"||ADCC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1015","moa":"CTLA-4x\/OX40","graph1":"Oncology","graph2":"Phase I","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ArsenalBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ArsenalBio \/ Inapplicable"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Bacterial DNA\/Bacterial cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Alphyn Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Bacterial DNA\/Bacterial cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Alphyn Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"University of Georgia Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ University of Georgia Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ University of Georgia Research Foundation"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aruna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aruna Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-161","moa":"PAPD5\/7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-2004","moa":"Microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-2004","moa":"Microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-2004","moa":"Microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AB-2004","moa":"Microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB-201","moa":"CD16","graph1":"Oncology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Artiva Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Angiocrine Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-205","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Angiocrine Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Angiocrine Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Angiocrine Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Angiocrine Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AB-205","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Angiocrine Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Angiocrine Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Angiocrine Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-2100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ArsenalBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-343","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB359","moa":"IL-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imdusiran","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Assembly Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Entecavir","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Assembly Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Assembly Biosciences"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Assembly Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Entecavir","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Assembly Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Assembly Biosciences"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB821","moa":"IL-21","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ABA-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"AChE","graph1":"Immunology","graph2":"Approved FDF","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Milla Pharmaceuticals \/ Alter Pharma group","highestDevelopmentStatusID":"15","companyTruncated":"Milla Pharmaceuticals \/ Alter Pharma group"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABBV-383","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elsubrutinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABBV-CLS-484","moa":"||PTPN2\/N1","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"eIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calico Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calico Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"eIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calico Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calico Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"eIF2B","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Regenxbio \/ AbbVie Inc"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Abcore","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Abcore \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Abcore \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"ABD-147","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abdera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ 2Seventy Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ 2Seventy Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ 2Seventy Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ 2Seventy Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"2Seventy Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ 2Seventy Bio"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"2Seventy Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"2Seventy Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Hematology","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX111","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"AmideBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-G023","moa":"GCGR","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AmideBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"||mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ABI-4334","moa":"cccDNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABI-4334","moa":"cccDNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABI-4334","moa":"cccDNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABI-4334","moa":"cccDNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABI-4334","moa":"cccDNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABI-5366","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABI-5366","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABI-5366","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABI-6250","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABI-H3733","moa":"HBV core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Civica Rx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"||CYP17A1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Civica Rx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Civica Rx \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abivertinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ABO-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABO-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbor Biotechnologies, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ABO-504","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interferon Alpha-2B","moa":"INF-alpha receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zydus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Abpro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Inapplicable"},{"orgOrder":0,"company":"Abpro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Docosanol","moa":"Viral fusion","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosette Pharma \/ Alembic Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Alembic Pharmaceuticals Limited"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KT-413","moa":"IRAKIMiD","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-501","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||JAK2\/FLT3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNS-510","moa":"PDK-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunesis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agendia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Agendia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Agendia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agendia \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"3-Antigen HBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Neurology","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lutikizumab","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"AC0676","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"AC0676","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"AC0682","moa":"Estrogen-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AC699","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Smallpox and Mpox Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACCG-2671","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Merck & Co"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Cytel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fluvoxamine","moa":"Sigma-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cytel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytel \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytel \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oregon State University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oregon State University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oregon State University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oregon State University \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACDN-01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ascidian Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ascidian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascidian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-083","moa":"GDF8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-1334","moa":"TGF-beta-2","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acebutolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osanetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osanetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osanetant","moa":"NK-3R","graph1":"Oncology","graph2":"Phase I","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elite Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elite Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genexa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genexa","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genexa \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genexa \/ Inapplicable"},{"orgOrder":0,"company":"Aceragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"||Bacterial protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aceragen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aceragen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Avirmax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Avirmax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Avirmax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avirmax \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcellx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ACLX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcellx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcellx \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACP-204","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acrivon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Prexasertib","moa":"||CHK1","graph1":"Oncology","graph2":"Phase II","graph3":"Acrivon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acrivon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acrivon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ACTUS-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"AIDS Clinical Trials Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIDS Clinical Trials Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AIDS Clinical Trials Group \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||HER2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"||Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Focal Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focal Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Focal Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Focal Medical \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Humanigen"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SEMA4D","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACTM-838","moa":"IL-15plex\/eSTING","graph1":"Oncology","graph2":"Phase I","graph3":"Actym Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actym Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Actym Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"||Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elraglusib","moa":"GSK-3 beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elraglusib","moa":"GSK-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alzheimer's Memory Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alzheimer\\'s Memory Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzheimer\\'s Memory Center \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzheimer\\'s Memory Center \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Hoag","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Hoag","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Hoag"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"SeegPharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Cosette Pharma \/ SeegPharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ SeegPharm"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AmyriAD","sponsor":"Societal CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"AmyriAD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AmyriAD \/ Societal CDMO","highestDevelopmentStatusID":"8","companyTruncated":"AmyriAD \/ Societal CDMO"},{"orgOrder":0,"company":"AmyriAD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"AmyriAD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AmyriAD \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmyriAD \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"AdAPT-001","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADP-TILIL7","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Uzatresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adastra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zotiraciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adastra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adastra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adastra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Altimmune","sponsor":"University Of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ University Of Alabama","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ University Of Alabama"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Saint Louis University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Saint Louis University","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Saint Louis University"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-456","moa":"CXCR2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"TPH","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AVB-500","moa":"||AXL\/GAS6 pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"4D-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecular Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IGM-6268","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Capsida","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Capsida \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Capsida \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Nephrology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Nephrology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Nephrology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aditxt","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-100","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-270","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-925","moa":"Tumor stress ligand","graph1":"Oncology","graph2":"Preclinical","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Polaris Group \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Polaris Group \/ Inapplicable"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Arginine","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Polaris Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Group \/ Inapplicable"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Polaris Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Global Coalition for Adaptive Research \/ Polaris Group","highestDevelopmentStatusID":"9","companyTruncated":"Global Coalition for Adaptive Research \/ Polaris Group"},{"orgOrder":0,"company":"Polaris Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"Arginine","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Polaris Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Group \/ Inapplicable"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HB-adMSCs","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aditxt","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vascular BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vascular BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vascular BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vascular BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Neurology","graph2":"Preclinical","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AGTC-501","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PneumoBlast","moa":"Tissue Factor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGenesis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ADP101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ADP101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ADP101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Pace Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Pace Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Pace Life Sciences"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ADRX-0405","moa":"IgG1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcentrx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adcentrx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADRX-0706","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcentrx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcentrx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ADS024","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"American Heart Association","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"American Heart Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"American Heart Association \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"American Heart Association \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX-246","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Nephrology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Immunology","graph2":"Phase I","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Addex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX71149","moa":"||mGluR2","graph1":"Neurology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Addex Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Addex Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Pharma Plc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bempikibart","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Horizon Pharma Plc","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Horizon Pharma Plc"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-PSA","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"VE-PTP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"University of Sheffield","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Delayed Clearance Parathyroid Hormone","moa":"PTH","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aeterna Zentaris \/ University of Sheffield","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Zentaris \/ University of Sheffield"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Uzatresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Affinivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AFX3772","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AFNT-111","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affini-T Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Basal Insulin","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VBI-2901","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VRDN-002","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALS001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Vaccine","moa":"B-cell antibody","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Affinivax \/ CEPI"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Allgenesis Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffaMed Therapeutics \/ Allgenesis Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AffaMed Therapeutics \/ Allgenesis Biotherapeutics"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tebapivat","moa":"PK","graph1":"Oncology","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tebapivat","moa":"PK","graph1":"Oncology","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebapivat","moa":"PK","graph1":"Hematology","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agastiya Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Agastiya Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agastiya Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Agastiya Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Botensilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AGN1181","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Botensilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AGEN1571","moa":"ILT2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Boston Scientific \/ Inapplicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AgenT-797","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AgenT-797","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TrenibotulinumtoxinE","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AGT103-T","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Gene Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"American Gene Technologies \/ Inapplicable"},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AGT103-T","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Gene Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"American Gene Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"RPGR gene modification","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"rAAV2tYF-PR1.7-hCNGB3","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Angiex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"AGX101","moa":"TM4SF1","graph1":"Oncology","graph2":"Phase I","graph3":"Angiex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angiex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Angiex \/ Inapplicable"},{"orgOrder":0,"company":"Angiex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AGX101","moa":"TM4SF1","graph1":"Oncology","graph2":"Phase I","graph3":"Angiex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angiex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Angiex \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eirion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eirion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eirion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eirion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffyImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"AQP4","graph1":"Neurology","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Aeterna Zentaris \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Zentaris \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Erenumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"Surfactant protein-D","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"Calcium channel","graph1":"Immunology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aisa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"IL-12 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OrphAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OrphAI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphAI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"IL-12 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Periocular Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenvatinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AV-GBM-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AJ1-11095","moa":"JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ajax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ajax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AJ1-11095","moa":"JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ajax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ajax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"AnnJi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ AnnJi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ AnnJi Pharmaceutical"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AJ201","moa":"Nrf1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DeFloria","sponsor":"AJNA BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"AJA001","moa":"CB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DeFloria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DeFloria \/ AJNA BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"DeFloria \/ AJNA BioSciences"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AJ1-10502","moa":"JAK2","graph1":"Oncology","graph2":"Preclinical","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ajax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Mast cell","graph1":"Dermatology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Mast cell","graph1":"Immunology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Preclinical","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK007","moa":"Siglec-10","graph1":"Oncology","graph2":"Preclinical","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"APOC-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"APOC-III","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Akelos","sponsor":"Weill Cornell Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AKE-1018","moa":"HCN1 channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Akelos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akelos \/ Weill Cornell Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Akelos \/ Weill Cornell Medicine"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Core One Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Core One Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Core One Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Core One Labs \/ Inapplicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAVAnc80-antiVEGF Vector","moa":"VEGF","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Akouos \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Akouos \/ Inapplicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Akouos \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Inapplicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Akouos \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Inapplicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Akouos \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Inapplicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Akouos \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Endocrinology","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"University Medical Centre Groningen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ University Medical Centre Groningen","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ University Medical Centre Groningen"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"University Medical Center Groningen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ University Medical Center Groningen","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ University Medical Center Groningen"},{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AKV9","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AKAVA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta plaque","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta plaque","graph1":"Neurology","graph2":"IND Enabling","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta plaque","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ AbbVie Inc"},{"orgOrder":0,"company":"Alector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta plaque","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL00804","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL1211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ADX-1612","moa":"HSP90","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"Reactive aldehyde species","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytRx Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Cancer Research UK\u2019s Centre for Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aleta Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aleta Biotherapeutics \/ Cancer Research UK\u2019s Centre for Drug Development","highestDevelopmentStatusID":"7","companyTruncated":"Aleta Biotherapeutics \/ Cancer Research UK\u2019s Centre for Drug Development"},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aleta Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aleta Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aleta Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Alligator Bioscience"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALG-000184","moa":"||Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALG-010133","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALG-020572","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALG-125755","moa":"siRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALG-125755","moa":"siRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alisertib","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||FGFR2B","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"OTC mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM831","moa":"||ILT3","graph1":"Oncology","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Reloxaliase","moa":"Oxalate","graph1":"Nephrology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Abbvie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Abbvie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Abbvie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abicipar Pegol","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"IgGenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ Inapplicable"},{"orgOrder":0,"company":"Allermi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Ach receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Inapplicable"},{"orgOrder":0,"company":"AllerPops","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AllerPops","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"AllerPops","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Lollipop","sponsorNew":"AllerPops \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AllerPops \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cemacabtagene Ansegedleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-605","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-605","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-819","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allomek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CIP-137401","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allomek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ Inapplicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"||ADCC","graph1":"Immunology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AB-101","moa":"||ADCC","graph1":"Nephrology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Artiva Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Atomwise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atomwise \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Korean Intellectual Property Office","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Korean Intellectual Property Office","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Korean Intellectual Property Office"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allysta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alume Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alume Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alume Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alume Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALN-HSD","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALN-HSD","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-KHK","moa":"Ketohexokinase","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nucresiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alpha CD27 mab","moa":"Anti-CD27","graph1":"Oncology","graph2":"Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mullerian hormone receptor II","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"212-Pb Dotamtate","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Bacterial DNA\/Bacterial cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Alphyn Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Davoceticept","moa":"CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Povetacicept","moa":"B cell cytokine","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Povetacicept","moa":"B cell cytokine","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Nephrology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Povetacicept","moa":"BAFF\/APRIL","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALS001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTA2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"VERO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"VERO Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VERO Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VERO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cotoretigene Toliparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DPPC","moa":"||Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTO-101","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTO-203","moa":"H3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALVR109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGluR5","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGluR5","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Yale University","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Yale University"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGluR5","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGluR5","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Merck & Co"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Eli Lilly"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Sanofi"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"ALY688","moa":"Adiponectin receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allysta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ALZN002","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"BitNile Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZN002","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzamend Neuro \/ BitNile Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ BitNile Holdings"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AMB-05X","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"AmMax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio \/ Inapplicable"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AMB-05X","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"AmMax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio \/ Inapplicable"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AMB-05X","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"AmMax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ambulero","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AMB-301","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ambulero","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ambulero \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ambulero \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Zolpidem Tartrate","moa":"GABA-A receptor-alpha1\/beta1\/gamma2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide-antibody Conjugate","year":"2022","type":"Inapplicable","leadProduct":"AMG 133","moa":"GIPR \/GLP-1","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Kyowa Kirin"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sovilnesib","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Volastra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Volastra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"||PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Global Coalition for Adaptive Research \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AMG 634","moa":"PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambys Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMI-918","moa":"Hepatocyte Cell","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ambys Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ambys Medicines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ambys Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Norelgestromin","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai Inc"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amplifica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMP-303","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Amplifica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amplifica \/ Inapplicable"},{"orgOrder":0,"company":"Amplifica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AMP-303","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Amplifica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amplifica \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ AstraZeneca"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ AstraZeneca"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine reuptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine reuptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Applied Molecular Transport \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"AMTX-100","moa":"Nf-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"AMTX-100","moa":"Nf-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AMV564","moa":"||T-cell mediated killing of myeloid derived suppressor cell","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AMV564","moa":"T-cell mediated killing of myeloid derived suppressor cell","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AMV564","moa":"T-cell mediated killing of myeloid derived suppressor cell","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Apoptosis","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"AMTX-100","moa":"Nf-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amytrx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menlo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IVX-411","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GOVX-B11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Labs \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||ICOS","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Casimersen","moa":"Exon 45","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Heme polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Washington University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Hydrolytic enzyme","graph1":"Neurology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"ClostraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Butyrate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ClostraBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ClostraBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ClostraBio \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1503","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AN2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ANA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AnaBios","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORM-11372","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AnaBios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaBios \/ Orion Corporation","highestDevelopmentStatusID":"4","companyTruncated":"AnaBios \/ Orion Corporation"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Vesicular Stomatitis Virus Delta G","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"University of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ University of Alabama","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ University of Alabama"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"SPR206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Inapplicable"},{"orgOrder":0,"company":"Guardant Health","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Guardant Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Guardant Health \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Guardant Health \/ Blueprint Medicines"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ANG-3070","moa":"RTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Angion Biomedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ANG-3070","moa":"RTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Angion Biomedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"HGF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Angion Biomedica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bivalirudin","moa":"Thrombin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fludrocortisone Acetate","moa":"Mineralocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levocarnitine","moa":"Carnitine acetyl","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Neurokinin 1 Receptor Positive Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PDS Biotechnology \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ National Institutes of Health"},{"orgOrder":0,"company":"Anivive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GC376","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anivive","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anivive \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anivive \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pradigastat","moa":"DGAT1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Calmette Guerin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"AdHER2DC","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Calmette Guerin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cytokine Induced Memory-Like Natural Killer Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunityBio \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ WPD Pharmaceuticals"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ANPD001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Aspen Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aspen Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aspen Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Belrestotug","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Auristatin","moa":"||Fibronectin EDB","graph1":"Oncology","graph2":"Phase I","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"AntiCancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Methioninase","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer \/ Inapplicable"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunitas Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Anti-Chitinase 1","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloy Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunai","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immunai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunai \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Immunai \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Aquaporin-4 protein","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeterna Zentaris \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Zentaris \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"OncoSec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ANX005","moa":"C1q","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ANX1502","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AO-176","moa":"CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AO-176","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Arch Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Braxlosiran","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Delpacibart Braxlosiran","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Delpacibart Braxlosiran","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"TfR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"TfR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"TfR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"TfR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"TfR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AOC 1086","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Appello Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AP-472","moa":"mGluR4","graph1":"Neurology","graph2":"Phase I","graph3":"Appello Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appello Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Appello Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APD418","moa":"ADRB3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Elevar Therapeutics \/ Tanner Pharma"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APL-9","moa":"C3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"APG808","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"APG990","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apogee Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aphios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APH-0812","moa":"||PKC","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphios \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aphios \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APL-102","moa":"VEGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"APN-346958","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Xencor","highestDevelopmentStatusID":"4","companyTruncated":"Atreca \/ Xencor"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"APN-850271","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"||Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"||GEF-H1","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Golimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ligand Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Crizotinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"HCN4","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Sentien Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sentien Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sentien Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sentien Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"NIHR","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"180 Life Sciences \/ NIHR","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ NIHR"},{"orgOrder":0,"company":"Apros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APR003","moa":"TLR7","graph1":"Oncology","graph2":"Phase I","graph3":"Apros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Karolinska Development AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APR-548","moa":"p53","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Karolinska Development AB","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Karolinska Development AB"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprocitentan","moa":"Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"AP-SA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"AP-SA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"AP-SA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Adaptin Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"APTN-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptin Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptin Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adaptin Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase III","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pyxis Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic receptor-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic receptor-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic receptor-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic receptor-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqualung Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqualung Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AQV-1122","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aquavit Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquavit Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dipivefrin","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enzastaurin","moa":"PKC-beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AR-12","moa":"PDK-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Virginia Commonwealth University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virginia Commonwealth University \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AVX012","moa":"TRPM8","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AVX012","moa":"TRPM8","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AR-711","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AR-711","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazarotene","moa":"RAR-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Allos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Allos Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allos Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ab-452","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"CSL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ CSL"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"CSL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ CSL"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ARCT-2304","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-810","moa":"OTC mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"OTC mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"iECURE","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ iECURE","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ iECURE"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ University of California"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorinab","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Subgingival Dry Powder","sponsorNew":"ORAPHARMA \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Bausch Health"},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dental and Oral Health","graph2":"Approved FDF","graph3":"ORAPHARMA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Subgingival Dry Powder","sponsorNew":"ORAPHARMA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ORAPHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Calyptus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calyptus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Amikacin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Mucous clearance","graph1":"Immunology","graph2":"Phase I","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Mucous clearance","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"ReGenTree \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Inapplicable"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"ReGenTree \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"CXCR2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ARM210","moa":"RYR2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ARMGO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"AP\u2010PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-C3","moa":"C3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ARO-CFB","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ARO-CFB","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-DM1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-DM1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-DUX4","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-ENaC","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ARO-ENaC","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-MMP7","moa":"MMP7","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-MMP7","moa":"MMP7","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-MMP7","moa":"MMP7","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-MUC5AC","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-PNPLA3","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"RAGE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"RAGE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-RAGE","moa":"RAGE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ARO-SOD1","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arpraziquantel","moa":"CYP11B1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrevus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Bacterial protein synthesis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrevus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-ENaC","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-HIF2","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-ENaC","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-C3","moa":"C3","graph1":"Nephrology","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"IND Enabling","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Oncology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ART5803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arialys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arialys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calroy Health Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rhamnan Sulfate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Calroy Health Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calroy Health Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calroy Health Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Amivas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Artesunate","moa":"Malaria protein EXP-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amivas \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amivas \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bioved Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ashwagandha Root Extract","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bioved Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bioved Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioved Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ARV-102","moa":"LRRK2","graph1":"Neurology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"Arrevus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Bacterial protein synthesis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrevus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2020","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Luxdegalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARX517","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARX788","moa":"||HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ARX788","moa":"||HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Inapplicable"},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ARZC-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Artizan Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artizan Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artizan Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"MGA012","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Seribantumab","moa":"ErbB3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Retinamide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SAGE-319","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Neurology","graph2":"Preclinical","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pinteon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HC-5404","moa":"Endoplasmic reticulum stress","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"M041","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M6P Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Ascletis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denifanstat","moa":"||Fatty acid synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Sagimet Biosciences \/ Ascletis Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Ascletis Pharma"},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASC41","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gannex Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gannex Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gannex Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC42","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gannex Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASC41","moa":"||THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gannex Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ASC618","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ASC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ASC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ASC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ASC618","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ASC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ASC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ASC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"AcuteBio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ascendia Pharmaceuticals \/ AcuteBio","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia Pharmaceuticals \/ AcuteBio"},{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASHA-624","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Asha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"VEGFR\/PDGFR tyrosine kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zofin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Organicell Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ASN004","moa":"5T4","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASN007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"TrialSpark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ASN008","moa":"NaV sodium channel","graph1":"Dermatology","graph2":"Phase II","graph3":"TrialSpark","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TrialSpark \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrialSpark \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ASP1012","moa":"Leptin-IL2 fusion protein expression","graph1":"Oncology","graph2":"IND Enabling","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KaliVir Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AFX3772","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Astellas Pharma"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Approved FDF","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arrivent \/ Inapplicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrivent \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Astrocyte Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CytRx Corporation \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase II","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PNV-5030","moa":"Adenosine A1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ERX-1000","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lannett Company, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"||GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||GCSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Caficrestat","moa":"Aldose reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Caficrestat","moa":"Aldose reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galactosemia Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Galactosemia Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Galactosemia Foundation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galactosemia Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-peptide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AT-752","moa":"Dengue viral polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA2271","moa":"Mesothelin protein","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATA2271","moa":"Mesothelin protein","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATA3219","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATA3219","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA3271","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ATCC (American Type Culture Collection)","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"ATCC (American Type Culture Collection)","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATCC (American Type Culture Collection) \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ATCC (American Type Culture Collection) \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ FGK Clinical Research"},{"orgOrder":0,"company":"UCLA Jonsson Comprehensive Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"UCLA Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCLA Jonsson Comprehensive Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCLA Jonsson Comprehensive Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AT-H201","moa":"SARS-CoV-2 N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NDX-1017","moa":"HGF","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATI-1428","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xyra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Budiodarone","moa":"Ion Channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Xyra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xyra \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xyra \/ Inapplicable"},{"orgOrder":0,"company":"Xyra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Budiodarone","moa":"Ion Channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Xyra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xyra \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xyra \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATI-2173","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATI-2173","moa":"||Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPK2","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"MAPK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"||MAPK2","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Antennova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antennova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antennova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antennova \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Translational Genomics Research Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atovaquone","moa":"||Cytochrome B","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Translational Genomics Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Genomics Research Institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Translational Genomics Research Institute \/ Inapplicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Staphylococcus Epidermidis","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azitra \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Azitra \/ Inapplicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Staphylococcus Epidermidis","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azitra \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Azitra \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATRC-101","moa":"||RNP complex","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATRN-1051","moa":"WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATRN-W1051","moa":"WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-101","moa":"||LCA1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-101","moa":"LCA1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATV-1601","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atavistik Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atavistik Bio \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Allay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATX-559","moa":"DHX9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accent Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Accent Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ATYR0101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Immunology","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"||NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Immunology","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATYR2810","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Biolojic Design"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase III","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase I","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Preclinical","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AT845","moa":"GAA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Audentes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"AUM LifeTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM LifeTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AUM LifeTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AUM LifeTech \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase III","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Eicos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Eicos Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eicos Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eicos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Serum Institute of India"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Neurology","graph2":"Preclinical","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AUTX-703","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aerovate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aerovate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aerovate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aerovate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aerovate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gates Biomanufacturing Facility","sponsor":"Institute for Molecular Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV-1980R","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Gates Biomanufacturing Facility","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gates Biomanufacturing Facility \/ Institute for Molecular Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Gates Biomanufacturing Facility \/ Institute for Molecular Medicine"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AV5124","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"ChemDiv \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ChemDiv \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avalon GloboCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Inapplicable"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"AVA-Trap","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalon GloboCare \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avalon GloboCare \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Nanjing Healthnice Pharmaceutical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyre Therapeutics \/ Nanjing Healthnice Pharmaceutical Technology","highestDevelopmentStatusID":"15","companyTruncated":"Gyre Therapeutics \/ Nanjing Healthnice Pharmaceutical Technology"},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AVB-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Avenge Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio \/ Inapplicable"},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AVB-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Avenge Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Avenge Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avenge Bio \/ Inapplicable"},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AVB-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Avenge Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio \/ Inapplicable"},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVB-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Avenge Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"PT AIVITA Biomedika","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AV-COVID-19","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ PT AIVITA Biomedika","highestDevelopmentStatusID":"7","companyTruncated":"Aivita Biomedical \/ PT AIVITA Biomedika"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aviceda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPAR-gamma","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NovaBay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPAR-gamma","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NovaBay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"4","companyTruncated":"Nutriband \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AV-GBM-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aviko Radiopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Avilar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Avilar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avilar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quantum Leap Healthcare \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-03","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"CTNS","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR\u2011RD\u201104","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"CTNS","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ University of California"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"CTNS","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-05","moa":"IDS","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-05","moa":"IDS","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avstera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVS100","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avstera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avstera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avstera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Quisovalimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ SOLTI"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1125","moa":"||Mitochondrial dysfunction","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPX-1009","moa":"QSOX1","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AXIM Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Acellular Human Extracellular Matrix","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Model Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"AXL","graph1":"Oncology","graph2":"Preclinical","graph3":"Model Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Model Medicines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Model Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM2","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Oxford Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Oxford Biomedica","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene Therapies \/ Oxford Biomedica"},{"orgOrder":0,"company":"Axovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Axovant","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axovant \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Axovant \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"AxoProtego Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EQ-6","moa":"HSP90","graph1":"Neurology","graph2":"Preclinical","graph3":"AxoProtego Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AxoProtego Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AxoProtego Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Gersizangitide","moa":"VEGFR 2","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"AsclepiX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Gersizangitide","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Unlimited Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Unlimited Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unlimited Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Unlimited Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Blueprint Medicines"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conduit Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Conduit Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Precision BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TG Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"5","companyTruncated":"TG Therapeutics \/ Precision BioSciences"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corium \/ Gurnet Point Capital","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Gurnet Point Capital"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IQVIA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Porcine PERT","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"B.More","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"B.More","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B.More \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"B.More \/ Inapplicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio4t2","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"B4T2-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bio4t2","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio4t2 \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio4t2 \/ Inapplicable"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cethrin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"BioAxone BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioAxone BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"BA3182","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BA3361","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Emerson Urology Associates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Mycobacterium Bovis Bacille Calmette-Guerin Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ludwig Enterprises \/ Emerson Urology Associates","highestDevelopmentStatusID":"1","companyTruncated":"Ludwig Enterprises \/ Emerson Urology Associates"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BAER-101","moa":"GABA-A-alpha 2\/3 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Banner Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Banner Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Banner Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Banner Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Banner Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Banner Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Linear DNA Vaccine","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DNA Sciences Inc \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ AbCellera","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ AbCellera"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Nephrology","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ National Institutes of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ National Institutes of Health"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai Inc \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Biogen"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XL114","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Resolve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Photoreceptor Neural Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rensselaer Polytechnic Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rensselaer Polytechnic Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rensselaer Polytechnic Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rensselaer Polytechnic Institute \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NC318","moa":"Siglec-15 \/LAIR-1","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytocom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CYTO-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytocom \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"OTC gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pracinostat","moa":"||pan-HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AB-2004","moa":"Microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SX-682","moa":"CXCR1\/2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Syntrix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syntrix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD3\/20","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CNGB3","moa":"CNGB3 gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CLBS201","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intrarenal Arterial Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"Collagen synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avalyn Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MEDIMETRIKS PHARMS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difamilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"MEDIMETRIKS PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"MEDIMETRIKS PHARMS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"MEDIMETRIKS PHARMS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"OncoSec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BX1000","moa":"nAchR","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Pfizer Inc"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bavituximab","moa":"||Phosphatidylserine","graph1":"Oncology","graph2":"Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Nephrology","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basking Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basking Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BB-031","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Basking Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bond Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bond Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBI-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBI-355","moa":"CHK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Inapplicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBI-825","moa":"RNR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBO-10203","moa":"||PI3K-alpha\/RAS","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Oncology Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBO-8520","moa":"GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBO-8520","moa":"GTP","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBP-454","moa":"KRAS G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ribitol","moa":"Alpha-dystroglycan","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BBP-631","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BBP-631","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBP-671","moa":"Glycolate oxidase","graph1":"Neurology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase I","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iterion Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Iterion Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tegavivint","moa":"||TBL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BCA356","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Cell","moa":"NK-1R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BCX10013","moa":"Factor D","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BCX10013","moa":"Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BCX9250","moa":"ALK-2","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BCX9250","moa":"ALK-2","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BDC-3042","moa":"||Dectin-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BEAM-201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"COX","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Beech Tree Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Thimerosal","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Beech Tree Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sublingual Solution\/Drops","sponsorNew":"Beech Tree Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Beech Tree Labs \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioDelivery Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Alvogen"},{"orgOrder":0,"company":"Xiromed","sponsor":"IntelGenx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Xiromed \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Xiromed \/ IntelGenx"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Preclinical","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"IL-2-beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benztropine","moa":"M1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Beroni Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beroni Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Beroni Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Beroni Group \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezafibrate","moa":"||PPA receptor-gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Whole-Virion Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Autologous Cytokine Induced Memory-Like NK Cell","moa":"||CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Biohaven Pharmaceuticals \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BHV-1510","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BHV-2100","moa":"TRPM3","graph1":"Neurology","graph2":"Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BHV-7000","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BHV-7000","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bond Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CASI Pharmaceuticals \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ BioInvent"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"Societal CDMO \/ BioCorRx","highestDevelopmentStatusID":"6","companyTruncated":"Societal CDMO \/ BioCorRx"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute of Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute of Drug Abuse"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institutes of Health"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ION541","moa":"Ataxin 2","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"AliveGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ALG-801","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"AliveGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AliveGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AliveGen \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"BiOneCure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BIO-106","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BiOneCure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiOneCure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiOneCure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BIO-11006","moa":"MARCKS protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acquist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Acquist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acquist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cerium Oxide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BioCurity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Altimmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"VT1021","moa":"CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Vigeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vigeo Therapeutics \/ Altimmune","highestDevelopmentStatusID":"9","companyTruncated":"Vigeo Therapeutics \/ Altimmune"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Naxitamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Zigakibart","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zigakibart","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zigakibart","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zigakibart","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Evotec","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"HEC Group","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lannett Company, Inc. \/ HEC Group","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ HEC Group"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Amniotic Membrane","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"Prostaglandin G\/H synthase 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Applied Biology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Applied Biology \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Virtuoso Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD38\/ICAM-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Virtuoso Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virtuoso Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virtuoso Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CHI3L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lakewood-Amedex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-Amedex \/ Inapplicable"},{"orgOrder":0,"company":"BITT","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BITT-2101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BITT \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bluejay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bluejay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bluejay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bluejay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bluejay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bluejay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bluejay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bluejay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bluejay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bluejay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bloom Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Inapplicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bloom Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"BLB-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Blue Lake Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Blue Lake Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Lake Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"BLB-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Blue Lake Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Lake Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Lake Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Cyanvac","sponsor":"Blue Lake Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BLB-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cyanvac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyanvac \/ Blue Lake Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Cyanvac \/ Blue Lake Biotechnology"},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Cyanvac","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BLB-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Blue Lake Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Blue Lake Biotechnology \/ Cyanvac","highestDevelopmentStatusID":"7","companyTruncated":"Blue Lake Biotechnology \/ Cyanvac"},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BLB-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Blue Lake Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Blue Lake Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Lake Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Biotech Acquisition Company"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BLD-2660","moa":"Calpain","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BIOKEY","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLEX 404","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABVC BioPharma \/ BIOKEY","highestDevelopmentStatusID":"5","companyTruncated":"ABVC BioPharma \/ BIOKEY"},{"orgOrder":0,"company":"Aralez Pharmaceuticals","sponsor":"Miravo Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aralez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aralez Pharmaceuticals \/ Miravo Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Aralez Pharmaceuticals \/ Miravo Healthcare"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-M11D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-M17D1","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"Wonderberlly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simethicone","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Wonderberlly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Wonderberlly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wonderberlly \/ Inapplicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Labcorp Drug Development"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLU-222","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLU-222","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX 0871","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMB-201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGluR5","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Milvexian","moa":"FXIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Milvexian","moa":"FXIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ GSK"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BMS-986249","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMS-986278","moa":"LPAR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMS-986278","moa":"LPAR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Nephrology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BNC375","moa":"Nicotinic-alpha7 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bionaut Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bionaut Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionaut Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bionaut Labs \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"OncoC4","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"OncoC4 \/ BioNTech"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BOLD-100","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Bone Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"rhNELL-1","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biologics \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"CTGF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Shilpa Medicare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Shilpa Medicare","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Shilpa Medicare"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efimosfermin Alpha","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boston Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efimosfermin Alpha","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boston Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Boston Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AR-15512","moa":"TRPM8","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Gilead Sciences"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LENZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1020","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ University of Michigan","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ University of Michigan"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tobevibart","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergen Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergen Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergen Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergen Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BP1002","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BP1002","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BP1002","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BP1002","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BP1003","moa":"STAT3","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"BP1003","moa":"STAT3","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"P-Borono-L-Phenylalanine","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAE Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BPGbio","sponsor":"Berg Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BPGbio \/ Berg Health","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Berg Health"},{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"},{"orgOrder":0,"company":"BPGbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"LDL-cholesterol oxidation","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BPGbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-603","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Amniotic Chorion Tissue Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Woolsey Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Woolsey Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Woolsey Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Woolsey Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Woolsey Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Woolsey Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Woolsey Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Woolsey Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"INO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"INO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"INO \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"INO \/ Inapplicable"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"BRB-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bitterroot Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bitterroot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"BRB-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bitterroot Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bitterroot Bio \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Biopharmaceutical Research Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Biopharmaceutical Research Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopharmaceutical Research Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biopharmaceutical Research Company \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pivekimab Sunirine","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Inapplicable"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Inapplicable"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"TheracosBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brequinar","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clear Creek Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clear Creek Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clear Creek Bio \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Hansoh Pharma"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Otsuka America Pharmaceutical, Inc.","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka America Pharmaceutical, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"VBI Vaccines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BRII-179","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ VBI Vaccines","highestDevelopmentStatusID":"7","companyTruncated":"Brii Biosciences \/ VBI Vaccines"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"TSB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ TSB Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ TSB Therapeutics"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BRII-297","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Islatravir Prodrug","moa":"||NRTI","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"NNRT","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"VIR-2218","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chimerix \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Orvacabtagene Autoleucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Romidepsin","moa":"HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986249","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Braeburn \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aphios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Bryoid","moa":"Protein kinase C","graph1":"Neurology","graph2":"Preclinical","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aphios \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aphios \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"IND Enabling","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"Curia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"Preclinical","graph3":"BryoLogyx Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ Curia","highestDevelopmentStatusID":"4","companyTruncated":"BryoLogyx Inc \/ Curia"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BSB-1001","moa":"HA-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BT051","moa":"Neutrophil trafficking","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vapendavir","moa":"Capsid","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altesa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Altesa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BTX-1188","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BTX-1188","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BTX-9341","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BTX-9341","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"Edgewood Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Edgewood Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Edgewood Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewood Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Edgewood Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Edgewood Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Edgewood Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewood Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posiphen tartrate","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Seton Pharmaceuticals","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Butalbital","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Seton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seton Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Seton Pharmaceuticals \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BV-101","moa":"CYP46A1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"BlueWillow Biologics","sponsor":"Medigen Vaccine Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BW-1019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BlueWillow Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"BlueWillow Biologics \/ Medigen Vaccine Biologics","highestDevelopmentStatusID":"4","companyTruncated":"BlueWillow Biologics \/ Medigen Vaccine Biologics"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nAchR","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nAchR","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nAchR","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nAchR","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RP-2000","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioXcel Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Saposin C","moa":"S1PR","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Saposin C","moa":"||S1PR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Saposin C","moa":"S1PR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osanetant","moa":"NK-3R","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NU-0129","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Calidi Biotherapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CD70 CAR-NK Cell","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ovarian Cancer Vaccine","moa":"ED-AMHR2","graph1":"Oncology","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anixa Biosciences \/ Cleveland Clinic","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ Cleveland Clinic"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EP-7041","moa":"Factor XIa","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lys-MDA","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin type II receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin type II receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin type II receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin type II receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Samsung Bioepis"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"C101248","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Locanabio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Hexanucleotide","graph1":"Neurology","graph2":"Preclinical","graph3":"Locanabio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Locanabio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Locanabio \/ Inapplicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ University of Florida"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"Tubulin polymerisation","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"Johnson & Johnson \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ ViiV Healthcare"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"Johnson & Johnson \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ ViiV Healthcare"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"cAd3-Marburg Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sabin Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sabin Vaccine Institute \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Sabin Vaccine Institute \/ GSK"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"CAL02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"CAL02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"CAL02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"CAL02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS12","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CM4620-IE","moa":"CRAC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Sanifit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNF472","moa":"Calcification","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sanifit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Personalized Stem Cells","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Personalized Stem Cells","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Personalized Stem Cells \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Personalized Stem Cells \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SVF-CAL1","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Naval Medical Research Center","sponsor":"Immuron","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CampETEC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Naval Medical Research Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Naval Medical Research Center \/ Immuron","highestDevelopmentStatusID":"5","companyTruncated":"Naval Medical Research Center \/ Immuron"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"PicnicHealth","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PicnicHealth","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PicnicHealth \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"PicnicHealth \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Self-Assembling Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nielsen BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Candin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nielsen BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Nielsen BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nielsen BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Vella Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Vella Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vella Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vella Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Capsida","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAP-001","moa":"IDS","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Capsida \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transendocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Cytonus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CA-IL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytonus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytonus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytonus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Caris Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"CancerVAX","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CancerVAX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CancerVAX \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CancerVAX \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"Arcellx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CART-ddBCMA","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcellx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Inapplicable"},{"orgOrder":0,"company":"Arcellx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CART-ddBCMA","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcellx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ GenScript Biotech Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ GenScript Biotech Corporation"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Legend Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Legend Biotech"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ GSK"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CID-103","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CASI Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAT-179","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAT-179","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAT-179","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAT-248","moa":"CD70","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nf-kB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nf-kB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CB-012","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Cleave Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CB-5339 Tosylate","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CASI Pharmaceuticals \/ Cleave Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CASI Pharmaceuticals \/ Cleave Therapeutics"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-668","moa":"IL4I1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Chimera Bioengineering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CBIO-007","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Chimera Bioengineering","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimera Bioengineering \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Chimera Bioengineering \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"CBO-212","moa":"CD73","graph1":"Oncology","graph2":"Preclinical","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CBX-12","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Crossbow Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CBX-250","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Crossbow Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crossbow Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Crossbow Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CC-31244","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CC-42344","moa":"||PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"C-CAR039","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"C-CAR066","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 t-haNK","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ GSK"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ GSK"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SY-5609","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CDX-005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"Tyrosine kinase KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Biosion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CDX-585","moa":"PD-1\/ILT4","graph1":"Oncology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celldex Therapeutics \/ Biosion","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Biosion"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase I","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Codexis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Codexis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase I","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Codexis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Codexis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Everest Medicines"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Everest Medicines"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CEL383","moa":"TREM-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Celsius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celsius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celsius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celavet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OK100 Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celavet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celavet \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Celavet \/ Inapplicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ National Institutes of Health"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA damage","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CK0801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Celmatix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celmatix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CEL-4000","moa":"IL-17-alpha receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CEL-SCI \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ National Institutes of Health"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pozelimab","moa":"C5 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Cend Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Cend Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Cend Therapeutics"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Caladrius Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Caladrius Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Caladrius Biosciences"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor-alpha 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor-alpha 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elite Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elite Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AEVI-002","moa":"LIGHT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AEVI-007","moa":"IL-18","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CERo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CER-1236","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CERo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CERo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CERo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CERo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"CERo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CERo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CERo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akorn Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Calyptus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Calyptus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cetrorelix Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akorn Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cellevolve","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CE-VST01-JC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cellevolve","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellevolve \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellevolve \/ Inapplicable"},{"orgOrder":0,"company":"Cellevolve","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CE-VST01-JC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cellevolve","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellevolve \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellevolve \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"CF33-hNIS-antiPDL1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"City of Hope \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CF-370","moa":"Pseudomonas aeruginosa cell wall","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CF-370","moa":"Pseudomonas aeruginosa cell wall","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CFI-400945","moa":"||PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFI-400945","moa":"||PLK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CFI-402257","moa":"||Tyrosine threonine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CFT1946","moa":"||BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFT8634","moa":"Bromodomain 9","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CG001419","moa":"TRK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CG Oncology \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Merck & Co"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"||KIT","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Icahn School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AS03","moa":"||Hemagglutinin-neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icahn School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icahn School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Icahn School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAd-SARS-CoV-2-S","moa":"SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Washington University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Treg-Derived Exosome","moa":"Treg","graph1":"Neurology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Charles River Laboratories, Inc \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Charles River Laboratories, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chenodeoxycholic Acid","moa":"Cholesterol","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Chenodeoxycholic Acid","moa":"Cholesterol","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"||HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Neopharm"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ OPKO Health"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Choline Chloride","moa":"Alpha 7-nAChR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ENaC","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Chromocell Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chromocell Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rusalatide Acetate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Chrysalis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Chrysalis BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Chrysalis BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CHS-006","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripaliamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Hims","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hims","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hims \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hims \/ Inapplicable"},{"orgOrder":0,"company":"Araim Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Araim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Araim Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Araim Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CID-078","moa":"Cyclin A\/B RxL","graph1":"Oncology","graph2":"Phase I","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circle Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Circle Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"CID-078","moa":"Cyclin A\/B RxL","graph1":"Oncology","graph2":"Preclinical","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Circle Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Circle Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CID-078","moa":"Cyclin A\/B RxL","graph1":"Oncology","graph2":"IND Enabling","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circle Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Circle Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Gebro Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD38","graph1":"Immunology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"CASI Pharmaceuticals \/ Gebro Pharma","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharmaceuticals \/ Gebro Pharma"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CASI Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CID-103","moa":"CD38","graph1":"Immunology","graph2":"IND Enabling","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CASI Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CASI Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Brand Institute"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deudomperidone","moa":"D2\/D3 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CinRx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinPhloro Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phloroglucinol","moa":"Beta-secretase 1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinPhloro Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CinPhloro Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinPhloro Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CIN-110","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CinRx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CIN-110","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CinRx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"||CD44","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Anika Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"||CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"||NaV sodium channel alpha subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"White Button Mushroom Extract","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CiVax","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CK0803","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CK0803","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CK0804","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CK-3772271","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CK-136","moa":"Cardiac troponin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-089","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Claritas Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Claritas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Claritas Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Claritas Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"ClearB Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CLB-3000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ClearB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ClearB Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ClearB Therapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"ClearB Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CLB-3000","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ClearB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ClearB Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ClearB Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CLBS201","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intrarenal Arterial Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Calidi Biotherapeutics \/ City of Hope","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ City of Hope"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KB105","moa":"Transglutaminase 1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-ZnAg","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor 1A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Inapplicable"},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Solaris Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Solaris Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Solaris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RPTR-147","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repertoire Immune Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire Immune Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MCY-M11","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AgenT-797","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD3\/20","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EDP-305","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSHA-120","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Tick-Borne Encephalitis Vaccine","moa":"Immunomodulator","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Spearmint Extract","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Healthy Extracts","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Healthy Extracts \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NantKwest \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oncoceutics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HHMI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HHMI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"HHMI \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HHMI \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Allos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Allos Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allos Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CLN-049","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CLN-049","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CLN-617","moa":"||IL-2\/12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CLN-617","moa":"||IL-2\/12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CLN-617","moa":"IL-2\/12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CLN-619","moa":"MICA\/MICB","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CLN-619","moa":"||MICA\/MICB","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CLN-619","moa":"MICA\/MICB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA damage","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"||VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cystetic Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CM001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cystetic Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Cystetic Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cystetic Medicines \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CM5480","moa":"CARC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CAMP4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CAMP4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CAMP4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarametyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarametyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarametyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarametyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"C101248","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CNBX RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CNBX RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CASI Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CASI Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-ZnAg","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CNP-106","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CNP-106","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cour Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CNP-201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNTY-102","moa":"CD19\/79b","graph1":"Oncology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cobomarsen","moa":"miR-155","graph1":"Oncology","graph2":"Phase II","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Miragen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Miragen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cobomarsen","moa":"miR-155","graph1":"Oncology","graph2":"Phase II","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Miragen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Miragen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Serum Institute of India"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSV Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CodaVax-H1N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSV Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Codagenix \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Codebase","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codebase","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codebase \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Codebase \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"IND Enabling","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"engEx-AAV","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"CB4211","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"MBT2","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACTR707","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Unum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Unum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zigakibart","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"||MAPK 1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Natera Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Natera Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Natera Inc."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Yale School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"||Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Yale School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yale School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Yale School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SBT6050","moa":"TLR8","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AT-H201","moa":"SARS-CoV-2 N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Misetionamide","moa":"||LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Panavance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VIR-2218","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Novavax","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ University of Oxford"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Comera Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BNT161","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ OntoChem"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AgenT-797","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Preclinical","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMU-935","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"Neuropilin-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NUV-422","moa":"CDK2\/4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4+ T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"AP-SA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Omburtamab-DTPA","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"SARS-CoV-2 viral spike protein 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tolperisone","moa":"NaV sodium channel","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"GP2","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506 binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Endo International","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Nicotinic receptor-alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Par Pharmaceutical \/ Endo International","highestDevelopmentStatusID":"15","companyTruncated":"Par Pharmaceutical \/ Endo International"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Kamuvudine-9","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GT90001","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"StemVacs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APL-9","moa":"C3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GIGA-2050","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Hoag Memorial Hospital Presbyterian","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gemfibrozil","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SLV213","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Selva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALN-HSD","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD19-targeted butyrophilin heterodimer","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||EGFR\/CD28","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"124-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"||Mesothelin protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lattice Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lattice Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Lattice Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lattice Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AR882","moa":"URAT1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arthrosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arthrosi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arthrosi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LN-145","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HPN328","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Follica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Follica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Follica \/ Inapplicable"},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"||IL-12 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kintai Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kintai Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fibroblast Cell","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"FibroGenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGenesis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"FibroGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Quratis Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Quratis Co., Ltd"},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PneumoBlast","moa":"Tissue Factor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGenesis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Altasciences Company Inc","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||ICOS","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Humantakinogene Hadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SLS-004","moa":"SNCA gene","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TG-1701","moa":"||BTK","graph1":"Oncology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vecabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sunesis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sunesis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"resTORbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dactolisib","moa":"TORC1","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"resTORbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"resTORbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"resTORbio \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"Neuropilin-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TNX-1700","moa":"TFF2","graph1":"Oncology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"CR2O","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ CR2O","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ CR2O"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"CF-296","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diakonos Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"BSP Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ BSP Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ BSP Pharmaceuticals"},{"orgOrder":0,"company":"Amniox Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX01","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"Amniox Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amniox Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amniox Medical \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"Bolder BioTechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"BBT-032","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bolder BioTechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolder BioTechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bolder BioTechnology \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tetraphase Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tetraphase Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetraphase Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prochlorperazine Maleate","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"E26 transformation-specific oncoproteins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"ReGenTree \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Inapplicable"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zelicapavir","moa":"N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ National Cancer Institute"},{"orgOrder":0,"company":"Altimmune","sponsor":"University Of Alabama","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ University Of Alabama","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ University Of Alabama"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Tesetaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Currax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"||Kappa\/Mu\/Delta Opioid receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Currax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Currax \/ Inapplicable"},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"225-Ac Rosopatamab Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Convergent Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Convergent Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"MHC-II gene","graph1":"Oncology","graph2":"Phase I","graph3":"Kinimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kinimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinimmune \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Mapi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Mapi Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Mapi Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Secura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Secura Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Secura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Approved FDF","graph3":"Secura Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Secura Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Secura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"COR588","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"COR588","moa":"Lysine gingipain","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"COR803","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AntiCancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Methioninase","moa":"Methionine","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer \/ Inapplicable"},{"orgOrder":0,"company":"Longhorn Vaccines & Diagnostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AddaVax","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Longhorn Vaccines & Diagnostics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Longhorn Vaccines & Diagnostics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Longhorn Vaccines & Diagnostics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 spike Protein Plasmid DNA Vaccine","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoSec Immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoSec Immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Whole-Virion Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Multitope Peptide-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Enterin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"COV-ENT-1","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Enterin \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enterin \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CERC-002","moa":"LIGHT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Grapiprant","moa":"Aldose reductase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"STI-2099","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"STI-4398","moa":"Spike protein S1 domain","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aegis Life","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Covigenix VAX-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aegis Life","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aegis Life \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Aegis Life \/ Entos Pharmaceuticals"},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Serum Institute of India"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Serum Institute of India"},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Serum Institute of India"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Wisconsin Medical Cyclotron & Radiopharmacy"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Immunology","graph2":"Preclinical","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Oncology","graph2":"Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Oncology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Oncology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Oncology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"Il-2 induced T-cell kinase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"Il-2 induced T-cell kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"Il-2 induced T-cell kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"Il-2 induced T-cell kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase I","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Panbela Therapeutics \/ US WorldMeds"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"JDRF","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Endocrinology","graph2":"Phase II","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ JDRF","highestDevelopmentStatusID":"8","companyTruncated":"Panbela Therapeutics \/ JDRF"},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosciclopirox","moa":"Cell membrane synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ CicloMed LLC"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"||AlphaVbeta8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRD-740","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Amniotic Fluid Derived Stem Cell","moa":"HGF-1","graph1":"Nephrology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Pancrelipase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GCSF","graph1":"Oncology","graph2":"Preclinical","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metagenomi \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crizotinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ National Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ National Cancer Institute"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Crestone","sponsor":"Praedicare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"CRS0540","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crestone \/ Praedicare","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/ Praedicare"},{"orgOrder":0,"company":"Crestone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CRS3123","moa":"Methionyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crestone \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crestone \/ Inapplicable"},{"orgOrder":0,"company":"Crestone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CRS3123","moa":"Methionyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Crestone","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crestone \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crestone \/ Inapplicable"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curevo Vaccine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Inapplicable"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curevo Vaccine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clear Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etifoxine","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Clear Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clear Scientific \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clear Scientific \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Rho D Immune Globulin","moa":"IgG","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Apolipoprotein A-I, Human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lovastatin Lactone","moa":"HMG-CoA reductase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3K-delta\/gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CST-103","moa":"||ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CuraSen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CST-103","moa":"ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CSTI-500","moa":"Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ConSynance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ConSynance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ConSynance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CSTI-500","moa":"Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ConSynance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ConSynance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ConSynance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cessation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cessation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cessation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Coagulant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Coagulant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Hematology","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coagulant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CT-0508","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Carisma Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CT-0525","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CT-0525","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CT-0525","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"CT-388","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Carmot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carmot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"GLP-1","graph1":"Endocrinology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"CT-868","moa":"GLP- 1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Carmot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CT-996","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Carmot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CT-996","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CT-996","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AFP TCR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Cellics Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTI-005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cellics Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellics Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellics Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Integral Molecular","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Integral Molecular","highestDevelopmentStatusID":"4","companyTruncated":"Context Therapeutics \/ Integral Molecular"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Integral Molecular \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytoAgents \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Inapplicable"},{"orgOrder":0,"company":"CytoAgents","sponsor":"TFS Health Science","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytoAgents \/ TFS Health Science","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ TFS Health Science"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CTS-2090","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asciminib","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CTX112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Dr. Vince Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"BDD Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ BDD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ BDD Pharma"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTX-471","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Daptomycin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-102","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-102","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-401","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Cure Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cure Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cure Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Cure Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CI-8993","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Excel Diagnostics and Nuclear Oncology Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"177-Lu DOTATOC","moa":"SSTR1","graph1":"Oncology","graph2":"Phase II","graph3":"Excel Diagnostics and Nuclear Oncology Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Excel Diagnostics and Nuclear Oncology Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Excel Diagnostics and Nuclear Oncology Center \/ Inapplicable"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnCusp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"CureVac","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CV7201 mRNA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"PharmaJet \/ CureVac","highestDevelopmentStatusID":"6","companyTruncated":"PharmaJet \/ CureVac"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CVL-871","moa":"D1\/D5 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CVL-871","moa":"D1\/D5 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CVN293","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CVN293","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CVN766","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"CV Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nicotine","moa":"||Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"CV Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CV Science \/ Inapplicable"},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CVXGA1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Blue Lake Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Blue Lake Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Blue Lake Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Currax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"||Kappa\/Mu\/Delta Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Currax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Currax \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"CX-2051","moa":"EpCAM","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"CX-2051","moa":"EpCAM","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CX-801","moa":"||IFN-alpha-2b","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CX-904","moa":"EGFR-CD3 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CX-904","moa":"EGFR-CD3 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Telparevir","moa":"PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Anthrax Vaccine Adsorbed, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYNK-101","moa":"CD38","graph1":"Oncology","graph2":"Preclinical","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyteir Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyteir Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyteir Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"REVIMMUNE INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"CYT107","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"REVIMMUNE INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"REVIMMUNE INC \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"REVIMMUNE INC \/ Inapplicable"},{"orgOrder":0,"company":"Cytonics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CYT-108","moa":"A2M protease","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytonics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytonics \/ Inapplicable"},{"orgOrder":0,"company":"Cytonics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CYT-108","moa":"A2M protease","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytonics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytonics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-338","moa":"CD38","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-338","moa":"CD38","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"On Target Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR Alpha 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYTO NK-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"Cytocom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cytocom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytocom \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Highly Active Anti-Retroviral Therapy","moa":"||CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CytRx Corporation \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CytRx Corporation \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ ImmunityBio"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytRx Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CytRx Corporation \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"D5-KRM-II-81","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DA-1241","moa":"GPR119","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DA-1241","moa":"GPR119","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DA-1241","moa":"||GPR119","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"COX","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"COX","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"DARA BIOSCIENCES","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"17-beta estradiol","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"DARA BIOSCIENCES","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"DARA BIOSCIENCES \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"DARA BIOSCIENCES \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"17-beta estradiol","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"17-beta estradiol","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Hematology","graph2":"Approved FDF","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MGD013","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CTX-2026","moa":"BTN3A","graph1":"Oncology","graph2":"Preclinical","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amunix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amunix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CT-1","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MRG-110","moa":"miR-92a","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Miragen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Miragen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tobevibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KT-413","moa":"IRAKIMiD","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"HBV core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orionis Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"exoVACC","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATSN-101","moa":"LCA1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PH-804","moa":"TIGIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"SYNB1891","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyteir Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Servier"},{"orgOrder":0,"company":"Prothione","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamic Acid","moa":"||Glutathione peroxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Prothione","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prothione \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothione \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-TT170","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"BioDelivery Sciences \/ Endo Pharm"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IRL201805","moa":"BiP protein","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Avelumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATYR2810","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PH-894","moa":"Bromodomain-containing protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Uzatresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Infinity Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Galidesivir","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Emergent BioSolutions","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Ring Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ring Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ring Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level reducer","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Osmol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OSM-0205","moa":"IntraCellular calcium","graph1":"Neurology","graph2":"Preclinical","graph3":"Osmol Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osmol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Osmol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VK2809","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"18-Methoxycoronaridine","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seagen \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Genmab"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vibecotamab","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SRF231","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caring Cross","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Caring Cross","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Caring Cross \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Caring Cross \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"T-2143","moa":"Pan-PI3K","graph1":"Oncology","graph2":"Preclinical","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarveda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tarveda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"||IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil","moa":"||CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"GABA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etifoxine","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GABA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"GABA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GABA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Dermira","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Dermira","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Dermira"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.ZEBOV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-204-C07","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rgenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SBT6050","moa":"TLR8","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MedGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Klf4","graph1":"Oncology","graph2":"Preclinical","graph3":"MedGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MedGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MedGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LYT-200","moa":"Galectin-9","graph1":"Oncology","graph2":"Preclinical","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"APOC-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dicerna Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TERN-201","moa":"SSAO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Trovagene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STK-002","moa":"Optic atrophy 1 protein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Sialoglycan","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SBT6050","moa":"||TLR8","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GMcSF","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Oncorus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ONCR-788","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncorus \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncorus \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-005","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CTX-471","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"IL-1-associated kinase 1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Micronized Dehydrated Human Amnion Chorion Membrane","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AU-007","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ABBV-3373","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracystic Injection","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OP-101","moa":"Glutathione synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genprex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Merck & Co"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AMP-CpG","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ELI-01","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"||CD155","graph1":"Oncology","graph2":"Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Istari Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Istari Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OPGx-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NR2E3-AAV","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TRX-1002","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Aria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HPK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BIO-11006","moa":"MARCKS protein","graph1":"Oncology","graph2":"Phase II","graph3":"Acquist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Acquist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acquist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ENOB-HV-21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enochian BioSciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enochian BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Merck Group"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TATX-21","moa":"LDL uptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TATX-21","moa":"LDL uptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"QED Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SQZ-AAC","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"||Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"||Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ExoFlo","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DB-007-4","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Liafensine","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Liafensine","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Flucytosine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Denovo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denovo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DC-806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DynamiCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DCBY02","moa":"CD93","graph1":"Oncology","graph2":"Phase I","graph3":"DynamiCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DynamiCure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"DynamiCure \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DCC-3116","moa":"||ULK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DCC-3116","moa":"ULK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Folia Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Folia Health","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Folia Health"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regen BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||IAP","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DCC-3116","moa":"ULK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||CDK2\/4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taro Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Augmenta Bioworks","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"AUG-3387","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Augmenta Bioworks","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Augmenta Bioworks"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Military Health System Research Symposium","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DNA-Based Venezuelan Equine Encephalitis Virus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Military Health System Research Symposium","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet \/ Military Health System Research Symposium"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Augmenta Bioworks","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"AUG-3387","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Augmenta Bioworks","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Augmenta Bioworks \/ TFF Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Augmenta Bioworks \/ TFF Pharmaceuticals"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Curia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Liafensine","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Curia","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Curia"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzastaurin","moa":"||PKC-beta","graph1":"Oncology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Merakris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beverly Hills","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dimethyl Sulfone","moa":"||DHT","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Beverly Hills","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beverly Hills \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beverly Hills \/ Inapplicable"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"Ach receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crisaborole","moa":"PDE4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Descartes-11","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-15","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||FGFR2B","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||STAT3\/NF-kB\/poly-tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Serum Institute of India"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Revakinagene Taroretcel","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurotech Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NGM438","moa":"LAIR-1","graph1":"Oncology","graph2":"Preclinical","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regen BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AUR102","moa":"CDK7","graph1":"Oncology","graph2":"Preclinical","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Aurigene","highestDevelopmentStatusID":"4","companyTruncated":"Exelixis \/ Aurigene"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"De-TIL-0255","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ NantKwest"},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shoreline Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shoreline Biosciences \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Shoreline Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Milla Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Milla Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Areteia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"Eosinophil maturation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Areteia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Areteia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Areteia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"AffaMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AffaMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"AffaMed Therapeutics \/ Ocular Therapeutix"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"15","companyTruncated":"AffaMed Therapeutics \/ Ocular Therapeutix"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"AffaMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AffaMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"DF6002","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase I","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"DGX-001","moa":"AVPR1A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Viage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"diABZI","moa":"STING","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Pennsylvania \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Nephrology","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Diasome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diasome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diasome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Diasome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"DCR-A1203","moa":"ALDH2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dichloroacetic Acid","moa":"PDK","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saol therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Saol therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yaral Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"COX-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Yaral Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Yaral Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Yaral Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NEXGEL Advanced Hydrogel Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"NEXGEL Advanced Hydrogel Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"NEXGEL Advanced Hydrogel Solutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NEXGEL Advanced Hydrogel Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dicyclomine Hydrochloride","moa":"mAChR","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"||Passive oxygen diffusion","graph1":"Oncology","graph2":"Phase III","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Affinia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Affinia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DB-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Disc medicine \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0998","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Preclinical","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MWTX-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"STI-2020","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-200-A02","moa":"MHC","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celiprolol Hydrochloride","moa":"Adrenergic-beta 1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Merck & Co"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Distributed Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"S-protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Distributed Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Distributed Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Distributed Bio \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DK210","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DK210","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"DK210","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sirexatamab","moa":"DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sirexatamab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delpor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Delpor \/ Inapplicable"},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DLQ01","moa":"F2 alpha receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dermaliq Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Dermaliq Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dermaliq Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DLQ02","moa":"Calcineurin","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dermaliq Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Liquid","sponsorNew":"Dermaliq Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dermaliq Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DLX-001","moa":"Neural circuits","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DLX-001","moa":"Neural circuits","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DLX-001","moa":"Neural circuits","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord BioPharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Accord BioPharma \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"ApolloBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ ApolloBio","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ ApolloBio"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"DNL126","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biogen \/ Denali Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Denali Therapeutics"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"DNL593","moa":"Progranulin protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Denali Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Denali Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Neurology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Hesperos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dianthus Therapeutics \/ Hesperos","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus Therapeutics \/ Hesperos"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Actg","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Actg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Actg \/ ViiV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Actg \/ ViiV Healthcare"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Arcus Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Bioscience"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Domvanalimab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DNL758","moa":"RIPK1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SRK-181","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Urate transporter 1","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fortress Biotech \/ Fuji Yakuhin","highestDevelopmentStatusID":"15","companyTruncated":"Fortress Biotech \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Urica Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Urate transporter 1","graph1":"Rheumatology","graph2":"Phase I","graph3":"Urica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Urica Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Urica Therapeutics \/ Fortress Biotech"},{"orgOrder":0,"company":"Piramal Critical Care","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline","moa":"MMP-13","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Piramal Critical Care","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Piramal Critical Care \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Piramal Critical Care \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 mAChR","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 mAChR","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"National Aeronautics and Space Administration","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 mAChR","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 mAChR","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 mAChR","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DPM-1001","moa":"PTP1B","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPTX3186","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dewpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Damona Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DPX-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Damona Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Damona Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Damona Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exatecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Squalamine phosphate","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enterin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AR-711","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Baylor College of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DF6215","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Innovation Ventures at Emory \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Drug Innovation Ventures at Emory \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"||Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumi Scientific \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rumi Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SK1-I","moa":"Sphingosine kinase 1","graph1":"Immunology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzo Biochem \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Biochem \/ Inapplicable"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TMPRSS2","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Applied Biology \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biology \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DSE Healthcare Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"DSE Healthcare Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DSE Healthcare Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"DSE Healthcare Solutions \/ Inapplicable"},{"orgOrder":0,"company":"DSG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"DSG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"DSG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DSG \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ombipepimut-S","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DT-216","moa":"FXN gene transcription","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-216","moa":"FXN gene transcription","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GIOSTAR","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"DT2-SCT","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"GIOSTAR","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GIOSTAR \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GIOSTAR \/ Inapplicable"},{"orgOrder":0,"company":"Dystrogen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Dystrophin Expressing Chimeric Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dystrogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dystrogen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dystrogen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dystrogen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Dystrophin Expressing Chimeric Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dystrogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dystrogen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dystrogen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"Ach receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DTx-1252","moa":"PMP22","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"DTx Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"OTC gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"DTX401","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lumen Bioscience \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Duet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"DUET-01","moa":"STAT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Duet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scopus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"DUET-02","moa":"CpG-STAT3 antisense","graph1":"Oncology","graph2":"Preclinical","graph3":"Scopus Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scopus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scopus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"OWP Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OWP Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"UNC School of Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"UNC School of Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UNC School of Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"UNC School of Medicine \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Marizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glutathione","moa":"||Glutathione peroxidase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Marizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marizyme \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Kappa\/Mu\/Delta Opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Statera Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Statera Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clofazimine","moa":"ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Abbvie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Allergan Aesthetics \/ Abbvie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Abbvie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dirocaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteostasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"DVX201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coeptis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coeptis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CDX-622","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DYV700","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Dyve Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Sialoglycan","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Sialoglycan","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spirita Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"E6201","moa":"||MEKK-1","graph1":"Oncology","graph2":"Phase I","graph3":"Spirita Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spirita Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spirita Oncology \/ Inapplicable"},{"orgOrder":0,"company":"H3 Biomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"E7766","moa":"Interferon gene","graph1":"Oncology","graph2":"Preclinical","graph3":"H3 Biomedicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"H3 Biomedicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"H3 Biomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EA-2351","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EA-2353","moa":"Progenitor cell","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EA-2353","moa":"Progenitor cell","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EA-2353","moa":"Progenitor cell","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methyldopa","moa":"Adrenergic alpha-2A receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ImprimisRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"ImprimisRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Troche\/Lozenge","sponsorNew":"ImprimisRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImprimisRx \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"CTNS","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"iBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"IBIO-201","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"iBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"iBio \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"D6PV","moa":"APOC-III","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Corvidia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvidia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Corvidia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EB-003","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Estrella Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Estrella Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.ZEBOV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VSV-vectored Lassa Virus Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Yale University","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Yale University"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EBT-101","moa":"CRISPR-Cas9 gene","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Excision BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EBT-101","moa":"CRISPR-Cas9 gene","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Excision BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EBT-101","moa":"CRISPR-Cas9 gene","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Excision BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EBT-101","moa":"CRISPR-Cas9 gene","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Excision BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EBT-101","moa":"CRISPR-Cas9 gene","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Excision BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EBT-104","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Excision BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Excision BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EBT-107","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Excision BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Excision BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SSTR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Molecular Targeting Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"National Institute for Biomedical Imaging and Bioengineering","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Molecular Targeting Technologies \/ National Institute for Biomedical Imaging and Bioengineering","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Targeting Technologies \/ National Institute for Biomedical Imaging and Bioengineering"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SSTR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Targeting Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Eclipse Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eclipse Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eclipse Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eclipse Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"EicOsis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EC5026","moa":"sEH","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EicOsis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ Inapplicable"},{"orgOrder":0,"company":"EicOsis","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EC5026","moa":"sEH","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EicOsis \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PSMA-I&T","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CURIUM US LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CURIUM US LLC \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ECP-101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"ECP Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECP Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ECP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ECP-101","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"ECP Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECP Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ECP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECT204","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nf-kB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rising Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"Metal ion","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Rising Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rising Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rising Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Muscular Dystrophy Association","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Muscular Dystrophy Association","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Muscular Dystrophy Association"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDG-7500","moa":"Sarcomere","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-101","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5 vector gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+ gene","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1815","moa":"Th1\/2\/17","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"EDP1815","moa":"Th1\/2\/17","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"Th1\/2\/17","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EDP-235","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EDP2939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EDP2939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EDP-297","moa":"Farnesoid X receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Enanta Pharmaceuticals \/ PRA Health Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ PRA Health Sciences"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EDP-323","moa":"L-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDP-323","moa":"L-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EDP-323","moa":"L-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EDP-323","moa":"L-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-514","moa":"HBV core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-721","moa":"RNA destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-721","moa":"RNA destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zelicapavir","moa":"N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celiprolol Hydrochloride","moa":"Adrenergic-beta 1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celiprolol Hydrochloride","moa":"Adrenergic-beta 1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Celiprolol Hydrochloride","moa":"Adrenergic-beta 1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"||NNRT","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"||NNRT","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Venlafaxine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zotatifin","moa":"||eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zotatifin","moa":"||eIF4A","graph1":"Oncology","graph2":"Preclinical","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zotatifin","moa":"||eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"||MAPK 1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"||MAPK 1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"EGL-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Egle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Egle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Egret Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EGT 101","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Egret Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egret Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Egret Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EHP-101","moa":"PPA receptor-gamma","graph1":"Immunology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emerald Health Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EHP-101","moa":"PPA receptor-gamma","graph1":"Neurology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emerald Health Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Electra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ELA026","moa":"SIRP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Electra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Electra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Electra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elastrin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Elastrin Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elastrin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Elastrin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"University of Miami","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ University of Miami","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ University of Miami"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Brown University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Navtemadlin","moa":"MDM2","graph1":"Oncology","graph2":"Preclinical","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Brown University \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elecare","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"TPH","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Elezanumab","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-005","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ELI-005","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ELI-005","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ELI-005","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-004","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Elixirgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"TPG Capital IP","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Ellodi Pharmaceuticals \/ TPG Capital IP","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pharmaceuticals \/ TPG Capital IP"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eltanexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Collegium Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Collegium Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EM-036","moa":"NMDA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuMentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EuMentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Vicineum","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Albutrepenonacog Alpha","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enzolytics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ITV-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enzolytics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Enzolytics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enzolytics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"International Partnership for Microbicides \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berzosertib","moa":"ATR","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Emerald Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"9-delta-Tetrahydrocannabinol-valine-hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Emerald Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emerald Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Emerald Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Eclipse Bioinnovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RNA-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Eclipse Bioinnovations","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eclipse Bioinnovations \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Eclipse Bioinnovations \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cranbury Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cranbury Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cranbury Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cranbury Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"EmphyCorp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp \/ Inapplicable"},{"orgOrder":0,"company":"Vers\u00e9a Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Vers\u00e9a Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vers\u00e9a Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vers\u00e9a Health \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"EN-2642","moa":"EGFR-Fc","graph1":"Oncology","graph2":"Discovery","graph3":"Enosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enosi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Enosi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eagle Pharmaceuticals \/ Enalare Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Enalare Therapeutics"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enalare Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-721","moa":"RNA destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EDP-305","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-721","moa":"RNA destabilizer","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EDP-323","moa":"L-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ENB Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ENB003","moa":"||ETB receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ENB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ENB Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ENB Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ENB Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ENB003","moa":"||ETB receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ENB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ENB Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ENB Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rebastinib","moa":"||ABL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MT-8421","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FORCE-M23D","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Natera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Natera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Inapplicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ENOB-DC-11","moa":"Treg","graph1":"Oncology","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enochian BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ENOB-DC-11","moa":"Treg","graph1":"Oncology","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enochian BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Seraph Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ENOB-HV-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enochian BioSciences \/ Seraph Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Enochian BioSciences \/ Seraph Research Institute"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Third Pole Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Third Pole Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Third Pole Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Pole Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Techdow USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sagent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"Proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sagent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ CytRx Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ CytRx Corporation"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dova Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Dova Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dova Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dova Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"ENS-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Concerto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concerto Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Concerto Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Enterin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ENT-03","moa":"PTP1B","graph1":"Endocrinology","graph2":"Phase I","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Enterin \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enterin \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ETX0282","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrinsic bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"||Water","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Entrinsic bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Entrinsic bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Entrinsic bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Enterin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Squalamine phosphate","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enterin \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enterin \/ Inapplicable"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Covigenix VAX-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entos Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entos Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Covigenix VAX-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entos Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entos Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ENTR-601-45","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ENU200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ennaid Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ennaid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ennaid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Inapplicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Inapplicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Inapplicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Inapplicable"},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Taladegib","moa":"PTCH1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Endeavor Biomedicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Biomedicines \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Enkephalin","moa":"Delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EVM301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVM201","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Effik","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Progesterone","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pfizer CentreOne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer CentreOne \/ Effik","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer CentreOne \/ Effik"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ENX-101","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engrail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"ENX-102","moa":"GABA A Alpha 2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Engrail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ENX-104","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engrail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SK1-I","moa":"Sphingosine kinase 1","graph1":"Oncology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzo Biochem \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Biochem \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EO-3021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Scripps Research","sponsor":"IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS01B","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scripps Research \/ IAVI","highestDevelopmentStatusID":"6","companyTruncated":"Scripps Research \/ IAVI"},{"orgOrder":0,"company":"EOM Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"EOM613","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"EOM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"EOM Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EOM Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Belrestotug","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Belrestotug","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EOS-984","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Kelun-Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP0031","moa":"RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ellipses Pharma \/ Kelun-Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Kelun-Biotech"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EP0031","moa":"RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EP0031","moa":"RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT-3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT-3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epic Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPRX2","graph1":"Immunology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EP547","moa":"MRGPRX4","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escient Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nevakar","sponsor":"Endo International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nevakar \/ Endo International","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Endo International"},{"orgOrder":0,"company":"Nevakar","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Nevakar \/ Par Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Par Pharmaceutical"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EPI-321","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epic Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Greenwich Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lyophilized Human Placental-based Allograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Elpis Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"EPIM-001","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elpis Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpis Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elpis Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"EpiVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Personalized Cancer Vaccine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Nephrology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Nephrology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"IL-2\/9\/15","graph1":"Dermatology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"EQ101","moa":"IL-2\/IL-9\/IL-15","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"EQ101","moa":"IL-2\/IL-9\/IL-15","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"EQ102","moa":"IL-15\/21","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"EQ302","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-3490","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ERAS-801","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ERAS-801","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ErbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Pfizer Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||ErbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Pfizer Inc"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Aragon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals"},{"orgOrder":0,"company":"Sail Biomedicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Sail Biomedicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sail Biomedicines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sail Biomedicines \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ebola Zaire Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ebola Zaire Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"eTiraRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERX-41","moa":"LIPA","graph1":"Oncology","graph2":"Preclinical","graph3":"eTiraRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"eTiraRx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"eTiraRx \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"L-Asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asparagine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Erythromycin Lactobionate","moa":"Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Erythromycin Lactobionate","moa":"Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rosalind Franklin University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Rosalind Franklin University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rosalind Franklin University \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rosalind Franklin University \/ Inapplicable"},{"orgOrder":0,"company":"Escend Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ES-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Escend Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Escend Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Escend Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medolife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Caribbean Blue Scorpion Peptides Derived Extract","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medolife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medolife \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medolife \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Gel","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Estradiol","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Gel","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metsera \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zonisamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ET3","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Expression Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Expression Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Expression Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Etokimab","moa":"IL-33","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA A receptor alpha-4\/beta-2\/delta","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Elysium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"O2P Hydrocodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elysium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elysium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"ETX0462","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"ETX0462","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ETX101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Encoded Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Encoded Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ETX101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Encoded Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ETX101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Encoded Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Encoded Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-155","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-155","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETX-19477","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"858 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"858 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innoviva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"POP Biotechnologies","sponsor":"EuBiologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"POP Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"POP Biotechnologies \/ EuBiologics","highestDevelopmentStatusID":"10","companyTruncated":"POP Biotechnologies \/ EuBiologics"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Samsung Bioepis"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ONC212","moa":"GPR132","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncoceutics Inc \/ Inapplicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"EV68-228-N","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"KBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBio \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"KBio \/ National Institutes of Health"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"Th1\/2\/17","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"Th1\/2\/17","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Constellation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Constellation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Polymyxin","moa":"Bacterial membrane integrity","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Constellation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Constellation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"M041","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M6P Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EVM301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"EV-104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"EV\u014cQ Nano","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVQ-218","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"EV\u014cQ Nano","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EV\u014cQ Nano \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EV\u014cQ Nano \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||Serotonin\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||Serotonin\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||Serotonin\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||Serotonin\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||Serotonin\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||Serotonin\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSDB 4295","moa":"||Serotonin\/Norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EVX-301","moa":"SNRI","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Evecxia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"ExeGi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExeGi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Inapplicable"},{"orgOrder":0,"company":"ExeGi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExeGi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ExeGi \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ExeGi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExeGi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Exegenesis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EXG001-307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Exegenesis Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exegenesis Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exegenesis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Exegenesis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EXG102-031","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Exegenesis Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Exegenesis Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Exegenesis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Fujita Health University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Elixirgen Therapeutics \/ Fujita Health University","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Fujita Health University"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Elixirgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DB-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"FoundationOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mobocertinib Succinate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"FoundationOne","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"FoundationOne \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"FoundationOne \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DB-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DB-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DB-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Exo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Exo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CDK-002","moa":"STING","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"exoVACC","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"exoVACC","moa":"Immunostimulant","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Prolonged-release Suspension for Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension, Liposomal","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentivirus-Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Expression Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Expression Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Expression Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Extend Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Extend Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Extend Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Extend Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Fabre-Kramer Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gepirone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Fabre-Kramer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Fabre-Kramer Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fabre-Kramer Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EydisBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EYD-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"EydisBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EydisBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"EydisBio \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PPC Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Echinacea","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"PPC Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PPC Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PPC Group \/ Inapplicable"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"F230","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Gyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydronidone","moa":"TGF-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"F3-8-60","moa":"RAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Factor Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Factor Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Factor Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Factor Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iloperidone","moa":"D2\/5-HT2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iloperidone","moa":"D2\/5-HT2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MuSK-CAART","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"FB-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Federation Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Federation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"TLR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FBX-101","moa":"GALC gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FBX-101","moa":"GALC gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FBX-101","moa":"GALC gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FBX-101","moa":"GALC gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"ForCast Orthopedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FC001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ForCast Orthopedics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular","sponsorNew":"ForCast Orthopedics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ForCast Orthopedics \/ Inapplicable"},{"orgOrder":0,"company":"ForCast Orthopedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FC001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ForCast Orthopedics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular","sponsorNew":"ForCast Orthopedics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ForCast Orthopedics \/ Inapplicable"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menlo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX-1","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"MAPK2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Medefil","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Medefil","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medefil \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medefil \/ Inapplicable"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"IMAC Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IMAC Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IMAC Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IMAC Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TPST-1495","moa":"PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracystic Injection","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeurOp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NP10679","moa":"GluN2B","graph1":"Neurology","graph2":"Phase I","graph3":"NeurOp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeurOp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeurOp \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Nephrology","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AgenT-797","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TissueGene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Kolon TissueGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon TissueGene \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hope Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Nevakar Injectables","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"Cytochrome P450 3A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nevakar Injectables","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nevakar Injectables \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar Injectables \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"STI-6643","moa":"CD47","graph1":"Oncology","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The AIDS Clinical Trials Group \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"The AIDS Clinical Trials Group \/ Shionogi"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"C-CAR039","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-310","moa":"GLA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"ST101","moa":"||C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MB-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA A receptor alpha-4\/beta-2\/delta","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PRAX-114","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"CTI BioPharma Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onco360 \/ CTI BioPharma Corp","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ CTI BioPharma Corp"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AMAG Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Iodide","moa":"ROS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Faraday Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faraday Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Faraday Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Iodide","moa":"ROS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Faraday Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faraday Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Faraday Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Iodide","moa":"ROS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Faraday Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faraday Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Faraday Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fesomersen","moa":"Factor XI","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CTGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"CTGF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||CTGF","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||CTGF","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"CTGF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"CTGF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"FG-3165","moa":"Galectin-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FGF-1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Zhittya Genesis Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Infusion","sponsorNew":"Zhittya Genesis Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhittya Genesis Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"FHD-609","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"FHD-609","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FHD-909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FHD-909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||CTGF","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||FGFR2B","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Darunavir","moa":"||HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travere Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"FIN-524","moa":"Microbiome","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"Opioid mu receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntrix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Syntrix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRTX007","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Primmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"FRAXA Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Anavex Life Sciences \/ FRAXA Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Life Sciences \/ FRAXA Research Foundation"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||VEGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ONM-400","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PF-06863135","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FT-6876","moa":"CBP\/p300","graph1":"Oncology","graph2":"Preclinical","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALG-020572-401","moa":"TR-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Giredestrant","moa":"||Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"IL-15-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TREM-1","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pionyr Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYT-303","moa":"||GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ORN-101","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Orna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DNA Sciences Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Izana Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Namilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Izana Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Izana Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Izana Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"15","companyTruncated":"AffaMed Therapeutics \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AVB-500","moa":"||AXL\/GAS6 pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PRT1419","moa":"MCL1","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IL-1 receptor-associated kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Nykode Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Nykode Therapeutics"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ NantKwest"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alvocidib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cleave Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HPN217","moa":"CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Principia Biopharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Principia Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Principia Biopharma \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Principia Biopharma \/ Sanofi"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Natera","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Natera \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Natera \/ Genentech"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Metacrine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MET642","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metacrine \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PTX-35","moa":"TNFRSF25","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RP-L301","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Clovis Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ZN-D5","moa":"Bcl-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT516","moa":"CD20","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gimsilumab","moa":"GCSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Amikacin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||VE-PTP","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Entospletinib","moa":"||SYK","graph1":"Oncology","graph2":"Phase III","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Viela Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viela Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viela Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ALPN-30x","moa":"BAFF","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-501","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SynDevRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eribulin","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I","graph3":"SynDevRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynDevRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SynDevRx \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||CD28","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA2271","moa":"Mesothelin protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TerSera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TerSera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"E3 ligase engager","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vividion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vividion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"VEGFR\/PDGFR tyrosine kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncoQuest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoQuest \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest \/ Inapplicable"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Pennsylvania \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"University of Pennsylvania \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"XmAb564","moa":"IL-2 beta","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sentien Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sentien Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sentien Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sentien Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-1175","moa":"Sodium channel","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nocion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nocion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quadriga BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"QBS10072S","moa":"SLC7A5","graph1":"Oncology","graph2":"Phase I","graph3":"Quadriga BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quadriga BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quadriga BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGFR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Complexa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CXA-10","moa":"Nrf2","graph1":"Nephrology","graph2":"Phase II","graph3":"Complexa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complexa \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Humantakinogene Hadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Flexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Theragent","sponsor":"CellVax Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"FK-PC101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Theragent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Theragent \/ CellVax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Theragent \/ CellVax Therapeutics"},{"orgOrder":0,"company":"CellVax Therapeutics","sponsor":"Society of Urologic Oncology Clinical Trials Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"FK-PC101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CellVax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"CellVax Therapeutics \/ Society of Urologic Oncology Clinical Trials Consortium","highestDevelopmentStatusID":"8","companyTruncated":"CellVax Therapeutics \/ Society of Urologic Oncology Clinical Trials Consortium"},{"orgOrder":0,"company":"Flag Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FLAG-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Flag Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flag Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Flag Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Flag Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FLAG-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Flag Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flag Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Flag Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Flecainide","moa":"SCN5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InCarda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mifepristone","moa":"||Glucocorticoid\/progesterone receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mifepristone","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluphenazine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IH201","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluorometholone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension\/Drops","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"||JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"||JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"||JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosaprepitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"FogPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FOG-001","moa":"Beta catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FogPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FogPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"FogPharma \/ Inapplicable"},{"orgOrder":0,"company":"FogPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FOG-001","moa":"Beta catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FogPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FogPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"FogPharma \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATI-2173","moa":"||Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bizaxofusp","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-204","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"3B Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ 3B Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ 3B Pharmaceuticals"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johns Hopkins Center for Health Security","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Flu-v Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johns Hopkins Center for Health Security","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins Center for Health Security \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins Center for Health Security \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Aelis Farma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Indivior \/ Aelis Farma","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Aelis Farma"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Rgenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RGX-104","moa":"||Liver X receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rgenix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rgenix \/ Inapplicable"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"FOR46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plixorafenib","moa":"BRAF","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fore Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plixorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fore Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plixorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fore Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plixorafenib","moa":"BRAF","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fore Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plixorafenib","moa":"BRAF","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fore Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Aucta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"TLR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Ambio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ambio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ambio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ambio \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"||NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brigatinib","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mount Sinai School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simeprevir","moa":"||HCV proteases\/NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mount Sinai School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mount Sinai School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mount Sinai School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Linvemastat","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Linvemastat","moa":"MMP-12","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fervent Pharmaceuticals","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FP-101","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Fervent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fervent Pharmaceuticals \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Fervent Pharmaceuticals \/ IQVIA"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FPA157","moa":"CCR8","graph1":"Oncology","graph2":"Preclinical","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Five Prime Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Five Prime Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fractyl Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Spray-Dried Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Velico Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FT-001","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FT-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FT-003","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Field Trip Psychedelics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FT-104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Psychedelics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Field Trip Psychedelics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip Psychedelics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FT516","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FT516","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT536","moa":"CD16","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD16","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT819","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT819","moa":"||CAR19 T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT819","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6746","moa":"PPARG","graph1":"Oncology","graph2":"Preclinical","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Flare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abivertinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Brand Institute"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALG-010133","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Adrulipase Alpha","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FX-345","moa":"GSK-3","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Flare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Hematopoietic cell","graph1":"Hematology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv BioSciences"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kashiv BioSciences \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv BioSciences"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Brand Institute","highestDevelopmentStatusID":"15","companyTruncated":"Kashiv BioSciences \/ Brand Institute"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qnovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Inapplicable"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GAL-201","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galimedix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galimedix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Galidesivir","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Galidesivir","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"IQ-AI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Maltolate","moa":"RRM2","graph1":"Oncology","graph2":"Phase I","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medical College of Wisconsin \/ IQ-AI","highestDevelopmentStatusID":"6","companyTruncated":"Medical College of Wisconsin \/ IQ-AI"},{"orgOrder":0,"company":"Imaging Biometrics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Maltolate","moa":"RRM2","graph1":"Oncology","graph2":"Preclinical","graph3":"Imaging Biometrics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imaging Biometrics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Imaging Biometrics \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"9-Valent HPV Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HPV Quadrivalent Types 6, 11, 16, and 18 Vaccine Recombinant","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apimostinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gate Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Gavocabtagene Autoleucel","moa":"||Mesothelin protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Phase III","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Blueprint Medicines \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GB-401","moa":"ADRB","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant, Sustained Release","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GC4711","moa":"Dismutase","graph1":"Oncology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Galera Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GC4711","moa":"Dismutase","graph1":"Oncology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GC4711","moa":"||Dismutase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Celcuity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Inapplicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ad\/PNP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"GeoVax Labs \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeoVax Labs \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gel","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Hinge Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Hinge Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hinge Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Hinge Bio \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CStone Pharmaceuticals"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||CD4+ T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||CD4+ T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Medidata"},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Medidata"},{"orgOrder":0,"company":"GenVivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GVO-1102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GenVivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenVivo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GenVivo \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL-6-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Generation Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ii-Key Peptide Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generex Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Generex Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CTG","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4+ T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Generium JSC","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"KBI Biopharma \/ Generium JSC","highestDevelopmentStatusID":"15","companyTruncated":"KBI Biopharma \/ Generium JSC"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Oncoprex","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"GeneVentiv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GENV HEM","moa":"Factor Va","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GeneVentiv Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GeneVentiv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneVentiv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"GeoVax Labs \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"GeoVax Labs \/ Inapplicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GEO-CM02","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GeoVax Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeoVax Labs \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GFB-024","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Goldfinch Bio, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Goldfinch Bio, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Gatehouse Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"GHB1589M","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Gatehouse Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gatehouse Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gatehouse Bio \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GIGA-2050","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"GIGA-2339","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"GIGA-2339","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GIGA-2050","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GIM-407","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Georgiamune \/ Inapplicable"},{"orgOrder":0,"company":"Georgiamune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GIM-531","moa":"Treg","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Georgiamune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgiamune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Georgiamune \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Eversana"},{"orgOrder":0,"company":"IPS Heart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GIVI-MPC","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IPS Heart","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IPS Heart \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IPS Heart \/ Inapplicable"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GLB-COV2-043","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GreenLight Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GreenLight Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GreenLight Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Sialoglycan","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Avion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Avion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||Granulocyte-macrophage","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||Granulocyte-macrophage","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Glycologix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"GLX-100","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Glycologix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycologix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycologix \/ Inapplicable"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"GLY-200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glyscend Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"GLY-200","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glyscend Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"GLY-200","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glyscend Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GM-1020","moa":"NMDAR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilgamesh Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GM-1020","moa":"NMDAR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilgamesh Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoMimetics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"PKX-001","moa":"COX-2 expression","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProtoKinetix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GNOS-PV02","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genascence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Genascence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Inapplicable"},{"orgOrder":0,"company":"Genascence","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Genascence \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GFB-024","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Goldfinch Bio, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Goldfinch Bio, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB004","moa":"HIF-1-alpha","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gosuranemab","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GP2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Misetionamide","moa":"||LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Panavance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Misetionamide","moa":"||LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Panavance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Misetionamide","moa":"||LPS","graph1":"Oncology","graph2":"Preclinical","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Panavance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Panavance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GPH102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GPX-002","moa":"Pdx1\/Mafa gene","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Grace Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Grace Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Science \/ Inapplicable"},{"orgOrder":0,"company":"Gradalis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"GRAD1405","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gradalis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gradalis \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C901","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0101","moa":"CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Itacitinib","moa":"||JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Greffex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Greffex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Greffex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Greffex \/ Inapplicable"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Inapplicable"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Inapplicable"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Inapplicable"},{"orgOrder":0,"company":"GRI Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Human iNKT cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"GRI Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Griseofulvin","moa":"CTPS1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gritstone bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone bio \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Greenfire Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GRN-300","moa":"||SIK2\/SIK3","graph1":"Oncology","graph2":"Phase I","graph3":"Greenfire Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Greenfire Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Greenfire Bio \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GRT-R910","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Grace Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Grace Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Science \/ Inapplicable"},{"orgOrder":0,"company":"Grace Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Grace Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Science \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Pharmacyclics"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Entospletinib","moa":"||SYK","graph1":"Oncology","graph2":"Phase III","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE705","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NY-ESO-1","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ GSK"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT-00513","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GT103","moa":"||CFH","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GT90001","moa":"||Angiogenesis","graph1":"Oncology","graph2":"Phase II","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GTB-3550 TriKE","moa":"CD16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GTB-5550","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GTB-5550","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GTB-7550","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GTP-506A","moa":"||PCSK9","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GTP-506A","moa":"||PCSK9","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"Modular Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Modular Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modular Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Modular Medical \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"GV20-0251","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GV20 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GV20 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nicardipine Hydrochloride","moa":"||L-Type VGCC","graph1":"Dermatology","graph2":"Phase I","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Petros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Petros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hybrid Medical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicardipine Hydrochloride","moa":"||L-Type VGCC","graph1":"Dermatology","graph2":"Phase I","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Petros Pharmaceuticals \/ Hybrid Medical","highestDevelopmentStatusID":"6","companyTruncated":"Petros Pharmaceuticals \/ Hybrid Medical"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"H1ssF-3928 mRNA-LNP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ NantKwest"},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Organon \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Samsung Bioepis"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Tri-Ax","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halberd Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Halberd Corporation \/ Inapplicable"},{"orgOrder":0,"company":"AT Research Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Halogenated Fullerene Nanoparticle","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"AT Research Partners","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AT Research Partners \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AT Research Partners \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Halobetasol","moa":"||Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Galveston National Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Galveston National Laboratory","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Galveston National Laboratory"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HB-200","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-200","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HB-200","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-300","moa":"PAP\/PSA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GS-6779","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HB-500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HB-500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HB-700","moa":"KRAS G12D","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Neurology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7H7","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7H7","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Porustobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HBM9033","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HBM9167","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SKB378","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HC-5404","moa":"PERK","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"hC Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HCB-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"hC Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"hC Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"hC Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Gennova Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Gennova Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Gennova Biopharmaceuticals"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Ftase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Cambridge Biomedical Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cambridge Biomedical Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cambridge Biomedical Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cambridge Biomedical Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Hematology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HS-130","moa":"||T-cell mediated immune response","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HemaXellerate","moa":"Undisclosed","graph1":"Hematology","graph2":"IND Enabling","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regen BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Regen BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HST5040","moa":"CoA","graph1":"Neurology","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"HemoShear Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dynavax Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dynavax Technologies \/ Inapplicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HepTcell","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HepTcell","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"HER2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Accord BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Petrolatum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Turn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Turn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HexaPro","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Vaxxas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HexaPro","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Patch","sponsorNew":"Vaxxas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HFB200301","moa":"||TNFR2","graph1":"Oncology","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HFB200603","moa":"||BLTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Inapplicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HIB210","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HI-Bio \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HFB301001","moa":"OX40 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"DiscGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"P-BCMA-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"HilleVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HilleVax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Inapplicable"},{"orgOrder":0,"company":"HilleVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HilleVax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Inapplicable"},{"orgOrder":0,"company":"HilleVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HilleVax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Inapplicable"},{"orgOrder":0,"company":"HilleVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HilleVax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Inapplicable"},{"orgOrder":0,"company":"Thrombolytic Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mutant Pro-Urokinase","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Thrombolytic Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thrombolytic Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Thrombolytic Science \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"HST-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Immune Globulin G","moa":"Neutralizing IgG\/Opsonins","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sermonix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sermonix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hummingbird Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbird Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HMBD-001","moa":"HER3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbird Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HMBD-002","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbird Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-102","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HMI-203","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SRI International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HOPO 14-1","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SRI International \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SRI International \/ Inapplicable"},{"orgOrder":0,"company":"University of Maryland School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Maryland School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Maryland School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HT-003","moa":"TLR2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Isoprene Pharmaceuticals"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HPN217","moa":"CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HPN217","moa":"CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HPN328","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HPN328","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HPN424","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HPN601","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HPN601","moa":"EpCAM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HPP737","moa":"PDE4","graph1":"Dermatology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HPP737","moa":"PDE4","graph1":"Dermatology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Sage Chemical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Sage Chemical","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Sage Chemical"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salinomycin","moa":"Ferroptosis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HSB-510","moa":"HDAC6\/PI3K-delta","graph1":"Oncology","graph2":"Preclinical","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HSB-510","moa":"HDAC6\/PI3K-delta","graph1":"Oncology","graph2":"Preclinical","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hillstream BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||CBL-B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HST-1011","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-4253","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-4253","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-6184","moa":"NEK7","graph1":"Oncology","graph2":"Phase II","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-6184","moa":"NEK7","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HT-6184","moa":"NEK7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HT-6184","moa":"NEK7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"KIT","graph1":"Hematology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HT-KIT","moa":"KIT","graph1":"Hematology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HT-KIT","moa":"KIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Endocrinology","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Signature Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Signature Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signature Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Signature Biologics \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MAN-19","moa":"Tie2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Clinigen Group"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||GCSF","graph1":"Oncology","graph2":"Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"huMNC2-CAR22","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Minerva Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Minerva Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Minerva Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BG505 MD39.3 mRNA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Anika Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Inapplicable"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Eisai"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA damage","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IAB56","moa":"Alpha-V beta 6 integrin","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImaginAb \/ Inapplicable"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IAM1363","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iambic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Iambic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAVI","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"rVSV\u2206G-SEBOV-GP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"iBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"iBio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ AmbioPharm"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IconOVir Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"ICVB-1042","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IconOVir Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"IconOVir Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IconOVir Bio \/ Inapplicable"},{"orgOrder":0,"company":"The Access to Advanced Health Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GLA-SE","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"The Access to Advanced Health Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Access to Advanced Health Institute \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"The Access to Advanced Health Institute \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE034","moa":"B7H3\/PTK7","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Darovasertib","moa":"PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darovasertib","moa":"PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE251","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE397","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darovasertib","moa":"PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Abbvie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||Isocitrate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Celgene Corporation \/ Abbvie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Abbvie Inc"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Celanese","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Celanese","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Celanese"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50s ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ortho Dermatologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Inapplicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||50s ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"IDRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Inapplicable"},{"orgOrder":0,"company":"IDRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Inapplicable"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PLX-300","moa":"TFEB","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Delpor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delpor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delpor \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fedratinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ MorphoSys"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"International Centre for Diarrhoeal Disease Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"International Centre for Diarrhoeal Disease Research \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"International Centre for Diarrhoeal Disease Research \/ Bharat Biotech"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ifetroban","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TPr","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IG-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intergalactic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Intergalactic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intergalactic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IGC-1A","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IGC-501","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20\/CD3","graph1":"Immunology","graph2":"IND Enabling","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD3\/20","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IGM-7354","moa":"IL-15\/IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IgGenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IGNX001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IgGenix \/ Inapplicable"},{"orgOrder":0,"company":"IgGenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IGNX001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IgGenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IgGenix \/ Inapplicable"},{"orgOrder":0,"company":"Ingenia Therapeutics","sponsor":"Mosaic Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IGT-427","moa":"VEGF","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ingenia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ingenia Therapeutics \/ Mosaic Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Ingenia Therapeutics \/ Mosaic Biosciences"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-175","moa":"||AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IK-175","moa":"||AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-595","moa":"MEK-RAF complex","graph1":"Oncology","graph2":"Preclinical","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"||TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IkT-148x","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Preclinical","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Illuminare Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Illuminare-1","moa":"Myelin","graph1":"Oncology","graph2":"Phase I","graph3":"Illuminare Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Illuminare Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Illuminare Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"SIFI","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ SIFI","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ SIFI"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IM156","moa":"||Protein complex 1","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoMet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMet \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IM156","moa":"Protein complex 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoMet \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoMet \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IM-3050","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8 alpha beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Imbria Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sunobinop","moa":"Nociceptin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMB-150","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMC-001","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralymphatic","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valacyclovir","moa":"||DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ChAdOx1-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbutus Biopharma \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Immunology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMG-008","moa":"IL-36","graph1":"Immunology","graph2":"IND Enabling","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Affibody","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Affibody"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Affibody","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Affibody"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Inapplicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunis \/ Inapplicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"||MEK receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"||MEK receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Boston University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-BCP-01","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Boston University","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Boston University"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMM20324","moa":"IL-38","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IMM-6-415","moa":"Dual MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMM-6-415","moa":"Dual MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM-6-415","moa":"Dual MEK","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Fox Chase Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Fox Chase Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Fox Chase Cancer Center"},{"orgOrder":0,"company":"Immunis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"iqDNA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Generation Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytRx Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Scancell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Scancell","highestDevelopmentStatusID":"8","companyTruncated":"PharmaJet \/ Scancell"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ITI-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Break Through Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Break Through Cancer","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Break Through Cancer"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"IMNN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"IMNN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"IMNN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"IMNN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CDX-1140","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Celldex Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Celldex Therapeutics"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmPACT Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Inapplicable"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMPT-314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmPACT Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bio \/ Inapplicable"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMPT-514","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmPACT Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmPACT Bio \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmuneSensor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmuneSensor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMSB301","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneSensor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IMS001","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunitas Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunitas Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMU-935","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD20\/CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMVT-1402","moa":"FcRn","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||STAT3\/NF-kB\/poly-tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||STAT3\/NF-kB\/poly-tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||STAT3\/NF-kB\/poly-tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ BeiGene"},{"orgOrder":0,"company":"Okogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"OKG-0301","moa":"Protein synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Okogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Okogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Okogen \/ Inapplicable"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atoltivimab","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Darigabat","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wake Forest Institute for Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Factor VIII transgene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wake Forest Institute for Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest Institute for Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wake Forest Institute for Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Creighton University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"BRAF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Creighton University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creighton University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Creighton University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APL-9","moa":"C3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tomivosertib","moa":"||MAPK 1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"GLP-1 ant","graph1":"Endocrinology","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Children's Hospital of Philadelphia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||BRAF","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"SNAP-25","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Epicardial Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EpiVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EPV-CoV-19","moa":"SARS-CoV-2 viral spike N-terminal","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mivavotinib","moa":"SYK","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tobevibart","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"StemVacs","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ ClearPoint Neuro"},{"orgOrder":0,"company":"Tsai Laboratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NFX-179","moa":"MEK receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Tsai Laboratory","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Tsai Laboratory \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tsai Laboratory \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VRG101","moa":"PIKfyve kinase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COVI-AMG","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Flugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Influenza Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Flugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Sollievo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Avizafone","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sollievo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sollievo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sollievo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"VEGFR\/PDGFR tyrosine kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AJ1-10502","moa":"JAK2","graph1":"Oncology","graph2":"Preclinical","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ajax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"iNexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Xequel Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Tick-Borne Encephalitis Vaccine","moa":"Immunomodulator","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Arcus Biosciences"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kannalife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KLS-13019","moa":"mNCX-1","graph1":"Neurology","graph2":"Phase I","graph3":"Kannalife","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kannalife \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kannalife \/ Inapplicable"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Acura Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Favezelimab","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Veloce BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Povidone-Iodine","moa":"Inflammatory mediator","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veloce BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Veloce BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Veloce BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Genmab"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-202","moa":"LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"Eosinophil maturation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Knopp Biosciences LLC \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Inapplicable"},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PTI-129","moa":"CFTR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteostasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Proteostasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Adlai Nortye","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Adlai Nortye","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Adlai Nortye"},{"orgOrder":0,"company":"RootPath","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"InfiniTIL","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RootPath","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RootPath \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RootPath \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-Based Flu Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Pennsylvania \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Pennsylvania \/ Inapplicable"},{"orgOrder":0,"company":"APIE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"APIE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"APIE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"APIE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Eryaspase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IVX-A12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"University of Heidelberg","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ University of Heidelberg","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ University of Heidelberg"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO53","moa":"Exon 53","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3K-delta","graph1":"Hematology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emtora Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BIIB078","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-810","moa":"PPA receptor-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-810","moa":"PPA receptor-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"177-Lu PNT2004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pinnacle Clinical Research","sponsor":"CymaBay Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Pinnacle Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pinnacle Clinical Research \/ CymaBay Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pinnacle Clinical Research \/ CymaBay Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IMGN151","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TK216","moa":"E26 transformation-specific oncoproteins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DT2216","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dialectic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxess","sponsor":"GC Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VX-103","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxess","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Microneedle Patch, Controlled Release","sponsorNew":"Vaxess \/ GC Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Vaxess \/ GC Pharma"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM707","moa":"||ILT2\/4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"AC0682","moa":"Estrogen-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Dermatology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ASKG712","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffaMed Therapeutics \/ AskGene Pharma Inc","highestDevelopmentStatusID":"6","companyTruncated":"AffaMed Therapeutics \/ AskGene Pharma Inc"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"AP-SA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Preclinical","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFT1946","moa":"BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DynamiCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DCBY02","moa":"CD93","graph1":"Oncology","graph2":"Phase I","graph3":"DynamiCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DynamiCure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"DynamiCure \/ Inapplicable"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FMC-376","moa":"GTP-bound","graph1":"Oncology","graph2":"IND Enabling","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontier Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Frontier Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"hAd5-S-Fusion+N-ETSD","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"IconOVir Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ICVB-1042","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IconOVir Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"IconOVir Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IconOVir Bio \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"ABL kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMU-935","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"REGN3048","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2A","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Defensin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salicyn-30","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG260","moa":"||CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SyneuRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentarlandir","moa":"TMPRSS2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SyneuRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SyneuRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SyneuRx \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COVI-AMG","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"XTX202","moa":"Tumor selective IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM-1-104","moa":"||MEK receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"ThinkEquity","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ ThinkEquity"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bile Salts","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STI-1558","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bavdegalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Campbell Neurosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Campbell Neurosciences","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Campbell Neurosciences"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"George Mason University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ George Mason University","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ George Mason University"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Loxo-305","moa":"BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Ipsen"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Lyophilized Human C1-esterase","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0203","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SHP099","moa":"SHP2","graph1":"Oncology","graph2":"Preclinical","graph3":"NYU Langone","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NYU Langone \/ Inapplicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"UCI Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"UCI Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCI Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"UCI Health \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"||JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Eisai"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapllicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapllicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapllicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"APOEII\/III","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"University of Maryland","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silo Pharma \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ University of Maryland"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mannitol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"CHIESI USA INC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CHIESI USA INC \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adaptive Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adaptive Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ National Institutes of Health"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Oppilan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OPL-002","moa":"S1P1R","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oppilan Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Oppilan Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oppilan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Reata Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Reata Pharmaceuticals"},{"orgOrder":0,"company":"Walter Reed Army Institute of Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MZ4","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Walter Reed Army Institute of Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walter Reed Army Institute of Research \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Walter Reed Army Institute of Research \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trovagene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Inapplicable"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GRF6021","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkahest \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Grifols International"},{"orgOrder":0,"company":"Biomarck Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"BIO-11006","moa":"MARCKS protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biomarck Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Biomarck Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomarck Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ITI-1001","moa":"pp65","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"WVE-120102","moa":"SNP3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Cyanvac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PIV5-SARS CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cyanvac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Cyanvac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyanvac \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Oncology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Kevetrin","moa":"p53 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Factor IX\/X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"4-Ethylphenol Sulfate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBFT02","moa":"AAV1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NDC80","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eureka Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Eureka Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fesomersen","moa":"Factor XI","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 DNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Aviv Clinics","sponsor":"Sagol Center for Hyperbaric Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Aviv Clinics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aviv Clinics \/ Sagol Center for Hyperbaric Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Aviv Clinics \/ Sagol Center for Hyperbaric Medicine"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-478","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zelicapavir","moa":"N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Transmucosal Patch","sponsorNew":"AFYX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BGE-117","moa":"HIF-PH","graph1":"Hematology","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"SHP2","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Hydrolytic enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BTG Specialty Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Garadacimab","moa":"Factor XIIa","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD20","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ITI214","moa":"PDE1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"CV Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"CV Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CV Science \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"||SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Immunology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brequinar","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clear Creek Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clear Creek Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clear Creek Bio \/ Inapplicable"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MDNA223","moa":"IL-2-beta receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","graph1":"Oncology","graph2":"Preclinical","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AMG 594","moa":"Cardiac troponin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Preclinical","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Uzatresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TXR-611","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"twoXAR Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TATX-03","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhalon Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IN-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inhalon Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Inhalon Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhalon Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-100","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"||TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Alabama at Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-200","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Infusion","sponsorNew":"IN8bio \/ University of Alabama at Birmingham","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ University of Alabama at Birmingham"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-300","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-300","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INB-400","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INB-400","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-400","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acorda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"INBRX-109","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Genialis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Genialis","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Genialis"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"INCAGN01876","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INCB000262","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3K-delta","graph1":"Hematology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INCB123667","moa":"CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Merus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Merus","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Merus"},{"orgOrder":0,"company":"NexImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NEXI-003","moa":"CD3\/4","graph1":"Oncology","graph2":"IND Enabling","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NexImmune \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NexImmune \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TATX-03","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ National Institutes of Health"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1096","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Hetero","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Hetero","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Hetero"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Indomethacin","moa":"COX-1\/COX-2","graph1":"Immunology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Rectal Suppository","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INDV-2000","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Infinant Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"INF108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Infinant Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinant Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Infinant Health \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"I27-Breg","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Eye Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"National Eye Institute \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"IL-38","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Inimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INI-2004","moa":"TLR4","graph1":"Immunology","graph2":"Phase I","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Inimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inimmune \/ Inapplicable"},{"orgOrder":0,"company":"Inimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INI-2004","moa":"TLR4","graph1":"Immunology","graph2":"Phase I","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Inimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inimmune \/ Inapplicable"},{"orgOrder":0,"company":"Inipharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INI-822","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Inipharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inipharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inipharm \/ Inapplicable"},{"orgOrder":0,"company":"Inipharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INI-822","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Inipharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inipharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inipharm \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HT-003","moa":"TLR2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"National Human Genome Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ National Human Genome Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ National Human Genome Research Institute"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Belrestotug","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-105","moa":"PSCA","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AGEN1571","moa":"||ILT2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Caring Cross","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||duoCAR T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Caring Cross","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caring Cross \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"Caring Cross \/ University of California"},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Lucius Partners","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VTX-067","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voltron Therapeutics \/ Lucius Partners","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Therapeutics \/ Lucius Partners"},{"orgOrder":0,"company":"Izana Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Namilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Izana Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Izana Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Izana Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atoltivimab","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LadRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"LadRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LadRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LadRx \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"PhotonPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Autologous Cellular-Based Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PhotonPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PhotonPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PhotonPharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Generation Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Innoviva \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Innoviva \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"INO-4201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"INO-4500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Biocon"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Decitabine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Astex Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fedratinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Palmitil","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INSTI - ULA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Exavir Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Exavir Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Exavir Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Embecta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Embecta","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embecta \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Embecta \/ Inapplicable"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INT2104","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Interius BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INT2104","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Intrommune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Intrommune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Intrommune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Intrommune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Intrommune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Intrommune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INT-787","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INT-787","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 RVPs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Integral Molecular \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eptifibatide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Preclinical","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ BARDA"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"C1q","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"resTORbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dactolisib","moa":"TORC1","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"resTORbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"resTORbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"resTORbio \/ Inapplicable"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ansun Biopharm \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ansun Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"C1q","graph1":"Hematology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"E26 transformation-specific oncoproteins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-200","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"Sodium\/bile acid cotransporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Oncologie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bavituximab","moa":"||Phosphatidylserine","graph1":"Oncology","graph2":"Phase II","graph3":"Oncologie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncologie \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Preclinical","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||Immunogenic apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Provectus Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Invenra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"INV322","moa":"CTLA-4\/CD25","graph1":"Oncology","graph2":"Preclinical","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invenra \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Invenra \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"DAAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nagourney Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Nagourney Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nagourney Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nagourney Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"TissueTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Membrane","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"TissueTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"TissueTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TissueTech \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"PhageBank","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INX-315","moa":"CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyclix Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Inapplicable"},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INX-315","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyclix Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix Bio \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INZ-701","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"IO Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"IO102-IO103","moa":"||IDO1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ IO Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ IO Biotech"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-106","moa":"LAIR-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-108","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-108","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IO-202","moa":"LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ION224","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION363","moa":"FUS","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ION363","moa":"FUS","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"IONIS-FB-LRx","moa":"Complement factor B","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"IONIS-FB-LRx","moa":"Complement factor B","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novo Integrated Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iodine","moa":"Immunostimulant","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Integrated Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Novo Integrated Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Integrated Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"Adrenergic receptor-alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||TIL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Cellectis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IOV-4001","moa":"TIL","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iovance Biotherapeutics \/ Cellectis","highestDevelopmentStatusID":"5","companyTruncated":"Iovance Biotherapeutics \/ Cellectis"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lifileucel","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TATX-03","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Theradex Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Theradex Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Theradex Oncology"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Infinity Pharmaceuticals \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ MEI Pharma"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn ImmunoTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"APOC-III","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"APOC-III","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CM4620-IE","moa":"CRAC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isoproterenol HCl","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"IPS Heart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ISX9-CPC","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"IPS Heart","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IPS Heart \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IPS Heart \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Sumitomo Dainippon Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KSP-1007","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitovant Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitovant Biopharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sumitovant Biopharma \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COH04S1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"LBP-EC01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intraurethral Infusion","sponsorNew":"Locus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Locus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Brain Trust Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Riluzole","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"IND Enabling","graph3":"Brain Trust Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Brain Trust Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Brain Trust Bio \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"ExeGi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Hydroxchloroquine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeGi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ExeGi \/ Inapplicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ITI-1000","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ITI-1001","moa":"pp65","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ITI-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ITI-3000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ITIL-168","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ITIL-168","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ITIL-168","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ITIL-306","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"iTOL-100","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iTolerance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Inapplicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Inapplicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"iTOL-101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iTolerance \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Inapplicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"VISTA","moa":"Checkpoint","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Choline Chloride","moa":"Alpha 7-nAChR","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VCAP-102","moa":"SOD1","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Zydus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"The American College of Medical Toxicology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The American College of Medical Toxicology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The American College of Medical Toxicology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The American College of Medical Toxicology \/ Inapplicable"},{"orgOrder":0,"company":"iVeena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copper Sulphate Pentahydrate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"iVeena \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ivonescimab","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inventprise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"25-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inventprise","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inventprise \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inventprise \/ Inapplicable"},{"orgOrder":0,"company":"Inventprise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"25-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inventprise","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inventprise \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inventprise \/ Inapplicable"},{"orgOrder":0,"company":"Innova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IVT-8086","moa":"SFRP2","graph1":"Oncology","graph2":"Preclinical","graph3":"Innova Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"iView Therapeutics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iView Therapeutics Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iView Therapeutics Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iView Therapeutics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IVX-A12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"IVX-241","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"IVX-241","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"IVX-241","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"IVX-241","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"IVX-A12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ AstraZeneca"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"IVX-A12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IVX-241","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IW-3300","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase I","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"US WorldMeds \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Inapplicable"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"ODC","graph1":"Oncology","graph2":"Approved FDF","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"US WorldMeds \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"US WorldMeds \/ Inapplicable"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Thea Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thea Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Thea Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thea Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Thea Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Thea Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thea Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Astellas Pharma"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Aucta Pharmaceuticals \/ Oakrum Pharma, LLC","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Oakrum Pharma, LLC"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Biorasi"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Neurology","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Neurology","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darunavir","moa":"||HIV protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.ZEBOV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JANX008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"JANX008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Clarus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Jaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JB111","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Jaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Jaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-1044","moa":"PADI4","graph1":"Oncology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-2174","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-589","moa":"PAD4","graph1":"Immunology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"Immorna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"JCXH-105","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immorna \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immorna \/ Inapplicable"},{"orgOrder":0,"company":"Immorna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JCXH-211","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immorna","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immorna \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immorna \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JK06","moa":"5T4 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salubris Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salubris Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JKB-122","moa":"TLR4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Immune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JKB-122","moa":"TLR4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Immune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mosnodenvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mosnodenvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"JNJ-3989","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"JNJ-3989","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"JNJ-3989","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Milvexian","moa":"FXIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lazertinib","moa":"||EGFR mutant-selective","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"JNJ-75220795","moa":"PNPLA3","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PANTHERx Rare Pharmacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"||TYRO3","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"||CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Briquilimab","moa":"||CD117","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Briquilimab","moa":"||CD117","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Titan Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pimivalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"JTX-8064","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Aurohealth","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aurohealth","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Aurohealth \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aurohealth \/ Aurobindo Pharma Limited"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Neurology","graph2":"IND Enabling","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Juvena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Juvena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Safety Shot \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Safety Shot \/ Inapplicable"},{"orgOrder":0,"company":"Kallyope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"||Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kallyope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Inapplicable"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"PPA receptor-alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Pharmaceuticals America \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"KTH-222","moa":"MAPK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Karuna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PureTech Health \/ Karuna Therapeutics"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KayoThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KAYO-1609","moa":"Retinoid pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"KayoThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KayoThera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"KayoThera \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"K\u00fcleon Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB-128","moa":"5-HT1A\/2A\/2B receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"K\u00fcleon Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"K\u00fcleon Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"K\u00fcleon Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Jeune Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Jeune Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jeune Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jeune Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Jeune Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Jeune Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Jeune Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jeune Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KB-7898","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KB-9558","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KBP Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KBP-7072","moa":"Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"KBP Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KBP Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"PEGASUS LABORATORIES INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Potassium Bromide","moa":"Adenosine kinase","graph1":"Neurology","graph2":"Approved FDF","graph3":"PEGASUS LABORATORIES INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"PEGASUS LABORATORIES INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PEGASUS LABORATORIES INC \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine\/norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cangrelor","moa":"P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CHIESI USA INC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CHIESI USA INC \/ Inapplicable"},{"orgOrder":0,"company":"Kentucky BioProcessing","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"KBP-COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kentucky BioProcessing","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kentucky BioProcessing \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kentucky BioProcessing \/ Inapplicable"},{"orgOrder":0,"company":"Sotira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"KEPTIDE COVID","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sotira","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Sotira \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotira \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Hematology","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"KER-065","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RKER-012","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Psycheceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ Inapplicable"},{"orgOrder":0,"company":"ERP Biomarker Qualification Consortium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase I","graph3":"ERP Biomarker Qualification Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ERP Biomarker Qualification Consortium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ERP Biomarker Qualification Consortium \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Frontage Laboratories, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Pfizer Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Seagen","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Seagen"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenvatinib Mesylate","moa":"||VEGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Japan Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Japan Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Japan Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"PanTheryx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution\/Drops","sponsorNew":"PanTheryx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PanTheryx \/ Inapplicable"},{"orgOrder":0,"company":"Kimera Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell-Derived Exosome","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Kimera Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kimera Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kimera Labs \/ Inapplicable"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Oritavancin","moa":"Peptidoglycan precursor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Melinta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Tempus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN004","moa":"CDK12","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinnate Biopharma \/ Tempus","highestDevelopmentStatusID":"5","companyTruncated":"Kinnate Biopharma \/ Tempus"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnjiu Biopharma","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnjiu Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnjiu Biopharma \/ Kinnate Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Kinnjiu Biopharma \/ Kinnate Biopharma"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR2 & FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR2 & FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR2 & FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR2 & FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR2 & FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR2 & FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinderfarms","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor 1A","graph1":"Sleep","graph2":"Approved FDF","graph3":"Kinderfarms","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinderfarms \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kinderfarms \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KVA12.1","moa":"||VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin M beta receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PP-001","moa":"DHODH","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Polystyrene Sulfonate","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PD-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Almirall"},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KME-0584","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kurome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kurome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kurome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Frevecitinib","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kinaset Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinaset Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinaset Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Alphamab Oncology"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB-3061","moa":"KV7.2\/7.3 potassium channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Knopp Biosciences LLC \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Knopp Biosciences LLC \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"Eosinophil maturation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Knopp Biosciences LLC \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KO-2806","moa":"Farnesyl transferase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MLL-KMT2A\/MLL","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||Menin","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ AstraZeneca"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||Menin","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||Menin","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"||Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole","moa":"||K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Brand Institute \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ Azurity Pharma"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole","moa":"||K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Glucocorticoid\/progesterone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Glucocorticoid\/progesterone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Glucocorticoid\/progesterone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"CSL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcturus Therapeutics \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ CSL"},{"orgOrder":0,"company":"MidAmerica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"MidAmerica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"MidAmerica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MidAmerica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"IND Enabling","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"IND Enabling","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KP1237","moa":"||CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine\/norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KPC34","moa":"PKC","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkido Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkido Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alkido Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abiprubart","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abiprubart","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CCM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"CCM Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CCM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"CCM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Qiagen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Qiagen","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Qiagen"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KRM-II-81","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"National Institutes on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KRM-II-81","moa":"GABA-A receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ National Institutes on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ National Institutes on Drug Abuse"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KRM-II-81","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KROS-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"KSI-501","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KSQ-001EX","moa":"SOCS1 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||SOCS1 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KSQ-004EX","moa":"SOCS1 gene","graph1":"Oncology","graph2":"IND Enabling","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KSQ-4279","moa":"||USP-1","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KSQ-4279","moa":"||USP-1","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KT-253","moa":"MDM2","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-253","moa":"||MDM2","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-333","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-333","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KT-333","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-333","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-413","moa":"IRAKIMiD","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Koligo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KT-PC-301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Koligo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Koligo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Koligo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"K36 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KTX-1001","moa":"Methyltransferase","graph1":"Oncology","graph2":"Phase I","graph3":"K36 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"K36 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"K36 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kuria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KTX-1161","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kuria Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kuria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kuria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kuur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Kurome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kurome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kurome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD27","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KVA12123","moa":"VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vogenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mizagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Vogenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Vogenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vogenx \/ Inapplicable"},{"orgOrder":0,"company":"Vogenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mizagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Vogenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Vogenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vogenx \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"KYORIN PHARMACEUTICAL CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ KYORIN PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ KYORIN PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Neurology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Neurology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Kezar Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Everest Medicines \/ Kezar Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Kezar Life Sciences"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Hematology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Osel Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Lactin-V","moa":"Hydrogen peroxide","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osel Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Osel Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osel Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"||SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"||SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"CellTrans","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Donislecel","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"CellTrans","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"CellTrans \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CellTrans \/ Inapplicable"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Rebiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"NKCC2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LASN01","moa":"IL-11-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lassen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lassen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ University of Minnesota","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ University of Minnesota"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Newsoara Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Newsoara Biopharma"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Newsoara Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Newsoara Biopharma"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LB1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB1908","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bivamelagon","moa":"MC4R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"LBP-EC01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intraurethral Infusion","sponsorNew":"Locus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Locus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"LBP-EC01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intraurethral Infusion","sponsorNew":"Locus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Locus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Celmatix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celmatix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT-02329","moa":"GCase level","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Second Genome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SG-5-00455","moa":"PAI-1\/PAI-2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Second Genome \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Second Genome \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"L.E.A.F. Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gamma L-Pentaglutamated Pemetrexed","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Preclinical","graph3":"L.E.A.F. Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"L.E.A.F. Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"L.E.A.F. Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"||IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||GCSF","graph1":"Oncology","graph2":"Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Tregs migration","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levocarnitine","moa":"Carnitine acetyl","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Norepinephrine Bitartrate","moa":"||Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Orion Corporation"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LX1004","moa":"TPP1","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"TPH","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LHF-535","moa":"Virus replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Kineta \/ Wellcome Trust","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Wellcome Trust"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LHP588","moa":"Gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lighthouse Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LHP588","moa":"Gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lighthouse Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LIB Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LIB Therapeutics \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Eiger BioPharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Interferon-alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ligandal","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Peptide-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ligandal","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligandal \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ligandal \/ Inapplicable"},{"orgOrder":0,"company":"Kesin Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kesin Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Kesin Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kesin Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medicines360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Medicines360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intrauterine Insert","sponsorNew":"Medicines360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medicines360 \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linsitinib","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sling Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Quolet Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quolet Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quolet Industries \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quolet Industries \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"SignPath Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Curcumin","moa":"PPA receptor-gamma","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SignPath Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SignPath Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SignPath Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Liquidia Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Liquidia Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"TRV027","moa":"AT1 receptor selective","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Livoletide","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Millendo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Millendo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LMN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lumen Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumen Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lifileucel","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lifileucel","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LN-145","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LN-145","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LNC-Docetaxel","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Lanier Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LNR 125","moa":"IL-25","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lanier Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lanier Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lanier Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lanier Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LNR 125","moa":"IL-25","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lanier Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lanier Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lanier Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Preclinical","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Linnaeus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LENZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LENZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LENZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"||Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"LENZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PH-894","moa":"Bromodomain-containing protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AGEPHA Pharma US","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AGEPHA Pharma US","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AGEPHA Pharma US \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AGEPHA Pharma US \/ Inapplicable"},{"orgOrder":0,"company":"Loki Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AWAKE-LM-TT","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Loki Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loki Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Loki Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bluebird Bio","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Bluebird Bio"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"JNJ-4528","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lomond Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lomond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lomond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Trifluridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"Akorn Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akorn Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Techdow USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Techdow USA \/ Inapplicable"},{"orgOrder":0,"company":"Alpheus Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alpheus Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpheus Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpheus Medical \/ Inapplicable"},{"orgOrder":0,"company":"Kaizen Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"||Potassium transporting ATPase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Kaizen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaizen Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kaizen Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"||DNA adduct","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"||DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dimesna","moa":"||ALK","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP-410","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP659","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LPCN 2101","moa":"GABA-A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"Tim3\/4","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"Tim3\/4","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"Tim3\/4","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"Tim3\/4","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"Tim3\/4","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LRK-A","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Larkspur Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larkspur Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Larkspur Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"Alpha-V integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ University of Sydney"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lucy Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LucyTx-1209","moa":"F1F0-ATPase","graph1":"Neurology","graph2":"Preclinical","graph3":"Lucy Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lucy Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lucy Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-810","moa":"OTC mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SSTR","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantheus Holding \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Inapplicable"},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CURIUM US LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CURIUM US LLC \/ Inapplicable"},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SSTR","graph1":"Oncology","graph2":"Phase III","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CURIUM US LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CURIUM US LLC \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"DAAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"APOEII\/III","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1001","moa":"APOEII\/III","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX1004","moa":"TPP1","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LX-101","moa":"||IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lirum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lirum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lirum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LX2020","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LX2020","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LXM.2","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laxxon Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Olaratumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Efsitora Alpha","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Efsitora Alpha","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Muvalaplin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor-alpha 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor-alpha 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"EEF2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Eisai"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Ajinomoto Company","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Ajinomoto Company"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LinPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lysine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"LinPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LinPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LinPharma \/ Inapplicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha 2-beta subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Galectin-9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"LYT-200","moa":"Galectin-9","graph1":"Oncology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"M011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M6P Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"M011","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M6P Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Itreas","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Itreas","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Itreas"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Hematology","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","graph1":"Hematology","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeterna Zentaris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aeterna Zentaris \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MGD013","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Magdalena Biosciences","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Magdalena Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Magdalena Biosciences \/ Jaguar Health","highestDevelopmentStatusID":"4","companyTruncated":"Magdalena Biosciences \/ Jaguar Health"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Jena University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Jena University Hospital","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Jena University Hospital"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Alter Pharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Athenex \/ Alter Pharma Group","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Alter Pharma Group"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KPMW135","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kleo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kleo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AMAG Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Mannin Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MAN-19","moa":"Tie2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Mannin Research","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Mannin Research"},{"orgOrder":0,"company":"MANA RBM","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"MANA RBM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MANA RBM \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MANA RBM \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"||PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Mangoceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Oncoprex","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Margetuximab","moa":"||HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Maridebart Cafraglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Topiramate","moa":"GABA-alpha 1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare"},{"orgOrder":0,"company":"Soligenix","sponsor":"Dr. Axel Lehrer","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Marburg Marburgvirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Dr. Axel Lehrer","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ Dr. Axel Lehrer"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Urology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mateon Therapeutics \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MAU868","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MAU868","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MyoKardia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ MyoKardia","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ MyoKardia"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MB-101","moa":"IL-13-alpha 2","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ City of Hope"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Immunology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutch Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Fred Hutch Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutch Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-107","moa":"IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MB-101","moa":"||IL-13-alpha 2","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Monomethyl Auristatin E","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MBrace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MitoChem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MC16","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"MitoChem Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MitoChem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"MitoChem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MCY-M11","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Camoteskimab","moa":"LIGHT","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"Model Medicines","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MDL-001","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Model Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Model Medicines \/ Icahn School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Model Medicines \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDL-101","moa":"Laminin-alpha 1 protein","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modalis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDL-101","moa":"Laminin-alpha 1 protein","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modalis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MDL-101","moa":"Laminin-alpha 1 protein","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modalis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MDL-101","moa":"Laminin-alpha 1 protein","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modalis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sunstone Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sunstone Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunstone Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sunstone Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lykos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MDNA11","moa":"IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MDNA413","moa":"IL-4\/13","graph1":"Oncology","graph2":"Discovery","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bizaxofusp","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MDbio Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabis Sativa Oil","moa":"||Undisclosed","graph1":"Sleep","graph2":"Approved FDF","graph3":"MDbio Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MDbio Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MDbio Wellness \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"||JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-PSA","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Erasmus University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Erasmus University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Erasmus University Medical Center"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bizaxofusp","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BC-PIV Vaccine","moa":"SARS-CoV-2 S1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MV-012-968","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Meissa Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Meissa Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Meissa Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MV-014-210","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Meissa Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meissa Vaccines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Meissa Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Approved FDF","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Meitheal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Memgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MEM-288","moa":"IFN-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Memgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Memgen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Memgen \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Mercaptor Discoveries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"COX-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mercaptor Discoveries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Mercaptor Discoveries \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mercaptor Discoveries \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-7110","moa":"CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Multivalent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-7110","moa":"CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zenith Epigenetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"NaPi2b","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Metacrine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MET409","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine \/ Inapplicable"},{"orgOrder":0,"company":"Metacrine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MET642","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metacrine \/ Inapplicable"},{"orgOrder":0,"company":"Metavant Sciences","sponsor":"Poxel","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imeglimin Hydrochloride","moa":"GSIS","graph1":"Endocrinology","graph2":"Phase III","graph3":"Metavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Metavant Sciences \/ Poxel","highestDevelopmentStatusID":"10","companyTruncated":"Metavant Sciences \/ Poxel"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elite Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elite Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methsuximide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Solaris Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Solaris Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Solaris Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Enoblituzumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Vobramitamab Duocarmazine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"||TYRO3","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"||TYRO3","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"10-1074","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MGTA-117","moa":"CD117","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CXCR2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR2 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MGX-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ Inapplicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MH002","moa":"Microbiome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MRM Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MRM Health \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MIE-101","moa":"TLR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mosaic ImmunoEngineering \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Miglustat","moa":"Glucosylceramide synthase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"WindMIL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Marrow-Infiltrating Lymphocytes","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"WindMIL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WindMIL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"WindMIL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Profounda Pharmaceuticals","sponsor":"Knight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Miltefosine","moa":"Cytochrome-C oxidase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Profounda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Profounda Pharmaceuticals \/ Knight Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Profounda Pharmaceuticals \/ Knight Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milvexian","moa":"FXIa","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Purion Processed Dehydrated Human Amnion\/Chorion Membrane","moa":"TGF-beta-1","graph1":"Dermatology","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ralinepag","moa":"IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ MorphoSys"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AgenT-797","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MiNK-215","moa":"FAP-expressing CAF","graph1":"Oncology","graph2":"Preclinical","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MiNK-413","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biorasi","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biorasi \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Immunology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-absorbable Film","sponsorNew":"Citius Pharmaceuticals \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ViaDerma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"ViaDerma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViaDerma \/ Inapplicable"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"||HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zevra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cobomarsen","moa":"miR-155","graph1":"Oncology","graph2":"Phase I","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Miragen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Miragen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"TYRO3","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MRTX9768","moa":"PRMT5","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MiroliverELAP","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mobius","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Mobius","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Mobius \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mobius \/ Inapplicable"},{"orgOrder":0,"company":"Vogenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mizagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Vogenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Vogenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vogenx \/ Inapplicable"},{"orgOrder":0,"company":"Vogenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mizagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Vogenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Vogenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vogenx \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MK-1084","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MK-1084","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MK-2060","moa":"Factor XI","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X3R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Solrikitug","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Uniquity Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniquity Bio \/ Blackstone Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Uniquity Bio \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ML-007","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MapLight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ML-007","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MapLight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"||TORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alisertib","moa":"||Aurora kinase A","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Enteric Coated","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alisertib","moa":"||Aurora kinase A","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alisertib","moa":"||Aurora kinase A","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Enteric Coated","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alisertib","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alisertib","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adhera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Nephrology","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Metabolexis","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MLX7000","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolexis Therapeutics \/ Metabolexis","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Metabolexis"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zolunicant HCl","moa":"nACh receptor alpha-3 beta-4","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MMS019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MMS019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Immunology","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ BARDA"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clofazimine","moa":"ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Lu","moa":"uPAR","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"North Star Processing, LLC.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ North Star Processing, LLC.","highestDevelopmentStatusID":"5","companyTruncated":"Monopar Therapeutics \/ North Star Processing, LLC."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Cancer Science Institute of Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MNPR-202","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Cancer Science Institute of Singapore","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Cancer Science Institute of Singapore"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MNPR-202","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1189","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"mRNA-6231","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1273.351","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.211","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SATB1 expression","graph1":"Oncology","graph2":"Preclinical","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moffitt Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clomiphene Citrate","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangoceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"CX-2051","moa":"EpCAM","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"MOMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MOMA-313","moa":"Polymerase theta helicase","graph1":"Oncology","graph2":"Phase I","graph3":"MOMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MOMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MOMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bebtelovimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Combined Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Combined Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Combined Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Combined Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Inapplicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HI-Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Inapplicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Inapplicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HI-Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Sapu Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Sapu Bioscience","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Sapu Bioscience"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Columbia University \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD3\/20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lacosamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Aucta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Mitochon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MP101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Mitochon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mitochon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mitochon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Monopteros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MPT-0118","moa":"||MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"Monopteros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monopteros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopteros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MRG-229","moa":"miR-29","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miragen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Miragen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1083","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1083","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1230","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1273.815","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1273.815","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1273.815","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1283","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1403","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1403","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IAVI","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"eOD-GT8 60mer mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"mRNA-3927","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MRNA-4157\/V940","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-4359","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MRT-048","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Cancer Research UK Cancer Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MRT-048","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Cancer Research UK Cancer Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Cancer Research UK Cancer Therapeutics"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MRT-6160","moa":"VAV1","graph1":"Immunology","graph2":"Phase I","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MRT-8102","moa":"Undisclosed","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MRTX1133","moa":"KRASG12D selective","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Benzodiazepine","moa":"GABA A receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Benzodiazepine","moa":"GABA A receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Benzodiazepine","moa":"GABA A receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Polymyxin","moa":"Bacterial membrane integrity","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cirius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MSDC-0602K","moa":"Mitochondrial pyruvate carrier","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Cirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cirius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cirius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MT-0169","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"MT-1002","moa":"SIRP alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navidea Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Navidea Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"MT-5111","moa":"Ribosome inactivation","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MT-8421","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MT-8421","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"TAK-169","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"||Cardiolipin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MTX-101","moa":"KIR dependent CD8 treg","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mozart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mozart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MTX-463","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mediar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MTX-474","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Mediar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mediar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mediar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pelareorep","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asapiprant","moa":"DP1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioAge Labs \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Shionogi"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NGM621","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||T-cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Encoded Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Endocrinology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TERN-101","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"The University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ The University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Athersys \/ The University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Invimestrocel","moa":"Treg","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Zinc","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"||CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Penn Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"MuSK-CAART","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Penn Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Penn Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Penn Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MV-012-968","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Meissa Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Meissa Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Meissa Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Attenuated COVID-19 Vaccine Recombinant, Live","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Meissa Vaccines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Meissa Vaccines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Meissa Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Matrivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MVX01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Matrivax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Matrivax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Matrivax \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MWTX-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Mabwell","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Mabwell"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MWTX-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD5-ATAK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Myeloid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","graph1":"Immunology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Virus-like Particle COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyMD Pharmaceuticals \/ Oramed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Oramed Pharmaceuticals"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myto Therapeutics","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Monomethyl Fumarate Prodrug","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Myto Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myto Therapeutics \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"Myto Therapeutics \/ University of California"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Mythic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MYTX-011","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Mythic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mythic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mythic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mythic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MYTX-011","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Mythic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mythic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mythic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MZ-301","moa":"APOL1","graph1":"Nephrology","graph2":"Preclinical","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MZE782","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Psilera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Psilera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Inapplicable"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terran Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Terran Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"EmphyCorp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp \/ Inapplicable"},{"orgOrder":0,"company":"Onchilles Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"N17350","moa":"ELANE pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Onchilles Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onchilles Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onchilles Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharmaceuticals L.P \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Inapplicable"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharmaceuticals L.P \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Inapplicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pocket Naloxone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pocket Naloxone","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Swab","sponsorNew":"Pocket Naloxone \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pocket Naloxone \/ Inapplicable"},{"orgOrder":0,"company":"Soin Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Soin Neuroscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soin Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soin Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"QXL138AM","moa":"CD138","graph1":"Oncology","graph2":"Phase I","graph3":"Nammi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nammi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nammi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NAN-101","moa":"PP1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hemagglutinin Protein Nanoparticle Influenza Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"qNIV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ US Biotest","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ US Biotest"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VMCO-I","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MCO-020","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NV-HHV-101","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Ananda Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Nebraska Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Nebraska Medical Center \/ Ananda Scientific","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska Medical Center \/ Ananda Scientific"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Lyotropic Delivery Systems"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ananda Scientific \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"University Of Nebraska Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ananda Scientific \/ University Of Nebraska Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ University Of Nebraska Medical Center"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Ananda Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ananda Scientific \/ NYU Langone Health","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ NYU Langone Health"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Grossman School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Ananda Scientific \/ NYU Grossman School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ NYU Grossman School of Medicine"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Lyotropic Delivery Systems"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"NantKwest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytRx Corporation \/ NantKwest","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ NantKwest"},{"orgOrder":0,"company":"NantKwest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NantKwest \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ Inapplicable"},{"orgOrder":0,"company":"Flugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Influenza Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Flugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ Inapplicable"},{"orgOrder":0,"company":"Fera Pharmaceuticals, LLC","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naproxcinod","moa":"COX","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fera Pharmaceuticals, LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fera Pharmaceuticals, LLC \/ Nicox SA","highestDevelopmentStatusID":"4","companyTruncated":"Fera Pharmaceuticals, LLC \/ Nicox SA"},{"orgOrder":0,"company":"Fera Pharmaceuticals, LLC","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Naproxcinod","moa":"COX","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fera Pharmaceuticals, LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fera Pharmaceuticals, LLC \/ Nicox SA","highestDevelopmentStatusID":"4","companyTruncated":"Fera Pharmaceuticals, LLC \/ Nicox SA"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Naproxen","moa":"COX-1","graph1":"Immunology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Belhaven Biopharma \/ Lovelace Biomedical"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Adenovirus-vectored Anthrax Vaccine","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vilamakitug","moa":"IL-1-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Vilamakitug","moa":"IL-1-alpha receptor","graph1":"Rheumatology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Vilamakitug","moa":"IL-1-alpha receptor","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD206","graph1":"Oncology","graph2":"Preclinical","graph3":"Navidea Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Navidea Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Navidea Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||BCL-XL\/BCL-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pocket Naloxone","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pocket Naloxone","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Swab","sponsorNew":"Pocket Naloxone \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pocket Naloxone \/ Inapplicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NB-4746","moa":"SARM1","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1065890","moa":"VMAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1070770","moa":"NMDA NR2B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1076986","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1117567","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NBI-1117568","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Sosei Heptares"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NBI-1117569","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Sosei Heptares"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NBI-827104","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NBI-921352","moa":"Nav1.6 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NBI-921352","moa":"Nav1.6 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Neurocrine Biosciences \/ Voyager Therapeutics, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Voyager Therapeutics, Inc"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NC318","moa":"Siglec-15 \/LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NC318","moa":"Siglec-15 \/LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NC318","moa":"||Siglec-15 \/LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"||LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Merck & Co"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NC410","moa":"LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NC525","moa":"||LAIR-1","graph1":"Oncology","graph2":"Preclinical","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/ National Cancer Institute"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"NC410","moa":"LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NC525","moa":"||LAIR-1","graph1":"Oncology","graph2":"Preclinical","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NC605","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NDI-101150","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Icahn School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CpG 1018","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Icahn School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Icahn School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Icahn School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Endocrinology","graph2":"Preclinical","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Veristat","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Veristat"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptar Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aptar Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai Co.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co.","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai Co."},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"AbGenomics B.V","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ AbGenomics B.V","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ AbGenomics B.V"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Guadecitabine","moa":"DNMT","graph1":"Oncology","graph2":"Phase III","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astex Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Astex Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Mural Oncology","sponsor":"Alkermes Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mural Oncology \/ Alkermes Plc","highestDevelopmentStatusID":"10","companyTruncated":"Mural Oncology \/ Alkermes Plc"},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NEO-201","moa":"||Treg","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NEO-201","moa":"||Treg","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision Biologics \/ Inapplicable"},{"orgOrder":0,"company":"University of Texas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"University of Texas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Texas \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of Texas \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NEO-PTC-01","moa":"Neoantigen-targeting T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Neon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NeoTCR-P1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PACT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NeoTCR-P1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PACT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NEO-TRA1","moa":"IL-2","graph1":"Immunology","graph2":"Preclinical","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"NERx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NERx-20-04","moa":"Replication protein A","graph1":"Oncology","graph2":"Preclinical","graph3":"NERx Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NERx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NERx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Neuron23","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NEU-411","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuron23 \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Neuron23 \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Neuron23","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NEU-411","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuron23 \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuron23 \/ Inapplicable"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NT-0231.F","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"NT0200","moa":"DMPK","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTM-006","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMRA-266","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Psycheceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ Inapplicable"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal \/ ATAI Life Sciences"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"Neutrolis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"NTR-441","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Neutrolis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neutrolis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Neutrolis \/ Inapplicable"},{"orgOrder":0,"company":"Neuvogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Neuvogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Neuvogen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Neuvogen \/ Inapplicable"},{"orgOrder":0,"company":"Nevakar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ephedrine","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nevakar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Erlotinib","moa":"||HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Funapide","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Flexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Flexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPAR-gamma","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NovaBay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"CCM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"CCM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CCM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CCM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Desethyloxybutynin","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Neos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Neos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SB 11285","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xeruborbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Biotech Acquisition Company"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"samRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Liquidia Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Liquidia Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imdusiran","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"LTBP-TGF beta 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BWV-201","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Blue Water Vaccines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Blue Water Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Rega Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1096","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleculin Biotech \/ Rega Institute","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Rega Institute"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TATX-03a","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Serum","sponsorNew":"NovaBay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MCY-M11","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VBI-2905","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"||BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Merck & Co"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLV213","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Selva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PH-894","moa":"Bromodomain-containing protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ablexis","sponsor":"AlivaMab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ablexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ablexis \/ AlivaMab","highestDevelopmentStatusID":"2","companyTruncated":"Ablexis \/ AlivaMab"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NMBS-2","moa":"HPK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Pelareorep","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"InvisiMask","moa":"SARS-CoV-2 S1 viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NexImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NEXI-002","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune \/ Inapplicable"},{"orgOrder":0,"company":"NexImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NEXI-004","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NexImmune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ACLY","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IMGN151","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NC318","moa":"Siglec-15 \/LAIR-1","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NPX887","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NextPoint \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Succinylcholine Chloride","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"NFlection Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NFX-179","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"NFlection Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"NFlection Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFlection Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NG-01","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"NeuroGenesis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metopimazine Mesylate","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogastrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ OPKO Health"},{"orgOrder":0,"company":"Next Generation Gene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NGGT002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Next Generation Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Next Generation Gene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Next Generation Gene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NGM120","moa":"||GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM120","moa":"||GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM120","moa":"GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NGM120","moa":"||GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM438","moa":"||LAIR-1","graph1":"Oncology","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"NGM Biopharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"NGM707","moa":"||ILT2\/4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NGM707","moa":"ILT2\/4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM707","moa":"||ILT2\/4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NGM831","moa":"ILT3","graph1":"Oncology","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM936","moa":"ILT\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ National Institutes of Health"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ National Institutes of Health"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1893","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HPK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HPK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XOMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Nitrofurantoin","moa":"30S ribosomal S10","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivatrotamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"TELA Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nivis Fibrillar Collagen Pack","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"TELA Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TELA Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TELA Bio \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2-viral spike protein","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GTB-5550","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NKT3447","moa":"CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NKTR-255","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cairo Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NKTR-255","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Cairo Laboratory","highestDevelopmentStatusID":"4","companyTruncated":"Nektar Therapeutics \/ Cairo Laboratory"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NKX019","moa":"CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NKX019","moa":"CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NL-201","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NL-201","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NL-201","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ Inapplicable"},{"orgOrder":0,"company":"Neuraly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP-1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP-1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM-136","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NM-136","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NM3086","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM3086","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM3086","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NM5072","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"C3\/5 convertase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"C3\/5 convertase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"C3\/5 convertase","graph1":"Nephrology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"C3\/5 convertase","graph1":"Hematology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"C3\/5 convertase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Aptar Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aptar Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Link Healthcare Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Pharma USA \/ Link Healthcare Group","highestDevelopmentStatusID":"15","companyTruncated":"Teikoku Pharma USA \/ Link Healthcare Group"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Xcovery","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xcovery \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"BlackThorn Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ BlackThorn Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ BlackThorn Therapeutics"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMRA-266","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMRA-511","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NNI-351","moa":"DYRK","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuronascent \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuronascent \/ Inapplicable"},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ National Institute on Aging"},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ National Institute on Aging"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||DKK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB1275","moa":"||CD11B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"EicOsis","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EC5026","moa":"sEH","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EicOsis \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Avance Clinical"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PSMA-I&T","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"CURIUM US LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CURIUM US LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CURIUM US LLC \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Nobilis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xenon","moa":"||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Nobilis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nobilis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nobilis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taplucainium","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nocion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nocion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akouos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AK-OTOF","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Akouos \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ Inapplicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Norepinephrine Bitartrate","moa":"||Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Norepinephrine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuLiv Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NuLiv Science \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Veracyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veracyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veracyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veracyte \/ Inapplicable"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"NB1000S","moa":"||Oxalate","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novome Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"NVX\u2011CoV2373","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-200","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALTO-102","moa":"||cyclic-AMP pathway","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Neuraly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Marijuana Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"Privo Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Privo Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transmucosal Patch","sponsorNew":"Privo Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Privo Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nitric Oxide Innovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nitric Oxide Innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nitric Oxide Innovations \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nitric Oxide Innovations \/ Inapplicable"},{"orgOrder":0,"company":"NOVOS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trehalose","moa":"||Amyloid-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"NOVOS","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"NOVOS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NOVOS \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi USA \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"NP-300","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NPI-002","moa":"Oxidative-induced cataract","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NPI-002","moa":"Oxidative-induced cataract","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"NPX267","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Inapplicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"NPX887","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Inapplicable"},{"orgOrder":0,"company":"Neurocentria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Magnesium L-Threonate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Neurocentria","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocentria \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurocentria \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"TORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NRL-1049","moa":"ROCK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NRL-1049","moa":"ROCK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRL-4","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neuroptika","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRO-1","moa":"Semaphorin-3A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuroptika \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"aNRP2-14","moa":"Sema3F\/NRP2","graph1":"Immunology","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ ClearPoint Neuro"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"||D-Ala-D-Ala ligase A","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ilginatinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ilginatinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ilginatinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NS-050\/NCNP-03","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NS-050\/NCNP-03","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NS-229","moa":"JAK1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nested Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NST-628","moa":"Pan-RAF\/MEK","graph1":"Oncology","graph2":"Phase I","graph3":"Nested Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nested Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nested Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NT-125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neogene \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neogene \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Revakinagene Taroretcel","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotech Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurotech Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Revakinagene Taroretcel","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurotech Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurotech Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-6001","moa":"CD30","graph1":"Oncology","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NTX-1088","moa":"||CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-1175","moa":"Sodium channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Nocion Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Nocion Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-470","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutcracker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NTX-801","moa":"Casitas B-lineage lymphoma B","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sentynl Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sentynl Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cocaine Hydrochloride","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Lannett Company, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ViaDerma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"ViaDerma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViaDerma \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-1607","moa":"CBL","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NUV-1511","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NUV-1511","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NUV-422","moa":"CDK2\/4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NUV-422","moa":"CDK2\/4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NUV-422","moa":"CDK2\/4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"SK Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ SK Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ SK Bioscience"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"SK Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ SK Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ SK Bioscience"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Department of Health and Human Services"},{"orgOrder":0,"company":"NuvOx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CAS 7632-00-0","moa":"Vasodilator","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NuvOx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"NuvOx Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NuvOx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Paratek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Pharmaceuticals \/ Zai Lab"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"Sulfated proteoglycans","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"Sulfated proteoglycans","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"Sulfated proteoglycans","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"Sulfated proteoglycans","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"Sulfated proteoglycans","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"Sulfated proteoglycans","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"||SARS-CoV-2 infection","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VYD222","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVG-2089","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Nuvig Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvig Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvig Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NV-HHV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Laboratoires Thea","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Laboratoires Thea","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Laboratoires Thea"},{"orgOrder":0,"company":"Vyluma","sponsor":"Nevakar","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Nevakar"},{"orgOrder":0,"company":"Vyluma","sponsor":"Nevakar","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Vyluma \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Nevakar"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVL-330","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVL-655","moa":"ALK receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JN.1 Subvariant SARS CoV-2 rS Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-1607","moa":"CBL","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-1607","moa":"CBL","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"NeuExcell therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXL-004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeuExcell therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuExcell therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeuExcell therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ The Institute of Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/ Src-family kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/ Src-family kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP900","moa":"||YES1\/ Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Institute of Genetics and Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/ Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Institute of Genetics and Cancer","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Institute of Genetics and Cancer"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/ Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Naya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Syena","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Replay Bio \/ Syena","highestDevelopmentStatusID":"7","companyTruncated":"Replay Bio \/ Syena"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ceruvia Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ceruvia Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-458","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NYX-458","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Oculos Development Services","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Oculos Development Services","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Oculos Development Services"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OA-201","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elusys Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elusys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Kedrion IVIG","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Omburtamab-DTPA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||IL-15 production","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Obsidian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Obsidian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"OCE-205","moa":"V1R","graph1":"Nephrology","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ocelot Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"OCE-205","moa":"V1R","graph1":"Nephrology","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ocelot Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"OCE-205","moa":"V1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ocelot Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocelot Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocelot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"2","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OCF-203","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ocrelizumab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"OCU500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ocugen \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ National Institutes of Health"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Cartilagenous Tissue","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Imprime PGG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Imprime PGG","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Imprime PGG"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Oligodeoxynucleotide","moa":"TLR9","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dacomitinib","moa":"ErbB1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ University of Colorado"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OKI-219","moa":"PI3K Alpha H1047R","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oblato","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OKN-007","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase II","graph3":"Oblato","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oblato \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oblato \/ Inapplicable"},{"orgOrder":0,"company":"Oblato","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OKN-007","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase II","graph3":"Oblato","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oblato \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oblato \/ Inapplicable"},{"orgOrder":0,"company":"American Society Of Clinical Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Phase II","graph3":"American Society Of Clinical Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Society Of Clinical Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American Society Of Clinical Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"||NLRP3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olatec Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Olatec Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Endocrinology","graph2":"Phase II","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olatec Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Olatec Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Olatec Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Olatec Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Genelux","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ GOG Foundation"},{"orgOrder":0,"company":"Genelux","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Inapplicable"},{"orgOrder":0,"company":"Genelux","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genelux \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omburtamab","moa":"Beta\/gamma radiation","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Nephrology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omeros \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Omeros","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quantum Leap Healthcare \/ Omeros","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Leap Healthcare \/ Omeros"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"MASP-3","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"MASP-3","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"MASP-3","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||KRAS","graph1":"Oncology","graph2":"Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"HanX Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ HanX Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ HanX Biopharmaceuticals"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"EvviVax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"LinearDNA COVID-19 Vaccine","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ EvviVax","highestDevelopmentStatusID":"4","companyTruncated":"Applied DNA Sciences Inc \/ EvviVax"},{"orgOrder":0,"company":"Orcosa","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Orcosa","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orcosa \/ NYU Langone Health","highestDevelopmentStatusID":"7","companyTruncated":"Orcosa \/ NYU Langone Health"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CB receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Applied Biology \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biology \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||RAS pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rigosertib","moa":"KRAS","graph1":"Oncology","graph2":"Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"||ARK5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Inapplicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ONC206","moa":"D2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoceutics Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoceutics Inc \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"OncoC4 \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gotistobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gotistobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONC-841","moa":"Siglec-10","graph1":"Oncology","graph2":"Phase I","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONC-841","moa":"Siglec-10","graph1":"Oncology","graph2":"Phase I","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncoGenerix USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OncoGenerix USA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoGenerix USA \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoGenerix USA \/ Inapplicable"},{"orgOrder":0,"company":"Oncologie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bavituximab","moa":"||Phosphatidylserine","graph1":"Oncology","graph2":"Phase II","graph3":"Oncologie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncologie \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoSec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoSec \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"OncoTartis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OT-82","moa":"Nicotinamide phosphoribosyl","graph1":"Oncology","graph2":"Phase I","graph3":"OncoTartis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"OncoTartis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoTartis \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncorus","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"ONCR-177","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Oncorus \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Oncorus \/ Merck & Co"},{"orgOrder":0,"company":"Oncorus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ONCR-719","moa":"EGFR\/EGFRvIII","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Oncorus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncorus \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Center for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Oncternal Therapeutics \/ Center for Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Center for Cancer Research"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ONCT-808","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Johnson & Johnson"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"MeiraGTx","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ MeiraGTx","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ MeiraGTx"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"T-cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Kansas Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ University of Kansas Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ University of Kansas Cancer Center"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"MeiraGTx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm \/ ONL Therapeutics"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT825","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Trovagene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trovagene \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OP-3136","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Aurigene","highestDevelopmentStatusID":"5","companyTruncated":"Olema Oncology \/ Aurigene"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Melanoma Research Alliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Melanoma Research Alliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melanoma Research Alliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Melanoma Research Alliance \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OPGx-001","moa":"LCA5 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OPGx-LCA5","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OPGx-LCA5","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OPGx-LCA5","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"Valo Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valo Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Inapplicable"},{"orgOrder":0,"company":"Valo Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valo Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OPN-019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Drinabant","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indivior \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Indivior \/ Sanofi"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Global Virus Network","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Oral poliovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Global Virus Network","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Virus Network \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Global Virus Network \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OR-449","moa":"SF-1\/ NR5A1","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OR-449","moa":"SF-1\/ NR5A1","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OR-449","moa":"NR5A1","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoResponse \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Inapplicable"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoResponse \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OncoResponse \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Terra CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-721","moa":"RNA destabilizer","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"SWK Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Enteris Biopharma Inc \/ SWK Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ SWK Holdings"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRTX007","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1867","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GAL-201","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galimedix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galimedix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AntiCancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Methioninase","moa":"DNA methylation","graph1":"Oncology","graph2":"Preclinical","graph3":"AntiCancer","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AntiCancer \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum Leap Healthcare \/ Athenex","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Athenex"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DR-18","moa":"IL-18","graph1":"Oncology","graph2":"Preclinical","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Simcha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Simcha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TERN-101","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"L-Asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TPX0022","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-310","moa":"GLA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LABP-104","moa":"LANCL2","graph1":"Immunology","graph2":"Phase I","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Landos Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Landos Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurodon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NDC-0009","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Neurodon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurodon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurodon \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xeruborbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Virus-like Particle COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Triple Antigen VLP Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORB-011","moa":"cDC1 dendritic cell","graph1":"Oncology","graph2":"Phase I","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orionis Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orionis Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Orionis Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORB-011","moa":"cDC1 dendritic cell","graph1":"Oncology","graph2":"Phase I","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemDiv \/ Orionis Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"ChemDiv \/ Orionis Biosciences"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-Q","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Analog Pharma","sponsor":"Dipharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitisinone","moa":"HPDD","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Analog Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Analog Pharma \/ Dipharma","highestDevelopmentStatusID":"15","companyTruncated":"Analog Pharma \/ Dipharma"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Brand Institute \/ Myovant Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ Myovant Sciences"},{"orgOrder":0,"company":"Onco360","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Myovant Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Myovant Sciences"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORIC-944","moa":"Polycomb repressive complex 2","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Pint Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Pint Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Pint Pharma"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ORM-6151","moa":"CD33\/GSPT1","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"||GLP-1","graph1":"Endocrinology","graph2":"Phase I","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edison Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Edison Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Edison Oncology \/ Inapplicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OrphoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Inapplicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OrphoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Inapplicable"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase III","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV.7m8-L-opsin","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AO-176","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arch Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eltanexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Arimoclomol","moa":"HSF-1 pathway","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CytRx Corporation \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corporation \/ Inapplicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OrphoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Inapplicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OrphoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Inapplicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OrphoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Inapplicable"},{"orgOrder":0,"company":"OrPro Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ORP100S","moa":"TXN1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OrPro Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OrPro Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"OrPro Therapeutics \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OrsoBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORX750","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Sosei Group Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Osmol Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OSM-0205","moa":"IntraCellular calcium","graph1":"Neurology","graph2":"IND Enabling","graph3":"Osmol Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osmol Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Osmol Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossium Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ossium Health \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ERBB 2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ERBB 2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ERBB 2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Children's Oncology Group"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ERBB 2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapu Bioscience","sponsor":"Cromos Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||TGF-beta-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sapu Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapu Bioscience \/ Cromos Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Sapu Bioscience \/ Cromos Pharma"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"NMDA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"NMDA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"OTO-413","moa":"BDNF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"OTO-413","moa":"BDNF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTO-825","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"OTO-413","moa":"BDNF","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Arrevus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrevus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ Inapplicable"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OTX-2002","moa":"||Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTX-2101","moa":"c-Myc cell proliferation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Omega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABA-A receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OV329","moa":"GABA-AT","graph1":"Neurology","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OV329","moa":"GABA-AT","graph1":"Neurology","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OV329","moa":"GABA-AT","graph1":"Neurology","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Graviton Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GV101","moa":"ROCK2","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ Graviton Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Therapeutics \/ Graviton Bioscience"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Bayer AG"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Enteris Biopharma Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STI-1558","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"STI-1558","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olgotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olgotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OmRx Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OX-4224","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"OmRx Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OmRx Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OmRx Oncology \/ Inapplicable"},{"orgOrder":0,"company":"OncoTEX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Oxaliplatin Pt(Iv) Prodrug","moa":"||Mutated p53","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoTEX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoTEX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoTEX \/ Inapplicable"},{"orgOrder":0,"company":"OncoTEX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Oxaliplatin Pt(Iv) Prodrug","moa":"||Mutated p53","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoTEX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoTEX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoTEX \/ Inapplicable"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxcarbazepine","moa":"Voltage sensitive sodium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aucta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avivagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Beta Carotene","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avivagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avivagen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avivagen \/ Inapplicable"},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"University of Kansas Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Human Ghrelin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"Tubulin polymerisation","graph1":"Oncology","graph2":"Phase I","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Oxysterol","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAX BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxysterol","moa":"TGF-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAX BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Suspension for Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH-1019","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"Sialoglycan","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||CTGF","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CTGF","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pandion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TERN-201","moa":"SSAO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zigakibart","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"UC San Francisco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UC San Francisco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"UC San Francisco \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UC San Francisco \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PAS002","moa":"EBNA-1","graph1":"Neurology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PAS002","moa":"EBNA-1","graph1":"Neurology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PAS-003","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PAS-003","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pasithea Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Hooke Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Hooke Laboratories","highestDevelopmentStatusID":"2","companyTruncated":"Pasithea Therapeutics \/ Hooke Laboratories"},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBFT02","moa":"AAV1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AIkido Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PPeptide-conjugated Ketamine","moa":"Glutamate receptor allosteic","graph1":"Neurology","graph2":"Undisclosed","graph3":"AIkido Pharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIkido Pharm \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pharm \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"BriOri BioTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical","sponsorNew":"BriOri BioTech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BriOri BioTech \/ Inapplicable"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Samarium-153 DOTMP","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ National Cancer Institute"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA damage","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Imbotolimod","moa":"TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adamas Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adamas Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamas Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Novant Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Novant Health","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Novant Health"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NUV-868","moa":"||BD2-selective BET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Johns Hopkins University Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CK0802","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Johns Hopkins University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johns Hopkins University Hospital \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilebesiran","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Antolimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"iCAD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Xoft Brain IORT","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"iCAD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iCAD \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"iCAD \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"NMDA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Zhejiang Medicine Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Zhejiang Medicine Co Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc \/ Zhejiang Medicine Co Ltd"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Providence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tucatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegadricase","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"CVS Pharmacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CVS Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CVS Pharmacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CVS Pharmacy \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Indian Council of Medical Research","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Yale School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Yale School of Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Yale School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Yale School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Pure Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PBA-0405","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Presage Biosciences \/ Pure Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Pure Biologics"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PBA-0405","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBCAR19B","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBCAR19B","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PBFT02","moa":"AAV1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"PBFT02","moa":"AAV1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBFT02","moa":"AAV1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pomotrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pardes Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PBI-200","moa":"TRK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pyramid Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bio \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pb-IFN-alpha 2b","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBKR03","moa":"Galactosylceramidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBKR03","moa":"Galactosylceramidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBML04","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"5","companyTruncated":"Passage Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"||p53","graph1":"Oncology","graph2":"Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PMV Pharma \/ Merck & Co"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"p53","graph1":"Oncology","graph2":"Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PMV Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PMV Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"P-CD19CD20-ALLO1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Enekinragene Inzadenovec","moa":"IL-1 receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PDA-002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Farmacore Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0203","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PDS Biotechnology \/ Farmacore Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ Farmacore Biotechnology"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Merck & Co"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Merck & Co"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Merck & Co"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Versamune-TARP","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PDS0203","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PEEL-224","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"PEEL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PEEL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEEL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TLR 7\/8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD19","graph1":"Oncology","graph2":"Discovery","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ElevateBio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"ElevateBio \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Constellation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Constellation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Pelacarsen","moa":"Apolipoprotein A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ SOLTI"},{"orgOrder":0,"company":"PellePharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Patidegib","moa":"Hedgehog signaling pathway","graph1":"Oncology","graph2":"Phase II","graph3":"PellePharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PellePharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PellePharm \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Specialised Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fox Chase Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fox Chase Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"||TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pemivibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pemivibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pemivibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pemivibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pemivibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pemivibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Shilpa Medicare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Shilpa Medicare","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Shilpa Medicare"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"||TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Pemetrexed","moa":"||TS\/DHFR\/GARFT","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Locnartecan","moa":"HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Locnartecan","moa":"||HSP90","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Meningococcal Group B Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aggrega Pharma","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aggrega Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aggrega Pharma \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aggrega Pharma \/ Breckenridge Pharmaceutical"},{"orgOrder":0,"company":"SyneuRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentarlandir","moa":"TMPRSS2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SyneuRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SyneuRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SyneuRx \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Neurology","graph2":"Preclinical","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"4","companyTruncated":"Partner Therapeutics \/ University of Colorado"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Perfuse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Perfuse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Perfuse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Perfuse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Perfuse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Perfuse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ablative Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA A receptor alpha-4\/beta-2\/delta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ablative Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ablative Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ablative Solutions \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PF-06425090","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"TYK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"6-valent Polysaccharide Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Danuglipron","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danuglipron","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PF-06954522","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-based Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emprumapimod","moa":"p38-alpha\/MAPK","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PF-07915234","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfenex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfenex \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Omicron XBB.1.5-adapted Monovalent COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Adrenergic receptor-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quinapril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Quinapril","moa":"ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PF-06482077","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"5-Valent Meningococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biora Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PH15","moa":"Chemoreceptor cell","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Pherin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epoxyestrenolone","moa":"Neurotransmitter receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Pherin Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Pherin Pharmaceuticals"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epoxyestrenolone","moa":"Neurotransmitter receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PH-894","moa":"Bromodomain-containing protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"AffaMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"PhageBank","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Palazestrant","moa":"Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DNA Vaccine Recombinant","moa":"SARS-CoV-2 S1 viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaJet \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALG-055009","moa":"THR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Kappa\/Mu\/Delta Opioid receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"8-Methoxycoronaridine HCl","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBCAR269A","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Iodide","moa":"ROS","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Faraday Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faraday Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Faraday Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bemarituzumab","moa":"FGFR2B","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OP-101","moa":"Glutathione synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"MT-5111","moa":"Ribosome inactivation","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Evalstotug","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tidutamab","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"RVAC Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DNL788","moa":"RIPK1","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Genmab"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CYNK-101","moa":"||CD38","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DNL201","moa":"LRRK2","graph1":"Neurology","graph2":"Phase I","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGFR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"Vanilloid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Viriom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elsulfavirine","moa":"||Non-nucleoside reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viriom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"AG013","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"TLR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"Neuropilin-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vixotrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribitol","moa":"Alpha-dystroglycan","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"GLP-1 ant","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Gilead Sciences"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"||KIT","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Pacmilimab","moa":"||CD166","graph1":"Oncology","graph2":"Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-2004","moa":"Microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cabiralizumab","moa":"||CSF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Five Prime Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Liquid","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ CytRx Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ CytRx Corporation"},{"orgOrder":0,"company":"WindMIL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Marrow-Infiltrating Lymphocytes","moa":"||T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"WindMIL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WindMIL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"WindMIL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Samumed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samumed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Samumed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Samumed \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viriom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VM1500A","moa":"Non-nucleoside reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Viriom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ Inapplicable"},{"orgOrder":0,"company":"Sanifit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNF472","moa":"Calcification","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sanifit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Inhibitor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Itraconazole","moa":"||CYP51A1","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibitor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibitor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibitor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carisbamate","moa":"MAP2","graph1":"Neurology","graph2":"Phase III","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Abbvie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Abbvie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Abbvie Inc"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enasidenib","moa":"||Isocitrate dehydrogenase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Zydus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaJet \/ Zydus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"PharmaJet \/ Zydus Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nf-kB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"5-Valent Meningococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ertugliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Genentech"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tolperisone","moa":"NaV sodium channel","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"CRF1-receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Yale University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sobetirome","moa":"TRb1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Yale University \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ipatasertib","moa":"||Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pheast Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PHST001","moa":"CD24","graph1":"Oncology","graph2":"Preclinical","graph3":"Pheast Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheast Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pheast Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Keck Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Keck Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Keck Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Keck Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Medolife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Caribbean Blue Scorpion Peptides Derived Extract","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medolife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medolife \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medolife \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PIC1-dPEG24","moa":"C1 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M1 receptor","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"RxOMEG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RxOMEG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PIPE-505","moa":"Gamma secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Pivekimab Sunirine","moa":"CD123","graph1":"Oncology","graph2":"Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gimsilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Celcuity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Inapplicable"},{"orgOrder":0,"company":"Celcuity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Inapplicable"},{"orgOrder":0,"company":"Celcuity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/ Inapplicable"},{"orgOrder":0,"company":"Celcuity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gedatolisib","moa":"||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celcuity \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/ Inapplicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProtoKinetix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProtoKinetix \/ Inapplicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"PKX-001","moa":"COX-2 expression","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProtoKinetix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 DNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 DNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Multivalent COVID-19 DNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"NEXT Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vasalgel","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"NEXT Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"NEXT Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NEXT Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ChemDiv \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ChemDiv \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Beta-1A","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Gelesis","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Citric Acid","moa":"||NGLY1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Gelesis","highestDevelopmentStatusID":"15","companyTruncated":"PureTech Health \/ Gelesis"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Plerixafor","moa":"CXCR4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Meitheal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Implant","sponsorNew":"Peptilogics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Implant","sponsorNew":"Peptilogics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogics \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Implant","sponsorNew":"Peptilogics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PLN-1474","moa":"Integrin-alpha 5\/beta 1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"UCSF QBI","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"eEF1A","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"UCSF QBI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCSF QBI \/ Icahn School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"UCSF QBI \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PLN-101095","moa":"Alpha 5-Beta 1\/alpha 5-beta 8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Boswellia Serata","moa":"||COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"BioAdaptives","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAdaptives \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioAdaptives \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ National Cancer Institute"},{"orgOrder":0,"company":"ProLynx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Inapplicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ Inapplicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Inapplicable"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gemfibrozil","moa":"PPA receptor-gamma","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PLX-300","moa":"PPA receptor-alpha","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plexium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PLX-4545","moa":"IKZF2","graph1":"Oncology","graph2":"Phase I","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Plexium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Plexium \/ Inapplicable"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PM359","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Defensin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"PN-881","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Neurology","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"PNT2001","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PSMA-I&T","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu PNT2002","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Lantheus Holding"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Zadavotide Guraxetan","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu PNT2002","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantheus Holding \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Point Biopharma"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Porosome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"T1D-PT101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Porosome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Porosome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Porosome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Porustobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-06","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apnimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atomoxetin Hydrochloride","moa":"||M2 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apnimed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Merck & Co"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Calmette Guerin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ AstraZeneca"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Macimorelin","moa":"Secretagogue receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aeterna Zentaris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aeterna Zentaris \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"||Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATYR2810","moa":"Neuropilin-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TPX-0046","moa":"RET kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1125","moa":"||Mitochondrial dysfunction","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sojournix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SJX-653","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix \/ Inapplicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Zigakibart","moa":"APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ELU001","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Elucida Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elucida Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bordetella Pertussis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ILiAD Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"QRA-244","moa":"KV7.2\/7.3 potassium channel","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"STING","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Davoceticept","moa":"CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Seal Rock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Potassium Phosphate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PP-001","moa":"DHODH","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pegylated Bovine Carboxyhemoglobin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prolong Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prolong Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pegylated Bovine Carboxyhemoglobin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prolong Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prolong Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Papillon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PPL-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Papillon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Papillon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Papillon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Papillon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PPL-002","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Papillon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Papillon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Papillon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Papillon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PPL-002","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Papillon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Papillon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Papillon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone Analog","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Pharmalabs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Pharmalabs \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR006","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PRA023","moa":"TNF 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prometheus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Phase III","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Alirocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Pacmilimab","moa":"||CD166","graph1":"Oncology","graph2":"Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OP-101","moa":"Glutathione synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Elsunersen","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Elsunersen","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Elsunersen","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Precision Medicines \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Elsunersen","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Invitae","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Elsunersen","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Bioresearch \/ Invitae","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Bioresearch \/ Invitae"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relutrigine","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relutrigine","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relutrigine","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PRAX-628","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PRAX-628","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PRAX-628","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PRAX-114","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Ananda Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ABI-4334","moa":"cccDNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-321","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VCAP-102","moa":"SOD1","graph1":"Oncology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX-101","moa":"HA-1 T cell receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-202","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Vast Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALX1","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vast Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Vast Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vast Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SL-9258","moa":"||TIGIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5 vector gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"XmAb306","moa":"IL-15-beta receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Varegacestat","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Codexis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CDX-6316","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Codexis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSV Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Anti-CD27","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KSQ-4279","moa":"USP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"XMT-1592","moa":"NaPi2b","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABI-H3733","moa":"HBV core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"NeoImmuneTech \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH-1020","moa":"HGF\/MET receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"mRNA-3745","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SZN-413","moa":"Wnt signaling","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"||CXCL12","graph1":"Oncology","graph2":"Preclinical","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Fate Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GTB-3650","moa":"||CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GT Biopharma \/ Fate Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Fate Therapeutics"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"KRAS\/P53\/EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4802","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OPGx-001","moa":"LCA5 gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CD33 CAR-T Cell","moa":"||CD33","graph1":"Oncology","graph2":"Preclinical","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"225-Ac","moa":"Alpha radiation ionising","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level reducer","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maverick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Maverick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GD2-SADA","moa":"GD2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Casdatifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"Mucin 16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Topotecan","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"hAd5 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CD70 CAR-NK Cell","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBKR03","moa":"Galactosylceramidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EDP-235","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PTX-35","moa":"TNFRSF25","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"VISTA","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BP1002","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NUV-422","moa":"CDK2\/4\/6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Stannus Protoporphyrin","moa":"Nrf2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"Surfactant protein-D","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GB-501","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrastromal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HCW9302","moa":"Treg","graph1":"Immunology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Davoceticept","moa":"CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Vilastobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Preclinical","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Access to Advanced Health Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AAHI-SC2 Self-amplifying RNA COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Access to Advanced Health Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Access to Advanced Health Institute \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Access to Advanced Health Institute \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha 4\/beta 1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University of Illinois","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ University of Illinois","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ University of Illinois"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darovasertib","moa":"PKC","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SL-9258","moa":"TIGIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-313","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha 2-beta subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Adalvo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"3-Antigen HBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"3-Antigen HBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Brand Institute","sponsor":"VBI Vaccines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"3-Antigen HBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brand Institute \/ VBI Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ VBI Vaccines"},{"orgOrder":0,"company":"Graminex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Graminex G63 Flower Pollen Extract","moa":"||Undisclosed","graph1":"Urology","graph2":"Undisclosed","graph3":"Graminex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Graminex \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Graminex \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amyris","sponsor":"Infectious Disease Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Amyris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Amyris \/ Infectious Disease Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amyris \/ Infectious Disease Research Institute"},{"orgOrder":0,"company":"NexImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune \/ Inapplicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BM-Allo.MSC","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NantKwest \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Quemliclustat","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Nelipepimut-S","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AgenT-797","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"VIR-2218","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Alpha synuclein","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeterna Zentaris \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Zentaris \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dubermatinib","moa":"AXL receptor tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ERAS-007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Virus-like Particle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tobevibart","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Eli Lilly"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"INCB001158","moa":"||Aarginase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Incyte Corporation"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Linear DNA Vaccine","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied DNA Sciences Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DNA Sciences Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Oklahoma Medical Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Oklahoma Medical Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Oklahoma Medical Research Foundation"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CF-370","moa":"Pseudomonas aeruginosa cell wall","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB1275","moa":"||CD11B","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"CareDx","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ CareDx","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pharmaceuticals \/ CareDx"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-104","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vycellix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Vycellix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vycellix \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vycellix \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"||PTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shasqi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"rAAVrh8-HexA\/HexB","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathalamic Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SENTI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Rubedo Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubedo Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC451","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Amring Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"ADRB","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Amring Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Amring Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amring Pharma \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Funapide","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Flexion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Flexion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Flexion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Letermovir","moa":"||DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"10","companyTruncated":"Precigen \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Precigen \/ National Institutes of Health"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"Mucin 16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PRGN-3006","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PRGN-3006","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PRGN-3006","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Aural Analytics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Aural Analytics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aural Analytics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aural Analytics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine reuptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"Eosinophil maturation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Knopp Biosciences LLC \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"L-Asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Olpasiran","moa":"APOA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mangoceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mangoceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RPTR-147","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repertoire Immune Medicines \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire Immune Medicines \/ Merck & Co"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-005","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"StemVacs-V","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ischemic-Tolerant Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stemedica Cell Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Stemedica Cell Technologies \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abiraterone Decanoate","moa":"||CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||CXCR5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||CXCR5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"SMC Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||CXCR5 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ SMC Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"CytoDyn \/ SMC Laboratories"},{"orgOrder":0,"company":"CytoDyn","sponsor":"SMC Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ SMC Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"CytoDyn \/ SMC Laboratories"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALEXIS-PRO-1","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALEXIS-ISO-1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aisa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"Calcium channel","graph1":"Immunology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aisa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Progenity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progenity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"ProLectin-I","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Alke Research Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Alke Research Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Alke Research Private Limited"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Promethazine Hydrochloride","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Avet Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avet Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avet Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avet Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hospira, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hospira, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"GB Sciences","sponsor":"University of Lethbridge","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CB receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"GB Sciences \/ University of Lethbridge","highestDevelopmentStatusID":"4","companyTruncated":"GB Sciences \/ University of Lethbridge"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Measles, Mumps, Rubella and Varicella Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"ProJenX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prosetin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"ProJenX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ProJenX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProJenX \/ Inapplicable"},{"orgOrder":0,"company":"ProJenX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prosetin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"ProJenX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ProJenX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProJenX \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Hematology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"STI-9167","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Methemoglobin","graph1":"Hematology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"American Regent \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BWV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Elarekibep","moa":"IL-4 alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Elarekibep","moa":"IL-4 alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT3645","moa":"CDK4\/6","graph1":"Oncology","graph2":"Preclinical","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PRT3789","moa":"SMARCA2","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRT3789","moa":"SMARCA2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||DDR1","graph1":"Oncology","graph2":"Phase I","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incendia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incendia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||DDR1","graph1":"Oncology","graph2":"Phase I","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incendia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incendia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PRTX007","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Primmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRTX007","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRTX007","moa":"TLR7","graph1":"Oncology","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PRTX007","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ordesekimab","moa":"IL-15 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PRV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Bioresearch \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Bioresearch \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Incannex Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Incannex Healthcare"},{"orgOrder":0,"company":"Psilera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psilera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Inapplicable"},{"orgOrder":0,"company":"Psilera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PSIL-006","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psilera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SABI Mind","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SABI Mind","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SABI Mind \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SABI Mind \/ Clairvoyant Therapeutics"},{"orgOrder":0,"company":"University of Alabama","sponsor":"Diamond Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"University of Alabama","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Alabama \/ Diamond Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"University of Alabama \/ Diamond Therapeutics"},{"orgOrder":0,"company":"Sunstone Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sunstone Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sunstone Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sunstone Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Usona Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Usona Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Usona Institute \/ Inapplicable"},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NYU Grossman School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Grossman School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Grossman School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharmass\u00eatX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Pharmass\u00eatX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmass\u00eatX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pharmass\u00eatX \/ Inapplicable"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PsyBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"PsyBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PsyBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promontory Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promontory Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Phosplatin Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promontory Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promontory Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promontory Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Promontory Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promontory Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Promontory Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT199","moa":"||CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT199","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Peluntamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Peluntamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Peluntamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Peluntamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Peluntamig","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emvododstat","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Votoplam","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Votoplam","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Votoplam","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Votoplam","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Votoplam","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Votoplam","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Unesbulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Utreloxastat","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NMDP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Cytochrome P450 3A4","graph1":"Oncology","graph2":"Phase II","graph3":"NMDP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NMDP \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMDP \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Oncology","graph2":"Preclinical","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institute on Aging"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"IND Enabling","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Providence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Providence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PTX-COVID-19-B","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Providence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Creative Bio-Peptides","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"RAP-103","moa":"CXCR4 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Creative Bio-Peptides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creative Bio-Peptides \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Creative Bio-Peptides \/ National Institutes of Health"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRV-101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CERC-002","moa":"LIGHT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Phoenix Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oleandrin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phoenix Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Pulmotect","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Oligodeoxynucleotide","moa":"||TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Pulmotect \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect \/ Inapplicable"},{"orgOrder":0,"company":"Pulmotect","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PUL-042","moa":"TLR 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Pulmotect \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Itraconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Artemisinin","moa":"Cytochrome P450 1A2","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Oncotelic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oncotelic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Oncotelic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PUR1800","moa":"p38\/MAPK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Medicines Evaluation Unit","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PUR1800","moa":"p38\/MAPK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pulmatrix \/ Medicines Evaluation Unit","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Medicines Evaluation Unit"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Purdue University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Purdue University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purdue University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Purdue University \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Rion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"Rion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Inapplicable"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||IL-17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"CD155","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Istari Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Istari Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"||CD155","graph1":"Oncology","graph2":"Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Istari Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Istari Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Istari Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Istari Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Proteovant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PVTX-321","moa":"ER","graph1":"Oncology","graph2":"Preclinical","graph3":"Proteovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteovant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Proteovant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PY265","moa":"MARCO receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pionyr Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pionyr Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pionyr Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31 gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acella Pharmaceuticals","sponsor":"Milla Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"AChE","graph1":"Immunology","graph2":"Approved FDF","graph3":"Acella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Syrup","sponsorNew":"Acella Pharmaceuticals \/ Milla Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acella Pharmaceuticals \/ Milla Pharmaceuticals"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Hematology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PYX-106","moa":"Siglec-15","graph1":"Oncology","graph2":"Preclinical","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PYX-106","moa":"Siglec-15","graph1":"Oncology","graph2":"Phase I","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Quadriga BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QBS72S","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Quadriga BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Quadriga BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quadriga BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"QLS-101","moa":"||Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Qlaris Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Inapplicable"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Latanoprost","moa":"||KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Inapplicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qnovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"QN-247","moa":"Nucleolin","graph1":"Oncology","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ University College London","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ University College London"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"QRA-244","moa":"KV7.2\/7.3 potassium channel","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QRL-101","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Sodium-dependent noradrenaline transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Mayo Clinic","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Mayo Clinic"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Sodium-dependent noradrenaline transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Sodium-dependent noradrenaline transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QTX3034","moa":"Allosteric KRAS","graph1":"Oncology","graph2":"Preclinical","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Quanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RAS-F","moa":"RAS protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Averitas Pharma \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Grunenthal"},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"QXL138AM","moa":"CD138","graph1":"Oncology","graph2":"Phase I","graph3":"Nammi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nammi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nammi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"QXL138AM","moa":"CD138","graph1":"Oncology","graph2":"Phase I","graph3":"Nammi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nammi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nammi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"R-2487","moa":"T reg Cells","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"R-2487","moa":"T reg Cells","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R289","moa":"IRAK1\/4","graph1":"Oncology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RABI-767","moa":"Lipase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ramipril","moa":"ACE receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVOVA-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aivita Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Metacrine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MET409","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine \/ Inapplicable"},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Avilar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Avilar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avilar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ IQVIA"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"CCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium ion channel","graph1":"Sleep","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enalare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"VFMCRP","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ VFMCRP","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ VFMCRP"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"VE-PTP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneration Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RB-ADSC","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Regeneration Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Regeneration Biomedical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regeneration Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RBI-4000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Replicate Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Replicate Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Curia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RBI-4000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Replicate Bioscience \/ Curia","highestDevelopmentStatusID":"6","companyTruncated":"Replicate Bioscience \/ Curia"},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RBI-4000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Replicate Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Replicate Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RBN-2397","moa":"||PARP7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RBN-2397","moa":"PARP7","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RBN-3143","moa":"PARP14","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ribon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RBN-3143","moa":"PARP14","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ribon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"||Phosphate","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"||Phosphate","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Stannus Protoporphyrin","moa":"Nrf2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Rebiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Inapplicable"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Rebiotix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"RCT1100","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT1100","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT1100","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT2100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT2100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"RCT223","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ImmTOR","moa":"||Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sedor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosphenytoin Sodium","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sedor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sedor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sedor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cilofexor","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"DiscGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"REC-1245","moa":"RBM39","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"REC-1245","moa":"RBM39","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"REC-2282","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"REC-3964","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REC-4881","moa":"MEK1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"REC-4881","moa":"MEK1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spherix Global Insights","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spherix Global Insights","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spherix Global Insights \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Spherix Global Insights \/ Astellas Pharma"},{"orgOrder":0,"company":"Triplet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"TTX-3360","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Triplet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Triplet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Triplet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp."},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||JAK1\/JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ONCOtherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||JAK1\/JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ONCOtherapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nitroglycerin","moa":"Vasodilator","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Ointment","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REC-3599","moa":"PKC","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"KCL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regen BioPharma \/ KCL Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioPharma \/ KCL Therapeutics"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Sonoma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Regeneron Pharmaceuticals \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron Pharmaceuticals \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"REGN10933","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Garetosmab","moa":"Activin A","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||CD28","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Neurology","graph2":"Phase I","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Regenxbio","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Regenxbio"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pozelimab","moa":"C5 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||CD28","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Tyrosine Kinase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Coalition for Adaptive Research \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Coalition for Adaptive Research \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RGLS4326","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RGLS4326","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"PAO Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAO Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PAO Group \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Filgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Alora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Brand Institute \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Brand Institute \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atox Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Reltecimod","moa":"CD28","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atox Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atox Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atox Bio \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rostaporfin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UCI Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UCI Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCI Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCI Health \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"NSP-15","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Biosciences \/ OntoChem"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"DEKA Research & Development","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United Therapeutics \/ DEKA Research & Development","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ DEKA Research & Development"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Renovacor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REN-001","moa":"BAG3 Gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renovacor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Inapplicable"},{"orgOrder":0,"company":"Renovacor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REN-001","moa":"BAG3 Gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renovacor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Unicycive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Unicycive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Unicycive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Unicycive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Oncology","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Oncology","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Northwell Health Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Northwell Health Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Northwell Health Cancer Institute"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Columbia University"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CMTX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarametyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clarametyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI-Innovative Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI-Innovative Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ SOLTI-Innovative Cancer Research"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imdusiran","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repertoire Immune Medicines \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Repertoire Immune Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RPTR-168","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Repertoire Immune Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire Immune Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TPX0022","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"Invea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Invea Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Invea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Repertoire Immune Medicines \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Repertoire Immune Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Virginia Tech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAM 15","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Virginia Tech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Virginia Tech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virginia Tech \/ Inapplicable"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Baylor College of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Inapplicable"},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kaiser Permanente Washington Health Research \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kaiser Permanente Washington Health Research \/ Inapplicable"},{"orgOrder":0,"company":"Montefiore Health System","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montefiore Health System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Montefiore Health System \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Montefiore Health System \/ National Institutes of Health"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lundquist Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lundquist Institute \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist Institute \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"University of New Hampshire","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"JQ-1","moa":"||BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of New Hampshire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Hampshire \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of New Hampshire \/ Inapplicable"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meitheal Pharmaceuticals \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier"},{"orgOrder":0,"company":"University of California","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Thrixopelma Pruriens Venom Peptide","moa":"NaV1.7 sodium channel","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ AmbioPharm"},{"orgOrder":0,"company":"The American College of Cardiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"The American College of Cardiology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The American College of Cardiology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"The American College of Cardiology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"PathAI, inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"PathAI, inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PathAI, inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PathAI, inc \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lannett Company, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Inapplicable"},{"orgOrder":0,"company":"Respivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Cromoglicate","moa":"Mast cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Respivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Respivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Liver Institute Northwest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Liver Institute Northwest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Liver Institute Northwest \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liver Institute Northwest \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OpRegen RPE Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Alphamab Oncology"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Navitoclax","moa":"||BCL-XL\/BCL-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RTX-T1D","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||PAR1 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogics \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vyome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"VB-1953","moa":"TLR\/MD2","graph1":"Dermatology","graph2":"Phase II","graph3":"Vyome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vyome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vyome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Merck & Co"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Topiramate","moa":"GABA-alpha 1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"VMT01","moa":"MC1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viewpoint Molecular Targeting","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viewpoint Molecular Targeting \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viewpoint Molecular Targeting \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor 1A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Aerosol for Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"ImmunSYS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunSYS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunSYS \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunSYS \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naproxen","moa":"||COX-1","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Blood coagulation factor","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"miR-155","graph1":"Neurology","graph2":"Preclinical","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regulus Therapeutics \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Regulus Therapeutics \/ Brigham and Women's Hospital"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"VIR-2218","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Greenwich Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Greenwich Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimodivir","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TERN-201","moa":"SSAO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"Cardiolipin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"eOD-GT8 60mer","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"L-Asparaginase","moa":"Amino acid metabolism","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"||CDK2\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osanetant","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"University of Utah Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Utah Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Utah Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of Utah Health \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"American Diabetes Association","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"American Diabetes Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"American Diabetes Association \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"American Diabetes Association \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cytonus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CA-IL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytonus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytonus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytonus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TAE Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Biolexis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Biolexis","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Biolexis"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"||Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"GLP-1 ant","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ALTA-2530","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Altavant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ALTA-2530","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"CDK 4\/6","graph1":"Hematology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"VEGFR 2","graph1":"Oncology","graph2":"Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Hematology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Opicapone","moa":"COMT","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Erenumab","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Naveris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Naveris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naveris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Naveris \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vesatolimod","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"University of Vermont Larner College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ University of Vermont Larner College of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ University of Vermont Larner College of Medicine"},{"orgOrder":0,"company":"IDBiologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IDB003","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IDBiologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IDBiologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IDBiologics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Hadassah Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NG-01","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"NeuroGenesis \/ Hadassah Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"NeuroGenesis \/ Hadassah Medical Center"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Royal Marsden NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncXerna Therapeutics \/ Royal Marsden NHS Foundation Trust","highestDevelopmentStatusID":"8","companyTruncated":"OncXerna Therapeutics \/ Royal Marsden NHS Foundation Trust"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Flugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Influenza Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Flugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"STX-N","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Neurology","graph2":"Preclinical","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olatec Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Olatec Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Revumenib","moa":"MLL1-menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-R910","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Enzyvant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Processed Thymus Tissue","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Enzyvant","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzyvant \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Enzyvant \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Nephrology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"IND Enabling","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"reVision Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"REV-0100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"reVision Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"reVision Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"reVision Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ReViral","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ReViral \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REVTx-300","moa":"TLR4","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REVTx-300","moa":"TLR4","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Oil\/Drops","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Oil\/Drops","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Melinta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PathoVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HPV16 RG1-VLP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"PathoVax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PathoVax \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PathoVax \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crovalimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta-4 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Oil\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"HLB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta-4 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Oil\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"HLB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta-4 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Oil\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"||Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-075","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGT-419B","moa":"CDK4","graph1":"Oncology","graph2":"Phase I","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-61159","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-61159","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rgenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"RGX-019","moa":"MerTK","graph1":"Oncology","graph2":"Preclinical","graph3":"Rgenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rgenix \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-104","moa":"||Liver X receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Rgenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RGX-104","moa":"Liver X receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-111","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RGX-111","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RGX-121","moa":"IDS gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-121","moa":"IDS gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-121","moa":"IDS gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RGX-121","moa":"IDS gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RGX-121","moa":"IDS gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-121","moa":"IDS gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-181","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan HCl Trihydrate","moa":"||SLC6A8\/CKB","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Regenxbio \/ AbbVie Inc"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"ReHeva Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RH324","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ReHeva Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReHeva Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReHeva Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Discovery Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Discovery Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Discovery Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Ring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ring Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Ring Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varegacestat","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Rion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rion \/ Inapplicable"},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"AR","graph1":"Oncology","graph2":"Preclinical","graph3":"Halda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Halda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"CXCR2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RIST4721","moa":"CXCR2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Transmucosal Patch","sponsorNew":"AFYX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harm Reduction Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"VEGFR 2","graph1":"Oncology","graph2":"Phase II","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGFR 2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gensco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B\/1D receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Gensco Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Gensco Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gensco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rejuvenate Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RJB-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Rejuvenate Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rejuvenate Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rejuvenate Bio \/ Inapplicable"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RJVA-001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ Inapplicable"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RJVA-001","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ Inapplicable"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Immunology","graph2":"IND Enabling","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Immunology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RLS-1496","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RLY-4008","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"RLYB-116","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RLYB-211","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"RM-718","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TissueTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX02","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"TissueTech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TissueTech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TissueTech \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RMC-9805","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RMG-03","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RxOMEG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RxOMEG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RxOMEG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RNA-Based Vaccine","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Orbital Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbital Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Orbital Therapeutics \/ Beam Therapeutics"},{"orgOrder":0,"company":"RNAimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RNAimmune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RNAimmune \/ Inapplicable"},{"orgOrder":0,"company":"RNA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BLA-761423","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"RNA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RNA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RNA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RNK05047","moa":"BRD4-selective protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ranok Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RNK05047","moa":"BRD4-selective protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ranok Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rochester Clinical Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rochester Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rochester Clinical Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Rochester Clinical Research \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Netarsudil","moa":"ROCK","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"ACh receptor-alpha4\/beta2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi USA \/ Inapplicable"},{"orgOrder":0,"company":"Genixus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"ACh receptor-alpha4\/beta2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genixus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genixus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genixus \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RTX-1688","moa":"15-hydroxyprostaglandin dehydrogenase","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"RLYB-211","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gimsilumab","moa":"GCSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gimsilumab","moa":"GCSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"Protega Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Protega Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protega Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protega Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase III","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase III","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase III","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase III","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||CD206","graph1":"Oncology","graph2":"Discovery","graph3":"Riptide Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Riptide Bioscience \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Riptide Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RP-A601","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RP-A601","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RP-A601","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||STAT3\/NF-kB\/poly-tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RP-L301","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RPTR-168","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Repertoire Immune Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire Immune Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"CD47","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EpicentRx \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Resolve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RS Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Thiostrepton","moa":"Peroxiredoxin 3","graph1":"Oncology","graph2":"Phase II","graph3":"RS Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrapleural Infusion","sponsorNew":"RS Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RS Oncology \/ Inapplicable"},{"orgOrder":0,"company":"RS Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Thiostrepton","moa":"Peroxiredoxin 3","graph1":"Oncology","graph2":"Phase II","graph3":"RS Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrapleural Infusion","sponsorNew":"RS Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RS Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Reset Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Reset Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reset Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Reset Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PF-06928316","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PF-06928316","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-23","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vardenafil Hydrochloride","moa":"PDE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Respira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RTX-224","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-321","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RTX-T1D","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rectify Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RTY-694","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Rectify Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rectify Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rectify Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GC4711","moa":"Dismutase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Rusfertide Analog","moa":"Hepcidin","graph1":"Hematology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RNAimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RV-1730","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RNAimmune \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune \/ Inapplicable"},{"orgOrder":0,"company":"RNAimmune","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RV-1770","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"RNAimmune \/ Sirnaomics","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune \/ Sirnaomics"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"RVAC Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"||TPH","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Amivantamab","moa":"EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"225-Ac Dotatate","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RayzeBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Viatris","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Viatris"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"S011806","moa":"IL-17","graph1":"Dermatology","graph2":"Phase I","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DICE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"DICE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SA53-OS","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lamassu Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lamassu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SAB-195","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"cAD3-Sudan Ebolavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sabin Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sabin Vaccine Institute \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sabin Vaccine Institute \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efbemalenograstim Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LN-145","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SAR439483","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SB 11285","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trupharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trupharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Trupharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trupharma \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-324","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"9","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"National Pediatric Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NovaBay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Prokarium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Salmonella Typhi","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prokarium \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Prokarium \/ Inapplicable"},{"orgOrder":0,"company":"Samus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icapamespib","moa":"Epichaperome","graph1":"Oncology","graph2":"Phase I","graph3":"Samus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Samus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanifit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNF472","moa":"Calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Sanifit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"TORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Sapphire Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SPX-1009","moa":"QSOX1","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AXIM Biotechnologies \/ Sapphire Biotech","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biotechnologies \/ Sapphire Biotech"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-101","moa":"||LCA1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-101","moa":"LCA1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-101","moa":"LCA1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DNL788","moa":"RIPK1","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SAR444836","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicinova \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Sanofi"},{"orgOrder":0,"company":"Hesperos","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Riliprubart","moa":"C1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Hesperos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hesperos \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hesperos \/ Sanofi"},{"orgOrder":0,"company":"Scleroderma Research Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Immunology","graph2":"IND Enabling","graph3":"Scleroderma Research Foundation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Scleroderma Research Foundation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scleroderma Research Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Ftase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"Gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"Premas Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRAK-03202 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Akers Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Akers Biosciences \/ Premas Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Akers Biosciences \/ Premas Biotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"HT-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase II","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spine BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spine BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scioto Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ligand Pharmaceuticals \/ Novan","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Novan"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SBI-100 OE","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dynavax Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sparian Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SBS-1000","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sparian Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sparian Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sparian Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"SwanBio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SBT115301","moa":"T cells effector","graph1":"Immunology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TLR8","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SBT8230","moa":"TLR8","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC262","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC451","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC-DARIC33","moa":"T Cell","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"2Seventy Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SRK-439","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"WEE1","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-2921","moa":"||CDC7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Vitronectin","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Sanford Burnham Prebys Medical Discovery Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Burnham Prebys Medical Discovery Institute \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Sanford Burnham Prebys Medical Discovery Institute \/ Inapplicable"},{"orgOrder":0,"company":"Georgia State University Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Georgia State University Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Georgia State University Institute \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Georgia State University Institute \/ Merck & Co"},{"orgOrder":0,"company":"City of Hope","sponsor":"Griffith University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ZPAMt","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Griffith University","highestDevelopmentStatusID":"4","companyTruncated":"City of Hope \/ Griffith University"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VRC-FLUMOS0111-00-VP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"C5-RIBOTAC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scripps Research \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Silver Creek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Scp776","moa":"IGF-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silver Creek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Silver Creek \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silver Creek \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SEA-TGT","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Nationwide Children\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Prolonged-release Suspension for Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trehalose","moa":"Autophagy","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegadricase","moa":"||Undisclosed","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Texas Liver Institute","sponsor":"CymaBay Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Texas Liver Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Texas Liver Institute \/ CymaBay Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Texas Liver Institute \/ CymaBay Therapeutics"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Anti-Aging Glycopeptide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProtoKinetix \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"ProtoKinetix \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selenious Acid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"HealthBioAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maraviroc","moa":"||CCR5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HealthBioAI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"HealthBioAI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"HealthBioAI \/ Inapplicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProLynx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPJ-001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Avrio Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sennosides","moa":"Aquaporin-3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Avrio Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Avrio Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avrio Health \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-401","moa":"VSIG2","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"9","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka America Pharmaceutical, Inc."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Septerna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SEP-786","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Septerna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Septerna \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-155","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seralutinib","moa":"PDGFR\/ CSF1R\/ c-KIT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Seribantumab","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Seribantumab","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"ApcinteX","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"APC receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ ApcinteX","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ ApcinteX"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Serpinpc","moa":"APC receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Omicron mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Polynoma","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Seviprotimut-L","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ U.S. Food and Drug Administration"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SFA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Calcium","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SFA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SFA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Second Genome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"SG-3-0020","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Genome \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Second Genome \/ Inapplicable"},{"orgOrder":0,"company":"Second Genome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"SG-3-06686","moa":"CXCR3 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Second Genome \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Second Genome \/ Inapplicable"},{"orgOrder":0,"company":"Second Genome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"SG-5-00455","moa":"PAI-1\/PAI-2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Second Genome \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Second Genome \/ Inapplicable"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seattle Gummy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gummy \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-1505","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SGR-1505","moa":"MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SGT-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Dusquetide","moa":"p62 protein","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dusquetide","moa":"p62 protein","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Dusquetide","moa":"Innate defense","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"Innate defense","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"Innate defense","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dusquetide","moa":"Innate defense","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oncoceutics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Volixibat","moa":"AAK-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Volixibat","moa":"AAK-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Volixibat","moa":"AAK-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"selectION","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"si-544","moa":"KV1.3 potassium ion channel","graph1":"Dermatology","graph2":"Phase I","graph3":"selectION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"selectION \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"selectION \/ Inapplicable"},{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SIG001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Arugula Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Arugula Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arugula Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SIG002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Arugula Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Arugula Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arugula Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SIG-005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SIG-005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SIG-005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"VIR-2218","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ulotaront","moa":"TAAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Aspargo Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aspargo Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TLR8","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"T Cell-Enhanced Self-Amplifying mRNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Injection","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CFT7455","moa":"||IKZF1\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NGM621","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraventricular Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CD45-ADC","moa":"CD45","graph1":"Neurology","graph2":"IND Enabling","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION449","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imetelstat","moa":"||Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SION-109","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SION-638","moa":"NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Nephrology","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"Yttrium Radioisotopes","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Sirtex Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirtex Medical \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Sirtex Medical \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ReViral","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ReViral \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tedizolid","moa":"50S Ribosomal Subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"SIWA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SIWA 318H","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIWA Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIWA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"SIWA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"OTC gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"ReGenTree","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"ReGenTree \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"||H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK.Tech","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK.Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sojournix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SJX-653","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Tirumotecan","moa":"Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Sichuan Kelun-Biotech Biopharmaceutical"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"SkinMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Caffeine","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SkinMedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"SkinMedica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SkinMedica \/ Inapplicable"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SkinTE","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PolarityTE \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SKY-0515","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skyhawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skyhawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SKY-0515","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skyhawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skyhawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SL-1002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saol therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saol therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SL-1002","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Saol therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saol therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SL-325","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"PLT Health Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Immuno","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PLT Health Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PLT Health Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLT Health Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Merck & Co"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Acadia Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pharmaceuticals \/ Seelos Therapeutics"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SLS-004","moa":"SNCA gene","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SLS-004","moa":"SNCA gene","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trehalose","moa":"Autophagy","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"IND Enabling","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SLS-007","moa":"Alpha-synuclein non-amyloid component","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SLV213","moa":"Cathepsin-L","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Selva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DermBiont","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"DermBiont \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Inapplicable"},{"orgOrder":0,"company":"DermBiont","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Oncology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DermBiont \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Inapplicable"},{"orgOrder":0,"company":"DermBiont","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruboxistaurin","moa":"PKC-beta","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"DermBiont \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lorecivivint","moa":"CLK2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"CHOP","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PEG-SN22","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PEEL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PEEL Therapeutics \/ CHOP","highestDevelopmentStatusID":"4","companyTruncated":"PEEL Therapeutics \/ CHOP"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||MLL1-menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Revumenib","moa":"MLL1-menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanifit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SNF472","moa":"Calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Sanifit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SNK02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SNK02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-102","moa":"PSGL-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SNS-103","moa":"CD39","graph1":"Oncology","graph2":"Preclinical","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Aspartyl-beta hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synnovation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SNV1521","moa":"PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"Synnovation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Synnovation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synnovation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silicon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"Silicon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silicon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silicon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SOD1-ALS","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Acetate","moa":"Carbonic anhydrase 1","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Milla Pharmaceuticals \/ Woodward Pharma Services","highestDevelopmentStatusID":"15","companyTruncated":"Milla Pharmaceuticals \/ Woodward Pharma Services"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"Sojournix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SJX\u2011653","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix \/ Inapplicable"},{"orgOrder":0,"company":"SOLA Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SOL-257","moa":"TDP-43","graph1":"Neurology","graph2":"Preclinical","graph3":"SOLA Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOLA Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SOLA Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"||M2 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Adalvo \/ Adamed Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Adamed Pharma"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"M3 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Dusquetide","moa":"p62 protein","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ricin Toxin","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Kamuvudine-8","moa":"Nucleoside reverse transcriptase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ OPKO Health"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||OX40 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||INF-gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||INF-gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||INF-gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||INF-gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"SonALAsense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SonALAsense \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SonALAsense \/ Inapplicable"},{"orgOrder":0,"company":"Sonoran Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sonoran Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoran Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonoran Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"STI-6991","moa":"Spike protein S1 domain","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"STI-4398","moa":"Spike protein S1 domain","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"NYU Grossman School of Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NYU Grossman School of Medicine \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"NYU Grossman School of Medicine \/ Amgen Inc"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Xencor","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Xencor","highestDevelopmentStatusID":"15","companyTruncated":"Vir Biotechnology \/ Xencor"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Stamford Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-002","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Stamford Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Stamford Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stamford Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spirovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Spirovant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spirovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Spirovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Pre-Filled Syringe","sponsorNew":"Scilex Pharmaceuticals \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Pre-Filled Syringe","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-1-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Oregon Health & Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Oregon Health & Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Oregon Health & Sciences"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Implant","sponsorNew":"Silo Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrivo BioVentures \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrivo BioVentures \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioDuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioDuro","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BioDuro \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BioDuro \/ Inapplicable"},{"orgOrder":0,"company":"Specifica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Specifica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Specifica \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Specifica \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Lost synapses","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Lost synapses","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Lost synapses","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPG302","moa":"Lost synapses","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SPG302","moa":"Lost synapses","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Lost synapses","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"||HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clofutriben","moa":"||HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"||HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clofutriben","moa":"||HSD-1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alcyone Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Alcyone Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Spirovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SPIRO-2101","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Spirovant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spirovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Spirovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fordine","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BIIB078","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sporos BioDiscovery","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SPR1","moa":"TEAD","graph1":"Oncology","graph2":"Preclinical","graph3":"Sporos BioDiscovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sporos BioDiscovery \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sporos BioDiscovery \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"SPR206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPR720","moa":"DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ketamine Wellness Center","sponsor":"Delic Corp","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ketamine Wellness Center","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ketamine Wellness Center \/ Delic Corp","highestDevelopmentStatusID":"15","companyTruncated":"Ketamine Wellness Center \/ Delic Corp"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"||Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glyph Allopregnanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seaport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seaport Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaport Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPX-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SparX Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SPX-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SparX Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPY001","moa":"Alpha 4 beta 7","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"SpyGlass Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shasqi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Inapplicable"},{"orgOrder":0,"company":"Shasqi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Inapplicable"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Caffeine","moa":"||Adenosine receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comera Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Medera","sponsor":"CADENCE","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medera \/ CADENCE","highestDevelopmentStatusID":"7","companyTruncated":"Medera \/ CADENCE"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SRF114","moa":"CCR8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SRF114","moa":"CCR8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"VIB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ VIB","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ VIB"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SRK-181","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SRK-181","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SRK-439","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Siren Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SRN-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Siren Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Siren Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Siren Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diethylamide","moa":"COX","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Quotient Sciences"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"South Rampart Pharma \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Quotient Sciences"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"Gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Seal Rock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"SciTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech \/ Inapplicable"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ST-00937","moa":"RBM39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sustained Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Sustained Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sustained Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sustained Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vezocolmitide","moa":"Helical collagen","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Stuart Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Stuart Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"||C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"||C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"||C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ST-503","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CoV-2 S-2P","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oragenics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ National Institutes of Health"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"STAC-BBB","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Engage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Engage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stanford Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Lambda","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Stanford Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Stanford Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Invikafusp Alpha","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marengo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Invikafusp Alpha","moa":"TCR-V beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marengo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Invikafusp Alpha","moa":"TCR-V beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marengo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Kappa\/Mu\/Delta Opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Statera Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Statera Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Entolimod","moa":"TLR5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Statera Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Statera Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Statera Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GP2","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||PTK","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"StemCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"StemCyte \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"StemCyte \/ Inapplicable"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Adult Mesenchymal Bone Marrow Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stemedica Cell Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemedica Cell Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Stemson Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"StemVacs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Auxilium Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"||Mesothelin protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"STI-1499","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"STI-1557","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STI-1558","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STI-1558","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STI-1558","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STI-1558","moa":"SARS-CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMC-001","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abivertinib","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STK-002","moa":"Optic atrophy 1 protein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"STK-002","moa":"Optic atrophy 1 protein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Resiquimod","moa":"TLR7\/8","graph1":"Oncology","graph2":"IND Enabling","graph3":"SURGE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SURGE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SURGE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Siolta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"STP125G","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP144G","moa":"Complement factor B","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta 1\/COX-2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Valensa International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Serenoa Repens Extract","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"Valensa International","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valensa International \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Valensa International \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amivas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"Malaria protein EXP-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amivas \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amivas \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5 vector gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vyriad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vyriad \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vyriad \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Transmucosal Patch","sponsorNew":"AFYX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Polynoma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Seviprotimut-L","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merz Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Nektar Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Tablet, Immediate Release","sponsorNew":"Vallon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP receptor 1","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QLS-101","moa":"Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Qlaris Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Inapplicable"},{"orgOrder":0,"company":"BostonGene","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BostonGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BostonGene \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BostonGene \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Intermountain Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Intermountain Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Intermountain Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intermountain Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DPPC","moa":"||Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novus Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Serlopitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase III","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Menlo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Menlo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bold Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INB03","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"||CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Hematology","graph2":"Phase II","graph3":"AcelRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AcelRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AcelRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-3106","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Centocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Phase II","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Centocor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Centocor \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"InGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Adipose-Derived Regenerative Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"InGeneron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"InGeneron \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"InGeneron \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PneumoBlast","moa":"Tissue Factor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGenesis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"University of Chicago Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Chicago Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Chicago Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University of Chicago Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AMP CpG","moa":"||KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"99mTc-Duramycin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Targeting Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecular Targeting Technologies \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Flugen","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Fluzone HD IIV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Flugen \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strand Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Strand Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"STX-241","moa":"C797S","graph1":"Oncology","graph2":"Preclinical","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-478","moa":"PI3K-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"STX-478","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"STX-721","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"European Myeloma Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ European Myeloma Network","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ European Myeloma Network"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RLYB-116","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TK216","moa":"E26 transformation-specific oncoproteins","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FBX-101","moa":"GALC gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"HepQuant","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ HepQuant","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ HepQuant"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Generation Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ERAS-601","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lifileucel","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrase enzyme","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innoviva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dasotraline","moa":"MAO transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunovion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"MimiVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Montanide","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MimiVax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Inapplicable"},{"orgOrder":0,"company":"MimiVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"M57-KLH","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MimiVax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Inapplicable"},{"orgOrder":0,"company":"MimiVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Montanide","moa":"||AChE","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MimiVax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Survivin","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regen BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"US Oncology Network","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"US Oncology Network","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"US Oncology Network \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"US Oncology Network \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Sudan Ebola Virus Glycoprotein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Syncromune","sponsor":"Williams Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SV-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syncromune \/ Williams Cancer Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Syncromune \/ Williams Cancer Foundation"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"Phase I","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seneca Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seneca Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"Phase I","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seneca Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seneca Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seneca Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seneca Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CART-TnMUC1-01","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Seattle Gummy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gummy \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpineThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"SpineThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Inapplicable"},{"orgOrder":0,"company":"SpineThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"SpineThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Inapplicable"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SX-682","moa":"CXCR1\/2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Syntrix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syntrix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Decitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SY-5609","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Clobazam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Assertio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Assertio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level reducer","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level reducer","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level reducer","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"SYNB8802","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"SYNB8802","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"SYNB8802","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Syncromune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SV-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syncromune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syncromune \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Entinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Revumenib","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SynKIR-310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"B.More","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"B.More","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B.More \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"B.More \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CDK12","graph1":"Oncology","graph2":"Preclinical","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Lrp6","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SZN-413","moa":"Wnt signaling","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"T3D-959","moa":"PPA receptor-delta\/gamma","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Vivera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vivera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"TAC-001","moa":"TLR9\/CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Tallac Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"TAC-001","moa":"TLR9\/CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Tallac Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"TAC-001","moa":"TLR9\/CD22","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Tallac Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tallac Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Endogenous T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triumvira Immunologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Inapplicable"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Endogenous T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triumvira Immunologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Inapplicable"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tachyon Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"Preclinical","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tachyon Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tachyon Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tachyon Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"Preclinical","graph3":"Tachyon Therapeutic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tachyon Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tachyon Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tachyon Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Endogenous T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triumvira Immunologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Inapplicable"},{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Prasco Laboratories","sponsor":"Thea Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Tafluprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Prasco Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Prasco Laboratories \/ Thea Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Prasco Laboratories \/ Thea Pharma"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"United Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ United Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ United Biomedical"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"DNL593","moa":"Progranulin protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Denali Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Denali Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1065845","moa":"AMPK","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Talquetamab","moa":"||BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ TFS Trial Form Support","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"FGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracystic Injection","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracystic Injection","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracystic Injection","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracystic Injection","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RAP-219","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapport Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Futibatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CLN-081","moa":"||EGFR ex20","graph1":"Oncology","graph2":"Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CLN-081","moa":"||EGFR ex20","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kratom Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tauriga Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Grifols International","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Grifols International"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"Tavanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TAVT-135","moa":"Chloride ion","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tavanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tavanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tavanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"||CYP17A1","graph1":"Oncology","graph2":"Phase III","graph3":"Tavanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tavanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tavanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tavanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"||CYP17A1","graph1":"Oncology","graph2":"Phase III","graph3":"Tavanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tavanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tavanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TSHA-101","moa":"HEXA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Xiromed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Xiromed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xiromed \/ Inapplicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazarotene","moa":"RAR-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Cosette Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Linezolid","moa":"||Adenosine triphosphatase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Inapplicable"},{"orgOrder":0,"company":"TearClear","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"TearClear","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"TearClear \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TearClear \/ Inapplicable"},{"orgOrder":0,"company":"TearClear","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"TearClear","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"TearClear \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TearClear \/ Inapplicable"},{"orgOrder":0,"company":"TearClear","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"TearClear","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"TearClear \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TearClear \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Replay Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Replay Bio \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TCRT-ESO-A2","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX-101","moa":"HA-1 T cell receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX \u2013 101","moa":"miHA-1","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX \u2013 101","moa":"miHA-1","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TCX-101","moa":"HA-1 T cell receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlueSphere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere Bio \/ Inapplicable"},{"orgOrder":0,"company":"TrippBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TD213","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"TrippBio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine reuptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"TearClear","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"TearClear","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"TearClear \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TearClear \/ Inapplicable"},{"orgOrder":0,"company":"280Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TEB-17231","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"280Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cadrenal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tecarfarin","moa":"Vitamin K","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cadrenal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase I","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Telisotuzumab Vedotin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Telisotuzumab Vedotin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Telisotuzumab Vedotin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telomir-1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telomir-1","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telomir-1","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telomir-1","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Human Immune Monitoring Center at Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Human Immune Monitoring Center at Stanford University","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Human Immune Monitoring Center at Stanford University"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Ancora Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TNB-486","moa":"CD3\/19","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Ancora Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Ancora Biotech"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation Medicine \/ EMD Serono","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ EMD Serono"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TERN-101","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TERN-101","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TERN-501","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TERN-201","moa":"SSAO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trospium Prodrug","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terran Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Terran Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Union Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Union Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Union Therapeutics"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HA Antigen-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Merck & Co"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TGN-S11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TGR-63","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Xenikos B.V","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"T-Guard","moa":"CD3\/7","graph1":"Immunology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Veloxis Pharmaceuticals \/ Xenikos B.V","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Xenikos B.V"},{"orgOrder":0,"company":"Tharimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Tharimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Tharimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tharimmune \/ Inapplicable"},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Exhale Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Exhale Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exhale Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil","moa":"||CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil","moa":"||CB1 receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous CD34+ Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"D-Ala-D-Ala moiety of NAM\/NAG peptide subunits of peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medtronic Plc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medtronic Plc \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TEAD","graph1":"Oncology","graph2":"Preclinical","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ASC Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASC Therapeutics \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"ASC Therapeutics \/ UMass Chan Medical School"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AAVCOVID","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Massachusetts General Hospital \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Massachusetts General Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"XTX201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CytoTIL15","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Obsidian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Obsidian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"APX601","moa":"TNFR2","graph1":"Oncology","graph2":"Preclinical","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Enochian BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Grapiprant","moa":"Aldose reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bizaxofusp","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antares Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Emmecell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EO2002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Emmecell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emmecell \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Emmecell \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AR-15512","moa":"TRPM8","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Fucose","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Avalo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avalo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bizaxofusp","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curevo Vaccine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Inapplicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.ZEBOV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Apolipoprotein A-I, Human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visiox Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visiox Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Visiox Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1244","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"The AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"The AIDS Clinical Trials Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The AIDS Clinical Trials Group \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova \/ National Institutes of Health"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tipelukast","moa":"5-LO","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBCAR19B","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Immunotherapies \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"VEGF\/PDGFRA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Amyris","sponsor":"Infectious Disease Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Amyris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Amyris \/ Infectious Disease Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amyris \/ Infectious Disease Research Institute"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AV-GBM-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KB-0742","moa":"CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"||CYP17A1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"D-Ala-D-Ala moiety of NAM\/NAG peptide subunits of peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NKT2152","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SINTX Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Silicon Nitride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SINTX Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SINTX Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SINTX Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bayer AG"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Centocor","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centocor \/ Legend Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Centocor \/ Legend Biotech"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1 gene","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Audentes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zonisamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Tavokinogene Telseplasmid","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoSec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoSec \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Halozyme Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Kato Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Liposome-loaded Urea","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kato Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kato Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kato Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dynavax Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Amikacin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Corium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Donepezil","moa":"AChE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Corium \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clayton Pharmaceuticals","sponsor":"Vista Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SucrAlphate","moa":"Pepsin A5","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Clayton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clayton Pharmaceuticals \/ Vista Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Clayton Pharmaceuticals \/ Vista Pharm"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maverick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Maverick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rejuveinix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AddaVax","moa":"||Mullerian hormone receptor II","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dantrolene","moa":"RYR1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novus Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Immunology","graph2":"Phase III","graph3":"CiVi Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CiVi Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CiVi Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Elorac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elorac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Elorac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elorac \/ Inapplicable"},{"orgOrder":0,"company":"Sprout Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Flibanserin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sprout Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sprout Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sprout Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BB-301","moa":"PABPN1 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ National Institutes of Health"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bluebird Bio","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Bluebird Bio"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ublituximab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Ludwig-Maximilians-University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TATX-03","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImmunoPrecise \/ Ludwig-Maximilians-University","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoPrecise \/ Ludwig-Maximilians-University"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abivertinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Vesicular Stomatitis Virus Delta G","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AGN-151587","moa":"CEP290","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Leucadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Calcitonin","moa":"CALCR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Leucadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leucadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Leucadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RP1208","moa":"Triple reuptake","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Filovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BIOQUAL","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BIOQUAL \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BIOQUAL \/ Inapplicable"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-Based Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Providence Therapeutics \/ Everest Medicines"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma secretase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWorks Therapeutics \/ GSK"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Naxitamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Chameleon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"AAV8 IgG","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Chameleon Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chameleon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Chameleon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNS-510","moa":"PDK-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunesis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"US Biologic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Flu Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"US Biologic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"US Biologic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"US Biologic \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amikacin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Galapagos"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pacira BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dynavax Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Maxwell Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Maxwell Biosciences \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Maxwell Biosciences \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PNT6555","moa":"FAP-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ideaya Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Progenabiome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Progenabiome \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Progenabiome \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Pulmotect","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Oligodeoxynucleotide","moa":"||TLR2\/6","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Pulmotect \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Bioeq IP AG","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Bioeq IP AG"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sotigalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||FR alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"||Apoptosis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"||TYRO3","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Therabest","sponsor":"Glycotope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GT-00AxIL15","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Therabest","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therabest \/ Glycotope","highestDevelopmentStatusID":"4","companyTruncated":"Therabest \/ Glycotope"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zenith Epigenetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aphios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"||PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aphios \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aphios \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"EDP1815","moa":"Th1\/2\/17","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KT-413","moa":"IRAKIMiD","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AR-15512","moa":"TRPM8","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EDP-514","moa":"HBV core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SYNB1618","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Savara \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lufotrelvir","moa":"SARS-CoV 3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inarigivir","moa":"INFs","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EDIT-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DHA-dFdC","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkido Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkido Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alkido Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"CF-296","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SG295","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"||Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Naxitamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HLCM051","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BLD-2660","moa":"Calpain","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1283","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alkahest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CXCR3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Inapplicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avanafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Petros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Petros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"CTNS","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SQZ-PBMC-HPV","moa":"CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BWV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Water Vaccines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Mayo Clinic"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||GBA1 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ribometrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ribometrix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribometrix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ribometrix \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THB001","moa":"KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Third Harmonic Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1 gene","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Audentes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"AnGes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NC-MSCs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabidivarin","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT538","moa":"CD16","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Omburtamab","moa":"Beta\/gamma radiation","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Wesana Health \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"IND Enabling","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TERN-201","moa":"SSAO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon-alpha\/beta receptor 1","graph1":"Neurology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Hepcidin","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RubrYc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"RTX-003","moa":"CD25","graph1":"Oncology","graph2":"Preclinical","graph3":"RubrYc Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RubrYc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RubrYc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Abbvie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Abbvie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Abbvie Inc"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KTX-201","moa":"STAT3 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Topiramate","moa":"Caveolin-1","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikonoklastes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklastes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TIM-3","graph1":"Oncology","graph2":"Preclinical","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Omburtamab","moa":"Beta\/gamma radiation","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Erlotinib","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Df1001","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Wellspring Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Wellspring Ophthalmics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension\/Drops","sponsorNew":"Wellspring Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wellspring Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Neurology","graph2":"IND Enabling","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-102","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FXR314","moa":"FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organovo Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Organovo Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"Alpha-V integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DCVax-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Northwest Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Northwest Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TSC-203-A0201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"MH002","moa":"Microbiome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MRM Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MRM Health \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Urology","graph2":"Phase II","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"C1q","graph1":"Immunology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-5552","moa":"||Bi-Steric mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Metacrine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MET409","moa":"FX receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Metacrine \/ Inapplicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Ozuriftamab Vedotin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAtla \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"E-Star Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Tolmar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Tolmar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PH-762","moa":"||TIGIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Epirium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Asapiprant","moa":"DP1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Factor H","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KRM-II-81","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"COR588","moa":"Lysine gingipain","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 spike Protein Plasmid DNA Vaccine","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OncoSec Immunotherapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoSec Immunotherapies \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"OncoSec Immunotherapies \/ National Institutes of Health"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kentucky BioProcessing","sponsor":"British American Tobacco","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"KBP-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kentucky BioProcessing","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kentucky BioProcessing \/ British American Tobacco","highestDevelopmentStatusID":"7","companyTruncated":"Kentucky BioProcessing \/ British American Tobacco"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Prochlorperazine Maleate","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Biophore India Pharmaceuticals Pvt Ltd","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Biophore India Pharmaceuticals Pvt Ltd"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"StemVacs","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"ALS Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ ALS Foundation","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ ALS Foundation"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"Johnson & Johnson \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ ViiV Healthcare"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VIR-2482","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Calcilytix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Encaleret","moa":"CaSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Calcilytix Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Calcilytix Therapeutics"},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"OM101","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoMyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoMyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoMyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cetuximab-conjugated IRDye 700DX","moa":"ErbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakuten Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rakuten Medical \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BRII-179","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"VIR-2218","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brii Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ AbbVie Inc"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EDP-514","moa":"HBV core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enanta Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Summit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Immunology","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"Il-2 induced T-cell kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"4D-125","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"4D-310","moa":"GLA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Imvax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"IGV-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OM1","moa":"IL-15 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoMyx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoMyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OncoMyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1a","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IL-1 receptor-associated kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zenith Epigenetics \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ Pfizer Inc"},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Bio-Thera Solutions"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RSBT-001","moa":"Cannabinoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Synthonics"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Roskamp Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nilvadipine","moa":"L-type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Roskamp Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Roskamp Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Roskamp Institute \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CF-370","moa":"Pseudomonas aeruginosa cell wall","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"||Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Nephrology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Venthera","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBP-681","moa":"PI3K","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BridgeBio Pharma \/ Venthera","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Venthera"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Chimerix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oncoceutics Inc \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Chimerix"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MORF-057","moa":"Alpha 4-beta 7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evenamide","moa":"NaV sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Newron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SGR-2921","moa":"||CDC7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stellate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"STL-101","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"Stellate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stellate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Stellate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SQZ TACs","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SkinTE","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"PolarityTE \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CDX-585","moa":"PD-1\/ILT4","graph1":"Oncology","graph2":"Preclinical","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"||HSPG","graph1":"Oncology","graph2":"Preclinical","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoMyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoMyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoMyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1908","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RUC-4","moa":"GPIIb\/IIIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CeleCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ MorphoSys"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATI-2173","moa":"||Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX111","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ARO-HSD","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TB202-3","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase III","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CAT-248","moa":"CD70","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Catamaran Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran Bio \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"RLYB-211","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shape Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Shape Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mirati Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Walter Reed Army Institute of Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Walter Reed Army Institute of Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walter Reed Army Institute of Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Walter Reed Army Institute of Research \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||HGF IgG1","graph1":"Oncology","graph2":"Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Ach receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirogacestat Hydrobromide","moa":"Gamma secretase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CMN-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ET140203","moa":"Alpha fetoprotein receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eureka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TGF-beta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GPX-002","moa":"Pdx1\/Mafa gene","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genprex \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AR-701","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sirexatamab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sirexatamab","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DNA-Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaJet \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet \/ Inapplicable"},{"orgOrder":0,"company":"Synagile","sponsor":"Clintrex Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Synagile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synagile \/ Clintrex Research Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Synagile \/ Clintrex Research Corporation"},{"orgOrder":0,"company":"Synagile","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Synagile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synagile \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synagile \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CinCor Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ATI-2173","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deuterated D-serine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Rutgers University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Rutgers University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Rutgers University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rutgers University \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"Sulfated proteoglycans","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Syrup","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"Cure Rare","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CRD-TMH-001","moa":"Dystrophin protein","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Cure Rare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure Rare \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"5","companyTruncated":"Cure Rare \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NC318","moa":"Siglec-15 \/LAIR-1","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Alirocumab","moa":"PCSK9","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Viriom","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viriom \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Viriom \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"cPMP","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Seralutinib","moa":"PDGFR\/ CSF1R\/ c-KIT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Errant Gene Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous CD34+ Cell","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Errant Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Errant Gene Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Errant Gene Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AV-GBM-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"SER","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic receptor-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rebastinib","moa":"||ABL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ OPKO Health"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hepatic Injection","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amikacin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"Eosinophil maturation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Knopp Biosciences LLC \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"Eosinophil maturation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Knopp Biosciences LLC \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zofin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Organicell Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lorlatinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CFI-402257","moa":"||Tyrosine threonine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Curcumin","moa":"||STAT3\/NF-kB\/poly-tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reboxetine Mesylate","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mid America Heart Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mid America Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mid America Heart Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mid America Heart Institute \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"||Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"SNAP-25","graph1":"Urology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ National Institutes of Health"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LION-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Labcorp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Labcorp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MT-0169","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GB5121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DNL919","moa":"TREM2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Cellspan Esophageal Implant","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harvard Apparatus Regenerative Technology \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AT-H201","moa":"SARS-CoV-2 N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"ROCK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ervogastat","moa":"||DGAT2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Weill Cornell Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffyImmune Therapeutics \/ Weill Cornell Medicine","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune Therapeutics \/ Weill Cornell Medicine"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA","graph1":"Neurology","graph2":"IND Enabling","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Regen BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||FGFR2B","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1220","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Mayo Clinic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-2004","moa":"Microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Herophilus","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"C4A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Herophilus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Herophilus \/ Cerevel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Herophilus \/ Cerevel Therapeutics"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hackensack Meridian CDI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hackensack Meridian CDI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack Meridian CDI \/ Inapplicable"},{"orgOrder":0,"company":"Metacrine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MET409","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OvaStem","moa":"T-cell","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bizaxofusp","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-203","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LN-145","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genexa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genexa","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Tablet, Extended Release","sponsorNew":"Genexa \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genexa \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AVX012","moa":"TRPM8","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CG Oncology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Merck & Co"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SL-9258","moa":"TIGIT","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lanraplenib","moa":"||SYK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kronos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lannett Company, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lannett Company, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AGT103-T","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Gene Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"American Gene Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"E3 ligand","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"HiberCell \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RSV Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"||GLP-1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Novo Nordisk"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"||GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"||GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-05","moa":"IDS","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Astellas Pharma"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Beijing Advaccine Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HT-ALZ","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CST-107","moa":"||ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CuraSen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SNP-7\/8a","moa":"CD8+ T-cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avidea Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avidea Technologies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avidea Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Duke-NUS Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Duke-NUS Medical School","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Duke-NUS Medical School"},{"orgOrder":0,"company":"Immunolight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Immunolight","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Immunolight \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunolight \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HFB30132A","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CBL","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"S-1117","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seismic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Titan Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phoenix Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oleandrin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phoenix Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-300","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"Bioventus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PTP-001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Bioventus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bioventus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioventus \/ Inapplicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Coagulant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||FGFR2B","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GEN-011","moa":"CD4+ T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CF-370","moa":"Pseudomonas aeruginosa cell wall","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EBT-101","moa":"CRISPR-Cas9 gene","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Excision BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Excision BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Excision BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NervGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NVG-291-R","moa":"PTP sigma","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"NervGen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NervGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NervGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Casimersen","moa":"Exon 45","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Immunology","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Odyssey Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey Health \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ IQVIA"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EDIT-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Modular Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Modular Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modular Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Modular Medical \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emvododstat","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Taiho Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VIB7734","moa":"IL-7 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Viela Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viela Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viela Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Seven and Eight Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BDB001","moa":"TLR7\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Seven and Eight Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seven and Eight Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seven and Eight Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Proteona","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Proteona","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Proteona"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ABI-H2158","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EDP-305","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"WRAIR_EPa11","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptive Phage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPAR-gamma","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ColonaryConcepts \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryConcepts \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cleveland Clinic \/ Anixa Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Cleveland Clinic \/ Anixa Biosciences"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||PAR1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cenicriviroc Sulfone","moa":"CCR5","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cenicriviroc Sulfone","moa":"||CCR5","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"VE-PTP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Q BioMed \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Q BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IC14","moa":"CD14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ University of Oxford","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ University of Oxford"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"||Bradykinin B2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Human C1 Esterase Inhibitor","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BA-1049","moa":"ROCK2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CRB-601","moa":"||AlphaVbeta8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IH201","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Athena Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Athena Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Belrestotug","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NMBS-1","moa":"HPK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"QN-302","moa":"G4-quadruplex transcription","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qualigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"LineaRx","sponsor":"EvviVax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"LinearDNA SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LineaRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LineaRx \/ EvviVax","highestDevelopmentStatusID":"4","companyTruncated":"LineaRx \/ EvviVax"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CCX140","moa":"CCR2","graph1":"Nephrology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALG-097558","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methamphetamine Hydrochloride","moa":"||Serotonin","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ENOB-HV-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enochian BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MiroliverELAP","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Extended Release","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kernal Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Kernal Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kernal Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kernal Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1020","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oregon State University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oregon State University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oregon State University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oregon State University \/ Inapplicable"},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexpramipexole","moa":"Eosinophil maturation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Knopp Biosciences LLC \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Biosciences LLC \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roblitinib","moa":"||FGFR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IGM-8444","moa":"DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CI-8993","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"TLR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ponce De Leon Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Alpha-Ketoglutarate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ponce De Leon Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ponce De Leon Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ponce De Leon Health \/ Inapplicable"},{"orgOrder":0,"company":"Texas Biomedical Research Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Mycobacterium Bovis Bacille Calmette-Guerin Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Texas Biomedical Research Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Texas Biomedical Research Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Texas Biomedical Research Institute \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CoV2373","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"APN","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CB 4332","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VX-961","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ecog-Acrin Cancer Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Afatinib","moa":"ERBB4","graph1":"Oncology","graph2":"Phase II","graph3":"Ecog-Acrin Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ecog-Acrin Cancer Research Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ecog-Acrin Cancer Research Group \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Phenylephrine Hydrochloride","moa":"||M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MyoKardia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ MyoKardia","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ MyoKardia"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Nectero Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pentagalloyl Glucose","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Nectero Medical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"Nectero Medical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nectero Medical \/ Inapplicable"},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BIOQUAL","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BIOQUAL \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BIOQUAL \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"National Institutes of Health \/ Eli Lilly"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"SYNB2081","moa":"Undisclosed","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synlogic \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Synlogic \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"LSU Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"LSU Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LSU Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"LSU Health \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Dusquetide","moa":"p62 protein","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Novotech"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"University Hospitals Geneva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospitals Geneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University Hospitals Geneva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"University Hospitals Geneva \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"||Glutaminase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Imdusiran","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CB 2679d-GT","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Lyophilized Powder for Injection","sponsorNew":"Revolo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Pretomanid","moa":"||Mycolic acid biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TB Alliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TB Alliance \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Revumenib","moa":"MLL1-menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CTGF","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-Based eVLP Vaccine Platform","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"GB Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GB Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GB Sciences \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Defensin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BLU-945","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"iBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"IBIO-201","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"iBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"iBio \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"SUO-CTC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nadofaragene Firadenovec","moa":"INF-alpha 2b","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"SUO-CTC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"SUO-CTC \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"SUO-CTC \/ Inapplicable"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Degarelix Acetate","moa":"GnRH receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"VE202","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-Based Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied DNA Sciences Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DNA Sciences Inc \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SP-3204","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"University of Wisconsin School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Wisconsin School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Wisconsin School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"University of Wisconsin School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eterna Therapeutics \/ Lineage Cell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eterna Therapeutics \/ Lineage Cell Therapeutics"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"HT-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Injection","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"NT0200","moa":"DMPK","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"4P Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sorrento Therapeutics \/ 4P Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ 4P Therapeutics"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mount Sinai Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RV001","moa":"T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Mount Sinai Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mount Sinai Hospital \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mount Sinai Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MBX-2982","moa":"GPR119","graph1":"Endocrinology","graph2":"Phase II","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Minerva Neurosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Neurosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"CBSET","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ CBSET","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ CBSET"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"University of Iowa Holden Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ University of Iowa Holden Comprehensive Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Checkmate Pharmaceuticals \/ University of Iowa Holden Comprehensive Cancer Center"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KER-047","moa":"ALK-2","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CytoTIL15","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Obsidian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Obsidian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABI-H3733","moa":"HBV core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"MAT9001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matinas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma secretase","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Seasonal Influenza Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FCX-013","moa":"||MMP-1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Castle Creek Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"CD155","graph1":"Oncology","graph2":"Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Istari Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Istari Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sermonix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alvocidib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"VIR-2218","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Virus-like Particle COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dirocaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteostasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3006","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"HGF","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"OX2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"hP1A8","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"OX2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OX2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OX2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sirexatamab","moa":"DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"BIO89-100","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"||Helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IL-1 receptor-associated kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DLX-1","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nafamstat Mesylate","moa":"||Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Allied Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ALID-10","moa":"CB receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Allied Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allied Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allied Corp \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"American BriVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"American BriVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Inapplicable"},{"orgOrder":0,"company":"NellOne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NELL1","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NellOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NellOne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NellOne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATI-2173","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"BriOri BioTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical","sponsorNew":"BriOri BioTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BriOri BioTech \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACQT1127","moa":"Xanthine oxidase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Acquist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acquist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Acquist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"NB-02","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allied Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Allied Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allied Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allied Corp \/ Inapplicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Staphylococcus Epidermidis","moa":"SPINK5 gene","graph1":"Dermatology","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Azitra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ Inapplicable"},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SK1-I","moa":"Sphingosine kinase 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzo Biochem \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Biochem \/ Inapplicable"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Liquidia Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Liquidia Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HDAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CB 2782-PEG","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Catalyst Biosciences \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Biogen"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uttroside B","moa":"MAPK","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q BioMed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyadic International, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dyadic International, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Survivin","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regen BioPharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VERO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VERO Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VERO Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"VERO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BS01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sight \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"AntiCancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"AntiCancer","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AntiCancer \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Apoptosis","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Liechti Lab"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LPCN 1144","moa":"Homeostasis","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"GlycoMimetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ GlycoMimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ GlycoMimetics"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAPK\/p38 alpha","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||PSCA","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tobevibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-201","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSV Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Codagenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NC410","moa":"LAIR-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NC762","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GT103","moa":"CFH","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epirium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"177-Lu FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||JAK2\/FLT3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Relmapirazin","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Aerovate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Citrulline","moa":"Atherogenic","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baylor College of Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"M5049","moa":"TLR7\/8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GT103","moa":"CFH","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"6","companyTruncated":"Insignis Therapeutics \/ HLK Pharmacin"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JS016","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EmpathBio","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"EmpathBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"EmpathBio \/ ATAI Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"EmpathBio \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Samus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icapamespib","moa":"Epichaperome","graph1":"Neurology","graph2":"Phase I","graph3":"Samus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Samus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ANG-3070","moa":"RTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Angion Biomedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Inapplicable"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Neurology","graph2":"Phase I","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neuropore Therapies \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Neuropore Therapies \/ Celerion"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Utreloxastat","moa":"15-LOX","graph1":"Neurology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyteir Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CVL-936","moa":"D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xeruborbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Qpex Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SL-172154","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AGEN1223","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Apic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"APB-102","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Apic Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apic Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Apic Bio \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Descartes-30","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-240","moa":"4-1BB ligand\/IL-15","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARO-HSD","moa":"HSD17B13","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olutasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"RLYB-211","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Belrestotug","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rezatapopt","moa":"p53 Y220C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NexImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune \/ Inapplicable"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NDI-101150","moa":"||HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"LTI-03","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Lung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Lung Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lung Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Arcus Biosciences"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"RGLS4326","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"||ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"CB4211","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"CB4211","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"Tyrosine kinase KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||VE-PTP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"||Dipeptidyl peptidase 8\/9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP-1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Ribaxamase","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ABI-H2158","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sojournix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SJX-653","moa":"NK-3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix \/ Inapplicable"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Visus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MAU868","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Neuroptika","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRO-1","moa":"Semaphorin-3A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuroptika \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Elritercept","moa":"Activin receptor type 2A","graph1":"Oncology","graph2":"Phase III","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Lerapolturev","moa":"PD-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Istari Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Istari Oncology \/ Inapplicable"},{"orgOrder":0,"company":"DNAtrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"DNAtrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"DNAtrix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DNAtrix \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"T3D-959","moa":"PPA receptor-delta\/gamma","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Votoplam","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Eusa Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"||VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Eusa Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Eusa Pharma"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BTRX-140","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"BlackThorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"RSLV-132","moa":"RNA","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resolve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"||NAD","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"||NAD","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"VEGF","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"HGF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Sun Yat-sen University"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deuterated D-serine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||CD24","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ ViiV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ ViiV Healthcare"},{"orgOrder":0,"company":"VelosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zilovertamab","moa":"ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"VelosBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VelosBio \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Phoenix Tissue Repair","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"BBP-589","moa":"rC7 replacer","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Phoenix Tissue Repair","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Phoenix Tissue Repair"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abpro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"||DLL4\/VEGF","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Metacrine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MET642","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metacrine \/ Inapplicable"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Arena Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"CXCR2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SAB-176","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin M beta receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KBP Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Olezarsen","moa":"APOC-III","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Rigel Pharmaceuticals \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Factor Xa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Levoketoconazole","moa":"CYP11B1\/CYP11A1\/CYP17A1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSVpreF","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"Organogenesis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AgenT-797","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"CBX-12","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Cybrexa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GTB-3550","moa":"CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRGN-2009","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-111","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATI-2173","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA2001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pharm-Olam \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Elorac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Elorac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Elorac \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elorac \/ Inapplicable"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-102","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Phylex Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Nipah mRNA Nanoparticle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phylex Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phylex Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phylex Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nedosiran","moa":"LDH","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vocacapsaicin","moa":"TRPV1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concentric Analgesics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"AbFero Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SP-420","moa":"Iron","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"AbFero Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbFero Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbFero Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProtoKinetix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Inapplicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ATI-2173","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clofutriben","moa":"HSD-1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SPR720","moa":"DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Magdalena Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jaguar Health \/ Magdalena Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Health \/ Magdalena Biosciences"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kamuvudine","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Centocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Centocor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centocor \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"26-kDa","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor-alpha 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Preclinical","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-783","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"QRA-244","moa":"KV7.2\/7.3 potassium channel","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bizaxofusp","moa":"IL-4 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV204","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HPN424","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Acazicolcept","moa":"CD28\/ICOS","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MDK-271","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nf-kB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nf-kB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"Gelesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Citric Acid","moa":"||NGLY1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Gelesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gelesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gelesis \/ Inapplicable"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"OWP Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Larsucosterol","moa":"DNMTs","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maverick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Maverick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"VPS4A","graph1":"Oncology","graph2":"Preclinical","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Tiburio Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tbr-760","moa":"D2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Tiburio Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tiburio Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiburio Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Discovery","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"AIM Biologicals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Aeterna Zentaris \/ AIM Biologicals","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Zentaris \/ AIM Biologicals"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IO-108","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Natural killer cell","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"PH-762","moa":"||PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Paragon Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"LV-FAH","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Castle Creek Biosciences \/ Paragon Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Castle Creek Biosciences \/ Paragon Biosciences"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PulmoSIM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"PD-L1","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"PulmoSIM Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PulmoSIM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PulmoSIM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CLS-002","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comera Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Isterian Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IST-01","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Isterian Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Isterian Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Isterian Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AT-H201","moa":"SARS-CoV-2 N-protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TPX-100","moa":"Type II collagen","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"OrthoTrophix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTrophix \/ Inapplicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ANG-3070","moa":"RTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Angion Biomedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Neurology","graph2":"Phase I","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"MBT2","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"MASP-3","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"||Helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OpRegen","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Amgen Inc"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SBT6050","moa":"TLR8","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MEM-288","moa":"CD40","graph1":"Oncology","graph2":"Preclinical","graph3":"Memgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memgen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Memgen \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"DHX9","graph1":"Oncology","graph2":"Preclinical","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Accent Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Accent Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"EGFR","graph1":"Oncology","graph2":"Discovery","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INT301","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Paste","sponsorNew":"Intrommune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"GBA1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolperisone","moa":"NaV sodium channel","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Synthetic AAV Capsid Protein","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Dyno Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Dyno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Promentis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SXC-2023","moa":"SLC7A11 protein","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Promentis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Promentis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promentis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TPX-100","moa":"Type II collagen","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"OrthoTrophix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTrophix \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Merck & Co"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MDR-101","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Seal Rock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Caficrestat","moa":"Aldose reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"H3B-6545","moa":"Selective estrogen receptor covalent","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"H3 Biomedicine Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"H3 Biomedicine Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"H3 Biomedicine Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ALG-010133","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Halobetasol","moa":"||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Saposin C","moa":"S1PR","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV200","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Vedere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-005","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avita Medical \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celecoxib","moa":"||COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kowa Pharmaceuticals America \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Kedrion IVIG","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Colesevelam Hydrochloride","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"HDV receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"TLR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Milademetan","moa":"MDM2","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dociparstat Sodium","moa":"HMGB1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Chimerix \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Yale School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Ceruvia Lifesciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ceruvia Lifesciences \/ Yale School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Ceruvia Lifesciences \/ Yale School of Medicine"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REVTx-99b","moa":"CCR3","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upacicalcet Sodium","moa":"CaR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pathalys Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pathalys Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACP-044","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HC-5404","moa":"Endoplasmic reticulum stress","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BNC210","moa":"nAChR alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuphoria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuphoria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"RG6501","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HilleVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HilleVax \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"CTGF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilparencel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProKidney \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coordination Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Coordination Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coordination Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coordination Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||PK M1\/M2","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enzomenib","moa":"||Menin and mixed-lineage leukemia interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AT-GTX-501","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Oncology","graph2":"Preclinical","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR006","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Bioresearch \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Bioresearch \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sermonix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tulane University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tulane University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tulane University \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QED Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tanfanercept","moa":"TNF-alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Endocrinology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"TGF-beta-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CiVax","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Palette Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Palette Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palette Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Palette Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRV-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methoxyamine","moa":"||DNA base excision repair pathway","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AGT103-T","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Gene Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"American Gene Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Seasonal Influenza Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Creative Bio-Peptides","sponsor":"The Center for Substance Abuse Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"RAP-103","moa":"CXCR4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Creative Bio-Peptides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creative Bio-Peptides \/ The Center for Substance Abuse Research","highestDevelopmentStatusID":"4","companyTruncated":"Creative Bio-Peptides \/ The Center for Substance Abuse Research"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolperisone","moa":"NaV sodium channel","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seurat Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"IGF-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Seurat Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Seurat Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seurat Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclacel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclacel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolperisone","moa":"NaV sodium channel","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HMI-102","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"REGN10933","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ ReGenTree"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GRT-C903","moa":"||CD8 positve cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EHP-101","moa":"PPA receptor-gamma","graph1":"Neurology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emerald Health Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"The ALS Association","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirasemtiv","moa":"Troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ The ALS Association","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ The ALS Association"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"R21\/Matrix-M Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FP-025","moa":"MMP-12","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Metyrapone","moa":"||CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Embera NeuroTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Hermann-Texas Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Hermann-Texas Medical Center","highestDevelopmentStatusID":"5","companyTruncated":"Akebia Therapeutics \/ Hermann-Texas Medical Center"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"IL-12 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darigabat","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ANX007","moa":"C1q","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Human Ghrelin","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxeia Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yiviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Sorafenib","moa":"||NFAT","graph1":"Oncology","graph2":"Phase II","graph3":"Yiviva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yiviva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yiviva \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Oregon Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VIR-1111","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Oregon Health","highestDevelopmentStatusID":"6","companyTruncated":"Vir Biotechnology \/ Oregon Health"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MKS Enterprise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Caviar","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"MKS Enterprise","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Sachet","sponsorNew":"MKS Enterprise \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MKS Enterprise \/ Inapplicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"REGN10933","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"REGN-EB3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Legend Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Legend Biotech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Myovant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Myovant Sciences"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irvine School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Irvine School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Pandion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Centivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Centivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Centivax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Centivax \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ab8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"VPS4A","graph1":"Oncology","graph2":"Preclinical","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MCB-613","moa":"Steroid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Baylor College of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Medolife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Caribbean Blue Scorpion Peptides Derived Extract","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medolife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medolife \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medolife \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Seribantumab","moa":"HER3","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"QPX9003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qpex Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Corino Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolcapone","moa":"COMT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Corino Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corino Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corino Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"RLYB-212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RHX-317","moa":"MALT1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AFX3772","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Astellas Pharma"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BSK01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"PathAI, inc","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"PathAI, inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PathAI, inc \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"PathAI, inc \/ Novo Nordisk"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SHP656","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xenetic Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Feinstein Institutes","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Feinstein Institutes","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Feinstein Institutes"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB174","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Cytokinetics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Cytokinetics","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Cytokinetics"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Stanford University","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Stanford University"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antares Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Enochian BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"||NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Panitumumab","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"Microbiome diversity","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Flotetuzumab","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-216","moa":"FXN gene transcription","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olorinab","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Fragile X Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Preclinical","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Fragile X Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Synaptogenix \/ Fragile X Foundation"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CYNK-101","moa":"||CD38","graph1":"Oncology","graph2":"Preclinical","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medolife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Medolife","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Medolife \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medolife \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Ligand gated ion channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Coda Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Coda Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASN008","moa":"NaV sodium channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coda Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Coda Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-253","moa":"MDM2","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HMI-102","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MedStar Washington Hospital Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"MedStar Washington Hospital Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MedStar Washington Hospital Center \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MedStar Washington Hospital Center \/ Inapplicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neratinib","moa":"||EGFR\/HER2\/HER4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"CSIRO","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Receptor Life Sciences \/ CSIRO","highestDevelopmentStatusID":"7","companyTruncated":"Receptor Life Sciences \/ CSIRO"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CD377","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Adenovirus-vectored Anthrax Vaccine","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ BARDA"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytoAgents \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"20vPnC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Batiraxcept","moa":"||AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"EMD Serono \/ Merck & Co"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"||FGFR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Erdafitinib","moa":"||FGFR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BB21217","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"2Seventy Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Idursulfase","moa":"||IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"FGF23","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Usona Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Usona Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Usona Institute \/ Inapplicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tolperisone","moa":"NaV sodium channel","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Nebraska Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"University of Nebraska Medical Center \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Nebraska Medical Center \/ Inapplicable"},{"orgOrder":0,"company":"Beroni Group","sponsor":"Tianjin University in China","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beroni Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Beroni Group \/ Tianjin University in China","highestDevelopmentStatusID":"4","companyTruncated":"Beroni Group \/ Tianjin University in China"},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PEEL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"PEEL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PEEL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-TT170","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ALLO-213","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncorus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ONCR-021","moa":"ICAM-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncorus \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Biocon"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HPK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MLE-301","moa":"NK3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Millendo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Immunology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Caffeine","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GNE-0723","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Adlon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adlon Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adlon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adlon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Segesterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Implant","sponsorNew":"TherapeuticsMD \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"||GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entera Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"EnteraGam","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Entera Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entera Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Entera Health \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD8","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rodatristat Ethyl","moa":"TPH","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inspirevax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oragenics \/ Inspirevax","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Inspirevax"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Evolocumab","moa":"PCSK9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncocyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Oncocyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncocyte \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncocyte \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ University of Oxford","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ University of Oxford"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone bio \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Columbia University \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Inapplicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"APP","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"LSNME\/SW1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capricor Therapeutics \/ Johns Hopkins University","highestDevelopmentStatusID":"4","companyTruncated":"Capricor Therapeutics \/ Johns Hopkins University"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Anandamide","moa":"C3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Anandamide","moa":"C3 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"H1 Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DNA-Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Applied DNA Sciences Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DNA Sciences Inc \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MVA-MARV-VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeoVax Labs \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GeoVax Labs \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GMI-1757","moa":"E-selectin","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarametyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clarametyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MET","graph1":"Oncology","graph2":"Undisclosed","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Tolmar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tolmar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ad26.Mos4.HIV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GX-03","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Turn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Timrepigene Emparvovec","moa":"Human choroideremia gene","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Segal Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Segal Trials","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Segal Trials"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Inapplicable","leadProduct":"177-Lu PNT6555","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Point Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of North Carolina \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of North Carolina \/ Inapplicable"},{"orgOrder":0,"company":"Aravive","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AVB-500","moa":"||AXL\/GAS6 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aravive \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Heidelberg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Heidelberg Pharma"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lupus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolperisone","moa":"NaV sodium channel","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Neurana Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurana Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffyImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HepTcell","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dibuprenorphine-ethyl-ether","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrphoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"VE-PTP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"RGLS4326","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Bioventus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PTP-001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Bioventus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Bioventus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioventus \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Eyenovia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"resTORbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dactolisib","moa":"TORC1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"resTORbio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"resTORbio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"resTORbio \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"AG019","moa":"IL-10","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Istaroxime","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-2004","moa":"Microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"||Androgen receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IONIS-ENAC-2.5Rx","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Grifola Frondosa Extract","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sangivamycin Hydrochloride","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oyagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oyagen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oyagen \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Boston University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boston University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boston University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boston University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GB-401","moa":"ADRB","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant, Sustained Release","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Relief Therapeutics"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Intestinal gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BXT-10","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioxytran \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioxytran \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beat AML, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||CD200","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beat AML, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beat AML, LLC \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beat AML, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"NeurAegis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Calpain-2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeurAegis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeurAegis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeurAegis \/ Inapplicable"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Kirsten rat sarcoma G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontier Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Frontier Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Netarsudil Mesylate","moa":"||ROCK","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recardio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dutogliptin Tartrate","moa":"||DPP-4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyldopa","moa":"Adrenergic alpha-2A receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"CogState","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-458","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ CogState","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ CogState"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SL-172154","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS119","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TP-3654","moa":"PIM kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"||G\/10-associated SHP1 signaling","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pelareorep","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MDNA11","moa":"IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Brigham and Women\u2019s Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brigham and Women\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brigham and Women\u2019s Hospital \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Brigham and Women\u2019s Hospital \/ Inapplicable"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Research \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Scripps Research \/ Inapplicable"},{"orgOrder":0,"company":"PATH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HeV-sG-V","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PATH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PATH \/ Inapplicable"},{"orgOrder":0,"company":"Shasqi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SQ3370","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"||HGF IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"REMD Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Volagidemab","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"REMD Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"REMD Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"REMD Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"NICHD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ NICHD","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ NICHD"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Evidation Health","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evidation Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evidation Health \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Evidation Health \/ Sanofi"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ OPKO Health"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"||HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BioCorRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"BioCorRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Organon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FOR-6219","moa":"HSD17B1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Organon \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Volixibat","moa":"AAK-1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ABM-05X","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"AmMax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tanezumab","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Eli Lilly"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WM382","moa":"Plasmepsins IX\/X","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"University of Notre Dame","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"B-I09","moa":"IRE-1 RNAse","graph1":"Oncology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Wistar Institute \/ University of Notre Dame","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar Institute \/ University of Notre Dame"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ricin Toxin Vaccine","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"||TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"EDP1815","moa":"Th1\/2\/17","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SON-1010","moa":"INF-gamma","graph1":"Oncology","graph2":"Preclinical","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PiN-21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"IncellDx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maraviroc","moa":"CCR5","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IncellDx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IncellDx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IncellDx \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gacyclidine","moa":"NMDA","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Monopteros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MPT-0118","moa":"||MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"Monopteros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monopteros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopteros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GEN-009","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Shimadzu","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Cetuximab Sarotalocan","moa":"ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rakuten Medical \/ Shimadzu","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ Shimadzu"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rigosertib","moa":"||RAS pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Lucinactant","moa":"SERCA2a","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Liquid","sponsorNew":"Windtree Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Entinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ AC Immune"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Temsirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mercator MedSystems \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mercator MedSystems \/ Inapplicable"},{"orgOrder":0,"company":"NanOlogy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/ Inapplicable"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TissueGene-C","moa":"Chondrocyte","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Kolon TissueGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon TissueGene \/ Inapplicable"},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AV-GBM-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Neihulizumab","moa":"PSGL-1","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Revolution Medicines \/ Amgen Inc"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CFI-400945","moa":"PLK4","graph1":"Oncology","graph2":"Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoMolecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyldopa","moa":"Adrenergic alpha-2A receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"ImmunoMolecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ImmunoMolecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMolecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BCDA-03","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-134","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DSG3-CAART","moa":"DSG3","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ALG-020572","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eprenetapopt","moa":"||p53 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"G\/10-associated SHP1 signaling","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Promethera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HepaStem","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Promethera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Promethera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Promethera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ANA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CRX100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Mast cell","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin M beta receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Vifor Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chiasma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiasma \/ Inapplicable"},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rencofilstat","moa":"Cyclophilin A","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Emvododstat","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cellf BIO","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Autologous Bioengineered Internal Anal Sphincter","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cellf BIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cellf BIO \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellf BIO \/ Inapplicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encapsulated Live Cell Ifosamide Prodrug","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Injection","sponsorNew":"PharmaCyte Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Cetuximab Sarotalocan","moa":"||ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rakuten Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ Inapplicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10","graph1":"Immunology","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Biolojic Design"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||GCSF","graph1":"Hematology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Nephrology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olatec Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Olatec Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trovagene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TERN-201","moa":"SSAO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ National Institutes of Health"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibutamoren","moa":"Growth hormone secretagogue receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lumos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NeurMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Circularity Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Circularity Healthcare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Circularity Healthcare \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Circularity Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||IL-23-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Inapplicable"},{"orgOrder":0,"company":"Alkahest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CXCR3 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkahest \/ Inapplicable"},{"orgOrder":0,"company":"Immunophotonics","sponsor":"Swiss Group for Clinical Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-dihydrogalactochitosan","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunophotonics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Immunophotonics \/ Swiss Group for Clinical Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Immunophotonics \/ Swiss Group for Clinical Cancer Research"},{"orgOrder":0,"company":"University Hospitals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cetylpyridinium Chloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University Hospitals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University Hospitals \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health Clinical Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"mAb CIS43LS","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health Clinical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health Clinical Center \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health Clinical Center \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"The Lundquist Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"IL-1 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"The Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Lundquist Institute \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"The Lundquist Institute \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boston Scientific \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Boston Scientific \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"SARS-CoV-2 viral spike protein 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"AnGes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Trishula Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ttx-030","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Trishula Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trishula Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trishula Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Antolimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molibresib","moa":"||BET","graph1":"Oncology","graph2":"Preclinical","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IM156","moa":"Protein complex 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoMet \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoMet \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Par Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Par Pharmaceutical"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aadi Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aadi Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aadi Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"QED Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ QED Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ QED Therapeutics"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Succinylcholine Chloride","moa":"Ach receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Polykinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brilacidin","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"HPN217","moa":"CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"TfR1","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HST5040","moa":"CoA","graph1":"Neurology","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"HemoShear Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THIO-103","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FX-322","moa":"Stem cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moffitt Cancer Center \/ Anixa Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Moffitt Cancer Center \/ Anixa Biosciences"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cytisinicline Analog","moa":"Nicotinic receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ublituximab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Minnesota \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Biorasi"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ocedurenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Dynavax Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HPN217","moa":"CTLs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Methemoglobin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1273.351","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Taiga Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TBX-3400","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Taiga Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiga Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiga Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"American CryoStem Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"American CryoStem Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American CryoStem Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"American CryoStem Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bexson Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"NellOne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NV1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NellOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NellOne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NellOne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Inactivated Seasonal Influenza Vaccine Quadrivalent","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"qIRV (22\/23)","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Global WholeHealth","sponsor":"Nunzia Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Global WholeHealth","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Global WholeHealth \/ Nunzia Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Global WholeHealth \/ Nunzia Pharmaceutical"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Fusogenix DNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entos Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Entos Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLA-SE Adjuvant","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Inapplicable"},{"orgOrder":0,"company":"University of Florida","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RNA-LNP Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Florida \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"University of Florida \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COH04S1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VSV-SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"University of Georgia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Georgia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Georgia \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"||Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Merck & Co"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Momenta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Momenta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Momenta Pharmaceuticals"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ World Health Organization","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ World Health Organization"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"XmAb30819","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"XMT-2056","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"THE-630","moa":"pan-variant KIT","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"THE-630","moa":"pan-variant KIT","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"ClearB Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CLB-3000","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ClearB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ClearB Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ClearB Therapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nezulcitinib","moa":"JAK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivumecirnon","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapt Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RP-L102","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"ThermoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ThermoGenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ThermoGenesis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ThermoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Brown Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HDAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Risuteganib","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"GeneDx","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSHA-120","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ GeneDx","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ GeneDx"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BNZ-1","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-201","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Exhale Wellness","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"Exhale Wellness \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exhale Wellness \/ Inapplicable"},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Decibel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Filovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KemPharm \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KemPharm \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-501","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"KB105","moa":"Transglutaminase 1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM120","moa":"||GFRAL","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MDNA11","moa":"IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"PhorMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"12-O-Tetradecanoylphorbol-13-acetate","moa":"IL-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"PhorMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhorMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PhorMed \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"IL-23-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Protein Filovirus Vaccine Recombinant, Aluminum-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THE-630","moa":"pan-variant KIT","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theseus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theseus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta 1\/COX-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Immunitybio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CytRx Corporation \/ Immunitybio","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corporation \/ Immunitybio"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SFA-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SFA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"OWP Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Preclinical","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Flatiron Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cetuximab","moa":"ErbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Flatiron Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flatiron Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Flatiron Health \/ Inapplicable"},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Devimistat","moa":"||Pyruvate dehydrogenase","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerstone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"Radiolabelled MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"1","companyTruncated":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Glycomimetics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Glycomimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Glycomimetics"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eagle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Hematology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ OPKO Health"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Celid Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AdCLD-CoV19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celid Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celid Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Celid Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NTM-006","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CohBar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"CB4211","moa":"Insulin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||CTGF","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Emerald Health Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cerium Oxide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCurity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ischemic-Tolerant Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stemedica Cell Technologies \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Stemedica Cell Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gemfibrozil","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Genentech"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celltex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Celltex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celltex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"National Heart, Lung, And Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ National Heart, Lung, And Blood Institute","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ National Heart, Lung, And Blood Institute"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BS01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sight \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Baylx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BX-U001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baylx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Athersys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Athersys \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Athersys \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"||Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Samsung Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Samsung Biologics"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Immunicom","sponsor":"Acibadem University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunicom","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunicom \/ Acibadem University","highestDevelopmentStatusID":"15","companyTruncated":"Immunicom \/ Acibadem University"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CFI-400945","moa":"||PLK4","graph1":"Oncology","graph2":"Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CRX100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Inapplicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inspyr Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RT-AR001","moa":"Adenosine receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Inspyr Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Inspyr Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Inspyr Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Protein synthesis","graph1":"Dermatology","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"Amyloid-beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"CX-2029","moa":"CD71","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CRX100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abzyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Abzyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abzyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abzyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SRK-181","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ADM03820","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ology Bioservices","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ology Bioservices \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ology Bioservices \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1215","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"PN-232","moa":"IL-23","graph1":"Immunology","graph2":"Phase I","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Betaliq","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BTQ-1901-A","moa":"Beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Betaliq","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Betaliq \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Betaliq \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Hepcidin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"GreenLight Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ GreenLight Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ GreenLight Clinical"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LN-145","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Merck Group"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"PKX-001","moa":"COX-2 expression","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProtoKinetix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Inapplicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famciclovir","moa":"||HSV-1 DNA polymerase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Virios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RBN-2397","moa":"PARP7","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Rebonuputemcel","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"DiscGenics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-CVX1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Applied Biology","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimozide","moa":"Dopamine receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Safety Shot \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Safety Shot \/ Applied Biology"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BNZ-1","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Immunology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avita Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medical \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ UCLA","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ UCLA"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CDX-527","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"NLC Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ NLC Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ NLC Pharma"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALG-010133","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALG-010133","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"ApolloBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","graph1":"Oncology","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ ApolloBio","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pharmaceuticals \/ ApolloBio"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Organicell Flow","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organicell Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ALG-010133","moa":"S-antigen transport","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ObvioHealth","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Upamostat","moa":"Serine protease S1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ObvioHealth","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ObvioHealth \/ RedHill Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"ObvioHealth \/ RedHill Biopharma"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BDC-2034","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||p-STAT3","graph1":"Oncology","graph2":"Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CymaBay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"TRV027","moa":"AT1 receptor selective","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trevena \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Imperial College London"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"NTFs","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TeraImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Onco360","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivosidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Servier","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Servier"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated Tick-Borne Encephalitis Vaccine","moa":"Immunomodulator","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TIDAL-01","moa":"T-lymphocyte","graph1":"Oncology","graph2":"IND Enabling","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Turnstone Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TIDAL-01","moa":"TIL","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tidutamab","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lifileucel","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LN-145","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lifileucel","moa":"T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"NightstaRx Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Timrepigene Emparvovec","moa":"Human choroideremia gene","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ NightstaRx Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ NightstaRx Ltd"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Teclison","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirapazamine","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Teclison","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Trans-arterial Injection","sponsorNew":"Teclison \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Teclison \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tirofiban","moa":"Integrin-alpha 2b\/beta 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"TissueTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"TTBT01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TissueTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TissueTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TissueTech \/ Inapplicable"},{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"University of Louisville","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Maxwell Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maxwell Biosciences \/ University of Louisville","highestDevelopmentStatusID":"4","companyTruncated":"Maxwell Biosciences \/ University of Louisville"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"||Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Genmab","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Genmab"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tivozanib","moa":"VEGFR1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TL-925","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Telios Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Lipocine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Antares Pharma \/ Lipocine","highestDevelopmentStatusID":"15","companyTruncated":"Antares Pharma \/ Lipocine"},{"orgOrder":0,"company":"Lipocine","sponsor":"Antares Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Antares Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Antares Pharma"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLC-2716","moa":"Liver X receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"OrsoBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Inapplicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLC-3595","moa":"ACC2","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OrsoBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ Inapplicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OrsoBio \/ Samsara BioCapital","highestDevelopmentStatusID":"5","companyTruncated":"OrsoBio \/ Samsara BioCapital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"OrsoBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Inapplicable"},{"orgOrder":0,"company":"Vial","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Vial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vial \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vial \/ Inapplicable"},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TLY012","moa":"DR5","graph1":"Immunology","graph2":"Preclinical","graph3":"Theraly Fibrosis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theraly Fibrosis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theraly Fibrosis \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sitaxentan","moa":"Endothelin receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TMP-301","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempero Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TN-301","moa":"HDAC6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TN-301","moa":"HDAC6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TN-301","moa":"HDAC6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TN-301","moa":"HDAC6","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-401","moa":"PKP2 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TN-401","moa":"PKP2 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-401","moa":"PKP2 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-401","moa":"PKP2 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-486","moa":"CD3\/19","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG260","moa":"CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG260","moa":"||CoREST-HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG348","moa":"||USP1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TNG462","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TNG908","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tango Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Nephrology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Nephrology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Nephrology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Nephrology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TNX-1700","moa":"||TFF2","graph1":"Oncology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"TNX-1800","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Magnesium Potentiated Oxytocin","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Oxytocin receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TNX-3400","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TNX-3600","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Estianeptine","moa":"PPAR-beta\/gamma\/delta","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT Reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Alberta","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Alberta","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Alberta"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tnx-801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"A&G Pharmaceutical","sponsor":"Precision Antibody","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Preclinical","graph3":"A&G Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A&G Pharmaceutical \/ Precision Antibody","highestDevelopmentStatusID":"4","companyTruncated":"A&G Pharmaceutical \/ Precision Antibody"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Seattle Children\u2019s Research Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seattle Children\u2019s Research Institute \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Seattle Children\u2019s Research Institute \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"||Cyclophilin A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension","sponsorNew":"Quantum Leap Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Leap Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TP-1454","moa":"PK M1\/M2","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dubermatinib","moa":"AXL receptor tyrosine kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-001","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Todos Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NLC-V-01","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Todos Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medical \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"||pH","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Transdermal Cream","sponsorNew":"Dyve Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||VE-PTP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"BriOri BioTech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"BriOri BioTech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BriOri BioTech \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"Gwt1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"CB2 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scioto Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TGN-S11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Luspatercept","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 signalling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tourmaline Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 signalling pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tourmaline Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TOUR006","moa":"IL-6 signalling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tourmaline Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline Bio \/ Inapplicable"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dyadic International, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic International, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TPN-101","moa":"Reverse transcriptase","graph1":"Neurology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Transposon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Transposon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TPN-101","moa":"Reverse transcriptase","graph1":"Neurology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Transposon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Transposon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Meridian Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Meridian Medical Technologies","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Meridian Medical Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Patheon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Patheon","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Patheon"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Adagene Suzhou Limited","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Adagene Suzhou Limited"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TPST-1495","moa":"PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Neurology","graph2":"Phase II","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Teikoku Pharma USA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Pharma USA \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Turning Point Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Turning Point Therapeutics"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"ROS1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TPX0022","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TPX-0131","moa":"Anaplastic lymphoma kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"TPX-100","moa":"Type II collagen","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"OrthoTrophix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTrophix \/ Inapplicable"},{"orgOrder":0,"company":"Novatek Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Thymoquinone","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novatek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Novatek Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novatek Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1a","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1a","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Dermatology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"||Passive oxygen diffusion","graph1":"Oncology","graph2":"Phase III","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Surmodics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Surmodics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"NICE","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ NICE","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ NICE"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80s ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"InGeneron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InGeneron \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"InGeneron \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TRexBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRB-061","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TRexBio \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methoxyamine","moa":"||DNA base excision repair pathway","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"TRACON Pharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ National Cancer Institute"},{"orgOrder":0,"company":"Trethera","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ UCLA"},{"orgOrder":0,"company":"Trethera","sponsor":"Mabwell Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Mabwell Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Mabwell Bioscience"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CFI-402411","moa":"||HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CFI-402411","moa":"HPK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bavituximab","moa":"||Phosphatidylserine","graph1":"Oncology","graph2":"Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OncXerna Therapeutics \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"8","companyTruncated":"OncXerna Therapeutics \/ National Comprehensive Cancer Network"},{"orgOrder":0,"company":"iCAD","sponsor":"Xoft Brain","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Phase II","graph3":"iCAD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"iCAD \/ Xoft Brain","highestDevelopmentStatusID":"8","companyTruncated":"iCAD \/ Xoft Brain"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ImmunoPrecise \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Aducanumab","moa":"Amyloid-beta aggregation","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AT-GTX-501","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"MeiraGTx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pozelimab","moa":"C5 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulfiram","moa":"Aldehyde dehydrogenase","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Aging \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"KIF18A","graph1":"Oncology","graph2":"Preclinical","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Volastra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Volastra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KTX-0200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kintai Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kintai Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"New York Heart Association","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ New York Heart Association","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ New York Heart Association"},{"orgOrder":0,"company":"Genelux","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Abatacept","moa":"||GMP-AMP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Organicell Flow","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Myovant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Myovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Myovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Surrozen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SZN-1326","moa":"Lrp6","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surrozen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MDNA19","moa":"PD-1\/IL-2 super","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMM20059","moa":"EPN1","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pentoxifylline","moa":"TNF-alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Powder for Inhalation","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Ad5 CEA\/MUC1\/Brachyury Vaccine Tri-Ad5","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elobixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"Neuropilin-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Marigold Extract","moa":"||Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Healthy Extracts","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Healthy Extracts \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TERN-101","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"89bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegozafermin","moa":"FGF21","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Merck & Co"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"LIPAC Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Oncology \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vebicorvir","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ BeiGene"},{"orgOrder":0,"company":"Kowa Research Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"PPA receptor-alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kowa Research Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Research Institute \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Apamistamab","moa":"CD45","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Old Dominion University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trident Cold Atmospheric Plasma","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Old Dominion University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Old Dominion University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Old Dominion University \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Suspension","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"||Transferrin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trilaciclib","moa":"||CDK 4\/6","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Trimethoprim","moa":"Tetrahydrofolatedehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"TrippBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TD213","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"TrippBio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tract Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TRK-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tract Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tract Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tract Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Everest Medicines"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ University of Florida"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triphase Accelerator \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Triphase Accelerator \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triphase Accelerator \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Triphase Accelerator \/ Inapplicable"},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TRPML1","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Caraway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TRPML1","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Caraway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"TRPML1","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Caraway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"TRV027","moa":"AT1 receptor selective","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"TRV027","moa":"AT1 receptor selective","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trevena \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ National Institutes of Health"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1R","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1R","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1R","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1R","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1R","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travatrelvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travatrelvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Trawsfynydd Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travatrelvir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trawsfynydd Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trawsfynydd Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trawsfynydd Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tr1X Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Amino acid metabolism","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine HCl","moa":"||Amino acid metabolism","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tryp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-101","moa":"HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-101","moa":"HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TSC-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-101","moa":"HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-101","moa":"HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-200-A02","moa":"MHC","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-203","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-200-A0201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-203-A0201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-204-A0201","moa":"MAGE-A1","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"T-cell","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSHA-101","moa":"HEXA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TSHA-101","moa":"HEXA gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TSHA-103","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TSHA-105","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TSHA-105","moa":"AChE","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSHA-120","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSHA-120","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSHA-120","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TT-816","moa":"||CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Trefoil Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"||STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tvardi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||SIRP alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Miami Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Miami Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Miami Cancer Institute"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pharmaceuticals \/ Michigan Medicine"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pharmaceuticals \/ Michigan Medicine"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Lenox Hill Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Lenox Hill Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Lenox Hill Hospital"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"||RAGE","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trishula Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ttx-030","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Trishula Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trishula Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Trishula Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TTX-080","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trueline Therapeutics","sponsor":"Broad Institute of Harvard","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TTX-810","moa":"MCL1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Trueline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Trueline Therapeutics \/ Broad Institute of Harvard","highestDevelopmentStatusID":"5","companyTruncated":"Trueline Therapeutics \/ Broad Institute of Harvard"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-RIGA","moa":"RIG-I","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-RIGA","moa":"RIG-I","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||PD-1\/PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||HER2 TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"ALT-702","moa":"TLR7\/8","graph1":"Oncology","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-605","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TVGN 920","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"T-VIVA-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Travecta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TVT-004","moa":"CB receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Travecta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travecta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Travecta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"||Androgen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agile Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"OTC mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.ZEBOV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"UT Southwestern Medical Center \/ Inapplicable"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"FIN-211","moa":"Gastrointestinal microbiome","graph1":"Neurology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Finch Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Nrf2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"4","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bavdegalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VIC-1911","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VITRAC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Codexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ Inapplicable"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evofem Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ENOB-HV-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enochian BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"GALDERMA LABS LP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||RAR beta\/gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"GALDERMA LABS LP","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"GALDERMA LABS LP \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GALDERMA LABS LP \/ Inapplicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tectonic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tectonic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TX200","moa":"HLA-A2 receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TX200","moa":"HLA-A2 receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tectonic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Tectonic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Angiotensin (1-7)","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Constant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TXR-1208","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"twoXAR Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TXR-311","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"twoXAR Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TXR-711","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"twoXAR Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TN-301","moa":"HDAC6","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TYME-18","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"||Tyrosine hydroxylase","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyme Technologies \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-200","moa":"FGFR1\/2\/3","graph1":"Oncology","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"nACh receptor alpha-4 beta-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Oyster Point Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teplizumab","moa":"CD3","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Saposin C-dioleoylphosphatidylserine","moa":"Spingomyelinase catalysis","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amifampridine Phosphate","moa":"KV potassium ion channel","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Filgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv BioSciences","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Kashiv BioSciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Taurolidine","moa":"||TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CorMedix \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carglumic Acid","moa":"CPS1","graph1":"Hematology","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"ProSciento","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Skye Bioscience \/ ProSciento","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ ProSciento"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha 4\/beta 1","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZN-D5","moa":"Bcl-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"B cell","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"||Glutamine","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidutolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Magnesium Potentiated Oxytocin","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"HST-003","moa":"Hyaline cartilage","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cudetaxestat","moa":"||Autotaxin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blade Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Metacrine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MET409","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2G receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYNK-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-189","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CERC-006","moa":"mTOR 1\/2 complex","graph1":"Oncology","graph2":"Preclinical","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecor \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cerecor \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ansuvimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ridgeback Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ridgeback Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Casimersen","moa":"Exon 45","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Signature Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Micronized Umbilical Cord Tissue","moa":"Cell growth","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Signature Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Signature Biologics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Signature Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pralsetinib","moa":"RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||26S proteasome","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Baylx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BX-U001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Baylx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BCX9930","moa":"Complement Factor D","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LNS8801","moa":"GPER","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ABI-H2158","moa":"||Viral core protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Polynoma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Seviprotimut-L","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"CTGF","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Cinrebafusp Alpha","moa":"4-1BB","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MetVital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enol-oxaloacetate","moa":"||Glutamate","graph1":"Oncology","graph2":"Phase II","graph3":"MetVital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MetVital \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MetVital \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Hematology","graph2":"Approved FDF","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rockwell Medical \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"PARP-delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NBI-921352","moa":"Nav1.6 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Morphine Sulfate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Orphenadrine","moa":"||H1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Galt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"||GMP-AMP synthase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Rilonacept","moa":"IL-1-alpha receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adaptive Biotechnologies \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Adaptive Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Pomalidomide","moa":"CBL-B","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Naxitamab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CLBS119","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AEVI-002","moa":"LIGHT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Acellular Vessel","moa":"Vascular Cell","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor-alpha3\/beta4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BPI-002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Cysteine Hydrochloride","moa":"Glutamate-cysteine ligase","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Norethisterone Acetate","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Slayback Pharma \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Lupin Ltd"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SRF617","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RP-L401","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Kaneka Nutrients","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Kaneka Nutrients","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Nutrients \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Nutrients \/ Inapplicable"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Spearmint Extract","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Healthy Extracts","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Healthy Extracts \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UB-VV100","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UB-VV111","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA2271","moa":"Mesothelin protein","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Rhizen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Rhizen Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Rhizen Pharmaceuticals"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ublituximab","moa":"CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"Mucin 16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"Mucin 16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Washington University School of Medicine"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ University of Minnesota","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ University of Minnesota"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Rhizen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"TG Therapeutics \/ Rhizen Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Rhizen Pharmaceuticals"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ George Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ George Clinical"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CG Oncology \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncology \/ Merck & Co"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Tevogen Bio \/ Thomas Jefferson University","highestDevelopmentStatusID":"5","companyTruncated":"Tevogen Bio \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"SYN-020","moa":"Intestinal alkaline phosphatase","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Inapplicable"},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GT103","moa":"CFH","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Envafolimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Unesbulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Erlotinib","moa":"||TUSC2 gene","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPR720","moa":"DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"13-cis-RAMBA Retinamide","moa":"MNK1\/2 protein","graph1":"Oncology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Sapphire Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SBI-183","moa":"QSOX1","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AXIM Biotechnologies \/ Sapphire Biotech","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biotechnologies \/ Sapphire Biotech"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Umbralisib","moa":"||PI3K delta\/CK1 epsilon","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CancerVAX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"CancerVAX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CancerVAX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CancerVAX \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of California","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of California \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of California \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rhenium-186","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Plus Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Plus Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Flow Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"FlowVax COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Flow Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flow Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Flow Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Inapplicable"},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BOXR1030","moa":"T lymphocyte","graph1":"Oncology","graph2":"Preclinical","graph3":"Unum Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Unum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"UP421","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Launch Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Upacicalcet Sodium","moa":"CaR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pathalys Pharma \/ Launch Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pathalys Pharma \/ Launch Therapeutics"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Verekitug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Inapplicable"},{"orgOrder":0,"company":"Upstream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Upstream \/ Inapplicable"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Lifileucel","moa":"||T lymphocyte","graph1":"Oncology","graph2":"Approved FDF","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Abbvie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Abbvie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Abbvie Inc"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"CTNS","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alvocidib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ACTX-401","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Alcyone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alcyone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Glofitamab","moa":"||CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||GALV-GP R-protein","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"||BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"CD19","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BMS-986249","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"CytomX Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"PKX-001","moa":"COX-2 expression","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"ProtoKinetix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CB-010","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ IQVIA"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Mayne Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Mayne Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Mayne Pharma"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor 1","graph1":"Sleep","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carbamazepine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Douglas CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Douglas CDMO","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Douglas CDMO"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ ClearPoint Neuro"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Verekitug","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Upstream Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Approved FDF","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Zalifrelimab","moa":"TLR7","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vibegron","moa":"||ADRB3","graph1":"Urology","graph2":"Phase III","graph3":"Sumitovant Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sumitovant Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitovant Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta 1\/COX-2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"xCures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ulixertinib","moa":"MAPK ERK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"xCures","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"xCures \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"xCures \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tepotinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolinapant","moa":"X-linked apoptosis protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cord Blood-Derived T-Regulatory Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"AmideBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-G023","moa":"GCGR","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AmideBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Red Blood Cell-Encapsulated Arginine Deiminase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"||PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Astellas Pharma"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA A receptor alpha-4\/beta-2\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Athena Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Athena Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Evoke Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evoke Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"||FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Drospirenone","moa":"PR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ennaid Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ennaid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ennaid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Redpin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Ion Channel","graph1":"Neurology","graph2":"Preclinical","graph3":"Redpin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Redpin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Redpin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Labcorp","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Labcorp \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ Amgen Inc"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CiVax","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Uvax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"UVAX-1107","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Uvax Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Uvax Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Uvax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Uvax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"UVAX-1107","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Uvax Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Uvax Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Uvax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Uvax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"UVAX-1107","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Uvax Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uvax Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Uvax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"UX053","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX701","moa":"ATP7B copper transport","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"UX701","moa":"ATP7B copper transport","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UX701","moa":"ATP7B copper transport","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UX701","moa":"ATP7B copper transport","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX701","moa":"ATP7B copper transport","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-4157","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Faricimab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HD-MAP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TNX-1800","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"U.S. Renal Care","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ U.S. Renal Care","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ U.S. Renal Care"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dianhydrogalactitol","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Therapeutics \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor-alpha 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavacamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MyoKardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase I","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Nephrology","graph2":"Phase I","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ George Clinical","highestDevelopmentStatusID":"6","companyTruncated":"ZyVersa Therapeutics, Inc \/ George Clinical"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"V2R","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Fresenius Kabi USA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi USA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi USA \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"15-LOX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"15-LOX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Flatley Discovery Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"15-LOX","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Flatley Discovery Lab","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flatley Discovery Lab \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Flatley Discovery Lab \/ Inapplicable"},{"orgOrder":0,"company":"Vault Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vault Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vault Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vault Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MTBhsp70-avidin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Voltron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"H7N9-Targeted Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxxas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"PLX Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLX Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lonigutamab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"ValenzaBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lonigutamab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"ValenzaBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ValenzaBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ValenzaBio \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Vicineum","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VBI-2901","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"3-Antigen HBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"3-Antigen HBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||GB\/pp65 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BRII-179","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Brii Biosciences"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BRII-179","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminum phosphate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"VBI Vaccines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"VBI Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VBI-S","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivacelle Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle Bio \/ Inapplicable"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ReveraGen BioPharma \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen BioPharma \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VC-02","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"ViaCyte Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"ViaCyte Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ViaCyte Inc \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"VCA-894A","moa":"IGHMBP2","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VCA-894A","moa":"IGHMBP2","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VCAR33","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"VCN Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Theriva Biologics \/ VCN Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ VCN Biosciences"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Vedere Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ION541","moa":"Ataxin 2","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Nephrology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"FR104","moa":"CD28","graph1":"Nephrology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Ainos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Inapplicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ainos \/ Inapplicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ Inapplicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Inapplicable"},{"orgOrder":0,"company":"Ainos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ainos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Ainos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ainos \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"NovaBay Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VEE DNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Needle-free Injection","sponsorNew":"PharmaJet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmaJet \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Ventus Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VENT-03","moa":"CGAS","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VENT-02","moa":"NLRP3","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ventus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VENT-02","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ventus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VENT-03","moa":"CGAS","graph1":"Immunology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VENT-03","moa":"CGAS","graph1":"Immunology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pozelimab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Verndari","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VaxiPatch COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verndari","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dermal Patch","sponsorNew":"Verndari \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Verndari \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vericiguat","moa":"sGC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Bayer AG"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PDS0203","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VERVE-102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VERVE-201","moa":"ANGPTL3 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vesselon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"STING","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Merck & Co \/ Vesselon","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co \/ Vesselon"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KaliVir Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KaliVir Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KaliVir Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KaliVir Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Vimgreen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VG081821AC","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Vimgreen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vimgreen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vimgreen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VG-3927","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VGT-1849A","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"University of Minnesota Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VITRAC Therapeutics \/ University of Minnesota Medical School","highestDevelopmentStatusID":"7","companyTruncated":"VITRAC Therapeutics \/ University of Minnesota Medical School"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VITRAC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Oportuzumab Monatox","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Oportuzumab Monatox","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Oportuzumab Monatox","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Oportuzumab Monatox","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Viventia Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Oportuzumab Monatox","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Viventia Bio","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Viventia Bio"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Vicineum","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Inapplicable"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pyros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pyros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Moxifloxacin Hydrochloride","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"Harrow \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Inapplicable"},{"orgOrder":0,"company":"Gradalis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gradalis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Inapplicable"},{"orgOrder":0,"company":"Gradalis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gradalis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Inapplicable"},{"orgOrder":0,"company":"Gradalis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gradalis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Inapplicable"},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pyros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pyros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pyros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1R\/GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vittoria Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VIR-2703","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VIR-1388","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tobevibart","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VIR-2482","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VIR-2482","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VIR-2482","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tobevibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Merimepodib","moa":"||IMPDH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Technologies \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"AlloVir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlloVir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vitalli Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"VIT-801","moa":"ITK\/BTK","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vitalli Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitalli Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vitalli Bio \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oteseconazole","moa":"CYP451","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mycovia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mycovia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin M beta receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1R\/GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1R\/GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1R\/GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1R\/GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VK2809","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VK2809","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VK2809","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VK2809","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Valneva","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Valneva"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynavax Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VLS-1488","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Volastra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Volastra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VLS-1488","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Volastra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Volastra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VLX-1005","moa":"12-LOX","graph1":"Hematology","graph2":"Phase II","graph3":"Veralox Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Veralox Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veralox Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VMT-alpha-NET","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Viewpoint Molecular Targeting","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viewpoint Molecular Targeting \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viewpoint Molecular Targeting \/ Inapplicable"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Melinta Therapeutics"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Volasertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Oncology","graph2":"Approved FDF","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CTI BioPharma Corp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CTI BioPharma Corp \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Phathom Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Phathom Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||CD33","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thermo Fisher Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Thermo Fisher Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vorasidenib","moa":"IDH-1","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Preclinical","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orsini Specialty Pharmacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Blueprint Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Blueprint Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VY-HTT01","moa":"HTT gene expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraparenchymal Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Sanofi"},{"orgOrder":0,"company":"Vyriad","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vyriad \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Vyriad \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31 gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31 gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VPO-227","moa":"CFTR","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"6","companyTruncated":"Vanda Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanqua Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vanqua Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanqua Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vanqua Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanqua Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanqua Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VQW-765","moa":"Alpha 7-nAChR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"VRDN-001","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Viridian Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viridian Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Viridian Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VRDN-003","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viridian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKFYVE","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKFYVE","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKFYVE","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKFYVE","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VRON-0200","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocean Biomedical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocean Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Virion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VRON-0200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocean Biomedical \/ Virion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ocean Biomedical \/ Virion Therapeutics"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VRON-0200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocean Biomedical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocean Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vasa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VS-041","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Vasa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vasa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vasa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"VT1021","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Vigeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VT1021","moa":"CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Vigeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vigeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Vigeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VT3989","moa":"TEAD autopalmitoylation","graph1":"Oncology","graph2":"Phase I","graph3":"Vivace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vivace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vita Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VTA-110","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vita Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vita Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vita Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Organon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Inapplicable"},{"orgOrder":0,"company":"Organon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Innovaderm","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Innovaderm"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trichostatin A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Massachusetts General Hospital's Vaccine and Immunotherapy Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VTX-067","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voltron Therapeutics \/ Massachusetts General Hospital's Vaccine and Immunotherapy Center","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Therapeutics \/ Massachusetts General Hospital's Vaccine and Immunotherapy Center"},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VTX-0P4","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voltron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VTX2735","moa":"NLRP3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"||NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VTX3232","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VTX3232","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tobramycin Sulfate","moa":"||Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tobramycin Sulfate","moa":"||Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tobramycin","moa":"||Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osteal Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PD-1\/CTLA-4","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"M3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Allergan Aesthetics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Diroximel fumarate","moa":"Nicotinic-alpha10 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP-1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vurolenatide","moa":"GLP-1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VVD-130037","moa":"KEAP1","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vividion Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vividion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxess","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MIMIX-flu Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxess","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxess \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxess \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"||SEMA4D","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"VX-264","moa":"Undisclosed","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VX-407","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"VX-522","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Preclinical","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VX-880","moa":"Pancreatic islet cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-G1.1-NN","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-G1.1-NN","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ad5 Norovirus GI.1 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-G1.1-NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VY1706","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Foslevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Novotech"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"VYD2311","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Pfizer Inc \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VY-HTT01","moa":"HTT gene expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraparenchymal Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Ointment","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Immunology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vyripharm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vyripharm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod Alpha","moa":"||FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neltependocel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"WAL0921","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Walden Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Walden Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"WAL0921","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Walden Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Walden Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"WAL0921","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Walden Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Walden Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SNP3","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Volanesorsen","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Otonomy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||MALT1","graph1":"Oncology","graph2":"Preclinical","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Gabaeron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human IPSC-Derived Interneuron Progenitors","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Gabaeron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabaeron \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gabaeron \/ Inapplicable"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PittCoVacc","moa":"Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Entinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of North Carolina \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"||CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MLE-301","moa":"NK-3R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Millendo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Levo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Levo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Levo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Levo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Choline","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Healthy Extracts","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Healthy Extracts \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Healthy Extracts \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Novavax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novavax \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Nephrology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalent Pharma Solutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"ActRIIA-Fc","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K-gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"22nd Century Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"22nd Century Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"22nd Century Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"22nd Century Group \/ Inapplicable"},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MV-012-968","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Meissa Vaccines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Meissa Vaccines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Meissa Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ocuphire Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PCS499","moa":"cGMP\/PDE","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1608","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HB-201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Emavusertib","moa":"||IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Aurigene"},{"orgOrder":0,"company":"Kannalife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KLS-13019","moa":"mNCX-1","graph1":"Neurology","graph2":"Preclinical","graph3":"Kannalife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kannalife \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kannalife \/ Inapplicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oncoceutics Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Zolpidem Tartrate","moa":"GABA-A receptor-alpha1\/beta1\/gamma2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Aytu BioScience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Aytu BioScience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioScience \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","graph1":"Immunology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ALG-000184","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aligos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Humanigen"},{"orgOrder":0,"company":"Centocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ponesimod","moa":"S1P1R","graph1":"Neurology","graph2":"Approved FDF","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centocor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centocor \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WNT974","moa":"||Porcupine","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"University Hospital of Vall d\u2019Hebron","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"MRM Health \/ University Hospital of Vall d\u2019Hebron","highestDevelopmentStatusID":"4","companyTruncated":"MRM Health \/ University Hospital of Vall d\u2019Hebron"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"Immunitybio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ Immunitybio","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest \/ Immunitybio"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"WRAIR_EPa11","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"WTX-921","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-003","moa":"SNP3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-003","moa":"SNP3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-004","moa":"C9orf72","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"EPI Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ EPI Health","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ EPI Health"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"Xcovery","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xcovery \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"||CXCR4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innoviva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innoviva \/ Inapplicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innoviva \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Innoviva \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Organon \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crizotinib","moa":"ALK receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Factor Xa","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Tissue Factor","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Invenra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||5T4","graph1":"Oncology","graph2":"Phase I","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invenra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invenra \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cenobamate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SK Life Science \/ SK Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SK Life Science \/ SK Biopharmaceuticals"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tarsus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Noven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"XEN-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xeno Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"B7-H3","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tidutamab","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"La Jolla Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"La Jolla Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"TPH","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TerSera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xevinapant","moa":"IAP","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Optinose","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Optinose \/ Inapplicable"},{"orgOrder":0,"company":"Amarillo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Amarillo Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amarillo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Amarillo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alvogen","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alvogen \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Alvogen \/ Bausch Health"},{"orgOrder":0,"company":"Alvogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alvogen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alvogen \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Salix Pharmaceuticals \/ Bausch Health"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||PTK","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||Cyclin-dependent kinase 7","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"XmAb564","moa":"IL-2-beta receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Plamotamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"XmAb306","moa":"IL-15-beta receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||NaPi2b","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"XMT-2056","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"XMT-2056","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Shionogi"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CLBS16","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||AMY1\/CALCR\/RAMP1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"TR","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"European Myeloma Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ European Myeloma Network","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ European Myeloma Network"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selinexor","moa":"||XPO1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Karyopharm Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Karyopharm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"XT-150","moa":"IL-10","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Xentria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xentria \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xentria \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"XTX202","moa":"Tumor selective IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"XTX301","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dolutegravir Prodrug","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exavir Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Exavir Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Exavir Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Topical Film-Forming Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YourChoice Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"YourChoice Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"YourChoice Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"YourChoice Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Center for International Blood and Marrow Transplant Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase IV","graph3":"Center for International Blood and Marrow Transplant Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Center for International Blood and Marrow Transplant Research \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Center for International Blood and Marrow Transplant Research \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yiviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||NFAT","graph1":"Oncology","graph2":"Preclinical","graph3":"Yiviva","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yiviva \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Yiviva \/ Inapplicable"},{"orgOrder":0,"company":"280Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"YL-17231","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"280Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Omburtamab","moa":"Beta\/gamma radiation","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Theravance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Theravance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Revefenacin","moa":"Muscarinic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Alimera Sciences \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Liquidia Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Liquidia Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Liquidia Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Liquidia Corporation \/ United Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Liquidia Corporation \/ United Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Z-1018","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynavax Technologies \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K-delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tipifarnib","moa":"||CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioPharma \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Obexelimab","moa":"CD19\/Fc\u03b3RIIb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ZielBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ZB131","moa":"CSP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ZielBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZielBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ZielBio \/ Inapplicable"},{"orgOrder":0,"company":"ZielBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ZB131","moa":"CSP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ZielBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZielBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ZielBio \/ Inapplicable"},{"orgOrder":0,"company":"ZielBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ZB131","moa":"CSP","graph1":"Oncology","graph2":"Preclinical","graph3":"ZielBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZielBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZielBio \/ Inapplicable"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Obexelimab","moa":"CD19\/Fc\u03b3RIIb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eiletoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Expert Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eiletoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Expert Systems","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Expert Systems"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Balamenib","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Zelpultide Alpha","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal Injection","sponsorNew":"Airway Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ligand Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ligand Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zenith Epigenetics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epigenetics \/ National Cancer Institute"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioPharma \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZN-D5","moa":"Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Neurology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celgene Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Prokarium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ZH9","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Prokarium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prokarium \/ Inapplicable"},{"orgOrder":0,"company":"Prokarium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ZH9","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Prokarium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prokarium \/ Inapplicable"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zhittya Genesis Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Zhittya Genesis Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhittya Genesis Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ US WorldMeds"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adamis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"C5","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IVERIC bio \/ Inapplicable"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zinc Sulphate","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Piramal Pharma Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Piramal Pharma Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Ad-RTS-hIL-12","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ZM008","moa":"LLT1 antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zumutor Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zofin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Organicell Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zofin","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zofin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Organicell Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"5-HT2 receptor\/Sigma -1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Zogenix \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"AnGes","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ AnGes","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ AnGes"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Ftase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"The Progeria Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation"},{"orgOrder":0,"company":"Innoviva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zoliflodacin","moa":"||DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innoviva \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Inapplicable"},{"orgOrder":0,"company":"PassPort Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PassPort Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"PassPort Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PassPort Technologies \/ Inapplicable"},{"orgOrder":0,"company":"PassPort Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PassPort Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"PassPort Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PassPort Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zonisamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Azurity Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Azurity Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zonisamide","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Azurity Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Azurity Pharma"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zotatifin","moa":"||eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Tenacia Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||GCSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Idelalisib","moa":"PIK3CD","graph1":"Oncology","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"NeuroRx","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ NeuroRx","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ NeuroRx"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||VPAC1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Periarticular Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/beta globulin","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ZZ Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"3K3A-APC","moa":"Tissue plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ZZ Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZZ Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ZZ Biotech \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Noramco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Noramco","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Noramco \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noramco \/ Inapplicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase II","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Talazoparib","moa":"||PARP 2","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Solution for Inhalation","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapport Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tenax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrase enzyme","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GLP1\/GIP\/GCG receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Prucalopride Succinate","moa":"5-HT4","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Shed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Shed","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shed \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shed \/ Inapplicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"||BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Everolimus","moa":"kinase","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Seladelpar Lysine","moa":"||PPAR-delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Macitentan","moa":"||Endothelin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Scienture","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"ACE2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Scienture","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Scienture \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Scienture \/ Inapplicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Meitheal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"||CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vapendavir","moa":"Capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Altesa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altesa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Halozyme Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Hyaluronidase Enzyme","moa":"||Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jaguar Health \/ Napo Therapeutics"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||JAK1\/JAK3","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release Daily","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Apellis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Evinacumab","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Omalizumab","moa":"IgE","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CK-586","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||CD38","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IM-1021","moa":"ROR1","graph1":"Oncology","graph2":"Phase I","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Xentria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xentria \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Myostatin activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"15-LOX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Adalvo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Indivior \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indivior \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ AstraZeneca"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zinc Acetate Dihydrate","moa":"Intestinal cell metallothionein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Trofinetide","moa":"Cytokine","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Chenodeoxycholic Acid","moa":"Cholesterol","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cytisine","moa":"nAchR-alpha-4 beta-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"WARPNINE","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ WARPNINE","highestDevelopmentStatusID":"7","companyTruncated":"Lisata Therapeutics \/ WARPNINE"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Sodium-dependent noradrenaline transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vimseltinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Approved FDF","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"SQ Innovation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SQ Innovation \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"IL-4-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LIB Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunovant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Oncology \/ National Cancer Institute"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||CXCR5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zoledronic Acid","moa":"Bone resorption","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase IV","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deutivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","graph1":"Neurology","graph2":"Phase IV","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Canvuparatide","moa":"PTH Replacer","graph1":"Endocrinology","graph2":"Phase II","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-C3","moa":"C3","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||DKK1","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Eisai"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Nogapendekin Alpha Inbakicept","moa":"IL-15-alpha receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"TTR mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artax Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artax Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"MASP-3","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor allosteric site","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ersodetug","moa":"Insulin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-45","moa":"Dystrophin","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Urology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"APG990","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lorundrostat","moa":"Aldosterone synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mineralys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tenecteplase","moa":"Tissue plasminogen","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mitapivat","moa":"PKR","graph1":"Hematology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pathos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"||CBP\/p300","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pathos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pathos \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase I","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"GLSI-100","moa":"||Granulocyte-macrophage","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich LifeSciences \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"PFOR","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AN2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mural Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Nemvaleukin Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mural Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mural Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate Therapeutics, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Mabxience","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Mabxience","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pharmaceuticals \/ Mabxience"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor-alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Inapplicable"},{"orgOrder":0,"company":"Geron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Geron","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Geron \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Resmetirom","moa":"TR-beta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Madrigal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Madrigal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"scPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"scPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mesalazine","moa":"COX","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cadisegliatin","moa":"Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"IBAT","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ananda Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ateganosine","moa":"||Telomere","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biotechnology \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Seclidemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Avexitide","moa":"GLP-1 ant","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Amniotic Fluid","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merakris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Outlook Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"RenovoRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APX3330","moa":"Ref-1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Checkpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Checkpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Jaguar Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Jaguar Health \/ Inapplicable"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"5-HT\/dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"c-KIT","graph1":"Dermatology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Soft gel Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Izokibep","moa":"IL-17A receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||ALK receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"S1PR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Onvansertib","moa":"||PLK1","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cardiff Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bempikibart","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"15-LOX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sotagliflozin","moa":"SGLT1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"VEGFR\/PDGFR","graph1":"Ophthalmology","graph2":"Phase III","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EyePoint Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xcovery","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Ensartinib","moa":"ALK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xcovery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xcovery \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Xcovery \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Artery Infusion","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CDK9","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Savara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Molgramostim","moa":"GM-CSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Savara \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Glucocorticoid\/progesterone receptor","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LIB Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LadRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Aldoxorubicin HCl","moa":"Cysteine-34 human serum albumin","graph1":"Oncology","graph2":"Phase III","graph3":"LadRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LadRx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LadRx \/ Inapplicable"},{"orgOrder":0,"company":"Omeros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"MASP-2","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Omeros \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38 alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belzutifan","moa":"HIF-2-alpha","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sound Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"PTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intra-Cellular Therapies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cellular Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Sotatercept","moa":"INHBA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Encorafenib","moa":"||BRAF","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Transdermal Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atea Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATRN-119","moa":"ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ateganosine","moa":"Telomere","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Inapplicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA alkylation","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"KRRO-110","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BHV-1300","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ensho Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NSHO-101","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase I","graph3":"Ensho Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensho Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensho Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PALI-2108","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"PL8177","moa":"MC1 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"R-3750","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Namilumab","moa":"GCSF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kinevant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Xentria","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"XTMAB-16","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xentria \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Xentria \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Derived Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sentynl Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Sentynl Therapeutics \/ Fortress Biotech"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone","moa":"UBE3A-AS","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elraglusib","moa":"||GSK-3 beta","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"||NMDA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laxxon Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Hydrogel","sponsorNew":"Alphyn Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Casdatifan","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arcus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avirmax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ABI-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Avirmax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Avirmax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avirmax \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ABI-1179","moa":"HSV helicase-primase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avirmax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ABI-201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Avirmax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Avirmax \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avirmax \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABI-4334","moa":"cccDNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assembly Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ABI-6250","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Assembly Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABO-101","moa":"GOX","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ABO-101","moa":"GOX","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Saniona","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ABS-0871","moa":"TRPV4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Actio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actio Biosciences \/ Saniona","highestDevelopmentStatusID":"6","companyTruncated":"Actio Biosciences \/ Saniona"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Autobahn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Nephrology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adimune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adimune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adimune \/ Inapplicable"},{"orgOrder":0,"company":"Adimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adimune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adimune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adimune \/ Inapplicable"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ADRX-0405","moa":"IgG1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcentrx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adcentrx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||VEGFR-A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Adverum Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Aer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fexlamose","moa":"Mucin","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Technosphere Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mannkind \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AI-011","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Aim ImmunoTech \/ AstraZeneca"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AiViva Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"DeFloria","sponsor":"AJNA BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"AJA001","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I","graph3":"DeFloria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DeFloria \/ AJNA BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"DeFloria \/ AJNA BioSciences"},{"orgOrder":0,"company":"Allakos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"AK006","moa":"Siglec-6","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allakos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"AliveGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"ALG-801","moa":"Smad2\/3 pathway","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AliveGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AliveGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AliveGen \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"Creative Medical Technology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative Medical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ALTA3263","moa":"KRAS ON\/OFF","graph1":"Oncology","graph2":"Phase I","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alterome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alto Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ALY-101","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Alys Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alys Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ALY-101","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Alys Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alys Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Kyowa Kirin"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AMG 513","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"AMX0114","moa":"CAPN2","graph1":"Neurology","graph2":"Phase I","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"BTLA","graph1":"Immunology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Inapplicable"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Anebulo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CAR-NK","moa":"||IL-15-alpha receptor","graph1":"Hematology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"ANX009","moa":"C1q","graph1":"Nephrology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"A2A Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AO-252","moa":"TACC3","graph1":"Oncology","graph2":"Phase I","graph3":"A2A Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"A2A Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"A2A Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon 44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"APG333","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apogee Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"AP\u2010PA02","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ARC101","moa":"CLDN6","graph1":"Oncology","graph2":"Phase I","graph3":"Third Arc Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Third Arc Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Arc Bio \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C gene","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C gene","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ART5803","moa":"NMDA receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arialys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arialys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"Vepdegestrant","moa":"||Androgen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ Pfizer Inc"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ascendia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neltependocel","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AUTX-703","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||SIGMAR1","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Sarborg Limited","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Conduit Pharma \/ Sarborg Limited","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Sarborg Limited"},{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Oncology Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainChild Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BCB-276","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"BrainChild Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"BrainChild Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BrainChild Bio \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BlossomHill Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BH-30643","moa":"OMNI-EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BlossomHill Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BlossomHill Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BlossomHill Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Humanetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Genistein","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Inapplicable"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bluejay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bluejay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Brelovitug","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bluejay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bluejay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bluejay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bloom Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BMF-219","moa":"||Menin","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"BP1002","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"TikunTX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BPN-36964","moa":"ELP1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"TikunTX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TikunTX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TikunTX \/ Inapplicable"},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"BRB-002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bitterroot Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bitterroot Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bitterroot Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BRTX-100","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Aglatimagene Besadenovec","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"\u00daHKT","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CAR123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied DNA Sciences Inc \/ \u00daHKT","highestDevelopmentStatusID":"6","companyTruncated":"Applied DNA Sciences Inc \/ \u00daHKT"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transendocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Legend Biotech \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Cefazolin Sodium","moa":"||Bacterial Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"B. Braun Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"||Alpha V integrin","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Porosome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CF PT-101","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Porosome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Porosome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Porosome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CG001419","moa":"TRK","graph1":"Neurology","graph2":"Phase I","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullgen \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"KIT","graph1":"Hematology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cogent Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Chlorpromazine Hydrochloride","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Piramal Pharma Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Piramal Pharma Solutions \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CID-103","moa":"CD38","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CASI Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CLN-081","moa":"EGFR ex20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taiho Oncology \/ Cullinan Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Oncology \/ Cullinan Therapeutics"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cryopreserved Platelet","moa":"Platelet level","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cellphire Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cellphire Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Axitinib","moa":"VEGFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CNP-103","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CNTY-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verastem Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Vipragen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangoceuticals \/ Vipragen Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Mangoceuticals \/ Vipragen Biosciences"},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Metaba","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"MAX BioPharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Metaba","highestDevelopmentStatusID":"3","companyTruncated":"MAX BioPharma \/ Metaba"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Sublingual Solution","sponsorNew":"AgelessRx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AgelessRx \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"COYA 301","moa":"||Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"Il-2 induced T-cell kinase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CRB-913","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paltusotine","moa":"SST2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Amezosvatein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curevo Vaccine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vaccine \/ Inapplicable"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CST-3056","moa":"Adrenergic receptor alpha-1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CuraSen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"Phase I","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OnCusp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OnCusp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyanvac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CVXGA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyanvac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Cyanvac \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyanvac \/ Inapplicable"},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Theophylline","moa":"Adenosine A1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Cyrano Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CYR212","moa":"IgG level","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyrus Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Cytonics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CYT-108","moa":"A2M protease","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Cytonics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Cytonics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytonics \/ Inapplicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DB-007-5","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Anova Enterprises","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"5-fluorocytosine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anova Enterprises","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Infusion","sponsorNew":"Anova Enterprises \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Anova Enterprises \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Implant","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Decoy20","moa":"||TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Decoy20","moa":"||TLR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Indaptus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indaptus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Descartes-08","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bitopertin","moa":"GlyT1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DLX-001","moa":"Neural circuits","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Delix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DNL343","moa":"eIF2B","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DPTX3496","moa":"CTNNB","graph1":"Oncology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Damona Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DPX-101","moa":"Alpha 5-GABAA-R","graph1":"Neurology","graph2":"Preclinical","graph3":"Damona Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Damona Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Damona Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ifetroban","moa":"Thromboxane prostanoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EB103","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Estrella Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Estrella Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zelicapavir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Inapplicable"},{"orgOrder":0,"company":"Ensoma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EN-374","moa":"CYBB gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensoma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ensoma \/ Inapplicable"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Revakinagene Taroretcel","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Neurotech Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurotech Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ENV-294","moa":"JAK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enveda Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EP0031","moa":"RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ellipses Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Inapplicable"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ERNA-101","moa":"IL-15\/IL-17","graph1":"Oncology","graph2":"Preclinical","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eterna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eterna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ERNA-101","moa":"IL-15\/IL-17","graph1":"Oncology","graph2":"Preclinical","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ET-02","moa":"CD19","graph1":"Dermatology","graph2":"Phase I","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Eirion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eirion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ETX101","moa":"SCN1A gene expression","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Encoded Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Encoded Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Encoded Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVER001","moa":"BTK","graph1":"Nephrology","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVM14","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVM16","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Evommune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"EVO301","moa":"IL-18","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Evommune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Inapplicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Evolus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Inapplicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EXG-34217","moa":"ZSCAN4 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elixirgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EXG-34217","moa":"ZSCAN4 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elixirgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fauna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Faun1083","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Fauna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fauna Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fauna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BS01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionic Sight \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sight \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ALLO-329","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gameto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Gameto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gameto \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gameto \/ Inapplicable"},{"orgOrder":0,"company":"Restem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Outer Lining Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Restem \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aveva Drug Delivery Sytems, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aveva Drug Delivery Sytems, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Aveva Drug Delivery Sytems, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aveva Drug Delivery Sytems, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"FGF-1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Zhittya Genesis Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray, Metered","sponsorNew":"Zhittya Genesis Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhittya Genesis Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"FMC-220","moa":"p53Y220C","graph1":"Oncology","graph2":"Preclinical","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frontier Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Frontier Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"GOG Foundation, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||TORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Faeth Therapeutics \/ GOG Foundation, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Faeth Therapeutics \/ GOG Foundation, Inc."},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GAL-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Galimedix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"HPV Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Inavolisib","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revelation Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"||E-selectin","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ashibio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Andecaliximab","moa":"MMP9","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Ashibio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashibio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ashibio \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HCAb","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"HB-500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HB-adMSCs","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hope Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HBM-9378","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Helicore Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HCR-188","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Helicore Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Helicore Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Helicore Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"HCW9302","moa":"Treg","graph1":"Dermatology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Anodyne Nanotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Anodyne Nanotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Anodyne Nanotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Anodyne Nanotech \/ Inapplicable"},{"orgOrder":0,"company":"Tharimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HS1940","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Preclinical","graph3":"Tharimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tharimmune \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tharimmune \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hoth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-6184","moa":"NEK7","graph1":"Oncology","graph2":"Phase II","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soligenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE161","moa":"||PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE892","moa":"MTA-PRMT5","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tarlatamab","moa":"DLL3\/CD3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||MAPK pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuneering Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneering Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Imunon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"IMNN-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhalon Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IN-002","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inhalon Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Inhalon Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Inhalon Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"INB-619","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"Transpire Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Transpire Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Transpire Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transpire Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INO-3107","moa":"HPV6","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Interius BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InvisiShield Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"H5N1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"InvisiShield Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"InvisiShield Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"InvisiShield Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Io Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"IRX4204","moa":"RXR nuclear receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Io Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Io Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Io Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"Insulin\/Glucagon","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance \/ Kadimastem"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Wipe","sponsorNew":"iView Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iView Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JK07","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Salubris Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Salubris Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Posdinemab","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"JNJ-78901563","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cibotercept","moa":"SMAD 2\/3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Frevecitinib","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kinaset Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Dry Powder","sponsorNew":"Kinaset Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinaset Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"KPL-387","moa":"IL-1 receptor 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiniksa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KROS-101","moa":"GITR","graph1":"Oncology","graph2":"Preclinical","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kashiv BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"SQ Innovation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SQ Innovation \/ Inapplicable"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LETI-101","moa":"mHTT protein level","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraparenchymal Infusion","sponsorNew":"ElevateBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ElevateBio \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Linsitinib","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sling Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"LNCB74","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"LNCB74","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Expert Systems","sponsor":"Lomond Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Expert Systems \/ Lomond Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Expert Systems \/ Lomond Therapeutics"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Liposomal Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"Lipella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"Tim3\/4","graph1":"Immunology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LTZ-301","moa":"CD79b\/B-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LTZ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LXM.2","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Enteric Coated Tablet","sponsorNew":"Laxxon Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Medical \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GLP1\/GIP\/GCG receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Imlunestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Volenrelaxin","moa":"RXFP1","graph1":"Nephrology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LYT-200","moa":"Galectin-9","graph1":"Oncology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"MANP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"E-Star Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"MAR001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Marea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/Serotonin\/Norepinephrine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAXONA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"MBX 1416","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MBX Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IC 100","moa":"ASC","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"MET-097i","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methadone Hydrochloride","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Epirium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MF-300","moa":"15-PGDH","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Clesrovimab","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Islatravir","moa":"||NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ML-007","moa":"||M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MapLight Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MapLight Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Lu","moa":"uPAR","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD38","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"mRNA-1018","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"mRNA-1403","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MRT-2359","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"70s Ribosomal subunit","graph1":"Podiatry","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Benzodiazepine","moa":"GABA A receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MZE829","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Osavampator","moa":"AMPA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NBI-1140675","moa":"VMAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Neuron23","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NEU-111","moa":"TYK2","graph1":"Immunology","graph2":"Phase I","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neuron23 \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuron23 \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"NGM120","moa":"GFRAL","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nipocalimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||HIF-2-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NKT3964","moa":"CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NKX019","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ruxoprubart","moa":"Complement factor B","graph1":"Immunology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovelMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novita Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NP-G2-044","moa":"Fascin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novita Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novita Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novita Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NRTX-1001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrahippocampal Infusion","sponsorNew":"Neurona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Inapplicable"},{"orgOrder":0,"company":"Hudson Therapeutics","sponsor":"Shaperon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"NLRP3","graph1":"Dermatology","graph2":"Phase II","graph3":"Hudson Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Hudson Therapeutics \/ Shaperon","highestDevelopmentStatusID":"8","companyTruncated":"Hudson Therapeutics \/ Shaperon"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NV-CoV-2","moa":"Sulfated proteoglycans","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Syrup","sponsorNew":"NanoViricides \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoViricides \/ Inapplicable"},{"orgOrder":0,"company":"Nuvie Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"NVI-100","moa":"CGRPR","graph1":"Neurology","graph2":"Phase I","graph3":"Nuvie Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nuvie Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvie Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vyluma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"mAChRs","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Vyluma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NXP900","moa":"||YES1\/ Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"NY-500","moa":"PD-1\/VEGF","graph1":"Oncology","graph2":"Preclinical","graph3":"Naya Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Naya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor-alpha 1\/2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"OCU200","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3 gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU410","moa":"RORA gene","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"OCU500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Day One Biopharmaceuticals \/ Foundation Medicine"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||PI3K Alpha H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Owkin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OKN4395","moa":"||EP2\/4","graph1":"Oncology","graph2":"Phase I","graph3":"Owkin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Owkin \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Owkin \/ Inapplicable"},{"orgOrder":0,"company":"Genelux","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Genelux \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ Inapplicable"},{"orgOrder":0,"company":"Genelux","sponsor":"Newsoara BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genelux \/ Newsoara BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Genelux \/ Newsoara BioPharma"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dordaviprone","moa":"DRD2","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chimerix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Inapplicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"ONP-002","moa":"PXR","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oragenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OP-3136","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OPC1","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OPGx-LCA5","moa":"LCA5 gene","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Valo Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valo Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Orca-T","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Orca-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Odronextamab","moa":"CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ORKA-002","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PBFT02","moa":"AAV1 gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PBGENE-DMD","moa":"DMD gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PBGENE-HBV","moa":"cccDNA\/HBV DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PBGENE-HBV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Pemivibart","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Rion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Lyophilised Powder for Solution","sponsorNew":"Rion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Inapplicable"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Perfuse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Perfuse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon 51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PH284","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PL7737","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AFTX-201","moa":"BAG3","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Affinia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Affinia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"HPV6\/HPV11","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"HPV6\/HPV11","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV sodium channel alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Signal 12","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Progesterone","moa":"PR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Signal 12","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Signal 12 \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Signal 12 \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Peluntamig","moa":"DLL3\/CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonist Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Fibronectin EDB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QRL-101","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QTX3544","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"R289","moa":"IRAK1\/IRAK4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ibafloxacin","moa":"IL-1-associated kinase 1 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"R-5780","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Radiprodil","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RCT2100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GTAEXS-617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"StemCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HPC Cord Blood","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"StemCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"StemCyte \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"REGN7508","moa":"Factor XI","graph1":"Hematology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repair Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"REP-0003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Repair Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repair Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Repair Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Pan-kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Inapplicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Resecabtagene Autoleucel","moa":"CD19","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Qnovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RGT-075","moa":"GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Rion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Purified Exosome Product","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Rion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rion \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rallybio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"RLYB212","moa":"HPA-1a","graph1":"Immunology","graph2":"Phase II","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rallybio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rallybio \/ Inapplicable"},{"orgOrder":0,"company":"Rondo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"RNDO-564","moa":"CD28\/Nectin-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rondo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rondo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Rondo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||GCSF","graph1":"Oncology","graph2":"Phase I","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Assertio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assertio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"RPESC-RPE-4W","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Luxa Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RSBT-001","moa":"Cannabinoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RS BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corstasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bumetanide","moa":"NK ATPase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corstasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Corstasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corstasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"PG-102","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||EGFR\/MET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S\u20111117","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Seismic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S\u20118484","moa":"IgE","graph1":"Immunology","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SAB-142","moa":"CD8","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAN711","moa":"GABA A-alpha 3 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SCY-247","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scynexis \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Septerna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SEP-786","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Septerna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Septerna \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SFA-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"SFA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SGT-212","moa":"FXN","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SGT-212","moa":"FXN","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Immunology","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generation Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Naproxen","moa":"||COX-1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sen-Jam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SkinTE","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"PolarityTE \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Inapplicable"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SKY-0515","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Skyhawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Skyhawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dichloroacetic Acid","moa":"PDK","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Saol therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Saol therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dichloroacetic Acid","moa":"PDK","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Saol therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Saol therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Saol therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SL-325","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tambiciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"SMSbiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"SMSbiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Suspension for Nebulizer","sponsorNew":"SMSbiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SMSbiotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Synnovation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||PI3K alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Synnovation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Synnovation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synnovation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Kamuvudine-8","moa":"Nucleoside reverse transcriptase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||INF-gamma","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"SON-1010","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Silo Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Silo Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPY002-091","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SPY003","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spyre Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Medera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medera \/ Inapplicable"},{"orgOrder":0,"company":"Medera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Medera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medera \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fenretinide","moa":"RAR","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ST-002","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"SteroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SteroTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SteroTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ST-01156","moa":"RBM39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Vevoctadekin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Simcha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Simcha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Wnt\/beta-catenin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"STAR-0310","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"STAR-0310","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"STC-004","moa":"NaV1.8","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SiteOne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Secretome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Secretome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"STM-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Secretome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Secretome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Secretome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate receptor-alpha","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"STX-478","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scorpion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MimiVax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Montanide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MimiVax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ Inapplicable"},{"orgOrder":0,"company":"Sydnexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Ach receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sydnexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sydnexis \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sydnexis \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mono Propylene Glycol","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transurethral Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase II","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Neurology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Oncology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||CD20","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Moberg Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Moberg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"THB335","moa":"KIT","graph1":"Immunology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Third Harmonic Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Inapplicable"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/Serotonin\/Norepinephrine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAXONA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"March Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"MB-105","moa":"PSCA","graph1":"Oncology","graph2":"Phase II","graph3":"March Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"March Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"March Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"HLD-0915","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Halda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||Alpha radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Actinium pharmaceuticals \/ National Cancer Institute"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Inapplicable"},{"orgOrder":0,"company":"TIXiMED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TIX100","moa":"TXNIP","graph1":"Endocrinology","graph2":"Phase I","graph3":"TIXiMED","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TIXiMED \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TIXiMED \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SIGA Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIGA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TPST-1495","moa":"PGE2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ UCLA"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"CMV-modified Vaccinia Ankara Vaccine","moa":"pp65 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fortress Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tivoxavir Marboxil","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Traws Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Corsair Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Corsair Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corsair Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Corsair Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen Sodium","moa":"APOC-III","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TVB-3567","moa":"FASN","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sagimet Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sagimet Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"TX000045","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tectonic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tectonic Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tectonic Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cyclarity Therapeutics","sponsor":"Monash University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cyclodextrin","moa":"Toxic oxidized cholesterol","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Cyclarity Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cyclarity Therapeutics \/ Monash University","highestDevelopmentStatusID":"5","companyTruncated":"Cyclarity Therapeutics \/ Monash University"},{"orgOrder":0,"company":"Restem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Restem \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"UP421","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9 gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"V350A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"OPKO Health \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"OPKO Health \/ Merck & Co"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Microneedle Patch","sponsorNew":"Vaxxas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ Inapplicable"},{"orgOrder":0,"company":"Vascarta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Immuno","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vascarta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lonigutamab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VENT-02","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ventus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ventus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cemdisiran","moa":"||C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase III","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"PDS0101","moa":"||CD8","graph1":"Oncology","graph2":"Phase III","graph3":"PDS Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PDS Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VG-3927","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gradalis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Gemogenovatucel-T","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gradalis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1R\/GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1R\/GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vittoria Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"VIR-5818","moa":"CD3\/HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vir Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Virion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VRON-0200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Virion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Virion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Vaxart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VXA-GI.1.NN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxart","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Vaxart \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxart \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"VY7523","moa":"C-terminal epitope Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"VY9323","moa":"SOD1","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Invivyd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"VYD2311","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Invivyd \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VYNE Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"WU-CART-007","moa":"CD7","graph1":"Oncology","graph2":"Phase II","graph3":"Wugen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Wugen \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Deoxyribonuclease I","moa":"||PD-1\/TIM-3 expression","graph1":"Oncology","graph2":"Preclinical","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xenetic Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Xenetic Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vensica Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"Ach receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Vensica Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vensica Medical \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"CXCR4 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Rheumatology","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zetagen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZetaMAST","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zetagen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Zetagen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Zetagen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Azenosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Roflumilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biopharma","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UKRAINE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Voxelotor","moa":"HbA-positive","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biopharma \/ Global Blood Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biopharma \/ Global Blood Therapeutics"},{"orgOrder":0,"company":"Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UKRAINE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"High affinity immunoglobulin gamma Fc receptor I","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Renaissance Pharma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Alchemab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alchemab \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ Eli Lilly"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"BlackfinBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"BFB-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ BlackfinBio","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ BlackfinBio"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":1.24,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.24,"dosageForm":"Undisclosed","sponsorNew":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Emergex Vaccines","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"PepGNP-COVID19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Emergex Vaccines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Emergex Vaccines \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Emergex Vaccines \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Maxion Therapeutics","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Series B Financing","leadProduct":"MAX001","moa":"GPCR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Maxion Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Maxion Therapeutics \/ General Catalyst","highestDevelopmentStatusID":"4","companyTruncated":"Maxion Therapeutics \/ General Catalyst"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Negev Labs","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Negev Labs","highestDevelopmentStatusID":"4","companyTruncated":"Beckley Psytech \/ Negev Labs"},{"orgOrder":0,"company":"INFEX Therapeutics","sponsor":"Venus Remedies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"||MBL","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"INFEX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INFEX Therapeutics \/ Venus Remedies","highestDevelopmentStatusID":"5","companyTruncated":"INFEX Therapeutics \/ Venus Remedies"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":1.04,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.04,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Biotherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Argent BioPharma","sponsor":"SINTEF","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Argent BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argent BioPharma \/ SINTEF","highestDevelopmentStatusID":"4","companyTruncated":"Argent BioPharma \/ SINTEF"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Hookipa Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Merger","leadProduct":"HB-700","moa":"KRAS G12D","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poolbeg Pharma \/ Hookipa Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Poolbeg Pharma \/ Hookipa Pharma"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbit Discovery \/ Evergreen Theragnostics","highestDevelopmentStatusID":"4","companyTruncated":"Orbit Discovery \/ Evergreen Theragnostics"},{"orgOrder":0,"company":"Verdiva Bio","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"VRB-101","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Verdiva Bio","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"Verdiva Bio \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Verdiva Bio \/ Forbion"},{"orgOrder":0,"company":"Ottimo Pharma","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Jankistomig","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ottimo Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Intravenous","sponsorNew":"Ottimo Pharma \/ OrbiMed","highestDevelopmentStatusID":"4","companyTruncated":"Ottimo Pharma \/ OrbiMed"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Indaco Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||CD8+ T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Indaco Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Indaco Venture Partners"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"AXV101","moa":"BBS1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"},{"orgOrder":0,"company":"Glox Therapeutics","sponsor":"LifeArc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Glox001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Glox Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glox Therapeutics \/ LifeArc","highestDevelopmentStatusID":"4","companyTruncated":"Glox Therapeutics \/ LifeArc"},{"orgOrder":0,"company":"Ignota Labs","sponsor":"Montage Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"PDE9A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ignota Labs","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Ignota Labs \/ Montage Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ignota Labs \/ Montage Ventures"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2025","type":"Funding","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Stablepharma","sponsor":"EIC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"SPVX02","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stablepharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stablepharma \/ EIC","highestDevelopmentStatusID":"5","companyTruncated":"Stablepharma \/ EIC"},{"orgOrder":0,"company":"TRIMTECH Therapeutics","sponsor":"Cambridge Innovation Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"TRIM21","graph1":"Neurology","graph2":"Preclinical","graph3":"TRIMTECH Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"TRIMTECH Therapeutics \/ Cambridge Innovation Capital","highestDevelopmentStatusID":"4","companyTruncated":"TRIMTECH Therapeutics \/ Cambridge Innovation Capital"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"Visus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tenpoint Therapeutics \/ Visus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Tenpoint Therapeutics \/ Visus Therapeutics"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Private Placement","leadProduct":"AKTX-101","moa":"TROP2","graph1":"Oncology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Akari Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"4","companyTruncated":"Akari Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Agility Life Sciences","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"CDT1656","moa":"Glucokinase","graph1":"Immunology","graph2":"Phase I","graph3":"Agility Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agility Life Sciences \/ Conduit Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Agility Life Sciences \/ Conduit Pharma"},{"orgOrder":0,"company":"Argent BioPharma","sponsor":"Sputnik Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Argent BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Argent BioPharma \/ Sputnik Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Argent BioPharma \/ Sputnik Enterprises"},{"orgOrder":0,"company":"Argent BioPharma","sponsor":"Sputnik Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Argent BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Argent BioPharma \/ Sputnik Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Argent BioPharma \/ Sputnik Enterprises"},{"orgOrder":0,"company":"Oxular","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Oxular \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Epitopea","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epitopea \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Epitopea \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"GCAR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"AZD1390","moa":"ATM","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ GCAR","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ GCAR"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Theramex","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2025","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Theramex \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Theramex \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"George Medicines","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Bausch Health"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ CPRIT"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Kyowa Kirin"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Beneluxa Initiative","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Beneluxa Initiative","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Beneluxa Initiative"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Erkim"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"7","companyTruncated":"Quotient Sciences \/ CytoAgents"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Population Health Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Tideglusib","moa":"GSK-3 beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Population Health Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"AMO Pharma \/ Population Health Research Institute"},{"orgOrder":0,"company":"F2G Limited","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ AMR Action Fund","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ AMR Action Fund"},{"orgOrder":0,"company":"Almac Group","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Almac Group \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"10","companyTruncated":"Almac Group \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Greenbrook TMS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Greenbrook TMS","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Greenbrook TMS"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Hackensack Meridian Health","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Hackensack Meridian Health"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Oxford Finance","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Oxford Finance"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Titan Partners Group"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"N-Methyl Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2024","type":"Agreement","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Mankind Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Mankind Pharma"},{"orgOrder":0,"company":"Hammersmith Medicines Research","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Hammersmith Medicines Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hammersmith Medicines Research \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hammersmith Medicines Research \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mina Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Mina Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Poolbeg Pharma \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Poolbeg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AlveoGene","sponsor":"Oxford Science Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"AVG-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AlveoGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AlveoGene \/ Oxford Science Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"AlveoGene \/ Oxford Science Enterprises"},{"orgOrder":0,"company":"RoslinCT","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"RoslinCT","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RoslinCT \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RoslinCT \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Intract Pharma","sponsor":"SGS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Intract Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Intract Pharma \/ SGS Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Intract Pharma \/ SGS Life Sciences"},{"orgOrder":0,"company":"NodThera","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"NT-0167","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/ Organovo Holdings"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Edinburgh \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Foralumab","moa":"CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ ThinkEquity"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"USP30","graph1":"Nephrology","graph2":"Preclinical","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Mission Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Efzofitimod","moa":"NRP2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ aTyr Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ aTyr Pharma"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"ALSA Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"AXV-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ ALSA Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ ALSA Ventures"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"EXO Biologics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"GF-3001","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Genflow Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Genflow Biosciences \/ EXO Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Genflow Biosciences \/ EXO Biologics"},{"orgOrder":0,"company":"GSK","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"OTL-103","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Orchard Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Orchard Therapeutics"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"AXV-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"},{"orgOrder":0,"company":"Arecor","sponsor":"TRx Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"GLP-1R","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arecor \/ TRx Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Arecor \/ TRx Biosciences"},{"orgOrder":0,"company":"Abzena Ltd","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Abzena Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abzena Ltd \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Abzena Ltd \/ Immunome"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"ATL001","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Nanna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nanna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanna Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Nanna Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Aerami","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Aerami","highestDevelopmentStatusID":"5","companyTruncated":"Vectura Ltd \/ Aerami"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enara Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Enara Bio \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Enara Bio \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Inclisiran","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"NHS England \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"VAL301","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ValiRx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"GSK \/ Government of Canada","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Government of Canada"},{"orgOrder":0,"company":"AI VIVO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AI VIVO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AI VIVO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AI VIVO \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"University College London","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Oncology","graph2":"Preclinical","graph3":"University College London","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University College London \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University College London \/ Qualigen Therapeutics"},{"orgOrder":0,"company":"Albumedix","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Expanded Collaboration","leadProduct":"Aluminium Hydroxide","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Albumedix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Albumedix \/ Valneva","highestDevelopmentStatusID":"15","companyTruncated":"Albumedix \/ Valneva"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"Etigilimab","moa":"TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ OrbiMed"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Amphista Therapeutics \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Ingenza","sponsor":"Amplifica","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ingenza","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Ingenza \/ Amplifica","highestDevelopmentStatusID":"1","companyTruncated":"Ingenza \/ Amplifica"},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Mecasermin Rinfabate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oak Hill Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oak Hill Bio \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Oak Hill Bio \/ Chiesi Group"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"ICR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apollo Therapeutics \/ ICR","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ ICR"},{"orgOrder":0,"company":"Aptorum","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Rilpivirine Hydrochloride","moa":"NNRT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Aptorum \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"AB-201","moa":"Tissue Factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Anastrozole","moa":"Aromatase","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Juvise Pharmaceuticals"},{"orgOrder":0,"company":"NHS England","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"NHS England \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"NHS England \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Iontas","sponsor":"Inotrem","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"TREM-1","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iontas \/ Inotrem","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ Inotrem"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Oxford Biomedica \/ AstraZeneca"},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mogrify \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Mogrify \/ Astellas Pharma"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mina Therapeutics \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Servier"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"AVB-101","moa":"GRN gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AviadoBio \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Astellas Pharma"},{"orgOrder":0,"company":"RQ Biotechnology Ltd","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"RQ Biotechnology Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"RQ Biotechnology Ltd \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"RQ Biotechnology Ltd \/ AstraZeneca"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"academia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AstraZeneca \/ academia","highestDevelopmentStatusID":"4","companyTruncated":"AstraZeneca \/ academia"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"ATNAHS PHARMA UK LIMITED","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Propranolol Hydrochloride","moa":"Adrenergic receptor-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ ATNAHS PHARMA UK LIMITED","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ ATNAHS PHARMA UK LIMITED"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ BARDA"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F-star Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"F-star Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Rigerimod","moa":"Immuno","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuPharma \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Avion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Momelotinib","moa":"||JAK2","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"AstraZeneca \/ GSK"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Integrated","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Series B Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beckley Psytech \/ Integrated","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Integrated"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bicycle Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2024","type":"Private Placement","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biodexa Pharmaceuticals \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Biodexa Pharmaceuticals \/ Midatech Pharma"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"AUT00206","moa":"KV3 potassium ion channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Autifony Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autifony Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Autifony Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enara Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Enara Bio \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Enara Bio \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Brazilian Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Brazilian Government","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Brazilian Government"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Ksana Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Ksana Health","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Ksana Health"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"C4X_6665","moa":"Nrf2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4X Discovery \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discovery \/ AstraZeneca"},{"orgOrder":0,"company":"GSK","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2021","type":"Divestment","leadProduct":"Cabozantinib","moa":"MET\/VEGFR\/AXL","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Royalty Pharma"},{"orgOrder":0,"company":"CellCentric","sponsor":"Morningside Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Inobrodib","moa":"p300\/CBP","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CellCentric \/ Morningside Venture","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Morningside Venture"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Nordic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Nordic Capital","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Nordic Capital"},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Divestment","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Sandoz B2B"},{"orgOrder":0,"company":"Chemify","sponsor":"Prepaire Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Chemify","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemify \/ Prepaire Labs","highestDevelopmentStatusID":"3","companyTruncated":"Chemify \/ Prepaire Labs"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"CombiGene","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"CG01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ CombiGene","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biologics \/ CombiGene"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Cobra Biologics \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Cobra Biologics \/ AstraZeneca"},{"orgOrder":0,"company":"Icagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion Channel","graph1":"Neurology","graph2":"Discovery","graph3":"Icagen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Icagen \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Icagen \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Crescendo Biologics Ltd","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crescendo Biologics Ltd \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"Crescendo Biologics Ltd \/ BioNTech"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"TRV027","moa":"AT1 receptor selective","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Trevena","highestDevelopmentStatusID":"6","companyTruncated":"Imperial College London \/ Trevena"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Champalimaud Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"IMM-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immodulon Therapeutics \/ Champalimaud Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Immodulon Therapeutics \/ Champalimaud Foundation"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Series B Financing","leadProduct":"CBP-4888","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Google Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Google Ventures"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"ATL001","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Aclidinium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AstraZeneca \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Covis Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Grunenthal"},{"orgOrder":0,"company":"TCRyption Inc","sponsor":"Treadwell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"TCRyption Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TCRyption Inc \/ Treadwell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"TCRyption Inc \/ Treadwell Therapeutics"},{"orgOrder":0,"company":"Abcam","sponsor":"Pionyr","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"PY314","moa":"TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Abcam","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abcam \/ Pionyr","highestDevelopmentStatusID":"6","companyTruncated":"Abcam \/ Pionyr"},{"orgOrder":0,"company":"GE Healthcare Inc","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Covigenix","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GE Healthcare Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GE Healthcare Inc \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"GE Healthcare Inc \/ Entos Pharmaceuticals"},{"orgOrder":0,"company":"Touchlight","sponsor":"University of Liverpool","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Touchlight \/ University of Liverpool","highestDevelopmentStatusID":"3","companyTruncated":"Touchlight \/ University of Liverpool"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evox Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Domainex","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"APN431","moa":"E3 ubiquitin ligase CBL-B","graph1":"Oncology","graph2":"Discovery","graph3":"Domainex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Domainex \/ Apeiron Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Domainex \/ Apeiron Biologics"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evox Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evox Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Imperial College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Partnership","leadProduct":"EBX-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Imperial College London","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Imperial College London"},{"orgOrder":0,"company":"Elastin BioSciences","sponsor":"Longaevus Technologies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Demerger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Elastin BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elastin BioSciences \/ Longaevus Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Elastin BioSciences \/ Longaevus Technologies"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Enara Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enara Bio \/ Pfizer Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Enara Bio \/ Pfizer Ventures"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Enara Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enara Bio \/ Pfizer Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Enara Bio \/ Pfizer Ventures"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Nuance Pharma"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"ETD002","moa":"TMEM16A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterprise Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"EPS 201","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Epsilogen \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Excivion","sponsor":"CPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Zika-HX Antigen","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Excivion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Excivion \/ CPI","highestDevelopmentStatusID":"1","companyTruncated":"Excivion \/ CPI"},{"orgOrder":0,"company":"Exscientia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Exscientia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Undisclosed"},{"orgOrder":0,"company":"Oxford Drug Discovery","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Oxford Drug Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Drug Discovery \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Drug Discovery \/ Exscientia"},{"orgOrder":0,"company":"Exscientia","sponsor":"Open Philanthropy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Open Philanthropy","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia \/ Open Philanthropy"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Faraday Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Adrenergic-beta 1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Faraday Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Faraday Pharmaceuticals"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"DNA polymerase","graph1":"Oncology","graph2":"Preclinical","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"Artios Pharma Limited \/ Omega Funds"},{"orgOrder":0,"company":"GSK","sponsor":"U.S. government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ U.S. government","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ U.S. government"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Series C Financing","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona Portfolio Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona Portfolio Limited","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Syncona Portfolio Limited"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"invoX Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"FS118","moa":"PD-L1\/LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F-star Therapeutics \/ invoX Pharma Limited","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ invoX Pharma Limited"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"invoX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"FS118","moa":"PD-L1\/LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F-star Therapeutics \/ invoX","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ invoX"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ BARDA"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"U.S Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ U.S Government","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ U.S Government"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Novavax"},{"orgOrder":0,"company":"Ochre Bio","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ochre Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ochre Bio \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ochre Bio \/ Khosla Ventures"},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"Mirae Asset Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Financing","leadProduct":"IKS03","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Iksuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iksuda Therapeutics \/ Mirae Asset Capital","highestDevelopmentStatusID":"4","companyTruncated":"Iksuda Therapeutics \/ Mirae Asset Capital"},{"orgOrder":0,"company":"Phico Therapeutics","sponsor":"Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"SASPject PT3.9","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phico Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phico Therapeutics \/ Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator","highestDevelopmentStatusID":"4","companyTruncated":"Phico Therapeutics \/ Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ ATAI Life Sciences"},{"orgOrder":0,"company":"MiroBio","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Medicxi","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Medicxi"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Immunocore","sponsor":"Gadeta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"GDT201","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Gadeta","highestDevelopmentStatusID":"4","companyTruncated":"Immunocore \/ Gadeta"},{"orgOrder":0,"company":"Venture Life","sponsor":"Jaguar Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Venture Life","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gel","sponsorNew":"Venture Life \/ Jaguar Health","highestDevelopmentStatusID":"15","companyTruncated":"Venture Life \/ Jaguar Health"},{"orgOrder":0,"company":"The University of Manchester","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"AVR-RD-05","moa":"IDS","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"The University of Manchester","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"The University of Manchester \/ Avrobio","highestDevelopmentStatusID":"4","companyTruncated":"The University of Manchester \/ Avrobio"},{"orgOrder":0,"company":"Scancell","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scancell \/ Genmab","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/ Genmab"},{"orgOrder":0,"company":"Genomics plc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Genomics plc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genomics plc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Genomics plc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Institution of biomedical academic research","sponsor":"genOway","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Institution of biomedical academic research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Institution of biomedical academic research \/ genOway","highestDevelopmentStatusID":"4","companyTruncated":"Institution of biomedical academic research \/ genOway"},{"orgOrder":0,"company":"Bio Immunitas","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bio Immunitas","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bio Immunitas \/ GenScript ProBio","highestDevelopmentStatusID":"3","companyTruncated":"Bio Immunitas \/ GenScript ProBio"},{"orgOrder":0,"company":"European Cooperative Group","sponsor":"Groupe Francophone","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","graph1":"Oncology","graph2":"Phase II","graph3":"European Cooperative Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"European Cooperative Group \/ Groupe Francophone","highestDevelopmentStatusID":"8","companyTruncated":"European Cooperative Group \/ Groupe Francophone"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"George Medicines","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Metformin","moa":"||NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ CUREator","highestDevelopmentStatusID":"8","companyTruncated":"George Medicines \/ CUREator"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Cemiplimab","moa":"||ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"GSK","sponsor":"Medicago","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CoVLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Medicago","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Medicago"},{"orgOrder":0,"company":"GSK","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ CEPI"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Forbion\u2019s Growth Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Forbion\u2019s Growth Opportunities Fund","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Forbion\u2019s Growth Opportunities Fund"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"HighTide Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","graph1":"Endocrinology","graph2":"Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Quotient Sciences \/ HighTide Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Quotient Sciences \/ HighTide Therapeutics"},{"orgOrder":0,"company":"IAG, Image Analysis Group","sponsor":"Cns Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"IAG, Image Analysis Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IAG, Image Analysis Group \/ Cns Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"IAG, Image Analysis Group \/ Cns Pharmaceuticals"},{"orgOrder":0,"company":"Immunocore","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Private Placement","leadProduct":"Durvalumab","moa":"||GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunocore \/ RTW Investments","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ RTW Investments"},{"orgOrder":0,"company":"Immunocore","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Public Offering","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Goldman Sachs","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Goldman Sachs"},{"orgOrder":0,"company":"Cardiff University","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Cardiff University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff University \/ Immutep","highestDevelopmentStatusID":"4","companyTruncated":"Cardiff University \/ Immutep"},{"orgOrder":0,"company":"Imophoron","sponsor":"Science Creates Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"ADDomer","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imophoron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Imophoron \/ Science Creates Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Imophoron \/ Science Creates Ventures"},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Influenza Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enesi Pharma Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Enesi Pharma Limited \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Enesi Pharma Limited \/ National Institutes of Health"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Divestment","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ RedHill Biopharma"},{"orgOrder":0,"company":"Exonate","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"EXN407","moa":"SRPK1-mediated VEGF splicing","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Exonate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Exonate \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Exonate \/ Johnson & Johnson"},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Vir Biotechnology"},{"orgOrder":0,"company":"The University of Dundee","sponsor":"Insmed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Brensocatib","moa":"DPP-1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Dundee","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Dundee \/ Insmed","highestDevelopmentStatusID":"1","companyTruncated":"The University of Dundee \/ Insmed"},{"orgOrder":0,"company":"Theramex","sponsor":"Endoceutics","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Prasterone","moa":"Corticosteroid-binding globulin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Pessary","sponsorNew":"Theramex \/ Endoceutics","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Endoceutics"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Inspira","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"IPA-001","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Inspira","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Inspira"},{"orgOrder":0,"company":"IsomAb","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ISM-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"IsomAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IsomAb \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"IsomAb \/ Pfizer Inc"},{"orgOrder":0,"company":"IXICO","sponsor":"Cyclerion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Zagociguat","moa":"sGC","graph1":"Neurology","graph2":"Phase II","graph3":"IXICO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IXICO \/ Cyclerion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"IXICO \/ Cyclerion Therapeutics"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"University of Oxford","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"dmGC_0817560","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"University of Oxford \/ CARB-X"},{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Elinzanetant","moa":"NK-1R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Kandy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kandy Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Kandy Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Medison Pharma"},{"orgOrder":0,"company":"LabGenius","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LabGenius","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LabGenius \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"LabGenius \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Funding","leadProduct":"rhBMP-2","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Locate Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locate Bio \/ Mercia Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Locate Bio \/ Mercia Ventures"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"New Therapies Council","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ New Therapies Council","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ New Therapies Council"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Italian Medicines Agency","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Italian Medicines Agency"},{"orgOrder":0,"company":"Avacta Group","sponsor":"AffyXell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Stefin A","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ AffyXell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Group \/ AffyXell Therapeutics"},{"orgOrder":0,"company":"Theramex","sponsor":"ObsEva","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theramex \/ ObsEva","highestDevelopmentStatusID":"10","companyTruncated":"Theramex \/ ObsEva"},{"orgOrder":0,"company":"Macomics","sponsor":"Institute of Oncology Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Macomics \/ Institute of Oncology Research","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ Institute of Oncology Research"},{"orgOrder":0,"company":"Macomics","sponsor":"Caribou Property Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Macomics \/ Caribou Property Limited","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ Caribou Property Limited"},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Medison Pharma"},{"orgOrder":0,"company":"Eleusis","sponsor":"Silver Spike Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eleusis \/ Silver Spike Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Eleusis \/ Silver Spike Acquisition Corp"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Mestag Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Mestag Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Mestag Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mina Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Modus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Sevuparin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imperial College London \/ Modus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Modus Therapeutics"},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mogrify \/ Sangamo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mogrify \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sterling Pharma Solutions \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Sterling Pharma Solutions \/ Moleculin Biotech"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Mucokinetica","sponsor":"Covistat","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mucokinetica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mucokinetica \/ Covistat","highestDevelopmentStatusID":"1","companyTruncated":"Mucokinetica \/ Covistat"},{"orgOrder":0,"company":"NeoPhore","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"DNA MMR","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeoPhore \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Aptorum","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Rilpivirine Hydrochloride","moa":"NNRT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Aptorum \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Alliance Global Partners"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"TZLS-501","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tiziana Life Sciences \/ Thinkequity","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Thinkequity"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Tibulizumab","moa":"IL-17\/BAFF","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zura Bio \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Access Biotechnology"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mexico Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Mexico Government","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Mexico Government"},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Orvepitant Maleate","moa":"NK-1R","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NeRRe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeRRe Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"NeRRe Therapeutics \/ Columbus Venture Partners"},{"orgOrder":0,"company":"NICE","sponsor":"Healthcare Improvement Scotland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"NICE","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NICE \/ Healthcare Improvement Scotland","highestDevelopmentStatusID":"15","companyTruncated":"NICE \/ Healthcare Improvement Scotland"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Starbloom Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"N-LIfT","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LIfT Biosciences \/ Starbloom Capital","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Starbloom Capital"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Novavax"},{"orgOrder":0,"company":"PhoreMost","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery","graph3":"PhoreMost","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PhoreMost \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"PhoreMost \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Ochre Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ochre Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ochre Bio \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Ochre Bio \/ GSK"},{"orgOrder":0,"company":"Touchlight","sponsor":"Odimma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Touchlight \/ Odimma Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Touchlight \/ Odimma Therapeutics"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tetris Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tetris Pharma \/ Arecor","highestDevelopmentStatusID":"15","companyTruncated":"Tetris Pharma \/ Arecor"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ ThinkEquity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ ThinkEquity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ ThinkEquity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ ThinkEquity"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Circassia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Aclidinium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol, Powder","sponsorNew":"AstraZeneca \/ Circassia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Circassia Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"D2\/3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Pharming","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"OTL-105","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Pharming","highestDevelopmentStatusID":"4","companyTruncated":"Orchard Therapeutics \/ Pharming"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"OncoTEX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Oxaliplatin Pt(Iv) Prodrug","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sterling Pharma Solutions \/ OncoTEX","highestDevelopmentStatusID":"4","companyTruncated":"Sterling Pharma Solutions \/ OncoTEX"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Oxford Biomedica \/ AstraZeneca"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"SAR422459","moa":"ABCR gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biomedica \/ Sanofi"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Oxford Biomedica \/ AstraZeneca"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Biomedica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Sio Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Biomedica \/ Sio Gene Therapies"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Kite Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Oxford Biotherapeutics \/ Kite Pharma"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"OXL001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"4","companyTruncated":"Quotient Sciences \/ CytoAgents"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"GPR65","graph1":"Oncology","graph2":"Discovery","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathios Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Pathios Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Suvratoxumab","moa":"Staphylococcus aureus alpha toxin binding","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AstraZeneca \/ Aridis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Aridis Pharmaceuticals"},{"orgOrder":0,"company":"PhoreMost","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"PhoreMost","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PhoreMost \/ Oxford Biomedica","highestDevelopmentStatusID":"2","companyTruncated":"PhoreMost \/ Oxford Biomedica"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"STI-001","moa":"||STING","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Portage Biotech \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"Portage Biotech \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Financing","leadProduct":"Pivmecillinam","moa":"PBP1A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UTILITY therapeutics \/ AMR Action Fund","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ AMR Action Fund"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"GV","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OMass Therapeutics \/ GV","highestDevelopmentStatusID":"2","companyTruncated":"OMass Therapeutics \/ GV"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Cowen"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pulmocide \/ Jeito Capital","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Jeito Capital"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Financing","leadProduct":"Neumifil","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen \/ Thairm Bio"},{"orgOrder":0,"company":"iosBio","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iosBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iosBio \/ Department of Health and Social Care","highestDevelopmentStatusID":"1","companyTruncated":"iosBio \/ Department of Health and Social Care"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"4","companyTruncated":"Apollo Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"JATT Acquisition Corp","sponsor":"Zura Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Merger","leadProduct":"ZB-168","moa":"IL7R-alpha","graph1":"Endocrinology","graph2":"Phase I","graph3":"JATT Acquisition Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JATT Acquisition Corp \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"JATT Acquisition Corp \/ Zura Bio"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Immunology","graph2":"Undisclosed","graph3":"OMass Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OMass Therapeutics \/ Syncona","highestDevelopmentStatusID":"1","companyTruncated":"OMass Therapeutics \/ Syncona"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"HSDB 4295","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evox Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Redmile Group"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"N-Methyl Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Braavos Investment Advisers","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpyBiotech \/ Braavos Investment Advisers","highestDevelopmentStatusID":"4","companyTruncated":"SpyBiotech \/ Braavos Investment Advisers"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Luminous Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Financing","leadProduct":"PolyPEPI-1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Luminous Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio \/ Luminous Ventures"},{"orgOrder":0,"company":"Oxular","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suprachoroidal Injection, Sustained Release","sponsorNew":"Oxular \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Forbion"},{"orgOrder":0,"company":"Ochre Bio","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ochre Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ochre Bio \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ochre Bio \/ Khosla Ventures"},{"orgOrder":0,"company":"William Harvey Research Institute","sponsor":"Cyxone AB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Rabeximod","moa":"TNF","graph1":"Immunology","graph2":"Phase II","graph3":"William Harvey Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"William Harvey Research Institute \/ Cyxone AB","highestDevelopmentStatusID":"8","companyTruncated":"William Harvey Research Institute \/ Cyxone AB"},{"orgOrder":0,"company":"Sixfold Bioscience","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sixfold Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sixfold Bioscience \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sixfold Bioscience \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Relation Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Relation Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Relation Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Aldesleukin","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Divestment","leadProduct":"Aldesleukin","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Pictet Alternative Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pulmocide \/ Pictet Alternative Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Pictet Alternative Advisors"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Charles River Laboratories International","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Preclinical","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Charles River Laboratories International","highestDevelopmentStatusID":"4","companyTruncated":"Purespring Therapeutics \/ Charles River Laboratories International"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"eXmoor pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ eXmoor pharma","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ eXmoor pharma"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Aprepitant","moa":"NK-1R","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ RedHill Biopharma"},{"orgOrder":0,"company":"Almac Group","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"DUBs","graph1":"Neurology","graph2":"Discovery","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Almac Group \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Almac Group \/ Merck & Co"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"University Medical Center of Johannes Gutenberg University Mainz","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"rNAPc2","moa":"Tissue factor pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ University Medical Center of Johannes Gutenberg University Mainz","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ University Medical Center of Johannes Gutenberg University Mainz"},{"orgOrder":0,"company":"Aptorum","sponsor":"Aenco Technologies Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Rilpivirine Hydrochloride","moa":"NNRT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Aptorum \/ Aenco Technologies Limited","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Aenco Technologies Limited"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sareum","sponsor":"UKRI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"SDC-1801","moa":"JAK1\/TYK2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ UKRI","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ UKRI"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Maltol","moa":"Integrin beta-3 substrate","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"GSK","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Jefferies LLC"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Sio Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Biomedica \/ Sio Gene Therapies"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"SPX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpectrumX \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Undisclosed"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Virus-like Particle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpyBiotech \/ Serum Institute of India","highestDevelopmentStatusID":"7","companyTruncated":"SpyBiotech \/ Serum Institute of India"},{"orgOrder":0,"company":"Stabilitech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"OraPro-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Stabilitech Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stabilitech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Stabilitech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"SPX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpectrumX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SpectrumX \/ Undisclosed"},{"orgOrder":0,"company":"Seqirus","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Influenza A (H5N1) Monovalent Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Synairgen","sponsor":"Aerogen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Aerogen"},{"orgOrder":0,"company":"University College London","sponsor":"Cure Parkinson\u2019S Trust","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Ambroxol","moa":"NO dependent soluble guanylate cyclase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University College London","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College London \/ Cure Parkinson\u2019S Trust","highestDevelopmentStatusID":"8","companyTruncated":"University College London \/ Cure Parkinson\u2019S Trust"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Tenpoint Therapeutics \/ British Patient Capital","highestDevelopmentStatusID":"3","companyTruncated":"Tenpoint Therapeutics \/ British Patient Capital"},{"orgOrder":0,"company":"Closed Loop Medicine","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Amlodipine","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Closed Loop Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Closed Loop Medicine \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Closed Loop Medicine \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"GSK","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Camphor","moa":"||TRPV1","graph1":"Neurology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"GSK \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Angelini Pharma"},{"orgOrder":0,"company":"Eleusis","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eleusis \/ Beckley Psytech","highestDevelopmentStatusID":"6","companyTruncated":"Eleusis \/ Beckley Psytech"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Merck & Co"},{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Merck & Co"},{"orgOrder":0,"company":"Theragnostics","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"ATD-001","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theragnostics \/ Ariceum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theragnostics \/ Ariceum Therapeutics"},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Gilead Sciences"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep \/ BioNTech"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep \/ BioNTech"},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Gilead Sciences"},{"orgOrder":0,"company":"NeoPhore","sponsor":"CRT Pioneer Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"MMR","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeoPhore \/ CRT Pioneer Fund","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ CRT Pioneer Fund"},{"orgOrder":0,"company":"Almac Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almac Group \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Almac Group \/ Undisclosed"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Vaccine Industrial Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8+","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gylden Pharma \/ Vaccine Industrial Company","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Vaccine Industrial Company"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"GlycoNex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"GNX102-ADC","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sterling Pharma Solutions \/ GlycoNex","highestDevelopmentStatusID":"4","companyTruncated":"Sterling Pharma Solutions \/ GlycoNex"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Laboratorios HIPRA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"COVID-19 Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Accord healthcare \/ Laboratorios HIPRA","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Laboratorios HIPRA"},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Autifony Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Autifony Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Autifony Therapeutics \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Tufts Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Tufts Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Tufts Medical Center"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"NHS England","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ NHS England","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ NHS England"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Government of Australia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Government of Australia","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Government of Australia"},{"orgOrder":0,"company":"Touchlight","sponsor":"Versameb","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Agreement","leadProduct":"VMB-100","moa":"Undisclosed","graph1":"Urology","graph2":"Preclinical","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Touchlight \/ Versameb","highestDevelopmentStatusID":"4","companyTruncated":"Touchlight \/ Versameb"},{"orgOrder":0,"company":"GSK","sponsor":"Xiamen Innovax Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Xiamen Innovax Biotech","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Xiamen Innovax Biotech"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Molecular Biology Institute of Parana","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8+","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gylden Pharma \/ Molecular Biology Institute of Parana","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Molecular Biology Institute of Parana"},{"orgOrder":0,"company":"Sciensus Rare","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Sciensus Rare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sciensus Rare \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sciensus Rare \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"Great Ormond Street Hospital","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Great Ormond Street Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Great Ormond Street Hospital \/ Leucid Bio","highestDevelopmentStatusID":"4","companyTruncated":"Great Ormond Street Hospital \/ Leucid Bio"},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"IKS014","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Iksuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iksuda Therapeutics \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Iksuda Therapeutics \/ LegoChem Biosciences"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Doxorubicin Prodrug","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Point Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Point Biopharma"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"ATCC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Yellow Fever Booster Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gylden Pharma \/ ATCC","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ ATCC"},{"orgOrder":0,"company":"Concept Life Sciences","sponsor":"AstronauTx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Astrocyte","graph1":"Neurology","graph2":"Discovery","graph3":"Concept Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Concept Life Sciences \/ AstronauTx","highestDevelopmentStatusID":"2","companyTruncated":"Concept Life Sciences \/ AstronauTx"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Immunogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"OBT227","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Immunogen","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biotherapeutics \/ Immunogen"},{"orgOrder":0,"company":"Kings College London","sponsor":"Epsilogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Mov18 IgE","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kings College London \/ Epsilogen","highestDevelopmentStatusID":"6","companyTruncated":"Kings College London \/ Epsilogen"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Brazilian Health Ministry","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Brazilian Health Ministry","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Brazilian Health Ministry"},{"orgOrder":0,"company":"Arix Bioscience Plc","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Arix Bioscience Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arix Bioscience Plc \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arix Bioscience Plc \/ EQT Life Sciences"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Midatech Pharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Midatech Pharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Ikarovec","sponsor":"UKI2S","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikarovec \/ UKI2S","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ UKI2S"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pulmocide \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ University of Oxford"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbit Discovery \/ Endevica Bio","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Endevica Bio"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"University College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ University College London","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth Therapeutics \/ University College London"},{"orgOrder":0,"company":"Lindus Health","sponsor":"Acinonyx Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Collaboration","leadProduct":"Alpha-Cyclodextrin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lindus Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindus Health \/ Acinonyx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lindus Health \/ Acinonyx Bio"},{"orgOrder":0,"company":"Arecor","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraperitoneal Implant","sponsorNew":"Arecor \/ Medtronic Plc","highestDevelopmentStatusID":"4","companyTruncated":"Arecor \/ Medtronic Plc"},{"orgOrder":0,"company":"Plasticell","sponsor":"LambdaGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Plasticell","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plasticell \/ LambdaGen","highestDevelopmentStatusID":"2","companyTruncated":"Plasticell \/ LambdaGen"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sanofi"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.24,"dosageForm":"Oral","sponsorNew":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"ONI","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ONI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ONI \/ University of Pennsylvania","highestDevelopmentStatusID":"1","companyTruncated":"ONI \/ University of Pennsylvania"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Osimertinib","moa":"||HER3","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Nafamostat Hcl","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Relation Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relation Therapeutics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Relation Therapeutics \/ GSK"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quell Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Quell Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Evergreen Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbit Discovery \/ Evergreen Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Orbit Discovery \/ Evergreen Discovery"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Texcell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"||CD8+ T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Texcell","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Texcell"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"GORTEC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ GORTEC","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ GORTEC"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-V integrin","graph1":"Oncology","graph2":"Preclinical","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valo Therapeutics \/ Lisata Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Valo Therapeutics \/ Lisata Therapeutics"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Queen Mary University of London","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TC BioPharm \/ Queen Mary University of London","highestDevelopmentStatusID":"2","companyTruncated":"TC BioPharm \/ Queen Mary University of London"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"EBV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpyBiotech \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"SpyBiotech \/ University of Oxford"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Journey Clinical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Journey Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Journey Clinical"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evox Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Evox Therapeutics \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Antiverse","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antiverse \/ Sosei Group Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apollo Therapeutics \/ The Institute of Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"Cancer Research","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Trifluridine","moa":"||Gremlin-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cancer Research \/ UCB Pharma S.A","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Papyrus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"PYTX-002","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ Papyrus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ Papyrus Therapeutics"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microbiotica \/ Cancer Research","highestDevelopmentStatusID":"1","companyTruncated":"Microbiotica \/ Cancer Research"},{"orgOrder":0,"company":"Reading Scientific Services","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Reading Scientific Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reading Scientific Services \/ Ethypharm","highestDevelopmentStatusID":"1","companyTruncated":"Reading Scientific Services \/ Ethypharm"},{"orgOrder":0,"company":"Synairgen","sponsor":"University of Southampton","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ University of Southampton","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ University of Southampton"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"University of Glasgow","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Glasgow \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"University of Glasgow \/ Eli Lilly"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Clinigen Group \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen Group \/ Synairgen"},{"orgOrder":0,"company":"Adrestia Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Adrestia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Adrestia Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Adrestia Therapeutics \/ GSK"},{"orgOrder":0,"company":"Macomics","sponsor":"IFOM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Macomics \/ IFOM","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ IFOM"},{"orgOrder":0,"company":"SiSaf","sponsor":"University of Leipzig","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"miR24-3p","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SiSaf","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SiSaf \/ University of Leipzig","highestDevelopmentStatusID":"4","companyTruncated":"SiSaf \/ University of Leipzig"},{"orgOrder":0,"company":"Epitopea","sponsor":"Universit\u00e9 de Montr\u00e9al","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Epitopea \/ Universit\u00e9 de Montr\u00e9al","highestDevelopmentStatusID":"3","companyTruncated":"Epitopea \/ Universit\u00e9 de Montr\u00e9al"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"ADAR1","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Storm Therapeutics \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Storm Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"Peptone","sponsor":"The Institute of Oncology Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Peptone","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptone \/ The Institute of Oncology Research","highestDevelopmentStatusID":"2","companyTruncated":"Peptone \/ The Institute of Oncology Research"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Exscientia \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"RNA Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Imperial College London \/ Enesi Pharma Limited","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Enesi Pharma Limited"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bicycle Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"CHARM Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"CHARM Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CHARM Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"CHARM Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Evox Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"University of Oxford \/ Evox Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"University of Oxford \/ Evox Therapeutics"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"BNT211","moa":"||CLDN6","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"H&T Presspart","sponsor":"Bilim Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Collaboration","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"H&T Presspart","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"H&T Presspart \/ Bilim Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"H&T Presspart \/ Bilim Pharmaceuticals"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"NeoPhore","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"MMR","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeoPhore \/ The Institute of Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"Wren Therapeutics","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Wren Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Wren Therapeutics \/ Eisai","highestDevelopmentStatusID":"3","companyTruncated":"Wren Therapeutics \/ Eisai"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Achilles Therapeutics \/ Arcturus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Bit Bio","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bit Bio \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Deubiquitylase enzyme","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ubiquigent \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of St Andrews","sponsor":"ILC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Human Alpha Interferon","moa":"INF-alpha 14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of St Andrews","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of St Andrews \/ ILC Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of St Andrews \/ ILC Therapeutics"},{"orgOrder":0,"company":"Morningside Pharmaceuticals","sponsor":"Aspire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Acquisition","leadProduct":"Gestodene","moa":"||PR","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Morningside Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Morningside Pharmaceuticals \/ Aspire Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Morningside Pharmaceuticals \/ Aspire Pharma"},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Iontas \/ FairJourney Biologics"},{"orgOrder":0,"company":"Zura Bio","sponsor":"JATT Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Merger","leadProduct":"ZB-168","moa":"IL7R-alpha","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zura Bio \/ JATT Acquisition Corp","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ JATT Acquisition Corp"},{"orgOrder":0,"company":"Exscientia","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Recursion Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Recursion Pharma"},{"orgOrder":0,"company":"IAG, Image Analysis Group","sponsor":"Vivacitas Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Silatecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"IAG, Image Analysis Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IAG, Image Analysis Group \/ Vivacitas Oncology","highestDevelopmentStatusID":"8","companyTruncated":"IAG, Image Analysis Group \/ Vivacitas Oncology"},{"orgOrder":0,"company":"Aptamer Group","sponsor":"PinotBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"FL-118","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Aptamer Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptamer Group \/ PinotBio","highestDevelopmentStatusID":"2","companyTruncated":"Aptamer Group \/ PinotBio"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ BARDA"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ EF Hutton","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ EF Hutton"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Private Placement","leadProduct":"Zerlasiran","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ 5AM Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ 5AM Ventures"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Guggenheim Securities, LLC"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"Libmeldy","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"CellCentric","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Inobrodib","moa":"||EP300\/CBP bromodomain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CellCentric \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Pfizer Inc"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"OV350","moa":"KCC2 transporter","graph1":"Neurology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ovid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AstraZeneca \/ Ovid Therapeutics"},{"orgOrder":0,"company":"LabGenius","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LabGenius","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LabGenius \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"LabGenius \/ M Ventures"},{"orgOrder":0,"company":"Glox Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"Engineered Protein Bacteriocin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Glox Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glox Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Glox Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"MitoRx Therapeutics","sponsor":"Wren Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MitoRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MitoRx Therapeutics \/ Wren Capital","highestDevelopmentStatusID":"4","companyTruncated":"MitoRx Therapeutics \/ Wren Capital"},{"orgOrder":0,"company":"T-Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"T-Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"T-Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"3","companyTruncated":"T-Therapeutics \/ Sofinnova Partners"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Open Orphan","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CodaVax-COVID","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Open Orphan","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Open Orphan \/ Codagenix","highestDevelopmentStatusID":"4","companyTruncated":"Open Orphan \/ Codagenix"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Ori Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Achilles Therapeutics \/ Ori Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Ori Biotech"},{"orgOrder":0,"company":"30 Technology","sponsor":"ConvaTec","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"RESP301","moa":"Membrane fusion protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"30 Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"30 Technology \/ ConvaTec","highestDevelopmentStatusID":"8","companyTruncated":"30 Technology \/ ConvaTec"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Biomedica \/ Beam Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ Beam Therapeutics"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"PARP","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cancer Research \/ Ideaya Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Research \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Theolytics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theolytics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics \/ M Ventures"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Expanded Collaboration","leadProduct":"Humabody","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Crescendo Biologics Ltd","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crescendo Biologics Ltd \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Crescendo Biologics Ltd \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Antiverse","sponsor":"GlobalBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"PD-1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antiverse \/ GlobalBio","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ GlobalBio"},{"orgOrder":0,"company":"EirGen Pharma","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Teprotumumab","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"EirGen Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EirGen Pharma \/ Horizon Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EirGen Pharma \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ TCGX","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Myricx Bio","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"MYX2468","moa":"N-Myristoyltransferase","graph1":"Oncology","graph2":"Preclinical","graph3":"Myricx Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myricx Bio \/ Organovo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Myricx Bio \/ Organovo Holdings"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ TCGX","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Epsilogen","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Mov18 IgE","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epsilogen \/ British Patient Capital","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ British Patient Capital"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"ICG\u2019s Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"GRWD5769","moa":"ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ ICG\u2019s Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ ICG\u2019s Life Sciences"},{"orgOrder":0,"company":"Yellowstone Bioscience","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Yellowstone Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yellowstone Bioscience \/ Syncona Limited","highestDevelopmentStatusID":"4","companyTruncated":"Yellowstone Bioscience \/ Syncona Limited"},{"orgOrder":0,"company":"Vicebio","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Series B Financing","leadProduct":"VXB-241","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vicebio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicebio \/ TCGX","highestDevelopmentStatusID":"6","companyTruncated":"Vicebio \/ TCGX"},{"orgOrder":0,"company":"Outrun Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Outrun Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Outrun Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Outrun Therapeutics \/ M Ventures"},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Eos Angel Investment Syndicate","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Financing","leadProduct":"Human Alpha Interferon","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ILC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ILC Therapeutics \/ Eos Angel Investment Syndicate","highestDevelopmentStatusID":"6","companyTruncated":"ILC Therapeutics \/ Eos Angel Investment Syndicate"},{"orgOrder":0,"company":"AstronauTx","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AstronauTx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstronauTx \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"AstronauTx \/ Novartis Venture Fund"},{"orgOrder":0,"company":"Nodus Oncology","sponsor":"Cumulus Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"DDR","graph1":"Oncology","graph2":"Preclinical","graph3":"Nodus Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nodus Oncology \/ Cumulus Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Nodus Oncology \/ Cumulus Oncology"},{"orgOrder":0,"company":"CHARM Therapeutics","sponsor":"NVentures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"CHARM Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CHARM Therapeutics \/ NVentures","highestDevelopmentStatusID":"2","companyTruncated":"CHARM Therapeutics \/ NVentures"},{"orgOrder":0,"company":"Engitix Therapeutics","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Engitix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engitix Therapeutics \/ Dompe Farmaceutici","highestDevelopmentStatusID":"3","companyTruncated":"Engitix Therapeutics \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Theolytics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theolytics \/ Epidarex Capital","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics \/ Epidarex Capital"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OMass Therapeutics \/ British Patient Capital","highestDevelopmentStatusID":"2","companyTruncated":"OMass Therapeutics \/ British Patient Capital"},{"orgOrder":0,"company":"Baseimmune","sponsor":"MSD Global Health Innovation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"BSI002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Baseimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baseimmune \/ MSD Global Health Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Baseimmune \/ MSD Global Health Innovation"},{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Dementia Discovery Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"LoQus23 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"LoQus23 Therapeutics \/ Dementia Discovery Fund","highestDevelopmentStatusID":"4","companyTruncated":"LoQus23 Therapeutics \/ Dementia Discovery Fund"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ Syncona","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Syncona"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Panakes Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Panakes Partners","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Panakes Partners"},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Curve Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Curve Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Curve Therapeutics \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Vickers Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Series A Financing","leadProduct":"Set-Point Vaccines","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gylden Pharma \/ Vickers Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Vickers Venture Partners"},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Venture Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Mogrify \/ Astellas Venture Management","highestDevelopmentStatusID":"4","companyTruncated":"Mogrify \/ Astellas Venture Management"},{"orgOrder":0,"company":"Orthox","sponsor":"Parkwalk","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"Fibroin","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Orthox","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orthox \/ Parkwalk","highestDevelopmentStatusID":"1","companyTruncated":"Orthox \/ Parkwalk"},{"orgOrder":0,"company":"IsomAb","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"ISM-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"IsomAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IsomAb \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"IsomAb \/ Broadview Ventures"},{"orgOrder":0,"company":"Epitopea","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epitopea \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"4","companyTruncated":"Epitopea \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"GSK","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"H1N1 Influenza Vaccine, AS03-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Government of Canada","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Government of Canada"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"MTX325","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Mission Therapeutics \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen \/ Thairm Bio"},{"orgOrder":0,"company":"ExpressionEdits","sponsor":"Octopus Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"ExpressionEdits","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExpressionEdits \/ Octopus Ventures","highestDevelopmentStatusID":"3","companyTruncated":"ExpressionEdits \/ Octopus Ventures"},{"orgOrder":0,"company":"Bit Bio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"Human iPSC-derived Glutamatergic Neurons","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bit Bio \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Glox Therapeutics","sponsor":"PACE","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Glox Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glox Therapeutics \/ PACE","highestDevelopmentStatusID":"4","companyTruncated":"Glox Therapeutics \/ PACE"},{"orgOrder":0,"company":"GSK","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"AS01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"VaxEquity","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"saRNA Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxEquity","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VaxEquity \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"VaxEquity \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"HEX17","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Liquid","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen \/ Thairm Bio"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"IL-17\/BAFF","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Alchemab","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alchemab \/ RA Capital Management","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ RA Capital Management"},{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Funding","leadProduct":"rhBMP-2","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Locate Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locate Bio \/ Mercia Asset Management","highestDevelopmentStatusID":"1","companyTruncated":"Locate Bio \/ Mercia Asset Management"},{"orgOrder":0,"company":"CellCentric","sponsor":"BrightEdge","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Inobrodib","moa":"EP300\/CBP bromodomain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CellCentric \/ BrightEdge","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ BrightEdge"},{"orgOrder":0,"company":"Scancell","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Scancell \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Government of Wallonia","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Muscle Progenitor Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genflow Biosciences \/ Government of Wallonia","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Biosciences \/ Government of Wallonia"},{"orgOrder":0,"company":"Senisca","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Senisca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senisca \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Senisca \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Maxion Therapeutics","sponsor":"LifeArc Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Maxion Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maxion Therapeutics \/ LifeArc Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Maxion Therapeutics \/ LifeArc Ventures"},{"orgOrder":0,"company":"Antiverse","sponsor":"InnoSpark","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antiverse \/ InnoSpark","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ InnoSpark"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Finnish Funding Agency for Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Valo Therapeutics \/ Finnish Funding Agency for Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Valo Therapeutics \/ Finnish Funding Agency for Innovation"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Government of United Kingdom","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Self-Amplifying Rna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Government of United Kingdom","highestDevelopmentStatusID":"4","companyTruncated":"Imperial College London \/ Government of United Kingdom"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Karolinska Institutet","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ Karolinska Institutet","highestDevelopmentStatusID":"4","companyTruncated":"Cobra Biologics \/ Karolinska Institutet"},{"orgOrder":0,"company":"Monument Therapeutics","sponsor":"Forster Foundation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"MT1988","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Monument Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monument Therapeutics \/ Forster Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Monument Therapeutics \/ Forster Foundation"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"SpyBiotech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SpyBiotech \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Chemify","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Chemify","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemify \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Chemify \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThirtyFiveBio \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFiveBio \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Antiverse","sponsor":"i&i Biotech Fund I","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antiverse \/ i&i Biotech Fund I","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ i&i Biotech Fund I"},{"orgOrder":0,"company":"EpilepsyGTx","sponsor":"UCL Technology Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"EPY201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"EpilepsyGTx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpilepsyGTx \/ UCL Technology Fund","highestDevelopmentStatusID":"4","companyTruncated":"EpilepsyGTx \/ UCL Technology Fund"},{"orgOrder":0,"company":"Adaptate Biotherapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"ADT-010","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptate Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptate Biotherapeutics \/ Abingworth","highestDevelopmentStatusID":"4","companyTruncated":"Adaptate Biotherapeutics \/ Abingworth"},{"orgOrder":0,"company":"AviadoBio","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"AVB-PGRN","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic Injection","sponsorNew":"AviadoBio \/ New Enterprise Associates","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ New Enterprise Associates"},{"orgOrder":0,"company":"Nucleome Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nucleome Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nucleome Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nucleome Therapeutics \/ M Ventures"},{"orgOrder":0,"company":"PharmEnable","sponsor":"MP Healthcare Venture Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"PharmEnable","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmEnable \/ MP Healthcare Venture Management","highestDevelopmentStatusID":"2","companyTruncated":"PharmEnable \/ MP Healthcare Venture Management"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ TCGX","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"UK government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathios Therapeutics \/ UK government","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Therapeutics \/ UK government"},{"orgOrder":0,"company":"Lario Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Lario Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Lario Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Lario Therapeutics \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Synthetic T-cell Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Gylden Pharma \/ Department of Health and Social Care","highestDevelopmentStatusID":"2","companyTruncated":"Gylden Pharma \/ Department of Health and Social Care"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LIfT Biosciences \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ ALS Association","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ ALS Association"},{"orgOrder":0,"company":"Alchemab","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Alchemab \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"ScaleReady","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ ScaleReady","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ ScaleReady"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Exscientia \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"SARS-CoV2 protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Storm Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Storm Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ateria Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ateria Health \/ Immuron","highestDevelopmentStatusID":"15","companyTruncated":"Ateria Health \/ Immuron"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Series A Financing","leadProduct":"PHN-010","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheon Therapeutics \/ Brandon Capital","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ Brandon Capital"},{"orgOrder":0,"company":"pHion Therapeutics","sponsor":"Invox Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"RALA-mRNA Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"pHion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"pHion Therapeutics \/ Invox Pharma","highestDevelopmentStatusID":"4","companyTruncated":"pHion Therapeutics \/ Invox Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"S-Pindolol Benzoate","moa":"5-HTA1a\/beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Grunenthal Meds","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Grunenthal Meds","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Grunenthal Meds \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"Grunenthal Meds \/ Grunenthal"},{"orgOrder":0,"company":"GSK","sponsor":"UNICEF","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"RTS, S\/AS01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ UNICEF","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ UNICEF"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"LSA","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Biomedica \/ LSA","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ LSA"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Recombinant Chadox1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Oxford Biomedica \/ AstraZeneca"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"SLN501","moa":"C3","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Imdusiran","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Barinthus Biotherapeutics \/ Arbutus Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Barinthus Biotherapeutics \/ Arbutus Biopharma"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Hercules Capital"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"IL-17\/BAFF","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Paulson Investment Company"},{"orgOrder":0,"company":"Epitopea","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epitopea \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Epitopea \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Multiomic Health","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery","graph3":"Multiomic Health","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Multiomic Health \/ Hoxton Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Multiomic Health \/ Hoxton Ventures"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Sulforaphane","moa":"||Nrf2","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evgen Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"finnCap Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"NTCD-M3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Destiny Pharma \/ finnCap Limited","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ finnCap Limited"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Financing","leadProduct":"EBX-102-02","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Thairm Bio"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"BT5528","moa":"||Ephrin type A receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Inoviv","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"HER-096","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Inoviv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inoviv \/ Hoxton Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Inoviv \/ Hoxton Ventures"},{"orgOrder":0,"company":"Harness Therapeutics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Harness Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Harness Therapeutics \/ Epidarex Capital","highestDevelopmentStatusID":"4","companyTruncated":"Harness Therapeutics \/ Epidarex Capital"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"PTT-4256","moa":"GPR65","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pathios Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Pathios Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Healx","sponsor":"R42 Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healx \/ R42 Group","highestDevelopmentStatusID":"6","companyTruncated":"Healx \/ R42 Group"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Endocrinology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ TCGX"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Jefferies"},{"orgOrder":0,"company":"NeoPhore","sponsor":"Sixth element capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"NP1867","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeoPhore \/ Sixth element capital","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/ Sixth element capital"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"DCVC","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Relation Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relation Therapeutics \/ DCVC","highestDevelopmentStatusID":"2","companyTruncated":"Relation Therapeutics \/ DCVC"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"NG-350A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vernalis","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vernalis \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Vernalis \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Ixaka","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Rexmyelocel-T","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ixaka","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial Catheter","sponsorNew":"Ixaka \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ixaka \/ Undisclosed"},{"orgOrder":0,"company":"Wren Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Amyloid-beta protein","graph1":"Neurology","graph2":"Discovery","graph3":"Wren Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wren Therapeutics \/ Baupost Group","highestDevelopmentStatusID":"2","companyTruncated":"Wren Therapeutics \/ Baupost Group"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Touchlight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"TGL-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Cancer Research \/ Touchlight"},{"orgOrder":0,"company":"Cardiff University","sponsor":"Ervaxx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"MHC-I","graph1":"Oncology","graph2":"Preclinical","graph3":"Cardiff University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff University \/ Ervaxx","highestDevelopmentStatusID":"4","companyTruncated":"Cardiff University \/ Ervaxx"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Elasmogen","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elasmogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Elasmogen \/ University of Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"Elasmogen \/ University of Minnesota"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Oxford Finance","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Oxford Finance"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Silicon Valley Bank","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Silicon Valley Bank"},{"orgOrder":0,"company":"Smartway Pharmaceuticals","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2023","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Smartway Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Smartway Pharmaceuticals \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Smartway Pharmaceuticals \/ Marinus Pharmaceuticals"},{"orgOrder":0,"company":"Domainex","sponsor":"LUNAC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Protease","graph1":"Hematology","graph2":"Discovery","graph3":"Domainex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Domainex \/ LUNAC Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Domainex \/ LUNAC Therapeutics"},{"orgOrder":0,"company":"aVaxziPen","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Protein-Based Vaccine","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"aVaxziPen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"aVaxziPen \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"aVaxziPen \/ CEPI"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"VTP-500","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barinthus Biotherapeutics \/ CEPI","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ CEPI"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Oncology","graph2":"Phase III","graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Sterling Pharma Solutions \/ Soligenix","highestDevelopmentStatusID":"10","companyTruncated":"Sterling Pharma Solutions \/ Soligenix"},{"orgOrder":0,"company":"Ochre Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Ochre Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Ochre Bio \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Ochre Bio \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Minaris","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LIfT Biosciences \/ Minaris","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Minaris"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ LG Chem"},{"orgOrder":0,"company":"ConserV Bioscience","sponsor":"eTheRNA immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ConserV Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ConserV Bioscience \/ eTheRNA immunotherapies","highestDevelopmentStatusID":"4","companyTruncated":"ConserV Bioscience \/ eTheRNA immunotherapies"},{"orgOrder":0,"company":"Leeds University","sponsor":"ChemomAb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Nebokitug","moa":"CCL24","graph1":"Immunology","graph2":"Phase I","graph3":"Leeds University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leeds University \/ ChemomAb","highestDevelopmentStatusID":"6","companyTruncated":"Leeds University \/ ChemomAb"},{"orgOrder":0,"company":"Theolytics","sponsor":"Sound Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Financing","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theolytics \/ Sound Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"Theolytics \/ Sound Bioventures"},{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"LoQus23 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"LoQus23 Therapeutics \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"LoQus23 Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"Mov18 IgE","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epsilogen \/ Novartis Venture Fund","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Novartis Venture Fund"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"M&G Investment Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"ChAdOx1-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ M&G Investment Management","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ M&G Investment Management"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Forbion"},{"orgOrder":0,"company":"ViaNautis Bio","sponsor":"SomaServe","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ViaNautis Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ViaNautis Bio \/ SomaServe","highestDevelopmentStatusID":"3","companyTruncated":"ViaNautis Bio \/ SomaServe"},{"orgOrder":0,"company":"EyeBio","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"Re-Vana Therapeutics","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Re-Vana Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"Re-Vana Therapeutics \/ Visionary Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Re-Vana Therapeutics \/ Visionary Ventures"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"Shift Bioscience","sponsor":"BGF","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Shift Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shift Bioscience \/ BGF","highestDevelopmentStatusID":"4","companyTruncated":"Shift Bioscience \/ BGF"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Prevail Partners","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Prevail Partners"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"MST-0300","moa":"FAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Mestag Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Cumulus Oncology","sponsor":"Eos Advisory","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Cumulus Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cumulus Oncology \/ Eos Advisory","highestDevelopmentStatusID":"4","companyTruncated":"Cumulus Oncology \/ Eos Advisory"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"Resolution Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"RTX001","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Resolution Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resolution Therapeutics \/ Syncona","highestDevelopmentStatusID":"7","companyTruncated":"Resolution Therapeutics \/ Syncona"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Sijbrandij Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LIfT Biosciences \/ Sijbrandij Foundation","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Sijbrandij Foundation"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"EBX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"1","companyTruncated":"EnteroBiotix \/ Thairm Bio"},{"orgOrder":0,"company":"University of Oxford","sponsor":"BD2","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ BD2","highestDevelopmentStatusID":"2","companyTruncated":"University of Oxford \/ BD2"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Flerie Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Series B Financing","leadProduct":"MB097","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microbiotica \/ Flerie Invest","highestDevelopmentStatusID":"4","companyTruncated":"Microbiotica \/ Flerie Invest"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"PS-002","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"5","companyTruncated":"Purespring Therapeutics \/ Sofinnova Partners"},{"orgOrder":0,"company":"Theolytics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theolytics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Theolytics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Immunocore","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Series C Financing","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ BlackRock","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ BlackRock"},{"orgOrder":0,"company":"Immunocore","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"MAGE-A4","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ General Atlantic"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"CB307","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Crescendo Biologics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescendo Biologics Ltd \/ Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Crescendo Biologics Ltd \/ Sofinnova Partners"},{"orgOrder":0,"company":"IMU Biosciences","sponsor":"Molten Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"IMU Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"IMU Biosciences \/ Molten Ventures","highestDevelopmentStatusID":"3","companyTruncated":"IMU Biosciences \/ Molten Ventures"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona Portfolio Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona Portfolio Limited","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Syncona Portfolio Limited"},{"orgOrder":0,"company":"Senisca","sponsor":"Emerging Longevity Ventures","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Senisca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senisca \/ Emerging Longevity Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Senisca \/ Emerging Longevity Ventures"},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rinri Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Oaktree Capital","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Oaktree Capital"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Atai Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Series B Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Atai Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Atai Life Sciences"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Mindful Health Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Mindful Health Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Mindful Health Solutions"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"USP30","graph1":"Neurology","graph2":"Preclinical","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Mission Therapeutics \/ The Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Mission Therapeutics \/ The Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"King\u2019s College London","sponsor":"Compass Pathways","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"King\u2019s College London","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"King\u2019s College London \/ Compass Pathways","highestDevelopmentStatusID":"4","companyTruncated":"King\u2019s College London \/ Compass Pathways"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"ATL001","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Center for Breakthrough Medicines"},{"orgOrder":0,"company":"Clock.bio","sponsor":"LocalGlobe","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Clock.bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clock.bio \/ LocalGlobe","highestDevelopmentStatusID":"4","companyTruncated":"Clock.bio \/ LocalGlobe"},{"orgOrder":0,"company":"Mosaic Therapeutics","sponsor":"Syncona Investment Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Mosaic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mosaic Therapeutics \/ Syncona Investment Management","highestDevelopmentStatusID":"4","companyTruncated":"Mosaic Therapeutics \/ Syncona Investment Management"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"PharmEnable","sponsor":"Denali Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"PharmEnable","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmEnable \/ Denali Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"PharmEnable \/ Denali Therapeutics"},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic E.coli","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Ateria Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ateria Health \/ Immuron","highestDevelopmentStatusID":"15","companyTruncated":"Ateria Health \/ Immuron"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"MiHKAL GmbH","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ MiHKAL GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Compass Pathways \/ MiHKAL GmbH"},{"orgOrder":0,"company":"University of Cambridge","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DIOS-CoVax2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cambridge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cambridge \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"University of Cambridge \/ UK Government"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Funding","leadProduct":"Vincristine Sulfate","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Birmingham \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Birmingham \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"GSK","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Troxerutin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"hVIVO","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"hVIVO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"hVIVO \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"hVIVO \/ UK Government"},{"orgOrder":0,"company":"Diamond Light Source","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Diamond Light Source","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Diamond Light Source \/ Exscientia","highestDevelopmentStatusID":"1","companyTruncated":"Diamond Light Source \/ Exscientia"},{"orgOrder":0,"company":"ConserV Bioscience","sponsor":"Lawrence Livermore","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ConserV Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ConserV Bioscience \/ Lawrence Livermore","highestDevelopmentStatusID":"4","companyTruncated":"ConserV Bioscience \/ Lawrence Livermore"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Queen\u2019s University of Belfast","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Queen\u2019s University of Belfast","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen\u2019s University of Belfast \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Queen\u2019s University of Belfast \/ Ipsen"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Revatis SA","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genflow Biosciences \/ Revatis SA","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Biosciences \/ Revatis SA"},{"orgOrder":0,"company":"GSK","sponsor":"Foundation Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Brompheniramine Maleate","moa":"||H1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Foundation Consumer Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Foundation Consumer Healthcare"},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ GT Apeiron Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ GT Apeiron Therapeutics"},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"KMO","graph1":"Immunology","graph2":"Discovery","graph3":"Kynos Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kynos Therapeutics \/ Epidarex Capital","highestDevelopmentStatusID":"2","companyTruncated":"Kynos Therapeutics \/ Epidarex Capital"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Vaccines Manufacturing and Innovation Centre","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ Vaccines Manufacturing and Innovation Centre","highestDevelopmentStatusID":"15","companyTruncated":"Oxford Biomedica \/ Vaccines Manufacturing and Innovation Centre"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Autolus Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autolus Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Almac Group","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Almac Group \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"15","companyTruncated":"Almac Group \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rinri Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Advent Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Disease causing protein","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amphista Therapeutics \/ Advent Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Advent Life Sciences"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Immuno","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F-star Therapeutics \/ Merck Group","highestDevelopmentStatusID":"4","companyTruncated":"F-star Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Cue Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"University of Oxford \/ Cue Biopharma"},{"orgOrder":0,"company":"Vernalis","sponsor":"HOX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vernalis \/ HOX Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vernalis \/ HOX Therapeutics"},{"orgOrder":0,"company":"Ixaka","sponsor":"Alaya.bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Celtic","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ixaka","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ixaka \/ Alaya.bio","highestDevelopmentStatusID":"4","companyTruncated":"Ixaka \/ Alaya.bio"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"KNS366","moa":"KMO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Kynos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kynos Therapeutics \/ Dr. Falk Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Kynos Therapeutics \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Redx Pharma \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Kyowa Kirin"},{"orgOrder":0,"company":"Thor Medical","sponsor":"Nordic Nanovector","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Thor Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Thor Medical \/ Nordic Nanovector","highestDevelopmentStatusID":"1","companyTruncated":"Thor Medical \/ Nordic Nanovector"},{"orgOrder":0,"company":"Haleon","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Haleon \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Haleon \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Lucis Pharma","sponsor":"Rosemont","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Alimemazine","moa":"H1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Lucis Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Lucis Pharma \/ Rosemont","highestDevelopmentStatusID":"15","companyTruncated":"Lucis Pharma \/ Rosemont"},{"orgOrder":0,"company":"Therakind","sponsor":"Shorla Oncology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Acquisition","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Therakind","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Therakind \/ Shorla Oncology","highestDevelopmentStatusID":"15","companyTruncated":"Therakind \/ Shorla Oncology"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Syncona"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Syncona"},{"orgOrder":0,"company":"Adaptate Biotherapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"ADT-010","moa":"Gamma-delta T-cell","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptate Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptate Biotherapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Adaptate Biotherapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViiV Healthcare \/ The Medicines Patent Pool","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"RXC007","moa":"ROCK2","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Redx Pharma \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Jounce Therapeutics"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apollo Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Apollo Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"INDV-2000","moa":"OX1R","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"C4X Discovery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"C4X Discovery \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"C4X Discovery \/ Indivior"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Conduit Pharma","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Conduit Pharma"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"},{"orgOrder":0,"company":"Tillomed Laboratories Ltd","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tillomed Laboratories Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tillomed Laboratories Ltd \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Tillomed Laboratories Ltd \/ Zentiva"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ The Medicines Patent Pool","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Foresee Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord healthcare \/ Foresee Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Foresee Pharmaceuticals"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Remedium","sponsor":"Tufts University","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"RMD 1101","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Remedium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Remedium \/ Tufts University","highestDevelopmentStatusID":"4","companyTruncated":"Remedium \/ Tufts University"},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Acquisition","leadProduct":"Cefuroxime Axetil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Sandoz B2B"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Stc Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"TZLS-501","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tiziana Life Sciences \/ Stc Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Stc Biologics"},{"orgOrder":0,"company":"University of Oxford","sponsor":"180 Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"HMGB1","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ 180 Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"University of Oxford \/ 180 Life Sciences"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Touchlight","sponsor":"University of Nottingham","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Transcutaneous Injection","sponsorNew":"Touchlight \/ University of Nottingham","highestDevelopmentStatusID":"4","companyTruncated":"Touchlight \/ University of Nottingham"},{"orgOrder":0,"company":"Horizon Discovery","sponsor":"TrueBinding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Chosource","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Horizon Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Discovery \/ TrueBinding","highestDevelopmentStatusID":"3","companyTruncated":"Horizon Discovery \/ TrueBinding"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Nanna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"DUBs","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ubiquigent \/ Nanna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent \/ Nanna Therapeutics"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Debio 0432","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ubiquigent \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Ubiquigent \/ Debiopharm"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"OBT700","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"5","companyTruncated":"Oxford Biotherapeutics \/ Genmab"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"TfR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bicycle Therapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Genpharm"},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIF-1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Curve Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curve Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Curve Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Medicines Discovery Catapult","sponsor":"Alchemab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Medicines Discovery Catapult","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicines Discovery Catapult \/ Alchemab","highestDevelopmentStatusID":"2","companyTruncated":"Medicines Discovery Catapult \/ Alchemab"},{"orgOrder":0,"company":"Alchemab","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alchemab \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ AstraZeneca"},{"orgOrder":0,"company":"Bit Bio","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bit Bio \/ BlueRock Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"ANGLE plc","sponsor":"Crescendo Biologics Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"CB307","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ANGLE plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ANGLE plc \/ Crescendo Biologics Ltd","highestDevelopmentStatusID":"6","companyTruncated":"ANGLE plc \/ Crescendo Biologics Ltd"},{"orgOrder":0,"company":"Oxford Vacmedix","sponsor":"DxVx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"OVM-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Vacmedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Vacmedix \/ DxVx","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Vacmedix \/ DxVx"},{"orgOrder":0,"company":"University of Rochester School of Medicine & Dentistry","sponsor":"Evgen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Sulforaphane","moa":"Nrf2","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of Rochester School of Medicine & Dentistry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F-star Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"F-star Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Modified Horsepox Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Argenx"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ KBI Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Hemogenyx Pharmaceuticals \/ KBI Biopharma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"||CA-125 IgC","graph1":"Oncology","graph2":"Phase III","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hikma Pharmaceuticals \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Hikma Pharmaceuticals \/ CanariaBio"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ Kyverna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biomedica \/ Kyverna Therapeutics"},{"orgOrder":0,"company":"Medicom Healthcare","sponsor":"Famar","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Medicom Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Medicom Healthcare \/ Famar","highestDevelopmentStatusID":"15","companyTruncated":"Medicom Healthcare \/ Famar"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"FS120","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F-star Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"PrecisionLife","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"PrecisionLife","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PrecisionLife \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"PrecisionLife \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ikarovec","sponsor":"Rentschler Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ikarovec \/ Rentschler Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ Rentschler Biopharma"},{"orgOrder":0,"company":"Immunocore","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"SAR444245","moa":"||IL-2-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Sanofi"},{"orgOrder":0,"company":"Healx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Healx \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Healx \/ Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"SNP318","moa":"Lp-PLA2","graph1":"Neurology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Symbiosis Pharmaceutical Services \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Symbiosis Pharmaceutical Services \/ AstraZeneca"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"SporeGen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Bacillus Bacteria","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Destiny Pharma \/ SporeGen","highestDevelopmentStatusID":"4","companyTruncated":"Destiny Pharma \/ SporeGen"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"IBMP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"EMX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gylden Pharma \/ IBMP","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ IBMP"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"SLN501","moa":"C3","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Sygnature Discovery","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Sygnature Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sygnature Discovery \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sygnature Discovery \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"GSK","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ US Government","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ US Government"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sanofi"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"OBT620","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Technology","graph2":"Undisclosed","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Touchlight \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Touchlight \/ Pfizer Inc"},{"orgOrder":0,"company":"Touchlight","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"IND Enabling","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Touchlight \/ Voyager Therapeutics, Inc","highestDevelopmentStatusID":"5","companyTruncated":"Touchlight \/ Voyager Therapeutics, Inc"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4X Discovery \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discovery \/ Sanofi"},{"orgOrder":0,"company":"Gaeta Therapeutics","sponsor":"Oncorus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gaeta Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gaeta Therapeutics \/ Oncorus","highestDevelopmentStatusID":"1","companyTruncated":"Gaeta Therapeutics \/ Oncorus"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"AstraZeneca \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"AstraZeneca \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Camallergy","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Camallergy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Camallergy \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Camallergy \/ OnDosis"},{"orgOrder":0,"company":"Chemify","sponsor":"Dewpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Chemify","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chemify \/ Dewpoint Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Chemify \/ Dewpoint Therapeutics"},{"orgOrder":0,"company":"Closed Loop Medicine","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Closed Loop Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Closed Loop Medicine \/ Pharmanovia","highestDevelopmentStatusID":"4","companyTruncated":"Closed Loop Medicine \/ Pharmanovia"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Emplicure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Tablet, Extended Release","sponsorNew":"Quotient Sciences \/ Emplicure","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Emplicure"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Crinetics Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Endocrinology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Sciences \/ Crinetics Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Crinetics Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"Chongqing Zhifei Biological Products","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Zoster Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Chongqing Zhifei Biological Products","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Chongqing Zhifei Biological Products"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sanofi"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"RXC007","moa":"ROCK2","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Redx Pharma \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Jounce Therapeutics"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Cancer Research UK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"BT7401","moa":"CD137","graph1":"Oncology","graph2":"Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bicycle Therapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"8","companyTruncated":"Bicycle Therapeutics \/ Cancer Research UK"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Oncologie","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Oncologie","highestDevelopmentStatusID":"6","companyTruncated":"Mereo BioPharma Group \/ Oncologie"},{"orgOrder":0,"company":"MicrofluidX","sponsor":"CCRM","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"MicrofluidX","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MicrofluidX \/ CCRM","highestDevelopmentStatusID":"2","companyTruncated":"MicrofluidX \/ CCRM"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Aclidinium Bromide","moa":"M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AstraZeneca \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Covis Pharma"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ EffRx Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ EffRx Pharmaceuticals"},{"orgOrder":0,"company":"DJS Antibodies","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"DJS-002","moa":"LPAR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"DJS Antibodies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DJS Antibodies \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"DJS Antibodies \/ AbbVie Inc"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Molteni Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Accord healthcare \/ Molteni Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Molteni Farmaceutici"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ AGC Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Allergy Therapeutics \/ AGC Biologics"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F-star Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"F-star Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Ossianix","sponsor":"Attralus","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody-peptide Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ossianix \/ Attralus","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/ Attralus"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Autolus Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Autolus Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Porton Biopharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Asparaginase","moa":"Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"Porton Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Lyophilized Powder for Solution","sponsorNew":"Porton Biopharma \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Porton Biopharma \/ Clinigen Group"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Seqirus","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Syringe","sponsorNew":"Seqirus \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ BARDA"},{"orgOrder":0,"company":"Dunad Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery","graph3":"Dunad Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dunad Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Dunad Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"DUBs","graph1":"Neurology","graph2":"Discovery","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mission Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Mission Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Forcefield Therapeutics","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Forcefield Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forcefield Therapeutics \/ Spur Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Forcefield Therapeutics \/ Spur Therapeutics"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F-star Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"F-star Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"F-star Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"F-star Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"Undisclosed","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Integral Molecular","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Integral Molecular","highestDevelopmentStatusID":"2","companyTruncated":"AstraZeneca \/ Integral Molecular"},{"orgOrder":0,"company":"Iontas","sponsor":"Quellis Biosciences Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iontas \/ Quellis Biosciences Inc","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ Quellis Biosciences Inc"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Isomorphic Labs \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Eli Lilly"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Expanded Collaboration","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ LG Chem"},{"orgOrder":0,"company":"LGC Group GB","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"OLX301D","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"LGC Group GB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LGC Group GB \/ OliX Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"LGC Group GB \/ OliX Pharmaceutical"},{"orgOrder":0,"company":"Macomics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Macomics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"IMM60","moa":"iNKT","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Portage Biotech \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Portage Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"MEN1309","moa":"||CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Agenus","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Agenus"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biomedica \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Oxford Biomedica \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Foralumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Precision BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Precision BioSciences"},{"orgOrder":0,"company":"Cardiff University","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Cardiff University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff University \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Cardiff University \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Sentinel Oncology","sponsor":"PharmaEngine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"SOL578","moa":"CHK1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sentinel Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sentinel Oncology \/ PharmaEngine","highestDevelopmentStatusID":"4","companyTruncated":"Sentinel Oncology \/ PharmaEngine"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Shionogi"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"SwanBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Purespring Therapeutics \/ SwanBio Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Purespring Therapeutics \/ SwanBio Therapeutics"},{"orgOrder":0,"company":"Engitix Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Engitix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Engitix Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Engitix Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Merck Group","highestDevelopmentStatusID":"4","companyTruncated":"Artios Pharma Limited \/ Merck Group"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Incannex Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Incannex Healthcare"},{"orgOrder":0,"company":"Vernalis","sponsor":"Unison Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vernalis \/ Unison Medicines","highestDevelopmentStatusID":"2","companyTruncated":"Vernalis \/ Unison Medicines"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ras\/Raf\/MAP kinase","graph1":"Oncology","graph2":"Discovery","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Redx Pharma \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Redx Pharma \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"German Cancer Research Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bicycle Therapeutics \/ German Cancer Research Center","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Therapeutics \/ German Cancer Research Center"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Oranomed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbit Discovery \/ Oranomed","highestDevelopmentStatusID":"4","companyTruncated":"Orbit Discovery \/ Oranomed"},{"orgOrder":0,"company":"Vernalis","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vernalis \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Vernalis \/ Pierre Fabre"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Microorganism","year":"2023","type":"Collaboration","leadProduct":"NTCD-M3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Destiny Pharma \/ Sebela Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Sebela Pharmaceuticals"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Dexrazoxane","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ CNX Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ CNX Therapeutics"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"RXC006","moa":"Porcupine","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redx Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Expanded Partnership","leadProduct":"Doxorubicin Prodrug","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ LG Chem"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail InfoWorks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Prevail InfoWorks","highestDevelopmentStatusID":"4","companyTruncated":"Hemogenyx Pharmaceuticals \/ Prevail InfoWorks"},{"orgOrder":0,"company":"GSK","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Azenosertib","moa":"||WEE1","graph1":"Oncology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tetris Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tetris Pharma \/ Arecor","highestDevelopmentStatusID":"15","companyTruncated":"Tetris Pharma \/ Arecor"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Grunenthal","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Grunenthal"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA-4157","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Autolus Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Autolus Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"DDR","graph1":"Oncology","graph2":"Preclinical","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Artios Pharma Limited \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Merck & Co"},{"orgOrder":0,"company":"Nuformix","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"4-Chlorokynurenine","moa":"||NMDA","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nuformix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuformix \/ VistaGen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nuformix \/ VistaGen Therapeutics"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"BenevolentAI \/ Merck Group"},{"orgOrder":0,"company":"Exscientia","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Merck Group"},{"orgOrder":0,"company":"Physiomics","sponsor":"ValiRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"VAL201","moa":"Androgen activated SRC kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Physiomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Physiomics \/ ValiRx","highestDevelopmentStatusID":"7","companyTruncated":"Physiomics \/ ValiRx"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Exothera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"PeptiCRAd-1","moa":"CD8+ T-cell","graph1":"Oncology","graph2":"Discovery","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valo Therapeutics \/ Exothera","highestDevelopmentStatusID":"2","companyTruncated":"Valo Therapeutics \/ Exothera"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Monash University"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Private Placement","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ RA Capital","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ RA Capital"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Gilead Sciences","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Gilead Sciences"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Quaternary Ammonium Palmitoyl Glycol Chitosan","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nanomerics \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Nanomerics \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"D2\/3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Complement Therapeutics","sponsor":"Gimv","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A gene","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Complement Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Complement Therapeutics \/ Gimv","highestDevelopmentStatusID":"4","companyTruncated":"Complement Therapeutics \/ Gimv"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"UK Research and Innovation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Barinthus Biotherapeutics \/ UK Research and Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Barinthus Biotherapeutics \/ UK Research and Innovation"},{"orgOrder":0,"company":"RIGImmune","sponsor":"RIGImmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Acquisition","leadProduct":"RIG-101","moa":"RIG-I","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RIGImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"RIGImmune \/ RIGImmune","highestDevelopmentStatusID":"5","companyTruncated":"RIGImmune \/ RIGImmune"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NHS England \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Targovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"ONCOS-102","moa":"||CD8","graph1":"Oncology","graph2":"Preclinical","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Valo Therapeutics \/ Targovax","highestDevelopmentStatusID":"4","companyTruncated":"Valo Therapeutics \/ Targovax"},{"orgOrder":0,"company":"Nodus Oncology","sponsor":"KHAN Technology Transfer Fund I","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"PARG","graph1":"Oncology","graph2":"Preclinical","graph3":"Nodus Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nodus Oncology \/ KHAN Technology Transfer Fund I","highestDevelopmentStatusID":"4","companyTruncated":"Nodus Oncology \/ KHAN Technology Transfer Fund I"},{"orgOrder":0,"company":"GSK","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Woodward Pharma Services","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Woodward Pharma Services"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Foundation Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Foundation Medicine"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Levacetylleucine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Celixir","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"iMP Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celixir","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celixir \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Celixir \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION449","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Z Factor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Z Factor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Z Factor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Z Factor \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Immutep"},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KNS366","moa":"KMO","graph1":"Immunology","graph2":"Phase I","graph3":"Kynos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kynos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Brazikumab","moa":"IL-23","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AbbVie Inc","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ AbbVie Inc"},{"orgOrder":0,"company":"NodThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NodThera \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MTX652","moa":"USP30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MTX652","moa":"USP30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Acerta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Acerta Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Acerta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Acerta Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OTL-101","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"OX40L","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Belimumab","moa":"BLyS","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"British Heart Foundation","sponsor":"Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"TRV027","moa":"AT1 receptor selective","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"British Heart Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"British Heart Foundation \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"British Heart Foundation \/ Imperial College London"},{"orgOrder":0,"company":"Ossianix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Transferrin","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Ossianix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/ Inapplicable"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Monash University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"MR1","graph1":"Oncology","graph2":"Discovery","graph3":"Enara Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Enara Bio \/ Monash University","highestDevelopmentStatusID":"2","companyTruncated":"Enara Bio \/ Monash University"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denosumab","moa":"||Porcupine","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThirtyFiveBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFiveBio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"University Of Dundee","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"||Nrf2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evgen Pharma \/ University Of Dundee","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Pharma \/ University Of Dundee"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ University of Oxford"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue Factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue Factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"rNAPc2","moa":"Tissue factor pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"IL-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acelarin","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"Kelso Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Kelso Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"Kelso Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kelso Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATL001","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"S-Pindolol Benzoate","moa":"5-HTA1a\/beta-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Adrenergic-beta 1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Adrenergic-beta 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Reaction Biology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Adavosertib","moa":"WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Reaction Biology","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Reaction Biology"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Zoster Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Grass MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Immunology","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper chelating agent","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tideglusib","moa":"GSK-3 beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tideglusib","moa":"GSK-3 beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tideglusib","moa":"GSK-3 beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tideglusib","moa":"GSK-3 beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tideglusib","moa":"GSK-3 beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Targeted protein degradation","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amphista Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amphista Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Amphista Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LIfT Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STC-15","moa":"METTL3","graph1":"Oncology","graph2":"Phase I","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Storm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Storm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Andexanet Alpha","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evox Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"||CD3","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"University of Cambridge","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Proguanil","moa":"||SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cambridge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cambridge \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"University of Cambridge \/ Inapplicable"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CAS 498-02-2","moa":"NFkB\/Nrf2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AKL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Ono Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ ViiV Healthcare"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue Factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"C0021158","moa":"Arginase 2","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ART0380","moa":"||ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART0380","moa":"||ATR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ART4215","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Forigerimod","moa":"HSPA8","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmuPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Inapplicable"},{"orgOrder":0,"company":"Aptamer Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AST-201","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptamer Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptamer Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptamer Group \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"MEDI2228","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ The Gamaleya National Center of Epidemiology and Microbiology","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ultra Rapid Acting Insulin Aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ultra Rapid Acting Insulin Aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Trivalent Influenza Vaccine, MF59-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SolasCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"SolasCure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AUTO4","moa":"||TRBC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"AVA3996","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"AVA6103","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"The Ohio State University Wexner Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AVB-101","moa":"GRN gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic Infusion","sponsorNew":"AviadoBio \/ The Ohio State University Wexner Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ The Ohio State University Wexner Medical Center"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVB-101","moa":"GRN gene","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic Injection","sponsorNew":"AviadoBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ Inapplicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AVB-101","moa":"GRN gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic Infusion","sponsorNew":"AviadoBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Inapplicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AVB-101","moa":"GRN gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic Infusion","sponsorNew":"AviadoBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Inapplicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AVB-101","moa":"GRN gene","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic Infusion","sponsorNew":"AviadoBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio \/ Inapplicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVB-101","moa":"GRN gene","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic Injection","sponsorNew":"AviadoBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Axalbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axalbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Inapplicable"},{"orgOrder":0,"company":"Axalbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rilvegostomig","moa":"PD-1\/TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Sipavibart","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"RQ Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AZD3152","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"RQ Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"RQ Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"RQ Bio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camizestrant","moa":"SERD","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amisulpride","moa":"D2\/3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amisulpride","moa":"D2\/3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Blueberry Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Induced Hepatocyte-Like Cell","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEN-2293","moa":"TRK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BEN-2293","moa":"TRK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"The Sheffield Institute for Translational Neuroscience","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEN-34712","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience","highestDevelopmentStatusID":"5","companyTruncated":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Belimumab","moa":"||BLyS","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Belimumab","moa":"||BLyS","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"Bloomsbury Genetic Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BGT-DTDS","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloomsbury Genetic Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Bloomsbury Genetic Therapies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bloomsbury Genetic Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 764532","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 764532","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type A receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bictegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tetanus Toxoid Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"NHS England","sponsor":"University of Manchester","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"||COX-1","graph1":"Oncology","graph2":"Phase II","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NHS England \/ University of Manchester","highestDevelopmentStatusID":"8","companyTruncated":"NHS England \/ University of Manchester"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vilanterol Trifenatate","moa":"||Adrenergic beta-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type A receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"BT7480","moa":"||CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BT7480","moa":"CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"BT7480","moa":"||CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"BT7480","moa":"||CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zelenectide Pevedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zelenectide Pevedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||SERD","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Carmustine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Birmingham \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Birmingham \/ Inapplicable"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CB307","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Crescendo Biologics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescendo Biologics Ltd \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crescendo Biologics Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"CBP-4888","moa":"||Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"CBP-4888","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"University of Southampton","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Southampton","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Southampton \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"University of Southampton \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Lindus Health","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chloral Hydrate","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Pharmanovia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanovia \/ Lindus Health","highestDevelopmentStatusID":"11","companyTruncated":"Pharmanovia \/ Lindus Health"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NICE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NICE","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NICE \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NICE \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sumitomo Dainippon Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DSP-0038","moa":"5-HT1A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM60","moa":"||iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATL001","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Coagulation Factor X (Human)","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Products Laboratory \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bio Products Laboratory \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||CD73","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Vir Biotechnology"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"The Centre for Mental Health Research and Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ The Centre for Mental Health Research and Innovation","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ The Centre for Mental Health Research and Innovation"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Interferon-alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OMass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"OMass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"ReNeuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"hRPC Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReNeuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ReNeuron \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReNeuron \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Polymerase theta helicase","graph1":"Oncology","graph2":"Preclinical","graph3":"Artios Pharma Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Artios Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PepGNP-COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gylden Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gylden Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Emergex Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PepGNP-COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Emergex Vaccines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Emergex Vaccines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Emergex Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Scancell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SCOV1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Scancell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scancell \/ Inapplicable"},{"orgOrder":0,"company":"Scancell","sponsor":"PharmaJet","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SCOV1","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Scancell \/ PharmaJet","highestDevelopmentStatusID":"6","companyTruncated":"Scancell \/ PharmaJet"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||dUTPase","graph1":"Oncology","graph2":"IND Enabling","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV6 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"CV6 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||dUTPase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CV6 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CV6 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS118","moa":"PD-L1\/LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exeporfinium chloride","moa":"Siglec-8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Linerixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Touchlight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"IND Enabling","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Touchlight \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Touchlight \/ Inapplicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"University of Lausanne Hospitals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8+","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gylden Pharma \/ University of Lausanne Hospitals","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ University of Lausanne Hospitals"},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"Genetic transcription","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGB Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tideglusib","moa":"GSK-3 beta","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exeporfinium chloride","moa":"Siglec-8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"NTCD-M3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Destiny Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TZLS-501","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dobutamine Hydrochloride","moa":"Adrenergic beta receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"AIDS Healthcare Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ AIDS Healthcare Foundation","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ AIDS Healthcare Foundation"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Fundaci\u00f3n Hu\u00e9sped","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Fundaci\u00f3n Hu\u00e9sped","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Fundaci\u00f3n Hu\u00e9sped"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DSP-2342","moa":"5-HT2A\/5-HT7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-102","moa":"Gene","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"EBX-102","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"EBX-102","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Elastin BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elastin BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elastin BioSciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Elastin BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Ellipses Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT-3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Institute of Cancer Research \/ Ellipses Pharma","highestDevelopmentStatusID":"7","companyTruncated":"The Institute of Cancer Research \/ Ellipses Pharma"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type A receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tularemia Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gylden Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acelarin","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ IQVIA"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MED3000","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Futura Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Futura Medical \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Estradiol Valerate","moa":"Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ETD002","moa":"TMEM16A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Evotec"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EXS4318","moa":"PKC-theta","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EXS74539","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"||IL-5-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Libmeldy","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Flaxeed","moa":"||Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Theramex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"GPR65","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pathios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AS01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Institute of Technology on Immunobiologicals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Yellow Fever Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gylden Pharma \/ Institute of Technology on Immunobiologicals","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ Institute of Technology on Immunobiologicals"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Fast Acting Insulin Aspart","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Exonate","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EXN407","moa":"SRPK1-mediated VEGF splicing","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Exonate","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Exonate \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Exonate \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"GW Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AZD5305","moa":"PARP1","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ University College London","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ University College London"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ CureVac"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Intranasal Influenza Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Vectura Ltd \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"TLR5","graph1":"Oncology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"Open Orphan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"OC43 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Open Orphan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Open Orphan \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Open Orphan \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"FS118","moa":"PD-L1\/LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS120","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"FS120","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS120","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"AnaptysBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ AnaptysBio","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ AnaptysBio"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MED3000","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Futura Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Futura Medical \/ Inapplicable"},{"orgOrder":0,"company":"GammaDelta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GDX012","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"GammaDelta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GammaDelta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GammaDelta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Otilimab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||ERAP1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grey Wolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Gepotidacin","moa":"Bacterial DNA replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Gepotidacin","moa":"Bacterial DNA replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Gepotidacin","moa":"Bacterial DNA replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Otilimab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVPreF3 OA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"GSK \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ IQVIA"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Linerixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GSK3036656","moa":"LeuRS","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"||HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"VH109","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AS01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"GSK3943104","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GSK4382276A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ CureVac"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ GT Apeiron","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ GT Apeiron"},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ GT Apeiron","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ GT Apeiron"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GTAEXS617","moa":"CDK7","graph1":"Oncology","graph2":"Preclinical","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VTP-300","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CV2CoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"4","companyTruncated":"GSK \/ CureVac"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Vectura Ltd \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HLX-0201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydralazine Hydrochloride","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"N-Acetyl-L-Leucine","moa":"Calcium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Granules for Oral Suspension","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"N-Acetyl-L-Leucine","moa":"Calcium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Granules for Oral Suspension","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Acetyl-L-Leucine","moa":"Calcium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Granules for Oral Suspension","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Acetyl-L-Leucine","moa":"Calcium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Granules for Oral Suspension","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Acetyl-L-Leucine","moa":"Calcium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Granules for Oral Suspension","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"N-Acetyl-L-Leucine","moa":"Calcium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Granules for Oral Suspension","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"N-Acetyl-L-Leucine","moa":"Calcium channel","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Granules for Oral Suspension","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"IKS014","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iksuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iksuda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iksuda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Alpha Interferon","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ILC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ILC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ILC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"||PRAME","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMC-M113V","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Precision-Panc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immodulon Therapeutics \/ Precision-Panc","highestDevelopmentStatusID":"8","companyTruncated":"Immodulon Therapeutics \/ Precision-Panc"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMM60","moa":"||iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Influenza A (H5N1) Monovalent Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic-beta 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostemsavir","moa":"||GP120","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Rosalind Franklin Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rosalind Franklin Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Rosalind Franklin Institute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rosalind Franklin Institute \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"University of Cambridge","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lenadogene Nolparvovec","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"University of Cambridge","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"University of Cambridge \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"University of Cambridge \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AviadoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVB-101","moa":"GRN gene","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathalamic Injection","sponsorNew":"AviadoBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ University of Oxford"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMC-I109V","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PTT-3196","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pathios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"ADRB2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tadalafil","moa":"PDE5","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Futura Medical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Futura Medical \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"In3Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IN01","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"In3Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"In3Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"In3Bio \/ Inapplicable"},{"orgOrder":0,"company":"In3Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IN01","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"In3Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"In3Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"In3Bio \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0005","moa":"IL-6 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lamellar Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lamellar Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Lamellar Biomedical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lamellar Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MEN1309","moa":"||CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CellCentric","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Inobrodib","moa":"||EP300\/CBP bromodomain","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CellCentric \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CellCentric \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Forigerimod","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmuPharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ImmuPharma \/ Inapplicable"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MAPT N279K","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen","moa":"ATTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Iontas","sponsor":"F-star Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iontas \/ F-star Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Iontas \/ F-star Therapeutics"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"Adrenergic receptor-alpha","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Essential Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Essential Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/3\/4\/5 receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Essential Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Essential Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KER-0193","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaerus Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kaerus Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"Neurocentrx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentrx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"Neurocentrx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentrx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kanna Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KH-001 Besylate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Kanna Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kanna Health \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kanna Health \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||GP100","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KNS366","moa":"KMO","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Kynos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kynos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"GSK","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine Succinate","moa":"||SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||TLR7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Levicept","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"LEVI-04","moa":"Neurotrophin pathway","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Levicept","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Levicept \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Levicept \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Libmeldy","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LivaNova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Vitaria","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"LivaNova","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LivaNova \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"LivaNova \/ Inapplicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theramex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Forigerimod","moa":"HSPA8","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmuPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ MSD"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ MSD"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ MSD"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"M300","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mestag Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mestag Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"ViiV Healthcare \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MB097","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbiotica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbiotica \/ Inapplicable"},{"orgOrder":0,"company":"Istesso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MBS2320","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Istesso","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Istesso \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Istesso \/ Inapplicable"},{"orgOrder":0,"company":"Radella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MD-18","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Radella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAdOx1-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"5-Valent Meningococcal Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Storm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"INFEX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"MET-X","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"INFEX Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INFEX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"INFEX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Ayrtons Saunders","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Nicotine","moa":"Ach receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ayrtons Saunders","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ayrtons Saunders \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ayrtons Saunders \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Milciclib","moa":"||CDK","graph1":"Oncology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Endocrinology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atovaquone","moa":"Cytochrome B","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quotient Sciences \/ Fresenius Kabi AG","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Scancell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Modi-1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Scancell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scancell \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"PATH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RTS, S\/AS01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ PATH","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ PATH"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Inapplicable"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Immunology","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||TLR5","graph1":"Oncology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Luca Szalontay","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Luca Szalontay","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Luca Szalontay"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Midatech Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Midatech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MTX325","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MTX652","moa":"DUBs","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Libmeldy","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naquinate","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haoma Medica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medica \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dioscorea Polystachya","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dioscorea Polystachya","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"Neuro-Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NBP14","moa":"Nicotinic-alpha7 allosteric receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuro-Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuro-Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Neuro-Bio \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Neumifil","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pneumagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HEX17","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pneumagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Neumifil","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pneumagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Chadox1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||SERD","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BT7480","moa":"CD137","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic-beta 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Washington University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IMC-I109V","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type A receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Neisseria Gonorrhoeae Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"R21 Malaria Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitisinone","moa":"HPDD","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"NovaBiotics Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Np339","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NovaBiotics Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaBiotics Ltd \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NovaBiotics Ltd \/ Inapplicable"},{"orgOrder":0,"company":"NodThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NodThera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"||Thymidylate synthase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||COX","graph1":"Neurology","graph2":"Approved FDF","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Reckitt Benckiser \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reckitt Benckiser \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acelarin","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"NovalGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NovalGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovalGen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NovalGen \/ Inapplicable"},{"orgOrder":0,"company":"NovalGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"NovalGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovalGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovalGen \/ Inapplicable"},{"orgOrder":0,"company":"NovalGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"NovalGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovalGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NovalGen \/ Inapplicable"},{"orgOrder":0,"company":"Nuformix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NXP004","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nuformix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuformix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuformix \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MEN1309","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MEN1309","moa":"||CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 764532","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanomerics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Inapplicable"},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mecasermin Rinfabate","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oak Hill Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oak Hill Bio \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Oak Hill Bio \/ Chiesi Group"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorofim","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"F2G Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limited \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"Cannabotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid Extract","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cannabotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cannabotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cannabotech \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Andexanet Alpha","moa":"Factor Xa","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ University of Oxford"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AUTO3","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relugolix","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dichlorphenamide","moa":"CA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"San Raffaele-Telethon Institute for Gene Therapy","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ San Raffaele-Telethon Institute for Gene Therapy","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ San Raffaele-Telethon Institute for Gene Therapy"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biomedica \/ Orchard Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ Orchard Therapeutics"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-204","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ottimo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Jankistomig","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ottimo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottimo Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ottimo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Mina Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Oxford Vacmedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"OVM-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Vacmedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Vacmedix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Vacmedix \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Oxilio","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OXL001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxilio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxilio \/ Quotient Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Oxilio \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OXL001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"Oxular","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OXU-003","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxular \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Oxular \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Syringe","sponsorNew":"Advanz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ETX001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type A receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Nebulizer","sponsorNew":"Pulmocide \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Inapplicable"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Nebulizer","sponsorNew":"Pulmocide \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imperial College London \/ Compass Pathways","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Compass Pathways"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD8+ T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ Vir Biotechnology"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elinzanetant","moa":"NK-1R","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Kandy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kandy Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kandy Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"IMM-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immodulon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immodulon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BT1718","moa":"MMP-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Pivmecillinam","moa":"PBP1A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UTILITY therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Pivmecillinam","moa":"PBP1A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UTILITY therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Pivmecillinam","moa":"PBP1A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"UTILITY therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UTILITY therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UTILITY therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plerixafor","moa":"CXCR4","graph1":"Oncology","graph2":"Phase III","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Pneumagen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Pneumagen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen \/ Inapplicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"POLB 001","moa":"p38\/MAPK","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Poolbeg Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"POLB 001","moa":"p38\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Poolbeg Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"POLB 001","moa":"p38\/MAPK","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Poolbeg Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"POLB 001","moa":"p38\/MAPK","graph1":"Oncology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Poolbeg Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Montanide ISA 51VG","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMM60","moa":"||iNKT","graph1":"Oncology","graph2":"Phase I","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Stimunity","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PORT-5","moa":"Interferon gene","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Portage Biotech \/ Stimunity","highestDevelopmentStatusID":"4","companyTruncated":"Portage Biotech \/ Stimunity"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exeporfinium chloride","moa":"Siglec-8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napp Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"AZD8601","moa":"VEGF-A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Epicardial Injection","sponsorNew":"AstraZeneca \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Forcefield Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chrdl1","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Forcefield Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forcefield Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Forcefield Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BT5528","moa":"||Ephrin type A receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Micron Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Linezolid","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Persica Pharmaceuticals \/ Micron Research Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Micron Research Ltd"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Linezolid","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Persica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Vir Biotechnology"},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CD4\/8","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LIfT Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Otilimab","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Almac Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ADP-c165","moa":"RTK transmembrane receptor ROR1","graph1":"Oncology","graph2":"Discovery","graph3":"Almac Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almac Group \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Almac Group \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ University of Oxford"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"GSK","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GSK4353001A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Measles, Mumps and Rubella Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CG01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biologics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Avillion LLP \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Avillion LLP \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Avillion LLP"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Oxide Adipate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shield Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PTT-4256","moa":"GPR65","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pathios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pathios Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Pathios Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pulmocide \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Inapplicable"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Quell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Vectura Ltd \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"PAS-nomacopan","moa":"Leukotriene B4","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue Factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ University of Oxford"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase I","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"University of Oxford \/ AstraZeneca"},{"orgOrder":0,"company":"EyeBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"EYE103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyeBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CAS 498-02-2","moa":"NFkB\/Nrf2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AKL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CAS 498-02-2","moa":"||NFkB\/Nrf2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AKL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ National Institutes of Health","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ National Institutes of Health"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Rezafungin","moa":"1,3-beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Napp Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue Factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Momelotinib","moa":"JAK2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ IQVIA"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Nuance Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Nuance Pharma"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicebio","sponsor":"Medicxi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VXB-211","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vicebio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vicebio \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Vicebio \/ Medicxi"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Resolution Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RTX001","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Resolution Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resolution Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Resolution Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Resolution Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RTX001","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Resolution Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resolution Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Resolution Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rilpivirine Hydrochloride","moa":"NNRT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilpivirine Hydrochloride","moa":"NNRT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Savolitinib","moa":"c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Hutchmed"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scancell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scancell \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/ Inapplicable"},{"orgOrder":0,"company":"Scancell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SCIB1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scancell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Scancell \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"N-Myc","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SRA737","moa":"||CHK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Scancell","sponsor":"University of Cape Town Lung Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SCOV1","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Scancell \/ University of Cape Town Lung Institute","highestDevelopmentStatusID":"6","companyTruncated":"Scancell \/ University of Cape Town Lung Institute"},{"orgOrder":0,"company":"Sareum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SDC-1801","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sareum \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sareum \/ Inapplicable"},{"orgOrder":0,"company":"Sareum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SDC-1801","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sareum \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sareum \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CV2CoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"4","companyTruncated":"GSK \/ CureVac"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Zoster Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Zoster Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Zoster Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Zoster Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"SiSaf","sponsor":"CSSi LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SIS-101-ADO","moa":"CLCN7","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SiSaf \/ CSSi LifeSciences","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ CSSi LifeSciences"},{"orgOrder":0,"company":"SiSaf","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SIS-101-ADO","moa":"CLCN7","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SiSaf \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divesiran","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Scancell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SN14","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scancell \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ National Institutes of Health"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase II","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avillion LLP \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Avillion LLP \/ Merck & Co"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase II","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avillion LLP \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avillion LLP \/ Inapplicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SPX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpectrumX \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deuterated N,N-dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated N,N-dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"SporeGen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Bacteria","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Destiny Pharma \/ SporeGen","highestDevelopmentStatusID":"4","companyTruncated":"Destiny Pharma \/ SporeGen"},{"orgOrder":0,"company":"SpectrumX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SPX-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"SpectrumX \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX \/ Inapplicable"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SPYVLP01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpyBiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SpyBiotech \/ Inapplicable"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SPYVLP01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpyBiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SpyBiotech \/ Inapplicable"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SPYVLP01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpyBiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SpyBiotech \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Birch Pollen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"STC-15","moa":"METTL3","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Storm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"STC-15","moa":"METTL3","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Storm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"STM2457","moa":"METTL3","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Storm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"STS-01","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Soterios Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soterios Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"STS-01","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Soterios Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soterios Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fostemsavir","moa":"GP120","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dimercaprol","moa":"Heavy metal","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Liverpool School of Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liverpool School of Tropical Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Liverpool School of Tropical Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Kings College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kings College London \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Kings College London \/ Inapplicable"},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"The Pirbright Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRRSV vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Enesi Pharma Limited","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enesi Pharma Limited \/ The Pirbright Institute","highestDevelopmentStatusID":"2","companyTruncated":"Enesi Pharma Limited \/ The Pirbright Institute"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Allergen Extract","moa":"IL-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Sublingual Liquid","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"Undisclosed","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"||PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rilpivirine Hydrochloride","moa":"NNRT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Palivizumab","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"Cytokine","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Nrf2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tree MATA MPL","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NIHR","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NIHR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NIHR \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NIHR \/ Inapplicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Neurology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Accord healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Antev","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Teverelix Trifluoroacetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Antev","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antev \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antev \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"A2AR","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Evotec"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ MSD"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AS01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAY1895344","moa":"Ataxia telangiectasia and Rad3-related","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ Bayer AG"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"VEGF-A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Centus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sareum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"BCMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Oracle Cancer Trust","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PLX4720","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute of Cancer Research \/ Oracle Cancer Trust","highestDevelopmentStatusID":"4","companyTruncated":"The Institute of Cancer Research \/ Oracle Cancer Trust"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute of Cancer Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"The Institute of Cancer Research \/ AstraZeneca"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Libmeldy","moa":"ARSA gene","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CN Bio","sponsor":"Cambridge University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"CN Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"CN Bio \/ Cambridge University","highestDevelopmentStatusID":"1","companyTruncated":"CN Bio \/ Cambridge University"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Maltol","moa":"Integrin beta-3 substrate","graph1":"Hematology","graph2":"Approved FDF","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shield Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shield Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILC Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ILC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ILC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"IL-5-alpha receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReNeuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReNeuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ReNeuron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReNeuron \/ Inapplicable"},{"orgOrder":0,"company":"MiroBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Saint Luke's Health System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Saint Luke's Health System","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Saint Luke's Health System"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Belimumab","moa":"||BLyS","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Nrf2","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evgen Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Vir Biotechnology"},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||VEGF-A","graph1":"Oncology","graph2":"Phase III","graph3":"Centus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Gepotidacin","moa":"Bacterial DNA replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olopatadine Hydrochloride","moa":"||5-HT1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Vir Biotechnology"},{"orgOrder":0,"company":"Immunocore","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMC-C103C","moa":"||MAGE-A4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Genentech"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acelarin","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"FS118","moa":"PD-L1\/LAG-3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Napp Pharmaceuticals \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Napp Pharmaceuticals \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Taw Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Taw Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taw Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Taw Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"5-Valent Meningococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue Factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Naquinate","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haoma Medica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medica \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMM60","moa":"||iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ University of Oxford","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ University of Oxford"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Nrf2","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evgen Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"70s ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Feladilimab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Merck & Co"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Novavax"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"T Cell Adaptive Chikungunya Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gylden Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Belimumab","moa":"||BLyS","graph1":"Nephrology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Meningococcal Groups A, C, Y, and W-135 Diphtheria Vaccine","moa":"Capsular polysaccharides","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Trivalent Influenza Vaccine, MF59-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"miRNA-125b","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Horizon Discovery Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Discovery Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Horizon Discovery Group \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Daprodustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Cambridge University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||SGLT2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cambridge University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cambridge University \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Cambridge University \/ Inapplicable"},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Iontas \/ FairJourney Biologics"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evox Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Evox Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"OKYO Pharma \/ AmbioPharm","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ AmbioPharm"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sareum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","graph1":"Oncology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Queen Mary University of London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Men ABCWY Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Zelenectide Pevedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Kings College London","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Kings College London","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Kings College London"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"||P2Y12 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Arecor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATL001","moa":"T-cell","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Nutrapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"RPI-78M","moa":"Ach receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutrapharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrapharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nutrapharma \/ Inapplicable"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Nomegestrol Acetate","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theramex \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theramex \/ Inapplicable"},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evox Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Evox Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evasins","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Eleusis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Eleusis \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eleusis \/ Inapplicable"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Chk-1\/2","graph1":"Neurology","graph2":"Discovery","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Birmingham \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"University of Birmingham \/ Inapplicable"},{"orgOrder":0,"company":"University of Glasgow","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ceralasertib","moa":"ATR","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Glasgow","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Glasgow \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"University of Glasgow \/ AstraZeneca"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"saRNA Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"||EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Hutchmed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Hutchmed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Pirbright Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pirbright Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pirbright Institute \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pirbright Institute \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Iontas \/ FairJourney Biologics"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Benralizumab","moa":"||IL-5-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NuCana","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosgemcitabine Palabenamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ Inapplicable"},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"Genetic transcription","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGB Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VTP-800","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Midatech Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Midatech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"GW Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||TLR5","graph1":"Oncology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EXS21546","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia \/ Evotec"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NG-347","moa":"||EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Bluebird Bio","highestDevelopmentStatusID":"5","companyTruncated":"Akamis Bio \/ Bluebird Bio"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GSK3640254","moa":"Maturation","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Open Orphan","sponsor":"Codagenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Open Orphan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Open Orphan \/ Codagenix","highestDevelopmentStatusID":"6","companyTruncated":"Open Orphan \/ Codagenix"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"National Immunisation Schedule Evaluation Consortium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"National Immunisation Schedule Evaluation Consortium","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Immunisation Schedule Evaluation Consortium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"National Immunisation Schedule Evaluation Consortium \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Ingenza","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ingenza","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Ingenza \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ingenza \/ Inapplicable"},{"orgOrder":0,"company":"Universities of Liverpool","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Neurology","graph2":"Preclinical","graph3":"Universities of Liverpool","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universities of Liverpool \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Universities of Liverpool \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ University of Oxford"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cediranib","moa":"||VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"National Institute for Health Research","sponsor":"Manchester University NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TGF-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute for Health Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute for Health Research \/ Manchester University NHS Foundation Trust","highestDevelopmentStatusID":"8","companyTruncated":"National Institute for Health Research \/ Manchester University NHS Foundation Trust"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"University of Exeter Medical School","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Exeter Medical School","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"University of Exeter Medical School \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter Medical School \/ Inapplicable"},{"orgOrder":0,"company":"Etcembly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Etcembly","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Etcembly \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Etcembly \/ Inapplicable"},{"orgOrder":0,"company":"Sareum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SDC-1802","moa":"TYK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ Inapplicable"},{"orgOrder":0,"company":"University of Liverpool","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Liverpool","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Liverpool \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"University of Liverpool \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GSK3888550A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Touchlight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Touchlight \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Touchlight \/ Inapplicable"},{"orgOrder":0,"company":"Theolytics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theolytics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theolytics \/ Inapplicable"},{"orgOrder":0,"company":"Theolytics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theolytics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Synairgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon-alpha\/beta receptor 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Synairgen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Inapplicable"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fostemsavir","moa":"GP120","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"rNAPc2","moa":"Tissue factor pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Oruka Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GSK3888550A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PepGNP-Dengue","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gylden Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Silence Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"IL-5 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NG-641","moa":"AP\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Akamis Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Nrf2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evgen Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"IL-17\/BAFF","graph1":"Dermatology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zura Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tiopronin","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Cilgavimab","moa":"||SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Foralumab","moa":"||CD3","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TZLS-501","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Brigham and Women\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Brigham and Women\u2019s Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Brigham and Women\u2019s Hospital"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ixaka","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Celtic","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Ixaka","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ixaka \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ixaka \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"Pneumagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Neumifil","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Pneumagen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dexrazoxane","moa":"Topoisomerase II","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMM60","moa":"||iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Intensity Therapeutics"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomacopan","moa":"||C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Etigilimab","moa":"||TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Axalbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AX-8","moa":"TRPM8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PolyPEPI-SCoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Treos Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PolyPEPI1018","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Treos Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Treos Bio \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tideglusib","moa":"GSK-3 beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kings College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"COX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kings College London \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Kings College London \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Trogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Trogenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trogenix \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Trogenix \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||AKT 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ Tarus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Tarus Therapeutics"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Greenwich Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"GW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Greenwich Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"GW Pharmaceutical \/ Greenwich Biosciences"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Advanz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TZLS-501","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"University College London Hospitals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University College London Hospitals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University College London Hospitals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"University College London Hospitals \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Acacia Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acacia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Pfizer Inc"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ FibroGen"},{"orgOrder":0,"company":"Aptorum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rilpivirine Hydrochloride","moa":"NNRT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Aptorum \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ Inapplicable"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Cancer Research UK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"AZD4547","moa":"FGFR1","graph1":"Oncology","graph2":"Phase II","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"University of Birmingham \/ Cancer Research UK","highestDevelopmentStatusID":"8","companyTruncated":"University of Birmingham \/ Cancer Research UK"},{"orgOrder":0,"company":"Imophoron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Imophoron","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Imophoron \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Imophoron \/ Inapplicable"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19-Adenovirus Vector-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Valo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Chadox1-S","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tuvatexib","moa":"VDAC\/HK2 interaction","graph1":"Dermatology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Vidac Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tuvatexib","moa":"Hexokinase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Vidac Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tuvatexib","moa":"Hexokinase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Vidac Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||VDAC\/HK2 interaction","graph1":"Oncology","graph2":"Preclinical","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vidac Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vidac Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VDA-1275","moa":"VDAC\/HK2 interaction","graph1":"Oncology","graph2":"Preclinical","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vidac Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vidac Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Abacavir","moa":"||HIV integrase strand transfer","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Pfizer Inc"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Suspension, Extended Release","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Votucalis","moa":"H1\/H2\/H3\/H4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Akari Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danicopan","moa":"||Factor D","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Varsity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Novobiocin Sodium","moa":"Polymerase theta helicase","graph1":"Oncology","graph2":"Preclinical","graph3":"Varsity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Varsity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Varsity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VTP-1000","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VTP-200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VTP-200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAdOx1-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ChAdOx1-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ChAdOx1-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ChAdOx1-PCAQ","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Barinthus Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Blueberry Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CV2CoV","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"4","companyTruncated":"GSK \/ CureVac"},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Vir Biotechnology"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exeporfinium chloride","moa":"Siglec-8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exeporfinium chloride","moa":"Siglec-8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"YCT529","moa":"RAR-alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quotient Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP 1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zibotentan","moa":"||SGLT2","graph1":"Nephrology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"AZD5396","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Inovio Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Meningococcal Groups A, B, C, W, and Y Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tiopronin","moa":"Urinary cystine concentration","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone 1 receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Compass Pathways \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pathways \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Eculizumab","moa":"C5 receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LB Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Camizestrant","moa":"||SERD","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Gepotidacin","moa":"Bacterial DNA replication","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"FX receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Advanz Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Advanz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dostarlimab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MB310","moa":"Gastrointestinal microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Microbiotica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Microbiotica \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu-rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Centauri Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ABX-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Centauri Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centauri Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Centauri Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR gene","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yaqrit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"Ammonia","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Yaqrit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Yaqrit \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yaqrit \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intranasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"SolasCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"SolasCure \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"||BCMA","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Carbachol","moa":"||M1 receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tenpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenpoint Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Nectin-4","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||BTK","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"CBP-4888","moa":"sFlt1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ChAd155-hIi-HBV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"EBX-102-02","moa":"Gastrointestinal microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EnteroBiotix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"E-therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ETX-148","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"E-therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"E-therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Depemokimab","moa":"IL-5 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"HG-CT-1","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMC-P115C","moa":"PRAME\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMC-R117C","moa":"PIWIL1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RQ Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Sipavibart","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ RQ Bio","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ RQ Bio"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KER-0193","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kaerus Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kaerus Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"EORTC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ EORTC","highestDevelopmentStatusID":"15","companyTruncated":"Immunocore \/ EORTC"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate receptor-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epsilogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Inapplicable"},{"orgOrder":0,"company":"Ananda Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Ananda Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ananda Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ananda Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Inapplicable"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Quotient Sciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Nanomerics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Quotient Sciences \/ Nanomerics","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Nanomerics"},{"orgOrder":0,"company":"Nanomerics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OC134","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanomerics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nanomerics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Nanomerics \/ Quotient Sciences"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OKYO Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Linezolid","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Persica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pheno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PTD802","moa":"GPR17","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pheno Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Pheno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Zoster Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SPR301","moa":"GCase85","graph1":"Neurology","graph2":"IND Enabling","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Rovaleucel","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"||CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ViiV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"IL-17\/BAFF","graph1":"Dermatology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zura Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adium Pharma","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"URUGUAY","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Elasomeran","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adium Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adium Pharma \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Adium Pharma \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Amnio Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"URUGUAY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Palingen Flow","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amnio Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amnio Technology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amnio Technology \/ Inapplicable"},{"orgOrder":0,"company":"Anova Pharma","sponsor":"Neonc Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"VIETNAM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Perillyl Alcohol","moa":"Farnesyl transferase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anova Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Anova Pharma \/ Neonc Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Anova Pharma \/ Neonc Technologies"},{"orgOrder":0,"company":"Vabiotech","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vabiotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vabiotech \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Vabiotech \/ Vingroup Innovation Foundation"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Pimicotinib","moa":"CSF-1R","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0.60999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Abbisko Therapeutics \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Thrive Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.59999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Isomorphic Labs \/ Thrive Capital","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Thrive Capital"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"KER-065","moa":"Myostatin\/Activin A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||HER-2","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Merck & Co"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Relacorilant","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"OST31-154","moa":"HER-2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Endoglin","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"AdjuTec Pharma","sponsor":"Venus Remedies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NORWAY","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"APC-148","moa":"||MBL","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AdjuTec Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AdjuTec Pharma \/ Venus Remedies","highestDevelopmentStatusID":"4","companyTruncated":"AdjuTec Pharma \/ Venus Remedies"},{"orgOrder":0,"company":"PinCell","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"PC111","moa":"FasL","graph1":"Immunology","graph2":"Preclinical","graph3":"PinCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PinCell \/ Scinai Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PinCell \/ Scinai Immunotherapeutics"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Yosemite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Lomond Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Lomond Therapeutics \/ Yosemite Capital","highestDevelopmentStatusID":"6","companyTruncated":"Lomond Therapeutics \/ Yosemite Capital"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Lomond Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Lomond Therapeutics \/ Deerfield Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Lomond Therapeutics \/ Deerfield Management Company"},{"orgOrder":0,"company":"Yoda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"YA-101","moa":"GluN1\/NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Yoda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Yoda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yoda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ICP-248","moa":"||Bcl-2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177Lu-vipivotide Tetraxetan","moa":"||PSMA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Fitusiran","moa":"AT mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||PD-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for CASPOFUNGIN (ACETATE)

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Check COS database
Check all USDMF suppliers

CASPOFUNGIN (ACETATE)

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

31 API Suppliers, 12 USDMF, 1 JDMF, 5 EU WC, 6 KDMF, 8 NDC API, 24 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

94 FDF Dossiers, 16 FDA Orange Book, 20 Europe, 6 Canada, 18 South Africa, 34 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - 50MG/VIAL, POWDER;INTRAVENOUS - 70MG/VIAL

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 2 Faran Shimi Pharmaceutical, 1 Gangwal Healthcare, 3 Pfanstiehl, 2 Actylis, 1 BASF, 3 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 2 Kerry, 2 Microlex e.U, 2 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 12 Taste Masking, 11 Chewable & Orodispersible Aids, 10 Direct Compression, 7 Disintegrants & Superdisintegrants, 7 Parenteral, 5 Co-Processed Excipients, 4 Thickeners and Stabilizers, 3 Granulation, 2 Coating Systems & Additives, 1 Solubilizers

DIGITAL CONTENT

15 News #PharmaBuzz

15 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 18 Regulatory FDF Prices, 9 Annual Reports

MARKET PLACE

17 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 4 Health Canada Patents

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Aspen API

Netherlands

TIDES USA

Booth #27, Level 2

Aspen API. More than just an API™

Lead Product(s) : Acetylcysteine

Therapeutic Area : Pharmacology/Toxicology

Study Phase : Approved FDF

Sponsor : Glenmark Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Acquisition

DEALS_DEV

Glenmark Acquires & Launches Acetylcysteine Injection 6gm/30mL Single-Dose Vials

Details : Glenmark has acquired generic version of Acetadote (acetylcysteine) injection from Aspen Pharma. It is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury.

Product Name : Acetadote-Generic

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

March 03, 2025

Lead Product(s) : Acetylcysteine

Therapeutic Area : Pharmacology/Toxicology

Highest Development Status : Approved FDF

Sponsor : Glenmark Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Acquisition

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02

Sanofi

France

BIO International Convention

Exhibiting

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Isatuximab,Bortezomib

Therapeutic Area : Oncology

Study Phase : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Details : Sarclisa (isatuximab) approved as a first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.

Product Name : Sarclisa

Product Type : Antibody

Upfront Cash : Inapplicable

November 14, 2024

Lead Product(s) : Isatuximab,Bortezomib

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

03

AbbVie Inc

U.S.A

BioTrinity 2025

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Emraclidine

Therapeutic Area : Psychiatry/Psychology

Study Phase : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

AbbVie’s $9B Bet Collapses as Closely Watched Schizophrenia Drug Fails Studies

Details : CVL-231 (emraclidine) is a potential novel M4-selective positive allosteric modulator in development for schizophrenia and other psychosis related diseases.

Product Name : CVL-231

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 11, 2024

Lead Product(s) : Emraclidine

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

04

Strides Pharma Science

India

CPhI WW Frankfurt

Booth # 9.1F6 & 9.1G41

Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

Lead Product(s) : Sevelamer Hydrochloride

Therapeutic Area : Nephrology

Study Phase : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Strides Receives USFDA Approval for Sevelamer Carbonate Tablets

Details : USFDA approved generic version of Sevelamer Carbonate which is used to manage elevated levels of phosphate in the blood of patients with chronic kidney disease.

Product Name : Renvela-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 05, 2024

Lead Product(s) : Sevelamer Hydrochloride

Therapeutic Area : Nephrology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

05

AbbVie Inc

U.S.A

BioTrinity 2025

Not Confirmed

Lead Product(s) : Tavapadon

Therapeutic Area : Neurology

Study Phase : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

AbbVie Announces Positive Topline Results from Phase 3 for Tavapadon in Parkinson's

Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.

Product Name : CVL-751

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 26, 2024

Lead Product(s) : Tavapadon

Therapeutic Area : Neurology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

06

Sanofi

France

BIO International Convention

Exhibiting

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Isatuximab,Bortezomib

Therapeutic Area : Oncology

Study Phase : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Sanofi Wins US Approval for Multiple Myeloma Drug in Newly Diagnosed Patients

Product Name : Sarclisa

Product Type : Antibody

Upfront Cash : Inapplicable

September 21, 2024

Lead Product(s) : Isatuximab,Bortezomib

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

07

Sanofi

France

BIO International Convention

Exhibiting

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : AMX-818,Pembrolizumab

Therapeutic Area : Oncology

Study Phase : Phase I/ Phase II

Sponsor : Vir Biotechnology

Deal Size : Undisclosed

Deal Type : Licensing Agreement

DEALS_DEV

Vir Biotech Closes Global License Deal with Sanofi For T-Cell Engagers

Details : Through the license agreement, Vir Biotechnology will gain the rights of three clinical-stage masked TCEs, which include SAR446309 (AMX-818) for the treatment of HER2-mutated Breast Neoplasms.

Product Name : SAR446309

Product Type : Cell and Gene therapy

Upfront Cash : Undisclosed

September 09, 2024

Lead Product(s) : AMX-818,Pembrolizumab

Therapeutic Area : Oncology

Highest Development Status : Phase I/ Phase II

Sponsor : Vir Biotechnology

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

08

Granules India Limited

India

CPhI Japan

Attending

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Lead Product(s) : Trazodone Hydrochloride

Therapeutic Area : Psychiatry/Psychology

Study Phase : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Granules India Gains ANDA approval for Trazodone Tablets

Details : Desyrel-Generic (trazodone hydrochloride) is a selective serotonin reuptake inhibitor indicated for the treatment of patients with major depressive disorder.

Product Name : Desyrel-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 08, 2024

Lead Product(s) : Trazodone Hydrochloride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

09

Granules India Limited

India

CPhI Japan

Attending

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Lead Product(s) : Glycopyrronium Bromide

Therapeutic Area : Neurology

Study Phase : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Granules India Gets USFDA Nod for Generic Glycopyrrolate Oral Solution

Details : Cuvposa is an anticholinergic indicated to reduce chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling.

Product Name : Cuvposa-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 20, 2024

Lead Product(s) : Glycopyrronium Bromide

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

10

Ever Pharma

Austria

ESOC 2025

Attending

Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

Lead Product(s) : Testosterone Enanthate

Therapeutic Area : Endocrinology

Study Phase : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

EVER Pharma Gained EU-Approval of Testosterone Enantate

Details :

Product Name : Testosterone Enantate Ever Pharma

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 19, 2024

Lead Product(s) : Testosterone Enanthate

Therapeutic Area : Endocrinology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

Find Clinical Drug Pipeline Developments & Deals for CASPOFUNGIN (ACETATE)

CASPOFUNGIN (ACETATE)

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

31 API Suppliers

12 USDMF

1 JDMF

5 EU WC

6 KDMF

8 NDC API

24 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

94 FDF Dossiers

16 FDA Orange Book

20 Europe

6 Canada

18 South Africa

34 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - 50MG/VIAL

POWDER;INTRAVENOUS - 70MG/VIAL

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

13 SPI Pharma

2 Faran Shimi Pharmaceutical

1 Gangwal Healthcare

3 Pfanstiehl

2 Actylis

1 BASF

3 Gangwal Chemicals

1 Ingredion Pharma Solutions

2 Kerry

2 Microlex e.U

2 Pluviaendo

3 Roquette

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders

12 Taste Masking

11 Chewable & Orodispersible Aids

10 Direct Compression

7 Disintegrants & Superdisintegrants

7 Parenteral

5 Co-Processed Excipients

4 Thickeners and Stabilizers

3 Granulation

2 Coating Systems & Additives

1 Solubilizers

DIGITAL CONTENT

15 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

18 Regulatory FDF Prices

9 Annual Reports

MARKET PLACE

17 APIs

5 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents

4 Health Canada Patents

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

01

02

03

04

05

06